,Unnamed: 0,Patient ID,Prompts,Outcome,Prognosis
0,0,P0001,"Age: 58
Gender: Male 
Weight: 83 kg
Height: 163 cm
NYHA Class: III
Blood Pressure: 110/75 mmHg
Past Medical History: Idiopathic dilated cardiomyopathy
Albumin (g/L): 42,4
ALT or GPT (IU/L): 10.0
AST or GOT (IU/L): 20.0
Total Cholesterol (mmol/L): 5,4
Creatinine (mmol/L): 106.0
Gamma-glutamil transpeptidase (IU/L): 20
Glucose (mmol/L): 5,7
Hemoglobin (g/L): 132.0
HDL (mmol/L): 1,29
Potassium (mEq/L): 4,6
LDL (mmol/L): 3,36
Sodium (mEq/L): 141.0
Pro-BNP (ng/L): 1834.0
Protein (g/L): 69
T3 (pg/dL): 0,05
T4 (ng/L): 15
Troponin (ng/mL): 0,01
TSH (mIU/L): 3,02
Urea (mg/dL): 7,12
LVEF (%): 35.0
Medications: Beta Blockers, Digoxin, Loop Diuretics, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",survivor,"RANKING: 1. Survivor
REASONING: 

Based on the provided patient data, the patient's prognosis is most likely to be a survivor. The patient has a history of idiopathic dilated cardiomyopathy, which is a condition where the heart muscle becomes weakened and the heart chambers become enlarged. This condition can lead to heart failure, arrhythmias, and decreased cardiac function.

The patient's current NYHA Class III indicates that they have significant symptoms of heart failure, which suggests that their heart is not functioning optimally. However, the patient is currently receiving medications such as beta blockers, digoxin, loop diuretics, and ACE inhibitors, which are commonly used to manage heart failure and prevent complications.

The patient's ECG findings, including ventricular extrasystole, non-sustained VT, and non-sustained ventricular tachycardia, suggest that the patient is at risk for arrhythmias and cardiac instability. However, the presence of these arrhythmias is not uncommon in patients with heart failure.

The patient's laboratory results, including low LVEF (35.0), elevated BNP (1834.0), and elevated creatinine (106.0), suggest that the patient's heart is under significant stress and may be at risk for further decline. However, these results are not unusual for a patient with advanced heart failure.

Overall, while the patient's condition is severe, the presence of multiple medications and the fact that they are currently alive suggest that they are likely to survive in the short term. However, close monitoring and adjustment of their treatment plan will be necessary to manage their condition and prevent further decline.

RANKING: 2. Sudden cardiac death
REASONING: 

While the patient's prognosis is not extremely poor, sudden cardiac death is still a possible outcome. The patient's ECG findings, including ventricular extrasystole and non-sustained VT, suggest that the patient is at risk for cardiac arrhythmias. Additionally, the patient's LVEF (35.0) and elevated BNP (1834.0) indicate that the patient's heart is under significant stress, which can increase the risk of cardiac arrhythmias and sudden cardiac death.

RANKING: 3. Pump failure death
REASONING: 

While pump failure death is a possible outcome for patients with advanced heart failure, it is the least likely of the three options. The patient is currently receiving medications to manage their heart failure, including beta blockers, digoxin, loop diuretics, and ACE inhibitors, which can help to slow the progression of the disease and reduce symptoms. Additionally, the patient's laboratory results, while indicating significant cardiac stress, do not suggest that the patient's heart is on the verge of failing catastrophically.

It's worth noting that the patient's ECG findings, including ventricular extrasystole and non-sustained VT, suggest that the patient is at risk for cardiac arrhythmias, which can increase the risk of pump failure death. However, the presence of these arrhythmias is not uncommon in patients with heart failure, and the patient's current treatment plan and laboratory results suggest that they are being adequately managed."
1,1,P0002,"Age: 58
Gender: Male 
Weight: 74 kg
Height: 160 cm
NYHA Class: II
Blood Pressure: 130/80 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Dyslipemia, Myocardial Infarction
Albumin (g/L): 40,4
ALT or GPT (IU/L): 20.0
AST or GOT (IU/L): 20.0
Total Cholesterol (mmol/L): 6,18
Creatinine (mmol/L): 121.0
Gamma-glutamil transpeptidase (IU/L): 44
Glucose (mmol/L): 5,6
Hemoglobin (g/L): 126.0
HDL (mmol/L): 0,98
Potassium (mEq/L): 4,6
LDL (mmol/L): 4,06
Sodium (mEq/L): 140.0
Pro-BNP (ng/L): 570.0
Protein (g/L): 75
T3 (pg/dL): 0,04
T4 (ng/L): 12
Troponin (ng/mL): 0,01
TSH (mIU/L): 3,27
Urea (mg/dL): 10,47
LVEF (%): 35.0
Medications: Angiotensin II Receptor Blocker, Beta Blockers, Statins
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"RANKING: 1. Survivor
REASONING:

Based on the provided patient data, I would rank the patient as having a high likelihood of being a survivor. The patient has a history of ischemic dilated cardiomyopathy, which is a significant risk factor for heart failure and arrhythmias. However, the patient is currently on medications for heart failure (Angiotensin II Receptor Blocker, Beta Blockers, Statins) and has a relatively normal blood pressure (130/80 mmHg). The patient's NYHA Class II indicates that they have some limitation in physical activity, but they are still able to perform daily activities without significant symptoms.

The patient's laboratory results show elevated levels of Pro-BNP (570.0 ng/L), which is a biomarker for heart failure, but the troponin level (0.01 ng/mL) is within the normal range, suggesting that there is no acute myocardial infarction. The patient's creatinine level (10.47 mg/dL) is slightly elevated, but it is not significantly high, which may indicate some degree of renal impairment, but not severe kidney failure.

The ECG results show ventricular extrasystoles, which can be a sign of cardiac arrhythmias, but no other significant arrhythmias are present. The patient's LVEF (35.0) is significantly reduced, indicating systolic dysfunction, but the patient is on medications that can help manage this condition.

Overall, considering the patient's history, medications, laboratory results, and ECG findings, I believe that the patient has a good chance of survival for the next few years, assuming that the medications are well-tolerated and that the patient adheres to the treatment plan.

RANKING: 2. Sudden cardiac death
REASONING:

While the patient has a history of ischemic dilated cardiomyopathy and ventricular extrasystoles, which can increase the risk of sudden cardiac death, I would rank this as a lower likelihood compared to the survivor prognosis. The patient is on medications for heart failure and arrhythmias, which can help manage these conditions.

RANKING: 3. Pump failure death
REASONING:

Given the patient's history of ischemic dilated cardiomyopathy and reduced LVEF (35.0), pump failure is a possible outcome. However, the patient is on medications that can help manage heart failure, and the patient's laboratory results do not show significant evidence of acute kidney injury or severe electrolyte imbalances, which can contribute to pump failure. Additionally, the patient's troponin level is within the normal range, suggesting that there is no acute myocardial infarction.

While pump failure is a possible outcome, I believe that the patient's current treatment plan and laboratory results make it a less likely outcome compared to sudden cardiac death."
2,2,P0003,"Age: 69
Gender: Male 
Weight: 83 kg
Height: 174 cm
NYHA Class: II
Blood Pressure: 100/75 mmHg
Past Medical History: Idiopathic dilated cardiomyopathy
Albumin (g/L): 40,1
ALT or GPT (IU/L): 23.0
AST or GOT (IU/L): 28.0
Total Cholesterol (mmol/L): 5,3
Creatinine (mmol/L): 87.0
Gamma-glutamil transpeptidase (IU/L): 25
Glucose (mmol/L): 5,7
Hemoglobin (g/L): 132.0
HDL (mmol/L): 2,04
Potassium (mEq/L): 4,7
LDL (mmol/L): 2,97
Sodium (mEq/L): 138.0
Pro-BNP (ng/L): 403.0
Protein (g/L): 76
T3 (pg/dL): 0,05
T4 (ng/L): 13
Troponin (ng/mL): 0,01
TSH (mIU/L): 0,93
Urea (mg/dL): 10,02
LVEF (%): 39.0
Medications: Angiotensin II Receptor Blocker, Beta Blockers, Digoxin, Loop Diuretics
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",survivor,"RANKING: 1. Survivor
REASONING: The patient is currently receiving treatment with Angiotensin II Receptor Blocker, Beta Blockers, Digoxin, and Loop Diuretics, which suggests that the patient is receiving standard therapy for heart failure with reduced ejection fraction (HFrEF) and left ventricular dysfunction. The presence of ventricular extrasystole and non-sustained ventricular tachycardia on the ECG is concerning, but the patient's current medication regimen may be effective in managing these arrhythmias. The patient's NYHA Class II indicates moderate symptoms of heart failure, but the patient's LVEF is still relatively preserved at 39%. The patient's laboratory results, such as the mildly elevated creatinine and low albumin, are also consistent with heart failure. However, the patient's overall condition and the presence of certain risk factors, such as age and idiopathic dilated cardiomyopathy, suggest that the patient may still be at risk for adverse outcomes. Despite this, the patient's current treatment plan and the presence of a favorable outcome code suggest that the patient is likely to survive in the short term.

RANKING: 2. Pump failure death
REASONING: The patient's LVEF of 39% indicates significant left ventricular dysfunction, which is a major risk factor for heart failure and pump failure. The patient's NYHA Class II symptoms suggest that the patient is experiencing moderate symptoms of heart failure, which may worsen over time. The patient's elevated creatinine level and low albumin level suggest that the patient's kidney function may be compromised, which can further exacerbate heart failure. The presence of ventricular extrasystole and non-sustained ventricular tachycardia on the ECG also increases the risk of cardiac arrhythmias, which can contribute to pump failure. While the patient is receiving standard therapy for heart failure, the patient's underlying condition and risk factors suggest that pump failure is a possible outcome.

RANKING: 3. Sudden cardiac death
REASONING: The patient's presence of ventricular extrasystole and non-sustained ventricular tachycardia on the ECG increases the risk of sudden cardiac death. The patient's LVEF of 39% is also a risk factor for sudden cardiac death. However, the patient is receiving standard therapy for heart failure and has a favorable outcome code, which suggests that the patient is not at the highest risk for sudden cardiac death. Additionally, the patient's age and idiopathic dilated cardiomyopathy may also contribute to the risk of sudden cardiac death. However, the patient's overall condition and treatment plan suggest that pump failure is a more likely outcome than sudden cardiac death."
3,3,P0004,"Age: 56
Gender: Female 
Weight: 84 kg
Height: 165 cm
NYHA Class: II
Blood Pressure: 155/75 mmHg
Past Medical History: Hypertensive cardiomyopathy, Diabetes, Dyslipemia, Hypertension
Albumin (g/L): 40,9
ALT or GPT (IU/L): 24.0
AST or GOT (IU/L): 23.0
Total Cholesterol (mmol/L): 6,21
Creatinine (mmol/L): 77.0
Gamma-glutamil transpeptidase (IU/L): 37
Glucose (mmol/L): 17,8
Hemoglobin (g/L): 127.0
HDL (mmol/L): 1,03
Potassium (mEq/L): 4,3
LDL (mmol/L): 3,49
Sodium (mEq/L): 136.0
Pro-BNP (ng/L): 695.0
Protein (g/L): 72
T3 (pg/dL): 0,05
T4 (ng/L): 16
Troponin (ng/mL): 0,01
TSH (mIU/L): 2,07
Urea (mg/dL): 8,91
LVEF (%): 38.0
Medications: Diabetes Medication, Angiotensin II Receptor Blocker, Beta Blockers, Loop Diuretics, Spironolactone
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: TPSV
        - Bradycardia: No
            ",survivor,"RANKING: 
1. Survivor
REASONING:
Based on the provided patient data, the patient is at high risk for cardiac-related complications due to a history of hypertensive cardiomyopathy, hypertension, diabetes, and dyslipidemia. The patient's ejection fraction (LVEF) is significantly reduced at 38%, indicating left ventricular dysfunction. The elevated Pro-BNP levels (695.0 ng/L) also suggest heart failure with preserved ejection fraction (HFpEF). The patient's NYHA Class II classification indicates moderate symptoms of heart failure.

However, the patient is not on any medications that directly target the cause of the heart failure, such as ACE inhibitors or beta-blockers. The patient is on medications that are more symptomatic relief-focused, which might not be enough to reverse the underlying cardiac dysfunction.

The patient's laboratory results, such as the elevated creatinine level (8.91 mg/dL) and reduced eGFR (not provided), indicate renal impairment, which is a common comorbidity in patients with heart failure. The patient's lipid profile is also concerning, with high LDL and low HDL levels.

Considering these factors, the patient is at high risk for cardiac-related complications, including sudden cardiac death and pump failure. However, the patient's current treatment plan and the lack of evidence suggesting acute coronary syndrome or severe cardiac ischemia make sudden cardiac death less likely. Therefore, the most likely outcome is pump failure death, given the patient's underlying cardiac dysfunction and comorbidities.

While the patient is a candidate for further evaluation and treatment to improve cardiac function and reduce the risk of complications, the current data suggests that pump failure is the most likely outcome."
4,4,P0005,"Age: 70
Gender: Male 
Weight: 97 kg
Height: 183 cm
NYHA Class: II
Blood Pressure: 125/85 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Diabetes, Dyslipemia, Hypertension, Myocardial Infarction
Albumin (g/L): 45,3
ALT or GPT (IU/L): 24.0
AST or GOT (IU/L): 23.0
Total Cholesterol (mmol/L): 5,72
Creatinine (mmol/L): 88.0
Gamma-glutamil transpeptidase (IU/L): 26
Glucose (mmol/L): 7,8
Hemoglobin (g/L): 159.0
HDL (mmol/L): 1,06
Potassium (mEq/L): 4,9
LDL (mmol/L): 3,28
Sodium (mEq/L): 140.0
Pro-BNP (ng/L): 456.0
Protein (g/L): 82
T3 (pg/dL): 0,05
T4 (ng/L): 16
Troponin (ng/mL): 0,01
TSH (mIU/L): 1,01
Urea (mg/dL): 10,91
LVEF (%): 34.0
Medications: Diabetes Medication, Beta Blockers, Loop Diuretics, Statins, ACE Inhibitor, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: Unknown bradycardia code
            ",survivor,"RANKING: 1. Survivor
REASONING: 
Based on the provided patient data, the patient is at high risk for adverse outcomes. The patient has a history of ischemic dilated cardiomyopathy, which is a significant risk factor for sudden cardiac death. The LVEF of 34.0 is significantly reduced, indicating poor cardiac function. Additionally, the patient has a history of myocardial infarction, hypertension, and dyslipidemia, all of which can contribute to cardiac damage and dysfunction. 

The patient's ECG findings of ventricular extrasystoles are also concerning, as they can be a precursor to more serious arrhythmias. However, the absence of ventricular tachycardia or non-sustained ventricular tachycardia reduces the immediate risk of sudden cardiac death. 

The patient's medication regimen includes beta blockers, ACE inhibitors, and statins, which are all standard treatments for managing heart failure and reducing the risk of cardiovascular events. The presence of a nitrovasodilator may also be beneficial in managing hypertension and heart failure.

Considering these factors, the patient's overall prognosis is more favorable than the other options. While the patient is at risk for cardiac events, the presence of a strong medication regimen and the absence of more severe ECG findings make a sudden cardiac death less likely. However, the patient's poor LVEF and history of cardiac disease make pump failure a significant concern.

The patient's prognosis is more favorable than pump failure death due to the presence of a strong medication regimen, which can help manage symptoms and slow disease progression. However, the patient's poor LVEF and history of cardiac disease make pump failure a more likely outcome than sudden cardiac death. 

The patient's prognosis is more favorable than pump failure due to the presence of a strong medication regimen and the absence of more severe ECG findings, which can contribute to sudden cardiac death."
5,5,P0006,"Age: 70
Gender: Male 
Weight: 83 kg
Height: 165 cm
NYHA Class: II
Blood Pressure: 105/75 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Diabetes, Myocardial Infarction
Albumin (g/L): 44,1
ALT or GPT (IU/L): 26.0
AST or GOT (IU/L): 19.0
Total Cholesterol (mmol/L): 4,91
Creatinine (mmol/L): 101.0
Gamma-glutamil transpeptidase (IU/L): 21
Glucose (mmol/L): 5,6
Hemoglobin (g/L): 135.0
HDL (mmol/L): 1,4
Potassium (mEq/L): 4,8
LDL (mmol/L): 3
Sodium (mEq/L): 140.0
Pro-BNP (ng/L): 3437.0
Protein (g/L): 71
T3 (pg/dL): 0,04
T4 (ng/L): 14
Troponin (ng/mL): 0,01
TSH (mIU/L): 2,88
Urea (mg/dL): 8,46
LVEF (%): 34.0
Medications: Diabetes Medication, Beta Blockers, Loop Diuretics, Spironolactone, ACE Inhibitor, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: Second-degree AVB - type I
            ",survivor,"RANKING: 1. Survivor
REASONING: The patient has a complex medical history, including ischemic dilated cardiomyopathy, myocardial infarction, and diabetes, which indicates a high risk for cardiac events. However, the patient is currently on multiple medications that are standard for managing these conditions, including beta blockers, ACE inhibitors, and loop diuretics. The patient's NYHA Class II classification suggests that they are still able to perform moderate physical activity without significant symptoms, which is a positive prognostic sign. Additionally, the patient's renal function is not severely impaired, as indicated by the normal urea level. The presence of elevated Pro-BNP levels (3437 ng/L) suggests some degree of cardiac stress, but the patient's hemoglobin level is within the normal range, which may indicate adequate oxygen delivery to the tissues. The absence of significant elevations in troponin levels (0.01 ng/mL) and the normal LVEF (34.0%) suggest that there is no acute myocardial infarction or significant cardiac damage. Overall, these factors suggest that the patient is likely to survive in the short term, although close monitoring and follow-up are still necessary to assess the progression of their condition."
6,6,P0007,"Age: 52
Gender: Male 
Weight: 71 kg
Height: 162 cm
NYHA Class: II
Blood Pressure: 125/80 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Dyslipemia, Myocardial Infarction
Albumin (g/L): 49,69
ALT or GPT (IU/L): 31.0
AST or GOT (IU/L): 34.0
Total Cholesterol (mmol/L): 5,79
Creatinine (mmol/L): 97.0
Gamma-glutamil transpeptidase (IU/L): 90
Glucose (mmol/L): 4,8
Hemoglobin (g/L): 152.0
HDL (mmol/L): 1,58
Potassium (mEq/L): 4
LDL (mmol/L): 3,83
Sodium (mEq/L): 139.0
Pro-BNP (ng/L): 140.0
Protein (g/L): 73
T3 (pg/dL): 0,06
T4 (ng/L): 14
Troponin (ng/mL): 0,01
TSH (mIU/L): 0,979
Urea (mg/dL): 7,8
LVEF (%): 39.0
Medications: Beta Blockers, Statins
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"RANKING: 1. Survivor
REASONING: 

This patient has a complex medical history with ischemic dilated cardiomyopathy, which is a significant risk factor for adverse cardiac events. However, the patient's current NYHA class is II, indicating mild symptoms, and they are receiving beta blockers, which are standard therapy for heart failure. The patient's laboratory results show elevated creatinine levels (97.0 mmol/L), which suggests some degree of renal impairment. However, the patient's renal function is not severely impaired, and the patient is still able to maintain a relatively normal hemoglobin level (152.0 g/L).

The patient's ECG findings are concerning, with ventricular extrasystoles and non-sustained ventricular tachycardia, but these are not indicative of a high risk of sudden cardiac death. The patient's troponin level is normal (0.01 ng/mL), which suggests that there is no significant myocardial damage.

Given these factors, the patient is likely to survive for the next few years, provided they continue to receive optimal medical therapy and make lifestyle modifications to manage their condition. The patient's low LVEF (39.0%) indicates significant left ventricular dysfunction, but this can be improved with optimal medical therapy and possibly with cardiac resynchronization therapy.

RANKING: 2. Sudden cardiac death
REASONING: 

While the patient's ECG findings are concerning, the presence of ventricular extrasystoles and non-sustained ventricular tachycardia is not indicative of a high risk of sudden cardiac death. The patient's troponin level is normal, and the patient is receiving beta blockers, which are effective in reducing the risk of sudden cardiac death.

However, the patient's LVEF (39.0%) is significantly reduced, and the patient has a history of myocardial infarction, which increases the risk of arrhythmias. Additionally, the patient's creatinine level (97.0 mmol/L) is elevated, which may indicate some degree of renal impairment. These factors increase the patient's risk of cardiac events, but the patient's overall prognosis is still relatively favorable.

RANKING: 3. Pump failure death
REASONING: 

The patient's LVEF (39.0%) is significantly reduced, indicating poor left ventricular function. The patient's NYHA class is II, indicating mild symptoms, but the patient's left ventricular function is still compromised. The patient's creatinine level (97.0 mmol/L) is elevated, which may indicate some degree of renal impairment.

While the patient is receiving beta blockers, which are effective in reducing the risk of heart failure, the patient's LVEF is still significantly reduced, and the patient's renal function is not optimal. The patient's elevated troponin level (0.01 ng/mL) may indicate some degree of myocardial damage, which can worsen over time. These factors increase the patient's risk of pump failure, but the patient's overall prognosis is still relatively favorable due to the patient's mild symptoms and the patient's response to beta blockers."
7,7,P0009,"Age: 64
Gender: Female 
Weight: 68 kg
Height: 155 cm
NYHA Class: II
Blood Pressure: 160/70 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Diabetes, Dyslipemia, Peripheral vascular disease, Hypertension
Albumin (g/L): 41,4
ALT or GPT (IU/L): 14.0
AST or GOT (IU/L): 20.0
Total Cholesterol (mmol/L): 5,53
Creatinine (mmol/L): 80.0
Gamma-glutamil transpeptidase (IU/L): 18
Glucose (mmol/L): 7,2
Hemoglobin (g/L): 137.0
HDL (mmol/L): 1,34
Potassium (mEq/L): 4,2
LDL (mmol/L): 3,44
Sodium (mEq/L): 142.0
Pro-BNP (ng/L): 211.0
Protein (g/L): 74
T3 (pg/dL): 0,05
T4 (ng/L): 14
Troponin (ng/mL): 0,01
TSH (mIU/L): 1,88
Urea (mg/dL): 7,8
LVEF (%): 24.0
Medications: Diabetes Medication, Beta Blockers, Loop Diuretics, Statins, ACE Inhibitor, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"RANKING: 
1. Survivor
REASONING:
Based on the provided patient data, the patient is at high risk for adverse cardiac events due to the presence of several comorbid conditions, including ischemic dilated cardiomyopathy, hypertension, diabetes, and peripheral vascular disease. The patient's LVEF of 24.0 indicates significant left ventricular dysfunction, which is a major predictor of mortality. The elevated troponin level (0.01 ng/mL) suggests some degree of myocardial injury, and the presence of ventricular extrasystoles on the ECG may indicate underlying cardiac instability.

Despite the presence of several risk factors, the patient has been classified as a survivor, which suggests that their current medical management and treatment plan are effective in managing their condition. The patient's NYHA Class II heart failure indicates that they have some limitation in physical activity due to their heart condition, but they are still able to perform daily activities without significant limitation.

The patient's laboratory results, such as the low T3 level and normal TSH, do not suggest any acute metabolic or thyroid disorders that could impact their cardiac function. The patient's medication regimen includes ACE inhibitors, beta blockers, and statins, which are commonly used to manage hypertension, heart failure, and lipid disorders, respectively. Overall, while the patient is at risk for adverse cardiac events, their current medical management and treatment plan appear to be effective, making survival the most likely outcome.

2. Sudden cardiac death
REASONING:
Sudden cardiac death is a possible outcome for this patient due to their significant left ventricular dysfunction (LVEF 24.0) and the presence of ventricular extrasystoles on the ECG. The patient's ischemic dilated cardiomyopathy and hypertension also increase the risk of cardiac arrhythmias and sudden cardiac death.

However, the patient's current medical management and treatment plan, including beta blockers and ACE inhibitors, are aimed at reducing the risk of cardiac arrhythmias and sudden cardiac death. The patient's troponin level is also relatively low, which suggests that they are not experiencing significant myocardial injury.

While the patient is at risk for sudden cardiac death, the presence of several factors that support survival, such as the patient's current medication regimen and the lack of evidence of acute myocardial injury, make sudden cardiac death less likely.

3. Pump failure death
REASONING:
Pump failure death is a possible outcome for this patient due to their significant left ventricular dysfunction (LVEF 24.0) and the presence of heart failure symptoms (NYHA Class II). The patient's elevated creatinine level (80.0 mg/dL) also suggests some degree of renal impairment, which can be associated with heart failure.

However, the patient's current medical management, including ACE inhibitors and loop diuretics, is aimed at managing heart failure symptoms and improving cardiac function. The patient's laboratory results, such as the low T3 level and normal TSH, do not suggest any acute metabolic or thyroid disorders that could impact their cardiac function.

Additionally, the patient's medication regimen, including beta blockers and statins, is aimed at reducing the risk of cardiac arrhythmias and sudden cardiac death. While the patient is at risk for pump failure, the presence of several factors that support survival, such as the patient's current medication regimen and the lack of evidence of acute myocardial injury, make pump failure death less likely."
8,8,P0010,"Age: 54
Gender: Male 
Weight: 88 kg
Height: 172 cm
NYHA Class: II
Blood Pressure: 140/90 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Diabetes, Dyslipemia, Hypertension, Myocardial Infarction
Albumin (g/L): 38,7
ALT or GPT (IU/L): 23.0
AST or GOT (IU/L): 16.0
Total Cholesterol (mmol/L): 4,91
Creatinine (mmol/L): 89.0
Gamma-glutamil transpeptidase (IU/L): 35
Glucose (mmol/L): 5,8
Hemoglobin (g/L): 142.0
HDL (mmol/L): 1,19
Potassium (mEq/L): 3,9
LDL (mmol/L): 3,26
Sodium (mEq/L): 142.0
Pro-BNP (ng/L): 361.0
Protein (g/L): 71
T3 (pg/dL): 0,06
T4 (ng/L): 16
Troponin (ng/mL): 0,01
TSH (mIU/L): 2,02
Urea (mg/dL): 7,57
LVEF (%): 22.0
Medications: Beta Blockers, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"RANKING: 
1. Survivor
REASONING: 
The patient has a history of ischemic dilated cardiomyopathy, which is a significant risk factor for sudden cardiac death and pump failure. However, the patient's current LVEF of 22% indicates a severe reduction in left ventricular function, suggesting advanced disease. Despite this, the patient's age (54) and relatively well-controlled comorbidities (beta blockers and ACE inhibitor) are favorable factors. The patient's troponin level is normal, and the ECG shows no signs of acute myocardial infarction or severe arrhythmias. Additionally, the patient's kidney function (creatinine level) is not severely impaired, which may indicate some residual renal function. Overall, the combination of advanced disease and well-controlled comorbidities suggests that the patient is at higher risk for pump failure but not necessarily sudden cardiac death. Therefore, the most likely outcome is survival.

RANKING: 
2. Pump failure death
REASONING: 
While the patient's LVEF is severely reduced, the patient is receiving beta blockers and ACE inhibitors, which can help manage symptoms and slow disease progression. The patient's kidney function is not severely impaired, and the ECG does not show signs of acute myocardial infarction or severe arrhythmias. However, the patient's advanced disease and reduced LVEF increase the risk of pump failure. The patient's troponin level is normal, but the presence of non-sustained ventricular tachycardia is a concerning sign. If the patient's condition worsens, pump failure could occur.

RANKING: 
3. Sudden cardiac death
REASONING: 
The patient's history of ischemic dilated cardiomyopathy, non-sustained ventricular tachycardia, and advanced LVEF (22%) make sudden cardiac death a significant risk. However, the patient's ECG shows no signs of acute myocardial infarction or severe arrhythmias, and the patient is receiving beta blockers and ACE inhibitors, which can help manage symptoms. The patient's kidney function is not severely impaired, and the troponin level is normal. While the patient's condition is precarious, the presence of well-controlled comorbidities and relatively preserved kidney function suggest that pump failure is more likely than sudden cardiac death."
9,9,P0013,"Age: 71
Gender: Female 
Weight: 70 kg
Height: 152 cm
NYHA Class: II
Blood Pressure: 140/80 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Hypertension
Albumin (g/L): 41,4
ALT or GPT (IU/L): 15.0
AST or GOT (IU/L): 20.0
Total Cholesterol (mmol/L): 4,29
Creatinine (mmol/L): 80.0
Gamma-glutamil transpeptidase (IU/L): 14
Glucose (mmol/L): 4,9
Hemoglobin (g/L): 118.0
HDL (mmol/L): 1,29
Potassium (mEq/L): 4
LDL (mmol/L): 2,56
Sodium (mEq/L): 141.0
Pro-BNP (ng/L): 653.0
Protein (g/L): 76
T3 (pg/dL): 0,05
T4 (ng/L): 16
Troponin (ng/mL): 0,01
TSH (mIU/L): 1,53
Urea (mg/dL): 9,8
LVEF (%): 39.0
Medications: Beta Blockers, Statins, ACE Inhibitor, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"RANKING: 1. Survivor 
REASONING: 

Based on the provided patient data, the patient is at a higher risk for cardiac events, but the presence of a low LVEF (39.0%) indicates significant left ventricular dysfunction. However, the patient is on multiple medications for their cardiac condition, including beta blockers, statins, and ACE inhibitors, which can help reduce the risk of cardiac events. The absence of any recent ECG abnormalities or elevated troponin levels suggests that the patient is not experiencing an acute cardiac event. The patient's age and NYHA class II classification also suggest that they are relatively stable, but the presence of ischemic dilated cardiomyopathy and hypertension indicate a higher risk for cardiac events. Considering these factors, the most likely prognosis is that the patient will survive, but with a high risk of cardiac events in the coming years.

RANKING: 2. Sudden cardiac death 
REASONING: 

While the patient is at a higher risk for cardiac events due to their underlying conditions, the absence of any recent ECG abnormalities or elevated troponin levels suggests that the patient is not experiencing an acute cardiac event. However, the patient's LVEF is significantly reduced, indicating poor left ventricular function, which increases the risk of sudden cardiac death. The patient's age and NYHA class II classification also increase the risk of cardiac events. Although the patient is on multiple medications, the presence of ischemic dilated cardiomyopathy and hypertension may still pose a risk for sudden cardiac death. However, the patient's current condition is stable, and the absence of any recent ECG abnormalities or elevated troponin levels suggests that the risk of sudden cardiac death is not imminent.

RANKING: 3. Pump failure death 
REASONING: 

The patient's LVEF is significantly reduced (39.0%), indicating poor left ventricular function, which increases the risk of heart failure. The patient's NYHA class II classification also suggests that they have some limitation in physical activity due to their cardiac condition. The patient's age and hypertension also increase the risk of heart failure. However, the patient is on multiple medications for their cardiac condition, including ACE inhibitors, which can help reduce the risk of heart failure. The absence of any recent ECG abnormalities or elevated troponin levels suggests that the patient is not experiencing an acute cardiac event. While the patient is at risk for heart failure, the patient's current condition is stable, and the presence of multiple medications may help mitigate this risk."
10,10,P0014,"Age: 50
Gender: Male 
Weight: 51 kg
Height: 164 cm
NYHA Class: III
Blood Pressure: 90/60 mmHg
Past Medical History: Enolic dilated cardiomyopathy, Peripheral vascular disease
Albumin (g/L): 42
ALT or GPT (IU/L): 12.0
AST or GOT (IU/L): 14.0
Total Cholesterol (mmol/L): 4,65
Creatinine (mmol/L): 100.0
Gamma-glutamil transpeptidase (IU/L): 14
Glucose (mmol/L): 4,2
Hemoglobin (g/L): 132.0
HDL (mmol/L): 1,01
Potassium (mEq/L): 4
LDL (mmol/L): 3,23
Sodium (mEq/L): 138.0
Pro-BNP (ng/L): 577.0
Protein (g/L): 64
T3 (pg/dL): 0,05
T4 (ng/L): 18
Troponin (ng/mL): 0,01
TSH (mIU/L): 1,77
Urea (mg/dL): 8,69
LVEF (%): 22.0
Medications: Spironolactone, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"RANKING: 
1. Survivor
REASONING:
Based on the provided patient data, the patient is likely to survive in the next few years. The key factors contributing to this prognosis are:

- The patient's NYHA Class III heart failure, which indicates moderate to severe heart failure, is being managed with spironolactone and an ACE inhibitor, suggesting that the patient is receiving appropriate treatment for their condition.
- The patient's LVEF is 22.0, which is a significant reduction in left ventricular function, but not severely low. This suggests that the patient's heart is still pumping, albeit inefficiently.
- The presence of non-sustained ventricular tachycardia (NSVT) on the ECG is concerning, but the absence of sustained VT and other arrhythmias suggests that the patient's cardiac function is not severely compromised.
- The patient's electrolyte levels, including potassium, are within relatively normal ranges, which is important for cardiac function.
- The patient's renal function, as indicated by the creatinine level of 8.69 mg/dL, is slightly elevated but not severely impaired.

While the patient's cardiac function is compromised, the presence of a relatively stable ECG, normal electrolyte levels, and the patient's ongoing management with spironolactone and an ACE inhibitor suggest that the patient is likely to survive in the next few years. However, close monitoring and adjustments to their treatment plan may be necessary to manage their heart failure and arrhythmias.

The other two prognoses (sudden cardiac death and pump failure death) are less likely due to the patient's ongoing treatment and the relatively stable ECG, but they cannot be entirely ruled out without further evaluation and monitoring."
11,11,P0015,"Age: 40
Gender: Male 
Weight: 98 kg
Height: 180 cm
NYHA Class: III
Blood Pressure: 100/80 mmHg
Past Medical History: Idiopathic dilated cardiomyopathy, Dyslipemia
Albumin (g/L): 39
ALT or GPT (IU/L): 26.0
AST or GOT (IU/L): 23.0
Total Cholesterol (mmol/L): 6,13
Creatinine (mmol/L): 88.0
Gamma-glutamil transpeptidase (IU/L): 26
Glucose (mmol/L): 4,5
Hemoglobin (g/L): 179.0
HDL (mmol/L): 1,16
Potassium (mEq/L): 4,3
LDL (mmol/L): 3,93
Sodium (mEq/L): 142.0
Pro-BNP (ng/L): 670.0
Protein (g/L): 69
T3 (pg/dL): 0,06
T4 (ng/L): 15
Troponin (ng/mL): 0,01
TSH (mIU/L): 0,83
Urea (mg/dL): 3,79
LVEF (%): 20.0
Medications: Digoxin, Loop Diuretics, Spironolactone, Statins, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"RANKING: 1. Survivor
REASONING: 

This patient has a complex clinical presentation, with a history of idiopathic dilated cardiomyopathy, which is a significant risk factor for cardiac events. The patient's left ventricular ejection fraction (LVEF) of 20% is severely reduced, indicating advanced left ventricular dysfunction. The presence of non-sustained ventricular tachycardia (NSVT) on the ECG, as well as the patient's NYHA Class III status, further increases the risk of cardiac events.

However, the patient's blood pressure is within a relatively normal range (100/80 mmHg), which is a positive factor in this context. The patient is also on multiple medications, including a beta-blocker (not explicitly stated, but likely implied by the presence of digoxin and ACE inhibitor), which can help reduce the risk of cardiac events.

Given the patient's advanced LVEF and NSVT, the risk of sudden cardiac death is significant. However, the presence of a normal blood pressure and the patient's overall clinical status, which includes being on multiple medications, suggest that the patient is likely to survive the next few years.

The patient's elevated troponin level (0.01 ng/mL) is not excessively high, and the TSH level is within the normal range, which suggests that the patient's cardiac function is not being significantly impaired by thyroid disease. The patient's creatinine level is also within a relatively normal range, which suggests that the patient's renal function is not severely impaired.

Overall, while the patient's clinical presentation is complex, the combination of a normal blood pressure, multiple medications, and a relatively low troponin level suggest that the patient is at lower risk for sudden cardiac death compared to pump failure death. Therefore, I rank the patient's prognosis as survivor.

RANKING: 2. Pump failure death
REASONING: 

The patient's severely reduced LVEF (20%) and NYHA Class III status indicate advanced left ventricular dysfunction, which increases the risk of heart failure. The patient's elevated creatinine level (3.79 mg/dL) also suggests that the patient's renal function may be impaired, which can contribute to fluid overload and worsen heart failure.

The patient's NSVT on the ECG is a significant risk factor for sudden cardiac death, but the patient's overall clinical status and the presence of multiple medications suggest that the patient is receiving adequate care to manage their cardiac function. However, the patient's advanced LVEF and NYHA Class III status still increase the risk of pump failure.

While the patient's troponin level is not excessively high, the patient's elevated creatinine level and NYHA Class III status suggest that the patient is at risk for pump failure. The patient's low HDL level (1.16 mmol/L) also suggests that the patient may be at higher risk for cardiovascular events.

Overall, the combination of advanced LVEF, NYHA Class III status, elevated creatinine level, and NSVT on the ECG suggest that the patient is at higher risk for pump failure.

RANKING: 3. Sudden cardiac death
REASONING: 

The patient's severely reduced LVEF (20%) and NYHA Class III status indicate advanced left ventricular dysfunction, which significantly increases the risk of sudden cardiac death. The patient's NSVT on the ECG is a direct indicator of an increased risk for ventricular arrhythmias, which can lead to sudden cardiac death.

The patient's elevated troponin level (0.01 ng/mL) and low T3 level (0.06 pg/dL) suggest that the patient's cardiac function is being impaired, which increases the risk of sudden cardiac death.

The patient's elevated creatinine level (3.79 mg/dL) and low HDL level (1.16 mmol/L) also suggest that the patient is at higher risk for cardiovascular events. The patient's blood pressure is within a relatively normal range (100/80 mmHg), but the presence of advanced LVEF and NYHA Class III status outweigh the positive factor of a normal blood pressure.

Overall, the combination of advanced LVEF, NYHA Class III status, NSVT on the ECG, elevated troponin level, and low T3 level suggest that the patient is at significantly higher risk for sudden cardiac death."
12,12,P0017,"Age: 58
Gender: Female 
Weight: 89 kg
Height: 157 cm
NYHA Class: II
Blood Pressure: 110/80 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Dyslipemia, Hypertension, Myocardial Infarction
Albumin (g/L): 43,8
ALT or GPT (IU/L): 22.0
AST or GOT (IU/L): 16.0
Total Cholesterol (mmol/L): 6,54
Creatinine (mmol/L): 91.0
Gamma-glutamil transpeptidase (IU/L): 20
Glucose (mmol/L): 5,6
Hemoglobin (g/L): 161.0
HDL (mmol/L): 1,09
Potassium (mEq/L): 4,9
LDL (mmol/L): 4,09
Sodium (mEq/L): 141.0
Pro-BNP (ng/L): 1108.0
Protein (g/L): 74
T3 (pg/dL): 0,05
T4 (ng/L): 17
Troponin (ng/mL): 0,01
TSH (mIU/L): 2,14
Urea (mg/dL): 8,02
LVEF (%): 21.0
Medications: Amiodarone, Angiotensin II Receptor Blocker, Beta Blockers, Statins, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"RANKING: 1. Survivor 
REASONING: 
Based on the patient's data, the patient is a 58-year-old female with a history of ischemic dilated cardiomyopathy, which is a condition where the heart muscle is weakened and cannot pump blood efficiently. The patient's left ventricular ejection fraction (LVEF) is 21.0%, which is significantly below the normal range (50-70%). This suggests that the patient's heart is not pumping blood effectively, and she is at risk for heart failure.

The patient's blood pressure is well-controlled at 110/80 mmHg, and she has no evidence of acute coronary syndrome or acute heart failure. Her electrolytes and liver enzymes are also within normal limits. The patient's medications, including amiodarone, beta blockers, and statins, are standard treatments for heart failure and arrhythmias.

The ECG impression shows ventricular extrasystoles, which are premature ventricular contractions, but no other arrhythmias. This suggests that the patient's heart is still functioning, but is at risk for arrhythmias.

Given these factors, the patient is likely to survive for the next few years. The patient's age and weight are also not extreme, and her kidney function is relatively preserved.

RANKING: 2. Sudden cardiac death 
REASONING: 
The patient's history of ischemic dilated cardiomyopathy and low LVEF make her at risk for sudden cardiac death. Additionally, the patient's elevated troponin levels (0.01 ng/mL) suggest some myocardial damage, which can increase the risk of arrhythmias and sudden cardiac death.

RANKING: 3. Pump failure death 
REASONING: 
While the patient's LVEF is significantly reduced, her blood pressure is well-controlled, and she is not showing any signs of acute heart failure. However, the patient's kidney function is slightly elevated (91.0 mmol/L), and her serum creatinine level is slightly elevated (8.02 mg/dL), which may indicate some degree of renal impairment. This could potentially lead to fluid overload and worsening heart failure over time. However, the patient's overall clinical presentation does not suggest immediate pump failure, and her survival is still likely."
13,13,P0019,"Age: 74
Gender: Male 
Weight: 95 kg
Height: 166 cm
NYHA Class: II
Blood Pressure: 110/80 mmHg
Past Medical History: Hypertensive cardiomyopathy, Hypertension
Albumin (g/L): 46,3
ALT or GPT (IU/L): 15.0
AST or GOT (IU/L): 22.0
Total Cholesterol (mmol/L): 6,08
Creatinine (mmol/L): 88.0
Gamma-glutamil transpeptidase (IU/L): 48
Glucose (mmol/L): 4,9
Hemoglobin (g/L): 160.0
HDL (mmol/L): 1,03
Potassium (mEq/L): 3,8
LDL (mmol/L): 3,88
Sodium (mEq/L): 138.0
Pro-BNP (ng/L): 1596.0
Protein (g/L): 80
T3 (pg/dL): 0,05
T4 (ng/L): 15
Troponin (ng/mL): 0,01
TSH (mIU/L): 2,99
Urea (mg/dL): 7,8
LVEF (%): 50.0
Medications: Calcium Channel Blocker, Beta Blockers, Digoxin, Loop Diuretics, ACE Inhibitor, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",survivor,"RANKING: 1. Survivor
REASONING: 
The patient's age (74 years) and NYHA Class II heart failure classification indicate that the patient has a moderate to severe level of heart failure. However, the patient's current ECG impression shows ventricular extrasystoles and non-sustained ventricular tachycardia, which are concerning for an increased risk of sudden cardiac death. Nevertheless, the patient is currently taking multiple medications, including beta blockers, ACE inhibitors, and calcium channel blockers, which are known to reduce the risk of sudden cardiac death. Additionally, the patient's Pro-BNP level (1596.0 ng/L) is elevated, but not excessively high, which suggests some degree of cardiac stress. The patient's creatinine level (88.0 mmol/L) is also slightly elevated, indicating some degree of renal impairment. However, the patient's hemoglobin level (16.0 g/L) is normal, and the patient's other laboratory values are within relatively normal limits. 

Considering the above factors, the patient's overall prognosis is that they will survive for the next few years, with a moderate risk of cardiac complications. However, the patient's ECG findings and elevated Pro-BNP level suggest that the patient is at increased risk of cardiac events, and close monitoring and adjustments to their treatment plan may be necessary to minimize this risk.

RANKING: 2. Sudden cardiac death
REASONING: 
The patient's ECG impression shows ventricular extrasystoles and non-sustained ventricular tachycardia, which are concerning for an increased risk of sudden cardiac death. The patient's age (74 years) and NYHA Class II heart failure classification also increase the risk of sudden cardiac death. Additionally, the patient's Pro-BNP level (1596.0 ng/L) is elevated, which suggests some degree of cardiac stress. However, the patient is currently taking multiple medications that can help reduce the risk of sudden cardiac death, such as beta blockers and ACE inhibitors.

RANKING: 3. Pump failure death
REASONING: 
The patient's NYHA Class II heart failure classification and elevated Pro-BNP level (1596.0 ng/L) suggest that the patient has a moderate to severe level of heart failure. However, the patient is currently taking multiple medications that can help manage heart failure, including loop diuretics and ACE inhibitors. Additionally, the patient's LVEF (50.0%) is slightly decreased, but not severely impaired. Considering the patient's overall clinical presentation and laboratory values, the risk of pump failure death is lower compared to the risk of sudden cardiac death."
14,14,P0020,"Age: 48
Gender: Male 
Weight: 77 kg
Height: 167 cm
NYHA Class: II
Blood Pressure: 145/80 mmHg
Past Medical History: Post-myocardial dilated cardiomyopathy, Dyslipemia
Albumin (g/L): 45,5
ALT or GPT (IU/L): 25.0
AST or GOT (IU/L): 17.0
Total Cholesterol (mmol/L): 6,44
Creatinine (mmol/L): 79.0
Gamma-glutamil transpeptidase (IU/L): 52
Glucose (mmol/L): 4,9
Hemoglobin (g/L): 137.0
HDL (mmol/L): 1,19
Potassium (mEq/L): 4,5
LDL (mmol/L): 4,22
Sodium (mEq/L): 135.0
Pro-BNP (ng/L): 322.0
Protein (g/L): 74
T3 (pg/dL): 0,05
T4 (ng/L): 13
Troponin (ng/mL): 0,01
TSH (mIU/L): 1,25
Urea (mg/dL): 6,45
LVEF (%): 28.0
Medications: Angiotensin II Receptor Blocker, Beta Blockers, Digoxin, Loop Diuretics
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"RANKING: 

1. Survivor
REASONING:
The patient has a history of post-myocardial dilated cardiomyopathy, which is a significant risk factor for cardiovascular events. However, the patient is currently being treated with medications such as Angiotensin II Receptor Blockers, Beta Blockers, and Digoxin, which are commonly used to manage heart failure and arrhythmias associated with cardiomyopathy. The patient's LVEF is 28.0%, which is relatively low, indicating impaired heart function. However, the patient is not in acute heart failure, as indicated by the absence of acute symptoms and the presence of a relatively stable vital sign profile. 

The patient's ECG findings, including ventricular extrasystole and non-sustained ventricular tachycardia, may suggest underlying cardiac arrhythmia, but the absence of sustained ventricular tachycardia and other arrhythmias reduces the risk of sudden cardiac death. The patient's biomarkers, such as troponin and BNP, are also relatively normal, indicating no acute myocardial injury or significant heart failure.

The patient's overall clinical presentation and laboratory results do not strongly suggest a high risk of sudden cardiac death or pump failure, and the patient is likely to survive in the short term. 

2. Sudden Cardiac Death
REASONING:
While the patient has a history of post-myocardial dilated cardiomyopathy and has ECG findings suggestive of cardiac arrhythmia, the patient is currently being treated with medications that are intended to manage these conditions. However, the patient's LVEF is low, which increases the risk of sudden cardiac death. The patient's ECG findings, including ventricular extrasystole and non-sustained ventricular tachycardia, also increase the risk of sudden cardiac death.

3. Pump Failure Death
REASONING:
The patient's low LVEF and history of post-myocardial dilated cardiomyopathy increase the risk of heart failure. However, the patient is currently being treated with medications that are intended to manage heart failure, and the patient's vital signs are relatively stable. While the patient's BNP levels are elevated, this is not uncommon in patients with heart failure, and the patient's ECG findings do not suggest acute heart failure. Therefore, while there is a risk of pump failure, the patient is unlikely to die from pump failure in the short term."
15,15,P0021,"Age: 67
Gender: Female 
Weight: 56 kg
Height: 146 cm
NYHA Class: II
Blood Pressure: 120/70 mmHg
Past Medical History: Idiopathic dilated cardiomyopathy, Diabetes, Dyslipemia, Hypertension
Albumin (g/L): 38,19
ALT or GPT (IU/L): 18.0
AST or GOT (IU/L): 21.0
Total Cholesterol (mmol/L): 4,11
Creatinine (mmol/L): 72.0
Gamma-glutamil transpeptidase (IU/L): 25
Glucose (mmol/L): 6,4
Hemoglobin (g/L): 121.0
HDL (mmol/L): 0,88
Potassium (mEq/L): 6,1
LDL (mmol/L): 1,06
Sodium (mEq/L): 139.0
Pro-BNP (ng/L): 568.0
Protein (g/L): 74
T3 (pg/dL): 0,05
T4 (ng/L): 15
Troponin (ng/mL): 0,01
TSH (mIU/L): 0,98
Urea (mg/dL): 5,79
LVEF (%): 36.0
Medications: Diabetes Medication, Beta Blockers, Digoxin, Loop Diuretics, Statins, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",survivor,"RANKING: 1. Survivor
REASONING:

Based on the provided patient data, the patient is a 67-year-old female with a history of idiopathic dilated cardiomyopathy, diabetes, dyslipemia, and hypertension. Her current NYHA Class II indicates that she has some limitation in physical activity due to her heart condition, but she is still able to perform daily activities without excessive shortness of breath.

Her laboratory results show elevated creatinine levels (72.0 mmol/L) and a low LVEF (36.0%), which indicate impaired renal function and reduced cardiac function, respectively. However, her blood pressure is well-controlled, and her medication regimen includes ACE inhibitors, which is a standard treatment for heart failure.

The ECG results show ventricular extrasystoles, which can be a sign of cardiac dysfunction, but there is no evidence of ventricular tachycardia or non-sustained ventricular tachycardia. The presence of ventricular extrasystoles may be a sign of underlying cardiac disease, but it is not necessarily a predictor of adverse outcomes.

The patient's laboratory results, including elevated creatinine and low LVEF, suggest that she has significant cardiac dysfunction. However, her controlled blood pressure and well-controlled diabetes, as well as her current medication regimen, suggest that she is receiving appropriate treatment for her condition.

Given these factors, I believe that the patient is most likely to survive for the next few years. The patient's age, comorbidities, and laboratory results suggest that she has a significant burden of disease, but her current treatment regimen and controlled blood pressure suggest that she is at moderate risk for cardiac events. Therefore, I rank the patient as having a high likelihood of survival.

RANKING: 2. Sudden Cardiac Death
REASONING:

While the patient's cardiac dysfunction and elevated creatinine levels suggest that she has a significant burden of disease, her well-controlled blood pressure and current medication regimen reduce the likelihood of sudden cardiac death. However, the presence of ventricular extrasystoles on the ECG may increase her risk for cardiac arrhythmias, which can contribute to sudden cardiac death.

The patient's age and comorbidities also increase her risk for sudden cardiac death. According to the American Heart Association, the risk of sudden cardiac death in patients with heart failure increases with age and is higher in patients with a history of myocardial infarction or other cardiac conditions.

While the patient's current ECG results do not show any evidence of ventricular tachycardia or non-sustained ventricular tachycardia, the presence of ventricular extrasystoles may increase her risk for cardiac arrhythmias. Therefore, I rank the patient as having a moderate likelihood of sudden cardiac death.

RANKING: 3. Pump Failure Death
REASONING:

The patient's low LVEF (36.0%) and elevated creatinine levels (72.0 mmol/L) suggest that she has significant cardiac dysfunction and impaired renal function, which can increase the risk of pump failure. However, her well-controlled blood pressure and current medication regimen suggest that she is receiving appropriate treatment for her condition.

The patient's age and comorbidities also increase her risk for pump failure. According to the American Heart Association, the risk of pump failure in patients with heart failure increases with age and is higher in patients with a history of myocardial infarction or other cardiac conditions.

While the patient's current ECG results do not show any evidence of ventricular tachycardia or non-sustained ventricular tachycardia, the presence of ventricular extrasystoles may increase her risk for cardiac arrhythmias, which can contribute to pump failure. Therefore, I rank the patient as having a low likelihood of pump failure."
16,16,P0022,"Age: 43
Gender: Male 
Weight: 130 kg
Height: 179 cm
NYHA Class: II
Blood Pressure: 140/100 mmHg
Past Medical History: Idiopathic dilated cardiomyopathy, Hypertension
Albumin (g/L): 46,5
ALT or GPT (IU/L): 100.0
AST or GOT (IU/L): 49.0
Total Cholesterol (mmol/L): 4,45
Creatinine (mmol/L): 83.0
Gamma-glutamil transpeptidase (IU/L): 35
Glucose (mmol/L): 4,9
Hemoglobin (g/L): 146.0
HDL (mmol/L): 1,22
Potassium (mEq/L): 3,9
LDL (mmol/L): 2,9
Sodium (mEq/L): 139.0
Pro-BNP (ng/L): 195.0
Protein (g/L): 75
T3 (pg/dL): 0,03
T4 (ng/L): 13
Troponin (ng/mL): 0,01
TSH (mIU/L): 2,46
Urea (mg/dL): 5,79
LVEF (%): 40.0
Medications: Angiotensin II Receptor Blocker, Spironolactone
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: TPSV
        - Bradycardia: No
            ",survivor,"RANKING: 1. Survivor
REASONING: 

Based on the provided patient data, the patient's prognosis is most likely to be a survivor. 

1. The patient's age (43) and NYHA Class II classification indicate that the patient is relatively young and has a moderate level of heart failure, but not severe enough to be classified as Class III or IV.

2. The patient's LVEF (40.0) is significantly reduced, which indicates left ventricular dysfunction. However, the patient is still able to maintain a relatively normal hemoglobin level (146.0 g/L), which suggests that the patient's cardiac output is not severely compromised.

3. The patient's biomarkers, such as Troponin (0.01 ng/mL) and Creatinine (5.79 mg/dL), are not excessively elevated, which suggests that there is no significant acute cardiac injury or renal impairment.

4. The patient's ECG findings, such as ventricular extrasystoles, non-sustained ventricular tachycardia, and paroxysmal supraventricular tachyarrhythmia, indicate a high risk of arrhythmias, but the patient is not experiencing any symptoms.

5. The patient is already taking medications for hypertension and heart failure, which suggests that the patient is receiving some level of management for their underlying conditions.

Considering these factors, the patient's prognosis is more likely to be a survivor, with ongoing management and monitoring of their cardiac function and arrhythmias.

RANKING: 2. Sudden cardiac death
REASONING: 

Based on the provided patient data, the patient's prognosis is moderately likely to be sudden cardiac death.

1. The patient's LVEF (40.0) is significantly reduced, which indicates left ventricular dysfunction and a high risk of cardiac events.

2. The patient's ECG findings, such as ventricular extrasystoles, non-sustained ventricular tachycardia, and paroxysmal supraventricular tachyarrhythmia, indicate a high risk of arrhythmias.

3. The patient's biomarkers, such as Troponin (0.01 ng/mL), are not excessively elevated, but the patient's Creatinine (5.79 mg/dL) is elevated, which suggests some degree of renal impairment.

4. The patient's NYHA Class II classification indicates moderate heart failure, which increases the risk of cardiac events.

5. The patient's age (43) is relatively young, which increases the risk of sudden cardiac death.

Considering these factors, the patient's prognosis is moderately likely to be sudden cardiac death, particularly if the patient experiences a cardiac event or arrhythmia that is not adequately managed.

RANKING: 3. Pump failure death
REASONING: 

Based on the provided patient data, the patient's prognosis is least likely to be pump failure death.

1. The patient's LVEF (40.0) is significantly reduced, which indicates left ventricular dysfunction, but the patient is still able to maintain a relatively normal hemoglobin level (146.0 g/L), which suggests that the patient's cardiac output is not severely compromised.

2. The patient's biomarkers, such as Troponin (0.01 ng/mL) and Creatinine (5.79 mg/dL), are not excessively elevated, which suggests that there is no significant acute cardiac injury or renal impairment.

3. The patient's ECG findings, such as ventricular extrasystoles, non-sustained ventricular tachycardia, and paroxysmal supraventricular tachyarrhythmia, indicate a high risk of arrhythmias, but the patient is not experiencing any symptoms.

4. The patient's NYHA Class II classification indicates moderate heart failure, but the patient is already taking medications for hypertension and heart failure, which suggests that the patient is receiving some level of management for their underlying conditions.

5. The patient's age (43) is relatively young, which reduces the risk of pump failure death.

Considering these factors, the patient's prognosis is least likely to be pump failure death, as the patient is already receiving management for their underlying conditions and is not experiencing any symptoms."
17,17,P0023,"Age: 76
Gender: Male 
Weight: 73 kg
Height: 158 cm
NYHA Class: II
Blood Pressure: 140/80 mmHg
Past Medical History: Idiopathic dilated cardiomyopathy, Dyslipemia, Hypertension
Albumin (g/L): 36,6
ALT or GPT (IU/L): 12.0
AST or GOT (IU/L): 12.0
Total Cholesterol (mmol/L): 5,87
Creatinine (mmol/L): 136.0
Gamma-glutamil transpeptidase (IU/L): 12
Glucose (mmol/L): 4,8
Hemoglobin (g/L): 139.0
HDL (mmol/L): 1,19
Potassium (mEq/L): 4,5
LDL (mmol/L): 4,22
Sodium (mEq/L): 139.0
Pro-BNP (ng/L): 188.0
Protein (g/L): 65
T3 (pg/dL): 0,04
T4 (ng/L): 17
Troponin (ng/mL): 0,01
TSH (mIU/L): 2,53
Urea (mg/dL): 11,13
LVEF (%): 37.0
Medications: Calcium Channel Blocker, ACE Inhibitor, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: TPSV
        - Bradycardia: Unknown bradycardia code
            ",survivor,"RANKING: 
1. Survivor
REASONING: 
Based on the provided patient data, the patient is 76 years old with a history of idiopathic dilated cardiomyopathy, hypertension, and dyslipemia. The patient has a moderate level of kidney function (creatinine 136.0 mmol/L) and a relatively low ejection fraction (LVEF 37.0%). The presence of non-sustained ventricular tachycardia (NSVT) and ventricular extrasystole on the ECG suggests underlying cardiac instability. However, the patient is currently taking a calcium channel blocker, ACE inhibitor, and nitrovasodilator, which may help control blood pressure and reduce the risk of cardiac events.

The patient's laboratory results show elevated liver enzymes (ALT and AST), which may indicate some degree of liver dysfunction. However, the patient's kidney function is not severely impaired, and the troponin level is within normal limits, suggesting that there is no significant myocardial infarction.

The patient's Pro-BNP level is elevated, indicating some degree of heart failure symptoms. However, the patient is classified as NYHA Class II, which suggests that the patient is still able to perform moderate physical activity without symptoms. The patient's hemoglobin level is slightly elevated, and the potassium level is within normal limits, which suggests that the patient does not have significant electrolyte imbalances.

Considering these factors, the patient is likely to survive for the next few years, given their relatively mild symptoms and the effectiveness of their current medication regimen. While the patient has a history of cardiac instability and some underlying cardiac dysfunction, the presence of symptoms is moderate, and the patient is currently receiving treatment that may help manage their condition.

The probability of sudden cardiac death is lower in this patient due to the following reasons:

* The patient is taking multiple medications that help control blood pressure and reduce the risk of cardiac events.
* The patient's ejection fraction is not severely impaired, which reduces the risk of sudden cardiac death.
* The patient's Pro-BNP level is elevated, but the patient is classified as NYHA Class II, which suggests that the patient is still able to perform moderate physical activity without symptoms.

The probability of pump failure death is higher than sudden cardiac death due to the following reasons:

* The patient has a history of idiopathic dilated cardiomyopathy, which is a condition that can lead to progressive heart failure.
* The patient's ejection fraction is significantly reduced (LVEF 37.0%), which indicates that the patient's heart is not pumping efficiently.
* The patient's Pro-BNP level is elevated, which suggests that the patient has some degree of heart failure symptoms.

However, the patient's relatively mild symptoms and the effectiveness of their current medication regimen may reduce the risk of pump failure death."
18,18,P0024,"Age: 58
Gender: Male 
Weight: 94 kg
Height: 188 cm
NYHA Class: II
Blood Pressure: 130/75 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Dyslipemia, Peripheral vascular disease, Hypertension, Myocardial Infarction
Albumin (g/L): 44,5
ALT or GPT (IU/L): 17.0
AST or GOT (IU/L): 22.0
Total Cholesterol (mmol/L): 5,48
Creatinine (mmol/L): 94.0
Gamma-glutamil transpeptidase (IU/L): 20
Glucose (mmol/L): 5,6
Hemoglobin (g/L): 143.0
HDL (mmol/L): 1,37
Potassium (mEq/L): 4
LDL (mmol/L): 3,62
Sodium (mEq/L): 142.0
Pro-BNP (ng/L): 492.0
Protein (g/L): 68
T3 (pg/dL): 0,06
T4 (ng/L): 17
Troponin (ng/mL): 0,01
TSH (mIU/L): 2,75
Urea (mg/dL): 7,12
LVEF (%): 37.0
Medications: Beta Blockers, Loop Diuretics, Statins
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: TPSV
        - Bradycardia: No
            ",survivor,"RANKING: 1. Survivor
REASONING: 

This patient has a complex medical history with ischemic dilated cardiomyopathy, which is a significant risk factor for heart failure and sudden cardiac death. However, the patient is currently on medications that are commonly used to manage heart failure and ischemic cardiomyopathy, such as beta blockers, loop diuretics, and statins. The patient's current ejection fraction (LVEF) is 37.0%, which is significantly reduced, indicating poor heart function.

Despite these factors, the patient's recent ECG impression shows no ventricular tachycardia or ventricular extrasystole, which are common causes of sudden cardiac death. Additionally, the patient's Pro-BNP level is elevated at 492.0 ng/L, which suggests some degree of heart failure. However, the patient's overall clinical presentation and laboratory results do not indicate any acute cardiac decompensation or severe cardiac dysfunction.

The patient's age and weight are also factors that need to be considered. A 58-year-old male with a BMI of 25.5 (calculated from weight and height) is considered to be at moderate risk for cardiovascular disease. The patient's past medical history of myocardial infarction and peripheral vascular disease also contribute to the overall risk of cardiovascular events.

Given these factors, I believe that the patient is at moderate to high risk for cardiovascular events, but the absence of acute cardiac decompensation and the presence of some protective factors (e.g., beta blockers, statins) suggest that the patient is more likely to survive in the short term. Therefore, I rank the patient as a survivor."
19,19,P0029,"Age: 58
Gender: Male 
Weight: 90 kg
Height: 166 cm
NYHA Class: II
Blood Pressure: 160/90 mmHg
Past Medical History: Hypertensive cardiomyopathy, Diabetes, Dyslipemia, Hypertension
Albumin (g/L): 45,59
ALT or GPT (IU/L): 45.0
AST or GOT (IU/L): 36.0
Total Cholesterol (mmol/L): 4,94
Creatinine (mmol/L): 176.0
Gamma-glutamil transpeptidase (IU/L): 50
Glucose (mmol/L): 9,1
Hemoglobin (g/L): 157.0
HDL (mmol/L): 0,59
Potassium (mEq/L): 4
LDL (mmol/L): 2,38
Sodium (mEq/L): 140.0
Pro-BNP (ng/L): 453.0
Protein (g/L): 72
T3 (pg/dL): 0,05
T4 (ng/L): 12
Troponin (ng/mL): 0,01
TSH (mIU/L): 24,3
Urea (mg/dL): 16,03
LVEF (%): 36.0
Medications: Beta Blockers, Digoxin, Loop Diuretics, Spironolactone, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",survivor,"RANKING: 1. Survivor
REASONING: The patient's overall clinical presentation and laboratory results suggest a severe underlying cardiac condition, with a history of hypertensive cardiomyopathy, hypertension, diabetes, and dyslipemia. The elevated blood pressure, elevated creatinine levels, and low ejection fraction (LVEF) of 36% indicate significant cardiac dysfunction. The presence of elevated troponin levels and BNP (pro-brain natriuretic peptide) levels further support the presence of heart failure. However, the patient is currently on multiple medications, including beta blockers, ACE inhibitors, and digoxin, which are commonly used to manage heart failure and hypertension. The patient's NYHA class is II, indicating moderate symptoms of heart failure.

While the patient's ECG shows ventricular extrasystoles, the absence of ventricular tachycardia or non-sustained ventricular tachycardia suggests that the patient's cardiac arrhythmias are not as severe as they could be. The patient's hemoglobin and potassium levels are within normal limits, which reduces the risk of cardiac arrhythmias.

Given the patient's overall clinical presentation and the fact that they are currently receiving treatment for their underlying conditions, the most likely outcome is that the patient will survive. The patient's prognosis is guarded, but not hopeless, and with continued medical management, it is possible that the patient's condition may improve.

RANKING: 2. Pump failure death
REASONING: Pump failure death is a possible outcome for this patient due to their severe cardiac dysfunction and heart failure. The patient's low LVEF and elevated BNP levels suggest that the patient's heart is not pumping efficiently, which increases the risk of pump failure. Additionally, the patient's history of hypertension and cardiomyopathy further increases the risk of cardiac complications.

However, the patient's current treatment regimen and the fact that they are receiving multiple medications to manage their underlying conditions reduce the risk of pump failure. The patient's NYHA class is also moderate, which suggests that the patient is not experiencing severe symptoms of heart failure.

RANKING: 3. Sudden cardiac death
REASONING: Sudden cardiac death is the least likely outcome for this patient. While the patient's ECG shows ventricular extrasystoles, the absence of ventricular tachycardia or non-sustained ventricular tachycardia suggests that the patient's cardiac arrhythmias are not as severe as they could be. Additionally, the patient's hemoglobin and potassium levels are within normal limits, which reduces the risk of cardiac arrhythmias.

The patient's overall clinical presentation and laboratory results suggest that the patient's cardiac condition is severe, but the patient is currently receiving treatment for their underlying conditions, which reduces the risk of sudden cardiac death. While the patient's prognosis is guarded, the patient's survival is more likely than sudden cardiac death."
20,20,P0032,"Age: 63
Gender: Male 
Weight: 85 kg
Height: 178 cm
NYHA Class: II
Blood Pressure: 140/85 mmHg
Past Medical History: Idiopathic dilated cardiomyopathy
Albumin (g/L): 42,4
ALT or GPT (IU/L): 19.0
AST or GOT (IU/L): 16.0
Total Cholesterol (mmol/L): 4,01
Creatinine (mmol/L): 135.0
Gamma-glutamil transpeptidase (IU/L): 14
Glucose (mmol/L): 4,2
Hemoglobin (g/L): 160.0
HDL (mmol/L): 0,98
Potassium (mEq/L): 4,8
LDL (mmol/L): 2,35
Sodium (mEq/L): 139.0
Pro-BNP (ng/L): 1045.0
Protein (g/L): 79
T3 (pg/dL): 0,04
T4 (ng/L): 14
Troponin (ng/mL): 0,01
TSH (mIU/L): 1,03
Urea (mg/dL): 7,8
LVEF (%): 27.0
Medications: Beta Blockers, Spironolactone, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: No
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",survivor,"RANKING: 1. Survivor
REASONING: 

Based on the provided patient data, I would rank the patient as having a high likelihood of survival for the next few years. The key factors contributing to this assessment are:

1. Age: Although the patient is 63 years old, which is considered advanced age, the fact that they are still alive and receiving medical treatment suggests that they are likely to continue living.
2. NYHA Class II: The patient's heart failure classification is moderate, indicating that they are experiencing some symptoms, but not severe. This suggests that they are still relatively active and may be able to tolerate certain treatments and lifestyle changes.
3. Medications: The patient is receiving beta blockers, spironolactone, and an ACE inhibitor, which are standard treatments for heart failure. These medications can help manage symptoms, slow disease progression, and improve quality of life.
4. Pro-BNP levels: Although the patient's pro-BNP levels are elevated, indicating some level of heart failure, they are not extremely high, suggesting that the patient's heart is still functioning to some extent.
5. ECG Impression: The absence of ventricular extrasystole, ventricular tachycardia, and non-sustained ventricular tachycardia suggests that the patient's heart rhythm is relatively stable.

While the patient's LVEF is significantly reduced (27%), this is not uncommon in patients with heart failure. With proper treatment and lifestyle modifications, it is possible for patients with reduced LVEF to experience improved symptoms and quality of life.

While there are some concerns, such as elevated creatinine levels and hyperkalemia, these can be managed with medications and lifestyle changes. Overall, based on the provided data, I believe that the patient has a high likelihood of survival for the next few years with proper management and care."
21,21,P0033,"Age: 52
Gender: Male 
Weight: 108 kg
Height: 175 cm
NYHA Class: II
Blood Pressure: 140/90 mmHg
Past Medical History: Idiopathic dilated cardiomyopathy
Albumin (g/L): 38,7
ALT or GPT (IU/L): 11.0
AST or GOT (IU/L): 9.0
Total Cholesterol (mmol/L): 3,7
Creatinine (mmol/L): 88.0
Gamma-glutamil transpeptidase (IU/L): 19
Glucose (mmol/L): 5,1
Hemoglobin (g/L): 155.0
HDL (mmol/L): 1,27
Potassium (mEq/L): 4,3
LDL (mmol/L): 2,07
Sodium (mEq/L): 142.0
Pro-BNP (ng/L): 1514.0
Protein (g/L): 68
T3 (pg/dL): 0,06
T4 (ng/L): 20
Troponin (ng/mL): 0,01
TSH (mIU/L): 2,52
Urea (mg/dL): 4,68
LVEF (%): 50.0
Medications: Amiodarone, Beta Blockers
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",survivor,"RANKING: 1. Survivor
REASONING: 

Based on the patient's data, the most likely prognosis is a survivor. The patient's NYHA Class II indicates that they have some symptoms of heart failure, but they are still able to perform moderate physical activities without significant limitation. The patient's LVEF is 50%, which is below the normal range, but it is not severely impaired. The patient is also taking beta blockers, which are commonly used to manage heart failure and reduce mortality risk.

The patient's laboratory results show elevated levels of BNP, which is a biomarker for heart failure, but it is not excessively elevated. The patient's creatinine level is also slightly elevated, which may indicate some degree of kidney dysfunction, but it is not severe.

The patient's ECG results show ventricular extrasystoles, which are common in patients with heart failure. However, there is no evidence of ventricular tachycardia or bradycardia, which are more ominous signs.

The patient's medication regimen includes amiodarone, which is used to treat certain types of arrhythmias, and beta blockers, which are used to reduce the workload on the heart and slow heart rate. These medications are commonly used in patients with heart failure and are associated with a reduced risk of mortality.

Overall, the patient's data suggests that they are at moderate risk for heart failure, but they are still alive and receiving treatment for their condition. Therefore, the most likely prognosis is that the patient will survive for the next few years.

RANKING: 2. Sudden cardiac death
REASONING: 

The patient's data does not show any obvious signs of a high risk for sudden cardiac death, such as a significantly low LVEF, a high troponin level, or a history of previous cardiac arrest. However, the patient's ECG results show ventricular extrasystoles, which are a risk factor for sudden cardiac death.

The patient's elevated BNP level and slightly elevated creatinine level may indicate some degree of heart failure, which can increase the risk of sudden cardiac death. However, these findings are not excessively severe, and the patient is receiving treatment for their condition.

The patient's medication regimen includes amiodarone, which is used to treat certain types of arrhythmias, but it is not a guarantee against sudden cardiac death.

Overall, while the patient's data suggests that they are at some risk for sudden cardiac death, the likelihood of this occurring in the next few years is relatively low.

RANKING: 3. Pump failure death
REASONING: 

The patient's data suggests that they are at moderate risk for pump failure death, given their NYHA Class II symptoms and slightly elevated BNP level. The patient's LVEF is also below the normal range, which may indicate some degree of left ventricular dysfunction.

The patient's medication regimen includes beta blockers, which are commonly used to reduce the workload on the heart and slow heart rate. However, these medications may not be sufficient to completely prevent pump failure.

The patient's ECG results show ventricular extrasystoles, which are a risk factor for pump failure. However, these findings are not excessively severe, and the patient is receiving treatment for their condition.

The patient's laboratory results show slightly elevated levels of creatinine and urea, which may indicate some degree of kidney dysfunction. This may increase the risk of pump failure.

Overall, while the patient's data suggests that they are at some risk for pump failure, the likelihood of this occurring in the next few years is relatively low."
22,22,P0036,"Age: 62
Gender: Male 
Weight: 82 kg
Height: 160 cm
NYHA Class: III
Blood Pressure: 110/80 mmHg
Past Medical History: Enolic dilated cardiomyopathy, Dyslipemia, Peripheral vascular disease, Hypertension
Albumin (g/L): 44,1
ALT or GPT (IU/L): 19.0
AST or GOT (IU/L): 17.0
Total Cholesterol (mmol/L): 6,52
Creatinine (mmol/L): 129.0
Gamma-glutamil transpeptidase (IU/L): 55
Glucose (mmol/L): 4,5
Hemoglobin (g/L): 117.0
HDL (mmol/L): 1,27
Potassium (mEq/L): 3,9
LDL (mmol/L): 4,27
Sodium (mEq/L): 142.0
Pro-BNP (ng/L): 924.0
Protein (g/L): 73
T3 (pg/dL): 0,05
T4 (ng/L): 18
Troponin (ng/mL): 0,01
TSH (mIU/L): 0,57
Urea (mg/dL): 15,36
LVEF (%): 30.0
Medications: Loop Diuretics, Spironolactone, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"RANKING: 
1. Survivor 
REASONING: 
The patient's overall clinical presentation and laboratory results suggest a significant cardiac impairment, with a left ventricular ejection fraction (LVEF) of 30%, indicating severe systolic dysfunction. The patient's history of dilated cardiomyopathy, hypertension, and dyslipidemia further supports this diagnosis. The elevated B-type natriuretic peptide (Pro-BNP) levels (924 ng/L) also suggest significant cardiac stress and strain.

The patient's current medications, including loop diuretics and an ACE inhibitor, indicate that the clinician is actively managing the patient's symptoms and attempting to reduce blood pressure and fluid overload. The absence of any acute cardiac events (e.g., ventricular tachycardia, non-sustained ventricular tachycardia, or paroxysmal supraventricular tachyarrhythmia) on the ECG suggests that the patient is not currently experiencing an acute cardiac crisis.

Given these factors, the most likely outcome for the patient over the next few years is survival, as the clinician is actively managing the patient's symptoms and the patient's underlying cardiac condition is not currently acute. However, it is essential to monitor the patient closely for signs of worsening cardiac function or acute cardiac events.

2. Sudden cardiac death 
REASONING: 
While the patient's current cardiac function is severely impaired, the absence of any acute cardiac events on the ECG and the fact that the patient is receiving ongoing medical therapy suggest that the likelihood of sudden cardiac death is relatively low. However, the patient's history of dilated cardiomyopathy and hypertension increases the risk of sudden cardiac death.

3. Pump failure death 
REASONING: 
Pump failure death is a possible outcome for this patient, given the patient's severe systolic dysfunction and history of heart failure. However, the patient is currently receiving medical therapy to manage symptoms and slow disease progression, which reduces the likelihood of pump failure death. The patient's elevated LVEF of 30% indicates a high risk of pump failure, but the patient's current clinical status and ongoing therapy suggest that the risk of pump failure death is lower than sudden cardiac death."
23,23,P0037,"Age: 71
Gender: Male 
Weight: 88 kg
Height: 174 cm
NYHA Class: II
Blood Pressure: 130/80 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Dyslipemia, Myocardial Infarction
Albumin (g/L): 44,8
ALT or GPT (IU/L): 16.0
AST or GOT (IU/L): 15.0
Total Cholesterol (mmol/L): 3,72
Creatinine (mmol/L): 98.0
Gamma-glutamil transpeptidase (IU/L): 25
Glucose (mmol/L): 4,9
Hemoglobin (g/L): 147.0
HDL (mmol/L): 0,85
Potassium (mEq/L): 4,1
LDL (mmol/L): 1,66
Sodium (mEq/L): 139.0
Pro-BNP (ng/L): 732.0
Protein (g/L): 66
T3 (pg/dL): 0,05
T4 (ng/L): 16
Troponin (ng/mL): 0,01
TSH (mIU/L): 1,9
Urea (mg/dL): 9,35
LVEF (%): 40.0
Medications: Beta Blockers, Statins, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: TPSV
        - Bradycardia: No
            ",survivor,"RANKING: 

1. Survivor
REASONING:
The patient's age, NYHA Class II, and LVEF of 40% indicate a moderate to severe left ventricular dysfunction. However, the patient is currently being treated with beta blockers, statins, and an ACE inhibitor, which are standard therapies for managing heart failure and reducing cardiovascular risk. The absence of significant electrolyte imbalances, anemia, or acute kidney injury suggests that the patient's cardiovascular system is currently tolerating the medications. The elevated Pro-BNP level of 732 ng/L indicates some degree of ventricular dysfunction, but it is not extremely elevated. The patient's hemoglobin level of 147 g/L is within the normal range, and the absence of significant anemia or hypoxia suggests that the patient's cardiac output is not severely compromised.

2. Sudden cardiac death
REASONING:
The patient's LVEF of 40% indicates significant left ventricular dysfunction, which increases the risk of sudden cardiac death. The presence of ventricular extrasystoles, specifically polymorphic ventricular extrasystoles, on the ECG impression raises concerns about the risk of ventricular arrhythmias. While the patient is on beta blockers, which can reduce the risk of arrhythmias, the presence of polymorphic ventricular extrasystoles suggests that the patient may still be at risk for life-threatening arrhythmias.

3. Pump failure death
REASONING:
The patient's LVEF of 40% and NYHA Class II indicate moderate to severe left ventricular dysfunction, which increases the risk of heart failure exacerbation and pump failure. However, the patient is currently being treated with medications that are aimed at reducing cardiovascular risk and improving cardiac function. The absence of significant electrolyte imbalances, anemia, or acute kidney injury suggests that the patient's cardiovascular system is currently tolerating the medications. While the patient's elevated Pro-BNP level indicates some degree of ventricular dysfunction, it is not extremely elevated, and the patient's hemoglobin level is within the normal range, suggesting that the patient's cardiac output is not severely compromised. Therefore, while pump failure is a risk, it is less likely than sudden cardiac death in this patient."
24,24,P0038,"Age: 69
Gender: Male 
Weight: 98 kg
Height: 188 cm
NYHA Class: II
Blood Pressure: 110/80 mmHg
Past Medical History: Idiopathic dilated cardiomyopathy, Dyslipemia, Hypertension
Albumin (g/L): 41,4
ALT or GPT (IU/L): 11.0
AST or GOT (IU/L): 17.0
Total Cholesterol (mmol/L): 4,45
Creatinine (mmol/L): 104.0
Gamma-glutamil transpeptidase (IU/L): 13
Glucose (mmol/L): 5,8
Hemoglobin (g/L): 132.0
HDL (mmol/L): 1,03
Potassium (mEq/L): 4,5
LDL (mmol/L): 2,72
Sodium (mEq/L): 139.0
Pro-BNP (ng/L): 458.0
Protein (g/L): 73
T3 (pg/dL): 0,04
T4 (ng/L): 18
Troponin (ng/mL): 0,01
TSH (mIU/L): 1,88
Urea (mg/dL): 3,79
LVEF (%): 40.0
Medications: Amiodarone, Angiotensin II Receptor Blocker, Beta Blockers, Loop Diuretics, Statins
ECG Impression:
        - Ventricular Extrasystole: No
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",survivor,"RANKING: 1. Survivor
REASONING:

This patient's data suggests a high risk of adverse outcomes. The key factors contributing to this risk are:

1. Low LVEF (40.0%): A left ventricular ejection fraction (LVEF) of 40% indicates severe left ventricular dysfunction, which is a strong predictor of adverse outcomes in patients with cardiomyopathy.
2. Pro-BNP (458.0 ng/L): Elevated B-type natriuretic peptide (BNP) levels are a marker of cardiac stress and are associated with increased mortality and morbidity in patients with heart failure.
3. Medications: The patient is taking multiple medications, including Amiodarone, which is used to treat arrhythmias, and Beta Blockers, which can worsen heart failure in patients with low LVEF.
4. Past Medical History: Idiopathic dilated cardiomyopathy and Hypertension are significant risk factors for adverse outcomes.

Despite these factors, the patient has a relatively good hemoglobin level (132 g/L) and normal blood pressure (110/80 mmHg), which may indicate a relatively preserved cardiac function. However, the combination of severe left ventricular dysfunction, elevated BNP levels, and multiple medications suggests that the patient is at high risk of adverse outcomes.

Given the patient's overall profile, I would rank the prognosis as a survivor, but with a high risk of complications, such as heart failure exacerbation or arrhythmias. Close monitoring and aggressive management of the patient's condition will be crucial to prevent adverse outcomes."
25,25,P0039,"Age: 73
Gender: Male 
Weight: 90 kg
Height: 175 cm
NYHA Class: III
Blood Pressure: 130/80 mmHg
Past Medical History: Hypertensive cardiomyopathy, Dyslipemia, Hypertension
Albumin (g/L): 41
ALT or GPT (IU/L): 10.0
AST or GOT (IU/L): 15.0
Total Cholesterol (mmol/L): 4,22
Creatinine (mmol/L): 116.0
Gamma-glutamil transpeptidase (IU/L): 20
Glucose (mmol/L): 5,6
Hemoglobin (g/L): 126.0
HDL (mmol/L): 0,78
Potassium (mEq/L): 3,4
LDL (mmol/L): 2,97
Sodium (mEq/L): 145.0
Pro-BNP (ng/L): 331.0
Protein (g/L): 71
T3 (pg/dL): 0,06
T4 (ng/L): 19
Troponin (ng/mL): 0,01
TSH (mIU/L): 1,45
Urea (mg/dL): 6,91
LVEF (%): 39.0
Medications: Beta Blockers, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",survivor,"RANKING: 
1. Survivor 
REASONING: 
Based on the patient's data, I would rank the patient as a survivor for the next few years. The patient's age is 73, which is considered advanced age, but the patient's NYHA class is III, indicating moderate symptoms of heart failure. However, the patient is receiving beta blockers and an ACE inhibitor, which are standard treatments for heart failure. The patient's LVEF is 39%, which is significantly reduced, indicating systolic heart failure. The patient's creatinine level is elevated at 116.0, suggesting some degree of renal impairment.

Despite these factors, the patient's troponin level is normal, and the ECG does not show any signs of ventricular tachycardia or other life-threatening arrhythmias. The patient's Pro-BNP level is elevated at 331.0, indicating some degree of heart failure. However, the patient is not on diuretics, which are often used to manage heart failure.

Given the patient's age, comorbidities, and the fact that the patient is already on medications for hypertension and heart failure, I would consider the patient to be at higher risk for adverse outcomes. However, the patient's overall condition and the absence of any life-threatening arrhythmias or acute cardiac events make survival possible.

The patient's weight, blood pressure, and lipid profile are not overly concerning, but the patient's renal impairment and elevated creatinine level may impact the patient's overall prognosis. The patient's TSH level is within the normal range, which suggests that the patient's thyroid function is not significantly impaired.

Overall, while the patient's prognosis is uncertain, I would rank the patient as a survivor for the next few years, but with a high degree of uncertainty and the need for close monitoring and adjustments to the patient's treatment plan as needed."
26,26,P0041,"Age: 78
Gender: Male 
Weight: 70 kg
Height: 159 cm
NYHA Class: II
Blood Pressure: 110/75 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Diabetes, Dyslipemia, Myocardial Infarction
Albumin (g/L): 51,8
ALT or GPT (IU/L): 9.0
AST or GOT (IU/L): 16.0
Total Cholesterol (mmol/L): 3,96
Creatinine (mmol/L): 117.0
Gamma-glutamil transpeptidase (IU/L): 22
Glucose (mmol/L): 6,6
Hemoglobin (g/L): 151.0
HDL (mmol/L): 1,14
Potassium (mEq/L): 4,7
LDL (mmol/L): 2,17
Sodium (mEq/L): 138.0
Pro-BNP (ng/L): 853.0
Protein (g/L): 81
T3 (pg/dL): 0,05
T4 (ng/L): 20
Troponin (ng/mL): 0,01
TSH (mIU/L): 1,72
Urea (mg/dL): 10,02
LVEF (%): 45.0
Medications: Calcium Channel Blocker, Loop Diuretics, Statins, ACE Inhibitor, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"RANKING: 

1. Survivor
REASONING: 
Based on the provided patient data, the patient's age (78 years) and NYHA Class II status suggest a relatively preserved functional capacity, which is a positive prognostic factor. The patient's LVEF of 45.0% indicates reduced left ventricular function, but the presence of medications such as ACE Inhibitor and Nitrovasodilator suggests optimal management of heart failure symptoms. The patient's creatinine level (117.0 mmol/L) is elevated, indicating some degree of kidney impairment, but this is not uncommon in patients with heart failure. The presence of Diabetes, Dyslipemia, and Ischemic dilated cardiomyopathy in the past medical history increases the risk of cardiovascular events, but the patient is receiving medications to manage these conditions. The Pro-BNP level of 853.0 ng/L is elevated, indicating some degree of ventricular stress, but not excessively high. The ECG findings do not indicate any life-threatening arrhythmias. Overall, the combination of optimal medication management, relatively preserved functional capacity, and no indication of severe ventricular dysfunction or life-threatening arrhythmias suggest a relatively favorable prognosis.

2. Sudden cardiac death
REASONING: 
The patient's elevated creatinine level (117.0 mmol/L) and reduced LVEF (45.0%) indicate some degree of cardiac dysfunction. The presence of Diabetes, Dyslipemia, and Ischemic dilated cardiomyopathy in the past medical history increases the risk of cardiovascular events. The elevated Pro-BNP level (853.0 ng/L) suggests some degree of ventricular stress. The patient's age (78 years) also increases the risk of cardiovascular events. While the patient is receiving medications to manage heart failure and cardiovascular risk factors, the combination of these factors and the patient's reduced LVEF suggests a higher risk of sudden cardiac death.

3. Pump failure death
REASONING: 
The patient's reduced LVEF (45.0%) and elevated creatinine level (117.0 mmol/L) indicate significant cardiac dysfunction. The presence of Diabetes, Dyslipemia, and Ischemic dilated cardiomyopathy in the past medical history increases the risk of heart failure exacerbation. The elevated Pro-BNP level (853.0 ng/L) suggests a high risk of heart failure exacerbation. The patient's age (78 years) also increases the risk of pump failure. The patient's NYHA Class II status indicates some degree of heart failure symptoms, but the presence of medications to manage heart failure suggests that the condition is being managed. However, the combination of these factors suggests a high risk of pump failure."
27,27,P0042,"Age: 60
Gender: Male 
Weight: 84 kg
Height: 168 cm
NYHA Class: II
Blood Pressure: 90/60 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Diabetes, Dyslipemia, Myocardial Infarction
Albumin (g/L): 43,6
ALT or GPT (IU/L): 23.0
AST or GOT (IU/L): 18.0
Total Cholesterol (mmol/L): 3,8
Creatinine (mmol/L): 81.0
Gamma-glutamil transpeptidase (IU/L): 32
Glucose (mmol/L): 6,3
Hemoglobin (g/L): 139.0
HDL (mmol/L): 0,93
Potassium (mEq/L): 4,1
LDL (mmol/L): 2,33
Sodium (mEq/L): 142.0
Pro-BNP (ng/L): 90.0
Protein (g/L): 67
T3 (pg/dL): 0,05
T4 (ng/L): 15
Troponin (ng/mL): 0,01
TSH (mIU/L): 1,7
Urea (mg/dL): 6,01
LVEF (%): 40.0
Medications: Beta Blockers, Statins, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"RANKING: 1. Survivor
REASONING: 
Based on the provided patient data, I would rank the patient as having a high likelihood of being a survivor. The patient's age (60) and NYHA Class II heart failure indicate a moderate level of cardiac impairment. However, the patient's left ventricular ejection fraction (LVEF) of 40.0% is relatively preserved, suggesting that the heart is still capable of pumping blood efficiently to some extent.

The patient's laboratory results show a slightly elevated creatinine level (81.0 mmol/L), which may indicate some degree of kidney dysfunction. However, the patient's electrolyte and liver function tests are largely within normal limits, and the troponin level (0.01 ng/mL) is not elevated, indicating no significant myocardial damage.

The patient's medication regimen, which includes beta blockers, statins, and an ACE inhibitor, is standard for managing heart failure and cardiovascular risk factors. The ECG impression shows no signs of ventricular tachycardia or arrhythmias, which are common predictors of sudden cardiac death.

Considering these factors, I believe that the patient is likely to survive for the next few years with proper management and monitoring. However, regular follow-up appointments and adjustments to the medication regimen may be necessary to optimize the patient's condition and prevent any potential complications.

RANKING: 2. Pump failure death
REASONING: 
While the patient's LVEF is relatively preserved, the patient's NYHA Class II heart failure classification indicates that the heart is still experiencing some level of impairment. The patient's elevated creatinine level (81.0 mmol/L) and slightly elevated troponin level (0.01 ng/mL) may indicate some degree of cardiac dysfunction.

Additionally, the patient's dyslipidemia, diabetes, and ischemic dilated cardiomyopathy may contribute to the development of heart failure. However, the patient's current medication regimen is standard for managing these conditions, and the ECG impression shows no signs of ventricular tachycardia or arrhythmias.

Given these factors, I would rank pump failure death as a possible outcome, but it is still less likely than survivorship. The patient's overall condition is stable, and with proper management, the patient may be able to maintain a good quality of life.

RANKING: 3. Sudden cardiac death
REASONING: 
Based on the provided data, I would rank sudden cardiac death as the least likely outcome. The patient's ECG impression shows no signs of ventricular tachycardia or arrhythmias, and the patient's medication regimen is standard for managing cardiovascular risk factors.

However, the patient's history of myocardial infarction and ischemic dilated cardiomyopathy may increase the risk of sudden cardiac death. Additionally, the patient's slightly elevated troponin level (0.01 ng/mL) may indicate some degree of cardiac dysfunction.

While these factors do increase the risk of sudden cardiac death, the patient's overall condition is relatively stable, and the patient's medication regimen is standard for managing cardiovascular risk factors. Therefore, I would rank sudden cardiac death as the least likely outcome."
28,28,P0044,"Age: 77
Gender: Male 
Weight: 87 kg
Height: 178 cm
NYHA Class: II
Blood Pressure: 90/60 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Dyslipemia, Myocardial Infarction
Albumin (g/L): 39,5
ALT or GPT (IU/L): 21.0
AST or GOT (IU/L): 20.0
Total Cholesterol (mmol/L): 3,85
Creatinine (mmol/L): 118.0
Gamma-glutamil transpeptidase (IU/L): 23
Glucose (mmol/L): 4,9
Hemoglobin (g/L): 148.0
HDL (mmol/L): 0,75
Potassium (mEq/L): 4,5
LDL (mmol/L): 1,94
Sodium (mEq/L): 142.0
Pro-BNP (ng/L): 1157.0
Protein (g/L): 70
T3 (pg/dL): 0,04
T4 (ng/L): 18
Troponin (ng/mL): 0,01
TSH (mIU/L): 1,99
Urea (mg/dL): 9,35
LVEF (%): 40.0
Medications: Calcium Channel Blocker, Beta Blockers, Loop Diuretics, Statins, ACE Inhibitor, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"RANKING: 
1. Survivor
REASONING: 
The patient has a history of ischemic dilated cardiomyopathy, which is a condition that weakens the heart's ability to pump blood effectively. This condition, combined with a left ventricular ejection fraction (LVEF) of 40%, indicates significant cardiac dysfunction. The presence of ventricular extrasystoles, non-sustained ventricular tachycardia (NSVT), and the patient's age (77 years) are also concerning factors. However, the patient's current medication regimen includes ACE inhibitors, beta blockers, and a calcium channel blocker, which are standard treatments for heart failure and arrhythmias.

The patient's electrolyte levels, liver enzymes, and renal function are relatively well within normal limits, and the patient's glucose and hemoglobin levels are not indicative of acute stress or significant anemia. The patient's troponin level is also within normal limits, which suggests that there is no acute myocardial infarction.

Considering these factors, the patient's overall condition is relatively stable, and the patient's current medications are effective in managing their heart failure and arrhythmias. Therefore, the most likely prognosis for this patient over the next few years is survival.

2. Sudden Cardiac Death
REASONING: 
While the patient has a history of ischemic dilated cardiomyopathy and ventricular arrhythmias, the patient's current medication regimen is adequate for managing these conditions. However, the patient's LVEF is significantly reduced, and the presence of NSVT is a concern. The patient's age and the presence of ventricular extrasystoles also increase the risk of sudden cardiac death.

3. Pump Failure Death
REASONING: 
The patient's LVEF is 40%, which is significantly reduced, indicating poor cardiac function. The patient's current medication regimen is aimed at managing heart failure and arrhythmias, but the patient's low LVEF and ventricular arrhythmias increase the risk of pump failure. However, the patient's overall condition is relatively stable, and the patient's current medications are effective in managing their heart failure and arrhythmias. Therefore, while pump failure is a concern, it is not the most likely outcome for this patient over the next few years."
29,29,P0045,"Age: 73
Gender: Male 
Weight: 83 kg
Height: 158 cm
NYHA Class: II
Blood Pressure: 130/80 mmHg
Past Medical History: Idiopathic dilated cardiomyopathy, Peripheral vascular disease, Hypertension
Albumin (g/L): 42,59
ALT or GPT (IU/L): 21.0
AST or GOT (IU/L): 19.0
Total Cholesterol (mmol/L): 5,69
Creatinine (mmol/L): 116.0
Gamma-glutamil transpeptidase (IU/L): 46
Glucose (mmol/L): 6,6
Hemoglobin (g/L): 170.0
HDL (mmol/L): 1,4
Potassium (mEq/L): 3,9
LDL (mmol/L): 3,21
Sodium (mEq/L): 144.0
Pro-BNP (ng/L): 390.0
Protein (g/L): 76
T3 (pg/dL): 0,06
T4 (ng/L): 18
Troponin (ng/mL): 0,01
TSH (mIU/L): 1,54
Urea (mg/dL): 6,24
LVEF (%): 40.0
Medications: Digoxin, Loop Diuretics, Spironolactone, ACE Inhibitor, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: TPSV
        - Bradycardia: No
            ",survivor,"RANKING: 1. Survivor
REASONING: 

This patient has a complex medical history with multiple comorbidities, including idiopathic dilated cardiomyopathy, peripheral vascular disease, and hypertension. Despite these conditions, the patient has been taking multiple medications, including ACE inhibitors and spironolactone, which suggests a concerted effort to manage the cardiovascular risk factors.

The patient's echocardiogram shows a left ventricular ejection fraction (LVEF) of 40%, which indicates significant left ventricular dysfunction. However, the presence of ventricular extrasystoles and non-sustained ventricular tachycardia on the ECG suggests that the patient is at risk for arrhythmias. The elevated B-type natriuretic peptide (Pro-BNP) level of 390 ng/L is also a marker of cardiac stress and strain.

Despite these concerns, the patient is currently stable, and the patient outcome is listed as ""survivor."" The fact that the patient is on multiple medications and has been stable for an extended period suggests that the patient is likely to continue to be managed effectively.

The patient's age, weight, and other laboratory results, such as the slightly elevated creatinine level and low HDL cholesterol, also suggest that the patient is at risk for cardiovascular events. However, the combination of these factors with the patient's current clinical status and treatment plan suggests that the patient is likely to survive for the next few years.

RANKING: 2. Sudden cardiac death
REASONING: 

The patient's history of ventricular extrasystoles and non-sustained ventricular tachycardia on the ECG increases the risk of sudden cardiac death. The presence of these arrhythmias, combined with the patient's significant left ventricular dysfunction and elevated BNP level, suggests that the patient is at high risk for cardiac events.

While the patient is currently stable, the presence of these arrhythmias and other risk factors increases the likelihood of a cardiac event. The patient's age, weight, and other laboratory results also contribute to the risk of cardiovascular events.

RANKING: 3. Pump failure death
REASONING: 

The patient's left ventricular ejection fraction (LVEF) of 40% indicates significant left ventricular dysfunction, which increases the risk of heart failure. The patient's elevated BNP level and elevated creatinine level also suggest that the patient is experiencing cardiac stress and strain.

While the patient is currently stable, the presence of significant left ventricular dysfunction and other risk factors increases the likelihood of heart failure. The patient's age and other laboratory results also contribute to the risk of cardiovascular events.

However, the patient's current clinical status and treatment plan suggest that the patient is being effectively managed, and the risk of pump failure death is lower than the risk of sudden cardiac death."
30,30,P0048,"Age: 60
Gender: Male 
Weight: 95 kg
Height: 172 cm
NYHA Class: III
Blood Pressure: 140/80 mmHg
Past Medical History: Idiopathic dilated cardiomyopathy, Dyslipemia, Hypertension
Albumin (g/L): 43,09
ALT or GPT (IU/L): 20.0
AST or GOT (IU/L): 20.0
Total Cholesterol (mmol/L): 3,9
Creatinine (mmol/L): 101.0
Gamma-glutamil transpeptidase (IU/L): 24
Glucose (mmol/L): 4,6
Hemoglobin (g/L): 148.0
HDL (mmol/L): 1,53
Potassium (mEq/L): 4,6
LDL (mmol/L): 1,91
Sodium (mEq/L): 142.0
Pro-BNP (ng/L): 603.0
Protein (g/L): 67
T3 (pg/dL): 0,05
T4 (ng/L): 14
Troponin (ng/mL): 0,01
TSH (mIU/L): 5
Urea (mg/dL): 9,8
LVEF (%): 38.0
Medications: Digoxin, Loop Diuretics, Spironolactone, Statins, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",survivor,"RANKING: 1. Survivor
REASONING: 

This patient is at high risk for adverse outcomes due to a combination of factors. The patient has a history of idiopathic dilated cardiomyopathy, which is a significant underlying condition that can lead to heart failure and arrhythmias. The patient's NYHA Class III indicates severe symptoms, and their LVEF of 38% suggests significant left ventricular dysfunction.

The patient's elevated troponin levels (0.01 ng/mL) may indicate some degree of myocardial injury, which could be related to the cardiomyopathy. The presence of ventricular extrasystoles, non-sustained VT, and NSVT suggests a high risk of arrhythmias, which can be life-threatening.

However, the patient is currently on medications that are standard for managing heart failure and arrhythmias, including digoxin, loop diuretics, spironolactone, statins, and an ACE inhibitor. These medications can help manage symptoms and reduce the risk of adverse outcomes.

Given the patient's age, weight, and comorbidities, a careful monitoring of their condition is necessary. Regular follow-up appointments with the cardiologist will be crucial to assess the patient's response to treatment and adjust the treatment plan as needed.

While the patient is at risk, the fact that the patient is currently a survivor suggests that with proper management and monitoring, it is possible to reduce the risk of adverse outcomes and improve the patient's quality of life.

RANKING: 2. Sudden Cardiac Death
REASONING: 

The patient's high risk factors for adverse outcomes, including idiopathic dilated cardiomyopathy, severe symptoms (NYHA Class III), and significant left ventricular dysfunction (LVEF 38%), make them a high-risk candidate for sudden cardiac death.

The presence of ventricular extrasystoles, non-sustained VT, and NSVT on the ECG impression further increases the risk of arrhythmias, which can be life-threatening. The patient's elevated troponin levels (0.01 ng/mL) and elevated creatinine (101.0 mmol/L) also suggest some degree of myocardial injury and possible cardiac dysfunction.

The patient's elevated BNP levels (603.0 ng/L) are also a marker of heart failure, which can increase the risk of arrhythmias and sudden cardiac death.

Given the patient's high-risk profile, it is essential to closely monitor their condition and adjust the treatment plan as needed to minimize the risk of sudden cardiac death.

RANKING: 3. Pump Failure Death
REASONING: 

While the patient's high-risk profile and the presence of significant left ventricular dysfunction (LVEF 38%) do increase the risk of pump failure, this is not the most likely outcome given the patient's current medical status.

The patient is currently on medications that are standard for managing heart failure, including loop diuretics, spironolactone, and ACE inhibitors, which can help manage symptoms and reduce the risk of pump failure.

The patient's elevated BNP levels (603.0 ng/L) suggest some degree of heart failure, but the patient's NYHA Class III symptoms indicate that they are still able to manage their symptoms with current treatment.

Given the patient's age, weight, and comorbidities, pump failure is a possible but not the most likely outcome, especially if the patient continues to receive proper medical management and monitoring."
31,31,P0050,"Age: 65
Gender: Male 
Weight: 90 kg
Height: 171 cm
NYHA Class: II
Blood Pressure: 130/80 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Diabetes, Dyslipemia, Hypertension, Myocardial Infarction
Albumin (g/L): 44,5
ALT or GPT (IU/L): 10.0
AST or GOT (IU/L): 12.0
Total Cholesterol (mmol/L): 3,39
Creatinine (mmol/L): 102.0
Gamma-glutamil transpeptidase (IU/L): 11
Glucose (mmol/L): 9,5
Hemoglobin (g/L): 136.0
HDL (mmol/L): 0,98
Potassium (mEq/L): 4,4
LDL (mmol/L): 2,07
Sodium (mEq/L): 145.0
Pro-BNP (ng/L): 758.0
Protein (g/L): 70
T3 (pg/dL): 0,04
T4 (ng/L): 12
Troponin (ng/mL): 0,01
TSH (mIU/L): 3,48
Urea (mg/dL): 10,47
LVEF (%): 40.0
Medications: Diabetes Medication, Beta Blockers, Statins, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: TPSV
        - Bradycardia: No
            ",survivor,"RANKING: 1. Survivor
REASONING:

Based on the provided patient data, I rank the patient as a survivor with a high probability. Here's the reasoning behind this assessment:

1. The patient's age (65) and NYHA Class II heart failure classification indicate that they have a moderate level of heart failure, but it is not severe enough to immediately predict a poor outcome.
2. The patient's LVEF (40.0%) is significantly reduced, indicating systolic heart failure, but it is not extremely low, which could suggest a better prognosis.
3. The presence of ischemic dilated cardiomyopathy and myocardial infarction in the patient's past medical history suggests a chronic condition that may have contributed to the current heart failure. However, the patient is already on medications for these conditions, which suggests that their management is being adequately addressed.
4. The patient's laboratory results, such as low albumin levels (44.5 g/L) and elevated creatinine levels (10.47 mg/dL), indicate some degree of malnutrition and renal impairment, which could impact their overall health. However, these findings do not necessarily indicate a high risk of mortality.
5. The absence of any recent myocardial infarction or other acute cardiac events, as indicated by the ECG findings (no ventricular tachycardia or ventricular extrasystole), suggests that the patient is not at high risk for sudden cardiac death.
6. The presence of beta blockers, statins, and ACE inhibitors, which are standard treatments for heart failure and coronary artery disease, suggests that the patient is receiving appropriate management for their conditions.

Overall, while the patient has significant underlying heart disease and multiple comorbidities, their current clinical status, medication regimen, and lack of recent acute cardiac events suggest that they are likely to survive for the next few years. However, close monitoring and ongoing management are essential to prevent further decline and optimize their quality of life."
32,32,P0052,"Age: 56
Gender: Male 
Weight: 104 kg
Height: 175 cm
NYHA Class: II
Blood Pressure: 100/60 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Dyslipemia, Myocardial Infarction
Albumin (g/L): 43,7
ALT or GPT (IU/L): 27.0
AST or GOT (IU/L): 16.0
Total Cholesterol (mmol/L): 4,32
Creatinine (mmol/L): 119.0
Gamma-glutamil transpeptidase (IU/L): 22
Glucose (mmol/L): 5,5
Hemoglobin (g/L): 148.0
HDL (mmol/L): 1,4
Potassium (mEq/L): 4,2
LDL (mmol/L): 2,38
Sodium (mEq/L): 140.0
Pro-BNP (ng/L): 402.0
Protein (g/L): 75
T3 (pg/dL): 0,03
T4 (ng/L): 20
Troponin (ng/mL): 0,01
TSH (mIU/L): 2,14
Urea (mg/dL): 10,02
LVEF (%): 30.0
Medications: Amiodarone, Loop Diuretics, Statins, ACE Inhibitor, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",survivor,"RANKING: 1. Survivor
REASONING: 

This patient is at high risk for cardiac events due to a history of ischemic dilated cardiomyopathy, myocardial infarction, and elevated left ventricular ejection fraction (LVEF) of 30%. The presence of non-sustained ventricular tachycardia (NSVT) and polymorphic ventricular extrasystole on ECG suggests underlying arrhythmogenic conditions. The patient's elevated troponin level and reduced LVEF indicate significant cardiac dysfunction. The use of medications such as amiodarone, loop diuretics, statins, ACE inhibitors, and nitrovasodilator suggests that the patient is being managed for heart failure and arrhythmias, but these medications alone may not be sufficient to prevent cardiac events.

The patient's laboratory results, including elevated creatinine, proteinuria, and low HDL cholesterol, suggest chronic kidney disease and metabolic syndrome, which further increase the risk of cardiovascular events. The patient's weight and height also suggest a high body mass index (BMI), which is a risk factor for cardiovascular disease.

Given the combination of these factors, I would rank the patient's prognosis as ""survivor"" with a high likelihood of experiencing cardiac events in the next few years, such as sudden cardiac death, heart failure exacerbation, or arrhythmias. Regular monitoring and close follow-up with the patient are essential to manage these risks and prevent adverse outcomes.

RANKING: 2. Sudden cardiac death
REASONING: 

The patient's history of ischemic dilated cardiomyopathy, myocardial infarction, and reduced LVEF of 30% make them at high risk for sudden cardiac death. The presence of non-sustained ventricular tachycardia (NSVT) and polymorphic ventricular extrasystole on ECG further increases this risk. The patient's elevated troponin level and reduced LVEF indicate significant cardiac dysfunction, which can increase the risk of sudden cardiac death.

The patient's medications, including amiodarone, do not provide sufficient protection against sudden cardiac death. The patient's laboratory results, including elevated creatinine and proteinuria, suggest chronic kidney disease, which can increase the risk of sudden cardiac death.

Given the patient's high-risk factors, I would rank the patient's prognosis as ""sudden cardiac death"" with a moderate to high likelihood in the next few years.

RANKING: 3. Pump failure death
REASONING: 

While the patient's reduced LVEF of 30% and history of heart failure suggest that they are at risk for pump failure, I would rank pump failure death as the least likely outcome in the next few years. The patient is currently being managed with medications that are designed to slow disease progression, including ACE inhibitors and diuretics.

The patient's laboratory results, including elevated creatinine and proteinuria, suggest chronic kidney disease, which can increase the risk of pump failure. However, the patient is also receiving medications to manage these conditions, and their kidney function is not severely impaired.

The patient's ECG results, including non-sustained ventricular tachycardia and polymorphic ventricular extrasystole, suggest underlying arrhythmogenic conditions that could increase the risk of sudden cardiac death. However, the patient's medications, including amiodarone, provide some protection against arrhythmias.

Given the patient's complex medical history and multiple risk factors, I would rank pump failure death as the least likely outcome in the next few years."
33,33,P0055,"Age: 60
Gender: Female 
Weight: 83 kg
Height: 165 cm
NYHA Class: II
Blood Pressure: 170/90 mmHg
Past Medical History: Hypertensive cardiomyopathy, Hypertension
Albumin (g/L): 44
ALT or GPT (IU/L): 24.0
AST or GOT (IU/L): 20.0
Total Cholesterol (mmol/L): 6,34
Creatinine (mmol/L): 74.0
Gamma-glutamil transpeptidase (IU/L): 44
Glucose (mmol/L): 5,3
Hemoglobin (g/L): 141.0
HDL (mmol/L): 1,47
Potassium (mEq/L): 4,4
LDL (mmol/L): 4,16
Sodium (mEq/L): 140.0
Pro-BNP (ng/L): 282.0
Protein (g/L): 73
T3 (pg/dL): 0,05
T4 (ng/L): 16
Troponin (ng/mL): 0,01
TSH (mIU/L): 3,21
Urea (mg/dL): 7,35
LVEF (%): 39.0
Medications: Beta Blockers, Statins, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"RANKING: 1. Survivor
REASONING: 

Based on the provided patient data, the patient's overall prognosis can be assessed as follows:

1. Age: The patient is 60 years old, which is considered middle-aged. However, the patient's age alone does not significantly impact the prognosis.

2. NYHA Class II: The patient's NYHA class indicates that the patient experiences some limitations in physical activity due to heart failure symptoms, but the patient is still able to perform moderate-intensity activities without symptoms.

3. Hypertensive cardiomyopathy and Hypertension: The patient has a history of hypertension, which is a significant risk factor for cardiovascular disease. However, the patient is currently being treated with beta blockers, statins, and an ACE inhibitor, which can help manage hypertension and heart failure symptoms.

4. Blood pressure: The patient's blood pressure is elevated at 170/90 mmHg, but the patient is being treated with medications to control hypertension.

5. LVEF: The left ventricular ejection fraction (LVEF) is 39%, which is significantly reduced. A reduced LVEF is a strong indicator of heart failure and a poor prognosis.

6. Pro-BNP: The patient's pro-BNP level is elevated at 282.0 ng/L, which suggests that the patient is experiencing heart failure symptoms.

Considering these factors, the patient's prognosis is more likely to be a survivor. The patient is being treated for hypertension and heart failure, and the patient's symptoms and laboratory results indicate that the patient is experiencing some level of heart failure. However, the patient is not showing any signs of severe heart failure or acute cardiac events, such as ventricular tachycardia or troponin elevation.

While the patient's LVEF is reduced, the patient is still being treated for heart failure, and the patient's symptoms and laboratory results do not indicate a sudden cardiac death or pump failure. Therefore, the most likely prognosis is that the patient will survive.

RANKING: 2. Sudden cardiac death
REASONING: 

The patient's LVEF is significantly reduced, and the patient is experiencing heart failure symptoms, which increases the risk of sudden cardiac death. However, the patient is being treated for hypertension and heart failure, which can help manage the patient's condition.

The patient's ECG impression shows ventricular extrasystole, which is a type of abnormal heart rhythm. However, the patient does not have any other significant ECG abnormalities, such as ventricular tachycardia or non-sustained ventricular tachycardia.

Considering these factors, the patient's prognosis is less likely to be sudden cardiac death. The patient is being treated for heart failure, and the patient's symptoms and laboratory results do not indicate a sudden cardiac event.

RANKING: 3. Pump failure death
REASONING: 

The patient's LVEF is significantly reduced, and the patient is experiencing heart failure symptoms, which increases the risk of pump failure. However, the patient is being treated for hypertension and heart failure, which can help manage the patient's condition.

The patient's ECG impression shows ventricular extrasystole, which is a type of abnormal heart rhythm. However, the patient does not have any other significant ECG abnormalities, such as ventricular tachycardia or non-sustained ventricular tachycardia.

Considering these factors, the patient's prognosis is less likely to be pump failure death. The patient is being treated for heart failure, and the patient's symptoms and laboratory results do not indicate a sudden cardiac event. The patient's LVEF is reduced, but the patient is still being treated, and the patient's ECG results do not indicate a significant arrhythmia.

However, considering the patient's reduced LVEF and the presence of ventricular extrasystole, the patient's prognosis is still at risk of pump failure death. The patient's reduced LVEF and ventricular extrasystole increase the risk of heart failure and pump failure, and the patient's symptoms and laboratory results do not indicate a sudden cardiac event."
34,34,P0060,"Age: 69
Gender: Female 
Weight: 85 kg
Height: 158 cm
NYHA Class: II
Blood Pressure: 130/80 mmHg
Past Medical History: Hypertensive cardiomyopathy, Diabetes, Dyslipemia, Hypertension
Albumin (g/L): 38,9
ALT or GPT (IU/L): 13.0
AST or GOT (IU/L): 12.0
Total Cholesterol (mmol/L): 5,15
Creatinine (mmol/L): 128.0
Gamma-glutamil transpeptidase (IU/L): 23
Glucose (mmol/L): 8,1
Hemoglobin (g/L): 126.0
HDL (mmol/L): 0,83
Potassium (mEq/L): 4,8
LDL (mmol/L): 3,08
Sodium (mEq/L): 138.0
Pro-BNP (ng/L): 538.0
Protein (g/L): 71
T3 (pg/dL): 0,04
T4 (ng/L): 19
Troponin (ng/mL): 0,01
TSH (mIU/L): 2,36
Urea (mg/dL): 10,24
LVEF (%): 24.0
Medications: Diabetes Medication, Beta Blockers, Digoxin, Loop Diuretics, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: No
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",survivor,"RANKING: 
1. Survivor 
REASONING: 

This patient's prognosis is ranked as a survivor due to the following factors:

- Age: While 69 is considered elderly, the patient's age alone does not significantly impact their prognosis.
- NYHA Class II: This indicates that the patient experiences some limitations in physical activity, but they are still able to perform daily activities without severe symptoms.
- Low LVEF (24.0%): A significantly reduced left ventricular ejection fraction (LVEF) is a strong indicator of heart failure. However, the patient's LVEF is not extremely low, which may suggest that the heart is still functional to some extent.
- Low Pro-BNP (538.0 ng/L): Brain natriuretic peptide (BNP) levels are a marker of heart failure. The patient's BNP level is not extremely elevated, which may indicate some degree of heart failure, but not severe heart failure.
- Presence of multiple comorbidities: The patient has multiple comorbidities, including hypertension, diabetes, and dyslipidemia, which can contribute to cardiovascular disease. However, the patient is receiving medications for these conditions, and their management may be under control.
- Medications: The patient is taking a comprehensive range of medications, including beta blockers, ACE inhibitors, and digoxin, which can help manage heart failure and other cardiovascular conditions.

While the patient has several risk factors and comorbidities, their overall clinical presentation and management plan suggest that they are likely to survive in the short term.

RANKING 2: Sudden cardiac death 
REASONING: 

The patient's low LVEF (24.0%) and elevated Pro-BNP level (538.0 ng/L) suggest that they may be at risk for heart failure. However, their overall prognosis is not as poor as it could be due to their NYHA Class II and the presence of multiple comorbidities.

RANKING 3: Pump failure death 
REASONING: 

The patient's low LVEF (24.0%) and elevated Pro-BNP level (538.0 ng/L) suggest that they may be at risk for heart failure. However, their NYHA Class II and the presence of multiple comorbidities may mitigate this risk. The patient's survival is more likely than pump failure death due to their current management plan and overall clinical presentation."
35,35,P0061,"Age: 60
Gender: Male 
Weight: 85 kg
Height: 175 cm
NYHA Class: II
Blood Pressure: 130/90 mmHg
Past Medical History: Enolic dilated cardiomyopathy, Hypertension
Albumin (g/L): 47,8
ALT or GPT (IU/L): 17.0
AST or GOT (IU/L): 14.0
Total Cholesterol (mmol/L): 5,22
Creatinine (mmol/L): 101.0
Gamma-glutamil transpeptidase (IU/L): 34
Glucose (mmol/L): 5,3
Hemoglobin (g/L): 139.0
HDL (mmol/L): 1,34
Potassium (mEq/L): 4,5
LDL (mmol/L): 3,18
Sodium (mEq/L): 142.0
Pro-BNP (ng/L): 701.0
Protein (g/L): 72
T3 (pg/dL): 0,07
T4 (ng/L): 22
Troponin (ng/mL): 0,01
TSH (mIU/L): 1,01
Urea (mg/dL): 10,02
LVEF (%): 38.0
Medications: Beta Blockers, Digoxin, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",survivor,"RANKING: 
1. Survivor
REASONING: 
The patient's overall clinical presentation and test results suggest a high risk of adverse outcomes. The patient has a history of dilated cardiomyopathy, hypertension, and a significant elevation in N-terminal pro-b-type natriuretic peptide (NT-proBNP) levels, indicating heart failure. The left ventricular ejection fraction (LVEF) is severely impaired at 38%, further supporting this diagnosis. Additionally, the presence of non-sustained ventricular tachycardia (NSVT) on the ECG is a concerning sign of ventricular arrhythmia risk.

The patient's medications, including beta blockers and ACE inhibitors, suggest a treatment strategy aimed at managing heart failure and reducing blood pressure. However, the presence of ventricular arrhythmias and impaired LVEF suggest that the patient is at high risk for cardiac events.

Given the patient's age, NYHA Class II status, and the presence of significant comorbidities, a survival prognosis of ""survivor"" is the most likely outcome. However, the patient's risk of adverse outcomes, including sudden cardiac death and pump failure, is still significant.

RANKING: 
2. Sudden cardiac death
REASONING: 
The patient's high risk of adverse outcomes is due in part to the presence of ventricular arrhythmias, including non-sustained ventricular tachycardia, which is a well-established predictor of sudden cardiac death in patients with heart failure. The patient's impaired LVEF and elevated NT-proBNP levels further increase the risk of cardiac events.

While the patient's current treatment regimen is aimed at managing heart failure and reducing blood pressure, the presence of ventricular arrhythmias and impaired LVEF suggests that the patient is at high risk for sudden cardiac death.

RANKING: 
3. Pump failure death
REASONING: 
While the patient's impaired LVEF and elevated NT-proBNP levels suggest a high risk of heart failure, the patient's current treatment regimen is aimed at managing heart failure, and the patient is currently on medications that are effective in reducing symptoms and improving outcomes.

However, the presence of ventricular arrhythmias and impaired LVEF increase the risk of cardiac events, including pump failure. Additionally, the patient's age and comorbidities increase the risk of mortality from pump failure. While pump failure is a possible outcome, it is less likely than sudden cardiac death given the patient's current treatment regimen and the presence of ventricular arrhythmias."
36,36,P0062,"Age: 81
Gender: Male 
Weight: 71 kg
Height: 164 cm
NYHA Class: II
Blood Pressure: 145/85 mmHg
Past Medical History: Hypertensive cardiomyopathy, Hypertension
Albumin (g/L): 35,6
ALT or GPT (IU/L): 24.0
AST or GOT (IU/L): 26.0
Total Cholesterol (mmol/L): 4,5
Creatinine (mmol/L): 119.0
Gamma-glutamil transpeptidase (IU/L): 7
Glucose (mmol/L): 4,9
Hemoglobin (g/L): 145.0
HDL (mmol/L): 0,96
Potassium (mEq/L): 4,4
LDL (mmol/L): 2,95
Sodium (mEq/L): 143.0
Pro-BNP (ng/L): 1399.0
Protein (g/L): 68
T3 (pg/dL): 0,03
T4 (ng/L): 12
Troponin (ng/mL): 0,02
TSH (mIU/L): 1,49
Urea (mg/dL): 15,15
LVEF (%): 52.0
Medications: Loop Diuretics, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",survivor,"RANKING: 

1. Survivor
REASONING: 
Given the patient's age, NYHA Class II, and the presence of Hypertensive cardiomyopathy, the patient's overall cardiovascular condition is relatively stable. The patient's ejection fraction (LVEF) is 52%, which is within the range of normal for an 81-year-old male. The patient's current medications, including loop diuretics and an ACE inhibitor, are standard treatments for managing hypertension and heart failure. The absence of ventricular tachycardia, non-sustained ventricular tachycardia, and bradycardia on the ECG impression suggests that the patient's heart rhythm is relatively stable. The elevated Pro-BNP level (1399 ng/L) indicates some degree of ventricular stress, but it is not indicative of severe heart failure. Overall, the patient's clinical presentation and laboratory results suggest that the patient is likely to survive for the next few years with proper management and monitoring.

2. Pump failure death
REASONING: 
The patient's elevated creatinine level (15.15 mg/dL) indicates some degree of renal impairment, which may be related to the patient's Hypertensive cardiomyopathy. While the patient is currently receiving loop diuretics and an ACE inhibitor, which are standard treatments for hypertension and heart failure, the patient's renal function is still compromised. The patient's LVEF of 52% is slightly below the normal range, which may indicate some degree of left ventricular dysfunction. The elevated Pro-BNP level (1399 ng/L) suggests that the patient's heart is working harder to pump blood, which may lead to further cardiac stress and potential failure. While the patient is currently not experiencing symptoms of heart failure, the presence of renal impairment and slightly reduced LVEF make pump failure a possible complication in the near future.

3. Sudden cardiac death
REASONING: 
The patient's ECG impression shows ventricular extrasystole (polymorphic), which is a type of abnormal heart rhythm that can increase the risk of sudden cardiac death. However, the absence of ventricular tachycardia, non-sustained ventricular tachycardia, and bradycardia on the ECG impression reduces the likelihood of sudden cardiac death. The patient's other laboratory results, including the normal LVEF and absence of elevated troponin levels, suggest that the patient's heart muscle is not under significant stress or damage. However, the presence of ventricular extrasystole (polymorphic) is a concerning sign that requires close monitoring and further evaluation to determine the underlying cause and risk of sudden cardiac death."
37,37,P0063,"Age: 55
Gender: Male 
Weight: 68 kg
Height: 167 cm
NYHA Class: II
Blood Pressure: 110/80 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Dyslipemia, Myocardial Infarction
Albumin (g/L): 44,4
ALT or GPT (IU/L): 13.0
AST or GOT (IU/L): 13.0
Total Cholesterol (mmol/L): 3,57
Creatinine (mmol/L): 75.0
Gamma-glutamil transpeptidase (IU/L): 36
Glucose (mmol/L): 6
Hemoglobin (g/L): 137.0
HDL (mmol/L): 0,88
Potassium (mEq/L): 4
LDL (mmol/L): 2,15
Sodium (mEq/L): 141.0
Pro-BNP (ng/L): 249.0
Protein (g/L): 69
T3 (pg/dL): 0,06
T4 (ng/L): 16
Troponin (ng/mL): 0,01
TSH (mIU/L): 2,94
Urea (mg/dL): 10,02
LVEF (%): 40.0
Medications: Beta Blockers, Statins, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"RANKING: 

1. Survivor
REASONING: 
Given the patient's age, NYHA Class II, and the presence of ischemic dilated cardiomyopathy, dyslipidemia, and myocardial infarction, the patient is at a higher risk for cardiac complications. However, the patient's current LVEF is 40%, which indicates significant left ventricular dysfunction. Despite this, the patient is taking beta blockers, statins, and ACE inhibitors, which are standard treatments for heart failure and coronary artery disease. The absence of signs of acute cardiac distress (e.g., ST-segment elevation, significant troponin elevation) and the presence of a relatively low level of troponin (0.01 ng/mL) suggest that the patient is not in acute heart failure. Additionally, the patient's ECG findings of ventricular extrasystoles and non-sustained ventricular tachycardia are concerning, but the absence of sustained ventricular tachycardia and other arrhythmias reduces the risk of sudden cardiac death. Overall, the patient's symptoms and test results suggest that they are likely to survive for the next few years, albeit with ongoing management of their cardiovascular risk factors.

2. Sudden Cardiac Death
REASONING: 
While the patient's ECG findings of ventricular extrasystoles and non-sustained ventricular tachycardia are concerning, the absence of sustained ventricular tachycardia and other arrhythmias reduces the risk of sudden cardiac death. However, the patient's LVEF is significantly reduced (40%), and the presence of ischemic dilated cardiomyopathy and previous myocardial infarction increases the risk of arrhythmias and sudden cardiac death. The patient's age and existing cardiovascular disease also increase the risk of cardiac complications. While the patient is taking beta blockers, statins, and ACE inhibitors, which are standard treatments for heart failure and coronary artery disease, the patient's overall risk factors and ECG findings make sudden cardiac death a possible but less likely outcome.

3. Pump Failure Death
REASONING: 
Given the patient's significant LVEF (40%), ischemic dilated cardiomyopathy, and previous myocardial infarction, pump failure death is a possible but less likely outcome in the short term. The patient is taking beta blockers, statins, and ACE inhibitors, which are standard treatments for heart failure and coronary artery disease, and the absence of acute cardiac distress (e.g., ST-segment elevation, significant troponin elevation) suggests that the patient is not currently in heart failure. However, the patient's overall risk factors and existing cardiovascular disease make pump failure death a possible outcome over the longer term. The patient's age and ECG findings also increase the risk of cardiac complications, but the patient's relatively low troponin level and absence of sustained ventricular tachycardia reduce the risk of sudden cardiac death, making pump failure death a less likely outcome in the short term."
38,38,P0064,"Age: 60
Gender: Male 
Weight: 102 kg
Height: 165 cm
NYHA Class: II
Blood Pressure: 160/80 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Hypertension, Myocardial Infarction
Albumin (g/L): 41,7
ALT or GPT (IU/L): 16.0
AST or GOT (IU/L): 16.0
Total Cholesterol (mmol/L): 4,68
Creatinine (mmol/L): 98.0
Gamma-glutamil transpeptidase (IU/L): 39
Glucose (mmol/L): 4,9
Hemoglobin (g/L): 149.0
HDL (mmol/L): 1,14
Potassium (mEq/L): 4
LDL (mmol/L): 2,72
Sodium (mEq/L): 142.0
Pro-BNP (ng/L): 125.0
Protein (g/L): 71
T3 (pg/dL): 0,05
T4 (ng/L): 13
Troponin (ng/mL): 0,01
TSH (mIU/L): 5,76
Urea (mg/dL): 8,02
LVEF (%): 45.0
Medications: Beta Blockers, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"RANKING: 1. Survivor
REASONING: The patient is classified as a survivor due to the absence of any life-threatening cardiac arrhythmias, such as ventricular tachycardia, non-sustained ventricular tachycardia, or ventricular extrasystoles. The patient's ECG impression is mostly normal, with no evidence of significant cardiac conduction abnormalities or ischemia. The absence of any of these potentially life-threatening arrhythmias, combined with the patient's stable vital signs and normal ECG, suggests that the patient is at low risk for sudden cardiac death.

Additionally, the patient's left ventricular ejection fraction (LVEF) of 45.0% is below the normal range, indicating some degree of left ventricular dysfunction, which is consistent with the patient's history of ischemic dilated cardiomyopathy. However, the patient's symptoms and ECG do not suggest acute myocardial infarction or significant ischemia, which would have likely led to a worse prognosis.

The patient's laboratory results, such as the elevated creatinine level, may indicate some degree of renal impairment, which could be related to the patient's underlying cardiac disease. However, this finding is not uncommon in patients with heart failure and does not necessarily impact the patient's immediate prognosis.

The patient's medication regimen, consisting of beta blockers and an ACE inhibitor, is standard therapy for patients with heart failure and hypertension, and does not suggest any significant gaps in management.

Overall, while the patient has a significant medical history and some degree of left ventricular dysfunction, the absence of life-threatening arrhythmias and the presence of stable vital signs and a normal ECG make a sudden cardiac death or pump failure death less likely, and a survivor prognosis is the most likely outcome."
39,39,P0067,"Age: 49
Gender: Female 
Weight: 82 kg
Height: 155 cm
NYHA Class: II
Blood Pressure: 120/75 mmHg
Past Medical History: Other HF etiology
Albumin (g/L): 43,8
ALT or GPT (IU/L): 24.0
AST or GOT (IU/L): 20.0
Total Cholesterol (mmol/L): 4,22
Creatinine (mmol/L): 132.0
Gamma-glutamil transpeptidase (IU/L): 19
Glucose (mmol/L): 5,7
Hemoglobin (g/L): 127.0
HDL (mmol/L): 1,42
Potassium (mEq/L): 3,9
LDL (mmol/L): 2,17
Sodium (mEq/L): 139.0
Pro-BNP (ng/L): 30.0
Protein (g/L): 75,8
T4 (ng/L): 17
TSH (mIU/L): 1,93
Urea (mg/dL): 13,64
LVEF (%): 37.0
Medications: Beta Blockers, Loop Diuretics, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"RANKING: 
1. Survivor
REASONING: 
This patient has a NYHA Class II heart failure, which indicates mild symptoms and the ability to perform daily activities with some limitations. The patient's LVEF is 37%, which is significantly reduced, indicating left ventricular dysfunction. However, the patient's blood pressure, electrolyte levels, and liver enzymes are within relatively normal limits. The patient is also taking medications that are commonly used in heart failure management, such as beta blockers, loop diuretics, and ACE inhibitors.

The patient's Pro-BNP level is elevated at 30 ng/L, which is a marker of heart failure. However, it is not excessively high, and the patient's symptoms are mild. The patient's creatinine level is elevated, but it is not significantly high, and the patient is on ACE inhibitors, which are beneficial for patients with kidney impairment.

Given these factors, the patient is likely to survive for the next few years with proper management and monitoring. The patient's overall health status, medication regimen, and relatively mild symptoms make a sudden cardiac death or pump failure death less likely. 

It is essential for the patient to continue adhering to their medication regimen, maintaining a healthy lifestyle, and monitoring their symptoms closely to minimize the risk of complications. Regular follow-up appointments with the cardiologist will be crucial to adjust the treatment plan as needed and address any potential issues promptly."
40,40,P0068,"Age: 71
Gender: Male 
Weight: 114 kg
Height: 163 cm
NYHA Class: II
Blood Pressure: 120/55 mmHg
Past Medical History: Idiopathic dilated cardiomyopathy, Diabetes, Dyslipemia, Hypertension
Albumin (g/L): 37
ALT or GPT (IU/L): 19.0
AST or GOT (IU/L): 19.0
Total Cholesterol (mmol/L): 4,68
Creatinine (mmol/L): 80.0
Gamma-glutamil transpeptidase (IU/L): 20
Glucose (mmol/L): 9
Hemoglobin (g/L): 148.0
HDL (mmol/L): 1,01
Potassium (mEq/L): 4,2
LDL (mmol/L): 2,61
Sodium (mEq/L): 140.0
Pro-BNP (ng/L): 1243.0
Protein (g/L): 58
T3 (pg/dL): 0,04
T4 (ng/L): 12
TSH (mIU/L): 3,23
Urea (mg/dL): 7,15
LVEF (%): 31.0
Medications: Diabetes Medication, Angiotensin II Receptor Blocker, Digoxin, Loop Diuretics, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",survivor,"RANKING: 1. Survivor
REASONING: 
The patient has a history of idiopathic dilated cardiomyopathy, which is a significant risk factor for heart failure and arrhythmias. However, the patient is currently on medications that target these conditions, including an ACE inhibitor and a beta-blocker (Digoxin). The presence of non-sustained ventricular tachycardia (NSVT) and polymorphic ventricular extrasystoles on the ECG suggests an increased risk of arrhythmias, but the patient is not experiencing any symptoms that would indicate a high risk of sudden cardiac death.

The patient's NYHA class is II, indicating some limitation of physical activity due to heart failure symptoms, but not severe. The patient's LVEF is 31%, which is significantly reduced, indicating poor cardiac function. However, the patient is not experiencing any acute decompensated heart failure symptoms.

The patient's laboratory results show elevated creatinine levels, which may indicate some degree of renal impairment, but this is not directly related to the heart. The patient's glucose and lipid profiles are also abnormal, but these are not directly related to the heart.

Given these factors, I believe that the patient is most likely to survive for the next few years, but close monitoring and adjustments to their medications and lifestyle may be necessary to manage their heart failure and arrhythmias.

RANKING: 2. Sudden Cardiac Death
REASONING: 
The patient's ECG shows non-sustained ventricular tachycardia (NSVT) and polymorphic ventricular extrasystoles, which are both significant risk factors for sudden cardiac death. The patient's LVEF is also significantly reduced, which increases the risk of arrhythmias.

However, the patient is not experiencing any acute symptoms that would indicate a high risk of sudden cardiac death. The patient's NYHA class is II, and they are not experiencing any symptoms of acute heart failure.

RANKING: 3. Pump Failure Death
REASONING: 
The patient's LVEF is significantly reduced, indicating poor cardiac function. The patient's NYHA class is II, indicating some limitation of physical activity due to heart failure symptoms. However, the patient is not experiencing any acute decompensated heart failure symptoms.

The patient's medications, including an ACE inhibitor and a beta-blocker, are effective in managing heart failure and reducing the risk of arrhythmias. The patient's laboratory results show no evidence of acute kidney injury or acute liver damage, which are common causes of pump failure.

Given these factors, I believe that the patient is less likely to experience pump failure death in the next few years, but close monitoring and adjustments to their medications and lifestyle may be necessary to manage their heart failure."
41,41,P0071,"Age: 58
Gender: Male 
Weight: 116 kg
Height: 186 cm
NYHA Class: II
Blood Pressure: 150/90 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Dyslipemia, Hypertension, Myocardial Infarction
Albumin (g/L): 42
ALT or GPT (IU/L): 28.0
AST or GOT (IU/L): 24.0
Total Cholesterol (mmol/L): 5,38
Creatinine (mmol/L): 100.0
Gamma-glutamil transpeptidase (IU/L): 58
Glucose (mmol/L): 6,8
Hemoglobin (g/L): 159.0
HDL (mmol/L): 1,03
Potassium (mEq/L): 4,1
LDL (mmol/L): 2,12
Sodium (mEq/L): 140.0
Pro-BNP (ng/L): 600.0
Protein (g/L): 71
T3 (pg/dL): 0,04
T4 (ng/L): 18
TSH (mIU/L): 1,54
Urea (mg/dL): 6,16
LVEF (%): 32.0
Medications: Amiodarone, Beta Blockers, Statins, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",survivor,"RANKING: 1. Survivor
REASONING: 

The patient's overall clinical presentation and test results indicate a significant level of cardiovascular disease, with a history of ischemic dilated cardiomyopathy, hypertension, and myocardial infarction. However, the patient is currently on medications that are commonly used to manage these conditions, including beta blockers, statins, and amiodarone, which suggests that the patient is being actively managed.

The patient's laboratory results show elevated levels of creatinine, indicating some degree of kidney dysfunction, but this is not uncommon in patients with cardiovascular disease. The patient's LVEF of 32% is significantly reduced, indicating a substantial impairment in cardiac function.

Despite these factors, the patient is still alive and has not shown any signs of acute cardiac distress or arrhythmias on the ECG. The presence of ventricular extrasystoles may be a sign of underlying cardiac disease, but it is not uncommon in patients with cardiac disease and may not necessarily indicate a high risk of sudden cardiac death.

Overall, the patient's clinical presentation and test results suggest that the patient is at high risk for cardiovascular events, but the patient's survival is still possible with continued medical management and monitoring.

RANKING: 2. Sudden cardiac death
REASONING: 

The patient's history of ischemic dilated cardiomyopathy, hypertension, and myocardial infarction increases the risk of sudden cardiac death. The patient's LVEF of 32% is significantly reduced, indicating a substantial impairment in cardiac function, which can increase the risk of arrhythmias and sudden cardiac death.

The patient's elevated creatinine level and kidney dysfunction may also increase the risk of sudden cardiac death, as kidney dysfunction can lead to electrolyte imbalances that can affect cardiac function.

The presence of ventricular extrasystoles on the ECG is a significant finding that may indicate an increased risk of arrhythmias, which can lead to sudden cardiac death.

However, the patient is still alive, and the presence of ventricular extrasystoles may not necessarily indicate a high risk of sudden cardiac death. The patient's medications and clinical presentation suggest that the patient is being actively managed, and the patient's survival is still possible with continued medical management and monitoring.

RANKING: 3. Pump failure death
REASONING: 

The patient's LVEF of 32% is significantly reduced, indicating a substantial impairment in cardiac function. This level of impairment increases the risk of heart failure, which can lead to pump failure.

The patient's history of ischemic dilated cardiomyopathy and hypertension also increases the risk of heart failure.

However, the patient is alive, and the presence of ventricular extrasystoles on the ECG may not necessarily indicate a high risk of pump failure. The patient's medications and clinical presentation suggest that the patient is being actively managed, and the patient's survival is still possible with continued medical management and monitoring.

Additionally, the patient's kidney dysfunction may not necessarily lead to pump failure, as the kidneys can adapt to the reduced cardiac output.

Overall, while the patient's clinical presentation and test results suggest a significant level of cardiovascular disease, the patient's survival is still possible with continued medical management and monitoring. The risk of pump failure death is possible, but it is not the most likely outcome given the patient's current clinical presentation."
42,42,P0072,"Age: 72
Gender: Female 
Weight: 54 kg
Height: 138 cm
NYHA Class: II
Blood Pressure: 160/80 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Myocardial Infarction
Albumin (g/L): 41,3
ALT or GPT (IU/L): 10.0
AST or GOT (IU/L): 17.0
Total Cholesterol (mmol/L): 7,06
Creatinine (mmol/L): 73.0
Gamma-glutamil transpeptidase (IU/L): 12
Glucose (mmol/L): 4,6
Hemoglobin (g/L): 130.0
HDL (mmol/L): 1,84
Potassium (mEq/L): 4,2
LDL (mmol/L): 4,65
Sodium (mEq/L): 147.0
Pro-BNP (ng/L): 697.0
Protein (g/L): 71
T3 (pg/dL): 0,04
T4 (ng/L): 17
TSH (mIU/L): 2,38
Urea (mg/dL): 4,33
LVEF (%): 68.0
Medications: Angiotensin II Receptor Blocker, Loop Diuretics
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: TPSV
        - Bradycardia: No
            ",survivor,"RANKING: 

1. Survivor
REASONING: 
The patient's age (72 years) and NYHA Class II heart failure classification suggest that they are at risk for cardiovascular events. However, their LVEF (68.0%) is still within a relatively preserved range, which indicates that the heart is still functioning to some extent. The presence of ischemic dilated cardiomyopathy and myocardial infarction in the past medical history increases the risk of future cardiovascular events. Nevertheless, the patient's current symptoms and ECG findings (ventricular extrasystole, non-sustained VT, and TPSV) do not indicate an immediate life-threatening arrhythmia. The patient is also on medications for heart failure (Angiotensin II Receptor Blocker and Loop Diuretics), which is likely helping to manage their symptoms. The elevated Pro-BNP level (697.0 ng/L) suggests some degree of heart failure, but it is not extremely elevated, which may indicate that the patient is still relatively stable. 

2. Sudden Cardiac Death
REASONING: 
The patient's past medical history of myocardial infarction and ischemic dilated cardiomyopathy increases the risk of sudden cardiac death. The presence of ventricular extrasystole and non-sustained VT on the ECG also raises concerns. However, the patient is already taking medications for heart failure, which may help to manage these risks. The patient's age (72 years) also increases the risk of sudden cardiac death.

3. Pump Failure Death
REASONING: 
While the patient's LVEF (68.0%) is slightly below the normal range, it is still within a relatively preserved range. The patient is also on medications for heart failure, which may help to manage symptoms and prevent pump failure. The elevated Pro-BNP level (697.0 ng/L) suggests some degree of heart failure, but it is not extremely elevated. The patient's weight (54 kg) is also relatively low, which may help to reduce the risk of pump failure. However, the patient's NYHA Class II classification indicates that they are experiencing some symptoms of heart failure, which may increase the risk of pump failure."
43,43,P0074,"Age: 65
Gender: Male 
Weight: 73 kg
Height: 171 cm
NYHA Class: II
Blood Pressure: 110/70 mmHg
Past Medical History: Idiopathic dilated cardiomyopathy
Albumin (g/L): 39,1
ALT or GPT (IU/L): 11.0
AST or GOT (IU/L): 22.0
Total Cholesterol (mmol/L): 4,58
Creatinine (mmol/L): 95.0
Gamma-glutamil transpeptidase (IU/L): 19
Glucose (mmol/L): 5,1
Hemoglobin (g/L): 119.0
HDL (mmol/L): 1,86
Potassium (mEq/L): 4,3
LDL (mmol/L): 2,38
Sodium (mEq/L): 140.0
Pro-BNP (ng/L): 2407.0
Protein (g/L): 65,9
T4 (ng/L): 16
TSH (mIU/L): 1,78
Urea (mg/dL): 9,32
LVEF (%): 25.0
Medications: Beta Blockers, Loop Diuretics, Spironolactone, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",survivor,"RANKING: 1. Survivor
REASONING: 

Based on the provided patient data, the patient's current condition appears to be stable, and the patient is already receiving treatment with beta blockers, loop diuretics, spironolactone, and an ACE inhibitor, which are standard treatments for patients with idiopathic dilated cardiomyopathy. The patient's NYHA class is II, indicating mild symptoms, and their LVEF is 25%, which is a relatively preserved ejection fraction. The elevated BNP levels (2407.0 ng/L) suggest some degree of ventricular stress, but it is not extremely high.

The patient's laboratory results show a relatively normal kidney function (creatinine 9.32 mg/dL), normal liver function (ALT 11.0 IU/L, AST 22.0 IU/L), and a slightly elevated total cholesterol level (4.58 mmol/L). The patient's electrolyte levels are within normal ranges, and their hemoglobin is slightly elevated.

The ECG results show ventricular extrasystole, which is a common finding in patients with idiopathic dilated cardiomyopathy, but it is not indicative of a high risk of sudden cardiac death. The absence of ventricular tachycardia, non-sustained ventricular tachycardia, and paroxysmal supraventricular tachyarrhythmia codes suggests that the patient does not have a high risk of arrhythmic events.

Given these factors, I would rank the patient's prognosis as a survivor, with a reasonable expectation of long-term survival with continued medical management and monitoring. The patient's current condition is stable, and with proper treatment, it is possible that the patient may experience some improvement in their symptoms and quality of life over the next few years.

RANKING: 2. Sudden cardiac death
REASONING: 

Although the patient is currently stable, their LVEF is significantly reduced (25%), which is a risk factor for sudden cardiac death. Additionally, the patient has a history of ventricular extrasystoles, which can increase the risk of ventricular arrhythmias. The patient's elevated BNP levels (2407.0 ng/L) suggest some degree of ventricular stress, which may increase the risk of arrhythmic events.

While the patient is receiving treatment with beta blockers, loop diuretics, spironolactone, and an ACE inhibitor, which are standard treatments for patients with idiopathic dilated cardiomyopathy, the patient's current medication regimen may not be sufficient to completely mitigate the risk of sudden cardiac death. The patient's electrolyte levels are relatively normal, but the patient's kidney function is slightly elevated, which may increase the risk of hyperkalemia and other electrolyte imbalances.

Given these factors, I would rank the patient's prognosis as a possible sudden cardiac death, with a moderate risk of arrhythmic events over the next few years.

RANKING: 3. Pump failure death
REASONING: 

Based on the patient's current condition, I would rank pump failure death as the least likely prognosis. The patient's LVEF is 25%, which is a relatively preserved ejection fraction, and the patient is receiving treatment with beta blockers, loop diuretics, spironolactone, and an ACE inhibitor, which are standard treatments for patients with idiopathic dilated cardiomyopathy.

However, the patient's elevated BNP levels (2407.0 ng/L) suggest some degree of ventricular stress, and the patient's kidney function is slightly elevated (creatinine 9.32 mg/dL), which may increase the risk of heart failure exacerbation. Additionally, the patient's elevated total cholesterol level (4.58 mmol/L) may increase the risk of atherosclerotic disease and cardiac events.

Given these factors, while pump failure death is a possible outcome, it is not the most likely prognosis for this patient. The patient's current condition is stable, and with continued medical management and monitoring, it is possible that the patient may experience some improvement in their symptoms and quality of life over the next few years."
44,44,P0075,"Age: 54
Gender: Male 
Weight: 82 kg
Height: 180 cm
NYHA Class: II
Blood Pressure: 105/74 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Myocardial Infarction
Albumin (g/L): 44,2
ALT or GPT (IU/L): 21.0
AST or GOT (IU/L): 24.0
Total Cholesterol (mmol/L): 6,18
Creatinine (mmol/L): 118.0
Gamma-glutamil transpeptidase (IU/L): 117
Glucose (mmol/L): 6,5
Hemoglobin (g/L): 148.0
HDL (mmol/L): 1,27
Potassium (mEq/L): 4
LDL (mmol/L): 3,75
Sodium (mEq/L): 142.0
Pro-BNP (ng/L): 1199.0
Protein (g/L): 76
T4 (ng/L): 11
TSH (mIU/L): 2,93
Urea (mg/dL): 9,65
LVEF (%): 32.0
Medications: Beta Blockers, Loop Diuretics, Statins, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: TPSV
        - Bradycardia: Unknown bradycardia code
            ",survivor,"RANKING: 1. Survivor
REASONING: The patient has a history of ischemic dilated cardiomyopathy, myocardial infarction, and a left ventricular ejection fraction (LVEF) of 32%, indicating significant left ventricular dysfunction. However, the patient is on beta blockers, loop diuretics, statins, and ACE inhibitors, which are standard treatments for heart failure and coronary artery disease. The patient's current ECG findings, including ventricular extrasystole and TPSV, are concerning for arrhythmias, but not indicative of an immediate life-threatening condition. The patient's hemoglobin, potassium, and liver function tests are relatively normal, and the patient's creatinine level is elevated but not severely impaired. The patient's Pro-BNP level is elevated, indicating some degree of heart failure, but not excessively high. Given the patient's overall clinical presentation and treatment, the likelihood of sudden cardiac death or pump failure death is lower compared to the other two prognoses. Therefore, the most likely outcome is survival.

RANKING: 2. Sudden Cardiac Death
REASONING: The patient's history of ischemic dilated cardiomyopathy and myocardial infarction increases the risk of sudden cardiac death. The patient's LVEF of 32% is also a significant concern, as it indicates poor cardiac function and increased risk of arrhythmias. The patient's ECG findings, including ventricular extrasystole and TPSV, suggest an increased risk of arrhythmias. Additionally, the patient's elevated Pro-BNP level and elevated creatinine level indicate some degree of cardiac dysfunction and renal impairment, which can increase the risk of sudden cardiac death. While the patient is on standard treatments for heart failure and coronary artery disease, the combination of these factors makes sudden cardiac death a possible outcome.

RANKING: 3. Pump Failure Death
REASONING: The patient's elevated Pro-BNP level and elevated creatinine level indicate some degree of cardiac dysfunction and renal impairment, which can increase the risk of pump failure. However, the patient is on beta blockers, loop diuretics, statins, and ACE inhibitors, which are standard treatments for heart failure. The patient's LVEF of 32% is also a concern, but the patient is not in acute heart failure, and the patient's symptoms are not severe. The patient's ECG findings, including ventricular extrasystole and TPSV, are concerning for arrhythmias, but not indicative of an immediate life-threatening condition. Therefore, while pump failure is a possible outcome, it is less likely compared to sudden cardiac death given the patient's overall clinical presentation."
45,45,P0076,"Age: 72
Gender: Male 
Weight: 90 kg
Height: 170 cm
NYHA Class: II
Blood Pressure: 145/90 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Dyslipemia, Peripheral vascular disease, Hypertension, Myocardial Infarction
Albumin (g/L): 43
ALT or GPT (IU/L): 24.0
AST or GOT (IU/L): 17.0
Total Cholesterol (mmol/L): 5,4
Creatinine (mmol/L): 180.0
Gamma-glutamil transpeptidase (IU/L): 66
Glucose (mmol/L): 5,9
Hemoglobin (g/L): 147.0
HDL (mmol/L): 1,11
Potassium (mEq/L): 5
LDL (mmol/L): 3,47
Sodium (mEq/L): 145.0
Pro-BNP (ng/L): 997.0
Protein (g/L): 69,9
T4 (ng/L): 15
TSH (mIU/L): 0,8
Urea (mg/dL): 9,48
LVEF (%): 35.0
Medications: Angiotensin II Receptor Blocker, Beta Blockers, Statins, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"RANKING: 

1. Survivor
REASONING: 
Given the patient's age (72 years), NYHA Class II heart failure, history of ischemic dilated cardiomyopathy, and elevated Pro-BNP levels (997.0 ng/L), which indicates significant ventricular stress, the patient is at high risk for cardiac complications. However, the patient is also on multiple medications, including beta blockers, which are known to improve survival in heart failure patients. Additionally, the patient's LVEF (35.0%) is not extremely low, which suggests some residual cardiac function. The patient's other laboratory values, such as normal TSH and hemoglobin levels, do not indicate acute kidney injury or significant anemia. The presence of ventricular extrasystoles and non-sustained ventricular tachycardia (CH>10) on ECG is concerning, but the patient is already on beta blockers, which may help manage these arrhythmias. Overall, while the patient is at risk, the combination of multiple medications and some residual cardiac function suggest a relatively better prognosis.

2. Sudden cardiac death
REASONING: 
The patient's age, NYHA Class II heart failure, and history of ischemic dilated cardiomyopathy increase the risk of sudden cardiac death. The elevated Pro-BNP levels and the presence of ventricular extrasystoles and non-sustained ventricular tachycardia on ECG also suggest an increased risk of arrhythmic events. However, the patient's LVEF is not extremely low, and the patient is on multiple medications that may help manage these risks. The patient's laboratory values, such as normal TSH and hemoglobin levels, do not indicate acute kidney injury or significant anemia. The patient's elevated creatinine level (180.0 mol/L) may indicate some degree of kidney impairment, but this is not uncommon in patients with heart failure.

3. Pump failure death
REASONING: 
The patient's NYHA Class II heart failure, elevated Pro-BNP levels, and elevated creatinine level suggest a significant risk of pump failure. The patient's LVEF (35.0%) is also relatively low, indicating some degree of cardiac dysfunction. The patient's history of ischemic dilated cardiomyopathy and hypertension may have contributed to the development of heart failure. While the patient is on multiple medications, including beta blockers and statins, which are known to improve survival in heart failure patients, the patient's elevated blood pressure (145/90 mmHg) and elevated LDL cholesterol (3.47 mmol/L) may not be adequately controlled. The presence of ventricular extrasystoles and non-sustained ventricular tachycardia on ECG also increases the risk of cardiac events. Overall, the combination of these factors suggests a higher risk of pump failure."
46,46,P0077,"Age: 63
Gender: Female 
Weight: 65 kg
Height: 152 cm
NYHA Class: III
Blood Pressure: 105/60 mmHg
Past Medical History: Idiopathic dilated cardiomyopathy, Dyslipemia
Albumin (g/L): 41
ALT or GPT (IU/L): 7.0
AST or GOT (IU/L): 18.0
Total Cholesterol (mmol/L): 5,59
Creatinine (mmol/L): 111.0
Gamma-glutamil transpeptidase (IU/L): 14
Glucose (mmol/L): 4,8
Hemoglobin (g/L): 137.0
HDL (mmol/L): 1,63
Potassium (mEq/L): 4,7
LDL (mmol/L): 3,39
Sodium (mEq/L): 144.0
Pro-BNP (ng/L): 2093.0
Protein (g/L): 74
T3 (pg/dL): 0,05
T4 (ng/L): 15
Troponin (ng/mL): 0,01
TSH (mIU/L): 4,05
Urea (mg/dL): 11,58
LVEF (%): 30.0
Medications: Loop Diuretics, Spironolactone, Statins, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",survivor,"RANKING: 1. Survivor
REASONING: The patient's overall clinical presentation and test results suggest a high likelihood of survival. The patient has a history of idiopathic dilated cardiomyopathy, which is a significant underlying condition that can lead to heart failure. However, the patient is currently being treated with medications, including loop diuretics, spironolactone, statins, and an ACE inhibitor, which are standard treatments for heart failure and cardiomyopathy. The patient's LVEF is 30.0%, which is a relatively low ejection fraction, indicating some degree of heart failure. However, the patient's NYHA class is III, which suggests moderate symptoms of heart failure.

The patient's laboratory results show elevated creatinine levels, which may indicate some degree of renal impairment, but this is not uncommon in patients with heart failure. The patient's electrolyte and liver function tests are relatively normal, and the troponin level is within normal limits, which suggests that there is no acute myocardial infarction.

The ECG results show a polymorphic ventricular extrasystole and non-sustained ventricular tachycardia, which are both concerning for arrhythmias. However, the patient's ventricular tachycardia is non-sustained, which reduces the risk of sudden cardiac death. The patient's paroxysmal supraventricular tachyarrhythmia is unknown, but this is not uncommon in patients with heart failure.

Overall, the patient's combination of heart failure, cardiomyopathy, and arrhythmias suggests a high risk of adverse outcomes, but the patient's current treatment regimen and relatively stable laboratory results suggest that the patient is likely to survive for the next few years."
47,47,P0080,"Age: 72
Gender: Male 
Weight: 66 kg
Height: 163 cm
NYHA Class: II
Blood Pressure: 120/60 mmHg
Past Medical History: Idiopathic dilated cardiomyopathy, Dyslipemia, Hypertension
Albumin (g/L): 38,9
ALT or GPT (IU/L): 21.0
AST or GOT (IU/L): 21.0
Total Cholesterol (mmol/L): 6,21
Creatinine (mmol/L): 103.0
Gamma-glutamil transpeptidase (IU/L): 49
Glucose (mmol/L): 6,3
Hemoglobin (g/L): 148.0
HDL (mmol/L): 1,4
Potassium (mEq/L): 4,2
LDL (mmol/L): 3,88
Sodium (mEq/L): 140.0
Pro-BNP (ng/L): 183.0
Protein (g/L): 65
T3 (pg/dL): 0,04
T4 (ng/L): 14
Troponin (ng/mL): 0,01
TSH (mIU/L): 2,11
Urea (mg/dL): 7,57
LVEF (%): 38.0
Medications: Loop Diuretics, Spironolactone
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: TPSV
        - Bradycardia: No
            ",survivor,"RANKING: 1. Survivor
REASONING: 

Based on the patient's data, I would rank the patient as having a high likelihood of survival over the next few years. The key factors contributing to this prognosis include:

1. NYHA Class II: The patient's heart failure is mild, indicating that they are still able to perform daily activities without significant symptoms.
2. Low ECG abnormalities: Although the patient has ventricular extrasystoles, which are irregular heartbeats, they are not sustained, and the overall ECG impression does not suggest any significant arrhythmias that could lead to sudden cardiac death.
3. Low Troponin levels: Elevated troponin levels are often associated with acute myocardial infarction or cardiac injury. The patient's troponin level is within normal limits, indicating that there is no acute cardiac damage.
4. Mild renal impairment: The patient's creatinine level is elevated, but it is not significantly high, suggesting that the kidneys are still functioning relatively well.
5. Presence of medications: The patient is taking loop diuretics and spironolactone, which are commonly used to manage heart failure and hypertension.

However, there are some concerns that need to be addressed:

1. Low LVEF: The patient's left ventricular ejection fraction (LVEF) is significantly reduced, indicating that the heart is not pumping efficiently.
2. High Pro-BNP levels: Elevated B-type natriuretic peptide (Pro-BNP) levels are associated with heart failure and may indicate increased cardiac stress.
3. Hypertension and dyslipidemia: The patient's past medical history of hypertension and dyslipidemia increases their risk of cardiovascular events.

Given these factors, I would rank the patient as having a moderate to high risk of cardiovascular events over the next few years. However, the patient's overall prognosis is still considered favorable due to the absence of severe cardiac abnormalities and the presence of effective medications.

RANKING: 2. Sudden cardiac death
REASONING: 

I would rank sudden cardiac death as a possible outcome for the patient over the next few years, but it is less likely compared to the survivor outcome. The reasons for this ranking are:

1. Presence of ventricular extrasystoles: Although the ventricular extrasystoles are not sustained, they are still a concern and may increase the risk of arrhythmias that could lead to sudden cardiac death.
2. Low LVEF: The patient's reduced LVEF increases the risk of cardiac events, including arrhythmias and sudden cardiac death.
3. Presence of hypertension and dyslipidemia: The patient's past medical history of hypertension and dyslipidemia increases their risk of cardiovascular events.

However, the patient's overall prognosis is still considered moderate due to the absence of severe cardiac abnormalities and the presence of effective medications.

RANKING: 3. Pump failure death
REASONING: 

I would rank pump failure death as the least likely outcome for the patient over the next few years. The reasons for this ranking are:

1. Effective medications: The patient is taking loop diuretics and spironolactone, which are commonly used to manage heart failure.
2. Mild renal impairment: The patient's creatinine level is not significantly high, suggesting that the kidneys are still functioning relatively well.
3. Absence of severe cardiac abnormalities: The patient does not have any severe cardiac abnormalities, such as significant arrhythmias or cardiac infarction, that would increase the risk of pump failure.

However, the patient's low LVEF and high Pro-BNP levels indicate that the heart is still under significant stress, and pump failure is a possible concern."
48,48,P0082,"Age: 71
Gender: Male 
Weight: 70 kg
Height: 167 cm
NYHA Class: II
Blood Pressure: 140/80 mmHg
Past Medical History: Idiopathic dilated cardiomyopathy, Hypertension
Albumin (g/L): 44,8
ALT or GPT (IU/L): 11.0
AST or GOT (IU/L): 18.0
Total Cholesterol (mmol/L): 4,6
Creatinine (mmol/L): 95.0
Gamma-glutamil transpeptidase (IU/L): 14
Glucose (mmol/L): 4,2
Hemoglobin (g/L): 143.0
HDL (mmol/L): 1,47
Potassium (mEq/L): 4,5
LDL (mmol/L): 2,66
Sodium (mEq/L): 140.0
Pro-BNP (ng/L): 430.0
Protein (g/L): 70
T3 (pg/dL): 0,04
T4 (ng/L): 15
Troponin (ng/mL): 0,01
TSH (mIU/L): 2,77
Urea (mg/dL): 7,57
LVEF (%): 24.0
Medications: Digoxin, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: TPSV
        - Bradycardia: No
            ",survivor,"RANKING: 1. Survivor
REASONING: The patient has a history of idiopathic dilated cardiomyopathy, which is a significant risk factor for sudden cardiac death. However, the patient is currently on ACE inhibitor therapy, which is standard treatment for heart failure and can help reduce the risk of sudden cardiac death. The patient's current LVEF is 24%, which is significantly reduced, indicating poor cardiac function. Despite this, the patient's NYHA class is II, indicating mild symptoms, which suggests that the patient is still relatively stable. The patient's ECG shows non-sustained ventricular tachycardia, which is a concerning finding, but the patient is not experiencing any symptoms. The presence of ventricular extrasystole and paroxysmal supraventricular tachyarrhythmia on ECG also raises concerns. However, the patient's overall clinical presentation and lack of symptoms suggest that the patient is currently stable. Therefore, the most likely outcome is survival, but close monitoring is required to assess the risk of adverse cardiac events.

RANKING: 2. Sudden cardiac death
REASONING: While the patient's history of idiopathic dilated cardiomyopathy and non-sustained ventricular tachycardia on ECG are concerning, the patient's current clinical presentation is relatively stable. However, the patient's LVEF is significantly reduced, and the presence of ventricular extrasystole and paroxysmal supraventricular tachyarrhythmia on ECG increases the risk of sudden cardiac death. The patient's ECG also shows non-sustained ventricular tachycardia, which is a significant finding. While the patient is on ACE inhibitor therapy, which can help reduce the risk of sudden cardiac death, the patient's underlying cardiac dysfunction and arrhythmias make it difficult to rule out sudden cardiac death as a possible outcome.

RANKING: 3. Pump failure death
REASONING: While the patient's LVEF is significantly reduced, indicating poor cardiac function, the patient's NYHA class is II, indicating mild symptoms. The patient is also on ACE inhibitor therapy, which can help reduce the risk of heart failure. Additionally, the patient's current ECG does not show any signs of acute heart failure or acute coronary syndrome. While pump failure is a concern, the patient's clinical presentation and lack of symptoms suggest that the patient is currently stable, and the risk of pump failure death is lower than sudden cardiac death."
49,49,P0084,"Age: 75
Gender: Male 
Weight: 83 kg
Height: 170 cm
NYHA Class: II
Blood Pressure: 120/60 mmHg
Past Medical History: Idiopathic dilated cardiomyopathy, Diabetes
Albumin (g/L): 47,19
ALT or GPT (IU/L): 52.0
AST or GOT (IU/L): 35.0
Total Cholesterol (mmol/L): 3,93
Creatinine (mmol/L): 149.0
Gamma-glutamil transpeptidase (IU/L): 40
Glucose (mmol/L): 14,7
Hemoglobin (g/L): 139.0
HDL (mmol/L): 0,59
Potassium (mEq/L): 5,2
LDL (mmol/L): 1,32
Sodium (mEq/L): 134.0
Pro-BNP (ng/L): 671.0
Protein (g/L): 68
T3 (pg/dL): 0,04
T4 (ng/L): 14
Troponin (ng/mL): 0,01
TSH (mIU/L): 4,04
Urea (mg/dL): 14,69
LVEF (%): 28.0
Medications: Diabetes Medication, Beta Blockers, Digoxin, Loop Diuretics, Spironolactone, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: No
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",survivor,"RANKING: 1. Survivor
REASONING: 
Based on the provided patient data, the patient's age (75), NYHA Class II, and the presence of idiopathic dilated cardiomyopathy, Diabetes, and elevated creatinine levels (149.0 mmol/L) suggest a significant cardiac impairment. The left ventricular ejection fraction (LVEF) is severely reduced at 28.0%, indicating poor cardiac function. The elevated BNP levels (671.0 ng/L) and the presence of anemia (Hemoglobin: 139.0 g/L) further support the severity of the condition. The patient's current medications, including beta blockers, digoxin, and ACE inhibitors, are standard treatments for heart failure and arrhythmias. The ECG results do not indicate any life-threatening arrhythmias, which reduces the risk of sudden cardiac death.

However, the patient's overall clinical presentation, including the presence of diabetes, elevated creatinine, and reduced LVEF, makes it challenging to predict the exact outcome. Given the patient's current condition, the most likely outcome is survival, but the exact duration of survival is uncertain.

RANKING: 2. Pump failure death
REASONING: 
While the patient's LVEF is severely reduced, and the patient is on medications for heart failure, the patient's current NYHA Class II classification suggests that the patient is still able to perform moderate physical activity without symptoms. The elevated BNP levels (671.0 ng/L) and the presence of anemia (Hemoglobin: 139.0 g/L) indicate a significant burden of disease, but the patient's current medications and ECG results do not suggest acute cardiac decompensation.

A pump failure death is possible, but it is less likely than survival, given the patient's current clinical status. The patient's diabetes and elevated creatinine levels increase the risk of complications, but the patient's current treatment regimen and ECG results do not indicate a high risk of sudden cardiac death.

RANKING: 3. Sudden cardiac death
REASONING: 
The patient's ECG results do not indicate any life-threatening arrhythmias, and the patient's current medications are standard treatments for heart failure and arrhythmias. The patient's NYHA Class II classification and the presence of anemia (Hemoglobin: 139.0 g/L) suggest that the patient is still able to perform moderate physical activity without symptoms. The elevated BNP levels (671.0 ng/L) and the presence of diabetes increase the risk of complications, but the patient's current treatment regimen and ECG results do not suggest a high risk of sudden cardiac death.

Given the patient's current clinical status, a sudden cardiac death is the least likely outcome. The patient's severe LVEF reduction and elevated creatinine levels increase the risk of complications, but the patient's current treatment regimen and ECG results do not indicate a high risk of sudden cardiac death."
50,50,P0086,"Age: 30
Gender: Male 
Weight: 103 kg
Height: 174 cm
NYHA Class: II
Blood Pressure: 140/80 mmHg
Past Medical History: Enolic dilated cardiomyopathy
Albumin (g/L): 50,8
ALT or GPT (IU/L): 191.0
AST or GOT (IU/L): 146.0
Total Cholesterol (mmol/L): 5,97
Creatinine (mmol/L): 113.0
Gamma-glutamil transpeptidase (IU/L): 700
Glucose (mmol/L): 5,4
Hemoglobin (g/L): 148.0
HDL (mmol/L): 1,29
Potassium (mEq/L): 4,2
LDL (mmol/L): 3,39
Sodium (mEq/L): 143.0
Pro-BNP (ng/L): 763.0
Protein (g/L): 80
T3 (pg/dL): 0,06
T4 (ng/L): 19
Troponin (ng/mL): 0,01
TSH (mIU/L): 1,78
Urea (mg/dL): 4,46
LVEF (%): 39.0
Medications: Beta Blockers, Digoxin, Loop Diuretics, Spironolactone, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"RANKING: 1. Survivor
REASONING:

This patient is at high risk for adverse outcomes due to several factors:

1. Advanced Cardiac Dysfunction: The patient has a low left ventricular ejection fraction (LVEF) of 39%, indicating severe left ventricular dysfunction, which is a hallmark of advanced cardiomyopathy.
2. High Pro-BNP Levels: Elevated Pro-BNP levels (763 ng/L) are associated with increased mortality and morbidity in patients with heart failure, particularly those with reduced ejection fraction.
3. Significant ECG Abnormalities: The presence of ventricular extrasystoles (polymorphic) and elevated troponin levels (0.01 ng/mL) suggest myocardial injury or inflammation, which can be a precursor to more severe cardiac events.
4. Poor Lipid Profile: The patient has a high total cholesterol level (5.97 mmol/L) and low HDL cholesterol level (1.29 mmol/L), which increases the risk of atherosclerotic cardiovascular disease.
5. Kidney Dysfunction: Elevated creatinine levels (113.0 mol/L) and urea levels (4.46 mg/dL) indicate impaired renal function, which is common in patients with advanced heart failure and cardiomyopathy.
6. Medication Non-Adherence: The patient is taking medications for heart failure, but the presence of ventricular extrasystoles and elevated troponin levels suggest that the patient may not be adhering to their medication regimen.

Given these factors, the patient is at high risk for adverse outcomes, including sudden cardiac death and pump failure. However, the patient's age, weight, and NYHA class II classification suggest that they may be able to survive with close monitoring and aggressive management of their condition.

RANKING: 2. Sudden Cardiac Death
REASONING:

This patient is at moderate to high risk for sudden cardiac death due to the presence of:

1. Advanced Cardiac Dysfunction: The patient's low LVEF (39%) and elevated Pro-BNP levels increase the risk of sudden cardiac death.
2. ECG Abnormalities: The presence of ventricular extrasystoles (polymorphic) and elevated troponin levels increase the risk of arrhythmias and sudden cardiac death.
3. Poor Lipid Profile: The patient's high total cholesterol level and low HDL cholesterol level increase the risk of atherosclerotic cardiovascular disease, which can lead to sudden cardiac death.

RANKING: 3. Pump Failure Death
REASONING:

While the patient is at risk for pump failure due to advanced cardiac dysfunction, the presence of ventricular extrasystoles and elevated troponin levels suggest that the patient is more likely to experience sudden cardiac death rather than pump failure. However, the patient's NYHA class II classification and age may reduce the likelihood of pump failure compared to sudden cardiac death."
51,51,P0088,"Age: 62
Gender: Male 
Weight: 74 kg
Height: 163 cm
NYHA Class: II
Blood Pressure: 120/80 mmHg
Past Medical History: Idiopathic dilated cardiomyopathy
Albumin (g/L): 44
ALT or GPT (IU/L): 18.0
AST or GOT (IU/L): 18.0
Total Cholesterol (mmol/L): 4,78
Creatinine (mmol/L): 111.0
Gamma-glutamil transpeptidase (IU/L): 46
Glucose (mmol/L): 5,2
Hemoglobin (g/L): 149.0
HDL (mmol/L): 1,22
Potassium (mEq/L): 3,9
LDL (mmol/L): 2,9
Sodium (mEq/L): 144.0
Pro-BNP (ng/L): 720.0
Protein (g/L): 73
T3 (pg/dL): 0,04
T4 (ng/L): 17
Troponin (ng/mL): 0,01
TSH (mIU/L): 0,997
Urea (mg/dL): 8,02
LVEF (%): 36.0
Medications: Digoxin, Loop Diuretics, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"RANKING: 1. Survivor
REASONING: 

Based on the provided patient data, I predict that the patient is most likely to survive for the next few years. Here's the reasoning behind this ranking:

1. The patient's NYHA Class II indicates that they have moderate symptoms of heart failure, but they are still able to perform daily activities without significant limitations. This suggests that the patient's heart function is not severely impaired, which is a positive prognostic factor.

2. The patient's LVEF (36.0%) is significantly reduced, but it is not extremely low. A reduced LVEF is a common finding in patients with idiopathic dilated cardiomyopathy, and it is not uncommon for patients with this condition to have a relatively preserved LVEF.

3. The patient's Pro-BNP level (720.0 ng/L) is elevated, indicating that the patient's heart is working harder to pump blood, which is a sign of heart failure. However, the level is not extremely high, which suggests that the patient's heart is not in acute failure.

4. The patient's Medications include Digoxin, Loop Diuretics, and ACE Inhibitor, which are commonly used to manage heart failure and cardiomyopathy. The presence of these medications suggests that the patient is receiving appropriate treatment for their condition.

5. The patient's laboratory values, including electrolytes, liver enzymes, and renal function tests, are relatively within normal limits, which suggests that the patient does not have any acute or chronic conditions that could compromise their survival.

While the patient's ECG findings indicate the presence of ventricular extrasystoles, this is not a significant finding that would necessarily impact their survival. The absence of ventricular tachycardia, non-sustained ventricular tachycardia, and paroxysmal supraventricular tachyarrhythmia further reduces the risk of sudden cardiac death.

Overall, based on the patient's clinical presentation, laboratory values, and treatment, I believe that the patient is most likely to survive for the next few years."
52,52,P0089,"Age: 69
Gender: Male 
Weight: 84 kg
Height: 172 cm
NYHA Class: III
Blood Pressure: 100/60 mmHg
Past Medical History: Hypertensive cardiomyopathy, Hypertension
Albumin (g/L): 46,9
ALT or GPT (IU/L): 18.0
AST or GOT (IU/L): 23.0
Total Cholesterol (mmol/L): 5,61
Creatinine (mmol/L): 116.0
Gamma-glutamil transpeptidase (IU/L): 50
Glucose (mmol/L): 5
Hemoglobin (g/L): 138.0
HDL (mmol/L): 1,14
Potassium (mEq/L): 4,9
LDL (mmol/L): 4,03
Sodium (mEq/L): 141.0
Pro-BNP (ng/L): 5432.0
Protein (g/L): 73
T3 (pg/dL): 0,04
T4 (ng/L): 15
Troponin (ng/mL): 0,01
TSH (mIU/L): 2,55
Urea (mg/dL): 7,8
LVEF (%): 18.0
Medications: Beta Blockers, Digoxin, Spironolactone, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",survivor,"RANKING: 1. Survivor
REASONING: 

The patient has a history of Hypertensive cardiomyopathy and is currently taking medications for hypertension, which suggests that they have a pre-existing condition that can lead to cardiac complications. However, the patient's current ECG impression does not show any evidence of ventricular tachycardia or non-sustained ventricular tachycardia, which are common causes of sudden cardiac death. The patient's NYHA Class III indicates a significant level of heart failure, but they are still able to maintain a relatively normal heart rate (60 bpm) and blood pressure (100/60 mmHg). The patient's elevated creatinine level (116.0 mmol/L) and low LVEF (18.0%) suggest some degree of cardiac dysfunction, but the patient's overall clinical presentation and the absence of other high-risk features on the ECG suggest that they are more likely to survive in the short-term. The patient's Pro-BNP level is elevated (5432.0 ng/L), which indicates some degree of heart failure, but it is not excessively high, which might suggest that the patient is not in acute heart failure. Overall, the patient's combination of symptoms, ECG findings, and medication regimen suggest that they are likely to survive in the short-term, but long-term prognosis remains uncertain."
53,53,P0090,"Age: 58
Gender: Female 
Weight: 67 kg
Height: 161 cm
NYHA Class: II
Blood Pressure: 105/80 mmHg
Past Medical History: Idiopathic dilated cardiomyopathy, Dyslipemia, Hypertension
Albumin (g/L): 38
ALT or GPT (IU/L): 16.0
AST or GOT (IU/L): 21.0
Total Cholesterol (mmol/L): 5,59
Creatinine (mmol/L): 97.0
Gamma-glutamil transpeptidase (IU/L): 27
Glucose (mmol/L): 6,4
Hemoglobin (g/L): 133.0
HDL (mmol/L): 1,29
Potassium (mEq/L): 4,3
LDL (mmol/L): 3,88
Sodium (mEq/L): 137.0
Pro-BNP (ng/L): 1486.0
Protein (g/L): 63
T3 (pg/dL): 0,04
T4 (ng/L): 17
TSH (mIU/L): 1,18
Urea (mg/dL): 10,98
LVEF (%): 20.0
Medications: Beta Blockers, Digoxin, Loop Diuretics, Spironolactone, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"RANKING: 1. Survivor 
REASONING: 

Based on the provided patient data, I would rank the patient as having a high likelihood of survival over the next few years. Here's the reasoning behind this assessment:

1. Age: Although the patient is 58 years old, which is considered middle-aged, her age is not a significant risk factor for mortality in this context. The patient's age alone does not indicate an increased risk of sudden cardiac death or pump failure.

2. NYHA Class II: The patient's New York Heart Association (NYHA) class II indicates that she has some limitations in physical activity, but she is still able to perform light physical activity without symptoms. This suggests that her heart function is not severely impaired.

3. Medications: The patient is on a comprehensive regimen of medications, including beta blockers, digoxin, loop diuretics, spironolactone, and an ACE inhibitor. This combination is commonly used to manage heart failure, hypertension, and arrhythmias. The presence of these medications suggests that the patient is receiving optimal medical therapy for her underlying conditions.

4. ECG Impression: The ECG results show various arrhythmias, including ventricular extrasystoles, non-sustained ventricular tachycardia, and non-sustained ventricular tachycardia (CH>10). However, these findings are not indicative of severe cardiac dysfunction or significant structural heart disease. The presence of these arrhythmias may require close monitoring and adjustments to the patient's medication regimen, but they do not necessarily predict a poor prognosis.

5. LVEF: The left ventricular ejection fraction (LVEF) is significantly reduced at 20%. However, an LVEF of 20% is not uncommon in patients with idiopathic dilated cardiomyopathy. With optimal medical therapy, many patients with LVEF values in this range can achieve significant improvements in symptoms and functional capacity.

Considering these factors, I believe that the patient is likely to survive for the next few years, provided that her medications are continued and adjusted as necessary to manage her arrhythmias and heart failure symptoms. However, regular monitoring and follow-up appointments will be crucial to assess the patient's response to treatment and make any necessary adjustments."
54,54,P0091,"Age: 53
Gender: Male 
Weight: 105 kg
Height: 170 cm
NYHA Class: II
Blood Pressure: 150/80 mmHg
Past Medical History: Hypertensive cardiomyopathy, Hypertension
Albumin (g/L): 47
ALT or GPT (IU/L): 26.0
AST or GOT (IU/L): 29.0
Total Cholesterol (mmol/L): 5,77
Creatinine (mmol/L): 80.0
Gamma-glutamil transpeptidase (IU/L): 41
Glucose (mmol/L): 6,9
Hemoglobin (g/L): 157.0
HDL (mmol/L): 1,06
Potassium (mEq/L): 4,3
LDL (mmol/L): 3,88
Sodium (mEq/L): 141.0
Pro-BNP (ng/L): 24.0
Protein (g/L): 79
T3 (pg/dL): 0,04
T4 (ng/L): 14
Troponin (ng/mL): 0,02
TSH (mIU/L): 1,26
Urea (mg/dL): 6,16
LVEF (%): 36.0
Medications: Calcium Channel Blocker, Beta Blockers, Digoxin, Loop Diuretics, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"RANKING: 
1. Survivor
2. Sudden cardiac death
3. Pump failure death

REASONING:

Based on the provided patient data, the patient is a 53-year-old male with a history of hypertensive cardiomyopathy, hypertension, and NYHA Class II heart failure. The patient's LVEF (Left Ventricular Ejection Fraction) is significantly reduced at 36.0%, indicating severe left ventricular dysfunction.

The patient's laboratory results show elevated troponin levels (0.02 ng/mL), which suggests some degree of myocardial injury. The elevated creatinine level (80.0 mmol/L) and low albumin level (47 g/L) also indicate impaired kidney function, which is often seen in patients with heart failure.

The patient's ECG shows ventricular extrasystoles, which can be a sign of cardiac arrhythmias. However, there is no evidence of ventricular tachycardia or other life-threatening arrhythmias.

Considering the patient's severe left ventricular dysfunction, elevated troponin levels, and impaired kidney function, I would rank the patient's outcome as follows:

1. Survivor: The patient's survival is likely due to the fact that they are already receiving treatment with medications such as calcium channel blockers, beta blockers, digoxin, loop diuretics, and ACE inhibitors, which are standard treatments for heart failure. However, the patient's severe left ventricular dysfunction and impaired kidney function may still pose a significant risk for complications.

2. Sudden cardiac death: Although the patient does not have any evidence of ventricular tachycardia or other life-threatening arrhythmias on the ECG, their severe left ventricular dysfunction and elevated troponin levels increase the risk of sudden cardiac death.

3. Pump failure death: Pump failure death is the most likely outcome in the absence of any significant improvement in the patient's condition. The patient's severe left ventricular dysfunction and impaired kidney function make it likely that the patient will experience a rapid decline in cardiac function, leading to pump failure and death.

It is essential to closely monitor the patient's condition and adjust their treatment plan as needed to minimize the risk of complications and improve their overall prognosis."
55,55,P0092,"Age: 50
Gender: Female 
Weight: 108 kg
Height: 155 cm
NYHA Class: II
Blood Pressure: 130/70 mmHg
Past Medical History: Hypertensive cardiomyopathy, Diabetes, Dyslipemia, Hypertension
Albumin (g/L): 38
ALT or GPT (IU/L): 19.0
AST or GOT (IU/L): 16.0
Total Cholesterol (mmol/L): 6,49
Creatinine (mmol/L): 80.0
Gamma-glutamil transpeptidase (IU/L): 88
Glucose (mmol/L): 19,7
Hemoglobin (g/L): 152.0
HDL (mmol/L): 1,58
Potassium (mEq/L): 5,1
LDL (mmol/L): 3,96
Sodium (mEq/L): 141.0
Pro-BNP (ng/L): 350.0
Protein (g/L): 67
T3 (pg/dL): 0,06
T4 (ng/L): 14
Troponin (ng/mL): 0,02
TSH (mIU/L): 4,3
Urea (mg/dL): 9,15
LVEF (%): 27.0
Medications: Diabetes Medication, Beta Blockers, Digoxin, Loop Diuretics, Spironolactone, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",survivor,"RANKING: 
1. Survivor
REASONING: 
Based on the provided patient data, I would rank the patient as a survivor for the next few years. The patient's age, NYHA Class II, and the presence of Hypertensive cardiomyopathy suggest a significant cardiac condition. However, the patient's blood pressure is well-controlled (130/70 mmHg), and they are on multiple medications for their hypertension, diabetes, and heart failure, which indicates a good level of medical management.

The patient's LVEF is 27.0%, which is slightly below the normal range (55%), but not severely impaired. The patient's troponin level is 0.02 ng/mL, which is within the normal range, indicating no significant myocardial injury. The patient's ejection fraction is not significantly reduced, and there is no evidence of acute coronary syndrome.

The patient's BNP level is elevated at 350 ng/L, which may indicate some degree of heart failure, but it is not excessively high. The patient's kidney function is also relatively preserved, with a creatinine level of 9.15 mg/dL.

Given these factors, I believe the patient is at a relatively high risk of cardiac events, but the overall picture suggests that they are likely to survive for the next few years. However, close monitoring and regular follow-up are essential to adjust their treatment plan and manage their condition.

RANKING 2: Sudden cardiac death
REASONING: 
While the patient's LVEF is below the normal range, the absence of troponin elevation, and the relatively preserved kidney function suggest that the patient's cardiac condition is not severely compromised. However, the patient's age, NYHA Class II, and the presence of Hypertensive cardiomyopathy increase the risk of cardiac events, including sudden cardiac death.

The patient's BNP level is elevated, which may indicate some degree of heart failure, and the patient's ECG shows ventricular extrasystole, which may be a sign of arrhythmia. However, the absence of ventricular tachycardia or non-sustained ventricular tachycardia makes it less likely that the patient is at high risk of sudden cardiac death.

RANKING 3: Pump failure death
REASONING: 
Given the patient's relatively preserved kidney function, LVEF, and the absence of significant myocardial injury, pump failure death is the least likely outcome. The patient's BNP level is elevated, but it is not excessively high, and the patient is on multiple medications for their heart failure, which suggests that their condition is being managed.

However, the patient's age, NYHA Class II, and the presence of Hypertensive cardiomyopathy do increase the risk of cardiac events, and the patient's elevated BNP level may eventually lead to decompensation and heart failure. However, based on the available data, pump failure death is not the most likely outcome."
56,56,P0093,"Age: 40
Gender: Female 
Weight: 67 kg
Height: 168 cm
NYHA Class: II
Blood Pressure: 100/60 mmHg
Past Medical History: Idiopathic dilated cardiomyopathy
Albumin (g/L): 38
ALT or GPT (IU/L): 15.0
AST or GOT (IU/L): 16.0
Total Cholesterol (mmol/L): 4,86
Creatinine (mmol/L): 62.0
Gamma-glutamil transpeptidase (IU/L): 10
Glucose (mmol/L): 5,4
Hemoglobin (g/L): 124.0
HDL (mmol/L): 1,09
Potassium (mEq/L): 4,5
LDL (mmol/L): 3,52
Sodium (mEq/L): 141.0
Pro-BNP (ng/L): 152.0
Protein (g/L): 65
T3 (pg/dL): 0,03
T4 (ng/L): 16
Troponin (ng/mL): 0,005
TSH (mIU/L): 2,23
Urea (mg/dL): 4,49
LVEF (%): 60.0
Medications: Beta Blockers, Loop Diuretics, Spironolactone, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"RANKING: 
1. Survivor
REASONING: 
Based on the provided patient data, the patient is classified as having idiopathic dilated cardiomyopathy, which is a condition where the heart's ability to pump blood is weakened due to the enlargement of the heart chambers. The patient's NYHA Class II indicates mild symptoms, suggesting that they are able to perform daily activities without significant limitation. The patient's LVEF (left ventricular ejection fraction) is 60.0%, which is within the range of 40-50% and indicates that the heart is still pumping blood, but not as efficiently as it should.

The patient's laboratory results show that their liver enzymes (ALT and AST) are slightly elevated, but not significantly abnormal. Their lipid profile shows a total cholesterol level of 4.86 mmol/L, which is within the normal range. The patient's kidney function is also within normal limits.

The patient is on medications that are commonly used to manage heart failure, including beta blockers, loop diuretics, spironolactone, and an ACE inhibitor. These medications can help reduce symptoms and slow the progression of heart failure.

The ECG results show no signs of ventricular tachycardia or bradycardia, which are conditions that can increase the risk of sudden cardiac death. The presence of ventricular extrasystoles is noted, but it is not a significant concern in this context.

Given the patient's mild symptoms, normal laboratory results, and the effectiveness of their current treatment regimen, the most likely outcome is that the patient will survive for the next few years without significant progression of their condition."
57,57,P0094,"Age: 31
Gender: Male 
Weight: 79 kg
Height: 165 cm
NYHA Class: II
Blood Pressure: 105/60 mmHg
Past Medical History: Post-myocardial dilated cardiomyopathy, Myocardial Infarction
Albumin (g/L): 47
ALT or GPT (IU/L): 20.0
AST or GOT (IU/L): 18.0
Total Cholesterol (mmol/L): 4,29
Creatinine (mmol/L): 97.0
Gamma-glutamil transpeptidase (IU/L): 19
Glucose (mmol/L): 4,6
Hemoglobin (g/L): 132.0
HDL (mmol/L): 1,24
Potassium (mEq/L): 4,5
LDL (mmol/L): 2,51
Sodium (mEq/L): 141.0
Pro-BNP (ng/L): 951.0
Protein (g/L): 80
T3 (pg/dL): 0,05
T4 (ng/L): 19
Troponin (ng/mL): 0,03
TSH (mIU/L): 1,79
Urea (mg/dL): 5,16
LVEF (%): 35.0
Medications: Beta Blockers, Digoxin, Loop Diuretics, Spironolactone, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"RANKING: 1. Survivor
REASONING: 

Based on the provided patient data, the patient is likely to survive for the next few years due to the following reasons:

1. Age: Although the patient is 31 years old, which may be considered relatively young for certain cardiac conditions, the patient has a history of post-myocardial infarction and dilated cardiomyopathy, which can increase the risk of cardiac events.
2. NYHA Class II: The patient's New York Heart Association (NYHA) Class II indicates that the patient has some limitation in physical activity due to heart disease, but it's not severe. This suggests that the patient is still relatively functional and may be able to tolerate some level of physical activity.
3. Medications: The patient is on a combination of beta blockers, digoxin, loop diuretics, spironolactone, and an ACE inhibitor, which are standard treatments for heart failure and myocardial infarction. This suggests that the patient is receiving appropriate medical therapy to manage their condition.
4. Pro-BNP levels: Although the patient's Pro-BNP levels are elevated, indicating some level of heart failure, it's not extremely high. This suggests that the patient may not be in acute heart failure, and the heart is still functioning to some extent.
5. Troponin levels: The patient's troponin levels are normal, which suggests that there is no significant myocardial injury or damage at the time of the test.

While the patient has a history of significant cardiac events, the combination of a relatively young age, NYHA Class II status, and the use of appropriate medications suggest that the patient is likely to survive for the next few years. However, close monitoring and follow-up with regular echocardiograms and cardiac monitoring would be necessary to assess the progression of the disease.

It's worth noting that the patient's LVEF (left ventricular ejection fraction) is 35%, which is significantly reduced, indicating left ventricular dysfunction. However, this can be managed with medication and lifestyle modifications, and the patient's overall clinical picture suggests that they are likely to survive for the next few years."
58,58,P0095,"Age: 50
Gender: Female 
Weight: 77 kg
Height: 165 cm
NYHA Class: III
Blood Pressure: 120/60 mmHg
Past Medical History: Idiopathic dilated cardiomyopathy
Albumin (g/L): 38
ALT or GPT (IU/L): 16.0
AST or GOT (IU/L): 21.0
Total Cholesterol (mmol/L): 6,08
Creatinine (mmol/L): 71.0
Gamma-glutamil transpeptidase (IU/L): 11
Glucose (mmol/L): 5
Hemoglobin (g/L): 129.0
HDL (mmol/L): 1,68
Potassium (mEq/L): 3,9
LDL (mmol/L): 3,1
Sodium (mEq/L): 142.0
Pro-BNP (ng/L): 40.0
Protein (g/L): 67
T3 (pg/dL): 0,05
T4 (ng/L): 15
Troponin (ng/mL): 0,005
TSH (mIU/L): 1,27
Urea (mg/dL): 6,49
LVEF (%): 50.0
Medications: Loop Diuretics, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",survivor,"RANKING: 1. Survivor
REASONING: The patient has a relatively preserved LVEF of 50.0%, which is a crucial factor in determining the prognosis. Although the patient has a history of idiopathic dilated cardiomyopathy, the current ejection fraction is not severely impaired. The patient is also taking an ACE inhibitor, which is a standard treatment for heart failure and can help improve survival. Additionally, the patient's hemoglobin level is within the normal range, and the electrolyte and liver function tests are relatively normal. The absence of ventricular tachycardia and non-sustained ventricular tachycardia on the ECG also suggests a lower risk of sudden cardiac death. Overall, these factors contribute to a relatively good prognosis.

RANKING: 2. Sudden Cardiac Death
REASONING: The patient's history of idiopathic dilated cardiomyopathy and the presence of ventricular extrasystole on the ECG are risk factors for sudden cardiac death. Although the patient is taking an ACE inhibitor, which can help reduce mortality, the presence of ventricular extrasystole is a significant concern. The patient's LVEF is 50.0%, which is lower than the normal range, indicating some degree of cardiac dysfunction. Additionally, the patient's elevated creatinine level (71.0 mmol/L) may indicate some degree of renal impairment, which can be a risk factor for cardiac complications.

RANKING: 3. Pump Failure Death
REASONING: The patient's LVEF is 50.0%, which is below the normal range, indicating some degree of cardiac dysfunction. The patient's NYHA Class III classification also suggests a significant degree of heart failure. Although the patient is taking an ACE inhibitor, which can help improve symptoms, the combination of these factors increases the risk of pump failure. Additionally, the patient's elevated creatinine level and slightly elevated liver enzymes (ALT and AST) may indicate some degree of cardiac strain, which can contribute to pump failure. However, the patient's overall condition is still relatively stable, and the absence of ventricular tachycardia on the ECG reduces the risk of sudden cardiac death."
59,59,P0096,"Age: 68
Gender: Male 
Weight: 71 kg
Height: 163 cm
NYHA Class: II
Blood Pressure: 120/60 mmHg
Past Medical History: Hypertensive cardiomyopathy, Hypertension
Albumin (g/L): 37
ALT or GPT (IU/L): 19.0
AST or GOT (IU/L): 23.0
Total Cholesterol (mmol/L): 4,97
Creatinine (mmol/L): 133.0
Gamma-glutamil transpeptidase (IU/L): 21
Glucose (mmol/L): 5,2
Hemoglobin (g/L): 133.0
HDL (mmol/L): 1,5
Potassium (mEq/L): 5,7
LDL (mmol/L): 2,4
Sodium (mEq/L): 139.0
Pro-BNP (ng/L): 675.0
Protein (g/L): 65
T3 (pg/dL): 0,04
T4 (ng/L): 14
Troponin (ng/mL): 0,16
TSH (mIU/L): 3,73
Urea (mg/dL): 12,15
LVEF (%): 31.0
Medications: Angiotensin II Receptor Blocker, Loop Diuretics, Spironolactone, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",survivor,"RANKING: 
1. Survivor
REASONING: 
The patient's age, NYHA Class II, and the presence of hypertension and cardiomyopathy suggest that the patient has a significant cardiovascular history. However, the patient is currently taking multiple medications that are commonly used to manage these conditions, such as an ACE inhibitor, Angiotensin II Receptor Blocker, Loop Diuretics, and Spironolactone, which indicate a relatively well-managed hypertension and heart failure. The patient's LVEF is 31%, which is within the normal range for a 68-year-old male. Although the patient has some cardiac arrhythmias, the ECG impression does not indicate any severe or life-threatening conditions. The patient's serum biomarkers, such as Troponin and Pro-BNP, are not significantly elevated, which suggests that the patient does not have an acute coronary syndrome or significant heart failure. Overall, considering the patient's age, comorbidities, and the presence of well-managed conditions, the most likely outcome is a favorable one, with a high chance of survival.

RANKING: 
2. Sudden cardiac death
REASONING: 
The patient's ECG impression indicates the presence of ventricular extrasystole and non-sustained ventricular tachycardia, which are potential precursors to more serious arrhythmias. The patient's age and NYHA Class II also increase the risk of sudden cardiac death. Although the patient is taking medications that are commonly used to manage these conditions, the presence of these arrhythmias suggests that the patient may be at increased risk for cardiac complications. The patient's LVEF is within the normal range, but the presence of non-sustained ventricular tachycardia indicates that the patient may have some underlying cardiac dysfunction.

RANKING: 
3. Pump failure death
REASONING: 
The patient's NYHA Class II and elevated creatinine level (133.0 mmol/L) suggest that the patient has some degree of cardiac dysfunction, which may lead to heart failure. However, the patient is taking medications that are commonly used to manage heart failure, such as Loop Diuretics and ACE Inhibitors, which indicate that the patient is receiving appropriate treatment. The patient's LVEF is within the normal range, and the absence of significantly elevated serum biomarkers (Troponin and Pro-BNP) suggests that the patient does not have an acute heart failure. While the patient's age and comorbidities increase the risk of pump failure, the presence of well-managed conditions and the patient's relatively normal LVEF make this outcome less likely compared to sudden cardiac death."
60,60,P0097,"Age: 68
Gender: Female 
Weight: 78 kg
Height: 163 cm
NYHA Class: II
Blood Pressure: 120/60 mmHg
Past Medical History: Idiopathic dilated cardiomyopathy, Hypertension
Albumin (g/L): 39
ALT or GPT (IU/L): 25.0
AST or GOT (IU/L): 30.0
Total Cholesterol (mmol/L): 3,88
Creatinine (mmol/L): 88.0
Gamma-glutamil transpeptidase (IU/L): 16
Glucose (mmol/L): 5,3
Hemoglobin (g/L): 130.0
HDL (mmol/L): 1,45
Potassium (mEq/L): 5
LDL (mmol/L): 2,59
Sodium (mEq/L): 140.0
Pro-BNP (ng/L): 1284.0
Protein (g/L): 74
T3 (pg/dL): 0,05
T4 (ng/L): 14
Troponin (ng/mL): 0,03
TSH (mIU/L): 4,53
Urea (mg/dL): 7,49
LVEF (%): 35.0
Medications: Beta Blockers, Digoxin, Loop Diuretics, Spironolactone, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"RANKING: 1. Survivor
REASONING: 

Based on the provided patient data, the patient is at high risk for cardiac events, but the presence of a ""Pump Failure Death"" prognosis is not explicitly stated, and the patient is currently being treated with medications that are aimed at managing heart failure and reducing the risk of cardiac events. The patient's LVEF is significantly reduced (35%), indicating poor cardiac function. However, the patient's NYHA Class is II, which suggests that the patient is still able to perform daily activities with some limitation. The patient's Pro-BNP levels are elevated, but not excessively high, which may indicate some degree of heart failure, but not severe.

The presence of non-sustained ventricular tachycardia (NSVT) and ventricular extrasystoles on the ECG impression is concerning, but the patient is being treated with medications that are aimed at managing arrhythmias. The patient's electrolyte levels, including potassium and sodium, are within normal limits, which reduces the risk of arrhythmias.

While the patient has a high risk of cardiac events, the presence of a strong treatment plan and the fact that the patient is currently being monitored for arrhythmias suggest that the patient is more likely to survive in the short term. Therefore, a survivor prognosis is the most likely outcome.

RANKING: 2. Sudden Cardiac Death
REASONING: 

The patient's ECG impression shows the presence of non-sustained ventricular tachycardia (NSVT) and ventricular extrasystoles, which are risk factors for sudden cardiac death. The patient's LVEF is significantly reduced, indicating poor cardiac function, and the patient's Pro-BNP levels are elevated, suggesting some degree of heart failure.

While the patient is being treated with medications that are aimed at managing arrhythmias and heart failure, the presence of NSVT and ventricular extrasystoles on the ECG impression increases the risk of sudden cardiac death. The patient's electrolyte levels, including potassium and sodium, are within normal limits, which reduces the risk of arrhythmias. However, the patient's low T3 level (0.05 pg/dL) may indicate hypothyroidism, which can increase the risk of cardiac events.

Given the presence of these risk factors, a sudden cardiac death prognosis is possible, but it is less likely than the survivor prognosis.

RANKING: 3. Pump Failure Death
REASONING: 

The patient's LVEF is significantly reduced (35%), indicating poor cardiac function, and the patient's Pro-BNP levels are elevated, suggesting some degree of heart failure. The patient's NYHA Class is II, which suggests that the patient is still able to perform daily activities with some limitation.

While the patient is being treated with medications that are aimed at managing heart failure and reducing the risk of cardiac events, the presence of NSVT and ventricular extrasystoles on the ECG impression increases the risk of cardiac events. The patient's low T3 level (0.05 pg/dL) may indicate hypothyroidism, which can increase the risk of cardiac events.

Given the presence of these risk factors, a pump failure death prognosis is possible, but it is the least likely outcome among the three options. The patient's treatment plan and current symptoms do not suggest a severe decline in cardiac function, and the patient is being monitored for arrhythmias."
61,61,P0098,"Age: 56
Gender: Female 
Weight: 60 kg
Height: 140 cm
NYHA Class: III
Blood Pressure: 140/80 mmHg
Past Medical History: Idiopathic dilated cardiomyopathy, Diabetes, Dyslipemia, Hypertension
Albumin (g/L): 37
ALT or GPT (IU/L): 66.0
AST or GOT (IU/L): 66.0
Total Cholesterol (mmol/L): 5,64
Creatinine (mmol/L): 80.0
Gamma-glutamil transpeptidase (IU/L): 23
Glucose (mmol/L): 6,3
Hemoglobin (g/L): 133.0
HDL (mmol/L): 1,16
Potassium (mEq/L): 5,2
LDL (mmol/L): 3,96
Sodium (mEq/L): 138.0
Pro-BNP (ng/L): 2081.0
Protein (g/L): 70
T3 (pg/dL): 0,05
T4 (ng/L): 19
TSH (mIU/L): 5,52
Urea (mg/dL): 4,99
LVEF (%): 38.0
Medications: Diabetes Medication, Amiodarone, Beta Blockers, Digoxin, Loop Diuretics, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",survivor,"RANKING: 1. Survivor
REASONING: 

Based on the provided patient data, I rank the patient as a survivor with the highest probability. The patient has a relatively well-controlled blood pressure (140/80 mmHg) and is on multiple medications to manage their conditions, including ACE inhibitors, beta blockers, and digoxin. The patient's laboratory results, such as a normal creatinine level (80.0 mmol/L) and a relatively low LDLC (3,96 mmol/L), suggest that their kidney function and lipid profile are well-managed.

The patient's ejection fraction (LVEF) is 38.0%, which is slightly below the normal range (40-60%), but not drastically low. However, the patient has a history of idiopathic dilated cardiomyopathy, which is a significant risk factor for cardiac complications.

The patient's ECG results show ventricular extrasystoles, which may indicate some degree of cardiac dysfunction, but there is no evidence of ventricular tachycardia or bradycardia. The presence of paroxysmal supraventricular tachyarrhythmia is unclear, but it is not immediately concerning.

The patient's BNP levels are elevated (2081.0 ng/L), which may indicate some degree of heart failure, but the patient is still on loop diuretics, which suggests that they are being treated for this condition.

Overall, while the patient has several risk factors and abnormal test results, their overall clinical picture suggests that they are likely to survive the next few years with continued management of their conditions and monitoring for any signs of worsening cardiac function."
62,62,P0100,"Age: 68
Gender: Female 
Weight: 70 kg
Height: 150 cm
NYHA Class: II
Blood Pressure: 150/70 mmHg
Past Medical History: Ischemic dilated cardiomyopathy
Albumin (g/L): 47,1
ALT or GPT (IU/L): 28.0
AST or GOT (IU/L): 23.0
Total Cholesterol (mmol/L): 3,83
Creatinine (mmol/L): 82.0
Gamma-glutamil transpeptidase (IU/L): 21
Glucose (mmol/L): 7,4
Hemoglobin (g/L): 141.0
HDL (mmol/L): 1,16
Potassium (mEq/L): 4,1
LDL (mmol/L): 1,76
Sodium (mEq/L): 140.0
Pro-BNP (ng/L): 200.0
Protein (g/L): 80
T3 (pg/dL): 0,05
T4 (ng/L): 16
Troponin (ng/mL): 0,01
TSH (mIU/L): 2,21
Urea (mg/dL): 6,01
LVEF (%): 27.0
Medications: Calcium Channel Blocker, Angiotensin II Receptor Blocker, Digoxin, Loop Diuretics, Spironolactone, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: TPSV
        - Bradycardia: No
            ",survivor,"RANKING: 1. Survivor 
REASONING: 
Based on the patient's data, the patient is a 68-year-old female with a history of ischemic dilated cardiomyopathy, which is a significant risk factor for sudden cardiac death. However, the patient's current NYHA Class II indicates that the disease is not severely limiting her physical activity. The patient's LVEF of 27.0 is low, which suggests that the heart is not functioning optimally. Despite this, the patient's cardiac biomarkers, such as Troponin and Pro-BNP, are not significantly elevated, indicating a relatively preserved cardiac function.

The patient's ECG findings of ventricular extrasystole and non-sustained ventricular tachycardia are concerning, but the absence of sustained ventricular tachycardia and paroxysmal supraventricular tachyarrhythmia reduces the risk of sudden cardiac death. The patient's medication regimen, including a calcium channel blocker, angiotensin II receptor blocker, and spironolactone, suggests that the patient is receiving optimal management for her heart failure and hypertension.

Considering these factors, I believe that the patient is most likely to survive over the next few years, given her relatively preserved cardiac function and optimal medication management. However, close monitoring and regular follow-up appointments will be necessary to adjust the treatment plan as needed to minimize the risk of cardiac events.

RANKING: 2. Sudden cardiac death 
REASONING: 
While the patient's ECG findings of ventricular extrasystole and non-sustained ventricular tachycardia are concerning, the absence of sustained ventricular tachycardia and paroxysmal supraventricular tachyarrhythmia reduces the risk of sudden cardiac death. However, the patient's history of ischemic dilated cardiomyopathy and low LVEF of 27.0 increase the risk of sudden cardiac death.

Additionally, the patient's Pro-BNP level of 200.0 is elevated, which may indicate some degree of cardiac stress or strain. The patient's age and gender also increase the risk of sudden cardiac death. While the patient's medication regimen is optimal, there is still a risk of cardiac events, and close monitoring will be necessary.

RANKING: 3. Pump failure death 
REASONING: 
Given the patient's low LVEF of 27.0, which indicates poor cardiac function, and her history of ischemic dilated cardiomyopathy, I would consider pump failure death as a possible outcome over the next few years. The patient's elevated Pro-BNP level and NYHA Class II symptoms suggest that the patient may experience worsening heart failure, which could lead to pump failure.

However, the patient's optimal medication regimen and relatively preserved cardiac biomarkers suggest that some degree of cardiac function is still present. Nevertheless, the patient's low LVEF and history of ischemic dilated cardiomyopathy increase the risk of pump failure, and close monitoring will be necessary to adjust the treatment plan as needed to minimize this risk."
63,63,P0101,"Age: 56
Gender: Male 
Weight: 72 kg
Height: 168 cm
NYHA Class: II
Blood Pressure: 110/50 mmHg
Past Medical History: Idiopathic dilated cardiomyopathy
Albumin (g/L): 42
ALT or GPT (IU/L): 14.0
AST or GOT (IU/L): 16.0
Total Cholesterol (mmol/L): 4,55
Creatinine (mmol/L): 106.0
Gamma-glutamil transpeptidase (IU/L): 11
Glucose (mmol/L): 5,1
Hemoglobin (g/L): 125.0
HDL (mmol/L): 1,16
Potassium (mEq/L): 4,6
LDL (mmol/L): 2,74
Sodium (mEq/L): 136.0
Pro-BNP (ng/L): 3566.0
Protein (g/L): 72
T3 (pg/dL): 0,04
T4 (ng/L): 17
Troponin (ng/mL): 0,02
TSH (mIU/L): 0,904
Urea (mg/dL): 6,32
LVEF (%): 17.0
Medications: Beta Blockers, Loop Diuretics, Spironolactone, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"RANKING: 1. Survivor 
REASONING: 

The patient has a history of idiopathic dilated cardiomyopathy, which is a condition that affects the heart's ability to pump blood effectively. The patient's left ventricular ejection fraction (LVEF) is significantly reduced at 17.0%, indicating severe impairment of the heart's pumping function. The patient's elevated creatinine level (106.0 mmol/L) also suggests impaired renal function, which is common in advanced heart failure.

Despite the presence of ventricular extrasystoles and non-sustained ventricular tachycardia on the ECG, the patient is currently on medications for heart failure (beta blockers, loop diuretics, spironolactone, and ACE inhibitor), which are standard treatments for heart failure. The patient's current blood pressure is also within a relatively normal range (110/50 mmHg).

Given the patient's severe heart failure and impaired renal function, the patient is at increased risk of decompensation and potentially life-threatening complications. However, the fact that the patient is currently on medications and has a relatively stable ECG suggests that the patient is not in acute distress and is likely to survive with proper management. 

While the patient's ejection fraction is severely impaired, the patient's current symptoms and ECG do not indicate an immediate risk of sudden cardiac death. Therefore, I rank the patient as having a high likelihood of survival."
64,64,P0102,"Age: 63
Gender: Male 
Weight: 102 kg
Height: 175 cm
NYHA Class: II
Blood Pressure: 110/70 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Diabetes, Dyslipemia, Hypertension, Myocardial Infarction
Albumin (g/L): 37
ALT or GPT (IU/L): 25.0
AST or GOT (IU/L): 15.0
Total Cholesterol (mmol/L): 4,65
Creatinine (mmol/L): 124.0
Gamma-glutamil transpeptidase (IU/L): 25
Glucose (mmol/L): 11,5
Hemoglobin (g/L): 128.0
HDL (mmol/L): 0,88
Potassium (mEq/L): 5,3
LDL (mmol/L): 2,66
Sodium (mEq/L): 139.0
Pro-BNP (ng/L): 346.0
Protein (g/L): 67
T3 (pg/dL): 0,05
T4 (ng/L): 15
Troponin (ng/mL): 0,06
TSH (mIU/L): 2,34
Urea (mg/dL): 6,99
LVEF (%): 43.0
Medications: Calcium Channel Blocker, Diabetes Medication, Beta Blockers, Loop Diuretics, Statins, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"RANKING: 1. Survivor
REASONING: 

Based on the provided patient data, the patient's prognosis is ranked as a survivor. The primary reasons for this ranking are:

1. The patient's LVEF is 43%, which is relatively preserved compared to the average LVEF in patients with ischemic dilated cardiomyopathy. A preserved LVEF is associated with a better prognosis.

2. The patient's NYHA Class is II, indicating mild symptoms, which suggests that the patient is still relatively functional and able to perform daily activities without significant limitation.

3. The patient's medications, including ACE inhibitors, beta blockers, and statins, are commonly used to manage heart failure and are associated with improved outcomes in patients with heart failure.

4. The patient's ECG findings, while showing some signs of arrhythmia (ventricular extrasystole and non-sustained VT), do not indicate a high risk for sudden cardiac death. The absence of sustained VT and other arrhythmias reduces the risk of sudden cardiac death.

5. The patient's laboratory values, including normal blood pressure, creatinine, and electrolytes, suggest that the patient is not in acute kidney injury or acute coronary syndrome, which could increase the risk of sudden cardiac death.

However, the patient's past medical history, including ischemic dilated cardiomyopathy, diabetes, dyslipidemia, and hypertension, indicates a higher risk for future cardiac events. Therefore, while the patient's current prognosis is ranked as a survivor, it is essential to closely monitor their condition and adjust their treatment plan as needed to minimize the risk of future cardiac events.

While the patient's prognosis is ranked as a survivor, it is essential to note that the patient's long-term outlook is still uncertain, and close monitoring and follow-up are necessary to assess the progression of their condition."
65,65,P0103,"Age: 50
Gender: Male 
Weight: 81 kg
Height: 177 cm
NYHA Class: II
Blood Pressure: 100/60 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Diabetes, Myocardial Infarction
Albumin (g/L): 43
ALT or GPT (IU/L): 22.0
AST or GOT (IU/L): 20.0
Total Cholesterol (mmol/L): 3,65
Creatinine (mmol/L): 115.0
Gamma-glutamil transpeptidase (IU/L): 25
Glucose (mmol/L): 6,1
Hemoglobin (g/L): 144.0
HDL (mmol/L): 0,78
Potassium (mEq/L): 3,9
LDL (mmol/L): 2,09
Sodium (mEq/L): 138.0
Pro-BNP (ng/L): 526.0
Protein (g/L): 68
T3 (pg/dL): 0,06
T4 (ng/L): 16
Troponin (ng/mL): 0,02
TSH (mIU/L): 2,05
Urea (mg/dL): 8,49
LVEF (%): 24.0
Medications: Beta Blockers, Statins, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"RANKING: 
1. Survivor
REASONING: 
This patient has a complex medical history, including ischemic dilated cardiomyopathy, myocardial infarction, and diabetes, which are risk factors for heart failure and arrhythmias. However, the patient is currently on beta blockers, statins, and an ACE inhibitor, which are standard treatments for managing heart failure and reducing cardiovascular risk. The patient's NYHA Class II indicates moderate symptoms of heart failure, but the patient is still able to perform daily activities with some limitation.

The ECG impression highlights the presence of ventricular extrasystole, polymorphic ventricular tachycardia, and non-sustained ventricular tachycardia, which are all concerning signs of arrhythmias. However, the absence of sustained ventricular tachycardia and paroxysmal supraventricular tachyarrhythmia reduces the risk of sudden cardiac death.

The patient's laboratory results show elevated creatinine levels, indicating some degree of renal impairment, but not severe kidney failure. The low albumin level may indicate some degree of malnutrition or liver disease, but the ALT and AST levels are within normal limits. The low T3 level may indicate hypothyroidism, but the TSH level is within normal limits.

Given these factors, the patient's overall prognosis is good, with a moderate risk of arrhythmias and heart failure exacerbation. However, the patient's age, sex, and medical history do not suggest a high risk of sudden cardiac death. Therefore, I predict that the patient is likely to survive for the next few years, provided that the current treatment plan is continued and any underlying conditions are managed effectively.

2. Sudden Cardiac Death
REASONING: 
While the patient's ECG impression shows signs of arrhythmias, the absence of sustained ventricular tachycardia and paroxysmal supraventricular tachyarrhythmia reduces the risk of sudden cardiac death. However, the patient's history of myocardial infarction and ischemic dilated cardiomyopathy increases the risk of arrhythmias and sudden cardiac death.

The patient's low LVEF of 24% indicates significant left ventricular dysfunction, which increases the risk of arrhythmias and sudden cardiac death. The patient's elevated creatinine levels and low albumin levels may indicate some degree of renal impairment and malnutrition, which can increase the risk of arrhythmias and sudden cardiac death.

3. Pump Failure Death
REASONING: 
While the patient's NYHA Class II indicates moderate symptoms of heart failure, the patient is currently on beta blockers, statins, and an ACE inhibitor, which are standard treatments for managing heart failure. The patient's LVEF of 24% is significantly reduced, indicating poor left ventricular function, but the patient is not currently in heart failure exacerbation.

However, the patient's history of myocardial infarction and ischemic dilated cardiomyopathy increases the risk of pump failure, and the patient's elevated creatinine levels and low albumin levels may indicate some degree of renal impairment and malnutrition. Additionally, the patient's arrhythmias, as indicated by the ECG impression, may increase the risk of sudden cardiac death and pump failure. Therefore, while the patient's prognosis is good, there is a moderate risk of pump failure over the next few years, making this prognosis the least likely."
66,66,P0104,"Age: 51
Gender: Male 
Weight: 75 kg
Height: 172 cm
NYHA Class: II
Blood Pressure: 120/70 mmHg
Past Medical History: Idiopathic dilated cardiomyopathy, Diabetes, Dyslipemia
Albumin (g/L): 39
ALT or GPT (IU/L): 14.0
AST or GOT (IU/L): 15.0
Total Cholesterol (mmol/L): 3,26
Creatinine (mmol/L): 106.0
Gamma-glutamil transpeptidase (IU/L): 20
Glucose (mmol/L): 7,6
Hemoglobin (g/L): 145.0
HDL (mmol/L): 1,01
Potassium (mEq/L): 4
LDL (mmol/L): 1,5
Sodium (mEq/L): 138.0
Pro-BNP (ng/L): 405.0
Protein (g/L): 66
T3 (pg/dL): 0,05
T4 (ng/L): 18
Troponin (ng/mL): 0,03
TSH (mIU/L): 2,63
Urea (mg/dL): 8,65
LVEF (%): 31.0
Medications: Diabetes Medication, Beta Blockers, Loop Diuretics, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"RANKING: 
1. Survivor
2. Sudden Cardiac Death
3. Pump Failure Death

REASONING:

Based on the provided patient data, the patient has a significant number of risk factors that contribute to a poor prognosis. However, the patient's current condition and the provided outcome of ""survivor"" suggest that the patient is still alive and relatively stable.

The patient's left ventricular ejection fraction (LVEF) is significantly reduced at 31%, indicating severe left ventricular dysfunction. This is a strong indicator of advanced heart failure, which increases the risk of both sudden cardiac death and pump failure.

However, the patient is currently taking medications that are commonly used to manage heart failure, including beta blockers, ACE inhibitors, and loop diuretics. These medications have been shown to improve survival and reduce the risk of adverse outcomes in patients with heart failure.

The patient's electrolyte levels, including potassium, sodium, and urea, are within relatively normal limits, which suggests that the patient is not experiencing acute kidney injury or severe electrolyte imbalances that could contribute to sudden cardiac death.

The patient's troponin level is also within normal limits, which suggests that there is no significant myocardial injury.

While the patient has a number of risk factors, including idiopathic dilated cardiomyopathy, diabetes, and dyslipemia, the patient's current condition and the provided outcome of ""survivor"" suggest that the patient is relatively stable and at low risk for sudden cardiac death in the short term.

Therefore, while pump failure is a significant risk, the patient's current condition and the provided outcome suggest that the patient is more likely to survive in the short term, making ""survivor"" the most likely outcome. Sudden cardiac death is still a potential risk, but it is less likely given the patient's current stable condition and the absence of acute electrolyte imbalances or myocardial injury. Pump failure death is also a risk, but it is less likely given the patient's current treatment and stable condition."
67,67,P0105,"Age: 75
Gender: Female 
Weight: 77 kg
Height: 154 cm
NYHA Class: II
Blood Pressure: 130/88 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Diabetes, Hypertension
Albumin (g/L): 40,4
ALT or GPT (IU/L): 15.0
AST or GOT (IU/L): 15.0
Total Cholesterol (mmol/L): 4,68
Creatinine (mmol/L): 131.0
Gamma-glutamil transpeptidase (IU/L): 18
Glucose (mmol/L): 11,4
Hemoglobin (g/L): 135.0
HDL (mmol/L): 1,42
Potassium (mEq/L): 4,7
LDL (mmol/L): 2,51
Sodium (mEq/L): 139.0
Pro-BNP (ng/L): 2176.0
Protein (g/L): 71
T4 (ng/L): 16
TSH (mIU/L): 1,48
Urea (mg/dL): 10,82
LVEF (%): 39.0
Medications: Diabetes Medication, Angiotensin II Receptor Blocker, Beta Blockers, Loop Diuretics, Spironolactone
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",survivor,"RANKING: 1. Survivor
REASONING: The patient's overall clinical presentation and test results suggest a poor prognosis, but the patient is already classified as a survivor. The patient's NYHA Class II indicates a moderate level of heart failure, and their LVEF of 39.0% is significantly reduced, indicating reduced cardiac function. The presence of ventricular extrasystole, non-sustained ventricular tachycardia, and paroxysmal supraventricular tachyarrhythmia further increases the risk of cardiac complications. However, the patient is already receiving treatment with medications for heart failure, hypertension, and diabetes, which suggests that the patient is receiving optimal management for their conditions. Additionally, the patient's biomarkers, such as the elevated creatinine and urea levels, indicate some degree of renal impairment, but this is not uncommon in patients with heart failure. The patient's protein level is slightly elevated, but not significantly high. Overall, while the patient's prognosis is uncertain, the patient's survival status as a survivor suggests that they are likely to survive for the next few years with close monitoring and continued optimal management of their conditions."
68,68,P0106,"Age: 56
Gender: Female 
Weight: 55 kg
Height: 148 cm
NYHA Class: II
Blood Pressure: 125/80 mmHg
Past Medical History: Idiopathic dilated cardiomyopathy
Albumin (g/L): 44
ALT or GPT (IU/L): 8.0
AST or GOT (IU/L): 17.0
Total Cholesterol (mmol/L): 6,41
Creatinine (mmol/L): 66.0
Gamma-glutamil transpeptidase (IU/L): 12
Glucose (mmol/L): 4,8
Hemoglobin (g/L): 127.0
HDL (mmol/L): 1,86
Potassium (mEq/L): 4,7
LDL (mmol/L): 4,16
Sodium (mEq/L): 138.0
Pro-BNP (ng/L): 1160.0
Protein (g/L): 74,9
T4 (ng/L): 15
TSH (mIU/L): 0,65
Urea (mg/dL): 6,99
LVEF (%): 26.0
Medications: Loop Diuretics, Spironolactone, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: TPSV
        - Bradycardia: No
            ",survivor,"RANKING: 
1. Survivor
REASONING: 

Based on the provided patient data, I would rank the patient as having a high likelihood of survival for the next few years. The patient's NYHA Class II indicates that they have some symptoms of heart failure, but they are still able to perform moderate physical activities without significant symptoms. The patient's LVEF of 26.0 is significantly reduced, indicating left ventricular dysfunction, which is consistent with idiopathic dilated cardiomyopathy. However, the patient is receiving medications for heart failure (loop diuretics, spironolactone, and an ACE inhibitor), which suggests that their condition is being managed.

The patient's ECG findings are concerning, with ventricular extrasystoles, non-sustained ventricular tachycardia, and non-sustained ventricular tachycardia, which may indicate arrhythmias and increased risk of cardiac events. However, the fact that these arrhythmias are non-sustained suggests that they are not severe and may not be a significant predictor of mortality.

The patient's laboratory results show some abnormalities, including elevated creatinine and urea, which may indicate kidney dysfunction. However, these findings are not directly related to cardiac function and may not significantly impact the patient's survival.

Considering these factors, I believe that the patient is likely to survive for the next few years, but it is essential to closely monitor their condition and adjust their treatment plan as needed to minimize the risk of cardiac events.

RANKING: 
2. Sudden cardiac death
REASONING: 

Sudden cardiac death is a possible outcome for this patient, given the patient's history of idiopathic dilated cardiomyopathy, ventricular extrasystoles, and non-sustained ventricular tachycardia. The patient's LVEF is significantly reduced, which increases the risk of sudden cardiac death.

However, the fact that the arrhythmias are non-sustained reduces the likelihood of sudden cardiac death. Additionally, the patient is receiving medications for heart failure, which may help to reduce the risk of sudden cardiac death.

RANKING: 
3. Pump failure death
REASONING: 

Pump failure death is a possible outcome for this patient, given the patient's history of idiopathic dilated cardiomyopathy and reduced LVEF. The patient's NYHA Class II symptoms indicate that they have some degree of heart failure, which may increase the risk of pump failure.

However, the patient is receiving medications for heart failure, which may help to reduce the risk of pump failure. Additionally, the patient's laboratory results do not show significant abnormalities that would suggest a high risk of pump failure.

Considering the patient's overall condition, I believe that pump failure death is less likely compared to sudden cardiac death, but still a possible outcome."
69,69,P0110,"Age: 67
Gender: Female 
Weight: 69 kg
Height: 158 cm
NYHA Class: II
Blood Pressure: 98/52 mmHg
Past Medical History: Idiopathic dilated cardiomyopathy, Diabetes
Albumin (g/L): 41
ALT or GPT (IU/L): 14.0
AST or GOT (IU/L): 21.0
Total Cholesterol (mmol/L): 4,45
Creatinine (mmol/L): 80.0
Gamma-glutamil transpeptidase (IU/L): 16
Glucose (mmol/L): 5,8
Hemoglobin (g/L): 117.0
HDL (mmol/L): 1,29
Potassium (mEq/L): 5
LDL (mmol/L): 2,43
Sodium (mEq/L): 137.0
Pro-BNP (ng/L): 125.0
Protein (g/L): 71
T4 (ng/L): 21
Troponin (ng/mL): 0,01
TSH (mIU/L): 2,72
Urea (mg/dL): 8,32
LVEF (%): 30.0
Medications: Diabetes Medication, Beta Blockers, Spironolactone, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"RANKING: 1. Survivor
REASONING: 

The patient's prognosis is likely to be a survivor due to several factors:

1. Age: The patient is 67 years old, which is considered middle-aged. While age can be a risk factor for cardiovascular disease, it is not the only factor at play. Many patients of this age can live a long and healthy life with proper management.

2. NYHA Class II: The patient's New York Heart Association (NYHA) class II indicates that the patient experiences some limitations in physical activity due to heart disease, but they are still able to carry on light activity without discomfort. This suggests that the patient's heart is not severely impaired.

3. Medications: The patient is taking a comprehensive regimen of medications, including beta blockers, spironolactone, and an ACE inhibitor. These medications are commonly used to manage heart failure, high blood pressure, and other cardiovascular conditions.

4. Pro-BNP level: The patient's Pro-BNP (N-terminal pro b-type natriuretic peptide) level is 125.0 ng/L, which is slightly elevated. However, this level is not extremely high, and it may indicate some degree of heart failure, but not severe.

5. Troponin level: The patient's troponin level is 0.01 ng/mL, which is within the normal range. This suggests that there is no significant cardiac muscle damage.

6. ECG findings: The patient's ECG shows ventricular extrasystoles, but no ventricular tachycardia or non-sustained ventricular tachycardia. This suggests that the patient's heart is not experiencing severe arrhythmias.

7. Other lab results: The patient's kidney function is slightly impaired (creatinine level 80.0 mol/L), but this is not uncommon in patients with heart failure. The patient's liver function tests are within normal limits.

Considering these factors, the patient's prognosis is likely to be a survivor. However, it is essential to closely monitor the patient's condition and adjust the treatment plan as needed to prevent any potential complications."
70,70,P0111,"Age: 60
Gender: Male 
Weight: 85 kg
Height: 166 cm
NYHA Class: II
Blood Pressure: 115/68 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Dyslipemia, Myocardial Infarction
Albumin (g/L): 43
ALT or GPT (IU/L): 17.0
AST or GOT (IU/L): 25.0
Total Cholesterol (mmol/L): 3,49
Creatinine (mmol/L): 97.0
Gamma-glutamil transpeptidase (IU/L): 40
Glucose (mmol/L): 5,4
Hemoglobin (g/L): 144.0
HDL (mmol/L): 1,16
Potassium (mEq/L): 4,5
LDL (mmol/L): 2,09
Sodium (mEq/L): 141.0
Pro-BNP (ng/L): 349.0
Protein (g/L): 76
T4 (ng/L): 14
Troponin (ng/mL): 0,01
TSH (mIU/L): 1,19
Urea (mg/dL): 7,49
LVEF (%): 25.0
Medications: Beta Blockers, Statins, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"RANKING: 1. Survivor
REASONING:

Based on the provided patient data, I would rank the patient as having the highest likelihood of survival over the next few years as a survivor. The following factors contribute to this prediction:

1. NYHA Class II: The patient's New York Heart Association (NYHA) functional class is II, indicating mild symptoms and a relatively preserved cardiac function, which is a good prognostic indicator for survival.
2. Medications: The patient is already taking beta blockers, statins, and an ACE inhibitor, which are standard treatments for managing heart failure, hypertension, and dyslipidemia. These medications can help slow disease progression and improve symptoms.
3. LVEF 25.0: The left ventricular ejection fraction (LVEF) is significantly reduced, indicating poor cardiac function. However, a mild reduction in LVEF is not uncommon in patients with ischemic dilated cardiomyopathy.
4. Pro-BNP 349.0: Elevated brain natriuretic peptide (BNP) levels indicate some degree of cardiac stress, but the level is not excessively high, suggesting that the patient may not be in acute decompensated heart failure.
5. Absence of high-risk ECG findings: The ECG does not show any high-risk findings, such as ventricular tachycardia, non-sustained ventricular tachycardia, or other arrhythmias that could indicate a high risk of sudden cardiac death.
6. No acute kidney injury: The creatinine level is slightly elevated, but it is not indicative of acute kidney injury, and the patient is not on dialysis.
7. No other life-threatening conditions: The patient does not have any other life-threatening conditions, such as severe anemia, significant hypokalemia, or acute electrolyte imbalances.

While the patient has several risk factors, including a history of myocardial infarction and ischemic dilated cardiomyopathy, the presence of NYHA Class II symptoms, current medications, and relatively mild LVEF reduction suggest that the patient is likely to survive over the next few years with close monitoring and optimal management of their condition."
71,71,P0113,"Age: 63
Gender: Male 
Weight: 66 kg
Height: 164 cm
NYHA Class: II
Blood Pressure: 105/68 mmHg
Past Medical History: Idiopathic dilated cardiomyopathy, Dyslipemia
Albumin (g/L): 43
ALT or GPT (IU/L): 29.0
AST or GOT (IU/L): 22.0
Total Cholesterol (mmol/L): 4,99
Creatinine (mmol/L): 97.0
Gamma-glutamil transpeptidase (IU/L): 14
Glucose (mmol/L): 5,2
Hemoglobin (g/L): 143.0
HDL (mmol/L): 1,71
Potassium (mEq/L): 3,8
LDL (mmol/L): 2,9
Sodium (mEq/L): 142.0
Pro-BNP (ng/L): 290.0
Protein (g/L): 66
T4 (ng/L): 15
Troponin (ng/mL): 0,01
TSH (mIU/L): 1,8
Urea (mg/dL): 9,65
LVEF (%): 25.0
Medications: Beta Blockers, Digoxin, Loop Diuretics, Statins, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: First-degree Atrioventricular block (AVB)
            ",survivor,"RANKING: 1. Survivor
REASONING:

The patient's age, NYHA Class II, and the presence of idiopathic dilated cardiomyopathy are significant risk factors for adverse outcomes. However, the patient's current medical history, laboratory results, and ECG findings do not indicate a high risk of sudden cardiac death or pump failure. The patient's LVEF of 25% is a strong indicator of poor cardiac function, but the patient is receiving medications that are typically used to manage heart failure symptoms and improve cardiac function (beta blockers, digoxin, loop diuretics, and ACE inhibitor).

The patient's creatinine level is slightly elevated, but this is not uncommon in patients with heart failure. The presence of non-sustained ventricular tachycardia (NSVT) is a concerning finding, but the patient's overall risk profile does not suggest a high risk of sudden cardiac death. The absence of other ECG findings such as bundle branch block, left bundle branch block, or QRS duration > 120ms, which are associated with an increased risk of ventricular arrhythmias, further reduces the likelihood of sudden cardiac death.

The patient's troponin level is within normal limits, which suggests that there is no acute myocardial infarction. The patient's renal function is also within normal limits, which reduces the risk of kidney-related complications.

Overall, considering the patient's age, NYHA Class II, and the presence of idiopathic dilated cardiomyopathy, the patient is at risk of worsening heart failure, but the patient's current medical history, laboratory results, and ECG findings do not indicate a high risk of sudden cardiac death or pump failure. Therefore, the most likely outcome for the patient is survival.

The patient's chances of sudden cardiac death and pump failure are lower than survivor due to the following reasons:

- Sudden cardiac death: The patient's ECG findings, such as non-sustained ventricular tachycardia, are concerning but not indicative of a high risk of sudden cardiac death. The absence of other ECG findings that increase the risk of sudden cardiac death, such as bundle branch block, left bundle branch block, or QRS duration > 120ms, further reduces the likelihood of sudden cardiac death.

- Pump failure: The patient's LVEF of 25% indicates poor cardiac function, but the patient is receiving medications that are typically used to manage heart failure symptoms and improve cardiac function. The patient's current laboratory results, including normal creatinine levels and normal troponin levels, do not indicate acute kidney injury or myocardial infarction, which are common causes of pump failure.

The patient's chances of survivor are the highest due to the following reasons:

- Age: The patient's age is 63, which is a risk factor for heart failure and arrhythmias, but the patient is not old enough to be considered a high-risk patient.

- NYHA Class II: The patient's NYHA Class II indicates mild heart failure symptoms, which are typically manageable with medication and lifestyle changes.

- Medications: The patient is receiving medications that are typically used to manage heart failure symptoms and improve cardiac function, which reduces the risk of worsening heart failure.

- Laboratory results: The patient's laboratory results, including normal creatinine levels and normal troponin levels, do not indicate acute kidney injury or myocardial infarction, which are common causes of pump failure.

- ECG findings: The patient's ECG findings, including non-sustained ventricular tachycardia, are concerning but not indicative of a high risk of sudden cardiac death or pump failure. The absence of other ECG findings that increase the risk of sudden cardiac death or pump failure further reduces the likelihood of these outcomes."
72,72,P0115,"Age: 67
Gender: Female 
Weight: 65 kg
Height: 161 cm
NYHA Class: II
Blood Pressure: 105/59 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Dyslipemia, Myocardial Infarction
Albumin (g/L): 38
ALT or GPT (IU/L): 16.0
AST or GOT (IU/L): 14.0
Total Cholesterol (mmol/L): 4,81
Creatinine (mmol/L): 80.0
Gamma-glutamil transpeptidase (IU/L): 16
Glucose (mmol/L): 4,7
Hemoglobin (g/L): 127.0
HDL (mmol/L): 1,97
Potassium (mEq/L): 4,2
LDL (mmol/L): 2,59
Sodium (mEq/L): 139.0
Pro-BNP (ng/L): 984.0
Protein (g/L): 61
T4 (ng/L): 14
Troponin (ng/mL): 0,01
TSH (mIU/L): 5,16
Urea (mg/dL): 6,99
LVEF (%): 35.0
Medications: Angiotensin II Receptor Blocker, Beta Blockers, Statins
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"RANKING: 
1. Survivor
REASONING:
Based on the patient's data, I would rank the patient as a survivor with a high probability. The patient's age (67) is not extremely high, but the presence of a history of ischemic dilated cardiomyopathy and myocardial infarction suggests a significant underlying cardiac disease. However, the patient's left ventricular ejection fraction (LVEF) is relatively preserved at 35%, which indicates some residual cardiac function.

The patient's biomarkers, such as troponin and creatinine levels, are within normal limits, which suggests that the patient is not experiencing acute cardiac stress or significant kidney dysfunction. The patient's lipid profile, with a total cholesterol level of 4.81 mmol/L, is not excessively high, and the patient is on statins, which are beneficial for cardiovascular health.

The patient's medication regimen, including angiotensin II receptor blockers, beta blockers, and statins, is also well-managed and indicates a good level of cardiovascular care.

The ECG findings are largely unremarkable, with no signs of ventricular tachycardia, ventricular extrasystoles, or significant arrhythmias. The patient's blood pressure is well-controlled, and the patient's renal function, as indicated by the creatinine level, is not severely impaired.

Overall, while the patient has a significant history of cardiac disease, the combination of preserved LVEF, normal biomarkers, and well-managed medication regimen suggest that the patient is likely to survive for the next few years with appropriate management and follow-up."
73,73,P0116,"Age: 64
Gender: Male 
Weight: 98 kg
Height: 168 cm
NYHA Class: II
Blood Pressure: 100/60 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Diabetes, Dyslipemia, Myocardial Infarction
Albumin (g/L): 38
ALT or GPT (IU/L): 18.0
AST or GOT (IU/L): 15.0
Total Cholesterol (mmol/L): 3,96
Creatinine (mmol/L): 71.0
Gamma-glutamil transpeptidase (IU/L): 16
Glucose (mmol/L): 15,3
Hemoglobin (g/L): 139.0
HDL (mmol/L): 0,7
Potassium (mEq/L): 4,5
LDL (mmol/L): 2,17
Sodium (mEq/L): 136.0
Pro-BNP (ng/L): 575.0
Protein (g/L): 67
T4 (ng/L): 15
Troponin (ng/mL): 0,01
TSH (mIU/L): 2,88
Urea (mg/dL): 9,32
LVEF (%): 30.0
Medications: Diabetes Medication, Angiotensin II Receptor Blocker, Beta Blockers, Loop Diuretics, Statins, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"RANKING: 
1. Survivor
REASONING: 
The patient has a complex medical history with multiple comorbidities, including ischemic dilated cardiomyopathy, diabetes, dyslipemia, and a previous myocardial infarction. However, the patient is currently on a regimen of medications that target these conditions, including beta blockers, statins, and diuretics, which are commonly used to manage these conditions. The patient's laboratory results, such as the elevated troponin level, suggest some degree of cardiac damage, but it is not excessively high. The patient's LVEF is significantly reduced, but it is not extremely low.

The patient's ECG shows ventricular extrasystole, which is a benign finding, and no other concerning arrhythmias. The patient's electrolyte levels are relatively normal, and the patient's renal function is mildly impaired, but not severely compromised.

Given the patient's overall medical history and current clinical status, I would estimate that the patient is likely to survive for the next few years. The patient's medications and current treatment plan should help manage their comorbid conditions and slow disease progression. The patient's LVEF is low, but it is not extremely low, and the patient is on medications that can help improve cardiac function.

While the patient's past medical history is concerning, the patient's current clinical status is relatively stable, and the patient is on a regimen of medications that target their comorbid conditions. Therefore, I would rank the patient as a survivor with a moderate risk of complications, but with the potential for some improvement with continued treatment and management of their conditions.

It is essential to monitor the patient closely and adjust their treatment plan as needed to minimize the risk of complications and optimize their outcomes. Regular follow-up appointments and regular monitoring of the patient's cardiac function, renal function, and other vital signs will be crucial in managing this patient's condition."
74,74,P0118,"Age: 61
Gender: Male 
Weight: 60 kg
Height: 156 cm
NYHA Class: II
Blood Pressure: 124/55 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Dyslipemia, Hypertension, Myocardial Infarction
Albumin (g/L): 43
ALT or GPT (IU/L): 24.0
AST or GOT (IU/L): 21.0
Total Cholesterol (mmol/L): 4,86
Creatinine (mmol/L): 80.0
Gamma-glutamil transpeptidase (IU/L): 14
Glucose (mmol/L): 5
Hemoglobin (g/L): 130.0
HDL (mmol/L): 1,78
Potassium (mEq/L): 4,2
LDL (mmol/L): 2,61
Sodium (mEq/L): 139.0
Pro-BNP (ng/L): 709.0
Protein (g/L): 66
T4 (ng/L): 15
Troponin (ng/mL): 0,01
TSH (mIU/L): 3,49
Urea (mg/dL): 7,32
LVEF (%): 35.0
Medications: Beta Blockers, Spironolactone, Statins, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"RANKING: 

1. Survivor
REASONING: 
The patient has a history of ischemic dilated cardiomyopathy, which is a condition where the heart's pumping ability is compromised due to scarring from a heart attack. The patient's current ejection fraction (LVEF) of 35% indicates significant impairment of the heart's pumping function. However, the patient is on medications such as beta blockers, spironolactone, and statins, which are commonly used to manage heart failure and reduce the risk of further cardiac events. Additionally, the patient's pro-BNP levels are elevated, which suggests some degree of heart failure. Despite these factors, the patient's overall condition is stable, and there is no indication of acute heart failure or life-threatening arrhythmias. Therefore, the most likely outcome for the next few years is that the patient will survive.

2. Pump failure death
REASONING: 
Although the patient has a significant history of heart disease and impaired LVEF, the patient's current condition is stable, and they are on medications to manage their heart failure. However, the patient's ejection fraction is still relatively low, and the presence of elevated pro-BNP levels suggests some degree of heart failure. If the patient's condition worsens or the medications are not effective, the risk of pump failure increases. Additionally, the patient's history of myocardial infarction and hypertension may lead to further cardiac complications. Therefore, while pump failure is a possible outcome, it is less likely compared to the patient surviving, given the current stable condition and management.

3. Sudden cardiac death
REASONING: 
The patient's ECG shows ventricular extrasystoles, which may indicate an increased risk of arrhythmias. However, the absence of ventricular tachycardia, non-sustained ventricular tachycardia, and paroxysmal supraventricular tachyarrhythmia reduces the risk of sudden cardiac death. The patient's medications, including beta blockers, which are known to reduce the risk of arrhythmias, also support this outcome. Additionally, the patient's stable condition and low troponin levels suggest that there is no acute myocardial injury. Therefore, the risk of sudden cardiac death is relatively low, making this outcome the least likely."
75,75,P0119,"Age: 58
Gender: Male 
Weight: 73 kg
Height: 161 cm
NYHA Class: II
Blood Pressure: 145/70 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Diabetes, Dyslipemia, Myocardial Infarction
Albumin (g/L): 49
ALT or GPT (IU/L): 18.0
AST or GOT (IU/L): 12.0
Total Cholesterol (mmol/L): 4,14
Creatinine (mmol/L): 88.0
Gamma-glutamil transpeptidase (IU/L): 23
Glucose (mmol/L): 9,7
Hemoglobin (g/L): 130.0
HDL (mmol/L): 0,91
Potassium (mEq/L): 4,4
LDL (mmol/L): 2,07
Sodium (mEq/L): 140.0
Pro-BNP (ng/L): 397.0
Protein (g/L): 75
T4 (ng/L): 17
Troponin (ng/mL): 0,01
TSH (mIU/L): 2,42
Urea (mg/dL): 7,49
LVEF (%): 23.0
Medications: Diabetes Medication, Beta Blockers, Statins, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: Sinus Node Dysfunction
            ",survivor,"RANKING: 1. Survivor
REASONING: 

Based on the provided patient data, the patient is at high risk for cardiac complications, but the overall prognosis is still favorable due to the presence of a few factors that suggest a better outcome. 

The patient has a history of ischemic dilated cardiomyopathy, which indicates that their heart muscle has been damaged, leading to reduced ejection fraction (LVEF 23.0). This is a significant risk factor for adverse outcomes. However, the patient is currently being treated with medications that are commonly used to manage heart failure and reduce the risk of further complications.

The patient's elevated troponin level (0.01 ng/mL) may indicate some degree of myocardial damage, but it is not excessively high. The presence of ventricular extrasystoles, non-sustained ventricular tachycardia, and sinus node dysfunction on the ECG also raise concerns about cardiac arrhythmias.

Despite these risks, the patient's age (58 years) is not considered old, and their weight (73 kg) is within a relatively normal range. The patient's NYHA class is II, indicating mild symptoms, which suggests that they are not severely impaired.

The patient's laboratory results show elevated creatinine levels (88.0 mmol/L), which may indicate some degree of kidney dysfunction. However, this is not uncommon in patients with heart failure.

The patient's lipid profile is not ideal, with high total cholesterol and LDL levels, but they are being treated with statins, which can help manage these risk factors.

Given these factors, I believe that the patient is at moderate to high risk for cardiac complications, but the presence of a favorable age, NYHA class, and treatment with evidence-based medications suggest that the patient is likely to survive for at least the next few years. Therefore, the most likely prognosis is that the patient will survive.

RANKING: 2. Sudden Cardiac Death
REASONING: 

While the patient is at risk for cardiac complications, the likelihood of sudden cardiac death (SCD) is not extremely high. However, the presence of ventricular extrasystoles, non-sustained ventricular tachycardia, and sinus node dysfunction on the ECG increase the risk of arrhythmias, which can lead to SCD.

The patient's LVEF is severely impaired (23.0%), which is a significant risk factor for SCD. However, the patient is being treated with beta blockers, which can help reduce the risk of arrhythmias.

The patient's elevated troponin level (0.01 ng/mL) may indicate some degree of myocardial damage, which could increase the risk of SCD. However, this is not excessively high.

The patient's age and NYHA class are not as favorable as those of the survivor, but the patient is still relatively young and has a mild NYHA class.

Given these factors, I believe that the patient is at moderate risk for SCD, but the presence of treatment with beta blockers and other evidence-based medications suggests that the likelihood of SCD is not extremely high.

RANKING: 3. Pump Failure Death
REASONING: 

The patient is at high risk for pump failure death due to their severely impaired LVEF (23.0%) and history of ischemic dilated cardiomyopathy. The patient's NYHA class is II, indicating mild symptoms, but this is not sufficient to mitigate the risk of pump failure.

The patient's elevated creatinine levels (88.0 mmol/L) and elevated BNP (397.0 ng/L) suggest that the patient has some degree of heart failure, which can lead to pump failure.

The patient's lipid profile is not ideal, with high total cholesterol and LDL levels, which can increase the risk of cardiovascular events, including pump failure.

The patient's treatment with diabetes medication, beta blockers, statins, and ACE inhibitor may help manage some of these risk factors, but they are not sufficient to completely mitigate the risk of pump failure.

Given these factors, I believe that the patient is at high risk for pump failure death, and this is the most likely outcome."
76,76,P0120,"Age: 61
Gender: Female 
Weight: 58 kg
Height: 150 cm
NYHA Class: II
Blood Pressure: 128/67 mmHg
Past Medical History: Idiopathic dilated cardiomyopathy, Dyslipemia, Hypertension
Albumin (g/L): 40
ALT or GPT (IU/L): 10.0
AST or GOT (IU/L): 9.0
Total Cholesterol (mmol/L): 4,34
Creatinine (mmol/L): 62.0
Gamma-glutamil transpeptidase (IU/L): 16
Glucose (mmol/L): 4,5
Hemoglobin (g/L): 150.0
HDL (mmol/L): 1,16
Potassium (mEq/L): 4,1
LDL (mmol/L): 2,33
Sodium (mEq/L): 138.0
Pro-BNP (ng/L): 822.0
Protein (g/L): 70
T4 (ng/L): 21
Troponin (ng/mL): 0,01
TSH (mIU/L): 0,07
Urea (mg/dL): 5,83
LVEF (%): 30.0
Medications: Beta Blockers, Statins, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"RANKING: 1. Survivor
REASONING: 

This patient has several factors that suggest a favorable prognosis. Firstly, the patient is on medications that are commonly used to manage heart failure, such as beta blockers, statins, and ACE inhibitors, which are known to improve survival and reduce morbidity in patients with heart failure. 

The patient's NYHA class is II, indicating mild symptoms of heart failure, which is a relatively mild stage of the disease. The patient's LVEF is 30%, which is a significant reduction in left ventricular function, but it is not extremely low. 

Additionally, the patient's creatinine level is elevated, but it is not severely elevated, which may indicate some residual renal function. The patient's glucose and lipid profiles are also within relatively normal limits, which may indicate that the patient is not at high risk for further cardiovascular events.

The patient's ECG findings are concerning, with ventricular extrasystoles and non-sustained ventricular tachycardia, but these are not extremely concerning for a poor outcome. The patient does not have any evidence of severe arrhythmias or significant left ventricular dysfunction.

Overall, while the patient has several risk factors for heart failure and arrhythmias, the presence of multiple medications, a relatively mild NYHA class, and a moderate level of LVEF suggest that the patient is likely to survive in the next few years.

RANKING: 2. Sudden cardiac death
REASONING: 

The patient's ECG findings, including ventricular extrasystoles and non-sustained ventricular tachycardia, are concerning for an increased risk of sudden cardiac death. The presence of ventricular extrasystoles and non-sustained ventricular tachycardia increases the risk of sudden cardiac death, especially in patients with pre-existing heart failure.

Additionally, the patient's LVEF is only 30%, which is a significant reduction in left ventricular function. This reduced function increases the risk of arrhythmias and sudden cardiac death.

The patient's age, gender, and other comorbidities, such as hypertension and dyslipidemia, also increase the risk of sudden cardiac death.

RANKING: 3. Pump failure death
REASONING: 

While the patient has several risk factors for heart failure, including a reduced LVEF and elevated creatinine level, the presence of multiple medications and a relatively mild NYHA class suggest that the patient is not at high risk for pump failure in the short term.

However, the patient's LVEF is only 30%, which is a significant reduction in left ventricular function. This reduced function increases the risk of pump failure, especially if the patient's condition does not improve with treatment.

Additionally, the patient's elevated creatinine level and elevated Pro-BNP level suggest that the patient's heart failure is not well-controlled, which increases the risk of pump failure.

Overall, while the patient has several risk factors for pump failure, the presence of multiple medications and a relatively mild NYHA class suggest that the patient is not at high risk for pump failure in the short term. However, the patient's LVEF and elevated creatinine level do increase the risk of pump failure in the long term."
77,77,P0121,"Age: 41
Gender: Female 
Weight: 97 kg
Height: 160 cm
NYHA Class: II
Blood Pressure: 120/70 mmHg
Past Medical History: Idiopathic dilated cardiomyopathy, Diabetes, Dyslipemia, Hypertension
Albumin (g/L): 38
ALT or GPT (IU/L): 25.0
AST or GOT (IU/L): 11.0
Total Cholesterol (mmol/L): 5,4
Creatinine (mmol/L): 88.0
Gamma-glutamil transpeptidase (IU/L): 29
Glucose (mmol/L): 9,8
Hemoglobin (g/L): 129.0
HDL (mmol/L): 1,14
Potassium (mEq/L): 4,7
LDL (mmol/L): 3,05
Sodium (mEq/L): 136.0
Pro-BNP (ng/L): 642.0
Protein (g/L): 70
T4 (ng/L): 14
Troponin (ng/mL): 0,01
TSH (mIU/L): 1,87
Urea (mg/dL): 6,99
LVEF (%): 35.0
Medications: Angiotensin II Receptor Blocker, Loop Diuretics, Statins, ACE Inhibitor, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"RANKING: 
1. Survivor
REASONING: 
Based on the provided patient data, the patient is at high risk for cardiac complications, but the overall clinical presentation and the absence of acute life-threatening arrhythmias or signs of acute coronary syndrome suggest that the patient may still be able to recover with proper management. The patient's NYHA Class II indicates that they have some symptoms with ordinary physical activity, but they are not severely limited in their daily activities. The patient's LVEF of 35% indicates significant left ventricular dysfunction, which is a major risk factor for adverse outcomes. However, the absence of elevated troponin levels suggests that there is no acute myocardial infarction, and the patient is not in acute cardiogenic shock. The patient's medications, including ACE inhibitors and beta-blockers, are standard therapy for heart failure and are likely to improve outcomes. The patient's ECG findings do not indicate any acute life-threatening arrhythmias, and the absence of non-sustained ventricular tachycardia is a positive sign. The patient's elevated Pro-BNP levels suggest some degree of ventricular stress, but the overall clinical picture is not as dire as it could be. Given the patient's age, comorbidities, and the presence of significant left ventricular dysfunction, I believe that the patient has the best chance of survival over the next few years.

2. Pump failure death
REASONING: 
While the patient's LVEF of 35% indicates significant left ventricular dysfunction, the patient's Pro-BNP levels are not extremely elevated, and the patient's medications are standard therapy for heart failure. However, the patient's NYHA Class II indicates that they have some symptoms with ordinary physical activity, which suggests that the patient may not be as severely limited in their daily activities as they could be. Additionally, the patient's blood pressure and electrolyte levels are relatively well-controlled, which is important for managing heart failure. However, the patient's elevated creatinine levels suggest some degree of kidney dysfunction, which can complicate heart failure management. The patient's elevated cholesterol levels are also a concern, as they can contribute to further cardiovascular disease. Given the patient's significant left ventricular dysfunction and the presence of comorbidities, I believe that the patient is at risk for heart failure exacerbation or decompensation over the next few years, which could lead to pump failure death.

3. Sudden cardiac death
REASONING: 
Given the patient's significant left ventricular dysfunction, the presence of ventricular extrasystole on the ECG, and the patient's history of idiopathic dilated cardiomyopathy, I believe that the patient is at high risk for sudden cardiac death. The patient's LVEF of 35% and elevated Pro-BNP levels suggest that the patient's heart is under significant stress, and the presence of ventricular extrasystole on the ECG indicates a high risk for arrhythmic events. The patient's history of idiopathic dilated cardiomyopathy also increases the risk for sudden cardiac death. While the patient is currently being treated with medications that are standard for heart failure and hypertension, the patient's risk for sudden cardiac death is still significant, and I believe that this is the least likely outcome over the next few years."
78,78,P0122,"Age: 65
Gender: Female 
Weight: 62 kg
Height: 160 cm
NYHA Class: II
Blood Pressure: 130/54 mmHg
Past Medical History: Idiopathic dilated cardiomyopathy, Dyslipemia, Hypertension
Albumin (g/L): 35
ALT or GPT (IU/L): 16.0
AST or GOT (IU/L): 15.0
Total Cholesterol (mmol/L): 3,47
Creatinine (mmol/L): 62.0
Gamma-glutamil transpeptidase (IU/L): 17
Glucose (mmol/L): 4,9
Hemoglobin (g/L): 117.0
HDL (mmol/L): 1,09
Potassium (mEq/L): 4,5
LDL (mmol/L): 1,86
Sodium (mEq/L): 140.0
Pro-BNP (ng/L): 173.0
Protein (g/L): 62
T4 (ng/L): 13
Troponin (ng/mL): 0,01
TSH (mIU/L): 1,03
Urea (mg/dL): 6,99
LVEF (%): 30.0
Medications: Beta Blockers, Statins, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"RANKING: 
1. Survivor 
REASONING: 
Based on the provided patient data, the patient is a 65-year-old female with a history of idiopathic dilated cardiomyopathy, dyslipemia, and hypertension. Her NYHA Class II indicates that she has some limitation in physical activity due to heart failure symptoms. The patient's elevated LVEF of 30.0% is a significant indicator of heart failure severity.

Her elevated Pro-BNP level of 173.0 ng/L suggests that she is experiencing ventricular strain, which is consistent with heart failure. However, the absence of symptoms such as orthopnea, paroxysmal nocturnal dyspnea, or fatigue on exertion, which are common symptoms of advanced heart failure, may suggest that the patient is relatively asymptomatic or mildly symptomatic.

The patient's blood pressure is elevated at 130/54 mmHg, which may be contributing to her heart failure symptoms. However, the presence of beta blockers, statins, and ACE inhibitors, which are standard treatments for heart failure, suggests that the patient is receiving appropriate medical therapy.

Given these factors, I predict that the patient is most likely to survive the next few years, with a reasonable quality of life and manageable symptoms. While there is a risk of cardiac events, the patient's overall condition and treatment plan suggest a favorable prognosis.

2. Sudden cardiac death 
REASONING: 
While the patient's LVEF of 30.0% and elevated Pro-BNP level indicate heart failure, the absence of ventricular tachycardia or non-sustained ventricular tachycardia on the ECG makes sudden cardiac death less likely. However, the patient's elevated blood pressure and hypertension may increase the risk of cardiac events.

The patient's elevated troponin level of 0.01 ng/mL is slightly elevated, but it is not significantly elevated, which may suggest that there is not a significant myocardial infarction or acute cardiac damage. However, the combination of elevated blood pressure, hypertension, and heart failure symptoms may still increase the risk of cardiac events.

3. Pump failure death 
REASONING: 
The patient's elevated LVEF of 30.0% and Pro-BNP level of 173.0 ng/L suggest that the patient's heart is under significant strain, which may lead to pump failure. The patient's NYHA Class II indicates that she has some limitation in physical activity due to heart failure symptoms.

However, the patient's relatively mild symptoms and the presence of beta blockers, statins, and ACE inhibitors, which are standard treatments for heart failure, suggest that the patient is receiving appropriate medical therapy. The patient's elevated blood pressure and hypertension may still contribute to her heart failure symptoms, but the overall prognosis is less favorable than sudden cardiac death due to the presence of established heart failure symptoms and the patient's relatively mild symptoms."
79,79,P0124,"Age: 80
Gender: Male 
Weight: 109 kg
Height: 178 cm
NYHA Class: III
Blood Pressure: 150/95 mmHg
Past Medical History: Hypertropic cardiomyopathy, Diabetes, Dyslipemia, Hypertension
Albumin (g/L): 37
ALT or GPT (IU/L): 38.0
AST or GOT (IU/L): 18.0
Total Cholesterol (mmol/L): 3,75
Creatinine (mmol/L): 177.0
Gamma-glutamil transpeptidase (IU/L): 32
Glucose (mmol/L): 6,3
Hemoglobin (g/L): 100.0
HDL (mmol/L): 0,8
Potassium (mEq/L): 4,8
LDL (mmol/L): 2,35
Sodium (mEq/L): 142.0
Pro-BNP (ng/L): 1475.0
Protein (g/L): 64
T3 (pg/dL): 0,02
T4 (ng/L): 9
Troponin (ng/mL): 0,05
TSH (mIU/L): 1,38
Urea (mg/dL): 23,13
LVEF (%): 62.0
Medications: Angiotensin II Receptor Blocker, Beta Blockers, Loop Diuretics, Statins, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"RANKING: 
1. Survivor 
REASONING: 
The patient has a complex medical history with multiple comorbidities, including hypertension, diabetes, dyslipidemia, and hypertrophic cardiomyopathy, which can increase the risk of cardiovascular events. However, the patient is currently on multiple medications, including an angiotensin II receptor blocker, beta blockers, loop diuretics, and statins, which are commonly used to manage these conditions. The patient's LVEF is 62%, which is within the normal range for an 80-year-old male. The ECG impression shows no signs of ventricular tachycardia or bradycardia, which are potential predictors of sudden cardiac death. The patient's troponin level is also within normal limits, which suggests that there is no significant myocardial damage. 

The patient's high creatinine level (177.0 mol/L) indicates some degree of renal impairment, but this is not uncommon in patients with hypertension and diabetes. The elevated Pro-BNP level (1475.0 ng/L) suggests some degree of heart failure, but the patient is on loop diuretics, which are commonly used to manage heart failure. 

Given these factors, I believe that the patient is at higher risk of experiencing a cardiovascular event, but the presence of multiple medications and the absence of significant ECG abnormalities and myocardial damage suggest that the patient is more likely to survive than experience sudden cardiac death or pump failure. Therefore, I predict that the patient will survive for the next few years."
80,80,P0125,"Age: 76
Gender: Male 
Weight: 79 kg
Height: 180 cm
NYHA Class: II
Blood Pressure: 140/70 mmHg
Past Medical History: Enolic dilated cardiomyopathy, Hypertension
Albumin (g/L): 44
ALT or GPT (IU/L): 37.0
AST or GOT (IU/L): 23.0
Total Cholesterol (mmol/L): 4,47
Creatinine (mmol/L): 115.0
Gamma-glutamil transpeptidase (IU/L): 54
Glucose (mmol/L): 6,2
Hemoglobin (g/L): 122.0
HDL (mmol/L): 1,29
Potassium (mEq/L): 4,4
LDL (mmol/L): 2,66
Sodium (mEq/L): 138.0
Pro-BNP (ng/L): 303.0
Protein (g/L): 74
T3 (pg/dL): 0,06
T4 (ng/L): 13
Troponin (ng/mL): 0,02
TSH (mIU/L): 12,9
Urea (mg/dL): 6,16
LVEF (%): 54.0
Medications: Amiodarone, Beta Blockers, Loop Diuretics, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: Sinus Node Dysfunction
            ",survivor,"RANKING: 1. Survivor
REASONING: 

The patient's overall clinical presentation and laboratory results suggest a high likelihood of survival. The patient's age (76) and NYHA Class II heart failure indicate a moderate level of cardiac dysfunction, but the patient is still relatively active and has a moderate level of physical exertion. The patient's blood pressure is within a relatively normal range (140/70 mmHg), and the presence of enolic dilated cardiomyopathy and hypertension is well-managed with medications.

The patient's laboratory results show elevated troponin levels (0.02 ng/mL) and a mildly elevated LVEF (54.0%), indicating some degree of cardiac dysfunction. However, these results are not severely abnormal and are consistent with a patient who has been on medications for heart failure and arrhythmias for some time.

The patient's ECG results show a history of ventricular extrasystole and non-sustained ventricular tachycardia, but these findings are not indicative of a high risk of sudden cardiac death. The absence of paroxysmal supraventricular tachyarrhythmia and bradycardia reduces the risk of arrhythmic events.

The patient's renal function is slightly impaired (creatinine 1.16 mg/dL), but this is not severe and is likely a result of the patient's age and comorbidities. The patient's electrolyte levels, including potassium (4.4 mEq/L), are within normal limits.

Given the patient's overall clinical presentation, laboratory results, and medication management, the likelihood of sudden cardiac death is low. The patient's history of ventricular extrasystole and non-sustained ventricular tachycardia may indicate some risk of arrhythmic events, but the absence of severe cardiac dysfunction, normal blood pressure, and well-managed comorbidities reduce this risk. Therefore, the most likely prognosis for this patient is survival.

Sudden cardiac death: Unlikely (2/10)
Reasoning: The patient's ECG results show a history of ventricular extrasystole and non-sustained ventricular tachycardia, but these findings are not indicative of a high risk of sudden cardiac death. The patient's cardiac dysfunction is moderate, but well-managed with medications, and the patient's blood pressure and electrolyte levels are within normal limits.

Pump failure death: Unlikely (3/10)
Reasoning: The patient's LVEF is mildly impaired (54.0%), but the patient is well-managed with medications and has a relatively normal blood pressure. The patient's renal function is slightly impaired, but this is not severe. The patient's electrolyte levels, including potassium, are within normal limits, and the patient's cardiac dysfunction is moderate but not severe. These factors reduce the likelihood of pump failure death."
81,81,P0126,"Age: 77
Gender: Female 
Weight: 70 kg
Height: 160 cm
NYHA Class: II
Blood Pressure: 120/80 mmHg
Past Medical History: Hypertensive cardiomyopathy, Hypertension
Albumin (g/L): 36
ALT or GPT (IU/L): 39.0
AST or GOT (IU/L): 22.0
Total Cholesterol (mmol/L): 5,35
Creatinine (mmol/L): 115.0
Gamma-glutamil transpeptidase (IU/L): 237
Glucose (mmol/L): 7,2
Hemoglobin (g/L): 139.0
HDL (mmol/L): 0,98
Potassium (mEq/L): 4,5
LDL (mmol/L): 3,28
Sodium (mEq/L): 139.0
Pro-BNP (ng/L): 4117.0
Protein (g/L): 66
T3 (pg/dL): 0,04
T4 (ng/L): 13
Troponin (ng/mL): 0,01
TSH (mIU/L): 2,42
Urea (mg/dL): 8,49
LVEF (%): 56.0
Medications: Angiotensin II Receptor Blocker, Loop Diuretics, Spironolactone
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",survivor,"RANKING: 1. Survivor
REASONING:

This patient's prognosis is ranked as a survivor due to several factors. Firstly, the patient's age of 77 is not unusually high for a cardiac event, but it does increase the risk of mortality. However, the patient's NYHA Class II indicates that they have some limitations with physical activity but can still perform daily activities with some difficulty. This suggests that the patient's cardiac function is not severely impaired.

The patient's blood pressure is well-controlled at 120/80 mmHg, which is a significant factor in reducing the risk of cardiovascular events. The patient's medication regimen, which includes an Angiotensin II Receptor Blocker and Loop Diuretics, is also well-managed, indicating that the patient is receiving standard treatment for their hypertension and heart failure.

The patient's laboratory results show elevated liver enzymes (ALT and AST), which may indicate some degree of liver dysfunction, but this is not directly related to cardiac function. The patient's kidney function is also slightly impaired, but this is not uncommon in patients with hypertension and heart failure.

The patient's echocardiogram results show a reduced LVEF of 56.0%, which indicates some degree of left ventricular dysfunction. However, this is not severe, and the patient's overall clinical presentation does not suggest acute cardiac decompensation.

The patient's biomarker results, including troponin and BNP, are not elevated, which suggests that there is no acute cardiac injury or strain. The patient's ECG results show ventricular extrasystole, which is a common finding in patients with cardiac disease, but it is not indicative of a high risk of sudden cardiac death.

Overall, considering the patient's age, NYHA Class, medication regimen, and laboratory results, the likelihood of a sudden cardiac death or pump failure is relatively low. Therefore, the most likely outcome is that the patient will survive."
82,82,P0128,"Age: 72
Gender: Male 
Weight: 74 kg
Height: 162 cm
NYHA Class: III
Blood Pressure: 110/60 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Diabetes, Dyslipemia, Hypertension, Myocardial Infarction
Albumin (g/L): 45
ALT or GPT (IU/L): 45.0
AST or GOT (IU/L): 21.0
Total Cholesterol (mmol/L): 3,65
Creatinine (mmol/L): 115.0
Gamma-glutamil transpeptidase (IU/L): 38
Glucose (mmol/L): 15,2
Hemoglobin (g/L): 132.0
HDL (mmol/L): 0,78
Potassium (mEq/L): 4,9
LDL (mmol/L): 1,91
Sodium (mEq/L): 134.0
Pro-BNP (ng/L): 208.0
Protein (g/L): 75
T3 (pg/dL): 0,02
T4 (ng/L): 26
Troponin (ng/mL): 0,01
TSH (mIU/L): 1,68
Urea (mg/dL): 6,82
LVEF (%): 36.0
Medications: Diabetes Medication, Beta Blockers, Digoxin, Loop Diuretics, Spironolactone, Statins, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: Paroxysmal AVB
            ",survivor,"RANKING: 1. Survivor
REASONING: 

The patient's age, NYHA Class III, and the presence of ischemic dilated cardiomyopathy, diabetes, dyslipemia, and hypertension all contribute to a high risk of adverse outcomes. However, the patient's current stable vital signs and the absence of acute coronary syndrome (indicated by normal troponin levels) suggest that the patient is currently tolerating their medications and has not experienced a recent myocardial infarction.

The patient's LVEF of 36.0 indicates severe left ventricular dysfunction, which is a significant predictor of mortality in patients with heart failure. However, the patient's current medication regimen includes ACE inhibitors, beta blockers, and digoxin, which are all recommended for patients with heart failure.

The elevated creatinine level (115.0 mmol/L) may indicate some degree of renal impairment, which can be a comorbidity that affects the patient's overall prognosis. However, the patient's hemoglobin level (132.0 g/L) is within the normal range, and the patient is receiving spironolactone, which may help to mitigate some of the adverse effects of hypertension on renal function.

The ECG results show ventricular extrasystoles, which may indicate some degree of ventricular dysfunction, but the absence of ventricular tachycardia or non-sustained ventricular tachycardia reduces the risk of sudden cardiac death.

Overall, while the patient has multiple comorbidities and significant left ventricular dysfunction, the patient's stable vital signs and current medication regimen suggest that they are currently tolerating their condition and may be at risk for heart failure exacerbation or pump failure over the next few years, but are less likely to experience sudden cardiac death.

The patient's Pro-BNP level (208.0 ng/L) is elevated, which may indicate some degree of ventricular dysfunction and heart failure, but this is not a contraindication to survival.

The patient's TSH level (1.68 mIU/L) is within the normal range, which suggests that the patient's thyroid function is not likely to be contributing to their cardiac status.

The patient's T3 and T4 levels are low, which may indicate some degree of hypothyroidism, but this is not a contraindication to survival.

Given the above factors, the patient is most likely to survive over the next few years, but there is still a risk of heart failure exacerbation or pump failure."
83,83,P0130,"Age: 48
Gender: Male 
Weight: 74 kg
Height: 182 cm
NYHA Class: II
Blood Pressure: 130/70 mmHg
Past Medical History: Idiopathic dilated cardiomyopathy, Dyslipemia, Peripheral vascular disease, Hypertension
Albumin (g/L): 44
ALT or GPT (IU/L): 41.0
AST or GOT (IU/L): 22.0
Total Cholesterol (mmol/L): 4,84
Creatinine (mmol/L): 106.0
Gamma-glutamil transpeptidase (IU/L): 24
Glucose (mmol/L): 5,2
Hemoglobin (g/L): 139.0
HDL (mmol/L): 0,75
Potassium (mEq/L): 5,1
LDL (mmol/L): 3,15
Sodium (mEq/L): 142.0
Pro-BNP (ng/L): 677.0
Protein (g/L): 74
T3 (pg/dL): 0,06
T4 (ng/L): 11
Troponin (ng/mL): 0,37
TSH (mIU/L): 2,4
Urea (mg/dL): 6,82
LVEF (%): 29.0
Medications: Beta Blockers, Digoxin, Loop Diuretics, Spironolactone, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: TPSV
        - Bradycardia: No
            ",survivor,"RANKING: 
1. Survivor
2. Pump failure death
3. Sudden cardiac death

REASONING:

The patient has a poor prognosis due to the presence of several risk factors and clinical findings. Here's a breakdown of the reasoning behind the ranking:

1. Survivor: The patient has a NYHA Class II heart failure, which indicates a moderate level of heart failure symptoms. However, the patient's LVEF (Left Ventricular Ejection Fraction) is 29%, which is relatively low. The patient's Pro-BNP levels are elevated, indicating some degree of heart failure. Despite these factors, the patient is on medications that are commonly used to manage heart failure, such as beta blockers, digoxin, loop diuretics, and spironolactone, which suggest that the patient is receiving adequate treatment. The patient's ECG findings, while concerning for arrhythmias, do not indicate a high risk of sudden cardiac death. Therefore, the patient's overall prognosis is more favorable, and they are likely to survive.

2. Pump failure death: The patient's LVEF is 29%, which is a significant indicator of heart failure. The patient's elevated Pro-BNP levels and NYHA Class II symptoms suggest that the patient is at risk of progressive heart failure. The patient's elevated creatinine level (106.0) and urea level (6.82) may indicate some degree of renal impairment, which can be a complication of heart failure. While the patient is on medications that can help manage heart failure, the patient's overall clinical picture suggests a higher risk of pump failure.

3. Sudden cardiac death: The patient's ECG findings, particularly the presence of non-sustained ventricular tachycardia (CH>10) and polymorphic ventricular extrasystoles, increase the risk of sudden cardiac death. The patient's elevated Troponin level (0.37 ng/mL) also suggests some degree of myocardial damage. While the patient is on medications that can help manage arrhythmias, the patient's overall clinical picture suggests a higher risk of sudden cardiac death. However, the patient's overall prognosis is still more favorable than pump failure death due to the presence of heart failure symptoms and the patient's relatively preserved renal function."
84,84,P0131,"Age: 66
Gender: Male 
Weight: 95 kg
Height: 164 cm
NYHA Class: II
Blood Pressure: 130/60 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Dyslipemia, Hypertension, Myocardial Infarction
Albumin (g/L): 41
ALT or GPT (IU/L): 15.0
AST or GOT (IU/L): 15.0
Total Cholesterol (mmol/L): 6,03
Creatinine (mmol/L): 106.0
Gamma-glutamil transpeptidase (IU/L): 9
Glucose (mmol/L): 4,4
Hemoglobin (g/L): 120.0
HDL (mmol/L): 1,71
Potassium (mEq/L): 4,4
LDL (mmol/L): 3,72
Sodium (mEq/L): 141.0
Pro-BNP (ng/L): 481.0
Protein (g/L): 65
T3 (pg/dL): 0,05
T4 (ng/L): 14
Troponin (ng/mL): 0,05
TSH (mIU/L): 2,63
Urea (mg/dL): 9,32
LVEF (%): 40.0
Medications: Amiodarone, Angiotensin II Receptor Blocker, Beta Blockers, Loop Diuretics, Spironolactone, Statins, ACE Inhibitor, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: Parosysmal AF
        - Bradycardia: No
            ",survivor,"RANKING: 
1. Survivor
REASONING: 
Based on the patient's data, the patient is a 66-year-old male with a history of ischemic dilated cardiomyopathy, hypertension, and myocardial infarction. The patient's ejection fraction (LVEF) is significantly reduced at 40%, indicating poor cardiac function. The patient's NT-proBNP level is elevated at 481 ng/L, suggesting increased ventricular wall stress. The patient's medications, including ACE inhibitors and beta blockers, are standard treatments for heart failure and hypertension. The absence of ventricular tachycardia, non-sustained ventricular tachycardia, and paroxysmal supraventricular tachyarrhythmia on the ECG suggests that the patient does not have a high risk of sudden cardiac death. However, the presence of ventricular extrasystoles, a type of abnormal heart rhythm, is a concern. Considering the patient's overall clinical presentation and the presence of ventricular extrasystoles, I would rank the patient as having a high risk of pump failure. Therefore, I would rank the patient as a survivor with a moderate risk of pump failure over the next few years. 

However, the patient's overall survival is still higher than the other two options due to the absence of high-risk features such as high NT-proBNP levels, and the presence of certain medications that can help manage heart failure symptoms."
85,85,P0132,"Age: 46
Gender: Female 
Weight: 53 kg
Height: 157 cm
NYHA Class: II
Blood Pressure: 90/60 mmHg
Past Medical History: Idiopathic dilated cardiomyopathy
Albumin (g/L): 40
ALT or GPT (IU/L): 25.0
AST or GOT (IU/L): 26.0
Total Cholesterol (mmol/L): 4,55
Creatinine (mmol/L): 80.0
Gamma-glutamil transpeptidase (IU/L): 29
Glucose (mmol/L): 5,2
Hemoglobin (g/L): 133.0
HDL (mmol/L): 0,85
Potassium (mEq/L): 4,3
LDL (mmol/L): 3,62
Sodium (mEq/L): 140.0
Pro-BNP (ng/L): 64.0
Protein (g/L): 76
T3 (pg/dL): 0,06
T4 (ng/L): 14
Troponin (ng/mL): 0,005
TSH (mIU/L): 1,07
Urea (mg/dL): 4,33
LVEF (%): 34.0
Medications: Beta Blockers, Digoxin, Loop Diuretics, Spironolactone, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"RANKING: 1. Survivor
REASONING:

This patient has several factors that suggest a good prognosis. 

Firstly, the patient's NYHA Class II indicates that their symptoms are mild, which is an improvement from a Class III or IV, suggesting that the patient has not yet experienced significant cardiac failure.

The patient's hemoglobin level of 133.0 g/L is within the normal range, indicating that they are not anemic, which is a common complication in patients with heart failure.

The patient's electrolyte levels, including potassium (4.3 mEq/L) and sodium (140.0 mEq/L), are also within the normal range, which suggests that they are not experiencing significant electrolyte imbalances.

The patient's LVEF (34.0%) is lower than the normal range, but it is not severely impaired. A lower LVEF is often associated with a worse prognosis, but the patient is still in the lower end of the spectrum.

The patient's medications, including beta blockers, digoxin, loop diuretics, spironolactone, and ACE inhibitor, are standard treatments for heart failure and cardiomyopathy. These medications can help to slow the progression of the disease and improve symptoms.

The ECG impression does not show any signs of ventricular tachycardia, non-sustained ventricular tachycardia, or paroxysmal supraventricular tachyarrhythmia, which are all potential indicators of a poor prognosis.

The patient's Pro-BNP level is elevated at 64.0 ng/L, which is a marker of cardiac stress. However, the patient is not experiencing symptoms, and the level is not excessively high.

Overall, considering the patient's mild symptoms, normal electrolyte levels, and standard medications, the patient is likely to survive for several years."
86,86,P0133,"Age: 36
Gender: Female 
Weight: 81 kg
Height: 170 cm
NYHA Class: III
Blood Pressure: 120/70 mmHg
Past Medical History: Idiopathic dilated cardiomyopathy, Dyslipemia
Albumin (g/L): 48
ALT or GPT (IU/L): 130.0
AST or GOT (IU/L): 89.0
Total Cholesterol (mmol/L): 4,86
Creatinine (mmol/L): 88.0
Gamma-glutamil transpeptidase (IU/L): 142
Glucose (mmol/L): 4,8
Hemoglobin (g/L): 151.0
HDL (mmol/L): 0,8
Potassium (mEq/L): 3,9
LDL (mmol/L): 2,05
Sodium (mEq/L): 139.0
Pro-BNP (ng/L): 57.0
Protein (g/L): 77
T3 (pg/dL): 0,05
T4 (ng/L): 15
Troponin (ng/mL): 0,06
TSH (mIU/L): 3,53
Urea (mg/dL): 6,32
LVEF (%): 24.0
Medications: Beta Blockers, Digoxin, Loop Diuretics, Spironolactone, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"RANKING: 
1. Survivor
REASONING:
This patient's prognosis is most likely to be a survivor due to several factors. Firstly, the patient's age of 36 is considered young for idiopathic dilated cardiomyopathy, which suggests a potentially reversible cause. Additionally, the patient's LVEF of 24% is relatively preserved, indicating that the heart is still capable of pumping blood efficiently, albeit not optimally.

The patient's medication regimen, which includes beta blockers, digoxin, loop diuretics, spironolactone, and an ACE inhibitor, suggests that the patient is receiving standard treatments for heart failure and arrhythmias. The absence of ventricular tachycardia, non-sustained ventricular tachycardia, and paroxysmal supraventricular tachyarrhythmia on the ECG also reduces the risk of sudden cardiac death.

Furthermore, the patient's laboratory values, such as the normal blood pressure, low creatinine levels, and relatively normal liver function tests, suggest that the patient's underlying condition is not severely advanced. The patient's albumin level is slightly low, but it is not significantly abnormal.

While the patient's dyslipidemia and elevated liver enzymes (ALT and AST) may indicate some degree of cardiac stress, the patient's overall clinical presentation and laboratory values suggest that the patient is not at high risk for sudden cardiac death or pump failure in the near future.

Overall, the combination of a young age, relatively preserved LVEF, and a standard treatment regimen make a survival prognosis more likely for this patient."
87,87,P0137,"Age: 58
Gender: Male 
Weight: 70 kg
Height: 173 cm
NYHA Class: II
Blood Pressure: 110/60 mmHg
Past Medical History: Enolic dilated cardiomyopathy
Albumin (g/L): 42
ALT or GPT (IU/L): 13.0
AST or GOT (IU/L): 23.0
Total Cholesterol (mmol/L): 6,44
Creatinine (mmol/L): 88.0
Gamma-glutamil transpeptidase (IU/L): 61
Glucose (mmol/L): 5,8
Hemoglobin (g/L): 160.0
HDL (mmol/L): 2,51
Potassium (mEq/L): 4,2
LDL (mmol/L): 3,39
Sodium (mEq/L): 142.0
Pro-BNP (ng/L): 320.0
Protein (g/L): 67
T3 (pg/dL): 0,06
T4 (ng/L): 20
Troponin (ng/mL): 0,01
TSH (mIU/L): 4,19
Urea (mg/dL): 6,16
LVEF (%): 53.0
Medications: Beta Blockers, Digoxin, Loop Diuretics, Spironolactone, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",survivor,"RANKING: 
1. Survivor
REASONING: 
The patient is currently taking medications for their Enolic dilated cardiomyopathy, including beta blockers, digoxin, loop diuretics, spironolactone, and an ACE inhibitor. These medications are commonly used to manage symptoms and slow the progression of heart failure in patients with cardiomyopathy. The patient's NYHA Class II classification indicates that they have moderate symptoms of heart failure, but they are still able to perform daily activities without severe limitation.

The patient's LVEF of 53.0 is within the range for someone with dilated cardiomyopathy, suggesting that the heart is still pumping effectively, albeit inefficiently. The patient's serum creatinine level is elevated, indicating some degree of renal impairment, but this is not uncommon in patients with heart failure.

The presence of non-sustained ventricular tachycardia (NSVT) on the ECG is concerning, but the fact that it is non-sustained (less than 10 seconds) and not sustained ventricular tachycardia (sVT) suggests that the patient's heart is still able to recover from these episodes. The presence of ventricular extrasystoles and paroxysmal supraventricular tachyarrhythmia is also concerning, but the patient's overall clinical status and medication regimen suggest that these are not immediately life-threatening.

Given the patient's overall clinical status and medication regimen, I believe that the patient is at low risk for sudden cardiac death or pump failure in the next few years. The patient's heart is still pumping effectively, and the medications are likely to continue to manage their symptoms and slow the progression of heart failure.

The patient's biomarkers, such as troponin and BNP, are not elevated, which suggests that the patient's heart is not experiencing significant acute damage or stress. The patient's kidney function is also not severely impaired, which is important because kidney dysfunction can be a predictor of poor outcomes in heart failure patients.

Overall, based on the patient's clinical status, medication regimen, and biomarkers, I believe that the patient is at low risk for sudden cardiac death or pump failure in the next few years, making survival the most likely outcome."
88,88,P0142,"Age: 67
Gender: Female 
Weight: 98 kg
Height: 171 cm
NYHA Class: II
Blood Pressure: 120/85 mmHg
Past Medical History: Valvular cardiomyopathy, Dyslipemia, Peripheral vascular disease, Hypertension
Albumin (g/L): 40,8
ALT or GPT (IU/L): 38.0
AST or GOT (IU/L): 26.0
Total Cholesterol (mmol/L): 4,8
Creatinine (mmol/L): 73.0
Gamma-glutamil transpeptidase (IU/L): 257
Glucose (mmol/L): 4,4
Hemoglobin (g/L): 125.0
HDL (mmol/L): 1,13
Potassium (mEq/L): 3,8
LDL (mmol/L): 2,81
Sodium (mEq/L): 143.0
Pro-BNP (ng/L): 683.0
Protein (g/L): 68,1
Troponin (ng/mL): 0,01
TSH (mIU/L): 1,3
Urea (mg/dL): 7,5
LVEF (%): 55.0
Medications: Digoxin, Loop Diuretics, Statins, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",survivor,"RANKING: 
1. Survivor
REASONING: 
The patient is 67 years old, with a history of valvular cardiomyopathy, dyslipemia, peripheral vascular disease, and hypertension. The patient's LVEF is 55%, indicating left ventricular dysfunction. The presence of ventricular extrasystoles on the ECG, elevated Pro-BNP levels (683.0 ng/L), and a history of heart failure (NYHA Class II) suggest that the patient is at risk for adverse cardiac events. However, the patient's blood pressure is well-controlled (120/85 mmHg), and they are on medications that are commonly used to manage heart failure and hypertension.

The patient's laboratory values, including a normal potassium level, low creatinine level, and low troponin level, do not indicate acute coronary syndrome or acute kidney injury. The patient's hemoglobin level is slightly elevated, which may be due to anemia or other factors. The patient's lipid profile shows elevated total cholesterol and LDL levels, but they are on statins, which should help manage dyslipidemia.

Considering these factors, I believe that the patient is at a higher risk for cardiac events, but the presence of well-controlled blood pressure, normal kidney function, and the absence of acute coronary syndrome or acute kidney injury reduce the likelihood of sudden cardiac death. Therefore, I rank the patient as a survivor.

2. Sudden cardiac death
REASONING: 
While the patient has a history of valvular cardiomyopathy and left ventricular dysfunction, the patient's LVEF is not severely impaired (55%), and the patient's blood pressure is well-controlled. However, the presence of ventricular extrasystoles on the ECG and elevated Pro-BNP levels suggest that the patient is at risk for cardiac arrhythmias.

The patient's history of peripheral vascular disease and hypertension may also contribute to the risk of cardiac events. However, the patient is on medications that are commonly used to manage these conditions, and their laboratory values do not indicate acute coronary syndrome or acute kidney injury.

While the patient's risk for cardiac events is present, the overall clinical picture does not suggest an immediate risk for sudden cardiac death. The patient's ECG does not show any signs of ventricular tachycardia or bradycardia, and the patient's hemoglobin level is normal.

3. Pump failure death
REASONING: 
The patient's LVEF is 55%, indicating left ventricular dysfunction, and the patient has a history of valvular cardiomyopathy. However, the patient's blood pressure is well-controlled, and they are on medications that are commonly used to manage heart failure.

While the patient's Pro-BNP levels are elevated, this is not a definitive indicator of pump failure. The patient's laboratory values do not indicate acute kidney injury or acute coronary syndrome, and the patient's hemoglobin level is normal.

Considering the patient's history of valvular cardiomyopathy and left ventricular dysfunction, pump failure death is a possible risk. However, the patient's overall clinical picture does not suggest an immediate risk for pump failure, and the patient's well-controlled blood pressure and normal kidney function reduce this risk. Therefore, I rank pump failure death as the least likely outcome."
89,89,P0145,"Age: 57
Gender: Male 
Weight: 106 kg
Height: 165 cm
NYHA Class: II
Blood Pressure: 170/100 mmHg
Past Medical History: Idiopathic dilated cardiomyopathy, Diabetes, Peripheral vascular disease, Hypertension
Albumin (g/L): 40,2
ALT or GPT (IU/L): 19.0
AST or GOT (IU/L): 12.0
Total Cholesterol (mmol/L): 4,76
Creatinine (mmol/L): 83.0
Gamma-glutamil transpeptidase (IU/L): 20
Glucose (mmol/L): 6
Hemoglobin (g/L): 130.0
HDL (mmol/L): 1,07
Potassium (mEq/L): 3,44
LDL (mmol/L): 3,09
Sodium (mEq/L): 138.0
Pro-BNP (ng/L): 431.0
Protein (g/L): 68,7
Troponin (ng/mL): 0,01
TSH (mIU/L): 1,73
Urea (mg/dL): 5,7
LVEF (%): 25.0
Medications: Diabetes Medication, Loop Diuretics, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"RANKING: 
1. Survivor 
REASONING: 
The patient's overall health status, despite the presence of multiple comorbidities such as idiopathic dilated cardiomyopathy, diabetes, and hypertension, suggests a relatively preserved cardiac function. The LVEF of 25.0 indicates significant left ventricular dysfunction, but it is not severe enough to immediately predict a poor outcome. The patient is also taking ACE inhibitors, which is a standard treatment for heart failure and can help reduce mortality. The presence of ventricular extrasystoles and non-sustained ventricular tachycardia on ECG is concerning, but it is not a guarantee of a poor outcome. The patient's blood pressure is elevated, but it is not severely high, and the patient is on loop diuretics, which can help manage fluid overload. The patient's laboratory values, including the slightly elevated creatinine and low albumin, suggest some degree of renal impairment, but it is not severe. Overall, the combination of these factors suggests that the patient has a relatively better prognosis compared to the other two options.

RANKING: 
2. Sudden Cardiac Death 
REASONING: 
The patient's presence of ventricular tachycardia, non-sustained ventricular tachycardia, and polymorphic ventricular extrasystoles on ECG significantly increases the risk of sudden cardiac death. The patient's LVEF of 25.0 indicates significant left ventricular dysfunction, which can increase the risk of arrhythmic events. The patient's elevated blood pressure and presence of hypertension also increase the risk of cardiac events. The patient's elevated troponin levels, although low, suggest some degree of cardiac injury, which can also increase the risk of arrhythmic events. However, the patient is on ACE inhibitors, which can help reduce mortality, and the patient's laboratory values, including the slightly elevated creatinine, suggest some degree of renal impairment, which may be contributing to the elevated blood pressure.

RANKING: 
3. Pump Failure Death 
REASONING: 
The patient's LVEF of 25.0 indicates significant left ventricular dysfunction, which is a hallmark of heart failure. The patient's NYHA Class II suggests that the patient has some limitations in physical activity due to heart failure, but it is not severe. The patient's elevated creatinine and low albumin suggest some degree of renal impairment, which can contribute to heart failure. The patient's elevated blood pressure and presence of hypertension also increase the risk of cardiac events. The patient's elevated troponin levels, although low, suggest some degree of cardiac injury, which can contribute to heart failure. However, the patient is on ACE inhibitors, which can help reduce mortality, and the patient's laboratory values, including the slightly elevated creatinine, suggest some degree of renal impairment, which may be contributing to the elevated blood pressure."
90,90,P0146,"Age: 49
Gender: Male 
Weight: 85 kg
Height: 169 cm
NYHA Class: III
Blood Pressure: 90/60 mmHg
Past Medical History: Enolic dilated cardiomyopathy
Albumin (g/L): 40,1
ALT or GPT (IU/L): 23.0
AST or GOT (IU/L): 17.0
Total Cholesterol (mmol/L): 4,07
Creatinine (mmol/L): 102.0
Gamma-glutamil transpeptidase (IU/L): 40
Glucose (mmol/L): 5
Hemoglobin (g/L): 128.0
Potassium (mEq/L): 4,31
Sodium (mEq/L): 140.0
Pro-BNP (ng/L): 3021.0
Protein (g/L): 65,8
Troponin (ng/mL): 0,01
TSH (mIU/L): 1,34
Urea (mg/dL): 5,2
LVEF (%): 19.0
Medications: Beta Blockers, Loop Diuretics, Statins, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"RANKING: 
1. Survivor
REASONING: 
Based on the provided patient data, I predict that the patient is most likely to survive in the next few years. The patient's NYHA Class III indicates severe heart failure, but the patient is already receiving medications for heart failure (Loop Diuretics) and has been prescribed beta blockers and ACE inhibitors, which are standard treatments for heart failure. The patient's LVEF is significantly reduced at 19%, indicating poor cardiac function, but the patient's troponin levels are normal, suggesting that there is no significant myocardial infarction in the recent past.

The patient's creatinine level is elevated, indicating kidney dysfunction, but this is not uncommon in patients with heart failure. The patient's potassium level is slightly elevated, which may be related to the use of beta blockers. The patient's liver enzymes are within normal limits, and the patient's glucose and hemoglobin levels are also within normal limits.

The ECG findings of ventricular extrasystole and non-sustained ventricular tachycardia are concerning, but the patient does not have any other significant arrhythmias. The patient's Pro-BNP level is elevated, indicating some degree of ventricular stress, but this is not unusual in patients with heart failure.

Overall, the patient's combination of severe heart failure, kidney dysfunction, and elevated Pro-BNP levels, but normal troponin levels and lack of other significant ECG findings, suggest that the patient is likely to survive in the next few years with proper management of their heart failure and medication regimen.

2. Sudden Cardiac Death
REASONING: 
While the patient's ECG findings of ventricular extrasystole and non-sustained ventricular tachycardia are concerning, I do not believe that the patient is at high risk for sudden cardiac death. The patient's troponin levels are normal, and the patient is already receiving beta blockers, which are known to reduce the risk of sudden cardiac death.

3. Pump Failure Death
REASONING: 
I do not believe that pump failure death is the most likely outcome for this patient. The patient is already receiving medications for heart failure, and the patient's kidney dysfunction may be related to the heart failure rather than a primary cause of pump failure. While the patient's LVEF is significantly reduced, the patient's troponin levels are normal, and the patient's ECG findings do not indicate any acute myocardial infarction or other significant cardiac dysfunction."
91,91,P0147,"Age: 81
Gender: Female 
Weight: 50 kg
Height: 150 cm
NYHA Class: II
Blood Pressure: 120/75 mmHg
Past Medical History: Hypertropic cardiomyopathy, Diabetes, Hypertension
Albumin (g/L): 39,7
ALT or GPT (IU/L): 13.0
AST or GOT (IU/L): 15.0
Total Cholesterol (mmol/L): 3,49
Creatinine (mmol/L): 96.0
Gamma-glutamil transpeptidase (IU/L): 23
Glucose (mmol/L): 16,2
Hemoglobin (g/L): 131.0
Potassium (mEq/L): 3,93
Sodium (mEq/L): 138.0
Pro-BNP (ng/L): 2167.0
Protein (g/L): 67,4
T3 (pg/dL): 0,07
T4 (ng/L): 20
Troponin (ng/mL): 0,01
TSH (mIU/L): 0,1
Urea (mg/dL): 13,1
LVEF (%): 40.0
Medications: Diabetes Medication, Amiodarone, Loop Diuretics, Statins, ACE Inhibitor, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"RANKING: 
1. Survivor
REASONING:
Based on the provided patient data, the patient is a 81-year-old female with a history of hypertrophic cardiomyopathy, diabetes, and hypertension. The patient has a relatively preserved kidney function (Creatinine: 96.0 mmol/L) and a mildly elevated Pro-BNP level (2167.0 ng/L), indicating some degree of heart failure. However, the patient's ejection fraction (LVEF: 40.0) is significantly reduced, suggesting severe left ventricular dysfunction.

The patient is on multiple medications, including ACE inhibitors, statins, and amiodarone, which are commonly used to manage hypertension, hyperlipidemia, and arrhythmias. The presence of non-sustained ventricular tachycardia (NSVT) on the ECG is concerning, but the patient is already on amiodarone, which is an antiarrhythmic medication that can help manage ventricular arrhythmias.

Given the patient's age, comorbidities, and the presence of NSVT, the most significant concern is the risk of sudden cardiac death. However, the patient's overall condition, including the presence of multiple medications and a relatively preserved kidney function, suggests that the patient is unlikely to have a sudden cardiac death in the short term.

Therefore, the most likely outcome for the next few years is that the patient will survive, albeit with close monitoring and management of their underlying conditions.

RANKING: 2. Sudden cardiac death
REASONING:
The patient's age, history of hypertrophic cardiomyopathy, and presence of non-sustained ventricular tachycardia (NSVT) on the ECG make them at increased risk for sudden cardiac death. The patient's reduced ejection fraction (LVEF: 40.0) and elevated Pro-BNP level (2167.0 ng/L) also suggest significant left ventricular dysfunction, which can increase the risk of sudden cardiac death.

RANKING: 3. Pump failure death
REASONING:
While the patient's reduced ejection fraction (LVEF: 40.0) and elevated Pro-BNP level (2167.0 ng/L) suggest significant left ventricular dysfunction, the patient is already on multiple medications, including ACE inhibitors, which are commonly used to manage heart failure. The patient's kidney function is also relatively preserved, which suggests that they may be able to tolerate some degree of heart failure. However, the patient's age and comorbidities make pump failure a possible long-term complication."
92,92,P0150,"Age: 73
Gender: Female 
Weight: 79 kg
Height: 155 cm
NYHA Class: III
Blood Pressure: 95/50 mmHg
Past Medical History: Valvular cardiomyopathy, Hypertension
Albumin (g/L): 43,8
ALT or GPT (IU/L): 14.0
AST or GOT (IU/L): 11.0
Total Cholesterol (mmol/L): 4,7
Creatinine (mmol/L): 95.0
Gamma-glutamil transpeptidase (IU/L): 14
Glucose (mmol/L): 6,5
Hemoglobin (g/L): 135.0
Potassium (mEq/L): 3,64
Sodium (mEq/L): 141.0
Pro-BNP (ng/L): 6343.0
Protein (g/L): 63,6
T4 (ng/L): 15,5
Troponin (ng/mL): 0,01
TSH (mIU/L): 5,78
Urea (mg/dL): 13,9
LVEF (%): 20.0
Medications: Beta Blockers, Loop Diuretics, Spironolactone, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: TPSV
        - Bradycardia: Unknown bradycardia code
            ",survivor,"RANKING: 
1. Survivor
REASONING:
The patient is a 73-year-old female with a history of valvular cardiomyopathy, hypertension, and NYHA Class III heart failure. The patient's LVEF is significantly reduced at 20.0%, indicating severe left ventricular dysfunction. The presence of ventricular extrasystole and non-sustained ventricular tachycardia on the ECG suggests ongoing arrhythmic instability.

Despite the patient's severe cardiac dysfunction and arrhythmias, the patient is currently on medications that are standard for managing heart failure and hypertension, including beta blockers, loop diuretics, spironolactone, and an ACE inhibitor. These medications have been shown to improve survival and reduce morbidity in patients with heart failure.

Additionally, the patient's creatinine level is not significantly elevated, and the liver function tests are within normal limits, which suggests that the patient's kidney function is relatively preserved. The patient's blood glucose level is also within a relatively normal range.

While the patient's Pro-BNP level is elevated, which is consistent with heart failure, it is not extremely high, which may suggest that the patient's heart failure is not severely decompensated at this time.

Considering these factors, the most likely prognosis for the patient is survival, as the patient is receiving standard treatment for their heart failure and arrhythmias, and their cardiac function is not severely impaired. However, it is essential to closely monitor the patient's condition and adjust their treatment plan as needed to ensure optimal management of their heart failure and arrhythmias.

The other two prognoses, sudden cardiac death and pump failure death, are less likely due to the patient's current treatment regimen and relatively preserved cardiac function. However, it is essential to continue close monitoring and adjust the treatment plan as needed to minimize the risk of adverse outcomes."
93,93,P0152,"Age: 64
Gender: Female 
Weight: 90 kg
Height: 155 cm
NYHA Class: II
Blood Pressure: 160/70 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Diabetes, Peripheral vascular disease, Hypertension, Myocardial Infarction
Albumin (g/L): 40,5
ALT or GPT (IU/L): 21.0
AST or GOT (IU/L): 19.0
Total Cholesterol (mmol/L): 4,48
Creatinine (mmol/L): 104.0
Gamma-glutamil transpeptidase (IU/L): 38
Glucose (mmol/L): 8,3
Hemoglobin (g/L): 135.0
Potassium (mEq/L): 4,04
Sodium (mEq/L): 139.0
Pro-BNP (ng/L): 1312.0
Protein (g/L): 68,7
Troponin (ng/mL): 0,01
TSH (mIU/L): 2,95
Urea (mg/dL): 9,8
LVEF (%): 40.0
Medications: Diabetes Medication, Angiotensin II Receptor Blocker, Beta Blockers, Loop Diuretics, Statins, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: Unknown bradycardia code
            ",survivor,"RANKING: 1. Survivor
REASONING: 

The patient's age, NYHA Class II, and multiple comorbidities (ischemic dilated cardiomyopathy, diabetes, peripheral vascular disease, hypertension, and myocardial infarction) indicate a high risk for cardiac complications. However, the patient has been taking medications that are commonly used to manage these conditions, such as beta blockers, angiotensin II receptor blockers, and statins, which can help reduce the risk of cardiac events. 

The patient's biomarkers, including elevated creatinine and BNP levels, suggest some degree of cardiac dysfunction and fluid overload, but the troponin level is within the normal range, which reduces the likelihood of acute myocardial infarction. The ECG findings of ventricular extrasystoles are also present, but the absence of ventricular tachycardia, non-sustained ventricular tachycardia, and paroxysmal supraventricular tachyarrhythmia suggests that the patient's cardiac function is still relatively preserved.

Considering these factors, I would rank the patient as having the highest likelihood of being a survivor, with a moderate to high risk of cardiac complications, but manageable with current medications and close monitoring."
94,94,P0154,"Age: 59
Gender: Male 
Weight: 96 kg
Height: 178 cm
NYHA Class: II
Blood Pressure: 90/60 mmHg
Past Medical History: Enolic dilated cardiomyopathy, Diabetes, Dyslipemia, Peripheral vascular disease, Myocardial Infarction
Albumin (g/L): 42,1
ALT or GPT (IU/L): 15.0
AST or GOT (IU/L): 13.0
Total Cholesterol (mmol/L): 4,14
Creatinine (mmol/L): 113.0
Gamma-glutamil transpeptidase (IU/L): 71
Glucose (mmol/L): 7,4
Hemoglobin (g/L): 127.0
Potassium (mEq/L): 4,28
Sodium (mEq/L): 134.0
Pro-BNP (ng/L): 706.0
Protein (g/L): 73,1
Troponin (ng/mL): 0,01
TSH (mIU/L): 1,8
Urea (mg/dL): 6,3
LVEF (%): 25.0
Medications: Calcium Channel Blocker, Diabetes Medication, Beta Blockers, Loop Diuretics, Statins, ACE Inhibitor, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"RANKING: 
1. Survivor
REASONING: 
The patient's overall clinical presentation and test results suggest a poor prognosis, but the fact that they are currently alive indicates that they have survived a significant cardiac event. Their NYHA Class II heart failure classification and the presence of multiple comorbidities such as diabetes, dyslipemia, and peripheral vascular disease increase the risk of adverse outcomes. However, the patient is currently on multiple medications that are standard of care for heart failure and other comorbid conditions, which suggests that the patient is being managed appropriately. Additionally, the absence of any evidence of acute cardiac events on the ECG, such as ventricular tachycardia or non-sustained ventricular tachycardia, suggests that the patient has not had a recent cardiac event that would have significantly impacted their prognosis. 

The patient's elevated troponin levels (0.01 ng/mL) and LVEF of 25% indicate some degree of cardiac dysfunction, but the patient is alive, and these values do not necessarily indicate an immediate life-threatening condition. The elevated creatinine level (6.3 mg/dL) may indicate some degree of renal impairment, but this is not uncommon in patients with heart failure. The patient's protein level is slightly elevated, but this is not unusual in patients with heart failure.

While the patient's prognosis is uncertain, the fact that they are currently alive suggests that they are at risk of experiencing a cardiac event or progression of their heart failure in the near future. However, without further information, it is difficult to predict the exact outcome.

Given the available information, the most likely outcome is that the patient will survive, but with a high risk of progression of their heart failure or a cardiac event in the near future."
95,95,P0156,"Age: 53
Gender: Male 
Weight: 82 kg
Height: 182 cm
NYHA Class: II
Blood Pressure: 110/75 mmHg
Past Medical History: Enolic dilated cardiomyopathy
Albumin (g/L): 40,3
ALT or GPT (IU/L): 25.0
AST or GOT (IU/L): 14.0
Total Cholesterol (mmol/L): 5,77
Creatinine (mmol/L): 79.0
Gamma-glutamil transpeptidase (IU/L): 31
Glucose (mmol/L): 11,6
Hemoglobin (g/L): 153.0
Potassium (mEq/L): 3,41
Sodium (mEq/L): 136.0
Pro-BNP (ng/L): 157.0
Protein (g/L): 66,7
Troponin (ng/mL): 0,01
TSH (mIU/L): 1,79
Urea (mg/dL): 5,3
LVEF (%): 35.0
Medications: Beta Blockers, Digoxin, Loop Diuretics, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",survivor,"RANKING: 1. Survivor
REASONING:

This patient has a poor prognosis due to several factors. Firstly, the patient has a history of Enolic dilated cardiomyopathy, a condition that significantly reduces the heart's ability to pump blood effectively, leading to reduced left ventricular ejection fraction (LVEF) of 35%. This is a strong indicator of advanced heart failure.

The patient's elevated BNP levels (157 ng/L) also suggest significant left ventricular stress and potential heart failure. Additionally, the patient has a history of ventricular extrasystoles and non-sustained ventricular tachycardia, which are both risk factors for sudden cardiac death.

The patient's NYHA class II indicates moderate symptoms of heart failure, which further supports the presence of advanced heart disease. The patient's weight, age, and elevated creatinine levels also contribute to the overall poor prognosis.

Despite being on medications for heart failure and arrhythmias, the patient's ECG findings suggest ongoing arrhythmias, which may not be adequately controlled. The patient's troponin levels are within normal limits, but the presence of ventricular extrasystoles and non-sustained ventricular tachycardia on the ECG increases the risk of sudden cardiac death.

While the patient's hemoglobin and potassium levels are within normal limits, the patient's sodium level is slightly low (136 mEq/L), which may be related to heart failure symptoms. The patient's LVEF is significantly reduced, and the patient's age and weight are also factors that contribute to the overall poor prognosis.

Overall, the combination of advanced heart failure, arrhythmias, and reduced LVEF make it more likely that the patient will experience a poor outcome, with sudden cardiac death being the most likely prognosis."
96,96,P0158,"Age: 65
Gender: Female 
Weight: 96 kg
Height: 164 cm
NYHA Class: II
Blood Pressure: 140/85 mmHg
Past Medical History: Idiopathic dilated cardiomyopathy, Dyslipemia, Hypertension
Albumin (g/L): 45,3
ALT or GPT (IU/L): 29.0
AST or GOT (IU/L): 24.0
Total Cholesterol (mmol/L): 6,16
Creatinine (mmol/L): 86.0
Gamma-glutamil transpeptidase (IU/L): 30
Glucose (mmol/L): 6,3
Hemoglobin (g/L): 125.0
Potassium (mEq/L): 4,73
Sodium (mEq/L): 138.0
Pro-BNP (ng/L): 288.0
Protein (g/L): 76,8
T4 (ng/L): 18,8
Troponin (ng/mL): 0,01
TSH (mIU/L): 0,18
Urea (mg/dL): 8,5
LVEF (%): 39.0
Medications: Angiotensin II Receptor Blocker, Beta Blockers, Loop Diuretics, Spironolactone, Statins
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: TPSV
        - Bradycardia: No
            ",survivor,"RANKING: 
1. Survivor
REASONING: 
Based on the patient's age, NYHA Class II, and the presence of idiopathic dilated cardiomyopathy, the patient is already at an increased risk for cardiac-related complications. However, the patient's LVEF is 39%, which indicates significant left ventricular dysfunction. Despite this, the patient's current ECG findings do not show any signs of ventricular tachycardia, non-sustained ventricular tachycardia, or other life-threatening arrhythmias. The patient's medication regimen, which includes ACE inhibitors, beta blockers, and spironolactone, is also well-established for managing heart failure and hypertension.

The patient's biomarker results, including elevated troponin and BNP levels, suggest some degree of cardiac stress and strain, but these are not indicative of acute coronary syndrome or severe heart failure. The patient's creatinine level is slightly elevated, which may be related to renal impairment secondary to heart failure or hypertension. However, the patient's kidney function is not severely impaired.

Given these factors, the patient's overall prognosis is that they are likely to survive the next few years, provided their current medication regimen is continued and monitored, and any potential comorbidities are managed effectively.

2. Sudden Cardiac Death
REASONING: 
While the patient's LVEF is significantly reduced, the absence of ventricular tachycardia, non-sustained ventricular tachycardia, or other life-threatening arrhythmias on the ECG reduces the likelihood of sudden cardiac death. However, the patient's NYHA Class II status indicates some degree of heart failure, which increases the risk of arrhythmias and sudden cardiac death.

The patient's biomarker results, including elevated troponin and BNP levels, suggest some degree of cardiac stress and strain, which could increase the risk of arrhythmias. The patient's age and gender also increase the risk of sudden cardiac death.

However, the patient's current medication regimen, including beta blockers, which are known to reduce the risk of sudden cardiac death, is in place. Additionally, the patient's creatinine level is not severely impaired, which reduces the risk of acute kidney injury and subsequent cardiac arrest.

Given these factors, the patient's overall prognosis is that they are at moderate risk for sudden cardiac death, but this risk is still relatively low.

3. Pump Failure Death
REASONING: 
The patient's LVEF is significantly reduced, indicating severe left ventricular dysfunction, which increases the risk of pump failure. The patient's NYHA Class II status also indicates some degree of heart failure.

The patient's biomarker results, including elevated troponin and BNP levels, suggest some degree of cardiac stress and strain, which could lead to pump failure. The patient's creatinine level is also elevated, which may indicate impaired kidney function secondary to heart failure.

However, the patient's current medication regimen, including ACE inhibitors, beta blockers, and spironolactone, is well-established for managing heart failure and hypertension. Additionally, the patient's kidney function is not severely impaired, which reduces the risk of acute kidney injury and subsequent cardiac arrest.

Given these factors, the patient's overall prognosis is that they are at moderate to high risk for pump failure, but this risk can be mitigated with close monitoring and adjustment of their medication regimen as needed."
97,97,P0162,"Age: 76
Gender: Female 
Weight: 71 kg
Height: 155 cm
NYHA Class: III
Blood Pressure: 150/100 mmHg
Past Medical History: Idiopathic dilated cardiomyopathy, Dyslipemia, Hypertension
Albumin (g/L): 37,7
ALT or GPT (IU/L): 85.0
AST or GOT (IU/L): 63.0
Total Cholesterol (mmol/L): 4,47
Creatinine (mmol/L): 105.0
Gamma-glutamil transpeptidase (IU/L): 199
Glucose (mmol/L): 8,8
Hemoglobin (g/L): 150.0
HDL (mmol/L): 1
Potassium (mEq/L): 3,84
LDL (mmol/L): 2,85
Sodium (mEq/L): 141.0
Pro-BNP (ng/L): 6915.0
Protein (g/L): 69,7
Troponin (ng/mL): 0,01
TSH (mIU/L): 1,09
Urea (mg/dL): 8,1
LVEF (%): 30.0
Medications: Digoxin, Loop Diuretics, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: TPSV
        - Bradycardia: No
            ",survivor,"RANKING: 
1. Survivor
REASONING: 

Based on the provided patient data, the patient is at high risk for adverse cardiac events, but the presence of a positive outcome indicates that the patient has survived the current event or episode. The patient has a history of idiopathic dilated cardiomyopathy, which is a significant risk factor for cardiac arrhythmias and sudden cardiac death. The ECG impression reveals polymorphic ventricular extrasystole and non-sustained ventricular tachycardia, which are both indicators of ventricular arrhythmias. However, the patient's survival suggests that the heart has been able to compensate for the arrhythmias to some extent.

The patient's hemodynamic status, as indicated by the low LVEF (30%), suggests severe cardiac dysfunction. The elevated troponin level (0.01 ng/mL) is also concerning, as it may indicate some degree of myocardial injury. However, the patient is not in acute myocardial infarction.

The patient's laboratory values, including the elevated creatinine level (105.0 mol/L), indicate some degree of renal impairment, which may be related to the cardiac dysfunction. The patient's electrolyte levels are relatively normal, except for the low HDL level (1 mmol/L), which may contribute to increased cardiovascular risk.

Considering these factors, the patient's survival is likely due to the effectiveness of their current treatment regimen, which includes digoxin, loop diuretics, and an ACE inhibitor. These medications may be helping to manage the patient's symptoms and prevent further cardiac decompensation.

While the patient is at high risk for cardiac events, the presence of a positive outcome suggests that the patient has been able to survive the current episode, and with continued close monitoring and management, it is possible that the patient may survive for several years.

RANKING: 
2. Sudden cardiac death
REASONING: 

The patient's ECG impression reveals polymorphic ventricular extrasystole and non-sustained ventricular tachycardia, which are both indicators of ventricular arrhythmias. The patient's LVEF (30%) is also severely impaired, which increases the risk of sudden cardiac death. The patient's history of idiopathic dilated cardiomyopathy and dyslipemia further increases the risk of arrhythmias and sudden cardiac death.

The patient's elevated troponin level (0.01 ng/mL) and elevated creatinine level (105.0 mol/L) also suggest some degree of cardiac dysfunction and renal impairment, which may increase the risk of sudden cardiac death.

However, the patient's survival is still possible due to the effectiveness of their current treatment regimen, which includes medications that may be helping to manage the patient's symptoms and prevent further cardiac decompensation.

RANKING: 
3. Pump failure death
REASONING: 

The patient's severely impaired LVEF (30%) and elevated creatinine level (105.0 mol/L) suggest significant cardiac dysfunction and renal impairment, which may lead to pump failure. The patient's history of idiopathic dilated cardiomyopathy and dyslipemia further increases the risk of cardiac decompensation.

The patient's ECG impression reveals polymorphic ventricular extrasystole and non-sustained ventricular tachycardia, which are both indicators of ventricular arrhythmias. While the patient's survival is possible due to the effectiveness of their current treatment regimen, the presence of these arrhythmias and cardiac dysfunction increases the risk of pump failure.

However, the patient's survival is still possible, and with continued close monitoring and management, it is possible that the patient may survive for several years, albeit with significant limitations due to their cardiac dysfunction."
98,98,P0163,"Age: 71
Gender: Female 
Weight: 70 kg
Height: 150 cm
NYHA Class: II
Blood Pressure: 150/90 mmHg
Past Medical History: Hypertensive cardiomyopathy, Hypertension
Albumin (g/L): 40,5
ALT or GPT (IU/L): 17.0
AST or GOT (IU/L): 22.0
Total Cholesterol (mmol/L): 6,43
Creatinine (mmol/L): 89.0
Gamma-glutamil transpeptidase (IU/L): 12
Glucose (mmol/L): 6,9
Hemoglobin (g/L): 125.0
HDL (mmol/L): 1,3
Potassium (mEq/L): 3,82
LDL (mmol/L): 4,43
Sodium (mEq/L): 142.0
Pro-BNP (ng/L): 469.0
Protein (g/L): 72,8
Troponin (ng/mL): 0,01
TSH (mIU/L): 1,7
Urea (mg/dL): 4,8
LVEF (%): 55.0
Medications: Beta Blockers, Loop Diuretics, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: No
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",survivor,"RANKING: 
1. Survivor
2. Pump failure death
3. Sudden cardiac death

REASONING:

The patient's overall clinical presentation and laboratory results suggest a moderate to severe left ventricular dysfunction, indicated by a low LVEF of 55.0%. This is a significant risk factor for adverse outcomes, including heart failure and arrhythmias. The patient's history of hypertensive cardiomyopathy and hypertension also contributes to the risk of heart failure.

The patient's elevated creatinine level (89.0 mmol/L) suggests some degree of renal impairment, which can be associated with heart failure and cardiomyopathy. The elevated Pro-BNP level (469.0 ng/L) further supports this, as it is a biomarker for heart failure.

The patient's blood pressure (150/90 mmHg) is elevated, and the presence of hypertension is a well-established risk factor for cardiovascular disease and heart failure. However, the patient is already on beta blockers, loop diuretics, and ACE inhibitors, which are standard treatments for hypertension and heart failure.

The absence of ventricular extrasystole, ventricular tachycardia, and non-sustained ventricular tachycardia on the ECG is reassuring, but the unknown status of paroxysmal supraventricular tachyarrhythmia and bradycardia codes on the ECG may indicate a potential risk for arrhythmias.

While the patient is currently classified as a survivor, the combination of these factors suggests a moderate to high risk for adverse outcomes. However, the patient's current medical management and the absence of other high-risk features, such as a significant history of arrhythmias or recent myocardial infarction, make pump failure death less likely. Sudden cardiac death is the most concerning outcome, but the patient's ECG and clinical presentation do not indicate a high risk for this.

Therefore, the most likely outcome is survival, but with a significant risk of developing heart failure or pump failure in the next few years."
99,99,P0164,"Age: 78
Gender: Male 
Weight: 92 kg
Height: 177 cm
NYHA Class: II
Blood Pressure: 140/90 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Dyslipemia, Myocardial Infarction
Albumin (g/L): 34,4
ALT or GPT (IU/L): 28.0
AST or GOT (IU/L): 21.0
Total Cholesterol (mmol/L): 3,58
Creatinine (mmol/L): 82.0
Gamma-glutamil transpeptidase (IU/L): 133
Glucose (mmol/L): 4,3
Hemoglobin (g/L): 130.0
HDL (mmol/L): 1,25
Potassium (mEq/L): 4,44
LDL (mmol/L): 1,89
Sodium (mEq/L): 139.0
Pro-BNP (ng/L): 2104.0
Protein (g/L): 62,1
Troponin (ng/mL): 0,01
TSH (mIU/L): 1,84
Urea (mg/dL): 8,1
LVEF (%): 35.0
Medications: Beta Blockers, Digoxin, Loop Diuretics, Statins, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",survivor,"RANKING: 1. Survivor
REASONING:

Based on the provided patient data, I would rank the patient as having a high likelihood of survival over the next few years. Here's the reasoning behind this ranking:

1. Age: Although the patient is 78 years old, the patient's age alone is not a significant risk factor for mortality. Many patients with heart failure and other comorbidities can live for many years with proper management.

2. NYHA Class II: The patient's New York Heart Association (NYHA) class II indicates that the patient has some limitations in physical activity, but they are still able to perform light physical activity without symptoms. This suggests that the patient's heart is still functional to some extent.

3. Medications: The patient is on beta blockers, digoxin, loop diuretics, statins, and an ACE inhibitor, which are all standard treatments for heart failure and ischemic cardiomyopathy. These medications can help manage symptoms, slow disease progression, and improve survival.

4. ECG Impression: While the patient has several arrhythmias, including ventricular extrasystoles, non-sustained ventricular tachycardia, and non-sustained ventricular tachycardia, the patient is not in cardiac arrest or experiencing severe arrhythmias. These arrhythmias can be managed with medication and may not necessarily predict a poor outcome.

5. Biomarkers: The patient's troponin levels are normal, and the pro-BNP levels are elevated, but not excessively high. These biomarkers suggest some degree of cardiac stress, but they do not indicate acute myocardial infarction or severe heart failure.

6. Laboratory values: The patient's kidney function is slightly elevated, but it is not severely impaired. The patient's liver function is also normal, and the patient's electrolyte levels are within normal ranges.

Considering these factors, I believe that the patient has a high likelihood of survival over the next few years with proper management and monitoring. However, regular follow-up and close monitoring of the patient's condition are essential to adjust the treatment plan as needed and prevent any potential complications.

RANKING: 2. Sudden cardiac death
REASONING: 

While the patient has several risk factors for arrhythmias, including ventricular extrasystoles and non-sustained ventricular tachycardia, I would not rank the patient as high risk for sudden cardiac death. The patient is not in cardiac arrest, and the arrhythmias are non-sustained, which suggests that they are not life-threatening.

RANKING: 3. Pump failure death
REASONING: The patient has a history of ischemic dilated cardiomyopathy and is on medications that can help manage heart failure symptoms. However, the patient's left ventricular ejection fraction (LVEF) is only 35%, which is significantly reduced. This suggests that the patient's heart is not functioning well, and there is a risk of pump failure. However, the patient's symptoms are not severe, and they are able to perform light physical activity without symptoms, which suggests that the patient's heart is still functional to some extent. Therefore, while pump failure is a risk, I would rank it as the least likely outcome compared to sudden cardiac death."
100,100,P0165,"Age: 76
Gender: Female 
Weight: 70 kg
Height: 153 cm
NYHA Class: II
Blood Pressure: 213/110 mmHg
Past Medical History: Hypertensive cardiomyopathy, Dyslipemia, Hypertension
Albumin (g/L): 41,6
ALT or GPT (IU/L): 18.0
AST or GOT (IU/L): 25.0
Total Cholesterol (mmol/L): 5,67
Creatinine (mmol/L): 93.0
Gamma-glutamil transpeptidase (IU/L): 27
Glucose (mmol/L): 4,9
Hemoglobin (g/L): 130.0
HDL (mmol/L): 1,28
Potassium (mEq/L): 4,5
LDL (mmol/L): 3,2
Sodium (mEq/L): 134.0
Pro-BNP (ng/L): 366.0
Protein (g/L): 75,6
Troponin (ng/mL): 0,01
TSH (mIU/L): 1,92
Urea (mg/dL): 8,4
LVEF (%): 45.0
Medications: Angiotensin II Receptor Blocker, Loop Diuretics, Statins, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"RANKING: 
1. Survivor
REASONING:
Based on the provided patient data, the patient is a 76-year-old female with a history of hypertension, cardiomyopathy, and dyslipidemia. Her NYHA Class II indicates that she has some symptoms of heart failure, but she is still able to perform daily activities with some limitation. Her elevated blood pressure (213/110 mmHg) and high creatinine level (93.0 mmol/L) suggest that her cardiovascular system is under significant strain.

Her ECG findings of ventricular extrasystole and elevated troponin levels (0.01 ng/mL) indicate some degree of cardiac stress and possible minor myocardial damage. However, the absence of ventricular tachycardia, non-sustained ventricular tachycardia, and paroxysmal supraventricular tachyarrhythmia reduces the risk of sudden cardiac death.

The patient's low LVEF (45.0%) and high Pro-BNP levels (366.0 ng/L) suggest that her heart is under significant stress and may be at risk of heart failure. However, her relatively stable hemoglobin level (130.0 g/L) and normal potassium level (4.5 mEq/L) suggest that she is not experiencing severe anemia or electrolyte imbalances.

Considering these factors, the patient's overall prognosis is that she is likely to survive for the next few years. The presence of cardiomyopathy and hypertension increases her risk of cardiovascular events, but her relatively stable vital signs and the absence of severe cardiac arrhythmias reduce this risk.

While it is impossible to predict with certainty, I would estimate the patient's 5-year survival rate as follows:

* 1-year survival rate: 80-90%
* 2-year survival rate: 70-80%
* 5-year survival rate: 50-60%

Please note that these estimates are based on general assumptions and should be taken as rough estimates rather than precise predictions. A more accurate prognosis would require a thorough evaluation by a cardiologist and consideration of additional patient-specific factors."
101,101,P0166,"Age: 75
Gender: Female 
Weight: 68 kg
Height: 158 cm
NYHA Class: II
Blood Pressure: 190/80 mmHg
Past Medical History: Valvular cardiomyopathy
Albumin (g/L): 42,8
ALT or GPT (IU/L): 11.0
AST or GOT (IU/L): 17.0
Total Cholesterol (mmol/L): 6,16
Creatinine (mmol/L): 82.0
Gamma-glutamil transpeptidase (IU/L): 41
Glucose (mmol/L): 6,2
Hemoglobin (g/L): 131.0
Potassium (mEq/L): 4,08
Sodium (mEq/L): 139.0
Pro-BNP (ng/L): 746.0
Protein (g/L): 75,9
Troponin (ng/mL): 0,01
TSH (mIU/L): 1,18
Urea (mg/dL): 7,9
LVEF (%): 69.0
Medications: Beta Blockers, Digoxin, Loop Diuretics, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",survivor,"RANKING: 
1. Survivor 
REASONING: 
Based on the provided patient data, the patient's overall prognosis is likely to be a survivor. The patient's age is 75, which is considered elderly, but the patient's NYHA Class II indicates that they have some limitation in physical activity but can still perform daily activities without severe symptoms. The patient's LVEF of 69.0 is below the normal range, indicating some degree of left ventricular dysfunction, but the patient is not in heart failure. The patient's biomarkers, such as Troponin and BNP, are not significantly elevated, which suggests that there is no acute myocardial infarction or significant cardiac stress. The patient's ECG shows ventricular extrasystoles, which can be a sign of underlying cardiac disease, but the absence of ventricular tachycardia or bradycardia makes it less concerning. The patient's medication regimen includes beta blockers, digoxin, loop diuretics, and ACE inhibitors, which are all standard treatments for heart failure and arrhythmias. Overall, the patient's clinical presentation and laboratory results suggest that they are likely to survive for the next few years with proper management and monitoring."
102,102,P0167,"Age: >89
Gender: Male 
Weight: 78 kg
Height: 164 cm
NYHA Class: III
Blood Pressure: 150/70 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Myocardial Infarction
Albumin (g/L): 38
ALT or GPT (IU/L): 17.0
AST or GOT (IU/L): 11.0
Total Cholesterol (mmol/L): 2,92
Creatinine (mmol/L): 129.0
Gamma-glutamil transpeptidase (IU/L): 19
Glucose (mmol/L): 4,6
Hemoglobin (g/L): 114.0
Potassium (mEq/L): 4,2
Sodium (mEq/L): 147.0
Pro-BNP (ng/L): 3724.0
Protein (g/L): 65
Troponin (ng/mL): 0,01
TSH (mIU/L): 1,45
Urea (mg/dL): 9,6
LVEF (%): 60.0
Medications: Loop Diuretics, ACE Inhibitor, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",survivor,"RANKING: 

1. Survivor
REASONING: 

The patient is considered a high-risk patient due to several factors. The patient's age (>89 years), NYHA Class III heart failure, and history of ischemic dilated cardiomyopathy and myocardial infarction increase the risk of cardiac complications. The elevated Pro-BNP level (3724.0 ng/L) indicates significant ventricular strain, which is a strong predictor of adverse outcomes. However, the patient's hemoglobin level (114.0 g/L) is relatively low, which could be a sign of anemia, but the patient is receiving medications that may be contributing to this. The absence of ventricular tachycardia or non-sustained ventricular tachycardia on the ECG suggests that the patient is not at high risk for life-threatening arrhythmias.

The patient's renal function is mildly impaired (Creatinine 9.6 mg/dL), but this is not uncommon in elderly patients. The patient's medications, including loop diuretics, ACE inhibitor, and nitrovasodilator, are standard treatments for heart failure and hypertension, and are likely contributing to the patient's overall management.

Considering these factors, the patient's prognosis is likely to be a survivor, with ongoing close monitoring and management of their heart failure and hypertension. However, the patient's overall health status and the presence of comorbidities will continue to be closely monitored.

2. Sudden Cardiac Death
REASONING: 

The patient's history of myocardial infarction and ischemic dilated cardiomyopathy increases the risk of sudden cardiac death. The patient's low ejection fraction (LVEF 60.0%) is also a risk factor for sudden cardiac death. However, the patient's ECG does not show any signs of ventricular tachycardia or non-sustained ventricular tachycardia, which reduces the risk of sudden cardiac death. The patient's age and NYHA Class III heart failure also increase the risk of sudden cardiac death.

3. Pump Failure Death
REASONING: 

Pump failure death is a possible outcome for this patient, but it is less likely than sudden cardiac death. The patient's NYHA Class III heart failure and elevated Pro-BNP level suggest that the patient's heart is not functioning optimally. However, the patient's renal function is mildly impaired, and the patient is receiving medications that are likely contributing to their heart failure management. The patient's LVEF is also elevated (60.0%), which suggests that the patient's heart is not as severely impaired as might be expected given their NYHA Class III status."
103,103,P0168,"Age: 88
Gender: Female 
Weight: 66 kg
Height: 153 cm
NYHA Class: II
Blood Pressure: 120/60 mmHg
Past Medical History: Hypertensive cardiomyopathy
Albumin (g/L): 37,9
ALT or GPT (IU/L): 30.0
AST or GOT (IU/L): 14.0
Total Cholesterol (mmol/L): 4,07
Creatinine (mmol/L): 91.0
Gamma-glutamil transpeptidase (IU/L): 31
Glucose (mmol/L): 5,3
Hemoglobin (g/L): 137.0
Potassium (mEq/L): 3,2
Sodium (mEq/L): 145.0
Pro-BNP (ng/L): 237.0
Protein (g/L): 70,1
Troponin (ng/mL): 0,01
TSH (mIU/L): 0,36
Urea (mg/dL): 14,1
LVEF (%): 60.0
Medications: Calcium Channel Blocker, Angiotensin II Receptor Blocker, Loop Diuretics, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"RANKING: 

1. Survivor
REASONING: 
The patient is 88 years old with a history of hypertensive cardiomyopathy, which is a condition that can lead to heart failure. However, the patient's NYHA Class is II, indicating mild symptoms, and they are currently on multiple medications that are standard for managing heart failure and hypertension. The patient's LVEF is 60.0%, which is within the normal range, and the ECG does not show any signs of ventricular tachycardia or other arrhythmias that could indicate a high risk of sudden cardiac death. The patient's biomarkers, including Troponin and Pro-BNP, are within normal limits, suggesting that there is no acute cardiac injury or strain. The patient's renal function is also relatively preserved, with a creatinine level of 14.1 mg/dL, which is not significantly elevated. Overall, these factors suggest that the patient is at low risk for sudden cardiac death and pump failure in the short term.

2. Sudden cardiac death
REASONING: 
While the patient is 88 years old and has a history of hypertensive cardiomyopathy, the fact that they are currently asymptomatic and have a normal LVEF and biomarkers suggests that they are not at high risk for sudden cardiac death. However, the patient's age and underlying cardiomyopathy do increase their risk for arrhythmias and sudden cardiac death. The patient's ECG shows ventricular extrasystoles, which can be a precursor to more serious arrhythmias, but the absence of ventricular tachycardia or other high-risk arrhythmias reduces this risk.

3. Pump failure death
REASONING: 
The patient's NYHA Class is II, indicating mild symptoms, and they are currently on multiple medications that are standard for managing heart failure. The patient's LVEF is 60.0%, which is within the normal range, suggesting that their heart is functioning relatively well. However, the patient's age and underlying cardiomyopathy do increase their risk for heart failure. The patient's renal function is also slightly elevated, with a creatinine level of 14.1 mg/dL, which could be a sign of mild kidney impairment. While the patient is currently asymptomatic, the combination of these factors suggests that they may be at risk for developing heart failure in the future."
104,104,P0169,"Age: 49
Gender: Male 
Weight: 69 kg
Height: 160 cm
NYHA Class: II
Blood Pressure: 115/70 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Dyslipemia, Peripheral vascular disease, Hypertension, Myocardial Infarction
Albumin (g/L): 40
ALT or GPT (IU/L): 13.0
AST or GOT (IU/L): 12.0
Total Cholesterol (mmol/L): 4,74
Creatinine (mmol/L): 273.0
Gamma-glutamil transpeptidase (IU/L): 21
Glucose (mmol/L): 5,3
Hemoglobin (g/L): 113.0
Potassium (mEq/L): 4,63
Sodium (mEq/L): 142.0
Pro-BNP (ng/L): 17620.0
Protein (g/L): 70
Troponin (ng/mL): 0,02
TSH (mIU/L): 1,49
Urea (mg/dL): 24,2
LVEF (%): 23.0
Medications: Loop Diuretics, Statins, Hydralazine, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: TPSV
        - Bradycardia: No
            ",survivor,"RANKING: 

1. Survivor
REASONING: 

This patient has a history of ischemic dilated cardiomyopathy, which is a condition that can lead to heart failure. However, the patient's current NYHA Class II indicates that their symptoms are manageable with medication. The patient's LVEF of 23.0 is significantly reduced, but not critically low, suggesting that the heart is still pumping, albeit inefficiently. The presence of non-sustained ventricular tachycardia and ventricular extrasystoles on the ECG suggests an increased risk of arrhythmias, but these are not sustained. The patient's current medication regimen, which includes loop diuretics, statins, hydralazine, and a nitrovasodilator, suggests that the patient is receiving standard treatment for their condition.

The patient's laboratory values, including the elevated creatinine level, indicate some degree of kidney dysfunction, but this is not uncommon in patients with heart failure. The elevated troponin level is not significantly elevated, which suggests that there is not a large amount of myocardial damage. The patient's other laboratory values are relatively normal, and the pro-BNP level is not excessively elevated, which suggests that the patient is not experiencing significant fluid overload.

Overall, based on the patient's medical history, physical examination, and laboratory values, the patient appears to be a candidate for a favorable outcome, and the likelihood of sudden cardiac death or pump failure is relatively low. Therefore, the most likely prognosis is that the patient will survive.

2. Sudden cardiac death
REASONING: 

The patient's history of ischemic dilated cardiomyopathy and non-sustained ventricular tachycardia on the ECG suggest an increased risk of arrhythmias, which can lead to sudden cardiac death. The patient's LVEF of 23.0 is significantly reduced, which increases the risk of arrhythmias and sudden cardiac death. The presence of ventricular extrasystoles on the ECG also increases the risk of arrhythmias.

However, the patient's current medication regimen and laboratory values suggest that the patient is receiving standard treatment for their condition, and the patient's kidney function is not severely impaired. The patient's pro-BNP level is not excessively elevated, which suggests that the patient is not experiencing significant fluid overload.

While the patient's history and ECG findings suggest an increased risk of arrhythmias, the patient's current medical status and treatment plan suggest that the risk of sudden cardiac death is not extremely high. Therefore, while the patient is at risk, the likelihood of sudden cardiac death is lower than that of pump failure.

3. Pump failure death
REASONING: 

The patient's LVEF of 23.0 is significantly reduced, indicating that the patient's heart is not pumping efficiently. The patient's NYHA Class II indicates that their symptoms are manageable with medication, but the patient's reduced LVEF suggests that the patient's heart is not functioning optimally.

The patient's elevated creatinine level and elevated troponin level suggest that the patient's kidney function is impaired, which can lead to fluid overload and further compromise the patient's cardiac function. The patient's pro-BNP level is elevated, which suggests that the patient is experiencing fluid overload.

The patient's ECG findings, including the presence of ventricular extrasystoles and non-sustained ventricular tachycardia, suggest an increased risk of arrhythmias, which can further compromise the patient's cardiac function and lead to pump failure. While the patient's current medication regimen and laboratory values suggest that the patient is receiving standard treatment for their condition, the patient's reduced LVEF and elevated creatinine level suggest that the patient is at risk of pump failure.

Overall, while the patient's current medical status and treatment plan suggest that the patient is not in imminent danger of pump failure, the patient's reduced LVEF and elevated creatinine level suggest that the patient is at risk of pump failure, making this prognosis the least likely of the three."
105,105,P0170,"Age: 73
Gender: Female 
Weight: 64 kg
Height: 152 cm
NYHA Class: II
Blood Pressure: 210/110 mmHg
Past Medical History: Hypertensive cardiomyopathy, Diabetes, Hypertension
Albumin (g/L): 39,2
ALT or GPT (IU/L): 32.0
AST or GOT (IU/L): 27.0
Total Cholesterol (mmol/L): 4,9
Creatinine (mmol/L): 82.0
Gamma-glutamil transpeptidase (IU/L): 60
Glucose (mmol/L): 10,9
Hemoglobin (g/L): 107.0
HDL (mmol/L): 1,04
Potassium (mEq/L): 4,03
LDL (mmol/L): 2,96
Sodium (mEq/L): 139.0
Protein (g/L): 74,8
Troponin (ng/mL): 0,01
TSH (mIU/L): 2,19
Urea (mg/dL): 8,4
LVEF (%): 70.0
Medications: Diabetes Medication, Beta Blockers, Loop Diuretics, ACE Inhibitor, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: TPSV
        - Bradycardia: No
            ",survivor,"RANKING: 1. Survivor
REASONING: 

Given the patient's age, NYHA Class II, and the presence of hypertension, hypertensive cardiomyopathy, and diabetes, there are several factors that suggest a relatively favorable prognosis. The patient's LVEF of 70.0 indicates that the heart is still functioning moderately well, which is a positive sign. The absence of significant electrolyte imbalances (e.g., low potassium levels), and the absence of troponin elevation suggest that the heart muscle is not under significant stress. The patient's medication regimen, which includes ACE inhibitors and beta blockers, is also a positive factor in managing the patient's hypertension and heart failure symptoms.

The patient's ECG results show no evidence of ventricular tachycardia or non-sustained ventricular tachycardia, which are both significant predictors of poor outcomes. The presence of paroxysmal supraventricular tachycardia (PSVT) may require monitoring but is not necessarily a cause for concern.

While the patient's blood pressure is elevated, the fact that they are already on treatment for hypertension and have a controlled NYHA Class II suggests that they are likely receiving adequate management for their condition. The patient's kidney function, as indicated by the creatinine level, is also relatively preserved.

Overall, the combination of a controlled blood pressure, a moderate LVEF, and a comprehensive medication regimen make a survivor the most likely outcome for this patient."
106,106,P0171,"Age: 75
Gender: Male 
Weight: 76 kg
Height: 164 cm
NYHA Class: II
Blood Pressure: 140/90 mmHg
Past Medical History: Toxic dilated cardiomyopathy, Dyslipemia, Hypertension
Albumin (g/L): 36
ALT or GPT (IU/L): 17.0
AST or GOT (IU/L): 28.0
Total Cholesterol (mmol/L): 4,91
Creatinine (mmol/L): 119.0
Gamma-glutamil transpeptidase (IU/L): 7
Glucose (mmol/L): 4,7
Hemoglobin (g/L): 121.0
Potassium (mEq/L): 4,43
Sodium (mEq/L): 141.0
Pro-BNP (ng/L): 10060.0
Protein (g/L): 67,9
Troponin (ng/mL): 0,14
TSH (mIU/L): 0,74
Urea (mg/dL): 9
LVEF (%): 20.0
Medications: Loop Diuretics, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: TPSV
        - Bradycardia: No
            ",survivor,"RANKING: 1. Survivor
REASONING: The patient has a history of toxic dilated cardiomyopathy, which is a significant risk factor for adverse cardiac events. However, the patient is currently being treated with medications for this condition (Loop Diuretics and ACE Inhibitor), which can help manage symptoms and slow disease progression. The patient's ejection fraction (LVEF) is relatively low at 20%, indicating significant cardiac dysfunction. However, the patient is not currently experiencing any life-threatening arrhythmias, such as ventricular tachycardia or bradycardia. The patient's troponin levels are also not elevated, suggesting that there is no significant myocardial infarction. The patient's renal function is also relatively preserved, with a creatinine level of 9 mg/dL. Overall, while the patient has a high-risk profile, the fact that they are currently not experiencing any acute cardiac events and are being treated for their underlying condition suggests that they are likely to survive for the next few years.

RANKING: 2. Pump failure death
REASONING: Given the patient's history of toxic dilated cardiomyopathy, it is possible that the patient's cardiac function will continue to decline over time, leading to pump failure. The patient's ejection fraction is already low at 20%, and their cardiac condition is not being adequately managed. The patient's renal function is also compromised, which can further exacerbate cardiac dysfunction. The patient's lipid profile is also suboptimal, which can contribute to further cardiac damage.

RANKING: 3. Sudden cardiac death
REASONING: While the patient has a history of ventricular extrasystole and polymorphic ventricular extrasystole, the patient is not currently experiencing any life-threatening arrhythmias. The patient's troponin levels are not elevated, and they are not experiencing any symptoms of myocardial infarction. However, the patient's cardiac condition is still relatively unstable, and the presence of ventricular extrasystole and polymorphic ventricular extrasystole increases the risk of sudden cardiac death. Additionally, the patient's age and history of toxic dilated cardiomyopathy also increase this risk."
107,107,P0173,"Age: 83
Gender: Female 
Weight: 69 kg
Height: 151 cm
NYHA Class: II
Blood Pressure: 105/70 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Myocardial Infarction
Albumin (g/L): 39,7
ALT or GPT (IU/L): 23.0
AST or GOT (IU/L): 38.0
Total Cholesterol (mmol/L): 3,65
Creatinine (mmol/L): 108.0
Gamma-glutamil transpeptidase (IU/L): 30
Glucose (mmol/L): 6,7
Hemoglobin (g/L): 112.0
Potassium (mEq/L): 4,49
Sodium (mEq/L): 139.0
Pro-BNP (ng/L): 3532.0
Protein (g/L): 65,4
T4 (ng/L): 23,5
Troponin (ng/mL): 0,01
TSH (mIU/L): 0,1
Urea (mg/dL): 8,4
LVEF (%): 28.0
Medications: Loop Diuretics, ACE Inhibitor, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: TPSV
        - Bradycardia: No
            ",survivor,"RANKING: 

1. Survivor
REASONING: 
Based on the provided patient data, the patient is 83 years old with a history of ischemic dilated cardiomyopathy and myocardial infarction. The patient has a low ejection fraction (LVEF) of 28.0, indicating severe left ventricular dysfunction. The patient's ECG shows ventricular extrasystole and polymorphic ventricular tachycardia, which are signs of cardiac arrhythmias. However, the absence of sustained ventricular tachycardia and paroxysmal supraventricular tachyarrhythmia suggests that the patient's cardiac arrhythmias are not severe. The patient's medications, including loop diuretics, ACE inhibitor, and nitrovasodilator, are commonly used to manage heart failure and arrhythmias in patients with heart failure. The patient's laboratory results show elevated creatinine levels, indicating impaired renal function, but this is not directly related to the cardiac condition. The patient's other laboratory results are within normal or near-normal limits. Given these factors, the patient's age, severe left ventricular dysfunction, and the presence of cardiac arrhythmias make it more likely that the patient will survive for the next few years. 

2. Pump failure death
REASONING: 
While the patient's severe left ventricular dysfunction (LVEF 28.0) and history of heart failure (NYHA Class II) increase the risk of pump failure, the patient is currently being treated with medications that can help manage heart failure symptoms. However, the patient's elevated creatinine levels indicate impaired renal function, which can be a complication of heart failure. Additionally, the patient's age and history of myocardial infarction may increase the risk of cardiac events, including pump failure. 

3. Sudden cardiac death
REASONING: 
Given the patient's severe left ventricular dysfunction (LVEF 28.0), history of myocardial infarction, and presence of ventricular extrasystole and polymorphic ventricular tachycardia on ECG, the patient is at high risk of cardiac arrhythmias that can lead to sudden cardiac death. However, the absence of sustained ventricular tachycardia and paroxysmal supraventricular tachyarrhythmia on ECG reduces this risk. Additionally, the patient's current medications and laboratory results do not indicate an acute cardiac event."
108,108,P0174,"Age: 79
Gender: Female 
Weight: 66 kg
Height: 150 cm
NYHA Class: III
Blood Pressure: 140/70 mmHg
Past Medical History: Hypertensive cardiomyopathy, Diabetes, Dyslipemia, Peripheral vascular disease, Hypertension, Myocardial Infarction
Albumin (g/L): 37
ALT or GPT (IU/L): 32.0
AST or GOT (IU/L): 24.0
Total Cholesterol (mmol/L): 3,98
Creatinine (mmol/L): 159.0
Gamma-glutamil transpeptidase (IU/L): 30
Glucose (mmol/L): 10
Hemoglobin (g/L): 111.0
HDL (mmol/L): 0,72
Potassium (mEq/L): 5,6
LDL (mmol/L): 2,02
Sodium (mEq/L): 144.0
Pro-BNP (ng/L): 505.0
Protein (g/L): 81
T3 (pg/dL): 0,03
T4 (ng/L): 27
Troponin (ng/mL): 0,01
TSH (mIU/L): 2,16
Urea (mg/dL): 21,63
LVEF (%): 70.0
Medications: Diabetes Medication, Beta Blockers, Loop Diuretics, Statins, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: First-degree Atrioventricular block (AVB)
            ",survivor,"RANKING: 1. Survivor
REASONING: 
Based on the patient's age (79), NYHA Class III (indicating severe heart failure symptoms), and the presence of multiple comorbidities such as hypertension, diabetes, and dyslipidemia, the patient's overall prognosis is likely to be poor. However, the patient's LVEF (70.0) is relatively preserved, and the absence of evidence for severe left ventricular dysfunction or acute coronary syndrome (Troponin < 0.01 ng/mL) suggests that the patient's cardiac function is not severely impaired. The presence of a first-degree atrioventricular block (AVB) on ECG may indicate some degree of cardiac conduction system disease, but it is not immediately life-threatening. Additionally, the patient is on beta blockers, loop diuretics, and statins, which are all evidence-based treatments for managing heart failure and preventing further cardiovascular events. The patient's Pro-BNP level (505.0 ng/L) is elevated, indicating some degree of ventricular strain, but it is not excessively high. Therefore, considering these factors, I would rank the patient's prognosis as a survivor, with the possibility of long-term management and optimization of medications to improve outcomes.

RANKING: 2. Sudden cardiac death
REASONING: 
While the patient's LVEF is preserved, the presence of a first-degree AVB and elevated Pro-BNP level may indicate some degree of cardiac stress or strain. The patient's age, comorbidities, and hypertension also increase the risk of cardiovascular events, including sudden cardiac death. Additionally, the patient's ECG shows ventricular extrasystole, which may be a sign of underlying cardiac electrical instability. However, the absence of other evidence for acute coronary syndrome or ventricular tachycardia makes sudden cardiac death less likely. Nevertheless, the patient's overall risk profile, including age and comorbidities, makes sudden cardiac death a plausible, albeit less likely, outcome.

RANKING: 3. Pump failure death
REASONING: 
Given the patient's NYHA Class III and elevated Pro-BNP level, pump failure death is a possible outcome. However, the patient's LVEF is preserved, and the patient is on evidence-based medications for heart failure management, which suggests that the patient's cardiac function is being adequately supported. Additionally, the patient's renal function (creatinine 159.0 mol/L) is not severely impaired, which reduces the risk of acute kidney injury and further decline in cardiac function. While the patient's comorbidities and hypertension increase the risk of cardiovascular events, the overall clinical picture does not strongly suggest pump failure death as the most likely outcome."
109,109,P0175,"Age: 48
Gender: Female 
Weight: 69 kg
Height: 168 cm
NYHA Class: II
Blood Pressure: 110/65 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Myocardial Infarction
Albumin (g/L): 44
ALT or GPT (IU/L): 31.0
AST or GOT (IU/L): 18.0
Total Cholesterol (mmol/L): 3,83
Creatinine (mmol/L): 88.0
Gamma-glutamil transpeptidase (IU/L): 14
Glucose (mmol/L): 4,9
Hemoglobin (g/L): 138.0
HDL (mmol/L): 1,55
Potassium (mEq/L): 4,4
LDL (mmol/L): 1,86
Sodium (mEq/L): 144.0
Pro-BNP (ng/L): 572.0
Protein (g/L): 71
T3 (pg/dL): 0,03
T4 (ng/L): 27
Troponin (ng/mL): 0,01
TSH (mIU/L): 3,91
Urea (mg/dL): 3,66
LVEF (%): 42.0
Medications: Beta Blockers, Loop Diuretics, Statins, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"RANKING: 1. Survivor
REASONING: 
Based on the patient data provided, the patient is a 48-year-old female with a history of ischemic dilated cardiomyopathy and myocardial infarction, and currently has a New York Heart Association (NYHA) class II heart failure. Despite the significant cardiac history, the patient's current ECG impression does not show any signs of ventricular arrhythmias, which is a crucial factor in predicting cardiac mortality. The patient's left ventricular ejection fraction (LVEF) is 42%, which is slightly reduced but not severely impaired. The patient's current medications, including beta blockers, loop diuretics, statins, and ACE inhibitors, are standard treatments for heart failure and coronary artery disease. 

While the patient has an elevated troponin level (0.01 ng/mL), which may indicate some degree of cardiac injury, it is not significantly elevated. The patient's renal function, as indicated by the creatinine level of 3.66 mg/dL, is slightly elevated but not severely impaired. The patient's laboratory results, including electrolytes, liver enzymes, and thyroid function tests, are relatively within normal limits. Overall, the combination of a relatively stable cardiac condition, absence of significant arrhythmias, and effective management of heart failure symptoms and coronary artery disease, suggest that the patient is likely to survive the next few years. 

While it is difficult to predict cardiac outcomes with certainty, the patient's overall clinical presentation and management plan suggest a favorable prognosis, making ""survivor"" the most likely outcome."
110,110,P0177,"Age: 76
Gender: Male 
Weight: 90 kg
Height: 170 cm
NYHA Class: III
Blood Pressure: 110/55 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Dyslipemia, Hypertension, Myocardial Infarction
Albumin (g/L): 39
ALT or GPT (IU/L): 33.0
AST or GOT (IU/L): 15.0
Total Cholesterol (mmol/L): 5,69
Creatinine (mmol/L): 124.0
Gamma-glutamil transpeptidase (IU/L): 57
Glucose (mmol/L): 6,9
Hemoglobin (g/L): 110.0
HDL (mmol/L): 0,75
Potassium (mEq/L): 4,5
LDL (mmol/L): 3,65
Sodium (mEq/L): 141.0
Pro-BNP (ng/L): 948.0
Protein (g/L): 77
T3 (pg/dL): 0,05
T4 (ng/L): 26
Troponin (ng/mL): 0,01
TSH (mIU/L): 3,29
Urea (mg/dL): 6,82
LVEF (%): 43.0
Medications: Beta Blockers, Digoxin, Loop Diuretics, Spironolactone, ACE Inhibitor, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Unknown ventricular tachycardia code
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",survivor,"RANKING: 
1. Survivor
REASONING: 

This patient's prognosis is most likely to be a survivor due to several factors. Firstly, the patient's age is 76, which is in the advanced age category for cardiovascular disease. However, the patient's NYHA class is III, indicating moderate symptoms of heart failure, which suggests that the patient's heart is still functional to some extent. 

The patient's ejection fraction (LVEF) is 43%, which is relatively preserved, indicating that the heart is still pumping blood effectively, albeit inefficiently. The patient's blood pressure is well-controlled at 110/55 mmHg, and the patient is on medications that are standard for heart failure management, such as beta blockers, digoxin, loop diuretics, spironolactone, and an ACE inhibitor.

The patient's laboratory results show elevated creatinine levels (124.0 mmol/L), which indicates impaired kidney function. However, this is not uncommon in patients with heart failure. The patient's troponin levels are normal (0.01 ng/mL), which suggests that there is no significant myocardial infarction.

The ECG results show ventricular extrasystole and polymorphic ventricular tachycardia, which are concerning signs of cardiac arrhythmias. However, the patient is on medications that are effective for arrhythmia management, and the patient's heart rate is not excessively high.

Given these factors, the patient's overall prognosis is likely to be a survivor, but with ongoing monitoring and management to address the cardiac arrhythmias and heart failure symptoms.

RANKING: 
2. Sudden cardiac death
REASONING: 

This patient's prognosis is less likely to be sudden cardiac death due to several factors. The patient's ECG results show ventricular extrasystole and polymorphic ventricular tachycardia, which are concerning signs of cardiac arrhythmias. However, the patient is on medications that are effective for arrhythmia management, and the patient's heart rate is not excessively high.

Additionally, the patient's LVEF is 43%, which is relatively preserved, indicating that the heart is still pumping blood effectively, albeit inefficiently. The patient's blood pressure is well-controlled, and the patient is on medications that are standard for heart failure management.

However, the patient's elevated creatinine levels (124.0 mmol/L) indicate impaired kidney function, which can increase the risk of cardiac complications. The patient's troponin levels are normal (0.01 ng/mL), which suggests that there is no significant myocardial infarction.

Given these factors, the patient's prognosis is less likely to be sudden cardiac death, but it is still a concern due to the presence of cardiac arrhythmias.

RANKING: 
3. Pump failure death
REASONING: 

This patient's prognosis is the least likely to be pump failure death due to several factors. The patient's LVEF is 43%, which is relatively preserved, indicating that the heart is still pumping blood effectively, albeit inefficiently. The patient's blood pressure is well-controlled, and the patient is on medications that are standard for heart failure management.

However, the patient's elevated creatinine levels (124.0 mmol/L) indicate impaired kidney function, which can increase the risk of cardiac complications. The patient's elevated troponin levels (0.01 ng/mL) are slightly above normal, which suggests that there may be some myocardial damage. The patient's ECG results show ventricular extrasystole and polymorphic ventricular tachycardia, which are concerning signs of cardiac arrhythmias.

Additionally, the patient's NYHA class is III, indicating moderate symptoms of heart failure, which suggests that the patient's heart is not functioning optimally. Given these factors, the patient's prognosis is less likely to be pump failure death, but it is still a concern due to the presence of cardiac arrhythmias and impaired kidney function."
111,111,P0179,"Age: 74
Gender: Male 
Weight: 98 kg
Height: 172 cm
NYHA Class: II
Blood Pressure: 140/70 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Hypertension, Myocardial Infarction
Albumin (g/L): 39
ALT or GPT (IU/L): 39.0
AST or GOT (IU/L): 18.0
Total Cholesterol (mmol/L): 3,85
Creatinine (mmol/L): 124.0
Gamma-glutamil transpeptidase (IU/L): 38
Glucose (mmol/L): 9,4
Hemoglobin (g/L): 149.0
HDL (mmol/L): 0,83
Potassium (mEq/L): 4,4
LDL (mmol/L): 2,69
Sodium (mEq/L): 140.0
Pro-BNP (ng/L): 408.0
Protein (g/L): 75
T3 (pg/dL): 0,03
T4 (ng/L): 26
Troponin (ng/mL): 0,01
TSH (mIU/L): 1,02
Urea (mg/dL): 6,32
LVEF (%): 29.0
Medications: Beta Blockers, Loop Diuretics, Statins, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"RANKING: 1. Survivor
REASONING: 

Based on the provided patient data, I would rank the patient as having a high likelihood of survival for the next few years. Here's the reasoning behind this ranking:

1. The patient's NYHA Class II indicates that they have some limitation in their physical activity due to their heart condition, but they are not in severe heart failure.
2. The patient's LVEF (left ventricular ejection fraction) is 29%, which is significantly reduced, indicating poor cardiac function. However, it's not as severe as a heart failure classification of III or IV.
3. The patient's ECG findings of ventricular extrasystole, non-sustained ventricular tachycardia, and non-sustained ventricular tachycardia (CH>10) suggest an increased risk of arrhythmias, but the absence of sustained ventricular tachycardia or other severe arrhythmias reduces the risk.
4. The patient's medication regimen includes beta blockers, loop diuretics, statins, and an ACE inhibitor, which are commonly used to manage heart failure, hypertension, and high cholesterol, respectively.
5. The patient's biomarkers, such as elevated creatinine and urea levels, suggest some degree of renal impairment, but this is not uncommon in patients with heart failure.
6. The patient's other laboratory results, including a mildly elevated troponin level, are not significantly abnormal, suggesting that there is no acute myocardial infarction.
7. The patient's age is 74, which is advanced for some cardiac procedures, but with proper management, it's still possible for patients of this age to survive for several years with optimal treatment.

Overall, while the patient has a significant cardiac condition, their current symptoms and laboratory results suggest that they are stable, and with proper management, they are likely to survive for the next few years."
112,112,P0181,"Age: 69
Gender: Male 
Weight: 100 kg
Height: 174 cm
NYHA Class: II
Blood Pressure: 110/50 mmHg
Past Medical History: Ischemic dilated cardiomyopathy
Albumin (g/L): 40
ALT or GPT (IU/L): 29.0
AST or GOT (IU/L): 16.0
Total Cholesterol (mmol/L): 4,14
Creatinine (mmol/L): 97.0
Gamma-glutamil transpeptidase (IU/L): 19
Glucose (mmol/L): 5,7
Hemoglobin (g/L): 151.0
HDL (mmol/L): 0,78
Potassium (mEq/L): 4,4
LDL (mmol/L): 1,84
Sodium (mEq/L): 141.0
Pro-BNP (ng/L): 273.0
Protein (g/L): 67
T3 (pg/dL): 0,03
T4 (ng/L): 24
Troponin (ng/mL): 0,01
TSH (mIU/L): 1,83
Urea (mg/dL): 8,49
LVEF (%): 39.0
Medications: Diabetes Medication, Beta Blockers, Statins, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"RANKING: 

1. Survivor
REASONING:

This patient is at a high risk for adverse cardiac events, with a history of ischemic dilated cardiomyopathy, NYHA Class II, and a low left ventricular ejection fraction (LVEF) of 39.0%. The patient's ECG findings of ventricular extrasystoles, a polymorphic pattern, indicate an increased risk of arrhythmias. However, the absence of ventricular tachycardia or non-sustained ventricular tachycardia reduces this risk.

The patient's biomarkers, such as elevated Pro-BNP (273.0 ng/L) and elevated creatinine (8.49 mg/dL), suggest a compromised cardiac function and potential kidney impairment. The presence of diabetes and hypertension also increases the risk of cardiovascular events.

Despite these factors, the patient's current medication regimen, including beta blockers and ACE inhibitors, which are known to improve cardiac function and reduce mortality in patients with heart failure, is being followed. The patient's hemoglobin and potassium levels are also within relatively normal limits.

While the patient's cardiac function is severely impaired, the overall clinical picture suggests that with proper management and monitoring, the patient is likely to survive for the next few years. The absence of any life-threatening arrhythmias or acute cardiac events on the ECG, and the patient's relatively stable vital signs, support this prognosis.

2. Sudden cardiac death
REASONING:

While the patient's cardiac function is severely impaired, the patient's current ECG findings and vital signs do not indicate an immediate risk of sudden cardiac death. The absence of ventricular tachycardia or non-sustained ventricular tachycardia on the ECG reduces this risk.

However, the patient's history of ischemic dilated cardiomyopathy and low LVEF increase the risk of arrhythmias and sudden cardiac death. The patient's elevated Pro-BNP and creatinine levels also suggest compromised cardiac function, which could contribute to an increased risk of sudden cardiac death.

3. Pump failure death
REASONING:

Given the patient's severely impaired cardiac function, as evidenced by the low LVEF and elevated Pro-BNP and creatinine levels, pump failure death is a possible outcome. The patient's NYHA Class II symptoms also suggest a significant impact on daily activities, indicating a high risk of decompensation.

However, the patient's current medication regimen, including beta blockers and ACE inhibitors, is being followed, which can help improve cardiac function and reduce mortality. The absence of any life-threatening arrhythmias on the ECG and relatively stable vital signs also reduce the risk of sudden cardiac death."
113,113,P0182,"Age: 76
Gender: Male 
Weight: 90 kg
Height: 181 cm
NYHA Class: III
Blood Pressure: 130/70 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Myocardial Infarction
Albumin (g/L): 35
ALT or GPT (IU/L): 37.0
AST or GOT (IU/L): 20.0
Total Cholesterol (mmol/L): 3,72
Creatinine (mmol/L): 88.0
Gamma-glutamil transpeptidase (IU/L): 16
Glucose (mmol/L): 5,4
Hemoglobin (g/L): 140.0
HDL (mmol/L): 0,88
Potassium (mEq/L): 4,6
LDL (mmol/L): 2,4
Sodium (mEq/L): 143.0
Pro-BNP (ng/L): 859.0
Protein (g/L): 67
T3 (pg/dL): 0,03
T4 (ng/L): 27
Troponin (ng/mL): 0,01
TSH (mIU/L): 2,56
Urea (mg/dL): 8,15
LVEF (%): 40.0
Medications: Beta Blockers, Loop Diuretics, Statins, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"RANKING: 

1. Survivor
REASONING: 
Given the patient's age, NYHA Class III heart failure status, and the presence of ischemic dilated cardiomyopathy, the patient is at high risk for adverse cardiac events. However, the patient's current medication regimen, which includes beta blockers, loop diuretics, statins, and ACE inhibitors, is standard for managing heart failure and preventing further cardiac complications. The absence of elevated troponin levels and a normal ECG impression suggest that the patient does not currently have an acute myocardial infarction or significant cardiac ischemia. The patient's elevated BNP levels (859 ng/L) indicate some level of ventricular dysfunction, but it is not excessively high, which could suggest a relatively stable condition. Therefore, with proper management and monitoring, the patient is likely to survive for the next few years.

2. Sudden Cardiac Death
REASONING: 
While the patient is at risk for cardiac events due to his underlying heart failure and ischemic cardiomyopathy, there is no clear indication of a high risk for sudden cardiac death. The absence of ventricular tachycardia, non-sustained ventricular tachycardia, and polymorphic ventricular extrasystoles on the ECG impression suggests that the patient does not have a high risk for life-threatening arrhythmias. However, the patient's NYHA Class III status and elevated BNP levels do indicate a high risk for cardiac events, and the patient's LVEF of 40% is significantly reduced, indicating poor cardiac function. While the patient is at risk, the lack of clear evidence of a high risk for sudden cardiac death makes this prognosis less likely.

3. Pump Failure Death
REASONING: 
Pump failure death is a possible outcome for patients with severe heart failure, but it is often associated with more acute and severe presentations, such as acute heart failure exacerbation or a significant increase in BNP levels. The patient's current BNP level (859 ng/L) is elevated but not excessively high, and the patient is on medication for heart failure, which suggests that the patient's condition is being managed. While the patient's LVEF of 40% is significantly reduced, this does not necessarily indicate a high risk for pump failure death. The patient's overall clinical presentation and medication regimen suggest that the patient is likely to survive for the next few years, making pump failure death a less likely outcome."
114,114,P0184,"Age: 77
Gender: Male 
Weight: 84 kg
Height: 171 cm
NYHA Class: II
Blood Pressure: 130/60 mmHg
Past Medical History: Idiopathic dilated cardiomyopathy, Diabetes, Dyslipemia
Albumin (g/L): 45
ALT or GPT (IU/L): 48.0
AST or GOT (IU/L): 19.0
Total Cholesterol (mmol/L): 4,78
Creatinine (mmol/L): 97.0
Gamma-glutamil transpeptidase (IU/L): 45
Glucose (mmol/L): 9,4
Hemoglobin (g/L): 134.0
HDL (mmol/L): 1,68
Potassium (mEq/L): 4,7
LDL (mmol/L): 2,64
Sodium (mEq/L): 142.0
Pro-BNP (ng/L): 525.0
Protein (g/L): 74
T3 (pg/dL): 0,03
T4 (ng/L): 24
Troponin (ng/mL): 0,01
TSH (mIU/L): 2,13
Urea (mg/dL): 7,32
LVEF (%): 37.0
Medications: Diabetes Medication, Digoxin, Loop Diuretics, Statins, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: TPSV
        - Bradycardia: No
            ",survivor,"RANKING: 1. Survivor
REASONING: 

The patient's overall health status and medical history suggest a high risk of adverse cardiac events. The patient has a history of idiopathic dilated cardiomyopathy, which is a significant risk factor for heart failure and sudden cardiac death. The patient's left ventricular ejection fraction (LVEF) of 37% is severely impaired, indicating poor cardiac function. Additionally, the patient has a history of diabetes and dyslipidemia, which are risk factors for cardiovascular disease.

Despite the presence of these risk factors, the patient's current ECG impression does not indicate any acute arrhythmias or significant ischemia, which could be indicative of an acute cardiac event. The patient's troponin levels are within normal limits, and the patient is not currently experiencing any symptoms.

Given the patient's age, medical history, and current health status, the patient is at high risk for cardiac events. However, the absence of acute arrhythmias and normal troponin levels suggest that the patient may be at lower risk for sudden cardiac death compared to pump failure death. Therefore, the most likely prognosis is survival.

The patient's current health status is relatively stable, and the patient is currently not experiencing any acute cardiac symptoms. With proper management of their diabetes, dyslipidemia, and heart failure, the patient may be able to improve their cardiac function and reduce their risk of adverse cardiac events."
115,115,P0189,"Age: 83
Gender: Female 
Weight: 58 kg
Height: 148 cm
NYHA Class: III
Blood Pressure: 140/70 mmHg
Past Medical History: Hypertensive cardiomyopathy, Hypertension, Myocardial Infarction
Albumin (g/L): 44
ALT or GPT (IU/L): 10.0
AST or GOT (IU/L): 27.0
Total Cholesterol (mmol/L): 6,7
Creatinine (mmol/L): 118.0
Gamma-glutamil transpeptidase (IU/L): 24,6
Glucose (mmol/L): 6,6
Hemoglobin (g/L): 130.0
HDL (mmol/L): 0,88
Potassium (mEq/L): 4,49
LDL (mmol/L): 2,77
Sodium (mEq/L): 141.0
Pro-BNP (ng/L): 1094.0
Protein (g/L): 77
T3 (pg/dL): 0,0609
T4 (ng/L): 17,03
Troponin (ng/mL): 0,4
TSH (mIU/L): 0,51
Urea (mg/dL): 11,3
LVEF (%): 50.0
Medications: Digoxin, Loop Diuretics, Spironolactone, ACE Inhibitor, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"RANKING: 1. Survivor
REASONING: 
This patient is at high risk for adverse outcomes due to a combination of factors. The patient is 83 years old with a history of hypertension, myocardial infarction, and cardiomyopathy, which indicates a significant burden of cardiovascular disease. The patient's NYHA Class III indicates severe heart failure symptoms, which may be related to the cardiomyopathy. The elevated LVEF of 50.0 suggests reduced left ventricular function, which is a risk factor for adverse outcomes. The presence of ventricular extrasystoles and non-sustained ventricular tachycardia on the ECG indicates arrhythmic instability, which is a significant concern in a patient with a history of cardiovascular disease.

The patient's laboratory values also show signs of cardiac stress, including elevated Troponin levels and a high Pro-BNP level, which indicates increased ventricular wall stress. The patient's electrolyte panel is relatively normal, but the elevated potassium level may be a sign of cardiac dysfunction.

Given the patient's overall clinical profile, the presence of multiple risk factors, and the laboratory findings, the likelihood of survival for the next few years is relatively high. However, the patient's heart failure symptoms and arrhythmic instability suggest that close monitoring and optimization of treatment are necessary to prevent further decline.

RANKING: 2. Sudden Cardiac Death
REASONING: 
While the patient's overall prognosis is guarded, the likelihood of sudden cardiac death is not the most likely outcome. The patient's arrhythmic instability, as evidenced by the presence of ventricular extrasystoles and non-sustained ventricular tachycardia, increases the risk of sudden cardiac death. However, the patient's ECG does not show any signs of ventricular fibrillation or ventricular tachycardia, which are more commonly associated with sudden cardiac death.

Additionally, the patient's LVEF is relatively preserved, and the patient's NYHA Class III symptoms suggest that the patient's heart failure is not severely decompensated, which reduces the likelihood of sudden cardiac death.

RANKING: 3. Pump Failure Death
REASONING: 
The likelihood of pump failure death is the least likely outcome in this patient. The patient's LVEF is relatively preserved, and the patient's NYHA Class III symptoms suggest that the patient's heart failure is not severely decompensated. While the patient has a history of cardiomyopathy and hypertension, the patient's current treatment regimen, including digoxin, loop diuretics, spironolactone, ACE inhibitors, and a nitrovasodilator, suggests that the patient's heart failure is being adequately managed.

However, the patient's elevated Pro-BNP level and elevated creatinine level suggest that the patient's kidney function may be compromised, which could potentially lead to further decline in cardiac function and increase the risk of pump failure. Nevertheless, the patient's overall clinical profile and treatment regimen suggest that pump failure death is the least likely outcome."
116,116,P0190,"Age: 58
Gender: Male 
Weight: 103 kg
Height: 165 cm
NYHA Class: II
Blood Pressure: 120/60 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Diabetes, Hypertension
Albumin (g/L): 42
ALT or GPT (IU/L): 9.0
AST or GOT (IU/L): 14.0
Total Cholesterol (mmol/L): 5,33
Creatinine (mmol/L): 133.0
Gamma-glutamil transpeptidase (IU/L): 21
Glucose (mmol/L): 6,6
Hemoglobin (g/L): 150.0
HDL (mmol/L): 1,06
Potassium (mEq/L): 3,88
LDL (mmol/L): 3,52
Sodium (mEq/L): 147.0
Pro-BNP (ng/L): 761.0
Protein (g/L): 72,9
T3 (pg/dL): 0,0636
T4 (ng/L): 15,97
Troponin (ng/mL): 0,2
TSH (mIU/L): 1,66
Urea (mg/dL): 7,6
LVEF (%): 50.0
Medications: Diabetes Medication, Beta Blockers, Loop Diuretics, ACE Inhibitor, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"RANKING: 1. Survivor 
REASONING: 

Based on the provided patient data, the patient's overall clinical profile suggests a high risk of adverse cardiac events. The patient has a history of ischemic dilated cardiomyopathy, diabetes, and hypertension, which are all risk factors for cardiac complications. The elevated Pro-BNP level (761.0 ng/L) and LVEF (50.0%) indicate significant cardiac dysfunction. The presence of ventricular extrasystole and non-sustained ventricular tachycardia on the ECG also suggests an increased risk of arrhythmias.

However, the patient is currently taking a combination of medications, including beta blockers, loop diuretics, and ACE inhibitors, which are standard treatments for managing heart failure and hypertension. These medications can help reduce the risk of adverse cardiac events.

Considering the patient's age (58), weight (103 kg), and NYHA Class II symptoms, the likelihood of pump failure is moderate. However, the presence of diabetes and hypertension suggests that the patient may still be at risk for cardiovascular complications.

Given these factors, I predict that the patient has a higher likelihood of survival over the next few years, with a moderate risk of pump failure. The presence of ventricular extrasystole and non-sustained ventricular tachycardia on the ECG suggests an increased risk of arrhythmias, but the patient's current medication regimen and relatively stable vital signs (blood pressure 120/60 mmHg) suggest that the risk of sudden cardiac death may be lower.

RANKING: 2. Pump Failure 
REASONING: 

While the patient's overall clinical profile suggests a high risk of cardiac complications, the presence of a medication regimen that includes beta blockers, loop diuretics, and ACE inhibitors suggests that the patient is being adequately managed for heart failure. However, the patient's LVEF (50.0%) is significantly reduced, indicating a moderate risk of pump failure.

The patient's weight (103 kg) and NYHA Class II symptoms also suggest that the patient may still be at risk for cardiovascular complications. The elevated Pro-BNP level (761.0 ng/L) and elevated creatinine level (133.0 mmol/L) suggest that the patient's cardiac function is not optimal.

Considering the patient's age (58) and the presence of diabetes and hypertension, the likelihood of pump failure is moderate.

RANKING: 3. Sudden Cardiac Death 
REASONING: 

The patient's ECG shows ventricular extrasystole and non-sustained ventricular tachycardia, which suggests an increased risk of arrhythmias. However, the patient's current medication regimen and relatively stable vital signs (blood pressure 120/60 mmHg) suggest that the risk of sudden cardiac death may be lower.

Additionally, the patient's LVEF (50.0%) is significantly reduced, which increases the risk of sudden cardiac death. However, the patient's age (58) and the presence of a medication regimen that includes beta blockers, loop diuretics, and ACE inhibitors suggest that the patient is being adequately managed for heart failure.

Considering the patient's overall clinical profile, I predict that the risk of sudden cardiac death is lower compared to pump failure, but still a concern. However, the presence of ventricular extrasystole and non-sustained ventricular tachycardia on the ECG suggests that the patient is at increased risk for arrhythmias, and the patient's LVEF is significantly reduced, making pump failure a more likely outcome."
117,117,P0191,"Age: 56
Gender: Male 
Weight: 67 kg
Height: 166 cm
NYHA Class: II
Blood Pressure: 130/75 mmHg
Past Medical History: Hypertensive cardiomyopathy, Diabetes, Hypertension
Albumin (g/L): 41
ALT or GPT (IU/L): 29.0
AST or GOT (IU/L): 24.0
Total Cholesterol (mmol/L): 4,37
Creatinine (mmol/L): 138.0
Gamma-glutamil transpeptidase (IU/L): 24
Glucose (mmol/L): 7,7
Hemoglobin (g/L): 140.0
HDL (mmol/L): 1,73
Potassium (mEq/L): 5,8
LDL (mmol/L): 2,09
Sodium (mEq/L): 133.0
Pro-BNP (ng/L): 341.0
Protein (g/L): 73
T3 (pg/dL): 0,0594
T4 (ng/L): 19,91
TSH (mIU/L): 1,12
Urea (mg/dL): 18,3
LVEF (%): 60.0
Medications: Diabetes Medication, Beta Blockers, Digoxin, Loop Diuretics, Spironolactone, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"RANKING: 1. Survivor
REASONING:

Based on the provided patient data, the patient is a 56-year-old male with a history of hypertensive cardiomyopathy, diabetes, and hypertension. His current NYHA Class II indicates that he has some symptoms of heart failure, but they are not severe enough to limit his daily activities.

The patient's laboratory results show:

- Elevated creatinine levels (138.0 mmol/L) and urea levels (18.3 mg/dL) suggest impaired renal function, which is a common complication of heart failure.
- The patient's blood pressure is well-controlled (130/75 mmHg), and his blood glucose levels are elevated (7.7 mmol/L), indicating that he is not diabetic ketoacidosis.
- The patient's lipid profile shows high total cholesterol (4.37 mmol/L) and LDL cholesterol (2.09 mmol/L), which are risk factors for cardiovascular disease.
- The patient's ECG shows ventricular extrasystoles, which may indicate a risk for cardiac arrhythmias.

However, the patient's most significant prognostic factor is his LVEF (left ventricular ejection fraction) of 60.0%, which is within the normal range. This suggests that the patient's heart is still pumping effectively, and he is less likely to experience sudden cardiac death.

Considering these factors, the most likely outcome for this patient over the next few years is a survival outcome. The patient's overall health status, despite some comorbidities, and his relatively preserved LVEF make him less likely to experience sudden cardiac death or pump failure.

However, it's essential to note that this is a general assessment and may not be accurate without further evaluation and monitoring. Regular follow-up appointments with the patient's cardiologist will be crucial to reassess his condition and adjust his treatment plan as needed."
118,118,P0193,"Age: 55
Gender: Female 
Weight: 100 kg
Height: 154 cm
NYHA Class: II
Blood Pressure: 130/70 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Diabetes, Dyslipemia, Hypertension, Myocardial Infarction
Albumin (g/L): 45
ALT or GPT (IU/L): 13.0
AST or GOT (IU/L): 17.0
Total Cholesterol (mmol/L): 4,27
Creatinine (mmol/L): 124.0
Gamma-glutamil transpeptidase (IU/L): 16
Glucose (mmol/L): 4,6
Hemoglobin (g/L): 119.0
HDL (mmol/L): 1,5
Potassium (mEq/L): 5,32
LDL (mmol/L): 2,15
Sodium (mEq/L): 139.0
Pro-BNP (ng/L): 281.0
Protein (g/L): 78
T3 (pg/dL): 0,0321
T4 (ng/L): 17,73
Troponin (ng/mL): 0,6
TSH (mIU/L): 0,94
Urea (mg/dL): 14,4
LVEF (%): 40.0
Medications: Calcium Channel Blocker, Diabetes Medication, Beta Blockers, Loop Diuretics, Spironolactone, Statins, ACE Inhibitor, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: Unknown bradycardia code
            ",survivor,"RANKING: 1. Survivor
REASONING: 
Based on the provided patient data, the patient has a complex medical history with multiple comorbid conditions, including ischemic dilated cardiomyopathy, diabetes, dyslipidemia, hypertension, and a history of myocardial infarction. The patient's left ventricular ejection fraction (LVEF) is severely impaired at 40%, indicating significant cardiac dysfunction. The elevated creatinine level (124.0 mmol/L) suggests impaired renal function, which can be associated with heart failure.

Despite these significant comorbidities, the patient is currently on a comprehensive regimen of medications, including ACE inhibitors, beta blockers, and diuretics, which are standard treatments for heart failure and hypertension. The presence of elevated troponin levels (0.6 ng/mL) indicates some degree of cardiac damage, but it is not excessively high, suggesting that the patient's cardiac function is not severely compromised at the moment.

The patient's Pro-BNP level is elevated (281 ng/L), which is a marker of cardiac stress and suggests that the patient's heart is working harder to pump blood. However, the absence of other indicators of acute cardiac stress, such as a significant increase in troponin levels or ventricular tachycardia, suggests that the patient's current condition is not acutely life-threatening.

Given these factors, the most likely outcome for the next few years is that the patient will survive, albeit with ongoing management of their multiple comorbidities and close monitoring of their cardiac function. Regular follow-up appointments and adjustments to their medication regimen as needed will be crucial to ensure optimal management of their condition.

RANKING: 2. Sudden cardiac death
REASONING: 
While the patient has a complex medical history and significant cardiac dysfunction, the absence of any acute indicators of cardiac stress or arrhythmias, such as ventricular tachycardia or non-sustained ventricular tachycardia, makes sudden cardiac death less likely. However, the patient's severely impaired LVEF and elevated troponin levels do increase the risk of cardiac events.

The patient's elevated creatinine level and impaired renal function may also contribute to an increased risk of cardiac events, as renal dysfunction can lead to fluid overload and increased blood pressure, which can strain the heart. However, the patient is already on diuretics and other medications to manage these conditions, which should help mitigate these risks.

Given the patient's age and comorbidities, the risk of sudden cardiac death is still present, but it is not the most likely outcome. The patient's overall health status and the presence of ongoing medical management make sudden cardiac death less likely than the other two options.

RANKING: 3. Pump failure death
REASONING: 
Pump failure death is a possible outcome for patients with severe cardiac dysfunction, such as this patient. However, the patient is already receiving medications that are standard for managing heart failure, including ACE inhibitors, beta blockers, and diuretics, which should help improve their cardiac function and reduce the risk of pump failure.

The patient's elevated Pro-BNP level and impaired LVEF do suggest that their cardiac function is severely compromised, but the absence of other indicators of acute cardiac stress or arrhythmias makes pump failure death less likely. Additionally, the patient's current medical management and regular follow-up appointments will help monitor their cardiac function and make adjustments to their treatment plan as needed.

While pump failure death is a possible outcome, it is not the most likely outcome for this patient, given their current medical management and the presence of ongoing treatment for their comorbidities."
119,119,P0195,"Age: 62
Gender: Female 
Weight: 60 kg
Height: 160 cm
NYHA Class: II
Blood Pressure: 120/60 mmHg
Past Medical History: Idiopathic dilated cardiomyopathy
Albumin (g/L): 40
ALT or GPT (IU/L): 6.0
AST or GOT (IU/L): 28.0
Total Cholesterol (mmol/L): 3,9
Creatinine (mmol/L): 109.0
Gamma-glutamil transpeptidase (IU/L): 7,4
Glucose (mmol/L): 4,1
Hemoglobin (g/L): 117.0
HDL (mmol/L): 1,29
Potassium (mEq/L): 4,11
LDL (mmol/L): 2,35
Sodium (mEq/L): 140.0
Pro-BNP (ng/L): 237.0
Protein (g/L): 66,8
T3 (pg/dL): 0,0402
T4 (ng/L): 13,59
TSH (mIU/L): 1,6
Urea (mg/dL): 8
LVEF (%): 25.0
Medications: Beta Blockers, Loop Diuretics, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"RANKING: 
1. Survivor
REASONING: 
Based on the provided patient data, the patient is a 62-year-old female with a history of idiopathic dilated cardiomyopathy (IDC), which is a condition where the heart's ability to pump blood is reduced due to an enlarged left ventricle. The patient's NYHA Class II indicates that they have some limitations in physical activity, but they are still able to perform everyday activities without severe shortness of breath.

The patient's LVEF (left ventricular ejection fraction) is 25.0%, which is significantly reduced, indicating that the heart is not pumping efficiently. However, the patient is not experiencing acute heart failure symptoms, which suggests that the heart is not yet failing catastrophically.

The patient's medication regimen includes beta blockers, loop diuretics, and an ACE inhibitor, which are standard treatments for IDC and heart failure. The patient's blood work shows elevated creatinine levels, indicating some degree of kidney impairment, but this is not uncommon in patients with IDC.

The patient's ECG shows ventricular extrasystoles, which are abnormal heart rhythms that can be a sign of underlying heart disease. However, the absence of ventricular tachycardia, non-sustained ventricular tachycardia, and other arrhythmias suggests that the patient's heart is not at high risk for sudden cardiac death.

Overall, the patient's clinical presentation and laboratory results suggest that they are likely to survive for the next few years, provided they continue to receive appropriate medical care and management of their underlying condition."
120,120,P0196,"Age: 71
Gender: Male 
Weight: 65 kg
Height: 167 cm
NYHA Class: III
Blood Pressure: 90/55 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Diabetes, Myocardial Infarction
Albumin (g/L): 45
ALT or GPT (IU/L): 15.0
AST or GOT (IU/L): 18.0
Total Cholesterol (mmol/L): 4,91
Creatinine (mmol/L): 187.0
Gamma-glutamil transpeptidase (IU/L): 137
Glucose (mmol/L): 7,1
Hemoglobin (g/L): 137.0
HDL (mmol/L): 1,24
Potassium (mEq/L): 6,1
LDL (mmol/L): 3,34
Sodium (mEq/L): 133.0
Pro-BNP (ng/L): 7460.0
Protein (g/L): 78,899
T3 (pg/dL): 0,0315
T4 (ng/L): 15,28
Troponin (ng/mL): 0,7
TSH (mIU/L): 3,14
Urea (mg/dL): 24,46
LVEF (%): 30.0
Medications: Digoxin, Loop Diuretics, Spironolactone, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"RANKING: 1. Survivor
REASONING: 
This patient has a complex medical history with ischemic dilated cardiomyopathy, diabetes, and a previous myocardial infarction, which increases the risk of cardiac events. However, the patient's current NYHA Class III status suggests that they are experiencing significant heart failure symptoms, which is a major risk factor for adverse outcomes. The patient's elevated creatinine level (187.0 mmol/L) and low LVEF (30.0%) further indicate compromised cardiac function. 

Despite these factors, the patient is currently on medications that are commonly used to manage heart failure (Digoxin, Loop Diuretics, Spironolactone, and ACE Inhibitor), which suggests that the healthcare team is actively managing their condition. The presence of ventricular extrasystole and non-sustained ventricular tachycardia on the ECG is concerning, but the patient is not experiencing any sustained arrhythmias, which may indicate a lower risk of sudden cardiac death. 

The patient's low troponin level (0.7 ng/mL) also suggests that there is no significant acute myocardial injury. The patient's overall clinical presentation, despite the significant comorbidities and compromised cardiac function, does not suggest an immediate life-threatening condition that would lead to a poor outcome. Therefore, the most likely prognosis for this patient is survivor.

RANKING: 2. Sudden cardiac death
REASONING: 
The patient's history of ischemic dilated cardiomyopathy, diabetes, and previous myocardial infarction increases the risk of sudden cardiac death. The patient's low LVEF (30.0%) and elevated creatinine level (187.0 mmol/L) indicate compromised cardiac function, which can lead to arrhythmias and sudden cardiac death. 

The presence of ventricular extrasystole and non-sustained ventricular tachycardia on the ECG is a significant concern, as it suggests an increased risk of arrhythmias. However, the absence of sustained ventricular tachycardia and the patient's current medication regimen may reduce the risk of sudden cardiac death.

RANKING: 3. Pump failure death
REASONING: 
Given the patient's significant heart failure symptoms (NYHA Class III) and compromised cardiac function (LVEF 30.0%), pump failure death is a possible outcome. The patient's elevated creatinine level (187.0 mmol/L) and low albumin level (45 g/L) suggest that the patient's kidneys are not functioning optimally, which can lead to further cardiac complications.

However, the patient is currently receiving medications that are commonly used to manage heart failure (Digoxin, Loop Diuretics, Spironolactone, and ACE Inhibitor), which suggests that the healthcare team is actively managing their condition. The presence of ventricular extrasystole and non-sustained ventricular tachycardia on the ECG is a concern, but the patient's overall clinical presentation does not suggest an immediate life-threatening condition that would lead to pump failure death."
121,121,P0197,"Age: 71
Gender: Male 
Weight: 73 kg
Height: 165 cm
NYHA Class: II
Blood Pressure: 110/60 mmHg
Past Medical History: Idiopathic dilated cardiomyopathy, Peripheral vascular disease
Albumin (g/L): 41
ALT or GPT (IU/L): 17.0
AST or GOT (IU/L): 28.0
Total Cholesterol (mmol/L): 6,78
Creatinine (mmol/L): 145.0
Gamma-glutamil transpeptidase (IU/L): 35
Glucose (mmol/L): 5,7
Hemoglobin (g/L): 135.0
HDL (mmol/L): 1,78
Potassium (mEq/L): 4,9
LDL (mmol/L): 4,37
Sodium (mEq/L): 141.0
Pro-BNP (ng/L): 1367.0
Protein (g/L): 74,5
T3 (pg/dL): 0,0384
T4 (ng/L): 17,4
Troponin (ng/mL): 0,3
TSH (mIU/L): 1,14
Urea (mg/dL): 13,4
LVEF (%): 40.0
Medications: Digoxin, Loop Diuretics, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",survivor,"RANKING: 
1. Survivor
REASONING: 
The patient is currently on medications for heart failure (Digoxin, Loop Diuretics, ACE Inhibitor) and has a history of idiopathic dilated cardiomyopathy, which is a condition that affects the heart's ability to pump blood effectively. The patient's NYHA Class II indicates that they have some limitation in physical activity due to their heart condition. 

The patient's current ejection fraction (LVEF) is 40.0%, which is significantly reduced, indicating poor heart function. However, the patient's Troponin level is within normal limits, suggesting that there is no significant myocardial infarction. The absence of ventricular tachycardia and non-sustained ventricular tachycardia on the ECG also reduces the risk of sudden cardiac death.

The patient's laboratory results show elevated creatinine levels, which may indicate some degree of kidney dysfunction, but this is not directly related to cardiac function. The patient's potassium level is within normal limits, and the absence of hyperkalemia is a good sign.

Given these factors, the patient's overall condition appears to be stable, and they are likely to survive for the next few years. However, close monitoring and adjustments to their medication regimen may be necessary to manage their heart failure and prevent any potential complications.

2. Sudden cardiac death
REASONING: 
While the patient's LVEF is significantly reduced, the absence of ventricular tachycardia and non-sustained ventricular tachycardia on the ECG reduces the risk of sudden cardiac death. However, the patient's elevated creatinine levels may indicate some degree of kidney dysfunction, which can be a risk factor for cardiac complications.

The patient's history of peripheral vascular disease also increases the risk of cardiovascular events, including sudden cardiac death. However, the patient is not currently experiencing any symptoms, and their medication regimen is in place to manage their heart failure.

3. Pump failure death
REASONING: 
Pump failure death is a possible outcome for patients with severe heart failure, and the patient's reduced LVEF and elevated creatinine levels suggest that their heart function is compromised. However, the patient is currently receiving treatment for heart failure, and their NYHA Class II indicates that they are not severely limited in their physical activity.

While the patient's Pro-BNP level is elevated, this is not uncommon in patients with heart failure. The absence of any other significant laboratory abnormalities, such as hyperkalemia or significant electrolyte imbalances, reduces the risk of pump failure death.

Given the patient's stable condition and the presence of a treatment plan in place, pump failure death is the least likely outcome, but still a possibility if the patient's condition worsens or if the treatment regimen is not adjusted as needed."
122,122,P0198,"Age: 53
Gender: Male 
Weight: 77 kg
Height: 171 cm
NYHA Class: II
Blood Pressure: 120/60 mmHg
Past Medical History: Enolic dilated cardiomyopathy, Dyslipemia
Albumin (g/L): 46
ALT or GPT (IU/L): 49.0
AST or GOT (IU/L): 22.0
Total Cholesterol (mmol/L): 5,15
Creatinine (mmol/L): 90.0
Gamma-glutamil transpeptidase (IU/L): 69
Glucose (mmol/L): 19,2
Hemoglobin (g/L): 144.0
HDL (mmol/L): 0,85
Potassium (mEq/L): 4,5
LDL (mmol/L): 2,48
Sodium (mEq/L): 138.0
Pro-BNP (ng/L): 41.0
Protein (g/L): 81,8
T3 (pg/dL): 0,0522
T4 (ng/L): 18,6
Troponin (ng/mL): 0,4
TSH (mIU/L): 1,79
Urea (mg/dL): 6,7
LVEF (%): 40.0
Medications: Beta Blockers, Digoxin, Loop Diuretics, Spironolactone, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"RANKING: 1. Survivor
REASONING: 

Based on the provided patient data, I predict that the patient will survive for the next few years. The patient's age, NYHA Class II, and the absence of severe symptoms suggest a relatively preserved functional capacity. The patient's LVEF of 40.0 indicates a significant reduction in left ventricular function, which is consistent with dilated cardiomyopathy. However, the patient's hemoglobin level of 144.0 g/L and the absence of anemia suggest that the patient is not severely anemic.

The patient's laboratory results show a mildly elevated creatinine level (90.0 mmol/L) and an elevated troponin level (0.4 ng/mL), which may indicate some degree of cardiac damage. However, these values are not significantly elevated, and the patient is not experiencing any acute symptoms.

The patient's medication regimen includes beta blockers, digoxin, loop diuretics, spironolactone, and an ACE inhibitor, which are all standard treatments for heart failure and cardiomyopathy. These medications should help manage the patient's symptoms and slow disease progression.

The patient's ECG results show ventricular extrasystoles, which are a common finding in patients with dilated cardiomyopathy. However, the absence of ventricular tachycardia or non-sustained ventricular tachycardia suggests that the patient is not at high risk for arrhythmic events.

Overall, based on the provided data, I predict that the patient will survive for the next few years, with the possibility of some degree of cardiac decline. However, the patient's current functional capacity and medication regimen suggest that the patient will not experience a sudden cardiac death or pump failure in the near future.

PROBABILITY OF SURVIVAL: 80% (over the next 2 years)
PROBABILITY OF SUDDEN CARDIAC DEATH: 10% (over the next 2 years)
PROBABILITY OF PUMP FAILURE DEATH: 10% (over the next 2 years)"
123,123,P0201,"Age: 48
Gender: Male 
Weight: 96 kg
Height: 175 cm
NYHA Class: II
Blood Pressure: 160/90 mmHg
Past Medical History: Enolic dilated cardiomyopathy
Albumin (g/L): 42
ALT or GPT (IU/L): 23.0
AST or GOT (IU/L): 20.0
Total Cholesterol (mmol/L): 5,17
Creatinine (mmol/L): 113.0
Gamma-glutamil transpeptidase (IU/L): 66
Glucose (mmol/L): 7,8
Hemoglobin (g/L): 179.0
HDL (mmol/L): 1,14
Potassium (mEq/L): 5,09
LDL (mmol/L): 3,59
Sodium (mEq/L): 138.0
Pro-BNP (ng/L): 1176.0
Protein (g/L): 72,3
T3 (pg/dL): 0,03
T4 (ng/L): 15,92
Troponin (ng/mL): 0,2
TSH (mIU/L): 0,88
Urea (mg/dL): 5,7
LVEF (%): 25.0
Medications: Beta Blockers, Digoxin, Loop Diuretics, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",survivor,"RANKING: 1. Survivor
REASONING: 

This patient has a complex medical history with Enolic dilated cardiomyopathy, which is a condition that weakens the heart muscle and impairs its ability to pump blood effectively. The patient's Left Ventricular Ejection Fraction (LVEF) is 25.0%, which is significantly below the normal range, indicating severe left ventricular dysfunction. The patient's high blood pressure, elevated troponin levels, and presence of non-sustained ventricular tachycardia and polymorphic ventricular extrasystoles on the ECG further suggest a high risk of cardiac complications.

The patient's current treatment regimen includes beta blockers, digoxin, loop diuretics, and an ACE inhibitor, which is a standard approach for managing heart failure and hypertension in patients with cardiomyopathy. However, the presence of significant cardiac dysfunction and arrhythmias suggests that the patient is at high risk of cardiac events.

Despite these factors, the patient has a relatively preserved kidney function (creatinine 113.0 mol/L) and a normal hemoglobin level (179.0 g/L), which may indicate that the patient's kidney function and oxygen delivery to the tissues are relatively preserved. Additionally, the patient's Pro-BNP level is elevated, which suggests some degree of cardiac stress, but it is not excessively high.

Considering these factors, I believe that the patient is most likely to survive the next few years, although the prognosis remains guarded due to the presence of significant cardiac dysfunction and arrhythmias. The patient will require close monitoring and careful management to minimize the risk of cardiac events.

RANKING: 2. Sudden cardiac death
REASONING: 

The patient's severe left ventricular dysfunction (LVEF 25.0%), presence of non-sustained ventricular tachycardia, and polymorphic ventricular extrasystoles on the ECG increase the risk of sudden cardiac death. The patient's high blood pressure and elevated troponin levels also suggest a high risk of cardiac events.

While the patient's current treatment regimen is standard for managing heart failure and hypertension, the presence of significant cardiac dysfunction and arrhythmias suggests that the patient is at high risk of cardiac events. The patient's kidney function and oxygen delivery to the tissues are relatively preserved, but the presence of cardiac dysfunction and arrhythmias increases the risk of sudden cardiac death.

RANKING: 3. Pump failure death
REASONING: 

The patient's severe left ventricular dysfunction (LVEF 25.0%) and elevated troponin levels suggest a high risk of pump failure. The patient's current treatment regimen includes digoxin, which is a digitalis glycoside that can increase the risk of digitalis toxicity and exacerbate cardiac dysfunction.

The patient's kidney function is relatively preserved, but the presence of cardiac dysfunction and arrhythmias increases the risk of cardiac events. While the patient's hemoglobin level is relatively high, the patient's anemia is not severe, and the patient's oxygen delivery to the tissues is likely sufficient.

Considering these factors, I believe that pump failure death is a possible outcome, but it is less likely than sudden cardiac death due to the patient's relatively preserved kidney function and oxygen delivery to the tissues. However, the patient's cardiac dysfunction and arrhythmias remain a significant concern, and close monitoring and careful management are essential to minimize the risk of cardiac events."
124,124,P0202,"Age: 75
Gender: Male 
Weight: 77 kg
Height: 157 cm
NYHA Class: II
Blood Pressure: 160/85 mmHg
Past Medical History: Hypertensive cardiomyopathy, Diabetes, Dyslipemia, Hypertension
Albumin (g/L): 39
ALT or GPT (IU/L): 25.0
AST or GOT (IU/L): 22.0
Total Cholesterol (mmol/L): 3,83
Creatinine (mmol/L): 123.0
Gamma-glutamil transpeptidase (IU/L): 20
Glucose (mmol/L): 13,2
Hemoglobin (g/L): 136.0
HDL (mmol/L): 0,93
Potassium (mEq/L): 4,32
LDL (mmol/L): 2,22
Sodium (mEq/L): 139.0
Pro-BNP (ng/L): 918.0
Protein (g/L): 71,6
T3 (pg/dL): 0,0585
T4 (ng/L): 12,73
Troponin (ng/mL): 0,2
TSH (mIU/L): 1,16
Urea (mg/dL): 8,3
LVEF (%): 45.0
Medications: Diabetes Medication, Beta Blockers, Loop Diuretics, Statins, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"RANKING: 
1. Survivor 
REASONING: 
Based on the provided patient data, I would rank the patient as a survivor for the next few years. The patient's age (75) and NYHA Class II heart failure indicate a moderate level of heart dysfunction, but the patient is still able to maintain a relatively normal hemoglobin level (136.0 g/L) and a normal liver function test (ALT/GPT 25.0 IU/L). The patient's medications, including beta blockers, loop diuretics, and ACE inhibitors, are standard treatments for heart failure and hypertension. Although the patient has a history of hypertension, diabetes, and dyslipemia, the patient's current creatinine level (123.0 mmol/L) is not severely elevated, suggesting that the patient's kidney function is not significantly impaired.

The elevated Pro-BNP level (918.0 ng/L) indicates some degree of heart failure, but it is not extremely high, which might suggest a more advanced stage of heart failure. The patient's LVEF (45.0%) is also within the normal range for a 75-year-old male, which indicates that the patient's heart function is not severely impaired.

Overall, while the patient has a history of heart disease and current heart failure, the patient's current medical condition and treatment plan suggest that the patient is likely to survive for the next few years with proper management."
125,125,P0203,"Age: 78
Gender: Female 
Weight: 90 kg
Height: 157 cm
NYHA Class: III
Blood Pressure: 150/70 mmHg
Past Medical History: Idiopathic dilated cardiomyopathy, Hypertension
Albumin (g/L): 44
ALT or GPT (IU/L): 30.0
AST or GOT (IU/L): 20.0
Total Cholesterol (mmol/L): 5,97
Creatinine (mmol/L): 159.0
Gamma-glutamil transpeptidase (IU/L): 31
Glucose (mmol/L): 6,3
Hemoglobin (g/L): 117.0
HDL (mmol/L): 1,58
Potassium (mEq/L): 3,8
LDL (mmol/L): 3,44
Sodium (mEq/L): 142.0
Pro-BNP (ng/L): 491.0
Protein (g/L): 80
T3 (pg/dL): 0,0363
T4 (ng/L): 16,39
Troponin (ng/mL): 0,1
TSH (mIU/L): 2,19
Urea (mg/dL): 18,8
LVEF (%): 30.0
Medications: Loop Diuretics, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: TPSV
        - Bradycardia: No
            ",survivor,"RANKING: 1. Survivor
REASONING:

This patient has a significant number of risk factors that suggest a high risk of adverse outcomes. The patient has a history of idiopathic dilated cardiomyopathy, which is a significant cause of heart failure and arrhythmias. The patient's left ventricular ejection fraction (LVEF) is severely impaired at 30%, indicating significant systolic dysfunction.

The patient's ECG shows several abnormal findings, including polymorphic ventricular extrasystoles, non-sustained ventricular tachycardia, and non-sustained ventricular tachycardia, which are all indicative of arrhythmias. The presence of these arrhythmias increases the risk of sudden cardiac death.

Despite the patient's use of medications, including an ACE inhibitor, which is typically used to reduce blood pressure and improve heart function, the patient's blood pressure is still elevated at 150/70 mmHg.

The patient's laboratory results also show elevated creatinine levels, indicating impaired kidney function, which can further increase the risk of adverse outcomes.

However, the patient's current condition is not immediately life-threatening, and with close monitoring and management, it is possible for the patient to survive for the next few years. The patient's age and sex are also not as significant a risk factor as some other factors, such as the patient's underlying heart disease.

Therefore, based on the available information, the most likely outcome for the next few years is that the patient will survive, although with a high risk of arrhythmias and heart failure exacerbations."
126,126,P0204,"Age: 69
Gender: Male 
Weight: 69 kg
Height: 160 cm
NYHA Class: II
Blood Pressure: 120/80 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Diabetes, Dyslipemia, Peripheral vascular disease, Hypertension
Albumin (g/L): 42
ALT or GPT (IU/L): 8.0
AST or GOT (IU/L): 38.0
Total Cholesterol (mmol/L): 4,24
Creatinine (mmol/L): 152.0
Gamma-glutamil transpeptidase (IU/L): 35
Glucose (mmol/L): 6,4
Hemoglobin (g/L): 115.0
HDL (mmol/L): 0,93
Potassium (mEq/L): 4,7
LDL (mmol/L): 2,4
Sodium (mEq/L): 139.0
Pro-BNP (ng/L): 7794.0
Protein (g/L): 77
T3 (pg/dL): 0,0351
T4 (ng/L): 18,87
Troponin (ng/mL): 0,7
TSH (mIU/L): 1,89
Urea (mg/dL): 11
LVEF (%): 40.0
Medications: Diabetes Medication, Angiotensin II Receptor Blocker, Loop Diuretics, Statins, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: TPSV
        - Bradycardia: No
            ",survivor,"RANKING: 1. Survivor
REASONING: 

The patient has a history of ischemic dilated cardiomyopathy, which is a significant risk factor for cardiac events. However, the patient's current NYHA class is II, indicating mild symptoms, and the patient is not currently experiencing heart failure symptoms. The patient is also taking medications that are standard for managing heart failure and high blood pressure, such as loop diuretics, angiotensin II receptor blockers, and statins.

The patient's ejection fraction (LVEF) is 40%, which is within the range of patients with mild to moderate heart failure. The patient's troponin level is normal, and the patient is not experiencing any acute cardiac events.

While the patient has a history of diabetes and dyslipidemia, which are risk factors for cardiovascular disease, the patient's current glucose and lipid profiles are not significantly abnormal. The patient's kidney function is also within a relatively normal range, as indicated by a creatinine level of 11 mg/dL.

The patient's ECG shows non-sustained ventricular tachycardia and paroxysmal supraventricular tachyarrhythmia, which are both relatively common in patients with heart disease. However, these findings are not indicative of a high risk of cardiac death.

Overall, considering the patient's relatively mild symptoms, normal laboratory values, and current treatment regimen, the most likely outcome is that the patient will survive for the next few years without significant cardiac events.

RANKING: 2. Sudden cardiac death
REASONING: 

The patient's history of ischemic dilated cardiomyopathy and non-sustained ventricular tachycardia (CH>10) make the patient at increased risk of sudden cardiac death. The patient's LVEF of 40% is also a significant risk factor for cardiac events.

While the patient is taking medications that are standard for managing heart failure and high blood pressure, the patient's current NYHA class is only II, indicating mild symptoms. The patient's troponin level is normal, and the patient is not experiencing any acute cardiac events.

The patient's ECG shows non-sustained ventricular tachycardia, which is a significant risk factor for sudden cardiac death. However, the fact that the patient is taking medications and has a relatively normal laboratory profile reduces the likelihood of sudden cardiac death.

RANKING: 3. Pump failure death
REASONING: 

The patient's LVEF of 40% is a significant risk factor for heart failure, and the patient's NYHA class is II, indicating mild symptoms. The patient's current treatment regimen includes loop diuretics, which are standard for managing heart failure.

The patient's ECG shows non-sustained ventricular tachycardia, which is a risk factor for heart failure. The patient's creatinine level is elevated at 11 mg/dL, which may indicate some degree of kidney impairment.

While the patient's laboratory values are relatively normal, the patient's history of ischemic dilated cardiomyopathy and non-sustained ventricular tachycardia make the patient at increased risk of pump failure death. The patient's current treatment regimen is standard for managing heart failure, but the patient's LVEF and NYHA class suggest that the patient may be at increased risk of pump failure."
127,127,P0206,"Age: 80
Gender: Male 
Weight: 88 kg
Height: 168 cm
NYHA Class: II
Blood Pressure: 140/90 mmHg
Past Medical History: Idiopathic dilated cardiomyopathy, Diabetes, Hypertension
Albumin (g/L): 39
ALT or GPT (IU/L): 17.0
AST or GOT (IU/L): 23.0
Total Cholesterol (mmol/L): 5,51
Creatinine (mmol/L): 113.0
Gamma-glutamil transpeptidase (IU/L): 16
Glucose (mmol/L): 4,7
Hemoglobin (g/L): 152.0
HDL (mmol/L): 1,5
Potassium (mEq/L): 4,2
LDL (mmol/L): 3,57
Sodium (mEq/L): 139.0
Pro-BNP (ng/L): 3087.0
Protein (g/L): 62,3
T3 (pg/dL): 0,0444
T4 (ng/L): 13,71
Troponin (ng/mL): 0,3
TSH (mIU/L): 1,46
Urea (mg/dL): 8,5
LVEF (%): 45.0
Medications: Loop Diuretics
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",survivor,"RANKING: 
1. Survivor
REASONING: 
Given the patient's age, NYHA Class II status, and the presence of idiopathic dilated cardiomyopathy, hypertension, and diabetes, the patient is already at a higher risk for adverse outcomes. However, the patient's recent ECG findings, including ventricular extrasystole, non-sustained ventricular tachycardia, and non-sustained ventricular tachycardia, suggest an increased risk for arrhythmic events. The patient's elevated BNP levels (3087.0 ng/L) also indicate significant left ventricular dysfunction. 

Despite these concerning signs, the patient is currently on loop diuretics, which is a common treatment for heart failure, and the patient's hemoglobin level is within the normal range. The patient's creatinine level is elevated, but it is not excessively high, and the patient's renal function may not be significantly impaired. The patient's LVEF is 45%, which is a relatively low value but not extremely low. 

Considering these factors, the most likely prognosis for the next few years is that the patient will survive, albeit with ongoing management of their heart failure and arrhythmias. The patient's symptoms and test results indicate that the patient is not in imminent danger of sudden cardiac death or pump failure death, but close monitoring and careful management will be necessary to prevent further deterioration.

2. Sudden Cardiac Death
REASONING: 
While the patient's ECG findings suggest an increased risk for arrhythmic events, the patient's recent ECG did not show any signs of ventricular fibrillation or ventricular tachycardia, which are common causes of sudden cardiac death. Additionally, the patient's LVEF is not extremely low, and the patient is on treatment for heart failure. However, the patient's elevated BNP levels and history of non-sustained ventricular tachycardia increase the risk for arrhythmic events. The patient's age and NYHA Class II status also contribute to the risk of sudden cardiac death. Therefore, while the patient is not at the highest risk, the patient is at a moderate risk for sudden cardiac death.

3. Pump Failure Death
REASONING: 
The patient's NYHA Class II status and elevated BNP levels indicate significant left ventricular dysfunction, which increases the risk for pump failure. However, the patient is on treatment for heart failure with loop diuretics, which helps manage symptoms. The patient's LVEF is relatively low, but not extremely low. The patient's creatinine level is elevated, but it is not excessively high. The patient's renal function may not be significantly impaired. The patient's blood pressure and electrolyte levels are also relatively stable. While the patient is at risk for pump failure, the patient's current symptoms and test results do not indicate imminent failure. Therefore, the patient is at a lower risk for pump failure death compared to sudden cardiac death."
128,128,P0208,"Age: 63
Gender: Male 
Weight: 83 kg
Height: 167 cm
NYHA Class: II
Blood Pressure: 160/70 mmHg
Past Medical History: Idiopathic dilated cardiomyopathy, Dyslipemia, Peripheral vascular disease, Hypertension
Albumin (g/L): 41
ALT or GPT (IU/L): 16.0
AST or GOT (IU/L): 16.0
Total Cholesterol (mmol/L): 6,31
Creatinine (mmol/L): 87.0
Gamma-glutamil transpeptidase (IU/L): 14
Glucose (mmol/L): 5,2
Hemoglobin (g/L): 160.0
HDL (mmol/L): 1,03
Potassium (mEq/L): 4,19
LDL (mmol/L): 4,53
Sodium (mEq/L): 137.0
Pro-BNP (ng/L): 520.0
Protein (g/L): 73,6
T3 (pg/dL): 0,0618
T4 (ng/L): 15,21
Troponin (ng/mL): 0,1
TSH (mIU/L): 1,43
Urea (mg/dL): 5,9
LVEF (%): 15.0
Medications: Calcium Channel Blocker, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"RANKING: 1. Survivor
REASONING: 

Based on the provided patient data, I predict that the patient will have a high likelihood of survival over the next few years. The patient's NYHA Class II indicates that they have moderate symptoms, but they are still able to perform daily activities without significant limitation. The patient's LVEF (Left Ventricular Ejection Fraction) is 15%, which is significantly reduced, indicating systolic heart failure. However, the patient's current medications, Calcium Channel Blocker and ACE Inhibitor, are standard treatments for heart failure and may help improve symptoms and reduce mortality.

The patient's laboratory results show elevated creatinine levels, which suggest some degree of renal impairment, but this is not uncommon in patients with heart failure. The patient's electrolyte levels, including potassium, sodium, and TSH, are within normal limits, which reduces the risk of complications.

The ECG findings of ventricular extrasystoles and polymorphic ventricular tachycardia are concerning, but the absence of non-sustained ventricular tachycardia and other arrhythmias suggests that the patient's heart is not in a state of severe instability. The patient's troponin levels are normal, which suggests that there is no significant myocardial injury.

Given the patient's age, comorbidities, and current medication regimen, the patient's overall prognosis is guarded but not hopeless. With close monitoring and adjustments to their treatment plan, I predict that the patient will survive for at least 2-3 years, but this will depend on various factors, including the effectiveness of their treatment and the presence of any new or worsening symptoms.

RANKING: 2. Sudden Cardiac Death
REASONING: 

The patient's LVEF is significantly reduced, indicating systolic heart failure, which increases the risk of sudden cardiac death. The patient's ECG findings of ventricular extrasystoles and polymorphic ventricular tachycardia also suggest an increased risk of arrhythmias, which can be life-threatening.

While the patient's current medications may help manage symptoms and reduce mortality, the presence of comorbidities, such as hypertension, dyslipidemia, and peripheral vascular disease, increases the risk of cardiovascular events. The patient's elevated creatinine levels and normal troponin levels suggest some degree of renal impairment, which may contribute to the development of cardiovascular events.

Given the patient's age and comorbidities, I predict that the patient has a moderate to high risk of sudden cardiac death over the next few years. However, this is still a less likely outcome compared to the patient's overall survival.

RANKING: 3. Pump Failure Death
REASONING: 

The patient's LVEF is significantly reduced, indicating systolic heart failure, and their NYHA Class II symptoms suggest that their heart is not functioning optimally. The patient's elevated creatinine levels and normal troponin levels suggest some degree of renal impairment, which can contribute to the development of pump failure.

The patient's ECG findings of ventricular extrasystoles and polymorphic ventricular tachycardia suggest an increased risk of arrhythmias, which can contribute to pump failure. The patient's comorbidities, such as hypertension, dyslipidemia, and peripheral vascular disease, also increase the risk of cardiovascular events.

Given the patient's age, comorbidities, and current medication regimen, I predict that the patient has a moderate risk of pump failure over the next few years. However, this is a more likely outcome compared to sudden cardiac death, and the patient's overall survival is more likely than pump failure."
129,129,P0209,"Age: 55
Gender: Male 
Weight: 84 kg
Height: 174 cm
NYHA Class: II
Blood Pressure: 140/80 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Hypertension, Myocardial Infarction
Albumin (g/L): 42
ALT or GPT (IU/L): 24.0
AST or GOT (IU/L): 24.0
Total Cholesterol (mmol/L): 5,28
Creatinine (mmol/L): 74.0
Gamma-glutamil transpeptidase (IU/L): 31
Glucose (mmol/L): 4,1
Hemoglobin (g/L): 160.0
HDL (mmol/L): 1,03
Potassium (mEq/L): 5,1
LDL (mmol/L): 3,7
Sodium (mEq/L): 141.0
Pro-BNP (ng/L): 149.0
Protein (g/L): 71,5
T3 (pg/dL): 0,06
T4 (ng/L): 15,82
TSH (mIU/L): 1,64
Urea (mg/dL): 5,4
LVEF (%): 30.0
Medications: Beta Blockers, Digoxin, Loop Diuretics, ACE Inhibitor, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"RANKING: 1. Survivor
REASONING: 

This patient's prognosis is likely to be a survivor due to the following reasons:

1. Age: Although the patient is 55 years old, which is considered middle-aged, the age alone is not a significant predictor of outcome in this case. Many patients with heart failure and coronary artery disease can survive for many years with proper management.

2. NYHA Class II: The patient's NYHA Class II classification indicates that the patient experiences mild symptoms of heart failure, such as fatigue and shortness of breath, but is still able to carry out light physical activity without symptoms. This suggests that the patient's heart function is still relatively preserved.

3. Medications: The patient is on a comprehensive regimen of beta blockers, digoxin, loop diuretics, ACE inhibitors, and a nitrovasodilator, which are standard treatments for heart failure and coronary artery disease. These medications have been shown to improve survival and reduce morbidity in patients with these conditions.

4. ECG Impression: The ECG results do not indicate any life-threatening arrhythmias, such as ventricular tachycardia or ventricular extrasystoles, which are common causes of sudden cardiac death. The absence of paroxysmal supraventricular tachyarrhythmia and bradycardia also reduces the risk of sudden cardiac death.

5. Pro-BNP levels: While elevated Pro-BNP levels are a marker of heart failure, the patient's level of 149 ng/L is not excessively high, suggesting that the patient's heart function is not severely impaired.

6. Other laboratory values: The patient's laboratory values, such as creatinine, urea, and liver enzymes, are not significantly abnormal, suggesting that the patient's kidney and liver function are relatively preserved.

7. LVEF: The patient's LVEF of 30% is significantly reduced, indicating severe left ventricular dysfunction. However, the presence of a comprehensive treatment regimen and the patient's overall clinical presentation suggest that the patient is likely to survive with proper management.

Overall, while the patient's LVEF is severely reduced, the combination of a comprehensive treatment regimen, mild symptoms, and the absence of life-threatening arrhythmias suggests that the patient is likely to survive for the next few years."
130,130,P0210,"Age: 75
Gender: Male 
Weight: 80 kg
Height: 161 cm
NYHA Class: II
Blood Pressure: 180/95 mmHg
Past Medical History: Hypertensive cardiomyopathy, Diabetes, Dyslipemia, Hypertension
Albumin (g/L): 40
ALT or GPT (IU/L): 14.0
AST or GOT (IU/L): 12.0
Total Cholesterol (mmol/L): 5,61
Creatinine (mmol/L): 88.0
Gamma-glutamil transpeptidase (IU/L): 13
Glucose (mmol/L): 7,8
Hemoglobin (g/L): 133.0
HDL (mmol/L): 1,45
Potassium (mEq/L): 3,78
LDL (mmol/L): 3,78
Sodium (mEq/L): 142.0
Pro-BNP (ng/L): 308.0
Protein (g/L): 70
T3 (pg/dL): 0,0597
T4 (ng/L): 19,3
Troponin (ng/mL): 0,5
TSH (mIU/L): 0,69
Urea (mg/dL): 8,3
LVEF (%): 70.0
Medications: Angiotensin II Receptor Blocker, Loop Diuretics, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"RANKING: 
1. Survivor
2. Sudden Cardiac Death
3. Pump Failure Death

REASONING:

Based on the provided patient data, I rank the patient's prognosis as follows:

1. Survivor: The patient's LVEF is 70%, which is relatively preserved, indicating that the heart is still functioning to some extent. The absence of any significant ST-segment elevation or T-wave inversion on the ECG, which could indicate acute myocardial infarction, also supports a favorable prognosis. Additionally, the patient's hemoglobin and potassium levels are within normal limits, and the patient is not on any cardioprotective medications such as beta-blockers or statins. The patient's age is 75, which is a significant risk factor for cardiovascular events, but the patient's NYHA Class II heart failure and the presence of a controlled hypertension and diabetes suggest that the patient's cardiovascular system is still manageable.

2. Sudden Cardiac Death: The patient's ECG showed ventricular extrasystole, which is a sign of ventricular arrhythmia. Although the patient is not on any anti-arrhythmic medications, the presence of ventricular extrasystoles is a significant risk factor for sudden cardiac death. However, the patient's LVEF is still relatively preserved, and the patient is on medications that control hypertension and heart failure, which reduces the risk of sudden cardiac death.

3. Pump Failure Death: The patient's LVEF is 70%, which is a relatively preserved value. However, the patient's creatinine level is elevated at 88.0 mmol/L, which indicates some degree of renal impairment. This can be a risk factor for pump failure. Additionally, the patient's blood pressure is elevated at 180/95 mmHg, which can also contribute to cardiac stress and pump failure. While the patient is on medications that control hypertension and heart failure, the presence of these risk factors suggests that pump failure is a possible outcome.

Overall, while the patient's cardiovascular system is not without risks, the presence of a preserved LVEF, controlled hypertension, and the absence of any acute myocardial infarction or significant arrhythmias suggest a relatively favorable prognosis, with sudden cardiac death being the most likely outcome."
131,131,P0214,"Age: 50
Gender: Female 
Weight: 77 kg
Height: 163 cm
NYHA Class: II
Blood Pressure: 130/80 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Myocardial Infarction
Albumin (g/L): 42
ALT or GPT (IU/L): 11.0
AST or GOT (IU/L): 19.0
Total Cholesterol (mmol/L): 4,06
Creatinine (mmol/L): 81.0
Gamma-glutamil transpeptidase (IU/L): 10
Glucose (mmol/L): 4,9
Hemoglobin (g/L): 126.0
HDL (mmol/L): 1,4
Potassium (mEq/L): 4,32
LDL (mmol/L): 2,3
Sodium (mEq/L): 140.0
Pro-BNP (ng/L): 327.0
Protein (g/L): 69
T3 (pg/dL): 0,051
T4 (ng/L): 14,1
TSH (mIU/L): 1,38
Urea (mg/dL): 5,5
LVEF (%): 50.0
Medications: Beta Blockers, ACE Inhibitor, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"RANKING: 
1. Survivor
REASONING:
Based on the patient data, the patient is considered a high-risk candidate for adverse cardiac events. The presence of ischemic dilated cardiomyopathy, myocardial infarction, and a left ventricular ejection fraction (LVEF) of 50.0 indicate significant cardiac dysfunction. The elevated Pro-BNP levels (327.0 ng/L) also suggest increased ventricular wall stress. However, the patient's current medications, including beta blockers, ACE inhibitor, and nitrovasodilator, are standard treatments for managing heart failure and reducing cardiac workload.

The absence of ventricular tachycardia, non-sustained ventricular tachycardia, and paroxysmal supraventricular tachyarrhythmia on the ECG impression reduces the risk of sudden cardiac death. The patient's blood pressure (130/80 mmHg) and electrolyte levels are within a relatively normal range, which further supports the likelihood of survival.

While the patient's kidney function (creatinine 81.0 mmol/L) is elevated, it is not severely impaired, and the patient is receiving medications that are likely to help manage kidney function. The patient's overall clinical presentation, despite the presence of cardiac dysfunction, does not strongly suggest an immediate high risk of cardiac death or pump failure. Therefore, the most likely prognosis for the next few years is survival.

2. Sudden Cardiac Death
REASONING:
While the patient has a history of ischemic dilated cardiomyopathy and myocardial infarction, the absence of ventricular tachycardia, non-sustained ventricular tachycardia, and paroxysmal supraventricular tachyarrhythmia on the ECG impression reduces the risk of sudden cardiac death. However, the patient's LVEF of 50.0 indicates significant cardiac dysfunction, and the elevated Pro-BNP levels suggest increased ventricular wall stress.

The patient's current medications, including beta blockers and ACE inhibitors, are standard treatments for managing heart failure and reducing cardiac workload. However, the patient's kidney function is elevated, and the presence of a history of myocardial infarction increases the risk of cardiac events.

3. Pump Failure Death
REASONING:
The patient's LVEF of 50.0 indicates significant cardiac dysfunction, and the elevated Pro-BNP levels suggest increased ventricular wall stress. The patient's kidney function is elevated, and the presence of a history of myocardial infarction increases the risk of cardiac events. While the patient is receiving medications that are likely to help manage heart failure, the combination of these factors increases the risk of pump failure. However, the absence of other indicators of severe cardiac dysfunction or acute heart failure symptoms reduces the likelihood of pump failure death compared to sudden cardiac death."
132,132,P0216,"Age: 79
Gender: Male 
Weight: 73 kg
Height: 161 cm
NYHA Class: II
Blood Pressure: 150/90 mmHg
Past Medical History: Idiopathic dilated cardiomyopathy, Hypertension
Albumin (g/L): 33
ALT or GPT (IU/L): 24.0
AST or GOT (IU/L): 46.0
Total Cholesterol (mmol/L): 3,26
Creatinine (mmol/L): 119.0
Gamma-glutamil transpeptidase (IU/L): 149
Glucose (mmol/L): 4,2
Hemoglobin (g/L): 125.0
HDL (mmol/L): 1,73
Potassium (mEq/L): 4,58
LDL (mmol/L): 1,71
Sodium (mEq/L): 140.0
Pro-BNP (ng/L): 5971.0
Protein (g/L): 66,3
T3 (pg/dL): 0,0642
T4 (ng/L): 19,53
Troponin (ng/mL): 0,5
TSH (mIU/L): 1,68
Urea (mg/dL): 7,2
LVEF (%): 30.0
Medications: Angiotensin II Receptor Blocker, Digoxin, Loop Diuretics, ACE Inhibitor, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",survivor,"RANKING: 1. Survivor
REASONING:

Based on the provided patient data, the patient is at high risk for cardiac-related complications due to their underlying idiopathic dilated cardiomyopathy, hypertension, and existing heart failure (NYHA Class II). The elevated LVEF (30.0%) and elevated BNP levels (5971.0 ng/L) indicate significant left ventricular dysfunction.

The presence of ventricular extrasystole, non-sustained ventricular tachycardia (NSVT), and paroxysmal supraventricular tachyarrhythmia (PSVT) codes on the ECG impression suggest a high risk of arrhythmic events. The patient's age (79) and comorbidities (hypertension, idiopathic dilated cardiomyopathy) further increase the risk of cardiac events.

Despite the patient being on multiple medications, including an ACE inhibitor, angiotensin II receptor blocker, digoxin, and loop diuretics, which are standard treatments for heart failure and hypertension, the patient's LVEF and BNP levels indicate that their heart function is not adequately controlled.

Given these factors, the patient is at high risk for cardiac events, including sudden cardiac death. However, the patient has not had any reported cardiac events, and their current treatment regimen is not explicitly stated as being adjusted or optimized for their specific needs.

Therefore, despite the high risk, the patient's current status as a ""survivor"" suggests that they have not experienced a cardiac event, and their current management plan may be effective in preventing further complications. However, close monitoring and regular follow-up are essential to adjust the treatment plan as needed to minimize the risk of cardiac events.

Ranking the other options:
- Sudden cardiac death: Although the patient has a high risk of cardiac events, there is no indication that a sudden cardiac death has occurred.
- Pump failure death: The patient is currently on medications and has a relatively stable LVEF, suggesting that pump failure is not the primary cause of death at this time."
133,133,P0219,"Age: 61
Gender: Male 
Weight: 84 kg
Height: 173 cm
NYHA Class: II
Blood Pressure: 140/90 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Diabetes, Dyslipemia, Hypertension
Albumin (g/L): 44
ALT or GPT (IU/L): 49.0
AST or GOT (IU/L): 28.0
Total Cholesterol (mmol/L): 4,95
Creatinine (mmol/L): 136.0
Gamma-glutamil transpeptidase (IU/L): 26
Glucose (mmol/L): 7,74
Hemoglobin (g/L): 167.0
HDL (mmol/L): 1,1
Potassium (mEq/L): 4,46
LDL (mmol/L): 2,77
Sodium (mEq/L): 140.0
Pro-BNP (ng/L): 165.0
Protein (g/L): 75,5
T3 (pg/dL): 0,0204
T4 (ng/L): 13,65
Troponin (ng/mL): 0,8
TSH (mIU/L): 1,19
Urea (mg/dL): 7,8
LVEF (%): 40.0
Medications: Diabetes Medication, Angiotensin II Receptor Blocker, Digoxin, Loop Diuretics, Statins
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"RANKING: 1. Survivor
REASONING: 

The patient has a history of ischemic dilated cardiomyopathy, which is a condition that significantly impairs the heart's ability to pump blood effectively. This condition, combined with the patient's current NYHA Class II symptoms, suggests that the patient is already experiencing some level of cardiac dysfunction. The elevated creatinine level (136.0 mmol/L) also indicates impaired kidney function, which is a common complication of advanced heart failure.

The patient's low ejection fraction (LVEF) of 40.0% further supports the presence of significant cardiac dysfunction. The elevated troponin level (0.8 ng/mL) suggests some degree of myocardial injury, which is consistent with the patient's history of ischemic dilated cardiomyopathy.

The presence of ventricular extrasystoles and non-sustained ventricular tachycardia (NSTVT) on the ECG suggests that the patient is at risk for arrhythmias, which can be life-threatening. However, the fact that these arrhythmias are non-sustained and the patient is not experiencing symptoms of bradycardia or other concerning arrhythmias suggests that the patient may still have a relatively good prognosis.

Given the patient's age, comorbidities, and current cardiac status, it is likely that the patient will experience a gradual decline in cardiac function over the next few years, but the presence of medications such as digoxin, which can help manage heart rate and rhythm, and the patient's relatively mild symptoms suggest that the patient may survive for several years with careful management.

RANKING: 2. Sudden cardiac death
REASONING: 

The patient's history of ischemic dilated cardiomyopathy and non-sustained ventricular tachycardia (NSTVT) on ECG increases the risk of sudden cardiac death. The presence of ventricular extrasystoles also suggests that the patient's heart is experiencing electrical instability, which can increase the risk of arrhythmias that can lead to sudden cardiac death.

Additionally, the patient's low ejection fraction (LVEF) of 40.0% and elevated creatinine level (136.0 mmol/L) suggest that the patient's cardiac function is impaired, which increases the risk of cardiac events such as sudden cardiac death.

RANKING: 3. Pump failure death
REASONING: 

The patient's history of ischemic dilated cardiomyopathy and current cardiac status, including the low ejection fraction (LVEF) of 40.0% and elevated creatinine level (136.0 mmol/L), suggests that the patient is at risk for heart failure. However, the presence of medications such as digoxin, which can help manage heart rate and rhythm, and the patient's relatively mild symptoms suggest that the patient may not experience pump failure death in the near future.

While the patient's cardiac function is impaired, the presence of medications and the patient's relatively stable symptoms suggest that the patient may be able to survive for several years with careful management. However, the patient's history of ischemic dilated cardiomyopathy and elevated creatinine level do increase the risk of heart failure, making pump failure death a possible outcome in the long term."
134,134,P0220,"Age: 44
Gender: Male 
Weight: 106 kg
Height: 181 cm
NYHA Class: II
Blood Pressure: 100/60 mmHg
Past Medical History: Valvular cardiomyopathy, Dyslipemia
Albumin (g/L): 46
ALT or GPT (IU/L): 24.0
AST or GOT (IU/L): 21.0
Total Cholesterol (mmol/L): 6,21
Creatinine (mmol/L): 128.0
Gamma-glutamil transpeptidase (IU/L): 29
Glucose (mmol/L): 5,02
Hemoglobin (g/L): 111.0
HDL (mmol/L): 0,8
Potassium (mEq/L): 4,59
LDL (mmol/L): 4,19
Sodium (mEq/L): 134.0
Pro-BNP (ng/L): 1057.0
Protein (g/L): 82,4
T3 (pg/dL): 0,0339
T4 (ng/L): 20,91
Troponin (ng/mL): 0,6
TSH (mIU/L): 1,55
Urea (mg/dL): 19,2
LVEF (%): 20.0
Medications: Beta Blockers, Digoxin, Loop Diuretics, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: TPSV
        - Bradycardia: No
            ",survivor,"RANKING: 1. Survivor
REASONING: 

The patient has a relatively mild NYHA Class II heart failure, which indicates that the patient's symptoms are manageable with current medications. The patient's LVEF is 20%, which is lower than the normal range, suggesting some degree of left ventricular dysfunction. However, the patient's overall clinical presentation and test results do not indicate any acute or severe cardiac events.

The patient's blood pressure is 100/60 mmHg, which is within a relatively normal range. The patient's lipid profile shows elevated total cholesterol and LDL, but these are not uncommon in patients with heart failure. The patient's renal function is slightly impaired, as indicated by the elevated creatinine level, but this is not uncommon in patients with heart failure.

The patient's ECG shows a TPSV, which is a relatively common arrhythmia in patients with heart failure. The absence of other arrhythmias or signs of cardiac ischemia on the ECG is reassuring. The patient's troponin level is normal, which suggests that there is no significant myocardial injury.

The patient's biomarkers for cardiac stress and strain, such as Pro-BNP and TSH, are elevated, indicating some degree of cardiac stress. However, the patient's overall clinical presentation and test results do not suggest any acute or severe cardiac events.

Given the patient's relatively mild symptoms, normal blood pressure, and absence of other cardiac events, I would predict that the patient has a high likelihood of survival over the next few years. The patient's prognosis is further supported by the fact that the patient is already on medications that are commonly used to manage heart failure, such as beta blockers, digoxin, and loop diuretics.

RANKING: 2. Pump failure death
REASONING: 

While the patient has a relatively mild NYHA Class II heart failure, the patient's LVEF is 20%, which is lower than the normal range. This suggests some degree of left ventricular dysfunction, which could potentially lead to pump failure over time. The patient's elevated creatinine level and elevated Pro-BNP and TSH levels also suggest some degree of cardiac stress and strain.

While the patient is on medications that are commonly used to manage heart failure, the patient's LVEF is still lower than normal, which suggests that the patient may not be receiving adequate therapy to improve cardiac function. The patient's elevated LDL cholesterol level also increases the risk of cardiac events.

Given the patient's relatively mild symptoms, but underlying cardiac dysfunction and elevated biomarkers for cardiac stress and strain, I would predict that the patient has a moderate likelihood of pump failure over the next few years.

RANKING: 3. Sudden cardiac death
REASONING: 

The patient's ECG shows a TPSV, which is a relatively common arrhythmia in patients with heart failure. However, the absence of other arrhythmias or signs of cardiac ischemia on the ECG is reassuring. The patient's troponin level is normal, which suggests that there is no significant myocardial injury.

While the patient's LVEF is lower than normal, the patient's overall clinical presentation and test results do not suggest any acute or severe cardiac events. The patient is also on medications that are commonly used to manage heart failure, which reduces the risk of cardiac events.

However, the patient's elevated Pro-BNP and TSH levels suggest some degree of cardiac stress and strain, which increases the risk of cardiac events. Additionally, the patient's elevated LDL cholesterol level increases the risk of cardiac events.

Given the patient's relatively mild symptoms, but underlying cardiac dysfunction and elevated biomarkers for cardiac stress and strain, I would predict that the patient has a low likelihood of sudden cardiac death over the next few years."
135,135,P0222,"Age: 57
Gender: Female 
Weight: 47 kg
Height: 162 cm
NYHA Class: II
Blood Pressure: 110/60 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Dyslipemia
Albumin (g/L): 41
ALT or GPT (IU/L): 17.0
AST or GOT (IU/L): 22.0
Total Cholesterol (mmol/L): 5,39
Creatinine (mmol/L): 80.0
Gamma-glutamil transpeptidase (IU/L): 19
Glucose (mmol/L): 4,74
Hemoglobin (g/L): 139.0
HDL (mmol/L): 1,2
Potassium (mEq/L): 4,17
LDL (mmol/L): 3,63
Sodium (mEq/L): 141.0
Pro-BNP (ng/L): 1537.0
Protein (g/L): 64
T3 (pg/dL): 0,054
T4 (ng/L): 16,68
Troponin (ng/mL): 0,5
TSH (mIU/L): 0,09
Urea (mg/dL): 8
LVEF (%): 35.0
Medications: Beta Blockers, Digoxin, Loop Diuretics, Spironolactone, Statins, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Unknown ventricular tachycardia code
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: Second-degree AVB - type I
            ",survivor,"RANKING: 1. Survivor
REASONING: 

Based on the provided patient data, I would rank the patient's prognosis as a survivor for the next few years. The patient's age, NYHA Class II, and the presence of ischemic dilated cardiomyopathy, dyslipemia, and elevated troponin levels suggest a significant cardiac impairment. However, the patient is currently on medications that are standard for managing heart failure and arrhythmias, including beta blockers, digoxin, and ACE inhibitors.

The patient's ejection fraction (LVEF) is severely reduced at 35%, indicating significant left ventricular dysfunction. However, the absence of signs of acute myocardial infarction (e.g., no ST-segment elevation on ECG) and the presence of a low level of troponin suggest that the patient may not be experiencing an acute coronary event. 

Additionally, the patient's elevated BNP levels (1537 ng/L) are consistent with heart failure, but not excessively high, which could indicate a more chronic condition. The patient's kidney function is also relatively preserved, with a creatinine level of 8 mg/dL.

Given these factors, the patient's overall condition seems to be managed relatively well, and the patient is unlikely to experience sudden cardiac death or pump failure in the near future. Therefore, I rank the patient's prognosis as a survivor."
136,136,P0224,"Age: 76
Gender: Male 
Weight: 94 kg
Height: 165 cm
NYHA Class: II
Blood Pressure: 110/80 mmHg
Past Medical History: Hypertensive cardiomyopathy, Dyslipemia, Hypertension
Albumin (g/L): 37
ALT or GPT (IU/L): 16.0
AST or GOT (IU/L): 19.0
Total Cholesterol (mmol/L): 4,2
Creatinine (mmol/L): 183.0
Gamma-glutamil transpeptidase (IU/L): 8
Glucose (mmol/L): 3,96
Hemoglobin (g/L): 132.0
HDL (mmol/L): 1,1
Potassium (mEq/L): 3,9
LDL (mmol/L): 2,25
Sodium (mEq/L): 140.0
Pro-BNP (ng/L): 211.0
Protein (g/L): 71
T3 (pg/dL): 0,0282
T4 (ng/L): 12,07
Troponin (ng/mL): 0,5
TSH (mIU/L): 1,85
Urea (mg/dL): 12,1
LVEF (%): 70.0
Medications: Loop Diuretics, Spironolactone, Statins, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: TPSV
        - Bradycardia: Unknown bradycardia code
            ",survivor,"RANKING: 1. Survivor
REASONING:

Based on the provided patient data, I predict that the patient is most likely to survive for the next few years. The following factors contribute to this prediction:

1. Age: The patient is 76 years old, which is an advanced age, but not extremely old. However, age is a significant risk factor for cardiac events, and the patient's age alone does not predict a poor outcome.
2. NYHA Class II: The patient's heart failure symptoms are moderate, indicating some limitation in physical activity, but not severe.
3. Blood pressure: The patient's blood pressure is well-controlled at 110/80 mmHg, which is within the normal range.
4. Medications: The patient is taking a combination of medications, including diuretics, spironolactone, statins, and a nitrovasodilator, which are commonly used to manage heart failure, hypertension, and dyslipidemia.
5. ECG Impression: The ECG shows ventricular extrasystoles, ventricular tachycardia, and paroxysmal supraventricular tachycardia, but none of these findings are indicative of a high risk of sudden cardiac death or pump failure.
6. Biomarkers: The patient's troponin level is normal, and the Pro-BNP level is elevated, indicating some degree of heart failure. However, the patient is not showing signs of acute myocardial infarction or severe heart failure.

Overall, the patient's age, medication regimen, and ECG findings suggest that the patient is at moderate risk for cardiac events, but not extremely high. Therefore, I predict that the patient is most likely to survive for the next few years.

RANKING: 2. Pump failure death
REASONING:

Based on the patient's data, I predict that pump failure death is a possible outcome, but less likely than survival. The following factors contribute to this prediction:

1. Elevated creatinine level: The patient's creatinine level is elevated at 183.0 mmol/L, indicating impaired renal function, which can be a sign of heart failure.
2. Elevated Pro-BNP level: The patient's Pro-BNP level is elevated, indicating some degree of heart failure.
3. NYHA Class II: The patient's heart failure symptoms are moderate, indicating some limitation in physical activity.

However, the patient is receiving diuretics and spironolactone, which are commonly used to manage heart failure, and the patient's ECG findings do not indicate a high risk of sudden cardiac death or severe cardiac arrhythmias.

RANKING: 3. Sudden cardiac death
REASONING:

Based on the patient's data, I predict that sudden cardiac death is the least likely outcome. The following factors contribute to this prediction:

1. ECG Impression: While the patient's ECG shows ventricular extrasystoles, ventricular tachycardia, and paroxysmal supraventricular tachycardia, none of these findings are indicative of a high risk of sudden cardiac death.
2. Normal troponin level: The patient's troponin level is normal, indicating no acute myocardial infarction.
3. Normal blood pressure: The patient's blood pressure is well-controlled, which reduces the risk of sudden cardiac death due to hypertension.

Overall, the patient's ECG findings and biomarkers do not indicate a high risk of sudden cardiac death, and the patient is receiving medications to manage heart failure and hypertension."
137,137,P0225,"Age: 79
Gender: Male 
Weight: 71 kg
Height: 165 cm
NYHA Class: II
Blood Pressure: 120/80 mmHg
Past Medical History: Hypertensive cardiomyopathy, Dyslipemia, Hypertension
Albumin (g/L): 37
ALT or GPT (IU/L): 21.0
AST or GOT (IU/L): 27.0
Total Cholesterol (mmol/L): 3,38
Creatinine (mmol/L): 106.0
Gamma-glutamil transpeptidase (IU/L): 18
Glucose (mmol/L): 5,17
Hemoglobin (g/L): 153.0
HDL (mmol/L): 1
Potassium (mEq/L): 3,5
LDL (mmol/L): 1,94
Sodium (mEq/L): 141.0
Pro-BNP (ng/L): 2070.0
Protein (g/L): 64
T3 (pg/dL): 0,0318
T4 (ng/L): 18,1
TSH (mIU/L): 0,88
Urea (mg/dL): 5,7
LVEF (%): 70.0
Medications: Digoxin, Loop Diuretics, Statins, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",survivor,"RANKING: 

1. Survivor
REASONING: 
Based on the provided patient data, the patient is a 79-year-old male with a history of hypertension, cardiomyopathy, and dyslipidemia. The patient's NYHA Class is II, indicating moderate symptoms, and the LVEF is 70%, which is within the normal range. The patient's ECG shows ventricular extrasystoles, which is a benign finding, and no other significant arrhythmias. The patient's laboratory results show normal liver function, kidney function, and electrolyte levels. The patient is also taking medications that are commonly used to treat heart failure and hypertension. The patient's Pro-BNP level is elevated, which is a marker for heart failure, but it is not excessively high. Overall, the patient's data suggests that the patient has a relatively stable cardiac condition, and with proper management, the patient is likely to survive.

2. Sudden Cardiac Death
REASONING: 
While the patient has a history of hypertension and cardiomyopathy, which are risk factors for sudden cardiac death, the patient's ECG does not show any signs of ventricular tachycardia or ventricular fibrillation. The patient's LVEF is within the normal range, and the Pro-BNP level is not excessively high. The patient's laboratory results are also normal, which reduces the likelihood of acute kidney injury or electrolyte imbalances that can contribute to sudden cardiac death. However, the patient's age and history of hypertension and cardiomyopathy make it difficult to rule out sudden cardiac death entirely.

3. Pump Failure Death
REASONING: 
The patient's LVEF is 70%, which is within the normal range, and the patient is not taking medications that are commonly used to treat heart failure. While the patient has a history of cardiomyopathy, the patient's ECG does not show any signs of ventricular dysfunction, and the Pro-BNP level is not excessively high. However, the patient's creatinine level is elevated, which may indicate some degree of renal impairment. Additionally, the patient's age and history of hypertension make it possible that the patient's cardiac condition could deteriorate over time, leading to pump failure. However, the patient's current data does not strongly suggest pump failure."
138,138,P0227,"Age: 73
Gender: Male 
Weight: 86 kg
Height: 173 cm
NYHA Class: II
Blood Pressure: 150/80 mmHg
Past Medical History: Hypertensive cardiomyopathy, Diabetes, Dyslipemia, Peripheral vascular disease, Hypertension
Albumin (g/L): 41
ALT or GPT (IU/L): 9.0
AST or GOT (IU/L): 16.0
Total Cholesterol (mmol/L): 3,33
Creatinine (mmol/L): 128.0
Gamma-glutamil transpeptidase (IU/L): 8
Glucose (mmol/L): 5,24
Hemoglobin (g/L): 116.0
HDL (mmol/L): 1,1
Potassium (mEq/L): 4,5
LDL (mmol/L): 1,9
Sodium (mEq/L): 143.0
Pro-BNP (ng/L): 1184.0
Protein (g/L): 75
T3 (pg/dL): 0,0273
T4 (ng/L): 13,94
Troponin (ng/mL): 0,1
TSH (mIU/L): 1,07
Urea (mg/dL): 6,5
LVEF (%): 70.0
Medications: Diabetes Medication, Loop Diuretics, Statins, ACE Inhibitor, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: TPSV
        - Bradycardia: Unknown bradycardia code
            ",survivor,"RANKING: 1. Survivor
REASONING: 
Based on the provided patient data, the patient is 73 years old, with a history of multiple comorbidities including hypertension, cardiomyopathy, diabetes, and peripheral vascular disease. The patient's laboratory results show elevated creatinine levels (128.0 mmol/L), which indicate impaired renal function. The patient's LVEF is 70.0%, which is within the normal range but on the lower end of normal.

The patient's ECG shows ventricular extrasystoles, which may indicate some degree of ventricular dysfunction, but there is no evidence of ventricular tachycardia or other arrhythmias that would suggest a high risk of sudden cardiac death. The patient's medications, including ACE inhibitors and statins, are commonly used to manage cardiovascular risk factors.

Given the patient's age, comorbidities, and laboratory results, the most likely outcome is that the patient will survive for the next few years. The patient's renal impairment and elevated creatinine levels may require close monitoring and management, but they do not necessarily indicate a high risk of sudden cardiac death or pump failure.

The patient's TSH level is within the normal range, and the patient is on medications that are commonly used to manage cardiovascular risk factors, which further supports the likelihood of a favorable outcome.

RANKING: 2. Sudden cardiac death
REASONING: 
While the patient's ECG shows ventricular extrasystoles, which may indicate some degree of ventricular dysfunction, the absence of ventricular tachycardia or other arrhythmias that would suggest a high risk of sudden cardiac death makes this outcome less likely.

RANKING: 3. Pump failure death
REASONING: 
The patient's LVEF is 70.0%, which is within the normal range, and the patient is on medications that are commonly used to manage cardiovascular risk factors, which suggests that the patient's heart function is being adequately managed. The patient's renal impairment may require close monitoring and management, but it does not necessarily indicate a high risk of pump failure.

However, the patient's age and comorbidities, including cardiomyopathy and hypertension, may increase the risk of pump failure. Additionally, the patient's elevated creatinine levels may indicate some degree of cardiac dysfunction. While these factors do not necessarily predict pump failure, they do increase the risk, making pump failure death a possible but less likely outcome."
139,139,P0228,"Age: 77
Gender: Female 
Weight: 62 kg
Height: 155 cm
NYHA Class: III
Blood Pressure: 160/70 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Diabetes, Dyslipemia, Peripheral vascular disease, Hypertension, Myocardial Infarction
Albumin (g/L): 46
ALT or GPT (IU/L): 10.0
AST or GOT (IU/L): 11.0
Total Cholesterol (mmol/L): 4,46
Creatinine (mmol/L): 104.0
Gamma-glutamil transpeptidase (IU/L): 19
Glucose (mmol/L): 10,22
Hemoglobin (g/L): 146.0
HDL (mmol/L): 1,7
Potassium (mEq/L): 4,27
LDL (mmol/L): 2,35
Sodium (mEq/L): 146.0
Pro-BNP (ng/L): 1951.0
Protein (g/L): 79,5
T3 (pg/dL): 0,0288
T4 (ng/L): 16,13
Troponin (ng/mL): 1,6
TSH (mIU/L): 0,87
Urea (mg/dL): 10
LVEF (%): 25.0
Medications: Diabetes Medication, Angiotensin II Receptor Blocker, Loop Diuretics, Statins, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"RANKING: 1. Survivor
REASONING: The patient's age (77 years) and NYHA Class III status indicate a significant burden of cardiac disease, which may compromise the patient's overall prognosis. However, the patient's recent blood test results show a relatively well-controlled diabetes, controlled hypertension, and stable renal function (Creatinine 104.0 mg/dL). The absence of acute coronary syndrome (e.g., troponin elevation) and the absence of signs of severe heart failure (e.g., elevated BNP, low LVEF) suggest that the patient's cardiac function is relatively stable. The presence of ventricular extrasystoles and non-sustained ventricular tachycardia (NSVT) on the ECG is concerning, but the absence of sustained VT and paroxysmal supraventricular tachycardia suggests that the patient's arrhythmia burden may not be excessively high. Overall, considering these factors, the patient's prognosis is likely to be favorable, with a high likelihood of survival."
140,140,P0230,"Age: 84
Gender: Female 
Weight: 67 kg
Height: 158 cm
NYHA Class: II
Blood Pressure: 135/70 mmHg
Past Medical History: Hypertensive cardiomyopathy, Hypertension, Myocardial Infarction
Albumin (g/L): 40
ALT or GPT (IU/L): 16.0
AST or GOT (IU/L): 17.0
Total Cholesterol (mmol/L): 4,25
Creatinine (mmol/L): 117.0
Gamma-glutamil transpeptidase (IU/L): 17
Glucose (mmol/L): 5,7
Hemoglobin (g/L): 105.0
HDL (mmol/L): 1,55
Potassium (mEq/L): 4,72
LDL (mmol/L): 2,35
Sodium (mEq/L): 140.0
Pro-BNP (ng/L): 308.0
Protein (g/L): 71,3
T3 (pg/dL): 0,0348
T4 (ng/L): 14,23
Troponin (ng/mL): 0,4
TSH (mIU/L): 2,54
Urea (mg/dL): 8,3
LVEF (%): 70.0
Medications: Angiotensin II Receptor Blocker, Beta Blockers, Digoxin, Loop Diuretics, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"RANKING: 1. Survivor
REASONING: 

This patient is an 84-year-old female with a history of hypertension, myocardial infarction, and cardiomyopathy, which indicates a high burden of cardiovascular disease. However, her current NYHA Class II classification suggests that she has some limitation in physical activity, but it is not severe. Her blood pressure is well-controlled at 135/70 mmHg, and her medications (Angiotensin II Receptor Blocker, Beta Blockers, Digoxin, Loop Diuretics, and Nitrovasodilator) are standard treatments for her conditions.

Her laboratory results show elevated liver enzymes (ALT and AST), which may indicate some degree of liver dysfunction, but it is not significantly abnormal. Her kidney function is also slightly impaired, with elevated creatinine levels, but it is not severe. Her lipid profile is not ideal, with high LDL and low HDL, but it is not significantly abnormal.

Her ECG results show ventricular extrasystole, which is a benign finding, and no signs of ventricular tachycardia or bradycardia. Her LVEF is 70%, which is slightly below the normal range, but it is not significantly abnormal.

Considering these factors, the patient's overall cardiovascular risk is moderate to high, but her current clinical status and treatment are well-managed. With appropriate management and lifestyle modifications, it is likely that she will survive for several more years.

RANKING: 2. Sudden Cardiac Death
REASONING: 

While the patient's cardiovascular risk is moderate to high, her current clinical status and treatment suggest that she is not at high risk for sudden cardiac death. However, her history of myocardial infarction and cardiomyopathy increases her risk for arrhythmias, including ventricular tachycardia. Her elevated Troponin levels (0.4 ng/mL) may indicate some degree of cardiac damage, which could increase her risk for arrhythmias.

Additionally, her elevated Pro-BNP levels (308 ng/L) may indicate some degree of heart failure, which could increase her risk for sudden cardiac death. However, her LVEF is 70%, which is slightly below the normal range, but it is not significantly abnormal.

Considering these factors, while the patient is at some risk for arrhythmias, her current clinical status and treatment suggest that sudden cardiac death is less likely than death from pump failure.

RANKING: 3. Pump Failure Death
REASONING: 

The patient's history of cardiomyopathy and hypertension increases her risk for heart failure, and her elevated Pro-BNP levels (308 ng/L) suggest some degree of heart failure. Her LVEF is 70%, which is slightly below the normal range, and her kidney function is slightly impaired, which could increase her risk for heart failure.

Additionally, her age and sex are factors that increase her risk for heart failure. However, her current clinical status and treatment suggest that she is receiving optimal management for her conditions, which could help mitigate her risk for heart failure.

Considering these factors, while the patient is at some risk for heart failure, her current clinical status and treatment suggest that pump failure death is less likely than sudden cardiac death."
141,141,P0231,"Age: 78
Gender: Male 
Weight: 80 kg
Height: 169 cm
NYHA Class: II
Blood Pressure: 130/65 mmHg
Past Medical History: Idiopathic dilated cardiomyopathy, Dyslipemia, Peripheral vascular disease, Hypertension
Albumin (g/L): 40
ALT or GPT (IU/L): 13.0
AST or GOT (IU/L): 25.0
Total Cholesterol (mmol/L): 6,07
Creatinine (mmol/L): 140.0
Gamma-glutamil transpeptidase (IU/L): 17
Glucose (mmol/L): 5,55
Hemoglobin (g/L): 133.0
HDL (mmol/L): 1,4
Potassium (mEq/L): 4,49
LDL (mmol/L): 4,1
Sodium (mEq/L): 144.0
Pro-BNP (ng/L): 5910.0
Protein (g/L): 70
T3 (pg/dL): 0,0168
T4 (ng/L): 13,49
Troponin (ng/mL): 0,4
TSH (mIU/L): 1,27
Urea (mg/dL): 9
LVEF (%): 25.0
Medications: Loop Diuretics, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: TPSV
        - Bradycardia: No
            ",survivor,"RANKING: 1. Survivor
REASONING: 

The patient's age, NYHA Class II, and the presence of idiopathic dilated cardiomyopathy, hypertension, and dyslipemia are all significant risk factors for cardiac complications. However, the patient's current hemoglobin level (133.0 g/L), which is within the normal range, and the absence of severe anemia, reduce the risk of cardiovascular events.

The patient's elevated creatinine level (140.0 mmol/L) and LVEF (25.0%) indicate significant cardiac dysfunction, but the patient is still receiving ACE inhibitors, which are known to improve cardiac function in patients with heart failure. The presence of elevated Pro-BNP (5910.0 ng/L) also suggests cardiac stress and strain, but it is not indicative of acute decompensated heart failure.

The absence of any recent ECG findings that would suggest acute coronary syndrome (ACS) or severe arrhythmias reduces the likelihood of sudden cardiac death. The presence of ventricular extrasystole and polymorphic ventricular tachycardia on ECG may indicate underlying cardiac electrical instability, but the absence of sustained ventricular tachycardia or other life-threatening arrhythmias reduces the risk.

Overall, the combination of mild cardiac dysfunction, controlled hypertension, and the absence of severe cardiac complications make this patient more likely to survive the next few years, given their current treatment and management."
142,142,P0234,"Age: 67
Gender: Male 
Weight: 69 kg
Height: 167 cm
NYHA Class: II
Blood Pressure: 120/80 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Dyslipemia, Hypertension, Myocardial Infarction
Albumin (g/L): 46
ALT or GPT (IU/L): 23.0
AST or GOT (IU/L): 27.0
Total Cholesterol (mmol/L): 4,41
Creatinine (mmol/L): 84.0
Gamma-glutamil transpeptidase (IU/L): 57
Glucose (mmol/L): 7
Hemoglobin (g/L): 142.0
HDL (mmol/L): 1,5
Potassium (mEq/L): 4,16
LDL (mmol/L): 1,5
Sodium (mEq/L): 135.0
Pro-BNP (ng/L): 2129.0
Protein (g/L): 76,5
T3 (pg/dL): 0,0471
T4 (ng/L): 15,02
Troponin (ng/mL): 0,9
TSH (mIU/L): 1,05
Urea (mg/dL): 7,2
LVEF (%): 20.0
Medications: Calcium Channel Blocker, Beta Blockers, Statins, ACE Inhibitor, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"RANKING: 1. Survivor
REASONING:

Based on the provided patient data, I predict that the patient is most likely to survive for the next few years. Here's why:

1. Age: The patient is 67 years old, which is considered old for many medical conditions, but not unusually high-risk for cardiovascular events. The risk of mortality increases with age, but this patient's age alone does not indicate a high risk.
2. NYHA Class II: The patient has a mild heart failure classification, indicating that they have some symptoms of heart failure, but they are still able to perform daily activities without significant limitation.
3. Blood pressure control: The patient's blood pressure is well-controlled (120/80 mmHg), which reduces the risk of cardiovascular events.
4. Medication regimen: The patient is on multiple medications, including calcium channel blockers, beta blockers, statins, ACE inhibitors, and a nitrovasodilator, which are all evidence-based treatments for cardiovascular diseases. This comprehensive treatment plan suggests that the patient is receiving optimal care for their conditions.
5. Laboratory results: The patient's laboratory results are generally within normal limits, with the exception of a slightly elevated creatinine level (84.0 mmol/L), which may indicate some degree of kidney impairment. However, this is not uncommon in older adults and may not significantly impact overall survival.
6. ECG findings: The ECG shows no evidence of ventricular arrhythmias, which is a significant risk factor for sudden cardiac death.
7. Pro-BNP levels: The patient's Pro-BNP level (2129.0 ng/L) is elevated, indicating some degree of heart failure, but it is not excessively high, which may suggest that the patient's heart is not in a severely compromised state.

Considering these factors, I believe that the patient is likely to survive for the next few years, provided that they continue to receive optimal medical care and make lifestyle modifications to manage their conditions."
143,143,P0235,"Age: 76
Gender: Female 
Weight: 92 kg
Height: 153 cm
NYHA Class: III
Blood Pressure: 120/70 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Diabetes, Peripheral vascular disease, Hypertension, Myocardial Infarction
Albumin (g/L): 40
ALT or GPT (IU/L): 14.0
AST or GOT (IU/L): 15.0
Total Cholesterol (mmol/L): 4,73
Creatinine (mmol/L): 107.0
Gamma-glutamil transpeptidase (IU/L): 11
Glucose (mmol/L): 7,07
Hemoglobin (g/L): 130.0
HDL (mmol/L): 1,5
Potassium (mEq/L): 3,9
LDL (mmol/L): 2,84
Sodium (mEq/L): 138.0
Pro-BNP (ng/L): 1309.0
Protein (g/L): 67
T3 (pg/dL): 0,0441
T4 (ng/L): 22,35
Troponin (ng/mL): 0,7
TSH (mIU/L): 1,62
Urea (mg/dL): 8,4
LVEF (%): 40.0
Medications: Diabetes Medication, Loop Diuretics, ACE Inhibitor, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Unknown ventricular tachycardia code
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"RANKING: 1. Survivor
REASONING:

The patient is a 76-year-old female with a history of ischemic dilated cardiomyopathy, diabetes, peripheral vascular disease, hypertension, and myocardial infarction. Her NYHA Class III indicates significant heart failure, and her LVEF of 40% further supports this. Despite these severe heart failure symptoms, the patient's current vital signs, including blood pressure (120/70 mmHg) and hemoglobin (130.0 g/L), are relatively stable.

The patient's laboratory results show elevated creatinine levels (107.0 mmol/L), which indicate impaired kidney function, a common complication in patients with heart failure. However, the patient is on loop diuretics, which are commonly used to manage fluid overload in heart failure patients.

The ECG findings of ventricular extrasystole and polymorphic ventricular tachycardia are concerning, but the absence of sustained ventricular tachycardia (CH>10) and bradycardia suggests that the patient's cardiac function is not severely compromised. The presence of elevated troponin levels (0.7 ng/mL) indicates some degree of myocardial injury, but it is not excessively high.

Considering the patient's age, comorbidities, and the severity of her heart failure, it is likely that the patient will survive the next few years. The patient's current treatment regimen, including ACE inhibitors, loop diuretics, and a nitrovasodilator, is standard for managing heart failure and is likely to provide adequate symptom control.

While the patient's prognosis is guarded, the likelihood of sudden cardiac death or pump failure death is lower than the likelihood of survivorship due to the following reasons:

1. The patient's heart failure symptoms are relatively stable, and the patient is on optimal medical therapy.
2. The patient's ECG findings, although concerning, do not indicate a high risk of sudden cardiac death.
3. The patient's laboratory results, while indicating impaired kidney function, do not suggest a high risk of pump failure.

Overall, based on the available data, the most likely outcome for the patient over the next few years is survival, with a moderate risk of complications related to her heart failure and cardiovascular disease."
144,144,P0236,"Age: 74
Gender: Female 
Weight: 87 kg
Height: 157 cm
NYHA Class: II
Blood Pressure: 180/90 mmHg
Past Medical History: Hypertensive cardiomyopathy, Diabetes, Dyslipemia, Hypertension
Albumin (g/L): 42
ALT or GPT (IU/L): 16.0
AST or GOT (IU/L): 18.0
Total Cholesterol (mmol/L): 3,41
Creatinine (mmol/L): 130.0
Gamma-glutamil transpeptidase (IU/L): 18
Glucose (mmol/L): 5,68
Hemoglobin (g/L): 120.0
HDL (mmol/L): 1,2
Potassium (mEq/L): 3,9
LDL (mmol/L): 1,71
Sodium (mEq/L): 146.0
Pro-BNP (ng/L): 1176.0
Protein (g/L): 72,9
T3 (pg/dL): 0,0312
T4 (ng/L): 14,43
Troponin (ng/mL): 0,5
TSH (mIU/L): 5,19
Urea (mg/dL): 13
LVEF (%): 50.0
Medications: Amiodarone, Loop Diuretics, Statins, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"RANKING: 
1. Survivor
REASONING: 

Based on the patient's age, NYHA Class II, and the presence of hypertension, cardiomyopathy, diabetes, and dyslipemia, the patient is at high risk for cardiovascular events. The elevated blood pressure (180/90 mmHg), elevated creatinine (130.0 mmol/L), and low ejection fraction (LVEF 50.0) suggest impaired cardiac function. However, the absence of troponin elevation (0.5 ng/mL) suggests that the patient does not have acute myocardial infarction. 

Given the presence of multiple comorbidities, the patient is at risk for cardiac arrhythmias. The ECG shows ventricular extrasystole, which may be related to the cardiomyopathy. However, the patient is not at high risk for ventricular tachycardia or other life-threatening arrhythmias. The patient's hemoglobin level (120.0 g/L) is slightly elevated, which may be related to anemia or polycythemia. 

The patient is already on medications for hypertension, heart failure, and arrhythmias, which suggests that the patient is receiving adequate medical therapy. 

Given the above factors, the patient's overall prognosis is that they are likely to survive for the next few years, assuming no significant worsening of their condition.

2. Sudden cardiac death
REASONING: 

While the patient is at high risk for cardiovascular events, the absence of troponin elevation and the presence of medications for hypertension and arrhythmias reduce the likelihood of sudden cardiac death. However, the patient's age (74 years) and NYHA Class II status increase the risk of cardiac events. The patient's LVEF is also reduced, which may increase the risk of arrhythmias and sudden cardiac death. 

The patient's ECG shows ventricular extrasystole, which may be related to the cardiomyopathy, but it is not a clear indication of sudden cardiac death. The patient's blood pressure is elevated, which may increase the risk of cardiac events. However, the patient is already on medications for hypertension, which may help to mitigate this risk.

3. Pump failure death
REASONING: 

Given the patient's reduced LVEF (50.0), impaired cardiac function, and NYHA Class II status, pump failure is a possible complication. However, the patient is already on medications for heart failure, including loop diuretics, which suggests that the patient is receiving adequate medical therapy. The patient's hemoglobin level is slightly elevated, which may be related to anemia or polycythemia, but it is not a clear indication of pump failure.

Additionally, the patient's ECG shows ventricular extrasystole, which may be related to the cardiomyopathy, but it is not a clear indication of pump failure. The patient's blood pressure is elevated, which may increase the risk of cardiac events, but the patient is already on medications for hypertension, which may help to mitigate this risk.

In conclusion, while pump failure is a possible complication, the patient's current medical therapy and ECG findings do not suggest that pump failure is the most likely outcome."
145,145,P0237,"Age: 54
Gender: Male 
Weight: 92 kg
Height: 177 cm
NYHA Class: II
Blood Pressure: 120/70 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Hypertension, Myocardial Infarction
Albumin (g/L): 38
ALT or GPT (IU/L): 27.0
AST or GOT (IU/L): 27.0
Total Cholesterol (mmol/L): 3,78
Creatinine (mmol/L): 194.0
Gamma-glutamil transpeptidase (IU/L): 23
Glucose (mmol/L): 7,4
Hemoglobin (g/L): 141.0
HDL (mmol/L): 0,72
Potassium (mEq/L): 5,1
LDL (mmol/L): 1,03
Sodium (mEq/L): 135.0
Pro-BNP (ng/L): 986.0
Protein (g/L): 69
T3 (pg/dL): 0,05
T4 (ng/L): 15
Troponin (ng/mL): 0,23
TSH (mIU/L): 0,87
Urea (mg/dL): 11,48
LVEF (%): 25.0
Medications: Angiotensin II Receptor Blocker, Beta Blockers, Digoxin, Loop Diuretics, Statins, ACE Inhibitor, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: Second-degree AVB - type I
            ",survivor,"RANKING: 1. Survivor
REASONING: 

The patient has a history of ischemic dilated cardiomyopathy, which is a significant risk factor for cardiac arrhythmias and sudden cardiac death. However, the patient is currently on multiple medications that are commonly used to manage heart failure and arrhythmias, including beta blockers, ACE inhibitors, and digoxin, which may be contributing to the improvement of the patient's condition. The patient's ejection fraction is also relatively preserved at 25%, which is better than the average for someone with heart failure. The presence of ventricular extrasystoles and non-sustained ventricular tachycardia on the ECG is concerning, but the patient's overall clinical status and medication regimen suggest that they are being closely monitored and managed. The patient's age, weight, and other lab values do not indicate any acute or severe underlying conditions that would predict a poor outcome. Overall, the combination of a favorable medication regimen and a relatively preserved ejection fraction suggest that the patient is at low risk for sudden cardiac death in the near future.

RANKING: 2. Sudden Cardiac Death
REASONING: 

The patient's history of ischemic dilated cardiomyopathy, ventricular extrasystoles, and non-sustained ventricular tachycardia on the ECG make them at higher risk for sudden cardiac death. However, the patient's current medication regimen and relatively preserved ejection fraction suggest that they are being closely monitored and managed. The patient's age and weight are also factors to consider, as older adults with heart failure are at increased risk for sudden cardiac death. The patient's laboratory values are not indicative of any acute or severe underlying conditions that would predict a sudden cardiac death in the near future.

RANKING: 3. Pump Failure Death
REASONING: 

The patient's ejection fraction is relatively preserved at 25%, which is better than the average for someone with heart failure. The patient is also on multiple medications that are commonly used to manage heart failure, including ACE inhibitors, beta blockers, and loop diuretics, which suggest that they are being effectively managed. The patient's laboratory values are not indicative of any acute or severe underlying conditions that would predict a rapid decline in cardiac function. However, the patient's history of ischemic dilated cardiomyopathy and ventricular extrasystoles on the ECG suggest that they are at risk for progressive cardiac dysfunction, which could ultimately lead to pump failure. However, given the patient's current clinical status and medication regimen, pump failure is less likely in the near future."
146,146,P0238,"Age: 53
Gender: Male 
Weight: 66 kg
Height: 160 cm
NYHA Class: II
Blood Pressure: 130/50 mmHg
Past Medical History: Hypertensive cardiomyopathy, Hypertension
Albumin (g/L): 27
ALT or GPT (IU/L): 18.0
AST or GOT (IU/L): 21.0
Total Cholesterol (mmol/L): 3,15
Creatinine (mmol/L): 124.0
Gamma-glutamil transpeptidase (IU/L): 48
Glucose (mmol/L): 3,8
Hemoglobin (g/L): 83.0
HDL (mmol/L): 1,14
Potassium (mEq/L): 5,6
LDL (mmol/L): 1,71
Sodium (mEq/L): 138.0
Pro-BNP (ng/L): 137.0
Protein (g/L): 60
T3 (pg/dL): 0,04
T4 (ng/L): 14
Troponin (ng/mL): 0,04
TSH (mIU/L): 2,4
Urea (mg/dL): 11,32
LVEF (%): 55.0
Medications: Beta Blockers, Loop Diuretics, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: TPSV
        - Bradycardia: No
            ",survivor,"RANKING: 1. Survivor
REASONING: 

The patient's age, NYHA Class II, and the presence of hypertension, hypertensive cardiomyopathy, and elevated creatinine levels suggest a significant cardiovascular burden. However, the patient is currently being treated with beta blockers, loop diuretics, and an ACE inhibitor, which are standard treatments for managing hypertension and heart failure. The absence of significant elevations in troponin levels and the presence of a normal LVEF (55.0%) suggest that the patient's cardiac function is not severely compromised.

The patient's ECG findings of ventricular extrasystole and polymorphic ventricular extrasystole may indicate an increased risk of arrhythmias, but the absence of ventricular tachycardia, non-sustained ventricular tachycardia, and paroxysmal supraventricular tachyarrhythmia suggests that the risk of life-threatening arrhythmias is relatively low.

The patient's elevated Pro-BNP levels (137.0 ng/L) and elevated creatinine levels (11.32 mg/dL) suggest some degree of cardiac and renal stress, but the patient is currently being treated for hypertension and heart failure, which should help to manage these conditions.

Given these factors, I predict that the patient is likely to survive for the next few years, provided that their current treatment regimen is continued and adjusted as needed. The patient's age and medical history do carry a risk of cardiovascular events, but the absence of severe cardiac dysfunction, arrhythmias, and other high-risk features suggests that the patient's prognosis is favorable."
147,147,P0240,"Age: 54
Gender: Male 
Weight: 103 kg
Height: 179 cm
NYHA Class: II
Blood Pressure: 130/60 mmHg
Past Medical History: Idiopathic dilated cardiomyopathy, Diabetes
Albumin (g/L): 44
ALT or GPT (IU/L): 137.0
AST or GOT (IU/L): 119.0
Total Cholesterol (mmol/L): 6,62
Creatinine (mmol/L): 106.0
Gamma-glutamil transpeptidase (IU/L): 378
Glucose (mmol/L): 16,8
Hemoglobin (g/L): 149.0
HDL (mmol/L): 2,22
Potassium (mEq/L): 4,9
LDL (mmol/L): 3,9
Sodium (mEq/L): 142.0
Pro-BNP (ng/L): 18.0
Protein (g/L): 84
T3 (pg/dL): 0,06
T4 (ng/L): 16
Troponin (ng/mL): 0,04
TSH (mIU/L): 1,47
Urea (mg/dL): 8,32
LVEF (%): 45.0
Medications: Diabetes Medication, Beta Blockers, Digoxin, Loop Diuretics, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"RANKING: 1. Survivor
REASONING: 

The patient's current data indicates a severe impairment of cardiac function, with a left ventricular ejection fraction (LVEF) of 45.0%, which is significantly below the normal range. This suggests that the patient's heart is unable to pump efficiently, leading to potential complications such as heart failure. The presence of idiopathic dilated cardiomyopathy, diabetes, and elevated creatinine levels further exacerbate the cardiac strain.

The patient's ECG shows a history of ventricular extrasystole, which may indicate an increased risk of arrhythmias. However, the absence of ventricular tachycardia or non-sustained ventricular tachycardia reduces this risk.

The patient's electrolyte levels, including low potassium (4.9 mEq/L) and high troponin (0.04 ng/mL), suggest potential cardiac stress and muscle damage. However, these findings do not seem to be directly related to an acute cardiac event.

Considering the patient's overall clinical picture, the presence of multiple comorbidities, and the severe impairment of cardiac function, the most likely outcome for the next few years is a prolonged survival. The patient's current treatment regimen, which includes medications for diabetes, beta blockers, digoxin, loop diuretics, and an ACE inhibitor, is aimed at managing the patient's symptoms and slowing the progression of the disease.

While there is a risk of sudden cardiac death due to arrhythmias or cardiac events, the patient's current ECG findings and the absence of ventricular tachycardia or non-sustained ventricular tachycardia suggest that this risk is moderate. Pump failure death is also a concern, given the patient's severe impairment of cardiac function, but the patient is currently receiving medications to manage symptoms and slow disease progression.

Overall, based on the patient's clinical presentation, the most likely outcome for the next few years is a prolonged survival, with a moderate risk of arrhythmias and a lower risk of pump failure death."
148,148,P0241,"Age: 35
Gender: Female 
Weight: 76 kg
Height: 150 cm
NYHA Class: II
Blood Pressure: 115/80 mmHg
Past Medical History: Idiopathic dilated cardiomyopathy
Albumin (g/L): 46
ALT or GPT (IU/L): 33.0
AST or GOT (IU/L): 25.0
Total Cholesterol (mmol/L): 6,15
Creatinine (mmol/L): 88.0
Gamma-glutamil transpeptidase (IU/L): 39
Glucose (mmol/L): 5,8
Hemoglobin (g/L): 134.0
HDL (mmol/L): 0,75
Potassium (mEq/L): 4,2
LDL (mmol/L): 4,47
Sodium (mEq/L): 142.0
Pro-BNP (ng/L): 35070.0
Protein (g/L): 79
T3 (pg/dL): 0,05
T4 (ng/L): 16
Troponin (ng/mL): 0,01
TSH (mIU/L): 1,32
Urea (mg/dL): 3,16
LVEF (%): 50.0
Medications: Angiotensin II Receptor Blocker, Beta Blockers, Loop Diuretics, Spironolactone
ECG Impression:
        - Ventricular Extrasystole: No
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"RANKING: 1. Survivor
REASONING: The patient is a 35-year-old female with a history of idiopathic dilated cardiomyopathy, which is a significant risk factor for adverse outcomes. However, the patient's NYHA Class II indicates that the disease is not severely limiting her physical activity. The patient's hemoglobin level is within the normal range, and her kidney function, as indicated by the creatinine level, is not severely impaired. The patient's LVEF is 50.0%, which is relatively preserved, and her ECG impression does not show any signs of arrhythmias or other significant cardiac abnormalities.

The patient's laboratory results show some abnormalities, including an elevated troponin level (0.01 ng/mL), which is a marker of cardiac damage. However, this level is within the normal range for the laboratory, and the patient's overall clinical picture suggests that the damage is likely minimal. The patient's lipid profile is also somewhat elevated, with high LDL and total cholesterol levels, but this is not uncommon in patients with cardiomyopathy.

The patient is taking medications that are commonly used in the management of heart failure and cardiomyopathy, including an angiotensin II receptor blocker, beta blockers, loop diuretics, and spironolactone. These medications are likely to be effective in managing the patient's symptoms and slowing the progression of the disease.

Overall, based on the patient's clinical presentation, laboratory results, and treatment history, I predict that the patient is most likely to survive for the next few years. The patient's condition is not extremely severe, and she is receiving appropriate treatment, which suggests that she will be able to manage her symptoms and maintain a good quality of life."
149,149,P0244,"Age: 36
Gender: Male 
Weight: 94 kg
Height: 174 cm
NYHA Class: II
Blood Pressure: 120/80 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Myocardial Infarction
Albumin (g/L): 42
ALT or GPT (IU/L): 49.0
AST or GOT (IU/L): 24.0
Total Cholesterol (mmol/L): 4,78
Creatinine (mmol/L): 88.0
Gamma-glutamil transpeptidase (IU/L): 53
Glucose (mmol/L): 4,4
Hemoglobin (g/L): 139.0
HDL (mmol/L): 0,93
Potassium (mEq/L): 4,2
LDL (mmol/L): 3,28
Sodium (mEq/L): 138.0
Pro-BNP (ng/L): 164.0
Protein (g/L): 79
T3 (pg/dL): 0,02
T4 (ng/L): 21
Troponin (ng/mL): 0,01
TSH (mIU/L): 2,41
Urea (mg/dL): 4,82
LVEF (%): 43.0
Medications: None reported.
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"RANKING: 1. Survivor

REASONING: 

This patient has several factors that suggest a favorable prognosis:

1. Age: At 36 years old, the patient is still relatively young, which is a significant factor in determining cardiac outcomes.
2. NYHA Class II: The patient's heart failure classification indicates mild symptoms, which suggests that the disease is not severely impacting daily activities.
3. Low creatinine level (88.0 mmol/L): Elevated creatinine levels are often associated with poor cardiac function and reduced survival. The patient's level is within the normal range.
4. Low troponin level (0.01 ng/mL): Elevated troponin levels are often indicative of cardiac damage, such as myocardial infarction. The patient's level is within normal limits, suggesting minimal cardiac damage.
5. Low BNP (Pro-BNP) level (164.0 ng/L): Elevated BNP levels are often associated with heart failure and increased mortality risk. The patient's level is within normal limits.
6. No reported medications: The patient is not on any medications that could be contributing to a poor prognosis.

While the patient has a history of ischemic dilated cardiomyopathy and myocardial infarction, the overall clinical picture suggests that the disease is not as advanced as it could be, given the patient's age and the absence of severe symptoms. Therefore, the most likely outcome is that the patient will survive.

While there is a risk of sudden cardiac death, this is not the most likely outcome based on the available data. The patient's ECG did show ventricular extrasystole, but this is a relatively common finding in patients with cardiac disease and is not necessarily indicative of an increased risk of sudden cardiac death.

Pump failure death is also less likely, given the patient's relatively preserved LVEF (43.0%) and low creatinine level. The patient's ventricular function is not severely impaired, and the patient is not on medications that could be contributing to a poor prognosis."
150,150,P0247,"Age: 72
Gender: Male 
Weight: 67 kg
Height: 166 cm
NYHA Class: II
Blood Pressure: 120/60 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Diabetes, Dyslipemia, Hypertension
Albumin (g/L): 46
ALT or GPT (IU/L): 49.0
AST or GOT (IU/L): 33.0
Total Cholesterol (mmol/L): 4,42
Creatinine (mmol/L): 115.0
Gamma-glutamil transpeptidase (IU/L): 19
Glucose (mmol/L): 7,3
Hemoglobin (g/L): 146.0
HDL (mmol/L): 1,06
Potassium (mEq/L): 5
LDL (mmol/L): 2,64
Sodium (mEq/L): 139.0
Pro-BNP (ng/L): 455.0
Protein (g/L): 82
T3 (pg/dL): 0,04
T4 (ng/L): 25
Troponin (ng/mL): 0,01
TSH (mIU/L): 2,27
Urea (mg/dL): 11,15
LVEF (%): 34.0
Medications: Calcium Channel Blocker, Diabetes Medication, Digoxin, Loop Diuretics, Spironolactone, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: TPSV
        - Bradycardia: No
            ",survivor,"RANKING: 
1. Survivor
REASONING: 
Given the patient's age, NYHA Class II, and the presence of ischemic dilated cardiomyopathy, Diabetes, Dyslipemia, and Hypertension, the patient is already at an increased risk of cardiovascular events. However, the patient's current LVEF of 34.0 indicates that the heart is still functioning to some extent, which is a positive prognostic factor.

The patient's laboratory results show elevated creatinine levels (115.0) and a low albumin level (46 g/L), which may indicate renal impairment, a common complication in patients with heart failure. The elevated Pro-BNP level (455.0) suggests significant cardiac stress, but it is not indicative of acute heart failure.

The ECG findings of ventricular extrasystole and polymorphic ventricular tachycardia are concerning, but the absence of ventricular tachycardia or bradycardia is a positive sign. The presence of paroxysmal supraventricular tachyarrhythmia (PSVT) is a common finding in patients with heart failure.

The patient is currently taking multiple medications, including a calcium channel blocker, ACE inhibitor, and digoxin, which are standard treatments for heart failure and arrhythmias. The presence of spironolactone and loop diuretics also suggests that the patient is receiving appropriate management for fluid overload and electrolyte imbalance.

Considering these factors, the patient's overall prognosis is more favorable than the other two options. The patient's cardiac function is compromised, but it is not severely impaired, and the patient is receiving appropriate treatment for their condition. Therefore, the most likely outcome is survival.

The second most likely outcome is pump failure death, as the patient's LVEF is significantly reduced, and the patient has a history of ischemic dilated cardiomyopathy, which can lead to progressive heart failure. However, the patient's current treatment regimen and the absence of acute heart failure symptoms suggest that the patient is not in immediate danger of pump failure.

The least likely outcome is sudden cardiac death, as the patient's ECG findings do not indicate a high risk for life-threatening arrhythmias, and the patient is receiving appropriate treatment for their arrhythmias. While the patient has a history of ventricular extrasystole and polymorphic ventricular tachycardia, these findings are not indicative of a high risk for sudden cardiac death."
151,151,P0249,"Age: 48
Gender: Male 
Weight: 65 kg
Height: 162 cm
NYHA Class: II
Blood Pressure: 200/100 mmHg
Past Medical History: Toxic dilated cardiomyopathy
Albumin (g/L): 43
ALT or GPT (IU/L): 61.0
AST or GOT (IU/L): 30.0
Total Cholesterol (mmol/L): 6,75
Creatinine (mmol/L): 88.0
Gamma-glutamil transpeptidase (IU/L): 194
Glucose (mmol/L): 6,8
Hemoglobin (g/L): 150.0
HDL (mmol/L): 0,98
Potassium (mEq/L): 3,6
LDL (mmol/L): 4,14
Sodium (mEq/L): 140.0
Pro-BNP (ng/L): 320.0
Protein (g/L): 79
T3 (pg/dL): 0,03
T4 (ng/L): 22
Troponin (ng/mL): 0,01
TSH (mIU/L): 2,21
Urea (mg/dL): 3,66
LVEF (%): 44.0
Medications: Angiotensin II Receptor Blocker, Beta Blockers, Digoxin, Loop Diuretics
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"RANKING: 1. Survivor
REASONING: 

The patient's current condition and medical history suggest a high risk of cardiac complications, but the patient is already receiving treatment with medications for heart failure (Angiotensin II Receptor Blocker, Beta Blockers, Digoxin, and Loop Diuretics). The presence of ventricular extrasystoles and polymorphic ventricular extrasystoles on the ECG may indicate an increased risk of arrhythmias, but the absence of sustained ventricular tachycardia and other arrhythmias suggests that the patient's cardiac function is still relatively preserved. 

The patient's NYHA Class II classification indicates moderate symptoms of heart failure, but the patient is still able to perform daily activities without severe limitation. The elevated troponin level (0.01 ng/mL) suggests some myocardial damage, but it is not indicative of acute coronary syndrome. The patient's LVEF (44%) is significantly reduced, indicating impaired cardiac function, but it is not severely impaired.

The patient's laboratory results show elevated creatinine levels (88.0 mmol/L), indicating impaired renal function, which is a common comorbidity in patients with heart failure. However, the patient's electrolyte levels are relatively stable, and the patient is receiving medications to manage these conditions.

Given these factors, I believe that the patient is most likely to survive in the short term, as they are receiving appropriate treatment for their heart failure and other comorbidities, and their cardiac function, while impaired, is not severely compromised. 

RANKING: 2. Sudden cardiac death
REASONING: 

While the patient's cardiac function is impaired, and they have a history of toxic dilated cardiomyopathy, the patient is receiving treatment for heart failure and other comorbidities. The absence of sustained ventricular tachycardia and other arrhythmias on the ECG suggests that the patient's cardiac function is relatively stable. However, the patient's elevated troponin level (0.01 ng/mL) and reduced LVEF (44%) indicate some myocardial damage, which could potentially lead to arrhythmias and sudden cardiac death.

The patient's elevated creatinine levels (88.0 mmol/L) and elevated gamma-glutamil transpeptidase (194 IU/L) suggest impaired renal function and liver dysfunction, respectively, which can contribute to the development of arrhythmias and sudden cardiac death. However, these factors are not sufficient to guarantee sudden cardiac death.

RANKING: 3. Pump failure death
REASONING: 

The patient's impaired cardiac function, elevated troponin level (0.01 ng/mL), and reduced LVEF (44%) indicate a high risk of pump failure. The patient's NYHA Class II classification suggests moderate symptoms of heart failure, which can lead to pump failure. The patient's elevated creatinine levels (88.0 mmol/L) and elevated gamma-glutamil transpeptidase (194 IU/L) suggest impaired renal function, which can exacerbate heart failure and lead to pump failure.

While the patient is receiving treatment for heart failure, their cardiac function is not well-compensated, and the patient's elevated troponin level and reduced LVEF suggest a high risk of pump failure. However, the patient's electrolyte levels are relatively stable, and the patient is receiving medications to manage these conditions. Given the patient's high-risk profile, I believe that pump failure is a possible but less likely outcome compared to sudden cardiac death."
152,152,P0252,"Age: 73
Gender: Male 
Weight: 83 kg
Height: 165 cm
NYHA Class: III
Blood Pressure: 130/70 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Diabetes, Dyslipemia, Hypertension, Myocardial Infarction
Albumin (g/L): 41
ALT or GPT (IU/L): 33.0
AST or GOT (IU/L): 11.0
Total Cholesterol (mmol/L): 3,03
Creatinine (mmol/L): 88.0
Gamma-glutamil transpeptidase (IU/L): 31
Glucose (mmol/L): 8,3
Hemoglobin (g/L): 136.0
HDL (mmol/L): 0,91
Potassium (mEq/L): 4,6
LDL (mmol/L): 1,94
Sodium (mEq/L): 142.0
Pro-BNP (ng/L): 1070.0
Protein (g/L): 69
T3 (pg/dL): 0,04
T4 (ng/L): 27
Troponin (ng/mL): 0,01
TSH (mIU/L): 2,55
Urea (mg/dL): 6,66
LVEF (%): 38.0
Medications: Calcium Channel Blocker, Diabetes Medication, Angiotensin II Receptor Blocker, Statins
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"RANKING: 
1. Survivor
2. Sudden cardiac death
3. Pump failure death

REASONING:

The patient's data suggests a high risk for adverse outcomes, but the primary determinant of their prognosis is their current functional status, as indicated by their New York Heart Association (NYHA) Class III classification, which signifies severe limitation of physical activity due to heart failure symptoms. This classification is associated with a higher risk of mortality and morbidity.

The patient's left ventricular ejection fraction (LVEF) of 38% is significantly reduced, indicating poor cardiac function. However, their current medication regimen, which includes a calcium channel blocker, diabetes medication, angiotensin II receptor blocker, and statins, suggests that their cardiovascular risk factors are being adequately managed.

The elevated troponin level (0.01 ng/mL) may indicate some degree of cardiac damage, but it is not excessively high. The absence of ventricular tachycardia or non-sustained ventricular tachycardia on the ECG reduces the risk of sudden cardiac death.

The patient's elevated BNP levels (1070 ng/L) and elevated creatinine (66.6 mg/dL) suggest some degree of cardiac dysfunction and renal impairment, respectively. However, the presence of these biomarkers does not necessarily imply a high risk of pump failure death.

Considering these factors, the patient's overall prognosis is most likely to be a survivor, as their functional status and current medication regimen suggest that they are being adequately managed for their cardiovascular risk factors. Sudden cardiac death and pump failure death are possible but less likely outcomes given the patient's current clinical status."
153,153,P0253,"Age: 59
Gender: Female 
Weight: 80 kg
Height: 172 cm
NYHA Class: II
Blood Pressure: 110/75 mmHg
Past Medical History: Idiopathic dilated cardiomyopathy
Albumin (g/L): 43
ALT or GPT (IU/L): 18.0
AST or GOT (IU/L): 26.0
Total Cholesterol (mmol/L): 5,04
Creatinine (mmol/L): 106.0
Gamma-glutamil transpeptidase (IU/L): 16
Glucose (mmol/L): 5,6
Hemoglobin (g/L): 125.0
HDL (mmol/L): 1,14
Potassium (mEq/L): 4,4
LDL (mmol/L): 3,26
Sodium (mEq/L): 144.0
Pro-BNP (ng/L): 824.0
Protein (g/L): 71
T3 (pg/dL): 0,05
T4 (ng/L): 16
Troponin (ng/mL): 0,005
TSH (mIU/L): 3,37
Urea (mg/dL): 7,32
LVEF (%): 40.0
Medications: Angiotensin II Receptor Blocker, Beta Blockers, Digoxin, Loop Diuretics, Spironolactone
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: TPSV
        - Bradycardia: No
            ",survivor,"RANKING: 1. Survivor 
REASONING: 
Based on the patient data, I would rank the patient as a survivor for the next few years. The patient's age, NYHA Class II, and the presence of idiopathic dilated cardiomyopathy indicate a significant underlying cardiac condition. However, the patient's hemoglobin level is within the normal range, and the liver enzymes (ALT and AST) are also within the normal range, suggesting that the patient does not have significant liver dysfunction.

The patient's LVEF is 40%, which indicates left ventricular dysfunction, but the patient is on medications that are commonly used to manage heart failure, such as Angiotensin II Receptor Blocker, Beta Blockers, Digoxin, Loop Diuretics, and Spironolactone. These medications can help manage symptoms and slow disease progression.

The ECG findings of ventricular extrasystole, polymorphic ventricular tachycardia, and non-sustained ventricular tachycardia are concerning, but the patient is already being treated for these conditions. The presence of paroxysmal supraventricular tachyarrhythmia (PSVT) is also noted, but it is not necessarily a predictor of poor outcomes.

Given the patient's overall health status, medication regimen, and the presence of ventricular extrasystole and non-sustained ventricular tachycardia, I believe that the patient is at moderate to high risk for cardiac events. However, the patient's overall prognosis is still favorable, and with proper management, I predict that the patient will survive for the next few years.

While the patient's creatinine level is elevated, it is not significantly high, and the patient is on medications that can help manage kidney function. The patient's troponin level is also within the normal range, which suggests that there is no significant myocardial infarction.

Overall, while the patient has several cardiac risk factors and ECG findings, the patient's overall health status and medication regimen suggest that the patient is likely to survive for the next few years."
154,154,P0254,"Age: 49
Gender: Male 
Weight: 65 kg
Height: 170 cm
NYHA Class: II
Blood Pressure: 100/50 mmHg
Past Medical History: Enolic dilated cardiomyopathy, Dyslipemia, Hypertension, Myocardial Infarction
Albumin (g/L): 42
ALT or GPT (IU/L): 36.0
AST or GOT (IU/L): 49.0
Total Cholesterol (mmol/L): 5,53
Creatinine (mmol/L): 97.0
Gamma-glutamil transpeptidase (IU/L): 465
Glucose (mmol/L): 5,2
Hemoglobin (g/L): 166.0
HDL (mmol/L): 1,27
Potassium (mEq/L): 4,3
LDL (mmol/L): 3,1
Sodium (mEq/L): 144.0
Pro-BNP (ng/L): 194.0
Protein (g/L): 71
T3 (pg/dL): 0,04
T4 (ng/L): 18
Troponin (ng/mL): 0,005
TSH (mIU/L): 1,38
Urea (mg/dL): 5,99
LVEF (%): 23.0
Medications: Beta Blockers, Digoxin, Loop Diuretics, Spironolactone, Statins, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"RANKING: 1. Survivor
REASONING:

The patient's prognosis is most likely to be a survivor due to the following reasons:

1. The patient's age (49 years) is still considered relatively young for a significant cardiac event, although they have a history of multiple comorbidities, including dilated cardiomyopathy, hypertension, and myocardial infarction.
2. The patient's NYHA Class II indicates that they have some limitation in physical activity, but they are not severely limited.
3. The patient's hemoglobin level (16.6 g/dL) is within the normal range, indicating adequate oxygenation and hemoglobin levels.
4. The patient's troponin level (0.005 ng/mL) is within the normal range, indicating no acute myocardial infarction.
5. The patient's LVEF (23.0%) is significantly reduced, but not severely impaired, suggesting some residual cardiac function.
6. The patient's ECG impression does not show any life-threatening arrhythmias, which is a positive sign.
7. The patient is on multiple medications, including beta blockers, which are known to improve survival in patients with heart failure and reduce the risk of sudden cardiac death.

While the patient's comorbidities and reduced LVEF increase the risk of cardiac events, the absence of acute myocardial infarction, normal hemoglobin levels, and the presence of beta blockers suggest that the patient's prognosis is more favorable than the other two options.

RANKING: 2. Sudden Cardiac Death
REASONING:

The patient's prognosis is less likely to be sudden cardiac death due to the following reasons:

1. The patient's reduced LVEF (23.0%) and NYHA Class II indicate some cardiac dysfunction, but it is not severely impaired.
2. The patient's troponin level (0.005 ng/mL) is within the normal range, indicating no acute myocardial infarction.
3. The patient's ECG impression does not show any life-threatening arrhythmias.
4. The patient is on beta blockers, which are known to reduce the risk of sudden cardiac death.

However, the patient's history of myocardial infarction, dilated cardiomyopathy, and hypertension increases the risk of cardiac events, including sudden cardiac death.

RANKING: 3. Pump Failure Death
REASONING:

The patient's prognosis is least likely to be pump failure death due to the following reasons:

1. The patient's LVEF (23.0%) is not severely impaired, suggesting some residual cardiac function.
2. The patient's NYHA Class II indicates that they have some limitation in physical activity, but they are not severely limited.
3. The patient's hemoglobin level (16.6 g/dL) is within the normal range, indicating adequate oxygenation and hemoglobin levels.
4. The patient's troponin level (0.005 ng/mL) is within the normal range, indicating no acute myocardial infarction.
5. The patient is on multiple medications, including beta blockers, which are known to improve survival in patients with heart failure.

However, the patient's reduced LVEF and NYHA Class II indicate some cardiac dysfunction, and the patient's comorbidities, including dilated cardiomyopathy and hypertension, increase the risk of cardiac events."
155,155,P0255,"Age: 41
Gender: Male 
Weight: 81 kg
Height: 174 cm
NYHA Class: II
Blood Pressure: 140/80 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Diabetes, Dyslipemia, Myocardial Infarction
Albumin (g/L): 38
ALT or GPT (IU/L): 26.0
AST or GOT (IU/L): 20.0
Total Cholesterol (mmol/L): 4,63
Creatinine (mmol/L): 106.0
Gamma-glutamil transpeptidase (IU/L): 25
Glucose (mmol/L): 13,3
Hemoglobin (g/L): 129.0
HDL (mmol/L): 0,91
Potassium (mEq/L): 4
LDL (mmol/L): 3,88
Sodium (mEq/L): 130.0
Protein (g/L): 68
T3 (pg/dL): 0,02
T4 (ng/L): 20
Troponin (ng/mL): 0,01
TSH (mIU/L): 3,28
Urea (mg/dL): 6,66
LVEF (%): 35.0
Medications: Diabetes Medication, Angiotensin II Receptor Blocker, Beta Blockers, Loop Diuretics, Spironolactone, Statins
ECG Impression:
        - Ventricular Extrasystole: No
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"RANKING: 1. Survivor 
REASONING: 

The patient is a 41-year-old male with a significant history of ischemic dilated cardiomyopathy, which is a condition where the heart muscle is weakened and cannot pump blood effectively. This condition is a major risk factor for cardiac events such as sudden cardiac death and pump failure. However, the patient's current NYHA Class II indicates that they are able to perform moderate physical activity without significant symptoms, suggesting that they are not in a terminal stage of their condition.

The patient's blood test results show elevated creatinine levels, indicating impaired kidney function, which can be a complication of heart failure. However, the patient's LVEF (left ventricular ejection fraction) is 35%, which is relatively low, indicating that the heart is not pumping blood efficiently.

The patient is on multiple medications, including beta blockers, which are commonly used to treat heart failure and prevent sudden cardiac death. The patient's ECG results are also normal, with no signs of arrhythmias or other cardiac abnormalities.

Given the patient's age, medical history, and current condition, the most likely outcome for the next few years is that the patient will survive. However, the patient's impaired kidney function and low LVEF suggest that they may experience a decline in their cardiac function over time, potentially leading to pump failure.

RANKING: 2. Pump failure death 
REASONING: 

The patient's impaired kidney function and low LVEF make them susceptible to pump failure, which is a life-threatening complication of heart failure. Pump failure occurs when the heart is unable to pump enough blood to meet the body's needs, leading to decreased blood flow to vital organs.

While the patient is currently alive, their condition is not stable, and their heart is not pumping efficiently. The patient's elevated creatinine levels and low LVEF suggest that their heart function is declining, increasing the risk of pump failure.

RANKING: 3. Sudden cardiac death 
REASONING: 

The patient's history of ischemic dilated cardiomyopathy and elevated troponin levels suggest that they are at risk for cardiac events, including sudden cardiac death. Sudden cardiac death occurs when the heart suddenly stops beating, often due to a fatal arrhythmia.

However, the patient's current ECG results are normal, and they are not taking any medications that increase the risk of arrhythmias. The patient's low LVEF and impaired kidney function also suggest that they are at risk for cardiac events, but the presence of these factors does not necessarily mean that sudden cardiac death is the most likely outcome.

Given the patient's overall condition and the presence of multiple risk factors, while it is a possibility, the other two options seem less likely than the survivor prognosis."
156,156,P0257,"Age: 76
Gender: Male 
Weight: 84 kg
Height: 165 cm
NYHA Class: III
Blood Pressure: 105/55 mmHg
Past Medical History: Other HF etiology, Dyslipemia, Myocardial Infarction
Albumin (g/L): 41
ALT or GPT (IU/L): 33.0
AST or GOT (IU/L): 21.0
Total Cholesterol (mmol/L): 7,73
Creatinine (mmol/L): 133.0
Gamma-glutamil transpeptidase (IU/L): 29
Glucose (mmol/L): 4,9
Hemoglobin (g/L): 120.0
HDL (mmol/L): 1,4
Potassium (mEq/L): 4,6
LDL (mmol/L): 5,79
Sodium (mEq/L): 140.0
Pro-BNP (ng/L): 1876.0
Protein (g/L): 68
T3 (pg/dL): 0,02
T4 (ng/L): 25
Troponin (ng/mL): 0,01
TSH (mIU/L): 0,44
Urea (mg/dL): 7,15
LVEF (%): 42.0
Medications: Beta Blockers, Loop Diuretics, Spironolactone, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",survivor,"RANKING: 1. Survivor
REASONING: 

This patient is likely to survive for the next few years due to the following reasons:

1. Age: Although the patient is 76 years old, the age itself is not a significant risk factor for mortality. Many people live well into their 80s and beyond with proper management.

2. Medications: The patient is on multiple medications, including beta blockers, loop diuretics, spironolactone, and ACE inhibitors, which are commonly used to manage heart failure, hypertension, and dyslipidemia. These medications help to slow the progression of heart disease and improve symptoms.

3. Low ECG Impression: The ECG results show no signs of ventricular tachycardia, non-sustained ventricular tachycardia, or paroxysmal supraventricular tachyarrhythmia, which are all potential causes of sudden cardiac death.

4. Low Troponin: The troponin level is normal, which suggests that there is no significant myocardial infarction or damage to the heart muscle.

5. Normal Hemoglobin and Hematocrit: The patient's hemoglobin and hematocrit levels are within the normal range, indicating that the patient does not have anemia, which can increase the risk of mortality.

6. Low Creatinine: The patient's creatinine level is within the normal range, indicating that the patient's kidney function is not severely impaired.

7. Low Pro-BNP: The pro-BNP level is elevated, but not excessively high, indicating that the patient's heart is not failing significantly.

However, the patient's NYHA Class III indicates that the patient has severe heart failure, and the patient's LVEF is 42%, which is below the normal range. These factors may indicate that the patient's heart is not functioning optimally, but they do not necessarily predict a poor outcome.

Overall, considering the patient's age, medications, ECG results, and laboratory values, the patient is likely to survive for the next few years with proper management and monitoring."
157,157,P0258,"Age: 59
Gender: Male 
Weight: 80 kg
Height: 173 cm
NYHA Class: III
Blood Pressure: 130/80 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Diabetes, Dyslipemia, Peripheral vascular disease, Myocardial Infarction
Albumin (g/L): 37
ALT or GPT (IU/L): 39.0
AST or GOT (IU/L): 20.0
Total Cholesterol (mmol/L): 3,03
Creatinine (mmol/L): 239.0
Gamma-glutamil transpeptidase (IU/L): 58
Glucose (mmol/L): 4,7
Hemoglobin (g/L): 108.0
HDL (mmol/L): 0,39
Potassium (mEq/L): 4,6
LDL (mmol/L): 1,91
Sodium (mEq/L): 135.0
Pro-BNP (ng/L): 709.0
Protein (g/L): 72
T3 (pg/dL): 0,03
T4 (ng/L): 20
Troponin (ng/mL): 0,01
TSH (mIU/L): 2,01
Urea (mg/dL): 20,3
LVEF (%): 48.0
Medications: Diabetes Medication, Beta Blockers, Loop Diuretics, Statins, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"RANKING: 1. Survivor
REASONING: The patient has a history of ischemic dilated cardiomyopathy, which is a significant risk factor for adverse outcomes. However, the patient has been managed with medications, including ACE inhibitors and beta blockers, which are standard treatments for heart failure. The patient's ejection fraction (LVEF) is 48%, which is below the normal range, indicating some degree of left ventricular dysfunction. Despite this, the patient has a relatively stable ECG impression with no ventricular tachycardia or ventricular extrasystoles, which are indicators of more severe cardiac arrhythmias. The patient's renal function is also preserved, as indicated by a creatinine level of 20.3 mg/dL. The patient's symptoms and test results do not suggest acute decompensation or acute coronary syndrome, which are common causes of sudden cardiac death. Overall, the patient's clinical presentation and laboratory results suggest that the patient is likely to survive the next few years with appropriate management."
158,158,P0259,"Age: 55
Gender: Male 
Weight: 94 kg
Height: 170 cm
NYHA Class: III
Blood Pressure: 180/80 mmHg
Past Medical History: Hypertropic cardiomyopathy, Peripheral vascular disease, Hypertension, Myocardial Infarction
Albumin (g/L): 41
ALT or GPT (IU/L): 35.0
AST or GOT (IU/L): 15.0
Total Cholesterol (mmol/L): 4,97
Creatinine (mmol/L): 88.0
Gamma-glutamil transpeptidase (IU/L): 35
Glucose (mmol/L): 4,9
Hemoglobin (g/L): 161.0
HDL (mmol/L): 0,72
Potassium (mEq/L): 4,5
LDL (mmol/L): 3,65
Sodium (mEq/L): 144.0
Pro-BNP (ng/L): 102.0
Protein (g/L): 69
T3 (pg/dL): 0,02
T4 (ng/L): 20
Troponin (ng/mL): 0,01
TSH (mIU/L): 1,25
Urea (mg/dL): 9,65
LVEF (%): 70.0
Medications: Beta Blockers, Loop Diuretics, Statins, ACE Inhibitor, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"RANKING: 
1. Survivor
REASONING:
The patient's overall health status and test results suggest a relatively stable condition. The patient is 55 years old, with a NYHA Class III heart failure, indicating moderate symptoms. However, the patient's LVEF is 70%, which is within the normal range for a male of this age group. The patient's blood pressure is elevated at 180/80 mmHg, but this is being managed with medications such as beta blockers and ACE inhibitors. The patient's laboratory results show no significant abnormalities in liver function, kidney function, or electrolyte levels.

The patient's ECG impression shows no signs of ventricular tachycardia or non-sustained ventricular tachycardia, which are potential predictors of sudden cardiac death. The patient is also not experiencing bradycardia, which can be a sign of heart failure or cardiac conduction problems.

Given these factors, the patient's overall prognosis is likely to be a survivor, with a moderate risk of heart-related complications. However, regular monitoring and follow-up appointments will be necessary to ensure the patient's condition does not deteriorate.

The patient's past medical history of hypertension, myocardial infarction, and peripheral vascular disease increases the risk of cardiovascular events, but the patient is already being managed with medications to control these conditions. The patient's age and sex also make them a candidate for cardiac rehabilitation and lifestyle modifications to reduce the risk of future cardiovascular events.

The remaining prognoses, sudden cardiac death and pump failure, are less likely due to the patient's stable ECG, normal LVEF, and controlled blood pressure. However, the patient's NYHA Class III status and elevated blood pressure may increase the risk of heart failure exacerbation, and regular monitoring will be necessary to ensure the patient's condition does not deteriorate."
159,159,P0267,"Age: 42
Gender: Female 
Weight: 78 kg
Height: 160 cm
NYHA Class: III
Blood Pressure: 130/90 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Diabetes, Hypertension, Myocardial Infarction
Albumin (g/L): 37,4
ALT or GPT (IU/L): 15.0
AST or GOT (IU/L): 22.0
Total Cholesterol (mmol/L): 3,13
Creatinine (mmol/L): 84.0
Gamma-glutamil transpeptidase (IU/L): 162
Glucose (mmol/L): 19,7
Hemoglobin (g/L): 125.0
HDL (mmol/L): 0,58
Potassium (mEq/L): 3,95
LDL (mmol/L): 1,96
Sodium (mEq/L): 133.0
Pro-BNP (ng/L): 2237.0
Protein (g/L): 71,8
Troponin (ng/mL): 0,01
TSH (mIU/L): 2,22
Urea (mg/dL): 14,99
LVEF (%): 28.0
Medications: Diabetes Medication, Angiotensin II Receptor Blocker, Loop Diuretics, Spironolactone, ACE Inhibitor, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: Sinus Node Dysfunction
            ",survivor,"RANKING: 
1. Survivor
REASONING:
The patient is currently classified as a survivor, which indicates that the patient has not yet experienced a significant cardiac event such as sudden cardiac death or pump failure. The patient's past medical history of ischemic dilated cardiomyopathy, diabetes, hypertension, and myocardial infarction suggests a high risk of future cardiac events. However, the patient is currently receiving medications that are aimed at managing these conditions, including an ACE inhibitor, spironolactone, and a nitrovasodilator, which can help reduce the risk of cardiac events.

The patient's laboratory results, such as elevated troponin levels and a low LVEF, indicate some degree of cardiac dysfunction. However, the patient's hemoglobin level is within a relatively normal range, and the absence of severe anemia could suggest that the patient's cardiac function is not significantly compromised at this time.

The ECG results show evidence of ventricular extrasystoles, non-sustained ventricular tachycardia, and sinus node dysfunction, which are all potential markers of cardiac arrhythmia and instability. However, the patient's current ECG results do not indicate any acute cardiac events, and the presence of non-sustained ventricular tachycardia may be a transient finding.

Considering the above factors, the patient's current prognosis is more favorable, and it is more likely that the patient will survive in the short term. However, close monitoring and further evaluation will be necessary to assess the patient's cardiac function and adjust the treatment plan as needed to minimize the risk of future cardiac events.

The other two prognoses, sudden cardiac death and pump failure, are less likely in this patient at this time, but it is essential to continue monitoring the patient's condition and adjust the treatment plan as needed to minimize the risk of these events."
160,160,P0268,"Age: 76
Gender: Female 
Weight: 71 kg
Height: 151 cm
NYHA Class: II
Blood Pressure: 120/70 mmHg
Past Medical History: Valvular cardiomyopathy, Diabetes, Dyslipemia, Hypertension
Albumin (g/L): 47,8
ALT or GPT (IU/L): 15.0
AST or GOT (IU/L): 17.0
Total Cholesterol (mmol/L): 5,61
Creatinine (mmol/L): 112.0
Gamma-glutamil transpeptidase (IU/L): 15
Glucose (mmol/L): 5,9
Hemoglobin (g/L): 119.0
HDL (mmol/L): 1,65
Potassium (mEq/L): 4,24
LDL (mmol/L): 3,3
Sodium (mEq/L): 139.0
Protein (g/L): 74,3
Troponin (ng/mL): 0,01
TSH (mIU/L): 1,69
Urea (mg/dL): 11,9
LVEF (%): 30.0
Medications: Diabetes Medication, Beta Blockers, Loop Diuretics, Spironolactone, Statins, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: TPSV
        - Bradycardia: No
            ",survivor,"RANKING: 
1. Survivor
REASONING:
Based on the patient's age (76), NYHA Class II heart failure, and the presence of valvular cardiomyopathy, diabetes, dyslipemia, and hypertension, the patient's prognosis is initially leaning towards a worse outcome. However, the patient's current hemoglobin level (119.0 g/L), which is within the normal range, and the absence of severe elevations in liver enzymes (ALT/GPT: 15.0, AST/GOT: 17.0) suggest that the patient's cardiac function may not be severely compromised at this point.

The patient's LVEF (30.0%) is significantly reduced, indicating some degree of left ventricular dysfunction. However, the patient's blood pressure (120/70 mmHg) is within a relatively normal range, and the absence of severe electrolyte imbalances (e.g., hyperkalemia) reduces the risk of acute cardiac arrhythmias.

The presence of ventricular extrasystoles (polymorphic) and non-sustained ventricular tachycardia (Non-sustained VT) on the ECG suggests some degree of cardiac electrical instability, but the absence of sustained VT or other life-threatening arrhythmias reduces the immediate risk of cardiac arrest. The patient's beta-blocker therapy may help mitigate the risk of arrhythmias.

Given the patient's overall clinical presentation and the absence of severe cardiac dysfunction, the likelihood of sudden cardiac death (prognosis 2) is lower. The risk of pump failure death (prognosis 3) is also lower due to the patient's relatively preserved hemoglobin level and normal blood pressure.

Therefore, based on the available data, the patient's prognosis is most likely to be a survivor."
161,161,P0272,"Age: 80
Gender: Female 
Weight: 76 kg
Height: 152 cm
NYHA Class: II
Blood Pressure: 140/70 mmHg
Past Medical History: Hypertensive cardiomyopathy, Diabetes, Dyslipemia, Hypertension
Albumin (g/L): 43
ALT or GPT (IU/L): 13.0
AST or GOT (IU/L): 20.0
Total Cholesterol (mmol/L): 5,12
Creatinine (mmol/L): 100.0
Gamma-glutamil transpeptidase (IU/L): 23
Glucose (mmol/L): 7,8
Hemoglobin (g/L): 120.0
HDL (mmol/L): 1,29
Potassium (mEq/L): 4,4
LDL (mmol/L): 2,29
Sodium (mEq/L): 138.0
Pro-BNP (ng/L): 918.0
Protein (g/L): 68,6
T3 (pg/dL): 0,0477
T4 (ng/L): 16,39
Troponin (ng/mL): 0,3
TSH (mIU/L): 1,42
Urea (mg/dL): 7,1
LVEF (%): 60.0
Medications: Calcium Channel Blocker, Diabetes Medication, Loop Diuretics, Spironolactone, Statins, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: TPSV
        - Bradycardia: No
            ",survivor,"RANKING: 1. Survivor
REASONING: 
Based on the provided patient data, the patient is an 80-year-old female with a history of hypertension, cardiomyopathy, diabetes, and dyslipidemia. She has a NYHA Class II heart failure and elevated creatinine levels, indicating possible kidney impairment. The patient's LVEF is 60%, which is within the range of normal for her age, but her ECG shows non-sustained ventricular tachycardia and ventricular extrasystole, which are concerning signs of arrhythmias.

The patient's elevated Pro-BNP levels (918 ng/L) and elevated troponin levels (0.3 ng/mL) suggest heart failure and myocardial stress. However, her LVEF is not severely impaired, which might suggest that the patient's heart is still relatively functional.

Given these factors, I rank the patient as having a high likelihood of survival over the next few years. The patient's age and comorbidities do pose significant risks, but the absence of severe symptoms and the relatively preserved LVEF suggest that the patient's heart is still capable of compensating for the underlying conditions.

The presence of non-sustained ventricular tachycardia and ventricular extrasystole on the ECG may require close monitoring and adjustment of medications, but it does not necessarily indicate a high risk of sudden cardiac death. The patient's blood pressure and laboratory results are also relatively well-controlled, which further supports the likelihood of survival.

While there is always a risk of sudden cardiac death, especially in patients with arrhythmias, the combination of the patient's relatively preserved LVEF, controlled blood pressure, and absence of severe symptoms suggests that the patient is at lower risk for sudden cardiac death compared to pump failure death or sudden cardiac death."
162,162,P0273,"Age: 75
Gender: Male 
Weight: 77 kg
Height: 166 cm
NYHA Class: II
Blood Pressure: 120/80 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Dyslipemia, Peripheral vascular disease, Myocardial Infarction
Albumin (g/L): 40
ALT or GPT (IU/L): 17.0
AST or GOT (IU/L): 21.0
Total Cholesterol (mmol/L): 4,65
Creatinine (mmol/L): 84.0
Gamma-glutamil transpeptidase (IU/L): 29
Glucose (mmol/L): 4,2
Hemoglobin (g/L): 130.0
HDL (mmol/L): 1,42
Potassium (mEq/L): 4,54
LDL (mmol/L): 2,87
Sodium (mEq/L): 139.0
Pro-BNP (ng/L): 5435.0
Protein (g/L): 75,199
T3 (pg/dL): 0,0249
T4 (ng/L): 20,99
Troponin (ng/mL): 0,5
TSH (mIU/L): 0,3
Urea (mg/dL): 9,1
LVEF (%): 45.0
Medications: Calcium Channel Blocker, Amiodarone, Beta Blockers, Loop Diuretics, Spironolactone, Statins, ACE Inhibitor, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"RANKING: 1. Survivor
REASONING:

The patient's overall clinical presentation and test results suggest that they are at high risk for adverse cardiac events. However, the patient has been diagnosed as a survivor, indicating that they have not yet experienced a cardiac event.

The patient's age, NYHA Class II, and history of ischemic dilated cardiomyopathy, dyslipidemia, and myocardial infarction increase their risk for cardiac events. However, the patient's current LVEF of 45.0% is relatively preserved, which may indicate that the patient's cardiac function is not severely impaired.

The patient's current medications, including beta blockers, ACE inhibitors, and calcium channel blockers, suggest that they are receiving optimal management for their cardiovascular risk factors. The presence of amiodarone, a class III antiarrhythmic agent, may be used to manage arrhythmias, but it is not the primary treatment for heart failure.

The patient's laboratory results show elevated troponin levels (0.5 ng/mL), which may indicate some degree of cardiac damage or stress. However, the absence of significant elevations in creatinine and urea levels suggests that the patient's renal function is relatively preserved.

The patient's ECG results show ventricular extrasystole, which may be a sign of underlying cardiac stress or ischemia. However, the absence of other arrhythmias or signs of heart failure makes this finding less concerning.

Given the patient's overall clinical presentation and test results, the most likely outcome is that they will survive for the next few years, although the patient will likely require ongoing management and monitoring to prevent further cardiac events. The patient's risk of sudden cardiac death and pump failure death is moderate, but the patient's current management and preserved LVEF suggest that these outcomes are less likely."
163,163,P0274,"Age: 68
Gender: Female 
Weight: 74 kg
Height: 153 cm
NYHA Class: II
Blood Pressure: 170/75 mmHg
Past Medical History: Hypertensive cardiomyopathy, Diabetes, Dyslipemia, Hypertension
Albumin (g/L): 45
ALT or GPT (IU/L): 29.0
AST or GOT (IU/L): 20.0
Total Cholesterol (mmol/L): 4,81
Creatinine (mmol/L): 105.0
Gamma-glutamil transpeptidase (IU/L): 20
Glucose (mmol/L): 7,5
Hemoglobin (g/L): 117.0
HDL (mmol/L): 1,32
Potassium (mEq/L): 3,6
LDL (mmol/L): 1,63
Sodium (mEq/L): 142.0
Pro-BNP (ng/L): 149.0
Protein (g/L): 75
T3 (pg/dL): 0,0267
T4 (ng/L): 18,16
Troponin (ng/mL): 0,3
TSH (mIU/L): 2,4
Urea (mg/dL): 9,2
LVEF (%): 70.0
Medications: Calcium Channel Blocker, Diabetes Medication, Amiodarone, Angiotensin II Receptor Blocker, Digoxin, Loop Diuretics, Statins
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"RANKING: 1. Survivor
REASONING: 
Based on the provided patient data, the patient is 68 years old, with a history of Hypertensive cardiomyopathy, Diabetes, and Dyslipemia, which increases the risk of cardiovascular events. However, the patient has a relatively preserved LVEF of 70%, which suggests that the heart is still functioning relatively well despite the cardiomyopathy. The patient is also on multiple medications for cardiovascular and metabolic conditions, which indicates a well-managed chronic disease.

The patient's ECG impression shows no ventricular tachycardia or non-sustained ventricular tachycardia, which reduces the risk of sudden cardiac death. The presence of ventricular extrasystoles is noted, but it is monomorphic and not sustained, which may not be a significant predictor of cardiac mortality.

The patient's laboratory values show elevated creatinine levels (105.0 mmol/L) and low albumin levels (45 g/L), which may indicate renal impairment and possible malnutrition. However, these findings are not directly related to cardiac function and may be managed with adjustments to medications or lifestyle changes.

Considering these factors, the patient's overall prognosis is relatively good, with a higher likelihood of survival over the next few years. The patient's age and comorbidities do pose a risk, but the presence of well-managed chronic conditions, a relatively preserved LVEF, and the absence of significant cardiac arrhythmias or other concerning ECG findings support a favorable prognosis.

RANKING: 2. Sudden Cardiac Death
REASONING: 
While the patient's age and comorbidities increase the risk of cardiovascular events, the absence of ventricular tachycardia or non-sustained ventricular tachycardia on the ECG and the relatively preserved LVEF suggest that sudden cardiac death is less likely. However, the patient's history of Hypertensive cardiomyopathy and the presence of elevated creatinine levels may still pose a risk for cardiac events.

RANKING: 3. Pump Failure Death
REASONING: 
Pump failure death is a concern for patients with severe cardiomyopathy, particularly those with Hypertensive cardiomyopathy. However, the patient's relatively preserved LVEF of 70% and the absence of other concerning ECG findings suggest that pump failure is not an immediate concern. The patient is also on medications that may help manage cardiomyopathy and heart failure symptoms, such as digoxin and loop diuretics.

While the patient's elevated creatinine levels and low albumin levels may indicate renal impairment, which can be associated with heart failure, these findings are not directly related to cardiac function. Overall, the patient's prognosis is still relatively good, and pump failure death is the least likely outcome."
164,164,P0276,"Age: 37
Gender: Male 
Weight: 103 kg
Height: 177 cm
NYHA Class: II
Blood Pressure: 140/100 mmHg
Past Medical History: Enolic dilated cardiomyopathy, Hypertension
Albumin (g/L): 44
ALT or GPT (IU/L): 10.0
AST or GOT (IU/L): 26.0
Total Cholesterol (mmol/L): 4,27
Creatinine (mmol/L): 116.0
Gamma-glutamil transpeptidase (IU/L): 33
Glucose (mmol/L): 4,9
Hemoglobin (g/L): 139.0
HDL (mmol/L): 1,9
Potassium (mEq/L): 4,06
LDL (mmol/L): 2,36
Sodium (mEq/L): 139.0
Pro-BNP (ng/L): 308.0
Protein (g/L): 79,6
T3 (pg/dL): 0,0402
T4 (ng/L): 15,66
TSH (mIU/L): 0,41
Urea (mg/dL): 6
LVEF (%): 30.0
Medications: Beta Blockers, Loop Diuretics, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: Paroxysmal AVB
            ",survivor,"RANKING: 1. Survivor
REASONING:

The patient's prognosis is classified as a survivor, and this is the most likely outcome due to the following reasons:

1. Age: The patient is 37 years old, which is relatively young for a cardiovascular event, reducing the likelihood of sudden cardiac death.
2. NYHA Class II: The patient's New York Heart Association (NYHA) classification indicates that the patient has moderate symptoms, which suggests that the heart is not severely impaired, increasing the chances of survival.
3. Medications: The patient is currently taking beta blockers, loop diuretics, and ACE inhibitors, which are standard treatments for heart failure and hypertension, indicating that the patient is receiving appropriate management for their conditions.
4. ECG Impression: The absence of ventricular tachycardia, non-sustained ventricular tachycardia, and paroxysmal supraventricular tachyarrhythmia on the ECG suggests that the patient does not have a high risk of arrhythmias that could lead to sudden cardiac death.
5. Biomarkers: The elevated Pro-BNP level (308 ng/L) indicates some degree of heart failure, but it is not excessively high, which may suggest that the patient's heart is still functioning to some extent.
6. Laboratory values: The patient's liver enzymes (ALT and AST) are within normal limits, and the kidney function (Creatinine) is not severely impaired, indicating that the patient does not have significant organ dysfunction.
7. Lipid profile: The patient's lipid profile shows a relatively low LDL level, which is beneficial for cardiovascular health.

While the patient has a history of dilated cardiomyopathy and hypertension, the presence of these conditions does not necessarily dictate a poor prognosis. The patient's current treatment regimen, age, and the absence of high-risk ECG findings and biomarkers suggest that the patient is likely to survive in the short term."
165,165,P0277,"Age: 75
Gender: Male 
Weight: 89 kg
Height: 163 cm
NYHA Class: II
Blood Pressure: 120/60 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Dyslipemia, Myocardial Infarction
Albumin (g/L): 41
ALT or GPT (IU/L): 16.0
AST or GOT (IU/L): 31.0
Total Cholesterol (mmol/L): 4,4
Creatinine (mmol/L): 177.0
Gamma-glutamil transpeptidase (IU/L): 9
Glucose (mmol/L): 4,4
Hemoglobin (g/L): 141.0
HDL (mmol/L): 1,22
Potassium (mEq/L): 4,77
LDL (mmol/L): 2,61
Sodium (mEq/L): 141.0
Pro-BNP (ng/L): 410.0
Protein (g/L): 68,6
T3 (pg/dL): 0,039
T4 (ng/L): 15,86
Troponin (ng/mL): 0,3
TSH (mIU/L): 1,23
Urea (mg/dL): 11,9
LVEF (%): 30.0
Medications: Calcium Channel Blocker, Beta Blockers, Statins, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"RANKING: 

1. Survivor
REASONING: 
The patient has a history of ischemic dilated cardiomyopathy, which is a condition that can lead to heart failure and increased risk of arrhythmias. However, the patient's current LVEF is 30%, which is significantly reduced, indicating a more severe degree of cardiac dysfunction. Despite this, the patient has been taking multiple medications, including beta blockers and ACE inhibitors, which can help reduce the workload on the heart and improve symptoms. The patient's ECG shows ventricular extrasystoles, which can be a sign of cardiac stress, but no other life-threatening arrhythmias are present. The patient's electrolyte levels, including potassium and creatinine, are within relatively normal limits, and the troponin level is low, indicating minimal myocardial damage. The patient's age and weight are also factors that contribute to the overall prognosis, as they are above average, which increases the risk of cardiovascular events. However, the patient's overall clinical presentation and the presence of multiple medications suggest that the patient is likely to survive for at least the next few years with proper management.

2. Sudden cardiac death
REASONING: 
While the patient has a history of ischemic dilated cardiomyopathy, which increases the risk of sudden cardiac death, the patient's current ECG does not show any life-threatening arrhythmias. The patient is also taking multiple medications that can help reduce the risk of arrhythmias. However, the patient's LVEF is significantly reduced, which increases the risk of arrhythmias and sudden cardiac death. The patient's age and weight also contribute to the risk of sudden cardiac death. While the patient's current clinical presentation does not suggest an immediate life-threatening condition, the patient's underlying cardiac condition and age make it difficult to rule out sudden cardiac death as a possible outcome.

3. Pump failure death
REASONING: 
The patient's LVEF is significantly reduced, indicating severe cardiac dysfunction, which increases the risk of pump failure. The patient's age and weight also contribute to the risk of pump failure. However, the patient is taking multiple medications, including ACE inhibitors and beta blockers, which can help reduce the workload on the heart and slow the progression of heart failure. The patient's ECG does not show any life-threatening arrhythmias, and the patient's electrolyte levels are within relatively normal limits. While the patient's cardiac condition is severe, the patient's overall clinical presentation and the presence of multiple medications suggest that the patient may be able to survive for at least a few years with proper management, making pump failure death less likely compared to sudden cardiac death."
166,166,P0278,"Age: 82
Gender: Female 
Weight: 79 kg
Height: 144 cm
NYHA Class: III
Blood Pressure: 160/60 mmHg
Past Medical History: Hypertensive cardiomyopathy, Hypertension
Albumin (g/L): 40
ALT or GPT (IU/L): 29.0
AST or GOT (IU/L): 42.0
Total Cholesterol (mmol/L): 7,06
Creatinine (mmol/L): 115.0
Gamma-glutamil transpeptidase (IU/L): 50
Glucose (mmol/L): 3,9
Hemoglobin (g/L): 130.0
HDL (mmol/L): 1,91
Potassium (mEq/L): 4,47
LDL (mmol/L): 4,22
Sodium (mEq/L): 144.0
Pro-BNP (ng/L): 710.0
Protein (g/L): 75,9
T3 (pg/dL): 0,045
T4 (ng/L): 23,19
Troponin (ng/mL): 0,3
TSH (mIU/L): 0,07
Urea (mg/dL): 11,2
LVEF (%): 67.0
Medications: Amiodarone, Loop Diuretics, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: Unknown bradycardia code
            ",survivor,"RANKING: 1. Survivor
REASONING: The patient's overall clinical presentation and test results suggest a moderate to severe cardiac impairment, as indicated by a NYHA Class III classification, elevated LVEF of 67%, and elevated creatinine levels. However, the patient is still alive, and there is no evidence of acute myocardial infarction or ventricular tachycardia. The presence of polymorphic ventricular extrasystoles is a concerning finding, but it does not necessarily indicate an immediate life-threatening arrhythmia. The patient's medication regimen, including Amiodarone, suggests a history of arrhythmias, but the current ECG impression does not indicate any acute arrhythmia. The patient's renal function is impaired, but not severely, and the patient is on loop diuretics, which may help manage edema and fluid overload. Overall, the combination of these factors suggests that the patient is at risk for cardiac-related complications but may still be able to survive for the next few years with proper management.

RANKING: 2. Sudden Cardiac Death
REASONING: This ranking is less likely than the survivor ranking because the patient is alive and has not shown any acute life-threatening arrhythmias or signs of cardiac failure. However, the patient's NYHA Class III classification and elevated creatinine levels indicate significant cardiac impairment. The presence of polymorphic ventricular extrasystoles is a risk factor for sudden cardiac death, but it is not an immediate indication for this outcome. The patient's renal function is also a concern, but it is not severe enough to predict a high risk of sudden cardiac death.

RANKING: 3. Pump Failure Death
REASONING: This ranking is the least likely because the patient is alive, and the patient's NYHA Class III classification and elevated creatinine levels indicate cardiac impairment, but not failure. The patient is on ACE inhibitors, which can help manage hypertension and reduce cardiac workload. The patient's renal function is impaired, but not severely enough to predict pump failure. The presence of polymorphic ventricular extrasystoles is a concern, but it is not an immediate indication for pump failure. The patient's current clinical presentation and test results do not suggest an acute cardiac failure or severe cardiac impairment that would lead to pump failure."
167,167,P0281,"Age: 50
Gender: Male 
Weight: 91 kg
Height: 176 cm
NYHA Class: II
Blood Pressure: 160/100 mmHg
Past Medical History: Enolic dilated cardiomyopathy, Diabetes, Dyslipemia, Hypertension
Albumin (g/L): 39
ALT or GPT (IU/L): 28.0
AST or GOT (IU/L): 20.0
Total Cholesterol (mmol/L): 4,29
Creatinine (mmol/L): 88.0
Gamma-glutamil transpeptidase (IU/L): 39
Glucose (mmol/L): 9
Hemoglobin (g/L): 148.0
HDL (mmol/L): 0,78
Potassium (mEq/L): 3,41
LDL (mmol/L): 3,4
Sodium (mEq/L): 140.0
Pro-BNP (ng/L): 1825.0
Protein (g/L): 66,2
T3 (pg/dL): 0,0402
T4 (ng/L): 17,78
Troponin (ng/mL): 0,3
TSH (mIU/L): 0,95
Urea (mg/dL): 3,9
LVEF (%): 60.0
Medications: Diabetes Medication, Beta Blockers, Digoxin, Loop Diuretics, Statins, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"RANKING: 1. Survivor
REASONING: 

Based on the patient's data, I would rank the patient as a survivor with a high probability. The patient's age, NYHA Class II, and the presence of a known underlying condition (dilated cardiomyopathy) are risk factors for adverse outcomes. However, the patient's LVEF is 60%, which is within the range of those who can still tolerate physical activity and may have a reasonable prognosis.

The patient's medication regimen includes beta blockers, ACE inhibitors, and digoxin, which are commonly used to manage heart failure and control blood pressure. The absence of ventricular tachycardia or non-sustained ventricular tachycardia on the ECG suggests that the patient's heart is not in a state of significant arrhythmia.

The patient's laboratory results show elevated troponin levels (0.3 ng/mL), which may indicate some degree of cardiac injury, but this is not excessively high. The patient's creatinine level is 3.9 mg/dL, which is elevated, indicating some degree of kidney impairment. However, this is not uncommon in patients with heart failure.

The patient's lipid profile shows dyslipidemia, which is a risk factor for cardiovascular events, but the patient is already on statins, which should help manage this condition.

Overall, while the patient has several risk factors, the presence of a reasonable LVEF, a comprehensive medication regimen, and the absence of significant arrhythmias or acute cardiac injury suggest that the patient is likely to survive for the next few years.

RANKING: 2. Sudden Cardiac Death
REASONING: 

While the patient's risk factors, such as dilated cardiomyopathy, hypertension, and diabetes, increase the risk of sudden cardiac death, I would rank this outcome as less likely. The patient's LVEF is 60%, which is within the range of those who can still tolerate physical activity, and the patient is on medications that should help manage their condition.

The patient's ECG shows ventricular extrasystoles, which can be a marker for cardiac stress, but the absence of ventricular tachycardia or non-sustained ventricular tachycardia makes this outcome less likely.

The patient's laboratory results show elevated troponin levels, which may indicate some degree of cardiac injury, but this is not excessively high. The patient's creatinine level is elevated, but this is not uncommon in patients with heart failure.

RANKING: 3. Pump Failure Death
REASONING: 

While the patient's risk factors, such as dilated cardiomyopathy, hypertension, and diabetes, increase the risk of heart failure, I would rank this outcome as the least likely. The patient's LVEF is 60%, which is within the range of those who can still tolerate physical activity, and the patient is on medications that should help manage their condition.

The patient's ECG shows ventricular extrasystoles, which can be a marker for cardiac stress, but the absence of ventricular tachycardia or non-sustained ventricular tachycardia makes this outcome less likely.

The patient's laboratory results show elevated troponin levels, which may indicate some degree of cardiac injury, but this is not excessively high. The patient's creatinine level is elevated, but this is not uncommon in patients with heart failure.

However, the patient's NYHA Class II indicates that they have some limitations in their physical activity, which may increase the risk of heart failure. Additionally, the patient's elevated blood pressure (160/100 mmHg) and elevated creatinine level (3.9 mg/dL) may indicate some degree of cardiac and renal impairment."
168,168,P0282,"Age: 58
Gender: Male 
Weight: 87 kg
Height: 165 cm
NYHA Class: II
Blood Pressure: 135/80 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Diabetes, Dyslipemia, Peripheral vascular disease, Myocardial Infarction
Albumin (g/L): 40
ALT or GPT (IU/L): 23.0
AST or GOT (IU/L): 16.0
Total Cholesterol (mmol/L): 4,06
Creatinine (mmol/L): 99.0
Gamma-glutamil transpeptidase (IU/L): 36
Glucose (mmol/L): 8,1
Hemoglobin (g/L): 137.0
HDL (mmol/L): 1,29
Potassium (mEq/L): 3,82
LDL (mmol/L): 2,2
Sodium (mEq/L): 139.0
Pro-BNP (ng/L): 165.0
Protein (g/L): 69,8
T3 (pg/dL): 0,0339
T4 (ng/L): 17,8
Troponin (ng/mL): 0,6
TSH (mIU/L): 1,62
Urea (mg/dL): 8,9
LVEF (%): 40.0
Medications: Diabetes Medication, Beta Blockers, Loop Diuretics, Statins, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: TPSV
        - Bradycardia: Sinus Node Dysfunction
            ",survivor,"RANKING: 
1. Survivor
REASONING:
The patient is classified as a survivor based on the provided PATIENT OUTCOME. This is the most likely prognosis because the patient's current medical condition, despite being in NYHA Class II and having a history of ischemic dilated cardiomyopathy, diabetes, and dyslipemia, does not indicate any immediate life-threatening arrhythmias or acute cardiac events that would suggest a high risk of sudden cardiac death or pump failure.

Although the patient has a low LVEF (40.0), which is a marker of reduced cardiac function, the patient is still receiving medications for their heart condition, including beta blockers, loop diuretics, statins, and an ACE inhibitor, which are commonly used to manage heart failure and reduce the risk of cardiac complications. The patient's biomarkers, such as troponin and pro-BNP, are also within relatively normal limits, indicating no acute cardiac damage or strain.

The patient's ECG findings, while showing ventricular extrasystole and sinus node dysfunction, do not indicate any life-threatening arrhythmias that would increase the risk of sudden cardiac death. The absence of non-sustained ventricular tachycardia and paroxysmal supraventricular tachyarrhythmia further supports this prognosis.

Overall, while the patient's heart condition is serious, the combination of their medical history, medications, and current biomarkers and ECG findings suggest that they are likely to survive for the next few years without significant cardiac complications."
169,169,P0283,"Age: 80
Gender: Female 
Weight: 87 kg
Height: 150 cm
NYHA Class: III
Blood Pressure: 160/70 mmHg
Past Medical History: Hypertensive cardiomyopathy, Hypertension
Albumin (g/L): 40
ALT or GPT (IU/L): 13.0
AST or GOT (IU/L): 14.0
Total Cholesterol (mmol/L): 4,58
Creatinine (mmol/L): 115.0
Gamma-glutamil transpeptidase (IU/L): 16
Glucose (mmol/L): 4,8
Hemoglobin (g/L): 119.0
HDL (mmol/L): 1,29
Potassium (mEq/L): 3,52
LDL (mmol/L): 2,48
Sodium (mEq/L): 142.0
Pro-BNP (ng/L): 4058.0
Protein (g/L): 67,699
T3 (pg/dL): 0,0354
T4 (ng/L): 17,65
Troponin (ng/mL): 0,4
TSH (mIU/L): 2,07
Urea (mg/dL): 12,1
LVEF (%): 70.0
Medications: Beta Blockers, Loop Diuretics, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: TPSV
        - Bradycardia: No
            ",survivor,"RANKING: 

1. Survivor
REASONING:
The patient's age is 80, which is a high-risk factor for cardiovascular mortality. However, the patient is receiving medications for hypertension, which suggests that the patient is being managed for their cardiovascular condition. The patient's LVEF is 70%, which is within the normal range, indicating that the patient's heart is still functioning relatively well. The patient's ECG impression does not show any signs of ventricular tachycardia, non-sustained ventricular tachycardia, or other arrhythmias that would indicate a high risk of sudden cardiac death. The patient's Pro-BNP level is elevated at 4058.0 ng/L, which is a marker of heart failure, but it is not extremely elevated. The patient is also receiving medications for heart failure, which suggests that the patient is being managed for this condition.

2. Sudden Cardiac Death
REASONING:
Although the patient's age is a risk factor for cardiovascular mortality, the patient's LVEF is within the normal range, and the patient is receiving medications for hypertension and heart failure. However, the patient's Pro-BNP level is elevated, which may indicate some degree of heart failure. The patient's ECG impression shows a TPSV, which could be a risk factor for sudden cardiac death. However, the patient is not receiving any medications specifically for arrhythmias, which may indicate that the patient's TPSV is not being adequately managed.

3. Pump Failure Death
REASONING:
Given the patient's elevated Pro-BNP level and the fact that the patient is already receiving medications for heart failure, it is possible that the patient may experience pump failure in the short term. However, the patient's LVEF is within the normal range, which suggests that the patient's heart is still functioning relatively well. Additionally, the patient is receiving medications for hypertension and heart failure, which suggests that the patient is being managed for these conditions. Therefore, while pump failure is a possible outcome, it is not the most likely outcome given the patient's current status."
170,170,P0284,"Age: 80
Gender: Female 
Weight: 54 kg
Height: 143 cm
NYHA Class: III
Blood Pressure: 120/80 mmHg
Past Medical History: Hypertensive cardiomyopathy, Hypertension, Myocardial Infarction
Albumin (g/L): 35
ALT or GPT (IU/L): 38.0
AST or GOT (IU/L): 57.0
Total Cholesterol (mmol/L): 4,14
Creatinine (mmol/L): 80.0
Gamma-glutamil transpeptidase (IU/L): 75
Glucose (mmol/L): 4,2
Hemoglobin (g/L): 118.0
HDL (mmol/L): 1,19
Potassium (mEq/L): 4,63
LDL (mmol/L): 2,37
Sodium (mEq/L): 139.0
Pro-BNP (ng/L): 1057.0
Protein (g/L): 76,8
T3 (pg/dL): 0,0726
T4 (ng/L): 14,63
Troponin (ng/mL): 0,6
TSH (mIU/L): 6,19
Urea (mg/dL): 6,7
LVEF (%): 45.0
Medications: Beta Blockers, Loop Diuretics, ACE Inhibitor, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",survivor,"RANKING: 1. Survivor
REASONING: 

The patient is 80 years old, with a history of Hypertensive cardiomyopathy, Myocardial Infarction, and NYHA Class III heart failure, indicating severe left ventricular dysfunction. The patient's LVEF is 45%, which is significantly below the normal range, suggesting that the heart is not pumping efficiently. 

The patient's ECG findings, including ventricular extrasystole, non-sustained ventricular tachycardia, and non-sustained ventricular tachycardia, suggest a high risk of arrhythmias, which can be life-threatening. However, the patient is already taking medications for hypertension, heart failure, and arrhythmias, which may help mitigate these risks.

The patient's laboratory results show elevated liver enzymes (ALT and AST), indicating some degree of liver dysfunction, which can be associated with heart failure and cardiomyopathy. The patient's electrolytes and renal function are also abnormal, with low potassium levels and elevated creatinine, which may be related to the underlying cardiac condition.

Despite these risks, the patient is still alive, and the patient's current medications and the presence of a good quality of life (NYHA Class III) suggest that the patient is tolerating their condition relatively well. Therefore, I predict that the patient has a high chance of survival over the next few years, provided that the patient's medications are adjusted as needed and the underlying cardiac condition is managed effectively.

RANKING: 2. Sudden Cardiac Death
REASONING: 

While the patient's ECG findings suggest a high risk of arrhythmias, which can be life-threatening, the patient is already taking medications for arrhythmias, which may help mitigate this risk. However, the patient's underlying cardiac condition, including Hypertensive cardiomyopathy and Myocardial Infarction, still poses a significant risk of sudden cardiac death. 

The patient's LVEF is severely impaired, and the patient's NYHA Class III heart failure indicates that the heart is not pumping efficiently, which increases the risk of sudden cardiac death. Additionally, the patient's elevated Troponin levels suggest some degree of myocardial damage, which can increase the risk of arrhythmias and sudden cardiac death.

RANKING: 3. Pump Failure Death
REASONING: 

The patient's severe LVEF impairment (45%) and NYHA Class III heart failure indicate that the heart is not pumping efficiently, which increases the risk of pump failure. The patient's elevated creatinine levels and low potassium levels suggest that the patient's kidneys are not functioning well, which can exacerbate heart failure.

While the patient is taking medications for heart failure, the patient's underlying cardiac condition, including Hypertensive cardiomyopathy and Myocardial Infarction, still poses a significant risk of pump failure. The patient's elevated liver enzymes and abnormal electrolytes also suggest that the patient's underlying condition is not being effectively managed.

Overall, while the patient is alive, the patient's underlying cardiac condition and laboratory results suggest that the patient is at high risk of pump failure over the next few years."
171,171,P0288,"Age: 80
Gender: Female 
Weight: 81 kg
Height: 161 cm
NYHA Class: III
Blood Pressure: 150/65 mmHg
Past Medical History: Valvular cardiomyopathy, Diabetes, Dyslipemia, Hypertension
Albumin (g/L): 39
ALT or GPT (IU/L): 15.0
AST or GOT (IU/L): 15.0
Total Cholesterol (mmol/L): 4,91
Creatinine (mmol/L): 118.0
Gamma-glutamil transpeptidase (IU/L): 16
Glucose (mmol/L): 4,8
Hemoglobin (g/L): 114.0
HDL (mmol/L): 1,32
Potassium (mEq/L): 4,4
LDL (mmol/L): 2,53
Sodium (mEq/L): 139.0
Pro-BNP (ng/L): 195.0
Protein (g/L): 69,2
T3 (pg/dL): 0,0327
T4 (ng/L): 13,05
TSH (mIU/L): 1,05
Urea (mg/dL): 15,7
LVEF (%): 70.0
Medications: Diabetes Medication, Angiotensin II Receptor Blocker, Beta Blockers, Loop Diuretics, Statins, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: TPSV
        - Bradycardia: Sinus Node Dysfunction
            ",survivor,"RANKING: 
1. Survivor 
REASONING: 
The patient's overall clinical presentation and test results suggest a relatively stable condition. The patient's age is 80, but the presence of valvular cardiomyopathy, diabetes, dyslipemia, and hypertension could contribute to cardiac complications. However, the patient's NYHA Class III indicates moderate symptoms, but the patient is still able to perform daily activities with some limitations. The patient's LVEF of 70.0 is within a relatively normal range, suggesting that the heart is still functioning adequately. The absence of ventricular tachycardia, non-sustained ventricular tachycardia, and other arrhythmias on the ECG also suggests that the heart is not in a state of acute distress. The patient's laboratory results show mild elevations in liver enzymes (ALT and AST), which could be related to the patient's diabetes and dyslipemia. However, these results are not indicative of acute cardiac damage. The patient's medication regimen includes angiotensin II receptor blockers, beta blockers, and statins, which are standard treatments for managing hypertension, heart failure, and high cholesterol. Overall, the patient's clinical presentation and laboratory results suggest a relatively stable condition, making a survivor prognosis the most likely outcome."
172,172,P0292,"Age: 64
Gender: Male 
Weight: 75 kg
Height: 170 cm
NYHA Class: III
Blood Pressure: 130/80 mmHg
Past Medical History: Idiopathic dilated cardiomyopathy, Dyslipemia, Peripheral vascular disease, Hypertension
Albumin (g/L): 39
ALT or GPT (IU/L): 11.0
AST or GOT (IU/L): 17.0
Total Cholesterol (mmol/L): 5,4
Creatinine (mmol/L): 118.0
Gamma-glutamil transpeptidase (IU/L): 12
Glucose (mmol/L): 4,11
Hemoglobin (g/L): 150.0
HDL (mmol/L): 1,11
Potassium (mEq/L): 3,9
LDL (mmol/L): 3,88
Sodium (mEq/L): 142.0
Pro-BNP (ng/L): 1363.0
Protein (g/L): 67
T3 (pg/dL): 0,0426
T4 (ng/L): 14,2
TSH (mIU/L): 0,96
Urea (mg/dL): 7,1
LVEF (%): 30.0
Medications: Beta Blockers, Loop Diuretics, Statins, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: TPSV
        - Bradycardia: No
            ",survivor,"RANKING: 1. Survivor
REASONING: 

The patient has a complex medical history with multiple comorbidities, including idiopathic dilated cardiomyopathy, dyslipidemia, peripheral vascular disease, and hypertension. However, the patient's current NYHA class is III, which indicates moderate symptoms of heart failure. The patient's LVEF is significantly reduced at 30.0%, which is a strong indicator of advanced heart failure.

Despite the presence of these comorbidities, the patient's hemoglobin level is within the normal range, and the patient is on multiple medications that are commonly used to manage heart failure, including beta blockers, loop diuretics, statins, and an ACE inhibitor. The patient's ECG impression shows no ventricular tachycardia, which is a significant risk factor for sudden cardiac death.

The patient's Pro-BNP level is elevated at 1363.0 ng/L, which is a marker of heart failure. However, the patient's Pro-BNP level is not extremely high, which may suggest that the patient's heart failure is not severely decompensated. Overall, considering the patient's age, comorbidities, and current medication regimen, the patient's prognosis is relatively favorable, and the patient is likely to survive for the next few years with proper management and monitoring.

RANKING: 2. Sudden cardiac death
REASONING: 

While the patient's heart failure is advanced, the patient's ECG impression shows no ventricular tachycardia, which is a significant risk factor for sudden cardiac death. However, the patient's Pro-BNP level is elevated, which may indicate that the patient's heart failure is not well-compensated. The patient's LVEF is also significantly reduced, which increases the risk of sudden cardiac death.

Additionally, the patient's peripheral vascular disease and hypertension may increase the risk of cardiac events. However, the patient's current medication regimen includes beta blockers, which are known to reduce the risk of sudden cardiac death.

RANKING: 3. Pump failure death
REASONING: 

The patient's heart failure is advanced, with a significantly reduced LVEF and an elevated Pro-BNP level. The patient's NYHA class is III, which indicates moderate symptoms of heart failure. The patient's medication regimen includes loop diuretics, which are commonly used to manage heart failure, but the patient's current medication regimen does not include any additional medications specifically indicated for heart failure, such as vasopressin receptor antagonists or phosphodiesterase-5 inhibitors.

While the patient's peripheral vascular disease and hypertension may increase the risk of cardiac events, the patient's current medication regimen and ECG impression do not suggest a high risk of sudden cardiac death. However, the patient's advanced heart failure and reduced LVEF increase the risk of pump failure, which may be the most likely cause of death in this patient."
173,173,P0295,"Age: 37
Gender: Male 
Weight: 94 kg
Height: 174 cm
NYHA Class: III
Blood Pressure: 140/80 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Diabetes, Dyslipemia, Peripheral vascular disease, Hypertension, Myocardial Infarction
Albumin (g/L): 45
ALT or GPT (IU/L): 32.0
AST or GOT (IU/L): 25.0
Total Cholesterol (mmol/L): 4,06
Creatinine (mmol/L): 97.0
Gamma-glutamil transpeptidase (IU/L): 29
Glucose (mmol/L): 5,6
Hemoglobin (g/L): 154.0
HDL (mmol/L): 0,75
Potassium (mEq/L): 4,2
LDL (mmol/L): 2,8
Sodium (mEq/L): 137.0
Pro-BNP (ng/L): 3232.0
Protein (g/L): 74
T3 (pg/dL): 0,03
T4 (ng/L): 27
Troponin (ng/mL): 0,01
TSH (mIU/L): 3,17
Urea (mg/dL): 6,99
LVEF (%): 21.0
Medications: Diabetes Medication, Beta Blockers, Loop Diuretics, Statins, ACE Inhibitor, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"RANKING: 1. Survivor
REASONING:

Based on the patient's data, I predict a high likelihood of survival for the next few years. The patient's age, weight, and NYHA class III heart failure classification suggest a significant underlying cardiac condition. However, the patient's hemoglobin level is within a relatively normal range, and the absence of any acute myocardial infarction or severe cardiac arrest on the ECG impression suggests that the patient has not experienced a recent catastrophic cardiac event.

The patient's laboratory results, including the elevated creatinine level, indicate some degree of renal impairment, which may be related to the underlying cardiomyopathy. However, the presence of an ACE inhibitor and loop diuretics in the medication list suggests that the patient is receiving appropriate management for heart failure.

The patient's elevated Pro-BNP level (3232.0 ng/L) suggests a significant burden of heart failure, but the patient's LVEF is only 21%, which is consistent with a dilated cardiomyopathy. The absence of any acute myocardial infarction or severe arrhythmias on the ECG impression suggests that the patient's cardiac condition is stable.

While the patient's ECG shows non-sustained ventricular tachycardia, this is a relatively common finding in patients with heart failure. The patient's medication list, including beta blockers and ACE inhibitors, suggests that the patient is receiving evidence-based treatment for heart failure.

Overall, considering the patient's age, NYHA class, and medication list, I predict a high likelihood of survival for the next few years, provided that the patient adheres to their medication regimen and makes lifestyle modifications to manage their underlying heart failure.

RANKING: 2. Sudden Cardiac Death
REASONING:

Based on the patient's data, I predict a moderate likelihood of sudden cardiac death over the next few years. The patient's LVEF of 21% and elevated Pro-BNP level suggest a significant burden of heart failure, which increases the risk of sudden cardiac death.

The patient's ECG impression shows non-sustained ventricular tachycardia, which is a risk factor for sudden cardiac death. Additionally, the patient's age and NYHA class III heart failure classification increase the risk of sudden cardiac death.

While the patient's medication list includes beta blockers and ACE inhibitors, which are evidence-based treatments for heart failure, the patient's elevated creatinine level and kidney impairment may limit the effectiveness of these medications. Furthermore, the patient's dyslipidemia and hypertension may contribute to atherosclerosis and cardiac arrhythmias, increasing the risk of sudden cardiac death.

RANKING: 3. Pump Failure Death
REASONING:

Based on the patient's data, I predict a low likelihood of pump failure death over the next few years. The patient's LVEF of 21% suggests a significant reduction in cardiac function, but the patient is receiving evidence-based treatment for heart failure, including beta blockers, ACE inhibitors, and loop diuretics.

The patient's medication list and laboratory results suggest that the patient is receiving optimal management for heart failure. The patient's hemoglobin level and kidney function are also relatively preserved, which reduces the risk of pump failure.

However, the patient's elevated Pro-BNP level and non-sustained ventricular tachycardia on the ECG impression suggest a significant burden of heart failure, which increases the risk of pump failure. Additionally, the patient's age and NYHA class III heart failure classification increase the risk of pump failure.

Overall, while the patient's risk of pump failure is present, the patient's treatment plan and laboratory results suggest a relatively low risk of pump failure over the next few years."
174,174,P0296,"Age: 69
Gender: Female 
Weight: 55 kg
Height: 150 cm
NYHA Class: II
Blood Pressure: 120/70 mmHg
Past Medical History: Idiopathic dilated cardiomyopathy
Albumin (g/L): 43
ALT or GPT (IU/L): 11.0
AST or GOT (IU/L): 17.0
Total Cholesterol (mmol/L): 5,84
Creatinine (mmol/L): 113.0
Gamma-glutamil transpeptidase (IU/L): 13,9
Glucose (mmol/L): 5,03
Hemoglobin (g/L): 131.0
HDL (mmol/L): 1,95
Potassium (mEq/L): 4,74
LDL (mmol/L): 3,09
Sodium (mEq/L): 142.0
Pro-BNP (ng/L): 267.0
Protein (g/L): 80
T3 (pg/dL): 0,0432
T4 (ng/L): 13,91
TSH (mIU/L): 1,51
Urea (mg/dL): 9
LVEF (%): 25.0
Medications: Digoxin, Loop Diuretics, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: TPSV
        - Bradycardia: No
            ",survivor,"RANKING: 1. Survivor
REASONING: 

This patient has a complex clinical picture, but the overall assessment suggests that they are at high risk for adverse outcomes. The patient has a history of idiopathic dilated cardiomyopathy, which is a significant risk factor for sudden cardiac death and pump failure. The patient's LVEF is severely reduced at 25%, indicating significant left ventricular dysfunction.

The patient's ejection fraction is the most critical factor in determining prognosis. A low ejection fraction is a strong predictor of adverse outcomes. The patient's low ejection fraction, combined with their NYHA class II status, suggests that they have moderate symptoms of heart failure.

The patient's biomarkers, including elevated troponin levels (not explicitly mentioned, but implied by the AST/GOT level of 17.0) and low albumin levels, also suggest cardiac stress and potential cardiac damage.

The patient's medication regimen includes ACE inhibitors, which are generally recommended for patients with heart failure. However, the presence of ventricular extrasystoles and a polymorphic ventricular extrasystole on the ECG impression raises concerns about the risk of arrhythmias.

Despite these concerns, the patient has not been diagnosed with any overt heart failure symptoms, and their medication regimen is adequate. The patient's recent biomarkers do not indicate acute myocardial infarction or cardiac rupture. 

Given these factors, the most likely outcome for this patient over the next few years is a survival, as the patient is currently not in acute distress and is receiving adequate medical management for their heart failure. However, the patient's underlying heart condition and the presence of ventricular extrasystoles require close monitoring and regular follow-up to adjust their treatment plan as needed.

RANKING: 2. Sudden Cardiac Death
REASONING: 

While the patient's underlying heart condition is a significant risk factor for sudden cardiac death, the patient's current clinical status does not suggest an immediate risk of sudden cardiac death. The patient is not experiencing any symptoms of acute heart failure, and their medication regimen is adequate.

However, the presence of ventricular extrasystoles and a polymorphic ventricular extrasystole on the ECG impression increases the risk of arrhythmias, which can be a precursor to sudden cardiac death. The patient's low ejection fraction and NYHA class II status also increase the risk of cardiac events.

Given the patient's complex clinical picture and the presence of ventricular extrasystoles, there is a moderate risk of sudden cardiac death over the next few years. However, this risk is not as high as the risk of pump failure death, as the patient is currently not in acute distress.

RANKING: 3. Pump Failure Death
REASONING: 

The patient's severely reduced ejection fraction (LVEF of 25%) and NYHA class II status indicate significant left ventricular dysfunction, which increases the risk of pump failure. The patient's low albumin levels and elevated creatinine levels also suggest renal impairment, which can be a complication of heart failure.

The patient's medication regimen includes loop diuretics, which are used to manage symptoms of heart failure. However, the patient's low ejection fraction and NYHA class II status suggest that their heart failure symptoms are not adequately controlled.

Given the patient's complex clinical picture and the presence of significant left ventricular dysfunction, there is a moderate to high risk of pump failure over the next few years. However, this risk is not as high as the risk of sudden cardiac death, as the patient is currently not in acute distress."
175,175,P0297,"Age: 73
Gender: Male 
Weight: 82 kg
Height: 159 cm
NYHA Class: III
Blood Pressure: 140/70 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Diabetes, Dyslipemia, Myocardial Infarction
Albumin (g/L): 41
ALT or GPT (IU/L): 21.0
AST or GOT (IU/L): 20.0
Total Cholesterol (mmol/L): 4,03
Creatinine (mmol/L): 118.0
Gamma-glutamil transpeptidase (IU/L): 19
Glucose (mmol/L): 15,7
Hemoglobin (g/L): 144.0
HDL (mmol/L): 1,14
Potassium (mEq/L): 3,79
LDL (mmol/L): 2,07
Sodium (mEq/L): 141.0
Pro-BNP (ng/L): 678.0
Protein (g/L): 65
T3 (pg/dL): 0,0396
T4 (ng/L): 13,66
Troponin (ng/mL): 0,1
TSH (mIU/L): 1,3
Urea (mg/dL): 3,4
LVEF (%): 25.0
Medications: Diabetes Medication, Beta Blockers, Loop Diuretics, Statins, ACE Inhibitor, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"RANKING: 
1. Survivor
REASONING: 
Based on the patient's clinical presentation and test results, the patient is at high risk for adverse cardiac events. The patient has a history of ischemic dilated cardiomyopathy, which is a condition that weakens the heart muscle and can lead to heart failure. The patient's left ventricular ejection fraction (LVEF) of 25% is significantly reduced, indicating severe systolic dysfunction. The presence of ventricular extrasystoles, as indicated by the ECG, also suggests an increased risk of arrhythmias. Additionally, the patient's elevated pro-BNP levels (678.0 ng/L) and high creatinine levels (118.0 mmol/L) indicate fluid overload and kidney dysfunction, which can further exacerbate cardiac dysfunction.

Despite the presence of several risk factors, the patient is currently receiving medications for diabetes, hypertension, and heart failure, which suggests that the patient is receiving adequate treatment for their underlying conditions. However, the combination of these factors suggests that the patient is at high risk for cardiac events, making a survival outcome the most likely.

2. Sudden cardiac death
REASONING: 
While the patient is at high risk for cardiac events, the presence of ventricular extrasystoles and elevated pro-BNP levels may suggest an increased risk for arrhythmias. However, the patient is not currently experiencing symptoms of ventricular tachycardia or non-sustained ventricular tachycardia, which are precursors to sudden cardiac death. Additionally, the patient is receiving medications for heart failure and hypertension, which can help to reduce the risk of sudden cardiac death.

However, the patient's reduced LVEF and elevated creatinine levels suggest that the patient's cardiac function is compromised, which increases the risk of arrhythmias and sudden cardiac death.

3. Pump failure death
REASONING: 
While the patient is at high risk for cardiac events, the presence of medications for heart failure and hypertension suggests that the patient is receiving adequate treatment for their underlying conditions. The patient's elevated pro-BNP levels and high creatinine levels do suggest fluid overload and kidney dysfunction, which can further exacerbate cardiac dysfunction. However, the patient's LVEF is 25%, which is a relatively preserved ejection fraction, indicating that the patient's cardiac function is not severely compromised.

Additionally, the patient is receiving medications for diabetes, hypertension, and heart failure, which can help to reduce the risk of pump failure. Therefore, while pump failure is a possible outcome, it is the least likely of the three options, given the patient's current treatment and clinical presentation."
176,176,P0298,"Age: 86
Gender: Male 
Weight: 90 kg
Height: 190 cm
NYHA Class: III
Blood Pressure: 125/80 mmHg
Past Medical History: Other HF etiology, Hypertension, Myocardial Infarction
Albumin (g/L): 40
ALT or GPT (IU/L): 27.0
AST or GOT (IU/L): 21.0
Total Cholesterol (mmol/L): 4,32
Creatinine (mmol/L): 62.0
Gamma-glutamil transpeptidase (IU/L): 25
Glucose (mmol/L): 6,7
Hemoglobin (g/L): 156.0
HDL (mmol/L): 1,47
Potassium (mEq/L): 3,8
LDL (mmol/L): 2,53
Sodium (mEq/L): 143.0
Pro-BNP (ng/L): 851.0
Protein (g/L): 71
T3 (pg/dL): 0,03
T4 (ng/L): 16
Troponin (ng/mL): 0,01
TSH (mIU/L): 1,59
Urea (mg/dL): 3,5
LVEF (%): 37.0
Medications: Digoxin, Loop Diuretics, Statins, ACE Inhibitor, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: TPSV
        - Bradycardia: No
            ",survivor,"RANKING: 
1. Survivor
REASONING: 
The patient's age (86 years) is a significant risk factor for cardiac complications. However, the patient's NYHA Class III indicates a severe heart failure, which requires close monitoring and management. The patient's LVEF of 37% suggests a severely impaired left ventricular function, which increases the risk of cardiac events. Despite this, the patient's ECG results do not show any signs of ventricular tachycardia, non-sustained ventricular tachycardia, or significant arrhythmias, which are common causes of sudden cardiac death. The patient's medication regimen, which includes ACE inhibitors, statins, and loop diuretics, suggests that the patient's heart failure and hypertension are being adequately managed. The patient's laboratory results, including a mildly elevated troponin level (0.01 ng/mL), are not indicative of acute myocardial infarction. Overall, the patient's clinical presentation, ECG results, and medication regimen suggest that the patient is at a higher risk for cardiac events, but the absence of acute coronary syndromes and arrhythmias makes a sudden cardiac death less likely. The patient's protein levels, kidney function, and other laboratory results are not significantly abnormal, which further supports the likelihood of survival. 

2. Pump failure death
REASONING: 
The patient's severely impaired LVEF (37%) and NYHA Class III status indicate a high risk of cardiac failure. The patient's elevated creatinine level (62.0 mmol/L) and mildly elevated urea level (3.5 mg/dL) suggest impaired kidney function, which can exacerbate heart failure and increase the risk of pump failure. The patient's elevated troponin level (0.01 ng/mL) may indicate some degree of cardiac stress or myocardial injury, which could contribute to pump failure. While the patient's medication regimen is adequate for managing heart failure, the combination of severe heart failure, impaired kidney function, and mildly elevated troponin levels make pump failure a plausible outcome.

3. Sudden cardiac death
REASONING: 
The patient's ECG results show ventricular extrasystole (polymorphic), which is a type of abnormal heart rhythm that can increase the risk of sudden cardiac death. However, the absence of ventricular tachycardia, non-sustained ventricular tachycardia, or significant arrhythmias on the ECG reduces the likelihood of sudden cardiac death. The patient's other laboratory results and clinical presentation do not suggest any acute coronary syndromes or other conditions that would increase the risk of sudden cardiac death. While the patient's age and NYHA Class III status increase the risk of cardiac events, the absence of other risk factors for sudden cardiac death makes this outcome less likely."
177,177,P0299,"Age: 71
Gender: Female 
Weight: 95 kg
Height: 158 cm
NYHA Class: II
Blood Pressure: 120/70 mmHg
Past Medical History: Idiopathic dilated cardiomyopathy, Hypertension
Albumin (g/L): 44
ALT or GPT (IU/L): 34.0
AST or GOT (IU/L): 20.0
Total Cholesterol (mmol/L): 5,07
Creatinine (mmol/L): 97.0
Gamma-glutamil transpeptidase (IU/L): 39
Glucose (mmol/L): 4,7
Hemoglobin (g/L): 129.0
HDL (mmol/L): 1,42
Potassium (mEq/L): 5,9
LDL (mmol/L): 3,26
Sodium (mEq/L): 141.0
Pro-BNP (ng/L): 3233.0
Protein (g/L): 72
T3 (pg/dL): 0,03
T4 (ng/L): 20
Troponin (ng/mL): 0,04
TSH (mIU/L): 2,86
Urea (mg/dL): 6,16
LVEF (%): 17.0
Medications: Amiodarone, Beta Blockers, Spironolactone, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",survivor,"RANKING: 1. Survivor
REASONING: 

This patient is at high risk for cardiac events due to their underlying idiopathic dilated cardiomyopathy, hypertension, and NYHA Class II heart failure. The elevated LVEF of 17% indicates severely reduced cardiac function. The presence of non-sustained ventricular tachycardia (NST) on the ECG impression also suggests an increased risk of arrhythmic events. However, the patient is currently on medications that are standard for managing heart failure and arrhythmias, including beta blockers, amiodarone, and an ACE inhibitor. The patient's renal function is also compromised, as indicated by the elevated creatinine level.

The patient's serum biomarkers, such as Troponin and Pro-BNP, suggest some degree of cardiac stress, but they are not excessively elevated. The patient's hemoglobin and other laboratory values are relatively normal, which is a positive sign. The patient's weight and height are also within a relatively normal range.

Given the combination of heart failure, arrhythmias, and compromised renal function, the patient is at high risk for cardiac events. However, the fact that the patient is already on standard medications and has not been reported to have any recent severe cardiac events suggests that the patient is currently stable and may be able to survive the next few years without significant cardiac complications.

Therefore, based on the available data, I predict that the patient is most likely to survive the next few years, provided that their current treatment regimen is maintained and there are no significant changes in their medical condition.

RANKING: 2. Sudden cardiac death
REASONING: 

While the patient is at high risk for cardiac events, the patient's current survival is more likely than sudden cardiac death. The presence of non-sustained ventricular tachycardia on the ECG impression does increase the risk of sudden cardiac death. However, the fact that the patient is already on medications that are standard for managing arrhythmias and heart failure reduces this risk.

Additionally, the patient's LVEF is severely reduced, which increases the risk of sudden cardiac death. However, the patient's current medications and relatively stable laboratory values suggest that the risk of sudden cardiac death may be lower than the risk of other cardiac events, such as heart failure exacerbation.

Therefore, while the patient is at risk for sudden cardiac death, the fact that the patient is already on standard medications and has not been reported to have any recent severe cardiac events suggests that the risk of sudden cardiac death may be lower than the risk of other cardiac events.

RANKING: 3. Pump failure death
REASONING: 

The patient is at high risk for pump failure due to their underlying idiopathic dilated cardiomyopathy and NYHA Class II heart failure. The patient's LVEF is severely reduced, which indicates poor cardiac function. The patient's elevated creatinine level also suggests compromised renal function, which is a common complication of heart failure.

The patient's elevated Pro-BNP level also suggests some degree of cardiac stress, which can contribute to heart failure exacerbation. However, the patient is already on medications that are standard for managing heart failure, including an ACE inhibitor, which can help reduce the risk of heart failure exacerbation.

While the patient is at high risk for pump failure, the fact that the patient is currently stable and on standard medications suggests that the risk of pump failure may be lower than the risk of sudden cardiac death. However, the patient's severely reduced LVEF and compromised renal function make it more likely that the patient will experience pump failure in the future.

Therefore, based on the available data, I predict that pump failure is the most likely cardiac event to occur in the next few years, provided that the patient's current treatment regimen is maintained and there are no significant changes in their medical condition."
178,178,P0301,"Age: 76
Gender: Male 
Weight: 83 kg
Height: 155 cm
NYHA Class: III
Blood Pressure: 100/60 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Diabetes, Dyslipemia, Hypertension, Myocardial Infarction
Albumin (g/L): 40
ALT or GPT (IU/L): 26.0
AST or GOT (IU/L): 12.0
Total Cholesterol (mmol/L): 3,96
Creatinine (mmol/L): 150.0
Gamma-glutamil transpeptidase (IU/L): 22
Glucose (mmol/L): 7,6
Hemoglobin (g/L): 124.0
HDL (mmol/L): 0,96
Potassium (mEq/L): 5,4
LDL (mmol/L): 2,38
Sodium (mEq/L): 137.0
Pro-BNP (ng/L): 3182.0
Protein (g/L): 68
T3 (pg/dL): 0,03
T4 (ng/L): 20
Troponin (ng/mL): 0,02
TSH (mIU/L): 1,07
Urea (mg/dL): 17,14
LVEF (%): 12.0
Medications: Beta Blockers, Loop Diuretics, Statins, ACE Inhibitor, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",survivor,"RANKING: 1. Survivor
REASONING: 

Based on the provided patient data, I would rank the patient's prognosis as a survivor with a high likelihood. The patient is 76 years old with a history of ischemic dilated cardiomyopathy, which is a significant risk factor for cardiac events. However, the patient is currently on optimal medical therapy with beta blockers, loop diuretics, statins, ACE inhibitors, and a nitrovasodilator, which are standard treatments for managing heart failure and reducing cardiovascular risk.

The patient's laboratory results, such as the elevated creatinine level (150.0 mol/L) and low LVEF (12.0%), indicate significant cardiac dysfunction. However, the patient's ejection fraction is not severely impaired, and the patient's troponin level (0.02 ng/mL) is not elevated, suggesting that there is no acute myocardial infarction.

The patient's electrolyte and liver function tests are also relatively normal, which suggests that there is no acute kidney injury or liver dysfunction that would further compromise the patient's prognosis.

The patient's ECG results show ventricular extrasystoles, which are common in patients with heart failure, but there is no evidence of ventricular tachycardia or bradycardia. The presence of paroxysmal supraventricular tachyarrhythmia is unknown, but this can be managed with appropriate treatment.

Overall, the patient's current medical condition, treatment, and laboratory results suggest that the patient is at high risk for cardiac events, but the patient is currently stable and receiving optimal medical therapy. Therefore, I would predict that the patient has a high likelihood of survival.

RANKING: 2. Sudden cardiac death
REASONING: 

Although the patient is at high risk for cardiac events, I would rank sudden cardiac death as a lower likelihood due to the patient's current stable condition and optimal medical therapy. The patient's ECG results show ventricular extrasystoles, which are a common finding in patients with heart failure, but there is no evidence of ventricular tachycardia or bradycardia.

However, the patient's low LVEF (12.0%) and elevated creatinine level (150.0 mol/L) suggest that the patient's cardiac function is compromised, and there is a risk of sudden cardiac death due to arrhythmias or cardiac failure.

RANKING: 3. Pump failure death
REASONING: 

Pump failure death is the least likely outcome in this patient. Although the patient's LVEF is low (12.0%), the patient is currently receiving optimal medical therapy with beta blockers, loop diuretics, statins, ACE inhibitors, and a nitrovasodilator, which are standard treatments for managing heart failure.

Additionally, the patient's troponin level (0.02 ng/mL) is not elevated, suggesting that there is no acute myocardial infarction, and the patient's ECG results do not show any evidence of ventricular tachycardia or bradycardia.

While the patient's cardiac function is compromised, the patient's stable condition, optimal medical therapy, and lack of evidence of acute cardiac events make pump failure death the least likely outcome."
179,179,P0302,"Age: 67
Gender: Male 
Weight: 80 kg
Height: 175 cm
NYHA Class: III
Blood Pressure: 130/70 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Diabetes, Dyslipemia, Myocardial Infarction
Albumin (g/L): 40
ALT or GPT (IU/L): 26.0
AST or GOT (IU/L): 16.0
Total Cholesterol (mmol/L): 4,84
Creatinine (mmol/L): 115.0
Gamma-glutamil transpeptidase (IU/L): 18
Glucose (mmol/L): 16
Hemoglobin (g/L): 134.0
HDL (mmol/L): 0,96
Potassium (mEq/L): 5,8
LDL (mmol/L): 2,97
Sodium (mEq/L): 134.0
Pro-BNP (ng/L): 589.0
Protein (g/L): 74
T4 (ng/L): 21
Troponin (ng/mL): 0,01
TSH (mIU/L): 1,09
Urea (mg/dL): 11,48
LVEF (%): 48.0
Medications: Diabetes Medication, Beta Blockers, Loop Diuretics, Spironolactone, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: No
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"RANKING: 
1. Survivor
REASONING: 
Based on the provided patient data, the patient is at high risk for adverse cardiac events, but the absence of significant ventricular arrhythmias, low troponin levels, and a stable ECG impression suggest that the patient is unlikely to experience a sudden cardiac death. The patient's NYHA Class III status indicates severe heart failure, which may contribute to a higher risk of pump failure. However, the presence of a low ejection fraction (LVEF) of 48% suggests that the patient's heart is not pumping efficiently, which may lead to heart failure. The patient's creatinine level is elevated, indicating renal impairment, which may further exacerbate the risk of pump failure. The patient's protein level is within normal limits, and the absence of significant laboratory abnormalities in other systems (e.g., liver function tests, electrolytes) suggests that the patient's prognosis is more closely tied to cardiac function. Therefore, based on the available data, the patient is more likely to survive than to experience sudden cardiac death or pump failure."
180,180,P0304,"Age: 75
Gender: Female 
Weight: 64 kg
Height: 155 cm
NYHA Class: II
Blood Pressure: 150/80 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Diabetes, Dyslipemia, Hypertension, Myocardial Infarction
Albumin (g/L): 42
ALT or GPT (IU/L): 31.0
AST or GOT (IU/L): 25.0
Total Cholesterol (mmol/L): 5,04
Creatinine (mmol/L): 106.0
Gamma-glutamil transpeptidase (IU/L): 36
Glucose (mmol/L): 14,7
Hemoglobin (g/L): 133.0
HDL (mmol/L): 0,91
Potassium (mEq/L): 4,1
LDL (mmol/L): 3,23
Sodium (mEq/L): 141.0
Pro-BNP (ng/L): 3866.0
Protein (g/L): 70
T3 (pg/dL): 0,02
T4 (ng/L): 22
Troponin (ng/mL): 0,01
TSH (mIU/L): 2,14
Urea (mg/dL): 5,99
LVEF (%): 42.0
Medications: Diabetes Medication, Beta Blockers, Loop Diuretics, Statins, ACE Inhibitor, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",survivor,"RANKING: 
1. Survivor 
REASONING:
The patient has a history of ischemic dilated cardiomyopathy, which is a significant risk factor for cardiac events. However, the patient has been receiving optimal medical therapy with beta blockers, ACE inhibitors, and statins, which are commonly used to manage heart failure and reduce the risk of cardiac events. The patient's NYHA class is II, indicating mild symptoms, and their LVEF is 42%, which is within the range for someone with heart failure.

The patient's laboratory results show elevated creatinine levels (106.0 mmol/L), which may indicate some degree of renal impairment, but this is not uncommon in patients with heart failure. The patient's electrolyte levels, including potassium, sodium, and TSH, are within normal limits.

The ECG impression shows ventricular extrasystoles and non-sustained ventricular tachycardia, which are both benign findings that do not necessarily indicate a high risk for cardiac events. The patient's Pro-BNP levels are elevated at 3866.0 ng/L, which is consistent with heart failure.

Given the patient's overall medical history, medication regimen, and laboratory results, the most likely prognosis is survival. The patient's symptoms and laboratory results do not indicate a high risk for cardiac events, and the patient is receiving optimal medical therapy for their heart failure.

While the patient's history of myocardial infarction and ischemic dilated cardiomyopathy do increase their risk for cardiac events, the patient's current medical condition and treatment plan suggest that they are at moderate risk. The patient's LVEF is not severely impaired, and their NYHA class is mild, which suggests that they may be able to tolerate some level of physical activity.

It is worth noting that the patient's T3 level is low (0.02 pg/dL), which may indicate hypothyroidism. This could potentially impact the patient's cardiac function and overall prognosis. However, without further testing or treatment, the low T3 level is not immediately life-threatening.

Overall, based on the patient's medical history, laboratory results, and current medical condition, the most likely prognosis is survival."
181,181,P0305,"Age: 52
Gender: Male 
Weight: 71 kg
Height: 172 cm
NYHA Class: II
Blood Pressure: 160/100 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Dyslipemia, Peripheral vascular disease, Hypertension, Myocardial Infarction
Albumin (g/L): 40
ALT or GPT (IU/L): 30.0
AST or GOT (IU/L): 26.0
Total Cholesterol (mmol/L): 4,06
Creatinine (mmol/L): 106.0
Gamma-glutamil transpeptidase (IU/L): 34
Glucose (mmol/L): 4,8
Hemoglobin (g/L): 141.0
HDL (mmol/L): 0,85
Potassium (mEq/L): 4,8
LDL (mmol/L): 1,58
Sodium (mEq/L): 141.0
Pro-BNP (ng/L): 89.0
Protein (g/L): 67
T3 (pg/dL): 0,03
T4 (ng/L): 21
Troponin (ng/mL): 0,02
TSH (mIU/L): 1,53
Urea (mg/dL): 3,99
LVEF (%): 66.0
Medications: Calcium Channel Blocker, Statins, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: No
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"RANKING: 1. Survivor
REASONING: 

This patient's prognosis is ranked as a survivor due to the following reasons:

1. The patient has a history of ischemic dilated cardiomyopathy, but the current LVEF is 66%, which is still within the normal range (40-55%). This suggests that the patient's heart function is not severely compromised.

2. The patient has several comorbid conditions such as hypertension, dyslipidemia, and peripheral vascular disease, but these conditions are being managed with medications (Calcium Channel Blocker, Statins, ACE Inhibitor). This indicates that the patient is receiving appropriate treatment for these conditions.

3. The patient's laboratory results show normal liver function (ALT and AST within normal limits), and the troponin level is within normal limits, suggesting that there is no acute myocardial infarction.

4. The patient's electrolyte levels are within normal limits, with a potassium level of 4.8 mEq/L, which is not elevated.

5. The patient's Pro-BNP level is elevated at 89 ng/L, which indicates some degree of ventricular strain. However, this level is not extremely high, and the patient's symptoms do not suggest acute heart failure.

6. The patient's ECG results are normal, with no signs of ventricular extrasystole, ventricular tachycardia, or non-sustained ventricular tachycardia.

Considering these factors, the patient's overall condition is stable, and the likelihood of a sudden cardiac death or pump failure death is relatively low. Therefore, the prognosis is ranked as a survivor."
182,182,P0306,"Age: 55
Gender: Male 
Weight: 78 kg
Height: 177 cm
NYHA Class: II
Blood Pressure: 110/60 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Dyslipemia, Hypertension, Myocardial Infarction
Albumin (g/L): 41
ALT or GPT (IU/L): 21.0
AST or GOT (IU/L): 21.0
Total Cholesterol (mmol/L): 5,04
Creatinine (mmol/L): 106.0
Gamma-glutamil transpeptidase (IU/L): 26
Glucose (mmol/L): 6,7
Hemoglobin (g/L): 129.0
HDL (mmol/L): 1,03
Potassium (mEq/L): 4,5
LDL (mmol/L): 3,88
Sodium (mEq/L): 145.0
Pro-BNP (ng/L): 453.0
Protein (g/L): 70
T3 (pg/dL): 0,03
T4 (ng/L): 22
Troponin (ng/mL): 0,01
TSH (mIU/L): 1,52
Urea (mg/dL): 6,99
LVEF (%): 51.0
Medications: Angiotensin II Receptor Blocker, Beta Blockers, Statins, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"RANKING: 
1. Survivor
2. Sudden cardiac death
3. Pump failure death

REASONING:

Based on the provided patient data, I would rank the patient's prognosis as follows:

1. Survivor: The patient's NYHA Class II indicates that they have moderate symptoms, but they are still able to perform daily activities without significant limitation. Their LVEF is 51%, which is a relatively preserved ejection fraction, indicating that the heart is still functioning to some extent. The patient's blood pressure is well-controlled, and their lipid profile and liver function tests are relatively normal. The patient is also taking medications that are commonly used to manage heart failure and ischemic heart disease. The absence of significant laboratory abnormalities, such as elevated troponin levels or severe kidney dysfunction, further supports a favorable prognosis.

2. Sudden cardiac death: Although the patient has a history of ischemic dilated cardiomyopathy, which increases the risk of sudden cardiac death, the patient's LVEF is not severely impaired, and they are taking medications that are known to reduce the risk of sudden cardiac death. The ECG impression does not show any signs of ventricular tachycardia or other arrhythmias that could increase the risk of sudden cardiac death. The patient's age and sex also make sudden cardiac death less likely, as it is more common in younger individuals.

3. Pump failure death: The patient's LVEF is 51%, which is relatively preserved, and they are taking medications that are known to improve heart function. However, the patient's NYHA Class II indicates that they have moderate symptoms, which suggests that the heart is not functioning optimally. Additionally, the patient has a history of hypertension, dyslipidemia, and myocardial infarction, which can contribute to heart failure. While the patient is taking medications to manage these conditions, the combination of these factors and the patient's relatively low ejection fraction make pump failure death a less likely outcome compared to sudden cardiac death."
183,183,P0307,"Age: 51
Gender: Male 
Weight: 112 kg
Height: 174 cm
NYHA Class: II
Blood Pressure: 120/75 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Diabetes, Dyslipemia, Peripheral vascular disease, Hypertension, Myocardial Infarction
Albumin (g/L): 45
ALT or GPT (IU/L): 82.0
AST or GOT (IU/L): 37.0
Total Cholesterol (mmol/L): 4,94
Creatinine (mmol/L): 88.0
Gamma-glutamil transpeptidase (IU/L): 33
Glucose (mmol/L): 13,6
Hemoglobin (g/L): 149.0
HDL (mmol/L): 0,91
Potassium (mEq/L): 4,1
LDL (mmol/L): 3,21
Sodium (mEq/L): 137.0
Pro-BNP (ng/L): 128.0
Protein (g/L): 80
T3 (pg/dL): 0,03
T4 (ng/L): 22
Troponin (ng/mL): 0,01
TSH (mIU/L): 3,45
Urea (mg/dL): 5,32
LVEF (%): 50.0
Medications: Calcium Channel Blocker, Diabetes Medication, Beta Blockers, Loop Diuretics, Statins, ACE Inhibitor, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"RANKING: 
1. Survivor
REASONING:
The patient has a complex medical history with multiple comorbidities, including ischemic dilated cardiomyopathy, diabetes, and hypertension. However, the patient is currently on multiple medications for these conditions, which suggests that the patient is receiving optimal management. The patient's NYHA Class II indicates that the patient has some limitation in physical activity, but the patient is still able to perform daily activities.

The patient's LVEF is 50%, which is significantly reduced, indicating systolic dysfunction. However, the patient's ventricular extrasystole on the ECG is monomorphic, which may not necessarily indicate a high risk for sudden cardiac death. The patient's troponin level is within normal limits, which suggests that there is no acute myocardial infarction.

The patient's creatinine level is elevated, which may indicate some degree of renal impairment. However, the patient is on ACE inhibitors and loop diuretics, which are commonly used to treat hypertension and heart failure. The patient's potassium level is slightly elevated, but the patient is on beta blockers, which can also help to manage hyperkalemia.

Overall, the patient's medical history, medications, and ECG findings do not indicate an immediate high risk for sudden cardiac death or pump failure. Therefore, the most likely prognosis for the patient is survival.

2. Sudden Cardiac Death
REASONING:
The patient's LVEF is significantly reduced, which indicates systolic dysfunction. While the patient is on medications for hypertension and heart failure, the patient's creatinine level is elevated, which may indicate some degree of renal impairment. The patient's potassium level is also slightly elevated, which can increase the risk for arrhythmias.

The patient's ECG shows ventricular extrasystole, which may indicate some degree of cardiac electrical instability. While the ventricular extrasystole is monomorphic, it is still a concerning sign. The patient's troponin level is within normal limits, but the patient's LVEF is significantly reduced, which may increase the risk for sudden cardiac death.

While the patient is on beta blockers, which can help to manage arrhythmias, the patient's ECG shows no signs of ventricular tachycardia or non-sustained ventricular tachycardia. However, the patient's ventricular extrasystole is a concerning sign that may increase the risk for sudden cardiac death.

3. Pump Failure Death
REASONING:
The patient's LVEF is significantly reduced, which indicates systolic dysfunction. The patient's creatinine level is elevated, which may indicate some degree of renal impairment. The patient's potassium level is slightly elevated, which can increase the risk for arrhythmias.

The patient's ECG shows ventricular extrasystole, which may indicate some degree of cardiac electrical instability. The patient's troponin level is within normal limits, but the patient's LVEF is significantly reduced, which may increase the risk for pump failure.

While the patient is on multiple medications for heart failure, the patient's NYHA Class II indicates that the patient is still able to perform daily activities. However, the patient's LVEF is significantly reduced, which may increase the risk for pump failure. Overall, the patient's medical history and ECG findings do not indicate an immediate high risk for pump failure, but the patient's LVEF is still significantly reduced, which may increase the risk for pump failure over time."
184,184,P0309,"Age: 51
Gender: Male 
Weight: 97 kg
Height: 182 cm
NYHA Class: III
Blood Pressure: 160/100 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Diabetes, Dyslipemia, Hypertension, Myocardial Infarction
Albumin (g/L): 42
ALT or GPT (IU/L): 60.0
AST or GOT (IU/L): 50.0
Total Cholesterol (mmol/L): 5,12
Creatinine (mmol/L): 88.0
Gamma-glutamil transpeptidase (IU/L): 60
Glucose (mmol/L): 10,3
Hemoglobin (g/L): 144.0
HDL (mmol/L): 0,91
Potassium (mEq/L): 3,9
LDL (mmol/L): 3,1
Sodium (mEq/L): 140.0
Pro-BNP (ng/L): 1185.0
Protein (g/L): 85
T3 (pg/dL): 0,02
T4 (ng/L): 23
Troponin (ng/mL): 0,01
TSH (mIU/L): 1,99
Urea (mg/dL): 7,49
LVEF (%): 36.0
Medications: Beta Blockers, Statins, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: No
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",survivor,"RANKING: 1. Survivor
REASONING: 

Based on the provided patient data, I would rank the patient as having a high likelihood of being a survivor over the next few years. Here's why:

1. Age: Although the patient is 51 years old, which is considered middle-aged, the age itself is not a significant risk factor for mortality in this context.
2. NYHA Class III: The patient has a moderate to severe heart failure, which indicates a more advanced stage of cardiomyopathy. However, the fact that the patient is still receiving beta blockers and ACE inhibitors suggests that the current treatment plan is effective in managing symptoms.
3. Medications: The patient is taking a combination of beta blockers, statins, and ACE inhibitors, which are standard treatments for managing heart failure, hypertension, and hyperlipidemia. This comprehensive approach suggests that the patient is receiving adequate care.
4. Pro-BNP levels: Although the Pro-BNP level is elevated (1185 ng/L), which indicates some level of heart failure, it is not excessively high, suggesting that the patient's heart is not severely failing.
5. LVEF: The left ventricular ejection fraction (LVEF) is 36%, which is a relatively low value, indicating significant left ventricular dysfunction. However, this is not uncommon in patients with ischemic cardiomyopathy.

The patient's prognosis is less likely to be sudden cardiac death (SCD) due to the following reasons:

* The patient's ECG impression does not show any signs of ventricular arrhythmias, which are a common cause of SCD.
* The patient is taking beta blockers, which are known to reduce the risk of SCD.

The patient's prognosis is less likely to be pump failure death due to the following reasons:

* The patient is taking ACE inhibitors, which are known to improve cardiac function and reduce the risk of heart failure.
* The patient's LVEF is not extremely low (although it is low), and the patient is receiving beta blockers, which can help improve cardiac function.

Overall, while the patient has significant heart disease, the comprehensive treatment plan, moderate NYHA class, and relatively low LVEF suggest that the patient is likely to survive over the next few years."
185,185,P0310,"Age: 58
Gender: Male 
Weight: 87 kg
Height: 172 cm
NYHA Class: II
Blood Pressure: 130/80 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Dyslipemia, Hypertension, Myocardial Infarction
Albumin (g/L): 41
ALT or GPT (IU/L): 27.0
AST or GOT (IU/L): 25.0
Total Cholesterol (mmol/L): 4,65
Creatinine (mmol/L): 97.0
Gamma-glutamil transpeptidase (IU/L): 33
Glucose (mmol/L): 6,1
Hemoglobin (g/L): 158.0
HDL (mmol/L): 1,06
Potassium (mEq/L): 4,2
LDL (mmol/L): 3,1
Sodium (mEq/L): 141.0
Pro-BNP (ng/L): 14.0
Protein (g/L): 72
T3 (pg/dL): 0,02
T4 (ng/L): 22
Troponin (ng/mL): 0,03
TSH (mIU/L): 2,05
Urea (mg/dL): 5,83
LVEF (%): 60.0
Medications: Beta Blockers, Statins
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"RANKING: 

1. Survivor
REASONING: 
Based on the provided patient data, the patient has a history of ischemic dilated cardiomyopathy, hypertension, and myocardial infarction, which are risk factors for heart failure and arrhythmias. However, the patient's current NYHA Class II indicates that the patient is experiencing some limitation in physical activity due to their heart condition, but it's not severe. The patient's LVEF is 60%, which is below the normal range, indicating some degree of left ventricular dysfunction. However, the absence of elevated troponin levels and no evidence of ventricular tachycardia or ventricular extrasystole on the ECG suggests that the patient does not have an acute myocardial infarction or significant cardiac ischemia. The patient's medication regimen includes beta blockers and statins, which are standard treatments for heart failure and hypertension. The patient's biomarkers, such as ALT, AST, and creatinine, are within normal limits, indicating no acute kidney injury or liver dysfunction. The patient's hemoglobin and electrolyte levels are also within normal limits. Overall, these factors suggest that the patient is likely to survive for the next few years with proper management of their condition.

2. Pump failure death
REASONING: 
The patient's LVEF is 60%, which is below the normal range, indicating some degree of left ventricular dysfunction. This could lead to progressive heart failure over time, especially if the patient's condition is not adequately managed. Additionally, the patient's NYHA Class II indicates some limitation in physical activity, which could worsen over time if the patient's heart function continues to decline. While the patient is on beta blockers and statins, which are standard treatments for heart failure and hypertension, the patient's lipid profile (high total cholesterol and LDL) may not be adequately controlled, which could contribute to further cardiac damage. However, the patient's biomarkers and ECG are within normal limits, suggesting that the patient does not have an acute cardiac event.

3. Sudden cardiac death
REASONING: 
The patient's ECG shows a monomorphic ventricular extrasystole, which is a potential indicator of ventricular arrhythmia. However, the absence of ventricular tachycardia or non-sustained ventricular tachycardia on the ECG makes this a less likely outcome. Additionally, the patient's medication regimen includes beta blockers, which are effective in reducing the risk of arrhythmias. While the patient's LVEF is below normal, the patient's biomarkers and ECG are within normal limits, suggesting that the patient does not have an acute cardiac event. However, the patient's history of ischemic dilated cardiomyopathy and hypertension may increase the risk of arrhythmias, making sudden cardiac death a possible long-term risk."
186,186,P0311,"Age: 64
Gender: Male 
Weight: 107 kg
Height: 176 cm
NYHA Class: II
Blood Pressure: 130/70 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Dyslipemia, Hypertension, Myocardial Infarction
Albumin (g/L): 39
ALT or GPT (IU/L): 53.0
AST or GOT (IU/L): 22.0
Total Cholesterol (mmol/L): 5,82
Creatinine (mmol/L): 124.0
Gamma-glutamil transpeptidase (IU/L): 254
Glucose (mmol/L): 5,9
Hemoglobin (g/L): 156.0
HDL (mmol/L): 1,24
Potassium (mEq/L): 4,7
LDL (mmol/L): 3,36
Sodium (mEq/L): 138.0
Pro-BNP (ng/L): 208.0
Protein (g/L): 73
T3 (pg/dL): 0,02
T4 (ng/L): 22
Troponin (ng/mL): 0,02
TSH (mIU/L): 3,26
Urea (mg/dL): 8,32
LVEF (%): 45.0
Medications: Beta Blockers, Statins, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: TPSV
        - Bradycardia: No
            ",survivor,"RANKING: 
1. Survivor 
REASONING: 
Based on the provided patient data, the patient has a significant history of ischemic dilated cardiomyopathy, hypertension, and previous myocardial infarction, which are all risk factors for heart failure and sudden cardiac death. The patient's left ventricular ejection fraction (LVEF) is 45%, indicating poor cardiac function. However, the patient is currently on beta blockers, statins, and an ACE inhibitor, which are standard treatments for managing heart failure and reducing cardiovascular risk.

The patient's electrolytes, liver enzymes, and kidney function are also within relatively normal limits, with the exception of a slightly elevated creatinine level. The ECG shows a polymorphic ventricular extrasystole, which may indicate a possible underlying arrhythmia, but it is not severe enough to suggest a high risk of sudden cardiac death.

The patient's laboratory results, including the elevated Pro-BNP level (208 ng/L), indicate some degree of cardiac stress and strain, but it is not extremely high. The patient's hemoglobin level is normal, and the rest of the blood work is relatively unremarkable.

Given these factors, the most likely outcome for the next few years is that the patient will survive, although it is essential to closely monitor the patient's condition and adjust the treatment plan as needed to minimize the risk of complications."
187,187,P0312,"Age: 69
Gender: Male 
Weight: 84 kg
Height: 170 cm
NYHA Class: II
Blood Pressure: 120/70 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Diabetes, Hypertension, Myocardial Infarction
Albumin (g/L): 42
ALT or GPT (IU/L): 32.0
AST or GOT (IU/L): 20.0
Total Cholesterol (mmol/L): 5,17
Creatinine (mmol/L): 97.0
Gamma-glutamil transpeptidase (IU/L): 18
Glucose (mmol/L): 8,3
Hemoglobin (g/L): 136.0
HDL (mmol/L): 1,16
Potassium (mEq/L): 4
LDL (mmol/L): 3,67
Sodium (mEq/L): 140.0
Pro-BNP (ng/L): 164.0
Protein (g/L): 70
T3 (pg/dL): 0,03
T4 (ng/L): 21
Troponin (ng/mL): 0,01
TSH (mIU/L): 1,95
Urea (mg/dL): 7,49
LVEF (%): 51.0
Medications: Diabetes Medication, Angiotensin II Receptor Blocker, Beta Blockers, Statins, ACE Inhibitor, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"RANKING: 1. Survivor 
REASONING: 
This patient's overall health status is a combination of chronic conditions, including ischemic dilated cardiomyopathy, diabetes, hypertension, and myocardial infarction. However, the patient is currently on multiple medications that are commonly used to manage these conditions, including beta blockers, ACE inhibitors, statins, and an angiotensin II receptor blocker, which are all aimed at reducing the strain on the heart and managing blood pressure. The patient's current ECG results are also relatively unremarkable, with no signs of ventricular tachycardia, non-sustained ventricular tachycardia, or paroxysmal supraventricular tachyarrhythmia. 

The patient's LVEF of 51.0 is significantly reduced, indicating a compromised cardiac function. However, the fact that the patient is still alive and not showing any acute cardiac events suggests that the patient's current treatment plan is effective in managing their condition. Additionally, the patient's recent troponin level of 0.01 ng/mL is within normal limits, indicating no acute myocardial infarction. The patient's kidney function is also relatively preserved, with a creatinine level of 7.49 mg/dL. Overall, these factors suggest that the patient is likely to survive in the short term, provided their treatment plan remains effective and any underlying conditions are well-managed."
188,188,P0314,"Age: 56
Gender: Male 
Weight: 62 kg
Height: 162 cm
NYHA Class: II
Blood Pressure: 160/80 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Dyslipemia, Hypertension, Myocardial Infarction
Albumin (g/L): 44
ALT or GPT (IU/L): 55.0
AST or GOT (IU/L): 30.0
Total Cholesterol (mmol/L): 4,84
Creatinine (mmol/L): 80.0
Gamma-glutamil transpeptidase (IU/L): 19
Glucose (mmol/L): 5,6
Hemoglobin (g/L): 142.0
HDL (mmol/L): 1,4
Potassium (mEq/L): 4,8
LDL (mmol/L): 2,66
Sodium (mEq/L): 142.0
Pro-BNP (ng/L): 133.0
Protein (g/L): 74
T3 (pg/dL): 0,03
T4 (ng/L): 23
Troponin (ng/mL): 0,01
TSH (mIU/L): 3,12
Urea (mg/dL): 8,32
LVEF (%): 50.0
Medications: Beta Blockers, Statins
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: TPSV
        - Bradycardia: No
            ",survivor,"RANKING: 1. Survivor
REASONING: 

This patient has a complex medical history with multiple comorbidities, including ischemic dilated cardiomyopathy, hypertension, and myocardial infarction. However, the patient is currently on beta blockers and statins, which are standard treatments for managing heart failure and cardiovascular risk factors. The patient's left ventricular ejection fraction (LVEF) is 50%, which is below the normal range, indicating some degree of heart failure. However, the patient's Pro-BNP levels are not significantly elevated, which suggests that the patient may not be experiencing severe heart failure symptoms.

The ECG results show a history of ventricular extrasystoles, but no ventricular tachycardia or sustained ventricular tachycardia. The absence of these more severe arrhythmias suggests that the patient's heart is not at high risk for life-threatening arrhythmias. The patient's troponin levels are also within normal limits, which suggests that there is no evidence of acute myocardial injury.

Overall, while the patient has a complex medical history, the absence of severe heart failure symptoms and the presence of standard treatments suggest that the patient is likely to survive for the next few years. However, it is essential to closely monitor the patient's condition and adjust their treatment plan as needed to manage their comorbidities and prevent complications.

RANKING: 2. Sudden Cardiac Death
REASONING: 

While the patient's medical history and ECG results suggest that they are at risk for arrhythmias, the absence of ventricular tachycardia or sustained ventricular tachycardia on the ECG makes sudden cardiac death less likely. However, the patient's history of ventricular extrasystoles and ischemic dilated cardiomyopathy increase the risk of sudden cardiac death. Additionally, the patient's LVEF is below the normal range, which increases the risk of cardiac events.

RANKING: 3. Pump Failure Death
REASONING: 

While the patient's LVEF is below the normal range, the patient's Pro-BNP levels are not significantly elevated, and they are currently on beta blockers and statins, which are standard treatments for managing heart failure. The patient's kidney function is also relatively preserved, with a creatinine level of 80.0 mmol/L, which is within the normal range. However, the patient's medical history of myocardial infarction and ischemic dilated cardiomyopathy increases the risk of pump failure. Additionally, the patient's elevated total cholesterol level of 4.84 mmol/L increases the risk of atherosclerotic disease, which can contribute to pump failure."
189,189,P0315,"Age: 71
Gender: Male 
Weight: 76 kg
Height: 173 cm
NYHA Class: III
Blood Pressure: 115/80 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Peripheral vascular disease, Myocardial Infarction
Albumin (g/L): 47,8
ALT or GPT (IU/L): 44.0
AST or GOT (IU/L): 51.0
Total Cholesterol (mmol/L): 3,47
Creatinine (mmol/L): 109.0
Gamma-glutamil transpeptidase (IU/L): 112
Glucose (mmol/L): 5,4
Hemoglobin (g/L): 134.0
HDL (mmol/L): 1,32
Potassium (mEq/L): 4,7
LDL (mmol/L): 1,68
Sodium (mEq/L): 142.0
Pro-BNP (ng/L): 5342.0
Protein (g/L): 76
T3 (pg/dL): 0,05
T4 (ng/L): 17
Troponin (ng/mL): 0,02
TSH (mIU/L): 3,26
Urea (mg/dL): 4,23
LVEF (%): 22.0
Medications: Beta Blockers, Loop Diuretics, Spironolactone, Statins, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",survivor,"RANKING: 1. Survivor
REASONING: 

Based on the patient's data, the patient is at a high risk for adverse cardiac events due to a combination of factors. The patient has a history of ischemic dilated cardiomyopathy, which is a significant risk factor for heart failure and sudden cardiac death. The patient's left ventricular ejection fraction (LVEF) is severely impaired at 22%, indicating poor cardiac function. The presence of non-sustained ventricular tachycardia (NSVT) and ventricular extrasystoles on the ECG impression also raises concerns about arrhythmias, which can be life-threatening.

The patient's elevated creatinine level (109.0 mmol/L) and elevated troponin level (0.02 ng/mL) suggest some degree of kidney dysfunction, which may be related to cardiac disease. The patient's elevated liver enzymes (ALT and AST) may also indicate some degree of liver dysfunction, possibly related to cardiac disease or medication side effects.

Despite these concerns, the patient is on beta blockers, which are commonly used to reduce the risk of heart failure and arrhythmias. However, the patient's NYHA class III status indicates severe symptoms, suggesting that the patient's cardiac function is severely compromised.

Considering these factors, I would rank the patient as having a high risk for adverse cardiac events. However, given the patient's age (71 years) and overall clinical presentation, I would still rank the patient as having a higher chance of survival compared to the other two options.

RANKING: 2. Sudden cardiac death
REASONING: 

While the patient is at a high risk for adverse cardiac events, the patient's survival is still possible due to their age and the presence of beta blockers, which can help reduce the risk of arrhythmias and heart failure.

RANKING: 3. Pump failure death
REASONING: 

The patient's severe cardiac dysfunction (LVEF 22%) and NYHA class III status make pump failure a significant concern. However, the patient is on medications that can help manage heart failure symptoms, such as loop diuretics and spironolactone. Additionally, the patient's elevated creatinine level may indicate some degree of kidney dysfunction, but this is not necessarily a direct indicator of pump failure.

Given the patient's overall clinical presentation, I would rank pump failure death as the least likely of the three options, but still a significant concern."
190,190,P0316,"Age: 71
Gender: Male 
Weight: 61 kg
Height: 155 cm
NYHA Class: II
Blood Pressure: 140/80 mmHg
Past Medical History: Hypertensive cardiomyopathy, Peripheral vascular disease, Hypertension
Albumin (g/L): 40,7
ALT or GPT (IU/L): 10.0
AST or GOT (IU/L): 15.0
Total Cholesterol (mmol/L): 5,12
Creatinine (mmol/L): 110.0
Gamma-glutamil transpeptidase (IU/L): 20
Glucose (mmol/L): 5,3
Hemoglobin (g/L): 124.0
HDL (mmol/L): 1,16
Potassium (mEq/L): 5
LDL (mmol/L): 3,36
Sodium (mEq/L): 142.0
Pro-BNP (ng/L): 1903.0
Protein (g/L): 76
T3 (pg/dL): 0,04
T4 (ng/L): 16
Troponin (ng/mL): 0,01
TSH (mIU/L): 3,42
Urea (mg/dL): 9,13
LVEF (%): 39.0
Medications: Beta Blockers, Loop Diuretics, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: TPSV
        - Bradycardia: No
            ",survivor,"RANKING: 
1. Survivor
REASONING: 
The patient is a 71-year-old male with a history of hypertension, cardiomyopathy, and peripheral vascular disease. The patient's NYHA class is II, indicating moderate symptoms. The patient's blood pressure is elevated at 140/80 mmHg, which is consistent with their past medical history. The patient's laboratory results show elevated creatinine levels (110.0 mmol/L) and a low LVEF (39.0%), indicating impaired kidney function and reduced cardiac function, respectively.

The patient's ECG impression shows ventricular extrasystoles and polymorphic ventricular tachycardia, which may indicate a higher risk of arrhythmias. However, the patient does not have a history of ventricular tachycardia or bradycardia, and the absence of non-sustained ventricular tachycardia (CH>10) is noted. The patient's troponin level is within normal limits, and the TSH level is within the normal range.

The patient's Pro-BNP level is elevated at 1903.0 ng/L, which may indicate cardiac stress or strain. However, the patient's age, weight, and other laboratory results do not suggest acute coronary syndrome.

Considering these factors, the patient's overall prognosis is likely to be a survivor, with the possibility of cardiac complications or hospitalization for arrhythmia management. However, without further information on the patient's symptoms, the likelihood of sudden cardiac death or pump failure death is relatively low.

RANKING: 
2. Sudden cardiac death (less likely)
REASONING: 
The patient's elevated Pro-BNP level and ECG impression of ventricular extrasystoles and polymorphic ventricular tachycardia may suggest an increased risk of cardiac arrhythmias. However, the patient's troponin level is within normal limits, and the absence of non-sustained ventricular tachycardia (CH>10) reduces the likelihood of sudden cardiac death.

The patient's age and NYHA class II symptoms may also contribute to a lower risk of sudden cardiac death, as this patient is not experiencing severe symptoms.

RANKING: 
3. Pump failure death (least likely)
REASONING: 
The patient's LVEF is 39.0%, which is significantly reduced, indicating impaired cardiac function. However, the patient is on beta blockers and ACE inhibitors, which are commonly used to manage heart failure.

The patient's creatinine level is elevated, indicating impaired kidney function, which may contribute to a higher risk of pump failure. However, the patient's blood pressure is controlled with loop diuretics, which may help manage fluid overload and reduce the risk of pump failure.

The patient's Pro-BNP level is elevated, but the patient's age and other laboratory results do not suggest acute heart failure. Therefore, the likelihood of pump failure death is relatively low."
191,191,P0318,"Age: 55
Gender: Male 
Weight: 63 kg
Height: 149 cm
NYHA Class: II
Blood Pressure: 105/70 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Diabetes, Dyslipemia
Albumin (g/L): 48,3
ALT or GPT (IU/L): 17.0
AST or GOT (IU/L): 19.0
Total Cholesterol (mmol/L): 6,67
Creatinine (mmol/L): 155.0
Gamma-glutamil transpeptidase (IU/L): 33
Glucose (mmol/L): 6,8
Hemoglobin (g/L): 137.0
HDL (mmol/L): 1,09
Potassium (mEq/L): 5,4
LDL (mmol/L): 3,1
Sodium (mEq/L): 137.0
Pro-BNP (ng/L): 142.0
Protein (g/L): 75
T3 (pg/dL): 0,06
T4 (ng/L): 19
Troponin (ng/mL): 0,01
TSH (mIU/L): 0,729
Urea (mg/dL): 15,15
LVEF (%): 39.0
Medications: Diabetes Medication, Angiotensin II Receptor Blocker, Beta Blockers, Digoxin, Loop Diuretics, Spironolactone
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: TPSV
        - Bradycardia: No
            ",survivor,"RANKING: 1. Survivor
REASONING: 

Based on the provided patient data, the patient is likely to survive for the next few years. The primary reasons for this are:

1. The patient's age is 55, which is relatively young for a cardiomyopathy patient, and they are still in NYHA Class II, indicating that they have some symptoms but can still perform daily activities with moderate difficulty. This suggests that the patient's cardiac function is not severely compromised.

2. The patient's LVEF is 39%, which is significantly reduced, but it is not as low as 20-30% that would typically indicate advanced heart failure. This suggests that the patient's heart is still pumping blood effectively, albeit inefficiently.

3. The patient's laboratory values, including electrolytes, liver enzymes, and kidney function, do not indicate any acute or chronic conditions that would pose an immediate threat to the patient's survival.

4. The presence of ventricular extrasystoles, polymorphic and non-sustained ventricular tachycardia, and paroxysmal supraventricular tachycardia may indicate an increased risk of arrhythmias, but the absence of sustained ventricular tachycardia and other high-risk features reduces this risk.

5. The patient is on a comprehensive regimen of medications, including beta blockers, ACE inhibitors, and digoxin, which are all recommended for patients with heart failure and arrhythmias.

While the patient's prognosis is uncertain and may depend on various factors, including lifestyle modifications, medication adherence, and potential future cardiac events, the overall assessment suggests that the patient is likely to survive for the next few years.

RANKING: 2. Sudden cardiac death
REASONING: 

Based on the provided patient data, the patient is at an increased risk of sudden cardiac death due to the following factors:

1. The patient's reduced LVEF of 39% indicates a compromised cardiac function, which can lead to arrhythmias and sudden cardiac death.

2. The presence of ventricular extrasystoles, polymorphic and non-sustained ventricular tachycardia, and paroxysmal supraventricular tachycardia increase the risk of arrhythmias, which can lead to sudden cardiac death.

3. The patient's history of ischemic dilated cardiomyopathy and dyslipemia may have contributed to the development of the cardiac dysfunction, increasing the risk of arrhythmias and sudden cardiac death.

4. The patient's age and NYHA Class II symptoms may indicate a gradual decline in cardiac function, increasing the risk of sudden cardiac death.

While the patient is currently on a comprehensive regimen of medications, the presence of these risk factors suggests that the patient is at an increased risk of sudden cardiac death.

RANKING: 3. Pump failure death
REASONING: 

Based on the provided patient data, the patient is at an increased risk of pump failure death due to the following factors:

1. The patient's reduced LVEF of 39% indicates a compromised cardiac function, which can lead to heart failure and pump failure.

2. The patient's history of ischemic dilated cardiomyopathy and dyslipemia may have contributed to the development of the cardiac dysfunction, increasing the risk of heart failure and pump failure.

3. The patient's elevated creatinine level of 155.0 indicates impaired kidney function, which can lead to fluid overload and heart failure.

4. The patient's elevated BNP level of 142.0 indicates increased ventricular wall stress, which can lead to heart failure and pump failure.

5. The patient's NYHA Class II symptoms may indicate a gradual decline in cardiac function, increasing the risk of pump failure.

However, the patient is currently on a comprehensive regimen of medications, including ACE inhibitors, beta blockers, and digoxin, which can help manage heart failure and reduce the risk of pump failure. Despite these factors, the patient's compromised cardiac function and risk of arrhythmias make pump failure death a possible outcome."
192,192,P0319,"Age: 52
Gender: Male 
Weight: 89 kg
Height: 168 cm
NYHA Class: II
Blood Pressure: 100/70 mmHg
Past Medical History: Idiopathic dilated cardiomyopathy, Diabetes
Albumin (g/L): 44,69
ALT or GPT (IU/L): 27.0
AST or GOT (IU/L): 22.0
Total Cholesterol (mmol/L): 6,31
Creatinine (mmol/L): 86.0
Gamma-glutamil transpeptidase (IU/L): 37
Glucose (mmol/L): 6,9
Hemoglobin (g/L): 155.0
HDL (mmol/L): 0,98
Potassium (mEq/L): 4,3
LDL (mmol/L): 4,68
Sodium (mEq/L): 140.0
Pro-BNP (ng/L): 984.0
Protein (g/L): 72
T3 (pg/dL): 0,04
T4 (ng/L): 14
Troponin (ng/mL): 0,01
TSH (mIU/L): 1,39
Urea (mg/dL): 9,57
LVEF (%): 30.0
Medications: Diabetes Medication, Digoxin, Loop Diuretics, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"RANKING: 1. Survivor
REASONING: 

Based on the provided patient data, the patient has a significant history of idiopathic dilated cardiomyopathy, which is a condition where the heart's ability to pump blood is compromised. The patient's left ventricular ejection fraction (LVEF) is 30.0%, indicating severe left ventricular dysfunction. This suggests that the patient's heart is not pumping efficiently, which increases the risk of complications.

The patient's current medication regimen includes ACE inhibitors, which are typically used to manage heart failure and reduce blood pressure. However, the patient's blood pressure is within a relatively normal range (100/70 mmHg), which may not be sufficient to adequately control the patient's blood pressure, especially considering their history of heart failure.

The patient's laboratory results show elevated troponin levels (0.01 ng/mL), which indicate some degree of cardiac muscle damage. The patient's pro-BNP level is also elevated (984 ng/L), which is a marker of heart failure. These findings suggest that the patient's heart is under significant stress, and their cardiac function is compromised.

Despite these concerning findings, the patient is currently classified as a survivor, indicating that they are alive. However, given the patient's severe heart failure and elevated troponin levels, it is likely that the patient will experience a cardiac event in the near future.

Given the patient's history of ventricular extrasystoles and non-sustained ventricular tachycardia on ECG, there is a moderate to high risk of sudden cardiac death. However, the patient's survival is currently classified as the most likely outcome due to the fact that they are alive and receiving treatment.

Therefore, while the patient is at risk for cardiac events, the likelihood of sudden cardiac death is not the most likely outcome at this time, making survivor the top-ranked prognosis."
193,193,P0323,"Age: 62
Gender: Male 
Weight: 108 kg
Height: 171 cm
NYHA Class: III
Blood Pressure: 130/80 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Diabetes, Dyslipemia, Hypertension, Myocardial Infarction
Albumin (g/L): 43,9
ALT or GPT (IU/L): 34.0
AST or GOT (IU/L): 32.0
Total Cholesterol (mmol/L): 5,07
Creatinine (mmol/L): 139.0
Gamma-glutamil transpeptidase (IU/L): 19
Glucose (mmol/L): 7,3
Hemoglobin (g/L): 176.0
HDL (mmol/L): 1,03
Potassium (mEq/L): 4,4
LDL (mmol/L): 2,92
Sodium (mEq/L): 141.0
Pro-BNP (ng/L): 535.0
Protein (g/L): 81
T3 (pg/dL): 0,05
T4 (ng/L): 16
Troponin (ng/mL): 0,01
TSH (mIU/L): 2,69
Urea (mg/dL): 12,03
LVEF (%): 38.0
Medications: Calcium Channel Blocker, Diabetes Medication, Angiotensin II Receptor Blocker, Beta Blockers, Loop Diuretics, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",survivor,"RANKING: 1. Survivor
REASONING: The patient's age, NYHA Class III, and multiple comorbid conditions (ischemic dilated cardiomyopathy, diabetes, dyslipemia, and hypertension) increase the risk of adverse outcomes. However, the patient's recent ECG impression does not show any evidence of ventricular tachycardia or non-sustained ventricular tachycardia, which is a good sign. The patient is also taking multiple medications that are commonly used to manage heart failure and arrhythmias, such as beta blockers, ACE inhibitors, and calcium channel blockers. The patient's biomarkers, such as troponin and BNP, are not significantly elevated, which suggests that there is no acute myocardial infarction or significant heart failure. The patient's hemoglobin and kidney function are also relatively preserved, which is another positive sign. Overall, considering these factors, the patient is more likely to survive in the next few years.

RANKING: 2. Sudden Cardiac Death
REASONING: The patient's history of ischemic dilated cardiomyopathy and multiple comorbid conditions increases the risk of sudden cardiac death. The patient's recent ECG impression shows ventricular extrasystoles, which can be a marker for increased risk of arrhythmias. Additionally, the patient's low LVEF (38%) indicates a reduced left ventricular function, which can contribute to an increased risk of sudden cardiac death. The patient's medications do not specifically address the risk of sudden cardiac death, and the patient's biomarkers and kidney function are not optimally managed.

RANKING: 3. Pump Failure Death
REASONING: While the patient's NYHA Class III indicates significant heart failure, the patient's LVEF is not severely reduced (38%), and the patient is taking multiple medications that are commonly used to manage heart failure. The patient's biomarkers, such as troponin and BNP, are not significantly elevated, which suggests that the patient's heart failure is not severely decompensated. However, the patient's multiple comorbid conditions, such as diabetes and hypertension, can contribute to worsening heart failure over time. Additionally, the patient's kidney function is slightly elevated, which can be a marker for worsening heart failure. Overall, while the patient is at risk for heart failure, the patient's current clinical status and biomarkers do not suggest an immediate risk of pump failure death."
194,194,P0324,"Age: 63
Gender: Male 
Weight: 78 kg
Height: 159 cm
NYHA Class: II
Blood Pressure: 140/80 mmHg
Past Medical History: Enolic dilated cardiomyopathy, Diabetes, Dyslipemia, Peripheral vascular disease, Hypertension
Albumin (g/L): 45,59
ALT or GPT (IU/L): 40.0
AST or GOT (IU/L): 42.0
Total Cholesterol (mmol/L): 4,53
Creatinine (mmol/L): 94.0
Gamma-glutamil transpeptidase (IU/L): 104
Glucose (mmol/L): 8,8
Hemoglobin (g/L): 113.0
HDL (mmol/L): 0,88
Potassium (mEq/L): 4,5
LDL (mmol/L): 2,59
Sodium (mEq/L): 135.0
Pro-BNP (ng/L): 1148.0
Protein (g/L): 72
T3 (pg/dL): 0,04
T4 (ng/L): 15
Troponin (ng/mL): 0,02
TSH (mIU/L): 2,61
Urea (mg/dL): 7,57
LVEF (%): 34.0
Medications: Angiotensin II Receptor Blocker, Beta Blockers, Digoxin, Loop Diuretics, Spironolactone
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",survivor,"RANKING: 1. Survivor
REASONING:

The patient is a 63-year-old male with a history of dilated cardiomyopathy, diabetes, dyslipidemia, peripheral vascular disease, and hypertension, which are all risk factors for cardiovascular disease. The patient's current NYHA class is II, indicating moderate symptoms of heart failure. The patient's elevated creatinine level (94.0 mmol/L) suggests impaired kidney function, which is a common comorbidity in patients with heart failure.

The patient's ECG impression shows ventricular extrasystole, non-sustained ventricular tachycardia, and non-sustained ventricular tachycardia, which are all signs of cardiac arrhythmias. However, the patient's LVEF (34.0) is significantly reduced, indicating poor cardiac function. Despite this, the patient's current medications, including angiotensin II receptor blockers, beta blockers, digoxin, loop diuretics, and spironolactone, suggest that the patient is receiving standard treatment for heart failure.

The patient's biomarkers, such as troponin (0.02 ng/mL) and BNP (1148 ng/L), are elevated, indicating cardiac stress and strain. However, the patient's hemoglobin level (113.0 g/L) and potassium level (4.5 mEq/L) are within normal limits, and the patient's liver function tests (ALT and AST) are also within normal limits.

Given the patient's age, comorbidities, and cardiac function, the most likely outcome is survival. The patient's elevated creatinine level and impaired kidney function may require closer monitoring and adjustments to their medication regimen to minimize further kidney damage. However, the patient's cardiac function, despite being reduced, is not critically compromised, and the patient is receiving standard treatment for heart failure.

While the patient's ECG findings suggest an increased risk of arrhythmias, the patient's medications and current cardiac function suggest that the risk of sudden cardiac death is not the most likely outcome. Pump failure death, which occurs when the heart is unable to pump enough blood to meet the body's needs, is also a possible outcome, but the patient's current treatment and cardiac function suggest that this is not the most likely outcome.

Overall, based on the patient's current condition and treatment, the most likely outcome is survival, with ongoing monitoring and adjustments to their medication regimen to minimize further cardiac and kidney damage."
195,195,P0325,"Age: 53
Gender: Male 
Weight: 99 kg
Height: 165 cm
NYHA Class: II
Blood Pressure: 125/85 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Diabetes, Dyslipemia, Hypertension, Myocardial Infarction
Albumin (g/L): 48,8
ALT or GPT (IU/L): 33.0
AST or GOT (IU/L): 21.0
Total Cholesterol (mmol/L): 4,58
Creatinine (mmol/L): 83.0
Gamma-glutamil transpeptidase (IU/L): 230
Glucose (mmol/L): 11,5
Hemoglobin (g/L): 153.0
HDL (mmol/L): 1,5
Potassium (mEq/L): 3,8
LDL (mmol/L): 2,15
Sodium (mEq/L): 137.0
Pro-BNP (ng/L): 171.0
Protein (g/L): 77
T3 (pg/dL): 0,05
T4 (ng/L): 19
Troponin (ng/mL): 0,01
TSH (mIU/L): 2,09
Urea (mg/dL): 5,79
LVEF (%): 50.0
Medications: Diabetes Medication, Loop Diuretics, Statins, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: TPSV
        - Bradycardia: No
            ",survivor,"RANKING: 1. Survivor
REASONING: The patient's overall clinical presentation and test results indicate a relatively stable condition, with a moderate level of symptoms (NYHA Class II) and a preserved left ventricular ejection fraction (LVEF) of 50.0%. The presence of ischemic dilated cardiomyopathy, diabetes, hypertension, and dyslipemia are significant comorbidities, but the patient is on multiple medications, including a nitrovasodilator, which may be contributing to blood pressure control. The patient's troponin level is normal, and there is no evidence of acute myocardial infarction. The ECG shows a mild bradycardia (TPSV) but no other significant arrhythmias. The patient's renal function is also relatively preserved, with a creatinine level of 5.79 mg/dL. Overall, these factors suggest that the patient is likely to survive for the next few years, given the current management and absence of acute complications.

RANKING: 2. Sudden Cardiac Death
REASONING: While the patient's cardiac function is compromised, the presence of a nitrovasodilator and the absence of acute myocardial infarction, significant arrhythmias, or acute kidney injury reduce the likelihood of sudden cardiac death. However, the patient's LVEF is only 50.0%, which indicates some level of cardiac dysfunction. The patient's history of ischemic dilated cardiomyopathy and hypertension also increases the risk of sudden cardiac death. Additionally, the patient's elevated troponin level (0.01 ng/mL) may indicate some degree of myocardial damage, which could increase the risk of sudden cardiac death. However, the overall clinical picture is still relatively stable, and the patient's medications and comorbidities may mitigate these risks.

RANKING: 3. Pump Failure Death
REASONING: Pump failure death is the most likely outcome in this patient due to the significant comorbidities, including ischemic dilated cardiomyopathy, hypertension, and diabetes. The patient's LVEF of 50.0% and elevated creatinine level (5.79 mg/dL) indicate some degree of cardiac dysfunction and renal impairment, respectively. The patient's elevated BNP level (171 ng/L) also suggests some level of ventricular stress. The presence of dyslipemia and hypertension further increases the risk of cardiac events, including heart failure. While the patient is on medications to manage these conditions, the cumulative effect of these comorbidities and the patient's cardiac dysfunction make pump failure death a more likely outcome than sudden cardiac death."
196,196,P0326,"Age: 67
Gender: Male 
Weight: 78 kg
Height: 157 cm
NYHA Class: III
Blood Pressure: 140/80 mmHg
Past Medical History: Idiopathic dilated cardiomyopathy, Dyslipemia, Peripheral vascular disease
Albumin (g/L): 52,4
ALT or GPT (IU/L): 15.0
AST or GOT (IU/L): 22.0
Total Cholesterol (mmol/L): 4,09
Creatinine (mmol/L): 106.0
Gamma-glutamil transpeptidase (IU/L): 36
Glucose (mmol/L): 4,2
Hemoglobin (g/L): 144.0
HDL (mmol/L): 1,29
Potassium (mEq/L): 4,1
LDL (mmol/L): 1,89
Sodium (mEq/L): 139.0
Pro-BNP (ng/L): 298.0
Protein (g/L): 73
T3 (pg/dL): 0,05
T4 (ng/L): 19
Troponin (ng/mL): 0,01
TSH (mIU/L): 2,29
Urea (mg/dL): 4,9
LVEF (%): 34.0
Medications: Spironolactone, Statins, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"RANKING: 1. Survivor
REASONING: 

Based on the provided patient data, the patient is at a higher risk for cardiac events, but the presence of a good prognosis can be attributed to the following factors:

1. Age: Although the patient is 67 years old, the NYHA class is III, indicating moderate symptoms, which may suggest that the patient is not yet at the end stage of heart failure.
2. Medications: The patient is on spironolactone, statins, and an ACE inhibitor, which are standard treatments for heart failure and can help manage symptoms and slow disease progression.
3. LVEF: Although the LVEF is low at 34%, it is not extremely low, suggesting that the patient's heart is still functioning to some extent.
4. Troponin levels: The troponin level is normal, which suggests that there is no significant myocardial infarction or acute cardiac injury.
5. No evidence of acute coronary syndrome: The ECG impression does not show any signs of acute coronary syndrome, which is a significant risk factor for cardiac events.

However, the patient's past medical history of idiopathic dilated cardiomyopathy, dyslipidemia, and peripheral vascular disease suggests a high risk for cardiac events. The patient's low LVEF and elevated creatinine levels also indicate significant cardiac dysfunction. Despite these factors, the patient's overall clinical picture and treatment plan suggest a relatively good prognosis, with a likelihood of survival for the next few years."
197,197,P0328,"Age: 64
Gender: Male 
Weight: 84 kg
Height: 174 cm
NYHA Class: II
Blood Pressure: 120/70 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Dyslipemia, Peripheral vascular disease, Hypertension, Myocardial Infarction
Albumin (g/L): 48,7
ALT or GPT (IU/L): 12.0
AST or GOT (IU/L): 12.0
Total Cholesterol (mmol/L): 6,21
Creatinine (mmol/L): 93.0
Gamma-glutamil transpeptidase (IU/L): 24
Glucose (mmol/L): 5,7
Hemoglobin (g/L): 148.0
HDL (mmol/L): 1,16
Potassium (mEq/L): 4,8
LDL (mmol/L): 4,42
Sodium (mEq/L): 141.0
Pro-BNP (ng/L): 511.0
Protein (g/L): 76
T3 (pg/dL): 0,03
T4 (ng/L): 14
Troponin (ng/mL): 0,01
TSH (mIU/L): 1,22
Urea (mg/dL): 6,68
LVEF (%): 35.0
Medications: Beta Blockers, Statins, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"RANKING: 1. Survivor
REASONING: 
The patient has a complex medical history with multiple comorbidities, including ischemic dilated cardiomyopathy, dyslipidemia, peripheral vascular disease, hypertension, and myocardial infarction. However, the patient is currently on beta blockers and statins, which are evidence-based treatments for heart failure and coronary artery disease. The patient's current ECG findings show ventricular extrasystole, but no other significant arrhythmias.

The patient's LVEF is 35%, which indicates significant left ventricular dysfunction. However, the patient's ejection fraction is not extremely low, and the patient is not in cardiogenic shock. The patient's renal function is also preserved, with a creatinine level of 6.68 mg/dL.

Considering the patient's overall clinical presentation, I would rank the patient as a survivor with a high probability. The patient's current medications and medical history suggest that the patient is being adequately managed, and the patient's ECG findings do not indicate an acute cardiac event. The patient's low troponin level (0.01 ng/mL) also suggests that the patient is not experiencing acute myocardial infarction.

While the patient's LVEF is significantly reduced, the patient's overall clinical presentation and medical history suggest that the patient is likely to survive in the short term. The patient's weight and height are also within a relatively normal range, which may help to reduce the risk of complications.

RANKING: 2. Sudden cardiac death
REASONING: 
The patient's history of ischemic dilated cardiomyopathy and myocardial infarction increases the risk of sudden cardiac death. The patient's LVEF is significantly reduced, which increases the risk of arrhythmias and sudden cardiac death.

However, the patient is currently on beta blockers, which can help to reduce the risk of arrhythmias and sudden cardiac death. The patient's ECG findings show ventricular extrasystole, but no other significant arrhythmias. The patient's troponin level is also low, which suggests that the patient is not experiencing acute myocardial infarction.

While the patient's medical history and ECG findings do suggest a risk for sudden cardiac death, the patient's current medications and overall clinical presentation suggest that the patient is not at immediate risk. The patient's low LVEF and renal dysfunction do increase the risk of complications, but the patient's overall clinical presentation does not suggest an acute cardiac event.

RANKING: 3. Pump failure death
REASONING: 
The patient's LVEF is significantly reduced, which indicates left ventricular dysfunction. The patient's renal function is also impaired, with a creatinine level of 6.68 mg/dL, which increases the risk of complications.

The patient's medical history of ischemic dilated cardiomyopathy and myocardial infarction also increases the risk of pump failure. The patient's current ECG findings show ventricular extrasystole, which may be a sign of ventricular dysfunction.

However, the patient is currently on beta blockers, which can help to reduce the risk of heart failure. The patient's overall clinical presentation does not suggest an acute cardiac event, and the patient's troponin level is low.

While the patient's medical history and ECG findings do suggest a risk for pump failure, the patient's current medications and overall clinical presentation suggest that the patient is not at immediate risk. However, the patient's LVEF and renal dysfunction do increase the risk of complications, and the patient should be closely monitored for signs of heart failure."
198,198,P0331,"Age: 52
Gender: Female 
Weight: 82 kg
Height: 167 cm
NYHA Class: II
Blood Pressure: 125/70 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Dyslipemia, Hypertension, Myocardial Infarction
Albumin (g/L): 41
ALT or GPT (IU/L): 15.0
AST or GOT (IU/L): 16.0
Total Cholesterol (mmol/L): 4,06
Creatinine (mmol/L): 88.0
Gamma-glutamil transpeptidase (IU/L): 18
Glucose (mmol/L): 5,7
Hemoglobin (g/L): 132.0
HDL (mmol/L): 1,27
Potassium (mEq/L): 4,2
LDL (mmol/L): 2,28
Sodium (mEq/L): 142.0
Pro-BNP (ng/L): 720.0
Protein (g/L): 69
T3 (pg/dL): 0,04
T4 (ng/L): 17
Troponin (ng/mL): 0,01
TSH (mIU/L): 2,74
Urea (mg/dL): 8,02
LVEF (%): 37.0
Medications: Angiotensin II Receptor Blocker, Beta Blockers, Statins
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: TPSV
        - Bradycardia: No
            ",survivor,"RANKING: 1. Survivor
REASONING: 

Based on the provided patient data, I predict that the patient will survive for the next few years. The patient's age, NYHA Class II, and LVEF of 37% indicate a moderate to severe left ventricular dysfunction, which is consistent with ischemic dilated cardiomyopathy. However, the patient's blood pressure is well-controlled, and they are on medications for hypertension, dyslipidemia, and heart failure. 

The patient's liver function tests (ALT, AST, GGT) are within normal limits, and the creatinine level is elevated, but not significantly so. The presence of elevated Pro-BNP levels suggests some degree of heart failure. However, the patient's hemoglobin, potassium, and sodium levels are within normal limits.

The ECG findings of ventricular extrasystole and paroxysmal supraventricular tachyarrhythmia are concerning, but the absence of ventricular tachycardia and non-sustained ventricular tachycardia suggests that the patient does not have an immediate life-threatening arrhythmia. The presence of beta blockers and an angiotensin II receptor blocker indicates that the patient is receiving appropriate treatment for heart failure and hypertension.

Considering these factors, I believe that the patient will survive for the next few years, provided that their medications are well-tolerated and adjusted as needed, and they do not experience any significant adverse events, such as myocardial infarction or significant worsening of heart failure.

RANKING: 2. Sudden Cardiac Death
REASONING: 

Based on the patient's history of myocardial infarction and ischemic dilated cardiomyopathy, there is a moderate risk of sudden cardiac death. The patient's LVEF of 37% indicates significant left ventricular dysfunction, which increases the risk of arrhythmias and sudden cardiac death. 

The patient's ECG findings of ventricular extrasystole are concerning, and the presence of paroxysmal supraventricular tachyarrhythmia increases the risk of arrhythmias. Although the patient is on beta blockers and an angiotensin II receptor blocker, which are beneficial for heart failure and hypertension, the patient's heart failure status and LVEF are not optimal.

RANKING: 3. Pump Failure Death
REASONING: 

Based on the patient's LVEF of 37% and NYHA Class II, there is a moderate risk of pump failure. The patient's elevated creatinine level and elevated Pro-BNP levels suggest some degree of heart failure. 

However, the patient's hemoglobin, potassium, and sodium levels are within normal limits, and the patient is on medications for heart failure and hypertension. The presence of ventricular extrasystole and paroxysmal supraventricular tachyarrhythmia on the ECG suggests that the patient may not be receiving optimal treatment for heart failure.

While the patient's LVEF is low, it is not extremely low, and the patient is receiving medications that can help improve heart function. However, the patient's overall risk of pump failure is higher than the risk of sudden cardiac death, given their history of heart failure and moderate to severe left ventricular dysfunction."
199,199,P0334,"Age: 52
Gender: Male 
Weight: 83 kg
Height: 167 cm
NYHA Class: II
Blood Pressure: 120/80 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Dyslipemia, Hypertension, Myocardial Infarction
Albumin (g/L): 50,09
ALT or GPT (IU/L): 26.0
AST or GOT (IU/L): 25.0
Total Cholesterol (mmol/L): 4,99
Creatinine (mmol/L): 93.0
Gamma-glutamil transpeptidase (IU/L): 45
Glucose (mmol/L): 5,5
Hemoglobin (g/L): 140.0
HDL (mmol/L): 1,55
Potassium (mEq/L): 4,1
LDL (mmol/L): 2,92
Sodium (mEq/L): 139.0
Pro-BNP (ng/L): 136.0
Protein (g/L): 78
T3 (pg/dL): 0,04
T4 (ng/L): 13
Troponin (ng/mL): 0,01
TSH (mIU/L): 1,36
Urea (mg/dL): 9,8
LVEF (%): 32.0
Medications: Calcium Channel Blocker, Beta Blockers, Statins, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"RANKING: 
1. Survivor
REASONING:
The patient's age, NYHA Class II, and the presence of ischemic dilated cardiomyopathy, dyslipidemia, hypertension, and myocardial infarction suggest a significant cardiovascular history. However, the patient is not in NYHA Class III or IV, indicating some level of preserved cardiac function. The patient's LVEF is 32.0%, which is within the range of 25-39% for NYHA Class II. The presence of medications such as beta blockers and ACE inhibitors, which are commonly used to manage heart failure and reduce mortality, also suggests a reasonable level of cardiac management.

The patient's biomarkers, such as troponin and creatinine, are not significantly elevated, indicating no acute myocardial infarction or severe kidney dysfunction. The absence of paroxysmal supraventricular tachycardia and bradycardia on the ECG impression suggests that the patient is not at high risk for arrhythmias that could lead to sudden cardiac death.

While the patient's Pro-BNP level is elevated, it is not extremely high, and the patient's protein level is within a relatively normal range. The presence of ventricular extrasystole and non-sustained ventricular tachycardia (CH>10) on the ECG impression is concerning, but the patient is already on beta blockers, which can help manage ventricular arrhythmias.

Overall, considering the patient's age, cardiovascular history, and current cardiac function, the most likely outcome is survival, albeit with ongoing cardiovascular risk."
200,200,P0335,"Age: 44
Gender: Male 
Weight: 90 kg
Height: 171 cm
NYHA Class: II
Blood Pressure: 100/70 mmHg
Past Medical History: Idiopathic dilated cardiomyopathy, Dyslipemia, Hypertension
Albumin (g/L): 42,8
ALT or GPT (IU/L): 30.0
AST or GOT (IU/L): 19.0
Total Cholesterol (mmol/L): 3,41
Creatinine (mmol/L): 78.0
Gamma-glutamil transpeptidase (IU/L): 38
Glucose (mmol/L): 5,7
Hemoglobin (g/L): 161.0
HDL (mmol/L): 0,57
Potassium (mEq/L): 4,3
LDL (mmol/L): 1,55
Sodium (mEq/L): 139.0
Pro-BNP (ng/L): 522.0
Protein (g/L): 69
T3 (pg/dL): 0,05
T4 (ng/L): 19
Troponin (ng/mL): 0,01
TSH (mIU/L): 2,03
Urea (mg/dL): 7,35
LVEF (%): 25.0
Medications: Beta Blockers, Spironolactone, Statins, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"RANKING: 1. Survivor
REASONING: The patient has a history of idiopathic dilated cardiomyopathy, which is a significant risk factor for heart failure and sudden cardiac death. However, the patient is currently taking medications that are standard for managing heart failure and ventricular arrhythmias (beta blockers, spironolactone, statins, and ACE inhibitor). The patient's left ventricular ejection fraction (LVEF) is 25%, which is significantly reduced, indicating poor heart function. However, the patient's serum creatinine level is within normal limits, and the patient is not showing signs of acute kidney injury.

The patient's ECG shows non-sustained ventricular tachycardia, which is a concerning sign of arrhythmia, but it is not sustained. The presence of ventricular extrasystole and polymorphic ventricular tachycardia is also concerning, but the absence of sustained ventricular tachycardia and paroxysmal supraventricular tachyarrhythmia reduces the risk.

The patient's biomarkers, such as troponin and creatinine, are within normal limits, which suggests that the patient is not experiencing acute myocardial infarction or kidney injury. The patient's hemoglobin and liver function tests are also within normal limits.

Given the patient's overall clinical picture, I believe that the patient is most likely to survive for the next few years. However, close monitoring and follow-up are necessary to adjust the treatment plan and address any potential arrhythmias or cardiac events.

RANKING: 2. Sudden cardiac death
REASONING: The patient's history of idiopathic dilated cardiomyopathy, non-sustained ventricular tachycardia, and polymorphic ventricular tachycardia on ECG increase the risk of sudden cardiac death. The patient's reduced LVEF and elevated pro-BNP levels also indicate poor heart function.

RANKING: 3. Pump failure death
REASONING: While the patient's reduced LVEF and elevated pro-BNP levels suggest heart failure, the patient is currently on medications that are standard for managing heart failure (beta blockers, spironolactone, statins, and ACE inhibitor). The patient's serum creatinine level is within normal limits, and the patient is not showing signs of acute kidney injury. Therefore, pump failure death is less likely compared to sudden cardiac death."
201,201,P0337,"Age: 55
Gender: Male 
Weight: 88 kg
Height: 164 cm
NYHA Class: II
Blood Pressure: 160/85 mmHg
Past Medical History: Hypertensive cardiomyopathy, Dyslipemia, Hypertension
Albumin (g/L): 48,7
ALT or GPT (IU/L): 27.0
AST or GOT (IU/L): 18.0
Total Cholesterol (mmol/L): 6,54
Creatinine (mmol/L): 96.0
Gamma-glutamil transpeptidase (IU/L): 60
Glucose (mmol/L): 6,2
Hemoglobin (g/L): 157.0
HDL (mmol/L): 1,09
Potassium (mEq/L): 3,6
LDL (mmol/L): 4,03
Sodium (mEq/L): 140.0
Pro-BNP (ng/L): 209.0
Protein (g/L): 77
T3 (pg/dL): 0,04
T4 (ng/L): 16
Troponin (ng/mL): 0,01
TSH (mIU/L): 0,544
Urea (mg/dL): 10,24
LVEF (%): 67.0
Medications: Calcium Channel Blocker, Angiotensin II Receptor Blocker, Beta Blockers, Statins
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: TPSV
        - Bradycardia: No
            ",survivor,"RANKING: 1. Survivor
REASONING: 

Based on the provided patient data, the patient's prognosis is predicted to be a survivor. The patient's age, NYHA Class II, and LVEF of 67% indicate that the patient has a relatively preserved cardiac function, which is a positive prognostic factor. The patient's past medical history of hypertensive cardiomyopathy and dyslipidemia, although significant, is being managed with medications, which suggests that the patient is under control.

The patient's laboratory results show elevated creatinine levels, indicating impaired renal function, which is a risk factor for cardiovascular events. However, the patient's other laboratory values, such as troponin, TSH, and electrolytes, are relatively normal, suggesting that the patient does not have acute cardiac injury or significant electrolyte imbalances.

The ECG results show a history of ventricular extrasystole, but no other significant arrhythmias. This suggests that the patient has some degree of cardiac conduction system dysfunction, but it is not severe enough to predict a poor prognosis.

Overall, the combination of the patient's preserved cardiac function, controlled hypertension, and absence of acute cardiac injury or significant arrhythmias suggests that the patient is at lower risk for cardiac events and is more likely to survive.

RANKING: 2. Sudden cardiac death
REASONING: 

A sudden cardiac death is unlikely in this patient due to the following reasons:

- The patient's LVEF is 67%, which is relatively preserved and suggests that the patient's cardiac function is not severely impaired.
- The patient is on medications to control hypertension, dyslipidemia, and heart failure, which suggests that the patient's cardiovascular risk factors are being managed.
- The ECG results show no ventricular tachycardia, non-sustained ventricular tachycardia, or other significant arrhythmias that could increase the risk of sudden cardiac death.
- The patient's laboratory values are relatively normal, with no evidence of acute cardiac injury or significant electrolyte imbalances.

However, the patient's elevated creatinine levels and impaired renal function are risk factors for cardiovascular events, and the patient's age and sex are also risk factors for cardiovascular disease. While these factors increase the risk of cardiovascular events, they do not necessarily increase the risk of sudden cardiac death.

RANKING: 3. Pump failure death
REASONING: 

Pump failure death is the least likely outcome for this patient due to the following reasons:

- The patient's LVEF is 67%, which suggests that the patient's cardiac function is not severely impaired.
- The patient is on medications to control hypertension, dyslipidemia, and heart failure, which suggests that the patient's cardiovascular risk factors are being managed.
- The ECG results show no significant arrhythmias that could increase the risk of pump failure.
- The patient's laboratory values are relatively normal, with no evidence of acute cardiac injury or significant electrolyte imbalances.

However, the patient's elevated creatinine levels and impaired renal function increase the risk of cardiovascular events, and the patient's age and sex are also risk factors for cardiovascular disease. While these factors increase the risk of cardiovascular events, they do not necessarily increase the risk of pump failure.

It is worth noting that the patient's past medical history of hypertensive cardiomyopathy and dyslipidemia, although managed, may still increase the risk of cardiovascular events and pump failure in the future. However, based on the available data, pump failure death is the least likely outcome for this patient."
202,202,P0338,"Age: 75
Gender: Male 
Weight: 63 kg
Height: 157 cm
NYHA Class: II
Blood Pressure: 160/80 mmHg
Past Medical History: Enolic dilated cardiomyopathy, Dyslipemia, Hypertension, Myocardial Infarction
Albumin (g/L): 52,19
ALT or GPT (IU/L): 13.0
AST or GOT (IU/L): 23.0
Total Cholesterol (mmol/L): 5,3
Creatinine (mmol/L): 84.0
Gamma-glutamil transpeptidase (IU/L): 38
Glucose (mmol/L): 6,6
Hemoglobin (g/L): 145.0
HDL (mmol/L): 1,34
Potassium (mEq/L): 4,6
LDL (mmol/L): 3,31
Sodium (mEq/L): 141.0
Pro-BNP (ng/L): 1121.0
Protein (g/L): 79
T3 (pg/dL): 0,05
T4 (ng/L): 16
Troponin (ng/mL): 0,01
TSH (mIU/L): 2,43
Urea (mg/dL): 5,79
LVEF (%): 39.0
Medications: Digoxin, Loop Diuretics, Statins, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: TPSV
        - Bradycardia: No
            ",survivor,"RANKING: 
1. Survivor
2. Pump failure death
3. Sudden cardiac death

REASONING:

Based on the provided patient data, the most likely outcome for this patient is survivor. The patient's age, NYHA Class II, and the presence of enolic dilated cardiomyopathy, hypertension, and myocardial infarction suggest a significant cardiovascular history. However, the patient's current LVEF of 39.0 is not extremely low, which might suggest some residual cardiac function.

The patient's elevated Pro-BNP level (1121.0 ng/L) indicates a moderate level of B-type natriuretic peptide, which is a marker of cardiac stress and strain. This, combined with the presence of non-sustained ventricular tachycardia (CH>10) on the ECG, suggests that the patient's heart is under significant stress and may be at risk of further complications.

While the patient's hemoglobin level is slightly elevated, which might be a sign of anemia, and the presence of a low T3 level (0.05 pg/dL), which can be associated with anemia, these factors do not seem to be the primary concerns in this case.

The patient is currently taking medications that are standard for managing heart failure (digoxin, loop diuretics, statins, and ACE inhibitor), which suggests that the patient's condition is being actively managed.

Considering these factors, the patient's overall prognosis is likely to be a survivor, but there is still a risk of pump failure death. The presence of non-sustained ventricular tachycardia on the ECG is a significant concern, as it may indicate a high risk of sudden cardiac death.

The patient's low T4 level (16 ng/L) could be related to anemia, but it's not a strong indicator of thyroid dysfunction, which is not a primary concern in this case.

In summary, while the patient's cardiovascular history and current condition suggest a high risk of complications, the presence of current medications and a relatively preserved LVEF make a survivor outcome more likely. However, the risk of pump failure death and sudden cardiac death remains a concern."
203,203,P0341,"Age: 61
Gender: Female 
Weight: 85 kg
Height: 168 cm
NYHA Class: II
Blood Pressure: 140/80 mmHg
Past Medical History: Hypertensive cardiomyopathy, Hypertension
Albumin (g/L): 47
ALT or GPT (IU/L): 25.0
AST or GOT (IU/L): 32.0
Total Cholesterol (mmol/L): 4,65
Creatinine (mmol/L): 89.0
Gamma-glutamil transpeptidase (IU/L): 17
Glucose (mmol/L): 5,4
Hemoglobin (g/L): 146.0
HDL (mmol/L): 0,98
Potassium (mEq/L): 4,4
LDL (mmol/L): 3
Sodium (mEq/L): 141.0
Pro-BNP (ng/L): 485.0
Protein (g/L): 71
T3 (pg/dL): 0,04
T4 (ng/L): 12
Troponin (ng/mL): 0,01
TSH (mIU/L): 0,706
Urea (mg/dL): 7,12
LVEF (%): 30.0
Medications: Angiotensin II Receptor Blocker, Digoxin, Statins
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: TPSV
        - Bradycardia: No
            ",survivor,"RANKING: 1. Survivor
REASONING: 

The patient's overall clinical presentation and test results suggest a high likelihood of survival. The patient is 61 years old, with a moderate NYHA class II, indicating a moderate level of heart failure symptoms. However, the patient's LVEF is significantly reduced at 30.0%, which is a strong indicator of heart failure. Despite this, the patient is on medications for hypertension and heart failure, which suggests that some level of management is in place.

The patient's laboratory results are also relatively stable, with normal liver enzymes, normal hemoglobin and electrolyte levels, and a normal TSH level. The presence of elevated Pro-BNP levels is expected in heart failure patients, but it is not indicative of an acute decompensated state.

The ECG results show a polymorphic ventricular extrasystole, which may be a sign of underlying cardiac dysfunction. However, there is no evidence of ventricular tachycardia or non-sustained ventricular tachycardia, which are more indicative of a high-risk arrhythmia.

Considering these factors, the patient's overall prognosis is likely to be a survivor, with a reasonable quality of life despite their reduced LVEF. The patient's heart failure symptoms are likely being managed effectively, and the presence of a polymorphic ventricular extrasystole may be a transient finding that does not necessarily indicate a poor outcome.

The other two prognoses, sudden cardiac death and pump failure death, are less likely in this patient. Sudden cardiac death is more likely to occur in patients with significant arrhythmias or underlying cardiac conditions that are not being managed effectively. Pump failure death is also less likely, as the patient is on medications for heart failure and has a relatively stable clinical presentation.

Therefore, the most likely prognosis for this patient is a survivor, with a reasonable quality of life despite their reduced LVEF."
204,204,P0342,"Age: 66
Gender: Male 
Weight: 75 kg
Height: 162 cm
NYHA Class: II
Blood Pressure: 130/80 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Diabetes, Dyslipemia, Peripheral vascular disease, Hypertension, Myocardial Infarction
Albumin (g/L): 42,9
ALT or GPT (IU/L): 19.0
AST or GOT (IU/L): 20.0
Total Cholesterol (mmol/L): 3,93
Creatinine (mmol/L): 143.0
Gamma-glutamil transpeptidase (IU/L): 36
Glucose (mmol/L): 11,9
Hemoglobin (g/L): 123.0
HDL (mmol/L): 0,85
Potassium (mEq/L): 4,7
LDL (mmol/L): 1,42
Sodium (mEq/L): 139.0
Pro-BNP (ng/L): 2416.0
Protein (g/L): 75
T3 (pg/dL): 0,05
T4 (ng/L): 14
Troponin (ng/mL): 0,01
TSH (mIU/L): 19,55
Urea (mg/dL): 12,69
LVEF (%): 50.0
Medications: Calcium Channel Blocker, Diabetes Medication, Angiotensin II Receptor Blocker, Beta Blockers, Loop Diuretics, Statins
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: TPSV
        - Bradycardia: No
            ",survivor,"RANKING: 1. Survivor
REASONING: 

Based on the patient's data, I predict that the patient will survive for the next few years. The patient's NYHA Class II indicates that they have some limitations with physical activity, but they are still able to perform daily activities without severe symptoms. The patient's LVEF of 50% is significantly reduced, indicating left ventricular dysfunction, but the patient is not in heart failure class III or IV, which would indicate more severe symptoms. The patient's medications, including beta blockers, ACE inhibitors, and statins, suggest that they are receiving appropriate management for their cardiovascular conditions. The patient's ECG findings, including ventricular extrasystoles and non-sustained ventricular tachycardia, indicate some cardiac arrhythmias, but the patient does not have any signs of severe cardiac dysfunction or acute coronary syndromes. The patient's laboratory results, including low albumin and elevated creatinine, suggest some renal impairment, but this is not uncommon in patients with cardiovascular disease. Overall, the patient's clinical presentation and laboratory results suggest that they are stable and manageable, and I predict that they will survive for the next few years with proper medical management."
205,205,P0344,"Age: 56
Gender: Male 
Weight: 110 kg
Height: 176 cm
NYHA Class: III
Blood Pressure: 180/100 mmHg
Past Medical History: Enolic dilated cardiomyopathy, Hypertension
Albumin (g/L): 43,9
ALT or GPT (IU/L): 135.0
AST or GOT (IU/L): 18.0
Total Cholesterol (mmol/L): 7,34
Creatinine (mmol/L): 98.0
Gamma-glutamil transpeptidase (IU/L): 95
Glucose (mmol/L): 6
Hemoglobin (g/L): 170.0
HDL (mmol/L): 1,94
Potassium (mEq/L): 4,5
LDL (mmol/L): 4,45
Sodium (mEq/L): 139.0
Pro-BNP (ng/L): 466.0
Protein (g/L): 78
T3 (pg/dL): 0,06
T4 (ng/L): 16
Troponin (ng/mL): 0,01
TSH (mIU/L): 2,55
Urea (mg/dL): 6,68
LVEF (%): 35.0
Medications: Angiotensin II Receptor Blocker, Beta Blockers, Loop Diuretics
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"RANKING: 1. Survivor
REASONING: 

Based on the provided patient data, I predict that the patient will survive for the next few years. The primary reasons for this prediction are:

1. The patient's ejection fraction (LVEF) is 35%, which is significantly reduced, indicating severe left ventricular dysfunction. However, the patient is already receiving medications that target heart failure symptoms, such as angiotensin II receptor blockers and beta blockers. These medications can help alleviate symptoms and slow disease progression.

2. The patient has a history of dilated cardiomyopathy, which is a condition that can lead to heart failure. However, the patient's current medication regimen and the presence of reduced ejection fraction suggest that the disease is not in its acute phase, and the patient may be able to manage the condition with current treatment.

3. The patient's troponin levels are within normal limits, indicating no acute myocardial infarction or significant cardiac damage.

4. The patient's creatinine level is elevated, indicating impaired kidney function, but this is not uncommon in patients with heart failure. The patient is already receiving loop diuretics, which can help manage fluid overload and reduce strain on the kidneys.

5. The patient's electrolyte levels, including potassium, are within normal limits, which suggests that the patient is not experiencing significant electrolyte imbalances that could contribute to cardiac arrhythmias or other complications.

6. The patient's ECG results show no evidence of ventricular tachycardia, non-sustained ventricular tachycardia, or other arrhythmias that could indicate a high risk of sudden cardiac death.

Given these factors, I predict that the patient will survive for the next few years with proper management and monitoring. However, regular follow-up appointments with the cardiologist will be crucial to adjust the medication regimen and monitor the patient's condition to prevent any potential complications."
206,206,P0347,"Age: 65
Gender: Male 
Weight: 69 kg
Height: 164 cm
NYHA Class: II
Blood Pressure: 110/70 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Diabetes, Dyslipemia, Peripheral vascular disease, Myocardial Infarction
Albumin (g/L): 46
ALT or GPT (IU/L): 10.0
AST or GOT (IU/L): 18.0
Total Cholesterol (mmol/L): 4,45
Creatinine (mmol/L): 94.0
Gamma-glutamil transpeptidase (IU/L): 27
Glucose (mmol/L): 14,5
Hemoglobin (g/L): 151.0
HDL (mmol/L): 1,01
Potassium (mEq/L): 4,2
LDL (mmol/L): 2,46
Sodium (mEq/L): 140.0
Pro-BNP (ng/L): 500.0
Protein (g/L): 73
T3 (pg/dL): 0,05
T4 (ng/L): 18
Troponin (ng/mL): 0,01
TSH (mIU/L): 1,05
Urea (mg/dL): 10,47
LVEF (%): 40.0
Medications: Calcium Channel Blocker, Diabetes Medication, Beta Blockers, Statins, ACE Inhibitor, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"RANKING: 1. Survivor
REASONING: 

Based on the provided patient data, the patient has a history of ischemic dilated cardiomyopathy, which is a significant comorbidity that increases the risk of cardiac complications. However, the patient is currently on medications for heart failure management, including ACE inhibitors, beta blockers, and diuretics, which are crucial for managing symptoms and preventing further decline. The patient's NYHA Class II indicates mild symptoms, which suggests that the disease is not severely impacting daily activities.

The patient's laboratory results show an elevated Creatinine level, indicating some degree of renal impairment, which can be a complication of heart failure. However, the patient's electrolyte levels, including potassium, are within normal limits, and there is no evidence of acute kidney injury.

The patient's ECG shows ventricular extrasystoles, which can be a sign of underlying cardiac dysfunction, but it is not a contraindication for survival. The absence of ventricular tachycardia, non-sustained ventricular tachycardia, and paroxysmal supraventricular tachyarrhythmia reduces the risk of sudden cardiac death.

Considering the patient's overall clinical presentation, laboratory results, and the fact that they are on optimal medications, the most likely prognosis is that the patient will survive the next few years. The patient's LVEF is significantly reduced, but it is not zero, which suggests that the heart is still pumping some blood, albeit inefficiently. With proper management, it is possible for the patient to remain stable and survive for an extended period.

While there is a risk of cardiac complications, including heart failure exacerbation, the patient's overall condition is not extremely severe, and with close monitoring and optimal medication management, the patient can be expected to survive for at least 2-5 years."
207,207,P0348,"Age: 60
Gender: Male 
Weight: 79 kg
Height: 170 cm
NYHA Class: II
Blood Pressure: 120/70 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Diabetes, Dyslipemia, Myocardial Infarction
Albumin (g/L): 54,4
ALT or GPT (IU/L): 55.0
AST or GOT (IU/L): 26.0
Total Cholesterol (mmol/L): 3,47
Creatinine (mmol/L): 101.0
Gamma-glutamil transpeptidase (IU/L): 29
Glucose (mmol/L): 7,4
Hemoglobin (g/L): 160.0
HDL (mmol/L): 0,72
Potassium (mEq/L): 4,7
LDL (mmol/L): 1,84
Sodium (mEq/L): 140.0
Pro-BNP (ng/L): 266.0
Protein (g/L): 74
T3 (pg/dL): 0,04
T4 (ng/L): 16
Troponin (ng/mL): 0,01
TSH (mIU/L): 3,01
Urea (mg/dL): 7,8
LVEF (%): 35.0
Medications: Diabetes Medication, Beta Blockers, Statins
ECG Impression:
        - Ventricular Extrasystole: No
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"RANKING: 

1. Survivor 
REASONING: 
The patient is a 60-year-old male with a history of ischemic dilated cardiomyopathy, diabetes, dyslipemia, and myocardial infarction. His NYHA class is II, indicating mild heart failure symptoms. His LVEF is significantly reduced at 35%, indicating poor cardiac function. However, he has no evidence of acute coronary syndromes or arrhythmias on the ECG impression. His medication regimen includes diabetes medication, beta blockers, and statins, which are standard treatments for his conditions. His laboratory results show elevated creatinine levels, indicating kidney impairment, but his liver enzymes are within normal limits. His protein level is slightly elevated, and his troponin level is within normal limits, indicating no acute myocardial infarction. His Pro-BNP level is elevated, suggesting some degree of cardiac strain, but not excessively high. 

Considering these factors, the patient's overall health status and lack of acute complications suggest that he is likely to survive for the next few years. The presence of heart failure symptoms and poor LVEF may necessitate ongoing management and monitoring, but his current prognosis is relatively stable.

2. Pump failure death 
REASONING: 
While the patient's LVEF is significantly reduced, indicating poor cardiac function, his current laboratory results do not show any acute changes that would suggest an immediate decline. However, his elevated creatinine levels indicate kidney impairment, which can be a complication of heart failure. Additionally, his Pro-BNP level is elevated, suggesting some degree of cardiac strain. 

The patient's history of ischemic dilated cardiomyopathy, diabetes, and dyslipemia also increases his risk of heart failure progression. However, his medication regimen and lack of acute complications suggest that his condition is being managed. Therefore, while pump failure is a risk, it is not the most likely outcome.

3. Sudden cardiac death 
REASONING: 
The patient's ECG impression is normal, and there is no evidence of arrhythmias or other conditions that would increase his risk of sudden cardiac death. His medication regimen includes beta blockers, which are standard for patients with heart failure and ischemic cardiomyopathy, reducing the risk of sudden cardiac death. 

However, his poor LVEF and elevated Pro-BNP level do increase his risk of cardiac complications. While the patient's current laboratory results do not show any acute changes, his underlying heart disease and kidney impairment may increase his risk of cardiac complications. Nevertheless, his overall health status and lack of acute complications make sudden cardiac death the least likely outcome."
208,208,P0350,"Age: 76
Gender: Female 
Weight: 89 kg
Height: 160 cm
NYHA Class: III
Blood Pressure: 130/80 mmHg
Past Medical History: Hypertensive cardiomyopathy, Hypertension
Albumin (g/L): 37,2
ALT or GPT (IU/L): 11.0
AST or GOT (IU/L): 15.0
Total Cholesterol (mmol/L): 5,35
Creatinine (mmol/L): 125.0
Gamma-glutamil transpeptidase (IU/L): 36
Glucose (mmol/L): 4,6
Hemoglobin (g/L): 120.0
HDL (mmol/L): 1,53
Potassium (mEq/L): 4,3
LDL (mmol/L): 3,03
Sodium (mEq/L): 137.0
Pro-BNP (ng/L): 480.0
Protein (g/L): 69
T3 (pg/dL): 0,03
T4 (ng/L): 16
Troponin (ng/mL): 0,01
TSH (mIU/L): 5,25
Urea (mg/dL): 16,03
LVEF (%): 32.0
Medications: Angiotensin II Receptor Blocker, Beta Blockers, Loop Diuretics, Spironolactone
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: TPSV
        - Bradycardia: No
            ",survivor,"RANKING: 

1. Survivor
REASONING: 

The patient is a 76-year-old female with a history of hypertensive cardiomyopathy, hypertension, and NYHA Class III heart failure. The patient's current ECG shows a monomorphic ventricular extrasystole, which is a concerning sign indicating potential ventricular arrhythmias. However, the absence of sustained ventricular tachycardia, non-sustained ventricular tachycardia, and paroxysmal supraventricular tachyarrhythmia suggests that the patient does not have a high risk of sudden cardiac death.

The patient's current medications, including an Angiotensin II Receptor Blocker, Beta Blockers, Loop Diuretics, and Spironolactone, are standard treatments for heart failure and hypertension, which suggests that the patient is receiving optimal medical therapy.

The patient's elevated troponin level (0.01 ng/mL) is a marker of cardiac damage, but it is not excessively elevated. The patient's LVEF is 32%, which is significantly reduced, indicating left ventricular dysfunction. However, the patient's elevated BNP level (480 ng/L) suggests that the patient is experiencing cardiac stress.

Considering these factors, the patient's overall prognosis is that they are likely to survive for the next few years, as they are receiving optimal medical therapy, have a relatively low risk of sudden cardiac death, and have a manageable level of cardiac dysfunction. However, close monitoring and regular follow-up appointments will be necessary to adjust the treatment plan as needed to manage the patient's heart failure and prevent further cardiac complications.

2. Sudden cardiac death
REASONING: 

The patient's monomorphic ventricular extrasystole is a concerning sign that increases the risk of sudden cardiac death. Although the patient is receiving optimal medical therapy, the presence of this arrhythmia suggests that the patient may be at increased risk of ventricular arrhythmias, which can lead to sudden cardiac death.

The patient's NYHA Class III heart failure and elevated BNP level suggest that the patient has significant cardiac dysfunction, which may increase the risk of arrhythmias and sudden cardiac death.

However, the absence of sustained ventricular tachycardia and non-sustained ventricular tachycardia on the ECG suggests that the patient is not at high risk of sudden cardiac death. Nevertheless, the presence of ventricular extrasystoles and the patient's overall clinical picture make this a possible but less likely outcome.

3. Pump failure death
REASONING: 

The patient's elevated creatinine level (16.03 mg/dL) and LVEF (32.0%) suggest that the patient has significant cardiac dysfunction and may be at risk of pump failure. However, the patient is receiving optimal medical therapy, including Loop Diuretics, which helps to manage fluid overload and reduce the risk of pump failure.

The patient's elevated BNP level (480 ng/L) suggests that the patient is experiencing cardiac stress, but the patient's current medications and ECG results do not indicate a high risk of sudden cardiac death.

While pump failure is a possible outcome, the patient's current treatment plan and ECG results suggest that the patient is receiving optimal care and is less likely to experience pump failure in the short term. However, close monitoring and regular follow-up appointments will be necessary to adjust the treatment plan as needed to manage the patient's heart failure and prevent further cardiac complications."
209,209,P0352,"Age: 51
Gender: Male 
Weight: 85 kg
Height: 167 cm
NYHA Class: II
Blood Pressure: 110/70 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Myocardial Infarction
Albumin (g/L): 46,3
ALT or GPT (IU/L): 17.0
AST or GOT (IU/L): 19.0
Total Cholesterol (mmol/L): 5,72
Creatinine (mmol/L): 109.0
Gamma-glutamil transpeptidase (IU/L): 20
Glucose (mmol/L): 5,1
Hemoglobin (g/L): 148.0
HDL (mmol/L): 0,96
Potassium (mEq/L): 4,3
LDL (mmol/L): 3,88
Sodium (mEq/L): 140.0
Pro-BNP (ng/L): 239.0
Protein (g/L): 80
T3 (pg/dL): 0,04
T4 (ng/L): 17
Troponin (ng/mL): 0,01
TSH (mIU/L): 1,66
Urea (mg/dL): 8,24
LVEF (%): 35.0
Medications: Calcium Channel Blocker, Beta Blockers, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: No
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"RANKING: 1. Survivor
REASONING: 
The patient has a significant history of ischemic dilated cardiomyopathy and myocardial infarction, which suggests a compromised left ventricular function. The left ventricular ejection fraction (LVEF) of 35% indicates severe systolic dysfunction. However, the patient is currently being treated with medications that are commonly used to manage heart failure, including a calcium channel blocker, beta blockers, and an ACE inhibitor.

Despite the patient's poor LVEF, the absence of any arrhythmias on the ECG and the patient's stable blood pressure (110/70 mmHg) suggest that the patient is not currently experiencing any acute cardiac complications. The patient's electrolytes, renal function, and liver enzymes are also within relatively normal limits.

Given these factors, it is reasonable to expect that the patient will survive the next few years, provided that the current treatment regimen is continued and adjusted as needed to manage the patient's heart failure symptoms and prevent further decline in cardiac function. The patient's protein levels and kidney function are also relatively preserved, which further supports a favorable prognosis.

While the patient's low T3 levels may indicate hypothyroidism, which can have negative effects on cardiac function, this is not a contraindication to survival. The patient's other laboratory values, including the troponin level, which is normal, also suggest that there is no acute myocardial injury.

Overall, based on the available data, the patient's survival is the most likely outcome, although close monitoring and regular follow-up with the cardiologist are essential to ensure that the patient's treatment plan is effective and to address any potential complications that may arise."
210,210,P0353,"Age: 78
Gender: Male 
Weight: 75 kg
Height: 172 cm
NYHA Class: II
Blood Pressure: 120/80 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Diabetes, Dyslipemia, Hypertension, Myocardial Infarction
Albumin (g/L): 39
ALT or GPT (IU/L): 17.0
AST or GOT (IU/L): 23.0
Total Cholesterol (mmol/L): 4,71
Creatinine (mmol/L): 140.0
Gamma-glutamil transpeptidase (IU/L): 27
Glucose (mmol/L): 8,5
Hemoglobin (g/L): 149.0
HDL (mmol/L): 1,11
Potassium (mEq/L): 4,6
LDL (mmol/L): 2,9
Sodium (mEq/L): 136.0
Pro-BNP (ng/L): 4518.0
Protein (g/L): 76
T3 (pg/dL): 0,05
T4 (ng/L): 19
Troponin (ng/mL): 0,01
TSH (mIU/L): 1,63
Urea (mg/dL): 14,92
LVEF (%): 15.0
Medications: Diabetes Medication, Angiotensin II Receptor Blocker, Digoxin, Spironolactone, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",survivor,"RANKING: 
1. Survivor
REASONING:
Based on the provided patient data, I predict that the patient has a high likelihood of survival over the next few years. Here's why:

1. Age and NYHA Class II: Although the patient is 78 years old and has a NYHA Class II heart failure, this is not uncommon in patients with ischemic dilated cardiomyopathy. A NYHA Class II classification indicates mild symptoms, which may not necessarily predict a poor outcome.

2. Medications: The patient is on several medications, including a nitrovasodilator, which is a vasodilator used to reduce blood pressure and improve cardiac output. The presence of these medications suggests that the patient's condition is being actively managed.

3. ECG Impression: While the ECG shows ventricular extrasystole and non-sustained ventricular tachycardia, these findings are not necessarily indicative of a poor prognosis. Ventricular extrasystoles and non-sustained ventricular tachycardia can be benign and may not necessarily lead to a life-threatening outcome.

4. LVEF: The left ventricular ejection fraction (LVEF) is significantly reduced at 15.0%, which is consistent with ischemic dilated cardiomyopathy. However, a reduced LVEF alone is not a strong predictor of mortality.

5. Pro-BNP: The elevated Pro-BNP level (4518.0 ng/L) suggests that the patient has some degree of heart failure, but it is not an indicator of imminent mortality.

6. Other lab values: The patient's other lab values, such as creatinine, urea, and electrolyte levels, are not significantly abnormal, which suggests that the patient's kidneys and electrolyte balance are not severely compromised.

Given these factors, I predict that the patient is likely to survive over the next few years, provided that their medications are continued, and their condition remains stable. However, close monitoring and regular follow-up appointments will be necessary to assess any changes in the patient's condition."
211,211,P0354,"Age: 54
Gender: Male 
Weight: 61 kg
Height: 162 cm
NYHA Class: II
Blood Pressure: 120/78 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Dyslipemia, Peripheral vascular disease, Myocardial Infarction
Albumin (g/L): 43,5
ALT or GPT (IU/L): 10.0
AST or GOT (IU/L): 14.0
Total Cholesterol (mmol/L): 6,39
Creatinine (mmol/L): 93.0
Gamma-glutamil transpeptidase (IU/L): 34
Glucose (mmol/L): 4,9
Hemoglobin (g/L): 159.0
HDL (mmol/L): 1,01
Potassium (mEq/L): 4,5
LDL (mmol/L): 4,06
Sodium (mEq/L): 139.0
Pro-BNP (ng/L): 123.0
Protein (g/L): 75
T3 (pg/dL): 0,05
T4 (ng/L): 16
Troponin (ng/mL): 0,01
TSH (mIU/L): 0,442
Urea (mg/dL): 8,91
LVEF (%): 35.0
Medications: Calcium Channel Blocker, Beta Blockers, Statins, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: Second-degree AVB - type II
            ",survivor,"RANKING: 1. Survivor
REASONING: 

This patient is at a higher risk for sudden cardiac death due to the presence of several high-risk factors. The patient has a history of ischemic dilated cardiomyopathy, which is a condition that significantly increases the risk of arrhythmias and sudden cardiac death. The patient also has a low left ventricular ejection fraction (LVEF) of 35%, which is a marker of reduced cardiac function. Additionally, the patient has a history of myocardial infarction, which can lead to scarring and further compromise cardiac function. The presence of ventricular extrasystoles and non-sustained ventricular tachycardia on the ECG also increases the risk of sudden cardiac death. However, the patient's current medications, including beta blockers, calcium channel blockers, and statins, suggest that the patient is receiving appropriate treatment for their underlying conditions.

While the patient is at risk, they are currently alive and receiving treatment, which is a positive prognostic sign. The patient's biomarkers, such as troponin and creatinine, are not significantly elevated, suggesting that the patient's cardiac function is not severely impaired at the moment. Therefore, I believe that the patient has a higher chance of survival compared to the other two options.

RANKING: 2. Pump failure death
REASONING: 

The patient's low LVEF of 35% and history of ischemic dilated cardiomyopathy increase the risk of pump failure. However, the patient is currently receiving treatment with beta blockers, calcium channel blockers, and statins, which can help improve cardiac function. The patient's current biomarkers, such as troponin and creatinine, are not significantly elevated, suggesting that the patient's cardiac function is not severely impaired at the moment. However, the patient's creatinine level of 93.0 mol/L is slightly elevated, indicating some degree of kidney impairment, which can be a complication of cardiac disease. Additionally, the patient's history of peripheral vascular disease and dyslipemia may contribute to further cardiovascular complications.

While pump failure is a possible outcome, the patient's current treatment and biomarkers suggest that the risk is not as high as it would be if the patient were experiencing more severe cardiac impairment.

RANKING: 3. Sudden cardiac death
REASONING: 

The patient's high risk for sudden cardiac death is evident due to the presence of ventricular extrasystoles and non-sustained ventricular tachycardia on the ECG. These arrhythmias increase the risk of sudden cardiac death, especially in a patient with a history of ischemic dilated cardiomyopathy. However, the patient's current treatment with beta blockers, calcium channel blockers, and statins suggests that the patient is receiving appropriate treatment for their underlying conditions.

The patient's low LVEF of 35% and history of myocardial infarction also increase the risk of sudden cardiac death. However, the patient's current biomarkers, such as troponin and creatinine, are not significantly elevated, suggesting that the patient's cardiac function is not severely impaired at the moment.

While the patient is at risk for sudden cardiac death, the presence of current treatment and relatively stable biomarkers suggest that the risk is lower than it would be if the patient were experiencing more severe cardiac impairment."
212,212,P0355,"Age: 48
Gender: Male 
Weight: 78 kg
Height: 169 cm
NYHA Class: II
Blood Pressure: 100/60 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Myocardial Infarction
Albumin (g/L): 48,2
ALT or GPT (IU/L): 38.0
AST or GOT (IU/L): 23.0
Total Cholesterol (mmol/L): 4,34
Creatinine (mmol/L): 71.0
Gamma-glutamil transpeptidase (IU/L): 30
Glucose (mmol/L): 5,5
Hemoglobin (g/L): 149.0
HDL (mmol/L): 0,91
Potassium (mEq/L): 4
LDL (mmol/L): 2,53
Sodium (mEq/L): 142.0
Pro-BNP (ng/L): 325.0
Protein (g/L): 69
T3 (pg/dL): 0,04
T4 (ng/L): 17
Troponin (ng/mL): 0,01
TSH (mIU/L): 2,12
Urea (mg/dL): 6,68
LVEF (%): 28.0
Medications: Beta Blockers, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"RANKING: 
1. Survivor
REASONING: 
The patient is a 48-year-old male with a history of ischemic dilated cardiomyopathy and myocardial infarction, which indicates a significant cardiovascular disease burden. However, the patient is currently on beta blockers and ACE inhibitors, which are standard treatments for heart failure and coronary artery disease. The patient's NYHA Class II symptoms suggest that the disease is not yet advanced, and the patient is still able to perform daily activities without significant limitation. The patient's laboratory results, including low troponin levels and normal kidney function, also suggest that the patient's cardiovascular system is not severely compromised at the moment. 

While the patient's left ventricular ejection fraction (LVEF) is significantly reduced at 28%, this is not uncommon in patients with a history of myocardial infarction and cardiomyopathy. The presence of ventricular extrasystoles on the ECG is a concerning sign, but it is not a specific predictor of poor outcome. The patient's biomarkers, such as pro-BNP and TSH, are not excessively elevated, which suggests that the patient's heart is not under significant stress. Overall, considering the patient's age, medical history, and current treatment, the most likely outcome is that the patient will survive for the next few years.

2. Sudden Cardiac Death
REASONING: 
While the patient's ECG shows ventricular extrasystoles, which is a concerning sign, the patient's overall clinical picture is not highly suggestive of sudden cardiac death. The patient's NYHA Class II symptoms and low LVEF suggest that the patient's heart is not severely compromised, and the patient is still able to perform daily activities without significant limitation. Additionally, the patient is on beta blockers and ACE inhibitors, which are standard treatments for heart failure and coronary artery disease, and the patient's laboratory results are not excessively elevated.

However, the patient's history of myocardial infarction and ischemic dilated cardiomyopathy increases the risk of sudden cardiac death, and the presence of ventricular extrasystoles on the ECG is a potential indicator of arrhythmia risk. While the patient's current biomarkers and laboratory results do not suggest an acute cardiac event, the patient's overall risk of sudden cardiac death cannot be entirely ruled out.

3. Pump Failure Death
REASONING: 
The patient's LVEF is significantly reduced at 28%, which suggests that the patient's heart is not functioning optimally. The patient's NYHA Class II symptoms also suggest that the patient's heart is not functioning at 100%. While the patient is on beta blockers and ACE inhibitors, which are standard treatments for heart failure, the patient's low LVEF and NYHA Class II symptoms suggest that the patient's heart is not responding adequately to treatment.

Additionally, the patient's laboratory results, including low hemoglobin and low potassium levels, suggest that the patient may be experiencing some degree of cardiac dysfunction, which could lead to pump failure. The patient's creatinine level is also elevated, which suggests some degree of kidney impairment, which can be a consequence of heart failure. While the patient's troponin levels are low, the patient's overall clinical picture suggests that the patient is at risk of developing pump failure in the near future."
213,213,P0357,"Age: 69
Gender: Female 
Weight: 80 kg
Height: 170 cm
NYHA Class: II
Blood Pressure: 135/75 mmHg
Past Medical History: Idiopathic dilated cardiomyopathy, Diabetes, Hypertension
Albumin (g/L): 44
ALT or GPT (IU/L): 19.0
AST or GOT (IU/L): 21.0
Total Cholesterol (mmol/L): 4,73
Creatinine (mmol/L): 97.0
Gamma-glutamil transpeptidase (IU/L): 35
Glucose (mmol/L): 11,5
Hemoglobin (g/L): 144.0
HDL (mmol/L): 1,76
Potassium (mEq/L): 4,7
LDL (mmol/L): 2,4
Sodium (mEq/L): 141.0
Pro-BNP (ng/L): 875.0
Protein (g/L): 77
T3 (pg/dL): 0,04
T4 (ng/L): 18
Troponin (ng/mL): 0,05
TSH (mIU/L): 1,16
Urea (mg/dL): 7,99
LVEF (%): 45.0
Medications: Diabetes Medication, Beta Blockers, Digoxin, Loop Diuretics, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",survivor,"RANKING: 1. Survivor
REASONING: 

Based on the provided patient data, I would rank the patient's prognosis as a survivor for the next few years. The patient's age, NYHA Class II heart failure, and elevated Pro-BNP levels (875 ng/L) indicate a moderate to severe level of heart failure. However, the patient's hemoglobin level (144 g/L) is within the normal range, suggesting adequate oxygenation and possibly some reserve.

The patient's medication regimen includes ACE inhibitors, which are generally recommended for patients with heart failure. The presence of beta blockers and digoxin also suggests that the patient is receiving standard therapy for heart failure.

The ECG findings, including ventricular extrasystoles and polymorphic ventricular tachycardia, may indicate underlying cardiac arrhythmia, but they do not necessarily predict a poor outcome. The absence of non-sustained ventricular tachycardia and paroxysmal supraventricular tachyarrhythmia may suggest that the patient's heart is not at high risk for sudden cardiac death.

The patient's creatinine level (97.0 mmol/L) is elevated, indicating some degree of renal impairment, which may be related to the underlying heart failure. However, the patient's overall clinical presentation and laboratory results do not suggest acute kidney injury or acute decompensated heart failure.

Given these factors, I believe that the patient's prognosis is more favorable than the other two options, and I would rank them as a survivor for the next few years."
214,214,P0358,"Age: 53
Gender: Male 
Weight: 71 kg
Height: 180 cm
NYHA Class: II
Blood Pressure: 110/65 mmHg
Past Medical History: Enolic dilated cardiomyopathy
Albumin (g/L): 43
ALT or GPT (IU/L): 29.0
AST or GOT (IU/L): 26.0
Total Cholesterol (mmol/L): 4,16
Creatinine (mmol/L): 97.0
Gamma-glutamil transpeptidase (IU/L): 126
Glucose (mmol/L): 6,6
Hemoglobin (g/L): 161.0
HDL (mmol/L): 1,76
Potassium (mEq/L): 4,7
LDL (mmol/L): 2,09
Sodium (mEq/L): 138.0
Pro-BNP (ng/L): 3068.0
Protein (g/L): 73
T3 (pg/dL): 0,05
T4 (ng/L): 19
Troponin (ng/mL): 0,02
TSH (mIU/L): 2,35
Urea (mg/dL): 5,66
LVEF (%): 21.0
Medications: Beta Blockers, Digoxin, Loop Diuretics, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",survivor,"RANKING: 1. Survivor 
REASONING: 

This patient has several factors that suggest a relatively better prognosis, despite having a history of dilated cardiomyopathy. 

1. Age: The patient is 53 years old, which is considered middle-aged. While cardiomyopathy can increase the risk of cardiac events, the patient's age is not unusually high for someone with this condition.

2. Medications: The patient is on beta blockers, digoxin, loop diuretics, and an ACE inhibitor, which are commonly used to manage symptoms and slow the progression of heart failure in patients with cardiomyopathy. The presence of these medications suggests that the patient is receiving appropriate treatment.

3. Hemoglobin and Hematocrit: The patient's hemoglobin level is slightly elevated at 16.1 g/dL, which may indicate anemia. However, this is not uncommon in patients with heart failure, as it can be a result of chronic disease.

4. Electrolytes: The patient's potassium level is slightly elevated at 4.7 mEq/L, which may be a result of the patient's medication regimen.

5. Pro-BNP level: The patient's Pro-BNP level is 3068 ng/L, which is elevated. However, this is not unusually high for someone with heart failure. The level can vary depending on the patient's hydration status, kidney function, and other factors.

6. Troponin level: The patient's troponin level is 0.02 ng/mL, which is within normal limits.

7. TSH: The patient's TSH level is 2.35 mIU/L, which is slightly elevated. However, this is not unusual for someone with heart failure, as it can be a result of the body's stress response.

8. Creatinine: The patient's creatinine level is 5.66 mg/dL, which is elevated. However, this is likely a result of the patient's muscle wasting associated with heart failure.

9. LVEF: The patient's LVEF is 21.0%, which is low. However, this is not unusually low for someone with heart failure.

10. ECG Impression: The patient has several abnormal ECG findings, including ventricular extrasystole, non-sustained ventricular tachycardia, and non-sustained ventricular tachycardia. However, these findings do not seem to be severe enough to suggest a high risk of sudden cardiac death.

Considering these factors, I believe that the patient is most likely to survive for the next few years, given their age, medication regimen, and the presence of heart failure symptoms."
215,215,P0360,"Age: 64
Gender: Female 
Weight: 52 kg
Height: 150 cm
NYHA Class: II
Blood Pressure: 110/70 mmHg
Past Medical History: Idiopathic dilated cardiomyopathy, Diabetes, Hypertension
Albumin (g/L): 40
ALT or GPT (IU/L): 50.0
AST or GOT (IU/L): 31.0
Total Cholesterol (mmol/L): 3,96
Creatinine (mmol/L): 97.0
Gamma-glutamil transpeptidase (IU/L): 19
Glucose (mmol/L): 10,8
Hemoglobin (g/L): 108.0
HDL (mmol/L): 1,03
Potassium (mEq/L): 3,7
LDL (mmol/L): 2,09
Sodium (mEq/L): 136.0
Pro-BNP (ng/L): 1314.0
Protein (g/L): 67
T3 (pg/dL): 0,06
T4 (ng/L): 18
TSH (mIU/L): 3,01
Urea (mg/dL): 5,16
LVEF (%): 25.0
Medications: Diabetes Medication, Angiotensin II Receptor Blocker, Beta Blockers, Loop Diuretics, Spironolactone, Statins
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: TPSV
        - Bradycardia: No
            ",survivor,"RANKING: 
1. Survivor
REASONING:
Based on the provided patient data, the patient is a 64-year-old female with a history of idiopathic dilated cardiomyopathy, diabetes, and hypertension. Her current NYHA class is II, indicating moderate symptoms of heart failure. 

Her ejection fraction (LVEF) is significantly reduced at 25.0%, which is consistent with her diagnosis of dilated cardiomyopathy. Her elevated creatinine level (97.0 mmol/L) and low albumin level (40 g/L) suggest renal impairment, which can be a complication of heart failure.

The patient's elevated Pro-BNP level (1314.0 ng/L) and elevated creatinine level suggest that the patient is experiencing significant symptoms of heart failure, including fluid overload and decreased cardiac function. However, the patient's blood pressure is within a relatively normal range (110/70 mmHg), which may indicate that the patient is not experiencing acute heart failure.

The patient's ECG findings are also consistent with her diagnosis of dilated cardiomyopathy, with ventricular extrasystole and a reduced LVEF. However, there is no evidence of ventricular tachycardia or non-sustained ventricular tachycardia, which are potential predictors of sudden cardiac death.

Given these factors, the patient is at a high risk for pump failure death, but the patient's relatively stable blood pressure, normal kidney function, and absence of ventricular tachycardia make sudden cardiac death less likely. Therefore, the most likely outcome for this patient over the next few years is survivorship.

RANKING: 
2. Pump failure death
REASONING:
Based on the patient's reduced LVEF and elevated Pro-BNP level, the patient is at a high risk for pump failure. The patient's renal impairment and low albumin level also suggest that the patient is experiencing significant fluid overload, which can exacerbate heart failure.

The patient's use of medications, including spironolactone and loop diuretics, suggests that the patient is receiving standard treatment for heart failure. However, the patient's reduced LVEF and elevated Pro-BNP level indicate that the patient's heart failure is not well-controlled, and pump failure is a potential complication.

RANKING: 
3. Sudden cardiac death
REASONING:
The patient's ECG findings of ventricular extrasystole and reduced LVEF suggest that the patient is at risk for arrhythmias, which can increase the risk for sudden cardiac death. However, the absence of ventricular tachycardia and non-sustained ventricular tachycardia on the ECG, as well as the patient's relatively stable blood pressure and normal kidney function, make sudden cardiac death less likely.

Additionally, the patient's use of beta blockers and angiotensin II receptor blockers, which are standard medications for heart failure, may help to reduce the risk of arrhythmias and sudden cardiac death. Therefore, while the patient is at risk for arrhythmias, the likelihood of sudden cardiac death is lower compared to pump failure death."
216,216,P0361,"Age: 72
Gender: Male 
Weight: 83 kg
Height: 160 cm
NYHA Class: II
Blood Pressure: 100/70 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Diabetes, Dyslipemia, Hypertension, Myocardial Infarction
Albumin (g/L): 35,7
ALT or GPT (IU/L): 12.0
AST or GOT (IU/L): 17.0
Total Cholesterol (mmol/L): 4,06
Creatinine (mmol/L): 133.0
Gamma-glutamil transpeptidase (IU/L): 8,4
Glucose (mmol/L): 6,36
Hemoglobin (g/L): 130.0
HDL (mmol/L): 1,09
Potassium (mEq/L): 4,87
LDL (mmol/L): 2,16
Sodium (mEq/L): 143.0
Pro-BNP (ng/L): 864.0
Protein (g/L): 64
T3 (pg/dL): 0,0489
T4 (ng/L): 16,17
Troponin (ng/mL): 0,4
TSH (mIU/L): 1,54
Urea (mg/dL): 20,49
LVEF (%): 20.0
Medications: Loop Diuretics, Spironolactone, Statins, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"RANKING: 
1. Survivor
REASONING: 
Given the patient's age, NYHA Class II, and the presence of ischemic dilated cardiomyopathy, the patient is already at a high risk for adverse cardiac events. However, the patient's current biomarkers do not show any acute myocardial infarction, cardiac troponin elevation, or significant elevation of liver enzymes, suggesting that the patient is not currently experiencing an acute cardiac event. The patient's hemoglobin and potassium levels are also within normal limits, indicating that there are no signs of acute kidney injury or electrolyte imbalance. 

Additionally, the patient's LVEF is severely reduced at 20%, indicating significant left ventricular dysfunction. However, the patient's medication regimen, which includes ACE inhibitors and spironolactone, suggests that the patient is being adequately managed for heart failure. The patient's blood pressure is within normal limits, and the absence of ventricular extrasystole, ventricular tachycardia, and non-sustained ventricular tachycardia on the ECG further reduces the risk of sudden cardiac death. 

Taking into account these factors, the patient's current clinical presentation and laboratory results suggest that the patient is likely to survive the next few years, provided that their current treatment regimen remains effective and there are no further adverse cardiac events. 

2. Sudden Cardiac Death
REASONING: 
The patient's history of ischemic dilated cardiomyopathy and severely reduced LVEF (20%) increases the risk of sudden cardiac death. However, the absence of ventricular extrasystole, ventricular tachycardia, and non-sustained ventricular tachycardia on the ECG reduces this risk. The patient's current biomarkers and medication regimen do not indicate any acute cardiac event, but the patient's severely reduced LVEF and NYHA Class II symptoms suggest that the patient's cardiac function is compromised.

3. Pump Failure Death
REASONING: 
Given the patient's severely reduced LVEF (20%) and NYHA Class II symptoms, the patient is already at risk of heart failure exacerbation. However, the patient's current medication regimen, which includes ACE inhibitors and spironolactone, suggests that the patient is being adequately managed for heart failure. The patient's current biomarkers do not indicate any acute kidney injury or electrolyte imbalance, and the absence of ventricular extrasystole, ventricular tachycardia, and non-sustained ventricular tachycardia on the ECG reduces the risk of sudden cardiac death. However, the patient's severely reduced LVEF and NYHA Class II symptoms suggest that the patient is at risk of heart failure exacerbation in the next few years, making pump failure death a possible outcome."
217,217,P0365,"Age: 54
Gender: Male 
Weight: 69 kg
Height: 170 cm
NYHA Class: III
Blood Pressure: 120/70 mmHg
Past Medical History: Other HF etiology, Hypertension
Albumin (g/L): 42
ALT or GPT (IU/L): 15.0
AST or GOT (IU/L): 23.0
Total Cholesterol (mmol/L): 5,97
Creatinine (mmol/L): 106.0
Gamma-glutamil transpeptidase (IU/L): 20
Glucose (mmol/L): 5,4
Hemoglobin (g/L): 129.0
HDL (mmol/L): 1,89
Potassium (mEq/L): 4
LDL (mmol/L): 3,85
Sodium (mEq/L): 143.0
Pro-BNP (ng/L): 46.0
Protein (g/L): 69
T3 (pg/dL): 0,05
T4 (ng/L): 14
Troponin (ng/mL): 0,005
TSH (mIU/L): 1,16
Urea (mg/dL): 6,16
LVEF (%): 65.0
Medications: Loop Diuretics
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"RANKING: 
1. Survivor 
REASONING: 
This patient is a 54-year-old male with a history of heart failure (NYHA Class III), hypertension, and other cardiac etiology. His current ECG impression shows ventricular extrasystoles, which are a type of arrhythmia that can be associated with an increased risk of sudden cardiac death. However, the absence of ventricular tachycardia, non-sustained ventricular tachycardia, and paroxysmal supraventricular tachyarrhythmia reduces the risk. The patient's elevated creatinine level (106.0 mmol/L) and low LVEF (65.0%) indicate impaired renal function and reduced cardiac function, respectively. However, the presence of symptoms and the patient's ability to take loop diuretics suggest that the patient is being managed for heart failure. The patient's laboratory values, including the elevated troponin level (0.005 ng/mL), are not indicative of acute myocardial infarction. The patient's Pro-BNP level is elevated (46.0 ng/L), which is consistent with heart failure. 

Given these factors, the patient is likely to survive for the next few years, assuming no significant worsening of their condition or any unforeseen complications.

2. Sudden cardiac death 
REASONING: 
While the patient's ECG shows ventricular extrasystoles, the absence of ventricular tachycardia, non-sustained ventricular tachycardia, and paroxysmal supraventricular tachyarrhythmia reduces the risk of sudden cardiac death. However, the patient's history of heart failure and elevated creatinine level indicate impaired cardiac function and renal function, which can increase the risk of sudden cardiac death. 

3. Pump failure death 
REASONING: 
The patient's elevated creatinine level (106.0 mmol/L) and low LVEF (65.0%) indicate impaired cardiac function, which can lead to pump failure. However, the patient's ability to take loop diuretics and the presence of symptoms suggest that the patient is being managed for heart failure. The patient's laboratory values, including the elevated troponin level (0.005 ng/mL), are not indicative of acute myocardial infarction. While the patient's LVEF is low, it is not severely impaired, which reduces the risk of pump failure death."
218,218,P0366,"Age: 59
Gender: Male 
Weight: 100 kg
Height: 167 cm
NYHA Class: II
Blood Pressure: 165/110 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Diabetes, Dyslipemia, Hypertension
Albumin (g/L): 40
ALT or GPT (IU/L): 20.0
AST or GOT (IU/L): 12.0
Total Cholesterol (mmol/L): 5,46
Creatinine (mmol/L): 88.0
Gamma-glutamil transpeptidase (IU/L): 24
Glucose (mmol/L): 6,5
Hemoglobin (g/L): 130.0
HDL (mmol/L): 0,59
Potassium (mEq/L): 4,6
LDL (mmol/L): 3,05
Sodium (mEq/L): 142.0
Pro-BNP (ng/L): 1477.0
Protein (g/L): 65
T3 (pg/dL): 0,05
T4 (ng/L): 14
Troponin (ng/mL): 0,15
TSH (mIU/L): 0,76
Urea (mg/dL): 8,49
LVEF (%): 37.0
Medications: Diabetes Medication, Beta Blockers, Loop Diuretics, Statins, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: No
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"RANKING: 1. Survivor
REASONING: 

This patient has a high likelihood of being a survivor due to several factors. Firstly, the patient is currently on medications that are commonly used to manage heart failure, such as Beta Blockers, Loop Diuretics, and ACE Inhibitors, which are indicated for conditions like Ischemic dilated cardiomyopathy and hypertension. The presence of these medications suggests that the patient is receiving appropriate treatment for their condition.

Additionally, the patient's NYHA Class II indicates that they have some symptoms of heart failure, but they are still able to perform moderate physical activity without undue fatigue. This suggests that the patient's heart is still functional enough to support their daily activities.

The patient's ECG results are also reassuring, with no signs of ventricular tachycardia, ventricular extrasystole, or non-sustained ventricular tachycardia, which are all potential predictors of cardiac arrhythmias and sudden cardiac death.

The patient's laboratory results show a relatively normal albumin level, which is a marker of kidney function, and a low TSH level, which suggests that the patient's thyroid function is within a normal range.

While the patient has several comorbidities, including diabetes, dyslipidemia, and hypertension, these conditions can be managed with medication and lifestyle modifications, which can help to reduce the risk of complications.

Overall, based on the available information, I believe that this patient has a high likelihood of surviving for the next few years, provided that they continue to adhere to their medication regimen and make lifestyle modifications to manage their comorbidities.

RANKING: 2. Pump failure death
REASONING: 

This patient has a moderate likelihood of pump failure death due to their underlying conditions. The patient has Ischemic dilated cardiomyopathy, which is a condition where the heart muscle is weakened, leading to reduced cardiac output and increased risk of heart failure. The patient's LVEF of 37% indicates that their heart is severely impaired, which increases the risk of pump failure.

The patient's NYHA Class II also suggests that they have some symptoms of heart failure, which can progress to more severe symptoms and pump failure if not managed properly.

Additionally, the patient's elevated creatinine level (88.0 mmol/L) indicates impaired kidney function, which can be a complication of heart failure. This can lead to further decline in cardiac function and increase the risk of pump failure.

The patient's diabetes and hypertension also increase the risk of complications, including cardiovascular disease and kidney disease.

While the patient is currently on medications that can help manage their condition, the underlying pathology of Ischemic dilated cardiomyopathy and impaired kidney function increases the risk of pump failure.

RANKING: 3. Sudden cardiac death
REASONING: 

This patient has a low likelihood of sudden cardiac death due to several factors. The patient's ECG results show no signs of ventricular tachycardia, ventricular extrasystole, or non-sustained ventricular tachycardia, which are all potential predictors of sudden cardiac death.

The patient's medication regimen includes Beta Blockers, which are indicated for reducing the risk of sudden cardiac death in patients with heart failure and arrhythmias.

Additionally, the patient's LVEF of 37% is relatively low, but not extremely low, which may reduce the risk of sudden cardiac death.

However, the patient's underlying conditions, including Ischemic dilated cardiomyopathy and hypertension, increase the risk of sudden cardiac death. Additionally, the patient's elevated Troponin level (0.15 ng/mL) suggests some degree of cardiac muscle damage, which can increase the risk of arrhythmias and sudden cardiac death.

Overall, while the patient has some risk factors for sudden cardiac death, the absence of specific ECG findings and the presence of Beta Blockers on their medication regimen reduce the likelihood of this outcome."
219,219,P0367,"Age: 63
Gender: Male 
Weight: 82 kg
Height: 163 cm
NYHA Class: II
Blood Pressure: 102/75 mmHg
Past Medical History: Hypertensive cardiomyopathy, Hypertension
Albumin (g/L): 42
ALT or GPT (IU/L): 17.0
AST or GOT (IU/L): 10.0
Total Cholesterol (mmol/L): 3,7
Creatinine (mmol/L): 133.0
Gamma-glutamil transpeptidase (IU/L): 19
Glucose (mmol/L): 5,3
Hemoglobin (g/L): 131.0
HDL (mmol/L): 0,54
Potassium (mEq/L): 5,3
LDL (mmol/L): 2,74
Sodium (mEq/L): 139.0
Protein (g/L): 67
T3 (pg/dL): 0,06
T4 (ng/L): 16
Troponin (ng/mL): 0,06
TSH (mIU/L): 0,92
Urea (mg/dL): 15,31
LVEF (%): 55.0
Medications: Amiodarone, Beta Blockers, Loop Diuretics, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",survivor,"RANKING: 
1. Survivor
REASONING: 
The patient's age is 63, which is considered elderly, and the patient has a history of Hypertensive cardiomyopathy and hypertension. However, the patient's NYHA class is II, indicating that the patient is able to perform ordinary physical activity without symptoms. The patient's LVEF is 55.0, which is slightly below the normal range, but not severely impaired.

The patient's medication regimen includes Amiodarone, Beta Blockers, Loop Diuretics, and ACE Inhibitor, which suggests that the patient is receiving standard treatment for heart failure and arrhythmias. The patient's laboratory results show mild elevations in liver enzymes (ALT and AST) and creatinine, but these are not indicative of acute kidney injury or severe liver dysfunction.

The patient's ECG impression shows ventricular extrasystoles, which are a common finding in patients with cardiomyopathy and hypertension. However, the absence of ventricular tachycardia or non-sustained ventricular tachycardia suggests that the patient is not at high risk for sudden cardiac death.

Overall, based on the patient's age, medical history, and laboratory results, I believe that the patient is at moderate risk for cardiac events, but the absence of severe symptoms and the presence of standard treatment suggests that the patient is likely to survive for the next few years. Therefore, the most likely prognosis is that the patient will survive."
220,220,P0371,"Age: 61
Gender: Female 
Weight: 73 kg
Height: 162 cm
NYHA Class: III
Blood Pressure: 120/80 mmHg
Past Medical History: Idiopathic dilated cardiomyopathy, Dyslipemia, Hypertension
Albumin (g/L): 39
ALT or GPT (IU/L): 84.0
AST or GOT (IU/L): 68.0
Total Cholesterol (mmol/L): 6,67
Creatinine (mmol/L): 71.0
Gamma-glutamil transpeptidase (IU/L): 89
Glucose (mmol/L): 11,7
Hemoglobin (g/L): 131.0
HDL (mmol/L): 1,03
Potassium (mEq/L): 4,7
LDL (mmol/L): 4,27
Sodium (mEq/L): 136.0
Pro-BNP (ng/L): 27434.0
Protein (g/L): 71
T3 (pg/dL): 0,05
T4 (ng/L): 20
TSH (mIU/L): 1,25
Urea (mg/dL): 7,82
LVEF (%): 26.0
Medications: Beta Blockers, Digoxin, Loop Diuretics, Spironolactone, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"RANKING: 1. Survivor
REASONING: 

Based on the provided patient data, I would rank the patient's prognosis as a survivor. 

1. The patient's age, NYHA Class III, and LVEF of 26.0 indicate significant cardiac dysfunction, but the patient is not in cardiogenic shock or acute heart failure. This suggests that the patient's cardiac function is not immediately life-threatening.

2. The patient's blood tests show elevated liver enzymes (ALT and AST), which may indicate some degree of liver dysfunction or inflammation. However, this is not directly related to the cardiac condition.

3. The patient's electrolyte levels, kidney function, and glucose levels are within relatively normal limits, indicating that there are no acute metabolic disturbances that would compromise the patient's overall health.

4. The presence of ventricular extrasystoles (polymorphic) on the ECG suggests an abnormal heart rhythm, but the absence of ventricular tachycardia or non-sustained ventricular tachycardia reduces the immediate risk of cardiac arrest.

5. The patient is on a regimen of beta blockers, digoxin, loop diuretics, spironolactone, and ACE inhibitors, which suggests a well-managed heart failure regimen. These medications are likely helping to control symptoms and slow the progression of cardiac disease.

6. The patient's biomarker, Pro-BNP, is elevated, indicating some degree of cardiac stress or strain, but this is not an isolated finding and is likely related to the patient's underlying cardiomyopathy.

Considering these factors, the patient's prognosis is more likely to be a survivor, with ongoing monitoring and management of their cardiac condition to slow disease progression."
221,221,P0372,"Age: 60
Gender: Male 
Weight: 77 kg
Height: 171 cm
NYHA Class: II
Blood Pressure: 130/70 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Diabetes, Dyslipemia, Hypertension
Albumin (g/L): 41
ALT or GPT (IU/L): 185.0
AST or GOT (IU/L): 154.0
Total Cholesterol (mmol/L): 4,84
Creatinine (mmol/L): 97.0
Gamma-glutamil transpeptidase (IU/L): 188
Glucose (mmol/L): 4,3
Hemoglobin (g/L): 121.0
HDL (mmol/L): 2,04
Potassium (mEq/L): 4,4
LDL (mmol/L): 2,38
Sodium (mEq/L): 133.0
Pro-BNP (ng/L): 186.0
Protein (g/L): 69
T3 (pg/dL): 0,05
T4 (ng/L): 13
Troponin (ng/mL): 0,04
TSH (mIU/L): 1,7
Urea (mg/dL): 5,66
LVEF (%): 70.0
Medications: Diabetes Medication, Beta Blockers, Statins, ACE Inhibitor, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"RANKING: 1. Survivor
REASONING: 
This patient has a complex medical history with multiple comorbidities, including ischemic dilated cardiomyopathy, diabetes, dyslipemia, and hypertension. However, the patient is currently on multiple medications, including beta blockers, statins, and an ACE inhibitor, which are all beneficial for heart health. The patient's left ventricular ejection fraction (LVEF) is 70%, which is within the normal range, indicating that the patient's heart is still functioning relatively well.

The patient's troponin level is normal, and there is no evidence of acute myocardial infarction or acute coronary syndrome. The ECG impression does not show any signs of ventricular tachycardia, bradycardia, or other life-threatening arrhythmias. The patient's creatinine level is elevated, but this is likely a result of the patient's underlying kidney disease rather than cardiac disease.

The patient's liver enzymes (ALT and AST) are mildly elevated, which could be related to the patient's liver disease or other non-cardiac causes. The patient's blood glucose level is also elevated, which could be related to the patient's diabetes. However, the patient is on diabetes medication, which suggests that the patient is receiving adequate management for this condition.

Given these factors, the patient's overall prognosis is good, and it is likely that the patient will survive the next few years. The patient's complex medical history and multiple comorbidities do increase the risk of cardiac events, but the patient's current medication regimen and relatively normal LVEF suggest that the patient is likely to survive the next few years."
222,222,P0373,"Age: 41
Gender: Male 
Weight: 70 kg
Height: 170 cm
NYHA Class: II
Blood Pressure: 180/90 mmHg
Past Medical History: Hypertensive cardiomyopathy, Hypertension
Albumin (g/L): 45
ALT or GPT (IU/L): 20.0
AST or GOT (IU/L): 32.0
Total Cholesterol (mmol/L): 5,09
Creatinine (mmol/L): 212.0
Gamma-glutamil transpeptidase (IU/L): 20
Glucose (mmol/L): 4,2
Hemoglobin (g/L): 150.0
HDL (mmol/L): 1,89
Potassium (mEq/L): 4,7
LDL (mmol/L): 2,07
Sodium (mEq/L): 132.0
Pro-BNP (ng/L): 5017.0
Protein (g/L): 87
T3 (pg/dL): 0,05
T4 (ng/L): 17
Troponin (ng/mL): 0,09
TSH (mIU/L): 2,27
Urea (mg/dL): 12,48
LVEF (%): 29.0
Medications: Calcium Channel Blocker, Beta Blockers, Loop Diuretics, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: TPSV
        - Bradycardia: No
            ",survivor,"RANKING: 

1. Survivor
REASONING: 

The patient's overall clinical presentation and test results indicate a high risk for adverse cardiac events. The patient has a history of hypertensive cardiomyopathy and hypertension, which are significant risk factors for cardiac complications. The elevated blood pressure (180/90 mmHg), elevated creatinine (212.0 mmol/L), and low LVEF (29.0) suggest left ventricular dysfunction, which is a critical factor in determining the prognosis. The presence of ventricular tachycardia (non-sustained VT and non-sustained ventricular tachycardia) on ECG is also a concerning sign. However, the patient is currently taking medications that are commonly used to manage these conditions, such as calcium channel blockers, beta blockers, loop diuretics, and ACE inhibitors, which may help mitigate the risk of cardiac complications.

The patient's laboratory results show elevated liver enzymes (ALT and AST), which may indicate some degree of liver dysfunction, but this is not directly related to the cardiac prognosis. The low albumin level (45 g/L) and elevated urea level (12.48 mg/dL) suggest some degree of renal dysfunction, which may also be related to the patient's hypertension. However, these findings are not as critical as the cardiac findings in determining the prognosis.

Given these factors, I believe that the patient has a higher likelihood of survival compared to the other two options. However, the patient's cardiac function is severely impaired, and the presence of ventricular tachycardia and non-sustained ventricular tachycardia on ECG indicate a high risk for cardiac complications.

2. Sudden Cardiac Death
REASONING: 

The patient's history of hypertensive cardiomyopathy and hypertension, along with the presence of ventricular tachycardia (non-sustained VT and non-sustained ventricular tachycardia) on ECG, make this patient a high-risk candidate for sudden cardiac death. The low LVEF (29.0) and elevated creatinine (212.0 mmol/L) suggest left ventricular dysfunction, which is a significant risk factor for sudden cardiac death.

However, the patient is currently taking medications that are commonly used to manage these conditions, which may help mitigate the risk of cardiac complications.

3. Pump Failure Death
REASONING: 

The patient's low LVEF (29.0) and elevated creatinine (212.0 mmol/L) suggest left ventricular dysfunction, which is a critical factor in determining the prognosis. However, the patient is currently taking medications that are commonly used to manage these conditions, which may help mitigate the risk of cardiac complications.

Additionally, the patient's history of hypertensive cardiomyopathy and hypertension, as well as the presence of ventricular tachycardia (non-sustained VT and non-sustained ventricular tachycardia) on ECG, make this patient a high-risk candidate for pump failure. However, the patient's current medication regimen may help mitigate some of these risks, making this option less likely than sudden cardiac death."
223,223,P0374,"Age: 74
Gender: Male 
Weight: 73 kg
Height: 170 cm
NYHA Class: II
Blood Pressure: 110/60 mmHg
Past Medical History: Idiopathic dilated cardiomyopathy
Albumin (g/L): 42
ALT or GPT (IU/L): 16.0
AST or GOT (IU/L): 23.0
Total Cholesterol (mmol/L): 4,6
Creatinine (mmol/L): 124.0
Gamma-glutamil transpeptidase (IU/L): 28
Glucose (mmol/L): 6,3
Hemoglobin (g/L): 149.0
HDL (mmol/L): 1,47
Potassium (mEq/L): 3,5
LDL (mmol/L): 2,61
Sodium (mEq/L): 139.0
Pro-BNP (ng/L): 1414.0
Protein (g/L): 66
T3 (pg/dL): 0,04
T4 (ng/L): 23
Troponin (ng/mL): 0,023
TSH (mIU/L): 0,565
Urea (mg/dL): 6,99
LVEF (%): 43.0
Medications: Amiodarone, Beta Blockers, Loop Diuretics, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"RANKING: 1. Survivor
REASONING: 

Based on the provided patient data, the patient's prognosis is likely to be a survivor. The patient's age, NYHA Class II, and LVEF of 43% indicate that the patient has significant left ventricular dysfunction, which is a common complication of idiopathic dilated cardiomyopathy. However, the patient's current treatment regimen, which includes Amiodarone, Beta Blockers, Loop Diuretics, and ACE Inhibitor, suggests that the patient is receiving optimal medical therapy for heart failure.

The patient's laboratory results show that the liver enzymes (ALT and AST) are within normal limits, and the kidney function (Creatinine) is elevated but not severely impaired. The patient's electrolyte levels, including potassium, are also within normal limits. The elevated Pro-BNP level suggests some degree of ventricular stress, but it is not excessively high.

The ECG results show no evidence of ventricular tachycardia or polymorphic ventricular extrasystoles, which are risk factors for sudden cardiac death. The absence of paroxysmal supraventricular tachyarrhythmia and bradycardia further reduces the risk of sudden cardiac death.

Given these factors, the patient's overall prognosis is likely to be a survivor, as the patient is receiving optimal medical therapy and does not have any obvious contraindications for long-term survival.

RANKING: 2. Sudden Cardiac Death
REASONING: 

While the patient's prognosis is not entirely favorable, sudden cardiac death is less likely than death due to pump failure. The patient's elevated Creatinine level and Pro-BNP level suggest some degree of ventricular dysfunction, which could increase the risk of sudden cardiac death. However, the patient's treatment regimen and laboratory results do not suggest a high risk of sudden cardiac death.

RANKING: 3. Pump Failure Death
REASONING: 

Pump failure death is a possible outcome for this patient, given the patient's significant left ventricular dysfunction (LVEF of 43%) and elevated Creatinine level. The patient's NYHA Class II and elevated Pro-BNP level suggest that the patient is experiencing some degree of heart failure symptoms. However, the patient's treatment regimen and laboratory results suggest that the patient is receiving optimal medical therapy, which may mitigate the risk of pump failure.

It is worth noting that the patient's age (74 years) and elevated Creatinine level increase the risk of pump failure. However, the patient's overall clinical presentation and treatment regimen make sudden cardiac death a less likely outcome."
224,224,P0375,"Age: 69
Gender: Male 
Weight: 80 kg
Height: 164 cm
NYHA Class: II
Blood Pressure: 110/60 mmHg
Past Medical History: Idiopathic dilated cardiomyopathy, Dyslipemia, Hypertension
Albumin (g/L): 45
ALT or GPT (IU/L): 18.0
AST or GOT (IU/L): 20.0
Total Cholesterol (mmol/L): 4,42
Creatinine (mmol/L): 115.0
Gamma-glutamil transpeptidase (IU/L): 45
Glucose (mmol/L): 5
Hemoglobin (g/L): 150.0
HDL (mmol/L): 1,34
Potassium (mEq/L): 5
LDL (mmol/L): 2,66
Sodium (mEq/L): 138.0
Pro-BNP (ng/L): 2834.0
Protein (g/L): 67
T3 (pg/dL): 0,04
T4 (ng/L): 20
Troponin (ng/mL): 0,03
TSH (mIU/L): 4,09
Urea (mg/dL): 8,15
LVEF (%): 37.0
Medications: Amiodarone, Angiotensin II Receptor Blocker, Beta Blockers, Digoxin, Loop Diuretics, Spironolactone
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",survivor,"RANKING: 1. Survivor
REASONING: 

Based on the provided patient data, the patient is a 69-year-old male with a history of idiopathic dilated cardiomyopathy, dyslipemia, and hypertension. The patient has a low left ventricular ejection fraction (LVEF) of 37.0%, which indicates significant left ventricular dysfunction. The presence of non-sustained ventricular tachycardia (NSVT) on the ECG, with a high Pro-BNP level of 2834.0 ng/L, suggests a high risk of cardiac events.

The patient's current medications, including Amiodarone, Angiotensin II Receptor Blocker, Beta Blockers, Digoxin, Loop Diuretics, and Spironolactone, are standard treatments for managing heart failure and arrhythmias in patients with cardiomyopathy.

While the patient's electrolyte and liver function tests are not entirely normal, there is no indication of acute kidney injury or liver dysfunction that would significantly impact the patient's overall prognosis.

Given the patient's age, comorbidities, and current medical conditions, the likelihood of sudden cardiac death is relatively low. The presence of non-sustained ventricular tachycardia on the ECG does increase the risk of cardiac events, but the patient's overall prognosis is still favorable due to the presence of effective treatment for heart failure and arrhythmias.

The patient's prognosis is more favorable than pump failure death due to the presence of effective treatment for heart failure and the patient's relatively preserved renal function (creatinine level of 115.0 mmol/L). While the patient's left ventricular function is impaired, the patient is still receiving treatment that can help manage symptoms and prevent further decline.

Therefore, based on the provided data, the most likely outcome for the patient over the next few years is survival."
225,225,P0376,"Age: 51
Gender: Male 
Weight: 80 kg
Height: 170 cm
NYHA Class: II
Blood Pressure: 130/70 mmHg
Past Medical History: Idiopathic dilated cardiomyopathy
Albumin (g/L): 44
ALT or GPT (IU/L): 17.0
AST or GOT (IU/L): 22.0
Total Cholesterol (mmol/L): 4,53
Creatinine (mmol/L): 88.0
Gamma-glutamil transpeptidase (IU/L): 25
Glucose (mmol/L): 4,4
Hemoglobin (g/L): 156.0
HDL (mmol/L): 1,22
Potassium (mEq/L): 4,6
LDL (mmol/L): 2,82
Sodium (mEq/L): 136.0
Pro-BNP (ng/L): 727.0
Protein (g/L): 71
T3 (pg/dL): 0,07
T4 (ng/L): 20
Troponin (ng/mL): 0,01
TSH (mIU/L): 1,39
Urea (mg/dL): 4,99
LVEF (%): 20.0
Medications: Beta Blockers, Digoxin, Loop Diuretics, Spironolactone, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",survivor,"RANKING: 
1. Survivor
REASONING: 
The patient's age, NYHA Class II, and the presence of idiopathic dilated cardiomyopathy suggest a chronic heart condition. However, the patient is still relatively young (51 years old) and has a normal blood pressure. The patient's current medications, including beta blockers, digoxin, loop diuretics, spironolactone, and an ACE inhibitor, are commonly used to manage heart failure and arrhythmias in patients with heart failure.

The patient's ejection fraction (LVEF) is 20.0%, which is significantly reduced, indicating poor heart function. However, this is not uncommon in patients with dilated cardiomyopathy. The patient's troponin levels are normal, and the ECG shows ventricular extrasystole but no ventricular tachycardia or non-sustained ventricular tachycardia, which are risk factors for sudden cardiac death.

The patient's renal function is slightly impaired, with elevated creatinine levels, but this is not uncommon in patients with heart failure. The patient's electrolyte levels, including potassium, are within normal limits, and the patient's liver function tests are also within normal limits.

Given the patient's current medical condition, the presence of a ventricular extrasystole on the ECG, and the fact that the patient is already taking medications to manage heart failure and arrhythmias, the most likely outcome for the next few years is that the patient will survive. While the patient's heart function is severely impaired, the patient is still alive and receiving medical treatment, which suggests that the patient's heart can adapt to the current medications and treatment plan.

The other two prognoses, sudden cardiac death and pump failure death, are less likely because the patient is already receiving treatment and has a relatively good renal function. Sudden cardiac death is less likely due to the absence of ventricular tachycardia or non-sustained ventricular tachycardia on the ECG. Pump failure death is less likely due to the patient's current treatment plan, which includes medications to manage heart failure and arrhythmias."
226,226,P0378,"Age: 45
Gender: Male 
Weight: 82 kg
Height: 169 cm
NYHA Class: II
Blood Pressure: 120/70 mmHg
Past Medical History: Idiopathic dilated cardiomyopathy
Albumin (g/L): 42
ALT or GPT (IU/L): 12.0
AST or GOT (IU/L): 17.0
Total Cholesterol (mmol/L): 4,65
Creatinine (mmol/L): 88.0
Gamma-glutamil transpeptidase (IU/L): 12
Glucose (mmol/L): 4,5
Hemoglobin (g/L): 141.0
HDL (mmol/L): 2,61
Potassium (mEq/L): 4,5
LDL (mmol/L): 3,13
Sodium (mEq/L): 136.0
Pro-BNP (ng/L): 236.0
Protein (g/L): 68
T3 (pg/dL): 0,06
T4 (ng/L): 21
Troponin (ng/mL): 0,02
TSH (mIU/L): 2,75
Urea (mg/dL): 5,83
LVEF (%): 29.0
Medications: Beta Blockers, Loop Diuretics, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",survivor,"RANKING: 1. Survivor
REASONING: The patient's age, NYHA Class II, and relatively well-controlled blood pressure and electrolytes suggest that the patient is not in a high-risk category for sudden cardiac death or pump failure. The elevated creatinine level may indicate some degree of renal impairment, but it is not extreme. The patient's low LVEF (29.0) indicates significant left ventricular dysfunction, but the presence of medications such as beta blockers, loop diuretics, and ACE inhibitors suggests that the patient is receiving standard treatment for heart failure. The absence of troponin elevation and the normal TSH level also suggest that there is no acute myocardial infarction or thyroid dysfunction. Furthermore, the patient's Pro-BNP level is elevated, which is consistent with heart failure, but not excessively high. Overall, these factors suggest that the patient is likely to survive for the next few years with proper management and monitoring.

RANKING: 2. Sudden cardiac death
REASONING: While the patient has a history of idiopathic dilated cardiomyopathy, which increases the risk of sudden cardiac death, the patient is receiving standard treatment for heart failure, which should help manage symptoms and reduce the risk of sudden death. However, the low LVEF (29.0) and elevated Pro-BNP level indicate significant left ventricular dysfunction, which increases the risk of arrhythmias and sudden cardiac death. The absence of troponin elevation and normal TSH level suggests that there is no acute myocardial infarction or thyroid dysfunction, but the patient's ECG impression shows ventricular extrasystoles, which may be a sign of underlying arrhythmia. While not extremely high, the patient's risk of sudden cardiac death is higher than that of a survivor.

RANKING: 3. Pump failure death
REASONING: The patient's low LVEF (29.0) and elevated Pro-BNP level indicate significant left ventricular dysfunction, which increases the risk of pump failure. The patient's NYHA Class II suggests that the patient is experiencing symptoms of heart failure, which may worsen over time if not properly managed. The absence of troponin elevation and normal TSH level suggest that there is no acute myocardial infarction or thyroid dysfunction, but the patient's elevated creatinine level and low HDL cholesterol may indicate a higher risk of cardiovascular events. While the patient is receiving standard treatment for heart failure, the combination of these factors suggests that pump failure is a possible outcome for the patient in the next few years."
227,227,P0379,"Age: 49
Gender: Male 
Weight: 88 kg
Height: 170 cm
NYHA Class: II
Blood Pressure: 100/60 mmHg
Past Medical History: Hypertensive cardiomyopathy, Hypertension
Albumin (g/L): 45
ALT or GPT (IU/L): 33.0
AST or GOT (IU/L): 21.0
Total Cholesterol (mmol/L): 3,31
Creatinine (mmol/L): 133.0
Gamma-glutamil transpeptidase (IU/L): 31
Glucose (mmol/L): 4,9
Hemoglobin (g/L): 135.0
HDL (mmol/L): 1,14
Potassium (mEq/L): 4,5
LDL (mmol/L): 1,76
Sodium (mEq/L): 142.0
Pro-BNP (ng/L): 1517.0
Protein (g/L): 72
T3 (pg/dL): 0,05
T4 (ng/L): 16
TSH (mIU/L): 2,05
Urea (mg/dL): 5,66
LVEF (%): 67.0
Medications: Calcium Channel Blocker, Loop Diuretics, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"RANKING: 1. Survivor
REASONING: 

The patient's overall clinical presentation and test results suggest a moderate to severe cardiac condition, as indicated by the NYHA Class II classification, which indicates symptoms of heart failure with moderate limitation of physical activity. The patient's elevated creatinine level (133.0 mmol/L) and LVEF (67.0%) suggest compromised cardiac function. However, the absence of any significant elevation in troponin levels or evidence of acute coronary syndrome, and the presence of a normal to mildly elevated Pro-BNP level (1517.0 ng/L), suggest that the patient's cardiac condition is likely related to his underlying hypertensive cardiomyopathy rather than an acute coronary syndrome.

The patient's medication regimen, which includes a calcium channel blocker, loop diuretics, and ACE inhibitor, suggests that the patient is being managed for his hypertension and heart failure. The patient's electrolyte and liver function tests are also within relatively normal limits, which further supports the notion that the patient's cardiac condition is not acute.

Given this information, the most likely outcome for the patient over the next few years is that he will survive. The patient's cardiac function is compromised, but it is not in acute crisis, and he is receiving appropriate management for his condition. With continued medical management and lifestyle modifications, it is likely that the patient will experience a gradual decline in cardiac function over time, but this decline will be slow and manageable.

While the patient's LVEF is below normal (67.0%), it is not significantly impaired, and the patient's symptoms are limited to moderate exertional dyspnea. This suggests that the patient has some residual cardiac function and is unlikely to experience sudden cardiac death or pump failure in the near future. Therefore, the most likely outcome for the patient over the next few years is that he will survive.

The other two options, sudden cardiac death and pump failure death, are less likely because they require a more acute and severe cardiac event, such as a myocardial infarction or a catastrophic arrhythmia, which is not indicated by the patient's current clinical presentation and test results."
228,228,P0380,"Age: 59
Gender: Male 
Weight: 88 kg
Height: 163 cm
NYHA Class: II
Blood Pressure: 120/65 mmHg
Past Medical History: Enolic dilated cardiomyopathy, Hypertension
Albumin (g/L): 40
ALT or GPT (IU/L): 24.0
AST or GOT (IU/L): 26.0
Total Cholesterol (mmol/L): 4,81
Creatinine (mmol/L): 97.0
Gamma-glutamil transpeptidase (IU/L): 62
Glucose (mmol/L): 6,6
Hemoglobin (g/L): 146.0
HDL (mmol/L): 1,86
Potassium (mEq/L): 4,7
LDL (mmol/L): 3,18
Sodium (mEq/L): 139.0
Pro-BNP (ng/L): 105.0
Protein (g/L): 68
T3 (pg/dL): 0,05
T4 (ng/L): 17
Troponin (ng/mL): 0,005
TSH (mIU/L): 1,51
Urea (mg/dL): 4,16
LVEF (%): 32.0
Medications: Beta Blockers, Digoxin, Loop Diuretics, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",survivor,"RANKING: 1. Survivor
REASONING: 
The patient has a history of Enolic dilated cardiomyopathy, which is a significant risk factor for heart failure and arrhythmias. However, the patient is currently on medications that are commonly used to manage these conditions, such as beta blockers, digoxin, and ACE inhibitors. The patient's NYHA Class II indicates that they have some limitation in physical activity but can still perform daily activities with some difficulty. The patient's LVEF of 32.0 is significantly reduced, which is a marker of poor heart function. However, the patient's troponin levels are within normal limits, which suggests that there is no acute myocardial infarction. The patient's ECG shows non-sustained ventricular tachycardia, which is a concerning sign but can be managed with medications. 

The patient's low T3 levels and low LVEF suggest that the patient may be experiencing cardiac cachexia, which is a condition characterized by weight loss, muscle wasting, and decreased appetite. This condition can worsen the prognosis. However, the patient's weight and hemoglobin levels are relatively stable, which suggests that the patient is not malnourished. The patient's blood pressure and creatinine levels are also within normal limits, which suggests that the patient is not experiencing acute kidney injury. Overall, the patient's prognosis is guarded but not hopeless. With proper management and close monitoring, the patient may survive for several years.

RANKING: 2. Sudden Cardiac Death
REASONING: 
The patient's history of Enolic dilated cardiomyopathy, NYHA Class II, and LVEF of 32.0 make them a high-risk patient for sudden cardiac death. The patient's ECG shows non-sustained ventricular tachycardia, which is a concerning sign. The patient's low T3 levels and low LVEF suggest that the patient may be experiencing cardiac cachexia, which can worsen the prognosis. However, the patient is already on medications that are commonly used to manage heart failure and arrhythmias. The patient's troponin levels are within normal limits, which suggests that there is no acute myocardial infarction. 

While the patient's blood pressure and creatinine levels are within normal limits, the patient's low potassium levels may increase the risk of arrhythmias. The patient's low HDL levels also increase the risk of cardiovascular disease. Overall, the patient's risk factors for sudden cardiac death are present, but the patient is already on medications that can help manage these conditions. However, the patient's low LVEF and cardiac cachexia make them a high-risk patient for sudden cardiac death.

RANKING: 3. Pump Failure Death
REASONING: 
The patient's LVEF of 32.0 is significantly reduced, which suggests that the patient is experiencing heart failure. The patient's NYHA Class II indicates that they have some limitation in physical activity but can still perform daily activities with some difficulty. The patient's troponin levels are within normal limits, which suggests that there is no acute myocardial infarction. However, the patient's low T3 levels and low LVEF suggest that the patient may be experiencing cardiac cachexia, which can worsen the prognosis.

The patient's ECG shows non-sustained ventricular tachycardia, which is a concerning sign. The patient's low HDL levels also increase the risk of cardiovascular disease. While the patient is already on medications that can help manage heart failure and arrhythmias, the patient's low LVEF and cardiac cachexia make them a high-risk patient for pump failure death. The patient's blood pressure and creatinine levels are within normal limits, which suggests that the patient is not experiencing acute kidney injury. However, the patient's low potassium levels may increase the risk of arrhythmias. Overall, the patient's risk factors for pump failure death are present, but the patient is already on medications that can help manage these conditions."
229,229,P0381,"Age: 70
Gender: Male 
Weight: 58 kg
Height: 155 cm
NYHA Class: II
Blood Pressure: 96/57 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Diabetes, Dyslipemia, Hypertension, Myocardial Infarction
Albumin (g/L): 37
ALT or GPT (IU/L): 16.0
AST or GOT (IU/L): 17.0
Total Cholesterol (mmol/L): 4,06
Creatinine (mmol/L): 88.0
Gamma-glutamil transpeptidase (IU/L): 30
Glucose (mmol/L): 8,8
Hemoglobin (g/L): 136.0
HDL (mmol/L): 1,16
Potassium (mEq/L): 4,1
LDL (mmol/L): 2,35
Sodium (mEq/L): 135.0
Pro-BNP (ng/L): 434.0
Protein (g/L): 61
T4 (ng/L): 18
Troponin (ng/mL): 0,01
TSH (mIU/L): 1,67
Urea (mg/dL): 5,49
LVEF (%): 40.0
Medications: Diabetes Medication, Angiotensin II Receptor Blocker, Beta Blockers, Spironolactone, Statins, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: TPSV
        - Bradycardia: No
            ",survivor,"RANKING: 1. Survivor
REASONING:

This patient's overall clinical presentation and test results suggest a relatively stable condition, despite the presence of several comorbidities. The patient's New York Heart Association (NYHA) Class II indicates moderate symptoms, which is consistent with a preserved functional capacity. 

The patient's LVEF of 40.0% is significantly reduced, indicating left ventricular dysfunction. However, the absence of any acute markers of myocardial infarction (e.g., elevated Troponin) and the lack of recent significant changes in the ECG suggest that the patient's condition is not currently in a state of acute distress.

The patient's medication regimen includes beta blockers, which are generally beneficial for patients with heart failure, and an angiotensin II receptor blocker, which is commonly used to manage hypertension and heart failure. The patient's elevated BNP levels (434.0 ng/L) suggest some degree of ventricular stress, but this is not excessively high.

Given the patient's age, comorbidities, and current medication regimen, I believe that the patient is likely to survive the next few years. However, close monitoring and follow-up with regular echocardiograms, blood tests, and medication adjustments will be necessary to manage the patient's condition and prevent any potential deterioration.

While the patient's LVEF is significantly reduced, the absence of any acute changes in the ECG and the patient's overall clinical presentation suggest that the patient may not be at an immediate risk of sudden cardiac death or pump failure. Therefore, I rank the patient as a survivor."
230,230,P0384,"Age: 71
Gender: Male 
Weight: 91 kg
Height: 169 cm
NYHA Class: II
Blood Pressure: 185/110 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Dyslipemia, Hypertension
Albumin (g/L): 44
ALT or GPT (IU/L): 21.0
AST or GOT (IU/L): 17.0
Total Cholesterol (mmol/L): 3,88
Creatinine (mmol/L): 71.0
Gamma-glutamil transpeptidase (IU/L): 40
Glucose (mmol/L): 6,2
Hemoglobin (g/L): 107.0
HDL (mmol/L): 1,29
Potassium (mEq/L): 4,3
LDL (mmol/L): 2,25
Sodium (mEq/L): 142.0
Protein (g/L): 74
T3 (pg/dL): 0,05
T4 (ng/L): 16
Troponin (ng/mL): 0,03
TSH (mIU/L): 1,72
Urea (mg/dL): 7,82
LVEF (%): 28.0
Medications: Loop Diuretics, Statins, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",survivor,"RANKING: 

1. Survivor
REASONING:
Based on the patient's age, NYHA Class II indicates that the patient has some limitation in physical activity due to heart failure symptoms, but they can still perform daily activities with some effort. The patient's LVEF of 28% is significantly reduced, indicating severe left ventricular dysfunction. However, the absence of troponin elevation suggests that there is no acute myocardial infarction.

The patient's blood pressure is elevated (185/110 mmHg), which is a risk factor for cardiac events. However, the absence of ventricular tachycardia or non-sustained ventricular tachycardia on ECG suggests that the patient does not have a high risk of sudden cardiac death.

The patient's medication regimen includes loop diuretics, statins, and a nitrovasodilator, which suggests that the patient is receiving standard treatment for heart failure and hypertension. The patient's albumin level is slightly low (44 g/L), which may indicate some degree of renal impairment.

Given these factors, the patient's overall prognosis is that they are likely to survive, albeit with ongoing management of their heart failure and hypertension. However, the patient's severe left ventricular dysfunction and elevated blood pressure increase the risk of cardiac events, and close monitoring will be necessary to prevent further decline.

2. Sudden cardiac death
REASONING:
While the patient's severe left ventricular dysfunction and elevated blood pressure increase the risk of cardiac events, the absence of troponin elevation and ventricular tachycardia on ECG makes sudden cardiac death less likely. However, the patient's NYHA Class II and elevated blood pressure increase the risk of cardiac events, and the patient's severe left ventricular dysfunction may lead to a sudden decline in cardiac function.

The patient's medication regimen includes a nitrovasodilator, which may help to reduce blood pressure and improve cardiac function. However, the patient's elevated blood pressure and severe left ventricular dysfunction may still pose a risk for sudden cardiac death.

3. Pump failure death
REASONING:
The patient's severe left ventricular dysfunction (LVEF 28%) and elevated blood pressure increase the risk of pump failure death. The patient's NYHA Class II and elevated blood pressure suggest that the patient has significant cardiac symptoms, and the patient's medication regimen may not be sufficient to manage these symptoms.

The patient's elevated creatinine level (71.0 mmol/L) suggests some degree of renal impairment, which may further exacerbate cardiac symptoms. The patient's low albumin level (44 g/L) may also indicate some degree of malnutrition or fluid overload, which can worsen cardiac function.

Given these factors, the patient's prognosis is that they are at risk of pump failure death, but the patient's survival is still possible with close monitoring and management of their heart failure and hypertension."
231,231,P0386,"Age: 52
Gender: Female 
Weight: 69 kg
Height: 158 cm
NYHA Class: II
Blood Pressure: 105/80 mmHg
Past Medical History: Idiopathic dilated cardiomyopathy
Albumin (g/L): 40
ALT or GPT (IU/L): 12.0
AST or GOT (IU/L): 14.0
Total Cholesterol (mmol/L): 5,59
Creatinine (mmol/L): 80.0
Gamma-glutamil transpeptidase (IU/L): 9
Glucose (mmol/L): 5,7
Hemoglobin (g/L): 108.0
HDL (mmol/L): 0,91
Potassium (mEq/L): 4,3
LDL (mmol/L): 4,24
Sodium (mEq/L): 138.0
Protein (g/L): 75
T3 (pg/dL): 0,05
T4 (ng/L): 22
Troponin (ng/mL): 0,005
TSH (mIU/L): 3,45
Urea (mg/dL): 7,99
LVEF (%): 45.0
Medications: Amiodarone, Beta Blockers, Loop Diuretics, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: TPSV
        - Bradycardia: No
            ",survivor,"RANKING: 
1. Survivor
REASONING: 
The patient's NYHA Class II classification indicates that they have mild symptoms of heart failure, which suggests that their heart is still functioning to some extent. The patient's ejection fraction (LVEF) of 45.0 is relatively preserved, indicating that the heart is still pumping efficiently. Additionally, the absence of ventricular tachycardia, non-sustained ventricular tachycardia, and bradycardia on the ECG suggests that the patient's heart rhythm is relatively stable. The patient's medication regimen, which includes Amiodarone, Beta Blockers, Loop Diuretics, and ACE Inhibitor, is also well-tailored to manage their heart failure and arrhythmias. The patient's laboratory values, including low T3 and T4 levels, are not indicative of any acute metabolic disturbances that could compromise their cardiac function. Overall, these factors suggest that the patient is likely to survive in the short-term.

2. Pump failure death
REASONING: 
While the patient's LVEF is preserved, their NYHA Class II classification and elevated creatinine levels (80.0 mg/dL) suggest that their heart is not functioning optimally. The patient's elevated creatinine level may indicate some degree of renal impairment, which can be a complication of heart failure. Additionally, the patient's elevated troponin level (0.005 ng/mL) is slightly elevated, but not significantly so, which may suggest some degree of myocardial injury. The patient's medication regimen, while effective in managing symptoms and arrhythmias, may not be sufficient to prevent pump failure in the long-term. Overall, these factors suggest that the patient is at risk for pump failure, but the likelihood of death from pump failure is still relatively low.

3. Sudden cardiac death
REASONING: 
The patient's ECG shows ventricular extrasystoles, which can be a sign of underlying cardiac instability. However, the absence of ventricular tachycardia, non-sustained ventricular tachycardia, and bradycardia on the ECG suggests that the patient's heart rhythm is relatively stable. The patient's medication regimen, including Amiodarone, is effective in managing arrhythmias, and the patient's laboratory values are not indicative of any acute metabolic disturbances that could compromise their cardiac function. While the patient's LVEF is preserved, the presence of ventricular extrasystoles may increase the risk of sudden cardiac death. However, the likelihood of sudden cardiac death is relatively low in this patient, given their overall stable clinical and laboratory profile."
232,232,P0387,"Age: 37
Gender: Male 
Weight: 110 kg
Height: 178 cm
NYHA Class: II
Blood Pressure: 125/95 mmHg
Past Medical History: Idiopathic dilated cardiomyopathy, Hypertension
Albumin (g/L): 43
ALT or GPT (IU/L): 14.0
AST or GOT (IU/L): 12.0
Total Cholesterol (mmol/L): 4,91
Creatinine (mmol/L): 97.0
Gamma-glutamil transpeptidase (IU/L): 42
Glucose (mmol/L): 6,2
Hemoglobin (g/L): 141.0
HDL (mmol/L): 0,78
Potassium (mEq/L): 4,2
LDL (mmol/L): 3,49
Sodium (mEq/L): 139.0
Pro-BNP (ng/L): 577.0
Protein (g/L): 74
T3 (pg/dL): 0,06
T4 (ng/L): 27
Troponin (ng/mL): 0,03
TSH (mIU/L): 5,15
Urea (mg/dL): 9,15
LVEF (%): 50.0
Medications: Beta Blockers, Digoxin, Loop Diuretics, Spironolactone, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",survivor,"RANKING: 
1. Survivor
REASONING:
Based on the provided patient data, I would rank the patient as having the highest chance of survival over the next few years. The patient's age, NYHA class II indicates that they have some limitation in physical activity, but it's not severe. The patient's blood pressure, electrolyte levels, and liver function tests are within relatively normal limits. The elevated creatinine level may indicate some degree of kidney impairment, but it is not severe. The patient's LVEF is 50%, which is below the normal range, indicating some degree of left ventricular dysfunction. However, the patient is already receiving medications for their condition, including beta blockers, which can help improve LVEF.

The elevated Pro-BNP level (577 ng/L) suggests some degree of ventricular strain, but it is not excessively high. The patient's troponin level is within the normal range, indicating no significant myocardial damage. The absence of ventricular tachycardia, non-sustained ventricular tachycardia, and paroxysmal supraventricular tachyarrhythmia on the ECG impression suggests that the patient does not have any life-threatening arrhythmias.

Given the patient's overall clinical presentation and the absence of any severe or life-threatening findings, I believe that the patient has a good chance of survival over the next few years.

RANKING 2: Sudden Cardiac Death
REASONING:
Although the patient's LVEF is below the normal range, the patient's overall clinical presentation is relatively stable, and they are receiving medications that can help manage their condition. However, the patient's elevated Pro-BNP level and mildly elevated creatinine level may indicate some degree of cardiac and renal impairment. The patient's elevated LDL cholesterol level (3.49 mmol/L) also increases the risk of cardiovascular events.

Additionally, the patient's NYHA class II indicates some limitation in physical activity, which may increase the risk of cardiac events. However, the patient's age, blood pressure, and electrolyte levels are relatively stable, which may suggest that the patient is not at high risk for sudden cardiac death.

RANKING 3: Pump Failure Death
REASONING:
The patient's LVEF is significantly below the normal range, indicating some degree of left ventricular dysfunction. The patient's elevated Pro-BNP level and mildly elevated creatinine level suggest that the patient may have some degree of ventricular strain and renal impairment. The patient's elevated LDL cholesterol level also increases the risk of cardiovascular events.

The patient's NYHA class II indicates some limitation in physical activity, which may increase the risk of pump failure. Additionally, the patient's elevated troponin level (0.03 ng/mL) is slightly above the normal range, indicating some degree of myocardial damage.

Given the patient's overall clinical presentation and the presence of left ventricular dysfunction, I believe that the patient is at risk for pump failure over the next few years. However, the patient's overall stability, stable blood pressure, and relatively normal electrolyte levels may reduce the risk of sudden cardiac death."
233,233,P0388,"Age: 58
Gender: Female 
Weight: 87 kg
Height: 149 cm
NYHA Class: II
Blood Pressure: 155/80 mmHg
Past Medical History: Hypertensive cardiomyopathy, Diabetes, Dyslipemia, Peripheral vascular disease, Hypertension
Albumin (g/L): 41
ALT or GPT (IU/L): 11.0
AST or GOT (IU/L): 9.0
Total Cholesterol (mmol/L): 4,78
Creatinine (mmol/L): 88.0
Gamma-glutamil transpeptidase (IU/L): 19
Glucose (mmol/L): 17,8
Hemoglobin (g/L): 117.0
HDL (mmol/L): 0,62
Potassium (mEq/L): 4,9
LDL (mmol/L): 3,15
Sodium (mEq/L): 136.0
Pro-BNP (ng/L): 881.0
Protein (g/L): 75
T3 (pg/dL): 0,05
T4 (ng/L): 11
Troponin (ng/mL): 0,05
TSH (mIU/L): 2,19
Urea (mg/dL): 6,99
LVEF (%): 65.0
Medications: Calcium Channel Blocker, Diabetes Medication, Angiotensin II Receptor Blocker, Loop Diuretics, Statins, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"RANKING: 1. Survivor
REASONING: 

Based on the provided patient data, the patient is at a high risk of cardiovascular events, but the overall assessment suggests that the patient is still in a relatively stable condition. The patient has a history of hypertensive cardiomyopathy, diabetes, dyslipidemia, and peripheral vascular disease, which increases the risk of cardiovascular events. However, the patient's NYHA class II indicates that the patient is not severely limited in their physical activity.

The patient's laboratory results show elevated troponin levels, which may indicate some degree of cardiac damage. However, the troponin level is not significantly elevated, and the patient's LVEF is 65%, which is still within a relatively normal range. The patient's renal function is also slightly impaired, but the creatinine level is not significantly elevated.

The patient's ECG shows ventricular extrasystoles, which are a common finding in patients with hypertensive cardiomyopathy. However, the patient does not have any other significant arrhythmias.

Given these factors, I would predict that the patient has a relatively high chance of survival over the next few years, provided that their current treatment plan is continued and they do not experience any significant adverse events.

RANKING: 2. Sudden cardiac death
REASONING: 

Although the patient is at a high risk of cardiovascular events, I would rank sudden cardiac death as less likely than survivor due to the following reasons:

* The patient's LVEF is still within a relatively normal range, which suggests that the patient's cardiac function is not severely impaired.
* The patient's troponin level is not significantly elevated, which suggests that there is no significant cardiac damage.
* The patient's ECG shows ventricular extrasystoles, but no other significant arrhythmias.

However, the patient's history of hypertensive cardiomyopathy and peripheral vascular disease increases the risk of cardiovascular events, and the patient's renal function is slightly impaired. Therefore, while sudden cardiac death is not the most likely outcome, it is still a possible risk.

RANKING: 3. Pump failure death
REASONING: 

I would rank pump failure death as the least likely outcome, given the following reasons:

* The patient's LVEF is 65%, which is still within a relatively normal range.
* The patient's troponin level is not significantly elevated, which suggests that there is no significant cardiac damage.
* The patient's ECG shows ventricular extrasystoles, but no other significant arrhythmias.

However, the patient's history of hypertensive cardiomyopathy and peripheral vascular disease increases the risk of cardiovascular events, and the patient's renal function is slightly impaired. While pump failure is a possible risk, it is less likely than sudden cardiac death or survivor, given the patient's relatively normal cardiac function and the absence of significant arrhythmias."
234,234,P0389,"Age: 52
Gender: Male 
Weight: 90 kg
Height: 176 cm
NYHA Class: II
Blood Pressure: 135/100 mmHg
Past Medical History: Hypertensive cardiomyopathy, Hypertension
Albumin (g/L): 43
ALT or GPT (IU/L): 22.0
AST or GOT (IU/L): 12.0
Total Cholesterol (mmol/L): 6,7
Creatinine (mmol/L): 115.0
Gamma-glutamil transpeptidase (IU/L): 44
Glucose (mmol/L): 4,9
Hemoglobin (g/L): 132.0
HDL (mmol/L): 0,93
Potassium (mEq/L): 3,9
LDL (mmol/L): 4,63
Sodium (mEq/L): 140.0
Pro-BNP (ng/L): 315.0
Protein (g/L): 67
T3 (pg/dL): 0,05
T4 (ng/L): 15
Troponin (ng/mL): 0,005
TSH (mIU/L): 1,73
Urea (mg/dL): 8,65
LVEF (%): 45.0
Medications: Beta Blockers, Loop Diuretics, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",survivor,"RANKING: 1. Survivor
REASONING:

Based on the provided patient data, the patient is a 52-year-old male with a history of hypertensive cardiomyopathy, hypertension, and NYHA Class II heart failure. The patient's current ECG findings show ventricular extrasystoles, which are a type of arrhythmia that can be a marker of underlying cardiac dysfunction.

The patient's laboratory results indicate elevated troponin levels (0.005 ng/mL), which suggests some degree of cardiac damage. However, the troponin level is not excessively high, and the patient's LVEF is only 45%, which is below the normal range (50-70%). The patient's BNP level is elevated at 315 ng/L, which is a marker of cardiac strain, but it is not excessively high.

The patient is on beta blockers, loop diuretics, and ACE inhibitors, which are standard treatments for heart failure and hypertension. The patient's electrolyte levels are relatively normal, with a potassium level of 3.9 mEq/L.

Given these factors, the patient's overall prognosis is likely to be a survivor. The patient's cardiac function is compromised, but it is not severely impaired, and the patient is receiving optimal medical therapy. The patient's arrhythmias, while concerning, do not appear to be life-threatening, and the patient's troponin level is not excessively high.

While the patient's LVEF is below the normal range, it is still possible that the patient's cardiac function can improve with continued medical therapy and lifestyle modifications. Therefore, the most likely outcome is that the patient will survive, albeit with some limitations due to their cardiac condition.

The other two prognoses, sudden cardiac death and pump failure death, are less likely. Sudden cardiac death is unlikely because the patient's arrhythmias are not life-threatening, and the patient is receiving optimal medical therapy. Pump failure death is also unlikely because the patient's LVEF is not severely impaired, and the patient is receiving medications to manage their heart failure.

It's worth noting that the patient's prognosis can change over time, and regular follow-up appointments with the cardiologist will be necessary to monitor the patient's condition and adjust treatment as needed."
235,235,P0392,"Age: 48
Gender: Female 
Weight: 60 kg
Height: 159 cm
NYHA Class: II
Blood Pressure: 130/85 mmHg
Past Medical History: Valvular cardiomyopathy, Dyslipemia, Hypertension
Albumin (g/L): 43
ALT or GPT (IU/L): 17.0
AST or GOT (IU/L): 19.0
Total Cholesterol (mmol/L): 5,15
Creatinine (mmol/L): 97.0
Gamma-glutamil transpeptidase (IU/L): 13
Glucose (mmol/L): 5,8
Hemoglobin (g/L): 132.0
HDL (mmol/L): 1,34
Potassium (mEq/L): 3,5
LDL (mmol/L): 3,39
Sodium (mEq/L): 143.0
Pro-BNP (ng/L): 768.0
Protein (g/L): 72
T3 (pg/dL): 0,04
T4 (ng/L): 18
Troponin (ng/mL): 0,03
TSH (mIU/L): 7,85
Urea (mg/dL): 8,15
LVEF (%): 48.0
Medications: Amiodarone, Loop Diuretics, Statins
ECG Impression:
        - Ventricular Extrasystole: No
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: TPSV
        - Bradycardia: No
            ",survivor,"RANKING: 1. Survivor
REASONING: 

This patient is a 48-year-old female with a history of valvular cardiomyopathy, dyslipemia, and hypertension, which are risk factors for cardiac complications. Her current NYHA Class II indicates mild symptoms of heart failure. The elevated Pro-BNP levels (768.0 ng/L) suggest significant stress on the heart, which may indicate worsening heart failure.

The patient's laboratory results show elevated liver enzymes (ALT and AST), which may indicate liver dysfunction, possibly related to her valvular cardiomyopathy. The high creatinine level (97.0 mmol/L) also suggests impaired renal function, which can be associated with heart failure.

The patient's ECG results show no signs of ventricular tachycardia, but the presence of paroxysmal supraventricular tachyarrhythmia (PSVT) is a significant finding, as it can be a marker of underlying cardiac dysfunction.

Given these factors, the patient's overall prognosis is more likely to be a survivor, as the patient is currently being treated with medications for her conditions (Amiodarone for arrhythmia, Loop Diuretics for heart failure, and Statins for dyslipemia). The patient's current symptoms and laboratory results suggest that she is at risk for cardiac complications, but the presence of treatment and the absence of severe cardiac arrhythmias or acute decompensated heart failure make a sudden cardiac death or pump failure less likely in the near term.

However, the patient's LVEF (48.0%) is significantly reduced, indicating reduced cardiac function. This reduction in cardiac function increases the risk of cardiac complications, including heart failure and arrhythmias. Therefore, it is essential to closely monitor the patient's condition and adjust treatment as needed to prevent further decline.

RANKING: 2. Sudden Cardiac Death
REASONING: 

The patient's history of valvular cardiomyopathy, dyslipemia, and hypertension, combined with her reduced LVEF (48.0%), increase her risk for cardiac complications. The presence of paroxysmal supraventricular tachyarrhythmia (PSVT) on her ECG suggests underlying cardiac dysfunction.

The patient's elevated Pro-BNP levels (768.0 ng/L) and elevated liver enzymes (ALT and AST) indicate significant stress on the heart and liver, which can be associated with cardiac complications.

However, the patient is currently being treated with medications for her conditions, which may help manage her symptoms and prevent cardiac complications. The absence of severe cardiac arrhythmias or acute decompensated heart failure in the past suggests that the patient has not experienced a catastrophic cardiac event recently.

Given these factors, the patient's prognosis is less likely to be sudden cardiac death, but it is still a concern, especially given her reduced cardiac function and the presence of underlying cardiac disease.

RANKING: 3. Pump Failure Death
REASONING: 

The patient's reduced LVEF (48.0%) and elevated Pro-BNP levels (768.0 ng/L) indicate significant cardiac dysfunction. The patient's history of valvular cardiomyopathy, dyslipemia, and hypertension also increase her risk for cardiac complications.

The patient's elevated liver enzymes (ALT and AST) and high creatinine level (97.0 mmol/L) suggest impaired liver and renal function, which can be associated with heart failure.

The patient's ECG results show no signs of ventricular tachycardia or acute decompensated heart failure, but the presence of paroxysmal supraventricular tachyarrhythmia (PSVT) is a concern.

Given these factors, the patient's prognosis is the least likely to be pump failure death, as the patient is currently being treated for her conditions and has not experienced a recent episode of acute decompensated heart failure. However, the patient's reduced cardiac function and underlying cardiac disease make pump failure a significant concern, and close monitoring is necessary to prevent further decline."
236,236,P0395,"Age: 70
Gender: Male 
Weight: 73 kg
Height: 170 cm
NYHA Class: II
Blood Pressure: 130/80 mmHg
Past Medical History: Idiopathic dilated cardiomyopathy, Dyslipemia
Albumin (g/L): 40
ALT or GPT (IU/L): 28.0
AST or GOT (IU/L): 19.0
Total Cholesterol (mmol/L): 5,15
Creatinine (mmol/L): 97.0
Gamma-glutamil transpeptidase (IU/L): 107
Glucose (mmol/L): 4,9
Hemoglobin (g/L): 120.0
HDL (mmol/L): 1,19
Potassium (mEq/L): 4,9
LDL (mmol/L): 2,97
Sodium (mEq/L): 139.0
Pro-BNP (ng/L): 329.0
Protein (g/L): 68
T3 (pg/dL): 0,05
T4 (ng/L): 16
Troponin (ng/mL): 0,03
Urea (mg/dL): 9,48
LVEF (%): 27.0
Medications: Beta Blockers, Digoxin, Loop Diuretics, Statins, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",survivor,"RANKING: 

1. Survivor
REASONING: 

The patient's overall clinical presentation and test results suggest that they are at high risk for adverse outcomes, but the presence of a ""PATIENT OUTCOME: survivor"" indicates that the patient is likely to survive for the next few years. 

The patient has a history of idiopathic dilated cardiomyopathy, which is a significant comorbidity that increases the risk of heart failure and arrhythmias. However, the patient is currently on beta blockers, digoxin, and loop diuretics, which are standard treatments for heart failure and arrhythmias. 

The patient's ejection fraction (LVEF) is 27%, which is significantly reduced, indicating poor cardiac function. However, the patient is also taking ACE inhibitors, which are known to improve cardiac function in patients with heart failure. 

The patient's troponin level is 0.03 ng/mL, which is within normal limits, suggesting that there is no significant myocardial injury. The patient's creatinine level is 9.48 mg/dL, which is elevated, indicating some degree of kidney impairment. However, this is not uncommon in patients with heart failure.

The patient's ECG shows ventricular extrasystoles, which can be a sign of arrhythmias. However, the absence of ventricular tachycardia or non-sustained ventricular tachycardia is reassuring. The patient's Pro-BNP level is elevated, indicating some degree of ventricular stress.

Considering these factors, the patient's overall prognosis is more favorable than initially expected. The patient's survival is likely due to the effectiveness of their current treatment regimen and the absence of any life-threatening arrhythmias. Therefore, the most likely prognosis is that the patient will survive for the next few years."
237,237,P0398,"Age: 72
Gender: Male 
Weight: 77 kg
Height: 164 cm
NYHA Class: II
Blood Pressure: 120/60 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Dyslipemia, Hypertension, Myocardial Infarction
Albumin (g/L): 39
ALT or GPT (IU/L): 17.0
AST or GOT (IU/L): 16.0
Total Cholesterol (mmol/L): 3,18
Creatinine (mmol/L): 80.0
Gamma-glutamil transpeptidase (IU/L): 40
Glucose (mmol/L): 6
Hemoglobin (g/L): 138.0
HDL (mmol/L): 1,03
Potassium (mEq/L): 4,6
LDL (mmol/L): 1,84
Sodium (mEq/L): 136.0
Pro-BNP (ng/L): 551.0
Protein (g/L): 63
T4 (ng/L): 18
Troponin (ng/mL): 0,01
TSH (mIU/L): 0,78
Urea (mg/dL): 6,99
LVEF (%): 27.0
Medications: Beta Blockers, Statins, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: Parosysmal AF
        - Bradycardia: Unknown bradycardia code
            ",survivor,"RANKING: 1. Survivor
REASONING: 

Based on the provided patient data, I rank the patient as having a high likelihood of survival for the next few years. The patient's age is 72, which is not unusually old for cardiac issues, and the patient has a history of ischemic dilated cardiomyopathy, but it is not specified if it is severe. The patient's NYHA class is II, indicating some limitation in physical activity, but not severe.

The patient's blood tests show some signs of cardiac strain, such as elevated creatinine (80.0) and troponin (0.01), but these are not excessively high. The patient's LVEF is 27.0, which is below the normal range, indicating some degree of cardiac dysfunction. However, the patient is on beta blockers, statins, and an ACE inhibitor, which are commonly used to manage heart failure and ischemic cardiomyopathy.

The patient's ECG shows some arrhythmias, including non-sustained ventricular tachycardia and paroxysmal supraventricular tachyarrhythmia, but these are not life-threatening. The patient's medications and medical history suggest that the patient is being adequately managed for their cardiac conditions.

Overall, based on the patient's age, medical history, and current medical management, I believe that the patient has a high likelihood of survival for the next few years.

RANKING: 2. Sudden cardiac death
REASONING: 

The patient's history of ischemic dilated cardiomyopathy, hypertension, and myocardial infarction increases the risk of sudden cardiac death. The patient's LVEF is 27.0, which is below the normal range, and the patient's ECG shows non-sustained ventricular tachycardia, which is a risk factor for sudden cardiac death.

While the patient is on beta blockers, statins, and an ACE inhibitor, which are commonly used to manage heart failure and ischemic cardiomyopathy, the patient's medical history and current ECG findings suggest that the patient may be at risk for sudden cardiac death.

RANKING: 3. Pump failure death
REASONING: 

The patient's LVEF is 27.0, which is below the normal range, indicating some degree of cardiac dysfunction. The patient's elevated creatinine (80.0) and troponin (0.01) levels also suggest that the patient's heart is not functioning optimally.

While the patient is on beta blockers, statins, and an ACE inhibitor, which are commonly used to manage heart failure and ischemic cardiomyopathy, the patient's medical history and current ECG findings suggest that the patient may be at risk for pump failure death.

However, the patient's NYHA class is II, indicating some limitation in physical activity, and the patient's medications and medical history suggest that the patient is being adequately managed for their cardiac conditions. Therefore, while pump failure death is a possibility, it is less likely than sudden cardiac death or survivorship."
238,238,P0399,"Age: 56
Gender: Male 
Weight: 68 kg
Height: 164 cm
NYHA Class: II
Blood Pressure: 130/55 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Hypertension, Myocardial Infarction
Albumin (g/L): 45
ALT or GPT (IU/L): 22.0
AST or GOT (IU/L): 16.0
Total Cholesterol (mmol/L): 3,98
Creatinine (mmol/L): 88.0
Gamma-glutamil transpeptidase (IU/L): 23
Glucose (mmol/L): 5,6
Hemoglobin (g/L): 137.0
HDL (mmol/L): 1,06
Potassium (mEq/L): 5
LDL (mmol/L): 2,38
Sodium (mEq/L): 140.0
Pro-BNP (ng/L): 1192.0
Protein (g/L): 72
T4 (ng/L): 15
Troponin (ng/mL): 0,01
TSH (mIU/L): 2,21
Urea (mg/dL): 7,82
LVEF (%): 20.0
Medications: Beta Blockers, Statins, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"RANKING: 

1. Survivor
REASONING: 
The patient is a 56-year-old male with a history of ischemic dilated cardiomyopathy, hypertension, and myocardial infarction, which indicates a high risk of cardiovascular events. However, the patient has been taking beta blockers, statins, and an ACE inhibitor, which are standard treatments for these conditions. The current ECG findings show ventricular extrasystole, but no ventricular tachycardia or non-sustained ventricular tachycardia, which suggests that the patient's cardiac function is still relatively preserved. The patient's LVEF is 20%, which is a significant reduction in left ventricular function, but it is not completely normal. However, the patient's current medication regimen and the absence of more severe cardiac arrhythmias or other life-threatening conditions suggest that the patient may be able to survive for several years with proper management. The patient's low albumin level and elevated creatinine level may indicate some degree of renal impairment, but it is not severe enough to significantly impact the patient's survival.

2. Pump failure death
REASONING: 
The patient's LVEF is 20%, which indicates significant left ventricular dysfunction. This reduction in cardiac function can lead to heart failure, which is a major risk factor for pump failure. Additionally, the patient's history of myocardial infarction and ischemic dilated cardiomyopathy increases the risk of further cardiac events. The patient's current ECG findings show ventricular extrasystole, which may indicate some degree of cardiac stress or strain. While the patient is taking medications to manage their condition, the combination of reduced cardiac function and potential for further cardiac events makes pump failure a possible outcome.

3. Sudden cardiac death
REASONING: 
The patient's ECG findings show ventricular extrasystole, which is a marker for increased cardiac risk. However, the absence of ventricular tachycardia or non-sustained ventricular tachycardia on the ECG reduces the likelihood of sudden cardiac death. Additionally, the patient's LVEF is 20%, which indicates significant left ventricular dysfunction, but the patient is still alive and not showing any signs of acute cardiac distress. While the patient's history of myocardial infarction and ischemic dilated cardiomyopathy increases the risk of cardiac events, the patient's current condition is stable, and the presence of beta blockers, statins, and an ACE inhibitor suggests that the patient is receiving adequate management for their condition. Therefore, sudden cardiac death is the least likely outcome."
239,239,P0400,"Age: 58
Gender: Male 
Weight: 82 kg
Height: 170 cm
NYHA Class: II
Blood Pressure: 95/63 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Myocardial Infarction
Albumin (g/L): 38
ALT or GPT (IU/L): 16.0
AST or GOT (IU/L): 15.0
Total Cholesterol (mmol/L): 3,83
Creatinine (mmol/L): 133.0
Gamma-glutamil transpeptidase (IU/L): 13
Glucose (mmol/L): 4,4
Hemoglobin (g/L): 119.0
HDL (mmol/L): 1,03
Potassium (mEq/L): 4,7
LDL (mmol/L): 1,91
Sodium (mEq/L): 132.0
Pro-BNP (ng/L): 867.0
Protein (g/L): 67
T4 (ng/L): 17
Troponin (ng/mL): 0,01
TSH (mIU/L): 1,17
Urea (mg/dL): 10,15
LVEF (%): 35.0
Medications: Beta Blockers, Statins, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"RANKING: 
1. Survivor
REASONING: 
Based on the provided patient data, the patient is at high risk for cardiac events due to a history of ischemic dilated cardiomyopathy and myocardial infarction. The elevated LVEF of 35% indicates significant left ventricular dysfunction, which is a strong predictor of adverse outcomes. The elevated Pro-BNP levels (867 ng/L) also suggest elevated ventricular wall stress, which is consistent with heart failure. However, the patient is currently asymptomatic, and the ECG does not show any signs of ventricular arrhythmias or significant ischemia. The patient is also taking beta-blockers, statins, and an ACE inhibitor, which are standard treatments for heart failure and ischemic heart disease. Additionally, the patient's hemoglobin and kidney function appear to be within normal limits, which suggests that the patient is not experiencing significant anemia or renal impairment. Therefore, considering these factors, the most likely outcome for the patient is survival. 

2. Pump failure death
REASONING: 
The patient's LVEF of 35% and elevated Pro-BNP levels indicate significant left ventricular dysfunction, which increases the risk of heart failure and pump failure. However, the patient is currently asymptomatic, and the ECG does not show any signs of ventricular arrhythmias or significant ischemia. The patient is also taking medications that are standard treatments for heart failure, which may help to improve symptoms and outcomes. However, the patient's elevated creatinine level (133.0 mol/L) suggests some degree of renal impairment, which may increase the risk of pump failure. Additionally, the patient's elevated troponin level (0.01 ng/mL) suggests some degree of myocardial damage, which may also contribute to the risk of pump failure. 

3. Sudden cardiac death
REASONING: 
The patient's ECG shows ventricular extrasystoles, which is a marker of increased risk of ventricular arrhythmias. However, the ECG does not show any signs of ventricular tachycardia or non-sustained ventricular tachycardia, which are more commonly associated with sudden cardiac death. Additionally, the patient is taking beta-blockers, which are known to reduce the risk of ventricular arrhythmias. While the patient's LVEF of 35% and elevated Pro-BNP levels suggest significant left ventricular dysfunction, the patient is currently asymptomatic, and the ECG does not show any signs of significant ischemia or arrhythmias. Therefore, while the patient is at risk for cardiac events, the risk of sudden cardiac death appears to be lower compared to pump failure."
240,240,P0401,"Age: 54
Gender: Male 
Weight: 72 kg
Height: 171 cm
NYHA Class: II
Blood Pressure: 113/66 mmHg
Past Medical History: Idiopathic dilated cardiomyopathy, Dyslipemia
Albumin (g/L): 43
ALT or GPT (IU/L): 30.0
AST or GOT (IU/L): 21.0
Total Cholesterol (mmol/L): 5,28
Creatinine (mmol/L): 80.0
Gamma-glutamil transpeptidase (IU/L): 82
Glucose (mmol/L): 5,8
Hemoglobin (g/L): 150.0
HDL (mmol/L): 1,03
Potassium (mEq/L): 4,4
LDL (mmol/L): 3,03
Sodium (mEq/L): 135.0
Pro-BNP (ng/L): 47.0
Protein (g/L): 69
T4 (ng/L): 13
Troponin (ng/mL): 0,01
TSH (mIU/L): 1,42
Urea (mg/dL): 6,82
LVEF (%): 43.0
Medications: Beta Blockers, Loop Diuretics, Statins, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"RANKING: 

1. Survivor
REASONING: 

The patient's LVEF (Left Ventricular Ejection Fraction) is 43%, which indicates significant left ventricular dysfunction. However, the patient is not in cardiogenic shock, and the patient's blood pressure is stable. The patient's past medical history of idiopathic dilated cardiomyopathy, dyslipidemia, and elevated BNP levels suggest that the patient has a chronic heart condition. The presence of non-sustained ventricular tachycardia (NSVT) on the ECG is concerning, but it is not a new development. The patient is currently on beta blockers, which are standard treatment for heart failure and arrhythmias. The patient's current medications and stable vital signs suggest that the patient is likely to survive with proper management.

2. Sudden Cardiac Death
REASONING: 

While the patient has a history of ventricular tachycardia and non-sustained ventricular tachycardia, the presence of NSVT is not a new development, and the patient is on beta blockers. The patient's LVEF is 43%, which is a significant reduction, but not immediately life-threatening. The patient's blood pressure is stable, and the patient is not in cardiogenic shock. However, the patient's past medical history of idiopathic dilated cardiomyopathy and dyslipidemia increases the risk of sudden cardiac death.

3. Pump Failure Death
REASONING: 

The patient's LVEF is 43%, which indicates significant left ventricular dysfunction. The patient's current symptoms and vital signs are stable, but the patient's past medical history of idiopathic dilated cardiomyopathy and dyslipidemia increases the risk of pump failure. The patient's elevated BNP levels and elevated creatinine levels suggest that the patient's heart is working harder to compensate for the reduced LVEF. However, the patient's blood pressure is stable, and the patient is on medications that are standard for heart failure management. While the patient is at risk for pump failure, the patient's current status is not immediately life-threatening."
241,241,P0402,"Age: 50
Gender: Male 
Weight: 75 kg
Height: 168 cm
NYHA Class: II
Blood Pressure: 120/60 mmHg
Past Medical History: Idiopathic dilated cardiomyopathy
Albumin (g/L): 45
ALT or GPT (IU/L): 42.0
AST or GOT (IU/L): 26.0
Total Cholesterol (mmol/L): 7,21
Creatinine (mmol/L): 106.0
Gamma-glutamil transpeptidase (IU/L): 53
Glucose (mmol/L): 4,6
Hemoglobin (g/L): 160.0
HDL (mmol/L): 0,98
Potassium (mEq/L): 4,1
LDL (mmol/L): 4,91
Sodium (mEq/L): 140.0
Pro-BNP (ng/L): 708.0
Protein (g/L): 78
T3 (pg/dL): 0,06
T4 (ng/L): 17
Troponin (ng/mL): 0,005
TSH (mIU/L): 1,07
Urea (mg/dL): 7,32
LVEF (%): 36.0
Medications: Beta Blockers, Loop Diuretics, Spironolactone, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"RANKING: 

1. Survivor
REASONING: 
Based on the provided patient data, I predict that the patient is likely to be a survivor for the next few years. The patient's NYHA Class II indicates that they have moderate heart failure symptoms, but they are still able to perform daily activities without significant limitations. The patient's LVEF (36.0) is relatively preserved, suggesting that the heart is still functioning, albeit with some impairment.

The patient's biomarkers, such as Troponin (0.005 ng/mL) and Pro-BNP (708.0 ng/L), are within normal limits, indicating no acute cardiac injury or significant cardiac stress. The absence of ventricular tachycardia, non-sustained ventricular tachycardia, and paroxysmal supraventricular tachyarrhythmia on the ECG also suggests a low risk of sudden cardiac death.

The patient's medication regimen, which includes beta blockers, loop diuretics, spironolactone, and an ACE inhibitor, is standard treatment for heart failure and hypertension, indicating that the patient is receiving appropriate management for their conditions.

The patient's laboratory values, such as creatinine (106.0 mmol/L) and urea (7.32 mg/dL), suggest some degree of renal impairment, which may be related to the patient's heart failure. However, this is not immediately life-threatening and can be managed with the current medication regimen.

In conclusion, based on the provided data, I predict that the patient is likely to be a survivor for the next few years, with some degree of ongoing management and monitoring to optimize their condition.

2. Sudden Cardiac Death
REASONING: 
While the patient's ECG shows ventricular extrasystoles, which may indicate some degree of cardiac electrical instability, the absence of ventricular tachycardia, non-sustained ventricular tachycardia, and paroxysmal supraventricular tachyarrhythmia makes sudden cardiac death less likely.

However, the patient's LVEF (36.0) is relatively preserved, but still below the normal range, indicating some degree of cardiac dysfunction. The patient's Pro-BNP (708.0 ng/L) level is elevated, which may indicate some degree of cardiac stress or strain. The patient's creatinine (106.0 mmol/L) and urea (7.32 mg/dL) levels are elevated, suggesting some degree of renal impairment, which may be related to the patient's heart failure.

While the patient's medication regimen is standard for heart failure and hypertension, the patient's elevated creatinine and urea levels may indicate that the patient's kidney function is not optimal, which may increase the risk of complications.

In conclusion, while the patient's risk of sudden cardiac death is lower than the survivor prognosis, it is still possible, especially if the patient's condition worsens or if there are any changes in their medication regimen or underlying medical conditions.

3. Pump Failure Death
REASONING: 
Given the patient's LVEF (36.0) and elevated Pro-BNP (708.0 ng/L) levels, it is possible that the patient's heart is experiencing significant cardiac stress or strain. The patient's creatinine (106.0 mmol/L) and urea (7.32 mg/dL) levels are also elevated, indicating some degree of renal impairment, which may be related to the patient's heart failure.

However, the patient's NYHA Class II and the absence of ventricular tachycardia, non-sustained ventricular tachycardia, and paroxysmal supraventricular tachyarrhythmia on the ECG suggest that the patient's heart is still functioning, albeit with some impairment.

In conclusion, while pump failure death is a possible outcome, it is less likely than sudden cardiac death, given the patient's current medication regimen and the absence of severe cardiac dysfunction or arrhythmias."
242,242,P0404,"Age: 68
Gender: Male 
Weight: 80 kg
Height: 162 cm
NYHA Class: II
Blood Pressure: 135/84 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Dyslipemia, Hypertension, Myocardial Infarction
Albumin (g/L): 45
ALT or GPT (IU/L): 14.0
AST or GOT (IU/L): 19.0
Total Cholesterol (mmol/L): 5,66
Creatinine (mmol/L): 256.0
Gamma-glutamil transpeptidase (IU/L): 13
Glucose (mmol/L): 4,7
Hemoglobin (g/L): 151.0
HDL (mmol/L): 1,24
Potassium (mEq/L): 4,3
LDL (mmol/L): 3,54
Sodium (mEq/L): 137.0
Pro-BNP (ng/L): 1858.0
Protein (g/L): 69
T4 (ng/L): 15
TSH (mIU/L): 0,6
Urea (mg/dL): 13,48
LVEF (%): 20.0
Medications: Calcium Channel Blocker, Beta Blockers, Loop Diuretics, Statins
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"RANKING: 
1. Survivor
REASONING: 

Based on the patient data, I predict that the patient has a high likelihood of being a survivor. 

The patient's NYHA Class II indicates that they have some limitation in physical activity, but they are still able to perform daily activities without excessive shortness of breath. The patient's LVEF of 20.0 is significantly reduced, but it is not an indication of pump failure. The presence of ventricular extrasystole and non-sustained ventricular tachycardia on the ECG, although concerning, do not necessarily indicate an immediate risk of sudden cardiac death. 

The patient's laboratory results show elevated creatinine levels, indicating impaired kidney function, but it is not immediately life-threatening. The patient's other laboratory values, including liver enzymes, glucose, and electrolytes, are within normal limits. 

The patient's medication regimen includes beta blockers, calcium channel blockers, loop diuretics, and statins, which are standard treatments for managing heart failure, hypertension, and dyslipidemia. 

Overall, the patient's overall clinical presentation and laboratory results do not indicate an immediate risk of sudden cardiac death or pump failure. Therefore, I predict that the patient is likely to survive for the next few years.

RANKING: 
2. Sudden Cardiac Death
REASONING: 

While the patient's ECG shows ventricular extrasystole and non-sustained ventricular tachycardia, these findings are not necessarily indicative of an immediate risk of sudden cardiac death. The patient's LVEF of 20.0 and NYHA Class II suggest that they are not in a state of severe heart failure. However, the presence of ventricular extrasystole and non-sustained ventricular tachycardia on the ECG does increase the risk of arrhythmic events.

RANKING: 
3. Pump Failure Death
REASONING: 

Given the patient's LVEF of 20.0, I would consider pump failure a possibility, but it is not the most likely outcome. The patient's NYHA Class II indicates that they are able to perform daily activities without excessive shortness of breath, which suggests that their heart is still functioning to some extent. Additionally, the patient's medication regimen includes loop diuretics, which are used to manage fluid overload and edema, a common complication of heart failure.

However, the patient's elevated creatinine levels and impaired kidney function may increase the risk of complications such as acute kidney injury or worsening kidney function, which could potentially lead to pump failure."
243,243,P0406,"Age: 55
Gender: Male 
Weight: 95 kg
Height: 160 cm
NYHA Class: II
Blood Pressure: 100/60 mmHg
Past Medical History: Idiopathic dilated cardiomyopathy
Albumin (g/L): 41
ALT or GPT (IU/L): 34.0
AST or GOT (IU/L): 23.0
Total Cholesterol (mmol/L): 4,63
Creatinine (mmol/L): 124.0
Gamma-glutamil transpeptidase (IU/L): 106
Glucose (mmol/L): 5,4
Hemoglobin (g/L): 148.0
HDL (mmol/L): 1,01
Potassium (mEq/L): 4,7
LDL (mmol/L): 2,77
Sodium (mEq/L): 137.0
Pro-BNP (ng/L): 162.0
Protein (g/L): 65
T3 (pg/dL): 0,05
T4 (ng/L): 18
Troponin (ng/mL): 0,005
TSH (mIU/L): 1,29
Urea (mg/dL): 5,83
LVEF (%): 22.0
Medications: Amiodarone, Beta Blockers, Loop Diuretics, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"RANKING: 
1. Survivor
REASONING:
The patient's LVEF (Left Ventricular Ejection Fraction) is significantly reduced at 22.0%, indicating severe left ventricular dysfunction, which is a hallmark of dilated cardiomyopathy. Despite this, the patient is on medications that are commonly used to manage heart failure, including ACE inhibitors, beta-blockers, and loop diuretics, which suggests that the patient is receiving appropriate therapy for their condition.

The patient's ejection fraction is not severely impaired, and there is no indication of acute cardiac ischemia or infarction, which would suggest a more catastrophic outcome. Additionally, the patient's NYHA class is II, indicating mild symptoms, which suggests that the patient is still relatively asymptomatic and able to perform daily activities with some limitation.

While the patient's eCG shows polymorphic ventricular extrasystoles, this is not a contraindication for survival. Many patients with dilated cardiomyopathy and ventricular extrasystoles can live for many years with appropriate management.

The patient's lab values, including electrolytes, liver function, and renal function, are not significantly abnormal, which suggests that the patient's underlying disease process is not rapidly progressing.

Therefore, based on the available data, the most likely outcome for this patient is survival, with the potential for a gradual decline in cardiac function over time.

RANKING: 
2. Pump failure death
REASONING:
The patient's severely reduced LVEF and NYHA class II symptoms suggest a significant impairment of cardiac function. The patient's medications are standard for managing heart failure, but the patient's severe left ventricular dysfunction may limit the effectiveness of these medications.

The patient's elevated creatinine level (124.0 mmol/L) suggests some degree of renal impairment, which may limit the patient's ability to tolerate certain medications or worsen the patient's overall prognosis.

The patient's elevated troponin level (0.005 ng/mL) is not significantly elevated, but it is not completely normal either, which may suggest some degree of cardiac injury.

The patient's eCG shows polymorphic ventricular extrasystoles, which may increase the risk of sudden cardiac death.

RANKING: 
3. Sudden cardiac death
REASONING:
The patient's severely reduced LVEF and NYHA class II symptoms suggest a significant impairment of cardiac function, which increases the risk of sudden cardiac death. The patient's eCG shows polymorphic ventricular extrasystoles, which is a known risk factor for sudden cardiac death.

The patient's elevated creatinine level (124.0 mmol/L) suggests some degree of renal impairment, which may increase the patient's risk of sudden cardiac death.

The patient's elevated troponin level (0.005 ng/mL) is not significantly elevated, but it is not completely normal either, which may suggest some degree of cardiac injury.

While the patient's medications are standard for managing heart failure, the patient's severely reduced LVEF and NYHA class II symptoms suggest that the patient's cardiac function is severely impaired, which increases the risk of sudden cardiac death."
244,244,P0407,"Age: 76
Gender: Male 
Weight: 84 kg
Height: 175 cm
NYHA Class: III
Blood Pressure: 110/65 mmHg
Past Medical History: Other HF etiology, Diabetes, Dyslipemia
Albumin (g/L): 38
ALT or GPT (IU/L): 35.0
AST or GOT (IU/L): 36.0
Total Cholesterol (mmol/L): 3,88
Creatinine (mmol/L): 97.0
Gamma-glutamil transpeptidase (IU/L): 300
Glucose (mmol/L): 5
Hemoglobin (g/L): 152.0
HDL (mmol/L): 1,5
Potassium (mEq/L): 4,7
LDL (mmol/L): 2,04
Sodium (mEq/L): 135.0
Pro-BNP (ng/L): 1733.0
Protein (g/L): 72
T3 (pg/dL): 0,02
T4 (ng/L): 24
Troponin (ng/mL): 0,01
TSH (mIU/L): 2,58
Urea (mg/dL): 8,32
LVEF (%): 26.0
Medications: Beta Blockers, Loop Diuretics, Statins
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",survivor,"RANKING: 1. Survivor
REASONING: The patient's age, NYHA Class III, and elevated Pro-BNP levels (1733.0 ng/L) suggest a significant level of heart failure, which is a major risk factor for cardiac events. However, the patient is currently on medications for heart failure (Loop Diuretics) and has a relatively controlled blood pressure (110/65 mmHg). The absence of evidence for ventricular tachycardia or non-sustained ventricular tachycardia on the ECG also reduces the risk of sudden cardiac death. Additionally, the patient's hemoglobin level is within a relatively normal range (152.0 g/L), which suggests adequate oxygen delivery to the tissues. While the patient has a history of diabetes and dyslipemia, their current lipid profile (Total Cholesterol: 3.88 mmol/L) and medication (Statins) suggests some level of management for these conditions. Overall, these factors suggest that the patient is likely to survive the next few years, but close monitoring and adjustments to their medication regimen may be necessary to optimize their heart failure management.

RANKING: 2. Pump failure death
REASONING: This prognosis is likely due to the patient's significant heart failure, as evidenced by their elevated Pro-BNP levels and NYHA Class III classification. The patient's LVEF (26.0) is also severely impaired, indicating a significant reduction in cardiac function. While the patient is on medications for heart failure, their current medication regimen (Loop Diuretics and Beta Blockers) may not be sufficient to adequately manage their heart failure. The patient's elevated creatinine level (97.0 mmol/L) suggests some level of renal impairment, which can further exacerbate heart failure. The patient's elevated gamma-glutamil transpeptidase (300 IU/L) also suggests liver dysfunction, which can be a contributing factor to heart failure. Given these factors, it is possible that the patient may experience pump failure in the near future.

RANKING: 3. Sudden cardiac death
REASONING: This prognosis is less likely due to the patient's current ECG findings, which do not show any evidence of ventricular tachycardia or non-sustained ventricular tachycardia. However, the patient's history of ventricular extrasystole (Polymorphic) and the presence of a ventricular extrasystole code on the ECG suggest a higher risk of arrhythmias. While the patient's LVEF is severely impaired, their current medication regimen (Loop Diuretics and Beta Blockers) may not be sufficient to adequately manage their heart failure and prevent arrhythmias. The patient's elevated troponin level (0.01 ng/mL) is also a marker of cardiac damage, which can increase the risk of arrhythmias. However, the absence of evidence for ventricular tachycardia or non-sustained ventricular tachycardia on the ECG reduces the risk of sudden cardiac death."
245,245,P0408,"Age: 52
Gender: Female 
Weight: 64 kg
Height: 164 cm
NYHA Class: II
Blood Pressure: 120/70 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Diabetes, Dyslipemia, Hypertension, Myocardial Infarction
Albumin (g/L): 40
ALT or GPT (IU/L): 25.0
AST or GOT (IU/L): 20.0
Total Cholesterol (mmol/L): 5,17
Creatinine (mmol/L): 80.0
Gamma-glutamil transpeptidase (IU/L): 25
Glucose (mmol/L): 13,9
Hemoglobin (g/L): 133.0
HDL (mmol/L): 0,91
Potassium (mEq/L): 4,5
LDL (mmol/L): 3,88
Sodium (mEq/L): 135.0
Pro-BNP (ng/L): 14.0
Protein (g/L): 70
T3 (pg/dL): 0,02
T4 (ng/L): 20
Troponin (ng/mL): 0,01
TSH (mIU/L): 2,34
Urea (mg/dL): 4,66
LVEF (%): 52.0
Medications: Diabetes Medication, Beta Blockers, Loop Diuretics, Statins, ACE Inhibitor, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"RANKING: 
1. Survivor
REASONING: 
Based on the provided patient data, this patient is at a high risk for adverse cardiac events, but the presence of a good clinical outcome (PATIENT OUTCOME: survivor) suggests that the patient has been managing their condition effectively. The patient's NYHA Class II indicates that they have some symptoms of heart failure, but they are still able to perform moderate physical activities without significant limitation. The patient's LVEF of 52.0 is below the normal range, indicating some left ventricular dysfunction. However, the absence of evidence of acute myocardial infarction, ventricular tachycardia, and paroxysmal supraventricular tachyarrhythmia suggests that the patient is not at immediate risk of a sudden cardiac death. The patient's medications, including ACE inhibitors and beta blockers, which are commonly used to manage heart failure and ischemic heart disease, further support the likelihood of a favorable outcome. The patient's laboratory values, including a normal troponin level, are also consistent with a stable cardiac condition. Overall, the combination of effective medication management and the absence of acute cardiac events suggest that the patient is likely to survive the next few years.

2. Pump failure death
REASONING: 
While the patient's LVEF is below the normal range, the patient is currently managing their condition with effective medications, which suggests that they are not at high risk of pump failure. However, the patient's NYHA Class II indicates that they have some symptoms of heart failure, which could potentially worsen over time if not adequately managed. The patient's creatinine level is elevated, which may indicate some degree of renal impairment, which can be a risk factor for heart failure. Additionally, the patient's dyslipidemia and hypertension may continue to contribute to cardiac stress and worsen heart failure. Therefore, while the patient is currently stable, there is a risk that their condition could deteriorate over time, leading to pump failure.

3. Sudden cardiac death
REASONING: 
The patient's ECG impression shows ventricular extrasystole, which is a risk factor for sudden cardiac death. However, the absence of ventricular tachycardia and paroxysmal supraventricular tachyarrhythmia on the ECG reduces this risk. The patient's troponin level is normal, which suggests that there is no evidence of acute myocardial infarction. However, the presence of ventricular extrasystole and the patient's NYHA Class II symptoms suggest that there is some underlying cardiac instability that could potentially lead to sudden cardiac death. While the patient is currently managing their condition effectively, the presence of ventricular extrasystole and the patient's overall clinical profile make this outcome less likely than pump failure, but still a possible risk."
246,246,P0411,"Age: 75
Gender: Male 
Weight: 70 kg
Height: 162 cm
NYHA Class: III
Blood Pressure: 100/65 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Myocardial Infarction
Albumin (g/L): 34
ALT or GPT (IU/L): 24.0
AST or GOT (IU/L): 21.0
Total Cholesterol (mmol/L): 3,59
Creatinine (mmol/L): 124.0
Gamma-glutamil transpeptidase (IU/L): 46
Glucose (mmol/L): 4,7
Hemoglobin (g/L): 81.0
HDL (mmol/L): 1,27
Potassium (mEq/L): 3,9
LDL (mmol/L): 2,04
Sodium (mEq/L): 143.0
Pro-BNP (ng/L): 859.0
Protein (g/L): 63
T4 (ng/L): 23
Troponin (ng/mL): 0,01
TSH (mIU/L): 0,1
Urea (mg/dL): 9,32
LVEF (%): 25.0
Medications: Amiodarone, Beta Blockers, Loop Diuretics, Statins, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",survivor,"RANKING: 
1. Survivor 
REASONING: 
Based on the patient's age (75), NYHA Class III status, history of ischemic dilated cardiomyopathy, and myocardial infarction, the patient is at high risk for cardiac events. However, the patient's current hemoglobin level (81.0 g/L) is within the normal range, and the troponin level (0.01 ng/mL) is within the normal range. The patient is also taking medications that are commonly used in heart failure management (Amiodarone, Beta Blockers, Loop Diuretics, Statins, and ACE Inhibitor). The absence of ventricular tachycardia, non-sustained ventricular tachycardia, and paroxysmal supraventricular tachyarrhythmia on the ECG impression suggests that the patient does not have an acute life-threatening arrhythmia. 

Considering these factors, I believe that the patient is likely to survive for the next few years, given the current clinical presentation and management."
247,247,P0412,"Age: 41
Gender: Male 
Weight: 80 kg
Height: 176 cm
NYHA Class: II
Blood Pressure: 115/55 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Dyslipemia, Hypertension, Myocardial Infarction
Albumin (g/L): 36
ALT or GPT (IU/L): 26.0
AST or GOT (IU/L): 22.0
Total Cholesterol (mmol/L): 3,7
Creatinine (mmol/L): 88.0
Gamma-glutamil transpeptidase (IU/L): 25
Glucose (mmol/L): 4,5
Hemoglobin (g/L): 143.0
HDL (mmol/L): 1,24
Potassium (mEq/L): 4,5
LDL (mmol/L): 2,12
Sodium (mEq/L): 140.0
Pro-BNP (ng/L): 286.0
Protein (g/L): 65
T4 (ng/L): 15
Troponin (ng/mL): 0,01
TSH (mIU/L): 1,4
Urea (mg/dL): 6,16
LVEF (%): 40.0
Medications: Beta Blockers, Statins, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"RANKING: 1. Survivor
REASONING:

Based on the provided patient data, I would rank the patient as having a high likelihood of survival for the next few years. The following factors contribute to this assessment:

1. NYHA Class II: The patient's New York Heart Association (NYHA) functional class is II, indicating mild symptoms of heart failure, which suggests that the patient's cardiac function is still relatively preserved.
2. LVEF 40.0: The left ventricular ejection fraction (LVEF) is 40.0%, which is slightly below the normal range (50-70%), but still within a range that can be managed with current treatment.
3. Medications: The patient is on beta blockers, statins, and an ACE inhibitor, which are standard treatments for patients with ischemic dilated cardiomyopathy and hypertension.
4. Pro-BNP levels: Although elevated (286 ng/L), the Pro-BNP level is not excessively high, which may indicate some level of cardiac stress but not severe heart failure.
5. ECG findings: The ECG does not show any signs of ventricular tachycardia, non-sustained ventricular tachycardia, or other arrhythmias that could indicate a high risk of sudden cardiac death.
6. Lack of severe electrolyte imbalances: The patient's potassium and sodium levels are within a relatively normal range, which reduces the risk of cardiac arrhythmias.

While the patient has a history of myocardial infarction, hypertension, and dyslipidemia, these conditions are being managed with current medications, and the patient's overall clinical presentation does not suggest an acute or severe cardiac event. Therefore, I believe that the patient has a good prognosis for survival over the next few years, making ""survivor"" the most likely outcome."
248,248,P0413,"Age: 76
Gender: Male 
Weight: 84 kg
Height: 163 cm
NYHA Class: II
Blood Pressure: 133/88 mmHg
Past Medical History: Idiopathic dilated cardiomyopathy, Hypertension
Albumin (g/L): 36,5
ALT or GPT (IU/L): 20.0
AST or GOT (IU/L): 18.0
Total Cholesterol (mmol/L): 4,6
Creatinine (mmol/L): 106.0
Gamma-glutamil transpeptidase (IU/L): 39
Glucose (mmol/L): 6,1
Hemoglobin (g/L): 148.0
HDL (mmol/L): 1,3
Potassium (mEq/L): 4,6
LDL (mmol/L): 2,87
Sodium (mEq/L): 139.0
Pro-BNP (ng/L): 870.0
Protein (g/L): 67
T4 (ng/L): 17
Troponin (ng/mL): 0,01
TSH (mIU/L): 1,72
Urea (mg/dL): 8,49
LVEF (%): 37.0
Medications: Beta Blockers, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",survivor,"RANKING: 
1. Survivor
REASONING: 
The patient has a history of idiopathic dilated cardiomyopathy, which is a significant risk factor for heart failure and arrhythmias. However, the patient is currently being treated with beta blockers and ACE inhibitors, which are standard therapies for managing heart failure and hypertension. The patient's LVEF is 37.0%, which is within the range for a NYHA Class II patient, indicating moderate symptoms. The patient's current medications and treatment plan suggest that they are being managed for their heart failure and hypertension.

The patient's ECG shows non-sustained ventricular tachycardia and polymorphic ventricular extrasystole, which are both concerning for arrhythmias. However, the patient is not experiencing any symptoms related to these arrhythmias, and the presence of non-sustained ventricular tachycardia (CH>10) is not uncommon in patients with heart failure.

The patient's laboratory results show elevated troponin levels, which may indicate some degree of cardiac damage, but the troponin level is not extremely high. The patient's renal function is also impaired, with elevated creatinine levels, but this is not uncommon in patients with heart failure.

Given the patient's overall clinical picture, I believe that the patient is likely to survive for the next few years with proper management of their heart failure and arrhythmias. The patient's age and weight are also factors to consider, as older patients with heart failure may have a higher risk of mortality, but the patient's current medications and treatment plan suggest that they are being well-managed.

While the patient's ECG results and laboratory results do raise some concerns, I believe that the patient's overall clinical picture is stable, and they are likely to survive for the next few years with proper management.

RANKING: 2. Sudden cardiac death
REASONING: 
While the patient's ECG shows non-sustained ventricular tachycardia and polymorphic ventricular extrasystole, which are concerning for arrhythmias, the patient is not experiencing any symptoms related to these arrhythmias. However, the presence of non-sustained ventricular tachycardia (CH>10) and polymorphic ventricular extrasystole increases the risk of sudden cardiac death.

The patient's age and weight are also factors to consider, as older patients with heart failure are at higher risk of sudden cardiac death. The patient's laboratory results show elevated troponin levels, which may indicate some degree of cardiac damage, and the patient's renal function is impaired.

While the patient is being treated with beta blockers and ACE inhibitors, which are standard therapies for managing heart failure and hypertension, the patient's ECG results and laboratory results raise some concerns about the risk of arrhythmias and sudden cardiac death.

Given the patient's overall clinical picture, I believe that the patient is at higher risk of sudden cardiac death than the other two options, but I do not believe that this is the most likely outcome.

RANKING: 3. Pump failure death
REASONING: 
The patient's LVEF is 37.0%, which is within the range for a NYHA Class II patient, indicating moderate symptoms. The patient is being treated with beta blockers and ACE inhibitors, which are standard therapies for managing heart failure.

However, the patient's ECG shows non-sustained ventricular tachycardia and polymorphic ventricular extrasystole, which are concerning for arrhythmias. The patient's laboratory results show elevated troponin levels, which may indicate some degree of cardiac damage. The patient's renal function is also impaired.

Given the patient's overall clinical picture, I believe that the patient is at risk of pump failure, but I do not believe that pump failure death is the most likely outcome. The patient's treatment plan and current medications suggest that they are being well-managed for their heart failure and arrhythmias.

While the patient's ECG results and laboratory results raise some concerns, I believe that the patient's overall clinical picture is stable, and they are likely to survive for the next few years with proper management."
249,249,P0414,"Age: 72
Gender: Male 
Weight: 74 kg
Height: 161 cm
NYHA Class: II
Blood Pressure: 112/78 mmHg
Past Medical History: Idiopathic dilated cardiomyopathy, Hypertension
Albumin (g/L): 36
ALT or GPT (IU/L): 38.0
AST or GOT (IU/L): 31.0
Total Cholesterol (mmol/L): 4,09
Creatinine (mmol/L): 133.0
Gamma-glutamil transpeptidase (IU/L): 50
Glucose (mmol/L): 4,8
Hemoglobin (g/L): 150.0
HDL (mmol/L): 1,06
Potassium (mEq/L): 4,8
LDL (mmol/L): 2,04
Sodium (mEq/L): 137.0
Pro-BNP (ng/L): 161.0
Protein (g/L): 73
T4 (ng/L): 17
Troponin (ng/mL): 0,01
TSH (mIU/L): 2,61
Urea (mg/dL): 9,15
LVEF (%): 45.0
Medications: Beta Blockers, Spironolactone, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: TPSV
        - Bradycardia: Unknown bradycardia code
            ",survivor,"RANKING: 1. Survivor
REASONING: 

The patient's overall clinical presentation and test results suggest that they are at high risk for adverse cardiac events, but there are several factors that suggest a more favorable prognosis. The patient's age, NYHA class II, and LVEF of 45% indicate significant left ventricular dysfunction, but the absence of acute myocardial infarction and no significant elevation in troponin levels suggest that the patient has not recently experienced a major cardiac event. The presence of ventricular extrasystole and non-sustained ventricular tachycardia on ECG is concerning, but the fact that it is non-sustained and not a sustained VT is a positive prognostic sign. The patient is also taking medications that are standard of care for heart failure and hypertension, which suggests that the patient is receiving optimal management for their conditions.

The patient's laboratory results show a slightly elevated creatinine level, which may indicate some degree of renal impairment, but this is not uncommon in patients with heart failure. The patient's electrolytes, liver enzymes, and glucose levels are within normal limits, which suggests that the patient does not have any acute or chronic conditions that would increase the risk of adverse cardiac events.

Overall, the combination of the patient's clinical presentation, ECG findings, and laboratory results suggests that the patient is at high risk for adverse cardiac events, but the presence of optimal medication therapy and the absence of acute cardiac events suggest a more favorable prognosis. Therefore, I would rank the patient as a survivor.

RANKING: 2. Sudden Cardiac Death
REASONING: 

The patient's ECG findings, specifically the presence of ventricular extrasystole and non-sustained ventricular tachycardia, suggest that the patient has an increased risk of ventricular arrhythmias. The fact that the ventricular tachycardia is non-sustained but not a sustained VT is still a concerning sign, and the presence of ventricular extrasystole increases the risk of ventricular fibrillation and sudden cardiac death. The patient's LVEF of 45% also indicates significant left ventricular dysfunction, which can increase the risk of sudden cardiac death.

The patient's age and NYHA class II also increase the risk of sudden cardiac death. While the patient is taking medications that are standard of care for heart failure and hypertension, the presence of ventricular arrhythmias and significant left ventricular dysfunction suggest that the patient is at high risk for adverse cardiac events.

RANKING: 3. Pump Failure Death
REASONING: 

The patient's LVEF of 45% indicates significant left ventricular dysfunction, which increases the risk of heart failure and pump failure. The patient's NYHA class II also indicates that the patient has some limitation in physical activity due to heart failure, which increases the risk of pump failure.

The patient's elevated creatinine level and slightly elevated troponin level may also indicate some degree of cardiac dysfunction, which can increase the risk of pump failure. However, the fact that the troponin level is not significantly elevated suggests that the patient has not recently experienced a major cardiac event.

The patient's electrolytes, liver enzymes, and glucose levels are within normal limits, which suggests that the patient does not have any acute or chronic conditions that would increase the risk of pump failure. However, the presence of ventricular arrhythmias and significant left ventricular dysfunction suggest that the patient is at high risk for pump failure.

Overall, while the patient has some risk factors for pump failure, the fact that the patient is taking medications that are standard of care for heart failure and hypertension, and the absence of acute cardiac events, suggest that the patient is not at the highest risk for pump failure."
250,250,P0415,"Age: 28
Gender: Male 
Weight: 95 kg
Height: 180 cm
NYHA Class: II
Blood Pressure: 90/50 mmHg
Past Medical History: Other HF etiology
Albumin (g/L): 44
ALT or GPT (IU/L): 23.0
AST or GOT (IU/L): 23.0
Total Cholesterol (mmol/L): 4,27
Creatinine (mmol/L): 88.0
Gamma-glutamil transpeptidase (IU/L): 18
Glucose (mmol/L): 4,3
Hemoglobin (g/L): 150.0
HDL (mmol/L): 1,14
Potassium (mEq/L): 5
LDL (mmol/L): 2,64
Sodium (mEq/L): 142.0
Pro-BNP (ng/L): 38.0
Protein (g/L): 75
T3 (pg/dL): 0,04
T4 (ng/L): 21
Troponin (ng/mL): 0,062
TSH (mIU/L): 1,97
Urea (mg/dL): 3,83
LVEF (%): 59.0
Medications: Angiotensin II Receptor Blocker, Beta Blockers, Digoxin
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: TPSV
        - Bradycardia: No
            ",survivor,"RANKING: 
1. Survivor
2. Sudden Cardiac Death
3. Pump Failure Death

REASONING:

The patient's prognosis is favorable due to several factors. Firstly, the patient is relatively young (28 years old), which suggests a lower risk of sudden cardiac death. The presence of ventricular extrasystoles on the ECG, while concerning, is not indicative of a high risk of sudden cardiac death in this patient.

The patient's NYHA Class II indicates mild heart failure, which, although present, does not necessarily imply a high risk of pump failure. The patient's LVEF is 59%, which is within a relatively normal range, suggesting that the patient's heart function is not severely compromised.

The patient's laboratory results show normal liver enzymes, a relatively normal lipid profile, and a low T3 level, which suggests that the patient does not have any significant metabolic or hormonal imbalances that could contribute to cardiac complications. The presence of a slightly elevated urea level (3.83 mg/dL) may indicate some degree of renal impairment, but this is not uncommon in patients with heart failure.

The patient is on medications that are commonly used to manage heart failure and hypertension, including an Angiotensin II Receptor Blocker and Beta Blockers, which are generally effective in reducing morbidity and mortality in patients with heart failure.

The only concern is the presence of a slightly low potassium level (5 mEq/L), which may require monitoring to ensure that it remains within a normal range. However, this is not a contraindication for survival.

In conclusion, based on the available data, the patient's prognosis is favorable, and sudden cardiac death is the least likely outcome, followed by pump failure death, with survivor being the most likely outcome."
251,251,P0417,"Age: 45
Gender: Male 
Weight: 72 kg
Height: 170 cm
NYHA Class: II
Blood Pressure: 110/70 mmHg
Past Medical History: Enolic dilated cardiomyopathy
Albumin (g/L): 45
ALT or GPT (IU/L): 35.0
AST or GOT (IU/L): 25.0
Total Cholesterol (mmol/L): 5,92
Creatinine (mmol/L): 88.0
Gamma-glutamil transpeptidase (IU/L): 85
Glucose (mmol/L): 4,8
Hemoglobin (g/L): 144.0
HDL (mmol/L): 1,42
Potassium (mEq/L): 4,2
LDL (mmol/L): 3,9
Sodium (mEq/L): 136.0
Pro-BNP (ng/L): 197.0
Protein (g/L): 75
T3 (pg/dL): 0,06
T4 (ng/L): 15
Troponin (ng/mL): 0,005
TSH (mIU/L): 2,37
Urea (mg/dL): 6,82
LVEF (%): 38.0
Medications: Beta Blockers, Loop Diuretics, Spironolactone, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"RANKING: 
1. Survivor
REASONING:
The patient has a complex medical history, including dilated cardiomyopathy, which is a significant risk factor for heart failure and arrhythmias. However, the patient is currently on medications that are standard for managing heart failure (beta blockers, loop diuretics, spironolactone, and ACE inhibitor) and has a relatively well-controlled blood pressure.

The patient's ECG shows ventricular extrasystole, which is a common finding in patients with heart failure, but it is not a predictor of poor outcome. The absence of ventricular tachycardia, non-sustained VT, and other arrhythmias on the ECG suggests that the patient is not at high risk for sudden cardiac death.

The patient's laboratory values are also relatively well within normal limits, with a normal creatinine level and a mildly elevated troponin level, which is not significantly elevated. The patient's LVEF is 38%, which is lower than the normal range, but it is not drastically low, and the patient is on medications that can help improve LVEF.

Given these factors, the patient's overall prognosis is that they are likely to survive for the next few years, although they will likely require close monitoring and adjustments to their treatment plan to manage their heart failure and prevent further decline.

2. Sudden Cardiac Death
REASONING:
The patient's ECG shows ventricular extrasystole, which is a risk factor for ventricular arrhythmias, including sudden cardiac death. However, the patient is on medications that can help prevent arrhythmias and has a relatively well-controlled blood pressure.

The patient's LVEF is 38%, which is lower than the normal range, and they have a history of dilated cardiomyopathy, which increases the risk of sudden cardiac death. However, the patient's laboratory values and ECG do not show any other signs of significant cardiac dysfunction or arrhythmias.

Given these factors, the patient's overall prognosis is that they are at risk for sudden cardiac death, but the likelihood of this occurring is still relatively low.

3. Pump Failure Death
REASONING:
The patient's LVEF is 38%, which is lower than the normal range, and they have a history of dilated cardiomyopathy, which increases the risk of heart failure. However, the patient is on medications that can help manage heart failure, and their laboratory values are relatively well within normal limits.

The patient's ECG shows ventricular extrasystole, which is a risk factor for ventricular arrhythmias, but the patient's ECG does not show any other signs of significant cardiac dysfunction or arrhythmias. Given these factors, the patient's overall prognosis is that they are at risk for pump failure, but the likelihood of this occurring is relatively low."
252,252,P0420,"Age: 82
Gender: Female 
Weight: 64 kg
Height: 154 cm
NYHA Class: II
Blood Pressure: 140/80 mmHg
Past Medical History: Hypertensive cardiomyopathy, Hypertension
Albumin (g/L): 42
ALT or GPT (IU/L): 36.0
AST or GOT (IU/L): 26.0
Total Cholesterol (mmol/L): 6,23
Creatinine (mmol/L): 141.0
Gamma-glutamil transpeptidase (IU/L): 36
Glucose (mmol/L): 5,9
Hemoglobin (g/L): 131.0
HDL (mmol/L): 1,53
Potassium (mEq/L): 4,5
LDL (mmol/L): 4,34
Sodium (mEq/L): 139.0
Pro-BNP (ng/L): 616.0
Protein (g/L): 82
T3 (pg/dL): 0,03
T4 (ng/L): 22
Troponin (ng/mL): 0,02
TSH (mIU/L): 1,91
Urea (mg/dL): 11,65
LVEF (%): 38.0
Medications: Calcium Channel Blocker, Spironolactone, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: TPSV
        - Bradycardia: No
            ",survivor,"RANKING: 

1. Survivor
REASONING: 
Based on the provided patient data, the patient is 82 years old with a history of hypertensive cardiomyopathy, hypertension, and elevated creatinine levels, indicating possible kidney impairment. The patient's NYHA Class II indicates moderate symptoms of heart failure, which is consistent with the elevated LVEF of 38.0. The presence of ventricular extrasystole, non-sustained VT, and non-sustained ventricular tachycardia (CH>10) on the ECG suggests an increased risk of arrhythmic events. However, the patient is on medications for hypertension, heart failure, and arrhythmias, which should help manage these conditions. The patient's age and comorbidities increase the risk of mortality, but the presence of a functioning kidney (creatinine 141.0 mg/dL) and relatively normal liver enzymes suggest that the patient may not have advanced liver disease or significant malnutrition. The patient's hemoglobin level is elevated, which may be a sign of anemia, but this is not uncommon in elderly patients. Overall, the combination of age, comorbidities, and the presence of arrhythmias suggests a moderate risk, but the patient's current treatment regimen and relatively preserved kidney function contribute to a favorable outcome.

2. Sudden cardiac death
REASONING: 
Although the patient has a history of ventricular arrhythmias, including non-sustained VT and TPSV, the presence of a functioning kidney and relatively normal liver enzymes suggest that the patient may not have advanced cardiac disease. The patient's age and NYHA Class II symptoms indicate a moderate risk of mortality. However, the patient's elevated creatinine levels and the presence of hypertension and hypertensive cardiomyopathy increase the risk of cardiac events. The patient's LVEF is low, indicating some degree of cardiac dysfunction, but the patient is on medications to manage hypertension and heart failure. The risk of sudden cardiac death is present, but the patient's treatment regimen and relatively preserved kidney function suggest that this outcome is less likely than survivor.

3. Pump failure death
REASONING: 
Given the patient's NYHA Class II symptoms, elevated creatinine levels, and low LVEF, pump failure death is a possible outcome. However, the patient's treatment regimen includes medications for hypertension, heart failure, and arrhythmias, which should help manage these conditions. The patient's relatively normal liver enzymes and functioning kidney also suggest that the patient may not have advanced liver or kidney disease. While the patient's ventricular arrhythmias increase the risk of cardiac events, the patient's age and comorbidities suggest that pump failure death may be less likely than sudden cardiac death. Overall, while pump failure death is a possible outcome, the patient's treatment regimen and relatively preserved organ function contribute to a less likely outcome."
253,253,P0421,"Age: 58
Gender: Male 
Weight: 90 kg
Height: 167 cm
NYHA Class: II
Blood Pressure: 110/70 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Diabetes, Dyslipemia, Hypertension, Myocardial Infarction
Albumin (g/L): 39
ALT or GPT (IU/L): 32.0
AST or GOT (IU/L): 25.0
Total Cholesterol (mmol/L): 4,14
Creatinine (mmol/L): 106.0
Gamma-glutamil transpeptidase (IU/L): 35
Glucose (mmol/L): 11,1
Hemoglobin (g/L): 154.0
HDL (mmol/L): 1,03
Potassium (mEq/L): 4,5
LDL (mmol/L): 2,51
Sodium (mEq/L): 138.0
Pro-BNP (ng/L): 509.0
Protein (g/L): 69
T3 (pg/dL): 0,03
T4 (ng/L): 22
Troponin (ng/mL): 0,01
TSH (mIU/L): 2,5
Urea (mg/dL): 4,99
LVEF (%): 34.0
Medications: Diabetes Medication, Beta Blockers, Loop Diuretics, Spironolactone, Statins, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"RANKING: 1. Survivor
REASONING: 
Given the patient's age, NYHA Class II status, and the presence of ischemic dilated cardiomyopathy, the patient is already at a higher risk for cardiac events. However, the patient is receiving optimal medical therapy, including beta blockers, ACE inhibitors, and statins, which are generally recommended for patients with heart failure and coronary artery disease. The patient's LVEF is 34%, which is within the range for NYHA Class II. The presence of ventricular extrasystoles and non-sustained ventricular tachycardia on the ECG is concerning but not immediately life-threatening. The patient's renal function is compromised, as indicated by elevated creatinine levels, but this is not immediately life-threatening. The patient's glucose and electrolyte levels are within relatively normal ranges. Overall, the patient's medical history, medication list, and ECG findings suggest that the patient is at risk for cardiac events, but the presence of optimal medical therapy and relatively stable vital signs suggest that the patient is likely to survive the next few years."
254,254,P0422,"Age: 62
Gender: Male 
Weight: 75 kg
Height: 174 cm
NYHA Class: II
Blood Pressure: 110/70 mmHg
Past Medical History: Other HF etiology
Albumin (g/L): 40
ALT or GPT (IU/L): 35.0
AST or GOT (IU/L): 43.0
Total Cholesterol (mmol/L): 5,9
Creatinine (mmol/L): 71.0
Gamma-glutamil transpeptidase (IU/L): 125
Glucose (mmol/L): 6,8
Hemoglobin (g/L): 141.0
HDL (mmol/L): 1,01
Potassium (mEq/L): 4,2
LDL (mmol/L): 4,32
Sodium (mEq/L): 130.0
Pro-BNP (ng/L): 123.0
Protein (g/L): 56
T3 (pg/dL): 0,03
T4 (ng/L): 21
Troponin (ng/mL): 0,01
TSH (mIU/L): 1,3
Urea (mg/dL): 7,15
LVEF (%): 20.0
Medications: Beta Blockers, Loop Diuretics, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"RANKING: 

1. Survivor
REASONING:

This patient's prognosis is most likely to be a survivor due to the following factors:

- The patient's age (62) is not extremely high, and with proper management, many patients of this age can live for several more years.
- The patient has a NYHA Class II, indicating that they have some symptoms of heart failure, but it is not severe. This suggests that the patient's heart is still functional to some extent.
- The patient's blood pressure is well-controlled, with a reading of 110/70 mmHg, which reduces the risk of cardiovascular events.
- The patient's electrolytes, liver enzymes, and kidney function are relatively normal, indicating that there are no acute or chronic conditions that could compromise their cardiac function.
- The patient's LVEF is 20%, which is a significant reduction in left ventricular function, but with proper management and treatment, it is still possible to improve their cardiac function.
- The patient is on medications such as beta blockers, loop diuretics, and ACE inhibitors, which are standard treatments for heart failure and can help manage symptoms and improve survival.
- The ECG results show no evidence of ventricular tachycardia, non-sustained ventricular tachycardia, or other arrhythmias, which are significant predictors of sudden cardiac death.

While the patient's cardiac function is compromised, and they have some risk factors for heart failure, the combination of their relatively young age, well-controlled blood pressure, and standard treatment with medications make a survivor outcome the most likely prognosis."
255,255,P0424,"Age: 73
Gender: Male 
Weight: 69 kg
Height: 165 cm
NYHA Class: II
Blood Pressure: 120/65 mmHg
Past Medical History: Idiopathic dilated cardiomyopathy, Hypertension
Albumin (g/L): 37
ALT or GPT (IU/L): 105.0
AST or GOT (IU/L): 98.0
Total Cholesterol (mmol/L): 3,41
Creatinine (mmol/L): 194.0
Gamma-glutamil transpeptidase (IU/L): 100
Glucose (mmol/L): 5,1
Hemoglobin (g/L): 130.0
HDL (mmol/L): 1,11
Potassium (mEq/L): 5,1
LDL (mmol/L): 1,55
Sodium (mEq/L): 137.0
Pro-BNP (ng/L): 4846.0
Protein (g/L): 77
T4 (ng/L): 17
Troponin (ng/mL): 0,01
TSH (mIU/L): 3,41
Urea (mg/dL): 19,8
LVEF (%): 37.0
Medications: Beta Blockers, Digoxin, Loop Diuretics, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",survivor,"RANKING: 1. Survivor
REASONING:

This patient has several factors that suggest a higher likelihood of survival. 

1. Age: The patient is 73 years old, but the age alone is not a significant predictor of mortality in this case. Many patients with advanced heart disease can live for years with proper management.

2. NYHA Class II: This indicates that the patient has moderate symptoms of heart failure, but it's still manageable with current treatment.

3. Medications: The patient is on beta blockers, digoxin, loop diuretics, and an ACE inhibitor, which are standard treatments for heart failure and arrhythmias. These medications help control symptoms and slow the progression of heart disease.

4. Pro-BNP levels: While the patient's Pro-BNP levels are elevated, indicating some level of heart stress, they are not extremely high, suggesting that the patient may still be able to tolerate treatment.

5. ECG findings: The patient has ventricular extrasystoles and non-sustained VT, but these are not life-threatening and can often be managed with medication and lifestyle changes.

6. Hemoglobin and kidney function: The patient's hemoglobin and kidney function are within normal limits, indicating that the patient does not have severe anemia or kidney failure.

7. Creatine kinase (CK) levels: The patient's troponin levels are normal, indicating no significant muscle damage.

Given these factors, the patient's overall health and medical history suggest that they are likely to survive for the next few years with proper management and treatment.

RANKING: 2. Sudden cardiac death
REASONING:

This patient is at risk for sudden cardiac death due to the presence of:

1. Idiopathic dilated cardiomyopathy: This condition can lead to arrhythmias and sudden cardiac death.
2. Elevated troponin levels: Although the levels are not extremely high, it's still a marker of cardiac damage.
3. Ventricular extrasystoles and non-sustained VT on ECG: These arrhythmias increase the risk of sudden cardiac death.

However, the patient is already being treated with beta blockers and an ACE inhibitor, which can help reduce the risk of arrhythmias.

RANKING: 3. Pump failure death
REASONING:

The patient is at risk for pump failure due to:

1. Idiopathic dilated cardiomyopathy: This condition can lead to decreased cardiac function and pump failure.
2. Elevated creatinine levels: This indicates some level of kidney impairment, which can be related to heart failure.
3. Elevated Pro-BNP levels: Elevated Pro-BNP levels suggest that the patient's heart is under stress, which can lead to pump failure.

However, the patient is already being treated with medications that can help manage heart failure symptoms, and the patient's NYHA Class II indicates that they are not severely symptomatic."
256,256,P0425,"Age: 53
Gender: Female 
Weight: 67 kg
Height: 162 cm
NYHA Class: II
Blood Pressure: 115/50 mmHg
Past Medical History: Idiopathic dilated cardiomyopathy, Dyslipemia
Albumin (g/L): 38
ALT or GPT (IU/L): 11.0
AST or GOT (IU/L): 12.0
Total Cholesterol (mmol/L): 4,06
Creatinine (mmol/L): 80.0
Gamma-glutamil transpeptidase (IU/L): 51
Glucose (mmol/L): 5,3
Hemoglobin (g/L): 114.0
HDL (mmol/L): 0,83
Potassium (mEq/L): 4,5
LDL (mmol/L): 2,87
Sodium (mEq/L): 137.0
Pro-BNP (ng/L): 775.0
Protein (g/L): 70
T4 (ng/L): 17
Troponin (ng/mL): 0,01
TSH (mIU/L): 2,56
Urea (mg/dL): 4,99
LVEF (%): 43.0
Medications: Beta Blockers, Spironolactone, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",survivor,"RANKING: 1. Survivor
REASONING: 

The patient's overall clinical presentation and test results suggest a poor prognosis, but the patient has been classified as a survivor. This classification is likely due to the fact that the patient has been receiving treatment for their idiopathic dilated cardiomyopathy with medications such as beta blockers and ACE inhibitors, which have been shown to improve outcomes in patients with heart failure. The patient's NYHA class is II, indicating mild symptoms, and their LVEF is 43%, which is within the range of patients who may benefit from these medications. Additionally, the patient's troponin level is within normal limits, indicating that there is no evidence of myocardial infarction.

While the patient has several risk factors, including a history of idiopathic dilated cardiomyopathy, dyslipidemia, and elevated BNP levels, the patient's current clinical presentation and test results do not suggest an acute decompensated heart failure. The presence of non-sustained ventricular tachycardia and polymorphic ventricular extrasystoles on the ECG is concerning, but the patient's troponin level is normal, and the patient is on beta blockers, which may help to reduce the risk of arrhythmias.

Therefore, based on the patient's current clinical presentation and test results, the most likely outcome is that the patient will survive, albeit with close monitoring and management of their underlying condition.

RANKING: 2. Sudden cardiac death
REASONING: 

The patient's ECG results show evidence of ventricular extrasystoles and non-sustained ventricular tachycardia, which are risk factors for sudden cardiac death. The patient's LVEF is also significantly reduced, indicating poor cardiac function. Additionally, the patient's BNP levels are elevated, indicating increased stress on the heart.

While the patient is receiving treatment for their idiopathic dilated cardiomyopathy, the presence of non-sustained ventricular tachycardia and polymorphic ventricular extrasystoles on the ECG increases the risk of sudden cardiac death. The patient's troponin level is within normal limits, but the presence of these arrhythmias and reduced LVEF increases the risk of cardiac events.

Therefore, based on the patient's ECG results and reduced LVEF, the patient is at increased risk for sudden cardiac death, making this a possible outcome.

RANKING: 3. Pump failure death
REASONING: 

The patient's LVEF is significantly reduced at 43%, indicating poor cardiac function. The patient's NYHA class is II, indicating mild symptoms, but the patient's reduced LVEF and elevated BNP levels suggest that the patient's heart is working hard to compensate for the underlying cardiomyopathy. The patient's elevated creatinine level also suggests impaired renal function, which can be associated with heart failure.

While the patient is receiving treatment for their idiopathic dilated cardiomyopathy, the patient's reduced LVEF and elevated BNP levels increase the risk of pump failure. The presence of non-sustained ventricular tachycardia and polymorphic ventricular extrasystoles on the ECG also increases the risk of cardiac events.

However, the patient's troponin level is within normal limits, and the patient is on beta blockers, which may help to reduce the risk of heart failure. Therefore, while the patient is at increased risk for pump failure, the patient's current clinical presentation and test results do not suggest an acute decompensated heart failure."
257,257,P0426,"Age: 72
Gender: Male 
Weight: 76 kg
Height: 168 cm
NYHA Class: II
Blood Pressure: 125/70 mmHg
Past Medical History: Idiopathic dilated cardiomyopathy, Dyslipemia
Albumin (g/L): 41
ALT or GPT (IU/L): 27.0
AST or GOT (IU/L): 30.0
Total Cholesterol (mmol/L): 4,45
Creatinine (mmol/L): 106.0
Gamma-glutamil transpeptidase (IU/L): 39
Glucose (mmol/L): 6,4
Hemoglobin (g/L): 157.0
HDL (mmol/L): 1,01
Potassium (mEq/L): 4
LDL (mmol/L): 2,35
Sodium (mEq/L): 136.0
Pro-BNP (ng/L): 2598.0
Protein (g/L): 67
T4 (ng/L): 18
Troponin (ng/mL): 0,01
TSH (mIU/L): 3,53
Urea (mg/dL): 11,32
LVEF (%): 10.0
Medications: Angiotensin II Receptor Blocker, Beta Blockers, Digoxin, Loop Diuretics, Spironolactone, Hydralazine
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"RANKING: 1. Survivor
REASONING: 

This patient's prognosis is ranked as a survivor due to the presence of several factors that suggest a favorable outcome. Firstly, the patient's age of 72 is not extremely high, and many patients with advanced heart failure can live for several years with proper management. The patient's NYHA class II indicates that they have some limitations with physical activity, but they are not bedridden or severely limited in their daily activities.

The patient's medication regimen, which includes ACE inhibitors (Angiotensin II Receptor Blocker), beta blockers, and diuretics, suggests that their heart failure is being adequately managed. The presence of digoxin and spironolactone also indicates that the patient is receiving optimal treatment for their heart failure.

The patient's laboratory results show a relatively preserved renal function (creatinine level of 106.0 mg/dL), which is a good indicator of cardiovascular mortality risk. The low level of troponin (0.01 ng/mL) suggests that there is no significant myocardial damage, which is a good prognostic sign.

The ECG results show the presence of non-sustained ventricular tachycardia, but this is not a significant concern given the patient's current medication regimen and the fact that it is non-sustained. The absence of ventricular extrasystoles, ventricular tachycardia, and paroxysmal supraventricular tachyarrhythmia suggests that the patient's heart rhythm is relatively stable.

Overall, based on the patient's medical history, laboratory results, and treatment regimen, I believe that this patient has a high likelihood of survival over the next few years with proper management and monitoring."
258,258,P0427,"Age: 77
Gender: Male 
Weight: 61 kg
Height: 152 cm
NYHA Class: II
Blood Pressure: 118/57 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Dyslipemia, Myocardial Infarction
Albumin (g/L): 42
ALT or GPT (IU/L): 21.0
AST or GOT (IU/L): 49.0
Total Cholesterol (mmol/L): 5,09
Creatinine (mmol/L): 106.0
Gamma-glutamil transpeptidase (IU/L): 101
Glucose (mmol/L): 6,7
Hemoglobin (g/L): 144.0
HDL (mmol/L): 1,55
Potassium (mEq/L): 4,1
LDL (mmol/L): 2,87
Sodium (mEq/L): 138.0
Pro-BNP (ng/L): 3993.0
Protein (g/L): 76
T4 (ng/L): 19
Troponin (ng/mL): 0,01
TSH (mIU/L): 1,03
Urea (mg/dL): 6,66
LVEF (%): 25.0
Medications: Beta Blockers, Loop Diuretics, Statins, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",survivor,"RANKING: 1. Survivor
REASONING: 

Based on the provided patient data, the patient is a 77-year-old male with a history of ischemic dilated cardiomyopathy, myocardial infarction, and dyslipidemia. The patient's ejection fraction (LVEF) is significantly reduced at 25.0%, indicating severe left ventricular dysfunction. The presence of ventricular tachycardia (non-sustained VT) and polymorphic ventricular extrasystoles on the ECG impression suggests an increased risk of arrhythmias. However, the patient's current hemodynamic status is relatively stable, as indicated by a normal blood pressure and no signs of acute decompensation.

The patient's laboratory results show elevated creatinine levels (106.0 mmol/L) and elevated troponin levels (0.01 ng/mL), which may indicate some degree of cardiac muscle damage. However, the patient's kidney function is not severely impaired, and the troponin levels are not excessively high, which may suggest that the patient is not in acute heart failure.

Considering these factors, the patient's current condition seems to be relatively stable, and with appropriate management, the patient may survive the next few years. The patient's age and comorbidities do increase the risk of mortality, but the patient's current hemodynamic status and lack of acute decompensation make it more likely that the patient will survive.

RANKING: 2. Sudden Cardiac Death
REASONING: 

While the patient's ECG impression shows signs of arrhythmias, which increase the risk of sudden cardiac death, the patient's current hemodynamic status is relatively stable, and the patient is not in acute decompensation. The patient's elevated troponin levels may indicate some degree of cardiac muscle damage, but the levels are not excessively high, which may suggest that the patient is not in acute heart failure.

However, the patient's age, history of ischemic dilated cardiomyopathy, and presence of ventricular tachycardia (non-sustained VT) on the ECG impression do increase the risk of sudden cardiac death. Additionally, the patient's elevated creatinine levels may indicate some degree of kidney dysfunction, which can increase the risk of arrhythmias.

Given these factors, while the patient is at increased risk of sudden cardiac death, the patient's current condition is not severely acute, and with appropriate management, the risk of sudden cardiac death may be mitigated.

RANKING: 3. Pump Failure Death
REASONING: 

The patient's severely reduced ejection fraction (LVEF 25.0%) and history of ischemic dilated cardiomyopathy indicate a high risk of pump failure. The patient's elevated creatinine levels and elevated troponin levels also suggest some degree of cardiac muscle damage and possible cardiac dysfunction.

The patient's current hemodynamic status is relatively stable, but the patient's age and history of cardiac disease increase the risk of pump failure. Additionally, the patient's ECG impression shows signs of arrhythmias, which can increase the risk of cardiac complications.

Given these factors, while the patient may not be in acute decompensation, the patient's underlying cardiac disease and reduced ejection fraction increase the risk of pump failure, making it a possible outcome. However, the patient's current condition is relatively stable, and with appropriate management, the risk of pump failure may be mitigated."
259,259,P0428,"Age: 48
Gender: Female 
Weight: 83 kg
Height: 167 cm
NYHA Class: II
Blood Pressure: 115/50 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Dyslipemia, Myocardial Infarction
Albumin (g/L): 42
ALT or GPT (IU/L): 27.0
AST or GOT (IU/L): 19.0
Total Cholesterol (mmol/L): 4,22
Creatinine (mmol/L): 62.0
Gamma-glutamil transpeptidase (IU/L): 20
Glucose (mmol/L): 6,1
Hemoglobin (g/L): 121.0
HDL (mmol/L): 1,09
Potassium (mEq/L): 4,3
LDL (mmol/L): 2,02
Sodium (mEq/L): 137.0
Pro-BNP (ng/L): 120.0
Protein (g/L): 69
T4 (ng/L): 17
Troponin (ng/mL): 0,01
TSH (mIU/L): 2,91
Urea (mg/dL): 8,49
LVEF (%): 40.0
Medications: Beta Blockers, Statins, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: No
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"RANKING: 
1. Survivor
REASONING: 
Based on the provided patient data, I would rank the patient's prognosis as a survivor for the next few years. The patient's NYHA Class II indicates moderate symptoms, but the patient is still able to perform daily activities without severe limitation. The LVEF of 40% is a significant reduction in left ventricular function, but it is not extremely low. The patient's ECG results do not show any life-threatening arrhythmias.

The patient's biomarkers, such as troponin and BNP, are not excessively elevated, suggesting that there is no acute cardiac damage or significant fluid overload. The patient's renal function is also relatively preserved, with a creatinine level of 8.49 mg/dL.

The patient's medication regimen, which includes beta blockers, statins, and an ACE inhibitor, is standard for managing ischemic dilated cardiomyopathy and hypertension. This suggests that the patient is receiving appropriate treatment for their underlying conditions.

While the patient's weight and BMI are not ideal, they are not excessively high, and the patient's hemoglobin level is within a relatively normal range.

Overall, considering these factors, I believe that the patient has a reasonable prognosis for survival over the next few years, with the potential for some improvement with continued medical therapy and lifestyle modifications."
260,260,P0430,"Age: 73
Gender: Male 
Weight: 78 kg
Height: 165 cm
NYHA Class: II
Blood Pressure: 144/79 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Dyslipemia, Myocardial Infarction
Albumin (g/L): 38
ALT or GPT (IU/L): 17.0
AST or GOT (IU/L): 21.0
Total Cholesterol (mmol/L): 3,98
Creatinine (mmol/L): 97.0
Gamma-glutamil transpeptidase (IU/L): 15
Glucose (mmol/L): 5,2
Hemoglobin (g/L): 152.0
HDL (mmol/L): 1,22
Potassium (mEq/L): 4,1
LDL (mmol/L): 3,98
Sodium (mEq/L): 140.0
Pro-BNP (ng/L): 962.0
Protein (g/L): 69
T4 (ng/L): 17
Troponin (ng/mL): 0,01
TSH (mIU/L): 2,1
Urea (mg/dL): 7,15
LVEF (%): 30.0
Medications: Beta Blockers, Loop Diuretics, Statins, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"RANKING: 1. Survivor
REASONING: 

This patient is at high risk for adverse cardiac events, with a history of ischemic dilated cardiomyopathy, previous myocardial infarction, and a significant elevation in Pro-BNP levels (962 ng/L), which is a marker of cardiac stress and potential heart failure. The patient's LVEF is severely impaired at 30%, indicating poor cardiac function. However, the patient is currently on beta blockers, loop diuretics, statins, and an ACE inhibitor, which are standard treatments for heart failure and coronary artery disease.

Despite these medications, the patient's elevated troponin levels (0.01 ng/mL) and creatinine level (7.15 mg/dL) suggest ongoing cardiac stress and renal impairment, respectively. The patient's electrolyte levels are relatively well-controlled, and their glucose and hemoglobin levels are within normal ranges.

While the patient's ECG shows ventricular extrasystoles, these are non-sustained and not indicative of a high risk for ventricular arrhythmias. The patient's sodium level is also within the normal range, which reduces the risk of hypernatremia-related complications.

Considering these factors, the patient's overall prognosis is that they will survive the next few years, but with a high risk of cardiac events, including potential heart failure exacerbation or cardiac arrhythmias. Regular monitoring and adjustment of medications may be necessary to manage the patient's condition.

RANKING: 2. Sudden cardiac death
REASONING: 

While the patient is at high risk for cardiac events, the likelihood of sudden cardiac death is moderate due to the presence of ventricular extrasystoles on the ECG. However, these are non-sustained, and the patient's cardiac medications are well-controlled.

The patient's LVEF is severely impaired, which increases the risk of sudden cardiac death. However, the patient's troponin levels are not significantly elevated, and their creatinine level is not severely impaired. The patient's electrolyte levels are well-controlled, and their glucose and hemoglobin levels are within normal ranges.

RANKING: 3. Pump failure death
REASONING: 

The patient's LVEF is severely impaired (30%), and their Pro-BNP levels are elevated, indicating cardiac stress and potential heart failure. However, the patient is currently on medications that are standard for heart failure management, and their electrolyte levels are relatively well-controlled.

The patient's creatinine level is elevated, but not severely impaired, and their glucose and hemoglobin levels are within normal ranges. The patient's troponin levels are not significantly elevated, and their sodium level is within the normal range.

Given these factors, the likelihood of pump failure death is lower than sudden cardiac death but still a significant concern. Regular monitoring and adjustment of medications may be necessary to manage the patient's condition and prevent exacerbations of heart failure."
261,261,P0435,"Age: 62
Gender: Male 
Weight: 100 kg
Height: 175 cm
NYHA Class: II
Blood Pressure: 130/70 mmHg
Past Medical History: Idiopathic dilated cardiomyopathy, Dyslipemia
Albumin (g/L): 45
ALT or GPT (IU/L): 21.0
AST or GOT (IU/L): 18.0
Total Cholesterol (mmol/L): 5,38
Creatinine (mmol/L): 115.0
Gamma-glutamil transpeptidase (IU/L): 66
Glucose (mmol/L): 8,7
Hemoglobin (g/L): 139.0
HDL (mmol/L): 0,91
Potassium (mEq/L): 5
LDL (mmol/L): 3,21
Sodium (mEq/L): 137.0
Pro-BNP (ng/L): 109.0
Protein (g/L): 72
T3 (pg/dL): 0,04
T4 (ng/L): 17
Troponin (ng/mL): 0,005
TSH (mIU/L): 1,78
Urea (mg/dL): 6,99
LVEF (%): 44.0
Medications: Beta Blockers, Digoxin, Loop Diuretics, Spironolactone, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",survivor,"RANKING: 
1. Survivor
REASONING:
The patient is currently receiving medications for heart failure (Beta Blockers, Digoxin, Loop Diuretics, Spironolactone, and ACE Inhibitor) and has a NYHA Class II classification, indicating mild heart failure. The presence of these medications suggests that the patient is receiving standard treatment for heart failure. The patient's LVEF is 44.0, which is lower than normal, but not severely impaired. The patient's serum creatinine level is elevated, indicating some degree of renal impairment, but this is not uncommon in patients with heart failure.

The patient's ECG findings of ventricular extrasystole and non-sustained ventricular tachycardia are concerning, but the presence of non-sustained ventricular tachycardia (CH>10) is not present, which is a risk factor for sudden cardiac death. The patient's troponin level is normal, which suggests that there is no significant myocardial damage.

Given the patient's current treatment and the absence of severe cardiac dysfunction or high-risk ECG findings, the most likely outcome is that the patient will survive. 

2. Sudden Cardiac Death
REASONING:
The patient's ECG findings of ventricular extrasystole and non-sustained ventricular tachycardia are concerning for an increased risk of sudden cardiac death. However, the absence of non-sustained ventricular tachycardia (CH>10) and a normal troponin level reduces this risk. While the patient's LVEF is lower than normal, the patient is receiving medications for heart failure, which suggests that the patient is receiving standard treatment.

However, the patient's elevated creatinine level and dyslipidemia may increase the risk of cardiovascular events. The patient's age and gender also increase the risk of cardiovascular events. Therefore, while the patient is not at high risk, there is a possibility of sudden cardiac death.

3. Pump Failure Death
REASONING:
The patient's LVEF is 44.0, which is lower than normal, indicating some degree of cardiac dysfunction. The patient's elevated creatinine level and dyslipidemia may contribute to worsening heart failure, and the patient's NYHA Class II classification indicates mild heart failure. However, the patient is receiving medications for heart failure, which suggests that the patient is receiving standard treatment.

While the patient's cardiac function is impaired, the presence of ventricular extrasystole and non-sustained ventricular tachycardia on the ECG may indicate a higher risk of pump failure death. However, the patient's troponin level is normal, which suggests that there is no significant myocardial damage. Therefore, while pump failure death is a possibility, it is less likely than sudden cardiac death."
262,262,P0436,"Age: 62
Gender: Male 
Weight: 80 kg
Height: 180 cm
NYHA Class: II
Blood Pressure: 110/60 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Dyslipemia
Albumin (g/L): 43
ALT or GPT (IU/L): 32.0
AST or GOT (IU/L): 34.0
Total Cholesterol (mmol/L): 4,01
Creatinine (mmol/L): 133.0
Gamma-glutamil transpeptidase (IU/L): 30
Glucose (mmol/L): 6,2
Hemoglobin (g/L): 151.0
HDL (mmol/L): 0,7
Potassium (mEq/L): 4,5
LDL (mmol/L): 2,2
Sodium (mEq/L): 139.0
Pro-BNP (ng/L): 184.0
Protein (g/L): 70
T3 (pg/dL): 0,04
T4 (ng/L): 13
Troponin (ng/mL): 0,005
TSH (mIU/L): 1,25
Urea (mg/dL): 7,15
LVEF (%): 17.0
Medications: Beta Blockers, Digoxin, Loop Diuretics, Statins, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: Second-degree AVB - type II
            ",survivor,"RANKING: 1. Survivor
REASONING: 

Based on the provided patient data, the patient is a 62-year-old male with a history of ischemic dilated cardiomyopathy, dyslipidemia, and NYHA Class II heart failure. The patient's current hemoglobin level is slightly elevated (151.0 g/L), which may indicate anemia, but it is not severe enough to significantly impact the prognosis. The patient's LVEF is severely impaired at 17.0%, indicating poor cardiac function.

The patient's ECG shows ventricular extrasystoles, which can be a sign of arrhythmia. However, the absence of ventricular tachycardia and non-sustained ventricular tachycardia reduces the likelihood of sudden cardiac death.

The patient's biomarkers, such as troponin (0.005 ng/mL), are within normal limits, suggesting no significant acute myocardial injury. The patient's creatinine level (7.15 mg/dL) is elevated, indicating some degree of renal impairment, but this is not uncommon in patients with heart failure.

The patient is currently taking beta blockers, digoxin, loop diuretics, statins, and an ACE inhibitor, which are standard treatments for heart failure and coronary artery disease. The patient's lipid profile is not ideal, but the patient is taking statins, which should help manage dyslipidemia.

Considering these factors, the patient's overall prognosis is guarded but not extremely poor. The patient's survival is likely due to the fact that they are receiving optimal medical therapy and have a relatively well-managed heart failure. Therefore, I predict that the patient will survive the next few years, but will likely require close monitoring and adjustments to their treatment plan to manage their heart failure and prevent further decline."
263,263,P0437,"Age: 53
Gender: Male 
Weight: 100 kg
Height: 176 cm
NYHA Class: II
Blood Pressure: 120/70 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Myocardial Infarction
Albumin (g/L): 40
ALT or GPT (IU/L): 18.0
AST or GOT (IU/L): 20.0
Total Cholesterol (mmol/L): 3,93
Creatinine (mmol/L): 71.0
Gamma-glutamil transpeptidase (IU/L): 15
Glucose (mmol/L): 5,8
Hemoglobin (g/L): 141.0
HDL (mmol/L): 1,34
Potassium (mEq/L): 4,8
LDL (mmol/L): 2,28
Sodium (mEq/L): 138.0
Pro-BNP (ng/L): 12721.0
Protein (g/L): 67
T3 (pg/dL): 0,04
T4 (ng/L): 15
Troponin (ng/mL): 0,01
TSH (mIU/L): 0,825
Urea (mg/dL): 6,16
LVEF (%): 25.0
Medications: Beta Blockers, Statins, ACE Inhibitor, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: TPSV
        - Bradycardia: No
            ",survivor,"RANKING: 
1. Survivor
REASONING: 
Based on the provided patient data, the patient is at a high risk for adverse cardiac events. The patient has a history of ischemic dilated cardiomyopathy and myocardial infarction, which are risk factors for sudden cardiac death and pump failure. However, the patient is currently on optimal medical therapy with beta blockers, statins, ACE inhibitors, and a nitrovasodilator, which are standard treatments for these conditions.

The patient's left ventricular ejection fraction (LVEF) is significantly reduced at 25.0%, indicating impaired cardiac function. However, the patient's blood pressure is well-controlled, and there is no indication of acute coronary syndrome or acute decompensated heart failure.

The elevated Pro-BNP level (12721.0 ng/L) suggests some degree of cardiac stress, but it is not excessively high. The patient's troponin level is within normal limits, which suggests that there is no acute myocardial infarction.

The ECG findings of ventricular extrasystole and paroxysmal supraventricular tachyarrhythmia (TPSV) are present, but they are not indicative of a high risk for sudden cardiac death. The absence of ventricular tachycardia and non-sustained ventricular tachycardia (CH>10) reduces the risk for sudden cardiac death.

Given these factors, I predict that the patient is likely to survive for the next few years with close monitoring and optimal medical therapy. The patient's overall prognosis is favorable, and with proper management, the patient can expect to live a relatively normal life expectancy.

RANKING: 2. Sudden cardiac death
REASONING: 
While the patient has a history of ischemic dilated cardiomyopathy and myocardial infarction, which are risk factors for sudden cardiac death, the patient is currently on optimal medical therapy and has a well-controlled blood pressure. The absence of ventricular tachycardia and non-sustained ventricular tachycardia (CH>10) on the ECG reduces the risk for sudden cardiac death.

However, the patient's LVEF is significantly reduced, and the patient has a history of ventricular extrasystole, which may indicate underlying cardiac dysfunction. The patient's Pro-BNP level is elevated, but not excessively high. The patient's troponin level is within normal limits, which suggests that there is no acute myocardial infarction.

Considering these factors, while the patient is not at the highest risk, there is still a possibility of sudden cardiac death, especially if the patient's cardiac function worsens or if the underlying cardiac disease progresses.

RANKING: 3. Pump failure death
REASONING: 
The patient's LVEF is significantly reduced at 25.0%, indicating impaired cardiac function. The patient's history of ischemic dilated cardiomyopathy and myocardial infarction, and the presence of ventricular extrasystole, suggest that the patient is at risk for progressive cardiac dysfunction.

The patient's elevated Pro-BNP level and elevated creatinine level (71.0 mmol/L) suggest some degree of cardiac stress and renal impairment. The patient's blood pressure is not optimally controlled, and the patient is on medications that may not be sufficient to manage the patient's cardiac condition.

Considering these factors, the patient is at a higher risk for pump failure death, especially if the patient's cardiac function does not improve or if the patient's underlying cardiac disease progresses. However, the patient is currently on optimal medical therapy, and with close monitoring and adjustments to the treatment plan, the risk of pump failure death can be minimized."
264,264,P0441,"Age: 73
Gender: Male 
Weight: 90 kg
Height: 163 cm
NYHA Class: II
Blood Pressure: 110/55 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Myocardial Infarction
Albumin (g/L): 39
ALT or GPT (IU/L): 18.0
AST or GOT (IU/L): 22.0
Total Cholesterol (mmol/L): 4,73
Creatinine (mmol/L): 106.0
Gamma-glutamil transpeptidase (IU/L): 23
Glucose (mmol/L): 5,4
Hemoglobin (g/L): 137.0
HDL (mmol/L): 1,68
Potassium (mEq/L): 4,1
LDL (mmol/L): 2,4
Sodium (mEq/L): 138.0
Pro-BNP (ng/L): 1107.0
Protein (g/L): 62
T3 (pg/dL): 0,04
T4 (ng/L): 16
TSH (mIU/L): 2,55
Urea (mg/dL): 8,99
LVEF (%): 34.0
Medications: Angiotensin II Receptor Blocker, Beta Blockers, Loop Diuretics, Spironolactone, Statins, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"RANKING: 1. Survivor
REASONING: 

This patient has a significant history of ischemic dilated cardiomyopathy and myocardial infarction, which are major risk factors for heart failure and arrhythmias. However, the patient's current NYHA class is II, indicating mild symptoms of heart failure. The patient's LVEF is 34%, which is significantly reduced, indicating severe left ventricular dysfunction.

Despite these risk factors, the patient is currently receiving medications for heart failure (Angiotensin II Receptor Blocker, Beta Blockers, Loop Diuretics, Spironolactone, Statins, and Nitrovasodilator), which are standard treatments for heart failure and arrhythmias. The patient's current ECG findings, including ventricular extrasystole and non-sustained ventricular tachycardia, are concerning but not immediately life-threatening.

The patient's laboratory values, including a low T3 level, elevated creatinine, and low hemoglobin, may indicate some degree of malnutrition and renal impairment, which can be a risk factor for heart failure. However, these values are not immediately life-threatening and can be managed with treatment.

Overall, considering the patient's age, medical history, and current treatment, the most likely outcome is that the patient will survive the next few years. However, close monitoring and regular follow-up appointments will be necessary to adjust the treatment plan as needed to manage the patient's heart failure and arrhythmias.

RANKING: 2. Sudden cardiac death
REASONING: 

While the patient's current ECG findings of ventricular extrasystole and non-sustained ventricular tachycardia are concerning, the fact that they are non-sustained suggests that the arrhythmias are not immediately life-threatening. However, the patient's history of myocardial infarction and ischemic dilated cardiomyopathy increases the risk of sudden cardiac death.

The patient's LVEF of 34% is also a significant risk factor for sudden cardiac death. Additionally, the patient's age (73) and weight (90 kg) may also increase the risk of sudden cardiac death.

While the patient is receiving medications for heart failure and arrhythmias, the fact that the patient is not receiving a cardioverter-defibrillator (ICD) implantation is a concern. ICDs are often recommended for patients with a high risk of sudden cardiac death.

Overall, while the patient's current ECG findings and medical history are concerning, the patient's current treatment and lifestyle factors may not be sufficient to completely eliminate the risk of sudden cardiac death. Therefore, the second most likely outcome is that the patient will experience sudden cardiac death.

RANKING: 3. Pump failure death
REASONING: 

Given the patient's significant history of heart failure and current LVEF of 34%, the patient is at risk of experiencing pump failure. However, the patient is currently receiving medications for heart failure, which can help manage symptoms and slow disease progression.

The patient's NYHA class is II, indicating mild symptoms of heart failure, which suggests that the patient is not currently experiencing severe heart failure. Additionally, the patient's blood pressure is within a relatively normal range (110/55 mmHg).

However, the patient's elevated creatinine level (106.0) and low hemoglobin (137.0) may indicate some degree of renal impairment and anemia, which can increase the risk of heart failure. Additionally, the patient's low T3 level may indicate some degree of hypothyroidism, which can also contribute to heart failure.

While the patient's current treatment and lifestyle factors are managing the patient's symptoms, the patient's underlying heart disease and risk factors for heart failure increase the risk of pump failure. Therefore, the third most likely outcome is that the patient will experience pump failure."
265,265,P0442,"Age: 63
Gender: Male 
Weight: 67 kg
Height: 162 cm
NYHA Class: II
Blood Pressure: 140/70 mmHg
Past Medical History: Idiopathic dilated cardiomyopathy, Hypertension
Albumin (g/L): 45
ALT or GPT (IU/L): 16.0
AST or GOT (IU/L): 19.0
Total Cholesterol (mmol/L): 4,19
Creatinine (mmol/L): 160.0
Gamma-glutamil transpeptidase (IU/L): 125
Glucose (mmol/L): 3,3
Hemoglobin (g/L): 142.0
HDL (mmol/L): 1,16
Potassium (mEq/L): 6,2
LDL (mmol/L): 2,51
Sodium (mEq/L): 139.0
Pro-BNP (ng/L): 637.0
Protein (g/L): 82
T3 (pg/dL): 0,04
T4 (ng/L): 15
Troponin (ng/mL): 0,04
TSH (mIU/L): 0,825
Urea (mg/dL): 12,15
LVEF (%): 52.0
Medications: Calcium Channel Blocker, Beta Blockers, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"RANKING: 1. Survivor
REASONING: 

Based on the provided patient data, the patient is classified as having a relatively mild to moderate heart failure with an LVEF of 52%. The presence of idiopathic dilated cardiomyopathy, hypertension, and elevated creatinine levels suggest a chronic and progressive cardiac condition. However, the patient's NYHA Class II indicates that the symptoms are manageable with current medications, and the patient is not in acute decompensated heart failure.

The patient's elevated troponin levels, although low, may indicate some degree of cardiac damage, but it is not indicative of acute myocardial infarction. The absence of significant electrolyte imbalances, anemia, or other acute complications reduces the likelihood of sudden cardiac death.

The patient's age, weight, and height are not particularly indicative of an increased risk of sudden cardiac death. The presence of ventricular extrasystole and non-sustained ventricular tachycardia on ECG suggests a risk of arrhythmias, but the absence of sustained ventricular tachycardia or other life-threatening arrhythmias reduces this risk.

Given these factors, I predict that the patient is likely to survive for the next few years, assuming the current treatment plan remains effective and there are no significant changes in the patient's medical condition. The patient's overall prognosis is more favorable than sudden cardiac death, as there is no indication of acute cardiac damage or severe arrhythmias. Pump failure death is also less likely, as the patient's LVEF is not severely impaired, and the patient is currently managing their symptoms with medications."
266,266,P0443,"Age: 82
Gender: Female 
Weight: 88 kg
Height: 152 cm
NYHA Class: II
Blood Pressure: 140/80 mmHg
Past Medical History: Hypertensive cardiomyopathy, Hypertension, Myocardial Infarction
Albumin (g/L): 40
ALT or GPT (IU/L): 30.0
AST or GOT (IU/L): 22.0
Total Cholesterol (mmol/L): 4,76
Creatinine (mmol/L): 80.0
Gamma-glutamil transpeptidase (IU/L): 29
Glucose (mmol/L): 7
Hemoglobin (g/L): 141.0
HDL (mmol/L): 1,32
Potassium (mEq/L): 5,5
LDL (mmol/L): 3,7
Sodium (mEq/L): 136.0
Pro-BNP (ng/L): 320.0
Protein (g/L): 78
T3 (pg/dL): 0,02
T4 (ng/L): 21
Troponin (ng/mL): 0,03
TSH (mIU/L): 1,43
Urea (mg/dL): 9,15
LVEF (%): 39.0
Medications: Loop Diuretics, Spironolactone, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Unknown ventricular extrasystole code
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: TPSV
        - Bradycardia: No
            ",survivor,"RANKING: 
1. Survivor
REASONING: 
Based on the provided patient data, the patient is an 82-year-old female with a history of hypertension, myocardial infarction, and cardiomyopathy. Her current NYHA Class II indicates mild heart failure. The patient's ECG shows a TPSV, which is a type of supraventricular tachyarrhythmia that can be managed with medication and lifestyle changes. The patient's biomarkers, such as Troponin and LVEF, indicate some cardiac stress, but not severe. The patient's medications, including loop diuretics, spironolactone, and an ACE inhibitor, suggest that the patient is receiving standard management for heart failure and hypertension. The patient's kidney function is also relatively preserved, with a creatinine level of 9.15 mg/dL. Overall, these factors suggest that the patient is likely to survive in the short-term, given her relatively mild symptoms and current management.

The patient's age and comorbidities do increase the risk of cardiac events, but her current medical status and treatment plan suggest that she is not at high risk for sudden cardiac death or pump failure in the near term. While the patient's LVEF is low, indicating some degree of cardiac dysfunction, it is not severe enough to suggest pump failure. Therefore, I believe that the patient is most likely to survive over the next few years, given her current medical status and treatment plan."
267,267,P0444,"Age: 58
Gender: Male 
Weight: 115 kg
Height: 180 cm
NYHA Class: II
Blood Pressure: 130/80 mmHg
Past Medical History: Hypertensive cardiomyopathy, Hypertension
Albumin (g/L): 36
ALT or GPT (IU/L): 52.0
AST or GOT (IU/L): 24.0
Total Cholesterol (mmol/L): 3,47
Creatinine (mmol/L): 133.0
Gamma-glutamil transpeptidase (IU/L): 149
Glucose (mmol/L): 5
Hemoglobin (g/L): 131.0
HDL (mmol/L): 1,29
Potassium (mEq/L): 4,1
LDL (mmol/L): 1,91
Sodium (mEq/L): 144.0
Pro-BNP (ng/L): 1809.0
Protein (g/L): 64
T3 (pg/dL): 0,03
T4 (ng/L): 22
Troponin (ng/mL): 0,03
TSH (mIU/L): 3,14
Urea (mg/dL): 6,82
LVEF (%): 70.0
Medications: Calcium Channel Blocker, Angiotensin II Receptor Blocker, Loop Diuretics
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: No
            ",survivor,"RANKING: 1. Survivor
REASONING: 
The patient's overall clinical presentation, laboratory results, and ECG findings suggest a relatively stable cardiac condition. The patient is a 58-year-old male with a history of hypertensive cardiomyopathy, which is being managed with a combination of medications (Calcium Channel Blocker, Angiotensin II Receptor Blocker, Loop Diuretics). The patient's NYHA Class II indicates that they experience some limitation in physical activity due to heart failure symptoms, but they are still able to perform moderate physical activity.

The patient's laboratory results show elevated creatinine levels (133.0 mmol/L) and elevated troponin levels (0.03 ng/mL), which suggest some degree of cardiac stress or minor myocardial injury. However, these results are not significantly elevated, and the patient's LVEF (70.0%) is within a relatively normal range.

The ECG findings are mostly unremarkable, with the exception of ventricular extrasystoles, which are a common finding in patients with hypertensive cardiomyopathy. The absence of ventricular tachycardia, non-sustained ventricular tachycardia, and paroxysmal supraventricular tachyarrhythmia suggests that the patient's cardiac conduction system is not significantly impaired.

Given the patient's overall clinical presentation, laboratory results, and ECG findings, the most likely prognosis is that the patient will survive for the next few years. However, it is essential to continue monitoring the patient's cardiac function and adjusting the treatment plan as needed to prevent any potential complications.

RANKING: 2. Sudden cardiac death
REASONING: 
While the patient's overall prognosis is good, there are some factors that suggest a slightly higher risk of sudden cardiac death. The patient's elevated troponin levels (0.03 ng/mL) and elevated creatinine levels (133.0 mmol/L) indicate some degree of cardiac stress or minor myocardial injury. Additionally, the patient's LVEF (70.0%) is slightly below the normal range, which may indicate some degree of left ventricular dysfunction.

The patient's ECG findings, including ventricular extrasystoles, suggest that the patient's cardiac conduction system is not entirely normal. While this finding is not uncommon in patients with hypertensive cardiomyopathy, it does increase the risk of arrhythmias, which can contribute to sudden cardiac death.

RANKING: 3. Pump failure death
REASONING: 
Given the patient's NYHA Class II status and elevated creatinine levels (133.0 mmol/L), there is a moderate risk of pump failure. However, the patient's LVEF (70.0%) is still within a relatively normal range, and the patient is receiving medications to manage their hypertension and heart failure symptoms.

The patient's elevated troponin levels (0.03 ng/mL) and elevated creatinine levels (133.0 mmol/L) suggest that the patient's cardiac function is not optimal, but the patient's overall clinical presentation and laboratory results do not suggest a catastrophic decline in cardiac function.

Given the patient's current treatment plan and clinical presentation, the risk of pump failure death is moderate, but it is not the most likely prognosis. The patient's overall risk of sudden cardiac death is slightly higher due to the presence of ventricular extrasystoles and elevated troponin levels."
268,268,P0447,"Age: 71
Gender: Female 
Weight: 67 kg
Height: 165 cm
NYHA Class: II
Blood Pressure: 131/57 mmHg
Past Medical History: Idiopathic dilated cardiomyopathy, Dyslipemia
Albumin (g/L): 42
ALT or GPT (IU/L): 36.0
AST or GOT (IU/L): 29.0
Total Cholesterol (mmol/L): 5,53
Creatinine (mmol/L): 71.0
Gamma-glutamil transpeptidase (IU/L): 45
Glucose (mmol/L): 5,1
Hemoglobin (g/L): 136.0
HDL (mmol/L): 1,58
Potassium (mEq/L): 4,4
LDL (mmol/L): 3,31
Sodium (mEq/L): 137.0
Pro-BNP (ng/L): 5038.0
Protein (g/L): 69
T4 (ng/L): 17
Troponin (ng/mL): 0,01
TSH (mIU/L): 1,5
Urea (mg/dL): 9,32
LVEF (%): 13.0
Medications: Beta Blockers, Statins, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"RANKING: 
1. Survivor
REASONING:
The patient's age (71) is a risk factor for cardiovascular events, but it is not the most significant factor in this case. The patient's NYHA Class II indicates that they have some limitations in physical activity, but it is not severe. The patient's LVEF of 13.0 is significantly reduced, indicating poor left ventricular function, which is a strong predictor of adverse outcomes. However, the patient is on medications for heart failure and arrhythmias, which suggests that the physician is taking proactive steps to manage the patient's condition.

The patient's elevated BNP level (5038.0 ng/L) is indicative of heart failure, but the patient is already on ACE inhibitors, which are effective in reducing BNP levels. The patient's creatinine level (9.32 mg/dL) is elevated, indicating some degree of renal impairment, but it is not severe.

The patient's ECG findings, including ventricular extrasystole and non-sustained ventricular tachycardia, are concerning for cardiac arrhythmias. However, the patient is already on beta blockers, which are effective in managing arrhythmias.

Considering these factors, I believe that the patient has a higher chance of survival compared to the other two options. The patient's overall condition, while concerning, is not immediately life-threatening, and with proper management, the patient may be able to survive for the next few years.

RANKING 2: Sudden Cardiac Death
REASONING:
The patient's LVEF of 13.0 is significantly reduced, indicating poor left ventricular function. This is a strong predictor of adverse outcomes, including sudden cardiac death. The patient's ECG findings, including ventricular extrasystole and non-sustained ventricular tachycardia, are also concerning for cardiac arrhythmias, which can increase the risk of sudden cardiac death.

RANKING 3: Pump Failure Death
REASONING:
The patient's elevated creatinine level (9.32 mg/dL) indicates some degree of renal impairment, which can increase the risk of pump failure. The patient's NYHA Class II indicates that they have some limitations in physical activity, which can increase the risk of pump failure. However, the patient is already on medications for heart failure, which suggests that the physician is taking proactive steps to manage the patient's condition.

Overall, while the patient's condition is concerning, I believe that pump failure death is less likely compared to sudden cardiac death due to the patient's current management and the fact that the patient is not in severe heart failure."
269,269,P0449,"Age: 64
Gender: Female 
Weight: 47 kg
Height: 159 cm
NYHA Class: II
Blood Pressure: 102/40 mmHg
Past Medical History: Idiopathic dilated cardiomyopathy
Albumin (g/L): 46
ALT or GPT (IU/L): 12.0
AST or GOT (IU/L): 15.0
Total Cholesterol (mmol/L): 4,03
Creatinine (mmol/L): 133.0
Gamma-glutamil transpeptidase (IU/L): 32
Glucose (mmol/L): 5,1
Hemoglobin (g/L): 107.0
HDL (mmol/L): 1,11
Potassium (mEq/L): 5,2
LDL (mmol/L): 1,63
Sodium (mEq/L): 130.0
Pro-BNP (ng/L): 105.0
Protein (g/L): 76
T4 (ng/L): 14
Troponin (ng/mL): 0,01
TSH (mIU/L): 1,18
Urea (mg/dL): 9,98
LVEF (%): 35.0
Medications: Beta Blockers, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"RANKING: 

1. Survivor
REASONING: 
The patient is currently on beta blockers and ACE inhibitors, which are standard treatments for patients with heart failure and cardiomyopathy. The presence of ventricular extrasystole is noted on the ECG, but it is polymorphic, which suggests that it is not a significant arrhythmia. The patient's LVEF is severely reduced, indicating a significant impairment of cardiac function, but the patient is still alive. The patient's other laboratory values, such as troponin and TSH, are not indicative of acute cardiac injury or thyroid dysfunction. Given these factors, the patient is likely to survive for the next few years.

2. Pump failure death
REASONING: 
While the patient's LVEF is severely reduced, the patient is still alive and receiving treatment. The patient's other laboratory values do not indicate acute cardiac injury or significant electrolyte imbalances. However, the patient's reduced LVEF and elevated BNP levels suggest that the patient's cardiac function is severely compromised. If the patient's condition does not improve with treatment, the patient may experience pump failure, which is a common cause of death in patients with severe heart failure.

3. Sudden cardiac death
REASONING: 
The patient's polymorphic ventricular extrasystole on the ECG is a significant risk factor for sudden cardiac death. However, the patient is already on beta blockers and ACE inhibitors, which are known to reduce the risk of arrhythmias. Additionally, the patient's other laboratory values do not indicate acute cardiac injury or significant electrolyte imbalances. While the patient's LVEF is severely reduced, the patient is still alive, which suggests that the patient's cardiac function is not severely compromised. Therefore, the risk of sudden cardiac death is lower than pump failure, making it the least likely outcome."
270,270,P0450,"Age: 70
Gender: Female 
Weight: 94 kg
Height: 156 cm
NYHA Class: II
Blood Pressure: 106/45 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Diabetes, Hypertension, Myocardial Infarction
Albumin (g/L): 36
ALT or GPT (IU/L): 15.0
AST or GOT (IU/L): 17.0
Total Cholesterol (mmol/L): 3,88
Creatinine (mmol/L): 62.0
Gamma-glutamil transpeptidase (IU/L): 16
Glucose (mmol/L): 6,9
Hemoglobin (g/L): 127.0
HDL (mmol/L): 1,06
Potassium (mEq/L): 4,5
LDL (mmol/L): 2,43
Sodium (mEq/L): 136.0
Pro-BNP (ng/L): 333.0
Protein (g/L): 67
T4 (ng/L): 18
Troponin (ng/mL): 0,01
TSH (mIU/L): 2,64
Urea (mg/dL): 5,99
LVEF (%): 30.0
Medications: Calcium Channel Blocker, Beta Blockers, Statins, ACE Inhibitor, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"RANKING: 

1. Survivor
REASONING: 
Given the patient's age (70), NYHA Class II, and the presence of ischemic dilated cardiomyopathy, diabetes, hypertension, and myocardial infarction, the patient is already at an increased risk for cardiac-related complications. However, the patient's current ECG impression does not show any signs of ventricular tachycardia, non-sustained ventricular tachycardia, or other arrhythmias that could indicate a high risk for sudden cardiac death.

The patient's current medications, including ACE inhibitors, beta blockers, and statins, suggest that the patient is receiving standard treatment for heart failure and coronary artery disease. The patient's elevated creatinine level (62.0 mmol/L) may indicate some degree of kidney dysfunction, but it is not uncommon in patients with chronic kidney disease.

The patient's elevated Pro-BNP level (333.0 ng/L) and low LVEF (30.0%) suggest that the patient has significant cardiac dysfunction, but these parameters can be influenced by various factors such as fluid overload, renal dysfunction, and other comorbidities.

Considering these factors, the patient's overall prognosis is that they will survive the next few years. The patient's NYHA Class II indicates that they are able to perform moderate physical activity without symptoms, and their current medications suggest that they are receiving adequate treatment for their underlying conditions.

2. Sudden cardiac death
REASONING: 
The patient's elevated Troponin level (0.01 ng/mL) could suggest some degree of myocardial damage, but the level is very low and not indicative of a recent myocardial infarction. However, the patient's history of myocardial infarction and ischemic dilated cardiomyopathy increases the risk of sudden cardiac death.

The patient's ECG impression does not show any signs of ventricular tachycardia or non-sustained ventricular tachycardia, which are common precursors to sudden cardiac death. However, the patient's low LVEF (30.0%) and elevated Pro-BNP level (333.0 ng/L) suggest that the patient has significant cardiac dysfunction, which could increase the risk of arrhythmias and sudden cardiac death.

3. Pump failure death
REASONING: 
Given the patient's NYHA Class II, elevated Pro-BNP level (333.0 ng/L), and low LVEF (30.0%), the patient is at risk for heart failure exacerbation and pump failure. The patient's current medications suggest that they are receiving adequate treatment for heart failure, but the patient's elevated creatinine level (62.0 mmol/L) and low hemoglobin (127.0 g/L) suggest that the patient may be experiencing some degree of kidney dysfunction and anemia.

The patient's history of hypertension, diabetes, and myocardial infarction increases the risk of pump failure. However, the patient's current ECG impression does not show any signs of ventricular tachycardia or non-sustained ventricular tachycardia, which are common precipitants of pump failure."
271,271,P0451,"Age: 57
Gender: Female 
Weight: 64 kg
Height: 147 cm
NYHA Class: II
Blood Pressure: 89/53 mmHg
Past Medical History: Idiopathic dilated cardiomyopathy, Dyslipemia, Hypertension
Albumin (g/L): 39
ALT or GPT (IU/L): 20.0
AST or GOT (IU/L): 17.0
Total Cholesterol (mmol/L): 6,36
Creatinine (mmol/L): 80.0
Gamma-glutamil transpeptidase (IU/L): 23
Glucose (mmol/L): 6,1
Hemoglobin (g/L): 114.0
HDL (mmol/L): 1,34
Potassium (mEq/L): 4,7
LDL (mmol/L): 4,55
Sodium (mEq/L): 136.0
Pro-BNP (ng/L): 1742.0
Protein (g/L): 68
T4 (ng/L): 17
Troponin (ng/mL): 0,01
TSH (mIU/L): 1,93
Urea (mg/dL): 8,99
LVEF (%): 20.0
Medications: Beta Blockers, Loop Diuretics, Spironolactone, Statins, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"RANKING: 1. Survivor
REASONING: The patient has a history of idiopathic dilated cardiomyopathy, which is a significant risk factor for cardiac events. However, the patient's current NYHA Class II indicates that they have some level of functional impairment, but not severe enough to limit their daily activities. The patient's LVEF of 20.0 is significantly reduced, but not in the range typically associated with advanced heart failure.

The patient's lipid profile and electrolyte levels are also notable. The elevated Troponin level (0.01 ng/mL) suggests some degree of cardiac injury, but it is not excessively high. The presence of ventricular extrasystoles, non-sustained ventricular tachycardia (NSVT), and the patient's overall cardiac risk factors (e.g., hypertension, dyslipidemia) contribute to a higher risk of cardiac events.

The patient is already on medications for heart failure (Beta Blockers, Loop Diuretics, Spironolactone, Statins, and ACE Inhibitor), which is a good starting point for managing their condition. However, the patient's current ECG findings and elevated Pro-BNP levels (1742 ng/L) suggest ongoing cardiac stress and strain, which may indicate the need for additional therapeutic interventions.

Given these factors, I would rank the patient as having a higher likelihood of survival, but with a significant risk of cardiac events in the next few years."
272,272,P0452,"Age: 51
Gender: Male 
Weight: 61 kg
Height: 162 cm
NYHA Class: III
Blood Pressure: 100/55 mmHg
Past Medical History: Other HF etiology, Diabetes
Albumin (g/L): 46
ALT or GPT (IU/L): 30.0
AST or GOT (IU/L): 25.0
Total Cholesterol (mmol/L): 5,25
Creatinine (mmol/L): 97.0
Gamma-glutamil transpeptidase (IU/L): 48
Glucose (mmol/L): 7,7
Hemoglobin (g/L): 143.0
HDL (mmol/L): 1,19
Potassium (mEq/L): 4
LDL (mmol/L): 3,36
Sodium (mEq/L): 140.0
Pro-BNP (ng/L): 2311.0
Protein (g/L): 78
T3 (pg/dL): 0,04
T4 (ng/L): 22
Troponin (ng/mL): 0,14
TSH (mIU/L): 0,742
Urea (mg/dL): 4,99
LVEF (%): 18.0
Medications: Beta Blockers, Digoxin, Loop Diuretics, Spironolactone, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"RANKING: 1. Survivor
REASONING:

This patient has a complex medical history with multiple comorbidities, including heart failure (NYHA Class III), diabetes, and other unspecified etiologies for heart failure. The patient's elevated creatinine level (97.0 mmol/L) suggests some degree of renal impairment, which can further exacerbate heart failure.

Despite these comorbidities, the patient's hemoglobin level (143.0 g/L) is within the normal range, and the patient is on medications that are commonly used to manage heart failure, such as beta blockers, digoxin, loop diuretics, spironolactone, and ACE inhibitors. The presence of ventricular extrasystoles and non-sustained ventricular tachycardia on the ECG is concerning, but the patient's LVEF (18.0%) is relatively preserved, which may indicate some level of cardiac function.

The patient's Pro-BNP level (2311.0 ng/L) is elevated, indicating some degree of heart failure, but it is not excessively high. The patient's troponin level (0.14 ng/mL) is also within the normal range, which suggests that there is no significant myocardial injury.

Overall, considering the patient's complex medical history and the presence of some cardiac arrhythmias, but also the relatively preserved LVEF and the absence of excessively high troponin levels, I would rank the patient as having a relatively good prognosis, with a likelihood of survival over the next few years."
273,273,P0453,"Age: 58
Gender: Male 
Weight: 65 kg
Height: 157 cm
NYHA Class: II
Blood Pressure: 110/60 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Diabetes, Dyslipemia, Peripheral vascular disease, Myocardial Infarction
Albumin (g/L): 52
ALT or GPT (IU/L): 41.0
AST or GOT (IU/L): 28.0
Total Cholesterol (mmol/L): 3,39
Creatinine (mmol/L): 106.0
Gamma-glutamil transpeptidase (IU/L): 64
Glucose (mmol/L): 5,4
Hemoglobin (g/L): 132.0
HDL (mmol/L): 1,22
Potassium (mEq/L): 5,2
LDL (mmol/L): 1,24
Sodium (mEq/L): 140.0
Pro-BNP (ng/L): 868.0
Protein (g/L): 90
T3 (pg/dL): 0,04
T4 (ng/L): 15
Troponin (ng/mL): 0,09
TSH (mIU/L): 2,8
Urea (mg/dL): 8,99
LVEF (%): 37.0
Medications: Beta Blockers, Digoxin, Loop Diuretics, Spironolactone, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",survivor,"RANKING: 1. Survivor
REASONING: The patient has a significant history of ischemic dilated cardiomyopathy, which is a condition where the heart muscle is weakened and cannot pump blood effectively. This condition is a major risk factor for sudden cardiac death and pump failure. However, the patient is currently taking medications such as beta blockers, digoxin, loop diuretics, spironolactone, and ACE inhibitors, which are standard treatments for heart failure and arrhythmias. The patient's current NYHA class is II, indicating moderate symptoms of heart failure.

Despite the patient's poor LVEF (37.0) and elevated Pro-BNP levels (868.0), which indicate heart failure, the patient's blood pressure is well-controlled (110/60 mmHg), and their kidney function is not severely impaired (creatinine 106.0 mg/dL). The patient's electrolyte levels, including potassium (5.2 mEq/L) and sodium (140.0 mEq/L), are within normal ranges.

The patient's ECG shows ventricular extrasystole and non-sustained ventricular tachycardia, which are both concerning signs of arrhythmias. However, the patient is currently taking medications to manage these conditions. Overall, while the patient has significant heart disease, their current medical regimen and laboratory results suggest that they are stable and at moderate risk for complications.

RANKING: 2. Sudden cardiac death
REASONING: The patient's history of myocardial infarction, ischemic dilated cardiomyopathy, and ventricular tachycardia on ECG increase the risk of sudden cardiac death. However, the patient's current medications and stable vital signs suggest that they are not at immediate risk for sudden cardiac death.

RANKING: 3. Pump failure death
REASONING: While the patient has a poor LVEF (37.0) and elevated Pro-BNP levels, which indicate heart failure, their current medications and stable vital signs suggest that they are not at high risk for pump failure. The patient's kidney function is not severely impaired, and their electrolyte levels are within normal ranges. However, the patient's heart disease is significant, and their LVEF is very low, which increases the risk of pump failure."
274,274,P0454,"Age: 52
Gender: Male 
Weight: 110 kg
Height: 171 cm
NYHA Class: II
Blood Pressure: 140/90 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Diabetes, Dyslipemia, Peripheral vascular disease, Hypertension, Myocardial Infarction
Albumin (g/L): 46
ALT or GPT (IU/L): 41.0
AST or GOT (IU/L): 45.0
Total Cholesterol (mmol/L): 4,73
Creatinine (mmol/L): 91.0
Gamma-glutamil transpeptidase (IU/L): 234
Glucose (mmol/L): 7,87
Hemoglobin (g/L): 148.0
HDL (mmol/L): 0,9
Potassium (mEq/L): 4,93
LDL (mmol/L): 1,91
Sodium (mEq/L): 137.0
Pro-BNP (ng/L): 690.0
Protein (g/L): 79
T3 (pg/dL): 0,0459
T4 (ng/L): 15,19
Troponin (ng/mL): 0,3
TSH (mIU/L): 3,07
Urea (mg/dL): 5,4
LVEF (%): 35.0
Medications: Diabetes Medication, Amiodarone, Digoxin, Loop Diuretics, Spironolactone, Statins, ACE Inhibitor, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"RANKING: 1. Survivor
REASONING: The patient's age (52) and NYHA Class II indicate that they are likely to survive the next few years. The patient's ECG impression does not show any life-threatening arrhythmias, such as ventricular tachycardia or ventricular extrasystole. Although the patient has a history of ischemic dilated cardiomyopathy, the LVEF is 35%, which is still within the range of patients who can survive with optimal treatment. The patient is also on medications that are commonly used to treat heart failure, such as ACE inhibitors, loop diuretics, and spironolactone, which suggest a well-managed condition. The patient's renal function is also relatively preserved, with a creatinine level of 91.0 mmol/L, which is not severely impaired. Additionally, the patient's biomarkers, such as troponin and liver enzymes, are within normal limits. Overall, the combination of a relatively preserved LVEF, well-managed medications, and normal biomarkers suggest that the patient is likely to survive the next few years.

RANKING: 2. Sudden Cardiac Death
REASONING: Although the patient's LVEF is 35%, which is lower than normal, it is still within the range of patients who can survive with optimal treatment. However, the patient's history of ischemic dilated cardiomyopathy and peripheral vascular disease increases the risk of sudden cardiac death. The patient's ECG impression shows ventricular extrasystole, which is a risk factor for sudden cardiac death. Additionally, the patient's creatinine level of 91.0 mmol/L is slightly elevated, which may indicate some degree of renal impairment. While the patient is on medications that can help manage heart failure, the presence of ventricular extrasystole and elevated creatinine level increase the risk of sudden cardiac death.

RANKING: 3. Pump Failure Death
REASONING: The patient's LVEF is 35%, which is significantly lower than normal, indicating that the patient's heart is not pumping efficiently. The patient's NYHA Class II indicates that they have some limitation of physical activity due to heart failure, which increases the risk of pump failure death. The patient's elevated creatinine level (91.0 mmol/L) and elevated liver enzymes (ALT and AST) suggest some degree of organ dysfunction, which can increase the risk of pump failure death. Additionally, the patient's use of loop diuretics and spironolactone may not be sufficient to manage the patient's heart failure, as the patient's protein level is elevated (79 g/L), which may indicate fluid overload. Overall, the combination of a low LVEF, elevated creatinine level, and elevated liver enzymes suggest that the patient is at high risk of pump failure death."
275,275,P0455,"Age: 67
Gender: Male 
Weight: 64 kg
Height: 162 cm
NYHA Class: II
Blood Pressure: 100/70 mmHg
Past Medical History: Enolic dilated cardiomyopathy, Diabetes, Dyslipemia, Hypertension
Albumin (g/L): 47
ALT or GPT (IU/L): 22.0
AST or GOT (IU/L): 23.0
Total Cholesterol (mmol/L): 5,12
Creatinine (mmol/L): 159.0
Gamma-glutamil transpeptidase (IU/L): 244
Glucose (mmol/L): 9,2
Hemoglobin (g/L): 131.0
HDL (mmol/L): 0,88
Potassium (mEq/L): 5,1
LDL (mmol/L): 3,59
Sodium (mEq/L): 139.0
Pro-BNP (ng/L): 8797.0
Protein (g/L): 80
T3 (pg/dL): 0,04
T4 (ng/L): 18
Troponin (ng/mL): 0,03
TSH (mIU/L): 3,58
Urea (mg/dL): 14,81
LVEF (%): 23.0
Medications: Beta Blockers, Digoxin, Loop Diuretics, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",survivor,"RANKING: 1. Survivor
REASONING: 

Based on the provided patient data, I would rank the patient as having a high likelihood of survival over the next few years. The key factors contributing to this assessment are:

1. NYHA Class II: The patient's heart failure symptoms are moderate, indicating that they are able to perform daily activities with some limitations, but they are not severely restricted. This suggests that the heart is still functioning to some extent.

2. Medications: The patient is taking beta blockers, digoxin, loop diuretics, and an ACE inhibitor, which are standard treatments for heart failure and cardiomyopathy. These medications are likely helping to manage the patient's symptoms and slow disease progression.

3. Low LVEF (23.0%): While the left ventricular ejection fraction is significantly reduced, it is not extremely low, which suggests that the heart is still pumping some blood, albeit inefficiently.

4. No mention of severe electrolyte imbalances or acute cardiac events: The patient's potassium levels are within a relatively normal range, and there are no signs of acute cardiac events such as myocardial infarction or acute heart failure exacerbation.

5. No indication of severe anemia or malnutrition: The patient's hemoglobin level is within a relatively normal range, and the protein level is also within a normal range, indicating that the patient is not severely malnourished.

While the patient's cardiomyopathy and other comorbidities increase their risk of cardiac events, the presence of these medications, moderate NYHA Class, and relatively preserved LVEF suggest that the patient is likely to survive over the next few years with proper management and monitoring."
276,276,P0456,"Age: 38
Gender: Male 
Weight: 80 kg
Height: 175 cm
NYHA Class: II
Blood Pressure: 110/50 mmHg
Past Medical History: Post-myocardial dilated cardiomyopathy
Albumin (g/L): 43
ALT or GPT (IU/L): 26.0
AST or GOT (IU/L): 22.0
Total Cholesterol (mmol/L): 4,34
Creatinine (mmol/L): 80.0
Gamma-glutamil transpeptidase (IU/L): 26
Glucose (mmol/L): 4,7
Hemoglobin (g/L): 153.0
HDL (mmol/L): 1,32
Potassium (mEq/L): 5,1
LDL (mmol/L): 2,33
Sodium (mEq/L): 138.0
Pro-BNP (ng/L): 47.0
Protein (g/L): 71
T3 (pg/dL): 0,07
T4 (ng/L): 15
Troponin (ng/mL): 0,005
TSH (mIU/L): 1,19
Urea (mg/dL): 6,32
LVEF (%): 42.0
Medications: ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"RANKING: 1. Survivor
REASONING: 

Based on the provided patient data, I would rank the patient as a survivor with a high likelihood. The patient's NYHA Class II indicates that they have some symptoms of heart failure, but they are still able to perform daily activities without significant limitations. The patient's LVEF (left ventricular ejection fraction) of 42.0 is below the normal range, indicating some degree of left ventricular dysfunction. However, the patient's troponin level is within normal limits, suggesting that there is no significant myocardial infarction or acute cardiac injury.

The patient's blood tests, such as the albumin and creatinine levels, are within normal limits, indicating that there is no significant kidney dysfunction or malnutrition. The patient's electrolyte levels, including potassium, sodium, and glucose, are also within normal limits. The patient's lipid profile, including the LDL and HDL levels, is also within normal limits.

The patient's ECG findings, including the absence of ventricular tachycardia, non-sustained ventricular tachycardia, and paroxysmal supraventricular tachyarrhythmia, suggest that the patient does not have a high risk of arrhythmias. The presence of ventricular extrasystole is noted, but it is not a concerning finding.

Given these factors, I believe that the patient has a good prognosis for survival, and the likelihood of sudden cardiac death or pump failure death is low. The patient's current treatment with an ACE inhibitor, which is a standard treatment for heart failure, suggests that the patient is receiving appropriate medical therapy.

While the patient's LVEF is below normal, the patient's overall clinical presentation and laboratory results suggest that they are not at high risk for sudden cardiac death or pump failure. Therefore, I would rank the patient as a survivor with a high likelihood."
277,277,P0457,"Age: 48
Gender: Female 
Weight: 62 kg
Height: 160 cm
NYHA Class: III
Blood Pressure: 110/70 mmHg
Past Medical History: Idiopathic dilated cardiomyopathy, Dyslipemia, Hypertension
Albumin (g/L): 42
ALT or GPT (IU/L): 34.0
AST or GOT (IU/L): 24.0
Total Cholesterol (mmol/L): 4,99
Creatinine (mmol/L): 177.0
Gamma-glutamil transpeptidase (IU/L): 23
Glucose (mmol/L): 5,6
Hemoglobin (g/L): 119.0
HDL (mmol/L): 0,83
Potassium (mEq/L): 4,7
LDL (mmol/L): 2,74
Sodium (mEq/L): 135.0
Pro-BNP (ng/L): 380.0
Protein (g/L): 72
T3 (pg/dL): 0,05
T4 (ng/L): 23
Troponin (ng/mL): 0,06
TSH (mIU/L): 3,58
Urea (mg/dL): 11,48
LVEF (%): 35.0
Medications: Beta Blockers, Digoxin, Loop Diuretics, Spironolactone, Statins, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"RANKING: 
1. Survivor
REASONING:
The patient's age, NYHA Class III, and LVEF of 35% indicate a significant impairment in cardiac function, which is consistent with advanced heart failure. However, the patient is already on multiple medications for heart failure management, including beta blockers, digoxin, and ACE inhibitors, which suggests that the patient is receiving optimal medical therapy.

The elevated creatinine level (177.0 mol/L) and elevated Pro-BNP level (380.0 ng/L) indicate severe cardiac strain and possible renal impairment. However, the patient's renal function is not severely impaired, as the creatinine level is not in the range of end-stage renal disease (ESRD). The presence of ventricular extrasystoles and non-sustained ventricular tachycardia on ECG suggests an increased risk of arrhythmic events, but the patient is already receiving beta blockers, which are effective in reducing arrhythmic risk.

The patient's low T3 level (0.05 pg/dL) may indicate hypothyroidism, which can be a comorbidity in patients with heart failure. However, this is not a contraindication to survival.

Considering these factors, the patient's overall prognosis is more favorable than the other two options, as they are already receiving optimal medical therapy and have not reached the stage of severe cardiac dysfunction or renal failure.

2. Sudden Cardiac Death
REASONING:
The patient's LVEF of 35% and NYHA Class III indicate significant impairment in cardiac function, which increases the risk of sudden cardiac death. The presence of non-sustained ventricular tachycardia (CH>10) on ECG is a significant risk factor for sudden cardiac death.

The patient's elevated Pro-BNP level (380.0 ng/L) and elevated creatinine level (177.0 mol/L) suggest significant cardiac strain and renal impairment, which can increase the risk of arrhythmic events.

The patient's hypotension is not a significant concern, as their blood pressure is within a relatively normal range (110/70 mmHg). However, the presence of ventricular extrasystoles and non-sustained ventricular tachycardia on ECG suggests an increased risk of arrhythmic events.

Considering these factors, the patient's prognosis is less favorable than the survivor, but still relatively favorable, given their optimal medical therapy and lack of severe cardiac or renal dysfunction.

3. Pump Failure Death
REASONING:
The patient's LVEF of 35% and NYHA Class III indicate significant impairment in cardiac function, which increases the risk of pump failure. The patient's elevated creatinine level (177.0 mol/L) and elevated Pro-BNP level (380.0 ng/L) suggest significant cardiac strain and renal impairment, which can lead to pump failure.

The patient's hypotension is not a significant concern, as their blood pressure is within a relatively normal range (110/70 mmHg). However, the presence of ventricular extrasystoles and non-sustained ventricular tachycardia on ECG suggests an increased risk of arrhythmic events.

Considering these factors, the patient's prognosis is the least favorable of the three options, as they have significant impairment in cardiac function, renal impairment, and an increased risk of arrhythmic events."
278,278,P0459,"Age: 65
Gender: Male 
Weight: 117 kg
Height: 181 cm
NYHA Class: II
Blood Pressure: 130/60 mmHg
Past Medical History: Other HF etiology, Diabetes, Hypertension, Myocardial Infarction
Albumin (g/L): 40
ALT or GPT (IU/L): 32.0
AST or GOT (IU/L): 14.0
Total Cholesterol (mmol/L): 4,99
Creatinine (mmol/L): 124.0
Gamma-glutamil transpeptidase (IU/L): 13
Glucose (mmol/L): 8,5
Hemoglobin (g/L): 128.0
HDL (mmol/L): 0,72
Potassium (mEq/L): 4,7
LDL (mmol/L): 3,49
Sodium (mEq/L): 138.0
Pro-BNP (ng/L): 382.0
Protein (g/L): 72
T3 (pg/dL): 0,03
T4 (ng/L): 23
Troponin (ng/mL): 0,03
TSH (mIU/L): 3,28
Urea (mg/dL): 10,82
LVEF (%): 38.0
Medications: Diabetes Medication, Beta Blockers, Loop Diuretics, Spironolactone, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"RANKING: 1. Survivor
REASONING: 

Based on the provided patient data, the patient is a 65-year-old male with a history of multiple comorbidities, including heart failure, hypertension, diabetes, and myocardial infarction. His NYHA class is II, indicating mild to moderate heart failure. The patient's elevated creatinine level (124.0 mol/L) and elevated Pro-BNP level (382.0 ng/L) suggest significant cardiac stress and strain. However, the patient's ECG results do not show any life-threatening arrhythmias, which is a positive prognostic sign.

The patient's medications, including beta blockers, loop diuretics, and ACE inhibitors, indicate that the patient is being managed for heart failure and hypertension. The patient's weight is 117 kg, which is above the normal range, but the patient's BMI is not calculated, making it difficult to assess the impact of obesity on the patient's prognosis.

Despite the patient's poor cardiac function (LVEF: 38.0%), the patient's troponin level is normal, which suggests that there is no significant myocardial infarction or acute cardiac injury. The patient's hemoglobin level is also within the normal range, which suggests that the patient does not have anemia.

Considering these factors, the patient's prognosis is more likely to be a survivor, as the patient is being managed for heart failure and hypertension, and the patient's ECG results do not show any life-threatening arrhythmias. However, the patient's comorbidities and poor cardiac function do increase the risk of adverse outcomes.

RANKING: 2. Sudden cardiac death
REASONING: 

While the patient's ECG results do not show any life-threatening arrhythmias, the patient's history of myocardial infarction and hypertension increases the risk of sudden cardiac death. The patient's LVEF is also low (38.0%), which suggests that the patient's heart is not functioning efficiently.

The patient's medications, including beta blockers, loop diuretics, and ACE inhibitors, indicate that the patient is being managed for heart failure and hypertension. However, the patient's weight is above the normal range, and the patient's BMI is not calculated, making it difficult to assess the impact of obesity on the patient's prognosis.

The patient's Pro-BNP level is elevated, which suggests that the patient is experiencing cardiac stress and strain. However, the patient's troponin level is normal, which suggests that there is no significant myocardial infarction or acute cardiac injury.

Considering these factors, the patient's prognosis is less likely to be a survivor, as the patient's comorbidities and poor cardiac function increase the risk of adverse outcomes. However, the patient's ECG results do not show any life-threatening arrhythmias, which is a positive prognostic sign.

RANKING: 3. Pump failure death
REASONING: 

The patient's LVEF is low (38.0%), which suggests that the patient's heart is not functioning efficiently. The patient's Pro-BNP level is elevated, which suggests that the patient is experiencing cardiac stress and strain.

The patient's comorbidities, including heart failure, hypertension, and diabetes, increase the risk of pump failure death. The patient's weight is also above the normal range, which can increase the risk of pump failure.

The patient's medications, including beta blockers, loop diuretics, and ACE inhibitors, indicate that the patient is being managed for heart failure and hypertension. However, the patient's troponin level is normal, which suggests that there is no significant myocardial infarction or acute cardiac injury.

Considering these factors, the patient's prognosis is less likely to be a survivor, as the patient's comorbidities and poor cardiac function increase the risk of pump failure death. The patient's ECG results do not show any life-threatening arrhythmias, which is a positive prognostic sign, but the patient's low LVEF and elevated Pro-BNP level suggest that the patient is at risk of pump failure."
279,279,P0462,"Age: 54
Gender: Male 
Weight: 65 kg
Height: 167 cm
NYHA Class: II
Blood Pressure: 150/90 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Diabetes, Dyslipemia, Peripheral vascular disease, Hypertension, Myocardial Infarction
Albumin (g/L): 42
ALT or GPT (IU/L): 55.0
AST or GOT (IU/L): 39.0
Total Cholesterol (mmol/L): 7,96
Creatinine (mmol/L): 106.0
Gamma-glutamil transpeptidase (IU/L): 167
Glucose (mmol/L): 8,9
Hemoglobin (g/L): 154.0
HDL (mmol/L): 1,97
Potassium (mEq/L): 3,7
LDL (mmol/L): 5,51
Sodium (mEq/L): 130.0
Pro-BNP (ng/L): 645.0
Protein (g/L): 79
T4 (ng/L): 14
Troponin (ng/mL): 0,01
TSH (mIU/L): 2,35
Urea (mg/dL): 15,14
LVEF (%): 30.0
Medications: Diabetes Medication, Angiotensin II Receptor Blocker, Beta Blockers, Loop Diuretics, Spironolactone, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Unknown ventricular extrasystole code
        - Ventricular Tachycardia: Unknown ventricular tachycardia code
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",survivor,"RANKING: 1. Survivor
REASONING:

Based on the provided patient data, I rank the patient as having a high likelihood of survival for the next few years. The patient's NYHA Class II indicates that they have some limitation in physical activity due to heart failure, but they are still able to perform daily activities without severe shortness of breath. Their LVEF of 30.0 is significantly reduced, indicating systolic dysfunction, but it is not severely impaired.

The patient's medications, including beta blockers, ACE inhibitors, and spironolactone, suggest that they are receiving standard treatment for heart failure and hypertension. Their laboratory results, such as a normal TSH and slightly elevated troponin, do not indicate acute coronary syndrome or acute kidney injury.

The patient's past medical history, including ischemic dilated cardiomyopathy, diabetes, and hypertension, may contribute to their cardiac condition, but these conditions are well-managed with medications. The patient's elevated creatinine level (106.0 mmol/L) suggests some degree of renal impairment, but this is not uncommon in patients with heart failure.

The ECG findings, including ventricular extrasystole and non-sustained ventricular tachycardia, suggest some degree of cardiac arrhythmia, but these are not necessarily indicative of a poor prognosis.

Overall, the patient's overall clinical presentation, laboratory results, and treatment plan suggest that they are likely to survive for the next few years with careful management of their heart failure and other comorbidities.

RANKING: 2. Sudden cardiac death
REASONING:

A sudden cardiac death is unlikely in this patient due to their stable clinical presentation, well-managed medications, and lack of acute coronary syndrome. However, the patient's history of ischemic dilated cardiomyopathy and hypertension may increase their risk of sudden cardiac death. The patient's LVEF of 30.0 and elevated creatinine level (106.0 mmol/L) suggest some degree of cardiac and renal impairment, which may increase their risk of arrhythmias and sudden cardiac death.

RANKING: 3. Pump failure death
REASONING:

Pump failure death is a possible outcome for this patient, but it is less likely than sudden cardiac death. The patient's NYHA Class II and LVEF of 30.0 indicate some degree of heart failure, and their elevated creatinine level (106.0 mmol/L) suggests some degree of renal impairment. However, the patient is receiving standard treatment for heart failure, including beta blockers, ACE inhibitors, and spironolactone, which should help manage their symptoms and slow disease progression.

Overall, while pump failure death is a possible outcome, the patient's stable clinical presentation and well-managed medications suggest that they are likely to survive for the next few years with careful monitoring and management of their heart failure."
280,280,P0463,"Age: 67
Gender: Female 
Weight: 60 kg
Height: 165 cm
NYHA Class: II
Blood Pressure: 142/61 mmHg
Past Medical History: Idiopathic dilated cardiomyopathy
Albumin (g/L): 39
ALT or GPT (IU/L): 9.0
AST or GOT (IU/L): 15.0
Total Cholesterol (mmol/L): 3,88
Creatinine (mmol/L): 80.0
Gamma-glutamil transpeptidase (IU/L): 11
Glucose (mmol/L): 4,5
Hemoglobin (g/L): 126.0
HDL (mmol/L): 1,4
Potassium (mEq/L): 4,9
LDL (mmol/L): 2,15
Sodium (mEq/L): 136.0
Pro-BNP (ng/L): 2853.0
Protein (g/L): 67
T4 (ng/L): 19
Troponin (ng/mL): 0,01
TSH (mIU/L): 4,56
Urea (mg/dL): 7,32
LVEF (%): 47.0
Medications: Angiotensin II Receptor Blocker, Beta Blockers, Loop Diuretics
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"RANKING: 
1. Survivor
REASONING: 

Based on the provided patient data, I would rank the patient as having a high likelihood of being a survivor. The patient's NYHA Class II indicates that they have moderate symptoms of heart failure, but it is still manageable with current medications. The patient's LVEF of 47% is significantly reduced, indicating severe left ventricular dysfunction, but it is not immediately life-threatening. The patient's elevated troponin level of 0.01 ng/mL is within the normal range, and the absence of any acute coronary syndromes or acute myocardial infarctions in the ECG impression suggests that the patient does not have an acute coronary event.

The patient's electrolyte and liver function tests are also within normal limits, and the patient's renal function is relatively preserved (creatinine level of 7.32 mg/dL). The patient's medications, including angiotensin II receptor blockers, beta blockers, and loop diuretics, are standard treatments for heart failure and are likely to be effective in managing the patient's symptoms.

The patient's Pro-BNP level of 2853 ng/L is elevated, indicating some degree of cardiac stress, but it is not extremely high, and the patient's hemoglobin and blood chemistry parameters are generally within normal limits. 

Overall, the patient's overall clinical picture suggests that they are likely to survive the next few years, but close monitoring and adjustments to their treatment plan may be necessary to optimize their outcomes.

RANKING: 
2. Sudden cardiac death
REASONING: 

Based on the patient's history of idiopathic dilated cardiomyopathy, the patient is at increased risk of sudden cardiac death. The patient's LVEF of 47% is significantly reduced, and the presence of ventricular extrasystoles and non-sustained ventricular tachycardia on the ECG impression increases the risk of arrhythmias, which can lead to sudden cardiac death.

However, the patient's current medications, including beta blockers, are likely to reduce the risk of arrhythmias, and the absence of any acute coronary syndromes or acute myocardial infarctions in the ECG impression suggests that the patient does not have an acute coronary event. The patient's troponin level is within normal limits, and the patient's overall clinical picture is not indicative of an acute myocardial infarction.

While the patient is at increased risk of sudden cardiac death, the presence of beta blockers and other medications that reduce the risk of arrhythmias, as well as the patient's relatively preserved renal function and electrolyte balance, suggest that the patient's risk of sudden cardiac death is not extremely high.

RANKING: 
3. Pump failure death
REASONING: 

Based on the patient's NYHA Class II symptoms and LVEF of 47%, the patient is at risk of progressive heart failure, which can lead to pump failure. However, the patient is currently receiving medications that are likely to slow the progression of heart failure, including beta blockers, which reduce the risk of pump failure.

The patient's elevated Pro-BNP level of 2853 ng/L indicates some degree of cardiac stress, but it is not extremely high, and the patient's hemoglobin and blood chemistry parameters are generally within normal limits. The patient's renal function is relatively preserved, and the absence of any acute coronary syndromes or acute myocardial infarctions in the ECG impression suggests that the patient does not have an acute coronary event.

While the patient is at risk of progressive heart failure, the presence of beta blockers and other medications that reduce the risk of pump failure, as well as the patient's relatively preserved renal function and electrolyte balance, suggest that the patient's risk of pump failure death is not extremely high.

However, the patient's LVEF of 47% is significantly reduced, and the patient's NYHA Class II symptoms suggest that the patient's heart failure is not well controlled, and the patient may require more aggressive treatment to prevent pump failure."
281,281,P0464,"Age: 52
Gender: Male 
Weight: 69 kg
Height: 160 cm
NYHA Class: II
Blood Pressure: 90/60 mmHg
Past Medical History: Valvular cardiomyopathy
Albumin (g/L): 44
ALT or GPT (IU/L): 11.0
AST or GOT (IU/L): 22.0
Total Cholesterol (mmol/L): 6,57
Creatinine (mmol/L): 53.0
Gamma-glutamil transpeptidase (IU/L): 18
Glucose (mmol/L): 4,8
Hemoglobin (g/L): 142.0
HDL (mmol/L): 1,45
Potassium (mEq/L): 4,4
LDL (mmol/L): 4,53
Sodium (mEq/L): 133.0
Protein (g/L): 73
T4 (ng/L): 14
Troponin (ng/mL): 0,01
TSH (mIU/L): 3,03
Urea (mg/dL): 5,49
LVEF (%): 30.0
Medications: Beta Blockers, Spironolactone, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: Unknown bradycardia code
            ",survivor,"RANKING: 
1. Survivor
REASONING: 
Based on the provided patient data, the patient's overall condition is quite concerning. The patient has a history of valvular cardiomyopathy, which is a significant risk factor for heart failure and arrhythmias. The patient's LVEF (left ventricular ejection fraction) is severely reduced at 30%, indicating left ventricular dysfunction. The presence of ventricular extrasystoles and polymorphic ventricular extrasystoles on the ECG suggests an increased risk of arrhythmias. 

However, the patient's blood pressure is relatively low (90/60 mmHg), which could be a sign of heart failure or another underlying condition. The patient's creatinine level is also elevated (53.0 mmol/L), indicating impaired kidney function, which is a common complication in heart failure patients. 

Despite these concerning findings, the patient is currently on beta blockers, spironolactone, and an ACE inhibitor, which are standard treatments for heart failure and hypertension. The patient's troponin levels are within normal limits, and the patient does not have any signs of acute myocardial infarction. The patient's glucose and hemoglobin levels are also within normal limits. 

Considering these factors, the patient's overall prognosis is more likely to be a survivor, given the presence of supportive treatments and the absence of acute life-threatening conditions. However, close monitoring and further evaluation are necessary to determine the patient's long-term prognosis and potential progression of their condition."
282,282,P0465,"Age: 69
Gender: Male 
Weight: 80 kg
Height: 170 cm
NYHA Class: II
Blood Pressure: 140/80 mmHg
Past Medical History: Idiopathic dilated cardiomyopathy, Diabetes, Dyslipemia, Hypertension
Albumin (g/L): 42
ALT or GPT (IU/L): 29.0
AST or GOT (IU/L): 21.0
Total Cholesterol (mmol/L): 3,21
Creatinine (mmol/L): 98.0
Gamma-glutamil transpeptidase (IU/L): 23
Glucose (mmol/L): 6,1
Hemoglobin (g/L): 149.0
HDL (mmol/L): 1,11
Potassium (mEq/L): 4,19
LDL (mmol/L): 1,58
Sodium (mEq/L): 140.0
Pro-BNP (ng/L): 799.0
Protein (g/L): 70
T3 (pg/dL): 0,0597
T4 (ng/L): 9,9
Troponin (ng/mL): 0,5
TSH (mIU/L): 0,73
Urea (mg/dL): 7,4
LVEF (%): 30.0
Medications: Beta Blockers, Digoxin, Loop Diuretics, Spironolactone, Statins, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: TPSV
        - Bradycardia: No
            ",survivor,"RANKING: 1. Survivor
REASONING: 

The patient's overall clinical presentation and laboratory results suggest a high risk of adverse cardiac events. The patient has a history of idiopathic dilated cardiomyopathy, which is a significant risk factor for cardiac mortality. The patient's LVEF of 30% is severely reduced, indicating significant left ventricular dysfunction.

The patient's elevated BNP level (799.0 ng/L) and elevated NT-proBNP level (not mentioned in the provided data, but implied by the high BNP level) suggest significant cardiac stress and strain. The presence of non-sustained ventricular tachycardia (NSVT) and polymorphic ventricular extrasystoles on ECG also indicate an increased risk of arrhythmias.

The patient's laboratory results show a slightly elevated creatinine level (98.0 mmol/L) and a low hemoglobin level (149.0 g/L), which may indicate some degree of renal impairment and anemia. The patient's lipid profile is not ideal, with high LDL and low HDL levels, which increases the risk of atherosclerotic cardiovascular disease.

Despite the presence of several comorbidities, the patient is currently taking a combination of medications that are standard for managing heart failure and arrhythmias, including beta blockers, digoxin, loop diuretics, spironolactone, statins, and an ACE inhibitor.

Given the patient's severe left ventricular dysfunction, elevated BNP levels, and presence of NSVT, I would rank the patient's prognosis as ""survivor"" with a high risk of adverse cardiac events, but with the possibility of significant morbidity and mortality in the next few years."
283,283,P0470,"Age: 73
Gender: Male 
Weight: 71 kg
Height: 158 cm
NYHA Class: II
Blood Pressure: 140/80 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Hypertension, Myocardial Infarction
Albumin (g/L): 33,8
ALT or GPT (IU/L): 11.0
AST or GOT (IU/L): 11.0
Total Cholesterol (mmol/L): 3,18
Creatinine (mmol/L): 124.0
Gamma-glutamil transpeptidase (IU/L): 20
Glucose (mmol/L): 4,4
Hemoglobin (g/L): 120.0
HDL (mmol/L): 0,87
Potassium (mEq/L): 3,65
LDL (mmol/L): 1,91
Sodium (mEq/L): 141.0
Pro-BNP (ng/L): 5374.0
Protein (g/L): 69
Troponin (ng/mL): 0,05
TSH (mIU/L): 0,68
Urea (mg/dL): 7,1
LVEF (%): 35.0
Medications: Loop Diuretics, Statins, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"RANKING: 1. Survivor
REASONING: 

The patient is a 73-year-old male with a history of ischemic dilated cardiomyopathy, hypertension, and myocardial infarction. His current NYHA class is II, indicating mild symptoms of heart failure. The patient's LVEF is significantly reduced at 35%, indicating severe left ventricular dysfunction. Despite these significant cardiac issues, the patient is currently taking medications for heart failure (loop diuretics, statins, and an ACE inhibitor), which suggests that his condition is being managed.

The patient's laboratory results show elevated levels of BNP (Pro-BNP), which is consistent with heart failure. However, the Troponin level is within normal limits, indicating that there is no acute myocardial infarction at the time of assessment.

The ECG impression is largely unremarkable, with no signs of ventricular tachycardia or bradycardia. The presence of ventricular extrasystoles (polymorphic) may be a concern, but it is not uncommon in patients with heart failure.

Considering these factors, the patient's overall prognosis is more favorable, and I would rank him as a survivor. The patient's current treatment regimen and lack of acute cardiac events make it more likely that he will survive for the next few years. However, close monitoring and adjustments to his treatment plan may be necessary to manage his heart failure and prevent further decline."
284,284,P0471,"Age: 74
Gender: Male 
Weight: 76 kg
Height: 164 cm
NYHA Class: II
Blood Pressure: 110/80 mmHg
Past Medical History: Hypertensive cardiomyopathy, Hypertension
Albumin (g/L): 33,8
ALT or GPT (IU/L): 25.0
AST or GOT (IU/L): 24.0
Total Cholesterol (mmol/L): 5,71
Creatinine (mmol/L): 106.0
Gamma-glutamil transpeptidase (IU/L): 19
Glucose (mmol/L): 4,3
Hemoglobin (g/L): 144.0
HDL (mmol/L): 1,36
Potassium (mEq/L): 4,05
LDL (mmol/L): 3,85
Sodium (mEq/L): 132.0
Pro-BNP (ng/L): 557.0
Protein (g/L): 57,7
Troponin (ng/mL): 0,02
TSH (mIU/L): 0,37
Urea (mg/dL): 6,8
LVEF (%): 70.0
Medications: Calcium Channel Blocker
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",survivor,"RANKING: 1. Survivor
REASONING: 

Based on the patient's age, NYHA Class II, and LVEF of 70%, which indicates mild systolic dysfunction, the patient is at risk for cardiac complications. However, the patient's current ECG and laboratory results do not show any signs of acute coronary syndrome or severe cardiac ischemia. The presence of hypertension and cardiomyopathy may contribute to the development of cardiac dysfunction, but the patient's current medication (Calcium Channel Blocker) is likely helping to manage these conditions.

The patient's troponin level is within normal limits, and the patient has no evidence of acute myocardial infarction or significant cardiac ischemia. The patient's renal function is also preserved, with a creatinine level of 6.8 mg/dL. These factors suggest that the patient is unlikely to experience sudden cardiac death or pump failure in the near future.

While the patient's age is 74, and there is a risk of cardiac complications, the patient's overall clinical presentation and laboratory results suggest that they are unlikely to experience sudden cardiac death or pump failure in the next few years. Therefore, the most likely prognosis is survivor."
285,285,P0472,"Age: 83
Gender: Male 
Weight: 67 kg
Height: 172 cm
NYHA Class: II
Blood Pressure: 105/55 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Diabetes, Hypertension, Myocardial Infarction
Albumin (g/L): 42,7
ALT or GPT (IU/L): 19.0
AST or GOT (IU/L): 23.0
Total Cholesterol (mmol/L): 3,65
Creatinine (mmol/L): 125.0
Gamma-glutamil transpeptidase (IU/L): 55
Glucose (mmol/L): 7,4
Hemoglobin (g/L): 128.0
HDL (mmol/L): 1,29
Potassium (mEq/L): 3,62
LDL (mmol/L): 1,84
Sodium (mEq/L): 136.0
Pro-BNP (ng/L): 4579.0
Protein (g/L): 74,9
Troponin (ng/mL): 0,09
TSH (mIU/L): 0,96
Urea (mg/dL): 12,2
LVEF (%): 60.0
Medications: Calcium Channel Blocker, Digoxin, Loop Diuretics, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",survivor,"RANKING: 1. Survivor 
REASONING: 

The patient's age, NYHA Class II, and the presence of ischemic dilated cardiomyopathy, diabetes, and hypertension suggest a significant cardiovascular burden. However, the patient's current hemoglobin level (128 g/L) and troponin level (0.09 ng/mL) indicate relatively preserved cardiac function. 

Additionally, the patient is on multiple medications, including a calcium channel blocker, digoxin, loop diuretics, and an ACE inhibitor, which are standard treatments for managing heart failure and hypertension. The patient's creatinine level (12.2 mg/dL) is elevated, but this could be due to various factors such as dehydration or kidney disease, rather than cardiac failure.

The patient's ECG findings of ventricular extrasystoles and unknown bradycardia code are concerning, but the absence of ventricular tachycardia and non-sustained ventricular tachycardia is a positive sign. The Pro-BNP level (4579 ng/L) is elevated, indicating some degree of heart failure, but it is not excessively high.

Considering these factors, the patient's overall prognosis is likely to be a survivor, with a moderate risk of complications. However, regular monitoring and adjustments to their medication regimen may be necessary to manage their heart failure and prevent further decline.

RANKING: 2. Pump failure death 
REASONING: 

Given the patient's elevated creatinine level and elevated Pro-BNP level, there is a moderate risk of pump failure. The patient's LVEF (60.0) is also below the normal range, indicating reduced cardiac function.

However, the patient's current hemoglobin level and troponin level suggest that they are not experiencing acute cardiac damage or significant ischemia at the moment. The patient's medications, including ACE inhibitors, are standard treatments for heart failure, which may help slow the progression of the disease.

While the patient's NYHA Class II indicates some limitation of physical activity, it does not necessarily indicate pump failure. Therefore, the risk of pump failure death is moderate, but not the most likely outcome.

RANKING: 3. Sudden cardiac death 
REASONING: 

The patient's ECG findings of ventricular extrasystoles are concerning, as they can increase the risk of sudden cardiac death. However, the absence of ventricular tachycardia and non-sustained ventricular tachycardia on the ECG reduces this risk.

The patient's elevated Pro-BNP level and LVEF below the normal range also suggest a higher risk of cardiac events, but the presence of multiple medications and the patient's relatively preserved cardiac function (hemoglobin and troponin levels) reduce this risk.

Considering the patient's age, medical history, and ECG findings, the risk of sudden cardiac death is moderate, but not the most likely outcome. Regular monitoring and adjustments to their medication regimen may help mitigate this risk.

However, the patient's overall prognosis is still leaning towards a survivor, as their cardiac function is not severely compromised, and they are receiving standard treatments for heart failure and hypertension."
286,286,P0474,"Age: 49
Gender: Male 
Weight: 88 kg
Height: 170 cm
NYHA Class: II
Blood Pressure: 110/75 mmHg
Past Medical History: Idiopathic dilated cardiomyopathy
Albumin (g/L): 45,9
ALT or GPT (IU/L): 20.0
AST or GOT (IU/L): 23.0
Total Cholesterol (mmol/L): 6,88
Creatinine (mmol/L): 100.0
Gamma-glutamil transpeptidase (IU/L): 22
Glucose (mmol/L): 5,9
Hemoglobin (g/L): 137.0
Potassium (mEq/L): 4,17
Sodium (mEq/L): 138.0
Pro-BNP (ng/L): 797.0
Protein (g/L): 82,1
Troponin (ng/mL): 0,01
TSH (mIU/L): 2,33
Urea (mg/dL): 9
LVEF (%): 19.0
Medications: Beta Blockers, Loop Diuretics, Spironolactone, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"RANKING: 
1. Survivor
REASONING: 
This patient has a complex clinical presentation with a history of idiopathic dilated cardiomyopathy, a reduced left ventricular ejection fraction (LVEF) of 19%, and elevated levels of N-terminal pro-b-type natriuretic peptide (Pro-BNP) at 797 ng/L, which suggests significant cardiac stress and potential heart failure. Despite these findings, the patient has a relatively preserved ejection fraction and no evidence of acute myocardial infarction or ventricular tachycardia on the ECG. The patient's current medications, including beta blockers, loop diuretics, and spironolactone, are standard treatments for heart failure and are likely effective in managing symptoms. The patient's hemoglobin and potassium levels are within normal ranges, and the liver enzymes are mildly elevated but not significantly abnormal. Overall, the combination of these factors suggests that the patient is likely to survive for the next few years with continued medical therapy and lifestyle modifications.

2. Pump failure death
REASONING: 
This patient's reduced LVEF and elevated Pro-BNP levels indicate significant cardiac dysfunction. While the patient is receiving standard treatments for heart failure, the degree of left ventricular dysfunction is substantial, and the patient's NYHA class is II, suggesting that symptoms are present but not severe. If left untreated or undertreated, this patient is at risk for progressive heart failure, which can lead to pump failure. The patient's elevated creatinine level (100.0 mol/L) may also indicate some degree of renal impairment, which can be a complication of heart failure. However, the presence of a normal potassium level and the absence of other signs of acute kidney injury or acute coronary syndrome reduce the likelihood of pump failure death in the short term.

3. Sudden cardiac death
REASONING: 
The patient's ECG shows ventricular extrasystoles, which may indicate an increased risk of ventricular arrhythmias. However, the absence of ventricular tachycardia or non-sustained ventricular tachycardia on the ECG reduces this risk. The patient's medication regimen includes beta blockers, which are effective in reducing the risk of ventricular arrhythmias. Additionally, the patient's ejection fraction is not severely reduced, and the patient's blood pressure is well-controlled, which further reduces the risk of sudden cardiac death. While there is a risk of arrhythmias, the combination of these factors suggests that sudden cardiac death is less likely in this patient."
287,287,P0475,"Age: 64
Gender: Female 
Weight: 73 kg
Height: 145 cm
NYHA Class: II
Blood Pressure: 115/70 mmHg
Past Medical History: Idiopathic dilated cardiomyopathy, Diabetes, Hypertension
Albumin (g/L): 43,2
ALT or GPT (IU/L): 26.0
AST or GOT (IU/L): 18.0
Total Cholesterol (mmol/L): 3,59
Creatinine (mmol/L): 149.0
Gamma-glutamil transpeptidase (IU/L): 46
Glucose (mmol/L): 6,6
Hemoglobin (g/L): 136.0
HDL (mmol/L): 1,38
Potassium (mEq/L): 4,6
LDL (mmol/L): 1,33
Sodium (mEq/L): 140.0
Pro-BNP (ng/L): 287.0
Protein (g/L): 77,6
Troponin (ng/mL): 0,01
TSH (mIU/L): 0,88
Urea (mg/dL): 15
LVEF (%): 35.0
Medications: Diabetes Medication, Amiodarone, Angiotensin II Receptor Blocker, Loop Diuretics, Spironolactone, Statins, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",survivor,"RANKING: 1. Survivor
REASONING: 
The patient's overall clinical presentation, lab results, and ECG findings suggest that the patient is at high risk for adverse cardiac events. The presence of idiopathic dilated cardiomyopathy, NYHA Class II heart failure, and a low LVEF of 35% indicate significant left ventricular dysfunction. The elevated creatinine level (149.0 mmol/L) and elevated Pro-BNP level (287.0 ng/L) further support the presence of heart failure. The patient's elevated troponin level (0.01 ng/mL) is also consistent with myocardial injury.

The patient's ECG shows ventricular extrasystoles, which can be a marker of electrical instability in the heart. The absence of ventricular tachycardia or non-sustained ventricular tachycardia may suggest that the patient is not currently experiencing a high-risk arrhythmia, but the presence of ventricular extrasystoles is still a cause for concern.

The patient's medication regimen, including Amiodarone and Spironolactone, suggests that the patient is being managed for heart failure and arrhythmias. However, the patient's high blood pressure (115/70 mmHg) is not well-controlled, and the patient's diabetes and hypertension are not well-managed.

Considering these factors, the patient is at high risk for cardiac events, including sudden cardiac death or pump failure. However, the patient's current ECG and laboratory results do not indicate an immediate life-threatening condition. Therefore, the most likely outcome for the next few years is that the patient will survive, but will require close monitoring and management to prevent further cardiac events.

RANKING: 2. Sudden cardiac death
REASONING: 
The patient's high-risk profile, including idiopathic dilated cardiomyopathy, NYHA Class II heart failure, and a low LVEF, makes them at risk for sudden cardiac death. The elevated Pro-BNP level and elevated creatinine level also indicate significant cardiac dysfunction.

The patient's ECG shows ventricular extrasystoles, which can be a marker of electrical instability in the heart. The absence of ventricular tachycardia or non-sustained ventricular tachycardia may suggest that the patient is not currently experiencing a high-risk arrhythmia, but the presence of ventricular extrasystoles is still a cause for concern.

The patient's high blood pressure (115/70 mmHg) is not well-controlled, and the patient's diabetes and hypertension are not well-managed. This increases the patient's risk for cardiac events.

While the patient is currently not experiencing a high-risk arrhythmia, the patient's underlying cardiac condition and risk factors make them at risk for sudden cardiac death in the future.

RANKING: 3. Pump failure death
REASONING: 
The patient's current clinical presentation, lab results, and ECG findings suggest that the patient is at risk for heart failure exacerbation and pump failure. The patient's elevated Pro-BNP level (287.0 ng/L) and elevated creatinine level (149.0 mmol/L) indicate significant cardiac dysfunction.

The patient's NYHA Class II heart failure and low LVEF (35%) indicate that the patient's heart is not functioning optimally, and the patient is at risk for pump failure.

The patient's ECG shows ventricular extrasystoles, which can be a marker of electrical instability in the heart. The absence of ventricular tachycardia or non-sustained ventricular tachycardia may suggest that the patient is not currently experiencing a high-risk arrhythmia, but the presence of ventricular extrasystoles is still a cause for concern.

The patient's high blood pressure (115/70 mmHg) is not well-controlled, and the patient's diabetes and hypertension are not well-managed. This increases the patient's risk for cardiac events.

While the patient is currently not experiencing a high-risk arrhythmia, the patient's underlying cardiac condition and risk factors make them at risk for pump failure in the future. However, the patient's survival and management of their condition suggest that pump failure death is less likely than sudden cardiac death."
288,288,P0476,"Age: 64
Gender: Male 
Weight: 93 kg
Height: 174 cm
NYHA Class: II
Blood Pressure: 103/57 mmHg
Past Medical History: Other HF etiology, Dyslipemia
Albumin (g/L): 41,8
ALT or GPT (IU/L): 37.0
AST or GOT (IU/L): 23.0
Total Cholesterol (mmol/L): 5,48
Creatinine (mmol/L): 111.0
Gamma-glutamil transpeptidase (IU/L): 21
Glucose (mmol/L): 4,8
Hemoglobin (g/L): 151.0
HDL (mmol/L): 2,09
Potassium (mEq/L): 4,4
LDL (mmol/L): 2,82
Sodium (mEq/L): 140.0
Pro-BNP (ng/L): 146.0
Protein (g/L): 68,2
T4 (ng/L): 20
TSH (mIU/L): 1,55
Urea (mg/dL): 10,48
LVEF (%): 38.0
Medications: Calcium Channel Blocker, Amiodarone, Beta Blockers, Statins, ACE Inhibitor, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: TPSV
        - Bradycardia: No
            ",survivor,"RANKING: 1. Survivor
REASONING:

The patient's age (64) and NYHA Class II status indicate a moderate level of heart failure, which increases the risk of cardiac complications. However, the patient's hemoglobin level (151.0 g/L) and normal kidney function (Creatinine 10.48 mg/dL) suggest relatively good overall health.

The patient's cardiac biomarkers are mostly within normal limits, with elevated Pro-BNP levels (146.0 ng/L) indicating some degree of heart failure. However, the patient is on ACE inhibitors and beta blockers, which are standard treatments for heart failure, and the LVEF is 38.0%, which is within the range for a patient with NYHA Class II.

The ECG impression does not indicate any significant arrhythmias, and the patient is not taking anti-arrhythmic medications for ventricular tachycardia or bradycardia. The presence of ventricular extrasystoles and polymorphic ventricular tachycardia may be concerning, but the absence of sustained ventricular tachycardia and paroxysmal supraventricular tachycardia reduces the risk of sudden cardiac death.

Given the patient's overall health status, medication regimen, and the absence of high-risk cardiac biomarkers, the likelihood of sudden cardiac death is low. The patient's heart failure status and elevated Pro-BNP levels do increase the risk of pump failure, but the patient is on medications that are effective for heart failure management.

Therefore, based on the provided data, the most likely outcome for the patient over the next few years is survivor."
289,289,P0478,"Age: 80
Gender: Male 
Weight: 63 kg
Height: 163 cm
NYHA Class: II
Blood Pressure: 110/60 mmHg
Past Medical History: Idiopathic dilated cardiomyopathy, Diabetes, Dyslipemia
Albumin (g/L): 44,4
ALT or GPT (IU/L): 15.0
AST or GOT (IU/L): 17.0
Total Cholesterol (mmol/L): 4,29
Creatinine (mmol/L): 103.0
Gamma-glutamil transpeptidase (IU/L): 16
Glucose (mmol/L): 7,2
Hemoglobin (g/L): 114.0
HDL (mmol/L): 1,09
Potassium (mEq/L): 4,4
LDL (mmol/L): 1,91
Sodium (mEq/L): 139.0
Pro-BNP (ng/L): 1544.0
Protein (g/L): 73,4
T4 (ng/L): 19
TSH (mIU/L): 0,38
Urea (mg/dL): 8,82
LVEF (%): 40.0
Medications: Diabetes Medication, Beta Blockers, Loop Diuretics, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"RANKING: 
1. Survivor
REASONING: 
The patient's age (80) is a significant factor in determining the prognosis. However, the patient's NYHA Class II heart failure classification suggests that they have some level of cardiac dysfunction, which may indicate a more advanced stage of heart disease. The patient's LVEF of 40% is also a concern, as it indicates significant left ventricular dysfunction.

Despite the patient's medical history of idiopathic dilated cardiomyopathy, diabetes, and dyslipidemia, the patient's current ECG findings, such as ventricular extrasystole and non-sustained ventricular tachycardia, are not extremely concerning. The patient's current medications, including beta blockers, loop diuretics, and an ACE inhibitor, are standard treatments for heart failure and may be contributing to their current stable condition.

The patient's laboratory values, including a slightly elevated creatinine level and a mildly elevated BNP level, suggest some degree of cardiac stress. However, the patient's hemoglobin level and other electrolyte values are within relatively normal limits.

Given these factors, the patient's overall prognosis is more likely to be a survivor, as they are receiving standard treatment for their heart failure and have not exhibited any severe cardiac arrhythmias or acute decompensation."
290,290,P0479,"Age: 72
Gender: Male 
Weight: 54 kg
Height: 151 cm
NYHA Class: II
Blood Pressure: 150/80 mmHg
Past Medical History: Idiopathic dilated cardiomyopathy, Dyslipemia
Albumin (g/L): 40
ALT or GPT (IU/L): 19.0
AST or GOT (IU/L): 22.0
Total Cholesterol (mmol/L): 6,67
Creatinine (mmol/L): 129.0
Gamma-glutamil transpeptidase (IU/L): 20
Glucose (mmol/L): 5,41
Hemoglobin (g/L): 160.0
HDL (mmol/L): 1,49
Potassium (mEq/L): 4,5
LDL (mmol/L): 4,48
Sodium (mEq/L): 141.0
Pro-BNP (ng/L): 624.0
Protein (g/L): 67
T3 (pg/dL): 0,0615
T4 (ng/L): 11,73
Troponin (ng/mL): 0,8
TSH (mIU/L): 6,94
Urea (mg/dL): 11,9
LVEF (%): 30.0
Medications: Amiodarone, Loop Diuretics, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"RANKING: 

1. Survivor
REASONING: 
Given the patient's age, NYHA Class II, and history of idiopathic dilated cardiomyopathy, the patient is already at a high risk for cardiac-related complications. The presence of non-sustained ventricular tachycardia (NSTVT) and polymorphic ventricular extrasystoles on the ECG is concerning for an increased risk of arrhythmic events. However, the patient's current symptoms and ECG findings do not suggest a life-threatening arrhythmia at this time. The patient's LVEF is severely impaired (30%), indicating advanced heart failure, but the patient is still on ACE inhibitors, which is a standard treatment for heart failure. The patient's medication regimen, including Amiodarone, also suggests a focus on managing arrhythmias. The patient's laboratory values are relatively stable, and there is no indication of acute myocardial infarction or severe kidney dysfunction. Overall, while the patient is at risk for cardiac complications, the combination of current symptoms, medication, and laboratory values suggests that the patient is likely to survive the next few years.

2. Sudden Cardiac Death
REASONING: 
The presence of non-sustained ventricular tachycardia (NSTVT) and polymorphic ventricular extrasystoles on the ECG is a significant risk factor for sudden cardiac death. While the patient is currently asymptomatic, the presence of these arrhythmias increases the risk of life-threatening arrhythmias. The patient's history of idiopathic dilated cardiomyopathy and current LVEF of 30% also contribute to the risk of cardiac events. However, the patient's current medication regimen and stable laboratory values suggest that the patient is not in an acute decompensated state.

3. Pump Failure Death
REASONING: 
Given the patient's severely impaired LVEF (30%) and NYHA Class II, the patient is already at a high risk for heart failure exacerbation. While the patient is on ACE inhibitors, which is a standard treatment for heart failure, the patient's current laboratory values (e.g., elevated creatinine, low albumin) suggest that the patient may not be optimally managed. The patient's history of dyslipidemia and elevated total cholesterol also contribute to the risk of cardiac events. However, the patient's current symptoms and medication regimen suggest that the patient is not in an acute decompensated state, and the patient is likely to survive the next few years."
291,291,P0484,"Age: 74
Gender: Female 
Weight: 83 kg
Height: 162 cm
NYHA Class: II
Blood Pressure: 140/80 mmHg
Past Medical History: Idiopathic dilated cardiomyopathy
Albumin (g/L): 46
ALT or GPT (IU/L): 30.0
AST or GOT (IU/L): 25.0
Total Cholesterol (mmol/L): 3,98
Creatinine (mmol/L): 79.0
Gamma-glutamil transpeptidase (IU/L): 22
Glucose (mmol/L): 9,4
Hemoglobin (g/L): 118.0
HDL (mmol/L): 0,72
Potassium (mEq/L): 4,4
LDL (mmol/L): 2,43
Sodium (mEq/L): 138.0
Pro-BNP (ng/L): 146.0
Protein (g/L): 77,5
T4 (ng/L): 6
TSH (mIU/L): 34,49
Urea (mg/dL): 6,82
LVEF (%): 35.0
Medications: Beta Blockers, Loop Diuretics, Spironolactone
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"RANKING: 

1. Survivor
REASONING:
The patient is a 74-year-old female with a history of idiopathic dilated cardiomyopathy, which is a significant risk factor for cardiac complications. However, the patient's current LVEF (Left Ventricular Ejection Fraction) is 35%, which is relatively preserved compared to the average LVEF for patients with dilated cardiomyopathy. The patient's NYHA Class is II, indicating mild symptoms, which suggests that the patient is not severely limited in her physical activities. 

The patient's laboratory results show elevated Pro-BNP levels (146 ng/L), which is consistent with heart failure, but not excessively high. The patient's creatinine level is elevated (6.82 mg/dL), indicating impaired renal function, which is a common comorbidity in patients with heart failure. The patient is also taking medications such as beta blockers, loop diuretics, and spironolactone, which are standard treatments for heart failure.

While the patient's ECG shows ventricular extrasystoles, which is a risk factor for sudden cardiac death, the absence of ventricular tachycardia or non-sustained ventricular tachycardia suggests that the patient does not have a high risk of arrhythmic events. The patient's hemoglobin and potassium levels are within normal limits, and the patient's lipid profile is relatively well-controlled.

Considering these factors, the patient's overall prognosis is good, and I predict that the patient will survive for the next few years with proper management and monitoring. The patient's age and comorbidities do pose some risks, but the patient's current clinical status and treatment plan suggest a relatively favorable outcome.

RANKING: 
2. Sudden cardiac death
REASONING:
The patient's ECG shows ventricular extrasystoles, which is a risk factor for sudden cardiac death. Additionally, the patient's LVEF is 35%, which is significantly reduced compared to the average LVEF for patients with dilated cardiomyopathy. The patient's Pro-BNP levels are elevated, indicating heart failure, which increases the risk of arrhythmic events.

While the patient is taking medications for heart failure, the patient's renal function is impaired, and the patient's lipid profile is not ideal. The patient's hemoglobin and potassium levels are within normal limits, but the patient's potassium level is slightly elevated (4.4 mEq/L), which may increase the risk of arrhythmias.

Considering these factors, while the patient's overall prognosis is still relatively good, the presence of ventricular extrasystoles and reduced LVEF increases the risk of sudden cardiac death. However, the patient's age and comorbidities do reduce the likelihood of sudden cardiac death.

RANKING: 
3. Pump failure death
REASONING:
The patient's LVEF is 35%, which is significantly reduced compared to the average LVEF for patients with dilated cardiomyopathy. The patient's Pro-BNP levels are elevated, indicating heart failure, and the patient's renal function is impaired. The patient's lipid profile is not ideal, and the patient is not taking medications to control high blood pressure or high cholesterol.

While the patient is taking medications for heart failure, the patient's renal function is impaired, which may reduce the effectiveness of these medications. The patient's hemoglobin and potassium levels are within normal limits, but the patient's potassium level is slightly elevated, which may increase the risk of arrhythmias.

Considering these factors, the patient's overall prognosis is guarded, and I predict that the patient is at risk of developing pump failure. The patient's age, comorbidities, and reduced LVEF increase the risk of complications, and the patient's impaired renal function and suboptimal lipid profile further reduce the likelihood of a favorable outcome."
292,292,P0485,"Age: 72
Gender: Male 
Weight: 78 kg
Height: 161 cm
NYHA Class: III
Blood Pressure: 160/80 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Diabetes, Hypertension, Myocardial Infarction
Albumin (g/L): 42,9
ALT or GPT (IU/L): 29.0
AST or GOT (IU/L): 22.0
Total Cholesterol (mmol/L): 4,37
Creatinine (mmol/L): 104.0
Gamma-glutamil transpeptidase (IU/L): 106
Glucose (mmol/L): 9,7
Hemoglobin (g/L): 122.0
HDL (mmol/L): 0,75
Potassium (mEq/L): 4,7
LDL (mmol/L): 1,91
Sodium (mEq/L): 140.0
Pro-BNP (ng/L): 903.0
Protein (g/L): 70
T4 (ng/L): 17
TSH (mIU/L): 1,44
Urea (mg/dL): 7,65
LVEF (%): 35.0
Medications: Diabetes Medication, Beta Blockers, Digoxin, Loop Diuretics, Spironolactone, Statins, ACE Inhibitor, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",survivor,"RANKING: 1. Survivor
REASONING: The patient's overall clinical presentation and laboratory results indicate a significant cardiac impairment, with a left ventricular ejection fraction (LVEF) of 35%, which suggests severe systolic dysfunction. The patient's NYHA class III classification indicates severe symptoms, and their medical history of ischemic dilated cardiomyopathy, myocardial infarction, and hypertension further supports the severity of their cardiac condition.

The elevated creatinine level (104.0 mmol/L) and elevated BNP level (903.0 ng/L) suggest impaired renal function and increased ventricular wall stress, respectively. The presence of ventricular extrasystoles and polymorphic ventricular extrasystoles on the ECG also indicate electrical instability, which is a risk factor for cardiac arrhythmias.

However, the patient is currently taking a comprehensive regimen of medications, including ACE inhibitors, beta blockers, and diuretics, which are standard treatments for heart failure and hypertension. The presence of a nitrovasodilator suggests an attempt to manage blood pressure and reduce afterload.

While the patient's prognosis is uncertain, their current medical regimen and the absence of any mention of significant symptoms or recent adverse events suggest that they may still be able to survive for the next few years with optimal management. Therefore, I rank survivor as the most likely outcome.

RANKING: 2. Sudden Cardiac Death
REASONING: Although the patient's current prognosis is uncertain, their history of ischemic dilated cardiomyopathy, myocardial infarction, and hypertension increases their risk of sudden cardiac death. The elevated BNP level and impaired renal function also suggest a high risk of cardiac decompensation.

The presence of ventricular extrasystoles and polymorphic ventricular extrasystoles on the ECG indicates an increased risk of arrhythmias, which can be a precursor to sudden cardiac death. While the patient is taking medications to manage their condition, the risk of arrhythmias cannot be entirely ruled out.

RANKING: 3. Pump Failure Death
REASONING: Pump failure death is a possible outcome for patients with severe cardiac impairment, but it is less likely in this case. The patient is currently receiving medications to manage their heart failure, including ACE inhibitors, beta blockers, and diuretics, which can help reduce symptoms and improve survival.

However, the patient's LVEF of 35% and elevated BNP level suggest that their cardiac function is severely impaired, and they may not be able to tolerate the demands of daily life without significant symptoms. While pump failure death is a concern, it is less likely than sudden cardiac death given the patient's current medical regimen and the absence of any recent adverse events."
293,293,P0486,"Age: 68
Gender: Male 
Weight: 83 kg
Height: 167 cm
NYHA Class: II
Blood Pressure: 140/80 mmHg
Past Medical History: Idiopathic dilated cardiomyopathy, Diabetes, Dyslipemia
Albumin (g/L): 48,1
ALT or GPT (IU/L): 15.0
AST or GOT (IU/L): 18.0
Total Cholesterol (mmol/L): 4,86
Creatinine (mmol/L): 74.0
Gamma-glutamil transpeptidase (IU/L): 25
Glucose (mmol/L): 7,5
Hemoglobin (g/L): 151.0
HDL (mmol/L): 1,53
Potassium (mEq/L): 5,4
LDL (mmol/L): 2,79
Sodium (mEq/L): 138.0
Pro-BNP (ng/L): 471.0
Protein (g/L): 78,9
T4 (ng/L): 19
TSH (mIU/L): 0,91
Urea (mg/dL): 5,32
LVEF (%): 40.0
Medications: Beta Blockers, Loop Diuretics, Statins, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",survivor,"RANKING: 1. Survivor
REASONING: 

The patient's age, NYHA Class II, and past medical history of idiopathic dilated cardiomyopathy, diabetes, and dyslipemia are significant risk factors for adverse outcomes. However, the patient is currently on optimal medical therapy with beta blockers, loop diuretics, statins, and an ACE inhibitor, which is standard of care for these conditions.

The patient's elevated creatinine level (74.0 mmol/L) and LVEF (40.0%) indicate compromised renal function and reduced cardiac function, respectively. The presence of non-sustained ventricular tachycardia (NSVT) on the ECG is a concerning sign, but it is not indicative of a specific cause of cardiac death. The patient's elevated Pro-BNP level (471.0 ng/L) suggests elevated ventricular wall stress.

Given these factors, the patient's overall prognosis is guarded, but not catastrophic. The patient's current medical therapy and relatively stable vital signs suggest that they are not at high risk of immediate cardiac death. Therefore, the most likely outcome for the next few years is that the patient will survive.

RANKING: 2. Pump failure death
REASONING: 

The patient's compromised cardiac function (LVEF 40.0%) and elevated Pro-BNP level (471.0 ng/L) indicate a high risk of heart failure. The patient's elevated creatinine level (74.0 mmol/L) also suggests impaired renal function, which can exacerbate heart failure.

The presence of non-sustained ventricular tachycardia (NSVT) on the ECG is a risk factor for cardiac arrhythmias, which can contribute to heart failure. The patient's elevated blood pressure (140/80 mmHg) and dyslipemia (Total Cholesterol 4.86 mmol/L) also contribute to cardiovascular risk.

Given these factors, the patient is at risk of developing heart failure, which can lead to pump failure. However, the patient's current medical therapy and relatively stable vital signs suggest that this outcome is not imminent.

RANKING: 3. Sudden cardiac death
REASONING: 

The patient's history of idiopathic dilated cardiomyopathy, non-sustained ventricular tachycardia (NSVT) on the ECG, and elevated Pro-BNP level (471.0 ng/L) increase the risk of sudden cardiac death. The patient's compromised cardiac function (LVEF 40.0%) and elevated creatinine level (74.0 mmol/L) also contribute to this risk.

However, the patient is currently on optimal medical therapy, and their vital signs are relatively stable, which reduces the likelihood of sudden cardiac death in the short term. Additionally, the patient's age (68) and NYHA Class II status suggest that they are not at high risk of sudden cardiac death.

Given these factors, the patient's risk of sudden cardiac death is moderate, but not extremely high. Therefore, this outcome is less likely than pump failure death but more likely than survival."
294,294,P0488,"Age: 31
Gender: Female 
Weight: 57 kg
Height: 164 cm
NYHA Class: II
Blood Pressure: 110/70 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Myocardial Infarction
Albumin (g/L): 47,3
ALT or GPT (IU/L): 11.0
AST or GOT (IU/L): 13.0
Total Cholesterol (mmol/L): 4,91
Creatinine (mmol/L): 55.0
Gamma-glutamil transpeptidase (IU/L): 9
Glucose (mmol/L): 5,2
Hemoglobin (g/L): 124.0
HDL (mmol/L): 1,24
Potassium (mEq/L): 4
LDL (mmol/L): 3,13
Sodium (mEq/L): 138.0
Pro-BNP (ng/L): 391.0
Protein (g/L): 85,5
T4 (ng/L): 14
TSH (mIU/L): 1,84
Urea (mg/dL): 4,82
LVEF (%): 25.0
Medications: Beta Blockers, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"RANKING: 
1. Survivor
REASONING: 
Based on the provided patient data, I predict that the patient is most likely to be a survivor. The patient's age (31) and NYHA Class II (mild symptoms) suggest that the patient's heart function is relatively preserved. The patient's LVEF (left ventricular ejection fraction) is 25.0%, which is significantly reduced, but not severely impaired. The presence of ventricular extrasystole and non-sustained ventricular tachycardia (VT) on ECG suggests underlying cardiac arrhythmias, but these are not indicative of a high-risk prognosis. The patient's medication regimen, which includes beta blockers and a nitrovasodilator, is standard for managing heart failure and arrhythmias. The patient's laboratory results, including normal blood pressure, normal kidney function (creatinine 4.82 mg/dL), and low urea (4.82 mg/dL), suggest that the patient's kidney function is preserved. The elevated Pro-BNP (391.0 ng/L) indicates some degree of heart failure, but it is not excessively high. Overall, these factors suggest that the patient's cardiac function is still relatively preserved, and the patient is likely to survive for the next few years.

RANKING: 2. Sudden cardiac death
REASONING: 
The patient's history of myocardial infarction and ischemic dilated cardiomyopathy increases the risk of sudden cardiac death. The patient's reduced LVEF (25.0%) and elevated Pro-BNP (391.0 ng/L) suggest that the patient's heart function is compromised, which increases the risk of arrhythmias and sudden cardiac death. The presence of ventricular extrasystole and non-sustained VT on ECG further supports this risk. However, the patient's relatively preserved kidney function and normal blood pressure reduce the likelihood of sudden cardiac death.

RANKING: 3. Pump failure death
REASONING: 
The patient's reduced LVEF (25.0%) and elevated Pro-BNP (391.0 ng/L) suggest that the patient's heart function is compromised, increasing the risk of heart failure. However, the patient's NYHA Class II (mild symptoms) and relatively preserved kidney function (creatinine 4.82 mg/dL) suggest that the patient's heart failure is not severe. Additionally, the patient's medication regimen, including beta blockers and a nitrovasodilator, is standard for managing heart failure. While the patient's risk of pump failure death cannot be ruled out, the combination of the patient's preserved kidney function and relatively mild symptoms reduces the likelihood of this outcome."
295,295,P0490,"Age: 74
Gender: Male 
Weight: 85 kg
Height: 177 cm
NYHA Class: II
Blood Pressure: 140/70 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Hypertension, Myocardial Infarction
Albumin (g/L): 43
ALT or GPT (IU/L): 54.0
AST or GOT (IU/L): 34.0
Total Cholesterol (mmol/L): 4,11
Creatinine (mmol/L): 150.0
Gamma-glutamil transpeptidase (IU/L): 155
Glucose (mmol/L): 6,9
Hemoglobin (g/L): 134.0
HDL (mmol/L): 0,88
Potassium (mEq/L): 4,3
LDL (mmol/L): 2,4
Sodium (mEq/L): 140.0
Pro-BNP (ng/L): 1375.0
Protein (g/L): 72
T4 (ng/L): 12
Troponin (ng/mL): 0,02
TSH (mIU/L): 2,79
Urea (mg/dL): 11,32
LVEF (%): 32.0
Medications: Beta Blockers, Loop Diuretics, Spironolactone, ACE Inhibitor, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"RANKING: 1. Survivor
REASONING: 

Based on the patient's data, I predict that the patient is most likely to be a survivor. Here's the reasoning behind this ranking:

1. NYHA Class II: The patient has a moderate level of heart failure symptoms, but they are still able to perform daily activities without severe limitation. This suggests that the patient's heart function is still relatively preserved, which is a positive prognostic indicator.
2. LVEF 32.0: The left ventricular ejection fraction (LVEF) is significantly reduced, indicating left ventricular dysfunction. However, it's not severely impaired, which suggests that the patient's heart can still pump blood effectively, albeit inefficiently.
3. No evidence of acute coronary syndrome: The patient's troponin levels are normal, and there is no mention of acute myocardial infarction or other acute coronary syndromes. This suggests that the patient's cardiac function is not currently under acute stress.
4. Medication regimen: The patient is on a comprehensive medication regimen that includes beta blockers, ACE inhibitors, and spironolactone, which are standard treatments for heart failure and hypertension. This suggests that the patient is receiving adequate management for their underlying conditions.
5. Low Pro-BNP levels: The patient's Pro-BNP levels are relatively low, which is a good indicator of heart failure severity. Elevated Pro-BNP levels are often associated with more severe heart failure.
6. Absence of other high-risk factors: There are no other high-risk factors mentioned, such as severe hypertension, diabetes, or significant kidney disease, which could indicate a higher risk of adverse outcomes.

While the patient has significant underlying heart disease, their current clinical status and treatment regimen suggest that they are at lower risk for adverse outcomes. Therefore, I predict that the patient is most likely to survive over the next few years."
296,296,P0492,"Age: 40
Gender: Male 
Weight: 73 kg
Height: 168 cm
NYHA Class: II
Blood Pressure: 100/70 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Diabetes, Dyslipemia, Myocardial Infarction
Albumin (g/L): 45
ALT or GPT (IU/L): 36.0
AST or GOT (IU/L): 14.0
Total Cholesterol (mmol/L): 3,7
Creatinine (mmol/L): 80.0
Gamma-glutamil transpeptidase (IU/L): 20
Glucose (mmol/L): 6,2
Hemoglobin (g/L): 136.0
HDL (mmol/L): 0,83
Potassium (mEq/L): 4,4
LDL (mmol/L): 1,94
Sodium (mEq/L): 141.0
Pro-BNP (ng/L): 575.0
Protein (g/L): 69
T4 (ng/L): 14
Troponin (ng/mL): 0,04
TSH (mIU/L): 2,59
Urea (mg/dL): 4,16
LVEF (%): 31.0
Medications: Calcium Channel Blocker, Diabetes Medication, Loop Diuretics, Statins, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"RANKING: 1. Survivor
REASONING:

This patient has a complex medical history, including ischemic dilated cardiomyopathy, diabetes, dyslipemia, and a history of myocardial infarction. However, the patient's current ECG impression does not show any signs of ventricular tachycardia or non-sustained ventricular tachycardia, which are common precursors to sudden cardiac death. 

Additionally, the patient's LVEF is 31%, which is relatively preserved compared to the average LVEF of 40-50% for patients with ischemic dilated cardiomyopathy. The patient's blood pressure is well-controlled (100/70 mmHg), and they are on medications that are commonly used to manage heart failure, such as ACE inhibitors, loop diuretics, and statins.

The patient's renal function is also relatively preserved, with a creatinine level of 4.16 mg/dL, which is not severely impaired. The patient's electrolyte levels are also relatively normal, with a potassium level of 4.4 mEq/L.

The patient's troponin level is 0.04 ng/mL, which is within the normal range. The patient's BNP level is elevated at 575 ng/L, but this is not uncommon in patients with heart failure.

Given these factors, I believe that the patient is at a lower risk for sudden cardiac death and pump failure in the next few years. Therefore, the most likely prognosis is that the patient will survive.

While the patient's past medical history and current medical conditions do increase their risk for adverse outcomes, the patient's current clinical presentation and laboratory results do not suggest an immediate high risk for sudden cardiac death or pump failure."
297,297,P0493,"Age: 67
Gender: Male 
Weight: 80 kg
Height: 175 cm
NYHA Class: II
Blood Pressure: 130/70 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Myocardial Infarction
Albumin (g/L): 40
ALT or GPT (IU/L): 49.0
AST or GOT (IU/L): 18.0
Total Cholesterol (mmol/L): 4,34
Creatinine (mmol/L): 71.0
Gamma-glutamil transpeptidase (IU/L): 75
Glucose (mmol/L): 5
Hemoglobin (g/L): 157.0
HDL (mmol/L): 1,4
Potassium (mEq/L): 4,2
LDL (mmol/L): 2,56
Sodium (mEq/L): 141.0
Pro-BNP (ng/L): 248.0
Protein (g/L): 75
T4 (ng/L): 10
Troponin (ng/mL): 0,09
TSH (mIU/L): 1,87
Urea (mg/dL): 4,16
LVEF (%): 35.0
Medications: Beta Blockers, Statins
ECG Impression:
        - Ventricular Extrasystole: Unknown ventricular extrasystole code
        - Ventricular Tachycardia: Unknown ventricular tachycardia code
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",survivor,"RANKING: 
1. Survivor
REASONING: 
Given the patient's age, NYHA Class II, and LVEF of 35%, the patient is already showing signs of advanced cardiac dysfunction. However, the absence of any evidence of acute myocardial infarction or significant arrhythmias (e.g., ventricular tachycardia, ventricular extrasystoles) in the ECG impression suggests that the patient may not be in an acute decompensated state. The presence of beta blockers and statins indicates that the patient is already on standard medical therapy for heart failure and lipid management. The elevated troponin level is not significantly elevated, suggesting that the patient may not have had a recent myocardial infarction. Additionally, the patient's hemoglobin and kidney function are relatively preserved, which may indicate that the patient is not in a state of severe cardiac decompensation. Overall, these factors suggest that the patient may be able to survive for the next few years with proper medical management and monitoring. 

2. Sudden cardiac death
REASONING: 
The patient's LVEF of 35% and NYHA Class II indicate significant cardiac dysfunction, which increases the risk of sudden cardiac death. However, the patient is not in an acute decompensated state, and the absence of evidence of ventricular tachycardia or other arrhythmias in the ECG impression reduces the likelihood of sudden cardiac death. The patient's elevated creatinine level and reduced kidney function may increase the risk of cardiac complications, but this is not sufficient to predict sudden cardiac death. 

3. Pump failure death
REASONING: 
The patient's LVEF of 35% and NYHA Class II indicate significant cardiac dysfunction, which increases the risk of heart failure exacerbation and pump failure. However, the patient is already on beta blockers and statins, which are standard treatments for heart failure management. The patient's hemoglobin and kidney function are relatively preserved, which may indicate that the patient is not in a state of severe cardiac decompensation. However, the patient's elevated creatinine level and reduced kidney function may increase the risk of cardiac complications, making pump failure death a possible but less likely outcome compared to sudden cardiac death."
298,298,P0495,"Age: 47
Gender: Male 
Weight: 89 kg
Height: 165 cm
NYHA Class: II
Blood Pressure: 130/70 mmHg
Past Medical History: Idiopathic dilated cardiomyopathy, Dyslipemia
Albumin (g/L): 42
ALT or GPT (IU/L): 43.0
AST or GOT (IU/L): 15.0
Total Cholesterol (mmol/L): 8,2
Creatinine (mmol/L): 88.0
Gamma-glutamil transpeptidase (IU/L): 56
Glucose (mmol/L): 7,5
Hemoglobin (g/L): 163.0
HDL (mmol/L): 0,83
Potassium (mEq/L): 4,3
LDL (mmol/L): 5,95
Sodium (mEq/L): 136.0
Pro-BNP (ng/L): 543.0
Protein (g/L): 79
T4 (ng/L): 12
Troponin (ng/mL): 0,01
TSH (mIU/L): 1,2
Urea (mg/dL): 4,99
LVEF (%): 35.0
Medications: Beta Blockers, Loop Diuretics, Statins, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",survivor,"RANKING: 

1. Survivor
REASONING: 
The patient is a 47-year-old male with a history of idiopathic dilated cardiomyopathy, which is a significant risk factor for cardiac events. However, the patient has a relatively preserved ejection fraction (LVEF 35%) and no evidence of acute myocardial infarction (Troponin 0.01 ng/mL). The patient is also on medications that are commonly used in the management of heart failure (Beta Blockers, Loop Diuretics, Statins, ACE Inhibitor). The patient's current NYHA Class II indicates mild symptoms, which is a good prognostic indicator for survival. Additionally, the patient's electrolytes, renal function, and liver function are relatively preserved. The presence of ventricular extrasystoles on the ECG may indicate a risk for arrhythmias, but the absence of ventricular tachycardia or non-sustained ventricular tachycardia suggests that the risk is not excessively high. Overall, the combination of preserved LVEF, mild symptoms, and the presence of a well-managed medication regimen suggest a relatively favorable prognosis for the patient to survive in the next few years."
299,299,P0497,"Age: 47
Gender: Male 
Weight: 88 kg
Height: 189 cm
NYHA Class: II
Blood Pressure: 115/70 mmHg
Past Medical History: Toxic dilated cardiomyopathy
Albumin (g/L): 43,4
ALT or GPT (IU/L): 25.0
AST or GOT (IU/L): 19.0
Total Cholesterol (mmol/L): 5,66
Creatinine (mmol/L): 107.0
Gamma-glutamil transpeptidase (IU/L): 22
Glucose (mmol/L): 4,7
Hemoglobin (g/L): 117.0
HDL (mmol/L): 1,22
Potassium (mEq/L): 3,73
LDL (mmol/L): 3,4
Sodium (mEq/L): 141.0
Pro-BNP (ng/L): 435.0
Protein (g/L): 69,9
Troponin (ng/mL): 0,01
TSH (mIU/L): 2,72
Urea (mg/dL): 9,2
LVEF (%): 55.0
Medications: Beta Blockers, Digoxin, Loop Diuretics, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"RANKING: 
1. Survivor
REASONING: 
This patient has several factors that suggest a favorable prognosis. Firstly, their age is 47, which is considered relatively young for heart failure. The patient's NYHA Class is II, indicating mild symptoms, which is a good indicator of functional capacity. Additionally, their LVEF is 55%, which is relatively preserved, suggesting that the heart is still functioning to some extent.

The patient's laboratory results also show relatively normal liver function, normal electrolytes, and low levels of inflammatory markers (ALT, AST, and Troponin). The presence of an elevated Pro-BNP level may indicate some degree of cardiac stress, but it is not extremely high, which could suggest a more severe disease process.

The patient is also taking medications that are commonly used to manage heart failure, such as beta blockers, digoxin, loop diuretics, and ACE inhibitors, which can help to slow the progression of the disease. The absence of any significant electrolyte imbalances or acute kidney injury (indicated by normal urea and creatinine levels) also suggests that the patient is not in acute distress.

The ECG findings do show some signs of cardiac stress, including ventricular extrasystoles, but these are not indicative of a high risk of sudden cardiac death. Overall, considering these factors, the patient's prognosis is likely to be good, and they are more likely to survive for the next few years.

2. Sudden cardiac death
REASONING: 
The patient's history of toxic dilated cardiomyopathy increases their risk of sudden cardiac death. This condition can lead to life-threatening arrhythmias and sudden cardiac arrest. Although the patient is on medications that can help manage heart failure, the presence of ventricular extrasystoles on the ECG is a concern.

The patient's elevated Pro-BNP level and mildly reduced LVEF (55%) also suggest that the heart is under significant stress, which can increase the risk of sudden cardiac death. The patient's electrolyte levels, including potassium, are also within normal limits, but the patient's hemoglobin level is slightly elevated, which could potentially lead to cardiac arrhythmias.

3. Pump failure death
REASONING: 
The patient's LVEF is 55%, which is below the normal range for a healthy individual, indicating some degree of cardiac dysfunction. The patient's NYHA Class is II, which suggests that the patient is experiencing some symptoms of heart failure, such as shortness of breath or fatigue. While the patient is on medications that can help manage heart failure, the patient's LVEF is not significantly improved, and the patient's Pro-BNP level is elevated, indicating ongoing cardiac stress.

The patient's elevated creatinine level (107.0) and slightly elevated urea level (9.2) suggest some degree of renal impairment, which can be a complication of heart failure. While the patient is on medications that can help manage these symptoms, the patient's overall clinical picture suggests that the patient is at risk of developing heart failure, which could lead to pump failure."
300,300,P0502,"Age: 57
Gender: Male 
Weight: 86 kg
Height: 174 cm
NYHA Class: II
Blood Pressure: 105/75 mmHg
Past Medical History: Idiopathic dilated cardiomyopathy
Albumin (g/L): 41,3
ALT or GPT (IU/L): 13.0
AST or GOT (IU/L): 20.0
Total Cholesterol (mmol/L): 6,37
Creatinine (mmol/L): 99.0
Gamma-glutamil transpeptidase (IU/L): 60
Glucose (mmol/L): 5,3
Hemoglobin (g/L): 148.0
Potassium (mEq/L): 4,22
Sodium (mEq/L): 140.0
Protein (g/L): 73,2
Troponin (ng/mL): 0,01
TSH (mIU/L): 1,87
Urea (mg/dL): 6
LVEF (%): 17.0
Medications: Beta Blockers, Loop Diuretics, Spironolactone, ACE Inhibitor, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"RANKING: 

1. Survivor
REASONING: 
Given the patient's NYHA Class II status, which indicates mild heart failure, and the presence of idiopathic dilated cardiomyopathy, a condition that affects the heart's pumping ability, the patient is already experiencing some degree of cardiac dysfunction. However, the patient's LVEF is 17.0%, which is still within the range of moderate heart failure (LVEF < 35%). The patient's current medications, including beta blockers, loop diuretics, spironolactone, and an ACE inhibitor, are commonly used to manage heart failure and reduce the risk of complications.

The patient's troponin level is within normal limits, and there is no evidence of acute myocardial infarction or significant cardiac ischemia. The ECG findings, including ventricular extrasystole and polymorphic ventricular extrasystole, indicate some degree of cardiac electrical instability, but not to the extent that it would immediately suggest a high risk of sudden cardiac death.

The patient's laboratory values, such as creatinine, urea, and liver enzymes, are within normal limits or not significantly elevated, suggesting that the patient is not experiencing acute kidney injury or liver dysfunction that could contribute to a poor prognosis.

Considering these factors, the patient is more likely to survive in the short term, and with proper management of their heart failure and cardiac rhythm, they can potentially improve their condition and avoid a worse outcome.

2. Sudden cardiac death
REASONING: 
The patient's NYHA Class II status and LVEF of 17.0% indicate some degree of cardiac dysfunction, but the patient's current medications and laboratory values do not suggest an immediate risk of sudden cardiac death. However, the presence of ventricular extrasystoles and polymorphic ventricular extrasystoles on the ECG could increase the risk of arrhythmic events.

Additionally, the patient's family history of idiopathic dilated cardiomyopathy is a risk factor for sudden cardiac death, and the patient's age and sex are also risk factors for cardiac arrhythmias. However, the patient's current medications and the lack of other significant risk factors (e.g., high blood pressure, diabetes, or coronary artery disease) reduce the likelihood of sudden cardiac death.

3. Pump failure death
REASONING: 
The patient's current NYHA Class II status and LVEF of 17.0% indicate that the patient is experiencing some degree of heart failure, but the patient's medications and laboratory values suggest that the patient is not at high risk of pump failure. The patient's creatinine and urea levels are within normal limits, and the patient's liver enzymes are not significantly elevated, suggesting that the patient is not experiencing acute kidney injury or liver dysfunction that could contribute to pump failure.

Additionally, the patient's troponin level is within normal limits, and the ECG findings do not suggest a significant risk of cardiac ischemia or acute myocardial infarction. While the patient's heart failure is present, the patient's current medications and laboratory values suggest that the patient can be managed with optimal medical therapy, reducing the risk of pump failure."
301,301,P0503,"Age: 47
Gender: Male 
Weight: 92 kg
Height: 165 cm
NYHA Class: II
Blood Pressure: 130/100 mmHg
Past Medical History: Idiopathic dilated cardiomyopathy, Myocardial Infarction
Albumin (g/L): 46
ALT or GPT (IU/L): 39.0
AST or GOT (IU/L): 21.0
Total Cholesterol (mmol/L): 5,59
Creatinine (mmol/L): 127.0
Gamma-glutamil transpeptidase (IU/L): 63
Glucose (mmol/L): 6,5
Hemoglobin (g/L): 172.0
HDL (mmol/L): 0,71
Potassium (mEq/L): 4,41
LDL (mmol/L): 4
Sodium (mEq/L): 138.0
Pro-BNP (ng/L): 1129.0
Protein (g/L): 78
Troponin (ng/mL): 0,01
TSH (mIU/L): 2,47
Urea (mg/dL): 13,2
LVEF (%): 17.0
Medications: Beta Blockers, Loop Diuretics, Spironolactone, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"RANKING: 

1. Survivor
REASONING: 
The patient's age (47) is relatively young, and the presence of idiopathic dilated cardiomyopathy (IDC) and myocardial infarction in the past may suggest that the patient's cardiac condition is severe. However, the patient is receiving medications for heart failure (beta blockers, loop diuretics, spironolactone, and ACE inhibitor) and has a relatively low troponin level (0.01 ng/mL), indicating minimal myocardial damage. The patient's LVEF is 17%, which is a significant reduction in left ventricular function, but not as severe as what is typically seen in advanced heart failure. The patient's Pro-BNP level is elevated (1129 ng/L), indicating some degree of ventricular stress. Considering these factors, the patient's overall prognosis is more favorable than severe, but the presence of IDC and myocardial infarction suggests that the patient is at risk for further cardiac events. 

2. Sudden Cardiac Death
REASONING: 
The patient's history of myocardial infarction and idiopathic dilated cardiomyopathy increases the risk of sudden cardiac death. The patient's LVEF of 17% is significantly reduced, which can lead to arrhythmias and sudden cardiac death. The presence of ventricular extrasystoles on the ECG impression also suggests an increased risk of arrhythmias. Although the patient is receiving medications for heart failure, the medications may not be sufficient to completely mitigate the risks associated with IDC and myocardial infarction.

3. Pump Failure Death
REASONING: 
The patient's LVEF is 17%, which indicates severe left ventricular dysfunction and a high risk of pump failure. The patient's elevated Pro-BNP level (1129 ng/L) and elevated creatinine level (13.2 mg/dL) also suggest significant ventricular stress and renal impairment. The patient's symptoms and laboratory results indicate that the patient is already experiencing heart failure, and the presence of ventricular extrasystoles on the ECG impression suggests an increased risk of arrhythmias and further cardiac decompensation. While the patient is receiving medications for heart failure, the severity of the patient's cardiac condition and the presence of renal impairment suggest that pump failure is a likely outcome in the near future."
302,302,P0505,"Age: 79
Gender: Female 
Weight: 78 kg
Height: 158 cm
NYHA Class: III
Blood Pressure: 120/80 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Diabetes, Dyslipemia, Hypertension, Myocardial Infarction
Albumin (g/L): 43,8
ALT or GPT (IU/L): 25.0
AST or GOT (IU/L): 25.0
Total Cholesterol (mmol/L): 3,44
Creatinine (mmol/L): 95.0
Gamma-glutamil transpeptidase (IU/L): 24
Glucose (mmol/L): 6,1
Hemoglobin (g/L): 143.0
HDL (mmol/L): 0,96
Potassium (mEq/L): 4,1
LDL (mmol/L): 1,24
Sodium (mEq/L): 139.0
Pro-BNP (ng/L): 593.0
Protein (g/L): 76
T3 (pg/dL): 0,04
T4 (ng/L): 15
Troponin (ng/mL): 0,01
TSH (mIU/L): 4,56
Urea (mg/dL): 8,02
LVEF (%): 50.0
Medications: Calcium Channel Blocker, Diabetes Medication, Beta Blockers, Digoxin, Loop Diuretics, Statins, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"RANKING: 1. Survivor

REASONING: 

Based on the patient's data, the patient is likely to survive for the next few years. Here's why:

1. The patient's age is 79, which is considered old, but not extremely high-risk for mortality. According to the American College of Cardiology/American Heart Association (ACC/AHA) guidelines, the 10-year mortality rate for patients with heart failure and an LVEF of 50% is around 50-60%. However, this rate can be lower for patients with a history of coronary artery disease, diabetes, and hypertension, which this patient has.

2. The patient's NYHA class is III, indicating severe heart failure. However, the patient is already receiving treatment with medications such as digoxin, loop diuretics, and beta blockers, which are standard treatments for heart failure.

3. The patient's biomarkers are not excessively elevated. The Troponin level is 0.01 ng/mL, which is within the normal range. The Pro-BNP level is 593 ng/L, which is elevated but not extremely high.

4. The patient's ECG shows non-sustained ventricular tachycardia, which is a concerning finding. However, the patient is already receiving a nitrovasodilator, which may help to manage this condition.

5. The patient's other medications, such as calcium channel blockers, statins, and diabetes medication, are standard treatments for various cardiovascular conditions.

Considering these factors, I believe that the patient is likely to survive for the next few years with proper management and monitoring. However, regular follow-up appointments and adjustments to the treatment plan may be necessary to ensure the patient's condition does not worsen.

RANKING: 2. Sudden cardiac death

REASONING: 

While the patient is unlikely to die from heart failure, the patient's ECG shows non-sustained ventricular tachycardia, which is a risk factor for sudden cardiac death. The patient's age, NYHA class, and other comorbidities also increase the risk of sudden cardiac death.

RANKING: 3. Pump failure death

REASONING: 

The patient's LVEF is 50%, which is significantly below the normal range. This indicates that the patient's heart is not functioning optimally, which increases the risk of pump failure. Additionally, the patient's NYHA class is III, indicating severe heart failure. While the patient is receiving treatment, the risk of pump failure is still a concern, especially if the treatment is not effective or if the patient's condition worsens."
303,303,P0506,"Age: 71
Gender: Female 
Weight: 63 kg
Height: 145 cm
NYHA Class: II
Blood Pressure: 110/50 mmHg
Past Medical History: Idiopathic dilated cardiomyopathy, Dyslipemia, Hypertension
Albumin (g/L): 44
ALT or GPT (IU/L): 32.0
AST or GOT (IU/L): 30.0
Total Cholesterol (mmol/L): 5,02
Creatinine (mmol/L): 80.0
Gamma-glutamil transpeptidase (IU/L): 32
Glucose (mmol/L): 7,3
Hemoglobin (g/L): 135.0
HDL (mmol/L): 1,47
Potassium (mEq/L): 4,7
LDL (mmol/L): 2,59
Sodium (mEq/L): 142.0
Pro-BNP (ng/L): 673.0
Protein (g/L): 69
T3 (pg/dL): 0,04
T4 (ng/L): 17
Troponin (ng/mL): 0,01
TSH (mIU/L): 2,03
Urea (mg/dL): 7,15
LVEF (%): 65.0
Medications: Angiotensin II Receptor Blocker, Beta Blockers, Loop Diuretics
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",survivor,"RANKING: 
1. Survivor 
REASONING: 
Based on the provided patient data, the patient's age, NYHA Class II heart failure, and the presence of idiopathic dilated cardiomyopathy are significant risk factors for adverse outcomes. However, the patient's current ejection fraction (LVEF) of 65% is relatively preserved, indicating that the heart is still functioning adequately to meet the body's demands. The patient's blood pressure, hemoglobin, and electrolyte levels are also relatively stable. The absence of troponin elevation and a normal TSH level suggest that there is no acute myocardial infarction or thyroid dysfunction. The patient's medication regimen, which includes an angiotensin II receptor blocker, beta blockers, and loop diuretics, is standard for managing heart failure. The ECG findings of ventricular extrasystole and polymorphic ventricular tachycardia are concerning but not indicative of a high risk of sudden cardiac death. Overall, the patient's clinical presentation and test results suggest that the patient is at a relatively low risk of sudden cardiac death and pump failure in the short term. Therefore, the most likely outcome is that the patient will survive."
304,304,P0507,"Age: 45
Gender: Male 
Weight: 90 kg
Height: 171 cm
NYHA Class: II
Blood Pressure: 120/80 mmHg
Past Medical History: Idiopathic dilated cardiomyopathy, Hypertension
Albumin (g/L): 43
ALT or GPT (IU/L): 17.0
AST or GOT (IU/L): 17.0
Total Cholesterol (mmol/L): 4,78
Creatinine (mmol/L): 88.0
Gamma-glutamil transpeptidase (IU/L): 14
Glucose (mmol/L): 4,7
Hemoglobin (g/L): 133.0
HDL (mmol/L): 0,93
Potassium (mEq/L): 4,4
LDL (mmol/L): 2,95
Sodium (mEq/L): 139.0
Pro-BNP (ng/L): 89.0
Protein (g/L): 75
T3 (pg/dL): 0,04
T4 (ng/L): 17
Troponin (ng/mL): 0,01
TSH (mIU/L): 1,23
Urea (mg/dL): 7,99
LVEF (%): 55.0
Medications: Beta Blockers, Loop Diuretics, Spironolactone, Statins, ACE Inhibitor, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: No
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"RANKING: 

1. Survivor
REASONING: 
Given the patient's age, NYHA Class II, and the presence of idiopathic dilated cardiomyopathy, the patient is already in a relatively advanced stage of heart disease. However, the absence of any severe arrhythmias or significant elevation in biomarkers such as troponin suggests that the heart muscle is not currently under significant stress. The patient is also on optimal medical therapy for their condition, including beta blockers, ACE inhibitors, and statins. The relatively low levels of natriuretic peptides (Pro-BNP) and the patient's relatively normal kidney function (creatinine 88.0 mol/L) suggest that the patient's heart is not currently failing catastrophically. 

2. Sudden Cardiac Death
REASONING: 
The patient's LVEF is 55%, indicating a significant impairment of cardiac function. While the patient is on optimal medical therapy, the fact that their LVEF is so low suggests that the heart is not functioning optimally, and the patient is at risk for cardiac events. The patient's low ejection fraction, combined with their NYHA Class II status, puts them at higher risk for cardiac events such as sudden cardiac death. However, the patient's current biomarkers do not indicate an acute myocardial infarction or significant cardiac stress.

3. Pump Failure Death
REASONING: 
The patient's LVEF is 55%, which is a significant impairment of cardiac function. The patient's NYHA Class II status indicates that they are experiencing symptoms of heart failure, which could lead to pump failure. However, the patient is currently on optimal medical therapy, and their kidney function is relatively preserved. While the patient's heart is not functioning optimally, the fact that they are not experiencing severe symptoms of heart failure at this time suggests that pump failure is not imminent."
305,305,P0508,"Age: 66
Gender: Male 
Weight: 77 kg
Height: 162 cm
NYHA Class: II
Blood Pressure: 150/60 mmHg
Past Medical History: Idiopathic dilated cardiomyopathy
Albumin (g/L): 44
ALT or GPT (IU/L): 28.0
AST or GOT (IU/L): 21.0
Total Cholesterol (mmol/L): 6,65
Creatinine (mmol/L): 94.0
Gamma-glutamil transpeptidase (IU/L): 23
Glucose (mmol/L): 5,3
Hemoglobin (g/L): 146.0
HDL (mmol/L): 1,6
Potassium (mEq/L): 4,62
LDL (mmol/L): 4,32
Sodium (mEq/L): 140.0
Pro-BNP (ng/L): 200.0
Protein (g/L): 74,5
T3 (pg/dL): 0,0669
T4 (ng/L): 15,24
Troponin (ng/mL): 0,5
TSH (mIU/L): 1,35
Urea (mg/dL): 5,3
LVEF (%): 35.0
Medications: Loop Diuretics, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"RANKING: 1. Survivor
REASONING: 

This patient is at high risk of sudden cardiac death (SCD) due to their history of idiopathic dilated cardiomyopathy, which is a well-established risk factor for SCD. The patient's left ventricular ejection fraction (LVEF) is severely impaired at 35%, indicating significant cardiac dysfunction. Additionally, the presence of non-sustained ventricular tachycardia (NSVT) and ventricular extrasystole on the ECG suggests a high risk of arrhythmias, which are a major contributor to SCD.

The patient's blood pressure is slightly elevated at 150/60 mmHg, but this is not a significant concern given their NYHA class II status, indicating mild symptoms. The presence of proteinuria (albumin 44 g/L) suggests some degree of renal impairment, but this is not directly related to the cardiac condition.

The patient's medication regimen includes loop diuretics and an ACE inhibitor, which are standard treatments for heart failure and hypertension. However, these medications do not address the underlying cardiac dysfunction or the risk of arrhythmias.

The patient's biomarkers, such as troponin and BNP, indicate some degree of cardiac stress and strain, but are not indicative of acute myocardial infarction or severe heart failure.

Given the patient's high risk of arrhythmias and cardiac dysfunction, the most likely outcome over the next few years is a survivor. However, close monitoring and optimization of their medication regimen and lifestyle modifications are crucial to reduce the risk of SCD.

RANKING: 2. Pump failure death
REASONING: 

Pump failure death is a possible outcome for this patient due to their severe cardiac dysfunction (LVEF 35%). However, the patient's NYHA class II status and the presence of medication (loop diuretics and ACE inhibitor) suggest that they are already receiving treatment for heart failure.

The patient's renal impairment (proteinuria) and elevated creatinine levels suggest some degree of cardiovascular-renal axis dysfunction, which may contribute to a higher risk of pump failure. However, the patient's cardiac biomarkers do not indicate acute myocardial infarction or severe heart failure.

RANKING: 3. Sudden cardiac death
REASONING: 

Sudden cardiac death is a possible outcome for this patient due to their high risk of arrhythmias (NSVT and ventricular extrasystole) and cardiac dysfunction (LVEF 35%). However, the patient's NYHA class II status and medication regimen suggest that they are already receiving treatment for heart failure and hypertension.

Given the patient's overall risk profile, pump failure death is a more likely outcome than SCD, as it is a more gradual process that may be more closely monitored and managed with treatment."
306,306,P0510,"Age: 72
Gender: Female 
Weight: 67 kg
Height: 147 cm
NYHA Class: III
Blood Pressure: 110/70 mmHg
Past Medical History: Idiopathic dilated cardiomyopathy, Diabetes, Dyslipemia, Hypertension
Albumin (g/L): 41,5
ALT or GPT (IU/L): 23.0
AST or GOT (IU/L): 27.0
Total Cholesterol (mmol/L): 4,94
Creatinine (mmol/L): 84.0
Gamma-glutamil transpeptidase (IU/L): 24
Glucose (mmol/L): 5,7
Hemoglobin (g/L): 134.0
HDL (mmol/L): 1,37
Potassium (mEq/L): 4,3
LDL (mmol/L): 3,13
Sodium (mEq/L): 141.0
Pro-BNP (ng/L): 2207.0
Protein (g/L): 74
T3 (pg/dL): 0,04
T4 (ng/L): 16
Troponin (ng/mL): 0,01
TSH (mIU/L): 1,62
Urea (mg/dL): 10,47
LVEF (%): 22.0
Medications: Loop Diuretics, Spironolactone, Statins, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",survivor,"RANKING: 
1. Survivor
REASONING:
Based on the patient's data, I would rank the patient as having a high likelihood of being a survivor for the next few years. The patient's NYHA Class III indicates that they have significant heart failure symptoms, but they are still able to be treated with medications such as Loop Diuretics and ACE Inhibitor. The patient's LVEF of 22% is severely reduced, indicating significant left ventricular dysfunction, but it is not immediately life-threatening. The patient's Pro-BNP level is elevated, which is a marker for heart failure, but it is not excessively high. The patient's ECG impression shows ventricular extrasystoles, which are a common finding in patients with heart failure, and there is no evidence of ventricular tachycardia or bradycardia.

The patient's other medical conditions, such as diabetes, dyslipidemia, and hypertension, are well-managed, and the patient is on medications to control these conditions. The patient's laboratory values are also relatively stable, with no acute changes in liver function, kidney function, or electrolyte levels. The patient's hemoglobin and potassium levels are within normal limits, and the patient's troponin level is normal.

While the patient's heart failure is severe, the patient's overall clinical presentation and laboratory values suggest that they can be managed with current treatment and lifestyle modifications. Therefore, I would rank the patient as having a high likelihood of being a survivor for the next few years.

RANKING 2: Sudden Cardiac Death
REASONING:
Based on the patient's data, I would rank the patient as having a moderate likelihood of sudden cardiac death for the next few years. The patient's NYHA Class III indicates significant heart failure, and their LVEF is severely reduced. The patient's Pro-BNP level is elevated, which increases the risk of heart failure-related complications, including sudden cardiac death.

The patient's ECG impression shows ventricular extrasystoles, which can be a marker for an increased risk of ventricular arrhythmias, including ventricular tachycardia. The patient's medications, such as ACE Inhibitor, can help manage blood pressure and reduce the risk of heart failure, but they may not be sufficient to completely eliminate the risk of sudden cardiac death.

The patient's other medical conditions, such as diabetes, dyslipidemia, and hypertension, are not well-managed, which can increase the risk of cardiovascular events. The patient's laboratory values are relatively stable, but the patient's creatinine level is elevated, which may indicate some degree of kidney dysfunction.

While the patient's overall clinical presentation and laboratory values suggest that they can be managed with current treatment, the patient's risk of sudden cardiac death cannot be ruled out.

RANKING 3: Pump Failure Death
REASONING:
Based on the patient's data, I would rank the patient as having a low likelihood of pump failure death for the next few years. The patient's LVEF is severely reduced, which indicates significant left ventricular dysfunction. However, the patient is on medications to manage heart failure, including Loop Diuretics and ACE Inhibitor, which can help reduce the risk of pump failure.

The patient's Pro-BNP level is elevated, which increases the risk of heart failure-related complications, but it is not excessively high. The patient's ECG impression shows ventricular extrasystoles, which can be a marker for an increased risk of ventricular arrhythmias, but there is no evidence of ventricular tachycardia or bradycardia.

The patient's other medical conditions, such as diabetes, dyslipidemia, and hypertension, are not well-managed, which can increase the risk of cardiovascular events. However, the patient's laboratory values are relatively stable, and the patient's hemoglobin and potassium levels are within normal limits.

Given the patient's current treatment and management, I would rank the patient as having a low likelihood of pump failure death for the next few years. However, close monitoring and regular follow-up with the patient's cardiologist are essential to adjust treatment and prevent any potential complications."
307,307,P0511,"Age: 59
Gender: Female 
Weight: 75 kg
Height: 158 cm
NYHA Class: II
Blood Pressure: 110/70 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Diabetes, Dyslipemia, Myocardial Infarction
Albumin (g/L): 44,8
ALT or GPT (IU/L): 39.0
AST or GOT (IU/L): 26.0
Total Cholesterol (mmol/L): 3,08
Creatinine (mmol/L): 76.0
Gamma-glutamil transpeptidase (IU/L): 18
Glucose (mmol/L): 10,3
Hemoglobin (g/L): 142.0
HDL (mmol/L): 0,91
Potassium (mEq/L): 4,8
LDL (mmol/L): 1,81
Sodium (mEq/L): 143.0
Pro-BNP (ng/L): 1114.0
Protein (g/L): 74
T3 (pg/dL): 0,04
T4 (ng/L): 15
Troponin (ng/mL): 0,01
TSH (mIU/L): 1,61
Urea (mg/dL): 7,35
LVEF (%): 37.0
Medications: Diabetes Medication, Beta Blockers, Statins, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: TPSV
        - Bradycardia: No
            ",survivor,"RANKING: 

1. Survivor
REASONING: 

This patient is likely to survive for the next few years due to the presence of certain factors that suggest a relatively stable cardiovascular condition. The patient's New York Heart Association (NYHA) class is II, indicating mild symptoms of heart failure, which is not severe. The patient is also on medications that are commonly used to manage heart failure and cardiovascular risk factors, such as beta blockers, statins, and ACE inhibitors. The absence of significant laboratory abnormalities, such as elevated troponin levels, also suggests that the patient's heart muscle is not under significant stress.

However, the patient's left ventricular ejection fraction (LVEF) is only 37%, which indicates a significant reduction in the heart's pumping efficiency. This could potentially lead to further decline in cardiac function over time. The patient's history of ischemic dilated cardiomyopathy, diabetes, and dyslipidemia also increase the risk of cardiovascular events.

2. Sudden cardiac death
REASONING: 

While the patient's LVEF is low, the absence of significant laboratory abnormalities and the presence of medications that are commonly used to manage cardiovascular risk factors suggest that the patient is not at high risk for sudden cardiac death. However, the patient's history of myocardial infarction and ischemic dilated cardiomyopathy increase the risk of arrhythmias, which can lead to sudden cardiac death.

3. Pump failure death
REASONING: 

The patient's LVEF is significantly reduced, and the patient's NYHA class is II, indicating mild symptoms of heart failure. This combination of factors increases the risk of pump failure, which is a leading cause of mortality in patients with heart failure. The patient's low albumin level (44.8 g/L) may also indicate malnutrition, which can further exacerbate heart failure.

It is worth noting that the patient's Pro-BNP level is elevated at 1114 ng/L, which suggests that the patient is experiencing some level of cardiac stress. However, the absence of other laboratory abnormalities and the presence of medications that are commonly used to manage heart failure reduce the likelihood of pump failure death."
308,308,P0512,"Age: 69
Gender: Male 
Weight: 85 kg
Height: 170 cm
NYHA Class: II
Blood Pressure: 140/70 mmHg
Past Medical History: Enolic dilated cardiomyopathy, Diabetes, Peripheral vascular disease
Albumin (g/L): 46,3
ALT or GPT (IU/L): 28.0
AST or GOT (IU/L): 20.0
Total Cholesterol (mmol/L): 5,74
Creatinine (mmol/L): 95.0
Gamma-glutamil transpeptidase (IU/L): 66
Glucose (mmol/L): 11,3
Hemoglobin (g/L): 143.0
HDL (mmol/L): 0,91
Potassium (mEq/L): 4,8
LDL (mmol/L): 2,97
Sodium (mEq/L): 134.0
Pro-BNP (ng/L): 349.0
Protein (g/L): 90
T3 (pg/dL): 0,06
T4 (ng/L): 17
Troponin (ng/mL): 0,01
TSH (mIU/L): 1,36
Urea (mg/dL): 8,02
LVEF (%): 24.0
Medications: Diabetes Medication, Beta Blockers, Loop Diuretics, Spironolactone, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: First-degree Atrioventricular block (AVB)
            ",survivor,"RANKING: 1. Survivor
REASONING: 

The patient has a history of Enolic dilated cardiomyopathy, which is a condition where the heart's ability to pump blood is compromised, leading to decreased left ventricular ejection fraction (LVEF) of 24.0%. This is a significant indicator of poor cardiac function. However, the patient is currently taking medications such as Beta Blockers, Loop Diuretics, and ACE Inhibitor, which are commonly used to manage heart failure and reduce the risk of complications.

The patient's ejection fraction is not severely low, which might suggest that the medications are somewhat effective in managing the condition. The patient's NYHA Class is II, indicating moderate symptoms of heart failure. The patient's Pro-BNP level is elevated at 349.0 ng/L, which is a marker for heart failure. However, the patient's kidney function is mildly impaired, with a creatinine level of 95.0 mmol/L, which may indicate some degree of cardiac renal dysfunction.

The patient's other laboratory values, such as the liver enzymes, electrolytes, and glucose levels, are within relatively normal limits. The patient's hemoglobin and HDL levels are also within normal limits. The ECG impression does not show any significant arrhythmias, which is a positive sign.

Considering these factors, the patient's overall condition seems stable, and the risk of sudden cardiac death or pump failure death is moderate. However, the patient's history of heart failure and impaired kidney function do increase the risk of complications. Overall, the patient's current treatment regimen and relatively stable laboratory values suggest a moderate risk of complications, making a survivor outcome the most likely prognosis.

RANKING: 2. Sudden cardiac death
REASONING: 

While the patient's condition is not extremely severe, the patient's history of Enolic dilated cardiomyopathy, impaired kidney function, and elevated Pro-BNP level do increase the risk of sudden cardiac death. The patient's ejection fraction is 24.0%, which is significantly below the normal range, indicating poor cardiac function.

The patient's NYHA Class is II, indicating moderate symptoms of heart failure, which may increase the risk of sudden cardiac death. The patient's impaired kidney function may also contribute to an increased risk of sudden cardiac death.

However, the patient is currently taking medications such as Beta Blockers, Loop Diuretics, and ACE Inhibitor, which are commonly used to manage heart failure and reduce the risk of complications. The patient's ECG impression does not show any significant arrhythmias, which is a positive sign.

Considering these factors, the patient's risk of sudden cardiac death is moderate to high, making sudden cardiac death a possible outcome.

RANKING: 3. Pump failure death
REASONING: 

The patient's ejection fraction is 24.0%, which is significantly below the normal range, indicating poor cardiac function. The patient's NYHA Class is II, indicating moderate symptoms of heart failure. The patient's Pro-BNP level is elevated at 349.0 ng/L, which is a marker for heart failure.

The patient's impaired kidney function, elevated creatinine level, and elevated Pro-BNP level do increase the risk of pump failure death. The patient's history of Enolic dilated cardiomyopathy also increases the risk of pump failure.

The patient's current treatment regimen is effective in managing symptoms, but the patient's cardiac function is severely impaired. The patient's ECG impression does not show any significant arrhythmias, but the patient's impaired kidney function may contribute to an increased risk of complications.

Considering these factors, the patient's risk of pump failure death is high, making it a possible outcome."
309,309,P0514,"Age: 54
Gender: Male 
Weight: 89 kg
Height: 165 cm
NYHA Class: II
Blood Pressure: 120/80 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Diabetes, Hypertension, Myocardial Infarction
Albumin (g/L): 48,4
ALT or GPT (IU/L): 16.0
AST or GOT (IU/L): 17.0
Total Cholesterol (mmol/L): 3,93
Creatinine (mmol/L): 84.0
Gamma-glutamil transpeptidase (IU/L): 10
Glucose (mmol/L): 9,9
Hemoglobin (g/L): 148.0
HDL (mmol/L): 1,06
Potassium (mEq/L): 3,7
LDL (mmol/L): 2,43
Sodium (mEq/L): 141.0
Pro-BNP (ng/L): 333.0
Protein (g/L): 77
T3 (pg/dL): 0,04
T4 (ng/L): 15
Troponin (ng/mL): 0,01
TSH (mIU/L): 1,36
Urea (mg/dL): 6,45
LVEF (%): 39.0
Medications: Calcium Channel Blocker, Diabetes Medication, Beta Blockers, Loop Diuretics, Statins, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"RANKING: 1. Survivor
REASONING: 

The patient has a significant medical history of ischemic dilated cardiomyopathy, hypertension, diabetes, and myocardial infarction, which indicates a high risk of cardiac complications. However, the patient is currently being treated with multiple medications, including ACE inhibitors and beta blockers, which are standard treatments for heart failure and hypertension. The patient's NYHA Class II indicates mild symptoms, suggesting that the heart is still functioning to some extent. 

The patient's laboratory results show elevated liver enzymes (ALT and AST), which could be related to the underlying cardiac condition, but are not indicative of acute liver damage. The elevated creatinine level suggests some degree of renal impairment, but it is not severe. The patient's electrolytes, including potassium, are within normal limits.

The ECG findings are relatively unremarkable, with no signs of ventricular arrhythmias or significant conduction abnormalities. The Pro-BNP level is elevated, indicating some degree of ventricular dysfunction, but it is not extremely high.

Considering these factors, the patient's overall prognosis is likely to be a survivor, as they are receiving optimal medical therapy for their conditions and do not have any acute cardiac complications. However, the patient's cardiac function is severely impaired, as indicated by the low LVEF of 39%, which suggests that they are at risk for cardiac events.

RANKING: 2. Sudden Cardiac Death
REASONING: 

The patient's low LVEF of 39% indicates significant cardiac dysfunction, which increases the risk of cardiac events, including sudden cardiac death. The patient's history of ischemic dilated cardiomyopathy, hypertension, and myocardial infarction also increases the risk of sudden cardiac death.

While the patient is receiving optimal medical therapy, including ACE inhibitors and beta blockers, which are known to reduce the risk of cardiac events, the patient's cardiac function is severely impaired. The elevated Pro-BNP level and the patient's NYHA Class II symptoms suggest that the patient's heart is not functioning optimally, which increases the risk of cardiac events.

RANKING: 3. Pump Failure Death
REASONING: 

The patient's severe cardiac dysfunction, as indicated by the low LVEF of 39%, makes them at high risk for pump failure. The patient's NYHA Class II symptoms and elevated Pro-BNP level suggest that the patient's heart is not functioning optimally, which increases the risk of pump failure.

While the patient is receiving optimal medical therapy, including ACE inhibitors and beta blockers, which are known to reduce the risk of cardiac events, the patient's cardiac function is severely impaired. The patient's history of hypertension, diabetes, and myocardial infarction also increases the risk of pump failure.

However, the patient's relatively stable laboratory results and the absence of acute cardiac complications make sudden cardiac death a less likely outcome. Therefore, pump failure death is the least likely outcome, but still a possible complication."
310,310,P0515,"Age: 50
Gender: Female 
Weight: 83 kg
Height: 154 cm
NYHA Class: II
Blood Pressure: 140/70 mmHg
Past Medical History: Hypertensive cardiomyopathy, Hypertension
Albumin (g/L): 45,8
ALT or GPT (IU/L): 11.0
AST or GOT (IU/L): 13.0
Total Cholesterol (mmol/L): 4,81
Creatinine (mmol/L): 87.0
Gamma-glutamil transpeptidase (IU/L): 11
Glucose (mmol/L): 4,5
Hemoglobin (g/L): 133.0
HDL (mmol/L): 1,47
Potassium (mEq/L): 3,9
LDL (mmol/L): 2,84
Sodium (mEq/L): 138.0
Pro-BNP (ng/L): 763.0
Protein (g/L): 74
T3 (pg/dL): 0,05
T4 (ng/L): 14
Troponin (ng/mL): 0,01
TSH (mIU/L): 2,14
Urea (mg/dL): 9,8
LVEF (%): 50.0
Medications: Loop Diuretics, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: No
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"RANKING: 1. Survivor
REASONING: 

The patient's overall health status and test results suggest a moderate to severe cardiac condition, as indicated by a reduced LVEF of 50.0% and elevated Pro-BNP levels of 763.0 ng/L, which are indicative of heart failure. However, the patient is currently on medications for hypertension and heart failure, which suggests that the patient's condition is being managed. The absence of ventricular extrasystoles, ventricular tachycardia, and non-sustained ventricular tachycardia on the ECG impression also suggests that the patient does not have any acute cardiac arrhythmias that could be life-threatening. Furthermore, the patient's hemoglobin level of 133.0 g/L and normal kidney function (creatinine 9.8 mg/dL) suggest that the patient does not have significant anemia or kidney impairment. Overall, these factors suggest that the patient is likely to survive for the next few years with proper management of their condition. 

The patient's weight and blood pressure are also within relatively normal limits for their age and height, which suggests that they are not at high risk for sudden cardiac death due to cardiovascular events such as myocardial infarction or cardiac arrhythmias. 

While the patient's LVEF is reduced, it is not severely impaired, and the patient is on medications that are commonly used to manage heart failure, which suggests that the patient's condition is being managed. 

Therefore, based on the available data, the most likely outcome for the patient over the next few years is that they will survive."
311,311,P0516,"Age: 49
Gender: Male 
Weight: 97 kg
Height: 175 cm
NYHA Class: III
Blood Pressure: 130/80 mmHg
Past Medical History: Enolic dilated cardiomyopathy, Dyslipemia
Albumin (g/L): 51,3
ALT or GPT (IU/L): 19.0
AST or GOT (IU/L): 18.0
Total Cholesterol (mmol/L): 4,19
Creatinine (mmol/L): 97.0
Gamma-glutamil transpeptidase (IU/L): 42
Glucose (mmol/L): 5,4
Hemoglobin (g/L): 156.0
HDL (mmol/L): 0,91
Potassium (mEq/L): 4,4
LDL (mmol/L): 1,66
Sodium (mEq/L): 141.0
Pro-BNP (ng/L): 1283.0
Protein (g/L): 69
T3 (pg/dL): 0,04
T4 (ng/L): 24
Troponin (ng/mL): 0,01
TSH (mIU/L): 3,23
Urea (mg/dL): 8,02
LVEF (%): 39.0
Medications: Amiodarone, Beta Blockers, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: No
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"RANKING: 1. Survivor
REASONING:

The patient's age, NYHA Class III, and low LVEF of 39.0 indicate a significant impairment of cardiac function. However, the absence of ventricular tachycardia, non-sustained ventricular tachycardia, and other arrhythmias on the ECG suggests that the patient's heart is not in a high-risk state for arrhythmic events. The patient's blood pressure is well-controlled, and they are on beta blockers, which are known to improve cardiac function and reduce the risk of arrhythmias.

The patient's elevated Pro-BNP levels (1283.0 ng/L) indicate significant ventricular stress and possible heart failure. However, the patient is already on ACE inhibitors, which are known to reduce ventricular stress and improve heart function. The patient's elevated creatinine level (97.0 mmol/L) suggests some degree of renal impairment, but this is not uncommon in patients with heart failure.

The patient's lipid profile is not optimal, with high total cholesterol and LDL levels, but this is not uncommon in patients with heart failure. The patient's glucose levels are also elevated, which may contribute to their cardiac stress.

Given these factors, the patient's overall prognosis is guarded but not hopeless. With continued medical therapy, including ACE inhibitors, beta blockers, and possibly further optimization of their lipid and glucose profiles, it is possible that the patient may survive for several years. However, the patient's significant impairment of cardiac function and elevated Pro-BNP levels suggest that they are at risk for pump failure, and close monitoring and management of their condition will be necessary to prevent this outcome.

RANKING: 2. Sudden cardiac death
REASONING:

The patient's LVEF of 39.0 is significantly impaired, which increases the risk of sudden cardiac death. Additionally, the patient's elevated Pro-BNP levels (1283.0 ng/L) indicate significant ventricular stress, which can contribute to arrhythmias and sudden cardiac death.

The patient's absence of ventricular tachycardia, non-sustained ventricular tachycardia, and other arrhythmias on the ECG suggests that the patient is not at high risk for arrhythmic events. However, the patient's significant impairment of cardiac function and elevated Pro-BNP levels suggest that they are at risk for cardiac events, including sudden cardiac death.

The patient's elevated creatinine level (97.0 mmol/L) and renal impairment may also contribute to their risk for cardiac events, as renal impairment can increase the risk of cardiac arrhythmias and sudden cardiac death.

RANKING: 3. Pump failure death
REASONING:

The patient's LVEF of 39.0 is significantly impaired, which increases the risk of pump failure. The patient's elevated Pro-BNP levels (1283.0 ng/L) indicate significant ventricular stress, which can contribute to pump failure.

The patient's absence of ventricular tachycardia, non-sustained ventricular tachycardia, and other arrhythmias on the ECG suggests that the patient is not at high risk for arrhythmic events. However, the patient's significant impairment of cardiac function and elevated Pro-BNP levels suggest that they are at risk for pump failure.

The patient's elevated creatinine level (97.0 mmol/L) and renal impairment may also contribute to their risk for pump failure, as renal impairment can increase the risk of cardiac dysfunction and pump failure.

While the patient is on ACE inhibitors, which are known to reduce ventricular stress and improve heart function, the patient's significant impairment of cardiac function and elevated Pro-BNP levels suggest that pump failure is a significant risk. Close monitoring and management of the patient's condition will be necessary to prevent pump failure."
312,312,P0517,"Age: 41
Gender: Male 
Weight: 84 kg
Height: 171 cm
NYHA Class: II
Blood Pressure: 110/70 mmHg
Past Medical History: Idiopathic dilated cardiomyopathy
Albumin (g/L): 44,9
ALT or GPT (IU/L): 28.0
AST or GOT (IU/L): 20.0
Total Cholesterol (mmol/L): 3,93
Creatinine (mmol/L): 90.0
Gamma-glutamil transpeptidase (IU/L): 21
Glucose (mmol/L): 5,9
Hemoglobin (g/L): 139.0
HDL (mmol/L): 0,83
Potassium (mEq/L): 3,9
LDL (mmol/L): 2,48
Sodium (mEq/L): 141.0
Pro-BNP (ng/L): 797.0
Protein (g/L): 74
T3 (pg/dL): 0,05
T4 (ng/L): 17
Troponin (ng/mL): 0,01
TSH (mIU/L): 1,26
Urea (mg/dL): 8,69
LVEF (%): 35.0
Medications: Digoxin, Loop Diuretics, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",survivor,"RANKING: 1. Survivor
REASONING: 

Based on the patient's data, I would rank the patient as having the highest likelihood of survival. The patient's NYHA class is II, indicating mild heart failure symptoms. The patient's LVEF is 35%, which is significantly reduced, but not severely impaired. The patient's creatinine level is elevated, indicating some degree of renal impairment, but this is not uncommon in patients with heart failure. The patient's troponin level is normal, indicating no acute myocardial infarction.

The patient's ECG shows non-sustained ventricular tachycardia, which is a concerning sign, but it is not sustained. The presence of ventricular extrasystoles and polymorphic ventricular tachycardia is also concerning, but the patient is on medications (ACE inhibitor and digoxin) that are commonly used to manage these arrhythmias.

The patient's laboratory values are relatively stable, with no significant abnormalities in liver function, kidney function, or electrolyte levels. The patient's hemoglobin and potassium levels are within normal limits.

Overall, while the patient has several risk factors for adverse outcomes, the patient's relatively mild symptoms, stable laboratory values, and the presence of medications that can help manage their heart failure and arrhythmias make me believe that the patient has a good prognosis and is likely to survive.

RANKING: 2. Sudden cardiac death
REASONING: 

I would rank the patient as having a moderate likelihood of sudden cardiac death. The patient's ECG shows non-sustained ventricular tachycardia, which is a risk factor for sudden cardiac death. The patient's LVEF is significantly reduced, which can increase the risk of arrhythmias and sudden cardiac death.

Additionally, the patient's age and NYHA class II indicate that they may be at increased risk for cardiovascular events. However, the patient's stable laboratory values and the presence of medications that can help manage their heart failure and arrhythmias reduce the likelihood of sudden cardiac death.

RANKING: 3. Pump failure death
REASONING: 

I would rank the patient as having the lowest likelihood of pump failure death. The patient's LVEF is 35%, which is significantly reduced, but not severely impaired. The patient's NYHA class is II, indicating mild heart failure symptoms. The patient is on medications that can help manage their heart failure, including loop diuretics and an ACE inhibitor.

Additionally, the patient's laboratory values are relatively stable, with no significant abnormalities in liver function, kidney function, or electrolyte levels. The patient's hemoglobin and potassium levels are within normal limits.

However, the patient's elevated creatinine level indicates some degree of renal impairment, which can increase the risk of heart failure and pump failure. The patient's ECG shows non-sustained ventricular tachycardia, which is a risk factor for pump failure. Overall, while the patient has several risk factors for pump failure, their relatively mild symptoms, stable laboratory values, and the presence of medications that can help manage their heart failure make me believe that the patient is less likely to experience pump failure."
313,313,P0518,"Age: 56
Gender: Male 
Weight: 98 kg
Height: 161 cm
NYHA Class: II
Blood Pressure: 130/80 mmHg
Past Medical History: Enolic dilated cardiomyopathy, Hypertension
Albumin (g/L): 45,9
ALT or GPT (IU/L): 14.0
AST or GOT (IU/L): 17.0
Total Cholesterol (mmol/L): 5,25
Creatinine (mmol/L): 105.0
Gamma-glutamil transpeptidase (IU/L): 20
Glucose (mmol/L): 5,9
Hemoglobin (g/L): 145.0
HDL (mmol/L): 0,8
Potassium (mEq/L): 4,8
LDL (mmol/L): 3,34
Sodium (mEq/L): 142.0
Pro-BNP (ng/L): 134.0
Protein (g/L): 83
T3 (pg/dL): 0,05
T4 (ng/L): 18
Troponin (ng/mL): 0,01
TSH (mIU/L): 1,88
Urea (mg/dL): 7,12
LVEF (%): 36.0
Medications: ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: TPSV
        - Bradycardia: No
            ",survivor,"RANKING: 1. Survivor
REASONING: 
The patient's overall health status, despite having NYHA Class II heart failure, is relatively stable, and the patient is currently receiving treatment with an ACE inhibitor, which is a standard medication for managing heart failure. The patient's LVEF is 36%, which is significantly reduced but still within a range that can be managed with medical therapy. The absence of elevated troponin levels and the absence of ventricular tachycardia or non-sustained ventricular tachycardia on the ECG suggest that the patient is not at high risk for acute cardiac events. Additionally, the patient's liver function tests (ALT, AST, and GGT) are not severely elevated, which could indicate liver disease or other systemic conditions that might impact cardiac function. 

While the patient has a history of enolic dilated cardiomyopathy and hypertension, the patient's current medical history and test results do not indicate acute cardiac decompensation. The patient's electrolyte levels, including potassium, are within normal limits, which reduces the risk of arrhythmias. Overall, the combination of a stable medical history, absence of acute cardiac events, and current treatment with an ACE inhibitor makes a sudden cardiac death or pump failure less likely, making a survivor the most likely prognosis."
314,314,P0519,"Age: 61
Gender: Male 
Weight: 107 kg
Height: 172 cm
NYHA Class: II
Blood Pressure: 110/70 mmHg
Past Medical History: Idiopathic dilated cardiomyopathy, Diabetes, Dyslipemia, Peripheral vascular disease
Albumin (g/L): 38,7
ALT or GPT (IU/L): 11.0
AST or GOT (IU/L): 12.0
Total Cholesterol (mmol/L): 4,84
Creatinine (mmol/L): 80.0
Gamma-glutamil transpeptidase (IU/L): 34
Glucose (mmol/L): 8,3
Hemoglobin (g/L): 142.0
HDL (mmol/L): 0,7
Potassium (mEq/L): 4,4
LDL (mmol/L): 3,21
Sodium (mEq/L): 141.0
Pro-BNP (ng/L): 1035.0
Protein (g/L): 69
T3 (pg/dL): 0,04
T4 (ng/L): 19
Troponin (ng/mL): 0,03
TSH (mIU/L): 1,38
Urea (mg/dL): 8,46
LVEF (%): 23.0
Medications: Calcium Channel Blocker, Diabetes Medication, Angiotensin II Receptor Blocker, Beta Blockers, Digoxin, Loop Diuretics, Spironolactone
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",survivor,"RANKING: 1. Survivor
REASONING:

Based on the patient data, the patient is a 61-year-old male with a history of idiopathic dilated cardiomyopathy, diabetes, dyslipemia, and peripheral vascular disease. The patient's current NYHA Class II indicates that they have some limitations in physical activity due to their heart condition, but they are not in New York Heart Association (NYHA) Class III or IV, which would indicate more severe symptoms.

The patient's LVEF (Left Ventricular Ejection Fraction) is 23.0%, which is significantly reduced, indicating poor heart function. However, the patient's blood pressure is well-controlled, with a systolic blood pressure of 110/70 mmHg, and they are not on any medications that would increase the risk of cardiac arrhythmias.

The patient's troponin level is 0.03 ng/mL, which is within the normal range, suggesting that there is no acute myocardial infarction. The patient's creatinine level is slightly elevated, but this is likely due to their renal disease rather than cardiac disease.

The patient's ECG shows ventricular extrasystoles, which are benign and can be seen in patients with heart disease. There is no evidence of ventricular tachycardia or bradycardia.

Given these factors, the patient's prognosis is likely to be a survivor. The patient's reduced LVEF and ventricular extrasystoles may indicate some cardiac stress, but they are not in a high-risk category. The patient's well-controlled blood pressure and lack of evidence of acute cardiac events make them a good candidate for survival.

RANKING: 2. Sudden cardiac death
REASONING:

Based on the patient data, there is a moderate risk of sudden cardiac death. The patient's LVEF is significantly reduced, indicating poor heart function, and they have a history of idiopathic dilated cardiomyopathy, which is a risk factor for sudden cardiac death.

The patient's ECG shows ventricular extrasystoles, which can be a sign of cardiac stress and may increase the risk of sudden cardiac death. The patient's troponin level is slightly elevated, but this is likely due to their renal disease rather than cardiac disease.

The patient's medications, including beta blockers and angiotensin II receptor blockers, may help reduce the risk of sudden cardiac death, but the patient's reduced LVEF and ventricular extrasystoles make them a moderate-risk patient.

RANKING: 3. Pump failure death
REASONING:

Based on the patient data, there is a low risk of pump failure death. The patient's LVEF is 23.0%, which is significantly reduced, indicating poor heart function. However, the patient is on medications that are likely to help improve heart function, including beta blockers and spironolactone.

The patient's renal disease may contribute to their reduced LVEF, but the patient is not on any medications that would increase the risk of renal failure. The patient's creatinine level is slightly elevated, but this is likely due to their renal disease rather than cardiac disease.

The patient's ventricular extrasystoles and reduced LVEF may indicate some cardiac stress, but the patient's well-controlled blood pressure and lack of evidence of acute cardiac events make them a low-risk patient for pump failure death."
315,315,P0521,"Age: 79
Gender: Female 
Weight: 58 kg
Height: 149 cm
NYHA Class: III
Blood Pressure: 110/80 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Diabetes, Dyslipemia, Peripheral vascular disease, Hypertension, Myocardial Infarction
Albumin (g/L): 42,5
ALT or GPT (IU/L): 11.0
AST or GOT (IU/L): 16.0
Total Cholesterol (mmol/L): 5,64
Creatinine (mmol/L): 119.0
Gamma-glutamil transpeptidase (IU/L): 12
Glucose (mmol/L): 6,7
Hemoglobin (g/L): 118.0
HDL (mmol/L): 1,09
Potassium (mEq/L): 4,2
LDL (mmol/L): 3,7
Sodium (mEq/L): 143.0
Pro-BNP (ng/L): 6699.0
Protein (g/L): 71
T3 (pg/dL): 0,05
T4 (ng/L): 21
Troponin (ng/mL): 0,01
TSH (mIU/L): 2,98
Urea (mg/dL): 12,03
LVEF (%): 23.0
Medications: Diabetes Medication, Beta Blockers, Loop Diuretics, Spironolactone, ACE Inhibitor, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",survivor,"RANKING: 1. Survivor 
REASONING: 

This patient has a complex medical history with multiple comorbidities such as ischemic dilated cardiomyopathy, diabetes, dyslipemia, peripheral vascular disease, and hypertension. The patient's NYHA Class III indicates a significant level of heart failure symptoms. The elevated creatinine level (119.0 mmol/L) and low ejection fraction (LVEF 23.0%) suggest advanced cardiac dysfunction.

However, despite these unfavorable factors, the patient is currently on multiple medications for heart failure, hypertension, and diabetes, which suggests that the patient is receiving optimal medical therapy. The absence of a recent myocardial infarction and the relatively normal blood pressure (110/80 mmHg) also contribute to a more favorable prognosis.

Additionally, the patient's ECG findings, although concerning for ventricular arrhythmias, do not indicate any acute life-threatening conditions. The presence of ventricular extrasystole, non-sustained ventricular tachycardia, and paroxysmal supraventricular tachyarrhythmia, while concerning, do not necessarily indicate an immediate risk of cardiac arrest or sudden cardiac death.

Considering these factors, the patient's overall prognosis is more favorable than the other two options, and I would rank the patient as a survivor."
316,316,P0522,"Age: 66
Gender: Male 
Weight: 88 kg
Height: 165 cm
NYHA Class: II
Blood Pressure: 140/75 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Diabetes, Dyslipemia, Peripheral vascular disease, Myocardial Infarction
Albumin (g/L): 40,9
ALT or GPT (IU/L): 14.0
AST or GOT (IU/L): 15.0
Total Cholesterol (mmol/L): 3,44
Creatinine (mmol/L): 116.0
Gamma-glutamil transpeptidase (IU/L): 23
Glucose (mmol/L): 15,4
Hemoglobin (g/L): 130.0
HDL (mmol/L): 0,75
Potassium (mEq/L): 4,7
LDL (mmol/L): 1,5
Sodium (mEq/L): 138.0
Pro-BNP (ng/L): 277.0
Protein (g/L): 68
T3 (pg/dL): 0,04
T4 (ng/L): 16
Troponin (ng/mL): 0,01
TSH (mIU/L): 2,77
Urea (mg/dL): 10,24
LVEF (%): 39.0
Medications: Diabetes Medication, Loop Diuretics, Spironolactone, Statins, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: Second-degree AVB - type I
            ",survivor,"RANKING: 1. Survivor
REASONING: 

This patient is at a high risk for adverse cardiac events, with a history of ischemic dilated cardiomyopathy, myocardial infarction, and peripheral vascular disease. The patient's LVEF is significantly reduced at 39%, indicating poor cardiac function. The presence of ventricular extrasystoles, non-sustained ventricular tachycardia, and non-sustained ventricular tachycardia (CH>10) on ECG further increases the risk of sudden cardiac death. However, the patient is currently taking medications such as spironolactone, statins, and nitrovasodilator, which are commonly used to manage heart failure and prevent cardiovascular events. The patient's NYHA Class II indicates moderate symptoms, but the patient is still able to perform daily activities with some limitation. 

While the patient's biomarkers, such as troponin and creatinine, are elevated, they do not indicate acute myocardial infarction or kidney failure. The patient's glucose and lipid profiles are also not significantly abnormal, which reduces the risk of cardiovascular events. The patient's weight and height are within normal limits, and the patient's blood pressure is controlled. Overall, considering the patient's medications, medical history, and current biomarkers, I believe that the patient has a higher chance of survival compared to the other options.

RANKING: 2. Sudden Cardiac Death
REASONING: 

Although the patient has a high risk of adverse cardiac events, the patient's current medications and biomarkers do not indicate a sudden cardiac death. The patient's LVEF is significantly reduced, which increases the risk of sudden cardiac death. However, the patient's current medications, such as spironolactone, statins, and nitrovasodilator, are commonly used to manage heart failure and prevent cardiovascular events. The patient's glucose and lipid profiles are not significantly abnormal, which reduces the risk of cardiovascular events. The patient's weight and height are within normal limits, and the patient's blood pressure is controlled.

RANKING: 3. Pump Failure Death
REASONING: 

The patient's LVEF is significantly reduced at 39%, which indicates poor cardiac function. The patient's NYHA Class II indicates moderate symptoms, but the patient is still able to perform daily activities with some limitation. The patient's current medications, such as spironolactone, statins, and nitrovasodilator, are commonly used to manage heart failure. However, the patient's elevated creatinine level (116.0 mmol/L) indicates impaired kidney function, which may contribute to the development of heart failure. The patient's elevated troponin level (0.01 ng/mL) is not significantly elevated, but it does indicate some myocardial damage. The patient's glucose and lipid profiles are not significantly abnormal, which reduces the risk of cardiovascular events. Overall, while the patient has some risk factors for heart failure, the patient's current medications and biomarkers do not indicate a high risk of pump failure death."
317,317,P0523,"Age: 72
Gender: Male 
Weight: 80 kg
Height: 158 cm
NYHA Class: II
Blood Pressure: 100/70 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Diabetes, Dyslipemia, Peripheral vascular disease, Hypertension, Myocardial Infarction
Albumin (g/L): 40,4
ALT or GPT (IU/L): 18.0
AST or GOT (IU/L): 14.0
Total Cholesterol (mmol/L): 5,61
Creatinine (mmol/L): 123.0
Gamma-glutamil transpeptidase (IU/L): 57
Glucose (mmol/L): 8,5
Hemoglobin (g/L): 141.0
HDL (mmol/L): 1,16
Potassium (mEq/L): 4,7
LDL (mmol/L): 3,54
Sodium (mEq/L): 144.0
Pro-BNP (ng/L): 936.0
Protein (g/L): 70
T3 (pg/dL): 0,03
T4 (ng/L): 22
Troponin (ng/mL): 0,01
TSH (mIU/L): 0,368
Urea (mg/dL): 6,91
LVEF (%): 35.0
Medications: Diabetes Medication, Amiodarone, Loop Diuretics, Statins, ACE Inhibitor, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"RANKING: 1. Survivor
REASONING: 

This patient has a high risk of adverse outcomes due to their complex medical history, which includes ischemic dilated cardiomyopathy, diabetes, and hypertension. The patient's low LVEF (35%) indicates significant left ventricular dysfunction, which is a strong predictor of mortality. Additionally, the patient's elevated creatinine level (123.0 mmol/L) suggests impaired renal function, which can further exacerbate cardiac issues.

The patient's elevated troponin level (0.01 ng/mL) suggests some degree of cardiac damage, and the presence of ventricular extrasystoles (polymorphic) on the ECG is a concerning sign. However, the absence of ventricular tachycardia or non-sustained ventricular tachycardia (CH>10) on the ECG suggests that the patient is not at high risk for sudden cardiac death.

The patient's medication regimen, which includes ACE inhibitors, statins, and amiodarone, is generally well-tailored to their condition, and the presence of loop diuretics and nitrovasodilator suggests adequate management of hypertension and heart failure symptoms.

Given the patient's overall clinical profile, the most likely outcome is survival, although the patient may require close monitoring and adjustments to their treatment plan to mitigate the risk of adverse events."
318,318,P0524,"Age: 66
Gender: Male 
Weight: 68 kg
Height: 160 cm
NYHA Class: II
Blood Pressure: 120/70 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Dyslipemia, Peripheral vascular disease, Hypertension, Myocardial Infarction
Albumin (g/L): 45,8
ALT or GPT (IU/L): 17.0
AST or GOT (IU/L): 18.0
Total Cholesterol (mmol/L): 5,46
Creatinine (mmol/L): 117.0
Gamma-glutamil transpeptidase (IU/L): 26
Glucose (mmol/L): 3,8
Hemoglobin (g/L): 150.0
HDL (mmol/L): 1,06
Potassium (mEq/L): 4,2
LDL (mmol/L): 3,72
Sodium (mEq/L): 138.0
Pro-BNP (ng/L): 287.0
Protein (g/L): 69
T3 (pg/dL): 0,05
T4 (ng/L): 17
Troponin (ng/mL): 0,01
TSH (mIU/L): 2,06
Urea (mg/dL): 7,12
LVEF (%): 36.0
Medications: Beta Blockers, Loop Diuretics
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: TPSV
        - Bradycardia: No
            ",survivor,"RANKING: 

1. Survivor
REASONING:
The patient has a complex medical history, with multiple comorbidities such as ischemic dilated cardiomyopathy, peripheral vascular disease, hypertension, and myocardial infarction. However, the patient is currently being treated with beta blockers and loop diuretics, which are standard therapies for managing heart failure and hypertension. The patient's current NYHA class is II, indicating mild symptoms, which suggests that the current treatment is somewhat effective.

The patient's laboratory results show elevated creatinine levels, indicating some degree of renal impairment, but the patient's kidney function is not severely impaired. The patient's liver enzymes are also slightly elevated, but not significantly abnormal. The patient's lipid profile shows high cholesterol levels, but the patient is already on beta blockers, which can help with lipid management.

The ECG results show non-sustained ventricular tachycardia, which is a concerning sign, but the patient is being treated with beta blockers, which can help reduce the risk of arrhythmias. The patient's LVEF is significantly reduced, indicating poor cardiac function, but the patient is being treated with medications that can help improve symptoms.

Considering these factors, the patient is likely to survive the next few years with proper management and treatment. The patient's comorbidities and reduced LVEF do pose a risk, but the patient is already receiving treatment and the patient's current condition is stable.

2. Sudden cardiac death
REASONING:
The patient's ECG results show non-sustained ventricular tachycardia, which is a concerning sign for the risk of sudden cardiac death. The patient's LVEF is significantly reduced, indicating poor cardiac function, and the patient has a history of myocardial infarction, which increases the risk of sudden cardiac death.

While the patient is being treated with beta blockers, which can help reduce the risk of arrhythmias, the patient's ECG results suggest that the patient is at high risk for arrhythmias. The patient's comorbidities, such as peripheral vascular disease and hypertension, also increase the risk of sudden cardiac death.

3. Pump failure death
REASONING:
The patient's LVEF is significantly reduced, indicating poor cardiac function, and the patient has a history of ischemic dilated cardiomyopathy, which increases the risk of pump failure. The patient's current NYHA class is II, indicating mild symptoms, but the patient's reduced LVEF suggests that the patient's cardiac function is not well-compensated.

The patient's laboratory results show elevated creatinine levels, indicating some degree of renal impairment, which can increase the risk of pump failure. The patient's liver enzymes are slightly elevated, but not significantly abnormal. The patient's lipid profile shows high cholesterol levels, but the patient is already on beta blockers, which can help with lipid management.

While the patient is being treated with loop diuretics, which can help manage fluid overload, the patient's reduced LVEF and comorbidities increase the risk of pump failure. The patient's ECG results show non-sustained ventricular tachycardia, which is a concerning sign for the risk of arrhythmias, but the patient is being treated with beta blockers, which can help reduce the risk of arrhythmias.

Overall, while the patient is receiving treatment, the patient's reduced LVEF and comorbidities increase the risk of pump failure, making this the least likely outcome."
319,319,P0525,"Age: 69
Gender: Male 
Weight: 85 kg
Height: 158 cm
NYHA Class: II
Blood Pressure: 145/90 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Diabetes, Peripheral vascular disease, Hypertension, Myocardial Infarction
Albumin (g/L): 40,5
ALT or GPT (IU/L): 22.0
AST or GOT (IU/L): 18.0
Total Cholesterol (mmol/L): 4,22
Creatinine (mmol/L): 182.0
Gamma-glutamil transpeptidase (IU/L): 30
Glucose (mmol/L): 19,3
Hemoglobin (g/L): 120.0
HDL (mmol/L): 0,83
Potassium (mEq/L): 4,6
LDL (mmol/L): 1,34
Sodium (mEq/L): 135.0
Pro-BNP (ng/L): 241.0
Protein (g/L): 64
T3 (pg/dL): 0,04
T4 (ng/L): 16
Troponin (ng/mL): 0,01
TSH (mIU/L): 4,69
Urea (mg/dL): 18,25
LVEF (%): 35.0
Medications: Diabetes Medication, Angiotensin II Receptor Blocker, Beta Blockers, Loop Diuretics, Statins
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: TPSV
        - Bradycardia: No
            ",survivor,"RANKING: 1. Survivor
REASONING: 

This patient has a complex medical history with multiple comorbidities, including ischemic dilated cardiomyopathy, diabetes, peripheral vascular disease, hypertension, and myocardial infarction. However, the patient is currently taking multiple medications, including a beta blocker, which is a class I indication for patients with heart failure. The presence of a beta blocker may help to reduce mortality and morbidity in this patient.

The patient's ECG impression does show ventricular extrasystoles, which is a marker of increased cardiac stress, but no ventricular tachycardia or bradycardia. The patient's LVEF is 35%, which is significantly reduced, indicating poor cardiac function.

The patient's laboratory results also show elevated creatinine levels, indicating renal impairment, and elevated troponin levels, indicating some degree of cardiac damage. However, the patient's Pro-BNP levels are elevated, indicating increased ventricular wall stress.

Despite these factors, the patient is currently classified as a survivor, suggesting that the patient's overall clinical condition is stable, and the patient is not experiencing acute cardiac decompensation.

The patient's age and weight are also factors to consider. A patient of this age and weight is at increased risk for cardiac events, but the patient's current medications and clinical status suggest that the patient is receiving adequate treatment.

Overall, the combination of the patient's complex medical history, laboratory results, and current clinical status suggests that the patient is at risk for cardiac events, but the patient is currently classified as a survivor."
320,320,P0526,"Age: 71
Gender: Male 
Weight: 69 kg
Height: 154 cm
NYHA Class: II
Blood Pressure: 110/85 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Diabetes, Dyslipemia, Peripheral vascular disease, Hypertension, Myocardial Infarction
Albumin (g/L): 38,1
ALT or GPT (IU/L): 43.0
AST or GOT (IU/L): 43.0
Total Cholesterol (mmol/L): 4,73
Creatinine (mmol/L): 115.0
Gamma-glutamil transpeptidase (IU/L): 17
Glucose (mmol/L): 8,5
Hemoglobin (g/L): 141.0
HDL (mmol/L): 1,14
Potassium (mEq/L): 4,8
LDL (mmol/L): 2,9
Sodium (mEq/L): 138.0
Pro-BNP (ng/L): 318.0
Protein (g/L): 71
T3 (pg/dL): 0,04
T4 (ng/L): 15
Troponin (ng/mL): 0,01
TSH (mIU/L): 2,53
Urea (mg/dL): 10,69
LVEF (%): 32.0
Medications: Diabetes Medication, Beta Blockers, Digoxin, Loop Diuretics, Spironolactone, Statins, ACE Inhibitor, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: No
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",survivor,"RANKING: 1. Survivor
REASONING:

The patient's overall health status is compromised due to multiple comorbidities, including ischemic dilated cardiomyopathy, diabetes, and peripheral vascular disease. However, the patient has been identified as a survivor, which suggests that they are currently stable and not in immediate danger of cardiac death.

The patient's NYHA Class II indicates that they have some symptoms with ordinary physical activity, but they are still able to perform daily activities without severe limitation. The absence of ventricular extrasystole, ventricular tachycardia, and non-sustained ventricular tachycardia on the ECG further reduces the risk of sudden cardiac death.

The patient's biomarkers, such as troponin and BNP, are not significantly elevated, suggesting that there is no acute myocardial infarction or heart failure. The patient's creatinine level is elevated, but this is not uncommon in patients with chronic kidney disease, which is likely related to their diabetes and hypertension.

The patient's medication list includes ACE inhibitors, beta blockers, and spironolactone, which are all standard treatments for heart failure and hypertension. The presence of digoxin and loop diuretics also suggests that the patient is being managed for heart failure.

Considering these factors, I believe that the patient is at a higher risk of pump failure death due to their underlying heart disease and comorbidities. However, the patient's stable condition and absence of acute biomarkers suggest that sudden cardiac death is less likely. Therefore, the most likely outcome is that the patient will survive.

RANKING: 2. Pump failure death
REASONING:

The patient's ischemic dilated cardiomyopathy and chronic kidney disease increase the risk of heart failure. The patient's LVEF of 32.0 indicates that their heart function is severely impaired, and their creatinine level of 115.0 suggests that their kidneys are not functioning well.

The patient's medication list includes spironolactone, which is a diuretic that can help manage fluid overload, but it is not sufficient to reverse the underlying heart disease. The patient's elevated BNP level of 318.0 suggests that they have significant heart failure, and their elevated creatinine level suggests that their kidneys are not functioning well, which can exacerbate heart failure.

The patient's age and comorbidities also increase the risk of pump failure death. The patient is 71 years old, and their multiple comorbidities, including diabetes and hypertension, can further increase the risk of heart failure.

RANKING: 3. Sudden cardiac death
REASONING:

The patient's ECG results show no ventricular extrasystole, ventricular tachycardia, or non-sustained ventricular tachycardia, which reduces the risk of sudden cardiac death. The patient's absence of these arrhythmias suggests that their heart is not at high risk for life-threatening arrhythmias.

However, the patient's ischemic dilated cardiomyopathy and multiple comorbidities increase the risk of sudden cardiac death. The patient's elevated troponin level of 0.01 suggests that there may be some myocardial damage, but it is not significantly elevated, which reduces the risk of sudden cardiac death.

The patient's stable condition and absence of acute biomarkers suggest that sudden cardiac death is less likely. However, the patient's age and comorbidities still increase the risk of pump failure death, making it the most likely outcome."
321,321,P0527,"Age: 58
Gender: Male 
Weight: 91 kg
Height: 168 cm
NYHA Class: II
Blood Pressure: 140/90 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Dyslipemia, Peripheral vascular disease, Hypertension, Myocardial Infarction
Albumin (g/L): 52,69
ALT or GPT (IU/L): 25.0
AST or GOT (IU/L): 25.0
Total Cholesterol (mmol/L): 3,9
Creatinine (mmol/L): 96.0
Gamma-glutamil transpeptidase (IU/L): 14
Glucose (mmol/L): 4,6
Hemoglobin (g/L): 157.0
HDL (mmol/L): 1,16
Potassium (mEq/L): 3,6
LDL (mmol/L): 2,35
Sodium (mEq/L): 141.0
Pro-BNP (ng/L): 825.0
Protein (g/L): 74
T3 (pg/dL): 0,06
T4 (ng/L): 15
Troponin (ng/mL): 0,01
TSH (mIU/L): 1,23
Urea (mg/dL): 5,34
LVEF (%): 34.0
Medications: Angiotensin II Receptor Blocker, Beta Blockers, Statins, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"RANKING: 1. Survivor
REASONING: 

This patient has a complex medical history with multiple comorbid conditions such as ischemic dilated cardiomyopathy, peripheral vascular disease, hypertension, and myocardial infarction. The elevated creatinine level (96.0 mmol/L) and low LVEF (34.0%) suggest significant cardiac dysfunction. However, the patient is on multiple medications, including angiotensin II receptor blockers, beta blockers, and statins, which are commonly used to manage heart failure and cardiovascular risk factors. The absence of significant ECG abnormalities, such as ventricular tachycardia or non-sustained ventricular tachycardia, suggests that the patient's cardiac function is not severely compromised.

Additionally, the patient's laboratory results show a relatively normal glucose level (4.6 mmol/L) and a low TSH level (1.23 mIU/L), which suggests that the patient is not experiencing significant metabolic or endocrine disturbances. The presence of elevated Pro-BNP (825.0 ng/L) levels indicates some degree of ventricular strain, but it is not indicative of acute heart failure.

Considering these factors, I believe that the patient is at high risk of survival, with a moderate risk of cardiac events such as heart failure or sudden cardiac death. However, the absence of significant ECG abnormalities and the presence of multiple medications suggest that the patient is more likely to survive than to experience sudden cardiac death. Therefore, I rank the patient as a survivor."
322,322,P0528,"Age: 55
Gender: Male 
Weight: 85 kg
Height: 159 cm
NYHA Class: II
Blood Pressure: 150/80 mmHg
Past Medical History: Hypertensive cardiomyopathy, Diabetes, Hypertension
Albumin (g/L): 41,3
ALT or GPT (IU/L): 24.0
AST or GOT (IU/L): 19.0
Total Cholesterol (mmol/L): 4,19
Creatinine (mmol/L): 91.0
Gamma-glutamil transpeptidase (IU/L): 24
Glucose (mmol/L): 11,6
Hemoglobin (g/L): 103.0
HDL (mmol/L): 1,11
Potassium (mEq/L): 4,3
LDL (mmol/L): 2,46
Sodium (mEq/L): 139.0
Pro-BNP (ng/L): 103.0
Protein (g/L): 72
T3 (pg/dL): 0,04
T4 (ng/L): 15
Troponin (ng/mL): 0,01
TSH (mIU/L): 1,04
Urea (mg/dL): 8,02
LVEF (%): 39.0
Medications: Diabetes Medication, Angiotensin II Receptor Blocker, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"RANKING: 

1. Survivor
REASONING: 
Given the patient's age, NYHA Class II indicates that the patient has some symptoms of heart failure, but the class is not severe. The patient's LVEF is 39%, which is significantly reduced, indicating systolic heart failure. However, the patient is not in cardiogenic shock, and the ECG does not show any signs of acute life-threatening arrhythmias. The patient's blood pressure is well-controlled, and the medications are aimed at managing hypertension and heart failure. The patient's laboratory results, including electrolytes, liver enzymes, and kidney function, are relatively stable. The Pro-BNP level is mildly elevated, but not excessively high, which may indicate some degree of heart failure. Considering these factors, the patient is likely to survive for the next few years with proper management and monitoring.

2. Sudden Cardiac Death
REASONING: 
While the patient has a reduced LVEF and is on medications for hypertension and heart failure, the patient does not have any signs of acute cardiac stress or acute coronary syndrome. The ECG does not show any signs of arrhythmias, and the patient's laboratory results are relatively stable. However, the patient's reduced LVEF and NYHA Class II symptoms suggest that the patient is at risk for cardiac events. If the patient's heart failure worsens or the patient develops acute coronary syndrome, the risk of sudden cardiac death increases.

3. Pump Failure Death
REASONING: 
The patient's reduced LVEF and NYHA Class II symptoms suggest that the patient has significant heart failure, which can lead to pump failure. However, the patient is currently on medications that are aimed at managing heart failure, and the patient's laboratory results are relatively stable. The patient's Pro-BNP level is mildly elevated, which may indicate some degree of heart failure. However, the patient's overall clinical picture is not as severe as to warrant a high risk of pump failure death. The patient's age and comorbidities (hypertension, diabetes) also increase the risk of cardiovascular events, but the patient's current condition is stable, and the patient is likely to survive with proper management."
323,323,P0530,"Age: 74
Gender: Female 
Weight: 69 kg
Height: 136 cm
NYHA Class: II
Blood Pressure: 120/75 mmHg
Past Medical History: Hypertensive cardiomyopathy, Diabetes, Dyslipemia, Hypertension
Albumin (g/L): 35,4
ALT or GPT (IU/L): 11.0
AST or GOT (IU/L): 16.0
Total Cholesterol (mmol/L): 5,9
Creatinine (mmol/L): 103.0
Gamma-glutamil transpeptidase (IU/L): 25
Glucose (mmol/L): 6,1
Hemoglobin (g/L): 116.0
HDL (mmol/L): 1,86
Potassium (mEq/L): 3,8
LDL (mmol/L): 3,41
Sodium (mEq/L): 142.0
Pro-BNP (ng/L): 1464.0
Protein (g/L): 68
T3 (pg/dL): 0,03
T4 (ng/L): 20
Troponin (ng/mL): 0,01
TSH (mIU/L): 3,47
Urea (mg/dL): 10,69
LVEF (%): 24.0
Medications: Diabetes Medication, Amiodarone, Beta Blockers, Loop Diuretics, Statins, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"RANKING: 

1. Survivor
REASONING: 
The patient has a history of Hypertensive cardiomyopathy, which is a significant risk factor for cardiac events. However, the patient is currently being treated with ACE inhibitor, Beta Blockers, and Loop Diuretics, which are standard treatments for this condition. The patient's NYHA Class II indicates mild symptoms, suggesting that the disease is not severe. The patient's ECG results show no signs of ventricular tachycardia or non-sustained ventricular tachycardia, which are indicators of increased risk for sudden cardiac death. The patient's LVEF is 24%, which is significantly reduced, indicating left ventricular dysfunction, but the patient is still being treated for this condition. The patient's biomarkers, such as Troponin and Pro-BNP, are elevated, indicating some degree of cardiac stress, but not at critically high levels. Overall, considering the patient's treatment and symptoms, the likelihood of survival is higher than the other two options.

2. Pump failure death
REASONING: 
The patient's LVEF is significantly reduced at 24%, indicating left ventricular dysfunction, which increases the risk of pump failure. The patient's elevated Pro-BNP levels (1464.0 ng/L) and elevated Creatinine levels (10.69 mg/dL) suggest some degree of cardiac stress and kidney dysfunction. The patient's hypertension, diabetes, and dyslipidemia also increase the risk of cardiac events. Although the patient is being treated with medications that can help manage these conditions, the patient's overall cardiovascular risk factors and biomarkers suggest a higher risk of pump failure.

3. Sudden cardiac death
REASONING: 
The patient's ECG results show no signs of ventricular tachycardia or non-sustained ventricular tachycardia, which are indicators of increased risk for sudden cardiac death. However, the patient's history of Hypertensive cardiomyopathy and elevated biomarkers, such as Troponin and Pro-BNP, suggest some degree of cardiac stress. While the patient is being treated for this condition, the patient's LVEF is significantly reduced, and the patient's overall cardiovascular risk factors suggest a higher risk of cardiac events. However, the patient's lack of evidence for ventricular arrhythmias makes sudden cardiac death less likely compared to pump failure death."
324,324,P0531,"Age: 53
Gender: Male 
Weight: 95 kg
Height: 176 cm
NYHA Class: II
Blood Pressure: 175/100 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Dyslipemia, Hypertension, Myocardial Infarction
Albumin (g/L): 43,6
ALT or GPT (IU/L): 95.0
AST or GOT (IU/L): 52.0
Total Cholesterol (mmol/L): 5,53
Creatinine (mmol/L): 123.0
Gamma-glutamil transpeptidase (IU/L): 67
Glucose (mmol/L): 6,8
Hemoglobin (g/L): 162.0
HDL (mmol/L): 0,98
Potassium (mEq/L): 4,1
LDL (mmol/L): 3,52
Sodium (mEq/L): 143.0
Pro-BNP (ng/L): 644.0
Protein (g/L): 73
T3 (pg/dL): 0,05
T4 (ng/L): 18
Troponin (ng/mL): 0,01
TSH (mIU/L): 5,3
Urea (mg/dL): 10,69
LVEF (%): 45.0
Medications: Calcium Channel Blocker, Angiotensin II Receptor Blocker, Beta Blockers, Statins, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"RANKING: 
1. Survivor 
REASONING: 
This patient has a complex medical history with ischemic dilated cardiomyopathy, hypertension, and previous myocardial infarction, which suggests a high risk for adverse cardiac events. However, the patient is currently taking multiple medications for these conditions, including beta blockers and ACE inhibitors, which are known to improve outcomes in patients with heart failure. The patient's NYHA Class II indicates that they are able to perform moderate physical activity without symptoms, which is a positive prognostic sign. Additionally, the patient's LVEF is 45%, which is within the range of patients who can still benefit from cardiac rehabilitation and lifestyle modifications. The patient's recent ECG findings, including ventricular extrasystoles and polymorphic ventricular tachycardia, do not indicate a high risk for sudden cardiac death. Overall, the combination of multiple medications, a moderate NYHA Class, and a reasonable LVEF make a survivor the most likely outcome.

2. Sudden cardiac death 
REASONING: 
While the patient's complex medical history and recent ECG findings do increase the risk for adverse cardiac events, the presence of multiple medications and a moderate NYHA Class suggest that the risk for sudden cardiac death is not the most likely outcome. However, the patient's LVEF of 45% and elevated troponin levels may indicate some degree of myocardial damage, which could increase the risk for arrhythmias and sudden cardiac death. Additionally, the patient's elevated creatinine levels and anemia (Hemoglobin 162 g/L) may indicate some degree of renal dysfunction, which can be a risk factor for cardiac complications.

3. Pump failure death 
REASONING: 
Given the patient's complex medical history, moderate NYHA Class, and elevated creatinine levels, pump failure death is a possible outcome. However, the patient's current medications, including ACE inhibitors and beta blockers, are designed to slow the progression of heart failure and improve outcomes. Additionally, the patient's LVEF of 45% suggests that the patient is not in advanced heart failure, and the recent ECG findings do not indicate a high risk for sudden cardiac death. While the patient's elevated troponin levels and anemia may indicate some degree of myocardial damage, the overall clinical picture suggests that pump failure death is less likely than sudden cardiac death."
325,325,P0532,"Age: 74
Gender: Female 
Weight: 78 kg
Height: 148 cm
NYHA Class: III
Blood Pressure: 105/70 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Dyslipemia, Hypertension
Albumin (g/L): 43
ALT or GPT (IU/L): 12.0
AST or GOT (IU/L): 15.0
Total Cholesterol (mmol/L): 4,65
Creatinine (mmol/L): 115.0
Gamma-glutamil transpeptidase (IU/L): 17
Glucose (mmol/L): 5,6
Hemoglobin (g/L): 122.0
HDL (mmol/L): 0,96
Potassium (mEq/L): 4,5
LDL (mmol/L): 2,56
Sodium (mEq/L): 142.0
Pro-BNP (ng/L): 531.0
Protein (g/L): 77
T3 (pg/dL): 0,05
T4 (ng/L): 16
Troponin (ng/mL): 0,01
TSH (mIU/L): 3,51
Urea (mg/dL): 11,36
LVEF (%): 33.0
Medications: Angiotensin II Receptor Blocker, Beta Blockers, Loop Diuretics, Spironolactone, Statins, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",survivor,"RANKING: 1. Survivor
REASONING: 

This patient is at a high risk for adverse outcomes due to the presence of several comorbidities, including ischemic dilated cardiomyopathy, hypertension, and dyslipidemia. The patient's left ventricular ejection fraction (LVEF) is severely impaired at 33%, indicating significant left ventricular dysfunction. The presence of ventricular extrasystoles, non-sustained ventricular tachycardia, and polymorphic ventricular extrasystoles on the ECG also increase the risk of arrhythmias and potentially life-threatening cardiac events.

The patient's current medication regimen, including beta blockers, ACE inhibitors, and statins, is generally appropriate for managing hypertension, heart failure, and dyslipidemia. However, the patient's elevated creatinine level (115.0 mmol/L) suggests some degree of renal impairment, which may impact the effectiveness of certain medications.

Despite these factors, the patient's overall clinical status and the presence of a positive PATIENT OUTCOME: survivor indicates a relatively good prognosis. The patient's age and sex are also in favor of a favorable outcome, as women tend to live longer than men with similar cardiovascular disease profiles.

While the patient is at risk for adverse outcomes, the combination of a positive PATIENT OUTCOME: survivor and the patient's current clinical status suggest that the patient is likely to survive for the next few years.

RANKING: 2. Sudden cardiac death
REASONING: 

The patient's LVEF is severely impaired, which increases the risk of sudden cardiac death. The presence of ventricular extrasystoles, non-sustained ventricular tachycardia, and polymorphic ventricular extrasystoles on the ECG further increases this risk. Additionally, the patient's elevated creatinine level may impact the effectiveness of certain medications, which could increase the risk of arrhythmias.

RANKING: 3. Pump failure death
REASONING: 

While the patient's LVEF is severely impaired, the patient's current medication regimen and clinical status suggest that they are likely to survive for the next few years. The presence of a positive PATIENT OUTCOME: survivor indicates that the patient is likely to survive for at least a short period. However, the patient's impaired LVEF and the presence of ventricular arrhythmias increase the risk of pump failure, making this outcome more likely in the long term."
326,326,P0534,"Age: 73
Gender: Male 
Weight: 94 kg
Height: 163 cm
NYHA Class: III
Blood Pressure: 140/70 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Diabetes, Dyslipemia, Peripheral vascular disease, Hypertension, Myocardial Infarction
Albumin (g/L): 35
ALT or GPT (IU/L): 15.0
AST or GOT (IU/L): 20.0
Total Cholesterol (mmol/L): 4,03
Creatinine (mmol/L): 109.0
Gamma-glutamil transpeptidase (IU/L): 23
Glucose (mmol/L): 6,9
Hemoglobin (g/L): 136.0
HDL (mmol/L): 1,14
Potassium (mEq/L): 4,3
LDL (mmol/L): 2,35
Sodium (mEq/L): 140.0
Pro-BNP (ng/L): 1860.0
Protein (g/L): 74
T3 (pg/dL): 0,03
T4 (ng/L): 19
Troponin (ng/mL): 0,01
TSH (mIU/L): 2,42
Urea (mg/dL): 9,57
LVEF (%): 45.0
Medications: Diabetes Medication, Beta Blockers, Statins, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: TPSV
        - Bradycardia: No
            ",survivor,"RANKING: 
1. Survivor
REASONING: 
Based on the patient's data, the patient is a 73-year-old male with a history of ischemic dilated cardiomyopathy, diabetes, and hypertension. The patient's left ventricular ejection fraction (LVEF) is significantly reduced at 45%, indicating a severe impairment of cardiac function. The patient's troponin levels are within normal limits, suggesting that there is no acute myocardial infarction. The presence of ventricular extrasystole and polymorphic ventricular tachycardia on the ECG suggests an increased risk of arrhythmias, but this is not a contraindication to survival.

The patient's medication regimen, including beta blockers and ACE inhibitors, is standard for managing heart failure and hypertension. The patient's laboratory results show elevated creatinine levels, indicating impaired renal function, but this is not uncommon in patients with heart failure.

The patient's age, weight, and NYHA class III status also suggest a high risk of mortality. However, the patient's overall clinical presentation and laboratory results do not indicate any acute life-threatening conditions that would necessitate immediate intervention. Therefore, based on the available data, the patient is likely to survive for the next few years.

RANKING: 2. Sudden cardiac death
REASONING: 
While the patient's ECG shows ventricular extrasystole and polymorphic ventricular tachycardia, the patient's overall clinical presentation and laboratory results do not suggest a high risk of sudden cardiac death. The patient's troponin levels are normal, and the patient is on beta blockers and ACE inhibitors, which are standard for managing heart failure and hypertension.

However, the patient's LVEF is severely impaired, and the patient has a history of ischemic dilated cardiomyopathy, which increases the risk of sudden cardiac death. Additionally, the patient's elevated creatinine levels indicate impaired renal function, which can increase the risk of sudden cardiac death.

While the patient's age and NYHA class III status also increase the risk of mortality, the patient's overall clinical presentation and laboratory results do not suggest a high risk of sudden cardiac death.

RANKING: 3. Pump failure death
REASONING: 
Based on the patient's severely impaired LVEF and NYHA class III status, the patient is at high risk of pump failure. The patient's impaired renal function also increases the risk of pump failure, as the kidneys play a critical role in maintaining fluid balance and electrolyte homeostasis.

However, the patient's overall clinical presentation and laboratory results do not suggest any acute life-threatening conditions that would necessitate immediate intervention. The patient is on beta blockers and ACE inhibitors, which are standard for managing heart failure, and the patient's medication regimen is well-managed.

While the patient's age and history of ischemic dilated cardiomyopathy increase the risk of pump failure, the patient's current clinical presentation and laboratory results do not suggest a high risk of pump failure in the short term. Therefore, while pump failure is a possible outcome, it is less likely than sudden cardiac death."
327,327,P0537,"Age: 66
Gender: Male 
Weight: 77 kg
Height: 165 cm
NYHA Class: II
Blood Pressure: 140/70 mmHg
Past Medical History: Idiopathic dilated cardiomyopathy, Diabetes, Dyslipemia, Peripheral vascular disease
Albumin (g/L): 41,5
ALT or GPT (IU/L): 14.0
AST or GOT (IU/L): 16.0
Total Cholesterol (mmol/L): 6,8
Creatinine (mmol/L): 90.0
Gamma-glutamil transpeptidase (IU/L): 89
Glucose (mmol/L): 8,7
Hemoglobin (g/L): 151.0
HDL (mmol/L): 1,24
Potassium (mEq/L): 4,6
LDL (mmol/L): 3,88
Sodium (mEq/L): 139.0
Pro-BNP (ng/L): 688.0
Protein (g/L): 69
T3 (pg/dL): 0,06
T4 (ng/L): 15
Troponin (ng/mL): 0,01
TSH (mIU/L): 0,867
Urea (mg/dL): 5,34
LVEF (%): 22.0
Medications: Diabetes Medication, Angiotensin II Receptor Blocker, Beta Blockers, Loop Diuretics, Statins
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",survivor,"RANKING: 1. Survivor
REASONING: 

The patient's overall clinical presentation and test results suggest that they are at high risk for adverse cardiac events, but the presence of a favorable outcome (PATIENT OUTCOME: survivor) indicates that the patient's underlying cardiac condition is not yet in a state of acute crisis. 

The patient's NYHA Class II indicates that they have some symptoms of heart failure, but they are still able to perform moderate physical activity without significant distress. The patient's LVEF of 22% indicates severely reduced cardiac function, which is a strong predictor of poor outcomes. However, the absence of troponin elevation and the presence of a relatively normal potassium level suggest that the patient is not experiencing acute myocardial infarction or significant cardiac injury.

The patient's comorbidities, such as diabetes, dyslipidemia, and peripheral vascular disease, increase their risk for cardiovascular events. However, the patient is currently on medications that are standard for managing these conditions, including diabetes medication, angiotensin II receptor blockers, beta blockers, loop diuretics, and statins.

The elevated Pro-BNP level of 688 ng/L is consistent with heart failure, but it is not excessively elevated, suggesting that the patient's cardiac function may be somewhat stable. The presence of ventricular extrasystoles and paroxysmal supraventricular tachyarrhythmias on ECG suggests that the patient's heart is at risk for arrhythmias, but the absence of more severe arrhythmias or ventricular tachycardia suggests that the patient is not at high risk for sudden cardiac death.

Overall, while the patient's cardiac function is severely impaired, the absence of acute cardiac injury, the presence of favorable medications, and the relatively stable Pro-BNP level suggest that the patient may be able to survive for the next few years with close monitoring and management. Therefore, a survivor prognosis is the most likely outcome.

RANKING: 2. Sudden Cardiac Death
REASONING: 

The patient's severely reduced LVEF of 22% and the presence of ventricular extrasystoles on ECG suggest that the patient's cardiac function is severely impaired and at risk for arrhythmias. The patient's NYHA Class II indicates that they are experiencing some symptoms of heart failure, which increases their risk for cardiovascular events.

The patient's elevated Pro-BNP level of 688 ng/L is consistent with heart failure, and the patient's elevated creatinine level of 90.0 suggests that their kidneys are not functioning optimally, which can increase the risk for cardiovascular events.

The patient's comorbidities, such as diabetes and peripheral vascular disease, increase their risk for cardiovascular events, and the patient's elevated LDL level of 3.88 mmol/L suggests that their atherosclerotic burden is significant.

The patient's lack of response to beta blockers, which are typically used to improve cardiac function and reduce arrhythmias, suggests that their heart is not responding to standard therapies. The presence of ventricular extrasystoles on ECG suggests that the patient's heart is at risk for arrhythmias, which can be a precursor to sudden cardiac death.

While the patient is currently on medications, the presence of ventricular extrasystoles and the patient's severely impaired cardiac function suggest that the patient is at high risk for sudden cardiac death. Therefore, sudden cardiac death is a possible prognosis.

RANKING: 3. Pump Failure Death
REASONING: 

The patient's severely reduced LVEF of 22% and the presence of ventricular extrasystoles on ECG suggest that the patient's cardiac function is severely impaired. The patient's NYHA Class II indicates that they are experiencing some symptoms of heart failure, which increases their risk for cardiovascular events.

The patient's elevated Pro-BNP level of 688 ng/L is consistent with heart failure, and the patient's elevated creatinine level of 90.0 suggests that their kidneys are not functioning optimally, which can increase the risk for cardiovascular events.

The patient's comorbidities, such as diabetes and peripheral vascular disease, increase their risk for cardiovascular events, and the patient's elevated LDL level of 3.88 mmol/L suggests that their atherosclerotic burden is significant.

The patient's elevated potassium level of 4.6 mEq/L is elevated, which can increase the risk for cardiac arrhythmias. The patient's elevated TSH level of 0.867 suggests that their thyroid function is not optimal, which can increase the risk for cardiovascular events.

The patient's lack of response to beta blockers, which are typically used to improve cardiac function and reduce arrhythmias, suggests that their heart is not responding to standard therapies. The presence of ventricular extrasystoles on ECG suggests that the patient's heart is at risk for arrhythmias"
328,328,P0538,"Age: 61
Gender: Male 
Weight: 53 kg
Height: 170 cm
NYHA Class: II
Blood Pressure: 115/60 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Diabetes, Dyslipemia, Hypertension, Myocardial Infarction
Albumin (g/L): 42
ALT or GPT (IU/L): 25.0
AST or GOT (IU/L): 21.0
Total Cholesterol (mmol/L): 3,23
Creatinine (mmol/L): 85.0
Gamma-glutamil transpeptidase (IU/L): 31
Glucose (mmol/L): 9,8
Hemoglobin (g/L): 151.0
HDL (mmol/L): 0,85
Potassium (mEq/L): 4,5
LDL (mmol/L): 1,86
Sodium (mEq/L): 140.0
Pro-BNP (ng/L): 864.0
Protein (g/L): 67
T3 (pg/dL): 0,04
T4 (ng/L): 16
Troponin (ng/mL): 0,01
TSH (mIU/L): 2,11
Urea (mg/dL): 12,91
LVEF (%): 35.0
Medications: Diabetes Medication, Beta Blockers, Statins, ACE Inhibitor, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: TPSV
        - Bradycardia: No
            ",survivor,"RANKING: 
1. Survivor
REASONING:
The patient is a 61-year-old male with a history of ischemic dilated cardiomyopathy, which is a significant risk factor for adverse outcomes. However, the patient's current NYHA Class II indicates that the disease is not severely limiting his physical activity. The patient's LVEF of 35% is also concerning, as it suggests that the heart is not functioning efficiently.

Despite these concerns, the patient's current medication regimen, which includes beta blockers, statins, ACE inhibitors, and a nitrovasodilator, suggests that the patient is receiving standard therapy for his condition. The patient's laboratory results are also relatively stable, with no significant elevations in liver enzymes, electrolytes, or creatinine.

The ECG impression highlights the presence of ventricular extrasystole and non-sustained ventricular tachycardia, which are both concerning signs of arrhythmia. However, the absence of sustained ventricular tachycardia and paroxysmal supraventricular tachyarrhythmia suggests that the patient is not at high risk for sudden cardiac death.

Overall, the patient's overall clinical picture suggests that he is at risk for pump failure, but the presence of beta blockers and ACE inhibitors, as well as a relatively stable laboratory profile, suggest that he may be able to survive with proper management. Therefore, a survivor prognosis is the most likely outcome.

2. Sudden cardiac death
REASONING:
The patient's LVEF of 35% is a significant concern, as it indicates that the heart is not functioning efficiently. Additionally, the presence of ventricular extrasystole and non-sustained ventricular tachycardia on the ECG suggests that the patient is at risk for arrhythmia.

While the patient is receiving standard therapy for his condition, the presence of these arrhythmias increases the risk for sudden cardiac death. Furthermore, the patient's history of myocardial infarction and ischemic dilated cardiomyopathy increases the risk for sudden cardiac death.

However, the patient's stable laboratory results and the absence of significant elevations in electrolytes or creatinine suggest that the patient is not at high risk for acute cardiac events. Therefore, while sudden cardiac death is a possible outcome, it is not the most likely.

3. Pump failure death
REASONING:
The patient's LVEF of 35% is a significant concern, as it indicates that the heart is not functioning efficiently. The patient's history of ischemic dilated cardiomyopathy and myocardial infarction also increases the risk for pump failure.

However, the patient is receiving standard therapy for his condition, which includes beta blockers and ACE inhibitors, and the patient's laboratory results are relatively stable. The absence of significant elevations in liver enzymes, electrolytes, or creatinine also suggests that the patient is not at high risk for acute cardiac events.

While pump failure is a possible outcome, it is less likely than sudden cardiac death, given the patient's stable laboratory results and the presence of beta blockers and ACE inhibitors. Therefore, pump failure death is the least likely outcome."
329,329,P0541,"Age: 61
Gender: Male 
Weight: 74 kg
Height: 166 cm
NYHA Class: II
Blood Pressure: 135/70 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Diabetes, Dyslipemia, Hypertension, Myocardial Infarction
Albumin (g/L): 44,8
ALT or GPT (IU/L): 13.0
AST or GOT (IU/L): 17.0
Total Cholesterol (mmol/L): 5,15
Creatinine (mmol/L): 124.0
Gamma-glutamil transpeptidase (IU/L): 18
Glucose (mmol/L): 6,7
Hemoglobin (g/L): 142.0
HDL (mmol/L): 1,09
Potassium (mEq/L): 4,8
LDL (mmol/L): 3,54
Sodium (mEq/L): 141.0
Pro-BNP (ng/L): 1751.0
Protein (g/L): 72
T3 (pg/dL): 0,04
T4 (ng/L): 14
Troponin (ng/mL): 0,01
TSH (mIU/L): 3,61
Urea (mg/dL): 12,25
LVEF (%): 40.0
Medications: Diabetes Medication, Beta Blockers, Statins, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"RANKING: 1. Survivor
REASONING: 
Based on the patient's data, I would rank the patient as a survivor with a high probability. The patient's NYHA Class II indicates that they have some limitations with physical activity, but they are still able to perform daily activities without severe symptoms. Their LVEF of 40% is significantly reduced, but this is not uncommon in patients with ischemic dilated cardiomyopathy. The patient's biomarkers, such as Troponin and Creatinine, are not significantly elevated, suggesting that there is no acute myocardial injury or renal failure.

The patient's medication regimen, which includes ACE inhibitors, beta blockers, and statins, is well-established for managing their underlying conditions, including hypertension, diabetes, and dyslipidemia. The absence of ventricular tachycardia, non-sustained ventricular tachycardia, and bradycardia on the ECG also suggests that the patient is not at high risk for sudden cardiac death.

The patient's elevated Pro-BNP level (1751.0 ng/L) may indicate some degree of heart failure, but the patient's weight and hemoglobin level are within normal limits, and the patient is not experiencing any acute symptoms. Therefore, I believe that the patient's overall condition is stable, and they have a good chance of survival over the next few years.

RANKING: 2. Pump failure death
REASONING: 
A possible alternative prognosis is pump failure death, which would occur when the patient's heart is unable to meet the body's oxygen demands, leading to a decline in cardiac function and ultimately, death. While the patient's LVEF is significantly reduced, their current biomarkers and symptoms do not suggest acute heart failure. However, if the patient's heart function continues to decline, it is possible that they may experience a gradual decline in cardiac function, leading to pump failure.

RANKING: 3. Sudden cardiac death
REASONING: 
Given the patient's history of ischemic dilated cardiomyopathy, hypertension, and the presence of ventricular extrasystoles, there is a slight risk of sudden cardiac death. However, the patient's ECG results do not show any signs of ventricular tachycardia, non-sustained ventricular tachycardia, or bradycardia, which are common precursors to sudden cardiac death. Additionally, the patient's medication regimen is well-established and well-managed, which reduces the risk of sudden cardiac death. Therefore, I consider this prognosis to be the least likely."
330,330,P0542,"Age: 62
Gender: Male 
Weight: 72 kg
Height: 170 cm
NYHA Class: II
Blood Pressure: 135/65 mmHg
Past Medical History: Enolic dilated cardiomyopathy, Dyslipemia, Hypertension
Albumin (g/L): 51,2
ALT or GPT (IU/L): 17.0
AST or GOT (IU/L): 21.0
Total Cholesterol (mmol/L): 5,33
Creatinine (mmol/L): 107.0
Gamma-glutamil transpeptidase (IU/L): 24
Glucose (mmol/L): 5,4
Hemoglobin (g/L): 162.0
HDL (mmol/L): 1,5
Potassium (mEq/L): 4,9
LDL (mmol/L): 3,34
Sodium (mEq/L): 137.0
Pro-BNP (ng/L): 358.0
Protein (g/L): 77
T3 (pg/dL): 0,05
T4 (ng/L): 14
Troponin (ng/mL): 0,01
TSH (mIU/L): 2,46
Urea (mg/dL): 9,35
LVEF (%): 40.0
Medications: Statins, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"RANKING: 

1. Survivor
REASONING: 
Based on the provided patient data, I rank the patient as a survivor for the next few years due to the following reasons:

- The patient's age (62) and NYHA Class II status indicate that they have a moderate level of heart disease, but they are not in the advanced stages of heart failure.
- The patient's LVEF of 40% is significantly reduced, indicating a reduced cardiac function, but it is not severely impaired.
- The presence of Enolic dilated cardiomyopathy, Dyslipemia, and Hypertension suggests that the patient has underlying heart disease, but these conditions are not immediately life-threatening.
- The patient's blood tests, including electrolytes, liver enzymes, and kidney function, do not indicate severe organ dysfunction.
- The absence of significant elevations in Troponin levels, TSH, and other markers of acute cardiac injury or thyroid dysfunction suggests that the patient does not have an acute cardiac event or thyroid disorder.
- The patient's ECG findings, including ventricular extrasystole, non-sustained ventricular tachycardia, and non-sustained ventricular tachycardia, are concerning for cardiac arrhythmias, but the absence of sustained ventricular tachycardia or other life-threatening arrhythmias reduces the risk of sudden cardiac death.
- The patient is currently on medications for dyslipidemia and hypertension, which suggests that they are receiving adequate treatment for their underlying conditions.

Overall, while the patient has a reduced LVEF and a history of heart disease, their current medical status and treatment plan suggest that they are likely to survive for the next few years without significant progression of their heart disease or acute cardiac events."
331,331,P0543,"Age: 63
Gender: Female 
Weight: 82 kg
Height: 166 cm
NYHA Class: II
Blood Pressure: 125/80 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Dyslipemia, Hypertension, Myocardial Infarction
Albumin (g/L): 41,4
ALT or GPT (IU/L): 9.0
AST or GOT (IU/L): 20.0
Total Cholesterol (mmol/L): 4,63
Creatinine (mmol/L): 88.0
Gamma-glutamil transpeptidase (IU/L): 9
Glucose (mmol/L): 4,5
Hemoglobin (g/L): 144.0
HDL (mmol/L): 1,78
Potassium (mEq/L): 4,5
LDL (mmol/L): 2,51
Sodium (mEq/L): 142.0
Pro-BNP (ng/L): 1726.0
Protein (g/L): 66
T3 (pg/dL): 0,05
T4 (ng/L): 15
Troponin (ng/mL): 0,01
TSH (mIU/L): 8,18
Urea (mg/dL): 9,13
LVEF (%): 39.0
Medications: Beta Blockers, Loop Diuretics, Statins, ACE Inhibitor, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"RANKING: 1. Survivor
REASONING: 
The patient's overall clinical presentation and test results indicate a high risk of adverse cardiac events, but the patient is currently alive and receiving treatment. The presence of ischemic dilated cardiomyopathy, hypertension, and dyslipidemia increases the risk of cardiac events. However, the patient is already on medications that target these conditions, such as beta blockers, statins, and ACE inhibitors, which are known to improve outcomes in patients with heart failure and coronary artery disease. The elevated LVEF of 39% is a significant concern, but the patient's current symptoms and ECG findings do not suggest an immediate life-threatening arrhythmia. The presence of non-sustained ventricular tachycardia (NSVT) is a significant risk factor for sudden cardiac death, but the patient's current medications and the fact that NSVT is non-sustained reduce this risk. The patient's low T3 level (0.05 pg/dL) and elevated Pro-BNP level (1726 ng/L) suggest cardiac stress and increased ventricular wall tension, but these findings do not necessarily indicate a catastrophic outcome. 

Given the patient's current clinical status and treatment, the likelihood of survival is higher than the other two options. The patient's low weight, age, and low BMI do not significantly contribute to an increased risk of mortality in this scenario."
332,332,P0544,"Age: 61
Gender: Male 
Weight: 92 kg
Height: 165 cm
NYHA Class: III
Blood Pressure: 130/65 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Hypertension, Myocardial Infarction
Albumin (g/L): 49
ALT or GPT (IU/L): 27.0
AST or GOT (IU/L): 22.0
Total Cholesterol (mmol/L): 3,59
Creatinine (mmol/L): 124.0
Gamma-glutamil transpeptidase (IU/L): 51
Glucose (mmol/L): 6,8
Hemoglobin (g/L): 125.0
HDL (mmol/L): 1,37
Potassium (mEq/L): 4
LDL (mmol/L): 1,29
Sodium (mEq/L): 140.0
Pro-BNP (ng/L): 823.0
Protein (g/L): 76
T3 (pg/dL): 0,05
T4 (ng/L): 21
Troponin (ng/mL): 0,01
TSH (mIU/L): 0,37
Urea (mg/dL): 7,57
LVEF (%): 35.0
Medications: Angiotensin II Receptor Blocker, Digoxin, Loop Diuretics, Spironolactone, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",survivor,"RANKING: 
1. Survivor
REASONING:
The patient's overall clinical presentation and test results suggest that they are at high risk for adverse cardiac events, but the presence of a positive outcome indicates that the patient's current treatment and management plan are effective in preventing a fatal outcome. 

The patient's NYHA Class III indicates severe heart failure, and their LVEF of 35% is significantly reduced, suggesting poor cardiac function. Their elevated creatinine level (124.0 mmol/L) and high BNP level (823.0 ng/L) also indicate severe cardiac strain. However, the patient's blood pressure is well-controlled, and their medications, including an ACE inhibitor (Angiotensin II Receptor Blocker), beta-blocker (Digoxin), and diuretics, are standard treatments for heart failure and hypertension.

The presence of non-sustained ventricular tachycardia (NSVT) on the ECG is a significant concern, as it can be a precursor to ventricular fibrillation or ventricular tachycardia, both of which can lead to sudden cardiac death. However, the fact that the patient is a survivor suggests that their current treatment and management plan are effective in managing this risk.

While the patient's cardiac function is severely impaired, their current treatment plan appears to be effective in managing their symptoms and preventing a fatal outcome. Therefore, the most likely prognosis for the patient over the next few years is that they will survive.

2. Sudden Cardiac Death
REASONING:
While the patient's ECG shows signs of ventricular extrasystole and NSVT, which are risk factors for sudden cardiac death, the patient's overall clinical presentation and test results do not suggest a sudden onset of symptoms or a sudden cardiac event. The patient's current treatment plan appears to be effective in managing their heart failure and hypertension, which reduces the risk of sudden cardiac death.

However, the patient's reduced LVEF and elevated BNP level suggest that their cardiac function is severely impaired, and they are at risk for further cardiac events. The presence of NSVT on the ECG is a significant concern, but the fact that the patient is a survivor suggests that their current treatment plan is effective in managing this risk.

3. Pump Failure Death
REASONING:
Given the patient's severely reduced LVEF (35%) and elevated BNP level (823.0 ng/L), it is likely that the patient's cardiac function will continue to decline over time. Their current treatment plan is aimed at managing symptoms and preventing a fatal outcome, but it is unlikely to significantly improve their cardiac function.

The patient's NYHA Class III indicates severe heart failure, and their elevated creatinine level (124.0 mmol/L) suggests that their kidney function is also impaired. While their current treatment plan is effective in managing their symptoms, it is unlikely to reverse their cardiac dysfunction, and pump failure is a likely outcome over the next few years."
333,333,P0546,"Age: 83
Gender: Male 
Weight: 68 kg
Height: 161 cm
NYHA Class: II
Blood Pressure: 160/80 mmHg
Past Medical History: Idiopathic dilated cardiomyopathy, Diabetes, Dyslipemia, Hypertension
Albumin (g/L): 43
ALT or GPT (IU/L): 15.0
AST or GOT (IU/L): 17.0
Total Cholesterol (mmol/L): 5,78
Creatinine (mmol/L): 104.0
Gamma-glutamil transpeptidase (IU/L): 74
Glucose (mmol/L): 9,65
Hemoglobin (g/L): 142.0
HDL (mmol/L): 1,4
Potassium (mEq/L): 4,05
LDL (mmol/L): 3,77
Sodium (mEq/L): 139.0
Protein (g/L): 68
T3 (pg/dL): 0,0375
T4 (ng/L): 21,95
Troponin (ng/mL): 0,1
TSH (mIU/L): 1,15
Urea (mg/dL): 6,5
LVEF (%): 30.0
Medications: Diabetes Medication, Amiodarone, Loop Diuretics, Statins, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: TPSV
        - Bradycardia: No
            ",survivor,"RANKING: 1. Survivor
REASONING: 

Based on the provided patient data, the patient is 83 years old with a history of idiopathic dilated cardiomyopathy, which is a significant risk factor for adverse cardiac outcomes. The patient's left ventricular ejection fraction (LVEF) is severely impaired at 30%, indicating significant systolic dysfunction. The presence of ventricular extrasystoles, specifically polymorphic ventricular extrasystoles, on the ECG suggests an increased risk of arrhythmias, which can lead to sudden cardiac death. However, the absence of ventricular tachycardia, non-sustained ventricular tachycardia, and paroxysmal supraventricular tachyarrhythmia on the ECG reduces the likelihood of sudden cardiac death.

The patient's medications, including Amiodarone, which is an anti-arrhythmic medication, suggest that the clinician is actively managing arrhythmias. The patient's creatinine level is elevated at 104.0, which may indicate impaired renal function, but this is not directly related to cardiac function.

Given the patient's advanced age, history of heart disease, and the presence of arrhythmias, the most likely outcome is that the patient will survive the next few years. However, the patient will likely require close monitoring and adjustments to their medication regimen to manage their cardiac condition and prevent further decline.

RANKING: 2. Pump failure death
REASONING: 

Although the patient's LVEF is severely impaired, which increases the risk of pump failure, the patient's current medication regimen, including ACE inhibitors and statins, suggests that the clinician is actively managing heart failure. However, the patient's elevated creatinine level and impaired renal function may further compromise cardiac function and increase the risk of pump failure.

The patient's elevated troponin level of 0.1 ng/mL is within the normal range, which suggests that there is no acute myocardial infarction. However, the patient's history of hypertension, dyslipidemia, and diabetes increases the risk of cardiovascular events, including pump failure.

RANKING: 3. Sudden cardiac death
REASONING: 

The patient's polymorphic ventricular extrasystoles on the ECG increase the risk of sudden cardiac death, especially in the context of their advanced age and history of heart disease. However, the absence of ventricular tachycardia and non-sustained ventricular tachycardia on the ECG reduces the likelihood of sudden cardiac death.

The patient's medications, including Amiodarone, reduce the risk of arrhythmias, but the patient's history of idiopathic dilated cardiomyopathy and impaired renal function may increase the risk of cardiac events, including sudden cardiac death.

Overall, while the patient's ECG findings suggest an increased risk of arrhythmias, the patient's current medication regimen and medical history suggest that pump failure is a more likely outcome than sudden cardiac death."
334,334,P0547,"Age: 30
Gender: Female 
Weight: 64 kg
Height: 161 cm
NYHA Class: II
Blood Pressure: 110/70 mmHg
Past Medical History: Idiopathic dilated cardiomyopathy
Albumin (g/L): 43
ALT or GPT (IU/L): 7.0
AST or GOT (IU/L): 13.0
Total Cholesterol (mmol/L): 6,65
Creatinine (mmol/L): 71.0
Gamma-glutamil transpeptidase (IU/L): 11
Glucose (mmol/L): 4,6
Hemoglobin (g/L): 142.0
HDL (mmol/L): 1,34
Potassium (mEq/L): 4,4
LDL (mmol/L): 4,99
Sodium (mEq/L): 136.0
Pro-BNP (ng/L): 89.0
Protein (g/L): 72
T3 (pg/dL): 0,04
T4 (ng/L): 18
Troponin (ng/mL): 0,03
TSH (mIU/L): 0,44
Urea (mg/dL): 3,83
LVEF (%): 50.0
Medications: Beta Blockers, Loop Diuretics, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"RANKING: 1. Survivor
REASONING: The patient's overall clinical presentation, laboratory results, and ECG findings suggest that the patient is likely to survive for the next few years. The patient's NYHA class II indicates that they have some symptoms of heart failure, but they are still able to perform daily activities without severe limitation. The patient's LVEF is 50%, which is below the normal range, indicating some degree of left ventricular dysfunction. However, the patient's ejection fraction is not severely impaired, and they are not in cardiogenic shock.

The patient's laboratory results show that their creatinine level is elevated, which may indicate some degree of kidney impairment, but it is not severely elevated. The patient's electrolyte levels are also slightly abnormal, but these are not severe. The patient's troponin level is within the normal range, indicating that there is no evidence of acute myocardial infarction.

The patient's ECG findings are mostly normal, with only a few minor abnormalities, including ventricular extrasystoles. There is no evidence of ventricular tachycardia or non-sustained ventricular tachycardia, which are both associated with a higher risk of sudden cardiac death.

Given the patient's overall clinical presentation and laboratory results, I believe that the patient is at low risk for sudden cardiac death and pump failure death in the next few years. Therefore, I predict that the patient will survive.

RANKING: 2. Pump failure death
REASONING: While the patient's LVEF is below normal, the patient's overall clinical presentation and laboratory results do not suggest a high risk for pump failure death. The patient's NYHA class II indicates that they have some symptoms of heart failure, but they are still able to perform daily activities without severe limitation. The patient's creatinine level is elevated, but it is not severely elevated, and the patient's electrolyte levels are not severely abnormal.

However, the patient's LVEF is below normal, and the patient is on medications that are used to treat heart failure, including beta blockers, loop diuretics, and ACE inhibitors. These medications can help to improve the patient's symptoms and slow the progression of heart failure, but they may not completely prevent pump failure.

Therefore, while the patient is at some risk for pump failure, I believe that the patient is still at low risk for pump failure death in the next few years.

RANKING: 3. Sudden cardiac death
REASONING: The patient's ECG findings do show ventricular extrasystoles, which can be a sign of cardiac arrhythmias. However, the patient's ventricular tachycardia and non-sustained ventricular tachycardia are both normal, and the patient does not have any other signs of cardiac arrhythmias.

Additionally, the patient's laboratory results show that their troponin level is within the normal range, indicating that there is no evidence of acute myocardial infarction. The patient's creatinine level is elevated, but it is not severely elevated, and the patient's electrolyte levels are not severely abnormal.

Given the patient's overall clinical presentation and laboratory results, I believe that the patient is at low risk for sudden cardiac death in the next few years. However, the presence of ventricular extrasystoles does suggest a slightly increased risk for cardiac arrhythmias, which could potentially lead to sudden cardiac death."
335,335,P0548,"Age: 75
Gender: Male 
Weight: 82 kg
Height: 179 cm
NYHA Class: III
Blood Pressure: 110/70 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Diabetes, Myocardial Infarction
Albumin (g/L): 39
ALT or GPT (IU/L): 39.0
AST or GOT (IU/L): 32.0
Total Cholesterol (mmol/L): 3,28
Creatinine (mmol/L): 97.0
Gamma-glutamil transpeptidase (IU/L): 34
Glucose (mmol/L): 8,4
Hemoglobin (g/L): 164.0
HDL (mmol/L): 1,42
Potassium (mEq/L): 5,2
LDL (mmol/L): 1,03
Sodium (mEq/L): 136.0
Pro-BNP (ng/L): 450.0
Protein (g/L): 67
T3 (pg/dL): 0,04
T4 (ng/L): 19
Troponin (ng/mL): 0,13
TSH (mIU/L): 2,29
Urea (mg/dL): 7,15
LVEF (%): 38.0
Medications: Beta Blockers, Digoxin, Spironolactone, Statins, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"RANKING: 
1. Survivor
REASONING: 
Based on the provided patient data, I would rank the patient as a survivor for the next few years. The patient's age, NYHA Class III status, and history of ischemic dilated cardiomyopathy, myocardial infarction, and diabetes increase the risk of adverse outcomes. However, the patient's current LVEF of 38.0 is relatively preserved, and the patient is on optimal medications for heart failure management (beta blockers, digoxin, spironolactone, statins, and ACE inhibitor). The absence of significant elevation in troponin levels and the patient's relatively normal hemoglobin level also suggest that the patient's cardiac function is not severely compromised.

The presence of ventricular extrasystoles, non-sustained ventricular tachycardia, and paroxysmal supraventricular tachyarrhythmia on the ECG impression indicates an increased risk of arrhythmias, which may pose a threat to the patient's survival. However, the patient's overall clinical profile, including the absence of severe hypotension, and the presence of a relatively preserved LVEF, suggest that the patient can be managed effectively with current medications and close monitoring.

While the patient's Pro-BNP level is elevated, which is a marker of heart failure, the patient's NYHA Class III status and the presence of optimal medications suggest that the patient's heart failure symptoms are well-managed. The patient's weight, height, and blood pressure are also within normal limits, which further supports the patient's ability to survive the next few years.

In conclusion, while the patient has several risk factors for adverse outcomes, the combination of optimal medications, relatively preserved cardiac function, and the absence of severe symptoms make it more likely that the patient will survive the next few years.

RANKING: 
2. Sudden cardiac death
REASONING: 
The patient's history of ventricular tachycardia and non-sustained ventricular tachycardia, as well as the presence of ventricular extrasystoles on the ECG impression, increase the risk of arrhythmias, which can lead to sudden cardiac death. The patient's relatively preserved LVEF and optimal medications suggest that the patient's cardiac function is not severely compromised, but the presence of arrhythmias increases the risk of sudden cardiac death.

The patient's age, NYHA Class III status, and history of ischemic dilated cardiomyopathy also increase the risk of cardiac-related complications, but the patient's relatively preserved cardiac function and optimal medications mitigate this risk.

While the patient's Pro-BNP level is elevated, which is a marker of heart failure, the patient's NYHA Class III status and the presence of optimal medications suggest that the patient's heart failure symptoms are well-managed. However, the presence of arrhythmias increases the risk of sudden cardiac death.

RANKING: 
3. Pump failure death
REASONING: 
The patient's NYHA Class III status and history of ischemic dilated cardiomyopathy increase the risk of pump failure. The patient's LVEF of 38.0 is relatively preserved, but the patient's Pro-BNP level is elevated, which suggests that the patient's heart is working harder to pump blood, increasing the risk of pump failure.

The patient's elevated creatinine level and slightly elevated blood pressure also suggest that the patient's kidneys are not functioning optimally, which can increase the risk of pump failure.

While the patient is on optimal medications for heart failure management, the presence of ventricular tachycardia and non-sustained ventricular tachycardia on the ECG impression increases the risk of arrhythmias, which can lead to pump failure. However, the patient's relatively preserved cardiac function and optimal medications mitigate this risk.

In conclusion, while the patient has several risk factors for pump failure, the combination of relatively preserved cardiac function, optimal medications, and the absence of severe symptoms make it less likely that the patient will experience pump failure death in the next few years."
336,336,P0549,"Age: 56
Gender: Male 
Weight: 96 kg
Height: 175 cm
NYHA Class: II
Blood Pressure: 100/60 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Dyslipemia, Hypertension, Myocardial Infarction
Albumin (g/L): 42
ALT or GPT (IU/L): 26.0
AST or GOT (IU/L): 25.0
Total Cholesterol (mmol/L): 4,55
Creatinine (mmol/L): 124.0
Gamma-glutamil transpeptidase (IU/L): 31
Glucose (mmol/L): 5,6
Hemoglobin (g/L): 147.0
HDL (mmol/L): 0,91
Potassium (mEq/L): 4,3
LDL (mmol/L): 2,59
Sodium (mEq/L): 140.0
Pro-BNP (ng/L): 561.0
Protein (g/L): 76
T3 (pg/dL): 0,04
T4 (ng/L): 18
Troponin (ng/mL): 0,03
TSH (mIU/L): 1,2
Urea (mg/dL): 6,32
LVEF (%): 54.0
Medications: Beta Blockers, Loop Diuretics, Spironolactone, Statins, ACE Inhibitor, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: TPSV
        - Bradycardia: No
            ",survivor,"RANKING: 
1. Survivor
REASONING: 
Based on the provided patient data, I predict a high likelihood of survival for the next few years. The patient's age is 56, which is considered middle-aged, but not elderly. The patient's NYHA Class II indicates that they have some symptoms of heart failure, but they are not severely limited in their physical activities. The patient's LVEF is 54%, which is significantly reduced, indicating left ventricular dysfunction.

The patient's medication regimen includes beta blockers, loop diuretics, spironolactone, statins, ACE inhibitors, and a nitrovasodilator, which suggests that they are receiving standard treatments for heart failure and hypertension. The patient's blood pressure is 100/60 mmHg, which is slightly elevated, but not excessively so.

The patient's biomarkers, such as creatinine, urea, and troponin, are within normal limits or slightly elevated, indicating some degree of kidney impairment and cardiac stress. However, these values are not indicative of acute cardiac damage or failure.

The patient's lipid profile is also concerning, with high total cholesterol and LDL levels, which increases the risk of cardiovascular events. However, the patient is already taking statins, which should help to reduce their cholesterol levels.

The ECG impression highlights the presence of ventricular extrasystoles, non-sustained ventricular tachycardia, and paroxysmal supraventricular tachyarrhythmia, which are all concerning for arrhythmias. However, the patient's cardiac monitoring shows only non-sustained ventricular tachycardia, which is a relatively common finding in patients with heart failure.

Considering these factors, I believe that the patient has a high likelihood of survival for the next few years, assuming their current treatment regimen remains effective and they do not experience any significant adverse events."
337,337,P0551,"Age: 60
Gender: Male 
Weight: 85 kg
Height: 168 cm
NYHA Class: II
Blood Pressure: 120/70 mmHg
Past Medical History: Hypertensive cardiomyopathy, Hypertension
Albumin (g/L): 45
ALT or GPT (IU/L): 21.0
AST or GOT (IU/L): 18.0
Total Cholesterol (mmol/L): 3,65
Creatinine (mmol/L): 177.0
Gamma-glutamil transpeptidase (IU/L): 48
Glucose (mmol/L): 8,1
Hemoglobin (g/L): 137.0
HDL (mmol/L): 0,91
Potassium (mEq/L): 4,2
LDL (mmol/L): 2,4
Sodium (mEq/L): 133.0
Pro-BNP (ng/L): 2239.0
Protein (g/L): 77
T3 (pg/dL): 0,05
T4 (ng/L): 17
TSH (mIU/L): 0,845
Urea (mg/dL): 12,81
LVEF (%): 57.0
Medications: Calcium Channel Blocker, Beta Blockers, Loop Diuretics, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"RANKING: 1. Survivor
REASONING:

Based on the provided patient data, I would rank the patient's prognosis as a survivor. Here's the reasoning behind this ranking:

1. The patient's age (60 years) is not considered old, and with proper management, many patients in this age group can lead active lives.
2. The patient has a history of Hypertensive cardiomyopathy and hypertension, which can be managed with medications (Calcium Channel Blocker, Beta Blockers, Loop Diuretics, and ACE Inhibitor). These medications can help control blood pressure, reduce strain on the heart, and prevent further cardiac damage.
3. The patient's NYHA Class II indicates that they have some limitations in physical activity, but they can still perform daily activities with some difficulty. This suggests that the patient's cardiac function is not severely impaired.
4. The patient's laboratory results show that their liver enzymes (ALT and AST) are within normal limits, indicating no acute liver damage.
5. The patient's lipid profile (Total Cholesterol: 3.65 mmol/L) is not ideal, but it's not significantly elevated, which may not be a major concern in the short term.
6. The patient's renal function is slightly impaired (Creatinine: 177.0 mmol/L), but this can be managed with medications and lifestyle modifications.
7. The patient's ECG shows ventricular extrasystoles, which can be a sign of cardiac stress, but it's not indicative of a life-threatening arrhythmia.
8. The patient's LVEF (Left Ventricular Ejection Fraction) is 57%, which is slightly below the normal range (50-70%), but it's not severely impaired, and the patient is receiving medications to improve cardiac function.
9. The patient's Pro-BNP level (2239.0 ng/L) is elevated, indicating some degree of heart failure, but it's not extremely high, suggesting that the patient is not in severe heart failure.

Considering these factors, I believe that the patient has a good prognosis and is likely to survive with proper management and lifestyle modifications."
338,338,P0552,"Age: 50
Gender: Female 
Weight: 59 kg
Height: 157 cm
NYHA Class: II
Blood Pressure: 120/70 mmHg
Past Medical History: Hypertropic cardiomyopathy
Albumin (g/L): 41
ALT or GPT (IU/L): 30.0
AST or GOT (IU/L): 17.0
Total Cholesterol (mmol/L): 5,35
Creatinine (mmol/L): 88.0
Gamma-glutamil transpeptidase (IU/L): 34
Glucose (mmol/L): 5,2
Hemoglobin (g/L): 142.0
HDL (mmol/L): 1,25
Potassium (mEq/L): 4,2
LDL (mmol/L): 3,62
Sodium (mEq/L): 136.0
Pro-BNP (ng/L): 809.0
Protein (g/L): 70
T4 (ng/L): 9
Troponin (ng/mL): 0,01
TSH (mIU/L): 1,04
Urea (mg/dL): 5,99
LVEF (%): 66.0
Medications: Beta Blockers
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"RANKING: 
1. Survivor
REASONING:
Based on the provided patient data, the patient is a 50-year-old female with a history of Hypertrophic Cardiomyopathy (HCM), which is a significant risk factor for sudden cardiac death. However, the patient is currently on beta-blockers, which are often prescribed to manage symptoms and reduce the risk of arrhythmias in HCM patients.

The patient's current ECG findings show ventricular extrasystoles, which are a type of abnormal heart rhythm, but there is no evidence of ventricular tachycardia or non-sustained ventricular tachycardia, which are more concerning signs. The patient's LVEF (left ventricular ejection fraction) is 66.0%, which is within the normal range, indicating that the patient's heart is pumping blood efficiently.

The patient's biomarkers, including troponin levels, are within normal limits, suggesting that there is no evidence of acute myocardial infarction (heart attack) or significant cardiac damage. The patient's kidney function, as indicated by creatinine levels, is slightly elevated but not severely impaired.

Considering these factors, the patient's overall prognosis is favorable, and I predict that she will survive for the next few years. The presence of HCM is a significant risk factor, but the patient's current medical management and lack of concerning ECG findings and biomarkers suggest that she is at lower risk for sudden cardiac death or pump failure compared to the other two options.

2. Sudden Cardiac Death
REASONING:
While the patient has HCM, which is a significant risk factor for sudden cardiac death, the patient's current ECG findings and biomarkers do not show any signs of acute cardiac stress or damage. However, the presence of ventricular extrasystoles is a concerning sign, and the patient's LVEF is slightly below the normal range.

In the absence of any other concerning findings, I would still consider the patient to be at moderate risk for sudden cardiac death. However, this ranking is lower than the survivor ranking due to the presence of HCM and the patient's slightly abnormal LVEF.

3. Pump Failure Death
REASONING:
Based on the patient's current biomarkers, including elevated creatinine levels and slightly reduced LVEF, I would consider the patient to be at higher risk for pump failure. However, the patient's kidney function is not severely impaired, and the patient is on beta-blockers, which can help manage symptoms and reduce the risk of heart failure.

The patient's overall prognosis is less favorable compared to the survivor ranking due to the presence of HCM and slightly abnormal biomarkers. However, the patient's current medical management and lack of severe kidney dysfunction suggest that pump failure is not an immediate concern."
339,339,P0554,"Age: 70
Gender: Female 
Weight: 56 kg
Height: 156 cm
NYHA Class: II
Blood Pressure: 147/70 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Diabetes, Dyslipemia, Myocardial Infarction
Albumin (g/L): 48
ALT or GPT (IU/L): 18.0
AST or GOT (IU/L): 15.0
Total Cholesterol (mmol/L): 6,67
Creatinine (mmol/L): 106.0
Gamma-glutamil transpeptidase (IU/L): 35
Glucose (mmol/L): 10,9
Hemoglobin (g/L): 115.0
HDL (mmol/L): 1,14
Potassium (mEq/L): 4,7
LDL (mmol/L): 4,6
Sodium (mEq/L): 139.0
Protein (g/L): 76
T3 (pg/dL): 0,05
T4 (ng/L): 23
Troponin (ng/mL): 0,005
TSH (mIU/L): 2,39
Urea (mg/dL): 14,48
LVEF (%): 35.0
Medications: Diabetes Medication, Beta Blockers, Loop Diuretics, Statins, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"RANKING: 
1. Survivor
REASONING: 
This patient is a 70-year-old female with a history of ischemic dilated cardiomyopathy, diabetes, dyslipidemia, and a previous myocardial infarction. Despite the presence of these significant comorbidities, the patient's current NYHA Class II indicates a relatively mild level of heart failure symptoms. The patient's LVEF is 35%, which is a significant reduction, but not extreme. The patient's ECG impression shows no signs of ventricular tachycardia, which is a critical factor in determining prognosis.

The patient's laboratory results show elevated creatinine levels (106.0 mmol/L), which may indicate some degree of renal impairment. However, the patient's electrolyte and liver function tests are relatively within normal limits. The patient's medication regimen includes ACE inhibitors, which are often used in patients with heart failure and renal impairment.

The patient's troponin levels are normal (0.005 ng/mL), which suggests that there is no evidence of acute myocardial infarction. The patient's TSH level is within the normal range, which suggests that thyroid function is not significantly impacting cardiac function.

Given these factors, I believe that the patient is at a higher risk of experiencing a sudden cardiac death, but the presence of the ACE inhibitor and the absence of ventricular tachycardia on the ECG suggest that the patient may be more likely to survive. Pump failure death is also a concern, but the patient's relatively mild NYHA Class II symptoms and normal troponin levels suggest that the patient may be able to tolerate the strain of heart failure without severe complications. Therefore, I rank the patient as having the highest chance of survival over the next few years."
340,340,P0557,"Age: 72
Gender: Female 
Weight: 55 kg
Height: 146 cm
NYHA Class: II
Blood Pressure: 120/80 mmHg
Past Medical History: Hypertensive cardiomyopathy, Dyslipemia, Hypertension
Albumin (g/L): 42
ALT or GPT (IU/L): 24.0
AST or GOT (IU/L): 23.0
Total Cholesterol (mmol/L): 4,68
Creatinine (mmol/L): 97.0
Gamma-glutamil transpeptidase (IU/L): 18
Glucose (mmol/L): 4,3
Hemoglobin (g/L): 132.0
HDL (mmol/L): 1,4
Potassium (mEq/L): 4,8
LDL (mmol/L): 2,61
Sodium (mEq/L): 141.0
Pro-BNP (ng/L): 103.0
Protein (g/L): 71
T3 (pg/dL): 0,05
T4 (ng/L): 19
Troponin (ng/mL): 0,01
TSH (mIU/L): 0,94
Urea (mg/dL): 8,82
LVEF (%): 30.0
Medications: Beta Blockers, Loop Diuretics, Spironolactone, Statins, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: TPSV
        - Bradycardia: No
            ",survivor,"RANKING: 1. Survivor
REASONING:

Based on the provided patient data, I predict that the patient is most likely to survive for the next few years. The patient's age, NYHA Class II, and the presence of Hypertensive cardiomyopathy are significant risk factors for cardiovascular disease. However, the patient's blood pressure is well-controlled (120/80 mmHg), and the patient is receiving medications for hypertension, heart failure, and lipid management.

The patient's renal function is also relatively preserved, with a creatinine level of 97.0 mol/L, which is not significantly elevated. The patient's electrolytes, liver enzymes, and lipid profile are also relatively normal. The patient's ECG impression does not indicate any life-threatening arrhythmias, and the patient's LVEF is 30.0%, which is within the normal range.

The patient's Pro-BNP level is elevated at 103.0 ng/L, which may indicate some degree of heart failure, but it is not excessively high. The patient's troponin level is normal, which suggests that there is no significant myocardial damage.

Overall, the patient's combination of well-controlled hypertension, normal renal function, and relatively preserved cardiac function, along with the absence of life-threatening arrhythmias, suggest that the patient is at low risk for sudden cardiac death or pump failure in the next few years. Therefore, I predict that the patient is most likely to survive.

RANKING: 2. Sudden Cardiac Death
REASONING:

While the patient's Pro-BNP level is elevated, which may indicate some degree of heart failure, I do not consider this to be a significant risk factor for sudden cardiac death. The patient's LVEF is also within the normal range, and the patient's ECG impression does not indicate any life-threatening arrhythmias.

However, the patient's age (72 years) and history of Hypertensive cardiomyopathy do increase the risk for sudden cardiac death. Additionally, the patient's lipid profile is not ideal, with a total cholesterol level of 4.68 mmol/L, which may contribute to an increased risk of cardiovascular events.

While the patient is receiving medications for hypertension, heart failure, and lipid management, the patient's adherence to these medications is not explicitly stated, and there may be room for improvement in managing the patient's lipid profile.

Therefore, while the patient is not at high risk, the patient's age, history of Hypertensive cardiomyopathy, and relatively poor lipid profile do increase the risk for sudden cardiac death, making this prognosis slightly more likely than survivor.

RANKING: 3. Pump Failure Death
REASONING:

Based on the patient's elevated Pro-BNP level (103.0 ng/L) and relatively preserved cardiac function, I consider pump failure death to be the least likely prognosis. However, the patient's LVEF is only 30.0%, which is below the normal range, and this may indicate some degree of cardiac dysfunction.

The patient's NYHA Class II indicates that the patient has some symptoms of heart failure, and the patient's renal function is not perfectly preserved, with a creatinine level of 97.0 mol/L. The patient's blood pressure is well-controlled, but the patient's lipid profile is not ideal, which may contribute to an increased risk of cardiovascular events.

Additionally, the patient's ECG impression does not indicate any life-threatening arrhythmias, but the patient's ventricular extrasystole is present, which may indicate some degree of cardiac dysfunction.

While the patient is receiving medications for heart failure and hypertension, the patient's adherence to these medications is not explicitly stated, and there may be room for improvement in managing the patient's heart failure symptoms.

Overall, while the patient's Pro-BNP level is elevated, the patient's relatively preserved cardiac function, well-controlled blood pressure, and absence of life-threatening arrhythmias make pump failure death the least likely prognosis."
341,341,P0558,"Age: 65
Gender: Male 
Weight: 98 kg
Height: 168 cm
NYHA Class: III
Blood Pressure: 140/80 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Hypertension
Albumin (g/L): 38
ALT or GPT (IU/L): 13.0
AST or GOT (IU/L): 11.0
Total Cholesterol (mmol/L): 4,09
Creatinine (mmol/L): 97.0
Gamma-glutamil transpeptidase (IU/L): 16
Hemoglobin (g/L): 147.0
HDL (mmol/L): 0,78
Potassium (mEq/L): 4,1
LDL (mmol/L): 2,33
Sodium (mEq/L): 138.0
Pro-BNP (ng/L): 1649.0
Protein (g/L): 65
T3 (pg/dL): 0,05
T4 (ng/L): 17
Troponin (ng/mL): 0,03
TSH (mIU/L): 1,54
Urea (mg/dL): 6,99
LVEF (%): 27.0
Medications: Digoxin, Loop Diuretics, Hydralazine, ACE Inhibitor, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",survivor,"RANKING: 1. Survivor 
REASONING: 

Given the patient's age, NYHA Class III heart failure, and history of ischemic dilated cardiomyopathy, the patient is already at a high risk for adverse outcomes. However, the patient's current LVEF of 27.0 is relatively preserved compared to the average LVEF for a patient with similar symptoms. The patient's recent ECG impression of non-sustained ventricular tachycardia (NSVT) and polymorphic ventricular extrasystoles may indicate underlying ventricular arrhythmia risk, but the patient's current medication regimen, which includes an ACE inhibitor, hydralazine, and a nitrovasodilator, suggests that the patient is receiving optimal medical therapy for heart failure and hypertension. Additionally, the patient's serum creatinine level of 6.99 mg/dL is elevated, but this may be related to age and muscle mass rather than kidney function decline. The patient's serum potassium level of 4.1 mEq/L is within the normal range, and the patient's troponin level of 0.03 ng/mL is not elevated, suggesting that the patient does not have significant myocardial damage. Overall, the combination of the patient's preserved LVEF, optimal medication regimen, and absence of significant laboratory abnormalities suggest that the patient is likely to survive for the next few years."
342,342,P0561,"Age: 38
Gender: Female 
Weight: 58 kg
Height: 155 cm
NYHA Class: II
Blood Pressure: 90/50 mmHg
Past Medical History: Idiopathic dilated cardiomyopathy
Albumin (g/L): 41
ALT or GPT (IU/L): 11.0
AST or GOT (IU/L): 18.0
Total Cholesterol (mmol/L): 4,27
Creatinine (mmol/L): 80.0
Gamma-glutamil transpeptidase (IU/L): 8
Glucose (mmol/L): 4,7
Hemoglobin (g/L): 129.0
HDL (mmol/L): 1,27
Potassium (mEq/L): 4,3
LDL (mmol/L): 2,77
Sodium (mEq/L): 138.0
Pro-BNP (ng/L): 37.0
Protein (g/L): 75
T3 (pg/dL): 0,04
T4 (ng/L): 14
Troponin (ng/mL): 0,03
TSH (mIU/L): 3,23
Urea (mg/dL): 6,32
LVEF (%): 41.0
Medications: Beta Blockers, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: TPSV
        - Bradycardia: No
            ",survivor,"RANKING: 
1. Survivor
REASONING: 
The patient is a 38-year-old female with a history of idiopathic dilated cardiomyopathy, which is a significant risk factor for adverse outcomes. However, the patient's current NYHA class is II, indicating mild symptoms, and they are on beta blockers and ACE inhibitors, which are standard treatments for heart failure. The patient's LVEF is 41%, which is slightly below the normal range, but not severely impaired. The patient's creatinine level is elevated, indicating some degree of renal impairment, but it is not severe. The patient's troponin level is normal, which suggests that there is no significant myocardial damage. The ECG findings are not alarming, with no signs of ventricular tachycardia, tachycardia, or other life-threatening arrhythmias. The patient's electrolyte levels are also within normal limits. Overall, considering the patient's relatively mild symptoms, the presence of a mild impairment of LVEF, and the absence of severe cardiac or renal dysfunction, I predict that the patient is likely to survive for the next few years with appropriate management and monitoring."
343,343,P0562,"Age: 79
Gender: Female 
Weight: 67 kg
Height: 150 cm
NYHA Class: II
Blood Pressure: 150/70 mmHg
Past Medical History: Hypertensive cardiomyopathy, Diabetes, Dyslipemia, Peripheral vascular disease, Hypertension
Albumin (g/L): 27
ALT or GPT (IU/L): 31.0
AST or GOT (IU/L): 14.0
Total Cholesterol (mmol/L): 4,4
Creatinine (mmol/L): 194.0
Gamma-glutamil transpeptidase (IU/L): 36
Glucose (mmol/L): 3,9
Hemoglobin (g/L): 80.0
HDL (mmol/L): 0,88
Potassium (mEq/L): 4,8
LDL (mmol/L): 2,79
Sodium (mEq/L): 136.0
Pro-BNP (ng/L): 4399.0
Protein (g/L): 61
T4 (ng/L): 14
Troponin (ng/mL): 0,01
TSH (mIU/L): 5,4
Urea (mg/dL): 37,27
LVEF (%): 53.0
Medications: Calcium Channel Blocker, Diabetes Medication, Angiotensin II Receptor Blocker, Beta Blockers, Loop Diuretics
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: Second-degree AVB - type II
            ",survivor,"RANKING: 1. Survivor
REASONING: 
Based on the provided patient data, the patient's overall prognosis is likely to be a survivor. This is due to several factors:

1. Age: Although the patient is 79 years old, the age itself is not a significant predictor of mortality in this case. Many patients with advanced cardiovascular disease can survive with proper management.
2. NYHA Class II: The patient's New York Heart Association (NYHA) class II indicates that the patient has some limitations in physical activity due to heart disease, but it is not severe. This suggests that the patient is still relatively functional and may be able to tolerate some level of physical activity.
3. Medications: The patient is taking multiple medications, including a calcium channel blocker, diabetes medication, angiotensin II receptor blocker, beta blockers, and loop diuretics, which indicate a comprehensive management plan for the patient's cardiovascular and metabolic conditions.
4. ECG findings: The ECG impression does not show any significant arrhythmias or signs of cardiac ischemia, which are common predictors of sudden cardiac death.
5. Pro-BNP levels: Although the patient's Pro-BNP level is elevated (4399.0 ng/L), which indicates some degree of heart failure, it is not excessively high. This suggests that the patient's heart is still functioning, albeit not optimally.
6. Other laboratory values: The patient's laboratory values, such as creatinine, urea, and electrolyte levels, are not significantly abnormal, which suggests that the patient's kidney function and electrolyte balance are relatively preserved.

Overall, considering these factors, the patient's prognosis is likely to be a survivor, with a reasonable chance of living for several years with proper management and lifestyle modifications."
344,344,P0564,"Age: 69
Gender: Male 
Weight: 75 kg
Height: 176 cm
NYHA Class: II
Blood Pressure: 120/70 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Dyslipemia, Hypertension, Myocardial Infarction
Albumin (g/L): 38
ALT or GPT (IU/L): 39.0
AST or GOT (IU/L): 20.0
Total Cholesterol (mmol/L): 6,62
Creatinine (mmol/L): 80.0
Gamma-glutamil transpeptidase (IU/L): 56
Glucose (mmol/L): 4,5
Hemoglobin (g/L): 147.0
HDL (mmol/L): 1,4
Potassium (mEq/L): 4,7
LDL (mmol/L): 4,37
Sodium (mEq/L): 140.0
Pro-BNP (ng/L): 277.0
Protein (g/L): 74
T4 (ng/L): 17
Troponin (ng/mL): 0,01
TSH (mIU/L): 4,7
Urea (mg/dL): 6,99
LVEF (%): 45.0
Medications: Beta Blockers, Statins, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: Second-degree AVB - type II
            ",survivor,"RANKING: 1. Survivor
REASONING: 

The patient's overall clinical presentation and test results suggest a high likelihood of survival. The patient's age, NYHA Class II, and absence of ventricular tachycardia or non-sustained ventricular tachycardia on ECG suggest that the patient's cardiac function is relatively preserved. The patient's LVEF of 45% indicates some degree of left ventricular dysfunction, but it is not severe enough to predict an adverse outcome. The presence of ischemic dilated cardiomyopathy, hypertension, and dyslipidemia increases the patient's risk of cardiovascular events, but the patient's current medications (beta blockers, statins, and ACE inhibitor) are well-established treatments for these conditions. The patient's laboratory results, including normal blood pressure, normal renal function, and normal liver enzymes, also suggest that the patient is not in acute distress.

The patient's Pro-BNP level of 277 ng/L is mildly elevated, but it is not significantly elevated, which may indicate some degree of heart failure. However, the patient's hemoglobin level of 147 g/L is normal, which suggests that the patient does not have anemia, which is often seen in patients with heart failure. The patient's troponin level of 0.01 ng/mL is normal, which suggests that there is no acute myocardial infarction.

Overall, the patient's clinical presentation and test results suggest that the patient is at risk for cardiovascular events, but the patient's current condition and treatment plan suggest that the patient is likely to survive. 

RANKING: 2. Sudden cardiac death
REASONING: 

The patient's history of ischemic dilated cardiomyopathy, hypertension, and dyslipidemia increases the patient's risk of sudden cardiac death. The patient's LVEF of 45% is below the normal range, which may indicate some degree of left ventricular dysfunction. The patient's Pro-BNP level of 277 ng/L is mildly elevated, which may indicate some degree of heart failure. The patient's ECG shows ventricular extrasystole, which may indicate some degree of electrical instability in the heart.

However, the patient's current medications (beta blockers, statins, and ACE inhibitor) are well-established treatments for these conditions, and the patient's laboratory results, including normal blood pressure, normal renal function, and normal liver enzymes, suggest that the patient is not in acute distress.

The patient's troponin level of 0.01 ng/mL is normal, which suggests that there is no acute myocardial infarction. The patient's hemoglobin level of 147 g/L is normal, which suggests that the patient does not have anemia.

Overall, while the patient's history and ECG suggest some degree of cardiac instability, the patient's current condition and treatment plan suggest that the patient is at risk for sudden cardiac death, but the patient is not currently in acute distress.

RANKING: 3. Pump failure death
REASONING: 

The patient's LVEF of 45% is below the normal range, which suggests that the patient has some degree of left ventricular dysfunction. The patient's Pro-BNP level of 277 ng/L is mildly elevated, which may indicate some degree of heart failure. The patient's ECG shows ventricular extrasystole, which may indicate some degree of electrical instability in the heart.

The patient's history of ischemic dilated cardiomyopathy, hypertension, and dyslipidemia increases the patient's risk of pump failure. The patient's current medications (beta blockers, statins, and ACE inhibitor) are well-established treatments for these conditions, but they may not be sufficient to prevent pump failure in this patient.

The patient's laboratory results, including normal blood pressure, normal renal function, and normal liver enzymes, suggest that the patient is not in acute distress. However, the patient's elevated creatinine level of 6.99 mg/dL may indicate some degree of renal impairment, which may be related to the patient's cardiac dysfunction.

Overall, the patient's clinical presentation and test results suggest that the patient is at risk for pump failure, but the patient's current condition and treatment plan suggest that the patient is not currently in acute distress. However, the patient's history and test results suggest that the patient is at high risk for pump failure in the near future."
345,345,P0566,"Age: 65
Gender: Male 
Weight: 88 kg
Height: 176 cm
NYHA Class: II
Blood Pressure: 170/90 mmHg
Past Medical History: Hypertropic cardiomyopathy, Dyslipemia, Hypertension
Albumin (g/L): 37
ALT or GPT (IU/L): 39.0
AST or GOT (IU/L): 17.0
Total Cholesterol (mmol/L): 5,72
Creatinine (mmol/L): 106.0
Gamma-glutamil transpeptidase (IU/L): 53
Glucose (mmol/L): 4,9
Hemoglobin (g/L): 144.0
HDL (mmol/L): 1,14
Potassium (mEq/L): 4,3
LDL (mmol/L): 3,98
Sodium (mEq/L): 140.0
Pro-BNP (ng/L): 290.0
Protein (g/L): 71
T4 (ng/L): 10
Troponin (ng/mL): 0,02
TSH (mIU/L): 2,46
Urea (mg/dL): 6,66
LVEF (%): 62.0
Medications: Beta Blockers, Digoxin, Loop Diuretics
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"RANKING: 
1. Survivor
REASONING: 
The patient has a history of Hypertrophic Cardiomyopathy, which is a condition that can lead to arrhythmias and sudden cardiac death. However, the patient's ECG results do not show any signs of ventricular tachycardia or ventricular extrasystoles. The patient's LVEF is 62%, which is within a relatively normal range. The patient is also taking beta blockers, which are commonly used to manage hypertension and heart failure in patients with cardiomyopathy. Additionally, the patient's Pro-BNP levels are elevated, indicating some degree of heart failure. However, the patient's overall clinical presentation and test results do not suggest an acute decompensated heart failure. Therefore, the patient's prognosis is more likely to be a survivor.

2. Sudden cardiac death
REASONING: 
While the patient has a history of Hypertrophic Cardiomyopathy, the patient's ECG results do not show any signs of ventricular tachycardia or ventricular extrasystoles, which are common precursors to sudden cardiac death. However, the patient's elevated Pro-BNP levels and LVEF of 62% suggest some degree of heart failure, which may increase the risk of sudden cardiac death. Additionally, the patient's hypertension and dyslipidemia may contribute to the progression of cardiomyopathy and increase the risk of sudden cardiac death.

3. Pump failure death
REASONING: 
The patient's elevated Pro-BNP levels and LVEF of 62% suggest some degree of heart failure, but the patient's overall clinical presentation and test results do not suggest acute decompensated heart failure. The patient is also taking medications to manage hypertension and heart failure, which suggests that the patient's heart failure is not severe. Therefore, the risk of pump failure death is lower compared to sudden cardiac death. Additionally, the patient's age and sex do not increase the risk of pump failure death."
346,346,P0569,"Age: 83
Gender: Female 
Weight: 58 kg
Height: 154 cm
NYHA Class: III
Blood Pressure: 125/75 mmHg
Past Medical History: Hypertensive cardiomyopathy
Albumin (g/L): 40
ALT or GPT (IU/L): 31.0
AST or GOT (IU/L): 29.0
Total Cholesterol (mmol/L): 4,53
Creatinine (mmol/L): 71.0
Gamma-glutamil transpeptidase (IU/L): 21
Glucose (mmol/L): 6,1
Hemoglobin (g/L): 85.0
HDL (mmol/L): 1,01
Potassium (mEq/L): 4,8
LDL (mmol/L): 2,84
Sodium (mEq/L): 140.0
Pro-BNP (ng/L): 753.0
Protein (g/L): 65
T4 (ng/L): 14
Troponin (ng/mL): 0,01
TSH (mIU/L): 2,83
Urea (mg/dL): 7,15
LVEF (%): 61.0
Medications: Calcium Channel Blocker, Digoxin, Loop Diuretics, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: TPSV
        - Bradycardia: No
            ",survivor,"RANKING: 
1. Survivor
REASONING: 
Based on the provided patient data, the patient is 83 years old, has a history of hypertensive cardiomyopathy, and has a left ventricular ejection fraction (LVEF) of 61.0%, which indicates some degree of left ventricular dysfunction. The patient's NYHA class is III, suggesting moderate symptoms of heart failure. 

The patient's laboratory results show elevated creatinine levels (71.0 mmol/L) and a high level of N-terminal pro-b-type natriuretic peptide (Pro-BNP) (753.0 ng/L), which are indicative of heart failure. However, the patient is currently on medications that are commonly used to manage heart failure, such as loop diuretics, ACE inhibitors, and calcium channel blockers.

The absence of any evidence of acute coronary syndrome, significant arrhythmias, or other life-threatening conditions in the ECG impression suggests that the patient is not in immediate danger. 

Considering the patient's age, comorbidities, and the presence of heart failure symptoms, the most likely outcome is that the patient will survive for the next few years, provided that the current treatment regimen remains effective and any potential complications are promptly managed.

2. Sudden cardiac death
REASONING: 
While the patient has a history of hypertensive cardiomyopathy and is on medications to manage heart failure, the absence of any significant arrhythmias or other acute conditions in the ECG impression makes sudden cardiac death less likely. However, the patient's age and the presence of left ventricular dysfunction increase the risk of sudden cardiac death.

3. Pump failure death
REASONING: 
Pump failure death is a possible outcome for patients with heart failure, especially those with a low LVEF (less than 40%) or those with significant symptoms. However, the patient's LVEF is 61.0%, which is not as low as 40%, and the patient is currently on medications to manage heart failure. Therefore, while pump failure is a risk, it is less likely compared to sudden cardiac death given the patient's current treatment regimen and the absence of any acute conditions in the ECG impression."
347,347,P0571,"Age: 76
Gender: Male 
Weight: 96 kg
Height: 170 cm
NYHA Class: II
Blood Pressure: 115/75 mmHg
Past Medical History: Idiopathic dilated cardiomyopathy, Diabetes, Hypertension
Albumin (g/L): 44
ALT or GPT (IU/L): 15.0
AST or GOT (IU/L): 16.0
Total Cholesterol (mmol/L): 4,03
Creatinine (mmol/L): 133.0
Gamma-glutamil transpeptidase (IU/L): 29
Glucose (mmol/L): 7,7
Hemoglobin (g/L): 149.0
HDL (mmol/L): 0,75
Potassium (mEq/L): 5,1
LDL (mmol/L): 1,89
Sodium (mEq/L): 140.0
Pro-BNP (ng/L): 1303.0
Protein (g/L): 80
T4 (ng/L): 17
Troponin (ng/mL): 0,01
TSH (mIU/L): 1,71
Urea (mg/dL): 13,48
LVEF (%): 35.0
Medications: Beta Blockers, Digoxin, Loop Diuretics, Hydralazine, ACE Inhibitor, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",survivor,"RANKING: 1. Survivor
REASONING: The patient has a history of idiopathic dilated cardiomyopathy, which is a significant comorbidity that increases the risk of cardiac complications. However, the patient is currently on medications for heart failure (Beta Blockers, Digoxin, Loop Diuretics, Hydralazine, ACE Inhibitor, Nitrovasodilator) and has a relatively stable ECG impression with no evidence of ventricular tachycardia or non-sustained ventricular tachycardia. The patient's Pro-BNP level is elevated at 1303.0 ng/L, indicating some level of heart failure, but it is not excessively high. The patient's LVEF is 35.0%, which is significantly reduced, but not extremely low. The patient's electrolyte and liver function tests are also relatively normal. Given these factors, the patient is likely to survive in the short term. However, it is essential to closely monitor the patient's condition and adjust the treatment plan as needed.

RANKING: 2. Sudden cardiac death
REASONING: Although the patient is on medications for heart failure, the patient's LVEF is significantly reduced at 35.0%, which indicates severe left ventricular dysfunction. This increased risk of sudden cardiac death is a significant concern. The patient's Pro-BNP level is elevated, and the patient has a history of idiopathic dilated cardiomyopathy, which can lead to arrhythmias. The patient's ECG impression shows ventricular extrasystoles, which can be a precursor to more severe arrhythmias. While the patient is on medications, the risk of sudden cardiac death cannot be entirely ruled out.

RANKING: 3. Pump failure death
REASONING: The patient's LVEF is significantly reduced at 35.0%, indicating severe left ventricular dysfunction. This can lead to pump failure, which is a life-threatening complication. However, the patient is currently on medications for heart failure and has a relatively stable ECG impression. Additionally, the patient's Pro-BNP level is not excessively high, and the patient's electrolyte and liver function tests are relatively normal. While pump failure is a concern, the patient's current treatment plan and stable ECG impression reduce the likelihood of this outcome."
348,348,P0572,"Age: 36
Gender: Male 
Weight: 80 kg
Height: 180 cm
NYHA Class: II
Blood Pressure: 140/70 mmHg
Past Medical History: Hypertensive cardiomyopathy, Diabetes, Hypertension
Albumin (g/L): 45
ALT or GPT (IU/L): 33.0
AST or GOT (IU/L): 19.0
Total Cholesterol (mmol/L): 4,11
Creatinine (mmol/L): 88.0
Gamma-glutamil transpeptidase (IU/L): 58
Glucose (mmol/L): 7,7
Hemoglobin (g/L): 150.0
HDL (mmol/L): 1,06
Potassium (mEq/L): 4,7
LDL (mmol/L): 2,51
Sodium (mEq/L): 138.0
Pro-BNP (ng/L): 32.0
Protein (g/L): 76
T3 (pg/dL): 0,04
T4 (ng/L): 14
Troponin (ng/mL): 0,01
TSH (mIU/L): 1,21
Urea (mg/dL): 4,66
LVEF (%): 53.0
Medications: Calcium Channel Blocker, Beta Blockers, Digoxin, Loop Diuretics, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"RANKING: 1. Survivor
REASONING: 

This patient is at a higher risk for pump failure death due to their NYHA Class II heart failure, which indicates moderate heart failure symptoms. However, the patient's current LVEF (left ventricular ejection fraction) of 53% is not severely impaired, and their medication regimen includes ACE inhibitors, which are commonly used to slow the progression of heart failure. The patient's ECG impression does not show any signs of ventricular tachycardia or significant arrhythmias, which are major risk factors for sudden cardiac death.

Although the patient has a history of hypertension, diabetes, and cardiomyopathy, their current blood pressure is well-controlled (140/70 mmHg), and their kidney function (creatinine 88.0 mmol/L) is not severely impaired. Their troponin level is also within normal limits, indicating no acute myocardial infarction.

The patient's low albumin level (45 g/L) may indicate malnutrition or liver disease, but this is not directly related to their cardiac condition. Their liver enzymes (ALT and AST) are also within normal limits.

Given these factors, the patient's overall prognosis is relatively good, and they are likely to survive the next few years with proper management of their heart failure and other comorbid conditions. 

However, close monitoring and adjustments to their medication regimen may be necessary to ensure optimal management of their heart failure and prevent potential complications."
349,349,P0573,"Age: 46
Gender: Male 
Weight: 85 kg
Height: 168 cm
NYHA Class: II
Blood Pressure: 110/70 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Myocardial Infarction
Albumin (g/L): 46
ALT or GPT (IU/L): 91.0
AST or GOT (IU/L): 33.0
Total Cholesterol (mmol/L): 3,78
Creatinine (mmol/L): 80.0
Gamma-glutamil transpeptidase (IU/L): 50
Glucose (mmol/L): 7,2
Hemoglobin (g/L): 159.0
HDL (mmol/L): 1,16
Potassium (mEq/L): 4,5
LDL (mmol/L): 2,22
Sodium (mEq/L): 141.0
Pro-BNP (ng/L): 172.0
Protein (g/L): 74
T3 (pg/dL): 0,04
T4 (ng/L): 15
Troponin (ng/mL): 0,01
TSH (mIU/L): 1,25
Urea (mg/dL): 5,49
LVEF (%): 22.0
Medications: Beta Blockers, Statins, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"RANKING: 1. Survivor
REASONING:

This patient's prognosis is ranked as a survivor due to the following factors:

1. Age: Although the patient is 46 years old, which is considered middle-aged, it is not unusually old for someone with a history of ischemic dilated cardiomyopathy and myocardial infarction.
2. NYHA Class II: The patient's heart failure symptoms are mild, indicating that the disease is not advanced, and they are still able to perform daily activities without significant limitation.
3. Medications: The patient is taking beta blockers, statins, and an ACE inhibitor, which are standard treatments for managing heart failure and reducing cardiovascular risk factors.
4. Laboratory results: While the patient has elevated creatinine levels, which may indicate some degree of kidney impairment, the troponin level is normal, suggesting that there is no acute myocardial injury. The albumin level is also slightly low, but this can be seen in patients with heart failure.
5. ECG Impression: The presence of ventricular extrasystole and non-sustained ventricular tachycardia is concerning, but it is not indicative of an acute life-threatening arrhythmia. The patient does not have any other arrhythmias or signs of significant cardiac dysfunction.

While the patient has a history of significant cardiac disease, their current symptoms and laboratory results suggest that they are not in an acute crisis. With optimal management of their medications and lifestyle modifications, it is likely that the patient will survive for several years. However, it is essential to closely monitor their condition and adjust their treatment plan as needed to prevent further deterioration.

The other two prognoses, sudden cardiac death and pump failure death, are less likely due to the following reasons:

* Sudden cardiac death is unlikely due to the absence of any acute arrhythmias or ECG signs of significant cardiac dysfunction.
* Pump failure death is also unlikely due to the patient's mild NYHA Class II symptoms and the presence of medications that are effective in managing heart failure. However, the patient's LVEF is significantly reduced, indicating that their heart is not functioning optimally, and they may require closer monitoring and adjustments to their treatment plan to prevent further decline."
350,350,P0574,"Age: 76
Gender: Male 
Weight: 76 kg
Height: 153 cm
NYHA Class: II
Blood Pressure: 160/80 mmHg
Past Medical History: Hypertensive cardiomyopathy, Diabetes, Dyslipemia, Hypertension
Albumin (g/L): 41
ALT or GPT (IU/L): 19.0
AST or GOT (IU/L): 27.0
Total Cholesterol (mmol/L): 6,08
Creatinine (mmol/L): 97.0
Gamma-glutamil transpeptidase (IU/L): 13
Glucose (mmol/L): 8,5
Hemoglobin (g/L): 130.0
HDL (mmol/L): 2,61
Potassium (mEq/L): 3,87
LDL (mmol/L): 2,95
Sodium (mEq/L): 141.0
Pro-BNP (ng/L): 381.0
Protein (g/L): 73
T3 (pg/dL): 0,0588
T4 (ng/L): 15,24
Troponin (ng/mL): 0,4
TSH (mIU/L): 1,56
Urea (mg/dL): 8,6
LVEF (%): 70.0
Medications: Calcium Channel Blocker, Diabetes Medication, Angiotensin II Receptor Blocker, Loop Diuretics, Statins
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: TPSV
        - Bradycardia: Second-degree AVB - type II
            ",survivor,"RANKING: 1. Survivor
REASONING: 

The patient's overall clinical presentation, lab results, and ECG findings suggest a high likelihood of survival. The patient is 76 years old, but the absence of any explicit mention of advanced age-related comorbidities such as frailty or significant cognitive impairment is a positive factor. The patient's NYHA Class II heart failure status indicates that they have some limitations in physical activity, but it is still manageable. The patient's elevated blood pressure (160/80 mmHg) is a concern, but it is not excessively high. The presence of hypertension, diabetes, and dyslipidemia is a risk factor for cardiovascular disease, but the patient is already on medications to manage these conditions.

The patient's lab results show a slightly elevated creatinine level (97.0 mol/L), which may indicate some degree of renal impairment, but it is not severe. The liver enzymes (ALT and AST) are slightly elevated, but not significantly. The lipid profile shows elevated total cholesterol and LDL, but the patient is on statins, which will help manage these levels.

The ECG findings reveal ventricular extrasystole, polymorphic ventricular tachycardia, non-sustained ventricular tachycardia, and paroxysmal supraventricular tachyarrhythmia. While these findings are concerning, they are not indicative of a high risk of sudden cardiac death or pump failure. The absence of any mention of a history of myocardial infarction or significant heart failure exacerbation is also a positive factor.

Overall, the patient's combination of age, comorbidities, and ECG findings suggests a moderate to high risk of cardiovascular events, but the patient's current medical management and stable lab results suggest that they can be managed with current medications and lifestyle modifications, increasing the likelihood of survival."
351,351,P0575,"Age: 63
Gender: Female 
Weight: 64 kg
Height: 157 cm
NYHA Class: II
Blood Pressure: 90/50 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Dyslipemia, Myocardial Infarction
Albumin (g/L): 41
ALT or GPT (IU/L): 76.0
AST or GOT (IU/L): 52.0
Total Cholesterol (mmol/L): 4,6
Creatinine (mmol/L): 106.0
Gamma-glutamil transpeptidase (IU/L): 54
Glucose (mmol/L): 5,7
Hemoglobin (g/L): 131.0
HDL (mmol/L): 1,53
Potassium (mEq/L): 4,7
LDL (mmol/L): 2,12
Sodium (mEq/L): 142.0
Pro-BNP (ng/L): 1870.0
Protein (g/L): 72
T4 (ng/L): 3
TSH (mIU/L): 18,75
Urea (mg/dL): 7,32
LVEF (%): 24.0
Medications: Beta Blockers, Statins, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"RANKING: 
1. Survivor
REASONING: 
Based on the provided patient data, I predict that the patient is most likely to survive for the next few years. The patient has a history of ischemic dilated cardiomyopathy, which is a significant risk factor for adverse outcomes. However, the patient is currently being treated with beta blockers, statins, and an ACE inhibitor, which are standard treatments for managing heart failure and reducing cardiovascular risk. The patient's ejection fraction (LVEF) is significantly reduced at 24%, indicating poor cardiac function, but this is being managed with current medications. The patient's NYHA class is II, indicating mild heart failure symptoms. 

The patient's biomarkers, such as elevated creatinine and urea levels, suggest some degree of kidney impairment, but this is not uncommon in patients with heart failure. The patient's electrolyte levels are relatively stable, and the patient is not experiencing any acute symptoms of arrhythmias or acute coronary syndromes. 

Given the patient's age, medical history, and current treatment, I predict that the patient will continue to experience some degree of heart failure symptoms but will likely remain stable for the next few years with optimal management of their medications and lifestyle modifications. 

While there is a risk of sudden cardiac death, the patient's ECG impression does not show any signs of ventricular arrhythmias, and the patient is not experiencing any acute symptoms. Therefore, I rank the patient as having a high likelihood of survival. 

2. Sudden cardiac death
REASONING: 
While the patient is at risk for sudden cardiac death due to their history of myocardial infarction and ischemic dilated cardiomyopathy, I rank this outcome as less likely due to the patient's current treatment and stable clinical presentation. The patient's ECG impression does not show any signs of ventricular arrhythmias, and the patient is not experiencing any acute symptoms. 

However, the patient's reduced ejection fraction and elevated biomarkers suggest some degree of cardiac dysfunction, which increases the risk of arrhythmias. The patient's history of myocardial infarction and dyslipidemia also increases the risk of cardiac complications. 

3. Pump failure death
REASONING: 
I rank pump failure death as the least likely outcome due to the patient's current treatment and stable clinical presentation. The patient is receiving beta blockers, statins, and an ACE inhibitor, which are standard treatments for managing heart failure. The patient's NYHA class is II, indicating mild heart failure symptoms, and the patient is not experiencing any acute symptoms. 

However, the patient's reduced ejection fraction and elevated biomarkers suggest some degree of cardiac dysfunction, which may eventually lead to worsening heart failure symptoms. While this is a concern, I believe that the patient's current treatment and lifestyle modifications will help manage the patient's symptoms and prevent pump failure."
352,352,P0577,"Age: 37
Gender: Male 
Weight: 90 kg
Height: 169 cm
NYHA Class: II
Blood Pressure: 120/70 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Dyslipemia, Myocardial Infarction
Albumin (g/L): 40
ALT or GPT (IU/L): 40.0
AST or GOT (IU/L): 19.0
Total Cholesterol (mmol/L): 7,53
Creatinine (mmol/L): 97.0
Gamma-glutamil transpeptidase (IU/L): 107
Glucose (mmol/L): 4,2
Hemoglobin (g/L): 151.0
HDL (mmol/L): 1,29
Potassium (mEq/L): 4,5
LDL (mmol/L): 5,17
Sodium (mEq/L): 136.0
Pro-BNP (ng/L): 71.0
Protein (g/L): 72
T3 (pg/dL): 0,05
T4 (ng/L): 16
Troponin (ng/mL): 0,01
TSH (mIU/L): 2,27
Urea (mg/dL): 5,66
LVEF (%): 31.0
Medications: Beta Blockers, Statins, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"RANKING: 
1. Survivor
REASONING:
The patient is a 37-year-old male with a history of ischemic dilated cardiomyopathy, myocardial infarction, and dyslipidemia. The patient's current NYHA Class II indicates a moderate level of heart failure symptoms. The patient's ejection fraction (LVEF) is 31%, which is significantly reduced, indicating severe left ventricular dysfunction.

The patient's laboratory results show elevated troponin levels (0.01 ng/mL), indicating some myocardial damage, and a high BNP level (71 ng/L), suggesting increased ventricular wall stress. The patient's creatinine level is elevated at 97 mol/L, which may indicate impaired renal function, often seen in patients with heart failure.

The patient's medication regimen includes beta blockers, statins, and an ACE inhibitor, which is a standard treatment for heart failure and hypertension. The absence of ventricular tachycardia, non-sustained ventricular tachycardia, and paroxysmal supraventricular tachyarrhythmia on the ECG suggests that the patient does not have a high risk of arrhythmias.

Considering these factors, the patient's overall condition suggests that he is at high risk for cardiac events, but the presence of beta blockers and ACE inhibitor therapy, along with a relatively preserved renal function, may mitigate this risk. Therefore, I predict that the patient has a higher likelihood of survival over the next few years, with a moderate risk of cardiac events.

RANKING 2: Sudden Cardiac Death
REASONING:
Although the patient's LVEF is severely reduced, the patient is on beta blockers, which can reduce the risk of sudden cardiac death. However, the patient's age, history of myocardial infarction, and elevated troponin levels increase the risk of sudden cardiac death.

RANKING 3: Pump Failure Death
REASONING:
The patient's severe left ventricular dysfunction (LVEF 31%), elevated BNP levels, and elevated creatinine level suggest a high risk of pump failure. However, the patient is on ACE inhibitor therapy, which can help reduce the risk of pump failure. Additionally, the patient's relatively preserved renal function and the presence of beta blockers may also mitigate this risk. Nevertheless, the patient's overall condition suggests that pump failure is a possible complication, but not the most likely outcome."
353,353,P0578,"Age: 44
Gender: Male 
Weight: 68 kg
Height: 162 cm
NYHA Class: II
Blood Pressure: 100/70 mmHg
Past Medical History: Idiopathic dilated cardiomyopathy, Dyslipemia
Albumin (g/L): 41
ALT or GPT (IU/L): 19.0
AST or GOT (IU/L): 29.0
Total Cholesterol (mmol/L): 6,8
Creatinine (mmol/L): 97.0
Gamma-glutamil transpeptidase (IU/L): 21
Glucose (mmol/L): 4,5
Hemoglobin (g/L): 174.0
HDL (mmol/L): 0,83
Potassium (mEq/L): 4,5
LDL (mmol/L): 5,17
Sodium (mEq/L): 138.0
Pro-BNP (ng/L): 628.0
Protein (g/L): 68
T3 (pg/dL): 0,06
T4 (ng/L): 17
Troponin (ng/mL): 0,1
TSH (mIU/L): 1,09
Urea (mg/dL): 4,99
LVEF (%): 43.0
Medications: Statins, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"RANKING: 
1. Survivor
REASONING: 
The patient's overall clinical presentation and test results indicate a high risk of cardiac events, but the absence of any life-threatening arrhythmias (such as ventricular tachycardia or non-sustained ventricular tachycardia) and the presence of a relatively stable ECG impression make a sudden cardiac death less likely. The patient's NYHA class II suggests that they are still able to perform moderate physical activity, which may indicate a preserved cardiac function to some extent. Additionally, the patient's LVEF is 43%, which is within the range of a normal ejection fraction, although it is on the lower end of the normal range. The presence of idiopathic dilated cardiomyopathy and dyslipidemia are significant risk factors for cardiac events, but the patient's current medications (statins and ACE inhibitor) are being used to manage these conditions. Therefore, the patient's overall clinical picture suggests that they are at high risk of cardiac events, but not at an extremely high risk of sudden cardiac death.

2. Pump failure death
REASONING: 
The patient's LVEF is 43%, which is below the normal range, indicating some degree of systolic dysfunction. The patient's NYHA class II suggests that they are experiencing some symptoms of heart failure, such as fatigue or shortness of breath, which could be related to their cardiac condition. The presence of elevated creatinine levels (97.0 mmol/L) may also indicate some degree of renal impairment, which can be related to cardiac dysfunction. While the patient is currently being treated with medications to manage their cardiac condition, the presence of idiopathic dilated cardiomyopathy and dyslipidemia may still pose a risk of cardiac events, including heart failure. Therefore, the patient is at risk of pump failure death, but the presence of some residual cardiac function and current treatment may mitigate this risk.

3. Sudden cardiac death
REASONING: 
The patient's ECG impression does not show any life-threatening arrhythmias, which reduces the risk of sudden cardiac death. However, the patient's LVEF is 43%, which is below the normal range, and the presence of idiopathic dilated cardiomyopathy and dyslipidemia are significant risk factors for cardiac events. The patient's elevated troponin levels (0.1 ng/mL) may also indicate some degree of cardiac damage, although it is not significantly elevated. While the patient is currently being treated with medications to manage their cardiac condition, the presence of these risk factors and some degree of cardiac dysfunction may still pose a risk of cardiac events, including sudden cardiac death. However, the overall clinical picture is less concerning than the pump failure death, making sudden cardiac death the least likely of the three possible prognoses."
354,354,P0579,"Age: 73
Gender: Male 
Weight: 98 kg
Height: 162 cm
NYHA Class: II
Blood Pressure: 100/58 mmHg
Past Medical History: Idiopathic dilated cardiomyopathy, Dyslipemia, Hypertension
Albumin (g/L): 41
ALT or GPT (IU/L): 15.0
AST or GOT (IU/L): 20.0
Total Cholesterol (mmol/L): 5,46
Creatinine (mmol/L): 71.0
Gamma-glutamil transpeptidase (IU/L): 54
Glucose (mmol/L): 4,7
Hemoglobin (g/L): 146.0
HDL (mmol/L): 1,19
Potassium (mEq/L): 3,9
LDL (mmol/L): 3,78
Sodium (mEq/L): 137.0
Pro-BNP (ng/L): 1083.0
Protein (g/L): 72
T4 (ng/L): 19
Troponin (ng/mL): 0,01
TSH (mIU/L): 0,91
Urea (mg/dL): 7,49
LVEF (%): 20.0
Medications: Beta Blockers, Loop Diuretics, Spironolactone, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",survivor,"RANKING: 1. Survivor
REASONING: 

Based on the provided patient data, the patient is a 73-year-old male with a history of idiopathic dilated cardiomyopathy, which is a significant risk factor for cardiac death. The patient's left ventricular ejection fraction (LVEF) of 20% is severely impaired, indicating poor cardiac function. The presence of non-sustained ventricular tachycardia (NSVT) and polymorphic ventricular extrasystoles on the ECG suggests a high risk of arrhythmias, which can lead to sudden cardiac death. The patient's elevated troponin levels (0.01 ng/mL) also indicate some degree of cardiac damage.

Despite the patient's poor cardiac function and arrhythmias, the patient is currently taking medications for heart failure management, including beta blockers, loop diuretics, spironolactone, and an ACE inhibitor. This suggests that the patient is receiving standard treatment for heart failure, which may help manage symptoms and slow disease progression.

While the patient's prognosis is concerning, the presence of a positive patient outcome and the fact that the patient is currently receiving treatment suggest that the patient may survive for the next few years. However, close monitoring and adjustments to the treatment plan may be necessary to manage the patient's cardiac function and reduce the risk of arrhythmias and cardiac death.

RANKING: 2. Sudden Cardiac Death
REASONING: 

Given the patient's severely impaired LVEF and history of arrhythmias, there is a significant risk of sudden cardiac death. The presence of non-sustained ventricular tachycardia (NSVT) and polymorphic ventricular extrasystoles on the ECG increases the risk of sudden cardiac death. The patient's elevated troponin levels also indicate some degree of cardiac damage, which can increase the risk of arrhythmias and cardiac death.

While the patient is receiving treatment for heart failure, the severity of the patient's cardiac impairment and the presence of arrhythmias make it challenging to predict a favorable outcome. The patient's age and comorbidities also contribute to the risk of sudden cardiac death.

RANKING: 3. Pump Failure Death
REASONING: 

Given the patient's severely impaired LVEF and history of arrhythmias, pump failure is a likely complication in the next few years. The patient's elevated creatinine levels (71.0 mmol/L) and urea (7.49 mg/dL) suggest some degree of renal impairment, which can be a complication of heart failure.

The patient's elevated troponin levels and non-sustained ventricular tachycardia on the ECG also indicate some degree of cardiac damage, which can lead to pump failure. However, the patient is currently receiving treatment for heart failure, which may help manage symptoms and slow disease progression.

While pump failure is a possible complication, the patient's current treatment and the presence of a positive patient outcome suggest that the patient may survive for the next few years, albeit with ongoing management and adjustments to the treatment plan."
355,355,P0580,"Age: 73
Gender: Female 
Weight: 49 kg
Height: 150 cm
NYHA Class: II
Blood Pressure: 135/40 mmHg
Past Medical History: Toxic dilated cardiomyopathy, Diabetes, Dyslipemia, Hypertension
Albumin (g/L): 23
ALT or GPT (IU/L): 15.0
AST or GOT (IU/L): 16.0
Total Cholesterol (mmol/L): 4,71
Creatinine (mmol/L): 88.0
Gamma-glutamil transpeptidase (IU/L): 37
Glucose (mmol/L): 12,4
Hemoglobin (g/L): 126.0
HDL (mmol/L): 0,96
Potassium (mEq/L): 4,6
LDL (mmol/L): 1,73
Sodium (mEq/L): 133.0
Pro-BNP (ng/L): 2932.0
Protein (g/L): 75
T4 (ng/L): 19
Troponin (ng/mL): 0,02
TSH (mIU/L): 2,78
Urea (mg/dL): 9,32
LVEF (%): 29.0
Medications: Diabetes Medication, Beta Blockers, Digoxin, Loop Diuretics, Statins, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"RANKING: 

1. Survivor
REASONING: 
This patient's prognosis is ranked as a survivor due to the presence of several factors that suggest a relatively preserved cardiac function despite the patient's advanced age, comorbidities, and ECG abnormalities. The patient's LVEF is 29%, which is significantly reduced, indicating some degree of left ventricular dysfunction. However, the absence of any overt signs of acute coronary syndrome (e.g., troponin elevation), the presence of a relatively preserved hemoglobin level, and the absence of any signs of severe heart failure (e.g., elevated BNP levels) contribute to this outcome.

The patient's medication regimen, which includes beta blockers, ACE inhibitors, and diuretics, suggests an attempt to manage heart failure symptoms and control blood pressure and fluid overload. The presence of diabetes, hypertension, and dyslipidemia, while concerning for long-term cardiovascular risk, do not necessarily preclude a favorable short-term outcome.

The ECG findings of ventricular extrasystole and non-sustained ventricular tachycardia are concerning, but the patient is not currently experiencing any symptoms, and the absence of sustained ventricular tachycardia or other arrhythmias is a positive sign.

2. Sudden Cardiac Death
REASONING: 
While the patient's ECG shows several abnormalities, the presence of a relatively preserved hemoglobin level, the absence of troponin elevation, and the patient's current asymptomatic status make sudden cardiac death less likely. However, the patient's LVEF is significantly reduced, indicating some degree of left ventricular dysfunction, and the presence of ventricular extrasystole and non-sustained ventricular tachycardia on ECG increases the risk of arrhythmic events.

Additionally, the patient's age, comorbidities, and the presence of a reduced LVEF make it more challenging to predict a favorable outcome.

3. Pump Failure Death
REASONING: 
The patient's reduced LVEF and elevated creatinine levels suggest some degree of left ventricular dysfunction and possible renal impairment, which could contribute to a higher risk of pump failure. However, the patient's current hemoglobin level, absence of severe heart failure symptoms, and relatively preserved kidney function (creatinine 9.32 mg/dL) make pump failure less likely.

The patient's ECG findings, while concerning, do not necessarily indicate a high risk of sudden cardiac death or pump failure. Overall, while the patient's comorbidities and reduced LVEF increase the risk of adverse outcomes, the patient's current asymptomatic status and relatively preserved hemoglobin level suggest a more favorable prognosis."
356,356,P0581,"Age: 45
Gender: Female 
Weight: 73 kg
Height: 169 cm
NYHA Class: II
Blood Pressure: 120/60 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Myocardial Infarction
Albumin (g/L): 47
ALT or GPT (IU/L): 26.0
AST or GOT (IU/L): 25.0
Total Cholesterol (mmol/L): 3,96
Creatinine (mmol/L): 106.0
Gamma-glutamil transpeptidase (IU/L): 66
Glucose (mmol/L): 4,8
Hemoglobin (g/L): 125.0
HDL (mmol/L): 1,22
Potassium (mEq/L): 4,4
LDL (mmol/L): 2,17
Sodium (mEq/L): 138.0
Pro-BNP (ng/L): 825.0
Protein (g/L): 81
T3 (pg/dL): 0,05
T4 (ng/L): 15
Troponin (ng/mL): 0,06
TSH (mIU/L): 8,69
Urea (mg/dL): 6,82
LVEF (%): 30.0
Medications: Beta Blockers, Digoxin, Loop Diuretics, Spironolactone, Statins, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"RANKING: 1. Survivor
REASONING: 

The patient's overall clinical presentation and test results suggest a high risk of adverse cardiac events. Key factors contributing to this risk include:

1. NYHA Class II: The patient has a moderate level of heart failure symptoms, indicating that their heart is not functioning optimally and is likely to continue to deteriorate if not adequately managed.

2. Ischemic dilated cardiomyopathy and previous myocardial infarction: These conditions indicate significant cardiac damage and scarring, which can lead to further complications such as arrhythmias and heart failure.

3. Elevated troponin levels (0.06 ng/mL) suggest some degree of myocardial injury, which may be indicative of ongoing cardiac stress or damage.

4. Low LVEF (30.0%): This indicates severely impaired left ventricular function, which is a strong predictor of poor outcomes.

5. Elevated BNP (825 ng/L): This biomarker is elevated, suggesting fluid overload and increased cardiac stress, which can lead to further heart failure and arrhythmias.

6. Presence of ventricular extrasystoles, non-sustained VT, and polymorphic VT on ECG: These arrhythmias indicate an increased risk of ventricular fibrillation and sudden cardiac death.

Considering these factors, the patient is at high risk for adverse cardiac events. However, the patient's age, gender, and the absence of other significant comorbidities are in their favor.

RANKING: 2. Sudden cardiac death
REASONING: 

Given the patient's severe left ventricular dysfunction, previous myocardial infarction, and presence of arrhythmias, the risk of sudden cardiac death is significant.

RANKING: 3. Pump failure death
REASONING: 

The patient's NYHA Class II symptoms, elevated BNP, and low LVEF indicate a high risk of heart failure. However, the presence of medications such as beta blockers, digoxin, loop diuretics, and ACE inhibitors suggests that the patient is receiving standard treatment for heart failure. Given the patient's overall clinical presentation and test results, the risk of pump failure death is less likely than sudden cardiac death."
357,357,P0582,"Age: 74
Gender: Female 
Weight: 72 kg
Height: 172 cm
NYHA Class: II
Blood Pressure: 143/76 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Dyslipemia, Myocardial Infarction
Albumin (g/L): 41
ALT or GPT (IU/L): 18.0
AST or GOT (IU/L): 24.0
Total Cholesterol (mmol/L): 4,73
Creatinine (mmol/L): 115.0
Gamma-glutamil transpeptidase (IU/L): 19
Glucose (mmol/L): 3,7
Hemoglobin (g/L): 131.0
HDL (mmol/L): 1,71
Potassium (mEq/L): 3,8
LDL (mmol/L): 2,59
Sodium (mEq/L): 139.0
Pro-BNP (ng/L): 2066.0
Protein (g/L): 72
T4 (ng/L): 17
Troponin (ng/mL): 0,01
TSH (mIU/L): 6,26
Urea (mg/dL): 7,32
LVEF (%): 28.0
Medications: Amiodarone, Loop Diuretics, Statins, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: No
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"RANKING: 
1. Survivor
REASONING:
The patient is a 74-year-old female with a history of ischemic dilated cardiomyopathy, which is a significant risk factor for heart failure and arrhythmias. However, the patient is currently on medications for these conditions, including Amiodarone, Loop Diuretics, Statins, and ACE Inhibitor, which suggests a good level of management. The patient's LVEF is 28%, which is lower than the normal range, indicating some degree of cardiac dysfunction.

The patient's ECG results show no evidence of ventricular tachycardia, ventricular extrasystoles, or non-sustained ventricular tachycardia, which are all potential indicators of arrhythmias. The absence of these findings, combined with the patient's relatively stable ECG impression, suggests that the patient is currently not at high risk for sudden cardiac death.

Additionally, the patient's biomarkers, such as Troponin and Pro-BNP, are not significantly elevated, indicating that there is no acute myocardial injury or significant cardiac stress. The patient's hemoglobin, kidney function, and liver function are also within relatively normal limits.

Overall, considering the patient's age, medical history, and current treatment, the most likely outcome is that the patient will survive for the next few years, assuming that the patient continues to adhere to their medication regimen and undergoes regular follow-up monitoring.

2. Sudden cardiac death
REASONING:
The patient's history of ischemic dilated cardiomyopathy and current LVEF of 28% make them at risk for cardiac events, including arrhythmias and sudden cardiac death. However, the patient is currently on medications that are commonly used to manage these conditions, and the ECG results do not show any signs of arrhythmias.

The patient's elevated creatinine level (115.0 mmol/L) may indicate some degree of renal impairment, which can be a risk factor for cardiac events. However, this finding alone is not sufficient to predict sudden cardiac death.

3. Pump failure death
REASONING:
Given the patient's current LVEF of 28%, which is significantly below the normal range, pump failure is a significant concern. The patient's NYHA Class II classification also indicates some degree of heart failure symptoms, which can lead to pump failure.

However, the patient is currently on medications that are commonly used to manage heart failure, including ACE inhibitors and diuretics. The patient's ECG results do not show any signs of arrhythmias, and the biomarkers are not significantly elevated.

Considering the patient's medical history, current treatment, and ECG results, while pump failure is a concern, it is less likely than sudden cardiac death given the patient's current stable ECG and lack of evidence of arrhythmias."
358,358,P0585,"Age: 72
Gender: Male 
Weight: 83 kg
Height: 171 cm
NYHA Class: II
Blood Pressure: 150/80 mmHg
Past Medical History: Valvular cardiomyopathy, Dyslipemia
Albumin (g/L): 45
ALT or GPT (IU/L): 18.0
AST or GOT (IU/L): 18.0
Total Cholesterol (mmol/L): 4,99
Creatinine (mmol/L): 124.0
Gamma-glutamil transpeptidase (IU/L): 18
Glucose (mmol/L): 4,7
Hemoglobin (g/L): 144.0
HDL (mmol/L): 1,19
Potassium (mEq/L): 4,8
LDL (mmol/L): 2,79
Sodium (mEq/L): 138.0
Pro-BNP (ng/L): 852.0
Protein (g/L): 77
T3 (pg/dL): 0,04
T4 (ng/L): 21
Troponin (ng/mL): 0,04
TSH (mIU/L): 0,43
Urea (mg/dL): 8,82
LVEF (%): 40.0
Medications: Amiodarone, Beta Blockers, Statins, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",survivor,"RANKING: 1. Survivor
REASONING: 

Based on the provided patient data, I predict that the patient has a high likelihood of survival for the next few years. Here's why:

1. Age: The patient is 72 years old, which is a significant risk factor for cardiac events. However, the patient's age alone is not a contraindication for survival.
2. NYHA Class II: The patient's heart failure is mild, indicating that they are still able to perform daily activities without severe limitations. This suggests that the patient's cardiac function is relatively preserved.
3. Medications: The patient is on a comprehensive regimen of medications, including amiodarone, beta blockers, statins, and an ACE inhibitor, which are all standard treatments for heart failure and arrhythmias. This suggests that the patient is receiving optimal medical therapy.
4. Pro-BNP levels: While elevated Pro-BNP levels indicate some degree of cardiac stress, the patient's level of 852.0 ng/L is not excessively high, suggesting that the patient's heart is not under significant stress.
5. LVEF: The patient's left ventricular ejection fraction (LVEF) is 40.0%, which is lower than the normal range (50-70%), but still within the range for someone with NYHA Class II heart failure. This suggests that the patient's heart is still pumping effectively, albeit with some impairment.
6. Other lab values: The patient's liver function tests, kidney function tests, and electrolyte levels are all within normal or near-normal ranges, which suggests that there are no significant underlying metabolic or electrolyte imbalances that could compromise cardiac function.
7. ECG findings: The patient's ECG shows ventricular extrasystoles, which are a common finding in patients with heart failure, but there is no evidence of ventricular tachycardia or other arrhythmias that could increase the risk of sudden cardiac death.

Overall, while the patient has a number of risk factors for cardiac events, their clinical presentation and treatment plan suggest that they are at low risk for sudden cardiac death and pump failure over the next few years."
359,359,P0586,"Age: 74
Gender: Male 
Weight: 74 kg
Height: 165 cm
NYHA Class: II
Blood Pressure: 110/80 mmHg
Past Medical History: Idiopathic dilated cardiomyopathy, Dyslipemia, Hypertension
Albumin (g/L): 41
ALT or GPT (IU/L): 24.0
AST or GOT (IU/L): 22.0
Total Cholesterol (mmol/L): 5,2
Creatinine (mmol/L): 115.0
Gamma-glutamil transpeptidase (IU/L): 23
Glucose (mmol/L): 6,1
Hemoglobin (g/L): 179.0
HDL (mmol/L): 1,27
Potassium (mEq/L): 4,4
LDL (mmol/L): 3,08
Sodium (mEq/L): 138.0
Pro-BNP (ng/L): 493.0
Protein (g/L): 75
T4 (ng/L): 14
Troponin (ng/mL): 0,01
TSH (mIU/L): 1,81
Urea (mg/dL): 8,82
LVEF (%): 23.0
Medications: Beta Blockers, Loop Diuretics, Statins, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",survivor,"RANKING: 
1. Survivor 
REASONING: 
This patient's prognosis is most likely to be a survivor due to the presence of certain factors that suggest a relatively stable and manageable condition. The patient's NYHA class is II, indicating mild symptoms, and their blood pressure is within a relatively normal range. The patient is also taking a combination of medications that are commonly used to manage heart failure and hypertension, such as beta blockers, loop diuretics, statins, and an ACE inhibitor. The absence of significant elevations in liver enzymes (ALT and AST) and creatinine suggests that the patient's kidney function is relatively preserved.

While the patient has a history of idiopathic dilated cardiomyopathy, which is a significant risk factor for adverse outcomes, the patient's left ventricular ejection fraction (LVEF) is only 23%, which is still within a range that can be managed with medical therapy. The presence of elevated BNP levels (493 ng/L) suggests some degree of cardiac stress, but it is not excessively high, and the patient's troponin levels are within normal limits, which suggests that there is no significant myocardial injury.

The patient's electrolyte levels, including potassium, sodium, and urea, are also relatively stable, which further supports a favorable prognosis. The absence of significant arrhythmias, such as ventricular tachycardia or bradycardia, also reduces the risk of sudden cardiac death.

Overall, while this patient has a significant underlying condition, the combination of their stable medical history, medication regimen, and relatively preserved organ function suggest a relatively favorable prognosis."
360,360,P0587,"Age: 58
Gender: Male 
Weight: 97 kg
Height: 171 cm
NYHA Class: II
Blood Pressure: 120/75 mmHg
Past Medical History: Idiopathic dilated cardiomyopathy, Dyslipemia
Albumin (g/L): 43
ALT or GPT (IU/L): 29.0
AST or GOT (IU/L): 23.0
Total Cholesterol (mmol/L): 2,95
Creatinine (mmol/L): 80.0
Gamma-glutamil transpeptidase (IU/L): 17
Glucose (mmol/L): 5,9
Hemoglobin (g/L): 136.0
HDL (mmol/L): 1,16
Potassium (mEq/L): 4,7
LDL (mmol/L): 1,47
Sodium (mEq/L): 137.0
Pro-BNP (ng/L): 65.0
Protein (g/L): 76
T4 (ng/L): 13
Troponin (ng/mL): 0,01
TSH (mIU/L): 1,93
Urea (mg/dL): 7,82
LVEF (%): 30.0
Medications: Beta Blockers, Spironolactone, Statins, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"RANKING: 1. Survivor
REASONING: 

Based on the provided patient data, the patient is classified as having a moderate to severe left ventricular dysfunction, indicated by an LVEF of 30.0%, which is below the normal range of 55-70%. The patient also has a history of idiopathic dilated cardiomyopathy, which is a significant risk factor for adverse cardiac events.

The patient's elevated Pro-BNP level (65.0 ng/L) suggests a moderate level of ventricular stress, which may indicate some degree of heart failure. However, the patient's NYHA Class II indicates that the symptoms are manageable with current medical therapy.

The patient's lipid profile shows elevated total cholesterol (2,95 mmol/L) and LDL (1,47 mmol/L), which is a risk factor for cardiovascular events. The patient's blood pressure is well-controlled at 120/75 mmHg, and the medications prescribed (beta blockers, spironolactone, statins, and ACE inhibitor) are standard treatments for managing heart failure and cardiovascular risk factors.

The absence of significant abnormalities in other laboratory values, such as electrolytes, liver enzymes, and renal function, suggests that the patient is not at high risk for acute complications. The ECG findings, except for ventricular extrasystole, are also unremarkable.

Given these factors, the patient's overall risk profile suggests a moderate risk for adverse cardiac events, but not an extremely high risk. Therefore, the most likely outcome is a favorable outcome, with the patient surviving the next few years."
361,361,P0588,"Age: 77
Gender: Male 
Weight: 92 kg
Height: 170 cm
NYHA Class: II
Blood Pressure: 135/100 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Myocardial Infarction
Albumin (g/L): 43
ALT or GPT (IU/L): 11.0
AST or GOT (IU/L): 10.0
Total Cholesterol (mmol/L): 6,21
Creatinine (mmol/L): 97.0
Gamma-glutamil transpeptidase (IU/L): 18
Glucose (mmol/L): 5,4
Hemoglobin (g/L): 145.0
HDL (mmol/L): 1,68
Potassium (mEq/L): 4,9
LDL (mmol/L): 4,09
Sodium (mEq/L): 139.0
Pro-BNP (ng/L): 514.0
Protein (g/L): 69
T3 (pg/dL): 0,05
T4 (ng/L): 14
Troponin (ng/mL): 0,1
TSH (mIU/L): 0,96
Urea (mg/dL): 9,15
LVEF (%): 50.0
Medications: Digoxin, Loop Diuretics, ACE Inhibitor, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Unknown ventricular extrasystole code
        - Ventricular Tachycardia: Unknown ventricular tachycardia code
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",survivor,"RANKING: 1. Survivor
REASONING: 

Based on the patient's age, NYHA Class II heart failure, history of ischemic dilated cardiomyopathy, and myocardial infarction, as well as elevated biomarkers such as troponin and BNP, the patient is at high risk for cardiac complications. However, the patient's current medication regimen, including ACE inhibitors and loop diuretics, suggests that the patient is being adequately managed for heart failure. The absence of significant elevations in liver enzymes and electrolytes, such as potassium, potassium, and troponin, also suggests that the patient's cardiac function is not severely impaired. Furthermore, the patient's hemoglobin and HDL levels are within normal limits, indicating no significant anemia or dyslipidemia. Given these factors, the patient's overall prognosis is likely to be a survivor, and with proper management, the patient may experience a gradual improvement in their cardiac function and quality of life.

RANKING: 2. Sudden cardiac death
REASONING: 

While the patient's cardiac history and biomarkers suggest a high risk for cardiac complications, the absence of significant elevations in troponin and BNP, as well as the patient's current medication regimen, suggests that the patient is not at high risk for sudden cardiac death. However, the patient's history of ischemic dilated cardiomyopathy and myocardial infarction, as well as the presence of ventricular extrasystole and non-sustained ventricular tachycardia on ECG, do increase the risk for arrhythmic events. However, the patient's age and NYHA Class II heart failure may also contribute to an increased risk for sudden cardiac death. Therefore, while the patient is at some risk, the likelihood of sudden cardiac death is lower than that of pump failure.

RANKING: 3. Pump failure death
REASONING: 

Given the patient's age, NYHA Class II heart failure, and history of ischemic dilated cardiomyopathy and myocardial infarction, the patient is at high risk for pump failure. The patient's LVEF of 50.0% also indicates significant left ventricular dysfunction. However, the patient's current medication regimen, including ACE inhibitors and loop diuretics, suggests that the patient is being adequately managed for heart failure. The absence of significant elevations in liver enzymes and electrolytes also suggests that the patient's cardiac function is not severely impaired. Additionally, the patient's hemoglobin and HDL levels are within normal limits, indicating no significant anemia or dyslipidemia. Therefore, while the patient is at risk for pump failure, the likelihood of this outcome is lower than that of sudden cardiac death due to the patient's current management and the absence of significant cardiac biomarkers."
362,362,P0590,"Age: 64
Gender: Female 
Weight: 75 kg
Height: 155 cm
NYHA Class: II
Blood Pressure: 135/95 mmHg
Past Medical History: Ischemic dilated cardiomyopathy
Albumin (g/L): 42
ALT or GPT (IU/L): 22.0
AST or GOT (IU/L): 16.0
Total Cholesterol (mmol/L): 3,72
Creatinine (mmol/L): 106.0
Gamma-glutamil transpeptidase (IU/L): 6
Glucose (mmol/L): 5,6
Hemoglobin (g/L): 113.0
HDL (mmol/L): 1,01
Potassium (mEq/L): 4,3
LDL (mmol/L): 2,17
Sodium (mEq/L): 137.0
Pro-BNP (ng/L): 667.0
Protein (g/L): 64
T3 (pg/dL): 0,04
T4 (ng/L): 20
Troponin (ng/mL): 0,03
TSH (mIU/L): 4,77
Urea (mg/dL): 12,15
LVEF (%): 32.0
Medications: Amiodarone, Loop Diuretics, Statins, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: TPSV
        - Bradycardia: No
            ",survivor,"RANKING: 1. Survivor
REASONING: 

The patient's age, NYHA Class II, and LVEF of 32.0 suggest that the patient has a moderate to severe heart failure. However, the absence of symptoms and the presence of a relatively stable vital sign profile (BP 135/95 mmHg) and a low level of troponin (0.03 ng/mL) indicate that the patient is not in acute decompensated heart failure. The patient's Pro-BNP level is elevated at 667.0 ng/L, but this is not unusually high for a patient with heart failure. 

The patient's medication regimen includes an ACE inhibitor, which is beneficial for patients with heart failure. The absence of ventricular tachycardia or non-sustained ventricular tachycardia on the ECG suggests that the patient does not have a high risk of ventricular arrhythmias. 

The patient's laboratory values are relatively stable, with no significant electrolyte imbalances or acute kidney injury. The patient's hemoglobin level is slightly elevated, which may be a sign of chronic anemia. However, this is not immediately concerning.

Considering these factors, the patient's overall prognosis is relatively favorable, and I predict that the patient will survive for the next few years. 

RANKING: 2. Sudden Cardiac Death
REASONING: 

While the patient's LVEF is low, the patient's Pro-BNP level is not unusually high, and the patient is on an ACE inhibitor, which is beneficial for patients with heart failure. However, the patient's age and NYHA Class II suggest that the patient has a moderate to severe heart failure. 

The patient's ECG shows a monomorphic ventricular extrasystole, which is a marker of ventricular arrhythmias. While this finding is not extremely concerning, it is still a sign of an increased risk of arrhythmias. The absence of ventricular tachycardia or non-sustained ventricular tachycardia on the ECG reduces the risk of sudden cardiac death, but does not eliminate it. 

The patient's creatinine level is elevated at 106.0 mmol/L, which may indicate some degree of renal impairment. This could be related to heart failure or other comorbidities. 

Considering these factors, while the patient's prognosis is still relatively favorable, the presence of a monomorphic ventricular extrasystole and elevated creatinine level increase the risk of sudden cardiac death. 

RANKING: 3. Pump Failure Death
REASONING: 

The patient's LVEF is severely low at 32.0, indicating a significant impairment of cardiac function. The patient's NYHA Class II and elevated Pro-BNP level suggest that the patient has moderate to severe heart failure. 

The patient's medication regimen includes an ACE inhibitor, which is beneficial for patients with heart failure, but the patient's LVEF is still quite low, indicating that the patient is not responding adequately to treatment. 

The patient's ECG shows a monomorphic ventricular extrasystole, which is a marker of ventricular arrhythmias, and the patient's elevated creatinine level may indicate some degree of renal impairment. 

Considering these factors, the patient's prognosis is less favorable, and I predict that the patient is at increased risk of pump failure death in the next few years."
363,363,P0591,"Age: 62
Gender: Male 
Weight: 72 kg
Height: 173 cm
NYHA Class: II
Blood Pressure: 125/90 mmHg
Past Medical History: Valvular cardiomyopathy
Albumin (g/L): 42
ALT or GPT (IU/L): 22.0
AST or GOT (IU/L): 23.0
Total Cholesterol (mmol/L): 3,72
Creatinine (mmol/L): 97.0
Gamma-glutamil transpeptidase (IU/L): 73
Glucose (mmol/L): 5,1
Hemoglobin (g/L): 120.0
HDL (mmol/L): 0,75
Potassium (mEq/L): 4,2
LDL (mmol/L): 2,38
Sodium (mEq/L): 138.0
Pro-BNP (ng/L): 279.0
Protein (g/L): 74
T3 (pg/dL): 0,05
T4 (ng/L): 19
Troponin (ng/mL): 0,03
TSH (mIU/L): 1,18
Urea (mg/dL): 8,32
LVEF (%): 64.0
Medications: Beta Blockers, Digoxin, Loop Diuretics
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",survivor,"RANKING: 
1. Survivor
REASONING: 

The patient's overall health status and lab results suggest that the patient is at high risk for cardiac complications, but the patient is currently receiving treatment with beta blockers, digoxin, and loop diuretics, which are standard therapies for managing heart failure and arrhythmias associated with valvular cardiomyopathy. The patient's NYHA class is II, indicating mild symptoms, and the LVEF is 64%, which is within the normal range for a 62-year-old male.

The patient's elevated troponin level (0.03 ng/mL) is not significantly elevated, and the ECG findings of ventricular extrasystoles are non-specific and may be related to the patient's underlying valvular cardiomyopathy. The lack of evidence for ventricular tachycardia, non-sustained ventricular tachycardia, or paroxysmal supraventricular tachyarrhythmia on the ECG suggests that the patient is not at high risk for sudden cardiac death.

While the patient's creatinine level (97.0 mol/L) is slightly elevated, which may indicate some degree of renal impairment, the patient's kidney function is not severely impaired, and the patient is receiving loop diuretics, which can help manage fluid overload.

The patient's lipid profile is not optimal, with high total cholesterol (3.72 mmol/L) and LDL levels (2.38 mmol/L), but these are not unusual for a patient with heart failure. The patient's hemoglobin level (120.0 g/L) is within the normal range, and the lack of evidence for anemia or other blood disorders suggests that the patient is not at high risk for bleeding complications.

Overall, based on the patient's clinical presentation, lab results, and treatment, I believe that the patient is at low risk for cardiac complications and is likely to survive for the next few years."
364,364,P0592,"Age: 66
Gender: Male 
Weight: 78 kg
Height: 165 cm
NYHA Class: II
Blood Pressure: 120/80 mmHg
Past Medical History: Valvular cardiomyopathy, Diabetes
Albumin (g/L): 40
ALT or GPT (IU/L): 23.0
AST or GOT (IU/L): 18.0
Total Cholesterol (mmol/L): 3,96
Creatinine (mmol/L): 115.0
Gamma-glutamil transpeptidase (IU/L): 85
Glucose (mmol/L): 8,9
Hemoglobin (g/L): 153.0
HDL (mmol/L): 0,54
Potassium (mEq/L): 5,4
LDL (mmol/L): 2,46
Sodium (mEq/L): 138.0
Pro-BNP (ng/L): 1537.0
Protein (g/L): 73
T3 (pg/dL): 0,05
T4 (ng/L): 18
Troponin (ng/mL): 0,03
TSH (mIU/L): 1,13
Urea (mg/dL): 8,65
LVEF (%): 30.0
Medications: Beta Blockers, Digoxin, Loop Diuretics, Spironolactone, Statins
ECG Impression:
        - Ventricular Extrasystole: Unknown ventricular extrasystole code
        - Ventricular Tachycardia: Unknown ventricular tachycardia code
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",survivor,"RANKING: 1. Survivor
REASONING: 

Based on the patient's data, I predict a high likelihood of survival for the next few years. The key factors contributing to this prediction are:

1. Age: The patient is 66 years old, which is considered advanced age, but not extremely high for cardiac surgery. Many patients with valvular cardiomyopathy and heart failure can survive for several years with proper management.
2. NYHA Class II: The patient has a moderate level of symptoms, which indicates that they are able to perform daily activities with some limitation, but they are not severely limited. This suggests that they have some residual cardiac function.
3. Blood Pressure: The patient's blood pressure is well-controlled, which is essential for preventing further cardiovascular damage.
4. Medications: The patient is taking beta blockers, digoxin, loop diuretics, spironolactone, and statins, which are all standard treatments for heart failure and valvular cardiomyopathy. These medications will help manage symptoms, slow disease progression, and prevent complications.
5. Pro-BNP levels: While elevated, the patient's Pro-BNP levels are not extremely high, indicating that they are not experiencing severe heart failure symptoms.
6. LVEF: The patient's left ventricular ejection fraction (LVEF) is 30%, which is a relatively preserved value. This suggests that the patient has some residual cardiac function, which will help them tolerate surgery and other interventions.
7. ECG findings: The ECG shows ventricular extrasystoles and non-sustained ventricular tachycardia, but no other concerning findings.

While the patient's data does not indicate a low risk for immediate complications, it is essential to monitor their condition closely and adjust their treatment plan as needed. Regular follow-up appointments and close monitoring will be crucial to ensure that the patient remains stable and to identify any potential issues early."
365,365,P0595,"Age: 69
Gender: Male 
Weight: 68 kg
Height: 165 cm
NYHA Class: II
Blood Pressure: 176/92 mmHg
Past Medical History: Hypertensive cardiomyopathy, Diabetes, Peripheral vascular disease, Hypertension
Albumin (g/L): 44
ALT or GPT (IU/L): 24.0
AST or GOT (IU/L): 17.0
Total Cholesterol (mmol/L): 4,29
Creatinine (mmol/L): 88.0
Gamma-glutamil transpeptidase (IU/L): 96
Glucose (mmol/L): 7,8
Hemoglobin (g/L): 156.0
HDL (mmol/L): 1,11
Potassium (mEq/L): 4,3
LDL (mmol/L): 2,53
Sodium (mEq/L): 137.0
Pro-BNP (ng/L): 290.0
Protein (g/L): 76
T3 (pg/dL): 0,05
T4 (ng/L): 15
TSH (mIU/L): 0,46
Urea (mg/dL): 7,15
LVEF (%): 35.0
Medications: Calcium Channel Blocker, Diabetes Medication, Loop Diuretics, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"RANKING: 

1. Survivor
REASONING:
The patient has a complex medical history, including hypertension, cardiomyopathy, diabetes, peripheral vascular disease, and elevated creatinine levels. However, the patient is currently on multiple medications for these conditions, including a calcium channel blocker, diabetes medication, loop diuretics, and an ACE inhibitor, which suggests that the patient is being actively managed. The patient's LVEF is significantly reduced at 35%, but this is not uncommon in patients with hypertensive cardiomyopathy. The ECG impression is largely unremarkable, with no evidence of ventricular tachycardia or bradycardia. The patient's Pro-BNP levels are elevated, but this can be seen in patients with heart failure and other conditions. Given the patient's overall medical history and current management, the likelihood of a sudden cardiac death or pump failure death appears low. 

2. Sudden Cardiac Death
REASONING:
The patient's LVEF is significantly reduced, which increases the risk of sudden cardiac death. However, the patient is being treated with medications that are typically used to manage heart failure and hypertension. The ECG impression does not show any arrhythmias that would increase the risk of sudden cardiac death. Additionally, the patient's Pro-BNP levels are elevated, which suggests some degree of heart failure, but this is not a guarantee of sudden cardiac death. Given the patient's complex medical history and reduced LVEF, there is still a moderate risk of sudden cardiac death, but it is not the most likely outcome.

3. Pump Failure Death
REASONING:
While the patient's LVEF is significantly reduced, the patient is currently being treated with medications that are used to manage heart failure. The patient's Pro-BNP levels are elevated, but this can be seen in patients with heart failure. The patient's ECG impression is largely unremarkable, which reduces the likelihood of pump failure death. Given the patient's overall medical history and current management, the likelihood of pump failure death is moderate, but it is not the most likely outcome. The patient's reduced LVEF and elevated Pro-BNP levels do increase the risk of heart failure, but the patient's current treatment plan and lack of other concerning ECG findings reduce this risk."
366,366,P0597,"Age: 74
Gender: Male 
Weight: 83 kg
Height: 164 cm
NYHA Class: III
Blood Pressure: 143/65 mmHg
Past Medical History: Valvular cardiomyopathy, Dyslipemia
Albumin (g/L): 39
ALT or GPT (IU/L): 25.0
AST or GOT (IU/L): 22.0
Total Cholesterol (mmol/L): 3,9
Creatinine (mmol/L): 71.0
Gamma-glutamil transpeptidase (IU/L): 76
Glucose (mmol/L): 5,8
Hemoglobin (g/L): 137.0
HDL (mmol/L): 0,75
Potassium (mEq/L): 4
LDL (mmol/L): 2,9
Sodium (mEq/L): 140.0
Pro-BNP (ng/L): 1874.0
Protein (g/L): 67
T3 (pg/dL): 0,08
T4 (ng/L): 29
Troponin (ng/mL): 0,03
TSH (mIU/L): 0,09
Urea (mg/dL): 9,32
LVEF (%): 70.0
Medications: Calcium Channel Blocker, Amiodarone, Loop Diuretics, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",survivor,"RANKING: 1. Survivor
REASONING: 

Based on the patient's data, I believe the most likely outcome for the next few years is a survivor. The patient's age of 74 and NYHA Class III heart failure classification indicate a high risk for cardiovascular events. However, the patient's left ventricular ejection fraction (LVEF) is 70%, which is within the normal range. The patient's creatinine level is slightly elevated, indicating some degree of renal impairment, but it is not severe. The patient's blood pressure is well-controlled, and the patient is on multiple medications, including a calcium channel blocker, amiodarone, loop diuretics, and a nitrovasodilator, which suggests that the patient is receiving optimal management for heart failure and arrhythmias.

The patient's troponin level is normal, which suggests that there is no significant myocardial infarction in the recent past. The patient's BNP level is elevated, which is consistent with heart failure, but it is not extremely high, suggesting that the patient is not in acute decompensated heart failure.

The patient's ECG shows ventricular extrasystoles, non-sustained ventricular tachycardia, and non-sustained ventricular tachycardia, which are all concerning for cardiac arrhythmias. However, the patient is on amiodarone, which is an antiarrhythmic medication that can help manage these arrhythmias. Overall, the patient's data suggests that the patient is receiving optimal management for heart failure and arrhythmias, and the patient's cardiovascular risk factors are not extremely high.

RANKING: 2. Sudden Cardiac Death
REASONING: 

While the patient's ECG shows ventricular extrasystoles, non-sustained ventricular tachycardia, and non-sustained ventricular tachycardia, which are all concerning for cardiac arrhythmias, the patient is on amiodarone, which can help manage these arrhythmias. However, the patient's NYHA Class III classification and elevated BNP level suggest that the patient has significant heart failure. The patient's LVEF is 70%, which is slightly below the normal range, indicating some degree of left ventricular dysfunction. While the patient's cardiovascular risk factors are not extremely high, the patient's age and NYHA Class III classification do increase the risk for cardiovascular events.

RANKING: 3. Pump Failure Death
REASONING: 

While the patient's LVEF is 70%, which is slightly below the normal range, indicating some degree of left ventricular dysfunction, the patient's NYHA Class III classification suggests that the patient has significant heart failure. The patient's elevated BNP level and elevated creatinine level suggest that the patient's heart failure is not well-compensated. The patient's age and cardiovascular risk factors do increase the risk for cardiovascular events, including pump failure. However, the patient's troponin level is normal, which suggests that there is no significant myocardial infarction in the recent past. Overall, while the patient's data suggests that the patient is at risk for pump failure, the patient's current management and cardiovascular risk factors do not make pump failure the most likely outcome."
367,367,P0598,"Age: 50
Gender: Male 
Weight: 65 kg
Height: 168 cm
NYHA Class: II
Blood Pressure: 100/60 mmHg
Past Medical History: Idiopathic dilated cardiomyopathy, Hypertension
Albumin (g/L): 45
ALT or GPT (IU/L): 20.0
AST or GOT (IU/L): 21.0
Total Cholesterol (mmol/L): 4,22
Creatinine (mmol/L): 264.0
Gamma-glutamil transpeptidase (IU/L): 11
Glucose (mmol/L): 5,9
Hemoglobin (g/L): 178.0
HDL (mmol/L): 2,17
Potassium (mEq/L): 4,9
LDL (mmol/L): 1,24
Sodium (mEq/L): 142.0
Pro-BNP (ng/L): 8083.0
Protein (g/L): 84
T3 (pg/dL): 0,03
T4 (ng/L): 14
Troponin (ng/mL): 0,3
TSH (mIU/L): 1,33
Urea (mg/dL): 18,47
LVEF (%): 52.0
Medications: Beta Blockers, Digoxin, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"RANKING: 

1. Survivor
REASONING: 
Given the patient's age, NYHA Class II indicates moderate symptoms, but the patient is still relatively young. The presence of idiopathic dilated cardiomyopathy, hypertension, and elevated creatinine levels suggest a significant impact on cardiac function. However, the patient's hemoglobin level is within normal limits, and the absence of significant electrolyte imbalances or acute kidney injury may indicate a relatively stable metabolic state. The patient's low LVEF (52.0%) indicates significant cardiac dysfunction, but the presence of beta blockers and ACE inhibitors may be mitigating symptoms. The absence of ventricular tachycardia or non-sustained ventricular tachycardia on the ECG suggests that the patient is not at high risk for sudden cardiac death. Overall, the combination of these factors suggests that the patient may be able to survive for several years with proper management.

2. Sudden cardiac death
REASONING: 
The patient's low LVEF (52.0%) and elevated creatinine levels indicate significant cardiac dysfunction. The presence of idiopathic dilated cardiomyopathy and hypertension increases the risk of sudden cardiac death. While the patient is taking beta blockers and ACE inhibitors, which can help reduce the risk of sudden cardiac death, the low LVEF and elevated creatinine levels suggest that the patient is still at risk for cardiac events. The absence of ventricular tachycardia or non-sustained ventricular tachycardia on the ECG is a positive sign, but the patient's overall cardiac function is still compromised.

3. Pump failure death
REASONING: 
Given the patient's significant cardiac dysfunction (LVEF 52.0%), elevated creatinine levels, and NYHA Class II symptoms, the risk of pump failure is relatively high. The patient's low LVEF indicates that the heart is not pumping efficiently, which can lead to increased symptoms and decreased quality of life. The patient's elevated creatinine levels suggest that the kidneys are also under strain, which can further exacerbate cardiac dysfunction. While the patient is taking beta blockers and ACE inhibitors, which can help manage symptoms, the underlying cardiac dysfunction may still lead to pump failure. The absence of ventricular tachycardia or non-sustained ventricular tachycardia on the ECG is a positive sign, but the patient's overall cardiac function is still compromised."
368,368,P0599,"Age: 66
Gender: Female 
Weight: 80 kg
Height: 162 cm
NYHA Class: II
Blood Pressure: 120/70 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Diabetes, Dyslipemia, Hypertension
Albumin (g/L): 48,7
ALT or GPT (IU/L): 38.0
AST or GOT (IU/L): 28.0
Total Cholesterol (mmol/L): 4,89
Creatinine (mmol/L): 83.0
Gamma-glutamil transpeptidase (IU/L): 46
Glucose (mmol/L): 9,2
Hemoglobin (g/L): 136.0
HDL (mmol/L): 1,4
Potassium (mEq/L): 4,2
LDL (mmol/L): 2,38
Sodium (mEq/L): 140.0
Pro-BNP (ng/L): 534.0
Protein (g/L): 75,6
T4 (ng/L): 17
TSH (mIU/L): 1,22
Urea (mg/dL): 6,16
LVEF (%): 36.0
Medications: Calcium Channel Blocker, Diabetes Medication, Beta Blockers, Loop Diuretics, Spironolactone, Statins, ACE Inhibitor, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",survivor,"RANKING: 1. Survivor
REASONING: 
The patient has a significant history of ischemic dilated cardiomyopathy, which is a major risk factor for cardiac events. However, the patient is currently on multiple medications, including ACE inhibitors, beta blockers, and spironolactone, which are known to improve outcomes in heart failure patients. The patient's NYHA class II indicates that they are experiencing some limitations in physical activity but are still able to carry on light activity without undue fatigue. The patient's LVEF of 36% is severely reduced, indicating significant left ventricular dysfunction. However, the patient's hemoglobin level is elevated, which may indicate some level of cardiac compensation. The absence of ventricular tachycardia or non-sustained ventricular tachycardia on the ECG is a positive sign. The patient's creatinine level is elevated, which may indicate some degree of renal impairment, but it is not severe. The patient's laboratory values, including the absence of significant electrolyte imbalances, do not indicate acute kidney injury or acute coronary syndrome. Overall, considering the patient's history, medications, and the absence of acute cardiac events, I predict a favorable outcome and survival.

RANKING: 2. Sudden cardiac death
REASONING: 
While the patient has a significant history of ischemic dilated cardiomyopathy, which is a risk factor for sudden cardiac death, the patient is on multiple medications that are known to reduce the risk of cardiac events. The absence of ventricular tachycardia or non-sustained ventricular tachycardia on the ECG is a negative sign. However, the patient's LVEF is severely reduced, which increases the risk of sudden cardiac death. The patient's elevated creatinine level and elevated glucose level may indicate some degree of cardiac and metabolic stress. The patient's NYHA class II indicates that they are experiencing some limitations in physical activity, which may increase the risk of cardiac events. While the patient's hemoglobin level is elevated, it is not significantly high, which may indicate some level of cardiac compensation. Overall, while the patient's risk factors are significant, the patient's medications and the absence of acute cardiac events make sudden cardiac death less likely.

RANKING: 3. Pump failure death
REASONING: 
The patient's LVEF is severely reduced, indicating significant left ventricular dysfunction, which increases the risk of heart failure. The patient's NYHA class II indicates that they are experiencing some limitations in physical activity, which is consistent with heart failure. The patient's elevated creatinine level and elevated glucose level may indicate some degree of cardiac and metabolic stress. The patient's medications, including ACE inhibitors and beta blockers, are known to improve outcomes in heart failure patients, but the patient's LVEF is severely reduced, which may indicate that the patient is at risk of pump failure. The patient's elevated Pro-BNP level is also consistent with heart failure. Overall, while the patient's medications and the absence of acute cardiac events make heart failure less likely, the patient's severe LVEF reduction and NYHA class II indicate a significant risk of pump failure."
369,369,P0600,"Age: 58
Gender: Female 
Weight: 57 kg
Height: 157 cm
NYHA Class: II
Blood Pressure: 110/70 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Myocardial Infarction
Albumin (g/L): 44,4
ALT or GPT (IU/L): 16.0
AST or GOT (IU/L): 16.0
Total Cholesterol (mmol/L): 4,53
Creatinine (mmol/L): 68.0
Gamma-glutamil transpeptidase (IU/L): 12
Glucose (mmol/L): 5,4
Hemoglobin (g/L): 142.0
HDL (mmol/L): 1,6
Potassium (mEq/L): 4,6
LDL (mmol/L): 2,56
Sodium (mEq/L): 141.0
Pro-BNP (ng/L): 828.0
Protein (g/L): 70,9
T4 (ng/L): 18
TSH (mIU/L): 1,93
Urea (mg/dL): 5,99
LVEF (%): 57.0
Medications: Calcium Channel Blocker, Beta Blockers, Loop Diuretics, Statins, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"RANKING: 
1. Survivor
REASONING:
Based on the patient's data, the patient is a 58-year-old female with a history of ischemic dilated cardiomyopathy and myocardial infarction, presenting with a current NYHA Class II functional status. The patient's LVEF is 57%, indicating a significant reduction in left ventricular function, which is consistent with the patient's history of heart failure.

The patient's laboratory results show a mild elevation in creatinine levels (68.0 mmol/L), which may indicate some degree of renal impairment, but this is not severe. The patient's lipid profile is also elevated, with high total cholesterol (4.53 mmol/L) and LDL (2.56 mmol/L) levels, which may contribute to further cardiac damage.

The patient's ECG shows ventricular extrasystoles, which is a non-specific finding but may indicate some degree of cardiac electrical instability. However, there is no evidence of ventricular tachycardia or other life-threatening arrhythmias.

Given the patient's overall clinical presentation and laboratory results, I believe the patient is at risk for cardiac events, but the presence of beta blockers and ACE inhibitors suggests that the patient is receiving appropriate treatment for heart failure. The patient's NYHA Class II functional status indicates that the patient is still able to perform moderate physical activity without significant symptoms.

Therefore, I predict that the patient is most likely to survive for the next few years, assuming the patient continues to receive appropriate medical therapy and does not experience any significant cardiac events.

RANKING 2: Sudden Cardiac Death
REASONING:
Based on the patient's history of ischemic dilated cardiomyopathy and myocardial infarction, the patient is at increased risk for sudden cardiac death. The patient's LVEF of 57% indicates significant left ventricular dysfunction, which can increase the risk for sudden cardiac death.

The patient's ECG shows ventricular extrasystoles, which may indicate some degree of cardiac electrical instability. While the patient is receiving beta blockers and ACE inhibitors, which can help reduce the risk of sudden cardiac death, the presence of ventricular extrasystoles remains a concern.

Additionally, the patient's elevated creatinine levels (68.0 mmol/L) may indicate some degree of renal impairment, which can increase the risk for cardiac events.

Therefore, while the patient is not at the highest risk for sudden cardiac death, the patient's history and laboratory results suggest that the patient is at increased risk for this outcome.

RANKING 3: Pump Failure Death
REASONING:
Based on the patient's current NYHA Class II functional status and LVEF of 57%, the patient is already experiencing significant left ventricular dysfunction. The patient's elevated creatinine levels (68.0 mmol/L) and mild elevation in liver enzymes (ALT and AST) may indicate some degree of renal and liver impairment, which can further compromise cardiac function.

The patient's lipid profile is also elevated, which can contribute to further cardiac damage. The presence of ventricular extrasystoles on the ECG may indicate some degree of cardiac electrical instability, which can further increase the risk for pump failure.

While the patient is receiving beta blockers and ACE inhibitors, which can help reduce the risk of heart failure, the patient's underlying cardiac disease and laboratory results suggest that the patient is at increased risk for pump failure. However, the patient's NYHA Class II functional status suggests that the patient is still able to perform moderate physical activity without significant symptoms, which may suggest that the patient is not at the highest risk for pump failure.

Therefore, while the patient is at increased risk for pump failure, the patient's overall clinical presentation and laboratory results suggest that the patient is not at the highest risk for this outcome."
370,370,P0601,"Age: 77
Gender: Male 
Weight: 60 kg
Height: 160 cm
NYHA Class: III
Blood Pressure: 110/70 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Peripheral vascular disease, Hypertension, Myocardial Infarction
Albumin (g/L): 47,4
ALT or GPT (IU/L): 13.0
AST or GOT (IU/L): 23.0
Total Cholesterol (mmol/L): 5,53
Creatinine (mmol/L): 72.0
Gamma-glutamil transpeptidase (IU/L): 14
Glucose (mmol/L): 5,3
Hemoglobin (g/L): 145.0
HDL (mmol/L): 1,68
Potassium (mEq/L): 4,9
LDL (mmol/L): 3,31
Sodium (mEq/L): 141.0
Pro-BNP (ng/L): 142.0
Protein (g/L): 74,2
T4 (ng/L): 22
TSH (mIU/L): 1,89
Urea (mg/dL): 7,15
LVEF (%): 35.0
Medications: Loop Diuretics, ACE Inhibitor, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: Unknown bradycardia code
            ",survivor,"RANKING: 

1. Survivor
REASONING:

This patient has several factors that suggest a poorer prognosis, but overall, the data points to a relatively stable condition. The patient's NYHA Class III indicates significant heart failure symptoms, and the LVEF of 35% is significantly reduced, indicating severe left ventricular dysfunction. The presence of ischemic dilated cardiomyopathy, hypertension, and myocardial infarction in the past medical history also suggests a high risk of cardiac complications. However, the patient's age (77) and relatively stable vital signs (BP 110/70 mmHg) do not immediately suggest acute distress.

The patient's lab results show elevated creatinine levels, indicating possible kidney impairment, but this is not uncommon in patients with heart failure. The elevated Pro-BNP levels (142 ng/L) also suggest heart failure, but it's not excessively high, which might indicate some level of compensation.

The ECG findings of ventricular extrasystole and non-sustained VT are concerning for arrhythmias, but the absence of sustained VT and the presence of a stable vital sign make this less immediately life-threatening.

Considering these factors, the patient's overall condition seems stable, and with appropriate management, it is likely that the patient will survive the next few years. The presence of multiple comorbidities and reduced LVEF still pose a risk, but the patient's current condition does not immediately suggest an acute, life-threatening event.

2. Sudden cardiac death
REASONING:

While the patient's ECG findings of ventricular extrasystole and non-sustained VT are concerning for arrhythmias, the absence of sustained VT and the patient's stable vital signs make this ranking less likely. However, the patient's reduced LVEF and ischemic dilated cardiomyopathy increase the risk of sudden cardiac death.

The patient's age and comorbidities also increase the risk of sudden cardiac death, as they can contribute to the development of arrhythmias and cardiac instability.

3. Pump failure death
REASONING:

Given the patient's severe LVEF reduction (35%) and NYHA Class III symptoms, pump failure is a significant concern. The patient's reduced LVEF and elevated Pro-BNP levels indicate significant left ventricular dysfunction, which increases the risk of heart failure exacerbation and pump failure.

However, the patient's stable vital signs and relatively low creatinine levels suggest that the patient is not currently experiencing acute kidney injury or heart failure exacerbation. The patient's ECG findings and lab results do not indicate a sudden onset of arrhythmias or acute cardiac distress.

Considering the patient's severe LVEF reduction and NYHA Class III symptoms, pump failure is a significant risk, but the patient's stable condition and lack of acute distress make this ranking less likely compared to sudden cardiac death."
371,371,P0602,"Age: 67
Gender: Male 
Weight: 62 kg
Height: 163 cm
NYHA Class: II
Blood Pressure: 160/90 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Diabetes, Dyslipemia
Albumin (g/L): 42,9
ALT or GPT (IU/L): 29.0
AST or GOT (IU/L): 22.0
Total Cholesterol (mmol/L): 4,37
Creatinine (mmol/L): 104.0
Gamma-glutamil transpeptidase (IU/L): 106
Glucose (mmol/L): 9,7
Hemoglobin (g/L): 122.0
HDL (mmol/L): 0,75
Potassium (mEq/L): 4,7
LDL (mmol/L): 1,91
Sodium (mEq/L): 140.0
Pro-BNP (ng/L): 923.0
Protein (g/L): 70
T4 (ng/L): 19
TSH (mIU/L): 0,56
Urea (mg/dL): 7,65
LVEF (%): 45.0
Medications: Diabetes Medication, Beta Blockers, Loop Diuretics, Spironolactone, Statins, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"RANKING: 

1. Survivor
REASONING: 
The patient's age, NYHA Class II, and the presence of ischemic dilated cardiomyopathy, diabetes, and dyslipemia are all risk factors for cardiovascular disease. However, the patient is already on several medications, including beta blockers, ACE inhibitors, and statins, which are commonly used to manage these conditions. The patient's LVEF of 45.0 is significantly below the normal range, indicating advanced heart failure, but the patient's creatinine level is not severely elevated, suggesting that the kidneys are not severely impaired. The presence of non-sustained ventricular tachycardia on the ECG is a concerning sign, but it is not a guarantee of sudden cardiac death. The patient's Pro-BNP level is elevated, indicating some level of heart failure. 

However, the patient's overall profile suggests that with proper management and treatment, the patient can still be managed and may survive for the next few years. The patient's ECG findings, while concerning, do not indicate a high risk of sudden cardiac death, and the patient's medication regimen is comprehensive, addressing multiple risk factors.

2. Pump failure death
REASONING: 
The patient's LVEF of 45.0 is significantly below the normal range, indicating advanced heart failure. The patient's creatinine level of 104.0 is also elevated, indicating some level of kidney impairment. The patient's Pro-BNP level is elevated, indicating some level of heart failure. While the patient is on several medications, including ACE inhibitors and beta blockers, which are commonly used to manage heart failure, the patient's NYHA Class II status suggests that the patient's heart failure is not fully controlled.

Given these factors, the patient is at risk of pump failure death, but this is not the most likely outcome.

3. Sudden cardiac death
REASONING: 
The patient's ECG findings, including non-sustained ventricular tachycardia and ventricular extrasystole, are concerning signs of arrhythmia. However, the patient's ECG is not indicative of a high risk of sudden cardiac death. The patient's medication regimen, including beta blockers and ACE inhibitors, is comprehensive, addressing multiple risk factors. 

Additionally, the patient's overall profile, including a relatively normal weight, normal kidney function, and a controlled diabetes, suggests that the patient is not at high risk of sudden cardiac death."
372,372,P0603,"Age: 74
Gender: Male 
Weight: 82 kg
Height: 163 cm
NYHA Class: III
Blood Pressure: 140/80 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Diabetes, Dyslipemia, Myocardial Infarction
Albumin (g/L): 40
ALT or GPT (IU/L): 48.0
AST or GOT (IU/L): 19.0
Total Cholesterol (mmol/L): 5,3
Creatinine (mmol/L): 177.0
Gamma-glutamil transpeptidase (IU/L): 36
Glucose (mmol/L): 7,9
Hemoglobin (g/L): 130.0
HDL (mmol/L): 0,93
Potassium (mEq/L): 5,3
LDL (mmol/L): 3,28
Sodium (mEq/L): 134.0
Pro-BNP (ng/L): 1626.0
Protein (g/L): 75
T4 (ng/L): 6
Troponin (ng/mL): 0,03
TSH (mIU/L): 5,82
Urea (mg/dL): 24,13
LVEF (%): 35.0
Medications: Diabetes Medication, Angiotensin II Receptor Blocker, Beta Blockers, Loop Diuretics
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"RANKING: 
1. Survivor
REASONING: 
This patient has a complex medical history with ischemic dilated cardiomyopathy, diabetes, dyslipidemia, and a history of myocardial infarction, which are all risk factors for adverse cardiac outcomes. However, the patient's current NYHA class III indicates moderate symptoms, and the patient is receiving multiple medications for their condition, including beta blockers and loop diuretics, which can help manage symptoms and slow disease progression. The patient's LVEF is significantly reduced at 35%, but the absence of any recent myocardial infarction, ventricular tachycardia, or other concerning ECG findings suggests that the patient's condition is not acutely deteriorating. The patient's elevated creatinine level and high BNP levels indicate some degree of cardiac dysfunction, but the patient's overall clinical presentation and medication regimen suggest that they can be managed with close monitoring and supportive care, making a survival outcome the most likely.

2. Sudden cardiac death
REASONING: 
While the patient's medical history and current condition are concerning, the absence of any recent myocardial infarction, ventricular tachycardia, or other ECG findings that would suggest an acute cardiac event makes sudden cardiac death less likely. However, the patient's significantly reduced LVEF and elevated BNP levels indicate some degree of cardiac dysfunction, and the patient's elevated creatinine level suggests some degree of kidney impairment, which can increase the risk of cardiac complications. Additionally, the patient's dyslipidemia and diabetes are risk factors for cardiac events. However, the patient's overall clinical presentation and medication regimen suggest that they are being adequately managed, and the patient's ECG findings are not concerning, making sudden cardiac death less likely than survivor.

3. Pump failure death
REASONING: 
Pump failure death is a possible outcome for patients with advanced heart failure, but the patient's current clinical presentation and medication regimen suggest that they are being adequately managed. The patient's LVEF is significantly reduced, but the patient is receiving beta blockers, which can help slow disease progression, and the patient's elevated BNP levels indicate some degree of cardiac dysfunction, but the patient's overall clinical presentation and ECG findings suggest that the patient is not acutely deteriorating. Additionally, the patient's kidney function is impaired, but the patient is receiving loop diuretics, which can help manage fluid overload and reduce the risk of pump failure. While pump failure death is a possible outcome, the patient's overall clinical presentation and medication regimen suggest that they are at lower risk for this outcome compared to sudden cardiac death."
373,373,P0604,"Age: 75
Gender: Female 
Weight: 57 kg
Height: 153 cm
NYHA Class: II
Blood Pressure: 120/70 mmHg
Past Medical History: Idiopathic dilated cardiomyopathy, Diabetes, Dyslipemia, Hypertension
Albumin (g/L): 40
ALT or GPT (IU/L): 36.0
AST or GOT (IU/L): 22.0
Total Cholesterol (mmol/L): 3,83
Creatinine (mmol/L): 106.0
Gamma-glutamil transpeptidase (IU/L): 24
Glucose (mmol/L): 5,8
Hemoglobin (g/L): 124.0
HDL (mmol/L): 1,02
Potassium (mEq/L): 5,2
LDL (mmol/L): 2,17
Sodium (mEq/L): 141.0
Pro-BNP (ng/L): 509.0
Protein (g/L): 76
T4 (ng/L): 13
Troponin (ng/mL): 0,01
TSH (mIU/L): 2,35
Urea (mg/dL): 15,47
LVEF (%): 30.0
Medications: Diabetes Medication, Beta Blockers, Loop Diuretics, Spironolactone, Statins, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"RANKING: 
1. Survivor
REASONING: 
Based on the patient's data, the patient is likely to be a survivor. The patient's age is 75, which is not extremely high, but still in the elderly category. The patient has a NYHA Class II heart failure, indicating that they have some symptoms of heart failure but are still able to perform daily activities with some limitation. The patient's ejection fraction (LVEF) is 30%, which is significantly reduced, indicating severe left ventricular dysfunction. However, the patient's blood pressure is well-controlled, and they are on medications for hypertension, diabetes, and heart failure.

The patient's laboratory results show elevated creatinine levels (106.0 mmol/L), which indicates some degree of kidney impairment. However, the patient's kidney function is not severely impaired, and they are on medications to manage their diabetes and hypertension. The patient's troponin level is 0.01 ng/mL, which is within normal limits, indicating no acute myocardial infarction.

The patient's ECG shows ventricular extrasystoles, which are a type of abnormal heart rhythm that can be a sign of underlying cardiac disease. However, the patient does not have any other significant ECG abnormalities, and they are not at high risk for sudden cardiac death.

Overall, based on the patient's age, NYHA class, LVEF, and the presence of ventricular extrasystoles, the patient's prognosis is guarded but not extremely poor. They are likely to survive for several years, but their heart failure symptoms may worsen over time.

The patient's weight is 57 kg, which is slightly below the normal range for a female of their age, but this is not a significant factor in their prognosis.

The patient's past medical history of idiopathic dilated cardiomyopathy, diabetes, and hypertension increases their risk for heart failure and other cardiovascular events. However, the patient is on medications to manage these conditions, and their laboratory results do not indicate any acute or severe complications.

Therefore, based on the available data, the patient's prognosis is most likely to be a survivor, with a moderate to poor outcome over the next few years."
374,374,P0606,"Age: 57
Gender: Male 
Weight: 70 kg
Height: 166 cm
NYHA Class: III
Blood Pressure: 140/90 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Dyslipemia, Myocardial Infarction
Albumin (g/L): 45,9
ALT or GPT (IU/L): 38.0
AST or GOT (IU/L): 28.0
Total Cholesterol (mmol/L): 3,03
Creatinine (mmol/L): 91.0
Gamma-glutamil transpeptidase (IU/L): 58
Glucose (mmol/L): 5,6
Hemoglobin (g/L): 122.0
HDL (mmol/L): 1,03
Potassium (mEq/L): 4,5
LDL (mmol/L): 1,58
Sodium (mEq/L): 141.0
Pro-BNP (ng/L): 4330.0
Protein (g/L): 78,2
T4 (ng/L): 20
TSH (mIU/L): 0,94
Urea (mg/dL): 6,82
LVEF (%): 25.0
Medications: Loop Diuretics, Spironolactone, Statins, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"RANKING: 1. Survivor
REASONING: 

Based on the patient data, the patient's prognosis is most likely to be a survivor. This is due to several factors:

1. Age: The patient is 57 years old, which is still considered relatively young for cardiac-related mortality. Many patients with advanced heart failure or significant cardiac disease can survive for several years with proper management.
2. NYHA Class III: Although the patient has a Class III heart failure classification, indicating severe symptoms, it is still possible for patients with this classification to survive with optimal medical therapy and lifestyle modifications.
3. Medications: The patient is on a combination of medications, including diuretics, spironolactone, statins, and an ACE inhibitor, which are commonly used to manage heart failure and related conditions. This suggests that the patient is receiving appropriate medical therapy.
4. ECG findings: The absence of ventricular tachycardia, non-sustained ventricular tachycardia, and paroxysmal supraventricular tachyarrhythmia suggests that the patient does not have an acute cardiac emergency that would necessitate immediate intervention.
5. Pro-BNP level: While the Pro-BNP level is elevated, it is not excessively high, which may indicate a more stable disease course.
6. Other lab values: The patient's other lab values, such as creatinine, urea, and electrolyte levels, are not significantly abnormal, which suggests that the patient's kidney function and electrolyte balance are relatively well-maintained.

While there are some concerning factors, such as the patient's LVEF of 25%, which indicates significant left ventricular dysfunction, the overall picture suggests that the patient is likely to survive for the next few years with proper management and lifestyle modifications. However, close monitoring and regular follow-up are necessary to adjust the treatment plan as needed."
375,375,P0608,"Age: 70
Gender: Male 
Weight: 71 kg
Height: 166 cm
NYHA Class: II
Blood Pressure: 110/70 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Dyslipemia, Hypertension, Myocardial Infarction
Albumin (g/L): 44,2
ALT or GPT (IU/L): 41.0
AST or GOT (IU/L): 24.0
Total Cholesterol (mmol/L): 4,68
Creatinine (mmol/L): 99.0
Gamma-glutamil transpeptidase (IU/L): 34
Glucose (mmol/L): 5,4
Hemoglobin (g/L): 150.0
HDL (mmol/L): 1,29
Potassium (mEq/L): 5,8
LDL (mmol/L): 2,92
Sodium (mEq/L): 141.0
Pro-BNP (ng/L): 108.0
Protein (g/L): 74,7
T4 (ng/L): 15
TSH (mIU/L): 2,24
Urea (mg/dL): 6,66
LVEF (%): 30.0
Medications: Amiodarone, Angiotensin II Receptor Blocker, Statins
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"RANKING: 

1. Survivor
REASONING: 
The patient's age is 70, which is a high risk factor for cardiac mortality. However, the patient has a NYHA Class II, indicating that the patient's symptoms are mild and not severe. The patient's LVEF is 30.0%, which is significantly reduced, indicating advanced left ventricular dysfunction. The patient has a history of ischemic dilated cardiomyopathy, which is a significant risk factor for cardiac mortality. The patient's creatinine level is elevated, indicating impaired kidney function, which is often seen in advanced heart failure. However, the patient's blood pressure is well-controlled, and the patient is on medications such as Amiodarone and Angiotensin II Receptor Blocker, which are commonly used to manage heart failure and arrhythmias.

The patient's Pro-BNP level is elevated, indicating increased ventricular wall stress, but the patient's hemoglobin level is normal, which suggests that the patient is not anemic. The patient's lipid profile shows dyslipidemia, but the patient is on statins, which can help to reduce cardiovascular risk. 

Considering these factors, the patient's overall prognosis is likely to be a survivor, as the patient's symptoms are mild, and the patient is on medications that can help to manage heart failure and arrhythmias. However, the patient's advanced LVEF and history of ischemic dilated cardiomyopathy make the patient a moderate-risk patient.

2. Sudden cardiac death
REASONING: 
While the patient's LVEF is significantly reduced, the patient is on medications that can help to manage arrhythmias and heart failure. The patient's ECG shows ventricular extrasystoles, but no ventricular tachycardia or non-sustained ventricular tachycardia. The patient's Pro-BNP level is elevated, indicating increased ventricular wall stress, but the patient's hemoglobin level is normal, which suggests that the patient is not anemic. 

However, the patient's history of myocardial infarction and ischemic dilated cardiomyopathy increases the risk of sudden cardiac death. The patient's creatinine level is elevated, indicating impaired kidney function, which can increase the risk of cardiac arrhythmias. 

Considering these factors, the patient's overall prognosis is not extremely high for sudden cardiac death, but the patient is still at moderate risk due to the patient's history of myocardial infarction and ischemic dilated cardiomyopathy.

3. Pump failure death
REASONING: 
The patient's LVEF is significantly reduced, indicating advanced left ventricular dysfunction. The patient's Pro-BNP level is elevated, indicating increased ventricular wall stress. The patient's creatinine level is elevated, indicating impaired kidney function, which can increase the risk of heart failure. The patient's history of ischemic dilated cardiomyopathy and myocardial infarction increases the risk of pump failure.

However, the patient is on medications that can help to manage heart failure, such as Amiodarone and Angiotensin II Receptor Blocker. The patient's hemoglobin level is normal, which suggests that the patient is not anemic. The patient's lipid profile shows dyslipidemia, but the patient is on statins, which can help to reduce cardiovascular risk.

Considering these factors, the patient's overall prognosis is not extremely high for pump failure, but the patient is at moderate to high risk due to the patient's advanced LVEF and history of ischemic dilated cardiomyopathy."
376,376,P0609,"Age: 67
Gender: Female 
Weight: 74 kg
Height: 158 cm
NYHA Class: II
Blood Pressure: 180/95 mmHg
Past Medical History: Hypertropic cardiomyopathy, Diabetes
Albumin (g/L): 46,2
ALT or GPT (IU/L): 24.0
AST or GOT (IU/L): 18.0
Total Cholesterol (mmol/L): 4,99
Creatinine (mmol/L): 61.0
Gamma-glutamil transpeptidase (IU/L): 140
Glucose (mmol/L): 7,9
Hemoglobin (g/L): 137.0
HDL (mmol/L): 1,91
Potassium (mEq/L): 4,6
LDL (mmol/L): 2,61
Sodium (mEq/L): 141.0
Pro-BNP (ng/L): 731.0
Protein (g/L): 75,2
T4 (ng/L): 14
TSH (mIU/L): 3,47
Urea (mg/dL): 3
LVEF (%): 70.0
Medications: Beta Blockers, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"RANKING: 
1. Survivor
REASONING:
The patient's age (67) and NYHA Class II heart failure indicate that they have a significant cardiovascular history, but the patient is still relatively young for this condition. The presence of Hypertrophic cardiomyopathy in the past medical history is a risk factor for sudden cardiac death, but the patient's current LVEF (70.0%) suggests that the condition has not significantly progressed.

The patient's elevated blood pressure (180/95 mmHg) and high creatinine level (61.0 mmol/L) suggest kidney damage, which can be a complication of hypertension and diabetes. However, the patient is on beta blockers, which are commonly used to manage hypertension and heart failure.

The patient's lipid profile shows high LDL and triglyceride levels, which are risk factors for cardiovascular disease. However, the patient's HDL level is relatively high, which can help mitigate this risk.

The patient's ECG findings, including ventricular extrasystole and non-sustained ventricular tachycardia, indicate an increased risk of arrhythmias. However, the patient is already on medications to manage these conditions.

The patient's Pro-BNP level (731.0 ng/L) is elevated, indicating some degree of heart failure. However, the patient's hemoglobin level (137.0 g/L) and urea level (3 mg/dL) are within relatively normal limits, suggesting that the patient's kidney function is not severely impaired.

Given these factors, I predict that the patient has a high likelihood of survival over the next few years, assuming that the patient continues to receive appropriate medical treatment and makes lifestyle changes to manage their cardiovascular risk factors.

RANKING: Survivor (High)
 
Reasoning:
The patient's overall cardiovascular risk factors and comorbidities suggest that they are at increased risk for cardiovascular events. However, the patient's age, LVEF, and current treatment plan suggest that they are not at high risk for sudden cardiac death. The patient's kidney function and hemoglobin level are also relatively normal, which suggests that they are not at high risk for pump failure.

RANKING: Sudden Cardiac Death (Low)
REASONING:
The patient's ECG findings, including ventricular extrasystole and non-sustained ventricular tachycardia, suggest an increased risk of arrhythmias. However, the patient is already on medications to manage these conditions, and the patient's LVEF and kidney function are relatively normal. The patient's age and NYHA Class II heart failure also suggest that they are not at high risk for sudden cardiac death.

RANKING: Pump Failure Death (Low)
REASONING:
The patient's elevated Pro-BNP level (731.0 ng/L) and NYHA Class II heart failure suggest that the patient has some degree of heart failure. However, the patient's LVEF (70.0%) is relatively preserved, and the patient's kidney function and hemoglobin level are within relatively normal limits. The patient's beta blockers and nitrovasodilator medications also suggest that they are being adequately managed for heart failure. Therefore, the patient's risk for pump failure is relatively low."
377,377,P0610,"Age: 71
Gender: Female 
Weight: 73 kg
Height: 162 cm
NYHA Class: II
Blood Pressure: 140/70 mmHg
Past Medical History: Hypertensive cardiomyopathy
Albumin (g/L): 44,3
ALT or GPT (IU/L): 22.0
AST or GOT (IU/L): 21.0
Total Cholesterol (mmol/L): 5,12
Creatinine (mmol/L): 123.0
Gamma-glutamil transpeptidase (IU/L): 13
Glucose (mmol/L): 7
Hemoglobin (g/L): 123.0
HDL (mmol/L): 1,29
Potassium (mEq/L): 4,2
LDL (mmol/L): 3,1
Sodium (mEq/L): 141.0
Pro-BNP (ng/L): 433.0
Protein (g/L): 73
T4 (ng/L): 15
TSH (mIU/L): 1,95
Urea (mg/dL): 8,49
LVEF (%): 62.0
Medications: Spironolactone, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: TPSV
        - Bradycardia: No
            ",survivor,"RANKING: 
1. Survivor
REASONING: 
Based on the patient data, I would rank the patient as having a high likelihood of survival for the next few years. The patient is 71 years old, but the NYHA Class II indicates that they have a moderate level of heart failure symptoms, which is manageable with current medications. The LVEF of 62.0 is slightly below the normal range, but it's not severely impaired. The patient's ejection fraction is not significantly reduced, and they are not experiencing any severe symptoms.

The patient's laboratory results show a mildly elevated creatinine level (123.0 mol/L), which may indicate some degree of kidney dysfunction, but this is not uncommon in patients with heart failure. The patient's liver function tests (ALT and AST) are within normal limits, and their electrolyte levels are mostly within normal limits.

The patient is taking spironolactone and an ACE inhibitor, which are standard treatments for heart failure. The presence of ventricular extrasystoles (polymorphic) is noted on the ECG, but it is not a contraindication for treatment. The patient does not have any other significant ECG abnormalities, such as ventricular tachycardia or paroxysmal supraventricular tachycardia.

Considering these factors, I believe that the patient has a high likelihood of survival for the next few years, making ""Survivor"" the most likely prognosis.

2. Sudden cardiac death
REASONING: 
The patient's age and NYHA Class II heart failure symptoms make them a moderate risk for cardiac events. However, the patient's LVEF is not severely impaired, and they are not experiencing any severe symptoms.

The presence of ventricular extrasystoles (polymorphic) on the ECG is a risk factor for sudden cardiac death, but it is not a contraindication for treatment. The patient is taking medications to manage their heart failure and blood pressure, which reduces the risk of cardiac events.

The patient's laboratory results show a mildly elevated creatinine level, which may indicate some degree of kidney dysfunction. However, this is not a direct contraindication for treatment.

Considering these factors, I believe that the patient has a moderate risk for cardiac events, but it is not extremely high, making ""Sudden cardiac death"" the second most likely prognosis.

3. Pump failure death
REASONING: 
The patient's NYHA Class II heart failure symptoms and mildly elevated creatinine level suggest that they may be at risk for worsening heart failure. However, the patient's LVEF is not severely impaired, and they are taking medications to manage their heart failure.

The presence of ventricular extrasystoles (polymorphic) on the ECG is a risk factor for cardiac events, but it is not a contraindication for treatment. The patient's laboratory results show normal liver function tests and electrolyte levels, which reduces the risk of cardiac events.

Considering these factors, I believe that the patient has a low risk for pump failure death, making it the least likely prognosis."
378,378,P0611,"Age: 66
Gender: Male 
Weight: 72 kg
Height: 169 cm
NYHA Class: II
Blood Pressure: 105/65 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Dyslipemia, Myocardial Infarction
Albumin (g/L): 40,7
ALT or GPT (IU/L): 29.0
AST or GOT (IU/L): 22.0
Total Cholesterol (mmol/L): 5,22
Creatinine (mmol/L): 99.0
Gamma-glutamil transpeptidase (IU/L): 33
Glucose (mmol/L): 5
Hemoglobin (g/L): 148.0
HDL (mmol/L): 1,19
Potassium (mEq/L): 4,9
LDL (mmol/L): 3,39
Sodium (mEq/L): 139.0
Pro-BNP (ng/L): 2919.0
Protein (g/L): 68,1
T4 (ng/L): 18
TSH (mIU/L): 0,38
Urea (mg/dL): 8,65
LVEF (%): 23.0
Medications: Beta Blockers, Loop Diuretics, Spironolactone, Statins, ACE Inhibitor, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"RANKING: 1. Survivor
REASONING: The patient is classified as a survivor based on the provided patient outcome. This outcome is the most likely due to the fact that the patient's current treatment regimen includes medications that are commonly used to manage heart failure, such as beta blockers, loop diuretics, spironolactone, statins, and ACE inhibitors. These medications can help to reduce symptoms, slow disease progression, and improve quality of life.

The patient's NYHA Class II classification indicates that they have some limitation in physical activity due to symptoms, but they are still able to carry on light physical activity without discomfort. This suggests that the patient is still relatively stable and able to tolerate their current treatment regimen.

While the patient has a history of ischemic dilated cardiomyopathy, dyslipidemia, and myocardial infarction, their current LVEF (left ventricular ejection fraction) is 23%, which is still within a range that can be managed with current treatment. The elevated Pro-BNP levels may indicate some degree of heart failure, but the patient's symptoms and medication regimen suggest that they are able to manage their condition.

The ECG results do not show any significant arrhythmias, which further supports the likelihood of a favorable outcome.

Overall, based on the patient's current treatment regimen, symptoms, and ECG results, the most likely outcome is that the patient will survive."
379,379,P0612,"Age: 67
Gender: Female 
Weight: 93 kg
Height: 175 cm
NYHA Class: II
Blood Pressure: 159/62 mmHg
Past Medical History: Other HF etiology, Diabetes, Dyslipemia, Hypertension
Albumin (g/L): 38
ALT or GPT (IU/L): 18.0
AST or GOT (IU/L): 20.0
Total Cholesterol (mmol/L): 4,37
Creatinine (mmol/L): 141.0
Gamma-glutamil transpeptidase (IU/L): 36
Glucose (mmol/L): 8,3
Hemoglobin (g/L): 117.0
HDL (mmol/L): 1,01
Potassium (mEq/L): 4
LDL (mmol/L): 2,72
Sodium (mEq/L): 138.0
Pro-BNP (ng/L): 233.0
Protein (g/L): 67
T4 (ng/L): 15
Troponin (ng/mL): 0,01
TSH (mIU/L): 1,5
Urea (mg/dL): 11,82
LVEF (%): 30.0
Medications: Diabetes Medication, Beta Blockers, Spironolactone, Statins, Hydralazine, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"RANKING: 1. Survivor
REASONING:

The patient is a 67-year-old female with a history of heart failure, diabetes, dyslipidemia, and hypertension. Her NYHA Class II indicates moderate symptoms, which suggests that she has some limitations in physical activity due to her heart condition. Her elevated creatinine level (141.0 mmol/L) and LVEF (30.0%) indicate impaired kidney function and reduced cardiac function, respectively.

Despite these concerning findings, the patient's ECG report does not show any signs of ventricular tachycardia or other life-threatening arrhythmias. The presence of ventricular extrasystoles is noted, but they are monomorphic, which is less concerning than non-sustained ventricular tachycardia.

The patient's biomarkers, including troponin (0.01 ng/mL), are within normal limits, which suggests that there is no acute myocardial infarction or significant cardiac injury. Her Pro-BNP level (233.0 ng/L) is elevated, indicating some degree of cardiac stress, but it is not excessively high, which might suggest decompensated heart failure.

The patient is on a comprehensive regimen of medications, including spironolactone, statins, and ACE inhibitors, which are all standard treatments for heart failure and hypertension. Her lipid profile is also relatively well-controlled, with a total cholesterol level of 4.37 mmol/L.

Given these factors, I predict that the patient is likely to survive for the next few years. While her heart failure and kidney impairment are significant concerns, her overall medical profile and the absence of acute cardiac events make a sudden cardiac death or pump failure less likely in the short term."
380,380,P0613,"Age: 65
Gender: Male 
Weight: 54 kg
Height: 157 cm
NYHA Class: II
Blood Pressure: 140/80 mmHg
Past Medical History: Enolic dilated cardiomyopathy, Dyslipemia, Hypertension
Albumin (g/L): 43
ALT or GPT (IU/L): 10.0
AST or GOT (IU/L): 20.0
Total Cholesterol (mmol/L): 5,72
Creatinine (mmol/L): 104.0
Gamma-glutamil transpeptidase (IU/L): 30
Glucose (mmol/L): 5,9
Hemoglobin (g/L): 126.0
HDL (mmol/L): 0,75
Potassium (mEq/L): 4,1
LDL (mmol/L): 3,54
Sodium (mEq/L): 140.0
Pro-BNP (ng/L): 2740.0
Protein (g/L): 76
T3 (pg/dL): 0,06
T4 (ng/L): 17
Troponin (ng/mL): 0,09
TSH (mIU/L): 1,96
Urea (mg/dL): 9,32
LVEF (%): 30.0
Medications: Beta Blockers, Digoxin, Loop Diuretics, Spironolactone, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: TPSV
        - Bradycardia: No
            ",survivor,"RANKING: 1. Survivor
REASONING: 

Based on the provided patient data, I would rank the patient as having a high likelihood of survival over the next few years. The patient's age (65) is relatively advanced, but they are not extremely old. Their NYHA Class II heart failure indicates that they have some limitations with physical activity, but they are still able to maintain a relatively normal quality of life. 

The patient's biomarkers, such as low LVEF (30.0%), high Pro-BNP (2740.0), and elevated Creatinine (104.0), suggest significant cardiac dysfunction and potential kidney impairment. However, the patient is already on medications that are commonly used to manage heart failure, such as Beta Blockers, Digoxin, Loop Diuretics, Spironolactone, and ACE Inhibitor, which suggests that the patient is receiving optimal management for their condition.

The patient's electrolyte levels, including low potassium (4.1 mEq/L), may indicate some degree of cardiac dysfunction, but it is not severe enough to suggest immediate cardiac arrest or sudden cardiac death. The patient's troponin level (0.09 ng/mL) is within the normal range, which suggests that there is no significant myocardial infarction.

The patient's ECG findings, including ventricular extrasystole (monomorphic) and paroxysmal supraventricular tachycardia (TPSV), suggest some degree of arrhythmia, but they are not severe enough to suggest an increased risk of sudden cardiac death.

Considering these factors, I believe that the patient has a good chance of survival over the next few years, and therefore, I rank them as having a high likelihood of survival.

RANKING: 2. Sudden Cardiac Death
REASONING: 

Given the patient's history of Enolic dilated cardiomyopathy, Dyslipemia, Hypertension, and the presence of ventricular extrasystole (monomorphic) on the ECG, there is a moderate risk of sudden cardiac death. However, the patient's overall clinical presentation and the fact that they are already on medications that are commonly used to manage heart failure suggest that the risk of sudden cardiac death is not extremely high.

RANKING: 3. Pump Failure Death
REASONING: 

The patient's low LVEF (30.0%), high Pro-BNP (2740.0), and elevated Creatinine (104.0) levels suggest significant cardiac dysfunction and potential kidney impairment, which increases the risk of pump failure. However, the patient is already on medications that are commonly used to manage heart failure, which suggests that the patient is receiving optimal management for their condition.

Additionally, the patient's ECG findings, including ventricular extrasystole (monomorphic), suggest some degree of arrhythmia, which could potentially increase the risk of pump failure. However, the patient's overall clinical presentation and the fact that they are already on medications that are commonly used to manage heart failure suggest that the risk of pump failure is not extremely high.

Therefore, while the patient has some risk factors that could increase the risk of pump failure, I believe that the risk is not extremely high, and therefore, I rank pump failure death as the least likely prognosis."
381,381,P0614,"Age: 58
Gender: Male 
Weight: 90 kg
Height: 163 cm
NYHA Class: II
Blood Pressure: 140/80 mmHg
Past Medical History: Idiopathic dilated cardiomyopathy, Hypertension
Albumin (g/L): 41,2
ALT or GPT (IU/L): 42.0
AST or GOT (IU/L): 35.0
Total Cholesterol (mmol/L): 5,78
Creatinine (mmol/L): 113.0
Gamma-glutamil transpeptidase (IU/L): 101
Glucose (mmol/L): 9,3
Hemoglobin (g/L): 110.0
HDL (mmol/L): 2,69
Potassium (mEq/L): 3,75
LDL (mmol/L): 2,52
Sodium (mEq/L): 143.0
Pro-BNP (ng/L): 4446.0
Protein (g/L): 68,4
Troponin (ng/mL): 0,01
TSH (mIU/L): 0,93
Urea (mg/dL): 11,4
LVEF (%): 18.0
Medications: Calcium Channel Blocker, Angiotensin II Receptor Blocker, Beta Blockers, Loop Diuretics
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",survivor,"RANKING: 
1. Survivor
REASONING: 
This patient's prognosis is most likely to be a survivor due to several factors. Firstly, the patient's LVEF (Left Ventricular Ejection Fraction) is 18.0%, which indicates significant left ventricular dysfunction. However, the patient's NYHA Class is II, suggesting that they are able to perform moderate physical activity without significant limitation. This suggests that the patient's cardiac function is not as severely impaired as it could be, increasing the likelihood of survival.

Additionally, the patient's Pro-BNP levels are elevated at 4446.0 ng/L, which is a marker of increased ventricular wall stress. However, the patient's Troponin levels are within normal limits, indicating no acute myocardial infarction or significant cardiac damage.

The patient's medication regimen includes a calcium channel blocker, an angiotensin II receptor blocker, beta blockers, and loop diuretics, which are all standard treatments for heart failure and hypertension. These medications will help to reduce the patient's blood pressure, alleviate symptoms, and slow the progression of cardiac disease.

The ECG results show ventricular extrasystoles and polymorphic ventricular extrasystoles, which are signs of arrhythmia. However, the patient does not have ventricular tachycardia or non-sustained ventricular tachycardia, which are more life-threatening arrhythmias. The patient's bradycardia code is also unknown, but the absence of a clear diagnosis does not necessarily affect the patient's prognosis.

Overall, while this patient has significant cardiac dysfunction and arrhythmias, their overall clinical presentation and treatment plan suggest that they are likely to survive for the next few years with proper management and monitoring."
382,382,P0615,"Age: 61
Gender: Male 
Weight: 103 kg
Height: 174 cm
NYHA Class: II
Blood Pressure: 125/80 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Diabetes, Dyslipemia, Hypertension, Myocardial Infarction
Albumin (g/L): 43
ALT or GPT (IU/L): 34.0
AST or GOT (IU/L): 27.0
Total Cholesterol (mmol/L): 3,42
Creatinine (mmol/L): 87.0
Gamma-glutamil transpeptidase (IU/L): 42
Glucose (mmol/L): 12,2
Hemoglobin (g/L): 145.0
HDL (mmol/L): 0,87
Potassium (mEq/L): 3,91
LDL (mmol/L): 1,47
Sodium (mEq/L): 139.0
Pro-BNP (ng/L): 86.0
Protein (g/L): 67,5
Troponin (ng/mL): 0,01
TSH (mIU/L): 1,91
Urea (mg/dL): 6,9
LVEF (%): 35.0
Medications: Diabetes Medication, Angiotensin II Receptor Blocker, Beta Blockers, Statins, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"RANKING: 1. Survivor
REASONING: 

Based on the provided patient data, the patient is at high risk for adverse cardiac events, but the overall clinical picture does not indicate an immediate life-threatening condition. The patient has a history of ischemic dilated cardiomyopathy, which is a significant comorbidity. However, the patient is currently on medications that are commonly used to manage heart failure and hypertension, such as beta blockers and angiotensin II receptor blockers. The patient's current ECG does not show any signs of ventricular tachycardia or ventricular extrasystoles, which are potential indicators of high-risk arrhythmias.

The patient's LVEF is 35%, which is significantly reduced, indicating severe left ventricular dysfunction. However, the patient's creatinine level is not excessively elevated, and the patient is not showing signs of acute kidney injury. The patient's troponin level is within normal limits, which suggests that there is no significant myocardial infarction.

The patient's lipid profile is also not ideal, with elevated total cholesterol and LDL levels. However, the patient is on statins, which are effective in lowering LDL levels. The patient's glucose level is elevated, but the patient is on diabetes medication, which is likely helping to manage the condition.

Given the patient's complex medical history, it is likely that the patient will survive for the next few years. However, the patient will likely require close monitoring and adjustments to their treatment plan to manage their cardiac and metabolic conditions.

RANKING: 2. Sudden Cardiac Death
REASONING: 

While the patient's LVEF is significantly reduced, there is no immediate indication of a high-risk arrhythmia or acute myocardial infarction. The patient's ECG does not show any signs of ventricular tachycardia or ventricular extrasystoles. However, the patient's history of ischemic dilated cardiomyopathy and hypertension increases the risk of sudden cardiac death.

The patient's creatinine level is not excessively elevated, and the patient is not showing signs of acute kidney injury. The patient's troponin level is within normal limits, which suggests that there is no significant myocardial infarction. However, the patient's reduced LVEF and elevated creatinine level do indicate significant cardiac dysfunction.

Given the patient's complex medical history, it is possible that the patient could experience a cardiac event, but the likelihood of sudden cardiac death is lower compared to the patient's overall survival.

RANKING: 3. Pump Failure Death
REASONING: 

Given the patient's severely reduced LVEF and elevated creatinine level, it is likely that the patient will experience heart failure in the next few years. The patient's history of ischemic dilated cardiomyopathy and hypertension increases the risk of pump failure.

The patient's current ECG does not show any signs of ventricular tachycardia or ventricular extrasystoles, which are potential indicators of high-risk arrhythmias. However, the patient's reduced LVEF and elevated creatinine level do indicate significant cardiac dysfunction.

The patient's lipid profile is not ideal, and the patient's glucose level is elevated, which may contribute to the development of heart failure. However, the patient is on diabetes medication, which is likely helping to manage the condition.

Given the patient's complex medical history and reduced LVEF, it is likely that the patient will experience heart failure in the next few years. However, the likelihood of pump failure death is lower compared to sudden cardiac death."
383,383,P0617,"Age: 50
Gender: Male 
Weight: 88 kg
Height: 169 cm
NYHA Class: II
Blood Pressure: 90/70 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Diabetes, Myocardial Infarction
Albumin (g/L): 40
ALT or GPT (IU/L): 46.0
AST or GOT (IU/L): 30.0
Total Cholesterol (mmol/L): 4,61
Creatinine (mmol/L): 105.0
Gamma-glutamil transpeptidase (IU/L): 71
Glucose (mmol/L): 8,6
Hemoglobin (g/L): 130.0
HDL (mmol/L): 1,17
Potassium (mEq/L): 4,53
LDL (mmol/L): 2,82
Sodium (mEq/L): 136.0
Pro-BNP (ng/L): 3172.0
Protein (g/L): 78,9
T4 (ng/L): 17,3
Troponin (ng/mL): 0,45
TSH (mIU/L): 6
Urea (mg/dL): 7,6
LVEF (%): 40.0
Medications: Digoxin, Loop Diuretics, Spironolactone, Statins, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: TPSV
        - Bradycardia: No
            ",survivor,"RANKING: 
1. Survivor 
REASONING: 
The patient is a 50-year-old male with a history of ischemic dilated cardiomyopathy, myocardial infarction, and diabetes, which are all significant risk factors for cardiac complications. However, the patient is currently being treated with medications that are commonly used to manage these conditions, such as ACE inhibitors, statins, and digoxin. The patient's NYHA Class II indicates that they have some symptoms of heart failure, but they are still able to perform daily activities without significant limitation. The patient's LVEF is 40%, which is below the normal range, but not severely impaired. The patient's ECG shows no evidence of ventricular tachycardia or non-sustained ventricular tachycardia, which are both indicators of high-risk arrhythmias. The patient's Pro-BNP level is elevated, but not extremely high, which suggests some degree of cardiac stress. 

The patient's creatinine level is elevated, which may indicate some degree of kidney impairment, but it is not severe. The patient's blood pressure is well-controlled, and their hemoglobin and potassium levels are within normal limits. 

Given these factors, the patient's overall prognosis is relatively good, and they are likely to survive for the next few years with proper management of their conditions. The patient's ECG results do not indicate any immediate life-threatening arrhythmias, and the patient is already on medications that are effective in managing their cardiac conditions. 

2. Sudden Cardiac Death 
REASONING: 
While the patient has a history of ischemic dilated cardiomyopathy and myocardial infarction, which are both risk factors for sudden cardiac death, the patient's current ECG results do not indicate any immediate life-threatening arrhythmias. The patient's Pro-BNP level is elevated, but not extremely high, and the patient's creatinine level is not severely impaired. 

However, the patient's LVEF is significantly impaired at 40%, which increases the risk of cardiac complications. The patient's NYHA Class II indicates that they have some symptoms of heart failure, which may increase the risk of sudden cardiac death. 

3. Pump Failure Death 
REASONING: 
The patient's LVEF is significantly impaired at 40%, which increases the risk of pump failure. The patient's NYHA Class II indicates that they have some symptoms of heart failure, which may indicate that the patient's heart is not functioning efficiently enough to meet their body's needs. 

Additionally, the patient's creatinine level is elevated, which may indicate some degree of kidney impairment, which can be a complication of heart failure. The patient's Pro-BNP level is elevated, which suggests that the patient's heart is under stress and may be at risk of further decline. 

While the patient is currently being treated with medications that are effective in managing their cardiac conditions, the patient's underlying cardiac disease is significant, and the patient's current ECG results do not indicate any immediate life-threatening arrhythmias. However, the patient's overall prognosis is less favorable than the ""survivor"" category, and the patient is at risk of developing cardiac complications, including pump failure."
384,384,P0620,"Age: 50
Gender: Male 
Weight: 85 kg
Height: 165 cm
NYHA Class: II
Blood Pressure: 100/65 mmHg
Past Medical History: Idiopathic dilated cardiomyopathy
Albumin (g/L): 41,5
ALT or GPT (IU/L): 10.0
AST or GOT (IU/L): 13.0
Total Cholesterol (mmol/L): 5,2
Creatinine (mmol/L): 89.0
Gamma-glutamil transpeptidase (IU/L): 18
Glucose (mmol/L): 5,7
Hemoglobin (g/L): 140.0
HDL (mmol/L): 0,94
Potassium (mEq/L): 4,22
LDL (mmol/L): 3,37
Sodium (mEq/L): 141.0
Pro-BNP (ng/L): 233.0
Protein (g/L): 68,1
Troponin (ng/mL): 0,01
TSH (mIU/L): 0,93
Urea (mg/dL): 4,7
LVEF (%): 39.0
Medications: Beta Blockers, Loop Diuretics, Spironolactone, Statins, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"RANKING: 1. Survivor
REASONING:

This patient has a poor prognosis due to the presence of idiopathic dilated cardiomyopathy (IDC), which is a significant risk factor for heart failure and sudden cardiac death. The patient's left ventricular ejection fraction (LVEF) is severely reduced at 39%, indicating significant systolic dysfunction. This, combined with the patient's NYHA Class II status, suggests that the patient is experiencing symptoms of heart failure, such as shortness of breath and fatigue.

The patient's elevated BNP levels (233 ng/L) further support the presence of heart failure, as BNP is a biomarker for ventricular strain. The patient's creatinine level (89.0 mmol/L) is also elevated, indicating impaired renal function, which is a common complication in heart failure.

The patient's lipid profile is relatively well-controlled, with low total cholesterol and LDL levels, which is a positive factor. However, the patient's weight and body mass index (BMI) are above the normal range, which may contribute to the development of further cardiovascular complications.

The absence of any arrhythmias on the ECG, such as ventricular tachycardia or atrial fibrillation, reduces the risk of sudden cardiac death. However, the presence of ventricular extrasystoles (monomorphic) suggests some degree of ventricular irritability, which may increase the risk of arrhythmias in the future.

Given these factors, the most likely outcome for this patient over the next few years is a survivor, as the patient is already experiencing symptoms of heart failure and has a significant risk of further cardiovascular complications. However, close monitoring and management of the patient's condition will be crucial to prevent further decline.

RANKING: 2. Sudden cardiac death
REASONING:

While the patient's ECG shows no evidence of ventricular tachycardia or atrial fibrillation, the presence of ventricular extrasystoles (monomorphic) and the patient's poor LVEF increase the risk of sudden cardiac death. Additionally, the patient's history of idiopathic dilated cardiomyopathy and heart failure may increase the risk of arrhythmias and sudden cardiac death.

RANKING: 3. Pump failure death
REASONING:

The patient's poor LVEF and elevated BNP levels suggest that the patient's heart is not functioning efficiently, which increases the risk of pump failure. However, the patient's current treatment regimen, including beta blockers, loop diuretics, spironolactone, statins, and ACE inhibitors, is generally effective in managing heart failure symptoms and reducing the risk of pump failure.

Given the patient's relatively well-controlled lipid profile and the absence of any other significant comorbidities, pump failure death is less likely compared to sudden cardiac death. However, close monitoring and adjustment of the patient's treatment regimen may be necessary to prevent further decline in the patient's cardiac function."
385,385,P0621,"Age: 56
Gender: Male 
Weight: 78 kg
Height: 163 cm
NYHA Class: III
Blood Pressure: 120/85 mmHg
Past Medical History: Idiopathic dilated cardiomyopathy, Hypertension
Albumin (g/L): 33,7
ALT or GPT (IU/L): 39.0
AST or GOT (IU/L): 38.0
Total Cholesterol (mmol/L): 3,46
Creatinine (mmol/L): 148.0
Gamma-glutamil transpeptidase (IU/L): 103
Glucose (mmol/L): 4,8
Hemoglobin (g/L): 156.0
HDL (mmol/L): 0,73
Potassium (mEq/L): 2,94
LDL (mmol/L): 2,23
Sodium (mEq/L): 137.0
Pro-BNP (ng/L): 16094.0
Protein (g/L): 60,2
Troponin (ng/mL): 0,01
TSH (mIU/L): 1,55
Urea (mg/dL): 11,8
LVEF (%): 16.0
Medications: Beta Blockers, Loop Diuretics, Spironolactone, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: TPSV
        - Bradycardia: No
            ",survivor,"RANKING: 1. Survivor
REASONING:

Based on the provided patient data, I would rank the patient's prognosis as a survivor. Here's the reasoning behind this ranking:

1. Mildly elevated troponin levels: The patient's troponin level is 0.01 ng/mL, which is within the normal range (0.01-0.03 ng/mL). This suggests that the patient's cardiac muscle is not severely damaged, which is a positive prognostic indicator.

2. Low LVEF: The patient's left ventricular ejection fraction (LVEF) is 16.0%, which is significantly reduced. However, a reduced LVEF is not uncommon in patients with idiopathic dilated cardiomyopathy. With appropriate treatment, it is possible to improve LVEF in some patients.

3. Absence of severe electrolyte imbalances: The patient's potassium level is 2.94 mEq/L, which is within the normal range (3.5-5.0 mEq/L). This suggests that the patient's heart is not experiencing severe electrolyte imbalances, which can be a contributing factor to cardiac arrhythmias and other complications.

4. Absence of severe renal impairment: The patient's creatinine level is 11.8 mg/dL, which is elevated but not severely impaired. This suggests that the patient's kidneys are still functioning relatively well, which is important for overall cardiovascular health.

5. Absence of severe anemia: The patient's hemoglobin level is 15.6 g/dL, which is within the normal range (13.5-17.5 g/dL). This suggests that the patient's red blood cell production is sufficient to maintain adequate oxygen delivery to the tissues.

6. Presence of beta blockers and other medications: The patient is taking beta blockers, loop diuretics, spironolactone, and an ACE inhibitor, which are all standard treatments for heart failure and arrhythmias. This suggests that the patient is receiving appropriate medical therapy.

7. Absence of severe hypertension: The patient's blood pressure is 120/85 mmHg, which is within the normal range (less than 140/90 mmHg). This suggests that the patient's blood pressure is well-controlled, which is important for preventing cardiovascular complications.

While the patient has several risk factors for cardiac complications, including idiopathic dilated cardiomyopathy, hypertension, and a history of arrhythmias, the absence of severe electrolyte imbalances, renal impairment, anemia, and hypertension suggests that the patient is at lower risk for sudden cardiac death and pump failure. Therefore, I predict that the patient will survive."
386,386,P0623,"Age: 52
Gender: Female 
Weight: 73 kg
Height: 160 cm
NYHA Class: II
Blood Pressure: 105/70 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Dyslipemia, Myocardial Infarction
Albumin (g/L): 45,9
ALT or GPT (IU/L): 104.0
AST or GOT (IU/L): 49.0
Total Cholesterol (mmol/L): 5,81
Creatinine (mmol/L): 91.0
Gamma-glutamil transpeptidase (IU/L): 79
Glucose (mmol/L): 5
Hemoglobin (g/L): 144.0
Potassium (mEq/L): 4,4
Sodium (mEq/L): 145.0
Protein (g/L): 75,9
Troponin (ng/mL): 0,01
TSH (mIU/L): 1,17
Urea (mg/dL): 7,6
LVEF (%): 28.0
Medications: Angiotensin II Receptor Blocker, Beta Blockers, Loop Diuretics, Statins
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"RANKING: 

1. Survivor
REASONING:
The patient has a history of ischemic dilated cardiomyopathy, which is a significant comorbidity. However, the patient is currently taking medications that are commonly used to manage heart failure, such as Angiotensin II Receptor Blockers, Beta Blockers, and Loop Diuretics. These medications are likely to be effective in managing the patient's symptoms and slowing the progression of the disease.

The patient's NYHA Class II indicates that they are experiencing some limitations in physical activity, but they are still able to carry on light physical activity without discomfort. This suggests that the patient's heart is still functioning to some extent.

The patient's troponin level is normal, which suggests that there is no acute myocardial infarction. The ECG impression does not show any signs of ventricular tachycardia or bradycardia, which are potential triggers for sudden cardiac death.

The patient's laboratory values, such as creatinine and urea levels, are not significantly elevated, which suggests that the patient's renal function is not severely impaired.

Considering these factors, I predict that the patient is likely to survive for the next few years with proper management and monitoring. The patient's age and gender are not particularly high-risk factors for sudden cardiac death or pump failure.

2. Sudden Cardiac Death
REASONING:
While the patient has a history of ischemic dilated cardiomyopathy, the patient's current ECG impression does not show any signs of ventricular tachycardia or bradycardia, which are potential triggers for sudden cardiac death. However, the patient's LVEF is significantly reduced, indicating that the patient's heart is not functioning efficiently.

The patient's medication regimen is adequate for managing heart failure, but the patient's NYHA Class II status suggests that the patient may not be receiving optimal treatment. The patient's troponin level is normal, but this does not rule out the possibility of a future myocardial infarction.

The patient's laboratory values are not significantly elevated, but the patient's creatinine level is slightly elevated, which may indicate some degree of renal impairment. This could potentially lead to fluid overload and worsening heart failure.

Considering these factors, I predict that the patient is at a moderate risk of sudden cardiac death, but it is not the most likely outcome.

3. Pump Failure Death
REASONING:
The patient's LVEF is significantly reduced, indicating that the patient's heart is not functioning efficiently. The patient's NYHA Class II status suggests that the patient is experiencing some limitations in physical activity, which could be due to heart failure.

The patient's medication regimen is adequate for managing heart failure, but the patient's troponin level is normal, which may indicate some degree of myocardial ischemia. The patient's laboratory values, such as creatinine and urea levels, are slightly elevated, which may indicate some degree of renal impairment.

Considering these factors, I predict that the patient is at a moderate to high risk of pump failure death. However, the patient's current ECG impression does not show any signs of ventricular tachycardia or bradycardia, which are potential triggers for sudden cardiac death."
387,387,P0625,"Age: 57
Gender: Female 
Weight: 70 kg
Height: 155 cm
NYHA Class: III
Blood Pressure: 130/80 mmHg
Past Medical History: Hypertensive cardiomyopathy, Diabetes, Dyslipemia, Myocardial Infarction
Albumin (g/L): 37,6
ALT or GPT (IU/L): 13.0
AST or GOT (IU/L): 14.0
Total Cholesterol (mmol/L): 5,71
Creatinine (mmol/L): 94.0
Gamma-glutamil transpeptidase (IU/L): 54
Glucose (mmol/L): 19,7
Hemoglobin (g/L): 118.0
HDL (mmol/L): 1,39
Potassium (mEq/L): 4,35
LDL (mmol/L): 3,73
Sodium (mEq/L): 142.0
Pro-BNP (ng/L): 1935.0
Protein (g/L): 70,2
T4 (ng/L): 9,4
Troponin (ng/mL): 0,01
TSH (mIU/L): 7,15
Urea (mg/dL): 8,6
LVEF (%): 48.0
Medications: Diabetes Medication, Beta Blockers, Loop Diuretics, Statins, ACE Inhibitor, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: TPSV
        - Bradycardia: No
            ",survivor,"RANKING: 
1. Survivor
REASONING: 
Based on the patient's age, NYHA Class III, and the presence of multiple comorbidities such as hypertension, diabetes, and dyslipidemia, it is reasonable to expect a relatively high risk of adverse outcomes. However, the patient's current LVEF of 48.0 suggests that the left ventricle is not severely impaired, which is a positive prognostic factor. Additionally, the patient is currently on multiple medications, including ACE inhibitors, beta blockers, and statins, which are known to be beneficial in managing heart failure and reducing the risk of adverse outcomes. The absence of elevated troponin levels and a normal ECG impression also suggest that the patient does not have significant acute myocardial injury or life-threatening arrhythmias. 

The patient's elevated Pro-BNP levels (1935.0 ng/L) and elevated creatinine (94.0 mmol/L) levels suggest that the patient has some degree of heart failure, but the overall clinical picture is not as severe as it could be. Therefore, the patient's current prognosis is that they will likely survive for the next few years, but it is essential to closely monitor their condition and adjust their treatment plan as needed.

2. Sudden Cardiac Death
REASONING: 
While the patient's ECG impression does show a polymorphic ventricular extrasystole, which could be a risk factor for sudden cardiac death, the patient's overall clinical picture is not as concerning as it could be. The absence of other risk factors such as a history of previous cardiac arrest or implantable cardioverter-defibrillator (ICD) placement makes this outcome less likely. However, the patient's elevated Pro-BNP levels and creatinine levels suggest that there is some degree of cardiac dysfunction, which could increase the risk of sudden cardiac death.

3. Pump Failure Death
REASONING: 
Given the patient's NYHA Class III and elevated Pro-BNP levels, it is possible that the patient may eventually develop pump failure. However, the patient's LVEF of 48.0 and the presence of multiple medications that are known to be beneficial in managing heart failure suggest that the patient is already receiving adequate treatment. While it is possible that the patient may require further interventions or adjustments to their treatment plan, the patient's current clinical picture does not suggest an immediate risk of pump failure. Therefore, this outcome is less likely in the short term."
388,388,P0627,"Age: 74
Gender: Male 
Weight: 67 kg
Height: 150 cm
NYHA Class: II
Blood Pressure: 120/60 mmHg
Past Medical History: Idiopathic dilated cardiomyopathy, Hypertension
Albumin (g/L): 37
ALT or GPT (IU/L): 38.0
AST or GOT (IU/L): 28.0
Total Cholesterol (mmol/L): 4,14
Creatinine (mmol/L): 118.0
Gamma-glutamil transpeptidase (IU/L): 47
Glucose (mmol/L): 4,4
Hemoglobin (g/L): 148.0
HDL (mmol/L): 0,67
Potassium (mEq/L): 4,4
LDL (mmol/L): 2,4
Sodium (mEq/L): 144.0
Pro-BNP (ng/L): 1312.0
Protein (g/L): 64
T3 (pg/dL): 0,04
T4 (ng/L): 13
TSH (mIU/L): 2,56
Urea (mg/dL): 5,49
LVEF (%): 37.0
Medications: Beta Blockers, Digoxin, Loop Diuretics, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: TPSV
        - Bradycardia: No
            ",survivor,"RANKING: 1. Survivor
REASONING:

Based on the patient's data, I would rank the prognosis as a survivor with a high likelihood. The patient's age, NYHA Class II indicates a moderate level of heart failure, but the fact that they are not in NYHA Class III or IV suggests that they are still relatively functional and may be able to tolerate some level of physical activity. 

The patient's LVEF of 37% is significantly reduced, indicating poor cardiac function. However, the presence of an ACE inhibitor and beta blockers, which are standard treatments for heart failure, suggests that the patient is receiving appropriate medical therapy. 

The patient's electrolyte levels, including potassium, sodium, and urea, are within normal limits, which reduces the risk of cardiac arrhythmias and other complications. The elevated Pro-BNP level, however, suggests some level of cardiac stress and strain.

The presence of non-sustained ventricular tachycardia (VT) and polymorphic ventricular extrasystoles on the ECG is concerning, but it is not immediately life-threatening. The fact that the patient is already taking medications for these arrhythmias suggests that the patient is receiving appropriate management.

Overall, while the patient has significant cardiac dysfunction and arrhythmias, the presence of standard treatments and relatively normal electrolyte levels suggests that the patient may be able to survive with close monitoring and management."
389,389,P0628,"Age: 68
Gender: Female 
Weight: 94 kg
Height: 168 cm
NYHA Class: II
Blood Pressure: 160/80 mmHg
Past Medical History: Hypertensive cardiomyopathy, Hypertension, Myocardial Infarction
Albumin (g/L): 34
ALT or GPT (IU/L): 40.0
AST or GOT (IU/L): 23.0
Total Cholesterol (mmol/L): 3,85
Creatinine (mmol/L): 71.0
Gamma-glutamil transpeptidase (IU/L): 32
Glucose (mmol/L): 9
Hemoglobin (g/L): 133.0
HDL (mmol/L): 0,98
Potassium (mEq/L): 4,3
LDL (mmol/L): 2,25
Sodium (mEq/L): 136.0
Pro-BNP (ng/L): 1747.0
Protein (g/L): 75
T4 (ng/L): 8
Troponin (ng/mL): 0,01
TSH (mIU/L): 1,7
Urea (mg/dL): 5,66
LVEF (%): 50.0
Medications: Beta Blockers, Digoxin, Loop Diuretics, Statins, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",survivor,"RANKING: 1. Survivor
REASONING: 
Based on the provided patient data, the patient is a 68-year-old female with a history of hypertension, myocardial infarction, and cardiomyopathy, who is currently taking medications for these conditions, including beta blockers, digoxin, and ACE inhibitors. The patient's NYHA class is II, indicating mild symptoms of heart failure. The patient's LVEF is 50%, which is within the normal range for a patient of her age, but still indicates some degree of left ventricular dysfunction.

The patient's laboratory results show elevated creatinine levels (71.0 mmol/L), indicating some degree of kidney impairment. However, the patient's electrolyte levels are relatively stable, and the patient is not on dialysis. The patient's troponin level is within normal limits, indicating no acute myocardial infarction.

The ECG impression shows ventricular extrasystoles, which are a type of abnormal heart rhythm that can be a sign of underlying cardiac disease. However, the patient's ventricular tachycardia and non-sustained ventricular tachycardia results are negative, which suggests that the patient does not have a high risk of sudden cardiac death.

The patient's Pro-BNP level is elevated at 1747.0 ng/L, which indicates some degree of ventricular dysfunction and stress. However, the patient's Pro-BNP level is not extremely high, which suggests that the patient may not be experiencing severe heart failure.

Overall, based on the patient's medical history, laboratory results, and ECG findings, I predict that the patient will have a high likelihood of survival over the next few years. The patient's age and NYHA class suggest that the patient may have some degree of underlying cardiac disease, but the patient's relatively stable laboratory results and lack of acute cardiac events suggest that the patient may not have a high risk of sudden cardiac death or pump failure.

RANKING: 2. Sudden cardiac death
REASONING: 
While the patient's ventricular extrasystoles on the ECG are a concern, the patient's overall clinical picture does not suggest a high risk of sudden cardiac death. The patient's Pro-BNP level is elevated, but not extremely high, and the patient's troponin level is within normal limits.

RANKING: 3. Pump failure death
REASONING: 
Based on the patient's NYHA class II and LVEF of 50%, the patient may have some degree of left ventricular dysfunction. However, the patient's laboratory results and ECG findings do not suggest a high risk of pump failure. The patient's elevated creatinine level may indicate some degree of kidney impairment, but the patient is not on dialysis, and the patient's electrolyte levels are relatively stable.

It is also worth noting that the patient is taking medications for hypertension, myocardial infarction, and heart failure, which suggests that the patient is receiving appropriate management for these conditions. While the patient's Pro-BNP level is elevated, the patient's overall clinical picture does not suggest a high risk of pump failure."
390,390,P0630,"Age: 61
Gender: Male 
Weight: 90 kg
Height: 173 cm
NYHA Class: II
Blood Pressure: 110/50 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Diabetes
Albumin (g/L): 44
ALT or GPT (IU/L): 45.0
AST or GOT (IU/L): 31.0
Total Cholesterol (mmol/L): 3,49
Creatinine (mmol/L): 97.0
Gamma-glutamil transpeptidase (IU/L): 20
Glucose (mmol/L): 7,4
Hemoglobin (g/L): 126.0
HDL (mmol/L): 0,8
Potassium (mEq/L): 5,2
LDL (mmol/L): 1,66
Sodium (mEq/L): 141.0
Pro-BNP (ng/L): 848.0
Protein (g/L): 71
T4 (ng/L): 17
Troponin (ng/mL): 0,01
TSH (mIU/L): 0,98
Urea (mg/dL): 6,99
LVEF (%): 35.0
Medications: Diabetes Medication, Beta Blockers, Statins, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"RANKING: 1. Survivor
REASONING:

Based on the provided patient data, I predict that the patient is most likely to survive for the next few years. Here's a breakdown of the reasoning:

1. Age: Although the patient is 61 years old, the NYHA Class II classification indicates that the patient has some symptoms of heart failure, but the patient is still able to perform daily activities without severe limitation. This suggests that the patient's cardiac function is not severely compromised.

2. LVEF: The left ventricular ejection fraction (LVEF) is significantly reduced at 35%, which indicates systolic dysfunction. However, the patient is still able to maintain a relatively normal blood pressure and does not have evidence of acute heart failure (e.g., elevated BNP levels). This suggests that the patient's cardiac function is not rapidly deteriorating.

3. Medications: The patient is taking a comprehensive regimen of medications, including beta blockers, statins, and an ACE inhibitor, which are all indicated for heart failure management. This suggests that the patient is receiving optimal medical therapy.

4. Electrocardiogram (ECG) results: The absence of ventricular tachycardia, non-sustained ventricular tachycardia, and other arrhythmias suggests that the patient does not have a high risk of life-threatening arrhythmias.

5. Laboratory results: The patient's electrolyte and liver function tests are relatively normal, and the troponin level is not elevated, which suggests that there is no acute myocardial infarction.

Given these factors, I believe that the patient is likely to survive for the next few years, although regular monitoring and follow-up are necessary to adjust the treatment plan as needed to manage the patient's heart failure and other comorbid conditions."
391,391,P0631,"Age: 39
Gender: Male 
Weight: 123 kg
Height: 176 cm
NYHA Class: II
Blood Pressure: 160/90 mmHg
Past Medical History: Idiopathic dilated cardiomyopathy, Diabetes, Dyslipemia, Hypertension
Albumin (g/L): 43
ALT or GPT (IU/L): 36.0
AST or GOT (IU/L): 26.0
Total Cholesterol (mmol/L): 3,98
Creatinine (mmol/L): 71.0
Gamma-glutamil transpeptidase (IU/L): 51
Glucose (mmol/L): 4,6
Hemoglobin (g/L): 145.0
HDL (mmol/L): 1,16
Potassium (mEq/L): 4,4
LDL (mmol/L): 1,86
Sodium (mEq/L): 137.0
Pro-BNP (ng/L): 37.0
Protein (g/L): 76
T4 (ng/L): 15
Troponin (ng/mL): 0,01
TSH (mIU/L): 1,81
Urea (mg/dL): 5,49
LVEF (%): 25.0
Medications: Calcium Channel Blocker, Diabetes Medication, Beta Blockers, Loop Diuretics, Statins, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"RANKING: 1. Survivor
REASONING: 
Based on the patient's age, NYHA Class II, and the presence of idiopathic dilated cardiomyopathy, diabetes, dyslipemia, and hypertension, the patient is at high risk for cardiac complications. The patient's LVEF is significantly reduced at 25%, indicating poor cardiac function. The patient's elevated creatinine level (71.0 mmol/L) suggests renal impairment, which is often associated with heart failure.

The patient's ECG impression shows ventricular extrasystoles, which is a common finding in patients with cardiomyopathy. However, there is no evidence of ventricular tachycardia or non-sustained ventricular tachycardia, which reduces the likelihood of sudden cardiac death.

Given the patient's current medications, which include ACE inhibitors and beta blockers, these are effective in managing heart failure and reducing the risk of cardiac complications. The patient's elevated troponin level (0.01 ng/mL) is within normal limits, indicating no significant myocardial damage.

While the patient's prognosis is guarded, the presence of a favorable medication regimen and the absence of high-risk ECG findings make survival a possible outcome. Therefore, I rank the patient as a survivor.

RANKING: 2. Sudden Cardiac Death
REASONING: 
While the patient's cardiomyopathy and hypertension increase the risk of sudden cardiac death, the patient's current ECG impression does not show any high-risk arrhythmias. The absence of ventricular tachycardia, non-sustained ventricular tachycardia, and paroxysmal supraventricular tachyarrhythmia reduces the likelihood of sudden cardiac death.

However, the patient's poor LVEF (25%) and elevated creatinine level (71.0 mmol/L) increase the risk of cardiac complications, including sudden cardiac death. The patient's high blood pressure (160/90 mmHg) also increases the risk of cardiac complications.

Given the patient's poor cardiac function and elevated creatinine level, sudden cardiac death cannot be ruled out. However, the patient's current ECG findings and medication regimen reduce the likelihood of sudden cardiac death.

RANKING: 3. Pump Failure Death
REASONING: 
The patient's poor LVEF (25%) and elevated creatinine level (71.0 mmol/L) indicate significant cardiac dysfunction, which increases the risk of heart failure. The patient's NYHA Class II classification also suggests that the patient is experiencing symptoms of heart failure.

The patient's elevated troponin level (0.01 ng/mL) is within normal limits, but the patient's elevated creatinine level and poor LVEF suggest that the patient's heart is not functioning optimally. The patient's elevated blood pressure (160/90 mmHg) and dyslipemia also increase the risk of cardiac complications, including heart failure.

While the patient's current medication regimen includes ACE inhibitors and beta blockers, which are effective in managing heart failure, the patient's poor cardiac function and elevated creatinine level increase the risk of pump failure. Therefore, pump failure death is a possible outcome, but the patient's current ECG findings and medication regimen reduce the likelihood of this outcome."
392,392,P0632,"Age: 73
Gender: Male 
Weight: 81 kg
Height: 165 cm
NYHA Class: II
Blood Pressure: 125/75 mmHg
Past Medical History: Other HF etiology, Hypertension
Albumin (g/L): 40
ALT or GPT (IU/L): 32.0
AST or GOT (IU/L): 14.0
Total Cholesterol (mmol/L): 4,78
Creatinine (mmol/L): 88.0
Gamma-glutamil transpeptidase (IU/L): 23
Glucose (mmol/L): 6,1
Hemoglobin (g/L): 162.0
HDL (mmol/L): 1,14
Potassium (mEq/L): 4,3
LDL (mmol/L): 2,92
Sodium (mEq/L): 134.0
Pro-BNP (ng/L): 1395.0
Protein (g/L): 70
T4 (ng/L): 17
Troponin (ng/mL): 0,01
TSH (mIU/L): 2,28
Urea (mg/dL): 7,99
LVEF (%): 35.0
Medications: Beta Blockers, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",survivor,"RANKING: 

1. Survivor
REASONING: 
Given the patient's age, NYHA Class II, and the presence of ventricular extrasystoles and non-sustained ventricular tachycardia on ECG, the patient is at increased risk for cardiac complications. However, the patient is on beta blockers and ACE inhibitors, which are standard treatments for heart failure and hypertension. The patient's LVEF is significantly reduced at 35%, indicating severe left ventricular dysfunction. Despite this, the patient's overall clinical presentation and laboratory results do not indicate acute coronary syndrome, severe hypotension, or acute kidney injury, which could have contributed to a worse outcome. Therefore, the patient is likely to survive, given the absence of severe symptoms and the presence of adequate treatment.

2. Sudden cardiac death
REASONING: 
The patient's ECG shows polymorphic ventricular extrasystoles and non-sustained ventricular tachycardia, which are indicators of increased risk for ventricular arrhythmias. While the patient is on beta blockers and ACE inhibitors, which can help reduce the risk of arrhythmias, the presence of ventricular tachycardia on ECG still raises concerns. However, the patient's overall clinical presentation is stable, and there is no indication of acute coronary syndrome or severe hypotension. Therefore, while there is a risk of sudden cardiac death, it is not the most likely outcome.

3. Pump failure death
REASONING: 
While the patient's LVEF is significantly reduced at 35%, indicating severe left ventricular dysfunction, the patient is on beta blockers and ACE inhibitors, which can help improve heart function. The patient's overall clinical presentation is stable, and there is no indication of acute coronary syndrome or severe hypotension. The patient's albumin level is slightly low, but not severely low, and the kidney function is not severely impaired. Given the patient's stable clinical presentation and adequate treatment, pump failure death is the least likely outcome."
393,393,P0633,"Age: 51
Gender: Male 
Weight: 97 kg
Height: 176 cm
NYHA Class: II
Blood Pressure: 140/90 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Dyslipemia, Myocardial Infarction
Albumin (g/L): 43
ALT or GPT (IU/L): 58.0
AST or GOT (IU/L): 35.0
Total Cholesterol (mmol/L): 4,47
Creatinine (mmol/L): 97.0
Gamma-glutamil transpeptidase (IU/L): 70
Glucose (mmol/L): 7,9
Hemoglobin (g/L): 168.0
HDL (mmol/L): 0,78
Potassium (mEq/L): 4
LDL (mmol/L): 2,2
Sodium (mEq/L): 136.0
Pro-BNP (ng/L): 193.0
Protein (g/L): 74
T4 (ng/L): 15
Troponin (ng/mL): 0,01
TSH (mIU/L): 2
Urea (mg/dL): 5,66
LVEF (%): 20.0
Medications: Beta Blockers, Statins, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"RANKING: 
1. Survivor
REASONING:
The patient's overall clinical presentation and test results suggest a poor prognosis for long-term survival. The patient has a history of ischemic dilated cardiomyopathy, which is a significant risk factor for cardiac events. The left ventricular ejection fraction (LVEF) is severely reduced at 20%, indicating poor cardiac function. The presence of ventricular extrasystole and non-sustained ventricular tachycardia on the ECG also suggests arrhythmias, which can be life-threatening. However, the patient is currently on beta blockers, statins, and an ACE inhibitor, which are standard treatments for heart failure and ischemic heart disease. 

Despite these factors, the patient's current medical condition, as indicated by the patient outcome ""survivor"", suggests that the patient is currently stable and not experiencing acute cardiac events. The patient's creatinine level is slightly elevated, but not significantly abnormal. The patient's troponin level is normal, which suggests that there is no significant myocardial infarction at the moment. The patient's medication regimen is also adequate for managing the patient's heart failure and ischemic heart disease.

While the patient's prognosis is still uncertain, the patient's current medical condition is stable, and the patient is not experiencing acute cardiac events, making survival the most likely outcome in the short term.

2. Sudden Cardiac Death
REASONING:
Sudden cardiac death is a possible outcome for the patient, given the patient's history of ischemic dilated cardiomyopathy and ventricular arrhythmias. However, the patient is currently on beta blockers, statins, and an ACE inhibitor, which are standard treatments for heart failure and ischemic heart disease. The patient's current medical condition is stable, and the patient is not experiencing acute cardiac events. 

While the patient's ECG shows ventricular extrasystole and non-sustained ventricular tachycardia, the patient is not experiencing sustained ventricular tachycardia or bradycardia. The patient's troponin level is normal, and the patient is not experiencing any acute myocardial infarction. The patient's current medication regimen is adequate for managing the patient's heart failure and ischemic heart disease.

Therefore, while sudden cardiac death is a possible outcome, it is less likely than survival given the patient's current medical condition and medication regimen.

3. Pump Failure Death
REASONING:
Pump failure death is a possible outcome for the patient, given the patient's history of ischemic dilated cardiomyopathy and reduced LVEF. However, the patient is currently on beta blockers, statins, and an ACE inhibitor, which are standard treatments for heart failure. The patient's current medical condition is stable, and the patient is not experiencing acute cardiac events.

While the patient's LVEF is severely reduced, the patient's current medication regimen is adequate for managing heart failure. The patient's current creatinine level is slightly elevated, but not significantly abnormal, and the patient's troponin level is normal, indicating no significant myocardial infarction at the moment. 

Therefore, pump failure death is the least likely outcome given the patient's current medical condition, medication regimen, and the absence of acute cardiac events."
394,394,P0634,"Age: 76
Gender: Male 
Weight: 72 kg
Height: 167 cm
NYHA Class: II
Blood Pressure: 114/77 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Diabetes, Dyslipemia, Hypertension
Albumin (g/L): 39
ALT or GPT (IU/L): 15.0
AST or GOT (IU/L): 13.0
Total Cholesterol (mmol/L): 3,67
Creatinine (mmol/L): 124.0
Gamma-glutamil transpeptidase (IU/L): 16
Glucose (mmol/L): 6,6
Hemoglobin (g/L): 141.0
HDL (mmol/L): 0,93
Potassium (mEq/L): 5,1
LDL (mmol/L): 1,66
Sodium (mEq/L): 138.0
Pro-BNP (ng/L): 716.0
Protein (g/L): 76
T4 (ng/L): 15
Troponin (ng/mL): 0,01
TSH (mIU/L): 1,67
Urea (mg/dL): 10,48
LVEF (%): 38.0
Medications: Diabetes Medication, Beta Blockers, Spironolactone, Statins, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: TPSV
        - Bradycardia: No
            ",survivor,"RANKING: 1. Survivor
REASONING: The patient's age, NYHA Class II, and the presence of ischemic dilated cardiomyopathy, diabetes, dyslipemia, and hypertension suggest a significant burden of cardiovascular disease. However, the patient's current medication regimen, which includes beta blockers, spironolactone, statins, and an ACE inhibitor, indicates that they are receiving evidence-based treatments for their conditions.

The patient's laboratory results, including a slightly elevated troponin level (0.01 ng/mL) and a low LVEF (38.0%), suggest some degree of cardiac dysfunction. However, the absence of any acute myocardial infarction or significant elevation in other biomarkers (e.g., ALT, AST, creatinine) suggests that the patient is not in an acute decompensated state.

The presence of a high Pro-BNP level (716 ng/L) suggests that the patient is experiencing some degree of ventricular stress and possibly volume overload, but the patient's current medications may be adequately controlling symptoms. The patient's ECG results are notable for ventricular extrasystoles, but this finding is not uncommon in patients with heart failure and may not necessarily indicate a high risk of sudden cardiac death.

Considering these factors, the patient is likely to survive for the next few years, given their current treatment and the absence of any acute life-threatening conditions. However, regular monitoring and follow-up are essential to adjust the treatment plan as needed and to address any potential complications.

RANKING: 2. Sudden cardiac death
REASONING: The patient's history of ischemic dilated cardiomyopathy, diabetes, and hypertension increases their risk of sudden cardiac death. The patient's low LVEF (38.0%) and elevated Pro-BNP level (716 ng/L) suggest significant cardiac dysfunction, which may increase the risk of arrhythmias, particularly ventricular tachycardia.

The patient's ECG results show ventricular extrasystoles, which may be a marker for underlying arrhythmia. While the absence of ventricular tachycardia or non-sustained ventricular tachycardia on the ECG is reassuring, the presence of ventricular extrasystoles may indicate an increased risk of sudden cardiac death.

RANKING: 3. Pump failure death
REASONING: The patient's low LVEF (38.0%) and elevated Pro-BNP level (716 ng/L) suggest significant cardiac dysfunction, which may lead to pump failure over time. The patient's NYHA Class II symptoms indicate that they are experiencing some degree of heart failure, which may worsen over time if not adequately managed.

The patient's current medication regimen, while evidence-based, may not be sufficient to control symptoms or prevent further decline in cardiac function. The patient's elevated creatinine level (124.0 mmol/L) also suggests some degree of renal impairment, which may be related to cardiac dysfunction.

While the patient is currently stable, the combination of cardiac dysfunction, elevated Pro-BNP levels, and potential renal impairment increase the risk of pump failure over time. Regular monitoring and follow-up are essential to adjust the treatment plan and address any potential complications."
395,395,P0636,"Age: 39
Gender: Male 
Weight: 79 kg
Height: 177 cm
NYHA Class: II
Blood Pressure: 115/85 mmHg
Past Medical History: Idiopathic dilated cardiomyopathy
Albumin (g/L): 47
ALT or GPT (IU/L): 52.0
AST or GOT (IU/L): 38.0
Total Cholesterol (mmol/L): 7,01
Creatinine (mmol/L): 102.0
Gamma-glutamil transpeptidase (IU/L): 162
Glucose (mmol/L): 5
Hemoglobin (g/L): 167.0
HDL (mmol/L): 0,91
Potassium (mEq/L): 5,1
LDL (mmol/L): 4,5
Sodium (mEq/L): 138.0
Pro-BNP (ng/L): 114.0
Protein (g/L): 75
T3 (pg/dL): 0,06
T4 (ng/L): 16
Troponin (ng/mL): 0,04
TSH (mIU/L): 0,701
Urea (mg/dL): 6,82
LVEF (%): 29.0
Medications: Beta Blockers, Loop Diuretics, Spironolactone, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",survivor,"RANKING: 
1. Survivor
REASONING: 
This patient has a significant history of idiopathic dilated cardiomyopathy, which is a condition that can lead to progressive heart failure. The patient's left ventricular ejection fraction (LVEF) is severely impaired at 29%, indicating poor heart function. However, the patient is currently being treated with medications that are standard for heart failure management, including beta blockers, loop diuretics, spironolactone, and an ACE inhibitor. 

Despite the severity of the patient's heart condition, the patient's recent ECG shows no evidence of ventricular tachycardia or non-sustained ventricular tachycardia, which are both indicators of high-risk arrhythmias that can lead to sudden cardiac death. The patient's troponin level is also within normal limits, indicating no evidence of myocardial infarction.

Given the patient's relatively stable vital signs, low blood pressure, and normal kidney function, the patient is less likely to experience sudden cardiac death. Furthermore, the patient's medication regimen is well-established and is aimed at managing symptoms of heart failure, which further supports a favorable prognosis.

2. Pump failure death
REASONING: 
While the patient's LVEF is severely impaired, the patient is currently being treated with medications that are standard for heart failure management. However, the patient's low albumin level (47 g/L) and elevated creatinine level (102.0 mmol/L) suggest possible malnutrition and renal impairment, which can exacerbate heart failure symptoms. Additionally, the patient's low HDL cholesterol level (0.91 mmol/L) and high triglyceride level (not provided) may increase the risk of cardiovascular events.

Given the patient's severe heart failure and potential for malnutrition and renal impairment, pump failure death is a possible complication, but it is less likely compared to sudden cardiac death.

3. Sudden cardiac death
REASONING: 
The patient's recent ECG shows no evidence of ventricular tachycardia or non-sustained ventricular tachycardia, which are both indicators of high-risk arrhythmias that can lead to sudden cardiac death. The patient's troponin level is also within normal limits, indicating no evidence of myocardial infarction.

However, the patient's history of idiopathic dilated cardiomyopathy and severe LVEF impairment increases the risk of arrhythmias and sudden cardiac death. Additionally, the patient's polymorphic ventricular extrasystole on the ECG is a concerning finding that may indicate an increased risk of ventricular arrhythmias.

Given the patient's stable vital signs and well-established medication regimen, pump failure death is less likely compared to sudden cardiac death, but it is still a possible complication."
396,396,P0637,"Age: 58
Gender: Male 
Weight: 75 kg
Height: 168 cm
NYHA Class: II
Blood Pressure: 120/70 mmHg
Past Medical History: Enolic dilated cardiomyopathy, Dyslipemia
Albumin (g/L): 43
ALT or GPT (IU/L): 24.0
AST or GOT (IU/L): 30.0
Total Cholesterol (mmol/L): 6,85
Creatinine (mmol/L): 103.0
Gamma-glutamil transpeptidase (IU/L): 23
Glucose (mmol/L): 5,4
Hemoglobin (g/L): 163.0
HDL (mmol/L): 1,42
Potassium (mEq/L): 4,8
LDL (mmol/L): 4,84
Sodium (mEq/L): 139.0
Pro-BNP (ng/L): 269.0
Protein (g/L): 73
T3 (pg/dL): 0,06
T4 (ng/L): 14
Troponin (ng/mL): 0,005
TSH (mIU/L): 1,83
Urea (mg/dL): 6,16
LVEF (%): 25.0
Medications: ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"RANKING: 1. Survivor
REASONING: The patient's age, NYHA Class II, and the presence of a past medical history of dilated cardiomyopathy are significant risk factors for cardiac complications. However, the patient's current hemoglobin level is elevated, which may indicate anemia, a condition that can be associated with an increased risk of cardiac complications. The patient's creatinine level is also elevated, suggesting possible kidney impairment. 

The patient's LVEF of 25% is significantly reduced, indicating severe left ventricular dysfunction. The presence of ventricular extrasystole on the ECG, although not sustained, is a concerning sign of arrhythmia. The patient's lipid profile, with elevated total cholesterol and LDL, is also a risk factor for cardiovascular disease. 

However, the patient is currently taking an ACE inhibitor, which can help reduce blood pressure and alleviate some of the strain on the heart. The absence of other concerning findings on the ECG, such as ventricular tachycardia or non-sustained ventricular tachycardia, suggests that the patient's heart is not in a state of acute crisis.

Considering these factors, the most likely prognosis for the patient is survival, but with a high risk of cardiac complications."
397,397,P0638,"Age: 55
Gender: Male 
Weight: 82 kg
Height: 164 cm
NYHA Class: II
Blood Pressure: 130/70 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Diabetes, Dyslipemia, Hypertension, Myocardial Infarction
Albumin (g/L): 48
ALT or GPT (IU/L): 21.0
AST or GOT (IU/L): 27.0
Total Cholesterol (mmol/L): 3,96
Creatinine (mmol/L): 99.0
Gamma-glutamil transpeptidase (IU/L): 25
Glucose (mmol/L): 12,5
Hemoglobin (g/L): 147.0
HDL (mmol/L): 0,93
Potassium (mEq/L): 4,7
LDL (mmol/L): 1,71
Sodium (mEq/L): 133.0
Pro-BNP (ng/L): 775.0
Protein (g/L): 79
T3 (pg/dL): 0,05
T4 (ng/L): 18
Troponin (ng/mL): 0,005
TSH (mIU/L): 1,18
Urea (mg/dL): 8,15
LVEF (%): 31.0
Medications: Beta Blockers, Spironolactone, Statins, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",survivor,"RANKING: 
1. Survivor
REASONING: 
Based on the provided patient data, I would rank the patient as having the highest likelihood of being a survivor. The patient's age, NYHA class II, and lack of severe symptoms suggest that the patient is not in a critical stage of heart failure. The patient's LVEF is 31%, which is significantly reduced, indicating some degree of systolic dysfunction, but it is not extreme. The patient's blood pressure is well-controlled, and the patient is on beta blockers, spironolactone, statins, and an ACE inhibitor, which are standard treatments for heart failure and coronary artery disease. The patient's electrolytes, liver function, and kidney function are also within relatively normal limits. Additionally, the patient's ECG shows non-sustained ventricular tachycardia, which is a concerning finding, but it is not a predictor of sudden cardiac death. Overall, the patient's clinical presentation and laboratory results suggest that the patient is likely to survive for the next few years with proper management and monitoring.

RANKING: 
2. Sudden cardiac death
REASONING: 
The patient's ECG shows non-sustained ventricular tachycardia, which is a risk factor for sudden cardiac death. Additionally, the patient's LVEF is significantly reduced, indicating some degree of systolic dysfunction, which can increase the risk of sudden cardiac death. The patient's age and past medical history of myocardial infarction also increase the risk of sudden cardiac death. However, the patient is already on beta blockers, which are known to reduce the risk of sudden cardiac death. The patient's other laboratory results are relatively normal, which suggests that the patient is not in a critical stage of heart failure or kidney dysfunction.

RANKING: 
3. Pump failure death
REASONING: 
Given the patient's reduced LVEF and NYHA class II, pump failure death is a possible outcome. However, the patient is already on medications that are standard for heart failure management, which suggests that the patient is receiving adequate treatment. Additionally, the patient's kidney function is relatively preserved, which suggests that the patient's heart failure is not severe enough to cause significant kidney dysfunction. The patient's other laboratory results are relatively normal, which suggests that the patient is not in a critical stage of heart failure. However, the patient's ECG shows non-sustained ventricular tachycardia, which increases the risk of pump failure death. Overall, while pump failure death is a possible outcome, it is less likely than sudden cardiac death or survival."
398,398,P0639,"Age: 49
Gender: Male 
Weight: 90 kg
Height: 172 cm
NYHA Class: II
Blood Pressure: 130/70 mmHg
Past Medical History: Idiopathic dilated cardiomyopathy, Hypertension
Albumin (g/L): 44
ALT or GPT (IU/L): 22.0
AST or GOT (IU/L): 22.0
Total Cholesterol (mmol/L): 4,97
Creatinine (mmol/L): 96.0
Gamma-glutamil transpeptidase (IU/L): 22
Glucose (mmol/L): 5,8
Hemoglobin (g/L): 157.0
HDL (mmol/L): 1,63
Potassium (mEq/L): 4,7
LDL (mmol/L): 2,53
Sodium (mEq/L): 139.0
Pro-BNP (ng/L): 59.0
Protein (g/L): 76
T3 (pg/dL): 0,06
T4 (ng/L): 21
Troponin (ng/mL): 0,01
TSH (mIU/L): 0,742
Urea (mg/dL): 6,49
LVEF (%): 50.0
Medications: Beta Blockers, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"RANKING: 1. Survivor
REASONING: 

The patient's age, NYHA Class II, and relatively normal blood pressure and electrolyte levels are favorable indicators of a relatively preserved cardiac function. The patient's LVEF of 50.0% is slightly below the normal range, but it is still within a range that can be managed with current medications. The absence of significant elevations in Troponin levels and the normal TSH level suggest that the patient's heart is not under significant stress or strain. The patient's medication regimen, which includes beta blockers and ACE inhibitors, is standard for managing heart failure and hypertension in patients with idiopathic dilated cardiomyopathy.

The presence of ventricular extrasystoles is noted on the ECG, but the absence of other significant arrhythmias and the patient's overall clinical presentation suggest that this is not a cause for significant concern. The elevated creatinine level may indicate some degree of renal impairment, but it is not severe and is likely managed by the patient's current medications.

Overall, the patient's clinical presentation and laboratory results suggest that the patient is at low risk for significant cardiac complications, and with continued management of their medications and lifestyle modifications, it is likely that the patient will survive for the next few years."
399,399,P0640,"Age: 69
Gender: Male 
Weight: 85 kg
Height: 168 cm
NYHA Class: II
Blood Pressure: 110/60 mmHg
Past Medical History: Idiopathic dilated cardiomyopathy, Dyslipemia
Albumin (g/L): 41,2
ALT or GPT (IU/L): 25.0
AST or GOT (IU/L): 22.0
Total Cholesterol (mmol/L): 5,82
Creatinine (mmol/L): 166.0
Gamma-glutamil transpeptidase (IU/L): 22
Glucose (mmol/L): 5,9
Hemoglobin (g/L): 162.0
HDL (mmol/L): 0,8
Potassium (mEq/L): 4,3
LDL (mmol/L): 2,33
Sodium (mEq/L): 143.0
Pro-BNP (ng/L): 1660.0
Protein (g/L): 76
T3 (pg/dL): 0,05
T4 (ng/L): 18
Troponin (ng/mL): 0,01
TSH (mIU/L): 3,97
Urea (mg/dL): 10,91
LVEF (%): 30.0
Medications: Digoxin, Loop Diuretics, Spironolactone, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"RANKING: 1. Survivor
REASONING: 

Based on the patient's data, the patient is at high risk for cardiac-related complications due to their history of idiopathic dilated cardiomyopathy, which is a significant risk factor for cardiac failure and arrhythmias. The patient's low left ventricular ejection fraction (LVEF) of 30% further supports this risk. The presence of non-sustained ventricular tachycardia (NSVT) and ventricular extrasystoles on the ECG also indicates an increased risk of arrhythmias, which can lead to sudden cardiac death.

The patient's NYHA Class II indicates mild heart failure symptoms, but the presence of significant comorbidities such as dyslipidemia and elevated creatinine levels suggests that the patient's cardiac function is compromised. The patient's medication regimen, which includes ACE inhibitors and loop diuretics, suggests that they are receiving standard treatment for heart failure and hypertension.

Given these factors, the patient's overall prognosis is that they will survive the next few years, but will likely require close monitoring and adjustments to their medication regimen to manage their cardiac function and prevent further decline.

While the patient's high Pro-BNP levels (1660.0 ng/L) suggest significant cardiac stress, the fact that they are a survivor on current treatment suggests that they are likely to continue to receive adequate care and monitoring. The presence of troponin at 0.01 ng/mL is also not significantly elevated, suggesting that there is no acute myocardial infarction. 

The patient's age and gender also play a role in the prognosis, as men over the age of 65 are at higher risk for cardiovascular mortality. However, the patient's overall clinical presentation and current treatment plan suggest that they are at a higher risk for cardiac-related complications, making survival the most likely outcome.

The other two options, sudden cardiac death and pump failure death, are less likely, as the patient is receiving treatment for heart failure and has a relatively stable ECG. However, close monitoring and adjustments to their medication regimen will be necessary to prevent further decline in cardiac function."
400,400,P0641,"Age: 68
Gender: Male 
Weight: 98 kg
Height: 166 cm
NYHA Class: II
Blood Pressure: 155/90 mmHg
Past Medical History: Hypertensive cardiomyopathy, Peripheral vascular disease, Hypertension
Albumin (g/L): 35,8
ALT or GPT (IU/L): 17.0
AST or GOT (IU/L): 18.0
Total Cholesterol (mmol/L): 5,02
Creatinine (mmol/L): 131.0
Gamma-glutamil transpeptidase (IU/L): 55
Glucose (mmol/L): 4,6
Hemoglobin (g/L): 117.0
HDL (mmol/L): 1,32
Potassium (mEq/L): 4,4
LDL (mmol/L): 3,08
Sodium (mEq/L): 144.0
Pro-BNP (ng/L): 718.0
Protein (g/L): 71
T3 (pg/dL): 0,02
T4 (ng/L): 21
Troponin (ng/mL): 0,01
TSH (mIU/L): 3,71
Urea (mg/dL): 9,35
LVEF (%): 64.0
Medications: Calcium Channel Blocker, Digoxin, Loop Diuretics, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: TPSV
        - Bradycardia: No
            ",survivor,"RANKING: 1. Survivor
REASONING: 
Given the patient's age, NYHA Class II, and the presence of hypertension, hypertensive cardiomyopathy, and peripheral vascular disease, the patient is already at a higher risk for cardiovascular events. However, the absence of any specific indications of heart failure (e.g., no evidence of acute coronary syndrome, no significant left ventricular dysfunction, and no cardiogenic shock) suggests that the patient's cardiovascular system may still be functional to some extent.

The patient's laboratory results show elevated troponin levels (0.01 ng/mL), which may indicate some degree of cardiac stress or minor myocardial damage. However, the troponin level is still within a relatively normal range, and the LVEF is 64%, which suggests that the patient's heart is still pumping effectively.

The patient's ECG findings, while showing some signs of arrhythmias, do not indicate any life-threatening conditions such as ventricular tachycardia or ventricular fibrillation. The presence of paroxysmal supraventricular tachycardia (PSVT) may require monitoring, but it is not necessarily a contraindication for survival.

Overall, considering the patient's age, comorbidities, and the absence of severe cardiac dysfunction, the most likely outcome is that the patient will survive for the next few years. However, close monitoring and management of the patient's hypertension, medications, and potential arrhythmias will be crucial to prevent further cardiac complications.

RANKING: 2. Sudden cardiac death
REASONING: 
The patient's age, hypertension, and hypertensive cardiomyopathy increase the risk of sudden cardiac death. The presence of peripheral vascular disease also increases the risk of atherosclerosis, which can lead to cardiac events.

The elevated troponin level (0.01 ng/mL) and the patient's NYHA Class II suggest that the patient's heart is under some degree of stress, which may increase the risk of a cardiac event. The patient's LVEF of 64% is also lower than the normal range, indicating some degree of left ventricular dysfunction.

The patient's ECG findings, while showing some signs of arrhythmias, do not rule out the possibility of sudden cardiac death. The presence of ventricular extrasystoles, particularly polymorphic ventricular extrasystoles, is a risk factor for sudden cardiac death.

RANKING: 3. Pump failure death
REASONING: 
The patient's NYHA Class II and elevated troponin level (0.01 ng/mL) suggest that the patient's heart is not functioning optimally. The patient's LVEF of 64% is also lower than the normal range, indicating some degree of left ventricular dysfunction.

The patient's elevated creatinine level (1.31 mmol/L) and urea level (9.35 mg/dL) suggest some degree of renal impairment, which can be a complication of heart failure. The patient's hypertension and hypertensive cardiomyopathy also increase the risk of heart failure.

The patient's ECG findings, particularly the presence of ventricular extrasystoles, may indicate some degree of cardiac stress or dysfunction. The patient's age and comorbidities also increase the risk of cardiac events, including heart failure.

While the patient's current condition does not meet the criteria for heart failure, the presence of some risk factors and the patient's NYHA Class II suggest that the patient is at risk of developing heart failure in the near future."
401,401,P0642,"Age: 72
Gender: Male 
Weight: 76 kg
Height: 161 cm
NYHA Class: II
Blood Pressure: 130/70 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Diabetes, Dyslipemia, Peripheral vascular disease, Myocardial Infarction
Albumin (g/L): 37,3
ALT or GPT (IU/L): 19.0
AST or GOT (IU/L): 20.0
Total Cholesterol (mmol/L): 4,55
Creatinine (mmol/L): 87.0
Gamma-glutamil transpeptidase (IU/L): 27
Glucose (mmol/L): 7
Hemoglobin (g/L): 140.0
HDL (mmol/L): 1,32
Potassium (mEq/L): 4,2
LDL (mmol/L): 2,51
Sodium (mEq/L): 145.0
Pro-BNP (ng/L): 413.0
Protein (g/L): 75
T3 (pg/dL): 0,04
T4 (ng/L): 18
Troponin (ng/mL): 0,01
TSH (mIU/L): 1,44
Urea (mg/dL): 5,13
LVEF (%): 30.0
Medications: Calcium Channel Blocker, Diabetes Medication, Beta Blockers, Loop Diuretics, Statins, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"RANKING: 1. Survivor
REASONING: 
The patient's age, NYHA Class II, and the presence of multiple comorbid conditions such as ischemic dilated cardiomyopathy, diabetes, dyslipidemia, and peripheral vascular disease suggest a high risk for cardiovascular events. However, the patient is currently taking multiple medications, including beta blockers, loop diuretics, and statins, which are commonly used to manage heart failure, hypertension, and high cholesterol. The patient's ejection fraction (LVEF) is 30.0%, which indicates significant left ventricular dysfunction.

The patient's creatinine level of 87.0 mmol/L suggests some degree of renal impairment, which can be a risk factor for cardiovascular events. However, the patient's renal function is not severely impaired, and the patient is on medications that are commonly used to manage kidney function.

The ECG impression is notable for ventricular extrasystole, which is a benign finding. There is no evidence of ventricular tachycardia, non-sustained ventricular tachycardia, or paroxysmal supraventricular tachyarrhythmia.

Given these factors, the patient is at high risk for cardiovascular events, but the presence of multiple medications and the absence of severe ventricular dysfunction suggest that the patient is likely to survive the next few years. However, the patient should be closely monitored for signs of worsening heart failure, arrhythmias, and other cardiovascular events.

The Pro-BNP level of 413.0 ng/L is elevated, which suggests some degree of ventricular dysfunction and stress. However, the patient's symptoms are not severe, and the patient is currently on medications that are commonly used to manage heart failure.

Overall, based on the available data, the patient is at high risk for cardiovascular events, but the patient's current symptoms and medication regimen suggest that the patient is likely to survive the next few years. However, close monitoring and regular follow-up appointments are essential to adjust the treatment plan as needed.

It is difficult to predict the exact outcome with certainty, but based on the available data, the probability of survivor is the highest."
402,402,P0644,"Age: 72
Gender: Male 
Weight: 85 kg
Height: 171 cm
NYHA Class: II
Blood Pressure: 120/75 mmHg
Past Medical History: Hypertropic cardiomyopathy, Dyslipemia
Albumin (g/L): 43,7
ALT or GPT (IU/L): 94.0
AST or GOT (IU/L): 95.0
Total Cholesterol (mmol/L): 6,1
Creatinine (mmol/L): 97.0
Gamma-glutamil transpeptidase (IU/L): 23
Glucose (mmol/L): 6
Hemoglobin (g/L): 151.0
HDL (mmol/L): 1,01
Potassium (mEq/L): 4
LDL (mmol/L): 3,9
Sodium (mEq/L): 141.0
Pro-BNP (ng/L): 823.0
Protein (g/L): 85
T3 (pg/dL): 0,05
T4 (ng/L): 13
Troponin (ng/mL): 0,18
TSH (mIU/L): 2,38
Urea (mg/dL): 6,91
LVEF (%): 60.0
Medications: Calcium Channel Blocker, Beta Blockers, Statins
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"RANKING: 1. Survivor
REASONING: 

Based on the patient's data, I would rank the patient as having a high likelihood of survival for the next few years. The key factors contributing to this prediction include:

1. Age: The patient is 72 years old, which is considered elderly, but not extremely high-risk. Many people survive well into their 70s and 80s with proper management of their condition.

2. NYHA Class II: This indicates that the patient has some symptoms of heart failure, but they are not severely limited in their physical activity. This suggests that the patient's heart is still functioning relatively well, despite the underlying cardiomyopathy.

3. Low LVEF (60%): While a reduced ejection fraction indicates some degree of heart dysfunction, it is not extremely low. Many patients with an LVEF of 60% can still live for several years with proper treatment.

4. Low Pro-BNP levels (823 ng/L): Elevated B-type natriuretic peptide (BNP) levels are often associated with heart failure. However, the patient's Pro-BNP level is relatively low, suggesting that the patient's heart is not under significant stress.

5. Medications: The patient is taking a calcium channel blocker, beta blockers, and statins, which are all commonly used to manage hypertension, heart failure, and high cholesterol. These medications are likely helping to control the patient's condition and reduce the risk of complications.

6. Absence of significant electrolyte imbalances, renal dysfunction, and other red flags: The patient's electrolyte levels, creatinine, and urea levels are all within relatively normal ranges, which suggests that the patient's kidneys are functioning well and that there are no significant electrolyte imbalances.

Overall, while the patient has a history of cardiomyopathy and some signs of heart failure, the combination of these factors suggests that the patient is likely to survive for several years with proper management of their condition."
403,403,P0645,"Age: 59
Gender: Male 
Weight: 85 kg
Height: 170 cm
NYHA Class: II
Blood Pressure: 130/85 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Diabetes, Dyslipemia, Hypertension
Albumin (g/L): 44,3
ALT or GPT (IU/L): 17.0
AST or GOT (IU/L): 16.0
Total Cholesterol (mmol/L): 5,25
Creatinine (mmol/L): 99.0
Gamma-glutamil transpeptidase (IU/L): 32
Glucose (mmol/L): 6,7
Hemoglobin (g/L): 136.0
HDL (mmol/L): 1,14
Potassium (mEq/L): 3,8
LDL (mmol/L): 2,84
Sodium (mEq/L): 143.0
Pro-BNP (ng/L): 395.0
Protein (g/L): 75
T3 (pg/dL): 0,05
T4 (ng/L): 18
Troponin (ng/mL): 0,01
TSH (mIU/L): 3,7
Urea (mg/dL): 4,68
LVEF (%): 39.0
Medications: Beta Blockers, Loop Diuretics, Statins, ACE Inhibitor, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"RANKING: 1. Survivor
REASONING: The patient's current clinical presentation and lab results indicate a significant cardiac impairment, with an LVEF of 39%, which is below the normal range (50-70%). The presence of ischemic dilated cardiomyopathy, diabetes, and hypertension further exacerbates the cardiac damage. However, the patient's current treatment regimen, which includes beta blockers, loop diuretics, statins, ACE inhibitors, and a nitrovasodilator, suggests a comprehensive approach to managing the patient's cardiac conditions.

Although the patient's creatinine level (99.0 mmol/L) is elevated, indicating some degree of renal impairment, it is not severe enough to immediately impact the patient's overall prognosis. The patient's hemoglobin level (136.0 g/L) and potassium level (3.8 mEq/L) are within normal limits, which reduces the risk of complications related to anemia and electrolyte imbalances.

The elevated Pro-BNP level (395.0 ng/L) suggests some degree of ventricular dysfunction, but it is not excessively high, which might indicate a relatively stable condition. The absence of ventricular tachycardia, non-sustained ventricular tachycardia, and other arrhythmias on the ECG impression suggests that the patient's cardiac rhythm is relatively stable.

Considering these factors, I believe that the patient is likely to survive for the next few years, with a moderate risk of cardiac-related complications. However, regular monitoring and adjustments to the treatment regimen may be necessary to ensure optimal management of the patient's cardiac conditions.

RANKING: 2. Pump failure death
REASONING: Pump failure is a possible outcome due to the patient's significant cardiac impairment, as indicated by the low LVEF of 39%. The patient's ischemic dilated cardiomyopathy and hypertension further increase the risk of pump failure.

However, the patient's current treatment regimen and relatively stable cardiac rhythm on the ECG impression suggest that the risk of pump failure is not imminent. Additionally, the patient's renal function is not severely impaired, which reduces the risk of acute kidney injury and subsequent pump failure.

RANKING: 3. Sudden cardiac death
REASONING: Sudden cardiac death is a possible outcome due to the patient's significant cardiac impairment and the presence of ventricular extrasystoles on the ECG impression. However, the patient's current treatment regimen, which includes beta blockers and ACE inhibitors, suggests a reduced risk of arrhythmias and sudden cardiac death.

Additionally, the patient's relatively stable cardiac rhythm and normal potassium level reduce the risk of fatal arrhythmias. While the patient's cardiac impairment is significant, the presence of beta blockers and ACE inhibitors in the treatment regimen suggests that the patient's cardiac function is being adequately managed, reducing the risk of sudden cardiac death."
404,404,P0646,"Age: 61
Gender: Male 
Weight: 74 kg
Height: 169 cm
NYHA Class: II
Blood Pressure: 160/90 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Dyslipemia, Hypertension, Myocardial Infarction
Albumin (g/L): 47,59
ALT or GPT (IU/L): 53.0
AST or GOT (IU/L): 38.0
Total Cholesterol (mmol/L): 4,84
Creatinine (mmol/L): 120.0
Gamma-glutamil transpeptidase (IU/L): 27
Glucose (mmol/L): 5,4
Hemoglobin (g/L): 133.0
HDL (mmol/L): 1,24
Potassium (mEq/L): 4,1
LDL (mmol/L): 2,66
Sodium (mEq/L): 144.0
Pro-BNP (ng/L): 174.0
Protein (g/L): 78
T3 (pg/dL): 0,05
T4 (ng/L): 15
Troponin (ng/mL): 0,01
TSH (mIU/L): 1,12
Urea (mg/dL): 10,24
LVEF (%): 35.0
Medications: Angiotensin II Receptor Blocker, Loop Diuretics, Statins, ACE Inhibitor, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: TPSV
        - Bradycardia: No
            ",survivor,"RANKING: 
1. Survivor
REASONING: 

The patient's age, NYHA Class II, and the presence of multiple comorbidities such as ischemic dilated cardiomyopathy, hypertension, and dyslipidemia increase the risk of cardiac complications. However, the patient's current medications, including ACE inhibitors and beta-blockers, suggest an attempt to manage hypertension and heart failure. The patient's LVEF of 35% is significantly reduced, indicating severe left ventricular dysfunction, which is a risk factor for adverse outcomes.

The elevated creatinine level (120.0 mmol/L) and elevated troponin level (0.01 ng/mL) suggest some degree of renal impairment and possible myocardial injury, respectively. The presence of ventricular extrasystole and non-sustained ventricular tachycardia on the ECG is concerning, but the absence of sustained VT and the presence of a normal heart rate suggests that the patient is not in immediate danger.

The patient's Pro-BNP level is elevated at 174 ng/L, which indicates some degree of fluid overload and possible heart failure. However, the patient's hemoglobin level is normal, and the absence of acute kidney injury or severe hypotension suggests that the patient is not in imminent danger.

Considering these factors, the patient is likely to survive, but close monitoring and adjustments to their treatment plan are necessary to mitigate the risk of adverse cardiac events."
405,405,P0648,"Age: 72
Gender: Female 
Weight: 78 kg
Height: 157 cm
NYHA Class: II
Blood Pressure: 130/90 mmHg
Past Medical History: Hypertropic cardiomyopathy, Diabetes, Dyslipemia, Hypertension
Albumin (g/L): 39,9
ALT or GPT (IU/L): 13.0
AST or GOT (IU/L): 20.0
Total Cholesterol (mmol/L): 5,15
Creatinine (mmol/L): 90.0
Gamma-glutamil transpeptidase (IU/L): 31
Glucose (mmol/L): 7,1
Hemoglobin (g/L): 156.0
HDL (mmol/L): 1,16
Potassium (mEq/L): 3,6
LDL (mmol/L): 2,97
Sodium (mEq/L): 141.0
Pro-BNP (ng/L): 126.0
Protein (g/L): 69
T3 (pg/dL): 0,04
T4 (ng/L): 15
Troponin (ng/mL): 0,01
TSH (mIU/L): 2
Urea (mg/dL): 8,46
LVEF (%): 60.0
Medications: Beta Blockers
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"RANKING: 1. Survivor
REASONING: 

Based on the patient data, the patient is 72 years old, has a history of Hypertrophic cardiomyopathy, Diabetes, Dyslipemia, and Hypertension, which are all risk factors for cardiovascular disease. The patient's NYHA Class II indicates moderate symptoms, suggesting some limitation in physical activity. The patient's ECG shows ventricular extrasystole, which is a sign of abnormal heart rhythm, but no other significant arrhythmias are present.

The patient's laboratory results show slightly elevated creatinine levels, indicating some degree of kidney dysfunction, which may be related to the patient's hypertension. The patient's lipid profile is also suboptimal, with high LDL and low HDL cholesterol levels.

However, the patient's LVEF is 60%, which is within the normal range for a 72-year-old patient. The patient's troponin levels are normal, and the patient is taking beta blockers, which is a common treatment for hypertension and heart failure.

Considering these factors, the patient's overall prognosis is relatively good, and I predict that the patient will survive for the next few years. The patient's ventricular extrasystole is a concerning sign, but it is not a life-threatening arrhythmia, and the patient is not at high risk for sudden cardiac death.

RANKING: 2. Sudden cardiac death
REASONING: 

While the patient's ventricular extrasystole is a concerning sign, it is not a guarantee of sudden cardiac death. However, if the patient's ventricular extrasystole is not well-controlled with medication, it may increase the risk of sudden cardiac death. Additionally, the patient's history of Hypertrophic cardiomyopathy and hypertension may increase the risk of sudden cardiac death.

RANKING: 3. Pump failure death
REASONING: 

Based on the patient's NYHA Class II symptoms and slightly elevated creatinine levels, there is a possibility of heart failure. However, the patient's LVEF is 60%, which is within the normal range for a 72-year-old patient. The patient is also taking beta blockers, which is a common treatment for hypertension and heart failure.

While the patient's lipid profile is suboptimal, the patient's troponin levels are normal, and the patient's kidney function is not severely impaired. Considering these factors, I do not predict that the patient will experience pump failure death in the next few years."
406,406,P0652,"Age: 68
Gender: Female 
Weight: 62 kg
Height: 144 cm
NYHA Class: II
Blood Pressure: 200/110 mmHg
Past Medical History: Idiopathic dilated cardiomyopathy, Hypertension
Albumin (g/L): 45,1
ALT or GPT (IU/L): 11.0
AST or GOT (IU/L): 17.0
Total Cholesterol (mmol/L): 6,39
Creatinine (mmol/L): 78.0
Gamma-glutamil transpeptidase (IU/L): 19
Glucose (mmol/L): 5
Hemoglobin (g/L): 144.0
HDL (mmol/L): 1,5
Potassium (mEq/L): 4,1
LDL (mmol/L): 3,8
Sodium (mEq/L): 143.0
Pro-BNP (ng/L): 170.0
Protein (g/L): 71,7
T4 (ng/L): 15
TSH (mIU/L): 5,21
Urea (mg/dL): 5,49
LVEF (%): 35.0
Medications: Calcium Channel Blocker, Loop Diuretics, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"RANKING: 
1. Survivor
REASONING: 
The patient has a significant history of idiopathic dilated cardiomyopathy, hypertension, and a low LVEF of 35%, which indicates severely impaired cardiac function. The presence of ventricular tachycardia and non-sustained ventricular tachycardia on the ECG impression further increases the risk of arrhythmic events. Despite the patient's NYHA Class II, which suggests moderate symptoms, the overall clinical picture is concerning for advanced cardiac disease. The patient's elevated blood pressure and high creatinine level also indicate significant cardiovascular strain.

While the patient is currently on medications to manage their condition, including a calcium channel blocker, loop diuretics, and an ACE inhibitor, the presence of these arrhythmic events and the patient's overall cardiac function suggest that the prognosis is guarded. However, the patient is currently not in acute distress and is receiving treatment for their condition.

Therefore, based on the available information, the most likely outcome is that the patient will survive for the next few years, although it is uncertain whether this outcome will be long-term.

RANKING: 
2. Sudden Cardiac Death
REASONING: 
The patient's history of idiopathic dilated cardiomyopathy, hypertension, and the presence of ventricular tachycardia and non-sustained ventricular tachycardia on the ECG impression increase the risk of sudden cardiac death. The patient's low LVEF and elevated blood pressure also contribute to this risk. 

While the patient is receiving treatment, the presence of these arrhythmic events and the patient's overall cardiac function suggest that the risk of sudden cardiac death is significant.

RANKING: 
3. Pump Failure Death
REASONING: 
While the patient's LVEF is severely impaired at 35%, the patient is currently not in acute distress and is receiving treatment to manage their condition. The presence of ventricular tachycardia and non-sustained ventricular tachycardia on the ECG impression also suggests that the patient is at risk of cardiac decompensation. However, the patient's NYHA Class II symptoms and the presence of medications to manage their condition suggest that pump failure is not currently imminent.

Given the patient's overall clinical picture, pump failure death is the least likely outcome, but it cannot be ruled out entirely."
407,407,P0653,"Age: 73
Gender: Male 
Weight: 88 kg
Height: 165 cm
NYHA Class: III
Blood Pressure: 120/80 mmHg
Past Medical History: Enolic dilated cardiomyopathy, Diabetes, Dyslipemia, Hypertension
Albumin (g/L): 45,3
ALT or GPT (IU/L): 6.0
AST or GOT (IU/L): 19.0
Total Cholesterol (mmol/L): 6,15
Creatinine (mmol/L): 124.0
Gamma-glutamil transpeptidase (IU/L): 36
Glucose (mmol/L): 8,8
Hemoglobin (g/L): 148.0
HDL (mmol/L): 1,01
Potassium (mEq/L): 3,9
LDL (mmol/L): 4,37
Sodium (mEq/L): 137.0
Pro-BNP (ng/L): 655.0
Protein (g/L): 80
T3 (pg/dL): 0,04
T4 (ng/L): 15
Troponin (ng/mL): 0,01
TSH (mIU/L): 1,87
Urea (mg/dL): 10,69
LVEF (%): 39.0
Medications: Beta Blockers, Loop Diuretics, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Unknown ventricular tachycardia code
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",survivor,"RANKING: 
1. Survivor
REASONING: 
Based on the provided patient data, the patient is a 73-year-old male with a history of dilated cardiomyopathy, diabetes, dyslipidemia, and hypertension, which are all significant risk factors for cardiac disease. The patient's NYHA Class III indicates a moderate to severe level of heart failure. 

The patient's laboratory results show elevated creatinine levels (124.0 mmol/L), indicating impaired renal function, and a low albumin level (45.3 g/L), suggesting malnutrition and possibly a poor nutritional status. The presence of ventricular extrasystole and polymorphic ventricular tachycardia on the ECG suggests an increased risk of arrhythmias, which can be life-threatening.

However, the patient's hemoglobin level (148.0 g/L) and normal TSH level (1.87 mIU/L) indicate that the patient does not have anemia or hypothyroidism, which could be contributing factors to cardiac disease. The patient is also taking medications that are commonly used to manage heart failure and hypertension, such as beta blockers, loop diuretics, and ACE inhibitors.

Given these factors, the patient's overall prognosis is likely to be a survivor, as they are receiving appropriate treatment for their cardiac condition and do not have any immediately life-threatening conditions that would suggest a high risk of sudden cardiac death or pump failure.

2. Sudden cardiac death
REASONING: 
The patient's ECG shows ventricular extrasystole and polymorphic ventricular tachycardia, which are both indicators of an increased risk of arrhythmias. However, the patient is also receiving beta blockers, which are commonly used to manage arrhythmias and reduce the risk of sudden cardiac death.

While the patient's laboratory results indicate impaired renal function and malnutrition, these factors do not necessarily increase the risk of sudden cardiac death. The patient's hemoglobin level and TSH level are also within normal limits, which reduces the risk of anemia and hypothyroidism contributing to cardiac disease.

However, the patient's ECG findings and history of ventricular dilated cardiomyopathy and hypertension do increase the risk of arrhythmias, which could potentially lead to sudden cardiac death.

3. Pump failure death
REASONING: 
Given the patient's NYHA Class III and elevated creatinine levels, it is likely that the patient has significant cardiac dysfunction. However, the patient is receiving medications that are commonly used to manage heart failure, such as beta blockers, loop diuretics, and ACE inhibitors.

While the patient's laboratory results indicate impaired renal function and malnutrition, these factors do not necessarily increase the risk of pump failure. The patient's hemoglobin level and TSH level are also within normal limits, which reduces the risk of anemia and hypothyroidism contributing to cardiac disease.

However, the patient's LVEF is significantly reduced (39.0%), indicating poor cardiac function. While the patient is receiving medications to manage heart failure, the patient's overall cardiac function is severely impaired, which increases the risk of pump failure."
408,408,P0654,"Age: 70
Gender: Female 
Weight: 75 kg
Height: 157 cm
NYHA Class: II
Blood Pressure: 130/70 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Diabetes, Peripheral vascular disease, Hypertension, Myocardial Infarction
Albumin (g/L): 45,9
ALT or GPT (IU/L): 17.0
AST or GOT (IU/L): 15.0
Total Cholesterol (mmol/L): 3,49
Creatinine (mmol/L): 90.0
Gamma-glutamil transpeptidase (IU/L): 17
Glucose (mmol/L): 7,5
Hemoglobin (g/L): 145.0
HDL (mmol/L): 1,14
Potassium (mEq/L): 4,7
LDL (mmol/L): 1,73
Sodium (mEq/L): 141.0
Pro-BNP (ng/L): 1789.0
Protein (g/L): 75
T3 (pg/dL): 0,04
T4 (ng/L): 13
Troponin (ng/mL): 0,01
TSH (mIU/L): 3,09
Urea (mg/dL): 8,46
LVEF (%): 25.0
Medications: Diabetes Medication, Beta Blockers, Statins, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"RANKING: 1. Survivor
REASONING:

Based on the provided patient data, the patient's prognosis is likely to be a survivor. The patient's age, NYHA Class II, and the presence of ischemic dilated cardiomyopathy suggest a significant cardiac impairment. However, the patient's blood pressure, hemoglobin, and electrolyte levels are within relatively normal limits.

The elevated Pro-BNP level (1789.0 ng/L) indicates some degree of ventricular dysfunction, but it is not excessively high. The LVEF (25.0%) is significantly reduced, indicating severe left ventricular dysfunction. Despite this, the patient is still on medications for diabetes, beta blockers, statins, and ACE inhibitors, which are commonly used to manage heart failure and prevent further cardiac damage.

The presence of non-sustained ventricular tachycardia (NST) and ventricular extrasystole (polymorphic) on the ECG suggests a high risk of arrhythmias, but the patient is not experiencing any symptoms, which is a positive prognostic sign. The absence of sustained ventricular tachycardia and paroxysmal supraventricular tachyarrhythmia also suggests that the patient is not at high risk of sudden cardiac death.

Overall, considering the patient's age, NYHA Class II, and the presence of cardiac impairment, but also the absence of severe symptoms and the presence of medications, the patient's prognosis is likely to be a survivor. However, close monitoring and follow-up are necessary to adjust the treatment plan and prevent any potential complications.

The other two prognoses, sudden cardiac death and pump failure death, are less likely due to the following reasons:

- Sudden cardiac death is unlikely due to the patient's absence of symptoms and the presence of medications that are known to reduce the risk of arrhythmias.
- Pump failure death is also less likely due to the patient's relatively preserved hemoglobin levels, which suggest a relatively preserved cardiac output.

Please note that this prognosis is based on the provided data and may change over time as the patient's condition evolves. Regular follow-up and monitoring are necessary to adjust the treatment plan and prevent any potential complications."
409,409,P0655,"Age: 55
Gender: Male 
Weight: 107 kg
Height: 180 cm
NYHA Class: II
Blood Pressure: 120/80 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Dyslipemia, Myocardial Infarction
Albumin (g/L): 46,1
ALT or GPT (IU/L): 28.0
AST or GOT (IU/L): 29.0
Total Cholesterol (mmol/L): 5,38
Creatinine (mmol/L): 108.0
Gamma-glutamil transpeptidase (IU/L): 53
Glucose (mmol/L): 5,7
Hemoglobin (g/L): 159.0
HDL (mmol/L): 0,98
Potassium (mEq/L): 4,7
LDL (mmol/L): 3,08
Sodium (mEq/L): 138.0
Pro-BNP (ng/L): 408.0
Protein (g/L): 79
T3 (pg/dL): 0,04
T4 (ng/L): 18
Troponin (ng/mL): 0,01
TSH (mIU/L): 1,96
Urea (mg/dL): 6,91
LVEF (%): 24.0
Medications: Beta Blockers, Loop Diuretics, Statins, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"RANKING: 
1. Survivor
REASONING: 

The patient has a complex medical history with ischemic dilated cardiomyopathy, a history of myocardial infarction, and a current NYHA Class II classification, indicating a moderate level of heart failure symptoms. The patient's LVEF is severely impaired at 24%, which suggests significant left ventricular dysfunction.

The patient's laboratory results show elevated creatinine levels (108.0 mmol/L), indicating renal impairment, which is a common complication in patients with heart failure. The elevated Pro-BNP level (408.0 ng/L) is also consistent with heart failure.

Despite the presence of ventricular extrasystole and non-sustained ventricular tachycardia on the ECG, the patient is currently being treated with beta blockers, loop diuretics, statins, and an ACE inhibitor, which are standard therapies for heart failure and ischemic cardiomyopathy.

Considering these factors, the patient's current medical condition and treatment plan suggest that they are likely to survive in the short term, provided that their treatment plan is continued and optimized.

2. Sudden Cardiac Death
REASONING: 

While the patient has a complex medical history and is at risk for cardiac arrhythmias, the presence of ventricular extrasystole and non-sustained ventricular tachycardia on the ECG may increase the risk of sudden cardiac death. However, the patient is currently being treated with beta blockers, which are known to reduce the risk of sudden cardiac death.

The patient's LVEF is severely impaired, and the presence of elevated Pro-BNP levels suggests significant heart failure. However, the patient's current medical condition and treatment plan do not necessarily indicate an imminent risk of sudden cardiac death.

3. Pump Failure Death
REASONING: 

The patient's severely impaired LVEF (24%) and elevated Pro-BNP levels (408.0 ng/L) suggest significant left ventricular dysfunction and heart failure. However, the patient is currently being treated with beta blockers, loop diuretics, statins, and an ACE inhibitor, which are standard therapies for heart failure.

While the patient's renal impairment (creatinine 108.0 mmol/L) and elevated creatinine levels may increase the risk of pump failure, the patient's current medical condition and treatment plan do not necessarily indicate an imminent risk of pump failure death."
410,410,P0658,"Age: 59
Gender: Male 
Weight: 69 kg
Height: 156 cm
NYHA Class: II
Blood Pressure: 130/60 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Diabetes, Dyslipemia, Peripheral vascular disease, Hypertension, Myocardial Infarction
Albumin (g/L): 42,9
ALT or GPT (IU/L): 19.0
AST or GOT (IU/L): 16.0
Total Cholesterol (mmol/L): 4,65
Creatinine (mmol/L): 81.0
Gamma-glutamil transpeptidase (IU/L): 17
Glucose (mmol/L): 5,6
Hemoglobin (g/L): 131.0
HDL (mmol/L): 1,11
Potassium (mEq/L): 4,5
LDL (mmol/L): 2,82
Sodium (mEq/L): 139.0
Pro-BNP (ng/L): 469.0
Protein (g/L): 69
T3 (pg/dL): 0,04
T4 (ng/L): 17
Troponin (ng/mL): 0,01
TSH (mIU/L): 1,53
Urea (mg/dL): 12,47
LVEF (%): 39.0
Medications: Diabetes Medication, Beta Blockers, Statins, ACE Inhibitor, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"RANKING: 1. Survivor
REASONING:

Based on the patient's data, I would rank the patient as having a high likelihood of survival over the next few years. Here's why:

1. Age: The patient is 59 years old, which is considered middle-aged. While age is a significant risk factor for cardiovascular disease, it's not the only factor. Many people with heart conditions can live long and healthy lives with proper management.
2. NYHA Class II: The patient has a mild heart failure classification, indicating that they experience some symptoms of heart failure, but they can still perform moderate physical activity without discomfort. This suggests that the patient's heart is still functional to some extent.
3. LVEF (39%): The left ventricular ejection fraction (LVEF) is a measure of the heart's pumping efficiency. A low LVEF indicates that the heart is not pumping blood efficiently, but it's not severely impaired. A more significant impairment would likely result in a poorer prognosis.
4. Blood pressure and electrolyte levels: The patient's blood pressure is within a relatively normal range, and their electrolyte levels (potassium, sodium, and T3/T4) are also within normal limits. These factors suggest that the patient's cardiovascular system is relatively stable.
5. Medications: The patient is taking a comprehensive regimen of medications, including beta blockers, statins, and an ACE inhibitor, which are standard treatments for heart failure and cardiovascular disease. This suggests that the patient is receiving adequate medical management.
6. ECG findings: The ECG shows no signs of ventricular tachycardia, non-sustained ventricular tachycardia, or other arrhythmias, which are potential indicators of increased risk. The presence of ventricular extrasystoles is not uncommon in patients with heart disease, but it's not necessarily a cause for concern.
7. Pro-BNP levels: Elevated Pro-BNP levels can indicate heart failure, but in this case, the level is not excessively high, suggesting that the patient's heart is not failing catastrophically.

Considering these factors, I believe that the patient has a good chance of survival over the next few years, assuming they continue to receive proper medical management and make lifestyle modifications to reduce their cardiovascular risk."
411,411,P0659,"Age: 77
Gender: Male 
Weight: 68 kg
Height: 163 cm
NYHA Class: II
Blood Pressure: 140/85 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Dyslipemia, Hypertension
Albumin (g/L): 48,3
ALT or GPT (IU/L): 15.0
AST or GOT (IU/L): 26.0
Total Cholesterol (mmol/L): 4,84
Creatinine (mmol/L): 138.0
Gamma-glutamil transpeptidase (IU/L): 22
Glucose (mmol/L): 5,3
Hemoglobin (g/L): 146.0
HDL (mmol/L): 1,47
Potassium (mEq/L): 4,1
LDL (mmol/L): 2,72
Sodium (mEq/L): 136.0
Pro-BNP (ng/L): 1071.0
Protein (g/L): 74
T3 (pg/dL): 0,04
T4 (ng/L): 15
Troponin (ng/mL): 0,04
TSH (mIU/L): 6,33
Urea (mg/dL): 13,36
LVEF (%): 50.0
Medications: Beta Blockers, Loop Diuretics, Statins, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"RANKING: 1. Survivor
REASONING: 

This patient is likely to survive for the next few years due to the presence of several factors that suggest a relatively stable condition. The patient is 77 years old, but the NYHA Class II classification indicates that the patient has some limitations in physical activity, but it's not severe. The patient has a history of ischemic dilated cardiomyopathy, which is a significant underlying condition, but the LVEF is 50%, which is still within the range of patients with heart failure with reduced ejection fraction (HFrEF). The patient is also on beta blockers, loop diuretics, statins, and an ACE inhibitor, which are standard treatments for heart failure and hypertension.

The patient's laboratory results show elevated liver enzymes (ALT and AST), but they are not significantly elevated, which suggests that the liver is not severely affected. The kidney function is also slightly impaired, but it's not severely impaired. The patient's electrolyte levels, including potassium, sodium, and magnesium, are within normal limits.

The ECG results show ventricular extrasystoles, but they are monomorphic and not sustained, which suggests that they are not a significant arrhythmic risk. The patient does not have any other significant ECG abnormalities.

The patient's Pro-BNP level is elevated, which suggests some level of cardiac stress, but it's not extremely high. The patient's medication regimen is well-managed, and the patient is on multiple medications that are known to improve outcomes in patients with heart failure.

Overall, considering the patient's age, medical history, laboratory results, and medication regimen, the likelihood of the patient surviving for the next few years is high."
412,412,P0660,"Age: 49
Gender: Male 
Weight: 81 kg
Height: 171 cm
NYHA Class: II
Blood Pressure: 155/80 mmHg
Past Medical History: Valvular cardiomyopathy, Diabetes, Hypertension
Albumin (g/L): 50,59
ALT or GPT (IU/L): 56.0
AST or GOT (IU/L): 53.0
Total Cholesterol (mmol/L): 7,89
Creatinine (mmol/L): 103.0
Gamma-glutamil transpeptidase (IU/L): 821
Glucose (mmol/L): 11
Hemoglobin (g/L): 166.0
HDL (mmol/L): 1,27
Potassium (mEq/L): 4,1
LDL (mmol/L): 5,02
Sodium (mEq/L): 137.0
Pro-BNP (ng/L): 114.0
Protein (g/L): 86
T3 (pg/dL): 0,05
T4 (ng/L): 19
Troponin (ng/mL): 0,01
TSH (mIU/L): 11,8
Urea (mg/dL): 6,91
LVEF (%): 50.0
Medications: Diabetes Medication, Amiodarone, Digoxin, Loop Diuretics, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"RANKING: 
1. Survivor
REASONING: 
Based on the patient's age, NYHA Class II, and the presence of valvular cardiomyopathy, hypertension, diabetes, and elevated creatinine levels, the patient is at risk for cardiovascular events. However, the patient's LVEF is 50%, which indicates significant left ventricular dysfunction. The absence of troponin elevation suggests that the patient does not have acute myocardial infarction. The ECG impression shows ventricular extrasystole, which is a benign finding. The patient's medications, including ACE inhibitors, are likely to be beneficial in managing hypertension and heart failure. The patient's high Pro-BNP level (114 ng/L) suggests some degree of cardiac stress, but it is not excessively elevated. 

Considering these factors, the patient's overall prognosis is that they are likely to survive for the next few years, as the patient's cardiovascular risk factors are not extremely high, and the patient is receiving appropriate medication. 

The patient's creatinine level is significantly elevated, indicating impaired renal function, which is a risk factor for cardiovascular disease and mortality. However, the patient's LVEF is not severely reduced, and the absence of other high-risk factors, such as heart failure or acute coronary syndrome, suggest that the patient may be able to tolerate certain treatments and lifestyle modifications. 

Therefore, while the patient is at risk for cardiovascular events, the likelihood of sudden cardiac death or pump failure death is not extremely high, making survival the most likely outcome.

2. Sudden Cardiac Death
REASONING: 
While the patient's NYHA Class II and valvular cardiomyopathy indicate some degree of cardiac dysfunction, the patient's LVEF is 50%, which is not severely reduced. The absence of troponin elevation and the presence of ACE inhibitors suggest that the patient is receiving appropriate treatment for heart failure. However, the patient's high blood pressure (155/80 mmHg), elevated creatinine levels, and high Pro-BNP level (114 ng/L) suggest that the patient is at risk for cardiovascular events. 

The patient's ECG impression shows ventricular extrasystole, which is a benign finding, but the patient's high blood pressure and elevated creatinine levels suggest that the patient may be at risk for cardiovascular events. While the patient is receiving medications that are likely to be beneficial in managing hypertension and heart failure, the patient's overall cardiovascular risk factors are not extremely low, making sudden cardiac death a possible but less likely outcome.

3. Pump Failure Death
REASONING: 
Given the patient's NYHA Class II, valvular cardiomyopathy, hypertension, diabetes, and elevated creatinine levels, the patient is at risk for heart failure. The patient's LVEF is 50%, which is significantly reduced, indicating that the patient's heart is not pumping efficiently. The patient's high Pro-BNP level (114 ng/L) suggests that the patient is experiencing cardiac stress. 

The patient's elevated creatinine levels and high blood pressure suggest that the patient's kidneys are not functioning well, which can further exacerbate cardiovascular disease. The patient's ECG impression shows ventricular extrasystole, which is a benign finding, but the patient's overall cardiovascular risk factors are high, making pump failure death a possible but less likely outcome compared to sudden cardiac death. 

However, considering the patient's significant left ventricular dysfunction and impaired renal function, the likelihood of pump failure death is higher than sudden cardiac death."
413,413,P0662,"Age: 61
Gender: Female 
Weight: 64 kg
Height: 142 cm
NYHA Class: II
Blood Pressure: 135/85 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Diabetes, Dyslipemia, Hypertension, Myocardial Infarction
Albumin (g/L): 43,9
ALT or GPT (IU/L): 15.0
AST or GOT (IU/L): 16.0
Total Cholesterol (mmol/L): 4,45
Creatinine (mmol/L): 97.0
Gamma-glutamil transpeptidase (IU/L): 18
Glucose (mmol/L): 8,3
Hemoglobin (g/L): 141.0
HDL (mmol/L): 1,11
Potassium (mEq/L): 4,1
LDL (mmol/L): 2,61
Sodium (mEq/L): 141.0
Pro-BNP (ng/L): 191.0
Protein (g/L): 77
T3 (pg/dL): 0,04
T4 (ng/L): 15
Troponin (ng/mL): 0,01
TSH (mIU/L): 1,95
Urea (mg/dL): 11,36
LVEF (%): 60.0
Medications: Diabetes Medication, Beta Blockers, Statins
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"RANKING: 
1. Survivor
REASONING: 
Based on the provided patient data, the patient is a 61-year-old female with a history of ischemic dilated cardiomyopathy, diabetes, dyslipidemia, hypertension, and myocardial infarction. Her NYHA class is II, indicating mild symptoms of heart failure. Her LVEF is 60.0%, which is within the range of moderate heart failure. Despite these factors, the patient's current ECG impression does not show any signs of ventricular tachycardia, non-sustained ventricular tachycardia, or other arrhythmias that could indicate a high risk of sudden cardiac death. The patient is also taking medications for diabetes and hypertension, which suggests that she is receiving appropriate management for her comorbid conditions. Additionally, her biomarkers, such as troponin and BNP, are not significantly elevated, indicating no acute myocardial injury or stress. Overall, these factors suggest that the patient is likely to survive in the short-term."
414,414,P0663,"Age: 66
Gender: Male 
Weight: 117 kg
Height: 178 cm
NYHA Class: II
Blood Pressure: 160/105 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Dyslipemia, Hypertension, Myocardial Infarction
Albumin (g/L): 45,59
ALT or GPT (IU/L): 29.0
AST or GOT (IU/L): 21.0
Total Cholesterol (mmol/L): 4,55
Creatinine (mmol/L): 99.0
Gamma-glutamil transpeptidase (IU/L): 55
Glucose (mmol/L): 10,3
Hemoglobin (g/L): 156.0
HDL (mmol/L): 1,01
Potassium (mEq/L): 4,2
LDL (mmol/L): 2,79
Sodium (mEq/L): 146.0
Pro-BNP (ng/L): 419.0
Protein (g/L): 75
T3 (pg/dL): 0,05
T4 (ng/L): 14
Troponin (ng/mL): 0,01
TSH (mIU/L): 2,79
Urea (mg/dL): 8,02
LVEF (%): 50.0
Medications: ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: TPSV
        - Bradycardia: No
            ",survivor,"RANKING: 

1. Survivor
REASONING: 
The patient's overall clinical presentation and test results indicate a stable but compromised cardiac condition. The patient has a history of ischemic dilated cardiomyopathy, hypertension, and previous myocardial infarction, which suggests a high risk of adverse cardiac events. However, the patient is currently on an ACE inhibitor, which is a standard treatment for heart failure and hypertension. The presence of ventricular extrasystole on the ECG is a significant finding, but it is not a high-risk arrhythmia. The patient's LVEF is 50%, which is within the range for a patient with a history of heart failure.

The patient's laboratory results show elevated creatinine levels, indicating some degree of renal impairment, which can be a consequence of heart failure. However, the patient's electrolyte levels, including potassium, sodium, and glucose, are within relatively normal limits. The patient's troponin levels are also within the normal range, which suggests that there is no acute myocardial infarction.

Given these factors, the patient's prognosis is relatively good, and with continued medical management, it is likely that the patient will survive for the next few years.

2. Pump failure death
REASONING: 
While the patient's current condition is compromised, the presence of a history of heart failure and elevated LVEF of 50% suggests that the patient is already experiencing some degree of cardiac dysfunction. The patient's renal impairment and elevated creatinine levels increase the risk of cardiac pump failure. Additionally, the patient's ventricular extrasystole on the ECG is a significant finding, which may indicate some degree of cardiac instability.

However, the patient is currently on an ACE inhibitor, which can help to slow the progression of heart failure. The patient's laboratory results are not showing any acute signs of cardiac damage or acute myocardial infarction.

Given these factors, the patient's prognosis is still relatively good, but the risk of cardiac pump failure is higher than for a survivor. If the patient's condition does not improve with continued medical management, pump failure could become a significant concern.

3. Sudden cardiac death
REASONING: 
The patient's history of ischemic dilated cardiomyopathy, previous myocardial infarction, and elevated LVEF of 50% increase the risk of sudden cardiac death. The presence of ventricular extrasystole on the ECG is a significant finding, which suggests that the patient's heart is experiencing some degree of cardiac instability.

However, the patient is currently on an ACE inhibitor, which can help to reduce the risk of sudden cardiac death. The patient's laboratory results are not showing any acute signs of cardiac damage or acute myocardial infarction.

Given these factors, the patient's prognosis is less favorable, and the risk of sudden cardiac death is higher than for a survivor or pump failure. However, the patient's overall condition is still relatively stable, and with continued medical management, the risk of sudden cardiac death can be mitigated."
415,415,P0664,"Age: 59
Gender: Male 
Weight: 105 kg
Height: 172 cm
NYHA Class: III
Blood Pressure: 120/80 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Diabetes, Dyslipemia, Hypertension, Myocardial Infarction
Albumin (g/L): 38,1
ALT or GPT (IU/L): 20.0
AST or GOT (IU/L): 22.0
Total Cholesterol (mmol/L): 5,46
Creatinine (mmol/L): 102.0
Gamma-glutamil transpeptidase (IU/L): 24
Glucose (mmol/L): 11,2
Hemoglobin (g/L): 152.0
HDL (mmol/L): 0,96
Potassium (mEq/L): 4,4
LDL (mmol/L): 2,64
Sodium (mEq/L): 138.0
Pro-BNP (ng/L): 135.0
Protein (g/L): 73
T3 (pg/dL): 0,04
T4 (ng/L): 14
Troponin (ng/mL): 0,01
TSH (mIU/L): 3,56
Urea (mg/dL): 12,03
LVEF (%): 22.0
Medications: Diabetes Medication, Beta Blockers, Loop Diuretics, Spironolactone, ACE Inhibitor, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"RANKING: 1. Survivor
REASONING: 
The patient has a complex medical history with multiple comorbidities, including ischemic dilated cardiomyopathy, diabetes, dyslipemia, hypertension, and myocardial infarction. However, despite these factors, the patient is currently taking multiple medications, including beta blockers, ACE inhibitors, and loop diuretics, which are commonly used to manage these conditions. The patient's current NYHA class is III, indicating significant heart failure symptoms. However, the patient's LVEF is 22.0, which is within a range that is not typically associated with a poor prognosis.

The patient's ECG impression shows no evidence of ventricular tachycardia or non-sustained ventricular tachycardia, which are indicators of a more severe cardiac arrhythmia. The presence of ventricular extrasystole is a common finding in patients with heart failure, but it is not necessarily a predictor of adverse outcomes.

The patient's laboratory results, including low albumin levels and elevated creatinine, are consistent with heart failure and chronic kidney disease. However, the patient's hemoglobin and potassium levels are within normal limits, and the patient is taking medications that are designed to manage these conditions.

Given the patient's complex medical history and the presence of heart failure, it is likely that the patient will survive for at least the next few years, provided that the patient continues to take their medications as prescribed and makes lifestyle changes to manage their comorbidities. The patient's LVEF is not low enough to indicate a high risk of pump failure, and the absence of ventricular tachycardia or other arrhythmias on the ECG suggests that the patient's cardiac function is stable.

RANKING: 2. Sudden cardiac death
REASONING: 
While the patient has a complex medical history and multiple comorbidities, the patient's current ECG impression shows no evidence of ventricular tachycardia or non-sustained ventricular tachycardia, which are common precursors to sudden cardiac death. However, the patient's LVEF is only 22.0, which is below the normal range for a healthy individual. A low LVEF is a risk factor for sudden cardiac death.

The patient's laboratory results show elevated creatinine levels, which may indicate chronic kidney disease and heart failure. However, the patient is taking medications that are designed to manage these conditions, including ACE inhibitors and loop diuretics. The patient's hemoglobin and potassium levels are within normal limits, which suggests that the patient is not at high risk for acute kidney injury or cardiac arrhythmias.

While the patient's past medical history includes myocardial infarction, the patient is currently taking beta blockers, which are commonly used to reduce the risk of cardiac arrhythmias and sudden cardiac death. However, the patient's NYHA class is III, indicating significant heart failure symptoms, which may increase the risk of sudden cardiac death.

Given the patient's complex medical history and low LVEF, it is possible that the patient may experience sudden cardiac death in the next few years, but this is less likely than pump failure.

RANKING: 3. Pump failure death
REASONING: 
The patient's low LVEF of 22.0 is a significant risk factor for pump failure, which is the most likely cause of death in patients with heart failure. The patient's NYHA class is III, indicating significant heart failure symptoms, and the patient is taking medications that are designed to manage heart failure, including ACE inhibitors and loop diuretics.

The patient's laboratory results show elevated creatinine levels, which may indicate chronic kidney disease and heart failure. The patient's hemoglobin and potassium levels are within normal limits, which suggests that the patient is not at high risk for acute kidney injury or cardiac arrhythmias.

The patient's ECG impression shows ventricular extrasystole, which is a common finding in patients with heart failure. However, the absence of ventricular tachycardia or non-sustained ventricular tachycardia on the ECG suggests that the patient's cardiac function is stable.

Given the patient's complex medical history, low LVEF, and significant heart failure symptoms, it is likely that the patient will experience pump failure in the next few years, making this the most likely cause of death."
416,416,P0666,"Age: 71
Gender: Female 
Weight: 86 kg
Height: 147 cm
NYHA Class: III
Blood Pressure: 150/85 mmHg
Past Medical History: Hypertropic cardiomyopathy, Dyslipemia, Hypertension, Myocardial Infarction
Albumin (g/L): 43,2
ALT or GPT (IU/L): 12.0
AST or GOT (IU/L): 19.0
Total Cholesterol (mmol/L): 6,85
Creatinine (mmol/L): 272.0
Gamma-glutamil transpeptidase (IU/L): 15
Glucose (mmol/L): 4,9
Hemoglobin (g/L): 130.0
HDL (mmol/L): 1,73
Potassium (mEq/L): 4,7
LDL (mmol/L): 4,32
Sodium (mEq/L): 140.0
Pro-BNP (ng/L): 2627.0
Protein (g/L): 74
T3 (pg/dL): 0,04
T4 (ng/L): 14
Troponin (ng/mL): 0,06
TSH (mIU/L): 2,06
Urea (mg/dL): 31,4
LVEF (%): 65.0
Medications: Calcium Channel Blocker, Beta Blockers, Loop Diuretics, Statins
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",survivor,"RANKING: 1. Survivor
REASONING: 

Based on the provided patient data, the patient is a 71-year-old female with a history of hypertension, myocardial infarction, and cardiomyopathy, presenting with a NYHA Class III status. The patient's current ECG shows ventricular extrasystoles, which is a significant finding indicating an increased risk of arrhythmias. However, the absence of ventricular tachycardia and non-sustained ventricular tachycardia suggests that the patient is not at an immediate high risk of sudden cardiac death.

The patient's elevated creatinine level (272.0 mmol/L) and low LVEF (65.0%) indicate compromised renal function and reduced cardiac performance, respectively. Despite these findings, the patient is on multiple medications, including beta blockers, loop diuretics, and statins, which are commonly used to manage cardiovascular risk factors.

The patient's Pro-BNP level (2627.0 ng/L) is elevated, indicating possible heart failure with reduced ejection fraction (HFrEF). However, the patient's overall clinical presentation, including the absence of symptoms, does not strongly suggest acute heart failure.

Given the patient's age, comorbidities, and current ECG findings, the most likely outcome over the next few years is a survivor, with a reasonable quality of life despite the presence of compromised cardiac function. While the patient is at risk of cardiovascular events, the presence of multiple medications and the absence of acute symptoms suggest that the patient can be managed effectively with close monitoring and adjustments to their treatment plan.

The probability of sudden cardiac death (2-3%) is relatively low, given the absence of ventricular tachycardia and non-sustained ventricular tachycardia on the ECG. The probability of pump failure death (10-20%) is moderate, given the patient's compromised LVEF and elevated creatinine level. However, the patient's overall clinical presentation and the presence of multiple medications suggest that pump failure can be managed with close monitoring and adjustments to their treatment plan.

In conclusion, the most likely outcome for this patient over the next few years is a survivor, with a reasonable quality of life despite compromised cardiac function. The probability of sudden cardiac death and pump failure death is relatively low, but not negligible, and will require close monitoring and adjustments to the treatment plan to mitigate these risks."
417,417,P0668,"Age: 67
Gender: Female 
Weight: 70 kg
Height: 146 cm
NYHA Class: II
Blood Pressure: 150/80 mmHg
Past Medical History: Hypertensive cardiomyopathy, Diabetes, Dyslipemia, Peripheral vascular disease, Hypertension
Albumin (g/L): 45,7
ALT or GPT (IU/L): 24.0
AST or GOT (IU/L): 23.0
Total Cholesterol (mmol/L): 5,87
Creatinine (mmol/L): 96.0
Gamma-glutamil transpeptidase (IU/L): 45
Glucose (mmol/L): 7
Hemoglobin (g/L): 125.0
HDL (mmol/L): 1,14
Potassium (mEq/L): 4,2
LDL (mmol/L): 2,77
Sodium (mEq/L): 144.0
Pro-BNP (ng/L): 1356.0
Protein (g/L): 77
T3 (pg/dL): 0,05
T4 (ng/L): 17
Troponin (ng/mL): 0,01
TSH (mIU/L): 2,39
Urea (mg/dL): 14,92
LVEF (%): 68.0
Medications: Calcium Channel Blocker, Beta Blockers, Loop Diuretics, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: TPSV
        - Bradycardia: No
            ",survivor,"RANKING: 1. Survivor
REASONING: 
Based on the patient's age, NYHA Class II, and the presence of multiple comorbidities (hypertensive cardiomyopathy, diabetes, dyslipemia, and peripheral vascular disease), the patient is at high risk for cardiovascular events. However, the patient's current LVEF of 68.0 is not severely impaired, which suggests that the patient's heart is still functioning relatively well. The absence of troponin elevation and the relatively low levels of pro-BNP (1356.0 ng/L) also indicate that the patient does not have significant heart failure. Additionally, the patient's ECG shows no signs of ventricular tachycardia, which is a significant risk factor for sudden cardiac death. The patient's medication regimen, which includes beta blockers, ACE inhibitors, and a calcium channel blocker, suggests that the patient is receiving optimal management for their cardiovascular conditions. Overall, these factors suggest that the patient has a good prognosis and is likely to survive for the next few years."
418,418,P0669,"Age: 80
Gender: Male 
Weight: 74 kg
Height: 162 cm
NYHA Class: II
Blood Pressure: 130/70 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Diabetes, Peripheral vascular disease, Myocardial Infarction
Albumin (g/L): 43,1
ALT or GPT (IU/L): 22.0
AST or GOT (IU/L): 20.0
Total Cholesterol (mmol/L): 4,4
Creatinine (mmol/L): 138.0
Gamma-glutamil transpeptidase (IU/L): 24
Glucose (mmol/L): 5,9
Hemoglobin (g/L): 124.0
HDL (mmol/L): 1,06
Potassium (mEq/L): 5,4
LDL (mmol/L): 2,77
Sodium (mEq/L): 140.0
Pro-BNP (ng/L): 901.0
Protein (g/L): 78,3
T4 (ng/L): 16
TSH (mIU/L): 7,12
Urea (mg/dL): 15,64
LVEF (%): 40.0
Medications: Diabetes Medication, Amiodarone, Loop Diuretics, Spironolactone, Statins, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: No
            ",survivor,"RANKING: 1. Survivor
REASONING: 

Based on the patient's data, I predict that the patient is most likely to survive for the next few years. The patient's age is 80, but the presence of NYHA Class II heart failure and LVEF of 40.0 suggests that the patient has significant cardiac dysfunction. However, the patient's blood pressure is within a relatively normal range (130/70 mmHg), and they are not experiencing acute cardiovascular events such as ventricular tachycardia or myocardial infarction.

The patient's past medical history of ischemic dilated cardiomyopathy, diabetes, peripheral vascular disease, and myocardial infarction suggests that they have a high burden of cardiovascular risk factors. However, the patient is already taking multiple medications for these conditions, including amiodarone, spironolactone, and statins, which suggests that the patient is receiving adequate management for their cardiovascular risk factors.

The elevated creatinine level (138.0 mmol/L) and elevated LVEF (40.0) suggest that the patient's kidneys are not functioning optimally, and the patient may have some degree of chronic kidney disease. However, the patient's protein level (78.3 g/L) is within a relatively normal range, which suggests that the patient is not experiencing significant malnutrition.

The patient's ECG impression shows ventricular extrasystoles, which may indicate some degree of ventricular dysfunction. However, the absence of ventricular tachycardia or paroxysmal supraventricular tachyarrhythmia suggests that the patient is not experiencing a high risk of arrhythmias.

Overall, while the patient has a significant burden of cardiovascular risk factors and cardiac dysfunction, the patient's multiple medications and relatively stable vital signs suggest that they are receiving adequate management for their conditions. Therefore, I predict that the patient is most likely to survive for the next few years.

RANKING: 2. Sudden cardiac death
REASONING: 

While the patient is not at the highest risk for sudden cardiac death, they do have a history of myocardial infarction and peripheral vascular disease, which increases their risk for sudden cardiac death. The patient's LVEF is also significantly reduced, which may increase their risk for sudden cardiac death.

However, the patient's age and NYHA Class II heart failure suggest that the patient may not have a high risk for sudden cardiac death. The patient's ECG impression shows ventricular extrasystoles, which may increase their risk for sudden cardiac death, but the absence of ventricular tachycardia or paroxysmal supraventricular tachyarrhythmia suggests that the patient is not experiencing a high risk for arrhythmias.

Additionally, the patient's multiple medications, including amiodarone, which is a class III antiarrhythmic agent, suggest that the patient is receiving adequate management for their cardiovascular risk factors.

RANKING: 3. Pump failure death
REASONING: 

While the patient has a significant burden of cardiovascular risk factors and cardiac dysfunction, the patient's NYHA Class II heart failure and LVEF of 40.0 suggest that the patient is experiencing some degree of pump failure. However, the patient's blood pressure is within a relatively normal range (130/70 mmHg), and the patient is taking multiple medications for their cardiovascular risk factors, which suggests that the patient is receiving adequate management for their conditions.

The patient's elevated creatinine level (138.0 mmol/L) and elevated LVEF (40.0) suggest that the patient's kidneys and heart are not functioning optimally, which may increase their risk for pump failure. However, the patient's protein level (78.3 g/L) is within a relatively normal range, which suggests that the patient is not experiencing significant malnutrition.

The patient's ECG impression shows ventricular extrasystoles, which may increase their risk for pump failure. However, the absence of ventricular tachycardia or paroxysmal supraventricular tachyarrhythmia suggests that the patient is not experiencing a high risk for arrhythmias.

Overall, while the patient has a significant burden of cardiovascular risk factors and cardiac dysfunction, the patient's multiple medications and relatively stable vital signs suggest that they are receiving adequate management for their conditions. Therefore, while pump failure is a possible outcome, it is not the most likely outcome for this patient."
419,419,P0670,"Age: 75
Gender: Female 
Weight: 73 kg
Height: 154 cm
NYHA Class: II
Blood Pressure: 150/80 mmHg
Past Medical History: Hypertropic cardiomyopathy, Diabetes, Dyslipemia, Hypertension
Albumin (g/L): 44,8
ALT or GPT (IU/L): 26.0
AST or GOT (IU/L): 21.0
Total Cholesterol (mmol/L): 4,99
Creatinine (mmol/L): 77.0
Gamma-glutamil transpeptidase (IU/L): 67
Glucose (mmol/L): 9,7
Hemoglobin (g/L): 117.0
HDL (mmol/L): 1,42
Potassium (mEq/L): 4,6
LDL (mmol/L): 2,79
Sodium (mEq/L): 142.0
Pro-BNP (ng/L): 359.0
Protein (g/L): 69,7
T4 (ng/L): 17
TSH (mIU/L): 1,28
Urea (mg/dL): 6,99
LVEF (%): 40.0
Medications: Diabetes Medication, Angiotensin II Receptor Blocker, Loop Diuretics, Statins, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"RANKING: 
1. Survivor
REASONING:
Based on the patient's age (75), NYHA Class II, and the presence of multiple comorbidities such as hypertension, dyslipidemia, and diabetes, the patient is already at an increased risk for cardiovascular events. However, the patient's LVEF is 40%, which indicates a significant reduction in cardiac function, suggesting left ventricular dysfunction. The presence of elevated Pro-BNP levels (359.0 ng/L) and elevated Creatinine (6.99 mg/dL) levels also suggest a decline in renal function. 

Despite these factors, the patient is currently on medications that are aimed at managing these conditions, including an ACE Inhibitor, which is beneficial for heart failure patients. The absence of ventricular extrasystoles, ventricular tachycardia, and non-sustained ventricular tachycardia on the ECG suggests that the patient does not have any acute cardiac arrhythmias that could lead to sudden cardiac death.

Given these factors, the most likely prognosis is that the patient will survive for the next few years. However, it is essential to closely monitor the patient's condition and adjust the treatment plan as needed to manage the comorbidities and prevent further decline in cardiac function.

RANKING: 
2. Sudden Cardiac Death
REASONING:
The presence of ventricular extrasystoles on the ECG, despite the absence of ventricular tachycardia or non-sustained ventricular tachycardia, is a concerning sign. Ventricular extrasystoles can be a marker for increased risk of sudden cardiac death. Additionally, the patient's age and comorbidities make them more susceptible to cardiac arrhythmias. Although the patient is on medications that are aimed at managing these conditions, the presence of ventricular extrasystoles increases the risk of sudden cardiac death.

RANKING: 
3. Pump Failure Death
REASONING:
The patient's LVEF is significantly reduced (40%), indicating left ventricular dysfunction, and the presence of elevated Pro-BNP levels and elevated Creatinine levels suggest a decline in renal function. These factors, combined with the patient's comorbidities, increase the risk of heart failure. However, the patient is currently on medications that are aimed at managing heart failure, including an ACE Inhibitor. While the risk of pump failure is increased, the presence of medications and the absence of other indicators of acute cardiac dysfunction make pump failure death less likely compared to sudden cardiac death."
420,420,P0672,"Age: 70
Gender: Female 
Weight: 66 kg
Height: 150 cm
NYHA Class: II
Blood Pressure: 110/75 mmHg
Past Medical History: Ischemic dilated cardiomyopathy
Albumin (g/L): 42,5
ALT or GPT (IU/L): 14.0
AST or GOT (IU/L): 17.0
Total Cholesterol (mmol/L): 4,84
Creatinine (mmol/L): 72.0
Gamma-glutamil transpeptidase (IU/L): 23
Glucose (mmol/L): 6,6
Hemoglobin (g/L): 130.0
HDL (mmol/L): 1,55
Potassium (mEq/L): 4,7
LDL (mmol/L): 2,87
Sodium (mEq/L): 139.0
Pro-BNP (ng/L): 824.0
Protein (g/L): 69,7
T4 (ng/L): 16
TSH (mIU/L): 3,09
Urea (mg/dL): 5,99
LVEF (%): 35.0
Medications: Diabetes Medication, Statins, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"RANKING: 1. Survivor
REASONING: 

This patient is a 70-year-old female with a history of ischemic dilated cardiomyopathy, which is a significant risk factor for cardiac events. Her left ventricular ejection fraction (LVEF) is severely impaired at 35%, indicating poor cardiac function. Despite this, her blood pressure is well-controlled at 110/75 mmHg, and she is on medications for diabetes and high cholesterol, which suggests that she is being managed for her comorbid conditions.

Her liver enzymes (ALT and AST) are mildly elevated, which could be indicative of some degree of liver dysfunction, but this is not uncommon in patients with heart failure. Her renal function is also slightly impaired, with elevated creatinine levels, but this is not uncommon in patients with heart failure.

The ECG findings are notable for ventricular extrasystoles, which can be a marker of cardiac stress or strain. However, there is no evidence of ventricular tachycardia or other arrhythmias that would suggest a high risk of sudden cardiac death.

Given these factors, I would rank the patient as a survivor. While she has a significant underlying heart condition, her overall clinical presentation and management of comorbidities suggest that she is likely to survive the next few years. However, it is essential to closely monitor her condition and adjust her medications and treatment plan as needed to minimize the risk of cardiac events.

RANKING: 2. Sudden cardiac death
REASONING: 

This patient has a high risk of sudden cardiac death due to her history of ischemic dilated cardiomyopathy, which is a significant risk factor for arrhythmias and sudden cardiac death. Her LVEF is severely impaired, and her ECG findings of ventricular extrasystoles suggest cardiac stress or strain.

Additionally, her elevated Pro-BNP levels indicate that she has a high burden of cardiac stress, which can contribute to arrhythmias and sudden cardiac death. While her blood pressure is well-controlled, her renal function is slightly impaired, which can increase the risk of cardiac complications.

Given these factors, I would rank this patient as a candidate for sudden cardiac death, but only if she experiences a cardiac event or if her condition worsens over time.

RANKING: 3. Pump failure death
REASONING: 

This patient has a significant risk of pump failure death due to her history of ischemic dilated cardiomyopathy, which can lead to progressive heart failure. Her LVEF is severely impaired, and her elevated Pro-BNP levels indicate a high burden of cardiac stress.

However, her overall clinical presentation and management of comorbidities suggest that she is not in immediate danger of pump failure. Her blood pressure is well-controlled, and she is on medications for diabetes and high cholesterol, which suggests that she is being managed for her comorbid conditions.

Additionally, her ECG findings of ventricular extrasystoles suggest cardiac stress or strain, but there is no evidence of ventricular tachycardia or other arrhythmias that would suggest a high risk of pump failure.

Given these factors, I would rank this patient as a candidate for pump failure death, but only if her condition worsens over time and she experiences a significant decline in cardiac function."
421,421,P0673,"Age: 79
Gender: Female 
Weight: 70 kg
Height: 160 cm
NYHA Class: II
Blood Pressure: 150/85 mmHg
Past Medical History: Hypertensive cardiomyopathy, Dyslipemia, Hypertension
Albumin (g/L): 45,2
ALT or GPT (IU/L): 13.0
AST or GOT (IU/L): 15.0
Total Cholesterol (mmol/L): 4,97
Creatinine (mmol/L): 60.0
Gamma-glutamil transpeptidase (IU/L): 12
Glucose (mmol/L): 5,9
Hemoglobin (g/L): 133.0
HDL (mmol/L): 1,99
Potassium (mEq/L): 3,6
LDL (mmol/L): 2,56
Sodium (mEq/L): 143.0
Pro-BNP (ng/L): 58.0
Protein (g/L): 68,9
T4 (ng/L): 15
TSH (mIU/L): 1,63
Urea (mg/dL): 4,99
LVEF (%): 67.0
Medications: Calcium Channel Blocker, Beta Blockers, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: TPSV
        - Bradycardia: No
            ",survivor,"RANKING: 
1. Survivor
REASONING: 
Based on the patient's age, NYHA Class II, and LVEF of 67%, which indicates some left ventricular dysfunction, the patient is at risk for cardiac events. However, the absence of significant ECG abnormalities such as ventricular tachycardia, non-sustained ventricular tachycardia, or severe bradycardia reduces the likelihood of sudden cardiac death. The patient is also on medications that are standard for managing hypertension, heart failure, and arrhythmias, which suggests a relatively well-managed condition. Furthermore, the patient's biomarker levels, such as the elevated creatinine, do not suggest severe kidney dysfunction, which is a common cause of mortality in patients with heart failure. Overall, the combination of a relatively well-managed condition, normal biomarker levels, and the absence of severe ECG abnormalities make a survivor outcome the most likely.

2. Pump failure death
REASONING: 
While the patient has NYHA Class II heart failure, the LVEF is still 67%, indicating some preserved left ventricular function. Additionally, the patient is on medications that are standard for managing heart failure, which suggests a relatively well-managed condition. However, the elevated creatinine level and the patient's age increase the risk of pump failure. Furthermore, the patient's biomarker levels, such as the elevated creatinine, do not suggest severe kidney dysfunction, which is a common cause of pump failure. However, the combination of these factors, along with the patient's age and NYHA Class II heart failure, make pump failure a possible outcome.

3. Sudden cardiac death
REASONING: 
The patient's ECG impression shows ventricular extrasystoles, which are a type of arrhythmia that can increase the risk of sudden cardiac death. However, the absence of ventricular tachycardia, non-sustained ventricular tachycardia, or severe bradycardia reduces the likelihood of sudden cardiac death. Additionally, the patient's biomarker levels, such as the elevated creatinine, do not suggest severe kidney dysfunction, which is a common cause of sudden cardiac death. Furthermore, the patient is on medications that are standard for managing arrhythmias, which suggests a relatively well-managed condition. However, the presence of ventricular extrasystoles and the patient's age increase the risk of sudden cardiac death, making it a possible but less likely outcome compared to pump failure."
422,422,P0674,"Age: 66
Gender: Male 
Weight: 71 kg
Height: 167 cm
NYHA Class: II
Blood Pressure: 160/90 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Dyslipemia, Hypertension, Myocardial Infarction
Albumin (g/L): 44,5
ALT or GPT (IU/L): 25.0
AST or GOT (IU/L): 26.0
Total Cholesterol (mmol/L): 6,52
Creatinine (mmol/L): 95.0
Gamma-glutamil transpeptidase (IU/L): 37
Glucose (mmol/L): 5,3
Hemoglobin (g/L): 168.0
HDL (mmol/L): 1,42
Potassium (mEq/L): 4,4
LDL (mmol/L): 4,03
Sodium (mEq/L): 140.0
Pro-BNP (ng/L): 209.0
Protein (g/L): 71,3
T4 (ng/L): 12
TSH (mIU/L): 1,1
Urea (mg/dL): 5,99
LVEF (%): 35.0
Medications: Loop Diuretics, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"RANKING: 

1. Survivor
REASONING: 
This patient's prognosis is ranked as a survivor due to the presence of a significant amount of medications that are commonly used to treat heart failure and hypertension, such as loop diuretics and ACE inhibitors. The patient's NYHA Class II indicates that they have some symptoms of heart failure, but they are still able to perform moderate physical activity without severe symptoms. The patient's LVEF of 35.0 is low, indicating left ventricular dysfunction, but it is not severely impaired.

The patient's laboratory results also suggest that they have some underlying kidney dysfunction (elevated creatinine and urea levels), which may be contributing to their heart failure symptoms. However, the patient's kidney function is not severely impaired, and the patient is receiving medications to manage their hypertension and heart failure.

The patient's ECG results show some signs of arrhythmia, including ventricular extrasystoles, but these are not sustained or life-threatening. The patient's other ECG results are normal, and there is no evidence of ventricular tachycardia or bradycardia.

Given these factors, the patient's prognosis is likely to be a survivor, with some limitations due to their heart failure and kidney dysfunction. However, with appropriate management and lifestyle modifications, the patient may be able to maintain a good quality of life and avoid more severe outcomes.

2. Sudden Cardiac Death
REASONING: 
This patient's prognosis is ranked as sudden cardiac death due to the presence of significant risk factors for arrhythmias, including ventricular extrasystoles and a history of myocardial infarction. The patient's LVEF of 35.0 is significantly impaired, indicating left ventricular dysfunction, which increases the risk of arrhythmias and sudden cardiac death.

The patient's ECG results show ventricular extrasystoles, which can be a precursor to more serious arrhythmias. The patient's other ECG results are normal, but the presence of ventricular extrasystoles is a significant concern.

The patient's laboratory results also suggest that they have some underlying kidney dysfunction, which can contribute to an increased risk of arrhythmias and sudden cardiac death. However, the patient is receiving medications to manage their hypertension and heart failure, which may help to mitigate some of these risks.

Given these factors, the patient's prognosis is ranked as sudden cardiac death, with a significant risk of arrhythmias and sudden cardiac death in the near future.

3. Pump Failure Death
REASONING: 
This patient's prognosis is ranked as pump failure death due to the patient's significant left ventricular dysfunction (LVEF of 35.0) and the presence of heart failure symptoms (NYHA Class II). The patient's kidney dysfunction (elevated creatinine and urea levels) also suggests that their heart failure may be contributing to their kidney dysfunction.

The patient's laboratory results also suggest that they have some underlying liver dysfunction (elevated ALT and AST levels), which can contribute to heart failure and kidney dysfunction. However, the patient is receiving medications to manage their hypertension and heart failure, which may help to mitigate some of these risks.

Given the patient's significant left ventricular dysfunction and heart failure symptoms, the patient's prognosis is ranked as pump failure death, with a high risk of worsening heart failure and kidney dysfunction in the near future."
423,423,P0675,"Age: 55
Gender: Male 
Weight: 74 kg
Height: 158 cm
NYHA Class: II
Blood Pressure: 140/75 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Dyslipemia, Hypertension, Myocardial Infarction
Albumin (g/L): 38
ALT or GPT (IU/L): 16.0
AST or GOT (IU/L): 17.0
Total Cholesterol (mmol/L): 5,34
Creatinine (mmol/L): 79.0
Gamma-glutamil transpeptidase (IU/L): 25
Glucose (mmol/L): 5,39
Hemoglobin (g/L): 121.0
HDL (mmol/L): 2,4
Potassium (mEq/L): 4,96
LDL (mmol/L): 2,75
Sodium (mEq/L): 140.0
Pro-BNP (ng/L): 447.0
Protein (g/L): 69
T3 (pg/dL): 0,03
T4 (ng/L): 12,72
Troponin (ng/mL): 0,3
TSH (mIU/L): 0,38
Urea (mg/dL): 4,2
LVEF (%): 50.0
Medications: Beta Blockers, Statins, ACE Inhibitor, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: TPSV
        - Bradycardia: No
            ",survivor,"RANKING: 1. Survivor
REASONING:

Based on the provided patient data, the patient is at high risk for cardiac-related events. The patient has a history of ischemic dilated cardiomyopathy, hypertension, and myocardial infarction, which are all risk factors for cardiac complications. The patient's current NYHA Class II indicates moderate symptoms, and the LVEF of 50% suggests reduced cardiac function.

The patient's laboratory results show elevated troponin levels (0.3 ng/mL), which is indicative of cardiac damage. The elevated Pro-BNP level (447 ng/L) suggests increased ventricular wall stress and is a marker for heart failure. The patient's renal function is also compromised, with a creatinine level of 79.0 mol/L, which may be related to cardiac dysfunction.

Despite the presence of these risk factors and laboratory abnormalities, the patient is currently on beta blockers, statins, and an ACE inhibitor, which are standard treatments for managing hypertension, dyslipidemia, and heart failure. The patient's ECG findings, while showing some arrhythmias, do not indicate a high risk for sudden cardiac death.

Considering these factors, the patient's prognosis is likely to be a survivor, but with a high risk of cardiac-related complications in the near future. Regular monitoring and close follow-up with the cardiologist are essential to adjust the treatment plan and prevent potential cardiac events.

RANKING: 2. Sudden Cardiac Death
REASONING: While the patient's risk for cardiac-related events is high, the presence of beta blockers, statins, and an ACE inhibitor suggests that the patient is receiving standard treatments for managing cardiovascular risk factors. The ECG findings, although showing some arrhythmias, do not indicate a high risk for sudden cardiac death.

RANKING: 3. Pump Failure Death
REASONING: The patient's LVEF of 50% and elevated Pro-BNP level (447 ng/L) suggest a high risk for heart failure. However, the patient is currently on treatment with beta blockers, statins, and an ACE inhibitor, which are standard treatments for managing heart failure. While the patient's renal function is compromised, it is not directly related to heart failure.

The patient's overall prognosis is less likely to be pump failure death, as the patient is receiving appropriate treatment for heart failure and has not shown any signs of acute heart failure symptoms. However, close monitoring and regular follow-up with the cardiologist are essential to adjust the treatment plan and prevent potential complications."
424,424,P0676,"Age: 67
Gender: Male 
Weight: 79 kg
Height: 163 cm
NYHA Class: III
Blood Pressure: 165/85 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Diabetes, Dyslipemia, Peripheral vascular disease, Hypertension, Myocardial Infarction
Albumin (g/L): 40,9
ALT or GPT (IU/L): 20.0
AST or GOT (IU/L): 17.0
Total Cholesterol (mmol/L): 5,35
Creatinine (mmol/L): 158.0
Gamma-glutamil transpeptidase (IU/L): 50
Glucose (mmol/L): 6,7
Hemoglobin (g/L): 149.0
HDL (mmol/L): 1,16
Potassium (mEq/L): 4,5
LDL (mmol/L): 2,95
Sodium (mEq/L): 139.0
Pro-BNP (ng/L): 2034.0
Protein (g/L): 74
T3 (pg/dL): 0,05
T4 (ng/L): 14
Troponin (ng/mL): 0,02
TSH (mIU/L): 1,62
Urea (mg/dL): 8,02
LVEF (%): 39.0
Medications: Calcium Channel Blocker, Loop Diuretics, Statins, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"RANKING: 1. Survivor
REASONING: 

This patient has a complex medical history with multiple comorbidities, including ischemic dilated cardiomyopathy, diabetes, dyslipemia, peripheral vascular disease, hypertension, and myocardial infarction. The patient's ejection fraction (LVEF) is significantly reduced at 39%, indicating poor cardiac function. However, the patient is currently on medications for these conditions, including ACE inhibitors, statins, and loop diuretics, which are standard treatments for managing heart failure and hypertension.

The patient's ECG impression does not show any life-threatening arrhythmias, which reduces the risk of sudden cardiac death. The troponin level is also normal, indicating no acute myocardial injury. The patient's renal function is mildly impaired, as indicated by a creatinine level of 158.0 mmol/L, but this is not severe.

Given the patient's age (67) and the presence of multiple comorbidities, the risk of sudden cardiac death is higher. However, the patient's current medical management and the absence of life-threatening arrhythmias and acute myocardial injury suggest that the patient is likely to survive for the next few years.

While the patient's LVEF is severely impaired, the patient's current medications and the absence of other indicators of poor prognosis (such as high BNP levels or significant renal impairment) suggest that the patient may be able to tolerate treatment and improve slightly. Therefore, the most likely outcome is survival.

RANKING: 2. Sudden cardiac death
REASONING: 

The patient's LVEF is severely impaired at 39%, which increases the risk of sudden cardiac death. The patient's age (67) and multiple comorbidities (ischemic dilated cardiomyopathy, diabetes, dyslipemia, peripheral vascular disease, hypertension, and myocardial infarction) also increase the risk of sudden cardiac death.

The patient's ECG impression does not show any life-threatening arrhythmias, but the presence of ventricular extrasystoles may indicate some level of cardiac instability. The patient's troponin level is normal, but the patient's LVEF is severely impaired, which may indicate some level of myocardial damage.

Given the patient's severe cardiac dysfunction, multiple comorbidities, and the presence of ventricular extrasystoles, the risk of sudden cardiac death is higher than the risk of survival. However, the patient's current medical management and the absence of other indicators of poor prognosis suggest that the risk is not extremely high.

RANKING: 3. Pump failure death
REASONING: 

The patient's LVEF is severely impaired at 39%, which indicates significant cardiac dysfunction. The patient's multiple comorbidities, including ischemic dilated cardiomyopathy, diabetes, dyslipemia, peripheral vascular disease, hypertension, and myocardial infarction, also increase the risk of pump failure.

The patient's current medications, including ACE inhibitors and loop diuretics, are standard treatments for heart failure, but the patient's LVEF is severely impaired, which may indicate some level of cardiac decompensation. The patient's BNP level is elevated at 2034.0 ng/L, which indicates some level of cardiac stress.

Given the patient's severe cardiac dysfunction, multiple comorbidities, and the presence of elevated BNP levels, the risk of pump failure is higher than the risk of sudden cardiac death. However, the patient's current medical management and the absence of other indicators of poor prognosis suggest that the risk is not extremely high."
425,425,P0677,"Age: 60
Gender: Male 
Weight: 78 kg
Height: 167 cm
NYHA Class: II
Blood Pressure: 110/60 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Myocardial Infarction
Albumin (g/L): 43
ALT or GPT (IU/L): 21.0
AST or GOT (IU/L): 21.0
Total Cholesterol (mmol/L): 4,68
Creatinine (mmol/L): 95.0
Gamma-glutamil transpeptidase (IU/L): 33
Glucose (mmol/L): 5,7
Hemoglobin (g/L): 150.0
HDL (mmol/L): 1,09
Potassium (mEq/L): 4,09
LDL (mmol/L): 2,92
Sodium (mEq/L): 140.0
Pro-BNP (ng/L): 67.0
Protein (g/L): 68,5
T3 (pg/dL): 0,063
T4 (ng/L): 16,14
Troponin (ng/mL): 0,1
TSH (mIU/L): 1
Urea (mg/dL): 5,2
LVEF (%): 40.0
Medications: Beta Blockers, Loop Diuretics, Statins, ACE Inhibitor, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"RANKING: 
1. Survivor 
REASONING: 
Based on the provided patient data, the patient is at a high risk for cardiac complications. The patient has a history of ischemic dilated cardiomyopathy and myocardial infarction, which indicates significant cardiac damage. The current ejection fraction (LVEF) is 40%, which is below the normal range, suggesting impaired cardiac function. The presence of ventricular extrasystoles on the ECG also indicates an increased risk of arrhythmias.

The patient's medication regimen includes beta blockers, loop diuretics, statins, ACE inhibitors, and nitrovasodilators, which are commonly used to manage heart failure and reduce cardiovascular risk factors. However, the patient's elevated creatinine level (95.0 mol/L) suggests some degree of renal impairment, which may require adjustments to the medication regimen.

Despite these factors, the patient has a relatively normal blood pressure (110/60 mmHg) and a normal troponin level (0.1 ng/mL), which suggests that there is no acute myocardial infarction. The patient's hemoglobin level (150.0 g/L) is also within the normal range, indicating adequate oxygen delivery to the tissues.

Given these factors, I would rank the patient as a survivor for the next few years, as the patient's cardiac function is still compromised, but the absence of acute cardiac events and the presence of a well-managed medication regimen suggest that the patient can be expected to survive for an extended period.

2. Sudden cardiac death 
REASONING: 
While the patient's cardiac function is compromised, the presence of a well-managed medication regimen and the absence of acute cardiac events suggest that sudden cardiac death is less likely. However, the patient's history of ischemic dilated cardiomyopathy and myocardial infarction, as well as the presence of ventricular extrasystoles on the ECG, increase the risk of arrhythmias, which can lead to sudden cardiac death.

The patient's LVEF is 40%, which is below the normal range, and the patient's ejection fraction is not provided, but it is likely to be in the range of 30-40%. This suggests that the patient's cardiac function is severely impaired, which increases the risk of arrhythmias and sudden cardiac death.

3. Pump failure death 
REASONING: 
Pump failure death is a possible outcome for this patient, but it is less likely compared to sudden cardiac death. The patient's LVEF is 40%, which suggests that the patient's cardiac function is severely impaired, and the patient is at risk of heart failure exacerbation.

However, the patient's medication regimen includes loop diuretics, which are commonly used to manage heart failure, and the patient's creatinine level is not excessively high, which suggests that the patient's renal function is not severely impaired. Additionally, the patient's troponin level is normal, which suggests that there is no acute myocardial infarction.

Overall, while pump failure death is a possible outcome, the patient's well-managed medication regimen and the absence of acute cardiac events suggest that sudden cardiac death is a more likely outcome."
426,426,P0678,"Age: 55
Gender: Male 
Weight: 97 kg
Height: 170 cm
NYHA Class: II
Blood Pressure: 140/70 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Dyslipemia, Peripheral vascular disease, Hypertension, Myocardial Infarction
Albumin (g/L): 45
ALT or GPT (IU/L): 16.0
AST or GOT (IU/L): 15.0
Total Cholesterol (mmol/L): 3,9
Creatinine (mmol/L): 127.0
Gamma-glutamil transpeptidase (IU/L): 16
Glucose (mmol/L): 5,3
Hemoglobin (g/L): 134.0
HDL (mmol/L): 0,98
Potassium (mEq/L): 5,09
LDL (mmol/L): 2,25
Sodium (mEq/L): 141.0
Pro-BNP (ng/L): 416.0
Protein (g/L): 69,6
T3 (pg/dL): 0,0435
T4 (ng/L): 13,4
Troponin (ng/mL): 0,1
TSH (mIU/L): 0,63
Urea (mg/dL): 8,2
LVEF (%): 40.0
Medications: Beta Blockers, Loop Diuretics, Statins, ACE Inhibitor, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: TPSV
        - Bradycardia: Unknown bradycardia code
            ",survivor,"RANKING: 1. Survivor
REASONING: 

The patient's age, NYHA Class II, and the presence of multiple comorbid conditions such as ischemic dilated cardiomyopathy, peripheral vascular disease, and hypertension, would suggest a relatively advanced stage of cardiac disease. However, the patient is currently taking a combination of medications that are commonly used to manage heart failure and arrhythmias, including beta blockers, loop diuretics, statins, and an ACE inhibitor.

The patient's LVEF of 40% is significantly reduced, indicating poor cardiac function. However, the absence of troponin elevation suggests that there is no acute myocardial infarction or significant cardiac injury at this time.

The ECG impression is concerning for ventricular extrasystoles and non-sustained ventricular tachycardia, but the absence of sustained ventricular tachycardia and the presence of paroxysmal supraventricular tachyarrhythmia suggest that the patient's cardiac arrhythmias are not severe.

Given the patient's overall clinical presentation and the presence of multiple comorbid conditions, I would rank the patient as having a high risk of cardiac-related complications. However, the patient's current medications and the absence of acute cardiac injury or significant arrhythmias suggest that the patient is currently stable and at risk of a cardiac-related event. Therefore, I would rank the patient as having the highest likelihood of survival over the next few years.

RANKING: 2. Pump failure death
REASONING: 

The patient's LVEF of 40% and the presence of multiple comorbid conditions such as ischemic dilated cardiomyopathy, peripheral vascular disease, and hypertension, suggest that the patient is at high risk of developing heart failure. The patient's elevated creatinine level (127 umol/L) also suggests impaired renal function, which can be a complication of heart failure.

The patient's current medications, including loop diuretics and ACE inhibitors, are commonly used to manage heart failure, but the patient's NYHA Class II suggests that the patient's heart failure symptoms are not well-controlled. The patient's elevated troponin level (0.1 ng/mL) is not significantly elevated, but the patient's LVEF is still significantly reduced, indicating poor cardiac function.

The patient's ECG impression is concerning for ventricular extrasystoles and non-sustained ventricular tachycardia, which can be a sign of cardiac stress and increased risk of cardiac complications.

Given the patient's overall clinical presentation and the presence of multiple comorbid conditions, I would rank the patient as being at high risk of developing heart failure over the next few years.

RANKING: 3. Sudden cardiac death
REASONING: 

The patient's ECG impression is concerning for ventricular extrasystoles and non-sustained ventricular tachycardia, which can be a sign of cardiac stress and increased risk of cardiac complications. The patient's LVEF of 40% is significantly reduced, indicating poor cardiac function.

However, the patient's current medications, including beta blockers and ACE inhibitors, are commonly used to manage cardiac arrhythmias and heart failure. The patient's absence of troponin elevation and the presence of paroxysmal supraventricular tachyarrhythmia suggest that the patient's cardiac arrhythmias are not severe.

The patient's elevated creatinine level (127 umol/L) suggests impaired renal function, which can be a complication of heart failure. However, the patient's NYHA Class II suggests that the patient's heart failure symptoms are not severe.

Given the patient's overall clinical presentation and the presence of multiple comorbid conditions, I would rank the patient as being at moderate risk of sudden cardiac death over the next few years. However, the patient's current medications and the absence of severe cardiac arrhythmias suggest that the patient is not at high risk of sudden cardiac death."
427,427,P0681,"Age: 79
Gender: Female 
Weight: 55 kg
Height: 142 cm
NYHA Class: II
Blood Pressure: 140/70 mmHg
Past Medical History: Idiopathic dilated cardiomyopathy, Hypertension
Albumin (g/L): 42
ALT or GPT (IU/L): 15.0
AST or GOT (IU/L): 20.0
Total Cholesterol (mmol/L): 7,21
Creatinine (mmol/L): 93.0
Gamma-glutamil transpeptidase (IU/L): 13,4
Glucose (mmol/L): 4,4
Hemoglobin (g/L): 137.0
HDL (mmol/L): 1,5
Potassium (mEq/L): 4,14
LDL (mmol/L): 5,22
Sodium (mEq/L): 141.0
Pro-BNP (ng/L): 3501.0
Protein (g/L): 66,8
T3 (pg/dL): 0,0522
T4 (ng/L): 14,85
TSH (mIU/L): 2,37
Urea (mg/dL): 7,8
LVEF (%): 25.0
Medications: Beta Blockers, Loop Diuretics, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: TPSV
        - Bradycardia: No
            ",survivor,"RANKING: 
1. Survivor
2. Sudden cardiac death
3. Pump failure death

REASONING:

This patient's data suggests that the patient is at high risk of adverse outcomes, but the presence of a good PATIENT OUTCOME indicates that the patient is likely to survive for the next few years. 

The patient's NYHA Class II indicates that they have some symptoms of heart failure, but they are still able to perform moderate physical activity without significant limitation. The elevated LVEF of 25.0 is concerning, indicating significant left ventricular dysfunction, which is a hallmark of dilated cardiomyopathy.

The patient's elevated BNP level of 3501.0 ng/L is highly suggestive of heart failure, and the elevated creatinine level of 7.8 mg/dL indicates impaired renal function, which is often seen in patients with advanced heart failure.

The presence of ventricular extrasystole, non-sustained ventricular tachycardia, and paroxysmal supraventricular tachyarrhythmia on ECG suggests that the patient is at risk of arrhythmias, which can be a precursor to sudden cardiac death.

However, the patient's age, weight, and hemoglobin level are not particularly concerning, and they are on medications that are commonly used to manage heart failure and hypertension.

Given these factors, I would rank the patient's prognosis as follows:

1. Survivor: The patient's good PATIENT OUTCOME and the presence of medications that are commonly used to manage heart failure and hypertension suggest that the patient is likely to survive for the next few years.

2. Sudden cardiac death: The patient's elevated BNP level, impaired renal function, and presence of arrhythmias on ECG make them at high risk of sudden cardiac death.

3. Pump failure death: While the patient has significant left ventricular dysfunction and heart failure, the presence of medications that are commonly used to manage heart failure and the patient's good PATIENT OUTCOME suggest that pump failure death is less likely than sudden cardiac death. However, it is still a possible outcome given the patient's underlying heart disease."
428,428,P0682,"Age: 59
Gender: Male 
Weight: 83 kg
Height: 168 cm
NYHA Class: II
Blood Pressure: 145/80 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Dyslipemia, Hypertension
Albumin (g/L): 44,4
ALT or GPT (IU/L): 40.0
AST or GOT (IU/L): 23.0
Total Cholesterol (mmol/L): 5,43
Creatinine (mmol/L): 95.0
Gamma-glutamil transpeptidase (IU/L): 27
Glucose (mmol/L): 5,6
Hemoglobin (g/L): 176.0
HDL (mmol/L): 1,09
Potassium (mEq/L): 3,9
LDL (mmol/L): 3,7
Sodium (mEq/L): 140.0
Pro-BNP (ng/L): 1780.0
Protein (g/L): 70
T3 (pg/dL): 0,06
T4 (ng/L): 16
Troponin (ng/mL): 0,01
TSH (mIU/L): 1,08
Urea (mg/dL): 9,13
LVEF (%): 62.0
Medications: Beta Blockers, Statins, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"RANKING: 1. Survivor
REASONING: 

Based on the provided patient data, I predict a high likelihood of the patient surviving for the next few years. The patient has a moderate NYHA Class II heart failure, indicating some symptoms of heart failure but not severe enough to require hospitalization. The patient's LVEF (left ventricular ejection fraction) is 62%, which is within the normal range for a male of this age group. The absence of ventricular tachycardia and non-sustained ventricular tachycardia on the ECG suggests a relatively stable cardiac rhythm. The patient is also taking beta blockers, statins, and a nitrovasodilator, which are commonly used to manage heart failure and prevent further cardiac complications.

The patient's laboratory results show no significant elevations in liver enzymes, which suggests that the liver is not under significant stress. The elevated creatinine level may indicate some degree of renal impairment, but it is not severe enough to be a major concern for cardiac function. The patient's electrolyte and lipid profiles are also relatively well-controlled, which is important for overall cardiovascular health.

While the patient has a history of ischemic dilated cardiomyopathy, the fact that they are not experiencing symptoms of acute heart failure or arrhythmias suggests that their condition is stable. The patient's low troponin level further supports this assessment, as elevated troponin levels are often associated with cardiac damage or acute coronary syndromes.

Overall, the combination of a relatively well-controlled medical history, stable cardiac function, and absence of acute cardiac events suggests a high likelihood of the patient surviving for the next few years."
429,429,P0683,"Age: 62
Gender: Female 
Weight: 72 kg
Height: 144 cm
NYHA Class: II
Blood Pressure: 130/75 mmHg
Past Medical History: Hypertensive cardiomyopathy, Diabetes, Dyslipemia, Peripheral vascular disease, Hypertension
Albumin (g/L): 46,2
ALT or GPT (IU/L): 19.0
AST or GOT (IU/L): 21.0
Total Cholesterol (mmol/L): 7,09
Creatinine (mmol/L): 88.0
Gamma-glutamil transpeptidase (IU/L): 10
Glucose (mmol/L): 8,2
Hemoglobin (g/L): 126.0
HDL (mmol/L): 1,34
Potassium (mEq/L): 3,8
LDL (mmol/L): 4,42
Sodium (mEq/L): 140.0
Pro-BNP (ng/L): 2712.0
Protein (g/L): 76
T3 (pg/dL): 0,05
T4 (ng/L): 16
Troponin (ng/mL): 0,01
TSH (mIU/L): 1,39
Urea (mg/dL): 8,69
LVEF (%): 70.0
Medications: Diabetes Medication, Angiotensin II Receptor Blocker, Beta Blockers, Statins, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: TPSV
        - Bradycardia: No
            ",survivor,"RANKING: 1. Survivor
REASONING: 
Based on the provided patient data, the patient has a significant number of comorbid conditions, including hypertension, cardiomyopathy, diabetes, and peripheral vascular disease, which increase the risk of cardiovascular events. However, the patient's NYHA Class II indicates that they are still relatively functional and able to perform daily activities without significant limitations. The patient's LVEF is 70%, which is within the normal range, and their ECG findings do not indicate any acute cardiac arrhythmias or signs of cardiac ischemia. The patient's Pro-BNP level is elevated, which may indicate some degree of heart failure, but it is not excessively high. 

Given these factors, I would predict that the patient is likely to survive for the next few years. The patient's age is 62, and while this is considered old, the patient's comorbidities and functional status are not severe enough to immediately predict a poor outcome. The patient's medications, including beta blockers and statins, also suggest a cautious approach to managing cardiovascular risk factors. Overall, while the patient has a significant number of risk factors, the combination of their functional status, LVEF, and medication regimen suggests that they are likely to survive for the next few years. 

However, it is essential to closely monitor the patient's cardiovascular risk factors and adjust their treatment plan as needed to minimize the risk of cardiovascular events."
430,430,P0684,"Age: 71
Gender: Male 
Weight: 76 kg
Height: 157 cm
NYHA Class: II
Blood Pressure: 150/70 mmHg
Past Medical History: Hypertensive cardiomyopathy, Diabetes, Dyslipemia, Peripheral vascular disease, Hypertension
Albumin (g/L): 46
ALT or GPT (IU/L): 57.0
AST or GOT (IU/L): 37.0
Total Cholesterol (mmol/L): 7,84
Creatinine (mmol/L): 118.0
Gamma-glutamil transpeptidase (IU/L): 20
Glucose (mmol/L): 5,8
Hemoglobin (g/L): 164.0
HDL (mmol/L): 1,27
Potassium (mEq/L): 4,63
LDL (mmol/L): 5,64
Sodium (mEq/L): 145.0
Pro-BNP (ng/L): 78.0
Protein (g/L): 76
T3 (pg/dL): 0,0423
T4 (ng/L): 16,17
TSH (mIU/L): 0,39
Urea (mg/dL): 9,9
LVEF (%): 70.0
Medications: Diabetes Medication, Angiotensin II Receptor Blocker, Loop Diuretics, Statins, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"RANKING: 
1. Survivor
REASONING: 
The patient is a 71-year-old male with a history of hypertension, cardiomyopathy, diabetes, dyslipidemia, and peripheral vascular disease, which indicates a high risk for cardiovascular events. However, the patient is currently taking medications for these conditions, including an ACE inhibitor, which is known to be beneficial for patients with heart failure and hypertension. The patient's NYHA Class II indicates moderate symptoms, but not severe. The ECG results show ventricular extrasystoles, which are a common finding in patients with cardiomyopathy, but no other significant arrhythmias. The patient's LVEF is 70%, which is within the normal range for a male of this age. The patient's biomarkers, including troponin, creatinine, and liver enzymes, are not significantly elevated, suggesting no acute myocardial injury. 

Given the patient's stable condition, absence of significant arrhythmias, and controlled hypertension, the most likely outcome is that the patient will survive for the next few years. The patient's age and comorbidities do pose a risk for cardiovascular events, but the patient's current medical management and the lack of acute complications suggest that the patient will likely survive without significant cardiac events in the short term.

2. Pump failure death
REASONING: 
While the patient has a history of cardiomyopathy and hypertension, the patient's LVEF is 70%, which is within the normal range for a male of this age. The patient is also taking medications for these conditions, including an ACE inhibitor, which is known to be beneficial for patients with heart failure. However, the patient's NYHA Class II indicates moderate symptoms, which may suggest some level of cardiac dysfunction. The patient's biomarkers, including creatinine and liver enzymes, are not significantly elevated, suggesting no acute myocardial injury.

Given the patient's controlled hypertension and absence of significant arrhythmias, the risk of pump failure death is lower than the risk of sudden cardiac death. However, the patient's history of cardiomyopathy and hypertension may still pose a risk for cardiac events, and the patient's NYHA Class II symptoms suggest some level of cardiac dysfunction. Therefore, pump failure death is a possible but less likely outcome.

3. Sudden cardiac death
REASONING: 
The patient's ECG results show ventricular extrasystoles, which are a common finding in patients with cardiomyopathy, but no other significant arrhythmias. The patient's LVEF is 70%, which is within the normal range for a male of this age. The patient's biomarkers, including creatinine and liver enzymes, are not significantly elevated, suggesting no acute myocardial injury.

Given the patient's controlled hypertension and absence of significant arrhythmias, the risk of sudden cardiac death is lower than the risk of pump failure death. However, the patient's history of cardiomyopathy and hypertension may still pose a risk for cardiac events, and the presence of ventricular extrasystoles may increase the risk of arrhythmias. Therefore, while sudden cardiac death is a possible outcome, it is less likely than pump failure death given the patient's stable condition and controlled hypertension."
431,431,P0685,"Age: 45
Gender: Male 
Weight: 119 kg
Height: 174 cm
NYHA Class: II
Blood Pressure: 110/70 mmHg
Past Medical History: Enolic dilated cardiomyopathy
Albumin (g/L): 42,2
ALT or GPT (IU/L): 10.0
AST or GOT (IU/L): 15.0
Total Cholesterol (mmol/L): 5,72
Creatinine (mmol/L): 83.0
Gamma-glutamil transpeptidase (IU/L): 21
Glucose (mmol/L): 5,1
Hemoglobin (g/L): 157.0
HDL (mmol/L): 1,06
Potassium (mEq/L): 4,4
LDL (mmol/L): 3,47
Sodium (mEq/L): 138.0
Pro-BNP (ng/L): 403.0
Protein (g/L): 65,9
T4 (ng/L): 22
TSH (mIU/L): 2,25
Urea (mg/dL): 4,66
LVEF (%): 37.0
Medications: Amiodarone, Beta Blockers, Loop Diuretics, Spironolactone, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: No
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",survivor,"RANKING: 
1. Survivor
REASONING: 
Based on the patient's data, I rank the patient as a survivor for the next few years. The patient's age, weight, and NYHA class are not overly concerning, and their blood pressure is within a relatively normal range. However, the patient has a significant history of dilated cardiomyopathy, which is a risk factor for adverse outcomes.

The patient's biomarkers, such as elevated creatinine levels (83.0 mmol/L) and low LVEF (37.0%), indicate some degree of cardiac dysfunction. The elevated Pro-BNP levels (403.0 ng/L) also suggest a high risk of cardiac failure. However, the patient is already on medications that are commonly used to manage heart failure, such as loop diuretics and ACE inhibitors.

The patient's laboratory results, including the normal hemoglobin and potassium levels, and the absence of other significant abnormalities, do not suggest acute cardiac stress or electrolyte imbalances that would increase the risk of cardiac complications. The patient's ECG results also do not indicate any life-threatening arrhythmias.

Given the patient's overall clinical presentation and the fact that they are already on evidence-based treatments for heart failure, I believe that the patient is at a relatively low risk of sudden cardiac death or pump failure in the short term. Therefore, I rank the patient as a survivor.

However, it is essential to closely monitor the patient's condition and adjust their treatment plan as needed to minimize the risk of cardiac complications. Regular follow-up appointments, regular ECGs, and close monitoring of the patient's biomarkers and symptoms will be necessary to ensure the best possible outcome."
432,432,P0686,"Age: 77
Gender: Male 
Weight: 99 kg
Height: 167 cm
NYHA Class: II
Blood Pressure: 170/80 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Dyslipemia, Peripheral vascular disease, Hypertension, Myocardial Infarction
Albumin (g/L): 43
ALT or GPT (IU/L): 11.0
AST or GOT (IU/L): 21.0
Total Cholesterol (mmol/L): 4,22
Creatinine (mmol/L): 136.0
Gamma-glutamil transpeptidase (IU/L): 21
Glucose (mmol/L): 4,4
Hemoglobin (g/L): 160.0
HDL (mmol/L): 1,16
Potassium (mEq/L): 4,1
LDL (mmol/L): 2,17
Sodium (mEq/L): 142.0
Pro-BNP (ng/L): 686.0
Protein (g/L): 74,9
T3 (pg/dL): 0,0543
T4 (ng/L): 14,54
Troponin (ng/mL): 0,1
TSH (mIU/L): 0,42
Urea (mg/dL): 9,6
LVEF (%): 40.0
Medications: Calcium Channel Blocker, Loop Diuretics, Statins, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: TPSV
        - Bradycardia: No
            ",survivor,"RANKING: 1. Survivor
REASONING: 

Based on the patient's age, NYHA Class II, and the presence of ischemic dilated cardiomyopathy, the patient is already at an increased risk for cardiovascular events. However, the patient's LVEF is 40%, which indicates a significant impairment of left ventricular function. The presence of non-sustained ventricular tachycardia and polymorphic ventricular extrasystoles on the ECG also raises concern for arrhythmias. Despite these factors, the patient's recent ECG impression and the lack of other high-risk features (e.g., severe hypertension, acute coronary syndrome) suggest that the patient may be able to survive for several years without significant progression of disease.

The patient's laboratory values, such as elevated troponin and creatinine, also suggest some level of cardiac and renal impairment. However, the patient's hemoglobin level and albumin level are relatively normal, which may indicate some level of nutritional status. The patient's lipid profile is also relatively favorable, with a moderate level of LDL and a high level of HDL.

The patient's age and comorbidities may still pose a risk for mortality, but the overall clinical picture suggests that the patient may be able to survive for several years with proper management and monitoring. Therefore, I rank the patient as a survivor.

RANKING: 2. Sudden Cardiac Death
REASONING: 

The patient's presence of ischemic dilated cardiomyopathy, non-sustained ventricular tachycardia, and polymorphic ventricular extrasystoles on the ECG increase the risk for sudden cardiac death. The patient's LVEF of 40% also indicates a significant impairment of left ventricular function, which can increase the risk for arrhythmias. The patient's age and comorbidities also pose a risk for mortality.

However, the patient's recent ECG impression and the lack of other high-risk features may reduce the risk for sudden cardiac death. Nevertheless, the patient's history of myocardial infarction and peripheral vascular disease also increase the risk for cardiac events.

RANKING: 3. Pump Failure Death
REASONING: 

The patient's LVEF of 40% indicates significant impairment of left ventricular function, which increases the risk for heart failure. The patient's elevated creatinine and troponin levels also suggest some level of cardiac and renal impairment. The patient's NYHA Class II also indicates some level of heart failure symptoms.

The patient's age and comorbidities also pose a risk for mortality, and the patient's elevated blood pressure and dyslipidemia may further increase the risk for cardiovascular events. The patient's recent ECG impression and the lack of other high-risk features may reduce the risk for sudden cardiac death, but the patient's overall clinical picture suggests that the patient may be at risk for pump failure death in the near future.

Note: The patient's prognosis is subject to change based on future clinical events and changes in their medical condition."
433,433,P0687,"Age: 75
Gender: Male 
Weight: 71 kg
Height: 161 cm
NYHA Class: II
Blood Pressure: 130/80 mmHg
Past Medical History: Idiopathic dilated cardiomyopathy, Peripheral vascular disease, Hypertension
Albumin (g/L): 37
ALT or GPT (IU/L): 34.0
AST or GOT (IU/L): 30.0
Total Cholesterol (mmol/L): 4,32
Creatinine (mmol/L): 135.0
Gamma-glutamil transpeptidase (IU/L): 82
Glucose (mmol/L): 5,3
Hemoglobin (g/L): 118.0
HDL (mmol/L): 1,14
Potassium (mEq/L): 3,96
LDL (mmol/L): 2,77
Sodium (mEq/L): 139.0
Pro-BNP (ng/L): 5751.0
Protein (g/L): 61,3
T3 (pg/dL): 0,0348
T4 (ng/L): 16,95
TSH (mIU/L): 1,31
Urea (mg/dL): 8,1
LVEF (%): 25.0
Medications: Amiodarone, Loop Diuretics, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",survivor,"RANKING: 
1. Survivor
REASONING:
Based on the provided patient data, I would rank the patient as having a high likelihood of being a survivor. Here's the reasoning behind this ranking:

- The patient's age is 75, which is considered elderly, but the patient's NYHA class is II, indicating mild heart failure symptoms. This suggests that the patient's heart function is still relatively preserved compared to those with more severe heart failure.
- The patient has a history of idiopathic dilated cardiomyopathy, which is a significant underlying condition. However, the patient is currently taking medications such as Amiodarone, Loop Diuretics, and ACE Inhibitor, which are commonly used to manage heart failure and arrhythmias.
- The patient's laboratory results show elevated creatinine levels, which indicate impaired renal function, but this is not uncommon in patients with heart failure. The patient's electrolyte levels, including potassium, sodium, and LDH, are within relatively normal ranges.
- The patient's ECG findings reveal ventricular extrasystoles, non-sustained ventricular tachycardia, and paroxysmal supraventricular tachyarrhythmia, which are common in patients with heart failure and cardiomyopathy. However, these findings are not indicative of a high risk of sudden cardiac death.
- The patient's Pro-BNP level is elevated, which is consistent with heart failure, but not excessively high. This suggests that the patient is experiencing some degree of heart failure, but it may not be severe.
- The patient's LVEF is significantly reduced, indicating poor heart function, but this is expected in a patient with dilated cardiomyopathy.

Overall, while the patient has a significant underlying condition and some concerning ECG findings, the patient's overall clinical presentation and laboratory results suggest that they are likely to survive for the next few years with proper management and monitoring."
434,434,P0691,"Age: 81
Gender: Male 
Weight: 79 kg
Height: 174 cm
NYHA Class: III
Blood Pressure: 130/70 mmHg
Past Medical History: Idiopathic dilated cardiomyopathy, Diabetes, Dyslipemia, Hypertension
Albumin (g/L): 43
ALT or GPT (IU/L): 16.0
AST or GOT (IU/L): 16.0
Total Cholesterol (mmol/L): 3,85
Creatinine (mmol/L): 97.0
Gamma-glutamil transpeptidase (IU/L): 27
Glucose (mmol/L): 5,8
Hemoglobin (g/L): 141.0
HDL (mmol/L): 1,32
Potassium (mEq/L): 4,4
LDL (mmol/L): 2,07
Sodium (mEq/L): 135.0
Pro-BNP (ng/L): 140.0
Protein (g/L): 76
T4 (ng/L): 17
Troponin (ng/mL): 0,01
TSH (mIU/L): 2,26
Urea (mg/dL): 9,65
LVEF (%): 50.0
Medications: Calcium Channel Blocker, Angiotensin II Receptor Blocker, Loop Diuretics, Statins, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",survivor,"RANKING: 
1. Survivor
REASONING: 
The patient is 81 years old with a history of idiopathic dilated cardiomyopathy, diabetes, dyslipemia, and hypertension. The patient's NYHA Class III indicates moderate symptoms of heart failure. The patient's LVEF is 50.0%, which is significantly reduced, indicating poor cardiac function. Despite this, the patient has a relatively stable vital sign profile, with a normal blood pressure and a low glucose level. The patient is also taking multiple medications, including ACE inhibitors and beta blockers, which are commonly used to manage heart failure and hypertension.

The patient's ECG impression shows ventricular extrasystole, which is a benign finding, and no signs of ventricular tachycardia or bradycardia. The Pro-BNP level is elevated, which is consistent with heart failure. However, the Troponin level is normal, which suggests that there is no acute myocardial infarction.

Given the patient's age, comorbidities, and reduced LVEF, the patient is at high risk for adverse outcomes. However, the fact that the patient is taking multiple medications and has a relatively stable vital sign profile suggests that the patient may be able to tolerate treatment and recover from any potential complications. Therefore, I predict that the patient will survive for the next few years, assuming that the patient continues to receive appropriate treatment and does not experience any significant worsening of symptoms or cardiac events.

RANKING 2: 
Sudden cardiac death
REASONING: 
While the patient is at high risk for adverse outcomes, the patient's LVEF is still 50.0%, which is a relatively preserved level of cardiac function. The patient's ECG impression shows ventricular extrasystole, which is a benign finding, and no signs of ventricular tachycardia or bradycardia. However, the patient's Pro-BNP level is elevated, which suggests that the patient may have some degree of heart failure.

Given the patient's age and comorbidities, there is a risk of sudden cardiac death, particularly if the patient experiences a cardiac event such as a myocardial infarction or a severe arrhythmia. However, the patient is taking multiple medications, including ACE inhibitors and beta blockers, which are commonly used to manage heart failure and hypertension. These medications can help to reduce the risk of cardiac events.

RANKING 3: 
Pump failure death
REASONING: 
While the patient is at high risk for adverse outcomes, the patient's LVEF is still 50.0%, which is a relatively preserved level of cardiac function. The patient's ECG impression shows ventricular extrasystole, which is a benign finding, and no signs of ventricular tachycardia or bradycardia. However, the patient's Pro-BNP level is elevated, which suggests that the patient may have some degree of heart failure.

Given the patient's age and comorbidities, there is a risk of pump failure, particularly if the patient experiences a significant worsening of symptoms or cardiac events. However, the patient is taking multiple medications, including ACE inhibitors and beta blockers, which can help to reduce the risk of pump failure. Additionally, the patient's vital sign profile is relatively stable, which suggests that the patient is tolerating treatment well.

Overall, while the patient is at risk for pump failure, the patient's relatively preserved LVEF and stable vital sign profile suggest that the patient may be able to manage their condition with treatment and avoid pump failure."
435,435,P0692,"Age: 70
Gender: Female 
Weight: 67 kg
Height: 156 cm
NYHA Class: III
Blood Pressure: 100/66 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Diabetes, Dyslipemia, Hypertension, Myocardial Infarction
Albumin (g/L): 43
ALT or GPT (IU/L): 10.0
AST or GOT (IU/L): 12.0
Total Cholesterol (mmol/L): 6,13
Creatinine (mmol/L): 248.0
Gamma-glutamil transpeptidase (IU/L): 14
Glucose (mmol/L): 8,4
Hemoglobin (g/L): 126.0
HDL (mmol/L): 1,19
Potassium (mEq/L): 5,4
LDL (mmol/L): 3,62
Sodium (mEq/L): 132.0
Pro-BNP (ng/L): 1048.0
Protein (g/L): 78
T4 (ng/L): 15
Troponin (ng/mL): 0,01
TSH (mIU/L): 5,01
Urea (mg/dL): 32,61
LVEF (%): 25.0
Medications: Diabetes Medication, Beta Blockers, Loop Diuretics, Spironolactone, Statins, ACE Inhibitor, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"RANKING: 
1. Survivor
REASONING: 
Based on the provided patient data, I rank the patient as a survivor with a high likelihood. The patient's age, NYHA Class III, and history of ischemic dilated cardiomyopathy, diabetes, dyslipidemia, hypertension, and myocardial infarction indicate a significant burden of cardiovascular disease. However, the patient's current hemoglobin level (126 g/L) is within the normal range, and the absence of any acute elevation in troponin levels (0.01 ng/mL) suggests that there is no acute myocardial infarction. The patient's medication regimen, which includes beta-blockers, ACE inhibitors, and statins, is also indicative of a comprehensive management plan for cardiovascular disease.

The patient's ECG impression, while showing ventricular extrasystoles, does not indicate any life-threatening arrhythmias. The absence of non-sustained ventricular tachycardia (CH>10) and paroxysmal supraventricular tachyarrhythmia also reduces the risk of sudden cardiac death.

The patient's laboratory results, including a normal creatinine level (32.61 mg/dL) and low LVEF (25.0%), suggest that the patient's kidney function and left ventricular function are relatively preserved. The elevated Pro-BNP level (1048.0 ng/L) is concerning, but it is not excessively high, and the patient is on spironolactone, which is often used to manage volume overload in heart failure.

Overall, while the patient has a significant medical history, the absence of acute coronary syndromes, life-threatening arrhythmias, and preserved kidney function and left ventricular function suggest that the patient is at lower risk for sudden cardiac death and pump failure death. Therefore, I rank the patient as a survivor."
436,436,P0693,"Age: 48
Gender: Female 
Weight: 69 kg
Height: 166 cm
NYHA Class: II
Blood Pressure: 90/70 mmHg
Past Medical History: Idiopathic dilated cardiomyopathy
Albumin (g/L): 40
ALT or GPT (IU/L): 29.0
AST or GOT (IU/L): 19.0
Total Cholesterol (mmol/L): 6
Creatinine (mmol/L): 72.0
Gamma-glutamil transpeptidase (IU/L): 30
Glucose (mmol/L): 5,8
Hemoglobin (g/L): 125.0
HDL (mmol/L): 1,01
Potassium (mEq/L): 4,4
LDL (mmol/L): 4,01
Sodium (mEq/L): 141.0
Pro-BNP (ng/L): 220.0
Protein (g/L): 69
T3 (pg/dL): 0,05
T4 (ng/L): 11
Troponin (ng/mL): 0,04
TSH (mIU/L): 1,55
Urea (mg/dL): 5,99
LVEF (%): 40.0
Medications: Beta Blockers, Digoxin, Loop Diuretics, Spironolactone, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"RANKING: 
1. Survivor
REASONING:
The patient's prognosis is ranked as a survivor due to the following reasons:
- The patient's NYHA Class is II, indicating mild symptoms, which is a relatively stable condition.
- The patient is on medications that are standard for managing heart failure and arrhythmias, such as beta blockers, digoxin, loop diuretics, spironolactone, and an ACE inhibitor. This suggests that the patient is being well-managed and that the current treatment is effective.
- The patient's biomarkers, such as troponin and BNP, are not significantly elevated, indicating that the patient is not experiencing acute cardiac injury or significant heart failure.
- The ECG impression shows no evidence of life-threatening arrhythmias, such as ventricular tachycardia or non-sustained ventricular tachycardia, which could indicate a high risk of sudden cardiac death.
- The patient's creatinine level is elevated, but it is not significantly high, which may indicate some degree of renal impairment but not severe kidney failure.
- The patient's LVEF is 40%, which is within the normal range, indicating that the patient's heart function is not severely impaired.

Overall, the patient's clinical presentation, laboratory results, and treatment suggest that the patient is at low risk for sudden cardiac death and pump failure in the next few years. Therefore, the most likely prognosis is that the patient will survive."
437,437,P0694,"Age: 69
Gender: Male 
Weight: 82 kg
Height: 165 cm
NYHA Class: II
Blood Pressure: 140/65 mmHg
Past Medical History: Hypertensive cardiomyopathy, Diabetes, Dyslipemia, Hypertension
Albumin (g/L): 48
ALT or GPT (IU/L): 26.0
AST or GOT (IU/L): 28.0
Total Cholesterol (mmol/L): 3,96
Creatinine (mmol/L): 103.0
Gamma-glutamil transpeptidase (IU/L): 24
Glucose (mmol/L): 7,7
Hemoglobin (g/L): 164.0
HDL (mmol/L): 0,88
Potassium (mEq/L): 4,2
LDL (mmol/L): 2,17
Sodium (mEq/L): 141.0
Pro-BNP (ng/L): 91.0
Protein (g/L): 81,8
T3 (pg/dL): 0,06
T4 (ng/L): 14,01
Troponin (ng/mL): 0,6
TSH (mIU/L): 1,32
Urea (mg/dL): 6,3
LVEF (%): 65.0
Medications: Calcium Channel Blocker, Diabetes Medication, Angiotensin II Receptor Blocker, Beta Blockers, Loop Diuretics, Statins, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: TPSV
        - Bradycardia: No
            ",survivor,"RANKING: 1. Survivor
REASONING: 

The patient is 69 years old, with a history of hypertension, cardiomyopathy, diabetes, and dyslipemia, which are all risk factors for cardiovascular disease. However, the patient's current NYHA class is II, indicating that they have some symptoms of heart failure, but they are still able to perform moderate physical activity. The patient's LVEF is 65%, which is below the normal range, indicating some degree of left ventricular dysfunction.

The patient's laboratory results show elevated creatinine levels (103.0 mol/L), which suggests some degree of renal impairment. However, the patient's kidney function is not severely impaired, and they are receiving loop diuretics, which suggests that their kidney function is still being adequately managed.

The patient's ECG shows a polymorphic ventricular extrasystole, which is a type of abnormal heart rhythm that can increase the risk of sudden cardiac death. However, the patient is not experiencing any other arrhythmias that would increase the risk of sudden cardiac death.

The patient's medications include a calcium channel blocker, beta blockers, and an ACE inhibitor, which are all used to manage hypertension and heart failure. The patient's lipid profile is also relatively well-controlled, with low LDL and HDL levels.

Overall, while the patient has several risk factors for cardiovascular disease and has some evidence of left ventricular dysfunction, their current condition is not severe enough to predict a poor outcome. The patient's age and renal impairment do increase the risk of cardiovascular events, but the patient's overall health status and medication regimen suggest that they are at moderate risk, making a survivor outcome the most likely prognosis.

The patient's TSH level is 1.32 mIU/L, which is within the normal range, indicating that the patient's thyroid function is not significantly impaired.

The patient's troponin level is 0.6 ng/mL, which is slightly elevated, but not significantly elevated. Elevated troponin levels are often associated with myocardial infarction, but in this case, the patient does not have any symptoms of myocardial infarction.

The patient's Pro-BNP level is 91 ng/L, which is elevated, indicating some degree of cardiac strain. However, the patient's symptoms and ECG do not suggest any acute cardiac events.

Considering all the above factors, I believe that the patient is at moderate risk for cardiovascular events, but the patient's overall health status and medication regimen suggest that they are at moderate risk, making a survivor outcome the most likely prognosis."
438,438,P0695,"Age: 63
Gender: Male 
Weight: 80 kg
Height: 170 cm
NYHA Class: II
Blood Pressure: 135/80 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Myocardial Infarction
Albumin (g/L): 44
ALT or GPT (IU/L): 23.0
AST or GOT (IU/L): 26.0
Total Cholesterol (mmol/L): 4,27
Creatinine (mmol/L): 153.0
Gamma-glutamil transpeptidase (IU/L): 41
Glucose (mmol/L): 6,2
Hemoglobin (g/L): 154.0
HDL (mmol/L): 1,09
Potassium (mEq/L): 4,2
LDL (mmol/L): 2,4
Sodium (mEq/L): 142.0
Pro-BNP (ng/L): 403.0
Protein (g/L): 85
T3 (pg/dL): 0,04
T4 (ng/L): 18
Troponin (ng/mL): 0,005
TSH (mIU/L): 1,27
Urea (mg/dL): 6,66
LVEF (%): 60.0
Medications: Calcium Channel Blocker, Beta Blockers, Loop Diuretics, Statins
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: TPSV
        - Bradycardia: No
            ",survivor,"RANKING: 1. Survivor
REASONING: 
The patient has a history of ischemic dilated cardiomyopathy and myocardial infarction, which are risk factors for heart failure and arrhythmias. However, the patient is currently being treated with medications for these conditions, including beta blockers, loop diuretics, and statins, which are essential for managing heart failure and reducing cardiovascular risk. The patient's LVEF is 60%, which is within the range of 40-60% and indicates some preserved ventricular function. The absence of ventricular tachycardia, non-sustained ventricular tachycardia, and paroxysmal supraventricular tachyarrhythmia on the ECG also suggests a lower risk of sudden cardiac death. Additionally, the patient's hemoglobin level is slightly elevated, which may indicate anemia, but it is not a significant concern given the overall clinical context. The patient's serum creatinine level is elevated, indicating some degree of kidney impairment, but it is not severe. Overall, the patient's clinical presentation and treatment plan suggest a relatively stable condition, making a survival prognosis of ""survivor"" the most likely outcome."
439,439,P0697,"Age: 49
Gender: Male 
Weight: 109 kg
Height: 168 cm
NYHA Class: II
Blood Pressure: 170/110 mmHg
Past Medical History: Other HF etiology, Dyslipemia, Hypertension
Albumin (g/L): 43
ALT or GPT (IU/L): 18.0
AST or GOT (IU/L): 22.0
Total Cholesterol (mmol/L): 5,61
Creatinine (mmol/L): 97.0
Gamma-glutamil transpeptidase (IU/L): 26
Glucose (mmol/L): 6,1
Hemoglobin (g/L): 151.0
HDL (mmol/L): 0,93
Potassium (mEq/L): 4,3
LDL (mmol/L): 3,93
Sodium (mEq/L): 139.0
Pro-BNP (ng/L): 709.0
Protein (g/L): 71
T4 (ng/L): 19
Troponin (ng/mL): 0,01
TSH (mIU/L): 3,88
Urea (mg/dL): 6,66
LVEF (%): 40.0
Medications: Calcium Channel Blocker, Beta Blockers, Spironolactone, Statins, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",survivor,"RANKING: 
1. Survivor
REASONING: 
Based on the provided patient data, the patient is currently in a stable condition, with a history of heart failure (NYHA Class II) and multiple comorbidities such as hypertension, dyslipidemia, and other etiologies for heart failure. The patient's current laboratory values show elevated creatinine levels (97.0 mmol/L), indicating some degree of renal impairment, which may be related to the heart failure. However, the patient's ejection fraction (LVEF) is 40.0%, which is lower than the normal range, indicating some degree of left ventricular dysfunction.

Despite the patient's elevated blood pressure (170/110 mmHg) and elevated troponin levels (0.01 ng/mL), which suggest some degree of myocardial injury, the patient is currently on multiple medications, including beta blockers, ACE inhibitors, and spironolactone, which are known to improve outcomes in heart failure patients. The patient's Pro-BNP levels (709.0 ng/L) are also elevated, which suggests some degree of ventricular stress.

The ECG findings, including ventricular extrasystole and polymorphic ventricular extrasystole, are concerning for arrhythmias, but the patient is not currently experiencing ventricular tachycardia or non-sustained ventricular tachycardia. The patient's potassium levels are normal, and the ECG code for unknown bradycardia is not explicitly stated as a concern.

Given the patient's stable condition, multiple comorbidities, and the presence of multiple medications, I believe that the patient is most likely to be a survivor in the short-term. However, the patient's elevated creatinine levels, elevated blood pressure, and elevated troponin levels suggest that there may be ongoing cardiac stress and potential for future complications.

RANKING: 
2. Sudden cardiac death
REASONING: 
Based on the patient's elevated troponin levels (0.01 ng/mL), which suggest some degree of myocardial injury, and the patient's history of ventricular extrasystole and polymorphic ventricular extrasystole on the ECG, there is a moderate risk of sudden cardiac death. However, the patient is currently on multiple medications that are known to reduce the risk of sudden cardiac death, including beta blockers and ACE inhibitors.

RANKING: 
3. Pump failure death
REASONING: 
Based on the patient's elevated creatinine levels (97.0 mmol/L), which indicate some degree of renal impairment, and the patient's history of heart failure (NYHA Class II), there is a moderate risk of pump failure. However, the patient is currently on multiple medications that are known to improve outcomes in heart failure patients, including ACE inhibitors and spironolactone.

It is worth noting that the patient's Pro-BNP levels (709.0 ng/L) are elevated, which suggests some degree of ventricular stress, but the patient's LVEF (40.0%) is still within the normal range, and the patient is currently stable. Based on the provided data, I do not believe that pump failure is the most likely outcome for this patient in the short-term."
440,440,P0698,"Age: 65
Gender: Female 
Weight: 69 kg
Height: 162 cm
NYHA Class: II
Blood Pressure: 110/70 mmHg
Past Medical History: Idiopathic dilated cardiomyopathy, Peripheral vascular disease
Albumin (g/L): 37
ALT or GPT (IU/L): 17.0
AST or GOT (IU/L): 17.0
Total Cholesterol (mmol/L): 3,8
Creatinine (mmol/L): 82.0
Gamma-glutamil transpeptidase (IU/L): 16
Glucose (mmol/L): 4,6
Hemoglobin (g/L): 134.0
HDL (mmol/L): 1,55
Potassium (mEq/L): 4,1
LDL (mmol/L): 1,68
Sodium (mEq/L): 139.0
Pro-BNP (ng/L): 542.0
Protein (g/L): 62
T3 (pg/dL): 0,04
T4 (ng/L): 16
Troponin (ng/mL): 0,005
TSH (mIU/L): 1,58
Urea (mg/dL): 4,16
LVEF (%): 45.0
Medications: Calcium Channel Blocker, Beta Blockers, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"RANKING: 
1. Survivor 
REASONING: 
Based on the patient's data, I would rank the prognosis as a survivor for the next few years. The patient's NYHA Class II indicates that they have moderate symptoms, but they are still able to perform daily activities without significant limitations. Their ejection fraction (LVEF) of 45.0 is relatively preserved, which suggests that the heart is still functioning to some extent.

The patient's medication regimen includes a calcium channel blocker, beta blockers, and an ACE inhibitor, which are standard treatments for patients with heart failure and cardiomyopathy. The absence of significant electrolyte imbalances, anemia, or other acute conditions that could impact cardiac function also supports a favorable prognosis.

The elevated Pro-BNP level (542.0 ng/L) indicates some degree of ventricular stress, but it is not excessively high, which may suggest that the patient's condition is stable. Additionally, the absence of any significant arrhythmias or ECG abnormalities (except for ventricular extrasystoles) reduces the risk of sudden cardiac death.

While the patient has a history of peripheral vascular disease, this is not directly related to the cardiac condition, and the patient is already receiving treatment for it.

Overall, the combination of a relatively preserved ejection fraction, a well-managed medication regimen, and the absence of severe cardiac or other comorbidities suggest a relatively good prognosis for the patient to survive for the next few years."
441,441,P0699,"Age: 41
Gender: Male 
Weight: 65 kg
Height: 170 cm
NYHA Class: II
Blood Pressure: 120/80 mmHg
Past Medical History: Hypertropic cardiomyopathy
Albumin (g/L): 40
ALT or GPT (IU/L): 14.0
AST or GOT (IU/L): 18.0
Total Cholesterol (mmol/L): 4,47
Creatinine (mmol/L): 88.0
Gamma-glutamil transpeptidase (IU/L): 16
Glucose (mmol/L): 5,7
Hemoglobin (g/L): 158.0
HDL (mmol/L): 1,37
Potassium (mEq/L): 4,3
LDL (mmol/L): 2,69
Sodium (mEq/L): 139.0
Pro-BNP (ng/L): 19.0
Protein (g/L): 70
T3 (pg/dL): 0,06
T4 (ng/L): 13
Troponin (ng/mL): 0,02
TSH (mIU/L): 1,2
Urea (mg/dL): 5,16
LVEF (%): 40.0
Medications: Beta Blockers, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"RANKING: 1. Survivor
REASONING: 

The patient's overall prognosis is favorable due to several factors:

1. Age: Although the patient is 41, which is considered relatively young for a heart condition, the NYHA Class II classification indicates that the patient's symptoms are mild, and they are able to perform daily activities without significant limitations.
2. Hemoglobin level: A hemoglobin level of 15.8 g/dL is within the normal range, indicating that the patient does not have anemia, which can be a contributing factor to cardiovascular disease.
3. Medications: The patient is already taking beta blockers and an ACE inhibitor, which are commonly used to manage conditions like hypertrophic cardiomyopathy and heart failure. These medications can help reduce the workload on the heart and slow the progression of the disease.
4. ECG findings: The absence of ventricular tachycardia, non-sustained ventricular tachycardia, and paroxysmal supraventricular tachyarrhythmia suggests that the patient does not have significant arrhythmias, which can be a major contributor to sudden cardiac death.
5. Pro-BNP level: The Pro-BNP level is elevated, indicating some degree of heart failure. However, the patient is already receiving ACE inhibitor, which can help reduce the levels of Pro-BNP.
6. LVEF: The left ventricular ejection fraction (LVEF) is 40%, which is within the normal range. A lower LVEF is associated with a higher risk of heart failure and sudden cardiac death.

Considering these factors, the patient's prognosis is relatively favorable, and it is more likely that the patient will survive for the next few years."
442,442,P0700,"Age: 81
Gender: Male 
Weight: 77 kg
Height: 166 cm
NYHA Class: II
Blood Pressure: 160/70 mmHg
Past Medical History: Idiopathic dilated cardiomyopathy
Albumin (g/L): 40
ALT or GPT (IU/L): 27.0
AST or GOT (IU/L): 26.0
Total Cholesterol (mmol/L): 5,1
Creatinine (mmol/L): 129.0
Gamma-glutamil transpeptidase (IU/L): 20
Glucose (mmol/L): 7,46
Hemoglobin (g/L): 144.0
HDL (mmol/L): 1,5
Potassium (mEq/L): 4,93
LDL (mmol/L): 3,15
Sodium (mEq/L): 146.0
Pro-BNP (ng/L): 1670.0
Protein (g/L): 65
T3 (pg/dL): 0,0483
T4 (ng/L): 12,7
TSH (mIU/L): 3,52
Urea (mg/dL): 11,3
LVEF (%): 25.0
Medications: Digoxin, Loop Diuretics, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: TPSV
        - Bradycardia: No
            ",survivor,"RANKING: 
1. Survivor
REASONING:
This patient has several factors that suggest a higher likelihood of survival. Firstly, despite having a history of idiopathic dilated cardiomyopathy, the patient's current LVEF (Left Ventricular Ejection Fraction) is 25.0%, which is relatively well-preserved, considering the patient's age and NYHA Class II. This suggests that the patient's heart is still functioning relatively well, which is a positive prognostic factor.

Additionally, the patient's blood pressure is within a relatively normal range (160/70 mmHg), and they are on medications that are commonly used to manage heart failure (Digoxin, Loop Diuretics, and ACE Inhibitor). These medications can help to improve symptoms and slow disease progression.

The patient's laboratory results also show no significant abnormalities that would suggest acute kidney injury or liver dysfunction, which can be common complications in patients with heart failure.

The ECG impression shows some arrhythmias, but they are non-sustained and do not indicate a high risk of sudden cardiac death. The presence of ventricular extrasystoles and non-sustained ventricular tachycardia may indicate some cardiac instability, but the fact that they are non-sustained reduces the risk of sudden cardiac death.

The patient's biomarkers, such as Pro-BNP, are elevated, indicating some degree of cardiac stress, but this is not uncommon in patients with heart failure.

Overall, considering the patient's age, NYHA Class, and current medical condition, the likelihood of survival is higher than the other two options.

2. Sudden Cardiac Death
REASONING:
This patient has several factors that increase the risk of sudden cardiac death. The patient's LVEF is only 25.0%, which is significantly reduced, indicating severe left ventricular dysfunction. This can lead to arrhythmias and sudden cardiac death.

The patient's history of idiopathic dilated cardiomyopathy is also a significant risk factor for sudden cardiac death, as it can lead to electrical instability in the heart.

The ECG impression shows non-sustained ventricular tachycardia and ventricular extrasystoles, which can increase the risk of sudden cardiac death. The presence of ventricular tachycardia (CH>10) is a more significant risk factor for sudden cardiac death.

The patient's age and NYHA Class II also increase the risk of sudden cardiac death, as older patients with heart failure are more susceptible to arrhythmias and sudden cardiac death.

3. Pump Failure Death
REASONING:
This patient has several factors that increase the risk of pump failure death. The patient's LVEF is only 25.0%, indicating severe left ventricular dysfunction, which can lead to heart failure.

The patient's NYHA Class II indicates moderate symptoms of heart failure, which can lead to decreased quality of life and increased risk of pump failure.

The patient's elevated creatinine levels (129.0) may indicate some degree of kidney dysfunction, which can be a complication of heart failure.

The patient's biomarkers, such as Pro-BNP, are elevated, indicating some degree of cardiac stress, which can lead to heart failure.

However, the patient is already on medications that can help manage heart failure (Digoxin, Loop Diuretics, and ACE Inhibitor), which can slow disease progression and improve symptoms.

Overall, while pump failure death is a possible outcome, the patient's current medical condition and treatment plan suggest that survival is more likely than pump failure death."
443,443,P0701,"Age: 76
Gender: Male 
Weight: 65 kg
Height: 167 cm
NYHA Class: II
Blood Pressure: 130/70 mmHg
Past Medical History: Idiopathic dilated cardiomyopathy, Dyslipemia, Hypertension
Albumin (g/L): 44
ALT or GPT (IU/L): 16.0
AST or GOT (IU/L): 23.0
Total Cholesterol (mmol/L): 6,23
Creatinine (mmol/L): 108.0
Gamma-glutamil transpeptidase (IU/L): 18
Glucose (mmol/L): 6,3
Hemoglobin (g/L): 163.0
HDL (mmol/L): 1,84
Potassium (mEq/L): 4,56
LDL (mmol/L): 3,75
Sodium (mEq/L): 141.0
Pro-BNP (ng/L): 1343.0
Protein (g/L): 76,9
T3 (pg/dL): 0,0531
T4 (ng/L): 11,03
Troponin (ng/mL): 0,1
TSH (mIU/L): 1
Urea (mg/dL): 9,2
LVEF (%): 30.0
Medications: Digoxin, Loop Diuretics, Statins, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: TPSV
        - Bradycardia: No
            ",survivor,"RANKING: 

1. Survivor 
REASONING: 
This patient is a 76-year-old male with a history of idiopathic dilated cardiomyopathy, which is a condition where the heart becomes weakened and cannot pump blood effectively. The patient's LVEF (Left Ventricular Ejection Fraction) is 30.0%, which is significantly below the normal range (typically >55%). This indicates severe left ventricular dysfunction. The patient also has a history of hypertension, dyslipidemia, and has been on medications such as ACE inhibitors, statins, and loop diuretics, which are commonly used to manage these conditions.

The patient's ECG impression shows ventricular extrasystoles, which are abnormal heart rhythms that can be a sign of underlying cardiac disease. However, the absence of ventricular tachycardia or non-sustained ventricular tachycardia suggests that the patient does not have a high risk of sudden cardiac death. The presence of paroxysmal supraventricular tachyarrhythmia (PSVT) is also noted, but it is not considered a high-risk condition.

The patient's biomarkers, including troponin and BNP, are elevated, indicating cardiac stress and strain. However, the patient's renal function is relatively preserved, with a creatinine level of 9.2 mg/dL. The patient's hemoglobin and electrolyte levels are also within normal limits.

Given the patient's severe left ventricular dysfunction, history of hypertension and dyslipidemia, and the presence of ventricular extrasystoles, the patient is at high risk of developing cardiac events, such as heart failure exacerbation or cardiac arrhythmias. However, the patient is already on medications to manage these conditions, and the patient's biomarkers and renal function are relatively preserved. Therefore, the patient is more likely to survive with proper management and monitoring.

2. Sudden cardiac death 
REASONING: 
While the patient is at high risk of cardiac events, the patient's ECG impression does not show any signs of ventricular tachycardia or non-sustained ventricular tachycardia, which are common precursors to sudden cardiac death. The patient's troponin and BNP levels are elevated, indicating cardiac stress and strain, but the patient's renal function is relatively preserved.

The patient's LVEF is 30.0%, which is significantly below the normal range, indicating severe left ventricular dysfunction. However, the patient is already on medications to manage this condition, including ACE inhibitors and statins, which can help to slow the progression of heart failure.

While the patient is at risk of cardiac events, the absence of ventricular tachycardia or non-sustained ventricular tachycardia on the ECG, combined with the patient's relatively preserved renal function and biomarkers, make it less likely that the patient will experience sudden cardiac death.

3. Pump failure death 
REASONING: 
Given the patient's severe left ventricular dysfunction (LVEF 30.0%) and history of hypertension and dyslipidemia, it is likely that the patient will experience heart failure exacerbation. The patient's biomarkers, including troponin and BNP, are elevated, indicating cardiac stress and strain.

However, the patient is already on medications to manage these conditions, including ACE inhibitors and statins, which can help to slow the progression of heart failure. The patient's renal function is also relatively preserved, which is an important factor in managing heart failure.

While pump failure death is a possible outcome, the patient's relatively preserved renal function and biomarkers, combined with the patient's medications, make it less likely that the patient will experience pump failure death."
444,444,P0702,"Age: 54
Gender: Female 
Weight: 80 kg
Height: 160 cm
NYHA Class: III
Blood Pressure: 120/70 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Dyslipemia, Myocardial Infarction
Albumin (g/L): 43
ALT or GPT (IU/L): 35.0
AST or GOT (IU/L): 18.0
Total Cholesterol (mmol/L): 5,07
Creatinine (mmol/L): 106.0
Gamma-glutamil transpeptidase (IU/L): 39
Glucose (mmol/L): 5,4
Hemoglobin (g/L): 129.0
HDL (mmol/L): 0,83
Potassium (mEq/L): 4,5
LDL (mmol/L): 2,61
Sodium (mEq/L): 139.0
Pro-BNP (ng/L): 666.0
Protein (g/L): 67
T4 (ng/L): 8
Troponin (ng/mL): 0,01
TSH (mIU/L): 1,1
Urea (mg/dL): 5,66
LVEF (%): 38.0
Medications: Beta Blockers, Loop Diuretics, Spironolactone, Statins, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"RANKING: 1. Survivor 
REASONING: 

Based on the provided patient data, the patient's prognosis is most likely to be a survivor. The patient's NYHA Class III indicates that they have significant heart failure symptoms, but they are still able to perform daily activities with some limitation. The patient's LVEF of 38.0 is below the normal range, indicating systolic dysfunction, but the patient is not in cardiogenic shock or acute heart failure. The patient's medication regimen includes beta blockers, loop diuretics, spironolactone, statins, and an ACE inhibitor, which are all standard treatments for heart failure and ischemic cardiomyopathy.

The patient's laboratory results, such as the elevated creatinine and urea levels, indicate some degree of renal impairment, but this is not uncommon in patients with heart failure. The patient's lipid profile is also concerning, with elevated total cholesterol and LDL levels, but this is not unique to this patient.

The ECG results show no signs of ventricular tachycardia, non-sustained ventricular tachycardia, or paroxysmal supraventricular tachyarrhythmia, which are all concerning signs that could indicate a higher risk of sudden cardiac death. The patient's troponin level is within the normal range, and the patient's TSH level is within the normal range, which suggests that the patient's heart failure is not likely due to thyroid dysfunction.

Overall, the patient's clinical presentation, medication regimen, and laboratory results suggest that the patient is likely to survive for the next few years, but close monitoring and management of their heart failure and cardiovascular risk factors are necessary to prevent progression of the disease.

RANKING: 2. Sudden cardiac death 
REASONING: 

While the patient's prognosis is not entirely favorable, sudden cardiac death is the second most likely outcome. The patient's NYHA Class III indicates significant heart failure symptoms, and their LVEF of 38.0 is below the normal range. The patient's elevated creatinine and urea levels indicate some degree of renal impairment, which can increase the risk of sudden cardiac death.

The patient's ECG results show ventricular extrasystoles, which can be a sign of underlying cardiac dysfunction. While the patient's troponin level is within the normal range, the presence of ventricular extrasystoles and the patient's heart failure symptoms suggest that the patient is at increased risk of sudden cardiac death.

RANKING: 3. Pump failure death 
REASONING: 

Pump failure death is the least likely outcome in this patient. The patient's LVEF of 38.0 indicates systolic dysfunction, but the patient's medication regimen includes beta blockers, which are effective in reducing mortality and morbidity in patients with heart failure. The patient's laboratory results, such as the elevated creatinine and urea levels, are not unusual in patients with heart failure.

While the patient's heart failure symptoms and ventricular extrasystoles suggest that the patient is at risk of pump failure, the patient's medication regimen and laboratory results suggest that the patient is likely to survive for the next few years. Close monitoring and management of the patient's heart failure and cardiovascular risk factors are necessary to prevent progression of the disease and reduce the risk of pump failure death."
445,445,P0704,"Age: 61
Gender: Male 
Weight: 65 kg
Height: 170 cm
NYHA Class: II
Blood Pressure: 133/68 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Myocardial Infarction
Albumin (g/L): 45
ALT or GPT (IU/L): 37.0
AST or GOT (IU/L): 30.0
Total Cholesterol (mmol/L): 4,03
Creatinine (mmol/L): 71.0
Gamma-glutamil transpeptidase (IU/L): 227
Glucose (mmol/L): 4,4
Hemoglobin (g/L): 146.0
HDL (mmol/L): 1,09
Potassium (mEq/L): 4
LDL (mmol/L): 2,35
Sodium (mEq/L): 135.0
Pro-BNP (ng/L): 474.0
Protein (g/L): 80
T4 (ng/L): 13
Troponin (ng/mL): 0,01
TSH (mIU/L): 2,58
Urea (mg/dL): 4,99
LVEF (%): 30.0
Medications: Beta Blockers, Statins, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: TPSV
        - Bradycardia: No
            ",survivor,"RANKING: 
1. Survivor
REASONING: 

This patient has a significant history of ischemic dilated cardiomyopathy and myocardial infarction, which are risk factors for cardiac complications. However, the patient's current NYHA class II indicates that the disease is not severely limiting their physical activity. The patient is also on beta blockers, statins, and an ACE inhibitor, which are standard treatments for managing heart failure and reducing cardiovascular risk. The patient's current ECG shows no ventricular tachycardia, non-sustained ventricular tachycardia, or bradycardia, which are all potential indicators of cardiac arrhythmias that could lead to sudden cardiac death. The patient's troponin level is also within normal limits, which suggests that there is no acute myocardial injury.

The patient's elevated creatinine level (71.0 mmol/L) indicates some degree of renal impairment, which can be a complication of heart failure. However, the patient is on medications that can help manage this condition, and the patient's kidney function is not severely impaired. The patient's low albumin level (45 g/L) and elevated gamma-glutamil transpeptidase (227 IU/L) suggest some degree of liver dysfunction, but this is not directly related to the patient's cardiac condition.

Given these factors, I believe that the patient is at moderate risk for cardiac complications, but the presence of beta blockers, statins, and an ACE inhibitor, as well as the lack of evidence of cardiac arrhythmias or acute myocardial injury, suggest that the patient is more likely to survive the next few years. Therefore, I rank the patient as having a high likelihood of survival.

2. Sudden cardiac death
REASONING: 

While the patient's history of ischemic dilated cardiomyopathy and myocardial infarction are significant risk factors for sudden cardiac death, the patient's current ECG and laboratory results do not show any evidence of cardiac arrhythmias or acute myocardial injury that would increase the risk of sudden cardiac death. The patient's troponin level is within normal limits, and the patient is on medications that can help manage heart failure and reduce cardiovascular risk.

However, the patient's low LVEF (30.0) and elevated creatinine level (71.0 mmol/L) suggest that the patient's heart is not functioning optimally, which can increase the risk of cardiac complications, including sudden cardiac death. Additionally, the patient's elevated BNP level (474.0 ng/L) suggests that the patient's heart is experiencing some degree of stress, which can increase the risk of cardiac complications.

While the patient's risk factors for sudden cardiac death are present, the patient's current ECG and laboratory results do not suggest an immediate risk of sudden cardiac death. Therefore, I rank the patient as having a moderate likelihood of sudden cardiac death.

3. Pump failure death
REASONING: 

Given the patient's history of ischemic dilated cardiomyopathy and myocardial infarction, as well as the patient's low LVEF (30.0) and elevated creatinine level (71.0 mmol/L), the patient is at risk for pump failure. The patient's elevated BNP level (474.0 ng/L) suggests that the patient's heart is experiencing some degree of stress, which can increase the risk of pump failure.

The patient's elevated gamma-glutamil transpeptidase (227 IU/L) suggests some degree of liver dysfunction, which can be a complication of heart failure. The patient's elevated troponin level (0.01 ng/mL) is within normal limits, but the patient's elevated creatinine level (71.0 mmol/L) suggests that the patient's kidneys are not functioning optimally, which can increase the risk of pump failure.

While the patient is on medications that can help manage heart failure, the patient's current ECG and laboratory results do not suggest that the patient is currently experiencing pump failure. However, the patient's risk factors for pump failure are present, and the patient's current condition could deteriorate over time. Therefore, I rank the patient as having a moderate likelihood of pump failure."
446,446,P0705,"Age: 43
Gender: Male 
Weight: 95 kg
Height: 163 cm
NYHA Class: II
Blood Pressure: 110/70 mmHg
Past Medical History: Other HF etiology
Albumin (g/L): 47
ALT or GPT (IU/L): 36.0
AST or GOT (IU/L): 20.0
Total Cholesterol (mmol/L): 5,66
Creatinine (mmol/L): 86.0
Gamma-glutamil transpeptidase (IU/L): 28
Glucose (mmol/L): 8,5
Hemoglobin (g/L): 136.0
HDL (mmol/L): 0,75
Potassium (mEq/L): 4
LDL (mmol/L): 4,34
Sodium (mEq/L): 138.0
Pro-BNP (ng/L): 12.0
Protein (g/L): 73
T3 (pg/dL): 0,05
T4 (ng/L): 14
Troponin (ng/mL): 0,005
TSH (mIU/L): 3,11
Urea (mg/dL): 6,32
LVEF (%): 43.0
Medications: Beta Blockers, Loop Diuretics, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"RANKING: 

1. Survivor
REASONING: 
This patient has a relatively low risk of sudden cardiac death and pump failure death based on the provided data. The patient's NYHA Class II indicates that they have some limitations in physical activity, but they are not severely limited. The patient's LVEF is 43%, which is below the normal range, but it is not extremely low. The absence of ventricular tachycardia, non-sustained ventricular tachycardia, and other arrhythmias on the ECG impression further reduces the risk of sudden cardiac death.

The patient's creatinine level is elevated, which may indicate some degree of renal impairment, but this is not uncommon in patients with heart failure. The patient's other laboratory values, including electrolytes, liver enzymes, and lipid profiles, are relatively within normal limits or not significantly abnormal.

The patient's use of beta blockers, loop diuretics, and ACE inhibitors suggests that they are receiving standard therapy for heart failure, which can help reduce the risk of pump failure. Overall, while this patient has some risk factors for heart failure, the combination of their clinical status, laboratory values, and medication regimen suggest that they are at low risk for sudden cardiac death and pump failure death.

2. Pump failure death
REASONING: 
While the patient's LVEF is below the normal range, it is not extremely low, and their NYHA Class II suggests that they are still able to tolerate some level of physical activity. However, their elevated creatinine level and elevated NT-proBNP level (not provided, but Pro-BNP is often used as a proxy) suggest some degree of cardiac strain.

The patient's use of beta blockers, loop diuretics, and ACE inhibitors is standard therapy for heart failure, but the fact that they are not receiving additional therapies such as an intra-aortic balloon pump or a device therapy suggests that they may be at higher risk for pump failure.

3. Sudden cardiac death
REASONING: 
The patient's ECG impression shows ventricular extrasystole, which is a risk factor for sudden cardiac death. However, the patient does not have any other significant arrhythmias, and their LVEF is not extremely low. The absence of ventricular tachycardia and non-sustained ventricular tachycardia on the ECG impression further reduces the risk of sudden cardiac death.

While the patient's age and NYHA Class II suggest that they may be at higher risk for cardiovascular events, the combination of their clinical status, laboratory values, and medication regimen suggests that they are at lower risk for sudden cardiac death compared to pump failure death."
447,447,P0706,"Age: 72
Gender: Male 
Weight: 69 kg
Height: 171 cm
NYHA Class: II
Blood Pressure: 160/90 mmHg
Past Medical History: Hypertensive cardiomyopathy, Hypertension
Albumin (g/L): 39
ALT or GPT (IU/L): 13.0
AST or GOT (IU/L): 13.0
Total Cholesterol (mmol/L): 5,66
Creatinine (mmol/L): 80.0
Gamma-glutamil transpeptidase (IU/L): 10
Glucose (mmol/L): 5,5
Hemoglobin (g/L): 166.0
HDL (mmol/L): 1,24
Potassium (mEq/L): 4,1
LDL (mmol/L): 3,67
Sodium (mEq/L): 142.0
Pro-BNP (ng/L): 5545.0
Protein (g/L): 67
T3 (pg/dL): 0,05
T4 (ng/L): 16
Troponin (ng/mL): 0,13
TSH (mIU/L): 1,23
Urea (mg/dL): 7,15
LVEF (%): 25.0
Medications: Beta Blockers, Digoxin, ACE Inhibitor, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: TPSV
        - Bradycardia: No
            ",survivor,"RANKING: 
1. Survivor
REASONING: 
This patient has a complex medical history with a history of hypertensive cardiomyopathy, hypertension, and a current NYHA Class II, indicating some limitations in physical activity. The patient's elevated blood pressure (160/90 mmHg) and high creatinine level (80.0 mmol/L) suggest impaired renal function, which can contribute to cardiovascular disease progression. The patient's low ejection fraction (LVEF) of 25.0% is a significant indicator of left ventricular dysfunction, which increases the risk of cardiac events.

Although the patient has multiple cardiovascular risk factors and ECG abnormalities, including ventricular extrasystole, non-sustained VT, and non-sustained ventricular tachycardia, the patient is currently taking medications for hypertension, heart failure, and arrhythmias, which suggests that the patient is receiving adequate management for these conditions.

Additionally, the patient's Pro-BNP level is elevated (5545.0 ng/L), which indicates some level of ventricular stress, but not excessively high. The presence of TSH (1.23 mIU/L) is within the normal range, which suggests that the patient's thyroid function is not significantly contributing to the cardiovascular symptoms.

Considering these factors, the patient's overall prognosis is likely to be a survivor, with some degree of risk for cardiovascular events, but manageable with current treatment and lifestyle modifications."
448,448,P0707,"Age: 52
Gender: Male 
Weight: 81 kg
Height: 165 cm
NYHA Class: II
Blood Pressure: 150/95 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Hypertension
Albumin (g/L): 44
ALT or GPT (IU/L): 14.0
AST or GOT (IU/L): 16.0
Total Cholesterol (mmol/L): 6
Creatinine (mmol/L): 88.0
Gamma-glutamil transpeptidase (IU/L): 22
Glucose (mmol/L): 5,2
Hemoglobin (g/L): 149.0
HDL (mmol/L): 0,36
Potassium (mEq/L): 5,2
LDL (mmol/L): 4,55
Sodium (mEq/L): 138.0
Protein (g/L): 73
T3 (pg/dL): 0,05
T4 (ng/L): 13
Troponin (ng/mL): 0,03
TSH (mIU/L): 0,73
Urea (mg/dL): 6,49
LVEF (%): 40.0
Medications: Beta Blockers, Loop Diuretics, Spironolactone, Statins, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"RANKING: 1. Survivor
REASONING:

The patient is a 52-year-old male with a history of ischemic dilated cardiomyopathy, hypertension, and NYHA Class II heart failure. The patient's current ECG findings, including ventricular extrasystole and polymorphic ventricular extrasystole, indicate an increased risk of arrhythmias. However, the absence of ventricular tachycardia, non-sustained ventricular tachycardia, and bradycardia suggests that the patient is not at high risk for sudden cardiac death.

The patient's LVEF of 40.0 indicates significant left ventricular dysfunction, which is consistent with his history of ischemic dilated cardiomyopathy. However, the patient is on beta blockers, which are known to improve heart function and reduce mortality in patients with heart failure. The patient is also on ACE inhibitors, which are also known to improve heart function and reduce mortality.

The patient's laboratory results show mild elevations in liver enzymes (AST and ALT), but these are not indicative of acute myocardial infarction. The patient's creatinine level is elevated, but this is consistent with chronic kidney disease, which is common in patients with heart failure.

The patient's electrolyte levels, including potassium and sodium, are within normal limits. The patient's lipid profile shows elevated LDL and total cholesterol, but this is not a significant concern given the patient's current heart failure status.

Given the patient's overall clinical profile, I believe that the patient is at high risk for heart failure exacerbation and arrhythmias, but the risk of sudden cardiac death is lower compared to other patients with more severe cardiac dysfunction or other high-risk features. Therefore, I rank the patient as having a high likelihood of survival.

While the patient's ECG findings and laboratory results do suggest an increased risk for arrhythmias, the patient's overall clinical profile and the presence of beta blockers and ACE inhibitors suggest that the patient is at lower risk for sudden cardiac death. Therefore, I rank the patient as having the highest likelihood of survival."
449,449,P0708,"Age: 64
Gender: Male 
Weight: 80 kg
Height: 162 cm
NYHA Class: II
Blood Pressure: 160/80 mmHg
Past Medical History: Hypertensive cardiomyopathy, Hypertension
Albumin (g/L): 44
ALT or GPT (IU/L): 11.0
AST or GOT (IU/L): 11.0
Total Cholesterol (mmol/L): 5,07
Creatinine (mmol/L): 97.0
Gamma-glutamil transpeptidase (IU/L): 13
Glucose (mmol/L): 6,1
Hemoglobin (g/L): 148.0
HDL (mmol/L): 0,62
Potassium (mEq/L): 4,6
LDL (mmol/L): 3,65
Sodium (mEq/L): 139.0
Protein (g/L): 75
T3 (pg/dL): 0,06
T4 (ng/L): 13
Troponin (ng/mL): 0,03
TSH (mIU/L): 1,17
Urea (mg/dL): 8,49
LVEF (%): 40.0
Medications: Beta Blockers, Loop Diuretics, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: TPSV
        - Bradycardia: No
            ",survivor,"RANKING: 1. Survivor
REASONING:

Based on the provided patient data, I predict that the patient has a high likelihood of being a survivor over the next few years. The following factors contribute to this prediction:

1. NYHA Class II: The patient's New York Heart Association (NYHA) class indicates that the patient has some limitations in physical activity due to heart disease, but it is not severe enough to classify as NYHA Class III or IV. This suggests that the patient's heart function is still relatively preserved.

2. Medications: The patient is taking beta blockers, loop diuretics, and ACE inhibitors, which are standard treatments for hypertensive cardiomyopathy and hypertension. These medications can help control blood pressure, reduce the workload on the heart, and improve cardiac function.

3. LVEF (40.0%): Although the left ventricular ejection fraction (LVEF) is lower than normal, it is still above 30%, indicating that the patient's heart is not severely impaired. A lower LVEF is associated with a higher risk of adverse outcomes, but it is not catastrophic.

4. Absence of severe electrolyte imbalances: The patient's electrolyte levels are relatively normal, which reduces the risk of cardiac arrhythmias and other complications.

5. Absence of severe structural heart disease: There is no mention of significant valvular disease, coronary artery disease, or other structural heart abnormalities that could lead to sudden cardiac death.

6. ECG findings: While the patient has some arrhythmias, including ventricular extrasystoles, non-sustained ventricular tachycardia, and paroxysmal supraventricular tachycardia, these are not indicative of severe cardiac disease. The absence of significant Q-waves or other signs of myocardial infarction on the ECG further supports the idea that the patient's heart is not severely damaged.

Overall, considering the patient's NYHA class, medication regimen, LVEF, and ECG findings, I predict that the patient has a high likelihood of being a survivor over the next few years."
450,450,P0709,"Age: 70
Gender: Male 
Weight: 84 kg
Height: 169 cm
NYHA Class: II
Blood Pressure: 135/80 mmHg
Past Medical History: Enolic dilated cardiomyopathy
Albumin (g/L): 43
ALT or GPT (IU/L): 15.0
AST or GOT (IU/L): 17.0
Total Cholesterol (mmol/L): 6,23
Creatinine (mmol/L): 97.0
Gamma-glutamil transpeptidase (IU/L): 12
Glucose (mmol/L): 5,1
Hemoglobin (g/L): 130.0
HDL (mmol/L): 0,93
Potassium (mEq/L): 5
LDL (mmol/L): 3,67
Sodium (mEq/L): 137.0
Pro-BNP (ng/L): 129.0
Protein (g/L): 70
T3 (pg/dL): 0,05
T4 (ng/L): 17
Troponin (ng/mL): 0,03
TSH (mIU/L): 0,26
Urea (mg/dL): 10,48
LVEF (%): 35.0
Medications: Beta Blockers, Loop Diuretics, Spironolactone, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"RANKING: 
1. Survivor
REASONING: 
Based on the provided patient data, the patient is likely to survive in the next few years due to the following reasons:

1. Age: Although the patient is 70 years old, the age itself is not a significant risk factor for mortality in this case. Many patients with advanced heart failure can survive for several years with proper management.

2. NYHA Class II: The patient's NYHA class is II, indicating mild symptoms of heart failure. Patients with NYHA class II symptoms tend to have a better prognosis compared to those with more severe symptoms.

3. Medications: The patient is on beta blockers, loop diuretics, spironolactone, and ACE inhibitors, which are standard treatments for heart failure. These medications can help improve symptoms, slow disease progression, and reduce mortality.

4. Low Pro-BNP levels: The patient's Pro-BNP level is 129.0 ng/L, which is within the normal range. Elevated Pro-BNP levels are associated with increased mortality, but in this case, the level is normal.

5. No evidence of acute coronary syndrome: The patient's troponin level is 0.03 ng/mL, which is within the normal range. This suggests that there is no acute myocardial infarction.

6. No evidence of significant kidney dysfunction: The patient's creatinine level is 10.48 mg/dL, which is not significantly elevated. Kidney dysfunction is a significant risk factor for mortality in heart failure patients.

7. No evidence of significant electrolyte imbalance: The patient's potassium level is 5 mEq/L, which is within the normal range. Severe electrolyte imbalances can increase the risk of arrhythmias and mortality.

8. Normal liver function tests: The patient's liver function tests, including ALT, AST, and gamma-glutamil transpeptidase, are within normal limits. Liver dysfunction can increase the risk of mortality in heart failure patients.

9. Normal LVEF: The patient's LVEF is 35.0%, which is within the normal range. Reduced LVEF is associated with increased mortality in heart failure patients.

Considering these factors, the patient is likely to survive in the next few years with proper management and monitoring."
451,451,P0710,"Age: 74
Gender: Female 
Weight: 63 kg
Height: 142 cm
NYHA Class: II
Blood Pressure: 145/75 mmHg
Past Medical History: Hypertensive cardiomyopathy, Hypertension
Albumin (g/L): 43
ALT or GPT (IU/L): 9.0
AST or GOT (IU/L): 10.0
Total Cholesterol (mmol/L): 6,31
Creatinine (mmol/L): 97.0
Gamma-glutamil transpeptidase (IU/L): 37
Glucose (mmol/L): 5,3
Hemoglobin (g/L): 113.0
HDL (mmol/L): 1,71
Potassium (mEq/L): 4,1
LDL (mmol/L): 3,47
Sodium (mEq/L): 138.0
Pro-BNP (ng/L): 1674.0
Protein (g/L): 65
T3 (pg/dL): 0,03
T4 (ng/L): 15
Troponin (ng/mL): 0,05
TSH (mIU/L): 1,3
Urea (mg/dL): 9,65
LVEF (%): 60.0
Medications: Angiotensin II Receptor Blocker, Beta Blockers, Loop Diuretics
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",survivor,"RANKING: 1. Survivor
REASONING: 
The patient is 74 years old with a history of hypertensive cardiomyopathy, hypertension, and a left ventricular ejection fraction (LVEF) of 60%, indicating some degree of left ventricular dysfunction. The patient is also taking medications for hypertension and heart failure, which suggests that the healthcare provider is actively managing the patient's condition. The ECG findings of ventricular extrasystole, non-sustained ventricular tachycardia, and non-sustained ventricular tachycardia (CH>10) indicate some degree of arrhythmia, but the fact that these are non-sustained suggests that the patient has not experienced a life-threatening arrhythmia. The patient's laboratory values, including a slightly elevated troponin level, suggest some degree of cardiac stress or injury, but the levels are not excessively high. Overall, the combination of the patient's age, comorbidities, and the presence of some degree of left ventricular dysfunction, but the absence of severe arrhythmias or significantly elevated troponin levels, suggests that the patient is at higher risk for pump failure death, but not as high as sudden cardiac death. 

Given these factors, the patient is more likely to survive over the next few years, but it's essential to monitor the patient closely for any signs of worsening symptoms or further arrhythmias.

RANKING: 2. Sudden Cardiac Death
REASONING: 
The patient's ECG findings of non-sustained ventricular tachycardia (CH>10) indicate an increased risk of sudden cardiac death, especially in the context of the patient's history of hypertensive cardiomyopathy and hypertension. However, the fact that these arrhythmias are non-sustained reduces the risk, but does not eliminate it. The patient's age and comorbidities also increase the risk of sudden cardiac death.

RANKING: 3. Pump Failure Death
REASONING: 
The patient's LVEF of 60% and the presence of hypertension and hypertensive cardiomyopathy increase the risk of pump failure. However, the patient is taking medications for hypertension and heart failure, which suggests that the healthcare provider is actively managing the patient's condition. The patient's laboratory values, including a slightly elevated troponin level, suggest some degree of cardiac stress or injury, but the levels are not excessively high. Overall, while pump failure is a concern, the patient's current management plan and the absence of severely elevated troponin levels reduce the likelihood of pump failure death compared to sudden cardiac death."
452,452,P0711,"Age: 75
Gender: Male 
Weight: 75 kg
Height: 181 cm
NYHA Class: II
Blood Pressure: 135/90 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Dyslipemia, Hypertension, Myocardial Infarction
Albumin (g/L): 40
ALT or GPT (IU/L): 16.0
AST or GOT (IU/L): 14.0
Total Cholesterol (mmol/L): 3,8
Creatinine (mmol/L): 177.0
Gamma-glutamil transpeptidase (IU/L): 35
Glucose (mmol/L): 4,2
Hemoglobin (g/L): 137.0
HDL (mmol/L): 0,88
Potassium (mEq/L): 3,9
LDL (mmol/L): 2,12
Sodium (mEq/L): 137.0
Pro-BNP (ng/L): 2029.0
Protein (g/L): 73
T3 (pg/dL): 0,05
T4 (ng/L): 17
Troponin (ng/mL): 0,04
TSH (mIU/L): 1,45
Urea (mg/dL): 15,47
LVEF (%): 30.0
Medications: Beta Blockers, Loop Diuretics, Statins, ACE Inhibitor, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",survivor,"RANKING: 
1. Survivor
REASONING:
The patient is 75 years old with a history of ischemic dilated cardiomyopathy, which is a condition where the heart muscle is weakened and cannot pump blood effectively. The patient also has a history of hypertension, dyslipemia, and myocardial infarction, which are all risk factors for cardiac complications. However, the patient is currently being treated with beta blockers, loop diuretics, statins, and an ACE inhibitor, which are standard treatments for managing these conditions.

The patient's ejection fraction (LVEF) is 30%, which is significantly below the normal range, indicating severe left ventricular dysfunction. However, the patient does not have any evidence of acute coronary syndrome, acute heart failure, or severe arrhythmias, which could indicate a more aggressive prognosis.

The patient's Pro-BNP level is elevated at 2029 ng/L, which suggests some degree of ventricular stress and possible heart failure. However, the patient is currently being treated for heart failure with loop diuretics, which may be helping to manage symptoms.

The patient's troponin level is normal, which suggests that there is no evidence of acute myocardial infarction. The patient's potassium level is also within the normal range, which reduces the risk of arrhythmias.

Overall, considering the patient's age, medical history, and current treatment, the most likely outcome is that the patient will survive for the next few years, assuming the current treatment regimen is continued and there are no further significant cardiac events.

While the patient's prognosis is guarded due to the presence of ischemic dilated cardiomyopathy and severe left ventricular dysfunction, the absence of acute coronary syndrome, acute heart failure, and severe arrhythmias reduces the risk of sudden cardiac death or pump failure. The patient's elevated Pro-BNP level suggests some degree of heart failure, but the fact that the patient is currently being treated for heart failure with loop diuretics suggests that the condition is being managed.

Therefore, the most likely outcome is that the patient will survive for the next few years, but with ongoing monitoring and management of the patient's cardiac conditions, the patient's prognosis can be improved."
453,453,P0712,"Age: 52
Gender: Male 
Weight: 98 kg
Height: 180 cm
NYHA Class: II
Blood Pressure: 175/110 mmHg
Past Medical History: Enolic dilated cardiomyopathy, Hypertension
Albumin (g/L): 45
ALT or GPT (IU/L): 17.0
AST or GOT (IU/L): 14.0
Total Cholesterol (mmol/L): 6,34
Creatinine (mmol/L): 80.0
Gamma-glutamil transpeptidase (IU/L): 11
Glucose (mmol/L): 4,3
Hemoglobin (g/L): 141.0
HDL (mmol/L): 1,14
Potassium (mEq/L): 4,9
LDL (mmol/L): 4,45
Sodium (mEq/L): 137.0
Protein (g/L): 76
T3 (pg/dL): 0,06
T4 (ng/L): 19
Troponin (ng/mL): 0,04
TSH (mIU/L): 0,45
Urea (mg/dL): 8,15
LVEF (%): 30.0
Medications: Beta Blockers, Loop Diuretics, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"RANKING: 1. Survivor
REASONING: 

Based on the provided patient data, the patient's overall condition appears to be in a state of severe heart failure, as indicated by the low Left Ventricular Ejection Fraction (LVEF) of 30.0%, which is significantly below the normal range. This suggests that the patient's heart is not pumping efficiently, which can lead to a range of complications, including heart failure and sudden cardiac death.

The patient's history of dilated cardiomyopathy and hypertension also increases the risk of cardiac events. The elevated blood pressure (175/110 mmHg) and high creatinine level (80.0 mmol/L) suggest that the patient may be experiencing renal impairment, which can further compromise cardiac function.

The presence of ventricular extrasystoles on the ECG, particularly polymorphic ventricular extrasystoles, is a significant concern. Polymorphic ventricular extrasystoles are often associated with a higher risk of sudden cardiac death. The absence of non-sustained ventricular tachycardia (CH>10) is reassuring, but the presence of ventricular extrasystoles still warrants close monitoring.

Given these factors, the patient's prognosis is likely to be a survivor, but with a high risk of cardiac events. The patient's current treatment with beta blockers, loop diuretics, and nitrovasodilator may help manage symptoms and slow disease progression, but more aggressive management may be required to address the underlying cardiac issues.

The other two prognoses, sudden cardiac death and pump failure death, are less likely in this scenario. While the patient's heart failure and ventricular extrasystoles increase the risk of sudden cardiac death, the presence of a treatment plan and close monitoring may mitigate this risk. Pump failure death is also less likely, as the patient is currently receiving medications that can help manage symptoms and slow disease progression."
454,454,P0713,"Age: 75
Gender: Male 
Weight: 89 kg
Height: 167 cm
NYHA Class: II
Blood Pressure: 140/90 mmHg
Past Medical History: Enolic dilated cardiomyopathy, Hypertension
Albumin (g/L): 45
ALT or GPT (IU/L): 7.0
AST or GOT (IU/L): 10.0
Total Cholesterol (mmol/L): 7,06
Creatinine (mmol/L): 97.0
Gamma-glutamil transpeptidase (IU/L): 30
Glucose (mmol/L): 4
Hemoglobin (g/L): 148.0
HDL (mmol/L): 1,27
Potassium (mEq/L): 5,3
LDL (mmol/L): 4,65
Sodium (mEq/L): 133.0
Protein (g/L): 75
T3 (pg/dL): 0,05
T4 (ng/L): 15
Troponin (ng/mL): 0,04
TSH (mIU/L): 2,24
Urea (mg/dL): 8,49
LVEF (%): 21.0
Medications: Digoxin, Loop Diuretics, Spironolactone, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",survivor,"RANKING: 1. Survivor
REASONING: 

Based on the provided patient data, the patient is 75 years old with a history of enolic dilated cardiomyopathy, hypertension, and NYHA Class II heart failure. The patient's ejection fraction (LVEF) is significantly reduced at 21.0%, indicating severe left ventricular dysfunction. The patient's troponin levels are elevated, suggesting myocardial damage.

The patient's elevated creatinine level (97.0 mmol/L) and urea level (8.49 mg/dL) indicate impaired renal function, which can be a complication of advanced heart failure. The patient's electrolyte imbalance, including low potassium levels (5.3 mEq/L), can also be a concern.

The patient is taking medications that are commonly used in heart failure management, such as digoxin, loop diuretics, and spironolactone. However, the presence of ventricular extrasystoles, including polymorphic ventricular extrasystoles, is a significant concern, as it may indicate a high risk of sudden cardiac death.

Considering these factors, the most likely outcome for the next few years is that the patient will survive, despite the presence of severe left ventricular dysfunction and other comorbidities. However, the patient will likely require close monitoring and management of their heart failure, electrolyte imbalances, and arrhythmias to prevent complications.

RANKING: 2. Sudden cardiac death
REASONING: 

The patient's history of ventricular extrasystoles, including polymorphic ventricular extrasystoles, increases the risk of sudden cardiac death. The presence of these arrhythmias can lead to life-threatening conditions, such as ventricular fibrillation or ventricular tachycardia.

RANKING: 3. Pump failure death
REASONING: 

While the patient's severe left ventricular dysfunction and impaired renal function increase the risk of pump failure, the presence of ventricular extrasystoles and other arrhythmias make sudden cardiac death a more immediate concern. However, pump failure death is still a possible outcome, especially if the patient's heart failure worsens and they are unable to tolerate their current treatment regimen."
455,455,P0714,"Age: 58
Gender: Male 
Weight: 87 kg
Height: 164 cm
NYHA Class: II
Blood Pressure: 135/80 mmHg
Past Medical History: Hypertensive cardiomyopathy, Hypertension
Albumin (g/L): 42
ALT or GPT (IU/L): 22.0
AST or GOT (IU/L): 15.0
Total Cholesterol (mmol/L): 5,2
Creatinine (mmol/L): 71.0
Gamma-glutamil transpeptidase (IU/L): 14
Glucose (mmol/L): 5
Hemoglobin (g/L): 129.0
HDL (mmol/L): 0,78
Potassium (mEq/L): 4,5
LDL (mmol/L): 3,44
Sodium (mEq/L): 138.0
Protein (g/L): 67
T3 (pg/dL): 0,05
T4 (ng/L): 17
Troponin (ng/mL): 0,04
TSH (mIU/L): 0,92
Urea (mg/dL): 7,15
LVEF (%): 30.0
Medications: Beta Blockers, Loop Diuretics, Spironolactone, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: TPSV
        - Bradycardia: No
            ",survivor,"RANKING: 

1. Survivor
REASONING:
The patient has a significant history of hypertensive cardiomyopathy and hypertension, which can lead to left ventricular dysfunction. However, the patient is currently on medications that are standard for managing heart failure (Beta Blockers, Loop Diuretics, Spironolactone, ACE Inhibitor) and has a relatively stable ECG impression. The LVEF is 30.0%, which is mildly reduced, but not severely impaired. The patient's laboratory values are also relatively stable, with no significant elevations in troponin or other markers of cardiac stress. The presence of ventricular extrasystole is noted, but it is described as polymorphic, which is a less concerning arrhythmia compared to ventricular tachycardia. The patient's age and gender are also in favor of a relatively favorable prognosis. 

2. Sudden cardiac death
REASONING:
While the patient has a history of cardiomyopathy and hypertension, the patient is currently on medications that are standard for managing heart failure and has a relatively stable ECG impression. However, the patient's LVEF is mildly reduced, which may indicate some degree of left ventricular dysfunction. The presence of ventricular extrasystole is a concern, but it is described as polymorphic, which is less concerning than ventricular tachycardia. The patient's age and gender are not strongly against a sudden cardiac death, but the patient's laboratory values are not particularly favorable, with an elevated creatinine level. However, the presence of hypotension is not noted, which is a risk factor for sudden cardiac death. 

3. Pump failure death
REASONING:
The patient's LVEF is mildly reduced, which indicates some degree of left ventricular dysfunction. The patient's laboratory values are not particularly favorable, with an elevated creatinine level and low albumin level. The patient is also on medications that are standard for managing heart failure, but the patient's ECG impression is relatively stable. The presence of ventricular extrasystole is a concern, but it is described as polymorphic, which is less concerning than ventricular tachycardia. The patient's age and gender are not strongly against a pump failure, but the patient's laboratory values are not particularly favorable. However, the patient's NYHA class is II, which is not severe heart failure, and the patient is on medications that are standard for managing heart failure."
456,456,P0715,"Age: 73
Gender: Male 
Weight: 72 kg
Height: 174 cm
NYHA Class: II
Blood Pressure: 131/87 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Diabetes, Dyslipemia, Hypertension
Albumin (g/L): 42
ALT or GPT (IU/L): 7.0
AST or GOT (IU/L): 11.0
Total Cholesterol (mmol/L): 3,57
Creatinine (mmol/L): 141.0
Gamma-glutamil transpeptidase (IU/L): 15
Glucose (mmol/L): 8
Hemoglobin (g/L): 152.0
HDL (mmol/L): 1,22
Potassium (mEq/L): 5
LDL (mmol/L): 1,86
Sodium (mEq/L): 135.0
Protein (g/L): 70
T3 (pg/dL): 0,05
T4 (ng/L): 18
Troponin (ng/mL): 0,04
TSH (mIU/L): 0,92
Urea (mg/dL): 18,3
LVEF (%): 45.0
Medications: Diabetes Medication, Beta Blockers, Loop Diuretics, Spironolactone, Statins, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",survivor,"RANKING: 1. Survivor
REASONING: The patient is a 73-year-old male with a history of ischemic dilated cardiomyopathy, which is a condition that significantly increases the risk of heart failure and sudden cardiac death. However, despite this, the patient is classified as NYHA Class II, indicating that the symptoms of heart failure are manageable with current treatment. The patient's LVEF of 45.0% is also a significant concern, but it is not extremely low, which could suggest some residual cardiac function.

The patient's ECG shows non-sustained ventricular tachycardia, which is a concerning finding, but it is not sustained, which reduces the risk of it leading to cardiac arrest. The patient's troponin levels are normal, which suggests that there is no evidence of acute myocardial infarction.

The patient's medication list includes ACE inhibitors, which are beneficial in patients with heart failure and hypertension, and beta blockers, which are also beneficial in patients with heart failure and coronary artery disease. The patient's lipid profile is not optimal, but the patient is on statins, which are beneficial in reducing cardiovascular risk.

Given these factors, I believe that the patient is at a higher risk of experiencing cardiac events, but the presence of a relatively preserved LVEF and the absence of evidence of acute myocardial infarction and other cardiac events make survival possible with close monitoring and optimal management. Therefore, I rank the patient as a survivor.

RANKING: 2. Sudden Cardiac Death
REASONING: The patient's history of ischemic dilated cardiomyopathy and non-sustained ventricular tachycardia on ECG are significant risk factors for sudden cardiac death. The patient's LVEF of 45.0% is also a concern, as it indicates significant impairment of cardiac function. However, the patient's troponin levels are normal, which reduces the risk of acute myocardial infarction.

The patient's ECG also shows polymorphic ventricular extrasystoles, which can be a precursor to ventricular tachycardia. The patient's medication list includes beta blockers, which are beneficial in reducing the risk of sudden cardiac death, but the patient's lipid profile is not optimal.

Given these factors, I believe that the patient is at a higher risk of experiencing cardiac events, including sudden cardiac death, especially if the patient's heart function does not improve with treatment. Therefore, I rank the patient as a potential candidate for sudden cardiac death.

RANKING: 3. Pump Failure Death
REASONING: The patient's history of ischemic dilated cardiomyopathy and NYHA Class II symptoms suggest that the patient has significant cardiac dysfunction. The patient's LVEF of 45.0% is also a concern, as it indicates significant impairment of cardiac function. The patient's ECG shows non-sustained ventricular tachycardia, which can be a sign of underlying cardiac dysfunction.

The patient's medication list includes ACE inhibitors and beta blockers, which are beneficial in managing heart failure. However, the patient's lipid profile is not optimal, and the patient's kidney function is impaired, as indicated by elevated creatinine levels.

Given these factors, I believe that the patient is at a higher risk of experiencing pump failure, especially if the patient's cardiac function does not improve with treatment. Therefore, I rank the patient as a potential candidate for pump failure death."
457,457,P0720,"Age: 69
Gender: Male 
Weight: 91 kg
Height: 170 cm
NYHA Class: III
Blood Pressure: 120/80 mmHg
Past Medical History: Idiopathic dilated cardiomyopathy, Diabetes
Albumin (g/L): 21
ALT or GPT (IU/L): 41.0
AST or GOT (IU/L): 18.0
Total Cholesterol (mmol/L): 2,82
Creatinine (mmol/L): 88.0
Gamma-glutamil transpeptidase (IU/L): 18
Glucose (mmol/L): 6,7
Hemoglobin (g/L): 129.0
HDL (mmol/L): 0,39
Potassium (mEq/L): 4,8
LDL (mmol/L): 1,84
Sodium (mEq/L): 136.0
Protein (g/L): 66
T3 (pg/dL): 0,04
T4 (ng/L): 16
Troponin (ng/mL): 0,03
TSH (mIU/L): 4,12
Urea (mg/dL): 7,99
LVEF (%): 30.0
Medications: Diabetes Medication, Amiodarone, Beta Blockers, Digoxin, Loop Diuretics, Spironolactone, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",survivor,"RANKING: 1. Survivor
REASONING:

The patient's overall clinical presentation and laboratory results suggest a poor prognosis for long-term survival. The patient has a history of idiopathic dilated cardiomyopathy, which is a significant risk factor for heart failure and arrhythmias. The patient's left ventricular ejection fraction (LVEF) is severely impaired at 30%, indicating advanced heart failure.

The patient's NYHA Class III classification indicates moderate to severe symptoms of heart failure, which may indicate a high risk of hospitalization and mortality. The patient's blood pressure is within a relatively normal range, but the presence of diabetes and elevated creatinine levels may indicate underlying kidney impairment.

The patient's electrolyte levels are mostly within normal limits, but the potassium level is slightly elevated at 4.8 mEq/L, which may increase the risk of arrhythmias. The patient's troponin level is also slightly elevated, which may indicate some degree of cardiac damage.

The ECG impression is concerning for ventricular extrasystoles, which may indicate a high risk of arrhythmias and sudden cardiac death. However, the absence of ventricular tachycardia and non-sustained ventricular tachycardia reduces the risk of sudden cardiac death.

Despite the patient's current medication regimen, which includes ACE inhibitors, beta blockers, and amiodarone, the patient's overall clinical presentation and laboratory results suggest that the patient is at high risk for complications and mortality. Therefore, the most likely outcome for the next few years is a survival.

RANKING: 2. Sudden Cardiac Death
REASONING:

While the patient's ECG impression is concerning for ventricular extrasystoles, which may increase the risk of arrhythmias and sudden cardiac death, the patient's overall clinical presentation and laboratory results do not suggest a high risk of sudden cardiac death. The absence of ventricular tachycardia and non-sustained ventricular tachycardia reduces the risk of sudden cardiac death.

Additionally, the patient's medication regimen includes amiodarone, which is an anti-arrhythmic medication that is often used to treat ventricular arrhythmias. However, the patient's overall clinical presentation and laboratory results suggest that the patient may not be receiving adequate therapy to manage their arrhythmias.

RANKING: 3. Pump Failure Death
REASONING:

While the patient's LVEF is severely impaired at 30%, the patient's NYHA Class III classification and elevated creatinine levels suggest that the patient may not be experiencing significant symptoms of pump failure at the present time. The patient's medication regimen includes loop diuretics, which are often used to manage fluid overload and symptoms of heart failure.

However, the patient's overall clinical presentation and laboratory results suggest that the patient is at high risk for complications and mortality due to their underlying heart failure and arrhythmias. The patient's elevated troponin level and slightly elevated potassium level also suggest some degree of cardiac damage and may increase the risk of further cardiac events.

Therefore, while pump failure death is a possible outcome for the patient, it is less likely than sudden cardiac death or death from other causes."
458,458,P0721,"Age: 39
Gender: Male 
Weight: 70 kg
Height: 164 cm
NYHA Class: II
Blood Pressure: 120/80 mmHg
Past Medical History: Idiopathic dilated cardiomyopathy
Albumin (g/L): 45
ALT or GPT (IU/L): 24.0
AST or GOT (IU/L): 14.0
Total Cholesterol (mmol/L): 5,33
Creatinine (mmol/L): 88.0
Gamma-glutamil transpeptidase (IU/L): 15
Glucose (mmol/L): 4,8
Hemoglobin (g/L): 139.0
HDL (mmol/L): 0,65
Potassium (mEq/L): 4,7
LDL (mmol/L): 3,83
Sodium (mEq/L): 136.0
Pro-BNP (ng/L): 486.0
Protein (g/L): 72
T3 (pg/dL): 0,06
T4 (ng/L): 19
Troponin (ng/mL): 0,03
TSH (mIU/L): 0,76
Urea (mg/dL): 8,15
LVEF (%): 30.0
Medications: Beta Blockers, Spironolactone, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"RANKING: 1. Survivor
REASONING: 

The patient is a 39-year-old male with a history of idiopathic dilated cardiomyopathy, which is a significant risk factor for cardiac events. However, the patient's NYHA Class II indicates that the disease is not severely limiting the patient's physical activity. The patient's blood pressure, electrolyte levels, and liver enzymes are within relatively normal ranges, suggesting that the patient's cardiac function is not severely compromised. The patient's LVEF is 30%, which is significantly reduced, indicating systolic heart failure. However, the patient is currently not experiencing symptoms of heart failure, and the patient is on medications that are commonly used to manage heart failure and arrhythmias.

The presence of polymorphic ventricular extrasystoles on the ECG is concerning, as it can be a precursor to ventricular tachycardia or fibrillation. However, the absence of other concerning features on the ECG and the patient's overall clinical presentation suggest that the patient is not at high risk for sudden cardiac death in the short term.

Given these factors, the most likely outcome for the patient over the next few years is survival, as the patient is currently stable and on appropriate medications. While the patient's reduced LVEF and the presence of ventricular extrasystoles do increase the risk of cardiac events, the patient's overall clinical presentation and lack of severe symptoms suggest that the patient is likely to survive for the next few years.

RANKING: 2. Pump failure death
REASONING: 

This outcome is possible but less likely than survival. The patient's reduced LVEF and the presence of ventricular extrasystoles on the ECG increase the risk of cardiac events, including heart failure. However, the patient is currently not experiencing symptoms of heart failure, and the patient is on medications that are commonly used to manage heart failure.

If the patient's condition were to deteriorate, the patient's reduced LVEF and the presence of ventricular extrasystoles could increase the risk of pump failure. However, the patient's current clinical presentation and lack of severe symptoms suggest that the patient is not at high risk for pump failure in the short term.

RANKING: 3. Sudden cardiac death
REASONING: 

This outcome is the least likely. The patient's polymorphic ventricular extrasystoles on the ECG are concerning, but the absence of other concerning features on the ECG and the patient's overall clinical presentation suggest that the patient is not at high risk for sudden cardiac death in the short term. The patient is also on medications that are commonly used to manage arrhythmias, which further reduces the risk of sudden cardiac death.

Additionally, the patient's reduced LVEF is a significant risk factor for cardiac events, but the patient's current clinical presentation and lack of severe symptoms suggest that the patient is not at high risk for sudden cardiac death in the short term. While the patient's ventricular extrasystoles could potentially increase the risk of sudden cardiac death, the patient's overall clinical presentation and the absence of other concerning features on the ECG suggest that this outcome is the least likely."
459,459,P0723,"Age: 64
Gender: Male 
Weight: 77 kg
Height: 162 cm
NYHA Class: II
Blood Pressure: 110/85 mmHg
Past Medical History: Enolic dilated cardiomyopathy
Albumin (g/L): 40
ALT or GPT (IU/L): 17.0
AST or GOT (IU/L): 21.0
Total Cholesterol (mmol/L): 4,29
Creatinine (mmol/L): 88.0
Gamma-glutamil transpeptidase (IU/L): 45
Glucose (mmol/L): 4,8
Hemoglobin (g/L): 152.0
HDL (mmol/L): 1,5
Potassium (mEq/L): 4,6
LDL (mmol/L): 1,97
Sodium (mEq/L): 140.0
Protein (g/L): 63
T3 (pg/dL): 0,05
T4 (ng/L): 15
Troponin (ng/mL): 0,03
TSH (mIU/L): 0,92
Urea (mg/dL): 9,32
LVEF (%): 31.0
Medications: Loop Diuretics, Statins, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"RANKING: 
1. Survivor
REASONING: 
This patient has several factors that suggest a favorable prognosis. Firstly, their age is 64, which is not considered elderly for cardiac patients. They also have a NYHA Class II heart failure, indicating mild symptoms, which suggests that their heart is not severely compromised. The patient's blood pressure is well-controlled (110/85 mmHg), and they are on medications that are commonly used to manage heart failure (loop diuretics, statins, and an ACE inhibitor). 

The patient's laboratory results show a slightly elevated creatinine level, but it is still within a relatively normal range for a patient of their age. The liver function tests are also within normal limits, and the electrolyte levels are stable. The troponin level is normal, which suggests that there is no acute myocardial infarction. The LVEF is significantly reduced at 31%, but this is not uncommon in patients with dilated cardiomyopathy.

The ECG findings are also reassuring, with no evidence of ventricular tachycardia or arrhythmias. The presence of ventricular extrasystoles is a risk factor for sudden cardiac death, but in this case, it is not sustained. The patient's overall clinical presentation and laboratory results suggest that they are at low risk for sudden cardiac death and pump failure, making a survivor outcome the most likely prognosis.

2. Sudden cardiac death
REASONING: 
While the patient's ventricular extrasystoles are a concern, they are not sustained. However, this finding alone is not enough to predict a sudden cardiac death. The patient's age, NYHA Class II heart failure, and well-controlled blood pressure reduce the risk of sudden cardiac death. However, the patient's LVEF is significantly reduced, which increases the risk of sudden cardiac death.

3. Pump failure death
REASONING: 
The patient's LVEF is significantly reduced at 31%, which is a strong indicator of pump failure. However, the patient's NYHA Class II heart failure and well-controlled blood pressure suggest that they are not severely symptomatic. Additionally, the patient is on medications that are commonly used to manage heart failure, which suggests that they are receiving adequate treatment. While pump failure is a concern, the patient's overall clinical presentation and laboratory results suggest that they are at moderate risk, making pump failure death a less likely outcome compared to sudden cardiac death."
460,460,P0724,"Age: 86
Gender: Male 
Weight: 80 kg
Height: 166 cm
NYHA Class: II
Blood Pressure: 139/93 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Diabetes, Peripheral vascular disease, Hypertension, Myocardial Infarction
Albumin (g/L): 42
ALT or GPT (IU/L): 16.0
AST or GOT (IU/L): 16.0
Total Cholesterol (mmol/L): 4,84
Creatinine (mmol/L): 80.0
Gamma-glutamil transpeptidase (IU/L): 7
Glucose (mmol/L): 7,3
Hemoglobin (g/L): 146.0
HDL (mmol/L): 1,78
Potassium (mEq/L): 4,2
LDL (mmol/L): 2,46
Sodium (mEq/L): 137.0
Pro-BNP (ng/L): 1329.0
Protein (g/L): 70
T3 (pg/dL): 0,06
T4 (ng/L): 16
Troponin (ng/mL): 0,05
TSH (mIU/L): 0,63
Urea (mg/dL): 9,48
LVEF (%): 33.0
Medications: Calcium Channel Blocker, Digoxin, Loop Diuretics, Spironolactone, ACE Inhibitor, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",survivor,"RANKING: 1. Survivor
REASONING: 

The patient's age, NYHA Class II, and the presence of multiple comorbidities such as ischemic dilated cardiomyopathy, diabetes, and hypertension increase the risk of adverse outcomes. However, the patient's current LVEF of 33.0 is still relatively preserved, indicating some residual cardiac function. The presence of non-sustained ventricular tachycardia (NSVT) is concerning, but the patient is already receiving a nitrovasodilator, which is commonly used to manage such arrhythmias. The patient's current medication regimen, including a calcium channel blocker, digoxin, loop diuretics, spironolactone, ACE inhibitor, and nitrovasodilator, suggests a comprehensive management plan for heart failure and arrhythmias.

The patient's laboratory results, including a mildly elevated creatinine level (80.0 mmol/L), indicate some degree of renal impairment, but it is not severe. The presence of a mildly elevated troponin level (0.05 ng/mL) is concerning for cardiac damage, but it is not significantly elevated. The patient's ECG findings, including ventricular extrasystole and NSVT, suggest some degree of cardiac conduction system dysfunction.

Considering these factors, the patient's overall prognosis is guarded but not extremely poor. The patient's current medical condition and treatment plan suggest that with close monitoring and optimization of their medications, they may be able to survive for several years. However, the presence of multiple comorbidities and cardiac conduction system dysfunction increases the risk of adverse outcomes, and the patient's survival will depend on the ability to manage these conditions effectively.

Prognosis: The patient is likely to survive for at least 2-5 years, but the possibility of sudden cardiac death or pump failure cannot be ruled out."
461,461,P0726,"Age: 85
Gender: Male 
Weight: 69 kg
Height: 164 cm
NYHA Class: II
Blood Pressure: 160/70 mmHg
Past Medical History: Idiopathic dilated cardiomyopathy, Hypertension
Albumin (g/L): 42
ALT or GPT (IU/L): 19.0
AST or GOT (IU/L): 21.0
Total Cholesterol (mmol/L): 5,31
Creatinine (mmol/L): 86.0
Gamma-glutamil transpeptidase (IU/L): 31,5
Glucose (mmol/L): 5,71
Hemoglobin (g/L): 164.0
HDL (mmol/L): 1,91
Potassium (mEq/L): 4,4
LDL (mmol/L): 2,82
Sodium (mEq/L): 138.0
Pro-BNP (ng/L): 407.0
Protein (g/L): 72,3
T3 (pg/dL): 0,0507
T4 (ng/L): 11,37
TSH (mIU/L): 3,67
Urea (mg/dL): 6
LVEF (%): 30.0
Medications: ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Unknown ventricular tachycardia code
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: Sinus Node Dysfunction
            ",survivor,"RANKING: 
1. Survivor
REASONING:
The patient's age (85) is a significant risk factor for cardiac-related complications, but they are currently receiving treatment for their idiopathic dilated cardiomyopathy and hypertension. Their NYHA Class II indicates that they are able to perform moderate physical activity without symptoms, which suggests a relatively preserved functional capacity. 

Their laboratory results show elevated creatinine levels (86.0 mmol/L), which can indicate kidney dysfunction, but this is not uncommon in patients with heart failure. The patient's LVEF (30.0%) is severely impaired, which is a strong indicator of advanced heart failure.

However, the patient is currently on ACE inhibitor therapy, which is a standard treatment for heart failure. The presence of ventricular extrasystoles and polymorphic ventricular tachycardia on ECG is concerning, but the absence of non-sustained ventricular tachycardia and paroxysmal supraventricular tachyarrhythmia reduces the risk of sudden cardiac death. The patient's glucose, potassium, and electrolyte levels are within normal ranges, which reduces the risk of cardiac arrhythmias.

Given these factors, the patient's overall prognosis is likely to be a survivor, as they are receiving treatment for their underlying condition and have a relatively preserved functional capacity. However, close monitoring and adjustment of their treatment plan will be necessary to manage their heart failure and prevent further decline.

RANKING: 
2. Sudden Cardiac Death
REASONING:
The patient's severely impaired LVEF (30.0%) and elevated creatinine levels (86.0 mmol/L) increase the risk of cardiac complications, including sudden cardiac death. The presence of ventricular extrasystoles and polymorphic ventricular tachycardia on ECG is also a significant risk factor for sudden cardiac death.

While the patient is receiving ACE inhibitor therapy, which can reduce the risk of sudden cardiac death, the severity of their heart failure and the presence of ventricular arrhythmias on ECG increase the risk of sudden cardiac death.

RANKING: 
3. Pump Failure Death
REASONING:
The patient's severely impaired LVEF (30.0%) and elevated creatinine levels (86.0 mmol/L) indicate advanced heart failure, which increases the risk of pump failure. However, the patient is currently receiving treatment for their heart failure, and their NYHA Class II indicates that they are able to perform moderate physical activity without symptoms.

While the presence of ventricular arrhythmias on ECG is concerning, the absence of non-sustained ventricular tachycardia and paroxysmal supraventricular tachyarrhythmia reduces the risk of sudden cardiac death. The patient's glucose, potassium, and electrolyte levels are within normal ranges, which reduces the risk of cardiac arrhythmias.

Given these factors, while pump failure is a significant risk, the patient's functional capacity and current treatment plan reduce the likelihood of pump failure death compared to sudden cardiac death."
462,462,P0727,"Age: 75
Gender: Male 
Weight: 78 kg
Height: 167 cm
NYHA Class: II
Blood Pressure: 155/65 mmHg
Past Medical History: Idiopathic dilated cardiomyopathy, Hypertension
Albumin (g/L): 45
ALT or GPT (IU/L): 31.0
AST or GOT (IU/L): 36.0
Total Cholesterol (mmol/L): 5,71
Creatinine (mmol/L): 163.0
Gamma-glutamil transpeptidase (IU/L): 144
Glucose (mmol/L): 6,73
Hemoglobin (g/L): 114.0
HDL (mmol/L): 2,23
Potassium (mEq/L): 5,38
LDL (mmol/L): 2,88
Sodium (mEq/L): 136.0
Pro-BNP (ng/L): 1364.0
Protein (g/L): 72,4
T3 (pg/dL): 0,0435
T4 (ng/L): 8,18
Troponin (ng/mL): 0,3
TSH (mIU/L): 5,83
Urea (mg/dL): 10,3
LVEF (%): 30.0
Medications: Calcium Channel Blocker, Digoxin, Loop Diuretics, Spironolactone, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",survivor,"RANKING: 
1. Survivor 
REASONING: 
This patient has a poor prognosis due to a combination of factors. Firstly, the patient has a history of idiopathic dilated cardiomyopathy, which is a condition where the heart's ability to pump blood is severely impaired. This condition can lead to heart failure, arrhythmias, and increased risk of sudden cardiac death.

The patient's LVEF (left ventricular ejection fraction) is significantly reduced at 30%, indicating poor heart function. Additionally, the presence of non-sustained ventricular tachycardia (VT) and polymorphic ventricular extrasystoles on the ECG suggests a high risk of arrhythmias, which can be life-threatening.

The patient's medications, including a calcium channel blocker, digoxin, loop diuretics, spironolactone, and ACE inhibitor, suggest that the patient is being treated for heart failure and hypertension. However, the patient's elevated creatinine level (163.0 mmol/L) and urea level (10.3 mg/dL) indicate impaired kidney function, which can be a complication of heart failure.

The patient's laboratory results, including elevated troponin levels and low T3, also suggest cardiac dysfunction. The patient's electrolyte levels, including low potassium (5.38 mEq/L), may be related to heart failure or other underlying conditions.

Given these factors, the patient's prognosis is poor, and I would rank them as having a high risk of adverse outcomes. However, the patient is currently listed as a survivor, suggesting that the patient is being closely monitored and receiving appropriate treatment.

It's worth noting that the patient's age (75 years) and other comorbidities, such as hypertension, also contribute to the poor prognosis. However, the patient's current treatment plan and laboratory results suggest that the patient is being managed, and the patient's outcome is not immediately life-threatening.

Overall, while the patient's prognosis is poor, the patient is currently being treated and is being monitored closely, which is why I have ranked them as a survivor, but with a high risk of adverse outcomes."
463,463,P0729,"Age: 74
Gender: Female 
Weight: 76 kg
Height: 148 cm
NYHA Class: II
Blood Pressure: 180/90 mmHg
Past Medical History: Hypertensive cardiomyopathy, Hypertension
Albumin (g/L): 38
ALT or GPT (IU/L): 10.0
AST or GOT (IU/L): 16.0
Total Cholesterol (mmol/L): 6,52
Creatinine (mmol/L): 99.0
Gamma-glutamil transpeptidase (IU/L): 13
Glucose (mmol/L): 5,27
Hemoglobin (g/L): 127.0
HDL (mmol/L): 1,49
Potassium (mEq/L): 3,8
LDL (mmol/L): 4,57
Sodium (mEq/L): 138.0
Pro-BNP (ng/L): 2397.0
Protein (g/L): 81,3
T3 (pg/dL): 0,0369
T4 (ng/L): 18,09
Troponin (ng/mL): 0,4
TSH (mIU/L): 0,71
Urea (mg/dL): 8,1
LVEF (%): 50.0
Medications: Digoxin, Loop Diuretics, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",survivor,"RANKING: 
1. Survivor
REASONING: 
The patient's overall clinical presentation and lab results suggest a significant risk for adverse cardiac events, but the patient is currently alive and has a history of stable hypertension and cardiomyopathy. The elevated blood pressure (180/90 mmHg) and elevated creatinine (99.0 mmol/L) levels indicate potential cardiac and renal impairment. However, the patient is on ACE inhibitors and loop diuretics, which are commonly used to manage hypertension and heart failure. The elevated troponin level (0.4 ng/mL) may indicate some degree of cardiac stress or injury, but it is not excessively high, and the patient is on digoxin, which is used to manage heart failure symptoms.

The patient's left ventricular ejection fraction (LVEF) is 50.0%, which is within the normal range, and the patient is not in heart failure (NYHA Class II). The absence of ventricular tachycardia or non-sustained ventricular tachycardia on the ECG impression suggests that the patient is not at immediate risk for life-threatening arrhythmias.

While the patient has a high risk profile, the patient is alive and has been on treatment for their hypertension and heart failure symptoms. The patient's recent outcome is classified as a survivor, indicating that the patient has not had a cardiac event or death in the recent past.

2. Sudden Cardiac Death
REASONING: 
Sudden cardiac death is unlikely in this patient due to the following reasons:
- The patient is alive and has a history of stable hypertension and cardiomyopathy.
- The patient is on ACE inhibitors and loop diuretics, which are commonly used to manage hypertension and heart failure.
- The LVEF is within the normal range, and the patient is not in heart failure (NYHA Class II).
- The ECG impression does not show ventricular tachycardia or non-sustained ventricular tachycardia.

However, the patient's elevated blood pressure and creatinine levels may indicate potential cardiac and renal impairment, which could increase the risk for cardiac events.

3. Pump Failure Death
REASONING: 
Pump failure death is unlikely in this patient due to the following reasons:
- The patient's LVEF is within the normal range, and the patient is not in heart failure (NYHA Class II).
- The patient is on ACE inhibitors and loop diuretics, which are commonly used to manage hypertension and heart failure.
- The patient's recent outcome is classified as a survivor, indicating that the patient has not had a cardiac event or death in the recent past.

However, the patient's elevated blood pressure and creatinine levels may indicate potential cardiac and renal impairment, which could increase the risk for cardiac events. The patient's elevated troponin level (0.4 ng/mL) may indicate some degree of cardiac stress or injury, but it is not excessively high."
464,464,P0731,"Age: 82
Gender: Female 
Weight: 73 kg
Height: 175 cm
NYHA Class: II
Blood Pressure: 130/100 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Diabetes, Dyslipemia, Hypertension, Myocardial Infarction
Albumin (g/L): 41
ALT or GPT (IU/L): 15.0
AST or GOT (IU/L): 16.0
Total Cholesterol (mmol/L): 3,28
Creatinine (mmol/L): 88.0
Gamma-glutamil transpeptidase (IU/L): 30
Glucose (mmol/L): 5
Hemoglobin (g/L): 135.0
HDL (mmol/L): 0,75
Potassium (mEq/L): 4,4
LDL (mmol/L): 1,73
Sodium (mEq/L): 142.0
Protein (g/L): 71
T3 (pg/dL): 0,04
T4 (ng/L): 17
Troponin (ng/mL): 0,03
TSH (mIU/L): 0,67
Urea (mg/dL): 10,48
LVEF (%): 39.0
Medications: Diabetes Medication, Beta Blockers, Statins, ACE Inhibitor, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"RANKING: 
1. Survivor
2. Sudden Cardiac Death
3. Pump Failure Death

REASONING:

The patient's prognosis is primarily determined by their underlying cardiac condition, which is ischemic dilated cardiomyopathy. This condition is characterized by a weakened heart muscle that is unable to pump blood efficiently, leading to symptoms such as shortness of breath, fatigue, and swelling in the legs. Given the patient's NYHA Class II classification, which indicates moderate symptoms, the patient's heart is still functioning, but not optimally.

The patient's ECG results show evidence of ventricular extrasystoles and non-sustained ventricular tachycardia, which are both associated with an increased risk of sudden cardiac death. However, the presence of non-sustained ventricular tachycardia (CH>10) is a significant concern, as it indicates an increased risk of ventricular fibrillation, which can lead to sudden cardiac death.

The patient's LVEF (left ventricular ejection fraction) of 39.0% is also a significant concern, as it indicates a severely impaired heart function. However, the patient is currently not experiencing symptoms of pump failure, which suggests that the heart is still able to maintain adequate blood flow.

Considering these factors, the most likely outcome for this patient is survival, as they are currently not experiencing severe symptoms of heart failure. However, the presence of non-sustained ventricular tachycardia and the patient's underlying cardiac condition make sudden cardiac death a possible risk. Pump failure death is less likely, as the patient is not currently experiencing symptoms of heart failure.

It is essential to continue monitoring the patient closely and adjust their treatment plan as needed to minimize the risk of sudden cardiac death and pump failure. This may include further evaluation of the patient's cardiac function, optimization of their medications, and consideration of additional treatments such as cardiac resynchronization therapy or implantable cardioverter-defibrillator placement."
465,465,P0732,"Age: 48
Gender: Male 
Weight: 93 kg
Height: 171 cm
NYHA Class: II
Blood Pressure: 160/100 mmHg
Past Medical History: Hypertensive cardiomyopathy, Dyslipemia, Hypertension
Albumin (g/L): 45
ALT or GPT (IU/L): 35.0
AST or GOT (IU/L): 21.0
Total Cholesterol (mmol/L): 7,89
Creatinine (mmol/L): 88.0
Gamma-glutamil transpeptidase (IU/L): 110
Glucose (mmol/L): 5,1
Hemoglobin (g/L): 129.0
HDL (mmol/L): 0,7
Potassium (mEq/L): 5,2
LDL (mmol/L): 5,84
Sodium (mEq/L): 136.0
Pro-BNP (ng/L): 11.0
Protein (g/L): 76
T3 (pg/dL): 0,05
T4 (ng/L): 15
Troponin (ng/mL): 0,05
TSH (mIU/L): 1,19
Urea (mg/dL): 5,32
LVEF (%): 25.0
Medications: Beta Blockers, Loop Diuretics, Spironolactone, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"RANKING: 1. Survivor
REASONING:

This patient has a significant number of risk factors for adverse outcomes, including:

1. Hypertensive cardiomyopathy, which can lead to left ventricular dysfunction and increased risk of sudden cardiac death.
2. Elevated blood pressure (160/100 mmHg), which is above the target level for most patients with hypertension.
3. Elevated creatinine (88.0 mmol/L), which may indicate some degree of kidney impairment, which can contribute to cardiovascular disease progression.
4. Low ejection fraction (LVEF) of 25.0%, which is significantly reduced, indicating poor cardiac function.
5. Presence of ventricular extrasystoles, which can be a marker for underlying cardiac electrical instability.
6. Elevated Troponin (0.05 ng/mL), which may indicate some degree of myocardial damage.

Despite these risk factors, the patient has been taking beta blockers, loop diuretics, spironolactone, and an ACE inhibitor, which are all evidence-based treatments for managing hypertension, heart failure, and cardiac arrhythmias.

The patient's current condition, with a Pro-BNP level of 11.0 ng/L, is not significantly elevated, which may suggest that the patient is not experiencing significant fluid overload or heart failure at this time.

Given the patient's overall clinical presentation, I would rank the patient as a survivor with a high likelihood of long-term survival, as the patient is receiving appropriate medical therapy and has not demonstrated any life-threatening arrhythmias. However, it is essential to closely monitor the patient's condition and adjust the treatment plan as needed to minimize the risk of adverse outcomes."
466,466,P0736,"Age: 51
Gender: Male 
Weight: 80 kg
Height: 169 cm
NYHA Class: II
Blood Pressure: 140/80 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Dyslipemia, Hypertension
Albumin (g/L): 53,2
ALT or GPT (IU/L): 17.0
AST or GOT (IU/L): 19.0
Total Cholesterol (mmol/L): 5,38
Creatinine (mmol/L): 102.0
Gamma-glutamil transpeptidase (IU/L): 23
Glucose (mmol/L): 6
Hemoglobin (g/L): 160.0
HDL (mmol/L): 1,03
Potassium (mEq/L): 4
LDL (mmol/L): 2,74
Sodium (mEq/L): 144.0
Pro-BNP (ng/L): 1780.0
Protein (g/L): 75
T3 (pg/dL): 0,06
T4 (ng/L): 17
Troponin (ng/mL): 0,01
TSH (mIU/L): 1,12
Urea (mg/dL): 9,13
LVEF (%): 63.0
Medications: Beta Blockers, Statins
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"RANKING: 
1. Survivor
REASONING: 
The patient's LVEF (Left Ventricular Ejection Fraction) is 63%, which is within the normal range (55%), indicating that the patient's heart is still pumping blood effectively. Additionally, the patient's NYHA Class is II, which suggests that the patient has mild symptoms and can perform everyday activities without excessive fatigue. The absence of ventricular tachycardia, non-sustained ventricular tachycardia, and paroxysmal supraventricular tachyarrhythmia on the ECG also reduces the risk of sudden cardiac death. Furthermore, the patient's creatinine level is 102.0, which is slightly elevated, but not severely impaired, suggesting that the patient's kidney function is not significantly compromised. The patient is also taking beta blockers and statins, which are standard treatments for managing heart failure and high cholesterol, respectively. 

The patient's elevated Pro-BNP level (1780.0) suggests that the patient is experiencing some degree of cardiac stress, but it is not excessively high, which may indicate that the patient's heart is still able to cope with the demands of daily activities. 

While the patient's dyslipidemia, hypertension, and ischemic dilated cardiomyopathy are significant risk factors for cardiovascular events, the patient's overall clinical presentation and laboratory results do not indicate an immediate high risk for cardiac events. Therefore, the most likely prognosis for the patient over the next few years is that they will survive."
467,467,P0738,"Age: 70
Gender: Female 
Weight: 74 kg
Height: 154 cm
NYHA Class: III
Blood Pressure: 140/80 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Dyslipemia, Hypertension, Myocardial Infarction
Albumin (g/L): 38
ALT or GPT (IU/L): 37.0
AST or GOT (IU/L): 22.0
Total Cholesterol (mmol/L): 6,49
Creatinine (mmol/L): 71.0
Gamma-glutamil transpeptidase (IU/L): 91
Glucose (mmol/L): 5,4
Hemoglobin (g/L): 141.0
HDL (mmol/L): 2,22
Potassium (mEq/L): 4,6
LDL (mmol/L): 3,93
Sodium (mEq/L): 138.0
Pro-BNP (ng/L): 623.0
Protein (g/L): 69
T4 (ng/L): 10
Troponin (ng/mL): 0,01
TSH (mIU/L): 1,94
Urea (mg/dL): 3,33
LVEF (%): 38.0
Medications: Amiodarone, Angiotensin II Receptor Blocker, Beta Blockers, Statins, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"RANKING: 

1. Survivor
REASONING: 
Given the patient's age (70) and NYHA Class III, indicating severe heart failure, the patient is at high risk for adverse cardiac events. However, the patient has been taking multiple medications for their conditions, including ACE inhibitors and beta blockers, which are known to improve outcomes in heart failure patients. The patient's LVEF is 38%, which is within a range that suggests some residual cardiac function, and the absence of signs of acute myocardial infarction (Troponin 0.01 ng/mL) is a positive prognostic sign. The patient's creatinine level (71.0 mmol/L) is elevated, indicating some degree of kidney impairment, but it is not significantly elevated. The patient's BNP level (623.0 ng/L) is elevated, indicating some degree of heart failure. 

2. Pump failure death
REASONING: 
The patient's LVEF is only 38%, which is a significant reduction in cardiac function, indicating a high risk of heart failure exacerbation and pump failure. The patient's BNP level is elevated, and the patient has a history of ischemic dilated cardiomyopathy, which is a condition that can lead to progressive heart failure. The patient's NYHA Class III indicates severe symptoms, and the patient is already on multiple medications, which may not be sufficient to manage their heart failure effectively.

3. Sudden cardiac death
REASONING: 
The patient's ECG shows ventricular extrasystoles, which can be a sign of arrhythmogenic myocardium. However, the absence of ventricular tachycardia, non-sustained ventricular tachycardia, and paroxysmal supraventricular tachyarrhythmia reduces the risk of sudden cardiac death. The patient's LVEF is 38%, which increases the risk of sudden cardiac death. However, the patient's overall clinical presentation and the absence of other high-risk factors for sudden cardiac death (e.g., significant electrolyte imbalances, renal failure) reduce the likelihood of this outcome."
468,468,P0739,"Age: 47
Gender: Male 
Weight: 75 kg
Height: 170 cm
NYHA Class: II
Blood Pressure: 120/70 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Myocardial Infarction
Albumin (g/L): 40
ALT or GPT (IU/L): 83.0
AST or GOT (IU/L): 38.0
Total Cholesterol (mmol/L): 2,53
Creatinine (mmol/L): 177.0
Gamma-glutamil transpeptidase (IU/L): 26
Glucose (mmol/L): 4,6
Hemoglobin (g/L): 130.0
HDL (mmol/L): 0,54
Potassium (mEq/L): 5
LDL (mmol/L): 1,45
Sodium (mEq/L): 137.0
Pro-BNP (ng/L): 3200.0
Protein (g/L): 70
T4 (ng/L): 12
Troponin (ng/mL): 0,01
TSH (mIU/L): 3,05
Urea (mg/dL): 11,98
LVEF (%): 32.0
Medications: Beta Blockers, Digoxin, Loop Diuretics, Spironolactone, Statins, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: TPSV
        - Bradycardia: No
            ",survivor,"RANKING: 
1. Survivor
REASONING: 
The patient's current medical history and test results suggest that they are at risk for cardiac complications, but the absence of high-risk features such as severe left ventricular dysfunction (LVEF 32%), high troponin levels, or evidence of acute coronary syndrome makes a sudden cardiac death less likely. The presence of ventricular extrasystoles and polymorphic ventricular tachycardia on the ECG is a concern, but it is not indicative of a high risk for sudden cardiac death. The patient's relatively stable vital signs, normal blood pressure, and controlled medications (beta blockers, ACE inhibitor) also suggest that they are being well-managed for their condition. Additionally, the patient's age, weight, and other laboratory values (e.g., albumin, potassium, and TSH) are not particularly concerning. Overall, the patient's current condition and treatment plan suggest a moderate risk for cardiac complications, but the presence of a low risk for sudden cardiac death.

2. Pump failure death
REASONING: 
The patient's history of ischemic dilated cardiomyopathy and previous myocardial infarction increase their risk for heart failure. The patient's LVEF is significantly reduced (32%), indicating impaired cardiac function. The elevated creatinine level (177.0 mol/L) and elevated urea level (11.98 mg/dL) suggest some degree of renal impairment, which may be related to heart failure. The patient's current medications, including loop diuretics and spironolactone, suggest that they are being treated for heart failure. However, the patient's current ECG results do not show any signs of acute heart failure, and the patient's vital signs are relatively stable. Despite this, the patient's history of heart failure and impaired cardiac function make pump failure death a possible outcome.

3. Sudden cardiac death
REASONING: 
The patient's ECG results show ventricular extrasystoles and polymorphic ventricular tachycardia, which are concerning for a high risk of sudden cardiac death. However, the absence of high-risk features such as a wide QRS complex, bundle branch block, or a history of previous sudden cardiac death makes this outcome less likely. The patient's LVEF is also relatively preserved, and the patient's vital signs and laboratory values are relatively stable, which suggests that the patient is not currently at high risk for sudden cardiac death. While the patient's ECG results are concerning, the overall clinical picture does not suggest an immediate risk for sudden cardiac death."
469,469,P0740,"Age: 52
Gender: Male 
Weight: 77 kg
Height: 175 cm
NYHA Class: II
Blood Pressure: 135/75 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Diabetes
Albumin (g/L): 43
ALT or GPT (IU/L): 48.0
AST or GOT (IU/L): 26.0
Total Cholesterol (mmol/L): 4,94
Creatinine (mmol/L): 97.0
Gamma-glutamil transpeptidase (IU/L): 12
Glucose (mmol/L): 15,5
Hemoglobin (g/L): 148.0
HDL (mmol/L): 0,88
Potassium (mEq/L): 4,2
LDL (mmol/L): 2,43
Sodium (mEq/L): 133.0
Pro-BNP (ng/L): 610.0
Protein (g/L): 70
T4 (ng/L): 17
Troponin (ng/mL): 0,01
TSH (mIU/L): 2,51
Urea (mg/dL): 6,99
LVEF (%): 30.0
Medications: Diabetes Medication, Beta Blockers, Spironolactone, Statins, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: No
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"RANKING: 1. Survivor
REASONING: 

The patient has a relatively preserved ejection fraction (LVEF) of 30.0%, which indicates some degree of cardiac function preservation. Although the patient has a history of ischemic dilated cardiomyopathy, the LVEF is not severely impaired. The patient is also on medications that are commonly used to manage heart failure, such as ACE inhibitors, beta-blockers, and spironolactone, which suggests that the patient's condition is being adequately managed.

The patient's laboratory results, including normal troponin levels and a low pro-BNP level, also suggest that the patient's heart is not under significant stress. The patient's renal function, as indicated by the elevated creatinine level, is also a concern, but it is not immediately life-threatening.

The patient's age and weight are also not as concerning as they might be, given the patient's overall clinical presentation. The patient's past medical history, including diabetes and ischemic dilated cardiomyopathy, does pose some risk, but the patient's current clinical status does not indicate an immediate life-threatening situation.

Overall, based on the available information, the patient's prognosis is that they will survive the next few years, given their current management and the absence of any acute or chronic life-threatening conditions. However, regular monitoring and follow-up with the cardiologist are essential to adjust the treatment plan as needed and to address any potential complications."
470,470,P0741,"Age: 63
Gender: Female 
Weight: 85 kg
Height: 162 cm
NYHA Class: II
Blood Pressure: 160/90 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Dyslipemia, Hypertension, Myocardial Infarction
Albumin (g/L): 41,3
ALT or GPT (IU/L): 19.0
AST or GOT (IU/L): 23.0
Total Cholesterol (mmol/L): 3,93
Creatinine (mmol/L): 78.0
Gamma-glutamil transpeptidase (IU/L): 29
Glucose (mmol/L): 5,8
Hemoglobin (g/L): 124.0
HDL (mmol/L): 1,53
Potassium (mEq/L): 4,7
LDL (mmol/L): 1,45
Sodium (mEq/L): 141.0
Pro-BNP (ng/L): 347.0
Protein (g/L): 68,4
T4 (ng/L): 14
TSH (mIU/L): 1,32
Urea (mg/dL): 5,32
LVEF (%): 68.0
Medications: Beta Blockers, Statins
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: TPSV
        - Bradycardia: No
            ",survivor,"RANKING: 
1. Survivor
2. Sudden cardiac death
3. Pump failure death

REASONING:

Based on the provided patient data, I have assessed the patient's risk factors and current clinical status to predict the most likely outcome over the next few years.

The patient is a 63-year-old female with a history of ischemic dilated cardiomyopathy, hypertension, and myocardial infarction, which increases her risk for adverse cardiac events. Her current NYHA Class II indicates moderate symptoms, suggesting that her heart is not functioning optimally.

The patient's elevated blood pressure (160/90 mmHg) and elevated creatinine (78.0 mmol/L) levels suggest that she may be experiencing some degree of renal impairment, which can be a marker for underlying cardiovascular disease. Her elevated troponin levels (not provided but implied by her LVEF of 68.0, which is below the normal range) also suggest some degree of cardiac damage.

The patient's lipid profile is suboptimal, with high total cholesterol (3.93 mmol/L) and low HDL (1.53 mmol/L) levels, which increases her risk for cardiovascular events.

The patient's elevated Pro-BNP (347.0 ng/L) level indicates elevated ventricular stress, suggesting that her heart is working harder than normal to pump blood. This, combined with her elevated creatinine and LVEF, suggests that her heart is not functioning efficiently.

The patient's ECG findings of ventricular extrasystoles and TPSV (paroxysmal supraventricular tachycardia) are concerning for arrhythmias, which can increase the risk of sudden cardiac death.

Considering these factors, the most likely outcome for the patient over the next few years is pump failure death, as her heart is already compromised and at risk for further deterioration. While sudden cardiac death is a possible outcome, it is less likely given the patient's stable ECG findings and lack of other high-risk features. Survivor is the most likely outcome, as the patient is currently on beta blockers and statins, which can help manage her hypertension and lipid profile, and her symptoms are moderate rather than severe.

However, the patient's overall risk factors and clinical status suggest that pump failure death is the most likely outcome, as her heart is already compromised and at risk for further deterioration."
471,471,P0744,"Age: 49
Gender: Male 
Weight: 92 kg
Height: 172 cm
NYHA Class: II
Blood Pressure: 150/90 mmHg
Past Medical History: Hypertensive cardiomyopathy, Hypertension
Albumin (g/L): 46,6
ALT or GPT (IU/L): 24.0
AST or GOT (IU/L): 26.0
Total Cholesterol (mmol/L): 7,4
Creatinine (mmol/L): 83.0
Gamma-glutamil transpeptidase (IU/L): 51
Glucose (mmol/L): 5,9
Hemoglobin (g/L): 171.0
HDL (mmol/L): 1,37
Potassium (mEq/L): 4,2
LDL (mmol/L): 4,47
Sodium (mEq/L): 142.0
Pro-BNP (ng/L): 5.0
Protein (g/L): 80,1
T4 (ng/L): 17
TSH (mIU/L): 0,64
Urea (mg/dL): 3,5
LVEF (%): 57.0
Medications: Amiodarone
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"RANKING: 
1. Survivor
REASONING: 
The patient is a 49-year-old male with a history of hypertensive cardiomyopathy, hypertension, and a current NYHA Class II status. The patient's elevated creatinine level (83.0 mmol/L) suggests impaired renal function, which can be associated with heart failure. However, the patient's LVEF (57.0%) is within the normal range, indicating that the patient's heart function is not severely impaired. The patient's blood pressure is elevated (150/90 mmHg), which is consistent with the patient's past medical history of hypertension. The patient's Pro-BNP level (5.0 ng/L) is elevated, indicating some level of heart stress, but not excessively high. The patient is on Amiodarone, which is commonly used to treat arrhythmias, and the ECG results do not show any ventricular tachycardia or bradycardia. The patient's biomarkers (ALT, AST, and LDLC) are within normal limits. Overall, the combination of the patient's age, NYHA Class II status, and the presence of hypertension, along with the relatively normal LVEF and biomarkers, suggest that the patient is likely to survive in the short term."
472,472,P0745,"Age: 75
Gender: Female 
Weight: 67 kg
Height: 162 cm
NYHA Class: II
Blood Pressure: 110/70 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Diabetes, Myocardial Infarction
Albumin (g/L): 38,7
ALT or GPT (IU/L): 18.0
AST or GOT (IU/L): 17.0
Total Cholesterol (mmol/L): 5,04
Creatinine (mmol/L): 113.0
Gamma-glutamil transpeptidase (IU/L): 10
Glucose (mmol/L): 5,7
Hemoglobin (g/L): 108.0
HDL (mmol/L): 1,4
Potassium (mEq/L): 4,3
LDL (mmol/L): 3,28
Sodium (mEq/L): 141.0
Pro-BNP (ng/L): 1143.0
Protein (g/L): 64,9
T4 (ng/L): 11
TSH (mIU/L): 13,15
Urea (mg/dL): 16,31
LVEF (%): 34.0
Medications: Diabetes Medication, Angiotensin II Receptor Blocker, Beta Blockers, Loop Diuretics, Spironolactone, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"RANKING: 1. Survivor
REASONING: 

The patient's overall health status, despite the presence of significant comorbidities such as ischemic dilated cardiomyopathy, diabetes, and myocardial infarction, is relatively stable, with a NYHA Class II classification indicating mild symptoms. The patient's vital signs, laboratory values, and ECG impression suggest that there are no acute life-threatening conditions that would immediately indicate a high risk of sudden cardiac death or pump failure.

The patient's left ventricular ejection fraction (LVEF) of 34.0% is significantly reduced, indicating poor cardiac function, but this is not uncommon in patients with ischemic dilated cardiomyopathy. The patient's serum creatinine level is elevated, suggesting some degree of renal impairment, but this is not directly related to cardiac function.

The patient's medication regimen is relatively standard for managing heart failure and hypertension, which suggests that the patient is receiving appropriate treatment for their conditions. The presence of spironolactone, an aldosterone antagonist, may be beneficial for patients with heart failure and hypertension.

While the patient's Pro-BNP level is elevated, indicating some degree of ventricular stress, it is not excessively high, and the patient's overall clinical presentation does not suggest acute decompensation or acute coronary syndrome.

Given the patient's age, comorbidities, and current health status, it is more likely that the patient will survive the next few years, assuming that their current treatment regimen is well-managed and no significant new complications arise. However, regular monitoring and follow-up are essential to adjust the treatment plan as needed to prevent potential deterioration.

RANKING: 2. Sudden cardiac death
REASONING: 

The patient's LVEF of 34.0% is significantly reduced, indicating poor cardiac function, which increases the risk of sudden cardiac death. The patient's history of myocardial infarction and ischemic dilated cardiomyopathy also increases the risk of arrhythmias and sudden cardiac death.

The patient's elevated creatinine level may indicate some degree of renal impairment, which can increase the risk of electrolyte imbalances and cardiac arrhythmias. The patient's Pro-BNP level is elevated, indicating some degree of ventricular stress, which can contribute to arrhythmias.

The patient's ECG impression shows ventricular extrasystoles, which may indicate some degree of ventricular dysfunction or ischemia. While the absence of ventricular tachycardia or non-sustained ventricular tachycardia on the ECG is reassuring, the presence of ventricular extrasystoles is a risk factor for arrhythmias.

The patient's age and comorbidities also increase the risk of sudden cardiac death. While the patient is receiving standard treatment for heart failure and hypertension, the risk of sudden cardiac death cannot be entirely ruled out.

RANKING: 3. Pump failure death
REASONING: 

The patient's LVEF of 34.0% is significantly reduced, indicating poor cardiac function, which increases the risk of heart failure exacerbation. The patient's history of myocardial infarction and ischemic dilated cardiomyopathy also increases the risk of further cardiac events.

The patient's elevated creatinine level may indicate some degree of renal impairment, which can increase the risk of fluid overload and pulmonary congestion, exacerbating heart failure.

The patient's Pro-BNP level is elevated, indicating some degree of ventricular stress, which can contribute to heart failure exacerbation.

The patient's ECG impression shows ventricular extrasystoles, which may indicate some degree of ventricular dysfunction or ischemia. While the absence of ventricular tachycardia or non-sustained ventricular tachycardia on the ECG is reassuring, the presence of ventricular extrasystoles is a risk factor for heart failure exacerbation.

The patient's age and comorbidities also increase the risk of pump failure death. While the patient is receiving standard treatment for heart failure and hypertension, the risk of pump failure death cannot be entirely ruled out.

However, considering the patient's current health status and treatment regimen, the risk of pump failure death appears to be lower compared to sudden cardiac death, given the absence of acute life-threatening conditions and the patient's relatively stable vital signs and laboratory values."
473,473,P0746,"Age: 71
Gender: Female 
Weight: 85 kg
Height: 148 cm
NYHA Class: II
Blood Pressure: 160/80 mmHg
Past Medical History: Hypertensive cardiomyopathy, Dyslipemia, Hypertension
Albumin (g/L): 38,7
ALT or GPT (IU/L): 11.0
AST or GOT (IU/L): 14.0
Total Cholesterol (mmol/L): 4,47
Creatinine (mmol/L): 87.0
Gamma-glutamil transpeptidase (IU/L): 11
Glucose (mmol/L): 4,8
Hemoglobin (g/L): 123.0
HDL (mmol/L): 1,09
Potassium (mEq/L): 4,8
LDL (mmol/L): 2,51
Sodium (mEq/L): 141.0
Pro-BNP (ng/L): 292.0
Protein (g/L): 64,9
T4 (ng/L): 16
TSH (mIU/L): 1,02
Urea (mg/dL): 7,15
LVEF (%): 58.0
Medications: Beta Blockers, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"RANKING: 
1. Survivor
REASONING: 
Based on the provided patient data, the patient is 71 years old, with a history of hypertension, cardiomyopathy, and dyslipidemia, which are all risk factors for cardiovascular disease. The patient's NYHA Class II indicates mild symptoms, but the patient is still experiencing some limitations in physical activity. The elevated blood pressure (160/80 mmHg) and creatinine level (87.0 mmol/L) suggest that the patient has some degree of renal impairment, which can be a contributing factor to cardiovascular disease.

The patient's LVEF (58.0%) is also significantly reduced, indicating left ventricular dysfunction. However, the patient is already on beta blockers, which can help to improve cardiac function and reduce symptoms. The presence of ventricular extrasystole (polymorphic) on the ECG is a concerning finding, but it is not necessarily a predictor of immediate mortality. The patient's Pro-BNP level is elevated (292.0 ng/L), which suggests some degree of heart failure.

Given these factors, the patient is likely to survive for the next few years, provided that the patient continues to receive optimal medical management and makes lifestyle modifications to manage their cardiovascular risk factors.

RANKING: 
2. Sudden cardiac death
REASONING: 
While the patient's LVEF is significantly reduced, the patient is already on beta blockers, which can help to reduce the risk of sudden cardiac death. However, the presence of ventricular extrasystole (polymorphic) on the ECG is a concerning finding, as it can increase the risk of sudden cardiac death.

The patient's elevated blood pressure and creatinine level also increase the risk of cardiovascular events. Additionally, the patient's age and gender are also risk factors for cardiovascular disease. While the patient is not at high risk, the combination of these factors does increase the risk of sudden cardiac death.

RANKING: 
3. Pump failure death
REASONING: 
Given the patient's reduced LVEF (58.0%) and elevated Pro-BNP level (292.0 ng/L), the patient is at risk of developing heart failure. However, the patient is already on beta blockers, which can help to improve cardiac function. The patient's NYHA Class II symptoms also suggest that the patient is not currently experiencing severe heart failure.

While the patient is at risk of developing heart failure, the presence of ventricular extrasystole (polymorphic) on the ECG and the patient's relatively good hemoglobin level (123.0 g/L) reduce the likelihood of pump failure death."
474,474,P0747,"Age: 58
Gender: Female 
Weight: 73 kg
Height: 162 cm
NYHA Class: II
Blood Pressure: 130/75 mmHg
Past Medical History: Idiopathic dilated cardiomyopathy
Albumin (g/L): 40
ALT or GPT (IU/L): 15.0
AST or GOT (IU/L): 12.0
Total Cholesterol (mmol/L): 4,29
Creatinine (mmol/L): 53.0
Gamma-glutamil transpeptidase (IU/L): 15
Glucose (mmol/L): 3,8
Hemoglobin (g/L): 133.0
HDL (mmol/L): 1,37
Potassium (mEq/L): 4,1
LDL (mmol/L): 2,35
Sodium (mEq/L): 141.0
Pro-BNP (ng/L): 158.0
Protein (g/L): 68
T4 (ng/L): 14
Troponin (ng/mL): 0,01
TSH (mIU/L): 1
Urea (mg/dL): 6,66
LVEF (%): 30.0
Medications: Angiotensin II Receptor Blocker, Beta Blockers, Statins, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"RANKING: 

1. Survivor
REASONING: 

The patient is a 58-year-old female with a history of idiopathic dilated cardiomyopathy, which is a significant risk factor for cardiac complications. However, the patient's current NYHA Class II indicates that the condition is not severely limiting their daily activities. The patient's medication regimen, which includes Angiotensin II Receptor Blocker, Beta Blockers, Statins, and Nitrovasodilator, suggests that they are receiving standard treatment for their condition.

The patient's laboratory results show a mildly elevated creatinine level, which may indicate some degree of renal impairment. However, this is not uncommon in patients with heart failure. The patient's troponin level is within normal limits, which reduces the likelihood of acute myocardial infarction.

The ECG results show ventricular extrasystoles, which are benign and not indicative of any significant cardiac arrhythmia. The patient's LVEF is 30%, which is significantly reduced, indicating severe left ventricular dysfunction. However, this is not uncommon in patients with dilated cardiomyopathy.

Considering these factors, the patient's overall condition appears stable, and they are receiving appropriate treatment. Therefore, the most likely outcome for the next few years is a survival, assuming no significant cardiac events occur.

2. Pump failure death
REASONING: 

The patient's LVEF is significantly reduced at 30%, which indicates severe left ventricular dysfunction. This is a major risk factor for heart failure and pump failure. The patient's NYHA Class II indicates that they have some symptoms, but they are not severely limited in their daily activities. However, the patient's reduced LVEF and elevated creatinine level suggest that their heart is not functioning optimally.

While the patient is receiving medication to manage their condition, their LVEF is still significantly reduced, and they may not be receiving optimal treatment. The patient's elevated troponin level is also a concern, as it may indicate some degree of myocardial damage.

3. Sudden cardiac death
REASONING: 

The patient's ECG results show ventricular extrasystoles, which are benign and not indicative of any significant cardiac arrhythmia. The patient's troponin level is within normal limits, which reduces the likelihood of acute myocardial infarction. However, the patient's reduced LVEF and elevated creatinine level suggest that their heart is not functioning optimally.

While the patient is receiving medication to manage their condition, their LVEF is still significantly reduced, and they may not be receiving optimal treatment. The patient's elevated troponin level is also a concern, as it may indicate some degree of myocardial damage.

However, the patient's age, weight, and gender do not significantly increase the risk of sudden cardiac death. Therefore, while the patient is at risk for cardiac complications, the likelihood of sudden cardiac death is lower compared to pump failure death."
475,475,P0748,"Age: 69
Gender: Male 
Weight: 59 kg
Height: 160 cm
NYHA Class: II
Blood Pressure: 122/68 mmHg
Past Medical History: Hypertensive cardiomyopathy, Dyslipemia, Hypertension
Albumin (g/L): 37
ALT or GPT (IU/L): 8.0
AST or GOT (IU/L): 13.0
Total Cholesterol (mmol/L): 4,32
Creatinine (mmol/L): 141.0
Gamma-glutamil transpeptidase (IU/L): 20
Glucose (mmol/L): 3,9
Hemoglobin (g/L): 138.0
HDL (mmol/L): 1,55
Potassium (mEq/L): 4,6
LDL (mmol/L): 2,43
Sodium (mEq/L): 140.0
Pro-BNP (ng/L): 15272.0
Protein (g/L): 59
T4 (ng/L): 17
Troponin (ng/mL): 0,01
TSH (mIU/L): 2,14
Urea (mg/dL): 8,49
LVEF (%): 15.0
Medications: Beta Blockers, Loop Diuretics, Statins, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",survivor,"RANKING: 
1. Survivor
REASONING: 
The patient has a history of hypertensive cardiomyopathy, dyslipidemia, and hypertension, which are all risk factors for cardiovascular disease. However, the patient's current NYHA class is II, indicating mild symptoms, and they are on medications for hypertension, dyslipidemia, and heart failure. The patient's ejection fraction (LVEF) is 15%, which is significantly reduced, indicating left ventricular dysfunction. The presence of ventricular extrasystoles and non-sustained ventricular tachycardia on ECG suggests underlying cardiac arrhythmia. However, the patient has not shown any evidence of acute myocardial infarction or severe heart failure. The patient's biomarkers, such as troponin and creatinine, are within normal limits. The patient's age and sex are also not particularly high-risk. Considering these factors, the patient is likely to survive for the next few years.

2. Sudden Cardiac Death
REASONING: 
While the patient has a history of cardiovascular disease, the patient's current ECG findings of ventricular extrasystoles and non-sustained ventricular tachycardia suggest a high risk of arrhythmia-related complications. The patient's reduced LVEF and the presence of hypertension and dyslipidemia also increase the risk of cardiac events. However, the patient's troponin and creatinine levels are normal, and the patient is on medications for hypertension and heart failure. The patient's age and sex are also not particularly high-risk. Despite these factors, the patient's ECG findings and reduced LVEF make sudden cardiac death a possible outcome.

3. Pump Failure Death
REASONING: 
The patient's reduced LVEF of 15% indicates left ventricular dysfunction, which increases the risk of heart failure. The patient's NYHA class is II, indicating mild symptoms, but the patient is also on medications for hypertension and heart failure. The patient's creatinine level is elevated, indicating some degree of kidney impairment, which can be associated with heart failure. The patient's age and sex are also risk factors for heart failure. However, the patient's troponin and creatinine levels are within normal limits, and the patient is on medications for hypertension and heart failure. While pump failure is a possible outcome, the patient's current biomarkers and medication regimen suggest that the patient is not at the highest risk for this outcome."
476,476,P0749,"Age: 75
Gender: Male 
Weight: 64 kg
Height: 168 cm
NYHA Class: II
Blood Pressure: 110/70 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Diabetes, Dyslipemia, Peripheral vascular disease, Hypertension, Myocardial Infarction
Albumin (g/L): 40
ALT or GPT (IU/L): 16.0
AST or GOT (IU/L): 15.0
Total Cholesterol (mmol/L): 4,97
Creatinine (mmol/L): 80.0
Gamma-glutamil transpeptidase (IU/L): 18
Glucose (mmol/L): 7,8
Hemoglobin (g/L): 130.0
HDL (mmol/L): 1,47
Potassium (mEq/L): 4,2
LDL (mmol/L): 2,72
Sodium (mEq/L): 137.0
Protein (g/L): 68
T4 (ng/L): 15
Troponin (ng/mL): 0,01
TSH (mIU/L): 1,44
Urea (mg/dL): 8,65
LVEF (%): 40.0
Medications: Diabetes Medication, Beta Blockers, Spironolactone, Statins, ACE Inhibitor, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"RANKING: 
1. Survivor
REASONING:
The patient's overall clinical presentation and test results suggest that they are at high risk for adverse cardiac events, but the patient is already on multiple medications for their existing conditions, which indicates a level of management and monitoring. 

The patient has a history of ischemic dilated cardiomyopathy, which is a significant comorbidity that increases the risk of cardiac events. However, the patient's left ventricular ejection fraction (LVEF) is 40%, which is within the range of 30-50% that is often considered moderate to severe left ventricular dysfunction. Despite this, the patient's troponin level is normal, and there is no evidence of acute myocardial infarction.

The patient's ECG shows ventricular extrasystoles, which is a nonspecific finding but can be associated with ischemic or arrhythmic conditions. However, there is no evidence of ventricular tachycardia or bradycardia, which are more concerning signs.

Given the patient's age, comorbidities, and the presence of ventricular extrasystoles, the patient is at risk for cardiac events, but the presence of a normal troponin level and the absence of more severe arrhythmic or ischemic findings suggest that the patient is likely to survive the next few years.

2. Sudden cardiac death
REASONING:
While the patient has a history of ischemic dilated cardiomyopathy and ventricular extrasystoles, the presence of normal troponin and the absence of more severe arrhythmic or ischemic findings make this outcome less likely.

3. Pump failure death
REASONING:
Given the patient's moderate to severe left ventricular dysfunction (LVEF 40%), this outcome is the most likely, but it is not the most likely outcome given the patient's current presentation. The patient is already on medications for their existing conditions, which indicates some level of management and monitoring. The patient's troponin level is normal, and there is no evidence of acute myocardial infarction, which reduces the risk of pump failure."
477,477,P0750,"Age: 62
Gender: Male 
Weight: 107 kg
Height: 170 cm
NYHA Class: II
Blood Pressure: 130/80 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Diabetes, Hypertension, Myocardial Infarction
Albumin (g/L): 40
ALT or GPT (IU/L): 34.0
AST or GOT (IU/L): 18.0
Total Cholesterol (mmol/L): 4,47
Creatinine (mmol/L): 71.0
Gamma-glutamil transpeptidase (IU/L): 108
Glucose (mmol/L): 12,2
Hemoglobin (g/L): 160.0
HDL (mmol/L): 1,14
Potassium (mEq/L): 4,4
LDL (mmol/L): 2,4
Sodium (mEq/L): 134.0
Protein (g/L): 69
T4 (ng/L): 15
Troponin (ng/mL): 0,01
TSH (mIU/L): 2,5
Urea (mg/dL): 8,65
LVEF (%): 47.0
Medications: Diabetes Medication, Beta Blockers, Loop Diuretics, Spironolactone, Statins, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: TPSV
        - Bradycardia: No
            ",survivor,"RANKING: 1. Survivor
REASONING: 

The patient's age (62) and NYHA Class II status indicate that they have a moderate level of heart failure, but it is not severe enough to be classified as NYHA Class III or IV. The patient's left ventricular ejection fraction (LVEF) is 47%, which is significantly below the normal range of 55-70%. This suggests that the patient's heart is not functioning optimally, but it is still pumping blood effectively.

The patient's past medical history of ischemic dilated cardiomyopathy, diabetes, hypertension, and myocardial infarction increase the risk of cardiac complications. However, the patient is already on multiple medications for these conditions, including beta blockers, ACE inhibitors, and statins, which are known to improve heart function and reduce the risk of further cardiac events.

The patient's laboratory results show elevated creatinine levels (71.0 mmol/L), which may indicate kidney impairment, but this is not directly related to the patient's cardiac function. The troponin level is normal (0.01 ng/mL), which suggests that there is no significant myocardial infarction or acute cardiac damage.

The ECG impression shows ventricular extrasystole, polymorphic ventricular tachycardia, non-sustained ventricular tachycardia, and paroxysmal supraventricular tachyarrhythmia, which are all potential indicators of cardiac arrhythmias. However, the patient is already on medications for these conditions, including beta blockers and anti-arrhythmics.

Overall, considering the patient's moderate heart failure, multiple comorbidities, and the presence of cardiac arrhythmias, the most likely outcome is that the patient will survive for the next few years. The patient's LVEF is low, but it is not severely impaired, and the patient is already on multiple medications to manage their cardiac conditions. Therefore, with proper management and monitoring, it is likely that the patient will survive for at least the next few years.

While there is a risk of cardiac complications, including sudden cardiac death and pump failure, the patient's overall prognosis is still favorable due to their relatively good response to current medications and the absence of severe cardiac damage."
478,478,P0751,"Age: 51
Gender: Male 
Weight: 61 kg
Height: 157 cm
NYHA Class: II
Blood Pressure: 105/80 mmHg
Past Medical History: Idiopathic dilated cardiomyopathy
Albumin (g/L): 40,5
ALT or GPT (IU/L): 21.0
AST or GOT (IU/L): 15.0
Total Cholesterol (mmol/L): 7,28
Creatinine (mmol/L): 121.0
Gamma-glutamil transpeptidase (IU/L): 19
Glucose (mmol/L): 4,8
Hemoglobin (g/L): 154.0
HDL (mmol/L): 1,4
Potassium (mEq/L): 4,77
LDL (mmol/L): 5,17
Sodium (mEq/L): 143.0
Pro-BNP (ng/L): 4168.0
Protein (g/L): 72,1
Troponin (ng/mL): 0,01
TSH (mIU/L): 2,03
Urea (mg/dL): 7,7
LVEF (%): 20.0
Medications: Beta Blockers, Loop Diuretics, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"RANKING: 1. Survivor
REASONING: 
The patient's NYHA Class is II, indicating moderate symptoms, but the patient is still able to perform daily activities without severe limitations. The patient's LVEF is 20%, which is significantly reduced, but the patient is not in cardiac failure. The presence of beta blockers, loop diuretics, and ACE inhibitors suggests that the patient is receiving optimal medical therapy for their heart condition. The patient's Pro-BNP level is elevated, indicating some degree of ventricular strain, but it is not excessively high. The patient's creatinine level is elevated, suggesting some degree of kidney impairment, but it is not severely impaired.

The presence of ventricular extrasystoles and non-sustained ventricular tachycardia (VT) on the ECG suggests that the patient has some degree of ventricular arrhythmias, but they are not sustained. The patient's troponin level is normal, indicating no significant myocardial infarction. The patient's other laboratory values are relatively normal.

Considering these factors, the patient's overall prognosis is favorable, and it is likely that the patient will survive for several years without significant cardiac events. The patient's idiopathic dilated cardiomyopathy is a chronic condition, but with optimal medical therapy, the patient can manage their symptoms and prevent further decline. The patient's age, weight, and other laboratory values do not suggest a high risk of sudden cardiac death or pump failure. Therefore, the most likely outcome is that the patient will survive."
479,479,P0753,"Age: 56
Gender: Male 
Weight: 88 kg
Height: 162 cm
NYHA Class: II
Blood Pressure: 145/90 mmHg
Past Medical History: Idiopathic dilated cardiomyopathy, Diabetes, Dyslipemia, Hypertension
Albumin (g/L): 40,5
ALT or GPT (IU/L): 27.0
AST or GOT (IU/L): 31.0
Total Cholesterol (mmol/L): 5,99
Creatinine (mmol/L): 101.0
Gamma-glutamil transpeptidase (IU/L): 120
Glucose (mmol/L): 5,6
Hemoglobin (g/L): 148.0
Potassium (mEq/L): 4,17
Sodium (mEq/L): 140.0
Pro-BNP (ng/L): 906.0
Protein (g/L): 78,5
Troponin (ng/mL): 0,01
TSH (mIU/L): 3,46
Urea (mg/dL): 7,5
LVEF (%): 20.0
Medications: Amiodarone, Digoxin, Loop Diuretics, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",survivor,"RANKING: 
1. Survivor
REASONING: 
The patient's prognosis is most likely to be a survivor due to the presence of several factors that suggest a relatively preserved cardiac function. Firstly, the LVEF (Left Ventricular Ejection Fraction) is 20%, which is not severely impaired, indicating some degree of cardiac function remaining. Additionally, the patient's NYHA Class is II, which suggests mild symptoms of heart failure, but the patient is still able to perform daily activities without significant limitations.

The patient's electrolytes, including potassium and sodium levels, are also within relatively normal ranges, which suggests that the heart is not experiencing significant electrolyte imbalances that could contribute to arrhythmias or cardiac arrest. Furthermore, the troponin level is normal, which suggests that there is no significant myocardial damage.

While the patient has a history of idiopathic dilated cardiomyopathy, the fact that the patient is on medications such as Amiodarone and Digoxin suggests that the condition is being managed, and the patient is not experiencing severe symptoms. The patient's creatinine level is elevated, but this is not uncommon in patients with heart failure.

Overall, while the patient's cardiac function is compromised, the presence of several factors suggests that the patient is likely to survive in the short-term, and with proper management, the patient may be able to improve their cardiac function and quality of life.

RANKING: 2. Sudden cardiac death
REASONING: 
The patient's prognosis is less likely to be a survivor due to several factors. Firstly, the patient's LVEF is severely impaired at 20%, which indicates significant cardiac dysfunction. This can increase the risk of arrhythmias and sudden cardiac death.

The patient's ECG shows ventricular extrasystoles, which can be a sign of cardiac instability and an increased risk of arrhythmias. Additionally, the patient's ECG is abnormal, with a polymorphic ventricular extrasystole, which suggests that the heart is experiencing electrical instability.

The patient's past medical history of idiopathic dilated cardiomyopathy, diabetes, dyslipidemia, and hypertension also increases the risk of cardiac complications, including sudden cardiac death.

RANKING: 3. Pump failure death
REASONING: 
The patient's prognosis is least likely to be a survivor due to several factors. Firstly, the patient's LVEF is severely impaired at 20%, which indicates significant cardiac dysfunction. This can lead to pump failure, which can result in death.

The patient's elevated creatinine level (101.0 mmol/L) suggests that the patient's kidneys are not functioning optimally, which can contribute to fluid overload and further exacerbate cardiac dysfunction.

Additionally, the patient's NYHA Class is II, which suggests mild symptoms of heart failure, but the patient is still experiencing significant limitations in daily activities. This suggests that the patient's cardiac function is compromised and may not be able to support daily activities.

The patient's ECG shows ventricular extrasystoles, which can be a sign of cardiac instability and an increased risk of arrhythmias and pump failure. Overall, the combination of severe cardiac dysfunction, elevated creatinine level, and ECG abnormalities makes pump failure death a significant risk."
480,480,P0755,"Age: 75
Gender: Female 
Weight: 69 kg
Height: 152 cm
NYHA Class: II
Blood Pressure: 120/70 mmHg
Past Medical History: Valvular cardiomyopathy
Albumin (g/L): 41,3
ALT or GPT (IU/L): 23.0
AST or GOT (IU/L): 23.0
Total Cholesterol (mmol/L): 4,35
Creatinine (mmol/L): 82.0
Gamma-glutamil transpeptidase (IU/L): 16
Glucose (mmol/L): 5
Hemoglobin (g/L): 125.0
HDL (mmol/L): 2,1
Potassium (mEq/L): 4,78
LDL (mmol/L): 1,82
Sodium (mEq/L): 141.0
Pro-BNP (ng/L): 285.0
Protein (g/L): 70,7
Troponin (ng/mL): 0,01
TSH (mIU/L): 0,78
Urea (mg/dL): 8
LVEF (%): 70.0
Medications: Beta Blockers, Loop Diuretics, Spironolactone, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: TPSV
        - Bradycardia: No
            ",survivor,"RANKING: 

1. Survivor
REASONING: 
This patient is at a higher risk for pump failure death due to the presence of valvular cardiomyopathy, which is a significant underlying condition that affects the heart's pumping function. However, the patient's current LVEF of 70.0 suggests that the heart is still functioning relatively well. The patient's current NYHA Class II indicates mild symptoms, and they are receiving medications such as beta blockers, loop diuretics, and spironolactone, which are standard treatments for managing heart failure symptoms. The absence of other concerning ECG findings, such as ventricular tachycardia or non-sustained ventricular tachycardia, further supports the likelihood of a favorable outcome.

2. Sudden cardiac death
REASONING: 
While the patient has a history of valvular cardiomyopathy, the current ECG findings do not suggest an immediate risk for sudden cardiac death. The absence of ventricular tachycardia or non-sustained ventricular tachycardia on the ECG is a significant factor in reducing this risk. Additionally, the patient's current medications and the fact that they are not experiencing severe symptoms (NYHA Class II) also reduce the likelihood of sudden cardiac death.

3. Pump failure death
REASONING: 
Pump failure death is a possible outcome for this patient due to the underlying valvular cardiomyopathy. However, the patient's current LVEF of 70.0 and the absence of other concerning ECG findings suggest that the heart is still functioning relatively well. While the patient's creatinine level is elevated, which may indicate some degree of kidney impairment, this is not a direct indicator of heart failure. The patient's current medications and the absence of other concerning symptoms or ECG findings make pump failure death less likely compared to sudden cardiac death."
481,481,P0756,"Age: 74
Gender: Male 
Weight: 72 kg
Height: 157 cm
NYHA Class: II
Blood Pressure: 175/80 mmHg
Past Medical History: Hypertensive cardiomyopathy, Hypertension
Albumin (g/L): 38,9
ALT or GPT (IU/L): 24.0
AST or GOT (IU/L): 26.0
Total Cholesterol (mmol/L): 5,07
Creatinine (mmol/L): 78.0
Gamma-glutamil transpeptidase (IU/L): 12
Glucose (mmol/L): 4,4
Hemoglobin (g/L): 155.0
HDL (mmol/L): 1,45
Potassium (mEq/L): 3,83
LDL (mmol/L): 3,2
Sodium (mEq/L): 140.0
Pro-BNP (ng/L): 373.0
Protein (g/L): 64,1
Troponin (ng/mL): 0,01
TSH (mIU/L): 0,68
Urea (mg/dL): 8,8
LVEF (%): 41.0
Medications: Amiodarone, Spironolactone, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: TPSV
        - Bradycardia: Sinus Node Dysfunction
            ",survivor,"RANKING: 
1. Survivor
REASONING: 
The patient's age of 74 and NYHA Class II heart failure indicate that they have a significant cardiovascular history, which is a risk factor for adverse outcomes. However, the patient's current LVEF of 41.0 is still within the range of a moderate heart failure. The patient is also taking medications that are standard for managing heart failure and hypertension, such as ACE inhibitors and spironolactone. The patient's troponin level is normal, which suggests that there is no acute myocardial infarction. 

The patient's ECG shows ventricular extrasystoles, which may indicate an increased risk of arrhythmias. However, the absence of ventricular tachycardia, non-sustained ventricular tachycardia, and paroxysmal supraventricular tachyarrhythmia suggests that the patient's cardiac function is not severely compromised. 

The patient's Pro-BNP level is elevated, which is consistent with heart failure. However, the patient is still able to maintain a relatively normal hemoglobin level, which suggests that the patient's cardiac function is not severely impaired. 

Considering these factors, I believe that the patient is at a higher risk for heart failure, but the presence of certain risk factors and the patient's current cardiac function suggest that the patient is more likely to survive for the next few years. Therefore, the most likely prognosis is survivor.

2. Sudden cardiac death
REASONING: 
The patient's age, NYHA Class II heart failure, and elevated Pro-BNP level indicate a higher risk for adverse outcomes. However, the patient's LVEF is still within the range of a moderate heart failure, which suggests that the patient's cardiac function is not severely compromised. 

The patient's ECG shows ventricular extrasystoles, which may indicate an increased risk of arrhythmias. The absence of ventricular tachycardia, non-sustained ventricular tachycardia, and paroxysmal supraventricular tachyarrhythmia suggests that the patient's cardiac function is not severely compromised. 

However, the patient's age and NYHA Class II heart failure increase the risk for sudden cardiac death, and the patient's elevated Pro-BNP level may indicate that the patient's heart is not functioning optimally. 

Considering these factors, I believe that the patient is at a higher risk for sudden cardiac death, but the presence of certain risk factors and the patient's current cardiac function suggest that this is not the most likely outcome.

3. Pump failure death
REASONING: 
The patient's NYHA Class II heart failure and elevated Pro-BNP level indicate a higher risk for heart failure. The patient's LVEF is 41.0, which is within the range of a moderate heart failure. 

The patient's ECG shows ventricular extrasystoles, which may indicate an increased risk of arrhythmias. The absence of ventricular tachycardia, non-sustained ventricular tachycardia, and paroxysmal supraventricular tachyarrhythmia suggests that the patient's cardiac function is not severely compromised. 

However, the patient's age, NYHA Class II heart failure, and elevated Pro-BNP level increase the risk for pump failure death. The patient's elevated creatinine level (78.0 mmol/L) also suggests that the patient's kidney function may be impaired, which can contribute to pump failure. 

Considering these factors, I believe that pump failure death is a possible outcome, but the patient's current cardiac function and the absence of certain risk factors suggest that this is not the most likely outcome."
482,482,P0757,"Age: 59
Gender: Male 
Weight: 91 kg
Height: 175 cm
NYHA Class: II
Blood Pressure: 115/70 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Hypertension, Myocardial Infarction
Albumin (g/L): 43,1
ALT or GPT (IU/L): 148.0
AST or GOT (IU/L): 85.0
Total Cholesterol (mmol/L): 3,74
Creatinine (mmol/L): 121.0
Gamma-glutamil transpeptidase (IU/L): 187
Glucose (mmol/L): 5,1
Hemoglobin (g/L): 144.0
HDL (mmol/L): 0,6
Potassium (mEq/L): 4,09
LDL (mmol/L): 2,43
Sodium (mEq/L): 144.0
Pro-BNP (ng/L): 182.0
Protein (g/L): 79,2
Troponin (ng/mL): 0,01
TSH (mIU/L): 0,7
Urea (mg/dL): 8
LVEF (%): 35.0
Medications: Calcium Channel Blocker, Beta Blockers, Loop Diuretics, Spironolactone, Statins, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"RANKING: 

1. Survivor
REASONING: 

The patient's prognosis is ranked as a survivor due to the following reasons:

- The patient is currently on multiple medications that are commonly used to manage heart failure, such as ACE inhibitors, beta blockers, and spironolactone, which suggest that the patient's cardiologist is actively managing the patient's heart failure symptoms.
- The patient's NYHA Class II classification indicates that the patient has mild heart failure symptoms, which is a relatively stable condition.
- The patient's creatinine level is elevated, but not significantly high, suggesting that the patient is not in acute kidney injury or acute heart failure.
- The patient's troponin level is within the normal range, indicating that there is no significant myocardial damage.
- The patient's LVEF is 35%, which is a reduced ejection fraction, but not severely reduced, indicating some residual cardiac function.
- The patient's ECG shows non-sustained ventricular tachycardia, which is a concerning finding but not immediately life-threatening.
- The patient's liver enzymes are elevated, but not significantly high, suggesting some liver damage, but it is unclear if this is related to the heart or other factors.
- The patient's BNP level is elevated, indicating some degree of heart failure, but not excessively high.

Overall, the patient's clinical presentation and laboratory results suggest that the patient is likely to survive the next few years, but with ongoing monitoring and management of their heart failure and arrhythmias.

2. Sudden cardiac death
REASONING: 

The patient's prognosis is ranked as sudden cardiac death due to the following reasons:

- The patient's LVEF is 35%, which is a significantly reduced ejection fraction, indicating severe cardiac dysfunction.
- The patient's ECG shows ventricular extrasystole and non-sustained ventricular tachycardia, which are concerning signs of arrhythmias that can increase the risk of sudden cardiac death.
- The patient's BNP level is elevated, indicating some degree of heart failure, which can increase the risk of sudden cardiac death.
- The patient's troponin level is slightly elevated, indicating some degree of myocardial damage, which can increase the risk of sudden cardiac death.
- The patient's ECG shows polymorphic ventricular extrasystole, which is a concerning sign of ventricular arrhythmias.

Overall, the patient's clinical presentation and laboratory results suggest that the patient is at increased risk of sudden cardiac death, but the patient's survival is still possible with close monitoring and management of their heart failure and arrhythmias.

3. Pump failure death
REASONING: 

The patient's prognosis is ranked as pump failure death due to the following reasons:

- The patient's LVEF is 35%, which is a significantly reduced ejection fraction, indicating severe cardiac dysfunction.
- The patient's BNP level is elevated, indicating some degree of heart failure, which can lead to pump failure.
- The patient's creatinine level is elevated, indicating some degree of kidney dysfunction, which can be related to heart failure.
- The patient's ECG shows ventricular extrasystole and non-sustained ventricular tachycardia, which are concerning signs of arrhythmias that can increase the risk of pump failure.
- The patient's liver enzymes are elevated, indicating some degree of liver damage, which can be related to heart failure.

Overall, the patient's clinical presentation and laboratory results suggest that the patient is at high risk of pump failure, but the patient's survival is still possible with close monitoring and management of their heart failure and arrhythmias."
483,483,P0758,"Age: 55
Gender: Male 
Weight: 81 kg
Height: 176 cm
NYHA Class: II
Blood Pressure: 130/80 mmHg
Past Medical History: Idiopathic dilated cardiomyopathy, Dyslipemia, Hypertension
Albumin (g/L): 44,5
ALT or GPT (IU/L): 13.0
AST or GOT (IU/L): 12.0
Total Cholesterol (mmol/L): 4,33
Creatinine (mmol/L): 110.0
Gamma-glutamil transpeptidase (IU/L): 16
Glucose (mmol/L): 4,6
Hemoglobin (g/L): 123.0
HDL (mmol/L): 1,08
Potassium (mEq/L): 4,76
LDL (mmol/L): 2,78
Sodium (mEq/L): 144.0
Pro-BNP (ng/L): 5004.0
Protein (g/L): 70,1
Troponin (ng/mL): 0,01
TSH (mIU/L): 3,29
Urea (mg/dL): 10,8
LVEF (%): 20.0
Medications: Beta Blockers, Loop Diuretics, Statins, ACE Inhibitor, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"RANKING: 

1. Survivor
REASONING: 
Based on the patient's data, I would rank the patient as a survivor for the next few years. The patient's age, NYHA Class II, and LVEF of 20.0 indicate significant left ventricular dysfunction, but the patient is not in acute decompensated heart failure. The patient's medication regimen, including beta blockers, loop diuretics, statins, ACE inhibitors, and nitrovasodilators, is standard for managing heart failure and reducing cardiovascular risk factors. The patient's elevated troponin level (0.01 ng/mL) may indicate some cardiac damage, but it is not significantly elevated. The absence of other concerning ECG findings, such as ventricular tachycardia or non-sustained ventricular tachycardia, further supports a favorable prognosis.

While the patient's LVEF is significantly reduced, the fact that it is not in the range of 15% or lower, which is often associated with advanced heart failure, suggests that the patient may still be able to tolerate some level of physical activity. The patient's renal function, as indicated by a creatinine level of 10.8 mg/dL, is also relatively preserved, which is important for overall cardiovascular health.

Overall, while the patient has significant underlying heart disease, the presence of a well-managed medication regimen, relatively preserved renal function, and the absence of other concerning ECG findings suggest that the patient is at a higher risk of survival compared to the other two options."
484,484,P0759,"Age: 69
Gender: Male 
Weight: 73 kg
Height: 169 cm
NYHA Class: II
Blood Pressure: 110/70 mmHg
Past Medical History: Idiopathic dilated cardiomyopathy, Hypertension
Albumin (g/L): 40,1
ALT or GPT (IU/L): 26.0
AST or GOT (IU/L): 18.0
Total Cholesterol (mmol/L): 5,94
Creatinine (mmol/L): 113.0
Gamma-glutamil transpeptidase (IU/L): 20
Glucose (mmol/L): 8,9
Hemoglobin (g/L): 173.0
HDL (mmol/L): 0,79
Potassium (mEq/L): 3,48
LDL (mmol/L): 3,82
Sodium (mEq/L): 142.0
Pro-BNP (ng/L): 1837.0
Protein (g/L): 71,5
Troponin (ng/mL): 0,01
TSH (mIU/L): 2,2
Urea (mg/dL): 10,1
LVEF (%): 18.0
Medications: Amiodarone, Beta Blockers, Loop Diuretics, Hydralazine, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"RANKING: 1. Survivor
REASONING: 

Based on the provided patient data, I would rank the patient as a survivor with a high probability. The patient's age of 69 is relatively young for heart failure, and their NYHA Class II indicates that they are still able to perform moderate physical activity without symptoms. Their blood pressure is within a relatively normal range, and their medication regimen, which includes beta blockers, loop diuretics, and hydralazine, suggests that they are receiving standard treatment for their hypertension and heart failure.

The patient's biomarker results, such as the elevated troponin level (0.01 ng/mL), suggest some cardiac injury, but it is not excessively high. The elevated creatinine level (113.0 mmol/L) indicates some degree of kidney dysfunction, which is not uncommon in patients with heart failure. However, the patient's LVEF (18.0) is still within a relatively normal range, indicating that the patient's heart function is not severely impaired.

The presence of ventricular extrasystoles and non-sustained ventricular tachycardia on the ECG suggests that the patient has some arrhythmias, but these are not excessively frequent or severe. The patient's Pro-BNP level (1837.0 ng/L) is elevated, indicating some degree of ventricular stress, but it is not excessively high.

Overall, considering the patient's age, medication regimen, and biomarker results, I believe that the patient has a high likelihood of survival over the next few years, with a moderate risk of progression of their heart failure and arrhythmias.

RANKING: 2. Sudden Cardiac Death
REASONING: 

While the patient's LVEF (18.0) is relatively low, which increases the risk of sudden cardiac death, I do not rank the patient as having a high risk of sudden cardiac death. The patient's age, medication regimen, and biomarker results do not suggest an excessively high risk of sudden cardiac death.

The patient's ECG results show some arrhythmias, but they are non-sustained and not excessively frequent. The patient's Pro-BNP level is elevated, but not excessively high, and the patient's troponin level is within a relatively normal range.

RANKING: 3. Pump Failure Death
REASONING: 

I would rank the patient as having a low risk of pump failure death. The patient's LVEF (18.0) is relatively low, but it is not excessively low, and the patient is receiving standard treatment for their heart failure. The patient's medication regimen, including beta blockers and hydralazine, suggests that they are receiving optimal treatment for their heart failure.

The patient's biomarker results, such as the elevated creatinine level (113.0 mmol/L), suggest some degree of kidney dysfunction, but this is not uncommon in patients with heart failure. The patient's Pro-BNP level (1837.0 ng/L) is elevated, but not excessively high, and the patient's troponin level (0.01 ng/mL) is within a relatively normal range.

Overall, considering the patient's age, medication regimen, and biomarker results, I believe that the patient has a low risk of pump failure death over the next few years, with a moderate risk of progression of their heart failure and arrhythmias."
485,485,P0763,"Age: 60
Gender: Male 
Weight: 74 kg
Height: 159 cm
NYHA Class: II
Blood Pressure: 95/60 mmHg
Past Medical History: Idiopathic dilated cardiomyopathy
Albumin (g/L): 41,4
ALT or GPT (IU/L): 14.0
AST or GOT (IU/L): 11.0
Total Cholesterol (mmol/L): 6
Creatinine (mmol/L): 100.0
Gamma-glutamil transpeptidase (IU/L): 32
Glucose (mmol/L): 7,7
Hemoglobin (g/L): 135.0
HDL (mmol/L): 1,27
Potassium (mEq/L): 4,18
LDL (mmol/L): 4,2
Sodium (mEq/L): 138.0
Pro-BNP (ng/L): 2774.0
Protein (g/L): 65,9
Troponin (ng/mL): 0,01
TSH (mIU/L): 0,76
Urea (mg/dL): 7,6
LVEF (%): 21.0
Medications: Beta Blockers, Loop Diuretics, Spironolactone, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"RANKING: 

1. Survivor
REASONING:
The patient's current data suggests that they are at high risk for adverse outcomes due to their significant left ventricular dysfunction (LVEF 21%), idiopathic dilated cardiomyopathy, and the presence of non-sustained ventricular tachycardia (NSVT) on ECG. However, the patient is currently receiving medications that are standard for heart failure management (Beta Blockers, Loop Diuretics, Spironolactone, ACE Inhibitor). The patient's hemoglobin and kidney function are also relatively well-preserved, which may indicate some degree of cardiac reserve.

2. Pump failure death
REASONING:
The patient's LVEF is very low (21%), and they have a history of idiopathic dilated cardiomyopathy, which is a significant risk factor for heart failure. The presence of NSVT on ECG may also indicate a high risk for arrhythmic events. While the patient is receiving medications for heart failure, their low LVEF and history of cardiomyopathy make them a high-risk patient for pump failure.

3. Sudden cardiac death
REASONING:
While the patient has a history of NSVT on ECG, which is a risk factor for sudden cardiac death, the patient is receiving beta blockers, which are effective in reducing the risk of arrhythmic events. Additionally, the patient's LVEF is not as severely impaired as might be expected given their NYHA Class II classification. The patient's overall clinical presentation and laboratory results do not suggest a high risk for sudden cardiac death at this time."
486,486,P0764,"Age: 75
Gender: Male 
Weight: 72 kg
Height: 181 cm
NYHA Class: II
Blood Pressure: 120/80 mmHg
Past Medical History: Idiopathic dilated cardiomyopathy
Albumin (g/L): 44,8
ALT or GPT (IU/L): 17.0
AST or GOT (IU/L): 24.0
Total Cholesterol (mmol/L): 6,64
Creatinine (mmol/L): 95.0
Gamma-glutamil transpeptidase (IU/L): 18
Glucose (mmol/L): 4,9
Hemoglobin (g/L): 148.0
Potassium (mEq/L): 4,74
Sodium (mEq/L): 141.0
Pro-BNP (ng/L): 2243.0
Protein (g/L): 80,4
Troponin (ng/mL): 0,01
TSH (mIU/L): 2,59
Urea (mg/dL): 8,8
LVEF (%): 26.0
Medications: Amiodarone, Beta Blockers, Spironolactone, Statins, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: TPSV
        - Bradycardia: No
            ",survivor,"RANKING: 
1. Survivor
REASONING: 
The patient's overall clinical presentation, laboratory results, and ECG findings suggest that the patient is at high risk of cardiac complications, but the presence of idiopathic dilated cardiomyopathy and the patient's age (75 years) contribute to a higher risk of mortality. However, the patient's current NYHA Class II indicates that the symptoms are not severe, and the patient is still able to perform daily activities without significant limitation. The patient's medication regimen, which includes Amiodarone, Beta Blockers, Spironolactone, Statins, and ACE Inhibitor, suggests that the patient is receiving appropriate management for their cardiac condition. The absence of significant elevation in liver enzymes (ALT and AST) and the normal kidney function (creatinine) levels also suggest that the patient's cardiac condition is not causing significant liver or kidney damage. The patient's LVEF of 26% indicates severe systolic dysfunction, but the patient's age and medication regimen may help mitigate this risk. The presence of non-sustained ventricular tachycardia (NSVT) and ventricular extrasystole (polymorphic) on the ECG suggests that the patient is at risk for cardiac arrhythmias, but the presence of Pro-BNP levels of 2243.0 ng/L, which is significantly elevated, suggests that the patient is experiencing symptoms of heart failure. Despite these factors, the patient's overall clinical presentation and laboratory results do not indicate an immediate life-threatening condition, and the patient's age and medication regimen suggest that the patient may survive for the next few years with proper management.

RANKING: 
2. Pump failure death
REASONING: 
While the patient's LVEF of 26% indicates severe systolic dysfunction, which increases the risk of pump failure, the patient's age (75 years) and medication regimen may help mitigate this risk. However, the patient's elevated Pro-BNP levels (2243.0 ng/L) and NSVT on the ECG suggest that the patient is experiencing symptoms of heart failure, which increases the risk of pump failure. The patient's NYHA Class II indicates that the symptoms are not severe, but the patient's LVEF is significantly impaired, which increases the risk of pump failure.

RANKING: 
3. Sudden cardiac death
REASONING: 
The patient's ECG findings of ventricular extrasystole (polymorphic) and NSVT, as well as the presence of a high Pro-BNP level (2243.0 ng/L), suggest that the patient is at high risk for cardiac arrhythmias and heart failure. However, the patient's age (75 years) and medication regimen may help mitigate this risk. The patient's LVEF of 26% is significantly impaired, which increases the risk of sudden cardiac death. However, the patient's overall clinical presentation and laboratory results do not indicate an immediate life-threatening condition, and the patient's age and medication regimen suggest that the patient may survive for a few years with proper management."
487,487,P0767,"Age: 70
Gender: Male 
Weight: 89 kg
Height: 168 cm
NYHA Class: II
Blood Pressure: 147/62 mmHg
Past Medical History: Other HF etiology, Diabetes, Hypertension
Albumin (g/L): 41
ALT or GPT (IU/L): 17.0
AST or GOT (IU/L): 20.0
Total Cholesterol (mmol/L): 5,33
Creatinine (mmol/L): 115.0
Gamma-glutamil transpeptidase (IU/L): 24
Glucose (mmol/L): 7,1
Hemoglobin (g/L): 152.0
HDL (mmol/L): 1,16
Potassium (mEq/L): 4,8
LDL (mmol/L): 3,7
Sodium (mEq/L): 136.0
Pro-BNP (ng/L): 723.0
Protein (g/L): 70
T4 (ng/L): 18
Troponin (ng/mL): 0,01
TSH (mIU/L): 1,56
Urea (mg/dL): 7,82
LVEF (%): 35.0
Medications: Diabetes Medication, Beta Blockers, Hydralazine, ACE Inhibitor, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: TPSV
        - Bradycardia: No
            ",survivor,"RANKING: 1. Survivor
REASONING:

Based on the provided patient data, the patient's prognosis is likely to be a survivor. Here's why:

1. Age: Although the patient is 70 years old, the age itself is not a significant factor in determining the prognosis. Many patients with similar age and comorbidities can survive for a long time with proper management.

2. NYHA Class II: The patient's heart failure is mild, which indicates that the patient has some residual cardiac function. This suggests that the heart is not severely compromised, and the patient may be able to tolerate certain treatments and lifestyle changes.

3. Blood Pressure: The patient's blood pressure is elevated, but it's not extremely high. This is not a significant concern, as it can be managed with medication.

4. Past Medical History: The patient has a history of other heart failure etiology, diabetes, and hypertension. These comorbidities are common in older adults and can be managed with medication and lifestyle changes.

5. Laboratory results: The patient's liver function tests (ALT and AST) are within normal limits, and the creatinine level is elevated, but not excessively high. The troponin level is normal, which suggests that there is no significant myocardial damage.

6. ECG Impression: The ECG shows ventricular extrasystole, which is a benign finding. There is no evidence of ventricular tachycardia, non-sustained ventricular tachycardia, or other arrhythmias that could indicate a high risk of sudden cardiac death.

7. Pro-BNP levels: The patient's Pro-BNP level is elevated, which indicates some degree of heart failure. However, it's not excessively high, and the patient's symptoms are mild.

8. LVEF: The patient's left ventricular ejection fraction (LVEF) is significantly reduced, indicating that the heart is not pumping efficiently. However, this is a common finding in heart failure patients, and the patient's NYHA Class II suggests that the heart is still tolerating some stress.

9. Medications: The patient is taking multiple medications, including beta blockers, ACE inhibitors, and hydralazine, which are all standard treatments for heart failure and hypertension.

Considering these factors, the patient's prognosis is likely to be a survivor. However, close monitoring and regular follow-up with the patient are necessary to adjust the treatment plan and prevent any potential complications."
488,488,P0768,"Age: 73
Gender: Male 
Weight: 94 kg
Height: 167 cm
NYHA Class: III
Blood Pressure: 150/80 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Dyslipemia, Hypertension, Myocardial Infarction
Albumin (g/L): 40
ALT or GPT (IU/L): 25.0
AST or GOT (IU/L): 23.0
Total Cholesterol (mmol/L): 4,84
Creatinine (mmol/L): 186.0
Gamma-glutamil transpeptidase (IU/L): 41
Glucose (mmol/L): 6,1
Hemoglobin (g/L): 129.0
HDL (mmol/L): 0,93
Potassium (mEq/L): 4
LDL (mmol/L): 2,51
Sodium (mEq/L): 138.0
Pro-BNP (ng/L): 600.0
Protein (g/L): 76
T4 (ng/L): 15
Troponin (ng/mL): 0,04
TSH (mIU/L): 1,13
Urea (mg/dL): 21,96
LVEF (%): 40.0
Medications: Beta Blockers, Loop Diuretics, Statins, ACE Inhibitor, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: TPSV
        - Bradycardia: Unknown bradycardia code
            ",survivor,"RANKING: 1. Survivor
REASONING:

The patient's overall health status and the provided data suggest a high likelihood of survival. The patient is 73 years old, which is considered elderly, but with a NYHA Class III heart failure, the patient's functional capacity is significantly limited. Despite this, the patient is on multiple medications for heart failure, hypertension, and dyslipidemia, indicating an attempt to manage their conditions.

The patient's laboratory results show:

* Elevated creatinine levels (186.0 mol/L) suggest impaired renal function, which is common in patients with heart failure.
* Elevated Pro-BNP levels (600.0 ng/L) indicate significant cardiac strain, but not at an extreme level.
* The presence of ventricular extrasystole, non-sustained VT, and TPSV on ECG suggests ventricular arrhythmias, but they are non-sustained, which may be manageable with current treatment.
* The absence of troponin elevation (0.04 ng/mL) suggests that there is no significant myocardial damage at this point.

Given these factors, the patient's overall prognosis is favorable, and with continued management of their heart failure, hypertension, and dyslipidemia, it is likely that the patient will survive. However, regular monitoring and adjustments to their treatment plan will be necessary to prevent progression of their condition.

RANKING: 2. Pump failure death
REASONING: 

This outcome is possible if the patient's heart failure worsens despite current treatment. Factors that could contribute to pump failure include:

* The patient's NYHA Class III heart failure indicates a significant limitation in functional capacity.
* Elevated creatinine levels (186.0 mol/L) suggest impaired renal function, which can be exacerbated by heart failure.
* The presence of ventricular arrhythmias, although non-sustained, may indicate underlying cardiac dysfunction.

RANKING: 3. Sudden cardiac death
REASONING: 

Sudden cardiac death is a possible outcome if the patient experiences a fatal arrhythmia, particularly if the ventricular arrhythmias become sustained. Factors that could contribute to sudden cardiac death include:

* The presence of ventricular extrasystole, non-sustained VT, and TPSV on ECG.
* The patient's history of myocardial infarction, which can increase the risk of arrhythmias.
* The patient's elevated troponin levels (0.04 ng/mL), which may indicate some degree of myocardial damage.

However, the absence of sustained ventricular arrhythmias and the patient's current stable condition make sudden cardiac death less likely."
489,489,P0769,"Age: 51
Gender: Female 
Weight: 79 kg
Height: 166 cm
NYHA Class: II
Blood Pressure: 100/60 mmHg
Past Medical History: Idiopathic dilated cardiomyopathy, Dyslipemia
Albumin (g/L): 43
ALT or GPT (IU/L): 22.0
AST or GOT (IU/L): 19.0
Total Cholesterol (mmol/L): 4,11
Creatinine (mmol/L): 62.0
Gamma-glutamil transpeptidase (IU/L): 11
Glucose (mmol/L): 4,8
Hemoglobin (g/L): 128.0
HDL (mmol/L): 1,47
Potassium (mEq/L): 4,5
LDL (mmol/L): 2,35
Sodium (mEq/L): 134.0
Pro-BNP (ng/L): 183.0
Protein (g/L): 75
T4 (ng/L): 17
Troponin (ng/mL): 0,01
TSH (mIU/L): 0,77
Urea (mg/dL): 6,99
LVEF (%): 33.0
Medications: Beta Blockers, Statins, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"RANKING: 1. Survivor

REASONING: 

Based on the provided patient data, the patient's overall condition is quite severe, with a left ventricular ejection fraction (LVEF) of 33%, which indicates significant left ventricular dysfunction. The patient's NYHA class is II, indicating moderate symptoms of heart failure. The presence of ventricular extrasystole, non-sustained ventricular tachycardia, and non-sustained ventricular tachycardia (CH>10) suggests a high risk of arrhythmias, which can be a significant predictor of adverse outcomes.

However, the patient's serum troponin level is within normal limits, which suggests that there is no acute myocardial infarction or significant cardiac damage. The patient's creatinine level is elevated, indicating impaired renal function, which may be related to the patient's cardiomyopathy.

The patient's medication regimen includes beta blockers, statins, and ACE inhibitors, which are commonly used to manage heart failure and hypertension. However, the patient's blood pressure is relatively low (100/60 mmHg), which may indicate hypotension.

Despite these factors, the patient's overall prognosis is still favorable, and I would rank them as a survivor. This is because the patient's cardiac function is not severely impaired, and the patient is receiving appropriate medication. Additionally, the patient's ECG findings, while concerning for arrhythmias, do not indicate a high risk of sudden cardiac death.

Therefore, while the patient's condition is serious, I believe that with proper management and treatment, the patient can survive for several years without significant adverse outcomes."
490,490,P0770,"Age: 55
Gender: Male 
Weight: 87 kg
Height: 166 cm
NYHA Class: II
Blood Pressure: 180/75 mmHg
Past Medical History: Idiopathic dilated cardiomyopathy, Dyslipemia
Albumin (g/L): 41
ALT or GPT (IU/L): 35.0
AST or GOT (IU/L): 28.0
Total Cholesterol (mmol/L): 4,63
Creatinine (mmol/L): 104.0
Gamma-glutamil transpeptidase (IU/L): 43
Glucose (mmol/L): 6,4
Hemoglobin (g/L): 132.0
HDL (mmol/L): 0,93
Potassium (mEq/L): 4,2
LDL (mmol/L): 1,68
Sodium (mEq/L): 137.0
Pro-BNP (ng/L): 536.0
Protein (g/L): 73
T3 (pg/dL): 0,06
T4 (ng/L): 12
Troponin (ng/mL): 0,005
TSH (mIU/L): 13,08
Urea (mg/dL): 7,65
LVEF (%): 53.0
Medications: Beta Blockers, Digoxin, Loop Diuretics, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",survivor,"RANKING: 1. Survivor
REASONING: The patient's age, NYHA Class II, and the presence of idiopathic dilated cardiomyopathy are significant risk factors for adverse outcomes. However, the patient's relatively preserved LVEF (53.0%) and the absence of any significant electrolyte imbalances, renal dysfunction, or acute coronary syndrome (indicated by normal troponin levels) suggest that the patient's cardiac function is not severely compromised. The patient is also taking medications that are commonly used in heart failure management, such as beta blockers, digoxin, and loop diuretics, which may help alleviate symptoms and slow disease progression. The patient's laboratory results, including normal liver enzymes and low T3 levels, do not indicate acute liver or thyroid dysfunction that could impact cardiac function. Overall, while the patient has several risk factors, the absence of acute complications and the presence of ongoing medical therapy suggest a relatively favorable prognosis. 

RANKING: 2. Sudden Cardiac Death
REASONING: The patient's history of idiopathic dilated cardiomyopathy and elevated Pro-BNP levels (536.0 ng/L) indicate a high risk of heart failure exacerbation and potential cardiac arrhythmias. The patient's elevated blood pressure (180/75 mmHg) and dyslipidemia may contribute to increased cardiac workload and atherosclerotic burden. The presence of ventricular extrasystoles on the ECG suggests a higher risk of arrhythmias, which can be a precursor to sudden cardiac death. While the patient is taking medications to manage these conditions, the combination of these risk factors and the patient's underlying heart disease make sudden cardiac death a plausible concern.

RANKING: 3. Pump Failure Death
REASONING: Pump failure death is a potential consequence of heart failure exacerbation, which is a concern given the patient's elevated Pro-BNP levels and NYHA Class II symptoms. However, the patient's relatively preserved LVEF (53.0%) and the absence of acute kidney injury or significant electrolyte imbalances suggest that the patient's cardiac function is not severely compromised. While the patient's heart disease is significant, the patient's ongoing medical therapy and relatively stable laboratory results suggest that pump failure death is less likely than sudden cardiac death or death due to heart failure exacerbation."
491,491,P0771,"Age: 73
Gender: Male 
Weight: 89 kg
Height: 169 cm
NYHA Class: II
Blood Pressure: 130/65 mmHg
Past Medical History: Other HF etiology
Albumin (g/L): 39
ALT or GPT (IU/L): 16.0
AST or GOT (IU/L): 11.0
Total Cholesterol (mmol/L): 3,34
Creatinine (mmol/L): 80.0
Gamma-glutamil transpeptidase (IU/L): 23
Glucose (mmol/L): 4,7
Hemoglobin (g/L): 154.0
HDL (mmol/L): 1,24
Potassium (mEq/L): 4
LDL (mmol/L): 1,71
Sodium (mEq/L): 136.0
Pro-BNP (ng/L): 720.0
Protein (g/L): 72
T4 (ng/L): 17
Troponin (ng/mL): 0,03
TSH (mIU/L): 1,06
Urea (mg/dL): 7,99
LVEF (%): 25.0
Medications: Beta Blockers, Statins, Hydralazine, ACE Inhibitor, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"RANKING: 1. Survivor
REASONING: 

The patient has a relatively stable set of lab results, with no acute elevation in troponin, normal electrolytes, and a controlled blood pressure. The patient is on multiple medications, including beta blockers, statins, and an ACE inhibitor, which are commonly used to manage heart failure and hypertension. The presence of a non-sustained ventricular tachycardia (NSVT) is concerning, but the patient is not experiencing any symptoms and is not on any anti-arrhythmic medications.

The patient's NYHA class II indicates that they have some symptoms of heart failure, but they are still able to perform moderate physical activity without symptoms. The LVEF of 25% is significantly reduced, indicating systolic heart failure.

However, the patient's age (73) and weight (89 kg) are not considered high-risk factors for sudden cardiac death, and the absence of any other concerning ECG findings (e.g., bundle branch block, left ventricular hypertrophy) reduces the likelihood of sudden cardiac death.

Therefore, based on the available information, the most likely outcome for the patient over the next few years is survival, with the possibility of continued management of their heart failure and monitoring for any signs of worsening heart function or arrhythmias.

RANKING: 2. Pump failure death
REASONING: 

The patient's LVEF of 25% indicates significant systolic heart failure, which increases the risk of pump failure. The patient's weight (89 kg) and age (73) also contribute to this risk.

While the patient is on multiple medications to manage their heart failure and hypertension, the presence of a non-sustained ventricular tachycardia (NSVT) and the patient's reduced LVEF increase the risk of pump failure. The patient's elevated creatinine (80.0) and urea (7.99) levels also suggest some degree of renal impairment, which can be a complication of heart failure.

However, the patient's overall clinical presentation and lab results are not as concerning as those of a patient with more severe heart failure or acute coronary syndromes.

RANKING: 3. Sudden cardiac death
REASONING: 

The patient's ECG findings, including the presence of ventricular extrasystole and NSVT, increase the risk of sudden cardiac death. However, the absence of any acute symptoms and the patient's stable lab results reduce this risk.

The patient's age (73) and weight (89 kg) are not considered high-risk factors for sudden cardiac death, and the absence of any other concerning ECG findings reduces the likelihood of this outcome.

The patient's reduced LVEF (25%) and elevated creatinine (80.0) levels do increase the risk of pump failure, but the presence of multiple medications to manage heart failure and hypertension reduces the risk of sudden cardiac death. Therefore, based on the available information, sudden cardiac death is the least likely outcome for the patient over the next few years."
492,492,P0773,"Age: 69
Gender: Male 
Weight: 68 kg
Height: 162 cm
NYHA Class: II
Blood Pressure: 108/68 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Diabetes, Dyslipemia, Hypertension, Myocardial Infarction
Albumin (g/L): 32
ALT or GPT (IU/L): 109.0
AST or GOT (IU/L): 116.0
Total Cholesterol (mmol/L): 3,65
Creatinine (mmol/L): 124.0
Gamma-glutamil transpeptidase (IU/L): 420
Glucose (mmol/L): 8,9
Hemoglobin (g/L): 133.0
HDL (mmol/L): 1,34
Potassium (mEq/L): 4,9
LDL (mmol/L): 1,86
Sodium (mEq/L): 136.0
Pro-BNP (ng/L): 2362.0
Protein (g/L): 60
T4 (ng/L): 18
Troponin (ng/mL): 0,02
TSH (mIU/L): 3,66
Urea (mg/dL): 12,15
LVEF (%): 20.0
Medications: Diabetes Medication, Beta Blockers, Loop Diuretics, Spironolactone, ACE Inhibitor, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"RANKING: 
1. Survivor
REASONING: 
The patient's overall clinical presentation and test results suggest a high likelihood of survival. The patient's age is 69, which is considered old for cardiac surgery, but not excessively so. The patient's NYHA Class II indicates moderate symptoms, which is also not uncommon in older adults. The patient's blood pressure is well-controlled, and the absence of ventricular tachycardia, non-sustained ventricular tachycardia, and paroxysmal supraventricular tachyarrhythmia on ECG is reassuring. The presence of a low LVEF (20%) is concerning, but in the context of ischemic dilated cardiomyopathy, it is not uncommon. The patient's elevated troponin level (0.02 ng/mL) may indicate some degree of myocardial damage, but it is not excessively high.

The patient's laboratory results show elevated liver enzymes (ALT and AST), which could be related to the patient's underlying ischemic dilated cardiomyopathy. The presence of diabetes, hypertension, and dyslipidemia also contribute to the patient's overall risk profile. However, the patient is on medications for these conditions, and the blood pressure is well-controlled.

The patient's elevated creatinine level (12.15 mg/dL) suggests some degree of renal impairment, which can be a concern in patients with heart failure. However, the patient is on diuretics, which may be helping to manage fluid overload.

Overall, the patient's clinical presentation and test results suggest that the patient has a high likelihood of survival, but the patient's underlying heart disease and comorbidities will likely continue to pose a risk for future cardiovascular events."
493,493,P0774,"Age: 51
Gender: Female 
Weight: 84 kg
Height: 168 cm
NYHA Class: II
Blood Pressure: 111/54 mmHg
Past Medical History: Idiopathic dilated cardiomyopathy
Albumin (g/L): 44
ALT or GPT (IU/L): 33.0
AST or GOT (IU/L): 21.0
Total Cholesterol (mmol/L): 4,65
Creatinine (mmol/L): 71.0
Gamma-glutamil transpeptidase (IU/L): 19
Glucose (mmol/L): 4,8
Hemoglobin (g/L): 142.0
HDL (mmol/L): 1,5
Potassium (mEq/L): 4,7
LDL (mmol/L): 2,77
Sodium (mEq/L): 138.0
Pro-BNP (ng/L): 577.0
Protein (g/L): 76
T4 (ng/L): 22
Troponin (ng/mL): 0,01
TSH (mIU/L): 0,53
Urea (mg/dL): 5,66
LVEF (%): 20.0
Medications: Beta Blockers, Digoxin, Loop Diuretics, Spironolactone, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"RANKING: 1. Survivor
REASONING: 

Based on the provided patient data, I rank the patient as a survivor with a high likelihood. The patient's NYHA Class II indicates that they have moderate symptoms of heart failure, but they are still able to perform daily activities with some limitation. The patient's LVEF of 20.0 is significantly reduced, indicating severe left ventricular dysfunction, which is consistent with idiopathic dilated cardiomyopathy. However, the patient is on multiple medications, including beta blockers, digoxin, and an ACE inhibitor, which are standard treatments for heart failure and cardiomyopathy.

The patient's ECG findings, including ventricular extrasystole, non-sustained VT, and non-sustained ventricular tachycardia, suggest a high risk of arrhythmias, but these are not necessarily indicative of a poor prognosis. The patient's serum creatinine level is elevated, indicating some degree of kidney impairment, but this is not uncommon in patients with heart failure.

The patient's biomarkers, including troponin and BNP, are elevated, indicating some degree of cardiac stress and strain. However, the troponin level is within the normal range, which is a good sign. The patient's lipid profile is also concerning, with high total cholesterol and LDL levels, which increases the risk of cardiovascular events. However, the patient is already on statins, which should help to manage this risk.

Overall, while the patient has several risk factors for adverse outcomes, their overall clinical picture suggests that they are likely to survive the next few years with proper management and monitoring. The patient's age, gender, and weight are not particularly concerning, and the patient's comorbidities, such as hypertension and kidney impairment, are well-managed.

Therefore, I predict that the patient will survive the next few years, with some degree of heart failure symptoms and the need for ongoing medical management. However, with proper care and monitoring, the patient can expect to live a relatively normal life expectancy for someone of their age and sex."
494,494,P0775,"Age: 61
Gender: Male 
Weight: 70 kg
Height: 168 cm
NYHA Class: II
Blood Pressure: 130/83 mmHg
Past Medical History: Other HF etiology, Dyslipemia
Albumin (g/L): 44
ALT or GPT (IU/L): 13.0
AST or GOT (IU/L): 15.0
Total Cholesterol (mmol/L): 4,47
Creatinine (mmol/L): 80.0
Gamma-glutamil transpeptidase (IU/L): 13
Glucose (mmol/L): 5,7
Hemoglobin (g/L): 146.0
HDL (mmol/L): 1,14
Potassium (mEq/L): 3,8
LDL (mmol/L): 2,87
Sodium (mEq/L): 141.0
Pro-BNP (ng/L): 413.0
Protein (g/L): 74
T4 (ng/L): 17
Troponin (ng/mL): 0,01
TSH (mIU/L): 1,41
Urea (mg/dL): 6,49
LVEF (%): 25.0
Medications: Beta Blockers, Statins, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"RANKING: 1. Survivor
REASONING: The patient has a moderate level of left ventricular dysfunction (LVEF 25.0%) and elevated Pro-BNP levels (413.0 ng/L), indicating some degree of heart failure. However, the patient is not in NYHA Class III or IV, and the patient is on medications for heart failure and dyslipidemia, suggesting that the patient is receiving appropriate management for their underlying conditions. The absence of ventricular tachycardia or non-sustained ventricular tachycardia on the ECG suggests that the patient does not have a high risk of sudden cardiac death. The patient's laboratory values, such as normal troponin levels and normal electrolyte and liver function tests, also suggest that the patient is not in acute distress. Therefore, the patient is at a higher risk of survival over the next few years due to the presence of heart failure and dyslipidemia, but not at an extremely high risk of sudden cardiac death or pump failure."
495,495,P0777,"Age: 69
Gender: Male 
Weight: 89 kg
Height: 170 cm
NYHA Class: II
Blood Pressure: 125/75 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Dyslipemia, Myocardial Infarction
Albumin (g/L): 40,6
ALT or GPT (IU/L): 21.0
AST or GOT (IU/L): 21.0
Total Cholesterol (mmol/L): 3,93
Creatinine (mmol/L): 115.0
Gamma-glutamil transpeptidase (IU/L): 23
Glucose (mmol/L): 6
Hemoglobin (g/L): 146.0
HDL (mmol/L): 0,92
Potassium (mEq/L): 4,71
LDL (mmol/L): 2,59
Sodium (mEq/L): 137.0
Pro-BNP (ng/L): 1487.0
Protein (g/L): 74,7
Troponin (ng/mL): 0,01
TSH (mIU/L): 1,48
Urea (mg/dL): 8,4
LVEF (%): 38.0
Medications: Amiodarone, Beta Blockers, Loop Diuretics, Spironolactone, Statins, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",survivor,"RANKING: 1. Survivor
REASONING: 
This patient has a complex medical history, with ischemic dilated cardiomyopathy, a history of myocardial infarction, and a low left ventricular ejection fraction (LVEF) of 38%, indicating significant cardiac dysfunction. However, the patient is on multiple medications, including beta blockers, ACE inhibitors, and amiodarone, which are all standard treatments for heart failure and arrhythmias.

The patient's current ECG findings also suggest a high risk of arrhythmias, with ventricular extrasystoles and non-sustained ventricular tachycardia. However, the patient is not currently experiencing any life-threatening arrhythmias, and the presence of beta blockers and amiodarone may help to control these symptoms.

The patient's laboratory results show elevated creatinine levels, which may indicate some degree of renal impairment, but this is not uncommon in patients with heart failure. The patient's albumin levels are also low, which may indicate some degree of malnutrition or liver disease.

Given the patient's overall medical history, medications, and current laboratory results, the most likely outcome is that the patient will survive for the next few years. The patient's cardiac function is still impaired, but the presence of multiple medications and the absence of any life-threatening arrhythmias suggest that the patient may be able to manage their symptoms and avoid a sudden cardiac death or pump failure.

RANKING: 2. Sudden Cardiac Death
REASONING: 
While the patient's cardiac function is impaired, the presence of beta blockers and amiodarone may help to reduce the risk of sudden cardiac death. However, the patient's ECG findings suggest a high risk of arrhythmias, particularly ventricular extrasystoles and non-sustained ventricular tachycardia. These arrhythmias can be life-threatening and may lead to sudden cardiac death.

Additionally, the patient's low LVEF and elevated creatinine levels may indicate a high risk of cardiac dysfunction, which can increase the risk of sudden cardiac death.

RANKING: 3. Pump Failure Death
REASONING: 
While the patient's cardiac function is impaired, the presence of beta blockers and ACE inhibitors may help to slow the progression of heart failure. However, the patient's low LVEF and elevated creatinine levels suggest a high risk of pump failure, particularly if the patient's medications are not optimized.

The patient's laboratory results also show elevated liver enzymes, which may indicate some degree of liver disease or malnutrition. This could further increase the risk of pump failure.

Overall, while the patient's cardiac function is impaired, the presence of multiple medications and the absence of any life-threatening arrhythmias suggest that pump failure death is less likely than sudden cardiac death. However, the patient's overall medical history and laboratory results make pump failure a possible outcome."
496,496,P0778,"Age: 73
Gender: Female 
Weight: 56 kg
Height: 145 cm
NYHA Class: II
Blood Pressure: 110/80 mmHg
Past Medical History: Valvular cardiomyopathy
Albumin (g/L): 49,5
ALT or GPT (IU/L): 16.0
AST or GOT (IU/L): 26.0
Total Cholesterol (mmol/L): 6,9
Creatinine (mmol/L): 110.0
Gamma-glutamil transpeptidase (IU/L): 41
Glucose (mmol/L): 4,3
Hemoglobin (g/L): 126.0
HDL (mmol/L): 0,79
Potassium (mEq/L): 4,5
LDL (mmol/L): 5,16
Sodium (mEq/L): 134.0
Pro-BNP (ng/L): 1058.0
Protein (g/L): 89,7
Troponin (ng/mL): 0,01
TSH (mIU/L): 1,35
Urea (mg/dL): 9,9
LVEF (%): 64.0
Medications: Calcium Channel Blocker, Beta Blockers, Loop Diuretics, Spironolactone, Statins
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",survivor,"RANKING: 
1. Survivor
REASONING: 
This patient's overall health status is relatively stable, with a NYHA Class II, indicating mild symptoms of heart failure. The patient's ejection fraction (LVEF) is 64%, which is within the normal range. The patient's medications, including beta blockers, diuretics, and statins, are standard treatments for managing heart failure and preventing further cardiac damage. The absence of ventricular tachycardia, non-sustained ventricular tachycardia, and paroxysmal supraventricular tachyarrhythmia on the ECG impression suggests that the patient does not have an acute cardiac emergency. The patient's laboratory values, including normal electrolytes, renal function, and liver enzymes, are also within normal limits. The presence of elevated Pro-BNP levels (1058 ng/L) may indicate some level of cardiac stress, but it is not indicative of heart failure exacerbation. Overall, based on the provided data, the patient's prognosis is favorable, and they are likely to survive for the next few years without significant cardiac events.

2. Sudden Cardiac Death
REASONING: 
While the patient's Pro-BNP levels are elevated, which may indicate some level of cardiac stress, the patient's overall health status is relatively stable. The absence of ventricular tachycardia, non-sustained ventricular tachycardia, and paroxysmal supraventricular tachyarrhythmia on the ECG impression reduces the likelihood of sudden cardiac death. However, the patient's past medical history of valvular cardiomyopathy increases the risk of cardiac arrhythmias and sudden cardiac death. The patient's age and NYHA Class II also contribute to this risk. While the patient's medications are standard treatments for heart failure, the patient's elevated creatinine level (110.0 mmol/L) may indicate some level of renal impairment, which could increase the risk of cardiac complications. However, this is not a direct indicator of sudden cardiac death.

3. Pump Failure Death
REASONING: 
The patient's LVEF is 64%, which is within the normal range, and the patient is currently taking medications to manage heart failure. However, the patient's NYHA Class II indicates some level of heart failure symptoms, and the patient's elevated Pro-BNP levels (1058 ng/L) may indicate some level of cardiac stress. The patient's elevated creatinine level (110.0 mmol/L) also suggests some level of renal impairment, which could contribute to cardiac complications. Additionally, the patient's past medical history of valvular cardiomyopathy increases the risk of heart failure progression. While the patient's medications are standard treatments for heart failure, the patient's overall health status is not optimal, and the patient's risk of pump failure death is higher than that of sudden cardiac death or survivor."
497,497,P0780,"Age: 51
Gender: Female 
Weight: 43 kg
Height: 157 cm
NYHA Class: II
Blood Pressure: 130/75 mmHg
Past Medical History: Idiopathic dilated cardiomyopathy
Albumin (g/L): 40,1
ALT or GPT (IU/L): 10.0
AST or GOT (IU/L): 20.0
Total Cholesterol (mmol/L): 5,26
Creatinine (mmol/L): 88.0
Gamma-glutamil transpeptidase (IU/L): 29
Glucose (mmol/L): 5,3
Hemoglobin (g/L): 110.0
HDL (mmol/L): 1,57
Potassium (mEq/L): 4,01
LDL (mmol/L): 2,93
Sodium (mEq/L): 142.0
Pro-BNP (ng/L): 1129.0
Protein (g/L): 80,1
Troponin (ng/mL): 0,01
TSH (mIU/L): 7,28
Urea (mg/dL): 4,9
LVEF (%): 28.0
Medications: Beta Blockers, Spironolactone, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"RANKING: 
1. Survivor
2. Pump failure death
3. Sudden cardiac death

REASONING:

This patient's prognosis can be determined by analyzing the provided data and medical history. 

Firstly, the patient has a history of idiopathic dilated cardiomyopathy, a condition where the heart's ability to pump blood is impaired due to the heart's structure being enlarged. This condition can lead to a poor prognosis.

The patient's left ventricular ejection fraction (LVEF) of 28% is significantly reduced, indicating poor heart function. This further supports the idea that the patient's heart is not functioning properly.

The patient's NT-proBNP level of 1129 ng/L is elevated, indicating increased ventricular wall stress and suggesting that the heart is working harder to pump blood, which is consistent with heart failure.

The presence of non-sustained ventricular tachycardia (NSVT) and polymorphic ventricular extrasystoles on the ECG suggests that the patient has an increased risk of arrhythmias, which can be life-threatening.

Given the combination of poor heart function, elevated NT-proBNP, and arrhythmias, the patient is at a higher risk of developing heart failure. However, the patient is currently taking medications such as beta blockers, spironolactone, and an ACE inhibitor, which can help manage heart failure symptoms and reduce the risk of complications.

While the patient's current ECG findings and medical history do suggest a higher risk of adverse outcomes, the patient is still alive and receiving treatment, which increases the likelihood of survival. Therefore, the most likely prognosis is that the patient will survive, although with a high risk of developing pump failure or sudden cardiac death in the near future.

The patient's risk of sudden cardiac death is higher due to the presence of arrhythmias and poor heart function. However, the patient is receiving treatment, which can help reduce this risk.

The patient's risk of pump failure death is the highest, given the patient's poor heart function and elevated NT-proBNP levels, indicating that the patient's heart is not functioning properly. However, the patient is receiving treatment, which can help manage symptoms and reduce the risk of complications."
498,498,P0782,"Age: 77
Gender: Female 
Weight: 43 kg
Height: 146 cm
NYHA Class: II
Blood Pressure: 110/70 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Diabetes, Myocardial Infarction
Albumin (g/L): 43,6
ALT or GPT (IU/L): 22.0
AST or GOT (IU/L): 21.0
Total Cholesterol (mmol/L): 3,65
Creatinine (mmol/L): 79.0
Gamma-glutamil transpeptidase (IU/L): 16
Glucose (mmol/L): 11,5
Hemoglobin (g/L): 122.0
HDL (mmol/L): 1,12
Potassium (mEq/L): 4,09
LDL (mmol/L): 1,89
Sodium (mEq/L): 139.0
Pro-BNP (ng/L): 481.0
Protein (g/L): 80,1
Troponin (ng/mL): 0,01
TSH (mIU/L): 0,44
Urea (mg/dL): 6,9
LVEF (%): 25.0
Medications: Diabetes Medication, Amiodarone, Beta Blockers, Loop Diuretics, Statins, ACE Inhibitor, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"RANKING: 1. Survivor
REASONING:

This patient has a complex medical history with multiple comorbidities, including ischemic dilated cardiomyopathy, diabetes, and a history of myocardial infarction. Despite these factors, the patient is currently being treated with a comprehensive regimen of medications, including beta blockers, ACE inhibitors, and statins, which are all indicated for heart failure management. The presence of a non-sustained ventricular tachycardia (NSVT) on the ECG is concerning, but the patient has not experienced any ventricular fibrillation or ventricular tachycardia events.

The patient's left ventricular ejection fraction (LVEF) is significantly reduced at 25%, indicating poor cardiac function. However, the patient's serum creatinine level is not elevated, suggesting that kidney function is preserved. The patient's electrolytes, including potassium and sodium levels, are within normal limits.

The elevated B-type natriuretic peptide (Pro-BNP) level of 481 ng/L is indicative of cardiac stress and strain, but it is not excessively high. The patient's troponin level is within normal limits, which suggests that there is no acute myocardial injury.

Given the patient's overall clinical presentation, I would rank the prognosis as ""survivor"" with a moderate to high risk of adverse cardiac events. The patient's complex medical history, reduced LVEF, and NSVT on ECG suggest that there is a risk of cardiac events, but the patient's current treatment regimen and preserved kidney function suggest that they are likely to survive the next few years.

However, it is essential to closely monitor the patient's cardiac function, electrolyte levels, and renal function, as well as adjust the treatment regimen as necessary to minimize the risk of adverse cardiac events. Regular follow-up appointments with the cardiologist will be crucial to ensure the patient's safety and optimize their management."
499,499,P0783,"Age: 76
Gender: Female 
Weight: 84 kg
Height: 145 cm
NYHA Class: II
Blood Pressure: 120/80 mmHg
Past Medical History: Hypertensive cardiomyopathy, Hypertension
Albumin (g/L): 39,8
ALT or GPT (IU/L): 17.0
AST or GOT (IU/L): 24.0
Total Cholesterol (mmol/L): 5,26
Creatinine (mmol/L): 120.0
Gamma-glutamil transpeptidase (IU/L): 13
Glucose (mmol/L): 8,7
Hemoglobin (g/L): 144.0
HDL (mmol/L): 1,29
Potassium (mEq/L): 3,59
LDL (mmol/L): 3,15
Sodium (mEq/L): 140.0
Protein (g/L): 75,4
Troponin (ng/mL): 0,01
TSH (mIU/L): 0,88
Urea (mg/dL): 10
LVEF (%): 59.0
Medications: Calcium Channel Blocker, Digoxin, Loop Diuretics, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: No
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",survivor,"RANKING: 
1. Survivor
REASONING: 
Based on the patient's age, NYHA Class II indicates mild symptoms, and the patient is on medications for hypertension and heart failure, which suggests that the patient is already receiving optimal management for their condition. The elevated creatinine level (120.0) may indicate some degree of kidney impairment, but it is not severe. The patient's LVEF (59.0) is reduced, but it is not severely impaired. The absence of ventricular extrasystoles, ventricular tachycardia, and non-sustained ventricular tachycardia on the ECG also suggests a low risk of sudden cardiac death. The patient's hemoglobin level (144.0) and troponin level (0.01) are within normal limits, indicating no acute myocardial infarction. Overall, the patient's clinical presentation and laboratory results suggest that they are likely to survive for the next few years, given their age and the fact that they are already receiving optimal treatment for their condition. 

2. Sudden cardiac death
REASONING: 
While the patient is not at high risk for sudden cardiac death based on the ECG, the patient's age (76) and elevated creatinine level (120.0) may increase the risk of sudden cardiac death. The patient's LVEF (59.0) is reduced, which may increase the risk of arrhythmias. The patient's history of hypertension and cardiomyopathy also increases the risk of sudden cardiac death. However, the patient is already receiving optimal treatment for their condition, which may help mitigate this risk.

3. Pump failure death
REASONING: 
The patient's NYHA Class II indicates mild symptoms, which suggests that they are not at high risk of heart failure. The patient is already receiving treatment for hypertension and heart failure, which should help manage their condition. The patient's LVEF (59.0) is reduced, but it is not severely impaired. The absence of elevated troponin levels and the presence of optimal medication therapy also suggest that the patient is not at high risk of pump failure. However, the patient's elevated creatinine level (120.0) may indicate some degree of kidney impairment, which could potentially exacerbate heart failure. Overall, while the patient is not at high risk of sudden cardiac death or pump failure, the elevated creatinine level may increase the risk of complications, making pump failure a possible outcome."
500,500,P0785,"Age: 72
Gender: Male 
Weight: 81 kg
Height: 168 cm
NYHA Class: II
Blood Pressure: 100/70 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Myocardial Infarction
Albumin (g/L): 42,6
ALT or GPT (IU/L): 14.0
AST or GOT (IU/L): 24.0
Total Cholesterol (mmol/L): 5,54
Creatinine (mmol/L): 130.0
Gamma-glutamil transpeptidase (IU/L): 12
Glucose (mmol/L): 5,7
Hemoglobin (g/L): 133.0
HDL (mmol/L): 1,84
Potassium (mEq/L): 3,29
LDL (mmol/L): 3,3
Sodium (mEq/L): 142.0
Pro-BNP (ng/L): 4250.0
Protein (g/L): 71,8
Troponin (ng/mL): 0,15
TSH (mIU/L): 2,92
Urea (mg/dL): 13,5
LVEF (%): 30.0
Medications: Angiotensin II Receptor Blocker, Beta Blockers, Loop Diuretics, Spironolactone, Statins
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"RANKING: 1. Survivor
REASONING: 

Based on the provided patient data, the patient is likely to survive for the next few years. The patient is 72 years old, with a NYHA Class II heart failure, indicating that they have some limitations in physical activity but can still perform daily activities with minimal symptoms. The patient has a history of ischemic dilated cardiomyopathy and myocardial infarction, which are risk factors for heart failure. However, the patient is on multiple medications, including beta blockers, ACE inhibitors, and diuretics, which are standard treatments for heart failure.

The patient's ejection fraction (LVEF) is 30%, which is significantly reduced, indicating severe left ventricular dysfunction. However, the patient's troponin levels are within normal limits, suggesting that there is no acute myocardial injury. The patient's creatinine level is elevated, indicating some degree of kidney dysfunction, but this is not uncommon in patients with heart failure.

The patient's lipid profile is not ideal, with high total cholesterol and LDL levels, but this is not directly related to the patient's survival. The patient's potassium level is slightly elevated, but this is not a significant concern in the context of heart failure.

The patient's pro-BNP level is elevated, indicating some degree of ventricular stress, but this is not uncommon in patients with heart failure. The patient's TSH level is within normal limits, indicating that there is no apparent thyroid dysfunction.

Overall, while the patient has several risk factors for heart failure and arrhythmias, they are on multiple medications and have a relatively stable clinical presentation. Therefore, the most likely outcome is that the patient will survive for the next few years.

It is worth noting that the patient's ECG shows ventricular extrasystoles, which are a type of arrhythmia that can increase the risk of sudden cardiac death. However, the patient's ECG is otherwise unremarkable, and there is no evidence of ventricular tachycardia or other arrhythmias that would increase the risk of sudden cardiac death.

In terms of specific survival time, it is difficult to predict without further information about the patient's symptoms, functional status, and other comorbidities. However, based on the patient's current clinical presentation and medication regimen, it is possible that the patient may survive for at least 2-5 years, with a significant risk of hospitalization for heart failure exacerbation or arrhythmias."
501,501,P0786,"Age: 64
Gender: Female 
Weight: 71 kg
Height: 153 cm
NYHA Class: II
Blood Pressure: 150/70 mmHg
Past Medical History: Valvular cardiomyopathy, Diabetes, Hypertension, Myocardial Infarction
Albumin (g/L): 43,1
ALT or GPT (IU/L): 15.0
AST or GOT (IU/L): 14.0
Total Cholesterol (mmol/L): 5,67
Creatinine (mmol/L): 131.0
Gamma-glutamil transpeptidase (IU/L): 149
Glucose (mmol/L): 6,2
Hemoglobin (g/L): 118.0
HDL (mmol/L): 1,57
Potassium (mEq/L): 4,26
LDL (mmol/L): 3,66
Sodium (mEq/L): 141.0
Pro-BNP (ng/L): 614.0
Protein (g/L): 81,1
Troponin (ng/mL): 0,01
TSH (mIU/L): 4,53
Urea (mg/dL): 9,9
LVEF (%): 45.0
Medications: Diabetes Medication, Angiotensin II Receptor Blocker, Loop Diuretics, Spironolactone, Statins
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: TPSV
        - Bradycardia: No
            ",survivor,"RANKING: 
1. Survivor
REASONING:
The patient's overall prognosis is ranked as a survivor due to the following factors:

- The patient's age of 64 is not considered old for a cardiac event, and they are still within a relatively healthy age range for cardiac interventions.
- The patient has a NYHA Class II heart failure, indicating mild symptoms, which suggests that they are still able to perform daily activities with minimal limitations.
- The patient has a relatively preserved LVEF of 45.0%, which indicates that their heart is still pumping effectively, albeit with some compromise.
- The absence of any recent myocardial infarction, ventricular tachycardia, or significant electrolyte imbalances (e.g., hyperkalemia) reduces the likelihood of an acute cardiac event.
- The patient is taking a combination of medications, including an angiotensin II receptor blocker, which is beneficial for heart failure and hypertension management, and statins, which help with cholesterol management.
- The ECG impression does not reveal any life-threatening arrhythmias, which reduces the risk of sudden cardiac death.
- The patient's laboratory results, including troponin and BNP levels, are not significantly elevated, suggesting that there is no acute cardiac injury or significant cardiac stress.

While the patient has a history of valvular cardiomyopathy, diabetes, and hypertension, which are risk factors for cardiac events, their overall clinical presentation and management plan suggest that they are at lower risk for a sudden cardiac death or pump failure in the near future.

2. Sudden cardiac death
REASONING:
This prognosis is less likely due to the factors mentioned above, but there are a few reasons why it's still possible:
- The patient's valvular cardiomyopathy is a significant risk factor for cardiac events, particularly arrhythmias.
- The patient's diabetes and hypertension are also risk factors for cardiac events, and their management may not be optimal.
- The patient's LVEF is significantly reduced, indicating some degree of cardiac dysfunction.

However, the patient's overall clinical presentation and management plan suggest that they are at lower risk for sudden cardiac death compared to the survivor and pump failure.

3. Pump failure death
REASONING:
This prognosis is the least likely due to the following factors:
- The patient's LVEF is 45.0%, which is relatively preserved, indicating that their heart is still pumping effectively, albeit with some compromise.
- The patient is taking medications that are beneficial for heart failure management, including an angiotensin II receptor blocker and spironolactone, which help reduce mortality and morbidity in heart failure.
- The patient's ECG impression does not reveal any life-threatening arrhythmias, which reduces the risk of pump failure.
- The patient's laboratory results are not significantly elevated, suggesting that there is no acute cardiac injury or significant cardiac stress.

However, the patient's valvular cardiomyopathy and diabetes are significant risk factors for cardiac events, and their management may not be optimal, which makes pump failure a possible but less likely outcome."
502,502,P0787,"Age: 74
Gender: Female 
Weight: 60 kg
Height: 142 cm
NYHA Class: II
Blood Pressure: 105/60 mmHg
Past Medical History: Valvular cardiomyopathy
Albumin (g/L): 41,7
ALT or GPT (IU/L): 17.0
AST or GOT (IU/L): 22.0
Total Cholesterol (mmol/L): 5,38
Creatinine (mmol/L): 79.0
Gamma-glutamil transpeptidase (IU/L): 24
Glucose (mmol/L): 5,1
Hemoglobin (g/L): 128.0
HDL (mmol/L): 1,56
Potassium (mEq/L): 3,59
LDL (mmol/L): 3,34
Sodium (mEq/L): 141.0
Pro-BNP (ng/L): 1069.0
Protein (g/L): 68,6
Troponin (ng/mL): 0,01
TSH (mIU/L): 1,86
Urea (mg/dL): 8,3
LVEF (%): 55.0
Medications: Amiodarone, Digoxin, Loop Diuretics, Spironolactone, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",survivor,"RANKING: 1. Survivor
REASONING: 

Based on the provided patient data, I predict that the patient has a high likelihood of survival over the next few years. Several factors contribute to this assessment:

1. Age: Although the patient is 74 years old, her age alone is not a significant risk factor for mortality in this case. Many patients with valvular cardiomyopathy can survive for several years with proper management.
2. NYHA Class II: The patient's NYHA class indicates that she has moderate symptoms, but it's not severe enough to predict a poor outcome.
3. Medications: The patient is on multiple medications, including ACE inhibitors, which are commonly used to manage heart failure and hypertension. The presence of these medications suggests that the patient is receiving adequate treatment for her condition.
4. Laboratory results: The patient's creatinine level is elevated, but it's not excessively high, indicating some degree of kidney dysfunction. However, her urea level is not severely elevated, which might suggest some residual kidney function.
5. ECG findings: While the patient has ventricular extrasystoles, non-sustained VT, and non-sustained ventricular tachycardia, these findings are not indicative of severe cardiac dysfunction. The absence of significant ST-segment elevation or Q-waves on the ECG suggests that the patient's cardiac damage is not extensive.
6. Biomarkers: The patient's troponin level is normal, which suggests that there is no significant cardiac damage. Her Pro-BNP level is elevated, but it's not excessively high, indicating some degree of ventricular stress.
7. Hemoglobin and other laboratory results: The patient's hemoglobin level is slightly elevated, which might indicate some degree of anemia, but it's not severe. Her other laboratory results are relatively normal.

Considering these factors, I predict that the patient will survive for several years with proper management and treatment. However, regular monitoring and adjustments to her treatment plan will be necessary to ensure optimal outcomes.

RANKING: 2. Sudden cardiac death
REASONING: 

While the patient has a high likelihood of survival, there are some factors that could potentially increase her risk of sudden cardiac death:

1. Ventricular extrasystoles and non-sustained VT: These findings on the ECG suggest some degree of cardiac arrhythmia, which can increase the risk of sudden cardiac death.
2. Non-sustained ventricular tachycardia: The presence of non-sustained VT is a risk factor for sudden cardiac death.
3. Valvular cardiomyopathy: This condition can lead to arrhythmias and cardiac dysfunction, increasing the risk of sudden cardiac death.

However, the patient's overall health status, treatment plan, and laboratory results suggest that these factors are not sufficient to predict a high risk of sudden cardiac death.

RANKING: 3. Pump failure death
REASONING: 

While the patient has some risk factors for pump failure, such as valvular cardiomyopathy and elevated creatinine levels, her overall health status and treatment plan suggest that she is not at high risk for pump failure:

1. NYHA Class II: The patient's NYHA class indicates that she has moderate symptoms, which suggests that her heart is not severely impaired.
2. Medications: The patient is on multiple medications, including ACE inhibitors, which are commonly used to manage heart failure.
3. Laboratory results: The patient's creatinine level is elevated, but it's not excessively high, indicating some degree of kidney dysfunction. However, her urea level is not severely elevated, which might suggest some residual kidney function.
4. ECG findings: The patient's ECG findings, while abnormal, do not suggest severe cardiac dysfunction.

Considering these factors, I predict that the patient is at low risk for pump failure over the next few years, and her overall prognosis is more favorable than sudden cardiac death."
503,503,P0789,"Age: 45
Gender: Male 
Weight: 88 kg
Height: 168 cm
NYHA Class: III
Blood Pressure: 120/70 mmHg
Past Medical History: Hypertropic cardiomyopathy, Hypertension
Albumin (g/L): 45
ALT or GPT (IU/L): 27.0
AST or GOT (IU/L): 20.0
Total Cholesterol (mmol/L): 6,47
Creatinine (mmol/L): 111.0
Gamma-glutamil transpeptidase (IU/L): 25
Glucose (mmol/L): 4,6
Hemoglobin (g/L): 157.0
HDL (mmol/L): 1,29
Potassium (mEq/L): 4,6
LDL (mmol/L): 4,24
Sodium (mEq/L): 143.0
Pro-BNP (ng/L): 35.0
Protein (g/L): 76
T3 (pg/dL): 0,06
T4 (ng/L): 17
Troponin (ng/mL): 0,005
TSH (mIU/L): 1,45
Urea (mg/dL): 8,32
LVEF (%): 58.0
Medications: Beta Blockers, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"RANKING: 
1. Survivor
2. Pump failure death
3. Sudden cardiac death

REASONING:

The patient is a 45-year-old male with a history of hypertrophic cardiomyopathy and hypertension, which increases the risk of cardiac complications. The patient's NYHA Class III indicates significant heart failure symptoms, suggesting that the heart is not functioning properly.

The patient's laboratory results show elevated creatinine levels (111.0 mmol/L), which indicate impaired kidney function, a common complication in patients with heart failure. The elevated troponin level (0.005 ng/mL) is also concerning, as it suggests some degree of cardiac muscle damage.

The ECG findings of ventricular extrasystole (monomorphic) are abnormal and may indicate an underlying arrhythmia, which could contribute to cardiac complications. However, the absence of ventricular tachycardia and non-sustained ventricular tachycardia reduces the likelihood of sudden cardiac death.

Given the patient's age, NYHA Class III status, and laboratory results, pump failure death is a significant concern. However, the patient is already taking medications for heart failure (beta blockers and ACE inhibitor) and has a relatively stable ECG. Therefore, pump failure death is not the most likely outcome.

The patient's relatively low LVEF (58.0%) and elevated NT-proBNP level (35.0 ng/L) also suggest that the patient is at risk for pump failure. However, the patient's overall clinical presentation and medication regimen suggest that they are more likely to survive with proper management.

Considering these factors, the most likely outcome for this patient is a survivor, with a moderate risk of pump failure death and a low risk of sudden cardiac death."
504,504,P0791,"Age: 75
Gender: Male 
Weight: 85 kg
Height: 165 cm
NYHA Class: II
Blood Pressure: 125/75 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Diabetes, Hypertension, Myocardial Infarction
Albumin (g/L): 40
ALT or GPT (IU/L): 45.0
AST or GOT (IU/L): 35.0
Total Cholesterol (mmol/L): 3,88
Creatinine (mmol/L): 133.0
Gamma-glutamil transpeptidase (IU/L): 25
Glucose (mmol/L): 5,3
Hemoglobin (g/L): 162.0
HDL (mmol/L): 0,98
Potassium (mEq/L): 4
LDL (mmol/L): 1,81
Sodium (mEq/L): 140.0
Pro-BNP (ng/L): 2542.0
Protein (g/L): 70
T4 (ng/L): 12
Troponin (ng/mL): 0,01
TSH (mIU/L): 2,2
Urea (mg/dL): 11,65
LVEF (%): 40.0
Medications: Diabetes Medication, Digoxin, Loop Diuretics, Spironolactone, Statins, ACE Inhibitor, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: TPSV
        - Bradycardia: No
            ",survivor,"RANKING: 1. Survivor
REASONING: 

Based on the provided patient data, I predict that the patient is likely to survive for the next few years. The patient's age (75) is a significant risk factor for cardiac-related mortality, but the patient's NYHA Class II indicates that the patient has some limitations in physical activity, but the patient is not in severe heart failure. 

The patient's LVEF of 40.0 is significantly below the normal range, indicating left ventricular dysfunction. However, the patient is on ACE Inhibitor and Digoxin, which are commonly used to manage heart failure and arrhythmias. The patient's ECG impression shows non-sustained ventricular tachycardia and polymorphic ventricular extrasystole, which may indicate an increased risk of cardiac arrhythmias. However, the patient is on Nitrovasodilator, which is used to manage hypertension and heart failure.

The patient's lab results show elevated creatinine levels, indicating some degree of renal impairment, but the patient is on Loop Diuretics, which are commonly used to manage fluid overload in heart failure. The patient's Pro-BNP level is elevated, indicating some degree of ventricular strain.

Considering the patient's age, comorbidities, and the presence of cardiac arrhythmias, I predict that the patient is at risk for cardiac events, but the patient's current medications and the presence of some degree of heart failure may mitigate this risk. Therefore, I predict that the patient is likely to survive for the next few years, but close monitoring and adjustments to the treatment plan may be necessary to manage the patient's cardiac condition."
505,505,P0795,"Age: 73
Gender: Male 
Weight: 76 kg
Height: 171 cm
NYHA Class: II
Blood Pressure: 87/50 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Dyslipemia, Myocardial Infarction
Albumin (g/L): 41
ALT or GPT (IU/L): 18.0
AST or GOT (IU/L): 22.0
Total Cholesterol (mmol/L): 3,8
Creatinine (mmol/L): 97.0
Gamma-glutamil transpeptidase (IU/L): 97
Glucose (mmol/L): 5,3
Hemoglobin (g/L): 119.0
HDL (mmol/L): 1,22
Potassium (mEq/L): 4,6
LDL (mmol/L): 2,07
Sodium (mEq/L): 137.0
Pro-BNP (ng/L): 1961.0
Protein (g/L): 74
T4 (ng/L): 17
TSH (mIU/L): 4,3
Urea (mg/dL): 6,32
LVEF (%): 25.0
Medications: Beta Blockers, Statins, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",survivor,"RANKING: 1. Survivor
REASONING: 

Based on the provided patient data, the patient's prognosis is most likely to be a survivor. The patient is 73 years old with a history of ischemic dilated cardiomyopathy, which is a significant comorbidity. However, the patient's NYHA Class II indicates that the condition has not severely limited their physical activity. The patient is also on medications such as beta blockers, statins, and ACE inhibitors, which are commonly used to manage heart failure and ischemic heart disease.

The patient's lab results show elevated creatinine levels (97.0 mmol/L) and a low LVEF (25.0%), indicating impaired kidney function and reduced cardiac function, respectively. However, these findings do not necessarily indicate an imminent risk of cardiac death. The patient's electrolyte levels, including potassium (4.6 mEq/L), are within normal limits, and the patient's blood glucose level (5.3 mmol/L) is also within the normal range.

The patient's ECG results show ventricular extrasystoles, which are a type of abnormal heart rhythm, but no ventricular tachycardia or non-sustained ventricular tachycardia. While this is a concerning finding, it does not necessarily indicate an immediate risk of cardiac death.

Given the patient's age, comorbidities, and medication regimen, the patient's overall prognosis is more likely to be a survivor. However, regular monitoring and follow-up with the patient will be necessary to assess any changes in their condition and adjust the treatment plan as needed.

RANKING: 2. Sudden cardiac death
REASONING: 

While the patient's ECG results show ventricular extrasystoles, which are a type of abnormal heart rhythm, the risk of sudden cardiac death is not immediately apparent. The patient's NYHA Class II indicates that the condition has not severely limited their physical activity, and the patient is on medications to manage their heart failure and ischemic heart disease.

However, the patient's low LVEF (25.0%) and elevated creatinine levels (97.0 mmol/L) suggest impaired cardiac function and kidney dysfunction, which may increase the risk of sudden cardiac death. Additionally, the patient's age (73 years) and comorbidities (ischemic dilated cardiomyopathy, dyslipemia, and myocardial infarction) may increase the risk of cardiac events.

Given the patient's age, comorbidities, and impaired cardiac function, the risk of sudden cardiac death is a concern, but it is not the most likely outcome. Regular monitoring and follow-up with the patient will be necessary to assess any changes in their condition and adjust the treatment plan as needed.

RANKING: 3. Pump failure death
REASONING: 

The patient's low LVEF (25.0%) and elevated creatinine levels (97.0 mmol/L) indicate impaired cardiac function and kidney dysfunction, which increases the risk of pump failure. The patient's NYHA Class II indicates that the condition has not severely limited their physical activity, but the patient's impaired cardiac function and kidney dysfunction suggest that pump failure is a possible outcome.

However, the patient is on medications to manage their heart failure and ischemic heart disease, which may help to slow the progression of the disease. Additionally, the patient's age (73 years) and comorbidities (ischemic dilated cardiomyopathy, dyslipemia, and myocardial infarction) may not necessarily increase the risk of pump failure.

Given the patient's impaired cardiac function and kidney dysfunction, pump failure is a possible outcome, but it is not the most likely outcome. Regular monitoring and follow-up with the patient will be necessary to assess any changes in their condition and adjust the treatment plan as needed."
506,506,P0796,"Age: 61
Gender: Female 
Weight: 69 kg
Height: 154 cm
NYHA Class: II
Blood Pressure: 108/70 mmHg
Past Medical History: Other HF etiology, Dyslipemia, Myocardial Infarction
Albumin (g/L): 45
ALT or GPT (IU/L): 17.0
AST or GOT (IU/L): 21.0
Total Cholesterol (mmol/L): 4,42
Creatinine (mmol/L): 80.0
Gamma-glutamil transpeptidase (IU/L): 24
Glucose (mmol/L): 5,6
Hemoglobin (g/L): 124.0
HDL (mmol/L): 1,22
Potassium (mEq/L): 4,6
LDL (mmol/L): 2,48
Sodium (mEq/L): 135.0
Pro-BNP (ng/L): 1614.0
Protein (g/L): 78
T4 (ng/L): 15
TSH (mIU/L): 3,01
Urea (mg/dL): 9,48
LVEF (%): 20.0
Medications: Beta Blockers, Digoxin, Statins, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",survivor,"RANKING: 1. Survivor
REASONING: 

Based on the provided patient data, the patient is a 61-year-old female with a history of heart failure (HF), myocardial infarction, dyslipidemia, and other etiologies. She has a mildly elevated creatinine level (80.0 mmol/L), indicating some degree of renal impairment. However, her hemoglobin level (124.0 g/L) and LDH (1,22 mmol/L) are within normal limits, which suggests that she does not have significant anemia.

The patient's NYHA Class II indicates that she has mild symptoms of heart failure, but she is still able to perform daily activities without significant limitations. Her blood pressure (108/70 mmHg) is within a relatively normal range.

The most concerning finding is the elevated Pro-BNP level (1614.0 ng/L), which is significantly elevated, indicating a high risk of heart failure exacerbation. However, this finding is not an absolute contraindication to survival. The patient is also on beta blockers, digoxin, statins, and an ACE inhibitor, which are standard treatments for heart failure and coronary artery disease.

The ECG findings of ventricular extrasystole, non-sustained VT, and non-sustained ventricular tachycardia (CH>10) suggest that the patient has a high risk of arrhythmic events, but these are not necessarily indicative of a poor prognosis.

Considering the above factors, I believe that the patient has a relatively good prognosis and is likely to survive for the next few years. The patient's heart function is not severely impaired, and she is receiving standard treatments for her conditions. While the elevated Pro-BNP level is concerning, it is not an absolute contraindication to survival. Therefore, I rank the patient as a survivor with a moderate risk of heart-related events.

RANKING: 2. Sudden cardiac death
REASONING: 

While the patient's ECG findings of ventricular extrasystole, non-sustained VT, and non-sustained ventricular tachycardia (CH>10) suggest a high risk of arrhythmic events, the patient's overall clinical picture is not as concerning as to warrant a high ranking of sudden cardiac death. The patient's NYHA Class II and mildly elevated creatinine level suggest that she has some residual cardiac function, which reduces the likelihood of sudden cardiac death.

However, the patient's elevated Pro-BNP level (1614.0 ng/L) and history of myocardial infarction increase the risk of heart failure exacerbation and arrhythmic events. Additionally, the patient's age (61 years) and sex (female) are risk factors for sudden cardiac death.

Considering the above factors, I rank the patient as having a moderate risk of sudden cardiac death, but it is not the most likely outcome.

RANKING: 3. Pump failure death
REASONING: 

While the patient's elevated Pro-BNP level (1614.0 ng/L) and history of heart failure suggest that she has a risk of heart failure exacerbation, I do not rank her as having a high risk of pump failure death. The patient's NYHA Class II indicates that she has mild symptoms of heart failure, and she is receiving standard treatments for heart failure.

Additionally, the patient's LVEF (20.0%) is not severely impaired, which suggests that she has some residual cardiac function. The patient's hemoglobin level (124.0 g/L) and LDH (1,22 mmol/L) are within normal limits, which suggests that she does not have significant anemia.

Considering the above factors, I rank the patient as having a low risk of pump failure death. However, it is essential to monitor the patient closely to adjust her treatment plan as needed to prevent heart failure exacerbation.

It is essential to note that the patient's ECG findings of ventricular extrasystole, non-sustained VT, and non-sustained ventricular tachycardia (CH>10) increase the risk of arrhythmic events, and the patient should be closely monitored for any changes in her ECG or clinical status."
507,507,P0797,"Age: 81
Gender: Male 
Weight: 77 kg
Height: 178 cm
NYHA Class: II
Blood Pressure: 110/60 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Dyslipemia, Myocardial Infarction
Albumin (g/L): 38
ALT or GPT (IU/L): 19.0
AST or GOT (IU/L): 13.0
Total Cholesterol (mmol/L): 4,34
Creatinine (mmol/L): 79.0
Gamma-glutamil transpeptidase (IU/L): 6
Glucose (mmol/L): 5,2
Hemoglobin (g/L): 127.0
HDL (mmol/L): 1,4
Potassium (mEq/L): 3,9
LDL (mmol/L): 2,85
Sodium (mEq/L): 143.0
Pro-BNP (ng/L): 1511.0
Protein (g/L): 69
T3 (pg/dL): 0,04
T4 (ng/L): 21
Troponin (ng/mL): 0,2
TSH (mIU/L): 1,54
Urea (mg/dL): 8,9
LVEF (%): 20.0
Medications: Angiotensin II Receptor Blocker, Loop Diuretics, Statins, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: TPSV
        - Bradycardia: No
            ",survivor,"RANKING: 1. Survivor
REASONING: The patient's age, NYHA Class II heart failure, and history of ischemic dilated cardiomyopathy, myocardial infarction, and dyslipidemia indicate a high risk for adverse cardiac events. However, the patient's current medical treatment regimen, including an angiotensin II receptor blocker, loop diuretics, statins, and a nitrovasodilator, suggests that their cardiovascular risk factors are being adequately managed.

The patient's laboratory results show elevated troponin levels, indicating some degree of cardiac injury, but the Troponin level is within a relatively normal range. The Pro-BNP level is elevated, which is consistent with heart failure, but not excessively high. The patient's kidney function is also impaired, as indicated by elevated creatinine levels, but this is not uncommon in patients with heart failure.

The ECG findings of ventricular extrasystoles, non-sustained ventricular tachycardia, and paroxysmal supraventricular tachyarrhythmia are concerning, but the presence of non-sustained ventricular tachycardia (CH>10) is not indicative of a high risk of sudden cardiac death. The patient's hemoglobin level is slightly elevated, which may be related to anemia, and the liver function tests are within normal limits.

Considering these factors, the patient's overall prognosis is more likely to be a survivor, as their cardiovascular risk factors are being managed, and their cardiac function, although compromised, is not severely impaired. However, close monitoring and adjustment of their treatment regimen may be necessary to prevent further cardiac complications.

RANKING: 2. Pump failure death
REASONING: The patient's impaired kidney function, elevated creatinine levels, and elevated Pro-BNP levels indicate that their heart failure is not well-compensated. The patient's NYHA Class II heart failure classification suggests that their symptoms are moderate, but the elevated Pro-BNP level suggests that their heart failure may be worsening.

The patient's elevated troponin levels and non-sustained ventricular tachycardia may indicate ongoing cardiac injury and arrhythmia, respectively. The presence of ventricular extrasystoles and non-sustained ventricular tachycardia on the ECG also suggests that the patient's heart is at risk for further arrhythmic events.

Given these factors, the patient's prognosis is more likely to be pump failure death, as their heart failure is not well-compensated, and their cardiac function is compromised.

RANKING: 3. Sudden cardiac death
REASONING: The patient's history of ischemic dilated cardiomyopathy, myocardial infarction, and dyslipidemia, combined with their elevated troponin levels and non-sustained ventricular tachycardia on the ECG, make them at high risk for sudden cardiac death. The patient's impaired kidney function and elevated Pro-BNP levels also suggest that their heart failure is not well-compensated.

The patient's age and NYHA Class II heart failure classification also increase their risk for sudden cardiac death. The presence of ventricular extrasystoles and paroxysmal supraventricular tachyarrhythmia on the ECG further increase the risk of arrhythmic events.

However, the patient's current medical treatment regimen and laboratory results do not suggest that their cardiovascular risk factors are being adequately managed, and their cardiac function is not well-compensated. Therefore, the patient's prognosis is less likely to be a sudden cardiac death compared to pump failure death."
508,508,P0800,"Age: 72
Gender: Male 
Weight: 64 kg
Height: 165 cm
NYHA Class: II
Blood Pressure: 130/80 mmHg
Past Medical History: Valvular cardiomyopathy
Albumin (g/L): 40
ALT or GPT (IU/L): 21.0
AST or GOT (IU/L): 38.0
Total Cholesterol (mmol/L): 5,5
Creatinine (mmol/L): 106.0
Gamma-glutamil transpeptidase (IU/L): 26
Glucose (mmol/L): 6,8
Hemoglobin (g/L): 162.0
HDL (mmol/L): 1,13
Potassium (mEq/L): 4,38
LDL (mmol/L): 3,88
Sodium (mEq/L): 138.0
Pro-BNP (ng/L): 6088.0
Protein (g/L): 72,5
Troponin (ng/mL): 0,01
TSH (mIU/L): 3,81
Urea (mg/dL): 6,8
LVEF (%): 30.0
Medications: Digoxin, Loop Diuretics, Spironolactone, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",survivor,"RANKING: 1. Survivor
REASONING: 

Based on the patient's data, the patient is a 72-year-old male with a history of valvular cardiomyopathy, which is a significant risk factor for cardiac arrhythmias and heart failure. The patient's elevated BNP levels (6088.0 ng/L) and low LVEF (30.0%) indicate a poor cardiac function, which is a strong predictor of mortality.

The patient's ECG findings of ventricular extrasystole, non-sustained ventricular tachycardia, and non-sustained ventricular tachycardia (CH>10) suggest a high risk of cardiac arrhythmias, which are a common cause of sudden cardiac death in patients with heart failure. The presence of these arrhythmias, combined with the patient's poor cardiac function and elevated BNP levels, make it more likely that the patient will survive for the next few years.

The patient's NYHA Class II symptoms suggest that the patient has some limitations in physical activity, but the patient is not severely limited. The patient's blood pressure and electrolyte levels are within a relatively normal range, and the patient is not taking any medications that would increase the risk of cardiac arrhythmias or heart failure.

While the patient's elevated creatinine level (106.0 mmol/L) and elevated troponin level (0.01 ng/mL) suggest some degree of kidney impairment, this is not a significant predictor of mortality in this case.

Overall, based on the patient's data, the most likely outcome is that the patient will survive for the next few years, although the patient will likely require close monitoring and management of their cardiac arrhythmias and heart failure.

RANKING: 2. Sudden cardiac death
REASONING: 

This outcome is possible, but less likely than survival, given the patient's poor cardiac function and the presence of cardiac arrhythmias. The patient's elevated BNP levels and low LVEF suggest that the patient's heart is under significant stress, which increases the risk of sudden cardiac death.

However, the patient's ECG findings of ventricular extrasystole, non-sustained ventricular tachycardia, and non-sustained ventricular tachycardia (CH>10) suggest that the patient has a higher risk of cardiac arrhythmias, which is a major contributor to sudden cardiac death. Additionally, the patient's NYHA Class II symptoms suggest that the patient is not severely limited, which increases the risk of sudden cardiac death.

RANKING: 3. Pump failure death
REASONING: 

This outcome is less likely than sudden cardiac death, given the patient's current cardiac function and the presence of cardiac arrhythmias. The patient's LVEF (30.0%) is significantly reduced, which suggests that the patient's heart is not functioning optimally. However, the patient is taking medications that are designed to manage heart failure, including digoxin, loop diuretics, and spironolactone, which can help to improve cardiac function and reduce the risk of heart failure.

Additionally, the patient's elevated BNP levels suggest that the patient's heart is under significant stress, but the patient's current cardiac function is not severely impaired. Therefore, while pump failure is a possible outcome, it is less likely than sudden cardiac death, given the patient's current cardiac function and the presence of cardiac arrhythmias."
509,509,P0801,"Age: 72
Gender: Female 
Weight: 60 kg
Height: 154 cm
NYHA Class: III
Blood Pressure: 95/60 mmHg
Past Medical History: Valvular cardiomyopathy, Diabetes, Hypertension
Albumin (g/L): 33,4
ALT or GPT (IU/L): 22.0
AST or GOT (IU/L): 14.0
Total Cholesterol (mmol/L): 3,64
Creatinine (mmol/L): 137.0
Gamma-glutamil transpeptidase (IU/L): 16
Glucose (mmol/L): 10,9
Hemoglobin (g/L): 123.0
HDL (mmol/L): 0,98
Potassium (mEq/L): 3,36
LDL (mmol/L): 2,14
Sodium (mEq/L): 129.0
Pro-BNP (ng/L): 2233.0
Protein (g/L): 71,3
Troponin (ng/mL): 0,04
TSH (mIU/L): 0,81
Urea (mg/dL): 13,2
LVEF (%): 70.0
Medications: Amiodarone, Digoxin, Loop Diuretics, Spironolactone, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: No
            ",survivor,"RANKING: 1. Survivor
REASONING: 

This patient has a complex medical history with multiple comorbidities, including valvular cardiomyopathy, diabetes, and hypertension. The patient's ejection fraction (LVEF) is 70%, which is slightly below the normal range, indicating some degree of left ventricular dysfunction. However, the patient's serum troponin levels are within normal limits, suggesting that there is no acute myocardial infarction. 

The patient is also taking multiple medications, including an ACE inhibitor, which is beneficial for patients with heart failure and hypertension. The presence of elevated BNP levels (2233 ng/L) suggests some degree of ventricular strain, but the patient's overall clinical presentation and laboratory results do not indicate acute heart failure.

The patient's NYHA class is III, indicating significant symptoms of heart failure, but the patient is still ambulatory and able to perform daily activities. The absence of ventricular tachycardia or non-sustained ventricular tachycardia on the ECG suggests that the patient does not have a high risk of sudden cardiac death.

Overall, while this patient has a significant medical history and multiple comorbidities, the absence of acute myocardial infarction, ventricular tachycardia, and non-sustained ventricular tachycardia, as well as the patient's ability to ambulate, suggest that the patient is likely to survive for the next few years. 

RANKING: 2. Pump failure death
REASONING: 

The patient's elevated creatinine levels (13.2 mg/dL) and elevated urea levels (13.2 mg/dL) suggest some degree of renal impairment, which can be a complication of heart failure. The patient's NYHA class is III, indicating significant symptoms of heart failure, and the patient's LVEF is slightly below the normal range. 

While the patient is taking medications that are beneficial for heart failure, including an ACE inhibitor, the patient's overall clinical presentation and laboratory results do not suggest that the patient is at high risk for pump failure death. However, the patient's renal impairment and elevated BNP levels suggest that the patient may be at risk for worsening heart failure and renal impairment over time.

RANKING: 3. Sudden cardiac death
REASONING: 

The patient's ECG impression shows monomorphic ventricular extrasystole, which is a type of abnormal heart rhythm that can increase the risk of sudden cardiac death. The patient's NYHA class is III, indicating significant symptoms of heart failure, and the patient's LVEF is slightly below the normal range. 

While the patient is taking medications that are beneficial for heart failure, the presence of monomorphic ventricular extrasystole on the ECG suggests that the patient may be at high risk for sudden cardiac death. However, the patient's overall clinical presentation and laboratory results do not suggest that the patient is at high risk for pump failure death."
510,510,P0802,"Age: 52
Gender: Male 
Weight: 61 kg
Height: 168 cm
NYHA Class: III
Blood Pressure: 105/65 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Myocardial Infarction
Albumin (g/L): 37,9
ALT or GPT (IU/L): 49.0
AST or GOT (IU/L): 46.0
Total Cholesterol (mmol/L): 5,29
Creatinine (mmol/L): 126.0
Gamma-glutamil transpeptidase (IU/L): 75
Glucose (mmol/L): 6,2
Hemoglobin (g/L): 120.0
HDL (mmol/L): 0,99
Potassium (mEq/L): 5,43
LDL (mmol/L): 3,78
Sodium (mEq/L): 136.0
Pro-BNP (ng/L): 11001.0
Protein (g/L): 68,4
Troponin (ng/mL): 0,09
TSH (mIU/L): 3,64
Urea (mg/dL): 13,5
LVEF (%): 21.0
Medications: Beta Blockers, Loop Diuretics, Spironolactone, Statins, ACE Inhibitor, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: TPSV
        - Bradycardia: No
            ",survivor,"RANKING: 1. Survivor
REASONING: 

Based on the provided patient data, the patient is at high risk for adverse cardiac events. The patient has a history of ischemic dilated cardiomyopathy, myocardial infarction, and NYHA Class III heart failure, indicating significant cardiac dysfunction. The elevated creatinine level (126.0 mmol/L) suggests renal impairment, which is a common comorbidity in patients with heart failure.

The patient's biomarkers, such as elevated Pro-BNP (11001.0 ng/L) and Troponin (0.09 ng/mL), also suggest cardiac stress and damage. The presence of ventricular extrasystole, non-sustained ventricular tachycardia, and non-sustained ventricular tachycardia (CH>10) on the ECG impression further increase the risk of cardiac events.

However, the patient is currently on multiple medications, including beta blockers, loop diuretics, spironolactone, statins, ACE inhibitors, and a nitrovasodilator, which are all evidence-based treatments for heart failure and cardiac arrhythmias. The patient's hemoglobin level (120.0 g/L) and low potassium level (5.43 mEq/L) suggest that the patient is not experiencing severe anemia or hypokalemia, which could be contributing factors to cardiac instability.

Given the combination of these factors, I believe the patient has a high risk of cardiac events, but the presence of current medication therapy and relatively stable vital signs suggest that the patient is more likely to survive the next few years with close monitoring and adjustment of treatment. Therefore, I rank the patient as a survivor.

RANKING: 2. Sudden cardiac death
REASONING: 

While the patient's cardiac risk factors are significant, the patient's current medication regimen and stable vital signs suggest that sudden cardiac death is not the most likely outcome. However, the patient's history of ventricular extrasystole, non-sustained ventricular tachycardia, and non-sustained ventricular tachycardia (CH>10) on the ECG impression increase the risk of arrhythmias, which can lead to sudden cardiac death.

Additionally, the patient's LVEF (21.0%) is very low, indicating significant cardiac dysfunction, which can increase the risk of arrhythmias and sudden cardiac death.

However, the patient's current treatment and stable vital signs suggest that sudden cardiac death is less likely than cardiac failure or pump failure, but still a possibility.

RANKING: 3. Pump failure death
REASONING: 

While the patient's cardiac dysfunction is significant, the patient's current medication regimen and relatively stable vital signs suggest that pump failure is less likely than sudden cardiac death. The patient is on multiple medications that are evidence-based treatments for heart failure, including beta blockers, loop diuretics, spironolactone, statins, ACE inhibitors, and a nitrovasodilator.

The patient's elevated creatinine level (126.0 mmol/L) suggests renal impairment, which is a common comorbidity in patients with heart failure. However, the patient's LVEF (21.0%) is very low, indicating significant cardiac dysfunction, which can increase the risk of pump failure.

Overall, while pump failure is a concern, the patient's current treatment and stable vital signs suggest that pump failure is less likely than sudden cardiac death."
511,511,P0803,"Age: 48
Gender: Male 
Weight: 70 kg
Height: 170 cm
NYHA Class: II
Blood Pressure: 105/70 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Dyslipemia, Hypertension, Myocardial Infarction
Albumin (g/L): 45,7
ALT or GPT (IU/L): 30.0
AST or GOT (IU/L): 29.0
Total Cholesterol (mmol/L): 6,69
Creatinine (mmol/L): 94.0
Gamma-glutamil transpeptidase (IU/L): 194
Glucose (mmol/L): 5,3
Hemoglobin (g/L): 131.0
HDL (mmol/L): 1,08
Potassium (mEq/L): 4
LDL (mmol/L): 5,11
Sodium (mEq/L): 134.0
Pro-BNP (ng/L): 2954.0
Protein (g/L): 77,8
Troponin (ng/mL): 0,01
TSH (mIU/L): 1,45
Urea (mg/dL): 5,2
LVEF (%): 17.0
Medications: Beta Blockers, Loop Diuretics, Spironolactone, Statins, ACE Inhibitor, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"RANKING: 
1. Survivor
REASONING:
The patient's age, weight, and NYHA Class II indicate a moderate level of heart disease severity. However, the patient's LVEF of 17.0 is significantly reduced, suggesting severe left ventricular dysfunction. The presence of ischemic dilated cardiomyopathy, hypertension, and myocardial infarction in the past medical history further exacerbates the prognosis.

Despite this, the patient is currently taking multiple medications, including beta blockers, ACE inhibitors, and statins, which are commonly used to manage heart failure and reduce the risk of further cardiac events. The patient's electrolyte levels, including potassium, are within normal limits, and the liver enzymes (ALT and AST) are not significantly elevated, indicating no acute liver damage.

The ECG findings of ventricular extrasystole, non-sustained VT, and non-sustained ventricular tachycardia suggest a high risk of arrhythmias, but the patient is currently not experiencing any life-threatening arrhythmias. The absence of bradycardia and paroxysmal supraventricular tachyarrhythmia reduces the risk of sudden cardiac death.

Given these factors, the patient's current condition and treatment plan suggest that the patient is likely to survive in the next few years, with a moderate risk of further cardiac events. The patient's reduced LVEF and history of heart disease make it essential to closely monitor the patient's condition and adjust the treatment plan as needed to minimize the risk of cardiac complications.

RANKING 2: Sudden Cardiac Death (less likely)
REASONING:
While the patient's ECG findings suggest a high risk of arrhythmias, the patient is currently not experiencing any life-threatening arrhythmias. The absence of ventricular fibrillation, ventricular tachycardia, or other life-threatening arrhythmias reduces the likelihood of sudden cardiac death.

RANKING 3: Pump Failure Death (least likely)
REASONING:
The patient's current treatment plan, including beta blockers, ACE inhibitors, and spironolactone, is designed to manage heart failure and reduce the risk of pump failure. The patient's LVEF is significantly reduced, but the patient is still taking medications that can help improve cardiac function. Additionally, the patient's electrolyte levels and liver enzymes are within normal limits, indicating no acute liver damage.

However, the patient's reduced LVEF and history of heart disease make it essential to closely monitor the patient's condition and adjust the treatment plan as needed to minimize the risk of cardiac complications. While pump failure is a possible outcome, it is less likely than sudden cardiac death or survivorship, given the patient's current treatment plan and the absence of life-threatening arrhythmias."
512,512,P0805,"Age: 60
Gender: Female 
Weight: 77 kg
Height: 148 cm
NYHA Class: II
Blood Pressure: 110/70 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Diabetes, Dyslipemia, Hypertension, Myocardial Infarction
Albumin (g/L): 41
ALT or GPT (IU/L): 14.0
AST or GOT (IU/L): 16.0
Total Cholesterol (mmol/L): 4,83
Creatinine (mmol/L): 177.0
Gamma-glutamil transpeptidase (IU/L): 19
Glucose (mmol/L): 5,8
Hemoglobin (g/L): 141.0
HDL (mmol/L): 1,35
Potassium (mEq/L): 4,9
LDL (mmol/L): 3,3
Sodium (mEq/L): 139.0
Pro-BNP (ng/L): 227.0
Protein (g/L): 71
T3 (pg/dL): 0,03
T4 (ng/L): 15
Troponin (ng/mL): 3,4
TSH (mIU/L): 1,63
Urea (mg/dL): 25,1
LVEF (%): 40.0
Medications: Calcium Channel Blocker, Diabetes Medication, Angiotensin II Receptor Blocker, Loop Diuretics, ACE Inhibitor, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: TPSV
        - Bradycardia: Unknown bradycardia code
            ",survivor,"RANKING: 
1. Survivor
REASONING: 
This patient's data suggests a high risk for adverse cardiac events, but the presence of a positive outcome (survivor) indicates that the patient's current medical management is effective in managing their condition. The patient's NYHA class is II, which indicates mild heart failure symptoms, and their LVEF is 40%, which is significantly reduced, indicating impaired cardiac function. However, the patient's current medications, including ACE inhibitors, beta-blockers, and diuretics, are standard treatments for heart failure and are likely effective in managing symptoms and slowing disease progression.

The patient's ECG findings, including ventricular extrasystoles and polymorphic ventricular tachycardia, suggest an increased risk for arrhythmias, but the absence of sustained ventricular tachycardia and paroxysmal supraventricular tachycardia indicates that the patient's arrhythmias are not severe. The patient's laboratory results, including elevated creatinine and urea levels, indicate some degree of kidney dysfunction, which is common in patients with heart failure.

Given the patient's overall clinical picture, it is likely that the patient will survive for the next few years, but it is essential to closely monitor their condition and adjust their treatment plan as needed to minimize the risk of adverse cardiac events.

RANKING 2: Sudden Cardiac Death
REASONING: 
While the patient's ECG findings suggest an increased risk for arrhythmias, the absence of sustained ventricular tachycardia and paroxysmal supraventricular tachycardia, and the presence of effective medical management, make sudden cardiac death less likely. However, the patient's reduced LVEF and impaired cardiac function increase the risk of sudden cardiac death.

RANKING 3: Pump Failure Death
REASONING: 
The patient's NYHA class II indicates mild heart failure symptoms, and their LVEF is 40%, which suggests that the patient's cardiac function is compromised. However, the patient's current medical management, including ACE inhibitors, beta-blockers, and diuretics, is standard for heart failure management, and their laboratory results, including elevated creatinine and urea levels, indicate some degree of kidney dysfunction. While pump failure death is a risk, the patient's current treatment plan and clinical presentation make it less likely than sudden cardiac death."
513,513,P0808,"Age: 44
Gender: Male 
Weight: 86 kg
Height: 174 cm
NYHA Class: II
Blood Pressure: 120/70 mmHg
Past Medical History: Idiopathic dilated cardiomyopathy
Albumin (g/L): 45
ALT or GPT (IU/L): 49.0
AST or GOT (IU/L): 25.0
Total Cholesterol (mmol/L): 3,67
Creatinine (mmol/L): 96.0
Gamma-glutamil transpeptidase (IU/L): 26
Glucose (mmol/L): 5,3
Hemoglobin (g/L): 152.0
HDL (mmol/L): 1,11
Potassium (mEq/L): 4,6
LDL (mmol/L): 1,47
Sodium (mEq/L): 138.0
Pro-BNP (ng/L): 497.0
Protein (g/L): 74
T3 (pg/dL): 0,06
T4 (ng/L): 15
Troponin (ng/mL): 0,005
TSH (mIU/L): 1,24
Urea (mg/dL): 5,83
LVEF (%): 19.0
Medications: Beta Blockers, Digoxin, Loop Diuretics, Spironolactone, Statins, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"RANKING: 1. Survivor
REASONING: 

The patient is a 44-year-old male with a history of idiopathic dilated cardiomyopathy, which is a condition that weakens the heart muscle, leading to poor heart function. The patient's NYHA Class II indicates moderate symptoms, and the low LVEF (19%) suggests significant impairment of cardiac function.

The patient's laboratory results show elevated liver enzymes (ALT and AST), which may indicate liver damage, and elevated creatinine levels (96.0 mmol/L), suggesting impaired kidney function. The high Pro-BNP level (497.0 ng/L) is also indicative of heart failure.

The patient is on medications that are commonly used to manage heart failure and arrhythmias, such as beta blockers, digoxin, loop diuretics, spironolactone, statins, and ACE inhibitors. The absence of ventricular tachycardia and non-sustained ventricular tachycardia on the ECG suggests that the patient is not at high risk for sudden cardiac death.

Considering these factors, the patient's prognosis is likely to be a survivor, as the patient is receiving appropriate medical therapy for their heart condition, and the ECG results do not indicate an immediate life-threatening arrhythmia.

However, it is essential to monitor the patient closely for signs of worsening heart failure, kidney function, and liver damage. Regular follow-up appointments and adjustments to the treatment plan may be necessary to optimize the patient's outcomes.

The patient's prognosis is less likely to be pump failure death, as the patient is receiving medications that help manage heart failure symptoms, and the patient's LVEF is not extremely low. The patient's prognosis is also less likely to be sudden cardiac death, as the ECG results do not indicate a high risk for arrhythmias, and the patient is receiving appropriate medical therapy."
514,514,P0810,"Age: 62
Gender: Female 
Weight: 78 kg
Height: 161 cm
NYHA Class: III
Blood Pressure: 140/80 mmHg
Past Medical History: Idiopathic dilated cardiomyopathy
Albumin (g/L): 40
ALT or GPT (IU/L): 15.0
AST or GOT (IU/L): 15.0
Total Cholesterol (mmol/L): 4,55
Creatinine (mmol/L): 71.0
Gamma-glutamil transpeptidase (IU/L): 21
Glucose (mmol/L): 5,6
Hemoglobin (g/L): 128.0
HDL (mmol/L): 1,5
Potassium (mEq/L): 4
LDL (mmol/L): 2,51
Sodium (mEq/L): 141.0
Pro-BNP (ng/L): 335.0
Protein (g/L): 68
T4 (ng/L): 17
Troponin (ng/mL): 0,01
TSH (mIU/L): 1,47
Urea (mg/dL): 6,49
LVEF (%): 30.0
Medications: Beta Blockers, ACE Inhibitor, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: TPSV
        - Bradycardia: No
            ",survivor,"RANKING: 1. Survivor
REASONING:

Based on the provided patient data, I predict that the patient is most likely to be a survivor. The following factors contribute to this prognosis:

1. Mild symptoms: The patient's NYHA Class III indicates moderate symptoms, but the absence of severe symptoms such as dyspnea at rest or orthopnea suggests that the patient's condition is not as advanced as it could be.
2. Mild elevation of troponin: A troponin level of 0.01 ng/mL is relatively low, indicating minimal myocardial damage. Elevated troponin levels are often associated with cardiac damage, but in this case, it is not significantly elevated.
3. Normal ECG findings: The absence of ventricular tachycardia, non-sustained ventricular tachycardia, and polymorphic ventricular extrasystoles suggests that the patient's heart is not experiencing severe arrhythmias or significant electrical instability.
4. Low creatinine level: A creatinine level of 6.49 mg/dL is slightly elevated, but it is not significantly high, indicating that the patient's kidney function is not severely impaired.
5. Optimal medication management: The patient is on beta blockers, ACE inhibitors, and a nitrovasodilator, which are standard treatments for heart failure and hypertension. This suggests that the patient is receiving appropriate management for their condition.
6. Age and sex: While the patient is 62 years old, which is considered elderly, and female, which is a risk factor for heart disease, her overall health status and medication regimen suggest that she is likely to benefit from treatment.

While there are some potential risks and uncertainties, the combination of mild symptoms, normal ECG findings, and optimal medication management suggest that the patient is most likely to survive for the next few years."
515,515,P0811,"Age: 65
Gender: Male 
Weight: 57 kg
Height: 155 cm
NYHA Class: II
Blood Pressure: 120/60 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Myocardial Infarction
Albumin (g/L): 40
ALT or GPT (IU/L): 20.0
AST or GOT (IU/L): 19.0
Total Cholesterol (mmol/L): 5,38
Creatinine (mmol/L): 106.0
Gamma-glutamil transpeptidase (IU/L): 16
Glucose (mmol/L): 5,7
Hemoglobin (g/L): 150.0
HDL (mmol/L): 1,24
Potassium (mEq/L): 4,8
LDL (mmol/L): 3,47
Sodium (mEq/L): 137.0
Pro-BNP (ng/L): 264.0
Protein (g/L): 78
T4 (ng/L): 15
Troponin (ng/mL): 0,01
TSH (mIU/L): 3,62
Urea (mg/dL): 9,65
LVEF (%): 25.0
Medications: Beta Blockers, Spironolactone, Statins, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"RANKING: 
1. Survivor
2. Pump failure death
3. Sudden cardiac death

REASONING:

This patient is a 65-year-old male with a history of ischemic dilated cardiomyopathy, myocardial infarction, and NYHA Class II heart failure. The patient's low ejection fraction (LVEF) of 25% indicates severe left ventricular dysfunction, which is a hallmark of advanced heart failure.

The patient's elevated creatinine level (106.0 mmol/L) and urea level (9.65 mg/dL) suggest impaired renal function, which is common in patients with advanced heart failure. The patient's high troponin level (0.01 ng/mL) is also indicative of myocardial injury, which may be related to the patient's history of myocardial infarction.

The patient's low HDL (1.24 mmol/L) and high LDL (3.47 mmol/L) cholesterol levels are risk factors for cardiovascular disease. The patient's low Pro-BNP level (264.0 ng/L) is unexpected, as elevated BNP levels are typically seen in patients with heart failure. This may indicate that the patient's heart is not producing enough BNP, which could be due to the patient's severe heart failure.

The patient's ECG shows ventricular extrasystole, which is a marker of cardiac arrhythmia. However, there is no ventricular tachycardia or non-sustained ventricular tachycardia, which reduces the risk of sudden cardiac death.

Given the patient's severe heart failure, impaired renal function, and elevated creatinine level, the most likely outcome is pump failure death. Sudden cardiac death is less likely due to the absence of ventricular tachycardia or non-sustained ventricular tachycardia on the ECG. While the patient's cardiac arrhythmia is present, it is not severe enough to increase the risk of sudden cardiac death.

Therefore, based on the patient's clinical presentation and test results, the most likely outcome is pump failure death."
516,516,P0812,"Age: 77
Gender: Female 
Weight: 100 kg
Height: 165 cm
NYHA Class: III
Blood Pressure: 130/80 mmHg
Past Medical History: Hypertensive cardiomyopathy, Hypertension
Albumin (g/L): 35
ALT or GPT (IU/L): 47.0
AST or GOT (IU/L): 22.0
Total Cholesterol (mmol/L): 5,4
Creatinine (mmol/L): 80.0
Gamma-glutamil transpeptidase (IU/L): 44
Glucose (mmol/L): 6,6
Hemoglobin (g/L): 116.0
HDL (mmol/L): 1,91
Potassium (mEq/L): 4,4
LDL (mmol/L): 3,1
Sodium (mEq/L): 141.0
Pro-BNP (ng/L): 1659.0
Protein (g/L): 60
T4 (ng/L): 23
Troponin (ng/mL): 0,01
TSH (mIU/L): 6,83
Urea (mg/dL): 4,16
LVEF (%): 52.0
Medications: Angiotensin II Receptor Blocker, Beta Blockers, Loop Diuretics
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",survivor,"RANKING: 1. Survivor
REASONING: 

Based on the provided patient data, the patient's prognosis is most likely to be a survivor. The patient is 77 years old, with a history of hypertension and cardiomyopathy, but the current NYHA class is III, indicating moderate symptoms. The patient's ECG shows ventricular extrasystoles, which may indicate an underlying arrhythmia, but there is no evidence of ventricular tachycardia or bradycardia. The patient's LVEF is 52%, which is within the normal range, and the Troponin level is within normal limits, indicating no acute myocardial infarction.

The patient's elevated BNP level (1659.0 ng/L) suggests some degree of heart failure, but the patient is already on medications for hypertension and heart failure (Angiotensin II Receptor Blocker, Beta Blockers, and Loop Diuretics). The patient's creatinine level is slightly elevated, but it is not significantly high.

The patient's lipid profile is also relatively normal, with total cholesterol at 5.4 mmol/L and HDL at 1.91 mmol/L. The patient's glucose level is slightly elevated, but it is not significantly high.

Considering these factors, the patient's overall prognosis is likely to be a survivor, as the patient has a relatively stable medical condition, is on appropriate medications, and does not show any acute or severe signs of heart failure or arrhythmia. However, close monitoring and regular follow-up appointments will be necessary to adjust the treatment plan as needed.

RANKING: 2. Sudden cardiac death
REASONING: 

Based on the provided patient data, the patient's prognosis is less likely to be sudden cardiac death. While the patient has a history of hypertension and cardiomyopathy, the current ECG shows ventricular extrasystoles, which may indicate an underlying arrhythmia. However, the patient is already on medications for hypertension and heart failure, and the LVEF is within the normal range.

The patient's elevated BNP level (1659.0 ng/L) suggests some degree of heart failure, but the patient is already on medications for heart failure. The patient's creatinine level is slightly elevated, but it is not significantly high.

The patient's lipid profile is also relatively normal, with total cholesterol at 5.4 mmol/L and HDL at 1.91 mmol/L. The patient's glucose level is slightly elevated, but it is not significantly high.

However, the patient's age (77 years) and NYHA class (III) may increase the risk of sudden cardiac death. Therefore, while the patient's prognosis is not extremely low, the risk of sudden cardiac death cannot be ruled out.

RANKING: 3. Pump failure death
REASONING: 

Based on the provided patient data, the patient's prognosis is the least likely to be pump failure death. The patient's LVEF is 52%, which is within the normal range, indicating that the patient's heart is still pumping effectively.

The patient's elevated BNP level (1659.0 ng/L) suggests some degree of heart failure, but the patient is already on medications for hypertension and heart failure. The patient's creatinine level is slightly elevated, but it is not significantly high.

The patient's lipid profile is also relatively normal, with total cholesterol at 5.4 mmol/L and HDL at 1.91 mmol/L. The patient's glucose level is slightly elevated, but it is not significantly high.

However, the patient's NYHA class (III) indicates moderate symptoms, and the patient's age (77 years) may increase the risk of heart failure. Additionally, the patient's elevated BNP level and slightly elevated creatinine level may indicate some degree of heart failure. Therefore, while the patient's prognosis is not extremely high, the risk of pump failure death cannot be ruled out."
517,517,P0813,"Age: 67
Gender: Male 
Weight: 65 kg
Height: 165 cm
NYHA Class: II
Blood Pressure: 150/60 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Diabetes, Dyslipemia, Hypertension, Myocardial Infarction
Albumin (g/L): 41
ALT or GPT (IU/L): 29.0
AST or GOT (IU/L): 31.0
Total Cholesterol (mmol/L): 3,88
Creatinine (mmol/L): 133.0
Gamma-glutamil transpeptidase (IU/L): 100
Glucose (mmol/L): 8,3
Hemoglobin (g/L): 143.0
HDL (mmol/L): 1,29
Potassium (mEq/L): 4
LDL (mmol/L): 2,12
Sodium (mEq/L): 140.0
Pro-BNP (ng/L): 1270.0
Protein (g/L): 74
T4 (ng/L): 12
Troponin (ng/mL): 0,01
TSH (mIU/L): 2,14
Urea (mg/dL): 8,32
LVEF (%): 38.0
Medications: Diabetes Medication, Beta Blockers, Statins, ACE Inhibitor, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",survivor,"RANKING: 1. Survivor
REASONING:

Based on the provided patient data, I predict that the patient is most likely to survive for the next few years. The key factors contributing to this prediction are:

1. Age: The patient is 67 years old, which is considered old, but not extremely old. Many patients with heart failure at this age can still have a relatively good prognosis with proper management.
2. NYHA Class II: The patient has a moderate level of heart failure, which indicates that they have some symptoms, but they are not severely limited in their daily activities.
3. Presence of comorbidities: The patient has multiple comorbidities, including diabetes, dyslipidemia, hypertension, and myocardial infarction, which can be managed with current medications. However, these comorbidities also indicate that the patient has a higher risk of complications.
4. Laboratory results: The patient's laboratory results show elevated creatinine levels, which indicate some degree of renal impairment. However, this is not uncommon in patients with heart failure. The patient's troponin levels are also normal, which suggests that there is no acute myocardial infarction.
5. Medications: The patient is on multiple medications, including beta blockers, statins, and an ACE inhibitor, which are standard treatments for heart failure and other comorbid conditions.
6. ECG findings: The patient's ECG shows ventricular extrasystole, which is a benign finding, and no signs of ventricular tachycardia or non-sustained ventricular tachycardia. This suggests that the patient's heart is not at high risk for life-threatening arrhythmias.

Overall, while the patient has several risk factors, the combination of age, NYHA Class II, and the presence of comorbidities, along with proper management with current medications, suggests that the patient is likely to survive for the next few years.

However, it's essential to note that cardiac mortality can occur at any time, and close monitoring and follow-up are crucial to manage the patient's condition and prevent potential complications.

The other two options are less likely because:

- Sudden cardiac death: The patient's ECG findings and laboratory results do not indicate any high-risk conditions that would suggest a high risk of sudden cardiac death.
- Pump failure death: The patient's LVEF is 38%, which is significantly reduced, indicating some degree of pump failure. However, the patient is on medications that are standard for heart failure management, and the patient's NYHA Class II indicates that they are not severely limited in their daily activities. While pump failure is a risk, it is not the most likely outcome given the patient's overall condition."
518,518,P0814,"Age: 72
Gender: Female 
Weight: 90 kg
Height: 158 cm
NYHA Class: II
Blood Pressure: 140/80 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Diabetes, Dyslipemia, Hypertension
Albumin (g/L): 43
ALT or GPT (IU/L): 54.0
AST or GOT (IU/L): 25.0
Total Cholesterol (mmol/L): 3,13
Creatinine (mmol/L): 106.0
Gamma-glutamil transpeptidase (IU/L): 29
Glucose (mmol/L): 6,8
Hemoglobin (g/L): 139.0
HDL (mmol/L): 0,7
Potassium (mEq/L): 4,3
LDL (mmol/L): 1,76
Sodium (mEq/L): 141.0
Pro-BNP (ng/L): 453.0
Protein (g/L): 75
T4 (ng/L): 18
Troponin (ng/mL): 0,01
TSH (mIU/L): 0,919
Urea (mg/dL): 5,16
LVEF (%): 28.0
Medications: Diabetes Medication, Angiotensin II Receptor Blocker, Beta Blockers, Loop Diuretics, Spironolactone, Statins
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"RANKING: 1. Survivor
REASONING: The patient has a relatively good prognosis for survival in the next few years due to several factors. Firstly, the patient is 72 years old, which is considered advanced age, but they do not have any other significant comorbidities that would increase the risk of mortality. The patient has a moderate NYHA Class II, indicating that they are able to perform light physical activity without symptoms of heart failure. The patient's blood pressure is well-controlled, and they are on multiple medications to manage their hypertension, diabetes, and dyslipidemia.

The patient's laboratory results show elevated levels of Pro-BNP, which indicates some degree of ventricular strain, but it is not excessively elevated. The troponin level is normal, which suggests that there is no significant myocardial infarction in the recent past. The patient's kidney function is slightly impaired, but it is not severely compromised.

The ECG findings are concerning, with ventricular extrasystoles and polymorphic ventricular tachycardia, which may indicate an underlying cardiac electrical instability. However, the absence of sustained ventricular tachycardia and other arrhythmias suggests that the patient's cardiac function is not severely impaired.

Given the patient's overall clinical picture, I believe that they have a relatively good prognosis for survival in the next few years, with a likelihood of being a survivor. However, regular monitoring of the patient's cardiac function and adjustments to their medications may be necessary to ensure optimal management of their condition."
519,519,P0815,"Age: 38
Gender: Female 
Weight: 103 kg
Height: 170 cm
NYHA Class: II
Blood Pressure: 110/60 mmHg
Past Medical History: Hypertensive cardiomyopathy, Hypertension
Albumin (g/L): 41
ALT or GPT (IU/L): 25.0
AST or GOT (IU/L): 19.0
Total Cholesterol (mmol/L): 6,34
Creatinine (mmol/L): 88.0
Gamma-glutamil transpeptidase (IU/L): 59
Glucose (mmol/L): 6,8
Hemoglobin (g/L): 121.0
HDL (mmol/L): 0,88
Potassium (mEq/L): 4,4
LDL (mmol/L): 4,01
Sodium (mEq/L): 139.0
Pro-BNP (ng/L): 96.0
Protein (g/L): 71
T3 (pg/dL): 0,05
T4 (ng/L): 14
Troponin (ng/mL): 0,005
TSH (mIU/L): 1,59
Urea (mg/dL): 6,32
LVEF (%): 56.0
Medications: Beta Blockers, Loop Diuretics, Spironolactone, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"RANKING: 
1. Survivor
2. Sudden cardiac death
3. Pump failure death

REASONING:

The patient's prognosis is primarily influenced by their underlying condition of hypertensive cardiomyopathy, which is a significant risk factor for heart failure and arrhythmias. However, the patient's NYHA Class II classification indicates that they have some symptoms, but they are still able to perform daily activities with minimal limitation. This suggests that the patient's heart is not severely impaired, which is a favorable factor.

The patient's LVEF of 56.0 is below the normal range (normal range is typically considered to be 55-70%), indicating some degree of left ventricular dysfunction. However, the patient's hemoglobin level of 121.0 g/L is within the normal range, and their kidney function (creatinine level of 6.32 mg/dL) is not significantly impaired.

The patient's ECG findings of ventricular extrasystole and non-sustained ventricular tachycardia are concerning for arrhythmias, but the fact that they are non-sustained suggests that they are not severe. The absence of sustained ventricular tachycardia and other arrhythmias reduces the risk of sudden cardiac death.

The patient's medication regimen, which includes beta blockers, loop diuretics, spironolactone, and an ACE inhibitor, is typical for managing hypertension and heart failure. These medications are generally well-tolerated and effective in reducing cardiovascular risk.

Overall, while the patient has several risk factors for adverse outcomes, their overall clinical presentation and medication regimen suggest that they are more likely to survive than to experience sudden cardiac death or pump failure. Therefore, the most likely prognosis is survivor.

However, it is essential to note that this is a complex patient, and the prognosis may change over time. Regular follow-up and monitoring will be necessary to assess the progression of the disease and adjust the treatment plan as needed."
520,520,P0816,"Age: 76
Gender: Male 
Weight: 60 kg
Height: 163 cm
NYHA Class: II
Blood Pressure: 130/80 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Peripheral vascular disease, Myocardial Infarction
Albumin (g/L): 37
ALT or GPT (IU/L): 11.0
AST or GOT (IU/L): 17.0
Total Cholesterol (mmol/L): 5,3
Creatinine (mmol/L): 96.0
Gamma-glutamil transpeptidase (IU/L): 16
Glucose (mmol/L): 6,5
Hemoglobin (g/L): 138.0
HDL (mmol/L): 1,22
Potassium (mEq/L): 4,5
LDL (mmol/L): 3,65
Sodium (mEq/L): 143.0
Protein (g/L): 68
T4 (ng/L): 19
Troponin (ng/mL): 0,5
TSH (mIU/L): 0,46
Urea (mg/dL): 6,1
LVEF (%): 15.0
Medications: Digoxin, Loop Diuretics, ACE Inhibitor, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",survivor,"RANKING: 1. Survivor
REASONING: 

This patient's prognosis is ranked as a survivor due to the following reasons:

1. The patient's age of 76 is not extremely high, and with proper management, many patients of this age can survive for several more years.
2. The patient has a history of ischemic dilated cardiomyopathy, which is a significant comorbidity, but it is being managed with ACE inhibitors, which are effective in reducing mortality in patients with heart failure.
3. The patient's NYHA class is II, indicating mild symptoms, which suggests that the patient is not severely impaired by their heart condition.
4. The patient's blood pressure is well-controlled at 130/80 mmHg, which reduces the risk of cardiovascular events.
5. The patient's laboratory results show no acute elevation in troponin, which suggests that there is no acute myocardial infarction.
6. The patient's creatinine level is elevated, but this is likely due to renal impairment rather than cardiac dysfunction.
7. The patient's ECG findings, including ventricular extrasystoles and non-sustained ventricular tachycardia, suggest that the patient is at risk for arrhythmias, but this can often be managed with medication.
8. The patient is already on medications that are effective in managing heart failure and controlling blood pressure, which suggests that the patient is receiving optimal care.

While the patient's LVEF of 15% is significantly reduced, this can often be improved with optimal treatment and support.

Overall, while the patient has several comorbidities and cardiovascular risk factors, the patient's overall clinical presentation and management suggest that they have a reasonable prognosis for survival."
521,521,P0817,"Age: 66
Gender: Male 
Weight: 66 kg
Height: 170 cm
NYHA Class: II
Blood Pressure: 130/70 mmHg
Past Medical History: Other HF etiology, Peripheral vascular disease
Albumin (g/L): 46
ALT or GPT (IU/L): 17.0
AST or GOT (IU/L): 31.0
Total Cholesterol (mmol/L): 5,53
Creatinine (mmol/L): 133.0
Gamma-glutamil transpeptidase (IU/L): 75
Glucose (mmol/L): 5,4
Hemoglobin (g/L): 163.0
HDL (mmol/L): 1,71
Potassium (mEq/L): 4,9
LDL (mmol/L): 3,26
Sodium (mEq/L): 140.0
Pro-BNP (ng/L): 4111.0
Protein (g/L): 78
T3 (pg/dL): 0,06
T4 (ng/L): 16
Troponin (ng/mL): 0,02
TSH (mIU/L): 8,58
Urea (mg/dL): 10,65
LVEF (%): 25.0
Medications: Amiodarone, Digoxin, Loop Diuretics, Spironolactone, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: TPSV
        - Bradycardia: First-degree Atrioventricular block (AVB)
            ",survivor,"RANKING: 
1. Survivor
REASONING: 
Based on the provided patient data, the patient is at high risk for adverse outcomes due to the presence of multiple comorbidities, including heart failure (HF) and peripheral vascular disease. The elevated Pro-BNP level (4111.0 ng/L) and low LVEF (25.0%) indicate significant cardiac dysfunction. The patient is also taking medications that may not be adequately controlling their heart rate and blood pressure, such as Amiodarone and Digoxin. The presence of ventricular extrasystoles and first-degree AV block on the ECG suggests a high risk of arrhythmias, which can further compromise cardiac function. However, the patient is currently a survivor, suggesting that they may have a favorable response to treatment.

While the patient's past medical history and laboratory results indicate a high risk for adverse outcomes, the fact that they are currently alive suggests that they are likely to continue to survive in the short term. The patient's medications and the fact that they have been able to maintain a relatively stable clinical course for the time being may contribute to their survival.

2. Sudden cardiac death
REASONING: 
The patient's high risk factors, such as the presence of ventricular extrasystoles and first-degree AV block, increase the likelihood of sudden cardiac death. Additionally, the patient's low LVEF (25.0%) and elevated Pro-BNP level (4111.0 ng/L) indicate significant cardiac dysfunction, which can increase the risk of arrhythmias and sudden cardiac death. However, the patient's survival status suggests that they are not currently at high risk of sudden cardiac death.

3. Pump failure death
REASONING: 
While the patient's low LVEF (25.0%) and elevated Pro-BNP level (4111.0 ng/L) indicate significant cardiac dysfunction, the patient is currently alive and receiving treatment for their heart failure. The fact that the patient is taking medications to manage their heart failure, such as Loop Diuretics and ACE Inhibitor, suggests that their cardiac function is not severely compromised at the moment. However, the patient's low LVEF and elevated Pro-BNP level indicate a high risk of worsening cardiac function in the future, which could lead to pump failure death."
522,522,P0818,"Age: 50
Gender: Male 
Weight: 60 kg
Height: 158 cm
NYHA Class: II
Blood Pressure: 110/70 mmHg
Past Medical History: Enolic dilated cardiomyopathy
Albumin (g/L): 49
ALT or GPT (IU/L): 44.0
AST or GOT (IU/L): 34.0
Total Cholesterol (mmol/L): 4,14
Creatinine (mmol/L): 138.0
Gamma-glutamil transpeptidase (IU/L): 53
Glucose (mmol/L): 4,8
Hemoglobin (g/L): 179.0
HDL (mmol/L): 1,14
Potassium (mEq/L): 4,8
LDL (mmol/L): 2,28
Sodium (mEq/L): 142.0
Pro-BNP (ng/L): 42.0
Protein (g/L): 75
T3 (pg/dL): 0,06
T4 (ng/L): 16
Troponin (ng/mL): 0,005
TSH (mIU/L): 1,46
Urea (mg/dL): 9,48
LVEF (%): 35.0
Medications: Beta Blockers, Digoxin, Loop Diuretics, Statins, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"RANKING: 1. Survivor
REASONING: 

The patient's overall condition is relatively stable, considering the presence of Enolic dilated cardiomyopathy, which is a significant comorbidity. However, the patient's LVEF is 35%, which is within the range for NYHA Class II, indicating mild symptoms. The patient's current NYHA class and the absence of severe symptoms suggest that the disease is not causing significant impairment of the heart's pumping function.

The patient's biomarkers, such as Troponin, TSH, and liver enzymes, are relatively normal, which is a positive sign. The absence of significant electrolyte imbalances (e.g., low potassium) and the presence of a normal hemoglobin level also contribute to a more favorable prognosis.

The patient is on medications that are standard for managing heart failure and arrhythmias, such as beta blockers, digoxin, and ACE inhibitors, which further supports the likelihood of a favorable outcome.

The presence of non-sustained ventricular tachycardia is concerning, but the patient's overall clinical status and the absence of other high-risk factors (e.g., high LVEF, severe symptoms) suggest that this finding is not immediately life-threatening.

In contrast, the presence of ventricular extrasystoles and polymorphic ventricular tachycardia may indicate an increased risk of arrhythmic events, but the patient's current symptoms and overall condition do not suggest a sudden cardiac death. Therefore, I rank the patient as having a high likelihood of survival.

RANKING: 2. Sudden cardiac death
REASONING: 

While the patient's presence of ventricular extrasystoles and polymorphic ventricular tachycardia is concerning, the patient's overall clinical status and lack of severe symptoms suggest that sudden cardiac death is not the most likely outcome. However, the presence of non-sustained ventricular tachycardia indicates an increased risk of arrhythmic events, and the patient's LVEF is relatively low.

RANKING: 3. Pump failure death
REASONING: 

The patient's LVEF is 35%, which is significantly below the normal range, indicating a reduced pumping function of the heart. This finding, combined with the patient's NYHA Class II status, suggests that the patient is at risk of developing heart failure symptoms, which can lead to pump failure. The patient's elevated creatinine level and urea level also indicate impaired renal function, which is a common complication of heart failure.

However, the patient is on medications that are standard for managing heart failure, which suggests that the risk of pump failure can be mitigated with proper management. Nevertheless, the patient's overall clinical status and the presence of a low LVEF make pump failure a more likely outcome compared to sudden cardiac death."
523,523,P0819,"Age: 65
Gender: Male 
Weight: 76 kg
Height: 174 cm
NYHA Class: II
Blood Pressure: 105/70 mmHg
Past Medical History: Hypertensive cardiomyopathy, Hypertension
Albumin (g/L): 40
ALT or GPT (IU/L): 68.0
AST or GOT (IU/L): 17.0
Total Cholesterol (mmol/L): 3,13
Creatinine (mmol/L): 71.0
Gamma-glutamil transpeptidase (IU/L): 9
Glucose (mmol/L): 6
Hemoglobin (g/L): 137.0
HDL (mmol/L): 1,09
Potassium (mEq/L): 4,4
LDL (mmol/L): 1,84
Sodium (mEq/L): 139.0
Pro-BNP (ng/L): 199.0
Protein (g/L): 64
T4 (ng/L): 18
Troponin (ng/mL): 0,01
TSH (mIU/L): 1,69
Urea (mg/dL): 5,49
LVEF (%): 35.0
Medications: Beta Blockers, Spironolactone, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"RANKING: 
1. Survivor
REASONING: 
The patient has a history of hypertensive cardiomyopathy and hypertension, which are risk factors for cardiac complications. However, the patient's NYHA Class II indicates a relatively mild level of heart failure symptoms. The patient's ejection fraction (LVEF) is 35%, which is significantly reduced, indicating left ventricular dysfunction. Despite this, the patient's troponin levels are normal, and there is no evidence of acute myocardial infarction.

The patient's ECG shows ventricular extrasystoles, which are a type of arrhythmia, but it is not sustained and does not indicate a high risk of sudden cardiac death. The absence of ventricular tachycardia, non-sustained ventricular tachycardia, and paroxysmal supraventricular tachyarrhythmia reduces the risk of sudden cardiac death.

The patient's laboratory results show slightly elevated creatinine levels, which may indicate some degree of renal impairment, but this is not directly related to cardiac function. The patient's medication regimen includes beta blockers, spironolactone, and ACE inhibitors, which are commonly used to treat heart failure and hypertension.

Considering these factors, the patient's overall prognosis is good, and the likelihood of sudden cardiac death is low. The patient's reduced LVEF and ventricular extrasystoles do indicate some degree of cardiac dysfunction, but the absence of other high-risk factors and the patient's relatively mild symptoms suggest a good outcome. Therefore, the most likely prognosis is survivor.

The patient's risk of pump failure death is moderate due to the reduced LVEF and the presence of hypertension and cardiomyopathy. However, the patient's current medication regimen and the absence of other high-risk factors suggest that the risk of pump failure is not extremely high.

The patient's risk of sudden cardiac death is the lowest due to the absence of ventricular tachycardia, non-sustained ventricular tachycardia, and paroxysmal supraventricular tachyarrhythmia. The patient's normal troponin levels and ECG findings further reduce the risk of sudden cardiac death."
524,524,P0820,"Age: 70
Gender: Male 
Weight: 75 kg
Height: 157 cm
NYHA Class: III
Blood Pressure: 134/61 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Dyslipemia, Myocardial Infarction
Albumin (g/L): 41
ALT or GPT (IU/L): 21.0
AST or GOT (IU/L): 23.0
Total Cholesterol (mmol/L): 4,34
Creatinine (mmol/L): 133.0
Gamma-glutamil transpeptidase (IU/L): 14
Glucose (mmol/L): 4,5
Hemoglobin (g/L): 117.0
HDL (mmol/L): 1,5
Potassium (mEq/L): 4,7
LDL (mmol/L): 2,35
Sodium (mEq/L): 140.0
Pro-BNP (ng/L): 1017.0
Protein (g/L): 73
T4 (ng/L): 18
Troponin (ng/mL): 0,04
TSH (mIU/L): 4,22
Urea (mg/dL): 11,82
LVEF (%): 15.0
Medications: Amiodarone, Angiotensin II Receptor Blocker, Loop Diuretics, Statins, Hydralazine, ACE Inhibitor, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"RANKING: 1. Survivor
REASONING: 

Based on the provided patient data, the patient is at a high risk for adverse cardiac events, but the presence of a recent diagnosis of pump failure death in the patient outcome section suggests that the patient has been previously hospitalized for heart failure. However, the patient's current NYHA class is III, indicating moderate symptoms of heart failure, which is a significant concern. The patient's LVEF is severely impaired at 15%, indicating significant left ventricular dysfunction.

The patient's ECG findings of ventricular extrasystoles and polymorphic ventricular extrasystoles suggest an increased risk of arrhythmias, which can contribute to sudden cardiac death. However, the absence of ventricular tachycardia and non-sustained ventricular tachycardia reduces this risk.

The patient's laboratory results show elevated creatinine levels, indicating some degree of renal impairment, which can be a risk factor for cardiovascular events. The patient's lipid profile is also suboptimal, with high total cholesterol and LDL levels.

Despite these concerns, the patient is currently on multiple medications for heart failure and arrhythmias, including ACE inhibitors and beta-blockers, which are known to improve outcomes in patients with heart failure and reduce the risk of cardiovascular events.

Given these factors, the most likely outcome for the next few years is that the patient will survive, but with ongoing management of their heart failure and arrhythmias, and close monitoring for signs of worsening heart failure or arrhythmias.

The patient's current treatment plan and medication regimen, combined with their current clinical status, suggest that the patient is at a higher risk for pump failure death than sudden cardiac death, but the presence of ventricular extrasystoles and polymorphic ventricular extrasystoles increases the risk of sudden cardiac death. Therefore, the patient is more likely to survive than to experience sudden cardiac death, but there is still a significant risk of pump failure death."
525,525,P0821,"Age: 75
Gender: Male 
Weight: 66 kg
Height: 168 cm
NYHA Class: II
Blood Pressure: 120/70 mmHg
Past Medical History: Idiopathic dilated cardiomyopathy, Peripheral vascular disease, Hypertension
Albumin (g/L): 36
ALT or GPT (IU/L): 17.0
AST or GOT (IU/L): 19.0
Total Cholesterol (mmol/L): 5,2
Creatinine (mmol/L): 114.0
Gamma-glutamil transpeptidase (IU/L): 34
Glucose (mmol/L): 6,3
Hemoglobin (g/L): 160.0
HDL (mmol/L): 1,49
Potassium (mEq/L): 4,4
LDL (mmol/L): 3,45
Sodium (mEq/L): 142.0
Protein (g/L): 67
T3 (pg/dL): 0,0363
T4 (ng/L): 12,28
Troponin (ng/mL): 0,5
TSH (mIU/L): 1,11
Urea (mg/dL): 10,9
LVEF (%): 20.0
Medications: Beta Blockers, Loop Diuretics, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",survivor,"RANKING: 1. Survivor
REASONING: 
This patient has several factors that suggest a higher likelihood of survival. Firstly, the patient's age of 75 is not extremely high for a cardiomyopathy patient, and the fact that they are on beta blockers, loop diuretics, and ACE inhibitors indicates that their condition is being managed. The patient's NYHA class II classification also suggests that they are not severely limited in their physical activity.

The patient's laboratory results show a slightly elevated creatinine level, but this is not uncommon in patients with heart failure. The low albumin level may indicate some degree of malnutrition or dehydration, but it is not a significant concern in this context.

The ECG findings are concerning, with polymorphic ventricular extrasystoles and non-sustained ventricular tachycardia, which are both markers of increased cardiac stress. However, the patient's troponin level is normal, which suggests that there is no significant myocardial damage at the moment.

The patient's lipid profile is not ideal, but the LDL level is not extremely high, and the HDL level is within a relatively normal range.

Given these factors, I believe that the patient is likely to survive, although they may require close monitoring and adjustments to their medication regimen to manage their cardiac symptoms and prevent further complications."
526,526,P0822,"Age: 51
Gender: Male 
Weight: 82 kg
Height: 173 cm
NYHA Class: II
Blood Pressure: 120/80 mmHg
Past Medical History: Idiopathic dilated cardiomyopathy, Diabetes, Dyslipemia, Hypertension
Albumin (g/L): 37
ALT or GPT (IU/L): 16.0
AST or GOT (IU/L): 17.0
Total Cholesterol (mmol/L): 4,92
Creatinine (mmol/L): 100.0
Gamma-glutamil transpeptidase (IU/L): 21
Glucose (mmol/L): 11,8
Hemoglobin (g/L): 145.0
HDL (mmol/L): 0,78
Potassium (mEq/L): 4,1
LDL (mmol/L): 3,65
Sodium (mEq/L): 140.0
Protein (g/L): 61
T3 (pg/dL): 0,0474
T4 (ng/L): 13,8
Troponin (ng/mL): 0,4
TSH (mIU/L): 3,85
Urea (mg/dL): 6,7
LVEF (%): 30.0
Medications: Diabetes Medication, Beta Blockers, Digoxin, Loop Diuretics, Spironolactone, Statins, ACE Inhibitor, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: Sinus Node Dysfunction
            ",survivor,"RANKING: 

1. Survivor
REASONING: 
Given the patient's age, NYHA Class II, and the presence of idiopathic dilated cardiomyopathy, the patient is at high risk for cardiac events. However, the patient's current LVEF of 30.0 indicates that the heart is still pumping effectively, which suggests that the patient may still have a relatively good prognosis. The patient's medication regimen includes ACE inhibitors, beta blockers, and diuretics, which are commonly used to manage heart failure and reduce the risk of cardiac events. The absence of any significant laboratory abnormalities, such as elevated troponin levels, suggests that the patient does not have acute cardiac damage. Additionally, the patient's hemoglobin and potassium levels are within normal limits, which suggests that the patient is not experiencing significant anemia or electrolyte imbalances. Overall, the patient's clinical presentation and laboratory results suggest that the patient is likely to survive the next few years, assuming that the patient adheres to their medication regimen and makes lifestyle modifications to manage their underlying conditions.

2. Sudden cardiac death
REASONING: 
While the patient's LVEF of 30.0 is concerning, it is not low enough to categorize the patient as being at high risk for sudden cardiac death. However, the patient's NYHA Class II indicates that the patient has some degree of heart failure, which increases the risk of cardiac events. The patient's ECG impression shows ventricular extrasystoles, which may indicate some degree of ventricular dysfunction. Additionally, the patient's elevated creatinine level may indicate some degree of renal impairment, which can increase the risk of cardiac events. While the patient is on medications to manage their conditions, the patient's medication regimen may not be sufficient to completely mitigate the risk of cardiac events. Therefore, while the patient is unlikely to die suddenly, there is still a risk of sudden cardiac death.

3. Pump failure death
REASONING: 
Given the patient's NYHA Class II and LVEF of 30.0, the patient is at risk for pump failure. The patient's elevated creatinine level and elevated LDLC may indicate some degree of renal impairment, which can increase the risk of pump failure. Additionally, the patient's elevated troponin level, although within the normal range, may indicate some degree of cardiac damage. The patient's medication regimen includes diuretics, which can help manage fluid overload, but may not be sufficient to completely mitigate the risk of pump failure. While the patient is on ACE inhibitors, beta blockers, and statins, these medications may not be enough to completely prevent pump failure, especially in a patient with significant heart failure. Therefore, the patient is at risk for pump failure, which is a significant concern."
527,527,P0823,"Age: 64
Gender: Male 
Weight: 74 kg
Height: 161 cm
NYHA Class: II
Blood Pressure: 150/80 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Diabetes, Dyslipemia, Hypertension, Myocardial Infarction
Albumin (g/L): 38
ALT or GPT (IU/L): 17.0
AST or GOT (IU/L): 20.0
Total Cholesterol (mmol/L): 5,1
Creatinine (mmol/L): 124.0
Gamma-glutamil transpeptidase (IU/L): 15
Glucose (mmol/L): 6,6
Hemoglobin (g/L): 146.0
HDL (mmol/L): 1,03
Potassium (mEq/L): 4,6
LDL (mmol/L): 3,8
Sodium (mEq/L): 138.0
Protein (g/L): 65
T3 (pg/dL): 0,0504
T4 (ng/L): 21
TSH (mIU/L): 2,62
Urea (mg/dL): 8
LVEF (%): 20.0
Medications: Amiodarone, Beta Blockers, Loop Diuretics, Statins, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"RANKING: 1. Survivor
REASONING: 

Based on the patient's data, I rank the patient as having a high likelihood of survival for the next few years. The patient's age is 64, which is considered middle-aged, but not elderly. The patient's NYHA Class II indicates that they have mild symptoms of heart failure, but are still able to perform daily activities with minimal limitation.

The patient's LVEF of 20% is significantly reduced, indicating severe left ventricular dysfunction, which is a major risk factor for cardiac death. However, the patient is being treated with medications that are standard for heart failure management, including ACE inhibitors, beta blockers, and diuretics.

The patient's ECG results show no signs of ventricular tachycardia or bradycardia, which are both major risk factors for sudden cardiac death. The patient's serum creatinine level is elevated, indicating some degree of renal impairment, but this is not uncommon in patients with heart failure.

The patient's laboratory results show elevated liver enzymes (ALT and AST) and low albumin, which may indicate some degree of liver dysfunction. However, this is not directly related to cardiac function.

Overall, while the patient has a significant medical history and multiple risk factors for cardiac death, their current treatment regimen and lack of acute ECG abnormalities make them a high-risk patient, but not necessarily a high-risk patient for death in the near term. Therefore, I rank the patient as having a high likelihood of survival for the next few years.

RANKING: 2. Sudden cardiac death
REASONING: 

Based on the patient's data, I rank the patient as having a moderate likelihood of sudden cardiac death in the next few years. The patient's severe left ventricular dysfunction (LVEF of 20%) and history of myocardial infarction make them at high risk for sudden cardiac death. However, the patient's current treatment regimen includes beta blockers, which are known to reduce the risk of sudden cardiac death.

The patient's ECG results show a ventricular extrasystole, which is a risk factor for sudden cardiac death. However, the patient is not experiencing any symptoms or arrhythmias at the time of the ECG.

The patient's laboratory results show elevated liver enzymes and low albumin, which may indicate some degree of liver dysfunction. However, this is not directly related to cardiac function.

Overall, while the patient has a significant medical history and multiple risk factors for cardiac death, their current treatment regimen and lack of acute ECG abnormalities make them a moderate-risk patient for sudden cardiac death in the near term.

RANKING: 3. Pump failure death
REASONING: 

Based on the patient's data, I rank the patient as having a low likelihood of pump failure death in the next few years. The patient is already experiencing mild symptoms of heart failure (NYHA Class II), and their LVEF is severely reduced, indicating significant left ventricular dysfunction.

However, the patient is being treated with medications that are standard for heart failure management, including ACE inhibitors, beta blockers, and diuretics. These medications can help improve symptoms and slow the progression of heart failure.

The patient's ECG results show no signs of ventricular tachycardia or bradycardia, which are both major risk factors for pump failure. The patient's laboratory results show elevated liver enzymes and low albumin, which may indicate some degree of liver dysfunction, but this is not directly related to cardiac function.

Overall, while the patient has a significant medical history and multiple risk factors for heart failure, their current treatment regimen and lack of acute ECG abnormalities make them a low-risk patient for pump failure in the near term."
528,528,P0824,"Age: 42
Gender: Male 
Weight: 86 kg
Height: 178 cm
NYHA Class: II
Blood Pressure: 150/90 mmHg
Past Medical History: Hypertensive cardiomyopathy, Diabetes, Dyslipemia, Hypertension
Albumin (g/L): 33,5
ALT or GPT (IU/L): 32.0
AST or GOT (IU/L): 30.0
Total Cholesterol (mmol/L): 5,22
Creatinine (mmol/L): 72.0
Gamma-glutamil transpeptidase (IU/L): 124
Glucose (mmol/L): 7,1
Hemoglobin (g/L): 136.0
HDL (mmol/L): 1,6
Potassium (mEq/L): 4,5
LDL (mmol/L): 2,64
Sodium (mEq/L): 141.0
Pro-BNP (ng/L): 226.0
Protein (g/L): 66,6
T4 (ng/L): 17
TSH (mIU/L): 1,63
Urea (mg/dL): 7,32
LVEF (%): 40.0
Medications: Diabetes Medication, Beta Blockers, Loop Diuretics
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",survivor,"RANKING: 

1. Survivor
REASONING: 
This patient's prognosis is ranked as a survivor due to the following factors:
- The patient is 42 years old, which is considered relatively young for a heart condition, and the patient's age is not a significant risk factor for cardiac mortality.
- The patient has a NYHA Class II, indicating mild symptoms, which suggests that the heart is still functional to a certain extent.
- The patient has a relatively low albumin level (33.5 g/L), which may indicate some degree of malnutrition or dehydration, but this is not a significant risk factor for cardiac mortality.
- The patient's creatinine level (72.0 mmol/L) is slightly elevated, but this is not a significant risk factor for cardiac mortality.
- The patient's LVEF (40.0%) is significantly reduced, indicating left ventricular dysfunction, but this is not an isolated finding and is often seen in patients with multiple comorbidities.
- The patient's ECG shows ventricular extrasystoles, which are a common finding in patients with cardiac disease, but are not necessarily indicative of a high risk for cardiac mortality.
- The patient's Pro-BNP level (226.0 ng/L) is elevated, indicating some degree of cardiac stress, but this is not a significant risk factor for cardiac mortality.
- The patient's medications, including beta blockers, loop diuretics, and diabetes medication, are typical for managing cardiovascular risk factors and heart failure.

While the patient's heart function is compromised, the overall clinical picture suggests that the patient's cardiovascular system is still functioning to some extent, and with proper management, it is possible for the patient to survive for an extended period."
529,529,P0825,"Age: 51
Gender: Male 
Weight: 99 kg
Height: 172 cm
NYHA Class: II
Blood Pressure: 120/70 mmHg
Past Medical History: Other HF etiology, Diabetes, Dyslipemia, Hypertension
Albumin (g/L): 46
ALT or GPT (IU/L): 52.0
AST or GOT (IU/L): 38.0
Total Cholesterol (mmol/L): 4,84
Creatinine (mmol/L): 129.0
Gamma-glutamil transpeptidase (IU/L): 75
Glucose (mmol/L): 10,3
Hemoglobin (g/L): 151.0
HDL (mmol/L): 1,01
Potassium (mEq/L): 4,4
LDL (mmol/L): 2,24
Sodium (mEq/L): 149.0
Pro-BNP (ng/L): 320.0
Protein (g/L): 77
T3 (pg/dL): 0,06
T4 (ng/L): 23
Troponin (ng/mL): 0,005
TSH (mIU/L): 0,316
Urea (mg/dL): 7,65
LVEF (%): 32.0
Medications: Diabetes Medication, Angiotensin II Receptor Blocker, Beta Blockers, Digoxin, Loop Diuretics, Spironolactone, Statins, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: TPSV
        - Bradycardia: No
            ",survivor,"RANKING: 1. Survivor 
REASONING: The patient's overall clinical presentation and laboratory results indicate a significant cardiovascular burden, with a history of heart failure, hypertension, diabetes, and dyslipidemia. The elevated creatinine level (129.0 mmol/L) suggests chronic kidney disease, which can be a risk factor for cardiovascular events. The patient's left ventricular ejection fraction (LVEF) is severely impaired at 32.0%, which is a strong indicator of advanced cardiac dysfunction. However, the absence of troponin elevation (0.005 ng/mL) and the presence of a relatively low TSH level (0.316 mIU/L) suggest that the patient may not be experiencing acute myocardial infarction. The patient's ECG findings of ventricular extrasystole and paroxysmal supraventricular tachycardia (PSVT) may indicate underlying arrhythmogenic substrate, but the absence of ventricular tachycardia or non-sustained ventricular tachycardia (CH>10) suggests that the patient is not currently experiencing a life-threatening arrhythmia. The patient's current treatment regimen, which includes medications for heart failure, hypertension, and diabetes, suggests a comprehensive approach to managing cardiovascular risk factors. Overall, while the patient has a high cardiovascular risk profile, the absence of acute cardiac events and the presence of a relatively stable clinical course suggest a favorable prognosis for survival.

RANKING: 2. Sudden Cardiac Death 
REASONING: While the patient has a high cardiovascular risk profile, the absence of troponin elevation and the presence of a relatively low TSH level suggest that the patient is not currently experiencing acute myocardial infarction. However, the patient's LVEF is severely impaired, and the presence of ventricular extrasystole and PSVT on the ECG may indicate underlying arrhythmogenic substrate. The patient's history of heart failure and hypertension also increases the risk of sudden cardiac death. Furthermore, the patient's creatinine level is elevated, which can be a risk factor for cardiovascular events. While the patient's current treatment regimen is comprehensive, the patient's underlying cardiovascular risk factors and the presence of arrhythmogenic substrate may still pose a risk for sudden cardiac death.

RANKING: 3. Pump Failure Death 
REASONING: Pump failure death is a possible outcome for patients with severe heart failure, as evidenced by the patient's severely impaired LVEF. However, the patient is currently receiving treatment for heart failure, which includes medications for heart failure, hypertension, and diabetes. The patient's current laboratory results, including a relatively low TSH level and absence of troponin elevation, suggest that the patient is not currently experiencing acute cardiac events. Additionally, the patient's ECG findings do not indicate a high risk for ventricular tachycardia or non-sustained ventricular tachycardia. While the patient's underlying cardiovascular risk factors and the presence of arrhythmogenic substrate may still pose a risk for pump failure, the patient's current treatment regimen and stable clinical course suggest a lower risk for pump failure death compared to sudden cardiac death."
530,530,P0826,"Age: 45
Gender: Male 
Weight: 74 kg
Height: 171 cm
NYHA Class: II
Blood Pressure: 100/60 mmHg
Past Medical History: Toxic dilated cardiomyopathy
Albumin (g/L): 43
ALT or GPT (IU/L): 21.0
AST or GOT (IU/L): 19.0
Total Cholesterol (mmol/L): 5,17
Creatinine (mmol/L): 100.0
Gamma-glutamil transpeptidase (IU/L): 20
Glucose (mmol/L): 6,1
Hemoglobin (g/L): 148.0
HDL (mmol/L): 1,29
Potassium (mEq/L): 5
LDL (mmol/L): 3,28
Sodium (mEq/L): 148.0
Pro-BNP (ng/L): 53.0
Protein (g/L): 74
T3 (pg/dL): 0,06
T4 (ng/L): 16
Troponin (ng/mL): 0,005
TSH (mIU/L): 1,62
Urea (mg/dL): 5,16
LVEF (%): 48.0
Medications: Beta Blockers, Digoxin, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: TPSV
        - Bradycardia: No
            ",survivor,"RANKING: 
1. Survivor
2. Sudden Cardiac Death
3. Pump Failure Death

REASONING:

The patient is a 45-year-old male with a history of toxic dilated cardiomyopathy, which is a significant risk factor for cardiac complications. However, the patient's current ejection fraction (LVEF) of 48.0% indicates that the heart is still pumping blood efficiently, which is a positive sign. The patient's NYHA Class II classification also suggests that the patient's symptoms are mild and manageable with current medications.

The patient's electrolyte levels, liver enzymes, and kidney function are relatively normal, which reduces the risk of acute cardiac complications. The absence of elevated troponin levels further supports this.

The presence of ventricular extrasystoles, non-sustained ventricular tachycardia, and paroxysmal supraventricular tarrhythmia on the ECG are concerning, but they are not indicative of a high-risk arrhythmia. The absence of sustained ventricular tachycardia and bradycardia on the ECG is also reassuring.

Given the patient's overall clinical presentation and the absence of any life-threatening abnormalities, I predict that the patient is most likely to survive in the next few years. However, the patient's history of toxic dilated cardiomyopathy and the presence of ventricular arrhythmias make it essential to closely monitor the patient's condition and adjust the treatment plan as needed to minimize the risk of cardiac complications.

Sudden Cardiac Death is the second most likely prognosis, as the patient's history of toxic dilated cardiomyopathy and ventricular arrhythmias increases the risk of life-threatening arrhythmias. However, the patient's current ECG and laboratory results do not indicate an immediate risk of sudden cardiac death.

Pump Failure Death is the least likely prognosis, as the patient's LVEF is still within a relatively normal range, and the patient is currently responding to treatment with beta blockers, digoxin, and an ACE inhibitor. However, the patient's history of toxic dilated cardiomyopathy and the presence of ventricular arrhythmias make it essential to closely monitor the patient's condition and adjust the treatment plan as needed to minimize the risk of cardiac complications."
531,531,P0827,"Age: 41
Gender: Male 
Weight: 54 kg
Height: 154 cm
NYHA Class: II
Blood Pressure: 130/70 mmHg
Past Medical History: Idiopathic dilated cardiomyopathy
Albumin (g/L): 46
ALT or GPT (IU/L): 17.0
AST or GOT (IU/L): 24.0
Total Cholesterol (mmol/L): 4,81
Creatinine (mmol/L): 84.0
Gamma-glutamil transpeptidase (IU/L): 17
Glucose (mmol/L): 5,3
Hemoglobin (g/L): 151.0
HDL (mmol/L): 1,47
Potassium (mEq/L): 4,4
LDL (mmol/L): 2,87
Sodium (mEq/L): 139.0
Pro-BNP (ng/L): 97.0
Protein (g/L): 75
T3 (pg/dL): 0,05
T4 (ng/L): 16
Troponin (ng/mL): 0,005
TSH (mIU/L): 1,13
Urea (mg/dL): 3,83
LVEF (%): 26.0
Medications: Beta Blockers, Digoxin, Loop Diuretics, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"RANKING: 
1. Survivor 
REASONING: 
The patient has been classified as a survivor, which is the most likely outcome based on the provided data. The patient has a relatively mild NYHA Class II heart failure, which suggests that they are still able to perform moderate physical activity without significant symptoms. The patient's ECG shows non-sustained ventricular tachycardia (NSVT), which is a common finding in patients with idiopathic dilated cardiomyopathy. However, the presence of NSVT does not necessarily indicate a high risk of sudden cardiac death. The patient's LVEF is 26%, which is within the range for someone with NYHA Class II heart failure. The patient's laboratory values, including troponin, creatinine, and electrolyte levels, are not significantly abnormal, which suggests that there is no acute cardiac injury or kidney dysfunction. The patient's medication regimen, which includes beta blockers, digoxin, loop diuretics, and an ACE inhibitor, is typical for managing heart failure and controlling ventricular rate. Overall, the patient's clinical presentation and laboratory values suggest that they are likely to survive in the short term, but ongoing monitoring and follow-up are necessary to assess the progression of their condition."
532,532,P0828,"Age: 70
Gender: Male 
Weight: 94 kg
Height: 172 cm
NYHA Class: II
Blood Pressure: 130/85 mmHg
Past Medical History: Valvular cardiomyopathy, Dyslipemia, Hypertension
Albumin (g/L): 42
ALT or GPT (IU/L): 33.0
AST or GOT (IU/L): 28.0
Total Cholesterol (mmol/L): 6,49
Creatinine (mmol/L): 175.0
Gamma-glutamil transpeptidase (IU/L): 100
Glucose (mmol/L): 5,8
Hemoglobin (g/L): 153.0
HDL (mmol/L): 1,29
Potassium (mEq/L): 5,2
LDL (mmol/L): 4,03
Sodium (mEq/L): 140.0
Pro-BNP (ng/L): 1603.0
Protein (g/L): 69
T3 (pg/dL): 0,07
T4 (ng/L): 20
TSH (mIU/L): 0,495
Urea (mg/dL): 11,98
LVEF (%): 55.0
Medications: Beta Blockers, Digoxin, Loop Diuretics, Statins, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",survivor,"RANKING: 1. Survivor
REASONING: 

The patient's overall clinical presentation and test results suggest that the patient has a significant cardiac history of valvular cardiomyopathy, hypertension, and dyslipidemia, which may have led to left ventricular dysfunction, as indicated by the low LVEF of 55%. The patient's elevated creatinine level (175.0 mmol/L) and elevated BNP levels (1603.0 ng/L) also suggest some degree of left ventricular dysfunction and fluid overload. However, the patient's current NYHA class II indicates that they are able to perform moderate physical activity without symptoms, which is a positive prognostic sign.

The patient's current medications, including beta blockers, digoxin, loop diuretics, statins, and an ACE inhibitor, are commonly used to manage heart failure, hypertension, and dyslipidemia. The absence of ventricular tachycardia or non-sustained ventricular tachycardia on the ECG suggests that the patient does not have a high risk of sudden cardiac death.

While the patient's T3 and T4 levels are low, which may indicate hypothyroidism, this is not a direct cause of cardiac dysfunction and is not immediately life-threatening. The patient's hemoglobin level is within the normal range, and the absence of anemia is a positive prognostic sign.

Overall, based on the patient's current clinical presentation and test results, the most likely outcome is that the patient will survive the next few years. However, close monitoring and regular follow-up with the cardiologist are essential to adjust the treatment plan and manage any potential complications.

RANKING: 2. Sudden cardiac death
REASONING: 

The patient's history of valvular cardiomyopathy and hypertension increases their risk of sudden cardiac death. The patient's low LVEF and elevated BNP levels suggest some degree of left ventricular dysfunction, which can increase the risk of sudden cardiac death. The patient's elevated creatinine level (175.0 mmol/L) and elevated potassium level (5.2 mEq/L) also suggest some degree of renal dysfunction, which can increase the risk of arrhythmias and sudden cardiac death.

The patient's ECG results show ventricular extrasystoles, which can be a sign of underlying cardiac dysfunction. While the absence of ventricular tachycardia or non-sustained ventricular tachycardia on the ECG suggests that the patient does not have a high risk of sudden cardiac death, the presence of ventricular extrasystoles is a concerning sign that requires close monitoring.

RANKING: 3. Pump failure death
REASONING: 

The patient's current NYHA class II and the presence of valvular cardiomyopathy and hypertension increase their risk of heart failure. The patient's elevated BNP levels (1603.0 ng/L) and elevated creatinine level (175.0 mmol/L) suggest some degree of fluid overload and left ventricular dysfunction, which can lead to pump failure.

The patient's low LVEF (55%) and elevated T3 and T4 levels (0.07 and 20, respectively) suggest some degree of cardiac dysfunction. The patient's hemoglobin level is within the normal range, and the absence of anemia is a positive prognostic sign.

However, the patient's age (70 years), weight (94 kg), and the presence of hypertension and dyslipidemia increase their risk of cardiovascular events, including pump failure. The patient's current medications, including beta blockers, digoxin, loop diuretics, statins, and an ACE inhibitor, are commonly used to manage heart failure, but may not be sufficient to prevent pump failure in this patient.

Overall, while the patient's current clinical presentation and test results suggest some degree of cardiac dysfunction, the presence of valvular cardiomyopathy and hypertension increase their risk of pump failure. Close monitoring and regular follow-up with the cardiologist are essential to adjust the treatment plan and manage any potential complications."
533,533,P0829,"Age: 60
Gender: Female 
Weight: 97 kg
Height: 169 cm
NYHA Class: II
Blood Pressure: 130/80 mmHg
Past Medical History: Other HF etiology, Hypertension
Albumin (g/L): 41
ALT or GPT (IU/L): 31.0
AST or GOT (IU/L): 26.0
Total Cholesterol (mmol/L): 4,91
Creatinine (mmol/L): 106.0
Gamma-glutamil transpeptidase (IU/L): 25
Glucose (mmol/L): 7,8
Hemoglobin (g/L): 155.0
HDL (mmol/L): 1,29
Potassium (mEq/L): 4,2
LDL (mmol/L): 3,1
Sodium (mEq/L): 140.0
Pro-BNP (ng/L): 27.0
Protein (g/L): 72
T4 (ng/L): 9
Troponin (ng/mL): 0,01
TSH (mIU/L): 5
Urea (mg/dL): 5,16
LVEF (%): 50.0
Medications: Angiotensin II Receptor Blocker, Digoxin
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"RANKING: 1. Survivor
REASONING: 

This patient is likely to survive for the next few years due to the following reasons:

1. Age: Although the patient is 60 years old, which may be considered elderly, the patient's age alone is not a significant predictor of mortality in this case. Many patients with heart failure and other comorbidities can live for many years with proper management.

2. NYHA Class II: The patient's New York Heart Association (NYHA) class II indicates that the patient experiences mild symptoms with ordinary physical activity, which suggests that the patient's heart function is not severely impaired.

3. Low Troponin levels: The patient's Troponin level is 0.01 ng/mL, which is within the normal range. Elevated Troponin levels are often associated with cardiac damage, and a low level suggests that the patient's heart muscle is not significantly damaged.

4. No evidence of acute coronary syndrome: The patient's ECG impression does not show any signs of acute coronary syndrome, which would increase the risk of mortality.

5. Low Creatinine levels: The patient's creatinine level is 5.16 mg/dL, which is slightly elevated but not significantly high. Elevated creatinine levels can indicate kidney dysfunction, which can increase the risk of mortality in patients with heart failure. However, in this case, the patient's kidney function is not severely impaired.

6. Presence of other comorbidities: The patient has other comorbidities, including hypertension and other heart failure etiology, but these comorbidities do not necessarily increase the risk of mortality in this patient.

7. Medications: The patient is taking Angiotensin II Receptor Blocker and Digoxin, which are commonly used to manage heart failure and hypertension. These medications can help to reduce the risk of mortality.

Considering these factors, the patient is likely to survive for the next few years with proper management and monitoring."
534,534,P0831,"Age: 66
Gender: Female 
Weight: 103 kg
Height: 165 cm
NYHA Class: II
Blood Pressure: 110/70 mmHg
Past Medical History: Hypertensive cardiomyopathy, Diabetes, Dyslipemia, Peripheral vascular disease, Hypertension, Myocardial Infarction
Albumin (g/L): 40
ALT or GPT (IU/L): 30.0
AST or GOT (IU/L): 25.0
Total Cholesterol (mmol/L): 3,88
Creatinine (mmol/L): 88.0
Gamma-glutamil transpeptidase (IU/L): 35
Glucose (mmol/L): 6,9
Hemoglobin (g/L): 139.0
HDL (mmol/L): 1,16
Potassium (mEq/L): 4,5
LDL (mmol/L): 3,1
Sodium (mEq/L): 140.0
Pro-BNP (ng/L): 65.0
Protein (g/L): 70
T4 (ng/L): 10
Troponin (ng/mL): 0,01
TSH (mIU/L): 2,1
Urea (mg/dL): 4,99
LVEF (%): 58.0
Medications: Diabetes Medication, Loop Diuretics, Spironolactone, Statins, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: Second-degree AVB - type I
            ",survivor,"RANKING: 

1. Survivor
REASONING:
The patient is a 66-year-old female with a history of multiple comorbidities, including hypertension, cardiomyopathy, diabetes, and peripheral vascular disease. Despite these comorbidities, the patient's ECG impression does not show any signs of ventricular tachycardia, non-sustained ventricular tachycardia, or other life-threatening arrhythmias. The absence of these conditions suggests that the patient's cardiac function is not severely compromised. The patient's left ventricular ejection fraction (LVEF) is 58%, which is within the normal range for a 66-year-old female. The patient's troponin levels are also within normal limits, indicating no significant myocardial infarction or damage.

The patient's laboratory results, such as the normal creatinine levels and relatively low urea levels, also suggest that the patient's renal function is not severely impaired. The patient's hemoglobin and electrolyte levels are within normal limits, and the patient is not on any medications that would suggest significant kidney dysfunction or electrolyte imbalances.

Given these factors, the patient's overall prognosis is more favorable, and I would rank the patient as a survivor.

2. Sudden cardiac death
REASONING:
While the patient's ECG impression does show ventricular extrasystoles, which can be a marker for cardiac dysfunction, the patient's overall clinical picture is not strongly suggestive of a high risk for sudden cardiac death. The patient's LVEF is within the normal range, and the troponin levels are normal, indicating no significant myocardial infarction or damage.

However, the patient's history of hypertension, cardiomyopathy, and diabetes may increase the risk for cardiac arrhythmias and sudden cardiac death. Additionally, the patient's age and weight may also contribute to an increased risk.

3. Pump failure death
REASONING:
The patient's LVEF is 58%, which is below the normal range for a 66-year-old female. This suggests that the patient's left ventricle is not functioning optimally, which may increase the risk for heart failure. The patient's history of hypertension, cardiomyopathy, and diabetes also increases the risk for heart failure.

However, the patient's ECG impression does not show any signs of heart failure, and the patient's laboratory results do not suggest significant kidney dysfunction or electrolyte imbalances. The patient's medications, such as loop diuretics and ACE inhibitors, also suggest that the patient is receiving treatment to manage heart failure.

While the patient's LVEF is below the normal range, the overall clinical picture is not strongly suggestive of pump failure death. However, the patient's comorbidities and history of cardiomyopathy do increase the risk for heart failure, making this a possible but less likely outcome."
535,535,P0832,"Age: 56
Gender: Male 
Weight: 94 kg
Height: 172 cm
NYHA Class: II
Blood Pressure: 145/85 mmHg
Past Medical History: Enolic dilated cardiomyopathy, Diabetes, Dyslipemia, Hypertension
Albumin (g/L): 43
ALT or GPT (IU/L): 30.0
AST or GOT (IU/L): 25.0
Total Cholesterol (mmol/L): 3,62
Creatinine (mmol/L): 97.0
Gamma-glutamil transpeptidase (IU/L): 30
Glucose (mmol/L): 7,9
Hemoglobin (g/L): 139.0
HDL (mmol/L): 0,93
Potassium (mEq/L): 5
LDL (mmol/L): 1,42
Sodium (mEq/L): 140.0
Pro-BNP (ng/L): 217.0
Protein (g/L): 74
T4 (ng/L): 12
Troponin (ng/mL): 0,01
TSH (mIU/L): 2,1
Urea (mg/dL): 7,49
LVEF (%): 35.0
Medications: Diabetes Medication, Beta Blockers, Loop Diuretics, Spironolactone, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"RANKING: 1. Survivor
REASONING:

Based on the provided patient data, I would rank the patient outcome as a survivor with a high degree of certainty. Here's why:

1. Age: The patient is 56 years old, which is considered middle-aged, and while this age group is more prone to cardiovascular events, it's not excessively high-risk.

2. NYHA Class II: The patient has a moderate level of heart failure, but this is not severe enough to indicate advanced heart failure.

3. Blood Pressure: The patient's blood pressure is elevated but controlled with medication, which suggests good management of hypertension.

4. Past Medical History: The patient has a history of enolic dilated cardiomyopathy, diabetes, dyslipidemia, and hypertension, all of which can contribute to cardiovascular risk. However, these conditions are being managed with medication, and the patient's current values are not excessively high.

5. Biomarkers: The patient's troponin levels are normal, and the pro-BNP levels are elevated, indicating some degree of cardiac stress. However, these values are not excessively high.

6. Medications: The patient is taking a comprehensive set of medications to manage their conditions, including beta blockers, loop diuretics, spironolactone, and an ACE inhibitor. This suggests that the patient is receiving adequate treatment for their cardiovascular conditions.

7. ECG Impression: The ECG shows ventricular extrasystoles, which are benign and not indicative of any significant cardiac pathology.

Considering these factors, I believe that the patient is at moderate to low risk for a cardiac event, and the likelihood of survival over the next few years is high. Therefore, I rank the patient outcome as a survivor."
536,536,P0833,"Age: 68
Gender: Female 
Weight: 66 kg
Height: 158 cm
NYHA Class: II
Blood Pressure: 140/70 mmHg
Past Medical History: Hypertensive cardiomyopathy, Diabetes, Dyslipemia, Peripheral vascular disease, Hypertension
Albumin (g/L): 37
ALT or GPT (IU/L): 32.0
AST or GOT (IU/L): 12.0
Total Cholesterol (mmol/L): 6,96
Creatinine (mmol/L): 115.0
Gamma-glutamil transpeptidase (IU/L): 20
Glucose (mmol/L): 10,4
Hemoglobin (g/L): 129.0
HDL (mmol/L): 0,36
Potassium (mEq/L): 4,9
LDL (mmol/L): 4,27
Sodium (mEq/L): 136.0
Pro-BNP (ng/L): 588.0
Protein (g/L): 73
T4 (ng/L): 15
Troponin (ng/mL): 0,01
TSH (mIU/L): 4,36
Urea (mg/dL): 9,82
LVEF (%): 55.0
Medications: Calcium Channel Blocker, Diabetes Medication, Angiotensin II Receptor Blocker, Loop Diuretics
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"RANKING: 1. Survivor
REASONING: 

This patient's prognosis is ranked as a survivor due to the presence of several factors that suggest a relatively preserved cardiac function and a lower risk of adverse cardiac events. 

The patient's left ventricular ejection fraction (LVEF) is 55%, which is within the normal range for a 68-year-old individual. The absence of ventricular tachycardia, non-sustained ventricular tachycardia, and polymorphic ventricular extrasystole on the ECG further supports this assessment. Additionally, the patient's troponin level is normal, which indicates no evidence of myocardial damage.

The patient's medication regimen, which includes a calcium channel blocker, diabetes medication, and an angiotensin II receptor blocker, suggests that their cardiovascular risk factors are being managed. The patient's blood pressure is also well-controlled, as indicated by the reading of 140/70 mmHg.

While the patient has several comorbidities, including hypertension, diabetes, and peripheral vascular disease, the absence of any acute cardiac events or significant laboratory abnormalities (e.g., elevated creatinine or urea) suggests that these comorbidities are not currently causing significant cardiac stress.

Therefore, based on the available data, the patient is at a higher risk of surviving the next few years, with a moderate to high likelihood of maintaining their current cardiovascular health.

RANKING: 2. Sudden cardiac death
REASONING: 

This patient's prognosis is ranked as sudden cardiac death due to several factors that suggest an increased risk of cardiac events.

The patient's LVEF is 55%, which is below the normal range, indicating some degree of left ventricular dysfunction. The patient's elevated creatinine level (115.0 mmol/L) may also suggest some degree of renal impairment, which can contribute to an increased risk of cardiac events.

The patient's elevated troponin level (0.01 ng/mL) is slightly above the normal range, although this finding is not diagnostic of myocardial infarction. However, it does suggest some degree of myocardial stress or damage.

The patient's high Pro-BNP level (588.0 ng/L) is also a concern, as it indicates increased ventricular wall stress and a higher risk of cardiac events.

Additionally, the patient's dyslipidemia, hypertension, and diabetes are significant cardiovascular risk factors that contribute to an increased risk of cardiac events.

RANKING: 3. Pump failure death
REASONING: 

This patient's prognosis is ranked as pump failure death due to several factors that suggest a high risk of cardiac decompensation.

The patient's elevated creatinine level (115.0 mmol/L) and high Pro-BNP level (588.0 ng/L) indicate significant ventricular wall stress and a higher risk of cardiac decompensation. The patient's LVEF is also below the normal range, indicating some degree of left ventricular dysfunction.

The patient's diabetes and hypertension are significant comorbidities that contribute to an increased risk of cardiac events and decompensation. The patient's dyslipidemia and peripheral vascular disease also suggest a high risk of cardiovascular events.

The patient's medication regimen, while effective in managing their cardiovascular risk factors, may not be sufficient to mitigate the risks associated with their comorbidities. The patient's blood pressure is not being aggressively controlled, and their renal function is impaired, which may contribute to a higher risk of cardiac decompensation."
537,537,P0834,"Age: 58
Gender: Male 
Weight: 76 kg
Height: 176 cm
NYHA Class: II
Blood Pressure: 90/70 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Dyslipemia, Hypertension, Myocardial Infarction
Albumin (g/L): 39,7
ALT or GPT (IU/L): 31.0
AST or GOT (IU/L): 24.0
Total Cholesterol (mmol/L): 4,07
Creatinine (mmol/L): 181.0
Gamma-glutamil transpeptidase (IU/L): 76
Glucose (mmol/L): 6,1
Hemoglobin (g/L): 170.0
HDL (mmol/L): 1,18
Potassium (mEq/L): 4,63
LDL (mmol/L): 2,48
Sodium (mEq/L): 140.0
Pro-BNP (ng/L): 6433.0
Protein (g/L): 74
Troponin (ng/mL): 0,01
TSH (mIU/L): 4,17
Urea (mg/dL): 17,8
LVEF (%): 26.0
Medications: Digoxin, Loop Diuretics, Statins, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"RANKING: 
1. Survivor
REASONING:
The patient has a history of ischemic dilated cardiomyopathy, which is a significant comorbidity that can lead to heart failure and arrhythmias. However, the patient is currently being treated with medications for heart failure (Loop Diuretics) and has a relatively stable hemodynamic status (NYHA Class II). The patient's creatinine level is elevated, but it's not extremely high, indicating some degree of renal impairment, but not acute kidney injury. The patient's troponin level is within normal limits, suggesting that there is no acute myocardial infarction. 

The patient's Pro-BNP level is elevated, which is consistent with heart failure. However, the patient's LVEF is 26%, which is relatively low, indicating some degree of systolic dysfunction. The patient's ECG shows ventricular extrasystoles, which can be a marker for arrhythmia risk, but the absence of ventricular tachycardia or non-sustained ventricular tachycardia reduces the risk of sudden cardiac death.

Given the patient's stable clinical status, controlled hypertension, and the absence of acute myocardial infarction, the patient is more likely to survive in the short term. The patient's low HDL level and elevated triglycerides increase the risk of cardiovascular events, but these factors are not severe enough to change the overall prognosis.

2. Sudden cardiac death
REASONING:
The patient's LVEF is significantly low (26%), which increases the risk of sudden cardiac death due to arrhythmias or cardiac failure. The patient's ECG shows ventricular extrasystoles, which can be a marker for arrhythmia risk. While the absence of ventricular tachycardia or non-sustained ventricular tachycardia reduces the risk, the patient's Pro-BNP level is elevated, indicating some degree of heart failure.

The patient's past medical history of myocardial infarction and ischemic dilated cardiomyopathy increases the risk of sudden cardiac death. The patient's low HDL level and elevated triglycerides also increase the risk of cardiovascular events.

3. Pump failure death
REASONING:
The patient's LVEF is very low (26%), which indicates significant systolic dysfunction and an increased risk of heart failure. The patient's Pro-BNP level is elevated, indicating some degree of heart failure. The patient's creatinine level is elevated, indicating some degree of renal impairment, which can be a complication of heart failure.

The patient's history of ischemic dilated cardiomyopathy and hypertension increases the risk of pump failure. The patient's low HDL level and elevated triglycerides also increase the risk of cardiovascular events. However, the patient's stable clinical status, controlled hypertension, and absence of acute myocardial infarction reduce the risk of sudden cardiac death, making pump failure death the least likely of the three options."
538,538,P0836,"Age: 53
Gender: Male 
Weight: 67 kg
Height: 172 cm
NYHA Class: II
Blood Pressure: 105/70 mmHg
Past Medical History: Idiopathic dilated cardiomyopathy
Albumin (g/L): 44,1
ALT or GPT (IU/L): 35.0
AST or GOT (IU/L): 36.0
Total Cholesterol (mmol/L): 4,73
Creatinine (mmol/L): 99.0
Gamma-glutamil transpeptidase (IU/L): 15
Glucose (mmol/L): 6,1
Hemoglobin (g/L): 135.0
HDL (mmol/L): 0,96
Potassium (mEq/L): 4,41
LDL (mmol/L): 3,48
Sodium (mEq/L): 135.0
Protein (g/L): 78,4
Troponin (ng/mL): 0,01
TSH (mIU/L): 0,89
Urea (mg/dL): 8,7
LVEF (%): 30.0
Medications: Beta Blockers, Loop Diuretics, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"RANKING: 1. Survivor
REASONING: The patient is currently receiving treatment for their idiopathic dilated cardiomyopathy with beta blockers, loop diuretics, and an ACE inhibitor, which is a standard treatment approach for this condition. The patient's current ECG findings, including ventricular extrasystoles and non-sustained ventricular tachycardia, may indicate underlying cardiac arrhythmias, but these can often be managed with medication and lifestyle modifications. The patient's LVEF of 30.0 is significantly reduced, indicating severe left ventricular dysfunction, but the presence of troponin levels within normal limits suggests that the patient has not experienced a recent myocardial infarction. The patient's laboratory values, including a normal glucose level and a slightly elevated creatinine level, do not suggest any acute kidney injury or severe metabolic disturbances. Overall, given the patient's current treatment and the absence of any severe acute findings, I believe the patient has a good chance of survival over the next few years with proper management and monitoring."
539,539,P0837,"Age: 84
Gender: Male 
Weight: 54 kg
Height: 176 cm
NYHA Class: II
Blood Pressure: 110/60 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Diabetes, Hypertension, Myocardial Infarction
Albumin (g/L): 36,2
ALT or GPT (IU/L): 22.0
AST or GOT (IU/L): 17.0
Total Cholesterol (mmol/L): 4,85
Creatinine (mmol/L): 86.0
Gamma-glutamil transpeptidase (IU/L): 41
Glucose (mmol/L): 15
Hemoglobin (g/L): 136.0
HDL (mmol/L): 1,54
Potassium (mEq/L): 4,62
LDL (mmol/L): 2,81
Sodium (mEq/L): 133.0
Pro-BNP (ng/L): 2619.0
Protein (g/L): 73,3
Troponin (ng/mL): 0,01
TSH (mIU/L): 5,54
Urea (mg/dL): 12,7
LVEF (%): 25.0
Medications: Digoxin, Loop Diuretics, Spironolactone, ACE Inhibitor, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",survivor,"RANKING: 1. Survivor
REASONING:

This patient's prognosis is classified as a survivor due to the following reasons:

1. Age: Although the patient is 84 years old, the age itself is not a significant risk factor for sudden cardiac death or pump failure death. Many patients with advanced age can survive with proper management and treatment.
2. NYHA Class II: The patient's NYHA class is II, indicating mild symptoms of heart failure. This suggests that the patient is not severely impaired and can still maintain a relatively normal quality of life with treatment.
3. Medications: The patient is on a comprehensive regimen of medications, including digoxin, loop diuretics, spironolactone, ACE inhibitor, and nitrovasodilator, which indicates that the patient's condition is being actively managed.
4. Pro-BNP level: Although the Pro-BNP level is elevated at 2619.0 ng/L, which is above the normal range, this is not an uncommon finding in patients with heart failure. The elevated level suggests some degree of ventricular stress, but it does not necessarily indicate an immediate risk of pump failure or sudden cardiac death.
5. LVEF: The left ventricular ejection fraction (LVEF) is 25.0%, which is significantly reduced, indicating some degree of left ventricular dysfunction. However, this can be managed with current treatment and may not necessarily lead to pump failure or sudden cardiac death.
6. Electrocardiogram (ECG) results: The ECG shows ventricular extrasystoles and polymorphic ventricular extrasystoles, which may indicate some degree of cardiac arrhythmia. However, the absence of ventricular tachycardia or non-sustained ventricular tachycardia reduces the risk of sudden cardiac death.

Overall, considering the patient's age, NYHA class, medication regimen, and ECG results, the likelihood of pump failure death or sudden cardiac death is relatively low, making a survivor prognosis the most likely outcome."
540,540,P0840,"Age: 55
Gender: Female 
Weight: 55 kg
Height: 145 cm
NYHA Class: III
Blood Pressure: 80/40 mmHg
Past Medical History: Valvular cardiomyopathy, Dyslipemia
Albumin (g/L): 44,9
ALT or GPT (IU/L): 17.0
AST or GOT (IU/L): 25.0
Total Cholesterol (mmol/L): 5,44
Creatinine (mmol/L): 94.0
Gamma-glutamil transpeptidase (IU/L): 21
Glucose (mmol/L): 6,7
Hemoglobin (g/L): 113.0
HDL (mmol/L): 1,34
Potassium (mEq/L): 4,15
LDL (mmol/L): 3,71
Sodium (mEq/L): 133.0
Pro-BNP (ng/L): 991.0
Protein (g/L): 77,3
Troponin (ng/mL): 0,01
TSH (mIU/L): 3,87
Urea (mg/dL): 7,8
LVEF (%): 40.0
Medications: Angiotensin II Receptor Blocker, Digoxin, Loop Diuretics, Spironolactone
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",survivor,"RANKING: 
1. Survivor
REASONING: 
The patient's overall condition is quite severe, with a history of valvular cardiomyopathy, which is a significant risk factor for cardiac complications. The patient's NYHA Class III indicates severe heart failure symptoms, which requires regular treatment and close monitoring. The patient's low blood pressure (80/40 mmHg) is concerning, but it is not immediately life-threatening. The patient's high creatinine level (94.0) suggests some degree of kidney impairment, but it is not severe. The patient's troponin level (0.01 ng/mL) is within normal limits, which suggests that there is no significant myocardial infarction. The patient's LVEF (40.0) is significantly reduced, indicating severe left ventricular dysfunction.

Despite these concerning factors, the patient is currently being treated with medications that are standard for heart failure management, such as Angiotensin II Receptor Blocker, Digoxin, Loop Diuretics, and Spironolactone. The patient's Pro-BNP level (991.0 ng/L) is elevated, which suggests some degree of cardiac strain.

Given the patient's current treatment regimen and the absence of acute life-threatening arrhythmias or significant myocardial infarction, I believe that the patient is likely to survive in the short term. However, the patient's severe heart failure symptoms, low blood pressure, and reduced LVEF make it a high-risk patient who requires close monitoring and regular follow-up appointments.

While the patient is currently a survivor, I would expect a high risk of cardiac complications in the next few years, including pump failure and sudden cardiac death. The patient's valvular cardiomyopathy and severe heart failure symptoms increase the risk of cardiac complications, and the patient's reduced LVEF and low blood pressure suggest a high risk of cardiac dysfunction.

It is essential to closely monitor the patient's condition, adjust the treatment regimen as needed, and consider additional interventions, such as cardiac resynchronization therapy or device therapy, to improve the patient's prognosis."
541,541,P0841,"Age: 54
Gender: Male 
Weight: 75 kg
Height: 178 cm
NYHA Class: II
Blood Pressure: 160/90 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Hypertension, Myocardial Infarction
Albumin (g/L): 42
ALT or GPT (IU/L): 14.0
AST or GOT (IU/L): 17.0
Total Cholesterol (mmol/L): 4,42
Creatinine (mmol/L): 94.0
Gamma-glutamil transpeptidase (IU/L): 15
Glucose (mmol/L): 5,3
Hemoglobin (g/L): 152.0
HDL (mmol/L): 1,09
Potassium (mEq/L): 4,18
LDL (mmol/L): 2,75
Sodium (mEq/L): 139.0
Protein (g/L): 67,9
T3 (pg/dL): 0,0648
T4 (ng/L): 12,24
Troponin (ng/mL): 0,3
TSH (mIU/L): 0,77
Urea (mg/dL): 5,5
LVEF (%): 25.0
Medications: Angiotensin II Receptor Blocker, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"RANKING: 1. Survivor
REASONING: 
The patient's overall prognosis is ranked as a survivor due to the following reasons:

1. The patient's left ventricular ejection fraction (LVEF) is 25.0%, which is significantly reduced, indicating severe left ventricular dysfunction. However, the patient is not listed as having heart failure (NYHA Class III or IV), suggesting that the patient may still have some residual cardiac function.
2. The patient's troponin level is 0.3 ng/mL, which is within the normal range, indicating that there is no significant myocardial damage.
3. The patient's ECG shows no signs of ventricular tachycardia or non-sustained ventricular tachycardia, which are risk factors for sudden cardiac death.
4. The patient is on medications for hypertension and heart failure, which suggests that the patient is receiving adequate treatment for their conditions.
5. The patient's laboratory values, such as albumin, creatinine, and electrolytes, are within relatively normal ranges, indicating that the patient does not have significant renal dysfunction or electrolyte imbalances.

While the patient has a history of ischemic dilated cardiomyopathy and myocardial infarction, the patient's current condition does not appear to be deteriorating, and the patient is receiving appropriate treatment. Therefore, the patient is likely to survive in the short term.

However, it is essential to note that the patient's prognosis is not without risk, and close monitoring and follow-up are necessary to adjust the treatment plan as needed."
542,542,P0842,"Age: 57
Gender: Male 
Weight: 84 kg
Height: 176 cm
NYHA Class: III
Blood Pressure: 125/80 mmHg
Past Medical History: Idiopathic dilated cardiomyopathy, Dyslipemia
Albumin (g/L): 41
ALT or GPT (IU/L): 15.0
AST or GOT (IU/L): 13.0
Total Cholesterol (mmol/L): 4,94
Creatinine (mmol/L): 80.0
Gamma-glutamil transpeptidase (IU/L): 23
Glucose (mmol/L): 4,3
Hemoglobin (g/L): 159.0
HDL (mmol/L): 1,14
Potassium (mEq/L): 4,6
LDL (mmol/L): 3,21
Sodium (mEq/L): 136.0
Pro-BNP (ng/L): 690.0
Protein (g/L): 74
T4 (ng/L): 14
Troponin (ng/mL): 0,01
TSH (mIU/L): 0,83
Urea (mg/dL): 5,16
LVEF (%): 20.0
Medications: Angiotensin II Receptor Blocker, Beta Blockers, Statins, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: TPSV
        - Bradycardia: No
            ",survivor,"RANKING: 1. Survivor
REASONING:

This patient's prognosis is ranked as a survivor due to the following factors:

1. Age: Although the patient is 57 years old, which is considered middle-aged, the overall health status and comorbidities suggest that the patient is still relatively young for heart failure. This increases the likelihood of survival.

2. NYHA Class III: The patient's NYHA Class III classification indicates severe heart failure, but with the presence of medications and other comorbidities, the likelihood of survival is relatively high.

3. Blood Pressure and Medications: The patient's blood pressure is within a relatively normal range, and the use of medications such as Angiotensin II Receptor Blocker, Beta Blockers, and ACE Inhibitor suggests that the patient is receiving optimal medical therapy for heart failure.

4. Pro-BNP: Although the patient's Pro-BNP levels are elevated, this is not uncommon in patients with heart failure. The level is not extremely high, and the presence of medications suggests that the patient is receiving appropriate treatment.

5. ECG Impression: The presence of ventricular extrasystole, non-sustained ventricular tachycardia, and non-sustained ventricular tachycardia is concerning, but the patient is not experiencing any sustained ventricular tachycardia, and the presence of beta blockers and other medications suggests that the patient is receiving optimal treatment for arrhythmias.

6. Troponin: The patient's troponin level is within a normal range, indicating no acute myocardial infarction.

7. Other lab values: The patient's other lab values, such as creatinine and urea levels, are relatively normal, suggesting that the patient's kidney function is not severely impaired.

Given these factors, the patient's overall prognosis is ranked as a survivor, with a moderate risk of progression to pump failure or sudden cardiac death. However, with optimal medical therapy and close monitoring, the patient can be expected to survive for several years.

RANKING: 2. Pump failure death
REASONING: 

This patient's prognosis is ranked as pump failure death due to the following factors:

1. Low LVEF: The patient's LVEF is 20%, which is significantly reduced, indicating severe left ventricular dysfunction.

2. NYHA Class III: The patient's NYHA Class III classification indicates severe heart failure, which increases the risk of pump failure.

3. Elevated Pro-BNP: Although the patient's Pro-BNP levels are not extremely high, the presence of elevated levels suggests that the patient's heart is working harder to pump blood, increasing the risk of pump failure.

4. Medication non-adherence: Although the patient is receiving medications, the presence of elevated Pro-BNP and NYHA Class III classification suggests that the patient may not be adhering to medication regimens, increasing the risk of pump failure.

5. Presence of ventricular tachycardia: The patient's presence of non-sustained ventricular tachycardia increases the risk of pump failure.

6. Elevated Creatinine and Urea: The patient's elevated creatinine and urea levels suggest that the patient's kidney function is impaired, which can increase the risk of pump failure.

7. Presence of idiopathic dilated cardiomyopathy: The patient's underlying condition of idiopathic dilated cardiomyopathy increases the risk of pump failure.

Given these factors, the patient's prognosis is ranked as pump failure death, with a moderate to high risk of progression to pump failure.

RANKING: 3. Sudden cardiac death
REASONING: 

This patient's prognosis is ranked as sudden cardiac death due to the following factors:

1. Presence of ventricular tachycardia: The patient's presence of non-sustained ventricular tachycardia increases the risk of sudden cardiac death.

2. Low LVEF: The patient's LVEF is 20%, which is significantly reduced, increasing the risk of sudden cardiac death.

3. Presence of idiopathic dilated cardiomyopathy: The patient's underlying condition of idiopathic dilated cardiomyopathy increases the risk of sudden cardiac death.

4. Elevated Troponin: Although the patient's troponin level is within a normal range, the presence of elevated levels can indicate myocardial damage, increasing the risk of sudden cardiac death.

5. Presence of ventricular extrasystole: The patient's presence of ventricular extrasystole increases the risk of sudden cardiac death.

6. Presence of polymorphic ventricular extrasystole: The patient's presence of polymorphic ventricular extrasystole is particularly concerning, as it can increase the risk of sudden cardiac death.

7. Presence of other arrhythmias: The patient's presence of paroxysmal supraventricular tachyarr"
543,543,P0844,"Age: 73
Gender: Male 
Weight: 66 kg
Height: 163 cm
NYHA Class: II
Blood Pressure: 130/88 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Diabetes, Dyslipemia, Hypertension
Albumin (g/L): 41
ALT or GPT (IU/L): 33.0
AST or GOT (IU/L): 35.0
Total Cholesterol (mmol/L): 3,1
Creatinine (mmol/L): 97.0
Gamma-glutamil transpeptidase (IU/L): 45
Glucose (mmol/L): 10,6
Hemoglobin (g/L): 179.0
HDL (mmol/L): 1,03
Potassium (mEq/L): 4,5
LDL (mmol/L): 1,53
Sodium (mEq/L): 137.0
Pro-BNP (ng/L): 1713.0
Protein (g/L): 78
T4 (ng/L): 14
Troponin (ng/mL): 0,01
TSH (mIU/L): 4,86
Urea (mg/dL): 7,15
LVEF (%): 20.0
Medications: Diabetes Medication, Angiotensin II Receptor Blocker, Beta Blockers, Spironolactone, Statins, ACE Inhibitor, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"RANKING: 
1. Survivor
REASONING:
Based on the provided patient data, I would rank the patient as a survivor with a high likelihood of survival for the next few years. The patient's age is 73, which is considered old for a cardiac event, but the NYHA Class II indicates that the patient's symptoms are not severe enough to limit their daily activities. The patient's LVEF is 20.0, which is significantly reduced, indicating poor heart function.

However, the patient has a good prognosis due to several factors:

- The patient is on multiple medications that are commonly used to manage heart failure, including ACE inhibitors, beta blockers, and spironolactone, which can help improve heart function and reduce symptoms.
- The patient's creatinine level is not severely elevated, indicating that kidney function is not severely impaired.
- The patient's troponin level is normal, indicating that there is no significant myocardial infarction.
- The patient's lipid profile is not severely abnormal, with a total cholesterol level of 3.1 mmol/L.
- The patient's glucose level is slightly elevated, but this is not uncommon in patients with diabetes.
- The patient's ECG impression does not show any signs of ventricular tachycardia or other life-threatening arrhythmias.

Overall, while the patient's heart function is poor, the combination of multiple medications, good kidney function, and a relatively normal lipid profile suggest that the patient can be managed with current treatment and may have a reasonable chance of survival for the next few years.

RANKING: 
2. Sudden Cardiac Death
REASONING:
Based on the patient's poor LVEF of 20.0 and the presence of ventricular extrasystoles on the ECG, there is a moderate risk of sudden cardiac death. The patient's age and NYHA Class II also increase the risk of cardiac events.

However, the patient is on multiple medications that are commonly used to manage heart failure and reduce the risk of sudden cardiac death, including beta blockers and ACE inhibitors. Additionally, the patient's creatinine level is not severely elevated, indicating that kidney function is not severely impaired.

While the patient's heart function is poor, the presence of ventricular extrasystoles on the ECG increases the risk of sudden cardiac death, and the patient's age and NYHA Class II also increase the risk.

RANKING: 
3. Pump Failure Death
REASONING:
Based on the patient's poor LVEF of 20.0, there is a high risk of pump failure death. The patient's NYHA Class II indicates that the patient's symptoms are not severe enough to limit their daily activities, but the patient's heart function is still significantly impaired.

The patient's creatinine level is elevated, indicating that kidney function is not optimal, and the patient's lipid profile is not ideal. The patient's glucose level is also slightly elevated, which can increase the risk of cardiac events.

Additionally, the patient's ventricular extrasystoles on the ECG increase the risk of cardiac events, and the patient's age and NYHA Class II also increase the risk of pump failure death.

While the patient is on multiple medications that can help manage heart failure, the patient's poor LVEF and other risk factors increase the risk of pump failure death, making this the least likely outcome."
544,544,P0847,"Age: 65
Gender: Male 
Weight: 67 kg
Height: 166 cm
NYHA Class: II
Blood Pressure: 100/50 mmHg
Past Medical History: Idiopathic dilated cardiomyopathy, Diabetes
Albumin (g/L): 47
ALT or GPT (IU/L): 15.0
AST or GOT (IU/L): 22.0
Total Cholesterol (mmol/L): 5,3
Creatinine (mmol/L): 133.0
Gamma-glutamil transpeptidase (IU/L): 42
Glucose (mmol/L): 15,2
Hemoglobin (g/L): 143.0
HDL (mmol/L): 0,88
Potassium (mEq/L): 6,3
LDL (mmol/L): 3,49
Sodium (mEq/L): 136.0
Pro-BNP (ng/L): 564.0
Protein (g/L): 78
T3 (pg/dL): 0,05
T4 (ng/L): 16
Troponin (ng/mL): 0,005
TSH (mIU/L): 1,96
Urea (mg/dL): 9,82
LVEF (%): 50.0
Medications: Beta Blockers, Digoxin, Loop Diuretics, Spironolactone, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",survivor,"RANKING: 
1. Survivor
REASONING:
The patient's overall clinical presentation and test results suggest a high likelihood of survival for the next few years. The patient's age and NYHA Class II indicate a moderate level of heart failure, but the patient is not in severe heart failure (NYHA Class III or IV). The presence of a low ejection fraction (LVEF) of 50% suggests significant left ventricular dysfunction, which is consistent with the patient's history of idiopathic dilated cardiomyopathy.

The patient's blood pressure is within a relatively normal range, and the use of beta blockers, digoxin, loop diuretics, spironolactone, and an ACE inhibitor indicates that the patient is receiving standard treatments for heart failure. The absence of significant elevations in troponin levels and normal TSH levels suggest that the patient's cardiac function is not severely compromised.

Additionally, the patient's renal function is preserved, with a creatinine level of 9.82 mg/dL, which is not indicative of significant kidney disease. The patient's lipid profile is also relatively well-controlled, with a total cholesterol level of 5.3 mmol/L.

While the patient has a history of idiopathic dilated cardiomyopathy, the patient's current clinical presentation and test results do not suggest an acute or acute decompensated heart failure episode. Therefore, based on the available information, the patient is at high risk of survival for the next few years.

RANKING: 
2. Pump failure death
REASONING:
While the patient's LVEF is 50%, which is significantly reduced, the patient's overall clinical presentation and test results suggest that the patient is not in a state of acute or acute decompensated heart failure. The patient is receiving standard treatments for heart failure, and the absence of significant elevations in troponin levels and normal TSH levels suggest that the patient's cardiac function is not severely compromised.

However, the patient's LVEF is significantly reduced, which may increase the risk of heart failure exacerbation or progression of heart failure over time. Additionally, the patient's history of idiopathic dilated cardiomyopathy and diabetes may increase the risk of long-term cardiac complications.

While the patient is at risk of pump failure, the patient's current clinical presentation and test results do not suggest an immediate or imminent risk of pump failure. Therefore, this ranking is based on a relatively lower likelihood of pump failure compared to the survivor prognosis.

RANKING: 
3. Sudden cardiac death
REASONING:
The patient's ECG impression does not suggest an increased risk of ventricular arrhythmias, with no evidence of ventricular tachycardia or ventricular extrasystole. The absence of significant elevations in troponin levels and normal TSH levels also suggest that the patient's cardiac function is not severely compromised.

However, the patient's history of idiopathic dilated cardiomyopathy and diabetes may increase the risk of long-term cardiac complications, including arrhythmias. Additionally, the patient's low HDL level of 0.88 mmol/L may increase the risk of cardiovascular events.

While the patient is at risk of long-term cardiac complications, the patient's current clinical presentation and test results do not suggest an immediate or imminent risk of sudden cardiac death. Therefore, this ranking is based on a relatively lower likelihood of sudden cardiac death compared to the survivor prognosis."
545,545,P0849,"Age: 81
Gender: Female 
Weight: 76 kg
Height: 151 cm
NYHA Class: III
Blood Pressure: 130/80 mmHg
Past Medical History: Idiopathic dilated cardiomyopathy, Diabetes
Albumin (g/L): 47
ALT or GPT (IU/L): 19.0
AST or GOT (IU/L): 19.0
Total Cholesterol (mmol/L): 5,46
Creatinine (mmol/L): 122.0
Gamma-glutamil transpeptidase (IU/L): 11
Glucose (mmol/L): 7
Hemoglobin (g/L): 119.0
HDL (mmol/L): 1,32
Potassium (mEq/L): 5,8
LDL (mmol/L): 3,52
Sodium (mEq/L): 153.0
Pro-BNP (ng/L): 1494.0
Protein (g/L): 78
T3 (pg/dL): 0,04
T4 (ng/L): 15
TSH (mIU/L): 3,52
Urea (mg/dL): 20,63
LVEF (%): 60.0
Medications: Diabetes Medication, Angiotensin II Receptor Blocker, Beta Blockers, Loop Diuretics, Spironolactone, ACE Inhibitor, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",survivor,"RANKING: 1. Survivor
REASONING: 
The patient's age (81) and NYHA Class III status indicate a significant level of cardiac dysfunction, which is a major risk factor for adverse outcomes. However, the patient's current medical history, laboratory results, and medication regimen do not suggest any immediate life-threatening conditions. The patient's LVEF is 60%, which is lower than the normal range, but not severely impaired. The absence of ventricular tachycardia and paroxysmal supraventricular tachyarrhythmia on the ECG also reduces the risk of sudden cardiac death.

The patient's laboratory results show elevated creatinine levels (122.0 mmol/L) and BNP (1494.0 ng/L), indicating some degree of cardiac stress and potential volume overload. However, these findings are not uncommon in patients with heart failure and can be managed with the current medication regimen.

Given the patient's overall clinical picture, I believe the most likely outcome is a survival for the next few years, provided that the current medication regimen is adhered to and any potential side effects are closely monitored.

RANKING: 2. Sudden cardiac death
REASONING: 
The patient's LVEF of 60% is below the normal range, which increases the risk of sudden cardiac death. The patient's elevated BNP levels (1494.0 ng/L) and creatinine levels (122.0 mmol/L) also suggest some degree of cardiac stress and potential volume overload, which can contribute to the risk of sudden cardiac death.

The patient's age (81) and NYHA Class III status also increase the risk of sudden cardiac death. However, the absence of ventricular tachycardia and paroxysmal supraventricular tachyarrhythmia on the ECG reduces this risk.

RANKING: 3. Pump failure death
REASONING: 
The patient's LVEF of 60% is below the normal range, which increases the risk of pump failure. The patient's elevated creatinine levels (122.0 mmol/L) and BNP levels (1494.0 ng/L) also suggest some degree of cardiac stress and potential volume overload, which can contribute to the risk of pump failure.

The patient's NYHA Class III status also indicates a significant level of cardiac dysfunction, which increases the risk of pump failure. However, the patient's current medication regimen and laboratory results do not suggest any immediate life-threatening conditions that would necessitate hospitalization or surgical intervention.

Overall, while pump failure is a concern, I believe that the patient's current clinical picture is more consistent with a risk of pump failure rather than sudden cardiac death."
546,546,P0850,"Age: 48
Gender: Male 
Weight: 60 kg
Height: 176 cm
NYHA Class: II
Blood Pressure: 120/60 mmHg
Past Medical History: Other HF etiology
Albumin (g/L): 42
ALT or GPT (IU/L): 13.0
AST or GOT (IU/L): 23.0
Total Cholesterol (mmol/L): 3,78
Creatinine (mmol/L): 80.0
Gamma-glutamil transpeptidase (IU/L): 14
Glucose (mmol/L): 5,1
Hemoglobin (g/L): 114.0
HDL (mmol/L): 1,73
Potassium (mEq/L): 4,6
LDL (mmol/L): 1,81
Sodium (mEq/L): 136.0
Pro-BNP (ng/L): 2429.0
Protein (g/L): 67
T3 (pg/dL): 0,04
T4 (ng/L): 17
Troponin (ng/mL): 0,11
TSH (mIU/L): 3,28
Urea (mg/dL): 4,66
LVEF (%): 12.0
Medications: Beta Blockers, Digoxin, Loop Diuretics, Spironolactone, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",survivor,"RANKING: 1. Survivor
REASONING: The patient's age, NYHA Class II, and the absence of any specific indications for a poor outcome (e.g., severe left ventricular dysfunction, severe anemia, or significant renal impairment) suggest that the patient is likely to survive. The patient's current medications, which include beta blockers, digoxin, loop diuretics, spironolactone, and an ACE inhibitor, indicate a well-managed heart failure regimen, which further supports a favorable prognosis. The presence of non-sustained ventricular tachycardia (NSVT) on the ECG is a concern, but the fact that it is non-sustained (CH > 10) may not be a significant predictor of mortality. Overall, the patient's clinical presentation and management suggest a reasonable expectation of survival.

RANKING: 2. Sudden cardiac death
REASONING: The presence of non-sustained ventricular tachycardia (NSVT) on the ECG is a significant concern, as it increases the risk of sudden cardiac death. The patient's age and NYHA Class II status also suggest that the patient is at risk for arrhythmic events. However, the fact that the NSVT is non-sustained (CH > 10) reduces the risk of sudden cardiac death. Nevertheless, the patient's underlying heart failure etiology, elevated BNP levels, and the presence of ventricular extrasystoles and polymorphic ventricular tachycardia on the ECG suggest that the patient is at increased risk for arrhythmic events, making sudden cardiac death a possible but less likely outcome.

RANKING: 3. Pump failure death
REASONING: The patient's NYHA Class II status and elevated BNP levels suggest that the patient has some degree of heart failure. However, the patient's current medications and the absence of any indications for severe left ventricular dysfunction or significant renal impairment suggest that the patient is well-managed and at reduced risk for pump failure. The presence of ventricular extrasystoles and polymorphic ventricular tachycardia on the ECG also increases the risk of arrhythmic events, but the patient's overall clinical presentation and management suggest that pump failure death is less likely."
547,547,P0852,"Age: 68
Gender: Male 
Weight: 75 kg
Height: 170 cm
NYHA Class: II
Blood Pressure: 120/80 mmHg
Past Medical History: Hypertensive cardiomyopathy, Hypertension
Albumin (g/L): 42
ALT or GPT (IU/L): 30.0
AST or GOT (IU/L): 20.0
Total Cholesterol (mmol/L): 4,34
Creatinine (mmol/L): 80.0
Gamma-glutamil transpeptidase (IU/L): 58
Glucose (mmol/L): 6,6
Hemoglobin (g/L): 140.0
HDL (mmol/L): 0,96
Potassium (mEq/L): 5
LDL (mmol/L): 2,51
Sodium (mEq/L): 139.0
Pro-BNP (ng/L): 457.0
Protein (g/L): 70
T4 (ng/L): 12
Troponin (ng/mL): 0,01
TSH (mIU/L): 2,4
Urea (mg/dL): 4,99
LVEF (%): 60.0
Medications: Beta Blockers, Digoxin, Loop Diuretics, Spironolactone, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",survivor,"RANKING: 
1. Survivor
REASONING: 
This patient has a relatively stable medical history, with controlled hypertension and no significant acute myocardial infarction or cardiac arrest. The patient's left ventricular ejection fraction (LVEF) is 60%, which is within the normal range for a 68-year-old male. The absence of significant elevations in troponin levels and normal ECG findings suggest that the patient's cardiac function is not severely compromised at this time. The patient's NYHA class is II, indicating mild symptoms, and the patient is on medications that are commonly used to manage heart failure and hypertension. The presence of elevated Pro-BNP levels may indicate some degree of heart failure, but the patient's overall clinical presentation and lack of other concerning findings make a poor outcome less likely.

2. Sudden cardiac death
REASONING: 
While the patient's Pro-BNP levels are elevated, which may suggest some degree of heart failure, the patient's overall clinical presentation and lack of other concerning findings make a sudden cardiac death less likely. The patient's LVEF is 60%, which is within the normal range for a 68-year-old male, and the patient is on medications that are commonly used to manage heart failure and hypertension. However, the presence of ventricular extrasystoles on the ECG may indicate some degree of cardiac arrhythmia, which could potentially increase the risk of sudden cardiac death. However, the absence of other concerning findings, such as a history of cardiac arrest or significant electrolyte imbalances, makes this outcome less likely.

3. Pump failure death
REASONING: 
Given the patient's elevated Pro-BNP levels and NYHA class II, there is a possibility of some degree of heart failure. However, the patient's overall clinical presentation and lack of other concerning findings make pump failure death less likely. The patient's LVEF is 60%, which is within the normal range for a 68-year-old male, and the patient is on medications that are commonly used to manage heart failure and hypertension. While the patient's elevated Pro-BNP levels may indicate some degree of heart failure, the patient's overall clinical presentation and lack of other concerning findings make pump failure death less likely."
548,548,P0854,"Age: 71
Gender: Male 
Weight: 72 kg
Height: 177 cm
NYHA Class: II
Blood Pressure: 100/65 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Hypertension, Myocardial Infarction
Albumin (g/L): 43
ALT or GPT (IU/L): 156.0
AST or GOT (IU/L): 130.0
Total Cholesterol (mmol/L): 3,05
Creatinine (mmol/L): 141.0
Gamma-glutamil transpeptidase (IU/L): 63
Glucose (mmol/L): 5,6
Hemoglobin (g/L): 134.0
HDL (mmol/L): 1,32
Potassium (mEq/L): 4,7
LDL (mmol/L): 1,29
Sodium (mEq/L): 141.0
Pro-BNP (ng/L): 1551.0
Protein (g/L): 73
T4 (ng/L): 17
Troponin (ng/mL): 0,01
TSH (mIU/L): 2,33
Urea (mg/dL): 12,48
LVEF (%): 30.0
Medications: Beta Blockers, Statins, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: TPSV
        - Bradycardia: No
            ",survivor,"RANKING: 1. Survivor
REASONING:

Based on the provided patient data, I predict that the patient is most likely to survive in the next few years. The key factors contributing to this prediction are:

1. Age: Although the patient is 71 years old, their age alone is not a contraindication for survival. In fact, with proper management and treatment, many patients with heart failure and coronary artery disease can live for several years with a good quality of life.
2. NYHA Class II: The patient's NYHA class II indicates that they experience mild symptoms with ordinary physical activity, which suggests that they are not severely limited in their daily activities. This level of symptom severity is often associated with a better prognosis.
3. Medications: The patient is taking beta blockers, statins, and an ACE inhibitor, which are standard treatments for heart failure and coronary artery disease. These medications can help improve symptoms, slow disease progression, and reduce the risk of complications.
4. ECG findings: While the patient has ventricular extrasystoles, which may indicate arrhythmias, there is no evidence of ventricular tachycardia or non-sustained ventricular tachycardia. The presence of paroxysmal supraventricular tachyarrhythmia (PSVT) may require further evaluation and treatment, but it is not necessarily a contraindication for survival.
5. Biomarkers: The patient's troponin levels are normal, which suggests that there is no acute myocardial infarction. Elevated BNP levels indicate heart failure, but they are not unusually high, suggesting that the patient's heart is not severely failing.
6. Laboratory values: The patient's creatinine level is elevated, but it is not significantly high, and the patient is on an ACE inhibitor, which can help reduce proteinuria and slow disease progression.

While there are some concerns, such as the patient's elevated creatinine level and ischemic dilated cardiomyopathy, the overall clinical picture suggests that the patient is likely to survive in the next few years with proper management and treatment."
549,549,P0855,"Age: 71
Gender: Male 
Weight: 70 kg
Height: 161 cm
NYHA Class: II
Blood Pressure: 135/70 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Diabetes, Hypertension, Myocardial Infarction
Albumin (g/L): 40
ALT or GPT (IU/L): 9.0
AST or GOT (IU/L): 10.0
Total Cholesterol (mmol/L): 2,14
Creatinine (mmol/L): 133.0
Gamma-glutamil transpeptidase (IU/L): 55
Glucose (mmol/L): 10,3
Hemoglobin (g/L): 110.0
HDL (mmol/L): 0,8
Potassium (mEq/L): 4,6
LDL (mmol/L): 0,97
Sodium (mEq/L): 144.0
Pro-BNP (ng/L): 17984.0
Protein (g/L): 71
T4 (ng/L): 21
Troponin (ng/mL): 0,01
TSH (mIU/L): 2,65
Urea (mg/dL): 7,15
LVEF (%): 18.0
Medications: Beta Blockers, Digoxin, Loop Diuretics, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",survivor,"RANKING: 
1. Survivor
REASONING: 
The patient has a complex medical history with multiple comorbidities, including ischemic dilated cardiomyopathy, diabetes, hypertension, and myocardial infarction. Despite these comorbidities, the patient is currently on medications that are standard for managing heart failure and arrhythmias (beta blockers, digoxin, loop diuretics, and ACE inhibitor). The patient's LVEF is 18.0%, which is significantly reduced, indicating impaired heart function. However, the patient's recent ECG findings show no evidence of acute arrhythmias, which is a positive sign. The patient's troponin levels are within normal limits, suggesting no acute myocardial infarction. The patient's BNP levels are elevated, but not extremely high, which may indicate some degree of heart failure. Given these factors, the patient's overall prognosis is guarded but not extremely poor. The patient's age and NYHA Class II status also suggest that the patient is relatively stable, and with proper management, the patient may survive for several years.

RANKING: 
2. Sudden Cardiac Death
REASONING: 
The patient's history of ischemic dilated cardiomyopathy, diabetes, and hypertension increases the risk of sudden cardiac death. The patient's reduced LVEF and elevated BNP levels suggest that the patient's heart function is compromised. The patient's ECG findings of ventricular extrasystoles and non-sustained ventricular tachycardia are concerning, but the fact that there are no sustained arrhythmias or other signs of acute myocardial infarction on the ECG is a positive sign. However, the patient's age and NYHA Class II status still make the patient more susceptible to cardiac events.

RANKING: 
3. Pump Failure Death
REASONING: 
The patient's LVEF is significantly reduced, and the patient is on medications that are standard for managing heart failure. While the patient's BNP levels are elevated, they are not extremely high, suggesting that the patient may be able to manage their heart failure symptoms with current medications. However, the patient's reduced LVEF and comorbidities increase the risk of pump failure. The patient's ECG findings of ventricular extrasystoles and non-sustained ventricular tachycardia are concerning, and the patient's age and NYHA Class II status make the patient more susceptible to cardiac events. Given these factors, pump failure death is a possible outcome, but it is less likely than sudden cardiac death due to the patient's current stable ECG findings and the fact that the patient is on medications that are standard for managing heart failure."
550,550,P0856,"Age: 63
Gender: Male 
Weight: 88 kg
Height: 167 cm
NYHA Class: II
Blood Pressure: 120/70 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Dyslipemia, Peripheral vascular disease, Hypertension, Myocardial Infarction
Albumin (g/L): 40
ALT or GPT (IU/L): 27.0
AST or GOT (IU/L): 25.0
Total Cholesterol (mmol/L): 3,88
Creatinine (mmol/L): 88.0
Gamma-glutamil transpeptidase (IU/L): 41
Glucose (mmol/L): 6,1
Hemoglobin (g/L): 169.0
HDL (mmol/L): 1,03
Potassium (mEq/L): 4
LDL (mmol/L): 2,46
Sodium (mEq/L): 140.0
Pro-BNP (ng/L): 406.0
Protein (g/L): 70
T4 (ng/L): 9
Troponin (ng/mL): 0,01
TSH (mIU/L): 1,02
Urea (mg/dL): 4,99
LVEF (%): 44.0
Medications: Calcium Channel Blocker, Beta Blockers, Loop Diuretics, Statins, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: Second-degree AVB - type I
            ",survivor,"RANKING: 1. Survivor
REASONING: The patient's overall clinical presentation and test results suggest that they are at risk for cardiac events, but the presence of a patent outcome of ""survivor"" indicates that the patient has already demonstrated resilience and a capacity to recover from cardiac stress. The patient's NYHA Class II indicates that they have some symptoms of heart failure, but they are still able to perform daily activities without severe limitation. The absence of symptoms such as orthopnea, paroxysmal nocturnal dyspnea, and fatigue in the patient's past medical history and the fact that they are able to maintain a relatively normal hemoglobin level suggest that their cardiac function is not severely compromised. Additionally, the patient's LVEF is 44%, which is within the normal range for a male of this age group, indicating that their cardiac function is not severely impaired. The absence of elevated troponin levels also suggests that there is no acute myocardial infarction. Overall, these factors suggest that the patient is likely to survive for the next few years without any major cardiac events.

RANKING: 2. Pump failure death
REASONING: The patient's LVEF is only 44%, which is below the normal range for a male of this age group, indicating some degree of cardiac dysfunction. The patient's NYHA Class II suggests that they have some symptoms of heart failure, which could potentially worsen over time. The patient's elevated creatinine level (88.0) may indicate some degree of renal impairment, which could be related to cardiac dysfunction. The patient's elevated Pro-BNP level (406.0) suggests that they have some degree of ventricular strain, which could be a sign of heart failure. While the patient is currently taking medications to manage their cardiac condition, the fact that they have multiple comorbidities (dyslipidemia, peripheral vascular disease, hypertension) increases their risk for cardiac events. Therefore, while the patient is currently surviving, there is a higher risk of pump failure death in the next few years.

RANKING: 3. Sudden cardiac death
REASONING: The patient's history of ischemic dilated cardiomyopathy, peripheral vascular disease, and hypertension increases their risk for cardiac events, including sudden cardiac death. The patient's elevated troponin level (0.01) is within the normal range, but the fact that they have a history of myocardial infarction and have been diagnosed with ischemic dilated cardiomyopathy suggests that they have some degree of cardiac scarring, which could increase their risk for arrhythmic events. The patient's ECG findings of ventricular extrasystole and bradycardia (second-degree AVB - type I) suggest that they have some degree of cardiac conduction system dysfunction, which could increase their risk for arrhythmic events. However, the patient's overall clinical presentation and test results do not suggest a high risk for sudden cardiac death, and their ability to survive for the next few years without major cardiac events makes pump failure death a more likely outcome."
551,551,P0857,"Age: 72
Gender: Female 
Weight: 76 kg
Height: 155 cm
NYHA Class: II
Blood Pressure: 160/80 mmHg
Past Medical History: Idiopathic dilated cardiomyopathy, Diabetes, Dyslipemia, Peripheral vascular disease, Hypertension
Albumin (g/L): 42
ALT or GPT (IU/L): 10.0
AST or GOT (IU/L): 10.0
Total Cholesterol (mmol/L): 6,08
Creatinine (mmol/L): 166.0
Gamma-glutamil transpeptidase (IU/L): 71
Glucose (mmol/L): 11,9
Hemoglobin (g/L): 105.0
HDL (mmol/L): 1,24
Potassium (mEq/L): 4,35
LDL (mmol/L): 3,44
Sodium (mEq/L): 139.0
Protein (g/L): 67,3
T3 (pg/dL): 0,0321
T4 (ng/L): 10
Troponin (ng/mL): 0,7
TSH (mIU/L): 14,9
Urea (mg/dL): 20,9
LVEF (%): 30.0
Medications: Diabetes Medication, Amiodarone, Loop Diuretics, ACE Inhibitor, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"RANKING: 1. Survivor
REASONING: 

This patient is at high risk for adverse cardiac events due to the presence of several comorbid conditions, including idiopathic dilated cardiomyopathy, diabetes, dyslipidemia, and hypertension. The patient's left ventricular ejection fraction (LVEF) is significantly reduced at 30%, indicating poor cardiac function. The elevated creatinine level (166.0 mmol/L) and high troponin level (0.7 ng/mL) suggest compromised renal function and cardiac strain. The presence of ventricular extrasystoles and polymorphic ventricular extrasystoles on the ECG also indicate a high risk of arrhythmias. However, the patient's current medication regimen, which includes an ACE inhibitor, amiodarone, and a nitrovasodilator, suggests that the patient is receiving appropriate treatment for their cardiovascular conditions. Considering these factors, I believe that the patient has a higher chance of survival compared to the other options."
552,552,P0859,"Age: 69
Gender: Male 
Weight: 75 kg
Height: 170 cm
NYHA Class: II
Blood Pressure: 110/60 mmHg
Past Medical History: Hypertensive cardiomyopathy, Diabetes, Hypertension
Albumin (g/L): 44,7
ALT or GPT (IU/L): 19.0
AST or GOT (IU/L): 18.0
Total Cholesterol (mmol/L): 5,56
Creatinine (mmol/L): 72.0
Gamma-glutamil transpeptidase (IU/L): 17
Glucose (mmol/L): 11,3
Hemoglobin (g/L): 136.0
HDL (mmol/L): 1,19
Potassium (mEq/L): 4,1
LDL (mmol/L): 3,57
Sodium (mEq/L): 140.0
Pro-BNP (ng/L): 185.0
Protein (g/L): 67,2
T4 (ng/L): 16
TSH (mIU/L): 1,17
Urea (mg/dL): 5,83
LVEF (%): 39.0
Medications: Diabetes Medication, Beta Blockers, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",survivor,"RANKING: 
1. Survivor
2. Pump failure death
3. Sudden cardiac death

REASONING:

The patient's overall clinical presentation and laboratory results suggest that they are at high risk for adverse cardiac events. Here's a breakdown of the factors contributing to each prognosis:

1. Survivor: The patient's age, NYHA Class II, and the presence of multiple comorbidities (hypertensive cardiomyopathy, diabetes, and hypertension) increase their risk for cardiac complications. However, the patient's ejection fraction (LVEF) is relatively preserved at 39%, which suggests some residual cardiac function. The patient's medication regimen, including beta blockers and ACE inhibitors, is also a positive factor, as these medications are known to improve cardiac outcomes in patients with heart failure and hypertension. The absence of significant electrolyte imbalances (e.g., potassium and sodium) and the relatively normal liver enzymes (ALT and AST) further support a favorable prognosis.

2. Pump failure death: The patient's LVEF of 39% indicates significant left ventricular dysfunction, which is a strong predictor of pump failure. Additionally, the patient's elevated creatinine level (5.83 mg/dL) suggests renal impairment, which can be a consequence of advanced heart failure. The patient's elevated BNP level (185 ng/L) also supports this prognosis, as it indicates increased ventricular wall stress. However, the patient's relatively preserved ejection fraction and the presence of beta blockers and ACE inhibitors in their medication regimen suggest that pump failure may not be imminent.

3. Sudden cardiac death: The patient's ECG findings of ventricular extrasystoles, although not sustained ventricular tachycardia, do raise concerns about arrhythmogenic potential. However, the absence of other significant ECG abnormalities (e.g., ventricular tachycardia, paroxysmal supraventricular tachyarrhythmia) and the patient's relatively preserved LVEF and normal liver enzymes reduce the likelihood of sudden cardiac death. Furthermore, the patient's hemoglobin level (136 g/L) is within the normal range, which suggests adequate oxygen delivery to the myocardium. While the patient's past medical history of hypertension and cardiomyopathy increases the risk of cardiac complications, the overall clinical picture is not as dire as it would be if the patient were experiencing more severe cardiac dysfunction or arrhythmias."
553,553,P0861,"Age: 59
Gender: Male 
Weight: 58 kg
Height: 169 cm
NYHA Class: II
Blood Pressure: 150/80 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Diabetes, Dyslipemia
Albumin (g/L): 42,4
ALT or GPT (IU/L): 11.0
AST or GOT (IU/L): 12.0
Total Cholesterol (mmol/L): 4,45
Creatinine (mmol/L): 95.0
Gamma-glutamil transpeptidase (IU/L): 27
Glucose (mmol/L): 11,5
Hemoglobin (g/L): 139.0
HDL (mmol/L): 0,83
Potassium (mEq/L): 5,4
LDL (mmol/L): 2,64
Sodium (mEq/L): 133.0
Pro-BNP (ng/L): 1410.0
Protein (g/L): 83,2
T4 (ng/L): 17
TSH (mIU/L): 2,83
Urea (mg/dL): 9,82
LVEF (%): 20.0
Medications: Diabetes Medication, Beta Blockers, Digoxin, Loop Diuretics, Spironolactone, Statins, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"RANKING: 

1. Survivor
REASONING:
The patient's age is 59, and their NYHA Class II indicates that they have some symptoms of heart failure, but they are still able to perform daily activities without significant limitations. Their LVEF is 20.0, which is significantly reduced, indicating poor heart function. However, they are on medications such as Beta Blockers, Digoxin, Loop Diuretics, and ACE Inhibitor, which are commonly used to manage heart failure and ischemic cardiomyopathy. The presence of these medications suggests that the patient is receiving appropriate treatment for their condition.

The patient's creatinine level is elevated at 95.0, which indicates some degree of renal impairment, but this can be managed with their current medications, including ACE Inhibitors. The patient's blood pressure is 150/80 mmHg, which is elevated but not severely high, and their lipid profile shows elevated cholesterol levels, but they are on Statins, which can help manage this.

The patient's ECG results show ventricular extrasystole, but no ventricular tachycardia or other arrhythmias. This suggests that the patient's heart is still functioning, albeit poorly.

Given these factors, the patient's overall prognosis is likely to be good, with a high likelihood of survival over the next few years. The patient's heart function is not severely impaired, and they are receiving appropriate treatment for their condition.

2. Sudden cardiac death
REASONING:
While the patient's LVEF is significantly reduced, their overall prognosis is still better than that of sudden cardiac death. The patient's age, NYHA Class II, and elevated creatinine level do increase their risk of complications, but their current treatment plan and the absence of ventricular tachycardia or other arrhythmias on ECG suggest that they are not at high risk of sudden cardiac death.

3. Pump failure death
REASONING:
The patient's LVEF is 20.0, which is a significant reduction in heart function, indicating poor heart pump efficiency. This, combined with their NYHA Class II symptoms, suggests that the patient's heart is not functioning optimally. While the patient is receiving treatment for heart failure, their elevated creatinine level and poor LVEF suggest that their heart is not responding well to treatment, increasing the risk of pump failure.

However, given the patient's age and the fact that they are already on medications for heart failure, the likelihood of pump failure death is still lower than sudden cardiac death."
554,554,P0862,"Age: 62
Gender: Female 
Weight: 66 kg
Height: 150 cm
NYHA Class: II
Blood Pressure: 150/95 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Hypertension, Myocardial Infarction
Albumin (g/L): 45,6
ALT or GPT (IU/L): 19.0
AST or GOT (IU/L): 18.0
Total Cholesterol (mmol/L): 4,58
Creatinine (mmol/L): 71.0
Gamma-glutamil transpeptidase (IU/L): 15
Glucose (mmol/L): 5,5
Hemoglobin (g/L): 118.0
HDL (mmol/L): 1,6
Potassium (mEq/L): 4,8
LDL (mmol/L): 2,61
Sodium (mEq/L): 140.0
Pro-BNP (ng/L): 266.0
Protein (g/L): 79,2
T4 (ng/L): 19
TSH (mIU/L): 4,59
Urea (mg/dL): 9,82
LVEF (%): 25.0
Medications: Amiodarone, Angiotensin II Receptor Blocker, Beta Blockers, Spironolactone
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"RANKING: 

1. Survivor
REASONING: 
This patient has a complex medical history with ischemic dilated cardiomyopathy, hypertension, and a previous myocardial infarction, which suggests a significant burden of cardiac disease. However, the patient is currently receiving multiple medications for heart failure and arrhythmias, which are likely contributing to the management of their condition. The presence of a ventricular extrasystole and non-sustained ventricular tachycardia on ECG may indicate underlying cardiac instability, but the absence of sustained ventricular tachycardia and other arrhythmias suggests that the patient is currently not in a high-risk state.

The patient's LVEF is 25%, which is significantly reduced, indicating severe left ventricular dysfunction. However, the patient is receiving medications that are commonly used to manage heart failure and arrhythmias, which may be contributing to some degree of symptom control. The elevated creatinine level (71.0 mmol/L) suggests some degree of kidney impairment, which may be related to the cardiac disease or other comorbidities.

Given the complexity of the patient's medical history and the presence of multiple medications, I believe that the patient is most likely to survive in the short term, despite the significant cardiac disease. The patient's biomarkers, such as the elevated troponin and creatinine, suggest ongoing cardiac and renal stress, but the patient is receiving aggressive management for these conditions, which may help to mitigate some of the risks.

2. Sudden cardiac death
REASONING: 
While the patient has a significant burden of cardiac disease, the presence of multiple medications and the absence of sustained ventricular tachycardia on ECG suggest that the patient is not currently at high risk for sudden cardiac death. The patient's LVEF is significantly reduced, which increases the risk for sudden cardiac death, but the patient's current management may be helping to mitigate this risk.

The patient's elevated creatinine level (71.0 mmol/L) and elevated troponin level (19.0) suggest ongoing cardiac and renal stress, which increases the risk for cardiac complications, including sudden cardiac death. However, the patient's current medications and the absence of other high-risk features on the ECG make this a less likely outcome.

3. Pump failure death
REASONING: 
Given the patient's significant reduction in LVEF (25%), severe left ventricular dysfunction, and elevated creatinine level, pump failure is a significant concern. However, the patient is receiving medications that are commonly used to manage heart failure, which may be contributing to some degree of symptom control.

While the patient's elevated troponin level and elevated creatinine level suggest ongoing cardiac and renal stress, the patient's current management may be helping to mitigate some of these risks. The patient's ECG findings, while concerning, do not suggest a high risk for pump failure. Overall, while pump failure is a significant concern, I believe that the patient is more likely to survive in the short term due to their current management and the absence of other high-risk features."
555,555,P0863,"Age: 55
Gender: Male 
Weight: 80 kg
Height: 169 cm
NYHA Class: II
Blood Pressure: 100/80 mmHg
Past Medical History: Ischemic dilated cardiomyopathy
Albumin (g/L): 45
ALT or GPT (IU/L): 18.0
AST or GOT (IU/L): 22.0
Total Cholesterol (mmol/L): 6,28
Creatinine (mmol/L): 104.0
Gamma-glutamil transpeptidase (IU/L): 35
Glucose (mmol/L): 5,7
Hemoglobin (g/L): 156.0
HDL (mmol/L): 1,19
Potassium (mEq/L): 4,74
LDL (mmol/L): 4,58
Sodium (mEq/L): 137.0
Protein (g/L): 73,8
T3 (pg/dL): 0,0597
T4 (ng/L): 14,3
Troponin (ng/mL): 0,2
TSH (mIU/L): 3,71
Urea (mg/dL): 6
LVEF (%): 25.0
Medications: Loop Diuretics, Statins, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"RANKING: 

1. Survivor
REASONING: 

This patient has a significant history of ischemic dilated cardiomyopathy, which is a major risk factor for cardiac complications and mortality. However, the patient's current NYHA class is II, indicating moderate symptoms, and they are receiving medications for heart failure and high cholesterol. The patient's LVEF is 25%, which is a critical indicator of cardiac function, but it is not extremely low.

The patient's laboratory results show mild elevations in liver enzymes (ALT and AST) and creatinine, which could indicate some degree of organ dysfunction. However, these values are not excessively high, and the patient is not showing signs of acute kidney injury or liver failure.

The ECG findings of ventricular extrasystole, non-sustained VT, and non-sustained ventricular tachycardia are concerning for cardiac arrhythmias, but the patient is not showing signs of severe ventricular instability. The absence of paroxysmal supraventricular tachyarrhythmia and bradycardia is also a positive sign.

Given these factors, I believe that the patient is most likely to survive in the next few years, assuming no significant worsening of their cardiac condition or new complications.

RANKING: 
2. Sudden Cardiac Death
REASONING: 

While the patient has a significant history of ischemic dilated cardiomyopathy and current cardiac arrhythmias, the patient's overall clinical presentation does not suggest an immediate risk of sudden cardiac death. The patient's NYHA class is moderate, and they are receiving medications for heart failure and high cholesterol.

However, the patient's LVEF is only 25%, which is a critical indicator of cardiac function, and the presence of ventricular extrasystole, non-sustained VT, and non-sustained ventricular tachycardia on ECG are concerning for cardiac instability. Additionally, the patient's creatinine level is elevated, which could indicate some degree of kidney dysfunction.

Given these factors, I believe that the patient is at a moderate risk of sudden cardiac death in the next few years, but it is not the most likely outcome.

RANKING: 
3. Pump Failure Death
REASONING: 

The patient's LVEF is 25%, which is a critical indicator of cardiac function, and they have a history of ischemic dilated cardiomyopathy. The patient's NYHA class is II, indicating moderate symptoms, and they are receiving medications for heart failure.

However, the patient's current laboratory results do not show signs of acute kidney injury or liver failure, and the patient is not showing signs of severe cardiac instability. The absence of paroxysmal supraventricular tachyarrhythmia and bradycardia is also a positive sign.

Additionally, the patient is receiving medications for heart failure and high cholesterol, which suggests that they are receiving adequate treatment for their cardiac condition. Given these factors, I believe that pump failure death is the least likely outcome in the next few years."
556,556,P0864,"Age: 68
Gender: Male 
Weight: 68 kg
Height: 162 cm
NYHA Class: III
Blood Pressure: 80/60 mmHg
Past Medical History: Idiopathic dilated cardiomyopathy, Diabetes, Dyslipemia, Hypertension
Albumin (g/L): 42
ALT or GPT (IU/L): 17.0
AST or GOT (IU/L): 19.0
Total Cholesterol (mmol/L): 3,59
Creatinine (mmol/L): 94.0
Gamma-glutamil transpeptidase (IU/L): 37
Glucose (mmol/L): 8,2
Hemoglobin (g/L): 130.0
HDL (mmol/L): 1,09
Potassium (mEq/L): 5,5
LDL (mmol/L): 1,78
Sodium (mEq/L): 137.0
Pro-BNP (ng/L): 3962.0
Protein (g/L): 73
T3 (pg/dL): 0,04
T4 (ng/L): 9
Troponin (ng/mL): 0,05
TSH (mIU/L): 32,58
Urea (mg/dL): 14,15
LVEF (%): 30.0
Medications: Diabetes Medication, Angiotensin II Receptor Blocker, Beta Blockers, Digoxin, Loop Diuretics, Spironolactone, Statins
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",survivor,"RANKING: 1. Survivor
REASONING: 

Based on the provided patient data, the patient is a 68-year-old male with a history of idiopathic dilated cardiomyopathy, diabetes, dyslipemia, and hypertension. His NYHA Class III status indicates severe heart failure symptoms. The patient's low ejection fraction (LVEF) of 30.0% further supports this, suggesting significant left ventricular dysfunction.

The patient's current ECG impression reveals polymorphic ventricular extrasystoles and non-sustained ventricular tachycardia, which are both indicative of arrhythmias. The presence of non-sustained ventricular tachycardia (CH>10) is particularly concerning, as it suggests an increased risk of ventricular arrhythmias.

Despite these concerning findings, the patient's blood pressure is relatively stable at 80/60 mmHg, and his medication list includes beta blockers, which can help reduce the risk of arrhythmias. The patient's troponin levels are also within normal limits, indicating no acute myocardial infarction.

Considering these factors, I believe that the patient is most likely to survive in the short-term (next few years) due to the presence of beta blockers, which can help manage arrhythmias, and the fact that the patient's blood pressure is relatively stable. However, the patient's underlying heart failure and arrhythmias will likely necessitate close monitoring and potential further interventions to prevent complications.

RANKING: 2. Sudden Cardiac Death
REASONING: 

While the patient's arrhythmias and low ejection fraction increase the risk of sudden cardiac death, I rank this as the second most likely outcome. The presence of beta blockers in the patient's medication list suggests that some measures are being taken to manage arrhythmias, and the patient's blood pressure is relatively stable.

However, the patient's LVEF of 30.0% and NYHA Class III status indicate significant left ventricular dysfunction, which increases the risk of sudden cardiac death. Additionally, the patient's ECG impression reveals polymorphic ventricular extrasystoles and non-sustained ventricular tachycardia, which are both associated with an increased risk of sudden cardiac death.

RANKING: 3. Pump Failure Death
REASONING: 

I rank pump failure death as the least likely outcome, despite the patient's significant heart failure symptoms and low ejection fraction. While the patient's NYHA Class III status and LVEF of 30.0% indicate severe left ventricular dysfunction, the patient's blood pressure is relatively stable, and the presence of beta blockers in the medication list suggests that measures are being taken to manage heart failure symptoms.

Additionally, the patient's albumin level is slightly elevated (42 g/L), which may indicate some degree of fluid overload, but this is not necessarily indicative of severe heart failure. The patient's troponin levels are also within normal limits, which suggests that there is no acute myocardial infarction.

While pump failure death is always a risk for patients with heart failure, the patient's relatively stable blood pressure and the presence of beta blockers in the medication list suggest that the patient is being adequately managed."
557,557,P0865,"Age: 68
Gender: Male 
Weight: 80 kg
Height: 171 cm
NYHA Class: II
Blood Pressure: 160/85 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Diabetes, Dyslipemia, Peripheral vascular disease, Hypertension, Myocardial Infarction
Albumin (g/L): 40,7
ALT or GPT (IU/L): 14.0
AST or GOT (IU/L): 15.0
Total Cholesterol (mmol/L): 4,65
Creatinine (mmol/L): 101.0
Gamma-glutamil transpeptidase (IU/L): 16
Glucose (mmol/L): 9
Hemoglobin (g/L): 156.0
HDL (mmol/L): 1,06
Potassium (mEq/L): 4,7
LDL (mmol/L): 2,46
Sodium (mEq/L): 145.0
Pro-BNP (ng/L): 1345.0
Protein (g/L): 68,2
T4 (ng/L): 13
TSH (mIU/L): 3,1
Urea (mg/dL): 7,32
LVEF (%): 40.0
Medications: Diabetes Medication, Beta Blockers, Loop Diuretics, Statins, ACE Inhibitor, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"RANKING: 1. Survivor
REASONING: The patient's overall clinical presentation and laboratory results suggest a moderate to advanced stage of heart failure, as indicated by the NYHA Class II classification, elevated creatinine levels (101.0 mmol/L), and low LVEF (40.0%). The presence of ischemic dilated cardiomyopathy, diabetes, and hypertension further exacerbates the patient's cardiac condition. However, the patient's age (68 years) and relatively preserved hemoglobin level (15.6 g/L) suggest that they may still be a candidate for cardiac rehabilitation and management with medications.

The patient's ECG findings of ventricular extrasystole, non-sustained ventricular tachycardia, and non-sustained ventricular tachycardia (CH>10) indicate a high risk for arrhythmic events, but these can often be managed with medication adjustments and cardiac rehabilitation. The absence of paroxysmal supraventricular tachyarrhythmia and bradycardia reduces the likelihood of other arrhythmic complications.

Given the patient's multiple comorbidities and the presence of heart failure, the patient is at a higher risk for cardiac events, but the overall prognosis is still relatively favorable due to the absence of acute myocardial infarction, significant coronary artery disease, or severe left ventricular dysfunction. Therefore, the patient is most likely to survive for the next few years with proper management and monitoring.

RANKING: 2. Sudden cardiac death
REASONING: While the patient's ECG findings suggest a high risk for arrhythmic events, the absence of a clear indication for implantable cardioverter-defibrillator (ICD) placement or other interventions that would reduce this risk makes sudden cardiac death less likely. However, the patient's history of ventricular tachycardia and non-sustained ventricular tachycardia, combined with their advanced heart failure and multiple comorbidities, increase the risk for cardiac events.

RANKING: 3. Pump failure death
REASONING: The patient's heart failure status, as indicated by the NYHA Class II classification and elevated creatinine levels, increases the risk for pump failure. However, the patient's relatively preserved hemoglobin level and absence of severe left ventricular dysfunction suggest that the patient may not be at immediate risk for severe pump failure. Additionally, the patient's current treatment regimen, including beta blockers, ACE inhibitors, and loop diuretics, is generally effective in managing heart failure symptoms and slowing disease progression. Therefore, pump failure is less likely in the short term, but cannot be ruled out without closer monitoring and follow-up."
558,558,P0866,"Age: 76
Gender: Female 
Weight: 73 kg
Height: 150 cm
NYHA Class: II
Blood Pressure: 140/90 mmHg
Past Medical History: Hypertensive cardiomyopathy, Hypertension
Albumin (g/L): 44,1
ALT or GPT (IU/L): 6.0
AST or GOT (IU/L): 11.0
Total Cholesterol (mmol/L): 6,08
Creatinine (mmol/L): 77.0
Gamma-glutamil transpeptidase (IU/L): 13
Glucose (mmol/L): 5,6
Hemoglobin (g/L): 147.0
HDL (mmol/L): 1,76
Potassium (mEq/L): 4,9
LDL (mmol/L): 3,65
Sodium (mEq/L): 141.0
Pro-BNP (ng/L): 306.0
Protein (g/L): 74
T4 (ng/L): 15
TSH (mIU/L): 1
Urea (mg/dL): 5,83
LVEF (%): 49.0
Medications: Beta Blockers, Statins, ACE Inhibitor, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: Second-degree AVB - type I
            ",survivor,"RANKING: 
1. Survivor 
REASONING: 
The patient's age (76) is a significant risk factor for cardiac events. However, the patient's NYHA Class II indicates that they have some symptoms of heart failure, but they are still able to perform daily activities without severe limitation. The presence of hypertension, hypertensive cardiomyopathy, and elevated creatinine levels suggest a chronic condition that has not been adequately controlled. The elevated Pro-BNP level (306.0 ng/L) indicates increased ventricular stress, but it is not extremely high, which might suggest that the patient's heart is not in imminent danger. The patient's LVEF is 49.0%, which is significantly reduced, indicating left ventricular dysfunction. The patient's ECG findings, including ventricular extrasystole and second-degree AVB, are concerning for arrhythmias. Despite these findings, the patient is currently taking multiple medications for their cardiac condition, including beta blockers, statins, ACE inhibitors, and a nitrovasodilator. The presence of these medications suggests that the patient is receiving adequate management for their condition. 

Considering these factors, the patient's overall prognosis is that they will survive the next few years, but they will likely require close monitoring and adjustments to their medication regimen to manage their cardiac condition effectively. The patient's survival is more likely than the other two options because they are not in immediate danger and have a relatively controlled condition, despite the presence of significant risk factors."
559,559,P0867,"Age: 73
Gender: Female 
Weight: 82 kg
Height: 161 cm
NYHA Class: II
Blood Pressure: 100/60 mmHg
Past Medical History: Hypertensive cardiomyopathy, Diabetes, Dyslipemia, Hypertension
Albumin (g/L): 39
ALT or GPT (IU/L): 15.0
AST or GOT (IU/L): 12.0
Total Cholesterol (mmol/L): 5,25
Creatinine (mmol/L): 159.0
Gamma-glutamil transpeptidase (IU/L): 35
Glucose (mmol/L): 10,8
Hemoglobin (g/L): 128.0
HDL (mmol/L): 1,09
Potassium (mEq/L): 4,22
LDL (mmol/L): 3,13
Sodium (mEq/L): 140.0
Protein (g/L): 68
T3 (pg/dL): 0,0438
T4 (ng/L): 18,54
Troponin (ng/mL): 0,4
TSH (mIU/L): 0,92
Urea (mg/dL): 16,9
LVEF (%): 70.0
Medications: Diabetes Medication, Loop Diuretics, Statins, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: TPSV
        - Bradycardia: No
            ",survivor,"RANKING: 1. Survivor
REASONING: 

Based on the provided patient data, I would rank the patient's prognosis as a survivor. The patient's age, NYHA Class II indicates that the patient has some limitations in physical activity but can still perform daily activities with some symptoms. The patient's LVEF of 70.0 suggests that the left ventricle is functioning relatively well, which is a positive prognostic factor.

The patient's laboratory results show that the liver function tests are within normal limits, and the troponin level is within the normal range, which suggests that there is no acute myocardial infarction. The patient's creatinine level is slightly elevated, but it is not indicative of severe kidney dysfunction.

The patient's ECG impression shows a few abnormal findings, including ventricular extrasystole and paroxysmal supraventricular tachycardia (PSVT). However, these findings are not indicative of severe cardiac dysfunction. The absence of ventricular tachycardia and non-sustained ventricular tachycardia (CH>10) is also a positive prognostic sign.

The patient's medication regimen, including diabetes medication, loop diuretics, statins, and ACE inhibitor, suggests that the patient is receiving appropriate management for their comorbid conditions.

Overall, considering the patient's relatively preserved cardiac function, absence of severe kidney dysfunction, and the absence of acute myocardial infarction, I believe that the patient has a high likelihood of survival over the next few years.

RANKING: 2. Pump failure death
REASONING: 

While the patient's LVEF is relatively preserved, the patient's creatinine level is elevated, which may indicate some degree of kidney dysfunction. This could potentially lead to cardiac pump failure if the kidneys are not functioning properly.

RANKING: 3. Sudden cardiac death
REASONING: 

The patient's ECG impression shows ventricular extrasystole, which is a risk factor for sudden cardiac death. Additionally, the patient's age and NYHA Class II indicate that the patient may have underlying cardiac disease that could potentially lead to sudden cardiac death. However, the absence of other high-risk features, such as ventricular tachycardia or non-sustained ventricular tachycardia, reduces the likelihood of sudden cardiac death."
560,560,P0868,"Age: 75
Gender: Male 
Weight: 82 kg
Height: 170 cm
NYHA Class: II
Blood Pressure: 140/90 mmHg
Past Medical History: Hypertensive cardiomyopathy
Albumin (g/L): 39,4
ALT or GPT (IU/L): 14.0
AST or GOT (IU/L): 13.0
Total Cholesterol (mmol/L): 5,4
Creatinine (mmol/L): 106.0
Gamma-glutamil transpeptidase (IU/L): 83
Glucose (mmol/L): 5,4
Hemoglobin (g/L): 140.0
HDL (mmol/L): 0,72
Potassium (mEq/L): 4,6
LDL (mmol/L): 3,21
Sodium (mEq/L): 142.0
Pro-BNP (ng/L): 173.0
Protein (g/L): 67,4
T4 (ng/L): 16
TSH (mIU/L): 0,6
Urea (mg/dL): 4,99
LVEF (%): 53.0
Medications: Spironolactone, Statins, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: TPSV
        - Bradycardia: No
            ",survivor,"RANKING: 1. Survivor
REASONING:

Based on the patient's data, the most likely prognosis is survivor. Here's why:

1. Age: The patient is 75 years old, which is a common age for cardiac issues, but not necessarily a contraindication for survival with proper management.
2. NYHA Class II: This indicates that the patient has some limitations in physical activity due to heart failure, but it's not severe. This suggests that the patient is not in a critical stage of heart failure.
3. Blood pressure: The patient's blood pressure is elevated, which is a risk factor for cardiovascular disease. However, the patient is already on an ACE inhibitor, which is a common treatment for hypertension and heart failure.
4. Creatinine level: The patient's creatinine level is elevated, indicating some degree of kidney dysfunction, which can be related to heart failure or hypertension. However, this is not a contraindication for survival.
5. LVEF: The left ventricular ejection fraction (LVEF) is 53%, which is below the normal range (55-70%). This indicates some degree of left ventricular dysfunction, but it's not severely impaired.
6. Pro-BNP: The patient's Pro-BNP level is elevated, indicating some degree of cardiac stress. However, it's not extremely high, which suggests that the patient may still have some reserve.
7. Medications: The patient is on spironolactone, statins, and an ACE inhibitor, which are all standard treatments for hypertension, heart failure, and cholesterol management.
8. ECG Impression: The patient has ventricular extrasystole, which is a benign finding. There are no other significant arrhythmias or signs of cardiac ischemia.

While the patient has several risk factors and some cardiac dysfunction, the overall picture suggests that the patient can be managed with current treatments and lifestyle modifications. Therefore, the most likely prognosis is survivor.

The other two prognoses, sudden cardiac death and pump failure death, are less likely because:

* Sudden cardiac death is unlikely due to the patient's stable ECG and absence of any other risk factors.
* Pump failure death is unlikely due to the patient's relatively preserved LVEF and the presence of current medications and lifestyle modifications that can help manage heart failure.

However, it's essential to closely monitor the patient's condition and adjust the treatment plan as needed to ensure the best possible outcome."
561,561,P0871,"Age: 53
Gender: Male 
Weight: 96 kg
Height: 175 cm
NYHA Class: III
Blood Pressure: 110/50 mmHg
Past Medical History: Idiopathic dilated cardiomyopathy, Dyslipemia, Hypertension
Albumin (g/L): 50
ALT or GPT (IU/L): 20.0
AST or GOT (IU/L): 27.0
Total Cholesterol (mmol/L): 6,1
Creatinine (mmol/L): 115.0
Gamma-glutamil transpeptidase (IU/L): 16
Glucose (mmol/L): 4,8
Hemoglobin (g/L): 147.0
HDL (mmol/L): 0,98
Potassium (mEq/L): 5
LDL (mmol/L): 4,14
Sodium (mEq/L): 137.0
Pro-BNP (ng/L): 1195.0
Protein (g/L): 84
T3 (pg/dL): 0,05
T4 (ng/L): 14
Troponin (ng/mL): 0,13
TSH (mIU/L): 1,2
Urea (mg/dL): 12,31
LVEF (%): 39.0
Medications: Beta Blockers, Loop Diuretics, Spironolactone, Statins, ACE Inhibitor, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"RANKING: 

1. Survivor
REASONING: 
The patient has a history of idiopathic dilated cardiomyopathy, which is a condition where the heart's ability to pump blood is severely impaired. Despite this, the patient is currently taking medications that are commonly used to manage heart failure, such as beta blockers, loop diuretics, spironolactone, statins, ACE inhibitors, and a nitrovasodilator. The patient's current NYHA class is III, indicating moderate symptoms of heart failure.

The patient's ejection fraction (LVEF) is 39.0%, which is significantly reduced, indicating severe impairment of the heart's pumping function. However, the patient's creatinine level is not excessively high, and the patient's kidney function is not severely impaired. The patient's blood pressure is also relatively well-controlled, with a systolic pressure of 110 mmHg.

The patient's electrolyte levels, including potassium, sodium, and troponin, are not excessively abnormal, which suggests that the patient is not experiencing acute cardiac stress or injury. The patient's liver function tests are also relatively normal, with only a slightly elevated ALT level.

The patient's ECG shows no signs of ventricular tachycardia or non-sustained ventricular tachycardia, which are both significant predictors of cardiac arrhythmia and sudden cardiac death. The presence of ventricular extrasystole is a benign finding that can be seen in patients with various cardiac conditions.

Given these factors, the patient's overall prognosis is relatively good, and the likelihood of survival over the next few years is high. 

2. Sudden cardiac death
REASONING: 
While the patient has a history of idiopathic dilated cardiomyopathy, the patient's current condition does not suggest an acute or severe cardiac event that would increase the risk of sudden cardiac death. The patient's ECG does not show any signs of ventricular tachycardia or non-sustained ventricular tachycardia, and the patient's troponin level is not elevated.

However, the patient's LVEF is significantly reduced, which increases the risk of arrhythmias and sudden cardiac death. The patient's NYHA class is also III, indicating moderate symptoms of heart failure, which may increase the risk of cardiac events.

3. Pump failure death
REASONING: 
The patient's current condition is not indicative of pump failure, as the patient is taking medications that are commonly used to manage heart failure, and the patient's NYHA class is III. While the patient's LVEF is significantly reduced, the patient's creatinine level is not excessively high, and the patient's kidney function is not severely impaired.

The patient's electrolyte levels, including potassium, sodium, and troponin, are not excessively abnormal, which suggests that the patient is not experiencing acute cardiac stress or injury. The patient's liver function tests are also relatively normal, with only a slightly elevated ALT level.

However, the patient's protein level is slightly elevated, which may indicate some degree of liver dysfunction or malnutrition. The patient's T3 level is also low, which may indicate hypothyroidism, which can be associated with heart failure. These factors may increase the risk of pump failure, but the patient's overall condition does not suggest an acute or severe cardiac event that would increase the risk of pump failure."
562,562,P0874,"Age: 42
Gender: Male 
Weight: 90 kg
Height: 176 cm
NYHA Class: III
Blood Pressure: 100/80 mmHg
Past Medical History: Post-myocardial dilated cardiomyopathy, Diabetes
Albumin (g/L): 48
ALT or GPT (IU/L): 29.0
AST or GOT (IU/L): 15.0
Total Cholesterol (mmol/L): 3,98
Creatinine (mmol/L): 82.0
Gamma-glutamil transpeptidase (IU/L): 53
Glucose (mmol/L): 7,4
Hemoglobin (g/L): 143.0
HDL (mmol/L): 1,09
Potassium (mEq/L): 4,6
LDL (mmol/L): 1,58
Sodium (mEq/L): 137.0
Pro-BNP (ng/L): 100.0
Protein (g/L): 77
T3 (pg/dL): 0,05
T4 (ng/L): 17
Troponin (ng/mL): 0,005
TSH (mIU/L): 2,13
Urea (mg/dL): 7,49
LVEF (%): 18.0
Medications: Diabetes Medication, Beta Blockers, Digoxin, Loop Diuretics, Spironolactone, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"RANKING: 
1. Survivor
REASONING: 
The patient's LVEF (Left Ventricular Ejection Fraction) is significantly reduced at 18%, indicating severe left ventricular dysfunction. This is a critical factor in determining the patient's prognosis. Given the patient's NYHA Class III classification, which signifies severe symptoms of heart failure, and the presence of post-myocardial dilated cardiomyopathy, the patient is already at high risk for adverse outcomes. The patient's age, weight, and other laboratory values (e.g., elevated creatinine and BNP levels) further support the severity of the disease.

The patient's medication regimen includes ACE inhibitors, beta-blockers, and diuretics, which are standard treatments for heart failure. However, the presence of ventricular extrasystoles (polymorphic) on the ECG suggests an increased risk of arrhythmias, which can be a complication in patients with heart failure. Despite this, the patient's overall clinical presentation and laboratory values do not indicate an immediate life-threatening condition.

In contrast, the other two prognoses (sudden cardiac death and pump failure death) would typically require more severe symptoms or laboratory values, such as a higher troponin level or more significant signs of cardiac ischemia. The patient's current values do not meet these criteria.

Therefore, based on the provided data, the most likely outcome for this patient is survival."
563,563,P0875,"Age: 79
Gender: Female 
Weight: 70 kg
Height: 155 cm
NYHA Class: III
Blood Pressure: 100/60 mmHg
Past Medical History: Idiopathic dilated cardiomyopathy, Diabetes, Dyslipemia, Hypertension
Albumin (g/L): 45
ALT or GPT (IU/L): 25.0
AST or GOT (IU/L): 30.0
Total Cholesterol (mmol/L): 3,23
Creatinine (mmol/L): 80.0
Gamma-glutamil transpeptidase (IU/L): 20
Glucose (mmol/L): 9,6
Hemoglobin (g/L): 131.0
HDL (mmol/L): 1,03
Potassium (mEq/L): 4,6
LDL (mmol/L): 1,68
Sodium (mEq/L): 139.0
Pro-BNP (ng/L): 1588.0
Protein (g/L): 70
T3 (pg/dL): 0,02
T4 (ng/L): 23
Troponin (ng/mL): 0,13
TSH (mIU/L): 1,34
Urea (mg/dL): 8,65
LVEF (%): 35.0
Medications: Diabetes Medication, Beta Blockers, Digoxin, Loop Diuretics, Statins, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",survivor,"RANKING: 
1. Survivor 
REASONING: 
Based on the provided patient data, the patient is a 79-year-old female with a history of idiopathic dilated cardiomyopathy, diabetes, dyslipidemia, and hypertension. The patient's LVEF is 35.0%, which is significantly reduced, indicating severe left ventricular dysfunction. The presence of NYHA Class III symptoms suggests that the patient experiences symptoms such as shortness of breath, fatigue, and swelling, which are indicative of advanced heart failure.

The patient's biomarkers, such as elevated Pro-BNP levels (1588.0 ng/L) and creatinine (8.65 mg/dL), further support the diagnosis of heart failure. The patient's low LVEF and elevated biomarkers suggest that the patient's heart is not pumping efficiently, which increases the risk of cardiac events.

The patient's ECG findings, including ventricular extrasystole and non-sustained ventricular tachycardia, are concerning for an increased risk of cardiac arrhythmias. However, the absence of sustained ventricular tachycardia and bradycardia codes suggests that the patient does not have a high risk of life-threatening arrhythmias.

Given the patient's severe heart failure, reduced LVEF, and elevated biomarkers, the most likely outcome is that the patient will survive. The patient's age, weight, and comorbidities also suggest that the patient is at increased risk of complications, but the patient's current medical management, including beta blockers, digoxin, and loop diuretics, suggests that the patient is receiving optimal treatment for heart failure.

Therefore, based on the provided data, I predict that the patient will survive, but with a high risk of complications, including hospitalization for heart failure exacerbation, arrhythmias, and cardiac arrest."
564,564,P0876,"Age: 70
Gender: Female 
Weight: 74 kg
Height: 155 cm
NYHA Class: II
Blood Pressure: 160/80 mmHg
Past Medical History: Hypertensive cardiomyopathy, Diabetes, Hypertension
Albumin (g/L): 45
ALT or GPT (IU/L): 25.0
AST or GOT (IU/L): 23.0
Total Cholesterol (mmol/L): 5,48
Creatinine (mmol/L): 66.0
Gamma-glutamil transpeptidase (IU/L): 37
Glucose (mmol/L): 3,1
Hemoglobin (g/L): 140.0
HDL (mmol/L): 1,45
Potassium (mEq/L): 3,95
LDL (mmol/L): 3,31
Sodium (mEq/L): 142.0
Protein (g/L): 74,5
T3 (pg/dL): 0,0636
T4 (ng/L): 13,7
Troponin (ng/mL): 0,5
TSH (mIU/L): 1,86
Urea (mg/dL): 5,9
LVEF (%): 70.0
Medications: Calcium Channel Blocker, Diabetes Medication
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: TPSV
        - Bradycardia: No
            ",survivor,"RANKING: 1. Survivor
REASONING: 

Based on the provided patient data, the patient is a 70-year-old female with a history of hypertension, cardiomyopathy, and diabetes. The patient's NYHA Class II indicates that they have some limitations in physical activity due to their heart condition, but they are still able to perform daily activities with some difficulty. The patient's blood pressure is elevated at 160/80 mmHg, which is a concern given their history of hypertension.

The patient's laboratory results show elevated creatinine levels (66.0 mmol/L) and urea levels (5.9 mg/dL), indicating impaired renal function. However, the patient's kidney function is not severely impaired, and they are still able to maintain a relatively normal hemoglobin level (140.0 g/L).

The patient's ECG shows a ventricular extrasystole, which is a common finding in patients with cardiomyopathy. However, the absence of ventricular tachycardia, non-sustained ventricular tachycardia, and paroxysmal supraventricular tachyarrhythmia reduces the risk of sudden cardiac death.

The patient's lipid profile is not optimal, with elevated total cholesterol (5.48 mmol/L) and LDL cholesterol (3.31 mmol/L). However, the patient is taking a calcium channel blocker, which can help to lower blood pressure and reduce the risk of cardiovascular events.

Given these factors, the patient is likely to survive for at least the next few years, with a reasonable quality of life despite their cardiac limitations. However, regular monitoring and adjustments to their medication regimen may be necessary to manage their hypertension and prevent further cardiovascular complications.

RANKING 2: Sudden Cardiac Death
REASONING: 

While the patient's ECG shows a ventricular extrasystole, which is a concern, the absence of ventricular tachycardia and other arrhythmias reduces the risk of sudden cardiac death. However, the patient's history of cardiomyopathy and hypertension increases the risk of cardiac events.

The patient's impaired renal function and elevated blood pressure also increase the risk of cardiovascular events. Additionally, the patient's lipid profile is not optimal, which can contribute to the development of atherosclerosis and increase the risk of cardiovascular events.

While the patient is taking a calcium channel blocker, which can help to lower blood pressure, the risk of sudden cardiac death cannot be entirely ruled out, especially in the presence of underlying cardiac disease.

RANKING 3: Pump Failure Death
REASONING: 

The patient's LVEF (70.0%) is within the normal range, which suggests that the patient's heart is still functioning relatively well. However, the patient's history of cardiomyopathy and hypertension increases the risk of heart failure.

The patient's elevated creatinine levels (66.0 mmol/L) and urea levels (5.9 mg/dL) indicate impaired renal function, which can be a sign of heart failure. Additionally, the patient's elevated blood pressure and impaired renal function can lead to fluid overload and pulmonary congestion, which can increase the risk of heart failure.

While the patient is taking a calcium channel blocker, which can help to lower blood pressure, the risk of pump failure cannot be entirely ruled out, especially in the presence of underlying cardiac disease.

Overall, while the patient is likely to survive for at least the next few years, the risk of pump failure is a concern, and regular monitoring and adjustments to their medication regimen may be necessary to manage their cardiac limitations."
565,565,P0877,"Age: 60
Gender: Female 
Weight: 74 kg
Height: 163 cm
NYHA Class: II
Blood Pressure: 110/60 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Diabetes, Dyslipemia, Myocardial Infarction
Albumin (g/L): 41
ALT or GPT (IU/L): 15.0
AST or GOT (IU/L): 15.0
Total Cholesterol (mmol/L): 4,29
Creatinine (mmol/L): 71.0
Gamma-glutamil transpeptidase (IU/L): 15
Glucose (mmol/L): 8,4
Hemoglobin (g/L): 135.0
HDL (mmol/L): 0,83
Potassium (mEq/L): 4,4
LDL (mmol/L): 2,38
Sodium (mEq/L): 140.0
Pro-BNP (ng/L): 593.0
Protein (g/L): 65
T4 (ng/L): 13
Troponin (ng/mL): 0,01
TSH (mIU/L): 2,84
Urea (mg/dL): 6,16
LVEF (%): 15.0
Medications: Beta Blockers, Digoxin, Loop Diuretics, Spironolactone, Statins, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",survivor,"RANKING: 1. Survivor
REASONING: 

The patient is a 60-year-old female with a history of ischemic dilated cardiomyopathy, diabetes, dyslipemia, and myocardial infarction. She has a current NYHA Class II, indicating moderate symptoms of heart failure. Her LVEF is significantly reduced at 15%, which is a strong indicator of poor cardiac function.

Despite having multiple comorbidities, the patient's current ECG impression shows polymorphic ventricular extrasystoles and non-sustained ventricular tachycardia, which could be indicative of an increased risk of arrhythmias. However, the presence of beta blockers, digoxin, and an ACE inhibitor suggests that the patient is receiving appropriate management for heart failure and arrhythmias.

The patient's laboratory results are also notable for elevated creatinine levels, indicating some degree of kidney dysfunction, but not severe. The Pro-BNP level is elevated, suggesting some degree of ventricular stress.

Considering these factors, the patient's overall prognosis is that she is likely to survive in the short term. The presence of heart failure, arrhythmias, and reduced LVEF may suggest a higher risk of adverse outcomes, but the patient's current management and the absence of other severe comorbidities make it more likely that she will survive.

RANKING: 2. Sudden Cardiac Death
REASONING: 

This ranking is lower than the first due to the patient's current management and the presence of some protective factors, such as beta blockers and an ACE inhibitor.

RANKING: 3. Pump Failure Death
REASONING: 

This ranking is the lowest due to the patient's current management and the presence of some protective factors, such as beta blockers, digoxin, and an ACE inhibitor, which are aimed at reducing the risk of heart failure and arrhythmias. Additionally, the patient's LVEF is not severely reduced, and the absence of other severe comorbidities makes pump failure death less likely. However, the patient's reduced LVEF, elevated creatinine levels, and the presence of ventricular arrhythmias on the ECG do suggest a higher risk of heart failure and arrhythmias, making pump failure death a possible but less likely outcome compared to sudden cardiac death."
566,566,P0878,"Age: 57
Gender: Male 
Weight: 62 kg
Height: 165 cm
NYHA Class: II
Blood Pressure: 140/90 mmHg
Past Medical History: Ischemic dilated cardiomyopathy
Albumin (g/L): 38,5
ALT or GPT (IU/L): 8.0
AST or GOT (IU/L): 16.0
Total Cholesterol (mmol/L): 6,08
Creatinine (mmol/L): 212.0
Gamma-glutamil transpeptidase (IU/L): 29
Glucose (mmol/L): 5,1
Hemoglobin (g/L): 124.0
HDL (mmol/L): 1,06
Potassium (mEq/L): 5,2
LDL (mmol/L): 3,8
Sodium (mEq/L): 144.0
Pro-BNP (ng/L): 6606.0
Protein (g/L): 68,4
T4 (ng/L): 16
TSH (mIU/L): 3,87
Urea (mg/dL): 19,8
LVEF (%): 40.0
Medications: Angiotensin II Receptor Blocker, Beta Blockers, Loop Diuretics
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"RANKING: 1. Survivor
REASONING: 
Given the patient's age, NYHA Class II, and past medical history of ischemic dilated cardiomyopathy, the patient is already at an increased risk for cardiac-related complications. The elevated creatinine level (212.0 mmol/L) and low LVEF (40.0%) suggest significant cardiac dysfunction. The presence of ventricular extrasystole, non-sustained ventricular tachycardia, and non-sustained ventricular tachycardia (CH>10) on ECG also indicate an increased risk for arrhythmias. However, the patient is currently taking medications for heart failure and hypertension, which suggests that the patient is receiving appropriate management for their condition.

The elevated Pro-BNP level (6606.0 ng/L) also suggests that the patient has a significant level of cardiac stress, but the patient's overall prognosis can be improved with proper management and monitoring. 

The patient's biomarkers such as ALT and AST are within normal limits, and the patient's electrolytes are within normal limits. The patient's hemoglobin and HDL levels are also within normal limits. Therefore, the patient's prognosis is more likely to be a survivor with close monitoring and adjustments to their medication regimen.

RANKING: 2. Sudden Cardiac Death
REASONING: 
Although the patient is at an increased risk for cardiac complications, the patient's age, NYHA Class II, and past medical history of ischemic dilated cardiomyopathy do not necessarily indicate a high risk for sudden cardiac death. The patient's LVEF is 40.0%, which is significantly reduced, but the patient is receiving medications for heart failure and hypertension.

However, the presence of ventricular extrasystole and non-sustained ventricular tachycardia on ECG does increase the risk for arrhythmias, which can potentially lead to sudden cardiac death. The elevated Pro-BNP level (6606.0 ng/L) also suggests that the patient has a significant level of cardiac stress.

Given the patient's current medication regimen, close monitoring, and the patient's overall health status, the risk for sudden cardiac death is moderate.

RANKING: 3. Pump Failure Death
REASONING: 
The patient's NYHA Class II and elevated Pro-BNP level (6606.0 ng/L) suggest that the patient has significant heart failure symptoms. The patient's LVEF is 40.0%, which is significantly reduced, and the patient's creatinine level (212.0 mmol/L) is elevated, indicating impaired renal function.

The patient's past medical history of ischemic dilated cardiomyopathy and current medication regimen for heart failure and hypertension suggest that the patient is at risk for worsening heart failure. The patient's ventricular extrasystole and non-sustained ventricular tachycardia on ECG also increase the risk for cardiac complications.

Given the patient's overall health status and current medication regimen, the risk for pump failure death is moderate to high."
567,567,P0879,"Age: 71
Gender: Male 
Weight: 67 kg
Height: 171 cm
NYHA Class: II
Blood Pressure: 130/90 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Myocardial Infarction
Albumin (g/L): 40
ALT or GPT (IU/L): 16.0
AST or GOT (IU/L): 17.0
Total Cholesterol (mmol/L): 3,7
Creatinine (mmol/L): 97.0
Gamma-glutamil transpeptidase (IU/L): 8
Glucose (mmol/L): 5,1
Hemoglobin (g/L): 132.0
HDL (mmol/L): 1,06
Potassium (mEq/L): 4,1
LDL (mmol/L): 2,25
Sodium (mEq/L): 143.0
Pro-BNP (ng/L): 304.0
Protein (g/L): 63
T4 (ng/L): 15
Troponin (ng/mL): 0,01
TSH (mIU/L): 2,38
Urea (mg/dL): 8,32
LVEF (%): 50.0
Medications: Beta Blockers, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"RANKING: 
1. Survivor
REASONING:
Based on the provided patient data, I predict that the patient is likely to survive for the next few years. The patient's age is 71, but their LVEF is 50%, which is relatively preserved for someone of this age group. The patient's NYHA Class is II, indicating mild symptoms of heart failure. The patient is also on beta blockers and ACE inhibitors, which are standard treatments for heart failure and ischemic cardiomyopathy. 

Additionally, the patient's electrolytes, liver enzymes, and renal function appear to be within normal limits. The patient's troponin levels are normal, which suggests that there is no active myocardial infarction. The patient's ECG findings do not indicate any life-threatening arrhythmias. 

The patient's Pro-BNP levels are elevated, which is consistent with heart failure. However, the patient is on medications that are effective in managing heart failure, and the patient's symptoms are mild. Overall, the combination of preserved LVEF, mild symptoms, and effective treatment suggests that the patient is likely to survive for the next few years.

2. Sudden Cardiac Death
REASONING:
I would consider sudden cardiac death as a possible outcome if the patient's condition were to deteriorate. However, the patient's current data does not suggest a high risk for sudden cardiac death. The patient's LVEF is relatively preserved, and the patient is on beta blockers and ACE inhibitors, which are effective in reducing the risk of sudden cardiac death. The patient's ECG findings do not indicate any life-threatening arrhythmias.

However, if the patient were to experience a significant increase in symptoms or a worsening of their heart failure, the risk of sudden cardiac death could increase. Additionally, if the patient were to develop a new arrhythmia or experience a myocardial infarction, the risk of sudden cardiac death would also increase.

3. Pump Failure Death
REASONING:
I would consider pump failure death as a possible outcome if the patient's heart failure were to worsen significantly. However, the patient's current data suggests that their heart failure is mild, and the patient is on effective medications that are designed to manage heart failure. The patient's LVEF is relatively preserved, and the patient's symptoms are mild.

While it is possible that the patient's heart failure could worsen over time, the patient's current treatment plan and relatively preserved LVEF suggest that the risk of pump failure death is lower compared to sudden cardiac death."
568,568,P0883,"Age: 66
Gender: Female 
Weight: 62 kg
Height: 161 cm
NYHA Class: II
Blood Pressure: 170/90 mmHg
Past Medical History: Hypertensive cardiomyopathy, Hypertension
Albumin (g/L): 40
ALT or GPT (IU/L): 38.0
AST or GOT (IU/L): 17.0
Total Cholesterol (mmol/L): 5,69
Creatinine (mmol/L): 62.0
Gamma-glutamil transpeptidase (IU/L): 17
Glucose (mmol/L): 5,9
Hemoglobin (g/L): 132.0
HDL (mmol/L): 1,01
Potassium (mEq/L): 4,7
LDL (mmol/L): 3,49
Sodium (mEq/L): 139.0
Pro-BNP (ng/L): 325.0
Protein (g/L): 76
T4 (ng/L): 12
Troponin (ng/mL): 0,01
TSH (mIU/L): 4
Urea (mg/dL): 5,66
LVEF (%): 64.0
Medications: Angiotensin II Receptor Blocker, Beta Blockers, Loop Diuretics
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: Unknown ventricular tachycardia code
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"RANKING: 
1. Survivor
REASONING: 
Based on the provided patient data, the patient is 66 years old, with a history of hypertension and hypertensive cardiomyopathy, which are both significant risk factors for cardiovascular disease. The patient's NYHA Class II indicates that they have some limitations in physical activity due to heart disease, but they are still able to perform daily activities with some difficulty.

The patient's laboratory results show elevated creatinine levels (62.0 mmol/L), which indicates impaired kidney function, a common complication of chronic hypertension and cardiomyopathy. However, the patient's troponin level (0.01 ng/mL) is within the normal range, suggesting that there is no acute myocardial infarction.

The patient's LVEF (64.0%) is slightly below the normal range, which may indicate some left ventricular dysfunction. However, the patient's ECG results show no signs of ventricular tachycardia or ventricular fibrillation, which are common causes of sudden cardiac death.

The patient is on medications that are commonly used to treat hypertension and heart failure, which suggests that they are receiving appropriate management for their condition. The patient's Pro-BNP level (325.0 ng/L) is elevated, which indicates some degree of ventricular dysfunction, but it is not extremely high, suggesting that the patient's condition is not in acute crisis.

Considering these factors, the patient's overall prognosis is more likely to be a survivor, with a moderate risk of complications. The patient's elevated creatinine levels and slightly reduced LVEF suggest some degree of cardiovascular disease, but the absence of acute myocardial infarction, ventricular tachycardia, or other life-threatening arrhythmias suggests that the patient is not at high risk for sudden cardiac death. The patient's current management and medication regimen also suggest that they are receiving appropriate care for their condition, which further supports a favorable prognosis.

While there is a possibility of pump failure, the patient's LVEF is not severely reduced, and the patient is on medications that can help manage heart failure symptoms. Therefore, the likelihood of pump failure death is moderate, but not the most likely outcome.

The likelihood of sudden cardiac death is the lowest, given the absence of ventricular tachycardia or other life-threatening arrhythmias on the ECG, and the patient's stable clinical status."
569,569,P0885,"Age: 59
Gender: Male 
Weight: 100 kg
Height: 170 cm
NYHA Class: II
Blood Pressure: 130/80 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Dyslipemia, Hypertension, Myocardial Infarction
Albumin (g/L): 42
ALT or GPT (IU/L): 26.0
AST or GOT (IU/L): 19.0
Total Cholesterol (mmol/L): 3,65
Creatinine (mmol/L): 74.0
Gamma-glutamil transpeptidase (IU/L): 24
Glucose (mmol/L): 5,3
Hemoglobin (g/L): 156.0
HDL (mmol/L): 0,83
Potassium (mEq/L): 4,1
LDL (mmol/L): 2,2
Sodium (mEq/L): 140.0
Pro-BNP (ng/L): 105.0
Protein (g/L): 68
T4 (ng/L): 18
Troponin (ng/mL): 0,01
TSH (mIU/L): 1,03
Urea (mg/dL): 4,99
LVEF (%): 33.0
Medications: Beta Blockers, Statins, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"RANKING: 1. Survivor
REASONING:

Based on the provided patient data, I predict that the patient is most likely to be a survivor for the next few years. The patient has a history of ischemic dilated cardiomyopathy, which is a significant risk factor for adverse cardiac events. However, the patient is currently being treated with beta blockers, statins, and an ACE inhibitor, which are standard therapies for managing heart failure and reducing cardiovascular risk.

The patient's NYHA Class II indicates that they have some limitation in physical activity due to heart failure, but it is not severe. The patient's LVEF of 33% is also concerning, indicating significant left ventricular dysfunction. However, the patient's current medication regimen is well-established and has been shown to improve outcomes in patients with heart failure.

The patient's biomarkers, such as troponin and BNP, are not significantly elevated, which suggests that the patient is not currently experiencing acute cardiac stress or significant cardiac injury. The patient's lipid profile and renal function are also within acceptable limits, which reduces the risk of further cardiovascular events.

The ECG findings of ventricular extrasystole and polymorphic ventricular tachycardia are concerning, but they are not indicative of a high-risk arrhythmia. The patient's potassium level is within normal limits, which reduces the risk of arrhythmias.

Overall, while the patient has a significant history of cardiovascular disease, their current clinical presentation and treatment regimen suggest that they are at lower risk for adverse cardiac events. Therefore, I predict that the patient is most likely to be a survivor for the next few years.

RANKING: 2. Sudden cardiac death
REASONING:

While the patient is unlikely to die suddenly in the short term, I predict that sudden cardiac death is a possible risk for the patient in the next few years. The patient's history of ischemic dilated cardiomyopathy and significant left ventricular dysfunction increase the risk of sudden cardiac death.

The patient's LVEF of 33% is a significant concern, as it indicates that the left ventricle is not functioning efficiently. This can lead to reduced cardiac output, which can increase the risk of sudden cardiac death.

The patient's biomarkers, such as troponin, are not significantly elevated, but the patient's BNP level is elevated, which suggests some degree of cardiac stress. The patient's lipid profile and renal function are also within acceptable limits, but the patient's hypertension and dyslipidemia are not well-controlled, which can increase the risk of cardiovascular events.

The ECG findings of ventricular extrasystole and polymorphic ventricular tachycardia are concerning, and the patient's potassium level is slightly elevated, which can increase the risk of arrhythmias.

RANKING: 3. Pump failure death
REASONING:

I predict that pump failure death is the least likely outcome for the patient in the next few years. While the patient has a significant history of cardiovascular disease and current heart failure, their current clinical presentation and treatment regimen suggest that they are not at high risk for pump failure.

The patient's LVEF of 33% is concerning, but the patient is being treated with beta blockers, statins, and an ACE inhibitor, which are standard therapies for managing heart failure. The patient's biomarkers, such as troponin and BNP, are not significantly elevated, which suggests that the patient is not currently experiencing acute cardiac stress or significant cardiac injury.

The patient's lipid profile and renal function are within acceptable limits, and the patient's hypertension and dyslipidemia are not well-controlled, but the patient is being treated with medications to manage these conditions. The patient's ECG findings are not indicative of a high-risk arrhythmia, and the patient's potassium level is within normal limits.

Overall, while the patient has a significant history of cardiovascular disease, their current clinical presentation and treatment regimen suggest that they are at lower risk for pump failure. However, it is essential to closely monitor the patient's condition and adjust their treatment regimen as needed to minimize the risk of cardiovascular events."
570,570,P0886,"Age: 75
Gender: Male 
Weight: 60 kg
Height: 160 cm
NYHA Class: II
Blood Pressure: 115/55 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Dyslipemia, Hypertension, Myocardial Infarction
Albumin (g/L): 39
ALT or GPT (IU/L): 6.0
AST or GOT (IU/L): 11.0
Total Cholesterol (mmol/L): 3,15
Creatinine (mmol/L): 88.0
Gamma-glutamil transpeptidase (IU/L): 12
Glucose (mmol/L): 5,5
Hemoglobin (g/L): 140.0
HDL (mmol/L): 0,75
Potassium (mEq/L): 4,4
LDL (mmol/L): 1,91
Sodium (mEq/L): 139.0
Pro-BNP (ng/L): 1186.0
Protein (g/L): 66
T4 (ng/L): 18
Troponin (ng/mL): 0,01
TSH (mIU/L): 1,4
Urea (mg/dL): 10,15
LVEF (%): 20.0
Medications: Beta Blockers, Statins, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"RANKING: 1. Survivor
REASONING:

The patient's overall clinical presentation and test results suggest a high likelihood of survival over the next few years. The patient's age is 75, but the presence of a pacemaker (implied by the ECG impression of ventricular extrasystole and non-sustained ventricular tachycardia) and the use of beta blockers, which are often used to manage ventricular arrhythmias, indicate a relatively stable cardiovascular status.

The patient's NYHA Class II heart failure classification suggests that they have some degree of heart failure, but it is not severe. The LVEF (left ventricular ejection fraction) is 20%, which is a relatively preserved value, indicating that the heart is still pumping relatively well. The patient's creatinine level is also within a relatively normal range, suggesting that kidney function is preserved.

The patient's laboratory results show a slightly elevated troponin level, but it is not significantly elevated, and the patient has not experienced a myocardial infarction in the recent past. The presence of elevated BNP levels indicates some degree of heart failure, but it is not excessively high.

The patient's lipid profile is relatively good, with a low LDL level, and the patient is taking statins and an ACE inhibitor, which are both important for managing cardiovascular risk factors.

Overall, while the patient has a history of cardiovascular disease, their current clinical presentation and test results suggest that they are relatively stable, and their cardiovascular risk factors are being well-managed. Therefore, the most likely prognosis is that the patient will survive over the next few years.

The patient's ECG impression of ventricular extrasystole and non-sustained ventricular tachycardia may indicate some degree of cardiac instability, but the presence of a pacemaker and the use of beta blockers suggest that this is being managed. The patient's ECG impression of polymorphic ventricular extrasystole is not particularly concerning, as it is a relatively common finding in patients with heart failure.

In contrast, sudden cardiac death is less likely, as the patient's ECG impression does not suggest any high-risk arrhythmias, and the patient is not taking any anti-arrhythmic medications. Pump failure death is also less likely, as the patient's LVEF is relatively preserved, and the patient is taking medications to manage heart failure.

Therefore, the most likely prognosis is that the patient will survive over the next few years, with the possibility of some degree of heart failure or arrhythmias, but overall, the patient's cardiovascular risk factors are being well-managed."
571,571,P0889,"Age: 66
Gender: Male 
Weight: 85 kg
Height: 162 cm
NYHA Class: II
Blood Pressure: 140/80 mmHg
Past Medical History: Hypertropic cardiomyopathy, Dyslipemia, Peripheral vascular disease
Albumin (g/L): 50
ALT or GPT (IU/L): 21.0
AST or GOT (IU/L): 22.0
Total Cholesterol (mmol/L): 6,47
Creatinine (mmol/L): 70.0
Gamma-glutamil transpeptidase (IU/L): 26
Glucose (mmol/L): 6,1
Hemoglobin (g/L): 150.0
HDL (mmol/L): 1,55
Potassium (mEq/L): 4,6
LDL (mmol/L): 4,37
Sodium (mEq/L): 141.0
Pro-BNP (ng/L): 54.0
Protein (g/L): 73,4
T4 (ng/L): 16
TSH (mIU/L): 1,16
Urea (mg/dL): 5,99
LVEF (%): 68.0
Medications: Calcium Channel Blocker
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: TPSV
        - Bradycardia: No
            ",survivor,"RANKING: 1. Survivor
REASONING: 

Based on the provided patient data, the patient is at moderate risk for cardiac-related complications. The patient's age (66) and NYHA Class II (mild symptoms) suggest that the patient has some degree of cardiac dysfunction, but it is not severe. The patient's LVEF (68.0) is within the normal range, indicating that the left ventricle is functioning relatively well.

The patient's blood pressure (140/80 mmHg) and lipid profile (Total Cholesterol: 6.47 mmol/L, LDL: 4.37 mmol/L) are not significantly elevated, which reduces the risk of atherosclerotic heart disease. However, the patient's history of hypertension and dyslipidemia, as well as peripheral vascular disease, suggest that the patient may have some degree of cardiovascular risk.

The patient's renal function (Creatinine: 5.99 mg/dL) is elevated, which may indicate some degree of kidney dysfunction. The patient's electrolyte levels (Potassium: 4.6 mEq/L) are also slightly elevated, which could be related to the renal dysfunction.

The patient's ECG results show ventricular extrasystoles (Monomorphic), which may indicate some degree of ventricular dysfunction. However, there is no evidence of ventricular tachycardia or bradycardia.

The patient's Pro-BNP (54.0 ng/L) is slightly elevated, which may indicate some degree of cardiac stress. However, the patient's overall clinical presentation and laboratory results do not suggest a high risk of cardiac events.

Given these factors, the patient is most likely to survive for the next few years, assuming no significant changes in their medical condition. The patient's NYHA Class II symptoms and relatively preserved LVEF suggest that the patient has a moderate degree of cardiac dysfunction, but it is not severe enough to lead to a high risk of cardiac events."
572,572,P0892,"Age: 61
Gender: Female 
Weight: 59 kg
Height: 155 cm
NYHA Class: II
Blood Pressure: 95/65 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Dyslipemia, Hypertension, Myocardial Infarction
Albumin (g/L): 43
ALT or GPT (IU/L): 12.0
AST or GOT (IU/L): 17.0
Total Cholesterol (mmol/L): 5,38
Creatinine (mmol/L): 97.0
Gamma-glutamil transpeptidase (IU/L): 23
Glucose (mmol/L): 4,7
Hemoglobin (g/L): 133.0
HDL (mmol/L): 1,47
Potassium (mEq/L): 4,5
LDL (mmol/L): 3,57
Sodium (mEq/L): 141.0
Pro-BNP (ng/L): 886.0
Protein (g/L): 69
T4 (ng/L): 27
Troponin (ng/mL): 0,01
TSH (mIU/L): 1,95
Urea (mg/dL): 12,81
LVEF (%): 43.0
Medications: Beta Blockers, Loop Diuretics, Spironolactone, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: TPSV
        - Bradycardia: No
            ",survivor,"RANKING: 1. Survivor
REASONING: The patient is a 61-year-old female with a history of ischemic dilated cardiomyopathy, which is a significant risk factor for adverse outcomes. However, she has been taking beta blockers, loop diuretics, and spironolactone, which are standard treatments for heart failure and cardiomyopathy. Her current NYHA class is II, indicating mild symptoms of heart failure. Her renal function is also relatively preserved, with a creatinine level of 97.0 mol/L, which is not severely impaired. The presence of ventricular extrasystoles and non-sustained ventricular tachycardia on the ECG may indicate some cardiac instability, but the absence of sustained VT and other arrhythmias suggests that the patient is not at high risk for sudden cardiac death. Her pro-BNP level of 886.0 ng/L is elevated, indicating some degree of heart failure, but it is not excessively high. Overall, the combination of her medical history, medication regimen, and current clinical status suggest that the patient is at moderate risk for adverse outcomes, but not at the highest risk.

RANKING: 2. Sudden Cardiac Death
REASONING: While the patient has a history of ischemic dilated cardiomyopathy, her current ECG findings are not as concerning as they would be for a higher ranking. The presence of non-sustained ventricular tachycardia is a risk factor for sudden cardiac death, but it is not sustained. The absence of other arrhythmias and the presence of beta blockers, which are known to reduce the risk of sudden cardiac death, also suggest that the patient is not at the highest risk. However, the patient's history of myocardial infarction and cardiomyopathy still carries a risk of sudden cardiac death, and her LVEF of 43% is below normal.

RANKING: 3. Pump Failure Death
REASONING: The patient's current NYHA class is II, indicating mild symptoms of heart failure, and she is taking medications to manage her condition. However, her LVEF is only 43%, which is significantly below the normal range. This suggests that her heart is not pumping efficiently, and she may be at risk for pump failure. Additionally, her elevated pro-BNP level of 886.0 ng/L indicates some degree of heart failure. While the patient's renal function is relatively preserved, her creatinine level is elevated, which may indicate some degree of renal impairment, which can be associated with heart failure. Overall, the combination of her heart failure symptoms, low LVEF, and elevated pro-BNP level suggest that pump failure is a possible outcome, but it is not as likely as sudden cardiac death or survivorship."
573,573,P0893,"Age: 62
Gender: Male 
Weight: 95 kg
Height: 183 cm
NYHA Class: II
Blood Pressure: 130/85 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Dyslipemia, Hypertension, Myocardial Infarction
Albumin (g/L): 40,4
ALT or GPT (IU/L): 16.0
AST or GOT (IU/L): 18.0
Total Cholesterol (mmol/L): 4,11
Creatinine (mmol/L): 93.0
Gamma-glutamil transpeptidase (IU/L): 24
Glucose (mmol/L): 5,7
Hemoglobin (g/L): 128.0
HDL (mmol/L): 0,88
Potassium (mEq/L): 4,2
LDL (mmol/L): 2,56
Sodium (mEq/L): 145.0
Pro-BNP (ng/L): 3572.0
Protein (g/L): 69,4
T4 (ng/L): 17
TSH (mIU/L): 1,32
Urea (mg/dL): 7,49
LVEF (%): 60.0
Medications: Beta Blockers, Digoxin, Loop Diuretics, Statins, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",survivor,"RANKING: 
1. Survivor
REASONING: 
The patient has a history of ischemic dilated cardiomyopathy, which is a condition where the heart muscle becomes weakened, leading to poor heart function. Despite this, the patient's NYHA class is II, indicating that the patient is experiencing some limitations in physical activity, but they are still able to carry out daily activities with minimal symptoms. The patient's LVEF is 60%, which is within the normal range, but on the lower end. 

The patient's medication regimen includes beta blockers, digoxin, loop diuretics, statins, and ACE inhibitors, which are commonly used to manage heart failure, arrhythmias, and high cholesterol. The patient's ECG results show ventricular extrasystole, but no ventricular tachycardia or non-sustained ventricular tachycardia, which are indicators of a higher risk of sudden cardiac death.

The patient's biomarkers, such as elevated creatinine and urea levels, suggest some degree of renal impairment, but this is not uncommon in patients with heart failure. The patient's lipid profile is also suboptimal, with high triglycerides and low HDL, but the patient is on statins, which should help to manage high cholesterol.

Overall, the patient's clinical presentation and laboratory results suggest that they are at moderate risk for cardiac events, but the presence of a strong medication regimen and a relatively preserved LVEF position them at a higher risk for survival compared to the other two options. 

2. Sudden cardiac death
REASONING: 
While the patient has a history of ischemic dilated cardiomyopathy, the patient's LVEF is 60%, which is within the normal range. The patient's ECG results show ventricular extrasystole, which can be a marker of cardiac disease, but it is not a definitive indicator of sudden cardiac death. The patient's biomarkers and lipid profile are also not particularly concerning.

The patient's NYHA class is II, indicating some limitations in physical activity, but they are still able to carry out daily activities with minimal symptoms. The patient's medication regimen is comprehensive, and the patient is on beta blockers, which are known to reduce the risk of sudden cardiac death.

While the patient's past medical history of myocardial infarction is concerning, it is not directly related to the patient's current cardiac function. The patient's renal impairment and elevated creatinine levels are also not uncommon in patients with heart failure.

Overall, the patient's clinical presentation and laboratory results suggest that they are at moderate risk for cardiac events, but the presence of a strong medication regimen and a relatively preserved LVEF position them at a lower risk for sudden cardiac death compared to the other two options.

3. Pump failure death
REASONING: 
The patient's LVEF is 60%, which is on the lower end of the normal range, indicating some degree of heart failure. The patient's NYHA class is II, indicating some limitations in physical activity, and the patient is on loop diuretics, which are commonly used to manage fluid overload in heart failure.

The patient's ECG results show ventricular extrasystole, which can be a marker of cardiac disease. The patient's biomarkers, such as elevated creatinine and urea levels, suggest some degree of renal impairment, which is common in patients with heart failure.

However, the patient's lipid profile is suboptimal, with high triglycerides and low HDL, and the patient is on statins, which should help to manage high cholesterol. The patient's medication regimen is comprehensive, and the patient is on beta blockers, which are known to reduce the risk of pump failure.

Overall, the patient's clinical presentation and laboratory results suggest that they are at higher risk for pump failure compared to the other two options. However, the presence of a strong medication regimen and a relatively preserved LVEF position them at a lower risk for pump failure compared to the other two options."
574,574,P0894,"Age: 57
Gender: Male 
Weight: 68 kg
Height: 165 cm
NYHA Class: II
Blood Pressure: 130/80 mmHg
Past Medical History: Enolic dilated cardiomyopathy, Hypertension
Albumin (g/L): 45,2
ALT or GPT (IU/L): 32.0
AST or GOT (IU/L): 31.0
Total Cholesterol (mmol/L): 7,01
Creatinine (mmol/L): 86.0
Gamma-glutamil transpeptidase (IU/L): 188
Glucose (mmol/L): 7
Hemoglobin (g/L): 158.0
HDL (mmol/L): 1,63
Potassium (mEq/L): 4,8
LDL (mmol/L): 4,6
Sodium (mEq/L): 139.0
Pro-BNP (ng/L): 710.0
Protein (g/L): 76,7
T4 (ng/L): 14
TSH (mIU/L): 6,21
Urea (mg/dL): 5,83
LVEF (%): 46.0
Medications: Digoxin, Loop Diuretics, ACE Inhibitor, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: Sinus Node Dysfunction
            ",survivor,"RANKING: 1. Survivor
REASONING: 

Based on the provided patient data, the patient is likely to survive in the next few years. Here's a breakdown of the reasons supporting this prognosis:

1. Age and NYHA Class II: The patient's age (57) and NYHA Class II classification indicate a relatively mild heart failure. This suggests that the patient's heart is still functioning relatively well, which is a positive factor in predicting survival.

2. Medications: The patient is taking a combination of medications, including digoxin, loop diuretics, ACE inhibitor, and nitrovasodilator. These medications are commonly used to manage heart failure, hypertension, and arrhythmias, indicating that the patient is receiving appropriate treatment for their conditions.

3. Electrocardiogram (ECG) findings: While the ECG shows some concerning findings, such as ventricular extrasystoles, non-sustained ventricular tachycardia, and sinus node dysfunction, they do not indicate an immediately life-threatening condition. The presence of non-sustained ventricular tachycardia is a risk factor for sudden cardiac death, but it is not necessarily a guarantee of an adverse outcome.

4. Other lab values: The patient's lab values, including the elevated creatinine level, indicate some degree of kidney impairment, but this is not uncommon in patients with heart failure.

5. Pro-BNP level: The elevated Pro-BNP level (710 ng/L) suggests some degree of ventricular strain, but it is not excessively high, which is a positive sign.

Considering these factors, the patient's overall condition is relatively stable, and with proper management, it is likely that the patient will survive in the next few years.

RANKING: 2. Sudden Cardiac Death
REASONING: 

While the patient's ECG findings, particularly the non-sustained ventricular tachycardia, indicate an increased risk of arrhythmias, the likelihood of sudden cardiac death is not extremely high. However, this patient's history of ventricular dilated cardiomyopathy, hypertension, and elevated Pro-BNP level do increase the risk of arrhythmias and sudden cardiac death.

RANKING: 3. Pump Failure Death
REASONING: 

The patient's LVEF (46%) is significantly reduced, indicating some degree of left ventricular dysfunction. This, combined with the patient's NYHA Class II classification and elevated creatinine level, suggests that the patient's heart is not functioning optimally. However, the presence of digoxin, loop diuretics, ACE inhibitor, and nitrovasodilator medications indicates that the patient is receiving treatment to manage their heart failure. While the patient's condition is concerning, the presence of these medications and the relatively stable ECG findings suggest that the patient's heart failure is not immediately life-threatening, making pump failure death less likely."
575,575,P0895,"Age: 77
Gender: Male 
Weight: 66 kg
Height: 168 cm
NYHA Class: II
Blood Pressure: 154/85 mmHg
Past Medical History: Hypertensive cardiomyopathy, Dyslipemia, Hypertension
Albumin (g/L): 41,2
ALT or GPT (IU/L): 16.0
AST or GOT (IU/L): 19.0
Total Cholesterol (mmol/L): 4,4
Creatinine (mmol/L): 95.0
Gamma-glutamil transpeptidase (IU/L): 11
Glucose (mmol/L): 5,2
Hemoglobin (g/L): 142.0
HDL (mmol/L): 1,03
Potassium (mEq/L): 5,1
LDL (mmol/L): 2,79
Sodium (mEq/L): 142.0
Pro-BNP (ng/L): 126.0
Protein (g/L): 66,3
T4 (ng/L): 15
TSH (mIU/L): 0,85
Urea (mg/dL): 8,99
LVEF (%): 63.0
Medications: ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: TPSV
        - Bradycardia: No
            ",survivor,"RANKING: 1. Survivor
REASONING:

Based on the provided patient data, the patient's age, NYHA Class II, and presence of Hypertensive cardiomyopathy, Dyslipemia, and Hypertension, suggest a history of cardiovascular disease. The elevated blood pressure (154/85 mmHg) and creatinine level (95.0 mmol/L) indicate potential kidney damage and possible left ventricular hypertrophy, which can be associated with cardiomyopathy. The patient's LVEF (63.0) is slightly below the normal range, which may indicate some level of left ventricular dysfunction.

The patient's ECG findings of ventricular extrasystole, non-sustained ventricular tachycardia, and non-sustained ventricular tachycardia (CH>10) suggest an increased risk of arrhythmias, which can be a precursor to sudden cardiac death. However, the fact that the patient is on an ACE inhibitor and has a relatively well-controlled blood pressure (154/85 mmHg) and electrolyte levels, which may indicate some level of cardiovascular stability.

The patient's elevated Pro-BNP level (126.0 ng/L) is also a concern, as it can indicate increased ventricular stress and potential heart failure. However, the patient is currently on an ACE inhibitor, which is a standard treatment for heart failure, and has a relatively well-controlled blood pressure.

Considering these factors, the patient's overall risk profile suggests that they are at moderate risk for cardiovascular events, but the presence of an ACE inhibitor and relatively controlled blood pressure and electrolytes suggest that they may be more likely to survive with proper management.

RANKING: 2. Sudden cardiac death
REASONING:

The patient's ECG findings of ventricular extrasystole, non-sustained ventricular tachycardia, and non-sustained ventricular tachycardia (CH>10) suggest an increased risk of arrhythmias, which can be a precursor to sudden cardiac death. The presence of ventricular extrasystole and non-sustained ventricular tachycardia may indicate a higher risk of sudden cardiac death, particularly if left untreated or not adequately managed.

RANKING: 3. Pump failure death
REASONING:

The patient's elevated Pro-BNP level (126.0 ng/L) and LVEF (63.0) suggest that the patient may be at risk for heart failure, which can lead to pump failure. However, the patient is currently on an ACE inhibitor, which is a standard treatment for heart failure, and has relatively well-controlled blood pressure and electrolytes. The patient's overall risk profile is lower compared to the risk of sudden cardiac death, but still warrants close monitoring and management to prevent progression of heart failure."
576,576,P0896,"Age: 47
Gender: Male 
Weight: 100 kg
Height: 170 cm
NYHA Class: II
Blood Pressure: 100/63 mmHg
Past Medical History: Idiopathic dilated cardiomyopathy, Dyslipemia
Albumin (g/L): 48
ALT or GPT (IU/L): 45.0
AST or GOT (IU/L): 26.0
Total Cholesterol (mmol/L): 4,34
Creatinine (mmol/L): 124.0
Gamma-glutamil transpeptidase (IU/L): 28
Glucose (mmol/L): 10,5
Hemoglobin (g/L): 154.0
HDL (mmol/L): 1,03
Potassium (mEq/L): 5,1
LDL (mmol/L): 2,61
Sodium (mEq/L): 137.0
Pro-BNP (ng/L): 226.0
Protein (g/L): 72
T4 (ng/L): 14
Troponin (ng/mL): 0,01
TSH (mIU/L): 2,77
Urea (mg/dL): 7,65
LVEF (%): 20.0
Medications: Beta Blockers, Statins, Hydralazine, ACE Inhibitor, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"RANKING: 1. Survivor
REASONING: 

The patient's current condition, with a left ventricular ejection fraction (LVEF) of 20.0, indicates significant left ventricular dysfunction, which is a hallmark of advanced heart failure. Despite this, the patient's NYHA class is II, suggesting that they are still able to perform moderate physical activity without symptoms. This suggests that the patient's heart is still functioning enough to meet their daily needs, at least to some extent.

Additionally, the patient's medication regimen, which includes beta blockers, statins, hydralazine, and an ACE inhibitor, is standard therapy for heart failure and coronary artery disease. This suggests that the patient is receiving optimal medical therapy for their underlying conditions.

The patient's biomarkers, such as elevated troponin and BNP levels, indicate some degree of cardiac stress and strain, but are not indicative of acute myocardial infarction or severe heart failure. The patient's creatinine level is also elevated, but this is likely due to renal impairment rather than cardiac dysfunction.

The absence of significant arrhythmias on the ECG and the absence of elevated potassium levels also suggest that the patient's cardiac function is not severely impaired. Overall, based on the patient's clinical presentation, medication regimen, and biomarkers, it is likely that the patient will survive the next few years.

RANKING: 2. Sudden cardiac death
REASONING: 

The patient's LVEF of 20.0 indicates significant left ventricular dysfunction, which increases the risk of sudden cardiac death. However, the patient's survival ranking is currently ranked as the highest due to the reasons mentioned above.

A sudden cardiac death would be more likely if the patient's LVEF were significantly lower (e.g., less than 15%) or if they had other risk factors such as a history of myocardial infarction, severe arrhythmias, or significant coronary artery disease. However, the patient's current ECG and biomarkers do not suggest an immediate risk of sudden cardiac death.

RANKING: 3. Pump failure death
REASONING: 

Pump failure death is a possible outcome for patients with advanced heart failure, but it is less likely than sudden cardiac death given the patient's current clinical presentation. The patient's LVEF of 20.0 indicates significant left ventricular dysfunction, but the patient is still able to maintain a NYHA class II, suggesting that their heart is still functioning enough to meet their daily needs.

Additionally, the patient's biomarkers and medication regimen suggest that they are receiving optimal medical therapy for their underlying conditions, which reduces the risk of pump failure. The patient's elevated creatinine level is likely due to renal impairment rather than cardiac dysfunction, and the absence of significant arrhythmias on the ECG reduces the risk of sudden cardiac death.

Overall, while pump failure is a possible outcome for this patient, it is less likely than sudden cardiac death given the patient's current clinical presentation and medication regimen."
577,577,P0900,"Age: 67
Gender: Male 
Weight: 74 kg
Height: 171 cm
NYHA Class: II
Blood Pressure: 120/53 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Diabetes, Dyslipemia, Myocardial Infarction
Albumin (g/L): 42,1
ALT or GPT (IU/L): 46.0
AST or GOT (IU/L): 29.0
Total Cholesterol (mmol/L): 3,05
Creatinine (mmol/L): 87.0
Gamma-glutamil transpeptidase (IU/L): 93
Glucose (mmol/L): 6,6
Hemoglobin (g/L): 121.0
HDL (mmol/L): 1,29
Potassium (mEq/L): 4,4
LDL (mmol/L): 1,34
Sodium (mEq/L): 144.0
Pro-BNP (ng/L): 3611.0
Protein (g/L): 66,9
T4 (ng/L): 19
TSH (mIU/L): 2,15
Urea (mg/dL): 5,99
LVEF (%): 40.0
Medications: Diabetes Medication, Beta Blockers, Statins, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"RANKING: 1. Survivor
REASONING: 

Based on the provided patient data, I predict that the patient will survive for the next few years. The key factors contributing to this prediction are:

1. The patient's NYHA Class II heart failure status indicates that they have some symptoms of heart failure, but it is not severe enough to limit their daily activities significantly. This suggests that the patient's heart is still functioning to some extent.
2. The patient's LVEF (Left Ventricular Ejection Fraction) is 40%, which is a relatively preserved ejection fraction for someone with a history of ischemic dilated cardiomyopathy. A preserved ejection fraction suggests that the patient's heart is still pumping effectively, albeit not optimally.
3. The patient's serum creatinine level is elevated (87.0 mmol/L), which indicates impaired renal function. However, this is not a direct indicator of cardiac mortality, and the patient's kidney function is likely being managed with their current medications.
4. The patient's lipid profile shows elevated total cholesterol and LDL levels, which increases the risk of cardiovascular events. However, the patient is already taking statins, which should help to manage their lipid levels.
5. The patient's blood pressure is well-controlled (120/53 mmHg), and their diabetes is being managed with medication.

While the patient's ECG shows signs of ventricular extrasystole and non-sustained ventricular tachycardia, these are not necessarily indicative of an immediate life-threatening condition. The patient's Pro-BNP level is elevated, which suggests some degree of heart failure, but it is not excessively high.

Overall, based on the patient's clinical presentation and laboratory results, I predict that they will survive for the next few years with careful management of their heart failure, diabetes, and lipid levels."
578,578,P0901,"Age: 52
Gender: Male 
Weight: 78 kg
Height: 167 cm
NYHA Class: III
Blood Pressure: 115/65 mmHg
Past Medical History: Idiopathic dilated cardiomyopathy, Hypertension
Albumin (g/L): 48
ALT or GPT (IU/L): 20.0
AST or GOT (IU/L): 24.0
Total Cholesterol (mmol/L): 5,74
Creatinine (mmol/L): 95.0
Gamma-glutamil transpeptidase (IU/L): 64
Glucose (mmol/L): 8,2
Hemoglobin (g/L): 135.0
HDL (mmol/L): 1,03
Potassium (mEq/L): 5
LDL (mmol/L): 4,01
Sodium (mEq/L): 137.0
Pro-BNP (ng/L): 1558.0
Protein (g/L): 75
T3 (pg/dL): 0,06
T4 (ng/L): 18
Troponin (ng/mL): 0,06
TSH (mIU/L): 2,56
Urea (mg/dL): 8,32
LVEF (%): 26.0
Medications: Diabetes Medication, Angiotensin II Receptor Blocker, Beta Blockers, Digoxin, Loop Diuretics, Spironolactone
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: TPSV
        - Bradycardia: No
            ",survivor,"RANKING: 1. Survivor
REASONING:

This patient's prognosis is ranked as a survivor due to the following factors:

1. Age: The patient is 52 years old, which is still considered middle-aged. While age is a significant risk factor for cardiovascular disease, it is not the most critical factor in this case.
2. NYHA Class III: The patient's heart failure is severe, but it is not the most significant factor in determining the prognosis. Patients with NYHA Class III heart failure often have a worse prognosis than those with milder heart failure.
3. Medications: The patient is taking a comprehensive regimen of medications, including beta blockers, ACE inhibitors, and diuretics, which are all evidence-based treatments for heart failure and hypertension. This suggests that the patient is receiving adequate medical therapy.
4. Pro-BNP levels: The patient's Pro-BNP levels are elevated, indicating some degree of heart failure, but not excessively high. Elevated Pro-BNP levels are associated with a worse prognosis, but in this case, the levels are not excessively high.
5. LVEF: The patient's LVEF is 26%, which is significantly reduced. However, this is not uncommon in patients with idiopathic dilated cardiomyopathy.
6. Troponin levels: The patient's troponin levels are normal, which suggests that there is no significant myocardial infarction or acute coronary syndrome.

Considering these factors, the patient's overall prognosis is more favorable than that of sudden cardiac death or pump failure. However, the patient's heart failure is severe, and the patient's LVEF is significantly reduced, indicating a high risk of worsening heart failure in the short term. Therefore, close monitoring and regular follow-up are essential to ensure the patient receives optimal care and to minimize the risk of complications.

The patient's risk of sudden cardiac death is moderate, given the presence of ventricular extrasystoles and a history of hypertension. However, the patient is taking beta blockers, which are effective in reducing the risk of sudden cardiac death.

The patient's risk of pump failure is high, given the patient's severely reduced LVEF and the presence of heart failure. However, the patient is receiving optimal medical therapy, and close monitoring will be essential to detect any signs of worsening heart failure early.

In summary, while the patient's prognosis is not entirely favorable, the patient's overall risk of sudden cardiac death and pump failure is moderate to high, making survival the most likely outcome."
579,579,P0902,"Age: 44
Gender: Male 
Weight: 75 kg
Height: 164 cm
NYHA Class: II
Blood Pressure: 140/100 mmHg
Past Medical History: Idiopathic dilated cardiomyopathy, Dyslipemia, Hypertension
Albumin (g/L): 46
ALT or GPT (IU/L): 33.0
AST or GOT (IU/L): 41.0
Total Cholesterol (mmol/L): 7,55
Creatinine (mmol/L): 89.0
Gamma-glutamil transpeptidase (IU/L): 151
Glucose (mmol/L): 5,5
Hemoglobin (g/L): 173.0
HDL (mmol/L): 1,11
Potassium (mEq/L): 5,2
LDL (mmol/L): 4,27
Sodium (mEq/L): 145.0
Pro-BNP (ng/L): 147.0
Protein (g/L): 73
T3 (pg/dL): 0,06
T4 (ng/L): 17
Troponin (ng/mL): 0,06
TSH (mIU/L): 0,753
Urea (mg/dL): 5,83
LVEF (%): 39.0
Medications: ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"RANKING: 1. Survivor
REASONING: 

This patient is at a high risk for adverse outcomes due to their underlying idiopathic dilated cardiomyopathy, which is a significant risk factor for sudden cardiac death. The patient's left ventricular ejection fraction (LVEF) is severely impaired at 39%, indicating poor cardiac function. Additionally, the presence of ventricular extrasystoles on the ECG suggests an increased risk of arrhythmias, which can be life-threatening. The patient's elevated troponin levels also indicate some degree of myocardial damage.

The patient's age and gender are also factors that contribute to their risk. The patient is 44 years old, which is considered middle-aged, and male, which is a higher risk factor for cardiovascular disease. The patient's weight and height are also within a normal range, but their blood pressure is elevated, which can further increase the risk of cardiovascular events.

The patient's medical history of hypertension and dyslipidemia also contribute to their risk. The patient's elevated creatinine levels and elevated liver enzymes (ALT and AST) may indicate some degree of kidney and liver dysfunction, which can also contribute to their risk.

Despite these factors, the patient is currently on an ACE inhibitor, which is a standard treatment for heart failure and hypertension. The patient's Pro-BNP levels are elevated, indicating some degree of heart failure symptoms. However, the patient is currently classified as NYHA Class II, indicating some limitations in physical activity but no severe symptoms.

Overall, while the patient has several risk factors, their current medical management and lack of severe symptoms suggest that they are likely to survive the next few years. However, close monitoring and regular follow-up with the cardiologist will be necessary to assess the patient's condition and adjust treatment as needed.

It is worth noting that the patient's TSH level is within the normal range, which suggests that thyroid function is not a contributing factor to their cardiac condition. The patient's potassium levels are also within a normal range, which reduces the risk of cardiac arrhythmias.

Given the patient's current condition and medical management, I would estimate the following 5-year survival rate:

* 5-year survival rate: 80-90%
* 10-year survival rate: 50-60%

Please note that these estimates are based on the available data and should be interpreted with caution. A more accurate prognosis can only be made after a comprehensive evaluation and discussion with the patient and their family."
580,580,P0903,"Age: 63
Gender: Male 
Weight: 59 kg
Height: 162 cm
NYHA Class: II
Blood Pressure: 110/80 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Myocardial Infarction
Albumin (g/L): 47,3
ALT or GPT (IU/L): 22.0
AST or GOT (IU/L): 22.0
Total Cholesterol (mmol/L): 9,46
Creatinine (mmol/L): 120.0
Gamma-glutamil transpeptidase (IU/L): 170
Glucose (mmol/L): 5,3
Hemoglobin (g/L): 156.0
HDL (mmol/L): 1,93
Potassium (mEq/L): 5,07
LDL (mmol/L): 6,65
Sodium (mEq/L): 137.0
Pro-BNP (ng/L): 1975.0
Protein (g/L): 76,4
Troponin (ng/mL): 0,02
TSH (mIU/L): 1,84
Urea (mg/dL): 11,7
LVEF (%): 20.0
Medications: Beta Blockers, Loop Diuretics, Spironolactone, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"RANKING: 1. Survivor
REASONING:

This patient has a complex clinical picture, but overall, the prognosis can be predicted as follows:

1. Survivor: The patient is already on multiple medications for their cardiovascular condition, including beta blockers, loop diuretics, spironolactone, and an ACE inhibitor, which suggests that their condition has been managed relatively well. Their LVEF is 20%, which is a significant impairment, but not the lowest. The patient's NYHA class is II, indicating moderate symptoms, but not severe. Their biomarkers, such as troponin, creatinine, and liver enzymes, are not excessively elevated, suggesting that there is no acute cardiac injury or significant renal dysfunction. The presence of ventricular extrasystoles and non-sustained ventricular tachycardia on the ECG is concerning, but it is not indicative of an immediate life-threatening arrhythmia. The patient's Pro-BNP level is elevated, but not excessively high, which suggests some degree of heart failure, but not severe.

2. Sudden cardiac death: This patient's ECG shows ventricular extrasystoles and non-sustained ventricular tachycardia, which are concerning signs of arrhythmia. However, the fact that these are non-sustained suggests that the patient is not at immediate risk of cardiac arrest. The presence of these arrhythmias, combined with the patient's history of myocardial infarction and ischemic cardiomyopathy, increases the risk of sudden cardiac death. However, this patient is already on beta blockers, which can help reduce the risk of arrhythmias.

3. Pump failure death: The patient's LVEF is 20%, which is a significant impairment, and they have a history of myocardial infarction and ischemic cardiomyopathy. However, the patient is already on multiple medications that can help manage heart failure symptoms, and their Pro-BNP level is not excessively high. The patient's kidney function is also relatively preserved, with a creatinine level of 11.7 mg/dL, which suggests that they are not at immediate risk of renal failure. While pump failure is a concern, the patient's overall clinical picture suggests that they are not at immediate risk of cardiac arrest due to heart failure.

Overall, while this patient has a complex clinical picture, their overall condition is managed relatively well, and they are not at immediate risk of cardiac arrest. Therefore, the most likely outcome is that the patient will survive, but with ongoing management and monitoring to address their arrhythmias and heart failure symptoms."
581,581,P0904,"Age: 74
Gender: Female 
Weight: 64 kg
Height: 158 cm
NYHA Class: III
Blood Pressure: 105/55 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Diabetes, Dyslipemia, Hypertension, Myocardial Infarction
Albumin (g/L): 39,2
ALT or GPT (IU/L): 19.0
AST or GOT (IU/L): 24.0
Total Cholesterol (mmol/L): 3,91
Creatinine (mmol/L): 137.0
Gamma-glutamil transpeptidase (IU/L): 22
Glucose (mmol/L): 7,2
Hemoglobin (g/L): 111.0
HDL (mmol/L): 1,18
Potassium (mEq/L): 3,81
LDL (mmol/L): 2,12
Sodium (mEq/L): 139.0
Pro-BNP (ng/L): 694.0
Protein (g/L): 68,2
Troponin (ng/mL): 0,01
TSH (mIU/L): 2,28
Urea (mg/dL): 12,7
LVEF (%): 31.0
Medications: Beta Blockers, Loop Diuretics, Statins, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: Sinus Node Dysfunction
            ",survivor,"RANKING: 1. Survivor
REASONING: 

Based on the provided patient data, the patient is a 74-year-old female with a history of ischemic dilated cardiomyopathy, diabetes, dyslipidemia, hypertension, and myocardial infarction. Her current NYHA Class III indicates severe heart failure, and her low left ventricular ejection fraction (LVEF) of 31% further supports this diagnosis. The patient's elevated creatinine level (137.0 mmol/L) and high BNP level (694.0 ng/L) also suggest significant cardiac dysfunction.

Despite the presence of multiple comorbidities, the patient's current ECG impression does not show any life-threatening arrhythmias, such as ventricular tachycardia or ventricular extrasystole. The absence of non-sustained ventricular tachycardia (CH>10) and paroxysmal supraventricular tachyarrhythmia also reduces the risk of sudden cardiac death.

Given the patient's age, comorbidities, and current cardiac status, a sudden cardiac death is less likely. However, the patient's low LVEF and elevated BNP levels suggest that the patient is at risk of pump failure. The presence of beta blockers, loop diuretics, statins, and an ACE inhibitor, which are standard treatments for heart failure, indicates that the patient is receiving appropriate therapy.

Therefore, while the patient is at risk of pump failure, the overall clinical picture suggests that the patient is more likely to survive over the next few years with proper management and monitoring."
582,582,P0905,"Age: 46
Gender: Male 
Weight: 69 kg
Height: 175 cm
NYHA Class: II
Blood Pressure: 100/60 mmHg
Past Medical History: Idiopathic dilated cardiomyopathy
Albumin (g/L): 47,3
ALT or GPT (IU/L): 50.0
AST or GOT (IU/L): 35.0
Total Cholesterol (mmol/L): 4,83
Creatinine (mmol/L): 92.0
Gamma-glutamil transpeptidase (IU/L): 96
Glucose (mmol/L): 7,2
Hemoglobin (g/L): 156.0
HDL (mmol/L): 1,02
Potassium (mEq/L): 5,25
LDL (mmol/L): 2,83
Sodium (mEq/L): 139.0
Pro-BNP (ng/L): 2470.0
Protein (g/L): 75,2
Troponin (ng/mL): 0,01
TSH (mIU/L): 0,93
Urea (mg/dL): 6,5
LVEF (%): 25.0
Medications: Beta Blockers, Loop Diuretics, Spironolactone, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"RANKING: 
1. Survivor
REASONING: 
Based on the patient's data, I would rank the patient as having a high likelihood of survival. The patient's NYHA Class II indicates that they have moderate symptoms of heart failure, but they are still able to perform daily activities with some limitations. The patient's LVEF of 25.0 is significantly reduced, indicating severe left ventricular dysfunction, but the patient is not in cardiogenic shock. The patient's blood pressure is within a relatively normal range, and their hemoglobin and potassium levels are also within normal limits. The patient's medication regimen includes beta blockers, loop diuretics, spironolactone, and an ACE inhibitor, which are all standard treatments for heart failure. The absence of ventricular tachycardia, non-sustained ventricular tachycardia, and paroxysmal supraventricular tachyarrhythmia on the ECG suggests that the patient does not have a high risk of life-threatening arrhythmias.

While the patient's elevated creatinine level (92.0) may indicate some degree of kidney dysfunction, this is not uncommon in patients with heart failure. The patient's liver function tests (ALT and AST) are also within normal limits, and the patient's glucose and protein levels are normal.

Overall, the patient's combination of moderate symptoms, severe left ventricular dysfunction, and a relatively stable ECG impression suggests that they are at high risk of survival with proper management and treatment.

2. Sudden cardiac death
REASONING: 
The patient's LVEF of 25.0 indicates severe left ventricular dysfunction, which increases the risk of sudden cardiac death. However, the patient's ECG impression does not show any evidence of ventricular tachycardia or non-sustained ventricular tachycardia, which are common precursors to sudden cardiac death. The patient's ventricular extrasystole (polymorphic) is a risk factor for sudden cardiac death, but it is not as significant as the patient's severe left ventricular dysfunction.

3. Pump failure death
REASONING: 
The patient's LVEF of 25.0 indicates severe left ventricular dysfunction, which would increase the risk of pump failure. However, the patient is currently not in cardiogenic shock, and their hemoglobin and potassium levels are within normal limits. The patient's medication regimen includes loop diuretics, which are used to manage fluid overload and reduce the risk of pump failure. The patient's elevated creatinine level (92.0) may indicate some degree of kidney dysfunction, but this is not uncommon in patients with heart failure.

While the patient's severe left ventricular dysfunction increases the risk of pump failure, the patient's overall clinical picture suggests that they are not at immediate risk of pump failure. The patient's ECG impression does not show any evidence of ventricular tachycardia or non-sustained ventricular tachycardia, which are common precursors to pump failure."
583,583,P0906,"Age: 82
Gender: Male 
Weight: 80 kg
Height: 170 cm
NYHA Class: III
Blood Pressure: 130/80 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Diabetes, Hypertension, Myocardial Infarction
Albumin (g/L): 42,5
ALT or GPT (IU/L): 29.0
AST or GOT (IU/L): 21.0
Total Cholesterol (mmol/L): 4,39
Creatinine (mmol/L): 185.0
Gamma-glutamil transpeptidase (IU/L): 52
Glucose (mmol/L): 5,9
Hemoglobin (g/L): 135.0
HDL (mmol/L): 1,15
Potassium (mEq/L): 4,02
LDL (mmol/L): 2,91
Sodium (mEq/L): 144.0
Pro-BNP (ng/L): 28179.0
Protein (g/L): 80,2
Troponin (ng/mL): 0,07
TSH (mIU/L): 1,92
Urea (mg/dL): 17,2
LVEF (%): 15.0
Medications: Calcium Channel Blocker, Diabetes Medication, Amiodarone, Angiotensin II Receptor Blocker, Loop Diuretics, Spironolactone
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",survivor,"RANKING: 1. Survivor
REASONING: 

This patient is at high risk for cardiac complications due to their history of ischemic dilated cardiomyopathy, which is a condition where the heart muscle becomes weakened and cannot pump blood effectively. The patient's NYHA Class III classification indicates severe symptoms, and their elevated creatinine level (185.0 mmol/L) suggests impaired renal function, which is often associated with heart failure. Additionally, their elevated Pro-BNP level (28179.0 ng/L) indicates a high level of brain natriuretic peptide, which is a marker of heart failure. 

The patient's medications, including Amiodarone, which is often used for arrhythmias, and Loop Diuretics, which are used to manage fluid overload, further support the presence of heart failure. The presence of ventricular extrasystoles and non-sustained ventricular tachycardia on the ECG suggests that the patient's heart is under significant stress and is at risk for further arrhythmic events.

Considering these factors, the patient's prognosis is likely to be a survivor, as they are receiving treatment for their conditions and are likely to continue receiving ongoing care to manage their heart failure and arrhythmias."
584,584,P0909,"Age: 40
Gender: Female 
Weight: 125 kg
Height: 167 cm
NYHA Class: II
Blood Pressure: 140/80 mmHg
Past Medical History: Idiopathic dilated cardiomyopathy, Diabetes, Dyslipemia, Hypertension
Albumin (g/L): 42,9
ALT or GPT (IU/L): 28.0
AST or GOT (IU/L): 17.0
Total Cholesterol (mmol/L): 5,04
Creatinine (mmol/L): 66.0
Gamma-glutamil transpeptidase (IU/L): 28
Glucose (mmol/L): 7,3
Hemoglobin (g/L): 117.0
HDL (mmol/L): 0,96
Potassium (mEq/L): 4,5
LDL (mmol/L): 3,26
Sodium (mEq/L): 139.0
Pro-BNP (ng/L): 12.0
Protein (g/L): 74,8
T4 (ng/L): 15
TSH (mIU/L): 1,49
Urea (mg/dL): 6,82
LVEF (%): 49.0
Medications: Diabetes Medication, Beta Blockers, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"RANKING: 1. Survivor
REASONING: 

Based on the provided patient data, I would rank the patient's prognosis as a survivor. Here's the reasoning behind this ranking:

1. The patient's left ventricular ejection fraction (LVEF) is 49%, which indicates a significant reduction in cardiac function, but it is not severely impaired. This suggests that the patient's heart is still able to pump blood effectively, albeit with reduced efficiency.
2. The patient's NYHA Class is II, indicating mild symptoms of heart failure, which may be manageable with current treatment.
3. The patient is on medications for diabetes, hypertension, and heart failure, which suggests that they are receiving appropriate management for their conditions.
4. The ECG results do not show any life-threatening arrhythmias, such as ventricular tachycardia or ventricular extrasystoles, which could indicate a higher risk of sudden cardiac death.
5. The patient's biomarkers, such as troponin and creatinine, are not significantly elevated, indicating no acute myocardial infarction or renal failure.
6. The patient's electrolyte and liver function tests are within normal or near-normal limits, which suggests that there are no acute metabolic disturbances that could compromise cardiac function.

While the patient has significant underlying conditions, including idiopathic dilated cardiomyopathy, diabetes, and hypertension, the overall clinical picture suggests that the patient is likely to survive for the next few years with appropriate management and treatment. However, it is essential to monitor the patient closely and adjust the treatment plan as needed to optimize their cardiac function and reduce the risk of complications.

RANKING: 2. Sudden cardiac death
REASONING: 

I would rank sudden cardiac death as a possible but less likely outcome due to the following reasons:

1. The patient's LVEF is not severely impaired, which reduces the risk of sudden cardiac death.
2. The absence of life-threatening arrhythmias on the ECG reduces the risk of ventricular tachycardia or ventricular extrasystoles.
3. The patient is on medications for diabetes, hypertension, and heart failure, which suggests that they are receiving appropriate management for their conditions.

However, the patient's underlying conditions, including idiopathic dilated cardiomyopathy, diabetes, and hypertension, increase the risk of cardiac complications, including sudden cardiac death.

RANKING: 3. Pump failure death
REASONING: 

I would rank pump failure death as the least likely outcome due to the following reasons:

1. The patient's LVEF is 49%, which suggests that the heart is still able to pump blood, albeit with reduced efficiency.
2. The patient is on medications for heart failure, which suggests that they are receiving appropriate management for their condition.
3. The patient's biomarkers, such as troponin and creatinine, are not significantly elevated, indicating no acute myocardial infarction or renal failure.

However, the patient's underlying conditions, including idiopathic dilated cardiomyopathy, diabetes, and hypertension, increase the risk of cardiac complications, including heart failure. While pump failure is a possible outcome, it is less likely than sudden cardiac death given the patient's overall clinical picture."
585,585,P0910,"Age: 73
Gender: Female 
Weight: 74 kg
Height: 156 cm
NYHA Class: II
Blood Pressure: 150/90 mmHg
Past Medical History: Hypertensive cardiomyopathy, Diabetes, Hypertension, Myocardial Infarction
Albumin (g/L): 46,6
ALT or GPT (IU/L): 20.0
AST or GOT (IU/L): 20.0
Total Cholesterol (mmol/L): 5,48
Creatinine (mmol/L): 66.0
Gamma-glutamil transpeptidase (IU/L): 37
Glucose (mmol/L): 11,1
Hemoglobin (g/L): 131.0
HDL (mmol/L): 1,5
Potassium (mEq/L): 4,6
LDL (mmol/L): 3,1
Sodium (mEq/L): 142.0
Pro-BNP (ng/L): 614.0
Protein (g/L): 79
T3 (pg/dL): 0,04
T4 (ng/L): 16
TSH (mIU/L): 0,67
Urea (mg/dL): 4,49
LVEF (%): 70.0
Medications: Diabetes Medication, Beta Blockers, Statins
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"RANKING: 1. Survivor
REASONING: The patient is a 73-year-old female with a history of hypertension, myocardial infarction, and cardiomyopathy, and currently has a NYHA Class II heart failure. Despite these comorbidities, the patient has a relatively preserved left ventricular ejection fraction (LVEF) of 70.0% and no signs of acute cardiac stress or arrhythmias on the ECG. The patient's current medication regimen includes beta blockers and statins, which are commonly used to manage hypertension, heart failure, and hyperlipidemia. The patient's laboratory results show a mild elevation in creatinine levels (66.0 mmol/L), which is consistent with chronic kidney disease, but not indicative of acute kidney injury. The patient's albumin levels (46.6 g/L) are within the normal range, and the liver function tests (ALT and AST) are within normal limits. The patient's Pro-BNP levels are elevated at 614.0 ng/L, which suggests some degree of heart failure, but not severe. Overall, the patient's clinical presentation and laboratory results suggest that the patient is at risk for heart failure progression, but the patient's age, comorbidities, and medication regimen suggest that the patient may be able to manage their condition and avoid cardiac death or sudden cardiac death in the short term. Therefore, a survival prognosis of ""survivor"" is the most likely outcome."
586,586,P0911,"Age: 64
Gender: Female 
Weight: 67 kg
Height: 155 cm
NYHA Class: III
Blood Pressure: 150/80 mmHg
Past Medical History: Hypertensive cardiomyopathy, Dyslipemia, Hypertension
Albumin (g/L): 41,4
ALT or GPT (IU/L): 44.0
AST or GOT (IU/L): 38.0
Total Cholesterol (mmol/L): 5,95
Creatinine (mmol/L): 87.0
Gamma-glutamil transpeptidase (IU/L): 57
Glucose (mmol/L): 4,9
Hemoglobin (g/L): 134.0
HDL (mmol/L): 2,54
Potassium (mEq/L): 4,7
LDL (mmol/L): 3,26
Sodium (mEq/L): 143.0
Pro-BNP (ng/L): 1114.0
Protein (g/L): 72,5
T3 (pg/dL): 0,04
T4 (ng/L): 14
TSH (mIU/L): 5,22
Urea (mg/dL): 6,49
LVEF (%): 65.0
Medications: Beta Blockers
ECG Impression:
        - Ventricular Extrasystole: No
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"RANKING: 1. Survivor
REASONING: 

Based on the patient's data, the patient is at high risk for cardiac complications. The patient has a history of hypertensive cardiomyopathy, which is a significant risk factor for heart failure and arrhythmias. The patient's NYHA Class III indicates moderate to severe symptoms of heart failure, which suggests that the patient's heart is not functioning optimally. 

The patient's laboratory results show elevated creatinine levels, indicating impaired kidney function, which is often associated with heart failure. The patient's LVEF (Left Ventricular Ejection Fraction) is 65%, which is below the normal range (50-70%). This suggests that the patient's heart is not pumping efficiently.

The patient's ECG results show no signs of ventricular extrasystole, ventricular tachycardia, or non-sustained ventricular tachycardia, which reduces the risk of sudden cardiac death. However, the patient's high Pro-BNP levels (1114.0 ng/L) indicate elevated stress on the heart, which may suggest cardiac strain.

Considering these factors, the patient is at high risk for cardiac complications, but the absence of signs of acute cardiac events and the presence of beta blockers, which are often used to manage heart failure, suggests that the patient may be able to survive for the next few years with proper management and treatment.

RANKING: 2. Sudden Cardiac Death
REASONING: 

While the patient is at high risk for cardiac complications, the absence of signs of ventricular extrasystole, ventricular tachycardia, or non-sustained ventricular tachycardia on the ECG reduces the risk of sudden cardiac death. However, the patient's high Pro-BNP levels and impaired kidney function (elevated creatinine levels) suggest that the patient's heart is under significant stress, which may increase the risk of sudden cardiac death.

RANKING: 3. Pump Failure Death
REASONING: 

Given the patient's history of hypertensive cardiomyopathy, impaired kidney function, and elevated Pro-BNP levels, pump failure is a significant concern. The patient's LVEF is below the normal range, indicating that the patient's heart is not pumping efficiently. The patient's NYHA Class III symptoms suggest that the patient's heart is not functioning optimally, and the patient's elevated creatinine levels indicate impaired kidney function, which is often associated with heart failure."
587,587,P0912,"Age: 75
Gender: Female 
Weight: 57 kg
Height: 158 cm
NYHA Class: III
Blood Pressure: 130/80 mmHg
Past Medical History: Hypertensive cardiomyopathy, Dyslipemia, Peripheral vascular disease, Hypertension
Albumin (g/L): 50,1
ALT or GPT (IU/L): 15.0
AST or GOT (IU/L): 16.0
Total Cholesterol (mmol/L): 6,28
Creatinine (mmol/L): 79.0
Gamma-glutamil transpeptidase (IU/L): 16
Glucose (mmol/L): 4
Hemoglobin (g/L): 131.0
HDL (mmol/L): 1,81
Potassium (mEq/L): 4,1
LDL (mmol/L): 4,11
Sodium (mEq/L): 137.0
Pro-BNP (ng/L): 1619.0
Protein (g/L): 71
T3 (pg/dL): 0,04
T4 (ng/L): 15
Troponin (ng/mL): 0,01
TSH (mIU/L): 5,04
Urea (mg/dL): 4,68
LVEF (%): 68.0
Medications: Beta Blockers, Digoxin, Loop Diuretics, Spironolactone, Statins, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",survivor,"RANKING: 1. Survivor
REASONING: 
Given the patient's age, NYHA Class III status, and multiple comorbidities such as hypertension, dyslipidemia, and peripheral vascular disease, the patient is at a high risk for adverse cardiac events. However, the patient's current ECG impression does not show any signs of ventricular tachycardia or ventricular extrasystoles, which are more common causes of sudden cardiac death. The patient's LVEF is also 68%, which is within a relatively normal range, indicating some preserved cardiac function.

The patient's biomarkers, such as troponin, are also within normal limits, suggesting that there is no acute myocardial infarction or significant cardiac injury. The patient's medication regimen, including beta blockers, digoxin, and ACE inhibitors, is well-managed and targets multiple risk factors.

While the patient's BNP levels are elevated, this is not uncommon in patients with heart failure and can be managed with the current treatment regimen. The patient's hemoglobin and kidney function are also within relatively normal limits.

Given these factors, the patient's overall prognosis is relatively favorable, with a higher likelihood of survival over the next few years. However, close monitoring and follow-up are essential to adjust the treatment plan as needed and address any potential complications.

RANKING: 2. Pump failure death
REASONING: 
The patient's NYHA Class III status and elevated BNP levels indicate some degree of heart failure, which increases the risk of pump failure. The patient's LVEF is also lower than average, which can be a predictor of future cardiac events.

While the patient's current treatment regimen is well-managed, the presence of multiple comorbidities and elevated BNP levels increases the risk of pump failure. However, the patient's current biomarkers and ECG impression do not show any signs of acute cardiac injury or significant arrhythmias.

RANKING: 3. Sudden cardiac death
REASONING: 
Given the patient's NYHA Class III status, elevated BNP levels, and elevated troponin, the risk of sudden cardiac death is higher than the other two options. The patient's ECG impression also shows ventricular extrasystoles, which can be a precursor to ventricular tachycardia and sudden cardiac death.

However, the patient's current medication regimen, including beta blockers and ACE inhibitors, which are known to reduce the risk of sudden cardiac death, and the absence of any acute cardiac injury or significant arrhythmias, suggest that the risk is not as high as pump failure death."
588,588,P0914,"Age: 54
Gender: Male 
Weight: 93 kg
Height: 171 cm
NYHA Class: II
Blood Pressure: 120/80 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Dyslipemia, Peripheral vascular disease, Hypertension, Myocardial Infarction
Albumin (g/L): 45,2
ALT or GPT (IU/L): 29.0
AST or GOT (IU/L): 25.0
Total Cholesterol (mmol/L): 4,19
Creatinine (mmol/L): 103.0
Gamma-glutamil transpeptidase (IU/L): 21
Glucose (mmol/L): 6
Hemoglobin (g/L): 141.0
HDL (mmol/L): 0,98
Potassium (mEq/L): 4,7
LDL (mmol/L): 2,51
Sodium (mEq/L): 142.0
Pro-BNP (ng/L): 464.0
Protein (g/L): 72,8
T3 (pg/dL): 0,05
T4 (ng/L): 14
TSH (mIU/L): 1,21
Urea (mg/dL): 7,32
LVEF (%): 20.0
Medications: Angiotensin II Receptor Blocker, Beta Blockers, Statins
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: Sinus Node Dysfunction
            ",survivor,"RANKING: 1. Survivor
REASONING: 

This patient has a complex medical history, with multiple comorbid conditions including ischemic dilated cardiomyopathy, hypertension, and peripheral vascular disease. The patient's current NYHA Class II indicates moderate symptoms of heart failure. However, the patient is currently receiving medications for angiotensin II receptor blocker, beta blockers, and statins, which are standard treatments for managing heart failure and reducing cardiovascular risk.

The patient's serum creatinine level is elevated at 103.0 mmol/L, which may indicate some degree of kidney dysfunction. However, the patient's glomerular filtration rate is not explicitly stated, and the creatinine level can be influenced by various factors such as muscle mass and age. The patient's hemoglobin level is within a normal range, and the patient's potassium level is also within a normal range.

The patient's ECG findings are concerning, with a polymorphic ventricular extrasystole, which may indicate an increased risk of arrhythmias. However, the absence of ventricular tachycardia or non-sustained ventricular tachycardia on the ECG suggests that the patient does not have an immediate life-threatening arrhythmia.

Given these factors, the patient's overall prognosis is that they are likely to survive for the next few years, assuming that their medications continue to be well-tolerated and that their medical conditions do not worsen significantly. The patient's LVEF is severely reduced at 20.0%, indicating significant left ventricular dysfunction, but this may not necessarily be a contraindication for survival.

While the patient's prognosis is uncertain, the combination of their current medications, medical history, and ECG findings suggest that they are more likely to survive than experience sudden cardiac death or pump failure. Therefore, a survival prognosis is the most likely outcome."
589,589,P0915,"Age: 78
Gender: Male 
Weight: 103 kg
Height: 169 cm
NYHA Class: II
Blood Pressure: 150/80 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Dyslipemia, Hypertension
Albumin (g/L): 36,4
ALT or GPT (IU/L): 13.0
AST or GOT (IU/L): 15.0
Total Cholesterol (mmol/L): 6,08
Creatinine (mmol/L): 85.0
Gamma-glutamil transpeptidase (IU/L): 20
Glucose (mmol/L): 6
Hemoglobin (g/L): 164.0
HDL (mmol/L): 1,14
Potassium (mEq/L): 4,6
LDL (mmol/L): 4,16
Sodium (mEq/L): 142.0
Pro-BNP (ng/L): 2390.0
Protein (g/L): 69
T3 (pg/dL): 0,05
T4 (ng/L): 17
Troponin (ng/mL): 0,01
TSH (mIU/L): 2,65
Urea (mg/dL): 8,69
LVEF (%): 38.0
Medications: Beta Blockers, Loop Diuretics, Spironolactone, ACE Inhibitor, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: TPSV
        - Bradycardia: No
            ",survivor,"RANKING: 1. Survivor
REASONING:

This patient has a complex medical history with multiple comorbidities, including ischemic dilated cardiomyopathy, dyslipidemia, and hypertension. The patient's left ventricular ejection fraction (LVEF) is significantly reduced at 38%, indicating poor cardiac function. The presence of non-sustained ventricular tachycardia (NSVT) and polymorphic ventricular extrasystole on the ECG further suggests a high risk of arrhythmias, which can be life-threatening.

Despite the patient's poor cardiac function, the absence of symptoms and the presence of a high level of B-type natriuretic peptide (BNP) suggests that the patient's heart is still able to compensate for the reduced function to some extent. The patient's hemoglobin level is within a relatively normal range, and the patient is not experiencing any acute symptoms such as dyspnea or chest pain.

Given the patient's age, weight, and comorbidities, the patient is at high risk for adverse outcomes, but the presence of a good response to medications (beta blockers, loop diuretics, spironolactone, ACE inhibitor, and nitrovasodilator) and the lack of symptoms suggest that the patient may be able to survive for the next few years with proper management.

However, the patient's LVEF is significantly reduced, and the presence of NSVT and polymorphic ventricular extrasystole on the ECG indicate a high risk of arrhythmias, which can lead to sudden cardiac death. Therefore, close monitoring and aggressive management of arrhythmias and cardiac function are crucial to prevent adverse outcomes.

Overall, while the patient is at high risk, the combination of good medication response, lack of symptoms, and relatively preserved cardiac function suggest that the patient is more likely to survive for the next few years, making ""survivor"" the most likely prognosis.

RANKING: 2. Sudden cardiac death
REASONING:

The patient's LVEF is significantly reduced at 38%, indicating poor cardiac function, which increases the risk of sudden cardiac death. The presence of NSVT and polymorphic ventricular extrasystole on the ECG further increases this risk. Additionally, the patient's age and weight are both risk factors for sudden cardiac death.

While the patient is taking medications that are commonly used to manage heart failure and arrhythmias, the patient's LVEF is still significantly reduced, and the presence of NSVT and polymorphic ventricular extrasystole on the ECG indicate a high risk of arrhythmias. If the patient experiences an arrhythmia, it could lead to sudden cardiac death.

RANKING: 3. Pump failure death
REASONING:

While the patient's LVEF is significantly reduced, the patient is not experiencing any symptoms of heart failure, and the patient is responding well to medications. However, the patient's cardiac function is still compromised, and the patient's LVEF is significantly reduced, increasing the risk of pump failure.

The patient's elevated creatinine level (85.0 mmol/L) suggests that the patient's kidneys are not functioning optimally, which can be a sign of worsening cardiac function. Additionally, the patient's elevated BNP level (2390.0 ng/L) suggests that the patient's heart is under significant stress, which can contribute to worsening cardiac function.

While the patient is not experiencing any symptoms, the combination of poor cardiac function, elevated BNP, and elevated creatinine level suggests that the patient is at risk for pump failure. However, the patient's response to medications and lack of symptoms suggest that the patient may be able to avoid pump failure for the next few years, making pump failure death a less likely prognosis compared to sudden cardiac death."
590,590,P0922,"Age: 65
Gender: Male 
Weight: 81 kg
Height: 167 cm
NYHA Class: II
Blood Pressure: 140/80 mmHg
Past Medical History: Hypertensive cardiomyopathy, Diabetes, Hypertension
Albumin (g/L): 40
ALT or GPT (IU/L): 39.0
AST or GOT (IU/L): 18.0
Total Cholesterol (mmol/L): 4,73
Creatinine (mmol/L): 80.0
Gamma-glutamil transpeptidase (IU/L): 27
Glucose (mmol/L): 8,5
Hemoglobin (g/L): 148.0
HDL (mmol/L): 0,96
Potassium (mEq/L): 4,2
LDL (mmol/L): 3,34
Sodium (mEq/L): 138.0
Pro-BNP (ng/L): 86.0
Protein (g/L): 72
T4 (ng/L): 12
Troponin (ng/mL): 0,01
TSH (mIU/L): 1,08
Urea (mg/dL): 8,99
LVEF (%): 58.0
Medications: Diabetes Medication, Beta Blockers, Loop Diuretics, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: TPSV
        - Bradycardia: No
            ",survivor,"RANKING: 1. Survivor
REASONING: 

The patient's overall health status and test results suggest that they are at a higher risk for cardiac events. The patient has a history of hypertensive cardiomyopathy, hypertension, and diabetes, which are all risk factors for cardiovascular disease. However, the patient's current NYHA class II indicates that they have some symptoms of heart failure, but they are still able to perform moderate physical activities without significant limitation.

The patient's laboratory results show elevated levels of creatinine (80.0 mmol/L) and BNP (86.0 ng/L), which indicate impaired renal function and possible cardiac stress. However, the Troponin level (0.01 ng/mL) is within the normal range, suggesting that there is no acute myocardial infarction.

The ECG impression shows ventricular extrasystole, which is a common finding in patients with cardiac disease, but it is not a specific indicator of poor prognosis. The absence of ventricular tachycardia, non-sustained ventricular tachycardia, and paroxysmal supraventricular tachyarrhythmia reduces the risk of sudden cardiac death.

Considering these factors, I believe that the patient is at a higher risk for cardiac events, but the absence of acute myocardial infarction, ventricular tachycardia, and other high-risk arrhythmias, along with the patient's current NYHA class II and the absence of other high-risk features, suggest that the patient is likely to survive for the next few years with appropriate management of their cardiovascular risk factors and medications.

RANKING: 2. Sudden cardiac death
REASONING: 

The patient's history of hypertensive cardiomyopathy, hypertension, and diabetes increases their risk for sudden cardiac death. The patient's elevated BNP level (86.0 ng/L) and creatinine level (80.0 mmol/L) suggest that they may have some cardiac stress and impaired renal function, which can contribute to an increased risk of sudden cardiac death.

The patient's ECG impression shows ventricular extrasystole, which is a risk factor for sudden cardiac death. While the absence of ventricular tachycardia, non-sustained ventricular tachycardia, and paroxysmal supraventricular tachyarrhythmia reduces the risk, the presence of ventricular extrasystole still warrants close monitoring.

RANKING: 3. Pump failure death
REASONING: 

The patient's impaired renal function (elevated creatinine level) and elevated BNP level suggest that they may have some degree of cardiac dysfunction. However, the patient's current NYHA class II indicates that they are still able to perform moderate physical activities without significant limitation, which reduces the risk of pump failure.

Additionally, the patient's ECG impression does not show any high-risk arrhythmias, and the absence of troponin elevation suggests that there is no acute myocardial infarction. The patient's medication regimen, including ACE inhibitors, beta blockers, and loop diuretics, is standard for managing cardiovascular risk factors and heart failure.

While the patient's impaired renal function and elevated BNP level suggest that they may be at risk for pump failure, the absence of other high-risk features and the patient's current NYHA class II status suggest that pump failure is less likely in the short term."
591,591,P0923,"Age: 78
Gender: Male 
Weight: 61 kg
Height: 167 cm
NYHA Class: II
Blood Pressure: 110/60 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Peripheral vascular disease, Myocardial Infarction
Albumin (g/L): 43
ALT or GPT (IU/L): 72.0
AST or GOT (IU/L): 35.0
Total Cholesterol (mmol/L): 4,32
Creatinine (mmol/L): 115.0
Gamma-glutamil transpeptidase (IU/L): 100
Glucose (mmol/L): 4,9
Hemoglobin (g/L): 132.0
HDL (mmol/L): 0,85
Potassium (mEq/L): 5
LDL (mmol/L): 2,56
Sodium (mEq/L): 140.0
Pro-BNP (ng/L): 487.0
Protein (g/L): 73
T4 (ng/L): 18
Troponin (ng/mL): 0,01
TSH (mIU/L): 4,75
Urea (mg/dL): 11,48
LVEF (%): 35.0
Medications: Beta Blockers, Loop Diuretics, Spironolactone, Statins, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: TPSV
        - Bradycardia: No
            ",survivor,"RANKING: 1. Survivor
REASONING:

Based on the provided patient data, I rank the patient as having a high likelihood of being a survivor for the next few years. The key factors contributing to this prediction are:

1. Current Medications: The patient is already taking a comprehensive regimen of beta blockers, loop diuretics, spironolactone, statins, and an ACE inhibitor, which are standard treatments for managing heart failure, hypertension, and high cholesterol. This suggests that the patient is receiving adequate management for their underlying conditions.

2. LVEF (Left Ventricular Ejection Fraction) of 35%: Although the LVEF is significantly reduced, indicating poor cardiac function, it is still within a range that can be managed with current treatments. In patients with LVEF < 40%, cardiac transplantation or device therapy may be considered, but in this case, the patient's overall clinical picture does not strongly suggest an immediate need for such interventions.

3. ECG Findings: The ECG shows polymorphic ventricular extrasystoles, which may indicate underlying arrhythmia. However, the absence of ventricular tachycardia or non-sustained ventricular tachycardia suggests that the arrhythmia is not as severe or frequent as it could be. Paroxysmal supraventricular tachycardia (PSVT) is also present, but it is not a cause for concern in this context.

4. Pro-BNP levels: Elevated Pro-BNP levels indicate some degree of heart failure, but they are not excessively high, suggesting that the patient's condition is not severely decompensated.

5. Hemoglobin and Renal Function: The patient's hemoglobin level is within a normal range, and the creatinine level, although elevated, is not significantly high, indicating that the patient's kidney function is not severely impaired.

Considering these factors, I believe that the patient is likely to be a survivor for the next few years, assuming the patient adheres to their current treatment regimen and any necessary adjustments are made to manage their conditions."
592,592,P0924,"Age: 72
Gender: Female 
Weight: 65 kg
Height: 165 cm
NYHA Class: II
Blood Pressure: 140/80 mmHg
Past Medical History: Hypertensive cardiomyopathy, Dyslipemia, Peripheral vascular disease, Hypertension
Albumin (g/L): 40
ALT or GPT (IU/L): 36.0
AST or GOT (IU/L): 20.0
Total Cholesterol (mmol/L): 3,78
Creatinine (mmol/L): 97.0
Gamma-glutamil transpeptidase (IU/L): 71
Glucose (mmol/L): 6,4
Hemoglobin (g/L): 143.0
HDL (mmol/L): 0,78
Potassium (mEq/L): 5,6
LDL (mmol/L): 2,43
Sodium (mEq/L): 143.0
Pro-BNP (ng/L): 2235.0
Protein (g/L): 70
T4 (ng/L): 14
Troponin (ng/mL): 0,01
TSH (mIU/L): 3,49
Urea (mg/dL): 8,15
LVEF (%): 55.0
Medications: Amiodarone, Angiotensin II Receptor Blocker, Loop Diuretics, Statins
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",survivor,"RANKING: 1. Survivor
REASONING: 

The patient's age (72) and NYHA Class II status suggest that the patient has some underlying cardiac disease, but it is not severe enough to cause significant symptoms. The patient's LVEF (55.0) is reduced, indicating some degree of left ventricular dysfunction, but not severe enough to suggest advanced heart failure.

The patient's biomarkers, such as Troponin (0.01 ng/mL), are within normal limits, suggesting that there is no significant acute myocardial injury. The Pro-BNP level (2235.0 ng/L) is elevated, indicating some degree of cardiac stress, but not to the extent that would suggest heart failure.

The patient's ECG findings, including ventricular extrasystoles and polymorphic ventricular extrasystoles, suggest some degree of cardiac conduction system dysfunction, but it is not severe enough to suggest a high risk of sudden cardiac death. The patient's medication list, including Amiodarone, an anti-arrhythmic medication, suggests that the patient is being treated for arrhythmias.

The patient's other laboratory results, such as creatinine (8.15 mg/dL) and urea (not provided), are not indicative of severe kidney disease. The patient's lipid profile, including LDL (2.43 mmol/L), is also not indicative of significant atherosclerotic disease.

Considering these factors, the patient's overall prognosis is good, and the patient is likely to survive for the next few years without significant cardiac complications. The patient's cardiac conduction system is not severely impaired, and the patient is being treated for arrhythmias, which suggests that the patient is being managed to prevent cardiac complications.

RANKING: 2. Sudden Cardiac Death
REASONING: 

While the patient's cardiac conduction system is not severely impaired, the patient's ECG findings, including ventricular extrasystoles and polymorphic ventricular extrasystoles, suggest some degree of cardiac conduction system dysfunction. This could potentially increase the risk of arrhythmias, including ventricular tachycardia, which is a risk factor for sudden cardiac death.

Additionally, the patient's Pro-BNP level (2235.0 ng/L) is elevated, which could indicate some degree of cardiac stress and increase the risk of arrhythmias.

However, the patient's medication list, including Amiodarone, and the patient's overall clinical presentation suggest that the patient is being managed to prevent cardiac complications. The patient's LVEF (55.0) is also not severely reduced, which reduces the risk of sudden cardiac death.

RANKING: 3. Pump Failure Death
REASONING: 

The patient's LVEF (55.0) is reduced, indicating some degree of left ventricular dysfunction, which increases the risk of heart failure. The patient's Pro-BNP level (2235.0 ng/L) is elevated, which suggests some degree of cardiac stress and increases the risk of heart failure.

Additionally, the patient's creatinine (8.15 mg/dL) and urea (not provided) levels are not indicative of severe kidney disease, but the patient's NYHA Class II status suggests that the patient has some underlying cardiac disease.

However, the patient's medication list, including Loop Diuretics, suggests that the patient is being treated for heart failure. The patient's overall clinical presentation, including the patient's age and medication list, suggests that the patient is being managed to prevent cardiac complications, which reduces the risk of pump failure death.

Therefore, while the patient's LVEF is reduced and the patient's Pro-BNP level is elevated, the patient's overall clinical presentation and medication list suggest that the patient is being managed to prevent cardiac complications, and the risk of pump failure death is moderate."
593,593,P0925,"Age: 77
Gender: Male 
Weight: 82 kg
Height: 170 cm
NYHA Class: II
Blood Pressure: 140/80 mmHg
Past Medical History: Hypertropic cardiomyopathy
Albumin (g/L): 40
ALT or GPT (IU/L): 34.0
AST or GOT (IU/L): 16.0
Total Cholesterol (mmol/L): 5,07
Creatinine (mmol/L): 106.0
Gamma-glutamil transpeptidase (IU/L): 27
Glucose (mmol/L): 5,2
Hemoglobin (g/L): 150.0
HDL (mmol/L): 0,96
Potassium (mEq/L): 4,7
LDL (mmol/L): 3,36
Sodium (mEq/L): 141.0
Pro-BNP (ng/L): 424.0
Protein (g/L): 68
T4 (ng/L): 10
Troponin (ng/mL): 0,01
TSH (mIU/L): 1,33
Urea (mg/dL): 6,66
LVEF (%): 57.0
Medications: Beta Blockers, Loop Diuretics
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: TPSV
        - Bradycardia: No
            ",survivor,"RANKING: 
1. Survivor 
REASONING: 
The patient's age, NYHA Class II, and the presence of Hypertrophic cardiomyopathy, a condition that can lead to cardiac arrhythmias and decreased cardiac function, suggest a higher risk for adverse cardiac events. However, the patient's current medications, including beta blockers and loop diuretics, are commonly used to manage symptoms and prevent complications in patients with hypertrophic cardiomyopathy. 

The patient's laboratory results show elevated creatinine levels (106.0 mmol/L), which may indicate some degree of kidney dysfunction. However, the patient's hemoglobin level (150.0 g/L) and lack of elevated troponin levels (0.01 ng/mL) suggest that the patient is not experiencing significant cardiac damage or acute myocardial infarction at this time.

The presence of paroxysmal supraventricular tachycardia (PSVT) is noted, which is a relatively common finding in patients with hypertrophic cardiomyopathy. However, the absence of ventricular tachycardia or ventricular extrasystoles suggests that the patient is not at high risk for sudden cardiac death.

Given these factors, I believe that the patient is at higher risk for experiencing cardiac complications, but the overall clinical picture suggests that the patient is likely to survive for the next few years with proper management and monitoring."
594,594,P0926,"Age: 81
Gender: Male 
Weight: 68 kg
Height: 165 cm
NYHA Class: II
Blood Pressure: 120/70 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Diabetes, Dyslipemia, Myocardial Infarction
Albumin (g/L): 36
ALT or GPT (IU/L): 41.0
AST or GOT (IU/L): 23.0
Total Cholesterol (mmol/L): 3,67
Creatinine (mmol/L): 133.0
Gamma-glutamil transpeptidase (IU/L): 35
Glucose (mmol/L): 10,3
Hemoglobin (g/L): 130.0
HDL (mmol/L): 1,14
Potassium (mEq/L): 5,2
LDL (mmol/L): 2,11
Sodium (mEq/L): 140.0
Pro-BNP (ng/L): 779.0
Protein (g/L): 68
T4 (ng/L): 8
Troponin (ng/mL): 0,01
TSH (mIU/L): 1,1
Urea (mg/dL): 14,81
LVEF (%): 42.0
Medications: Calcium Channel Blocker, Diabetes Medication, Beta Blockers, Statins, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"RANKING: 
1. Survivor
REASONING: 
Based on the patient's age (81), NYHA Class II, and the presence of ischemic dilated cardiomyopathy, diabetes, dyslipemia, and myocardial infarction, the patient is at a higher risk for adverse cardiac events. However, the patient's current hemoglobin level (130.0 g/L) is within the normal range, and the LVEF (42.0%) is not severely impaired. The absence of ventricular tachycardia or non-sustained ventricular tachycardia on the ECG also suggests that the patient's cardiac function is relatively preserved. Additionally, the patient is on multiple medications, including beta blockers, statins, and a calcium channel blocker, which are all beneficial for cardiovascular health. Given these factors, the patient's overall prognosis is more likely to be a survivor.

2. Sudden cardiac death
REASONING: 
While the patient has a history of ischemic dilated cardiomyopathy, diabetes, and myocardial infarction, the patient's current LVEF (42.0%) is not severely impaired, and the absence of ventricular tachycardia or non-sustained ventricular tachycardia on the ECG suggests that the patient's cardiac function is relatively preserved. However, the patient's age (81) and the presence of ventricular extrasystoles on the ECG are potential risk factors for sudden cardiac death. Furthermore, the patient's elevated creatinine level (133.0 mmol/L) may indicate some degree of renal impairment, which can be a risk factor for cardiac complications. While the patient is on multiple medications, the patient's overall prognosis is still more likely to be a survivor, but the risk of sudden cardiac death cannot be entirely ruled out.

3. Pump failure death
REASONING: 
The patient's NYHA Class II indicates that they have some limitation in physical activity due to heart failure, but the patient's LVEF (42.0%) is not severely impaired. However, the patient's age (81), history of ischemic dilated cardiomyopathy, diabetes, and dyslipemia, and the presence of ventricular extrasystoles on the ECG all suggest that the patient is at risk for cardiac complications. The patient's elevated creatinine level (133.0 mmol/L) and elevated BNP (779.0 ng/L) levels also suggest that the patient has some degree of heart failure. Given these factors, the patient's prognosis is less likely to be a survivor, and pump failure death is a possible outcome."
595,595,P0928,"Age: 62
Gender: Female 
Weight: 55 kg
Height: 162 cm
NYHA Class: II
Blood Pressure: 130/80 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Hypertension, Myocardial Infarction
Albumin (g/L): 32
ALT or GPT (IU/L): 39.0
AST or GOT (IU/L): 23.0
Total Cholesterol (mmol/L): 5,51
Creatinine (mmol/L): 80.0
Gamma-glutamil transpeptidase (IU/L): 35
Glucose (mmol/L): 4,9
Hemoglobin (g/L): 119.0
HDL (mmol/L): 1,06
Potassium (mEq/L): 4,6
LDL (mmol/L): 3,67
Sodium (mEq/L): 137.0
Pro-BNP (ng/L): 712.0
Protein (g/L): 68
T4 (ng/L): 10
Troponin (ng/mL): 0,01
TSH (mIU/L): 1,67
Urea (mg/dL): 9,15
LVEF (%): 32.0
Medications: Beta Blockers, Loop Diuretics, Spironolactone, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"RANKING: 1. Survivor
REASONING:

This patient's prognosis is ranked as a survivor due to the following reasons:

1. Age: Although the patient is 62 years old, which is considered elderly, the age itself is not a significant predictor of mortality in this case. Many patients with advanced heart disease can live for several years with proper management.

2. NYHA Class II: The patient's New York Heart Association (NYHA) Class II indicates that the patient has some limitations in physical activity due to heart disease, but they can still perform ordinary activities without excessive fatigue, wheezing, or palpitations.

3. Medications: The patient is on beta blockers, loop diuretics, spironolactone, and an ACE inhibitor, which are standard treatments for heart failure and hypertension. These medications have been shown to improve survival and reduce hospitalization rates in patients with heart failure.

4. Laboratory values: The patient's laboratory values are not significantly abnormal, with the exception of a mildly elevated troponin level, which could indicate some degree of cardiac damage. However, this value is not high enough to suggest a significant acute myocardial infarction.

5. ECG impression: The patient's ECG shows ventricular extrasystoles, which can be a sign of abnormal heart rhythm, but it is not a life-threatening finding in itself.

6. Pro-BNP level: The patient's Pro-BNP level is elevated, which is consistent with heart failure. However, the level is not extremely high, which suggests that the patient's heart is not severely failing.

Considering these factors, the patient's prognosis is ranked as a survivor, with a reasonable expectation of survival for several years with proper management and lifestyle modifications.

However, it's essential to note that this is a general prognosis, and individual outcomes can vary depending on various factors, such as the presence of other comorbidities, the patient's adherence to treatment, and the presence of any new or worsening symptoms. Regular follow-up and monitoring are crucial to adjust the treatment plan and improve the patient's outcome."
596,596,P0930,"Age: 56
Gender: Male 
Weight: 79 kg
Height: 173 cm
NYHA Class: III
Blood Pressure: 105/75 mmHg
Past Medical History: Idiopathic dilated cardiomyopathy, Diabetes, Dyslipemia, Hypertension
Albumin (g/L): 47
ALT or GPT (IU/L): 32.0
AST or GOT (IU/L): 24.0
Total Cholesterol (mmol/L): 3,49
Creatinine (mmol/L): 97.0
Gamma-glutamil transpeptidase (IU/L): 120
Glucose (mmol/L): 8,7
Hemoglobin (g/L): 157.0
HDL (mmol/L): 0,98
Potassium (mEq/L): 5,5
LDL (mmol/L): 2,28
Sodium (mEq/L): 130.0
Pro-BNP (ng/L): 7066.0
Protein (g/L): 83
T3 (pg/dL): 0,05
T4 (ng/L): 27
Troponin (ng/mL): 0,06
TSH (mIU/L): 2,72
Urea (mg/dL): 10,65
LVEF (%): 25.0
Medications: Digoxin, Loop Diuretics, Spironolactone, Statins, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: TPSV
        - Bradycardia: No
            ",survivor,"RANKING: 
1. Survivor
REASONING: 
The patient is currently in a stable condition with a New York Heart Association (NYHA) Class III, indicating moderate symptoms of heart failure. The patient's LVEF is significantly reduced at 25%, indicating severe left ventricular dysfunction. Despite this, the patient is on multiple medications for heart failure management, including digoxin, loop diuretics, spironolactone, statins, and an ACE inhibitor, which suggests that the patient is receiving appropriate treatment. The patient's Pro-BNP levels are elevated at 7066.0 ng/L, which is consistent with heart failure. However, the patient's hemoglobin level is slightly elevated at 15.7 g/dL, which may indicate some degree of anemia.

The patient's ECG shows ventricular extrasystoles, but no ventricular tachycardia or non-sustained ventricular tachycardia, which suggests that the patient's arrhythmias are not life-threatening. The patient's TSH level is slightly elevated at 2.72 mIU/L, which may indicate some degree of thyroid dysfunction, but this is not directly related to the patient's cardiac condition.

Considering these factors, the patient is likely to survive in the short-term, but the patient's severe left ventricular dysfunction and elevated Pro-BNP levels suggest that the patient is at risk of worsening heart failure over time. Therefore, close monitoring and adjustment of the patient's medications and treatment plan will be necessary to prevent further deterioration.

RANKING: 
2. Sudden Cardiac Death
REASONING: 
The patient's severe left ventricular dysfunction (LVEF 25%) and elevated Pro-BNP levels suggest that the patient is at risk of worsening heart failure over time. The patient's NYHA Class III symptoms indicate moderate symptoms of heart failure, which increases the risk of sudden cardiac death. The patient's elevated troponin level at 0.06 ng/mL may indicate some degree of myocardial injury, which could be a precursor to a heart attack or sudden cardiac death.

The patient's ECG shows ventricular extrasystoles, which could be a sign of underlying cardiac electrical instability. While the patient's ECG does not show ventricular tachycardia or non-sustained ventricular tachycardia, the presence of ventricular extrasystoles increases the risk of sudden cardiac death.

However, the patient is on multiple medications for heart failure management, which suggests that the patient is receiving some level of cardiac protection. Therefore, while the patient is at risk of sudden cardiac death, it is not the most likely outcome.

RANKING: 
3. Pump Failure Death
REASONING: 
The patient's severe left ventricular dysfunction (LVEF 25%) and elevated Pro-BNP levels suggest that the patient is at risk of worsening heart failure over time. The patient's NYHA Class III symptoms indicate moderate symptoms of heart failure, which increases the risk of pump failure.

However, the patient is on multiple medications for heart failure management, including digoxin, loop diuretics, spironolactone, statins, and an ACE inhibitor, which suggests that the patient is receiving some level of cardiac protection. The patient's elevated troponin level at 0.06 ng/mL may indicate some degree of myocardial injury, but this is not necessarily a predictor of pump failure.

The patient's ECG shows ventricular extrasystoles, which increases the risk of sudden cardiac death, but the patient's ventricular tachycardia and non-sustained ventricular tachycardia are not present. Therefore, while the patient is at risk of worsening heart failure, the risk of pump failure death is not the most likely outcome."
597,597,P0931,"Age: 60
Gender: Female 
Weight: 74 kg
Height: 158 cm
NYHA Class: III
Blood Pressure: 110/70 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Diabetes, Dyslipemia, Myocardial Infarction
Albumin (g/L): 43
ALT or GPT (IU/L): 18.0
AST or GOT (IU/L): 20.0
Total Cholesterol (mmol/L): 3,34
Creatinine (mmol/L): 90.0
Gamma-glutamil transpeptidase (IU/L): 41
Glucose (mmol/L): 12,8
Hemoglobin (g/L): 129.0
HDL (mmol/L): 1,06
Potassium (mEq/L): 5,3
LDL (mmol/L): 1,06
Sodium (mEq/L): 149.0
Pro-BNP (ng/L): 1853.0
Protein (g/L): 78
T3 (pg/dL): 0,06
T4 (ng/L): 21
Troponin (ng/mL): 0,06
TSH (mIU/L): 0,167
Urea (mg/dL): 5,83
LVEF (%): 24.0
Medications: Diabetes Medication, Beta Blockers, Digoxin, Loop Diuretics, Statins, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: TPSV
        - Bradycardia: No
            ",survivor,"RANKING: 1. Survivor
REASONING: The patient's overall clinical presentation and laboratory results suggest a high likelihood of survival. The patient is 60 years old, with a NYHA Class III heart failure, indicating significant cardiac dysfunction. However, the patient's blood pressure is well-controlled (110/70 mmHg), and they are on multiple medications for their heart failure, diabetes, and lipid management. The patient's creatinine level is elevated (90.0 mmol/L), which may indicate some degree of renal impairment, but this is not uncommon in patients with heart failure.

The patient's liver enzymes (ALT and AST) are mildly elevated, but this is not unusual in patients with heart failure. The patient's lipid profile is also suboptimal, but this is not a contraindication for survival.

The most concerning aspect of this patient's presentation is the presence of ventricular extrasystoles (polymorphic) on the ECG. This finding is a risk factor for sudden cardiac death. However, the absence of ventricular tachycardia or non-sustained ventricular tachycardia (CH>10) on the ECG is reassuring.

The patient's BNP level is elevated (1853.0 ng/L), which indicates significant cardiac stress and heart failure. However, this is not uncommon in patients with NYHA Class III heart failure.

The patient's hemoglobin level is slightly elevated (129.0 g/L), which may indicate some degree of anemia, but this is not a contraindication for survival.

In conclusion, while the patient's presentation is concerning, the absence of ventricular tachycardia or non-sustained ventricular tachycardia on the ECG, combined with the presence of multiple medications for heart failure and other comorbidities, suggest a high likelihood of survival."
598,598,P0932,"Age: 61
Gender: Male 
Weight: 76 kg
Height: 169 cm
NYHA Class: III
Blood Pressure: 170/90 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Dyslipemia
Albumin (g/L): 46,1
ALT or GPT (IU/L): 45.0
AST or GOT (IU/L): 33.0
Total Cholesterol (mmol/L): 8,71
Creatinine (mmol/L): 109.0
Gamma-glutamil transpeptidase (IU/L): 101
Glucose (mmol/L): 5,3
Hemoglobin (g/L): 162.0
HDL (mmol/L): 1,55
Potassium (mEq/L): 4,6
LDL (mmol/L): 6,05
Sodium (mEq/L): 142.0
Pro-BNP (ng/L): 797.0
Protein (g/L): 78,8
T3 (pg/dL): 0,05
T4 (ng/L): 15
TSH (mIU/L): 2,43
Urea (mg/dL): 4,49
LVEF (%): 49.0
Medications: Beta Blockers, Statins, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",survivor,"RANKING: 1. Survivor
REASONING:

The patient's prognosis is likely to be a survivor due to the following reasons:

1. Age: The patient is 61 years old, which is considered middle-aged. While age is a risk factor for cardiovascular disease, it is not the sole determining factor in this case.
2. NYHA Class III: The patient has a severe heart failure classification, which indicates a significant impairment of cardiac function. However, the patient is already receiving beta blockers and ACE inhibitors, which are standard treatments for heart failure. This suggests that the patient is receiving appropriate management for their condition.
3. Medications: The patient is taking beta blockers, statins, and ACE inhibitors, which are all evidence-based treatments for heart failure and coronary artery disease. This indicates that the patient is receiving evidence-based care.
4. Laboratory results: While the patient has elevated creatinine levels, which may indicate some degree of kidney dysfunction, the patient's kidney function is not severely impaired. The patient's LVEF is also significantly reduced, but it is not extremely low, which suggests that the patient may still have some residual cardiac function.
5. ECG Impression: The patient does not have any signs of ventricular tachycardia or non-sustained ventricular tachycardia, which are both indicators of a higher risk of sudden cardiac death.

While the patient's prognosis is uncertain, the combination of evidence-based treatments, relatively preserved kidney function, and the absence of severe arrhythmias or other life-threatening conditions suggest that the patient is likely to survive for the next few years. However, close monitoring and follow-up are essential to adjust treatment and address any potential complications.

The other two prognoses (sudden cardiac death and pump failure death) are less likely due to the following reasons:

* Sudden cardiac death is unlikely due to the absence of ventricular tachycardia or non-sustained ventricular tachycardia on the ECG.
* Pump failure death is less likely due to the patient's relatively preserved kidney function and the fact that the patient is receiving evidence-based treatments for heart failure. However, the patient's LVEF is significantly reduced, which may increase the risk of pump failure."
599,599,P0933,"Age: 71
Gender: Male 
Weight: 66 kg
Height: 165 cm
NYHA Class: II
Blood Pressure: 124/68 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Dyslipemia, Hypertension, Myocardial Infarction
Albumin (g/L): 41
ALT or GPT (IU/L): 15.0
AST or GOT (IU/L): 14.0
Total Cholesterol (mmol/L): 3,78
Creatinine (mmol/L): 194.0
Gamma-glutamil transpeptidase (IU/L): 18
Glucose (mmol/L): 5,4
Hemoglobin (g/L): 124.0
HDL (mmol/L): 1,22
Potassium (mEq/L): 5,1
LDL (mmol/L): 2,28
Sodium (mEq/L): 142.0
Protein (g/L): 76
T4 (ng/L): 18
Troponin (ng/mL): 0,03
TSH (mIU/L): 2,15
Urea (mg/dL): 13,64
LVEF (%): 20.0
Medications: Amiodarone, Angiotensin II Receptor Blocker, Statins
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"RANKING: 1. Survivor

REASONING: 

Based on the provided patient data, the patient is a 71-year-old male with a history of ischemic dilated cardiomyopathy, hypertension, and dyslipemia. The patient has a NYHA Class II classification, indicating mild symptoms of heart failure. The elevated creatinine level (194.0 mmol/L) suggests impaired renal function, which is a common comorbidity in patients with heart failure.

The patient's ejection fraction (LVEF) is 20.0%, which is significantly reduced, indicating poor heart function. The presence of ventricular extrasystole on the ECG, although polymorphic, does not necessarily indicate a high risk of sudden cardiac death. The absence of non-sustained ventricular tachycardia and paroxysmal supraventricular tachyarrhythmia on the ECG further reduces the risk.

The patient is currently taking medications such as amiodarone, an angiotensin II receptor blocker, and statins, which are commonly used to manage heart failure, hypertension, and dyslipemia. These medications may help control the patient's symptoms and slow disease progression.

Considering these factors, the patient's overall prognosis is that they are likely to survive for the next few years, albeit with ongoing management of their heart failure and other comorbidities. However, regular follow-up and monitoring will be crucial to adjust the treatment plan as needed and prevent any potential complications.

While there is a risk of sudden cardiac death, the patient's current condition and treatment do not indicate an extremely high risk. The patient's reduced ejection fraction and ventricular extrasystole on the ECG do suggest a higher risk of pump failure death, but this is still a more likely outcome compared to sudden cardiac death. Therefore, the patient's overall prognosis is ranked as a survivor."
600,600,P0935,"Age: 46
Gender: Male 
Weight: 79 kg
Height: 173 cm
NYHA Class: II
Blood Pressure: 100/60 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Dyslipemia, Hypertension, Myocardial Infarction
Albumin (g/L): 47,2
ALT or GPT (IU/L): 82.0
AST or GOT (IU/L): 36.0
Total Cholesterol (mmol/L): 3,85
Creatinine (mmol/L): 87.0
Gamma-glutamil transpeptidase (IU/L): 35
Glucose (mmol/L): 4,6
Hemoglobin (g/L): 162.0
HDL (mmol/L): 0,78
Potassium (mEq/L): 4,3
LDL (mmol/L): 2,56
Sodium (mEq/L): 140.0
Pro-BNP (ng/L): 272.0
Protein (g/L): 69,7
T3 (pg/dL): 0,05
T4 (ng/L): 15
TSH (mIU/L): 1,67
Urea (mg/dL): 4,99
LVEF (%): 30.0
Medications: Beta Blockers, ACE Inhibitor, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"RANKING: 1. Survivor
REASONING: 
Based on the provided patient data, the patient is likely to survive for the next few years due to several factors:

1. Age: The patient is 46 years old, which is still considered relatively young, and many patients with cardiomyopathy can survive for many years with proper management.

2. Medication regimen: The patient is already on beta blockers, ACE inhibitors, and a nitrovasodilator, which are standard treatments for ischemic dilated cardiomyopathy. These medications can help slow the progression of the disease and reduce symptoms.

3. LVEF: Although the left ventricular ejection fraction (LVEF) is low at 30%, which is indicative of poor cardiac function, it is not extremely low. With proper treatment and management, some patients with LVEF in this range can still survive for several years.

4. No evidence of acute cardiac events: The ECG impression does not show any signs of acute cardiac events such as ventricular tachycardia, ventricular extrasystole, or non-sustained ventricular tachycardia, which could indicate a more severe cardiac condition.

However, despite these factors, the patient's prognosis is not without risks. The patient has a history of myocardial infarction, dyslipidemia, and hypertension, which can contribute to further cardiac complications. The patient also has a mildly elevated creatinine level, which could indicate some degree of renal impairment. Additionally, the patient's low T3 level (0.05 pg/dL) could indicate hypothyroidism, which can also impact cardiac function.

Overall, while the patient's prognosis is uncertain, the combination of a relatively young age, current medication regimen, and lack of acute cardiac events make survival for the next few years the most likely outcome.

RANKING: 2. Sudden cardiac death
REASONING: 
Sudden cardiac death is a possible outcome for this patient due to the following factors:

1. Low LVEF: The patient's LVEF is very low at 30%, which increases the risk of sudden cardiac death due to arrhythmias.

2. History of myocardial infarction: The patient has a history of myocardial infarction, which can lead to further cardiac complications, including arrhythmias and sudden cardiac death.

3. Presence of ventricular extrasystoles: The ECG impression shows ventricular extrasystoles, which can be a sign of underlying cardiac disease.

4. Low HDL cholesterol: The patient's low HDL cholesterol level (0.78 mmol/L) can contribute to increased cardiovascular risk.

5. Presence of dyslipidemia: The patient's dyslipidemia can also contribute to increased cardiovascular risk.

While the patient is currently on medications to manage their condition, the presence of these risk factors increases the likelihood of sudden cardiac death.

RANKING: 3. Pump failure death
REASONING: 
Pump failure death is a possible outcome for this patient due to the following factors:

1. Low LVEF: The patient's LVEF is very low at 30%, which indicates poor cardiac function and an increased risk of pump failure.

2. History of myocardial infarction: The patient's history of myocardial infarction can lead to further cardiac complications, including pump failure.

3. Presence of ventricular extrasystoles: The ECG impression shows ventricular extrasystoles, which can be a sign of underlying cardiac disease.

4. Low albumin level: The patient's low albumin level (47.2 g/L) can indicate malnutrition or liver disease, both of which can contribute to cardiac complications.

5. Presence of renal impairment: The patient's mildly elevated creatinine level (87.0 mmol/L) can indicate some degree of renal impairment, which can contribute to cardiac complications.

While the patient is currently on medications to manage their condition, the presence of these risk factors increases the likelihood of pump failure death."
601,601,P0937,"Age: 67
Gender: Female 
Weight: 64 kg
Height: 151 cm
NYHA Class: II
Blood Pressure: 160/90 mmHg
Past Medical History: Hypertropic cardiomyopathy, Hypertension
Albumin (g/L): 41,2
ALT or GPT (IU/L): 50.0
AST or GOT (IU/L): 41.0
Total Cholesterol (mmol/L): 5,59
Creatinine (mmol/L): 105.0
Gamma-glutamil transpeptidase (IU/L): 149
Glucose (mmol/L): 5,6
Hemoglobin (g/L): 134.0
HDL (mmol/L): 1,86
Potassium (mEq/L): 4,1
LDL (mmol/L): 3,08
Sodium (mEq/L): 142.0
Pro-BNP (ng/L): 3315.0
Protein (g/L): 66,6
T3 (pg/dL): 0,04
T4 (ng/L): 20
TSH (mIU/L): 1,8
Urea (mg/dL): 9,32
LVEF (%): 64.0
Medications: Amiodarone, Beta Blockers, Loop Diuretics, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: No
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: TPSV
        - Bradycardia: No
            ",survivor,"RANKING: 
1. Survivor
REASONING: 
Based on the patient data, I predict a high likelihood of survival over the next few years. The patient is 67 years old, which is an advanced age for many medical conditions, but the patient's overall health profile is relatively stable. The patient has a history of Hypertensive Cardiomyopathy and Hypertension, which are risk factors for heart failure and cardiac arrhythmias. However, the patient is currently on medications that are commonly used to manage these conditions, including ACE inhibitors, Beta Blockers, and Loop Diuretics.

The patient's laboratory results show a mild elevation in creatinine levels (105.0 mol/L), which may indicate some degree of renal impairment, but this is not uncommon in patients with hypertension and cardiac disease. The patient's LVEF (Left Ventricular Ejection Fraction) is 64.0%, which is within the normal range, indicating that the patient's heart is still functioning relatively well.

The patient's ECG results are also reassuring, with no signs of ventricular tachycardia, ventricular extrasystoles, or paroxysmal supraventricular tachyarrhythmia. The presence of TPSV (Paroxysmal Supraventricular Tachycardia) is noted, but this is a relatively common finding in patients with Hypertrophic Cardiomyopathy.

Overall, while the patient has several underlying medical conditions that increase their risk for cardiac complications, the patient's current health status and treatment plan suggest a high likelihood of survival over the next few years."
602,602,P0939,"Age: 52
Gender: Male 
Weight: 85 kg
Height: 175 cm
NYHA Class: II
Blood Pressure: 104/72 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Diabetes, Dyslipemia, Myocardial Infarction
Albumin (g/L): 43
ALT or GPT (IU/L): 23.0
AST or GOT (IU/L): 11.0
Total Cholesterol (mmol/L): 7,68
Creatinine (mmol/L): 97.0
Gamma-glutamil transpeptidase (IU/L): 13
Glucose (mmol/L): 11
Hemoglobin (g/L): 149.0
HDL (mmol/L): 0,57
Potassium (mEq/L): 5,3
LDL (mmol/L): 2,25
Sodium (mEq/L): 137.0
Pro-BNP (ng/L): 34.0
Protein (g/L): 68
Troponin (ng/mL): 0,03
TSH (mIU/L): 1,08
Urea (mg/dL): 8,82
LVEF (%): 30.0
Medications: Beta Blockers, Spironolactone, Statins, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"RANKING: 1. Survivor

REASONING: 

This patient has a complex medical history, including ischemic dilated cardiomyopathy, diabetes, and dyslipemia, which are all risk factors for adverse cardiac outcomes. However, the patient's current clinical status, as indicated by the ECG impression and lab results, does not suggest an acute myocardial infarction or significant cardiac dysfunction. The patient's LVEF is 30.0%, which is within the range of 20-40% and is consistent with heart failure, but the patient is on medications that are standard for heart failure management, such as beta blockers, spironolactone, statins, and an ACE inhibitor. 

The patient's electrolytes, liver enzymes, and renal function are also within normal limits, which suggests that the patient is not experiencing acute kidney injury or liver dysfunction. The patient's hemoglobin and potassium levels are also within normal limits, which reduces the risk of cardiac arrhythmias. The Pro-BNP level is elevated, but it is not excessively high, and the patient is on spironolactone, which is a diuretic that can help reduce BNP levels.

Given these factors, the patient's overall prognosis is more favorable, and it is likely that the patient will survive in the next few years."
603,603,P0941,"Age: 64
Gender: Male 
Weight: 81 kg
Height: 163 cm
NYHA Class: II
Blood Pressure: 145/80 mmHg
Past Medical History: Idiopathic dilated cardiomyopathy, Hypertension
Albumin (g/L): 44
ALT or GPT (IU/L): 16.0
AST or GOT (IU/L): 13.0
Total Cholesterol (mmol/L): 5,74
Creatinine (mmol/L): 80.0
Gamma-glutamil transpeptidase (IU/L): 21
Glucose (mmol/L): 5,1
Hemoglobin (g/L): 161.0
HDL (mmol/L): 0,57
Potassium (mEq/L): 4,1
LDL (mmol/L): 4,09
Sodium (mEq/L): 138.0
Pro-BNP (ng/L): 189.0
Protein (g/L): 73
T3 (pg/dL): 0,05
T4 (ng/L): 15
Troponin (ng/mL): 0,01
TSH (mIU/L): 1,89
Urea (mg/dL): 5,16
LVEF (%): 50.0
Medications: Beta Blockers, Loop Diuretics, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",survivor,"RANKING: 1. Survivor
REASONING: 
Based on the provided patient data, the patient is a 64-year-old male with a history of idiopathic dilated cardiomyopathy, hypertension, and NYHA Class II heart failure. The patient's current LVEF is 50%, which is significantly below the normal range, indicating impaired cardiac function. 

The patient's ECG shows ventricular extrasystole, which is a type of abnormal heart rhythm that can be a marker of underlying cardiac dysfunction. The absence of ventricular tachycardia, non-sustained ventricular tachycardia, and paroxysmal supraventricular tachyarrhythmia suggests that the patient's heart rhythm is not excessively arrhythmic. However, the presence of ventricular extrasystole and the patient's impaired LVEF suggest that the patient is at risk for cardiac complications.

The patient's laboratory values are relatively stable, with no significant elevations in liver enzymes (ALT/GPT), kidney function (creatinine), or electrolytes (potassium). The patient's medication regimen includes beta blockers, loop diuretics, and ACE inhibitors, which are standard treatments for heart failure and hypertension.

Considering these factors, the patient's overall prognosis is favorable, and I predict that they will survive for the next few years. The patient's impaired cardiac function and abnormal ECG findings suggest that close monitoring and ongoing management of their heart failure and hypertension are crucial to prevent further decline in their condition. However, the absence of severe cardiac dysfunction, arrhythmias, and other complicating factors supports a relatively good prognosis."
604,604,P0942,"Age: 57
Gender: Male 
Weight: 82 kg
Height: 173 cm
NYHA Class: II
Blood Pressure: 126/79 mmHg
Past Medical History: Idiopathic dilated cardiomyopathy, Dyslipemia, Hypertension
Albumin (g/L): 47
ALT or GPT (IU/L): 26.0
AST or GOT (IU/L): 15.0
Total Cholesterol (mmol/L): 4,89
Creatinine (mmol/L): 80.0
Gamma-glutamil transpeptidase (IU/L): 21
Glucose (mmol/L): 6,2
Hemoglobin (g/L): 140.0
HDL (mmol/L): 0,34
Potassium (mEq/L): 5,3
LDL (mmol/L): 3,03
Sodium (mEq/L): 139.0
Pro-BNP (ng/L): 74.0
Protein (g/L): 72
T3 (pg/dL): 0,06
T4 (ng/L): 14
Troponin (ng/mL): 0,03
TSH (mIU/L): 2,47
Urea (mg/dL): 5,83
LVEF (%): 30.0
Medications: Beta Blockers, Digoxin, Spironolactone, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: TPSV
        - Bradycardia: No
            ",survivor,"RANKING: 
1. Survivor
REASONING: 
Based on the patient's clinical presentation and laboratory results, the most likely outcome is a survivor. The patient's NYHA Class II indicates a moderate level of heart failure, but the patient is still able to perform daily activities without significant symptoms. The presence of a mild elevation in Pro-BNP (74 ng/L) and an LVEF of 30% suggests some degree of ventricular dysfunction, but the patient is not in cardiogenic shock. The patient is also taking multiple medications, including beta-blockers, digoxin, and spironolactone, which are commonly used to manage heart failure and arrhythmias. The absence of troponin elevation and the patient's stable vital signs further support a favorable prognosis.

While the patient has a history of idiopathic dilated cardiomyopathy, which is a significant risk factor for adverse outcomes, the patient's current clinical status and medication regimen suggest that they are well-managed and likely to remain stable. The patient's age, weight, and blood pressure are also not particularly high-risk factors for adverse outcomes.

In contrast, the sudden cardiac death and pump failure death prognoses are less likely because the patient is not in acute distress, and their current medications are effective in managing their heart failure and arrhythmias. The patient's ECG results do show some signs of arrhythmia (TPSV), but this is not severe enough to predict a poor outcome.

Therefore, based on the available information, the most likely outcome is a survivor, with a moderate risk of adverse events due to their underlying heart disease."
605,605,P0943,"Age: 71
Gender: Male 
Weight: 70 kg
Height: 172 cm
NYHA Class: II
Blood Pressure: 134/85 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Myocardial Infarction
Albumin (g/L): 44
ALT or GPT (IU/L): 9.0
AST or GOT (IU/L): 9.0
Total Cholesterol (mmol/L): 3,85
Creatinine (mmol/L): 80.0
Gamma-glutamil transpeptidase (IU/L): 10
Glucose (mmol/L): 5,2
Hemoglobin (g/L): 126.0
HDL (mmol/L): 1,03
Potassium (mEq/L): 4,6
LDL (mmol/L): 2,07
Sodium (mEq/L): 134.0
Pro-BNP (ng/L): 709.0
Protein (g/L): 68
T3 (pg/dL): 0,06
T4 (ng/L): 16
Troponin (ng/mL): 0,03
TSH (mIU/L): 0,61
Urea (mg/dL): 7,32
LVEF (%): 40.0
Medications: Beta Blockers, Spironolactone, Statins, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: TPSV
        - Bradycardia: No
            ",survivor,"RANKING: 1. Survivor
REASONING:

This patient has a complex medical history with ischemic dilated cardiomyopathy and a previous myocardial infarction, which increases the risk of cardiovascular events. However, the patient is currently being treated with beta blockers, spironolactone, statins, and an ACE inhibitor, which are standard therapies for managing heart failure and reducing cardiovascular risk.

The patient's LVEF is 40%, which is significantly reduced, indicating impaired cardiac function. However, the patient's troponin levels are normal, which suggests that there is no acute myocardial damage. The patient's creatinine level is slightly elevated, but this is not uncommon in patients with heart failure.

The patient's ECG findings are concerning, with ventricular extrasystoles and polymorphic ventricular tachycardia, but these are not indicative of a high risk for sudden cardiac death. The absence of non-sustained ventricular tachycardia (CH>10) and paroxysmal supraventricular tachyarrhythmia reduces the risk of arrhythmic events.

The patient's biomarkers, such as pro-BNP and TSH, are elevated, indicating fluid overload and possible cardiac dysfunction. However, the patient's hemoglobin level is within the normal range, and the absence of significant anemia reduces the risk of cardiac hypoperfusion.

Considering the patient's age, comorbidities, and current treatment, the likelihood of sudden cardiac death is moderate. However, the patient's overall clinical picture suggests that the patient is more likely to survive than to experience sudden cardiac death or pump failure death. The patient's cardiac function, although impaired, is not severely compromised, and the patient is receiving optimal medical therapy. Therefore, the most likely outcome is survival.

The ranking is as follows:

1. Survivor: The patient's complex medical history, impaired cardiac function, and current treatment make survival the most likely outcome.
2. Sudden cardiac death: The patient's ECG findings and biomarkers suggest a moderate risk of arrhythmic events, but the overall clinical picture is not as concerning as to rule out sudden cardiac death.
3. Pump failure death: The patient's impaired cardiac function and elevated biomarkers suggest a risk of heart failure, but the patient's current treatment and hemoglobin level reduce the risk of severe cardiac dysfunction."
606,606,P0945,"Age: 57
Gender: Male 
Weight: 115 kg
Height: 167 cm
NYHA Class: II
Blood Pressure: 135/99 mmHg
Past Medical History: Enolic dilated cardiomyopathy, Dyslipemia
Albumin (g/L): 47
ALT or GPT (IU/L): 28.0
AST or GOT (IU/L): 22.0
Total Cholesterol (mmol/L): 5,51
Creatinine (mmol/L): 88.0
Gamma-glutamil transpeptidase (IU/L): 25
Glucose (mmol/L): 7
Hemoglobin (g/L): 158.0
HDL (mmol/L): 0,54
Potassium (mEq/L): 4,3
LDL (mmol/L): 3,7
Sodium (mEq/L): 143.0
Pro-BNP (ng/L): 192.0
Protein (g/L): 75
T3 (pg/dL): 0,05
T4 (ng/L): 14
Troponin (ng/mL): 0,03
TSH (mIU/L): 1,29
Urea (mg/dL): 7,49
LVEF (%): 39.0
Medications: Angiotensin II Receptor Blocker, Beta Blockers, Digoxin, Loop Diuretics
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Sinus Node Dysfunction
            ",survivor,"RANKING: 1. Survivor
REASONING: 

This patient's prognosis is likely to be a survivor due to the presence of certain factors that suggest a relatively preserved cardiac function and the absence of severe symptoms. The patient's LVEF of 39% indicates a significant impairment of cardiac function, but the absence of evidence of acute myocardial infarction (Troponin < 0.03 ng/mL) and the lack of severe ventricular arrhythmias (non-sustained ventricular tachycardia) suggest that the patient's cardiac function is not severely compromised. Additionally, the patient's blood pressure is relatively well-controlled (135/99 mmHg), and the patient is on medications that are commonly used to manage heart failure and arrhythmias. The patient's NYHA Class II indicates mild symptoms, suggesting that the patient is still able to perform daily activities without significant limitation. Overall, while the patient has a significant underlying condition (dilated cardiomyopathy), the current data suggest that the patient is likely to survive for the next few years with proper management.

RANKING: 2. Pump failure death
REASONING: 

A pump failure death is a possible outcome for this patient, but it is less likely than a survivorship. The patient's LVEF of 39% indicates significant impairment of cardiac function, which increases the risk of heart failure. The patient's elevated creatinine level (88.0 mmol/L) also suggests impaired renal function, which can be a complication of heart failure. However, the patient is already on medications that are commonly used to manage heart failure (Angiotensin II Receptor Blocker, Beta Blockers, Digoxin, Loop Diuretics), which may help to slow disease progression. The patient's blood pressure is also relatively well-controlled, which reduces the risk of further cardiac stress. However, the patient's elevated troponin level (0.03 ng/mL) and the presence of ventricular extrasystole (monomorphic) suggest that the patient's cardiac function is not entirely preserved.

RANKING: 3. Sudden cardiac death
REASONING: 

Sudden cardiac death is the least likely outcome for this patient, but it cannot be ruled out entirely. The patient's LVEF of 39% and elevated troponin level (0.03 ng/mL) suggest that the patient's cardiac function is impaired, which increases the risk of arrhythmias. The presence of ventricular extrasystole (monomorphic) is a significant finding that suggests an increased risk of arrhythmias. However, the absence of evidence of ventricular tachycardia or non-sustained ventricular tachycardia (CH > 10) reduces the risk of sudden cardiac death. The patient's blood pressure is relatively well-controlled, and the patient is already on medications that are commonly used to manage arrhythmias (Angiotensin II Receptor Blocker, Beta Blockers). Overall, while the patient's cardiac function is impaired, the current data suggest that the risk of sudden cardiac death is relatively low."
607,607,P0946,"Age: 70
Gender: Male 
Weight: 91 kg
Height: 172 cm
NYHA Class: II
Blood Pressure: 125/68 mmHg
Past Medical History: Idiopathic dilated cardiomyopathy, Dyslipemia
Albumin (g/L): 43
ALT or GPT (IU/L): 31.0
AST or GOT (IU/L): 16.0
Total Cholesterol (mmol/L): 4,68
Creatinine (mmol/L): 115.0
Gamma-glutamil transpeptidase (IU/L): 161
Glucose (mmol/L): 5,7
Hemoglobin (g/L): 155.0
HDL (mmol/L): 0,52
Potassium (mEq/L): 4,6
LDL (mmol/L): 3,36
Sodium (mEq/L): 139.0
Pro-BNP (ng/L): 1455.0
Protein (g/L): 68
T3 (pg/dL): 0,05
T4 (ng/L): 17
Troponin (ng/mL): 0,03
TSH (mIU/L): 0,49
Urea (mg/dL): 15,47
LVEF (%): 30.0
Medications: Beta Blockers, Spironolactone, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",survivor,"RANKING: 1. Survivor 
REASONING: The patient has a complex medical history, including idiopathic dilated cardiomyopathy, dyslipidemia, and a significantly reduced LVEF of 30.0%. These factors contribute to an increased risk of adverse cardiac events. However, the patient is currently on medications that are commonly used to manage heart failure and prevent arrhythmias, such as beta blockers, spironolactone, and an ACE inhibitor. The presence of ventricular extrasystoles, as indicated by the ECG, is a concerning sign, but the absence of other indications for more severe arrhythmias or ventricular dysfunction on the ECG suggests that the patient may not be at imminent risk of sudden cardiac death. The patient's elevated troponin level (0.03 ng/mL) is also a concern, but it is not significantly elevated, and the patient's overall clinical presentation does not suggest acute myocardial infarction. Overall, considering the patient's current clinical status and medication regimen, a survivor is the most likely outcome."
608,608,P0947,"Age: 63
Gender: Male 
Weight: 72 kg
Height: 182 cm
NYHA Class: II
Blood Pressure: 124/76 mmHg
Past Medical History: Enolic dilated cardiomyopathy, Diabetes
Albumin (g/L): 45
ALT or GPT (IU/L): 10.0
AST or GOT (IU/L): 11.0
Total Cholesterol (mmol/L): 5,22
Creatinine (mmol/L): 106.0
Gamma-glutamil transpeptidase (IU/L): 8
Glucose (mmol/L): 6,7
Hemoglobin (g/L): 111.0
HDL (mmol/L): 0,54
Potassium (mEq/L): 5,1
LDL (mmol/L): 4,47
Sodium (mEq/L): 137.0
Pro-BNP (ng/L): 747.0
Protein (g/L): 77
T3 (pg/dL): 0,05
T4 (ng/L): 15
Troponin (ng/mL): 0,03
TSH (mIU/L): 3,14
Urea (mg/dL): 11,65
LVEF (%): 40.0
Medications: Diabetes Medication, Beta Blockers, Digoxin, Loop Diuretics, Spironolactone, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",survivor,"RANKING: 1. Survivor
REASONING: 
The patient's overall clinical presentation and laboratory results suggest a high risk of adverse outcomes. The patient has a history of Enolic dilated cardiomyopathy, which is a significant risk factor for heart failure and arrhythmias. The patient's LVEF of 40.0% is also indicative of reduced cardiac function, which can lead to heart failure. Additionally, the patient's elevated creatinine level (106.0 mmol/L) suggests impaired renal function, which can further compromise cardiac function. The presence of ventricular extrasystoles on the ECG, although non-sustained, indicates an increased risk of arrhythmias. However, the patient's NYHA class II suggests that the patient is not severely symptomatic, which may contribute to a better prognosis.

The patient's laboratory results, such as the elevated Troponin level (0.03 ng/mL) and the presence of mild liver dysfunction (ALT or GPT: 10.0 IU/L), do not suggest any acute cardiac injury or liver failure. The patient's electrolyte levels are also within normal limits, which reduces the risk of electrolyte imbalances that can contribute to cardiac arrhythmias.

Considering these factors, the patient's overall risk profile suggests a high risk of adverse outcomes, but the patient's NYHA class II and the absence of severe symptoms may contribute to a better prognosis. Therefore, the most likely outcome is that the patient will survive, albeit with a high risk of cardiac complications.

RANKING: 2. Sudden cardiac death
REASONING: 
The patient's history of Enolic dilated cardiomyopathy and the presence of ventricular extrasystoles on the ECG increase the risk of sudden cardiac death. The patient's LVEF of 40.0% is also a risk factor for cardiac arrhythmias, which can lead to sudden cardiac death. The patient's elevated creatinine level (106.0 mmol/L) and mild liver dysfunction (ALT or GPT: 10.0 IU/L) may contribute to a higher risk of cardiac complications.

Although the patient's NYHA class II suggests that the patient is not severely symptomatic, the presence of ventricular extrasystoles on the ECG is a significant risk factor for sudden cardiac death. The patient's elevated Troponin level (0.03 ng/mL) may also indicate some degree of cardiac injury, which could contribute to a higher risk of arrhythmias.

RANKING: 3. Pump failure death
REASONING: 
The patient's LVEF of 40.0% is a significant indicator of reduced cardiac function, which increases the risk of heart failure. The patient's elevated creatinine level (106.0 mmol/L) and mild liver dysfunction (ALT or GPT: 10.0 IU/L) also suggest impaired renal function, which can further compromise cardiac function.

However, the patient's NYHA class II suggests that the patient is not severely symptomatic, which reduces the risk of pump failure death. Additionally, the patient's elevated Troponin level (0.03 ng/mL) is not indicative of acute cardiac injury, which reduces the risk of sudden cardiac death.

While the patient's history of Enolic dilated cardiomyopathy and the presence of ventricular extrasystoles on the ECG increase the risk of cardiac complications, the patient's overall clinical presentation and laboratory results suggest that pump failure death is less likely than sudden cardiac death."
609,609,P0949,"Age: 59
Gender: Male 
Weight: 103 kg
Height: 184 cm
NYHA Class: II
Blood Pressure: 128/78 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Dyslipemia, Hypertension, Myocardial Infarction
Albumin (g/L): 33
ALT or GPT (IU/L): 15.0
AST or GOT (IU/L): 9.0
Total Cholesterol (mmol/L): 3,49
Creatinine (mmol/L): 80.0
Gamma-glutamil transpeptidase (IU/L): 16
Glucose (mmol/L): 4,7
Hemoglobin (g/L): 118.0
HDL (mmol/L): 1,4
Potassium (mEq/L): 3,6
LDL (mmol/L): 1,27
Sodium (mEq/L): 141.0
Pro-BNP (ng/L): 1152.0
Protein (g/L): 64
T3 (pg/dL): 0,05
T4 (ng/L): 15
Troponin (ng/mL): 0,03
TSH (mIU/L): 1,38
Urea (mg/dL): 4,49
LVEF (%): 30.0
Medications: Digoxin, Loop Diuretics, Statins, ACE Inhibitor, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"RANKING: 1. Survivor
REASONING: 
This patient has a history of ischemic dilated cardiomyopathy, which is a significant risk factor for sudden cardiac death. However, the patient's NYHA Class II indicates that they are not experiencing severe symptoms and are still able to perform daily activities without significant limitation. The patient's LVEF is 30%, which is a significant impairment, but it is not immediately life-threatening. The patient's ECG shows non-sustained ventricular tachycardia, which is a concerning finding but not a guarantee of sudden cardiac death. The patient's medications, including ACE inhibitors and beta-blockers, are appropriate for managing heart failure and reducing the risk of sudden cardiac death. The patient's biomarkers, such as troponin and creatinine, are within normal limits. Overall, while this patient has several risk factors for adverse outcomes, their overall clinical presentation and treatment plan suggest that they are at a lower risk for sudden cardiac death compared to pump failure death. 

RANKING: 2. Pump failure death
REASONING: 
This patient has a history of ischemic dilated cardiomyopathy, which is a significant risk factor for heart failure. The patient's LVEF is 30%, which is a significant impairment, and their NYHA Class II indicates that they are experiencing some symptoms. The patient's creatinine level is elevated, which may indicate some degree of kidney dysfunction, which can be a complication of heart failure. The patient's medications, including loop diuretics, are appropriate for managing heart failure, but the patient's current ECG findings and biomarkers do not suggest an immediate risk of pump failure. However, the patient's overall clinical presentation and treatment plan suggest that they are at a moderate risk for heart failure, which could potentially lead to pump failure.

RANKING: 3. Sudden cardiac death
REASONING: 
This patient has a history of ischemic dilated cardiomyopathy, which is a significant risk factor for sudden cardiac death. The patient's ECG shows non-sustained ventricular tachycardia, which is a concerning finding that increases the risk of sudden cardiac death. The patient's LVEF is 30%, which is a significant impairment, and their NYHA Class II indicates that they are experiencing some symptoms. The patient's biomarkers, such as troponin, are within normal limits, but the patient's ECG findings and medical history suggest that they are at a higher risk for sudden cardiac death compared to pump failure death. However, the patient's overall clinical presentation and treatment plan suggest that they are at a lower risk compared to the survivor category."
610,610,P0954,"Age: 57
Gender: Male 
Weight: 109 kg
Height: 178 cm
NYHA Class: II
Blood Pressure: 117/87 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Myocardial Infarction
Albumin (g/L): 43
ALT or GPT (IU/L): 29.0
AST or GOT (IU/L): 20.0
Total Cholesterol (mmol/L): 4,45
Creatinine (mmol/L): 80.0
Gamma-glutamil transpeptidase (IU/L): 25
Glucose (mmol/L): 5,8
Hemoglobin (g/L): 147.0
HDL (mmol/L): 0,88
Potassium (mEq/L): 4,2
LDL (mmol/L): 2,9
Sodium (mEq/L): 136.0
Pro-BNP (ng/L): 72.0
Protein (g/L): 71
T3 (pg/dL): 0,06
T4 (ng/L): 15
Troponin (ng/mL): 0,03
TSH (mIU/L): 1,9
Urea (mg/dL): 4,82
LVEF (%): 45.0
Medications: Loop Diuretics, Statins, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",survivor,"RANKING: 1. Survivor
REASONING: The patient is currently classified as a survivor, and the data provided suggests that the patient is not in immediate danger of cardiac death. The patient's New York Heart Association (NYHA) class is II, indicating mild symptoms, and the patient is receiving medications such as loop diuretics, statins, and ACE inhibitors, which are commonly used to manage heart failure and ischemic heart disease. The patient's creatinine level is slightly elevated, but it is not severely impaired, and the patient's kidney function is not severely compromised. The patient's LVEF is 45%, which is below the normal range, but it is not extremely low. The patient's troponin level is within normal limits, indicating no acute myocardial infarction. The ECG impression shows no signs of ventricular tachycardia, non-sustained ventricular tachycardia, or paroxysmal supraventricular tachyarrhythmia, which are all potential predictors of cardiac death. Overall, the patient's data suggests that the patient is not at high risk for cardiac death in the short term."
611,611,P0955,"Age: 59
Gender: Male 
Weight: 94 kg
Height: 170 cm
NYHA Class: II
Blood Pressure: 148/79 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Dyslipemia, Hypertension
Albumin (g/L): 41
ALT or GPT (IU/L): 11.0
AST or GOT (IU/L): 9.0
Total Cholesterol (mmol/L): 6,57
Creatinine (mmol/L): 97.0
Gamma-glutamil transpeptidase (IU/L): 11
Glucose (mmol/L): 5,7
Hemoglobin (g/L): 123.0
HDL (mmol/L): 0,54
Potassium (mEq/L): 4,8
LDL (mmol/L): 2,66
Sodium (mEq/L): 139.0
Pro-BNP (ng/L): 553.0
Protein (g/L): 71
T3 (pg/dL): 0,05
T4 (ng/L): 14
Troponin (ng/mL): 0,01
TSH (mIU/L): 1,63
Urea (mg/dL): 9,65
LVEF (%): 35.0
Medications: Beta Blockers, Loop Diuretics, Spironolactone, Statins, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"RANKING: 1. Survivor
REASONING: 

The patient's prognosis is predicted to be a survivor due to several factors. Firstly, the patient's age (59 years) is not considered old for a male patient, and the absence of advanced age-related comorbidities. The patient's NYHA Class II indicates that they have some limitation in physical activity due to their heart condition, but it is not severe.

The patient's laboratory results show that the liver enzymes (ALT and AST) are within normal limits, and the kidney function is slightly elevated, but not critically impaired. The patient's lipid profile is also within normal limits, which is beneficial for cardiovascular health. The patient's electrolyte levels are within normal limits, and the glucose level is slightly elevated, but not significantly so.

The patient's medication regimen is well-managed, with beta blockers, loop diuretics, spironolactone, statins, and ACE inhibitors, which are standard treatments for heart failure and hypertension. The absence of ventricular extrasystoles, ventricular tachycardia, non-sustained ventricular tachycardia, and paroxysmal supraventricular tachyarrhythmia on the ECG is also a positive sign.

The patient's LVEF (left ventricular ejection fraction) is significantly reduced at 35%, indicating severe left ventricular dysfunction. However, this is not uncommon in patients with ischemic dilated cardiomyopathy. The elevated Pro-BNP level (553 ng/L) suggests that the patient is experiencing some degree of ventricular strain, but it is not excessively high.

Overall, considering the patient's age, NYHA Class, and medication regimen, the predicted prognosis is a survivor. However, close monitoring and follow-up are essential to adjust the treatment plan as needed to prevent further deterioration.

RANKING: 2. Sudden cardiac death
REASONING: 

The patient's prognosis is predicted to be at risk for sudden cardiac death due to several factors. Firstly, the patient's LVEF is significantly reduced at 35%, indicating severe left ventricular dysfunction. This increases the risk of arrhythmias and sudden cardiac death.

The patient's Pro-BNP level (553 ng/L) is elevated, which suggests that the patient is experiencing some degree of ventricular strain. This could be a sign of worsening heart failure, which increases the risk of sudden cardiac death.

The patient's ECG shows ventricular extrasystoles, which is a risk factor for sudden cardiac death. Although the ventricular tachycardia, non-sustained ventricular tachycardia, and paroxysmal supraventricular tachyarrhythmia were not present, the presence of ventricular extrasystoles is still a concern.

The patient's medication regimen is well-managed, but the patient's high blood pressure (148/79 mmHg) and elevated creatinine (97.0 mmol/L) levels may not be adequately controlled, which could increase the risk of sudden cardiac death.

RANKING: 3. Pump failure death
REASONING: 

The patient's prognosis is predicted to be at risk for pump failure death due to several factors. Firstly, the patient's LVEF is significantly reduced at 35%, indicating severe left ventricular dysfunction. This increases the risk of heart failure and pump failure.

The patient's Pro-BNP level (553 ng/L) is elevated, which suggests that the patient is experiencing some degree of ventricular strain. This could be a sign of worsening heart failure, which increases the risk of pump failure.

The patient's ECG shows ventricular extrasystoles, which is a risk factor for pump failure. Although the ventricular tachycardia, non-sustained ventricular tachycardia, and paroxysmal supraventricular tachyarrhythmia were not present, the presence of ventricular extrasystoles is still a concern.

The patient's NYHA Class II indicates that they have some limitation in physical activity due to their heart condition, which increases the risk of pump failure. The patient's elevated creatinine (97.0 mmol/L) level also indicates impaired kidney function, which can exacerbate heart failure and pump failure.

The patient's medication regimen is well-managed, but the patient's high blood pressure (148/79 mmHg) and elevated creatinine (97.0 mmol/L) levels may not be adequately controlled, which could increase the risk of pump failure."
612,612,P0956,"Age: 80
Gender: Female 
Weight: 64 kg
Height: 165 cm
NYHA Class: II
Blood Pressure: 135/80 mmHg
Past Medical History: Valvular cardiomyopathy, Hypertension
Albumin (g/L): 41
ALT or GPT (IU/L): 12.0
AST or GOT (IU/L): 17.0
Total Cholesterol (mmol/L): 5,72
Creatinine (mmol/L): 88.0
Gamma-glutamil transpeptidase (IU/L): 36
Glucose (mmol/L): 5,8
Hemoglobin (g/L): 128.0
HDL (mmol/L): 1,37
Potassium (mEq/L): 4,7
LDL (mmol/L): 3,78
Sodium (mEq/L): 140.0
Pro-BNP (ng/L): 1032.0
Protein (g/L): 65
T3 (pg/dL): 0,04
T4 (ng/L): 16
Troponin (ng/mL): 0,04
TSH (mIU/L): 2,31
Urea (mg/dL): 8,15
LVEF (%): 56.0
Medications: Beta Blockers, Digoxin, Loop Diuretics, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",survivor,"RANKING: 1. Survivor
REASONING:

This patient's prognosis is ranked as a survivor due to the following reasons:

1. Age: The patient is 80 years old, which is a significant risk factor for cardiovascular disease. However, with proper management and treatment, many patients with similar age and comorbidities can survive for several years.
2. NYHA Class II: The patient's New York Heart Association (NYHA) class II indicates that they have mild symptoms of heart failure, which can be managed with current treatment.
3. Blood Pressure: The patient's blood pressure is well-controlled at 135/80 mmHg, which reduces the risk of cardiovascular events.
4. Medications: The patient is taking beta blockers, digoxin, loop diuretics, and an ACE inhibitor, which are standard treatments for managing heart failure and hypertension.
5. Pro-BNP levels: The patient's Pro-BNP level of 1032 ng/L is elevated, indicating some degree of heart failure. However, this level is not extremely high, suggesting that the patient's heart is still functioning relatively well.
6. LVEF: The patient's left ventricular ejection fraction (LVEF) is 56.0%, which is within the normal range. This indicates that the patient's heart is still pumping effectively, albeit with some impairment.

While the patient has a history of valvular cardiomyopathy and hypertension, which are risk factors for cardiovascular events, their current clinical presentation and treatment plan suggest that they are at moderate risk. With proper management and monitoring, this patient is likely to survive for several years.

The other two prognoses, sudden cardiac death and pump failure death, are less likely due to the following reasons:

- Sudden cardiac death is unlikely due to the patient's well-controlled blood pressure and absence of other risk factors such as electrolyte imbalances, cardiac arrhythmias, or significant left ventricular dysfunction.
- Pump failure death is also less likely due to the patient's relatively preserved LVEF and the effectiveness of their current treatment regimen.

However, close monitoring and follow-up are necessary to ensure that the patient's condition does not deteriorate."
613,613,P0957,"Age: 70
Gender: Male 
Weight: 66 kg
Height: 150 cm
NYHA Class: II
Blood Pressure: 158/80 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Diabetes, Dyslipemia, Hypertension, Myocardial Infarction
Albumin (g/L): 46
ALT or GPT (IU/L): 9.0
AST or GOT (IU/L): 16.0
Total Cholesterol (mmol/L): 5,95
Creatinine (mmol/L): 88.0
Gamma-glutamil transpeptidase (IU/L): 12
Glucose (mmol/L): 6,2
Hemoglobin (g/L): 127.0
HDL (mmol/L): 1,32
Potassium (mEq/L): 3,7
LDL (mmol/L): 3,93
Sodium (mEq/L): 143.0
Protein (g/L): 71
T3 (pg/dL): 0,02
T4 (ng/L): 5
Troponin (ng/mL): 0,03
TSH (mIU/L): 70,54
Urea (mg/dL): 4,33
LVEF (%): 40.0
Medications: Calcium Channel Blocker, Beta Blockers, Loop Diuretics, Statins, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"RANKING: 

1. Survivor
REASONING:
This patient's prognosis is most likely to be a survivor due to the presence of several factors that suggest a relatively stable cardiovascular system. The patient's age is 70, but the patient is still considered to be in the ""older adult"" category, and the absence of any severe symptoms or acute changes in the ECG impression suggests that the patient's cardiovascular system is not in a critical state. Additionally, the patient's NYHA Class II indicates that the patient has some limitations in physical activity, but the patient is still able to perform daily activities. The patient's LVEF of 40% is below normal, but this is not uncommon in patients with ischemic dilated cardiomyopathy.

The patient's laboratory results show some signs of cardiovascular stress, such as elevated creatinine (88.0 mmol/L) and troponin (0.03 ng/mL), but these values are not significantly elevated. The patient's lipid profile is also concerning, with high total cholesterol and LDL levels, but the patient is already on statins and has a good response to this medication.

The patient's medications, including calcium channel blockers, beta blockers, loop diuretics, statins, and ACE inhibitors, suggest that the patient is receiving appropriate treatment for their cardiovascular conditions. The patient's ECG impression does not show any signs of acute arrhythmias or other concerning findings.

Overall, while the patient has several cardiovascular risk factors and underlying conditions, the patient's overall clinical presentation and laboratory results suggest that the patient is likely to survive for the next few years with proper management and treatment.

2. Sudden cardiac death
REASONING:
This patient's prognosis is less likely due to the presence of several factors that increase the risk of sudden cardiac death. The patient's LVEF of 40% is significantly below normal, indicating a poor ejection fraction and potential left ventricular dysfunction. The patient's NYHA Class II also suggests that the patient has some limitations in physical activity, which may increase the risk of cardiac events.

The patient's elevated creatinine (88.0 mmol/L) and troponin (0.03 ng/mL) levels suggest some degree of cardiac stress and potential kidney impairment. The patient's lipid profile is also concerning, with high total cholesterol and LDL levels. The patient's ECG impression shows ventricular extrasystoles, which may indicate some degree of ventricular instability.

However, the patient's age is 70, and the patient is already on multiple medications that are indicated for cardiovascular conditions, which suggests that the patient is receiving some level of cardiovascular management.

3. Pump failure death
REASONING:
This patient's prognosis is the least likely due to the presence of several factors that suggest the patient is not currently experiencing severe left ventricular dysfunction. The patient's LVEF of 40% is significantly below normal, but the patient is already on beta blockers, which can help improve LVEF over time. The patient's NYHA Class II also suggests that the patient is able to perform some level of physical activity, which may help maintain cardiac output.

The patient's laboratory results show some signs of cardiovascular stress, but the patient's troponin level is not significantly elevated, and the patient's ECG impression does not show any signs of acute arrhythmias or other concerning findings. The patient's medication regimen is also well-managed, with multiple medications for cardiovascular conditions.

However, the patient's elevated creatinine (88.0 mmol/L) and urea (4.33 mg/dL) levels suggest some degree of kidney impairment, which may increase the risk of cardiac complications. Overall, while the patient has several cardiovascular risk factors and underlying conditions, the patient's overall clinical presentation and laboratory results suggest that the patient is unlikely to experience pump failure in the near future."
614,614,P0958,"Age: 68
Gender: Male 
Weight: 74 kg
Height: 168 cm
NYHA Class: III
Blood Pressure: 117/61 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Diabetes, Dyslipemia
Albumin (g/L): 33
ALT or GPT (IU/L): 19.0
AST or GOT (IU/L): 13.0
Total Cholesterol (mmol/L): 6,03
Creatinine (mmol/L): 115.0
Gamma-glutamil transpeptidase (IU/L): 7
Glucose (mmol/L): 4,3
Hemoglobin (g/L): 94.0
HDL (mmol/L): 1,22
Potassium (mEq/L): 5,6
LDL (mmol/L): 4,16
Sodium (mEq/L): 139.0
Pro-BNP (ng/L): 252.0
Protein (g/L): 52
T3 (pg/dL): 0,02
T4 (ng/L): 5
Troponin (ng/mL): 0,05
TSH (mIU/L): 83,92
Urea (mg/dL): 16,97
LVEF (%): 30.0
Medications: Diabetes Medication, Amiodarone, Loop Diuretics, Spironolactone, ACE Inhibitor, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: TPSV
        - Bradycardia: No
            ",survivor,"RANKING: 1. Survivor
REASONING: 

This patient's prognosis is likely to be a survivor due to the following reasons:

1. Age: Although the patient is 68 years old, their age alone does not necessarily determine their prognosis. However, age is a risk factor for cardiac events, and this patient's age is not excessively high.

2. NYHA Class III: The patient's New York Heart Association (NYHA) class III indicates moderate symptoms of heart failure, which suggests that the patient has significant cardiac dysfunction. However, this does not necessarily mean that the patient will die from cardiac causes.

3. Medications: The patient is taking several medications that are commonly used to manage heart failure and arrhythmias, such as amiodarone and spironolactone. These medications can help control symptoms and prevent complications.

4. Blood tests: The patient's blood tests show elevated creatinine levels, which may indicate some degree of kidney dysfunction. However, this is not uncommon in patients with heart failure. The patient's troponin levels are also slightly elevated, which may indicate some degree of cardiac stress, but not necessarily a heart attack.

5. ECG Impression: The patient's ECG shows ventricular extrasystoles and TPSV (paroxysmal supraventricular tachycardia), which are common arrhythmias that can be managed with medication. The patient does not have any evidence of ventricular tachycardia or non-sustained ventricular tachycardia, which are more ominous signs.

6. Pro-BNP levels: The patient's Pro-BNP (N-terminal pro-b-type natriuretic peptide) levels are elevated, which is a marker of heart failure. However, this is not a contraindication to survival.

7. Other factors: The patient's weight, height, blood pressure, and other laboratory values are not particularly concerning.

Overall, while this patient has significant cardiac dysfunction and some risk factors for cardiac events, their age, medications, and ECG findings suggest that they are likely to survive for the next few years.

RANKING: 2. Sudden Cardiac Death
REASONING: 

This patient's prognosis is less likely to be sudden cardiac death due to the following reasons:

1. Medications: The patient is taking amiodarone, which is an antiarrhythmic medication that can help prevent sudden cardiac death.

2. ECG Impression: The patient's ECG shows ventricular extrasystoles and TPSV, but no ventricular tachycardia or non-sustained ventricular tachycardia.

3. Pro-BNP levels: The patient's Pro-BNP levels are elevated, which suggests heart failure, but this is not a contraindication to survival.

4. Other factors: The patient's age, weight, blood pressure, and other laboratory values are not particularly concerning.

However, the patient's NYHA class III and elevated creatinine levels suggest that they have significant cardiac dysfunction and kidney impairment, which increases the risk of sudden cardiac death.

RANKING: 3. Pump Failure Death
REASONING: 

This patient's prognosis is less likely to be pump failure death due to the following reasons:

1. Medications: The patient is taking spironolactone, which is an aldosterone antagonist that can help reduce mortality in heart failure patients.

2. ECG Impression: The patient's ECG shows ventricular extrasystoles and TPSV, but no ventricular tachycardia or non-sustained ventricular tachycardia.

3. Pro-BNP levels: The patient's Pro-BNP levels are elevated, which suggests heart failure, but this is not a contraindication to survival.

4. Other factors: The patient's age, weight, blood pressure, and other laboratory values are not particularly concerning.

However, the patient's NYHA class III and elevated creatinine levels suggest that they have significant cardiac dysfunction and kidney impairment, which increases the risk of pump failure. Additionally, the patient's elevated troponin levels suggest some degree of cardiac stress, which may increase the risk of pump failure."
615,615,P0960,"Age: 74
Gender: Female 
Weight: 64 kg
Height: 154 cm
NYHA Class: II
Blood Pressure: 141/72 mmHg
Past Medical History: Ischemic dilated cardiomyopathy
Albumin (g/L): 42
ALT or GPT (IU/L): 15.0
AST or GOT (IU/L): 14.0
Total Cholesterol (mmol/L): 4,76
Creatinine (mmol/L): 80.0
Gamma-glutamil transpeptidase (IU/L): 10
Glucose (mmol/L): 5
Hemoglobin (g/L): 115.0
HDL (mmol/L): 1,03
Potassium (mEq/L): 4,9
LDL (mmol/L): 2,9
Sodium (mEq/L): 140.0
Pro-BNP (ng/L): 588.0
Protein (g/L): 67
T3 (pg/dL): 0,04
T4 (ng/L): 14
Troponin (ng/mL): 0,01
TSH (mIU/L): 0,97
Urea (mg/dL): 11,15
LVEF (%): 25.0
Medications: Angiotensin II Receptor Blocker, Beta Blockers, Loop Diuretics, Statins
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"RANKING: 
1. Survivor
REASONING: 
Based on the provided patient data, the patient is 74 years old, with a history of ischemic dilated cardiomyopathy, which is a condition that significantly impairs the heart's ability to pump blood effectively. The left ventricular ejection fraction (LVEF) is 25%, indicating severe systolic dysfunction. Despite this, the patient has a relatively stable vital sign profile, with no signs of acute decompensation or acute coronary syndrome.

The patient's medication regimen is also noteworthy, as it includes angiotensin II receptor blockers, beta blockers, and statins, which are commonly used to manage heart failure, hypertension, and hyperlipidemia, respectively. The patient's electrolyte and liver function tests are also within relatively normal limits, with no significant abnormalities in liver enzymes or kidney function.

While the patient has a history of ventricular extrasystole, which may indicate some degree of cardiac conduction system dysfunction, it is not severe enough to be a major concern. The absence of non-sustained ventricular tachycardia, ventricular tachycardia, or other arrhythmias on the ECG suggests that the patient does not have a high risk of sudden cardiac death.

Overall, considering the patient's age, medical history, and medication regimen, I believe that the patient is at a relatively low risk for adverse outcomes, and the most likely prognosis is survival."
616,616,P0962,"Age: 55
Gender: Male 
Weight: 105 kg
Height: 182 cm
NYHA Class: II
Blood Pressure: 137/102 mmHg
Past Medical History: Enolic dilated cardiomyopathy, Dyslipemia, Peripheral vascular disease, Hypertension
Albumin (g/L): 46
ALT or GPT (IU/L): 11.0
AST or GOT (IU/L): 12.0
Total Cholesterol (mmol/L): 4,16
Creatinine (mmol/L): 97.0
Gamma-glutamil transpeptidase (IU/L): 12
Glucose (mmol/L): 5
Hemoglobin (g/L): 151.0
HDL (mmol/L): 0,7
Potassium (mEq/L): 4,4
LDL (mmol/L): 2,38
Sodium (mEq/L): 139.0
Pro-BNP (ng/L): 1083.0
Protein (g/L): 75
T3 (pg/dL): 0,06
T4 (ng/L): 18
Troponin (ng/mL): 0,03
TSH (mIU/L): 2,22
Urea (mg/dL): 6,82
LVEF (%): 40.0
Medications: Beta Blockers, Digoxin, Loop Diuretics, Spironolactone, Hydralazine, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",survivor,"RANKING: 
1. Survivor
REASONING:
The patient's prognosis is ranked as a survivor due to the following reasons:

- The patient's NYHA Class is II, indicating mild symptoms of heart failure, which suggests that the heart is still functioning to some extent.
- The patient's LVEF is 40.0%, which is lower than the normal range, but not severely impaired. This suggests that the heart is still pumping blood, albeit inefficiently.
- The patient's Pro-BNP level is elevated, indicating some degree of heart failure, but not extremely high.
- The patient is on medications for heart failure (Loop Diuretics, Spironolactone), which suggests that the condition is being managed.
- The ECG findings are not indicative of severe cardiac dysfunction, with no evidence of ventricular tachycardia or significant arrhythmias.
- The patient's laboratory values, such as electrolytes, liver enzymes, and renal function, are relatively stable, indicating that there is no acute or chronic condition that would rapidly deteriorate the patient's prognosis.

While the patient has a significant number of comorbidities, including hypertension, dyslipidemia, and peripheral vascular disease, these conditions are being managed with medications. The patient's overall clinical presentation and laboratory values suggest that they are likely to survive in the short term.

RANKING 2: Sudden Cardiac Death
REASONING:
The patient's prognosis is ranked as Sudden Cardiac Death due to the following reasons:

- The patient's LVEF is severely impaired (40.0%), indicating significant left ventricular dysfunction.
- The patient has a history of Enolic dilated cardiomyopathy, which is a condition that can lead to sudden cardiac death.
- The patient's Pro-BNP level is elevated, indicating some degree of heart failure.
- The patient has a history of hypertension, dyslipidemia, and peripheral vascular disease, which are all risk factors for sudden cardiac death.
- The patient's ECG findings, including ventricular extrasystoles, suggest some degree of cardiac instability.

While the patient is on medications for heart failure, the presence of severe left ventricular dysfunction and the patient's history of cardiac conditions make sudden cardiac death a significant concern.

RANKING 3: Pump Failure Death
REASONING:
The patient's prognosis is ranked as Pump Failure Death due to the following reasons:

- The patient's LVEF is severely impaired (40.0%), indicating significant left ventricular dysfunction.
- The patient has a history of Enolic dilated cardiomyopathy, which can lead to progressive heart failure.
- The patient's Pro-BNP level is elevated, indicating some degree of heart failure.
- The patient's history of hypertension, dyslipidemia, and peripheral vascular disease increases the risk of pump failure.
- The patient's laboratory values, such as elevated creatinine and urea, suggest some degree of renal impairment, which can be a complication of heart failure.

While the patient is on medications for heart failure, the severity of left ventricular dysfunction and the patient's history of cardiac conditions make pump failure a likely outcome in the long term."
617,617,P0964,"Age: 81
Gender: Female 
Weight: 70 kg
Height: 160 cm
NYHA Class: II
Blood Pressure: 125/75 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Dyslipemia, Myocardial Infarction
Albumin (g/L): 42
ALT or GPT (IU/L): 39.0
AST or GOT (IU/L): 26.0
Total Cholesterol (mmol/L): 4,68
Creatinine (mmol/L): 80.0
Gamma-glutamil transpeptidase (IU/L): 101
Glucose (mmol/L): 7,1
Hemoglobin (g/L): 137.0
HDL (mmol/L): 2,48
Potassium (mEq/L): 5
LDL (mmol/L): 1,5
Sodium (mEq/L): 130.0
Pro-BNP (ng/L): 2733.0
Protein (g/L): 66
T3 (pg/dL): 0,05
T4 (ng/L): 19
Troponin (ng/mL): 0,03
TSH (mIU/L): 1,8
Urea (mg/dL): 10,31
LVEF (%): 70.0
Medications: Calcium Channel Blocker, Loop Diuretics, Spironolactone, Statins, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",survivor,"RANKING: 1. Survivor
REASONING: 

The patient's overall clinical presentation and laboratory results suggest a high likelihood of survival. The patient's age is 81, but their NYHA Class II indicates that they have some level of cardiac dysfunction, which is manageable with their current medications. The patient's LVEF is 70%, which is within the normal range, indicating that their heart is still functioning relatively well.

The patient's laboratory results show elevated levels of BNP, which is a marker of cardiac stress and strain. However, the patient's Troponin level is within the normal range, indicating that there is no acute myocardial injury. The patient's electrolyte levels, including potassium, are within normal limits, and their liver function tests are also within normal limits.

The patient's ECG results show ventricular extrasystoles, which are common in patients with cardiac disease, but there is no indication of more serious arrhythmias. The patient is also not showing any signs of acute myocardial infarction or other cardiac events.

Given the patient's overall clinical presentation and laboratory results, it is likely that they will survive for the next few years without any significant cardiac events. The patient's medications, including calcium channel blockers, loop diuretics, and statins, are likely to continue to manage their cardiac symptoms and prevent further cardiac events.

While it is impossible to predict with certainty, the combination of the patient's age, NYHA Class, LVEF, and laboratory results suggest that a survivor outcome is the most likely."
618,618,P0969,"Age: 75
Gender: Male 
Weight: 91 kg
Height: 177 cm
NYHA Class: II
Blood Pressure: 130/80 mmHg
Past Medical History: Idiopathic dilated cardiomyopathy, Diabetes, Hypertension
Albumin (g/L): 42
ALT or GPT (IU/L): 21.0
AST or GOT (IU/L): 18.0
Total Cholesterol (mmol/L): 3,41
Creatinine (mmol/L): 88.0
Gamma-glutamil transpeptidase (IU/L): 74
Glucose (mmol/L): 14,5
Hemoglobin (g/L): 156.0
HDL (mmol/L): 1,34
Potassium (mEq/L): 4
LDL (mmol/L): 1,58
Sodium (mEq/L): 140.0
Pro-BNP (ng/L): 3298.0
Protein (g/L): 70
T4 (ng/L): 14
Troponin (ng/mL): 0,02
TSH (mIU/L): 6,45
Urea (mg/dL): 6,49
LVEF (%): 47.0
Medications: Diabetes Medication, Angiotensin II Receptor Blocker, Beta Blockers, Statins, ACE Inhibitor, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: No
            ",survivor,"RANKING: 1. Survivor
REASONING: The patient's current condition and medical history suggest that they are at high risk for cardiac complications. The patient has a history of idiopathic dilated cardiomyopathy, which is a significant risk factor for heart failure and sudden cardiac death. The patient's ejection fraction (LVEF) is 47%, which is below the normal range, indicating impaired heart function. Additionally, the patient has a history of hypertension and diabetes, both of which can contribute to cardiac damage and worsening heart function.

The patient's current medications, including beta blockers, ACE inhibitors, and statins, are standard treatments for managing heart failure and hypertension. However, the patient's elevated troponin level (0.02 ng/mL) suggests some degree of cardiac muscle damage, which may indicate that the patient's heart is not responding optimally to treatment.

Despite these factors, the patient's overall clinical impression is that of a survivor, as there is no mention of any acute cardiac events or severe symptoms that would indicate a sudden cardiac death or pump failure. The patient's ECG findings do not show any life-threatening arrhythmias, and the patient's biomarkers, such as troponin and BNP, are not excessively elevated.

Therefore, based on the available data, I predict that the patient is most likely to survive for the next few years, although it is essential to continue monitoring their condition and adjusting their treatment plan as needed to minimize the risk of cardiac complications."
619,619,P0970,"Age: 66
Gender: Male 
Weight: 66 kg
Height: 168 cm
NYHA Class: II
Blood Pressure: 84/49 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Dyslipemia, Myocardial Infarction
Albumin (g/L): 43
ALT or GPT (IU/L): 29.0
AST or GOT (IU/L): 26.0
Total Cholesterol (mmol/L): 4,97
Creatinine (mmol/L): 115.0
Gamma-glutamil transpeptidase (IU/L): 47
Glucose (mmol/L): 5,3
Hemoglobin (g/L): 148.0
HDL (mmol/L): 1,16
Potassium (mEq/L): 4,5
LDL (mmol/L): 2,95
Sodium (mEq/L): 142.0
Pro-BNP (ng/L): 2694.0
Protein (g/L): 73
T4 (ng/L): 18
Troponin (ng/mL): 0,01
TSH (mIU/L): 2,63
Urea (mg/dL): 10,15
LVEF (%): 17.0
Medications: Beta Blockers, Loop Diuretics, Statins, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: No
            ",survivor,"RANKING: 
1. Survivor
REASONING: 
Based on the provided patient data, I rank the patient as a survivor for the next few years. The patient's age, NYHA Class II indicates that they have a moderate level of heart failure, but they are still able to perform daily activities without severe limitation. The presence of ischemic dilated cardiomyopathy and myocardial infarction in the past medical history suggests that the patient has a significant cardiac history, but the patient is currently receiving optimal medical therapy with beta blockers, loop diuretics, statins, and an ACE inhibitor. The patient's ejection fraction (LVEF) is 17%, which is relatively preserved, indicating that the patient's heart is still pumping blood efficiently, albeit with reduced efficiency.

The patient's biomarkers, such as troponin and creatinine, are not significantly elevated, indicating that there is no acute cardiac injury or kidney dysfunction. The patient's liver enzymes, albumin, and kidney function tests are also within normal limits.

The patient's ECG shows ventricular extrasystole, which is a common finding in patients with heart failure, but it is not indicative of a high risk of sudden cardiac death. The absence of ventricular tachycardia, non-sustained ventricular tachycardia, and paroxysmal supraventricular tachyarrhythmia further reduces the risk of sudden cardiac death.

Overall, based on the patient's clinical presentation, medical history, and laboratory results, I believe that the patient is at low risk for sudden cardiac death and pump failure, and therefore, the most likely outcome for the next few years is survival."
620,620,P0971,"Age: 66
Gender: Female 
Weight: 78 kg
Height: 160 cm
NYHA Class: III
Blood Pressure: 150/90 mmHg
Past Medical History: Hypertensive cardiomyopathy, Diabetes, Dyslipemia, Hypertension
Albumin (g/L): 36
ALT or GPT (IU/L): 24.0
AST or GOT (IU/L): 18.0
Total Cholesterol (mmol/L): 6,05
Creatinine (mmol/L): 106.0
Gamma-glutamil transpeptidase (IU/L): 160
Glucose (mmol/L): 12,1
Hemoglobin (g/L): 112.0
HDL (mmol/L): 1,14
Potassium (mEq/L): 4,1
LDL (mmol/L): 3,7
Sodium (mEq/L): 139.0
Pro-BNP (ng/L): 104.0
Protein (g/L): 75
T3 (pg/dL): 0,02
T4 (ng/L): 13
Troponin (ng/mL): 0,01
TSH (mIU/L): 49,17
Urea (mg/dL): 8,99
LVEF (%): 56.0
Medications: Diabetes Medication, Beta Blockers, Loop Diuretics, Spironolactone, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: Second-degree AVB - type II
            ",survivor,"RANKING: 1. Survivor
REASONING: 

The patient's overall prognosis is favorable, and they are currently classified as a survivor. Several factors contribute to this outcome:

1. Age: Although the patient is 66 years old, their age alone is not a contraindication for a favorable outcome. In fact, many patients with similar age and comorbidities can survive for many years with proper management.
2. NYHA Class III: The patient's heart failure classification indicates that they have severe symptoms, but this classification is not uncommon in patients with long-standing hypertension and cardiomyopathy. With proper treatment, many patients with NYHA Class III can experience significant improvement in symptoms.
3. Low Pro-BNP levels: The patient's Pro-BNP level is within the normal range, indicating that their heart is not experiencing excessive stress. Elevated Pro-BNP levels are often associated with more severe heart failure.
4. Low Troponin levels: The patient's troponin level is within the normal range, indicating that their heart muscle is not experiencing significant damage.
5. Normal LVEF: The patient's left ventricular ejection fraction (LVEF) is 56%, which is within the normal range for many adults. This suggests that the patient's heart is still functioning relatively well.
6. Absence of ECG abnormalities: The patient's ECG does not show any signs of significant arrhythmias or other abnormalities that could indicate a high risk of sudden cardiac death.
7. Presence of multiple medications: The patient is taking a combination of medications that are commonly used to manage heart failure, hypertension, and diabetes. This suggests that the patient is receiving comprehensive care and is likely to benefit from ongoing management.
8. Low T3 levels: The patient's thyroid function is within the normal range, which reduces the risk of cardiac complications associated with hypothyroidism.

While the patient has several comorbidities, including hypertension, cardiomyopathy, and diabetes, their overall clinical presentation and laboratory results suggest that they are at low risk for adverse outcomes. Therefore, I predict that the patient is likely to survive for the next few years with proper management and monitoring."
621,621,P0973,"Age: 51
Gender: Male 
Weight: 80 kg
Height: 160 cm
NYHA Class: II
Blood Pressure: 120/80 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Dyslipemia, Hypertension, Myocardial Infarction
Albumin (g/L): 44
ALT or GPT (IU/L): 43.0
AST or GOT (IU/L): 19.0
Total Cholesterol (mmol/L): 4,94
Creatinine (mmol/L): 80.0
Gamma-glutamil transpeptidase (IU/L): 36
Glucose (mmol/L): 5,7
Hemoglobin (g/L): 144.0
HDL (mmol/L): 0,83
Potassium (mEq/L): 4,6
LDL (mmol/L): 2,72
Sodium (mEq/L): 141.0
Pro-BNP (ng/L): 80.0
Protein (g/L): 74
T4 (ng/L): 14
Troponin (ng/mL): 0,01
TSH (mIU/L): 2,68
Urea (mg/dL): 3,83
LVEF (%): 41.0
Medications: Beta Blockers, Loop Diuretics, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Second-degree AVB - type I
            ",survivor,"RANKING: 

1. Survivor
REASONING: 

This patient's prognosis is ranked as a survivor due to the following factors:

- The patient's age of 51 is not considered elderly, and with proper management, many patients with ischemic dilated cardiomyopathy can survive for many years with optimal treatment.
- The patient's NYHA Class II indicates mild symptoms, which suggests that the patient is still relatively active and can tolerate moderate physical activity without significant symptoms.
- The patient's medication regimen includes beta blockers, loop diuretics, and ACE inhibitors, which are standard treatments for managing heart failure and reducing cardiovascular risk.
- The patient's LVEF of 41% is lower than normal, but it is not severely reduced, and with optimal treatment, it is possible to improve the ejection fraction over time.
- The patient's troponin level is normal, which suggests that there is no significant myocardial damage.
- The patient's ECG findings, including ventricular extrasystole and non-sustained ventricular tachycardia, are not indicative of severe cardiac dysfunction.
- The patient's renal function, as indicated by the creatinine level of 3.83 mg/dL, is not severely impaired.

While the patient has a history of myocardial infarction and hypertension, these factors do not necessarily dictate a poor prognosis, and with proper management, the patient can be expected to survive for many years.

2. Sudden Cardiac Death
REASONING: 

This patient's prognosis is ranked as sudden cardiac death due to the following factors:

- The patient's history of myocardial infarction and ischemic dilated cardiomyopathy increases the risk of sudden cardiac death.
- The patient's LVEF of 41% is significantly reduced, indicating poor cardiac function.
- The patient's ECG findings, including ventricular extrasystole and non-sustained ventricular tachycardia, indicate an increased risk of arrhythmias.
- The patient's elevated troponin level (0.01 ng/mL) suggests some degree of myocardial damage, which can increase the risk of sudden cardiac death.

While the patient is currently on beta blockers and ACE inhibitors, which can help reduce the risk of sudden cardiac death, the patient's underlying cardiac dysfunction and history of myocardial infarction still make sudden cardiac death a significant risk.

3. Pump Failure Death
REASONING: 

This patient's prognosis is ranked as pump failure death due to the following factors:

- The patient's LVEF of 41% is significantly reduced, indicating poor cardiac function.
- The patient's NYHA Class II indicates that the patient experiences symptoms with moderate physical activity, which suggests that the patient's cardiac function is not well-compensated.
- The patient's elevated creatinine level (3.83 mg/dL) indicates impaired renal function, which can be a sign of advanced cardiac failure.
- The patient's elevated BNP level (80 ng/L) suggests that the patient has significant cardiac stress and is at risk of developing heart failure.
- The patient's medication regimen, while adequate for managing hypertension and heart failure, may not be sufficient to reverse the patient's cardiac dysfunction.

While the patient is currently on beta blockers and ACE inhibitors, which can help manage heart failure, the patient's underlying cardiac dysfunction and impaired renal function make pump failure death a significant risk."
622,622,P0976,"Age: 66
Gender: Male 
Weight: 68 kg
Height: 163 cm
NYHA Class: II
Blood Pressure: 140/80 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Diabetes, Hypertension, Myocardial Infarction
Albumin (g/L): 44
ALT or GPT (IU/L): 31.0
AST or GOT (IU/L): 16.0
Total Cholesterol (mmol/L): 3,36
Creatinine (mmol/L): 88.0
Gamma-glutamil transpeptidase (IU/L): 34
Glucose (mmol/L): 8,8
Hemoglobin (g/L): 134.0
HDL (mmol/L): 0,88
Potassium (mEq/L): 4
LDL (mmol/L): 1,24
Sodium (mEq/L): 140.0
Pro-BNP (ng/L): 652.0
Protein (g/L): 74
T4 (ng/L): 12
Troponin (ng/mL): 0,01
TSH (mIU/L): 3,13
Urea (mg/dL): 4,82
LVEF (%): 32.0
Medications: Calcium Channel Blocker, Diabetes Medication, Beta Blockers, Statins, ACE Inhibitor, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: TPSV
        - Bradycardia: No
            ",survivor,"RANKING: 1. Survivor
REASONING:

Based on the provided patient data, I would rank the patient as having a high likelihood of survival over the next few years. Here's a breakdown of the reasoning:

1. Age and NYHA Class: The patient is 66 years old and has a NYHA Class II heart failure, indicating mild symptoms. While age is a significant risk factor for mortality, the patient's NYHA Class is relatively mild, suggesting that the heart is still functional to some extent.

2. Medications: The patient is on a combination of medications that are commonly used to manage heart failure, hypertension, and coronary artery disease. This suggests that the patient is receiving appropriate treatment for their underlying conditions.

3. Electrocardiogram (ECG) findings: While the patient has a polymorphic ventricular extrasystole, this finding is not necessarily a cause for concern. The absence of ventricular tachycardia, non-sustained ventricular tachycardia, and paroxysmal supraventricular tachyarrhythmia reduces the risk of sudden cardiac death.

4. Laboratory results: The patient's creatinine level is elevated, but this is not uncommon in patients with heart failure. The troponin level is normal, indicating that there is no significant myocardial infarction. The patient's renal function is also mildly impaired, but this is not a contraindication for survival.

5. Biomarkers: The Pro-BNP level is elevated, indicating some degree of heart failure. However, the level is not excessively high, suggesting that the patient's heart is not severely failing.

6. Lipid profile: The patient's lipid profile is not ideal, but this is not a significant risk factor for mortality.

Considering these factors, I believe that the patient has a high likelihood of survival over the next few years, with a relatively low risk of sudden cardiac death or pump failure. However, regular follow-up and monitoring are necessary to adjust the treatment plan and manage the patient's conditions effectively."
623,623,P0977,"Age: 68
Gender: Female 
Weight: 95 kg
Height: 178 cm
NYHA Class: II
Blood Pressure: 140/80 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Diabetes, Hypertension, Myocardial Infarction
Albumin (g/L): 39
ALT or GPT (IU/L): 29.0
AST or GOT (IU/L): 11.0
Total Cholesterol (mmol/L): 3,96
Creatinine (mmol/L): 115.0
Gamma-glutamil transpeptidase (IU/L): 28
Glucose (mmol/L): 7,4
Hemoglobin (g/L): 107.0
HDL (mmol/L): 0,7
Potassium (mEq/L): 5,2
LDL (mmol/L): 1,73
Sodium (mEq/L): 141.0
Pro-BNP (ng/L): 3701.0
Protein (g/L): 71
T4 (ng/L): 17
Troponin (ng/mL): 0,01
TSH (mIU/L): 1,21
Urea (mg/dL): 17,97
LVEF (%): 33.0
Medications: Calcium Channel Blocker, Diabetes Medication, Beta Blockers, Loop Diuretics
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: TPSV
        - Bradycardia: No
            ",survivor,"RANKING: 

1. Survivor
REASONING:
Based on the patient's data, I predict that the patient is most likely to survive for the next few years. The patient has a history of Ischemic dilated cardiomyopathy, which is a significant risk factor for cardiac death. However, the patient is currently taking medications for their condition, including Beta Blockers, Loop Diuretics, and Calcium Channel Blockers, which are commonly used to manage symptoms and improve heart function in patients with heart failure.

The patient's ejection fraction (LVEF) is 33%, which is within the range of 20-40% and indicates that the patient has significant left ventricular dysfunction. However, the patient's NYHA class is II, which indicates mild symptoms and a relatively preserved functional capacity. The patient's renal function is also compromised, with elevated creatinine levels, but this is not uncommon in patients with heart failure.

The patient's biomarkers, such as Troponin and Pro-BNP, are elevated, indicating cardiac stress and strain. However, the absence of significant elevation in these biomarkers suggests that the patient's heart is not in a state of acute injury or severe stress.

The patient's ECG findings, including ventricular extrasystoles and TPSV, are non-specific and do not indicate a high risk of arrhythmic events. Overall, while the patient has significant underlying cardiac disease, the presence of medications and the patient's functional capacity suggest that they are likely to survive for the next few years.

2. Sudden Cardiac Death
REASONING:
While the patient has a history of ischemic dilated cardiomyopathy and other risk factors for cardiac death, the absence of significant biomarkers and the presence of medications that manage their symptoms and heart failure make sudden cardiac death less likely. However, the patient's LVEF is significantly reduced, and the patient's NYHA class is II, indicating a relatively preserved functional capacity. A sudden cardiac death would likely require a more significant and unexpected event, such as a ventricular arrhythmia or a myocardial infarction, which is not indicated by the patient's ECG or biomarkers.

3. Pump Failure Death
REASONING:
Pump failure death is a possible outcome for patients with significant left ventricular dysfunction, such as the patient in this case. However, the patient's functional capacity is relatively preserved, and they are taking medications that manage their symptoms and heart failure. The patient's renal function is also compromised, but this is not uncommon in patients with heart failure. The presence of medications and the patient's functional capacity suggest that pump failure death is less likely than sudden cardiac death, but more likely than survival."
624,624,P0980,"Age: 67
Gender: Male 
Weight: 77 kg
Height: 170 cm
NYHA Class: II
Blood Pressure: 130/80 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Dyslipemia, Myocardial Infarction
Albumin (g/L): 47,5
ALT or GPT (IU/L): 25.0
AST or GOT (IU/L): 31.0
Total Cholesterol (mmol/L): 4,91
Creatinine (mmol/L): 93.0
Gamma-glutamil transpeptidase (IU/L): 25
Glucose (mmol/L): 5,8
Hemoglobin (g/L): 153.0
HDL (mmol/L): 1,66
Potassium (mEq/L): 4,7
LDL (mmol/L): 2,56
Sodium (mEq/L): 141.0
Protein (g/L): 74,9
T4 (ng/L): 18
TSH (mIU/L): 1,33
Urea (mg/dL): 10,65
LVEF (%): 40.0
Medications: Angiotensin II Receptor Blocker, Loop Diuretics, Spironolactone, Statins, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"RANKING: 
1. Survivor
REASONING:
The patient is a 67-year-old male with a history of ischemic dilated cardiomyopathy, which is a condition where the heart muscle is weakened, leading to reduced ejection fraction (LVEF) of 40.0%. This indicates that the heart is not pumping efficiently, and the patient is at risk for heart failure. 

The patient's NYHA Class II indicates that the patient experiences mild symptoms, but the patient's age, weight, and past medical history of myocardial infarction also contribute to the risk of cardiovascular events. The patient's ECG findings show ventricular extrasystole, which is a common finding in patients with heart failure and is often associated with a poor prognosis.

However, the patient is currently on medications that are commonly used to treat heart failure, such as spironolactone, which is a diuretic and a mineralocorticoid receptor antagonist that helps to reduce mortality and morbidity in patients with heart failure. The patient's creatinine level is elevated, indicating impaired kidney function, but this is not uncommon in patients with heart failure.

Given the patient's age, medical history, and current medication regimen, the patient is at risk for cardiovascular events, but the patient is not currently showing signs of acute decompensated heart failure or acute coronary syndrome. Therefore, the most likely outcome for the next few years is a survivor.

2. Sudden cardiac death
REASONING:
Sudden cardiac death (SCD) is a possible outcome for patients with heart failure, especially those with a history of myocardial infarction and reduced LVEF. The patient's elevated creatinine level and impaired kidney function increase the risk of cardiovascular events, including SCD. However, the patient's current ECG findings do not show any signs of ventricular tachycardia or non-sustained ventricular tachycardia, which are common precursors to SCD.

3. Pump failure death
REASONING:
Pump failure death is a possible outcome for patients with severe heart failure, but the patient's NYHA Class II indicates that the patient is experiencing mild symptoms. The patient is also on medications that are commonly used to treat heart failure, which suggests that the patient is being adequately managed. While the patient's reduced LVEF and elevated creatinine level do increase the risk of pump failure, the patient's current ECG findings and medication regimen suggest that the patient is not at immediate risk for severe heart failure."
625,625,P0982,"Age: 73
Gender: Female 
Weight: 89 kg
Height: 157 cm
NYHA Class: II
Blood Pressure: 140/80 mmHg
Past Medical History: Other HF etiology, Dyslipemia
Albumin (g/L): 39,7
ALT or GPT (IU/L): 17.0
AST or GOT (IU/L): 19.0
Total Cholesterol (mmol/L): 4,63
Creatinine (mmol/L): 71.0
Gamma-glutamil transpeptidase (IU/L): 19
Glucose (mmol/L): 7,3
Hemoglobin (g/L): 128.0
HDL (mmol/L): 1,19
Potassium (mEq/L): 5,4
LDL (mmol/L): 2,43
Sodium (mEq/L): 142.0
Protein (g/L): 63,4
T4 (ng/L): 21
TSH (mIU/L): 0,18
Urea (mg/dL): 7,32
LVEF (%): 55.0
Medications: Beta Blockers, Loop Diuretics, Spironolactone, Statins, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"RANKING: 1. Survivor
REASONING:

This patient's prognosis is ranked as ""survivor"" due to several factors. Firstly, the patient's age is 73, which is relatively older, but not unusually high for a patient with heart failure. The patient's NYHA Class II indicates moderate heart failure, which is a relatively mild form of the condition.

The patient's blood tests reveal a slightly elevated creatinine level (71.0 mmol/L), which suggests some degree of kidney impairment, but it is not severe enough to significantly impact the patient's overall prognosis. The patient's liver enzymes (ALT and AST) are within normal limits, and the patient's glucose and lipid profiles are also within normal limits.

The patient's LVEF (Left Ventricular Ejection Fraction) is 55.0%, which is lower than the normal range, indicating some degree of left ventricular dysfunction. However, this is not severe enough to indicate significant cardiomyopathy or severe heart failure.

The patient is currently taking beta blockers, loop diuretics, spironolactone, statins, and an ACE inhibitor, which are all standard treatments for heart failure. The patient's ECG impression shows no signs of ventricular tachycardia, non-sustained ventricular tachycardia, or paroxysmal supraventricular tachyarrhythmia, which are all potential indicators of a high risk of sudden cardiac death.

Overall, considering the patient's age, NYHA Class II heart failure, and the absence of severe kidney impairment, liver dysfunction, or arrhythmias, the patient's prognosis is ranked as ""survivor""."
626,626,P0984,"Age: 58
Gender: Male 
Weight: 58 kg
Height: 162 cm
NYHA Class: II
Blood Pressure: 120/70 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Dyslipemia, Myocardial Infarction
Albumin (g/L): 37,3
ALT or GPT (IU/L): 13.0
AST or GOT (IU/L): 19.0
Total Cholesterol (mmol/L): 3,96
Creatinine (mmol/L): 90.0
Gamma-glutamil transpeptidase (IU/L): 133
Glucose (mmol/L): 6,3
Hemoglobin (g/L): 119.0
HDL (mmol/L): 1,76
Potassium (mEq/L): 4,9
LDL (mmol/L): 1,76
Sodium (mEq/L): 143.0
Protein (g/L): 62,1
T4 (ng/L): 16
TSH (mIU/L): 1,71
Urea (mg/dL): 6,49
LVEF (%): 51.0
Medications: Beta Blockers, Loop Diuretics, Statins, ACE Inhibitor, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: TPSV
        - Bradycardia: No
            ",survivor,"RANKING: 1. Survivor
REASONING: 

Based on the provided patient data, I predict a high likelihood of survival for the next few years. The patient's age, NYHA Class II, and the presence of ischemic dilated cardiomyopathy are significant risk factors for adverse outcomes. However, the patient's current hemoglobin level (119.0 g/L) is within the normal range, and the lack of severe anemia is a positive prognostic factor.

The patient's LVEF (51.0) is mildly reduced, but not severely impaired, indicating that the heart's pumping function is still relatively preserved. The absence of symptoms and the presence of beta blockers, loop diuretics, statins, ACE inhibitors, and a nitrovasodilator suggest that the patient is receiving optimal medical therapy for managing their underlying conditions.

The ECG findings, including ventricular extrasystoles, non-sustained ventricular tachycardia, and paroxysmal supraventricular tachycardia, indicate a history of arrhythmias. However, the presence of beta blockers, which are effective in reducing the risk of arrhythmias, suggests that the patient is well-managed.

Given these factors, I predict that the patient has a high likelihood of survival for the next few years, provided that their current treatment regimen is continued and adjusted as necessary to manage their underlying conditions.

RANKING: 2. Pump failure death
REASONING: 

The patient's LVEF (51.0) is mildly reduced, indicating that the heart's pumping function is compromised. The patient's NYHA Class II suggests that they have some limitations in physical activity, which may be related to their cardiac function.

While the patient is receiving optimal medical therapy, the presence of ischemic dilated cardiomyopathy and dyslipemia may continue to worsen their cardiac function over time. The patient's elevated creatinine level (6.49 mg/dL) and elevated gamma-glutamil transpeptidase (133 IU/L) suggest some degree of renal impairment, which may be related to cardiac dysfunction.

The patient's lipid profile, with high total cholesterol and LDL levels, is also a risk factor for further cardiovascular events. The presence of ventricular extrasystoles and non-sustained ventricular tachycardia on the ECG suggests a high risk of arrhythmias, which can contribute to cardiac decompensation.

Given these factors, I predict a moderate likelihood of pump failure death over the next few years, provided that the patient's treatment regimen is continued and adjusted as necessary to manage their underlying conditions.

RANKING: 3. Sudden cardiac death
REASONING: 

The patient's history of myocardial infarction and ischemic dilated cardiomyopathy increases their risk of sudden cardiac death. The patient's LVEF (51.0) is mildly reduced, and the presence of ventricular extrasystoles and non-sustained ventricular tachycardia on the ECG suggests a high risk of arrhythmias.

The patient's elevated creatinine level (6.49 mg/dL) and elevated gamma-glutamil transpeptidase (133 IU/L) suggest some degree of renal impairment, which may be related to cardiac dysfunction. The patient's lipid profile, with high total cholesterol and LDL levels, is also a risk factor for further cardiovascular events.

While the patient is receiving optimal medical therapy, the presence of these risk factors and the patient's underlying cardiac conditions suggest a high risk of sudden cardiac death over the next few years. However, the patient's overall prognosis is still better than pump failure death, given their relatively preserved hemoglobin level and optimal treatment regimen.

It is essential to closely monitor the patient's cardiac function and adjust their treatment regimen as necessary to minimize the risk of adverse outcomes."
627,627,P0988,"Age: 68
Gender: Female 
Weight: 67 kg
Height: 150 cm
NYHA Class: II
Blood Pressure: 195/85 mmHg
Past Medical History: Hypertropic cardiomyopathy
Albumin (g/L): 40,9
ALT or GPT (IU/L): 20.0
AST or GOT (IU/L): 13.0
Total Cholesterol (mmol/L): 5,3
Creatinine (mmol/L): 57.0
Gamma-glutamil transpeptidase (IU/L): 66
Glucose (mmol/L): 8,9
Hemoglobin (g/L): 150.0
HDL (mmol/L): 1,14
Potassium (mEq/L): 4,4
LDL (mmol/L): 3,52
Sodium (mEq/L): 140.0
Protein (g/L): 74
T4 (ng/L): 16
TSH (mIU/L): 2,74
Urea (mg/dL): 4,66
LVEF (%): 52.0
Medications: Diabetes Medication, Loop Diuretics
ECG Impression:
        - Ventricular Extrasystole: Unknown ventricular extrasystole code
        - Ventricular Tachycardia: Unknown ventricular tachycardia code
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",survivor,"RANKING: 1. Survivor
REASONING: 

Based on the provided patient data, the patient is likely to survive for the next few years due to the following reasons:

1. Age: The patient is 68 years old, which is considered elderly, but not extremely old. Many patients in this age group can survive with proper management and treatment.
2. NYHA Class II: The patient has a moderate level of heart failure, but it is not severe. This indicates that the patient is still able to perform daily activities with some limitations.
3. Blood Pressure: The patient's blood pressure is elevated (195/85 mmHg), which is a risk factor for cardiovascular disease. However, it is not extremely high, and the patient is already taking loop diuretics, which can help manage blood pressure.
4. Past Medical History: Hypertrophic cardiomyopathy is a significant risk factor for sudden cardiac death, but the patient's LVEF is 52%, which is relatively preserved. This suggests that the patient's heart is still functioning relatively well.
5. Medications: The patient is taking diabetes medication and loop diuretics, which can help manage blood pressure and heart failure symptoms.
6. ECG Impression: The ECG shows ventricular extrasystole and ventricular tachycardia, but these are not immediately life-threatening. Non-sustained ventricular tachycardia is not present, which is a good sign.

While the patient has some risk factors, the combination of a relatively preserved LVEF, moderate NYHA Class, and the presence of medications to manage blood pressure and heart failure symptoms suggest that the patient is likely to survive for the next few years with proper management and treatment. However, close monitoring and follow-up are essential to ensure that the patient's condition does not deteriorate.

The other two prognoses, sudden cardiac death and pump failure death, are less likely because:

* Sudden cardiac death is unlikely due to the absence of non-sustained ventricular tachycardia on the ECG and the relatively preserved LVEF.
* Pump failure death is unlikely due to the patient's moderate NYHA Class and the presence of medications to manage heart failure symptoms."
628,628,P0991,"Age: 71
Gender: Female 
Weight: 70 kg
Height: 152 cm
NYHA Class: II
Blood Pressure: 160/85 mmHg
Past Medical History: Hypertensive cardiomyopathy, Hypertension
Albumin (g/L): 46,2
ALT or GPT (IU/L): 14.0
AST or GOT (IU/L): 20.0
Total Cholesterol (mmol/L): 5,2
Creatinine (mmol/L): 73.0
Gamma-glutamil transpeptidase (IU/L): 22
Glucose (mmol/L): 5,4
Hemoglobin (g/L): 131.0
HDL (mmol/L): 1,58
Potassium (mEq/L): 4,3
LDL (mmol/L): 2,4
Sodium (mEq/L): 143.0
Protein (g/L): 78,6
T4 (ng/L): 15
TSH (mIU/L): 1,28
Urea (mg/dL): 7,99
LVEF (%): 35.0
Medications: Beta Blockers, Loop Diuretics, Spironolactone, Statins, ACE Inhibitor, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"RANKING: 1. Survivor
REASONING: 

The patient's prognosis is ranked as a survivor due to the following factors:

1. Age: Although the patient is 71 years old, the age itself is not a significant determinant of prognosis in this case, as many patients with heart failure and cardiomyopathy can live for several more years with proper management.

2. NYHA Class II: The patient's NYHA class indicates that they have some limitations in physical activity, but they are still able to perform daily activities with some difficulty. This suggests that the patient has some residual cardiac function, which increases the likelihood of survival.

3. Blood Pressure: The patient's blood pressure is elevated, but it is not excessively high, and the patient is already taking medications to control hypertension.

4. Medications: The patient is taking a range of medications, including beta blockers, loop diuretics, and ACE inhibitors, which are commonly used to manage heart failure and hypertension. The presence of these medications suggests that the patient is receiving appropriate treatment.

5. ECG Impression: The patient's ECG shows ventricular extrasystole and non-sustained ventricular tachycardia, which are both common in patients with cardiomyopathy and heart failure. However, the absence of other concerning features, such as a widened QRS complex or bundle branch block, reduces the risk of sudden cardiac death.

6. LVEF: The patient's left ventricular ejection fraction (LVEF) is 35%, which is significantly reduced, indicating poor cardiac function. However, the presence of some residual cardiac function (NYHA Class II) suggests that the patient may still have some remaining functional capacity.

7. Other laboratory values: The patient's laboratory values are generally within normal limits, with the exception of a slightly elevated creatinine level, which may indicate some degree of renal impairment. However, this is not uncommon in patients with heart failure.

Considering these factors, the patient's overall prognosis is ranked as a survivor, with a moderate to high likelihood of survival over the next few years. However, regular monitoring and close follow-up with the patient and the healthcare team will be necessary to adjust the treatment plan and address any potential complications.

RANKING: 2. Sudden cardiac death
REASONING: 

The patient's prognosis is ranked as sudden cardiac death due to the following factors:

1. LVEF: The patient's LVEF is significantly reduced, indicating poor cardiac function and a high risk of sudden cardiac death.

2. Non-sustained ventricular tachycardia: The presence of non-sustained ventricular tachycardia on the ECG is a significant risk factor for sudden cardiac death.

3. Ventricular extrasystole: The presence of ventricular extrasystole is also a risk factor for sudden cardiac death, as it can indicate underlying cardiac arrhythmia.

4. ECG Impression: The patient's ECG shows ventricular extrasystole and non-sustained ventricular tachycardia, which increases the risk of sudden cardiac death.

5. Age: Although the patient is 71 years old, the presence of these risk factors increases the likelihood of sudden cardiac death.

Considering these factors, the patient's prognosis is ranked as sudden cardiac death, with a moderate to high likelihood of sudden cardiac death over the next few years.

RANKING: 3. Pump failure death
REASONING: 

The patient's prognosis is ranked as pump failure death due to the following factors:

1. LVEF: The patient's LVEF is significantly reduced, indicating poor cardiac function and a high risk of pump failure.

2. NYHA Class II: The patient's NYHA class indicates that they have some limitations in physical activity, which suggests that the patient's cardiac function is not optimal.

3. Elevated creatinine level: The patient's elevated creatinine level may indicate some degree of renal impairment, which can be a sign of pump failure.

4. ECG Impression: The patient's ECG shows ventricular extrasystole and non-sustained ventricular tachycardia, which increases the risk of pump failure.

5. Medications: Although the patient is taking a range of medications, including ACE inhibitors and beta blockers, which can help manage heart failure, the patient's LVEF and NYHA class indicate that the patient's cardiac function is not well-controlled.

Considering these factors, the patient's prognosis is ranked as pump failure death, with a moderate to high likelihood of pump failure over the next few years."
629,629,P0992,"Age: 72
Gender: Male 
Weight: 95 kg
Height: 172 cm
NYHA Class: III
Blood Pressure: 130/80 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Hypertension, Myocardial Infarction
Albumin (g/L): 43,9
ALT or GPT (IU/L): 17.0
AST or GOT (IU/L): 18.0
Total Cholesterol (mmol/L): 4,68
Creatinine (mmol/L): 90.0
Gamma-glutamil transpeptidase (IU/L): 16
Glucose (mmol/L): 5,8
Hemoglobin (g/L): 158.0
HDL (mmol/L): 1,19
Potassium (mEq/L): 4,4
LDL (mmol/L): 2,87
Sodium (mEq/L): 142.0
Protein (g/L): 70,5
T4 (ng/L): 14
TSH (mIU/L): 1,04
Urea (mg/dL): 5,66
LVEF (%): 37.0
Medications: Calcium Channel Blocker, Loop Diuretics, Statins, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"RANKING: 
1. Survivor
REASONING: 

Based on the provided patient data, the patient is at high risk for cardiac-related complications due to their history of ischemic dilated cardiomyopathy, hypertension, myocardial infarction, and NYHA Class III symptoms. However, the patient is currently being treated with a combination of medications, including a calcium channel blocker, loop diuretics, statins, and an ACE inhibitor, which are standard treatments for managing these conditions.

The patient's left ventricular ejection fraction (LVEF) is significantly reduced at 37.0%, indicating poor cardiac function. However, the patient's hemoglobin level is within a relatively normal range, and the patient is not showing any signs of acute cardiac distress.

Considering these factors, the patient's prognosis is likely to be a survivor, as they are being managed with evidence-based treatments and do not display any acute signs of cardiac distress. The patient's eGFR is not severely impaired, which suggests that they are not in the late stages of kidney disease.

While the patient is at risk for cardiac-related complications, the presence of ventricular extrasystole on the ECG is a concerning sign, and the patient should be closely monitored for any signs of worsening cardiac function. However, without further information, the patient's prognosis is more likely to be a survivor.

2. Sudden cardiac death
REASONING: 

The patient's history of ischemic dilated cardiomyopathy, hypertension, and myocardial infarction increases their risk for sudden cardiac death. The patient's reduced LVEF of 37.0% further increases this risk. However, the patient is currently being treated with evidence-based medications, which suggests that their condition is being managed.

While the presence of ventricular extrasystole on the ECG is concerning, it is not a guarantee of sudden cardiac death. The patient's hemoglobin level is within a relatively normal range, and they do not display any signs of acute cardiac distress.

However, the patient's age (72 years) and history of cardiovascular disease increase their risk for sudden cardiac death. Therefore, while the patient's prognosis is not the worst, they are at a higher risk for sudden cardiac death than for being a survivor.

3. Pump failure death
REASONING: 

Given the patient's reduced LVEF of 37.0% and NYHA Class III symptoms, the patient is at high risk for heart failure exacerbation and pump failure. However, the patient is currently being treated with evidence-based medications, which suggests that their condition is being managed.

While the patient's eGFR is not severely impaired, the patient's creatinine level is elevated, which may indicate some degree of kidney dysfunction. The patient's protein level is also elevated, which may be related to their kidney function.

Considering these factors, the patient's prognosis is not the worst, as they are being managed with evidence-based treatments. However, the patient's reduced LVEF and NYHA Class III symptoms increase their risk for pump failure, making this prognosis more likely than sudden cardiac death."
630,630,P0996,"Age: 58
Gender: Male 
Weight: 97 kg
Height: 171 cm
NYHA Class: II
Blood Pressure: 140/80 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Diabetes, Dyslipemia, Myocardial Infarction
Albumin (g/L): 41,5
ALT or GPT (IU/L): 22.0
AST or GOT (IU/L): 18.0
Total Cholesterol (mmol/L): 4,5
Creatinine (mmol/L): 72.0
Gamma-glutamil transpeptidase (IU/L): 18
Glucose (mmol/L): 7,8
Hemoglobin (g/L): 154.0
HDL (mmol/L): 1,27
Potassium (mEq/L): 4,8
LDL (mmol/L): 2,69
Sodium (mEq/L): 143.0
Protein (g/L): 67,7
T4 (ng/L): 19
TSH (mIU/L): 1,53
Urea (mg/dL): 5,66
LVEF (%): 29.0
Medications: Beta Blockers, Statins
ECG Impression:
        - Ventricular Extrasystole: No
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"RANKING: 1. Survivor
REASONING: 

The patient's overall health status and medical history suggest a moderate to high risk for adverse cardiac events. The patient has a history of ischemic dilated cardiomyopathy, which indicates a significant impairment of the heart's pumping function. The left ventricular ejection fraction (LVEF) of 29% is also a strong indicator of this. 

Despite being on beta blockers and statins, which are standard treatments for managing heart failure and managing cholesterol levels, the patient's LVEF is not improving, indicating that the heart's pumping function is not being adequately supported.

Additionally, the patient has a history of myocardial infarction, which is a significant risk factor for further cardiac events. The patient's laboratory results show elevated creatinine levels, which may indicate some degree of kidney dysfunction, which can be a complication of heart failure.

The patient's ECG results are relatively normal, with no signs of ventricular arrhythmias, which reduces the risk of sudden cardiac death. However, the patient's overall health status and medical history make them more susceptible to cardiac events, making a survivor the most likely outcome.

The other two options, sudden cardiac death and pump failure death, are less likely because the patient is not in a state of acute cardiac distress and is not showing signs of severe heart failure. Sudden cardiac death is unlikely due to the absence of ventricular arrhythmias on the ECG. Pump failure death is also unlikely because the patient is not in a state of acute heart failure, as indicated by the lack of symptoms and the fact that the patient is being treated with beta blockers and statins."
631,631,P0998,"Age: 68
Gender: Male 
Weight: 82 kg
Height: 176 cm
NYHA Class: II
Blood Pressure: 110/70 mmHg
Past Medical History: Other HF etiology, Dyslipemia
Albumin (g/L): 44,3
ALT or GPT (IU/L): 16.0
AST or GOT (IU/L): 22.0
Total Cholesterol (mmol/L): 5,09
Creatinine (mmol/L): 101.0
Gamma-glutamil transpeptidase (IU/L): 15
Glucose (mmol/L): 4,6
Hemoglobin (g/L): 149.0
HDL (mmol/L): 1,14
Potassium (mEq/L): 4,6
LDL (mmol/L): 3,41
Sodium (mEq/L): 146.0
Protein (g/L): 71,8
T4 (ng/L): 21
TSH (mIU/L): 0,78
Urea (mg/dL): 6,32
LVEF (%): 65.0
Medications: Calcium Channel Blocker, Beta Blockers
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: TPSV
        - Bradycardia: No
            ",survivor,"RANKING: 

1. Survivor
REASONING: 

The patient's overall health status, despite having a NYHA Class II heart failure, is relatively stable, as evidenced by the absence of any life-threatening arrhythmias and a stable hemoglobin level. The patient's LVEF is 65%, which indicates some level of cardiac dysfunction, but not severe. The patient's medication regimen, which includes calcium channel blockers and beta blockers, suggests a cautious approach to managing cardiovascular risk factors. The patient's laboratory results, including a relatively low creatinine level and normal liver enzymes, also suggest that the patient's kidneys are functioning adequately. Additionally, the patient's hemoglobin level is within the normal range, which reduces the risk of cardiac complications related to anemia. While the patient's dyslipidemia and other medical history factors may contribute to cardiovascular risk, the overall picture suggests that the patient is at relatively low risk for immediate cardiac complications.

2. Sudden cardiac death
REASONING: 

While the patient's LVEF is 65%, which is below the normal range, the patient's overall health status is relatively stable, and there is no evidence of acute cardiac complications. However, the presence of ventricular extrasystoles and TPSV may indicate a potential risk for arrhythmias. The patient's medications, while adequate, do not address the underlying cardiac dysfunction or dyslipidemia. Furthermore, the patient's elevated creatinine level and slightly elevated LDL cholesterol level may contribute to cardiovascular risk. However, the patient's overall health status and the absence of any life-threatening arrhythmias make sudden cardiac death less likely.

3. Pump failure death
REASONING: 

Given the patient's NYHA Class II heart failure and elevated creatinine level, pump failure death is a possible risk. However, the patient's overall health status and medication regimen suggest that the patient is being managed to mitigate cardiovascular risk factors. The patient's LVEF is 65%, which is relatively preserved, and the absence of any life-threatening arrhythmias reduces the risk of sudden cardiac death. Additionally, the patient's laboratory results, including a normal liver enzyme level and hemoglobin, suggest that the patient's kidneys and other organs are functioning adequately. While pump failure is a concern, the patient's overall health status and management plan make it the least likely of the three prognoses."
632,632,P0999,"Age: 67
Gender: Male 
Weight: 88 kg
Height: 160 cm
NYHA Class: II
Blood Pressure: 110/70 mmHg
Past Medical History: Valvular cardiomyopathy, Diabetes, Dyslipemia, Peripheral vascular disease
Albumin (g/L): 39,6
ALT or GPT (IU/L): 44.0
AST or GOT (IU/L): 28.0
Total Cholesterol (mmol/L): 3,78
Creatinine (mmol/L): 104.0
Gamma-glutamil transpeptidase (IU/L): 30
Glucose (mmol/L): 6,2
Hemoglobin (g/L): 115.0
HDL (mmol/L): 1,19
Potassium (mEq/L): 4,7
LDL (mmol/L): 1,99
Sodium (mEq/L): 139.0
Protein (g/L): 76,5
T4 (ng/L): 14
TSH (mIU/L): 0,84
Urea (mg/dL): 10,48
LVEF (%): 25.0
Medications: Calcium Channel Blocker, Diabetes Medication, Beta Blockers, Loop Diuretics, Statins
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",survivor,"RANKING: 

1. Survivor
REASONING:

The patient's overall clinical presentation and test results indicate a high risk for adverse cardiac events, but the patient is already receiving optimal medical therapy for their valvular cardiomyopathy, diabetes, dyslipemia, and peripheral vascular disease. The patient's NYHA Class II heart failure is manageable with current medications, and the patient's hemoglobin level and kidney function are relatively preserved.

The presence of ventricular extrasystoles, non-sustained ventricular tachycardia, and paroxysmal supraventricular tarrhythmias on the ECG are concerning for cardiac arrhythmias, but the patient is receiving beta-blockers, which are effective in managing these conditions. The patient's LVEF is low, but the patient's overall cardiovascular risk factors and the effectiveness of current medications suggest that the patient may be able to tolerate the treatment and avoid more severe cardiac events.

The patient's creatinine level is elevated, but this may be due to dehydration or other non-cardiac causes. The patient's liver enzymes are within normal limits, and the patient's lipid profile is not significantly abnormal. The patient's glucose level is elevated, but the patient is receiving diabetes medication, which should help manage this condition.

Given the patient's overall clinical presentation, test results, and management plan, I believe that the patient has a reasonable chance of survival for the next few years.

2. Pump failure death
REASONING:

The patient's LVEF is significantly reduced, indicating left ventricular dysfunction, which is a major predictor of cardiac events and mortality. The patient's NYHA Class II heart failure suggests that the patient's heart is not functioning optimally, and the patient may be at risk for decompensation and pump failure.

The patient's elevated creatinine level and elevated liver enzymes may indicate some degree of cardiac dysfunction or other non-cardiac causes, but the patient's overall cardiovascular risk factors and the effectiveness of current medications suggest that the patient may be at risk for cardiac events.

The patient's ventricular extrasystoles, non-sustained ventricular tachycardia, and paroxysmal supraventricular tarrhythmias on the ECG are concerning for cardiac arrhythmias, which can increase the risk of cardiac events.

3. Sudden cardiac death
REASONING:

The patient's LVEF is significantly reduced, indicating left ventricular dysfunction, which is a major predictor of cardiac events and mortality. The patient's NYHA Class II heart failure suggests that the patient's heart is not functioning optimally, and the patient may be at risk for decompensation and cardiac events.

The patient's elevated creatinine level and elevated liver enzymes may indicate some degree of cardiac dysfunction or other non-cardiac causes, but the patient's overall cardiovascular risk factors and the effectiveness of current medications suggest that the patient may be at risk for cardiac events.

The patient's ventricular extrasystoles, non-sustained ventricular tachycardia, and paroxysmal supraventricular tarrhythmias on the ECG are concerning for cardiac arrhythmias, which can increase the risk of cardiac events.

However, the patient is receiving beta-blockers, which are effective in managing these conditions, and the patient's overall cardiovascular risk factors are not as severe as those in the pump failure death category. Therefore, while the patient is at risk for cardiac events, I believe that the patient is less likely to experience sudden cardiac death than pump failure death."
633,633,P1002,"Age: 71
Gender: Female 
Weight: 70 kg
Height: 160 cm
NYHA Class: II
Blood Pressure: 120/70 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Diabetes, Dyslipemia, Hypertension, Myocardial Infarction
Albumin (g/L): 39
ALT or GPT (IU/L): 39.0
AST or GOT (IU/L): 23.0
Total Cholesterol (mmol/L): 4,45
Creatinine (mmol/L): 62.0
Gamma-glutamil transpeptidase (IU/L): 13
Glucose (mmol/L): 4,3
Hemoglobin (g/L): 113.0
HDL (mmol/L): 1,47
Potassium (mEq/L): 3,7
LDL (mmol/L): 2,46
Sodium (mEq/L): 140.0
Pro-BNP (ng/L): 305.0
Protein (g/L): 66
T4 (ng/L): 14
Troponin (ng/mL): 0,01
TSH (mIU/L): 0,306
Urea (mg/dL): 10,31
LVEF (%): 48.0
Medications: Diabetes Medication, Beta Blockers
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"RANKING: 1. Survivor
REASONING: 

Based on the provided patient data, I would rank the patient as having a high likelihood of survival over the next few years. The patient's age of 71 is not particularly high, and they have a relatively good NYHA Class II heart failure classification, indicating that their symptoms are not severe. 

The patient's LVEF of 48.0 is slightly below the normal range, but it is not severely impaired. The presence of ischemic dilated cardiomyopathy is a significant concern, but the patient's current medication regimen includes beta blockers, which can help reduce the risk of sudden cardiac death. The patient's blood pressure is well-controlled, and their lipid profile is not severely abnormal. 

The patient's biomarkers, such as troponin and creatinine, are not significantly elevated, suggesting that there is no acute cardiac injury or significant kidney dysfunction. The patient's liver function tests are also within normal limits. 

The ECG findings do not indicate any life-threatening arrhythmias, and the patient does not have any significant electrolyte imbalances. Overall, while the patient has a history of significant cardiovascular disease, the combination of their current medical status and treatment regimen suggests that they are likely to survive over the next few years."
634,634,P1011,"Age: 69
Gender: Female 
Weight: 66 kg
Height: 160 cm
NYHA Class: II
Blood Pressure: 120/70 mmHg
Past Medical History: Idiopathic dilated cardiomyopathy
Albumin (g/L): 40
ALT or GPT (IU/L): 24.0
AST or GOT (IU/L): 20.0
Total Cholesterol (mmol/L): 4,34
Creatinine (mmol/L): 71.0
Gamma-glutamil transpeptidase (IU/L): 18
Glucose (mmol/L): 5,4
Hemoglobin (g/L): 145.0
HDL (mmol/L): 1,4
Potassium (mEq/L): 4,9
LDL (mmol/L): 2,22
Sodium (mEq/L): 140.0
Protein (g/L): 64
T3 (pg/dL): 0,05
T4 (ng/L): 14
Troponin (ng/mL): 0,03
TSH (mIU/L): 0,6
Urea (mg/dL): 7,65
LVEF (%): 40.0
Medications: Beta Blockers, Loop Diuretics, Statins, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",survivor,"RANKING: 1. Survivor
REASONING: 

Based on the provided patient data, I would rank the patient as having a high likelihood of being a survivor. The patient's age is 69, which is considered elderly, but not extreme. The NYHA class is II, indicating mild symptoms, and the patient is taking medications for heart failure management, including beta blockers, loop diuretics, statins, and an ACE inhibitor. The patient's ejection fraction (LVEF) is 40%, which is below the normal range, but not severely impaired. The patient's troponin level is normal, indicating no acute myocardial infarction. 

The patient's electrolyte levels, liver function tests, and renal function are relatively normal, with no significant abnormalities that would indicate acute kidney injury or liver disease. The patient's blood pressure is well-controlled, and the patient's lipid profile is not significantly abnormal. The patient's hemoglobin level is elevated, which may indicate anemia, but this is not uncommon in patients with heart failure. 

The ECG findings are concerning for ventricular extrasystoles, but this is a common finding in patients with heart failure and is not necessarily a predictor of poor outcome. The patient's potassium level is slightly elevated, which may be related to the use of beta blockers, but is not significantly abnormal. 

Given the patient's overall clinical picture, I believe that the patient is likely to survive for the next few years. The patient's age, NYHA class, and medication regimen suggest that the patient is well-managed, and the patient's LVEF is not severely impaired. However, it's essential to monitor the patient closely for any signs of worsening heart failure or arrhythmias. 

It's also worth noting that the patient's TSH level is low, which may indicate hypothyroidism. This could potentially impact the patient's heart function, but without further testing, it's difficult to determine the impact. 

Overall, based on the provided data, I believe that the patient has a high likelihood of survival for the next few years."
635,635,P1013,"Age: 82
Gender: Male 
Weight: 52 kg
Height: 155 cm
NYHA Class: II
Blood Pressure: 170/100 mmHg
Past Medical History: Valvular cardiomyopathy
Albumin (g/L): 43
ALT or GPT (IU/L): 14.0
AST or GOT (IU/L): 12.0
Total Cholesterol (mmol/L): 6,18
Creatinine (mmol/L): 97.0
Gamma-glutamil transpeptidase (IU/L): 23
Glucose (mmol/L): 5,2
Hemoglobin (g/L): 138.0
HDL (mmol/L): 1,91
Potassium (mEq/L): 4,5
LDL (mmol/L): 3,7
Sodium (mEq/L): 141.0
Protein (g/L): 70
T3 (pg/dL): 0,04
T4 (ng/L): 15
Troponin (ng/mL): 0,03
TSH (mIU/L): 3,79
Urea (mg/dL): 11,32
LVEF (%): 50.0
Medications: Calcium Channel Blocker, Digoxin, Loop Diuretics, Statins, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",survivor,"RANKING: 
1. Survivor
REASONING: 
The patient's age is 82, but the patient is in NYHA Class II, which indicates that the patient is still relatively active and has some level of functional capacity. The patient's LVEF is 50%, which is within the normal range for an elderly patient, and the patient is not experiencing any severe symptoms. The patient's creatinine level is elevated, but it is not severely elevated, which suggests that the patient's kidney function is still relatively preserved. The patient is on medications that are commonly used to manage heart failure and arrhythmias, and the patient has a relatively low level of inflammation and oxidative stress, as indicated by the normal albumin and low levels of liver enzymes.

The patient's ECG shows ventricular extrasystole and non-sustained ventricular tachycardia, which are both relatively common in elderly patients. However, the presence of these arrhythmias is not indicative of a high risk of sudden cardiac death. The patient's troponin level is also normal, which suggests that there is no evidence of myocardial infarction.

Overall, based on the patient's clinical presentation, laboratory results, and ECG findings, I believe that the patient is at low risk for sudden cardiac death and pump failure death in the next few years. Therefore, I predict that the patient will be a survivor.

2. Sudden cardiac death
REASONING: 
The patient's ECG shows ventricular extrasystole and non-sustained ventricular tachycardia, which are both risk factors for sudden cardiac death. The patient's LVEF is 50%, which is below the normal range for an elderly patient, and the patient's creatinine level is elevated, which may indicate some degree of kidney dysfunction. The patient is also on medications that can increase the risk of arrhythmias, such as digoxin.

However, the patient's age is 82, and the patient is in NYHA Class II, which suggests that the patient may not be as vulnerable to sudden cardiac death as a younger patient. Additionally, the patient's troponin level is normal, which suggests that there is no evidence of myocardial infarction.

Despite these factors, I still believe that the patient is at moderate risk for sudden cardiac death in the next few years. Therefore, I predict that the patient has a 20-30% chance of experiencing sudden cardiac death.

3. Pump failure death
REASONING: 
The patient's LVEF is 50%, which is below the normal range for an elderly patient, and the patient is on medications that can increase the risk of heart failure, such as digoxin and loop diuretics. The patient's creatinine level is elevated, which may indicate some degree of kidney dysfunction, which can contribute to heart failure.

However, the patient's NYHA Class II suggests that the patient is still relatively active and has some level of functional capacity, and the patient's troponin level is normal, which suggests that there is no evidence of myocardial infarction. The patient's ECG shows ventricular extrasystole and non-sustained ventricular tachycardia, but these findings are not indicative of a high risk of pump failure death.

Overall, I believe that the patient is at moderate risk for pump failure death in the next few years, but the patient's overall clinical presentation and laboratory results suggest that the patient is more likely to survive than to experience pump failure death. Therefore, I predict that the patient has a 10-20% chance of experiencing pump failure death."
636,636,P1016,"Age: 68
Gender: Male 
Weight: 62 kg
Height: 168 cm
NYHA Class: II
Blood Pressure: 138/88 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Dyslipemia, Myocardial Infarction
Albumin (g/L): 43
ALT or GPT (IU/L): 15.0
AST or GOT (IU/L): 16.0
Total Cholesterol (mmol/L): 4,03
Creatinine (mmol/L): 88.0
Gamma-glutamil transpeptidase (IU/L): 27
Glucose (mmol/L): 5,9
Hemoglobin (g/L): 159.0
HDL (mmol/L): 0,78
Potassium (mEq/L): 4
LDL (mmol/L): 2,74
Sodium (mEq/L): 140.0
Protein (g/L): 70
T3 (pg/dL): 0,05
T4 (ng/L): 18
Troponin (ng/mL): 0,17
TSH (mIU/L): 2,16
Urea (mg/dL): 5,66
LVEF (%): 55.0
Medications: Beta Blockers, Statins, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"RANKING: 1. Survivor
REASONING: 

The patient's prognosis is ranked as a survivor due to the following factors:

1. Age: The patient is 68 years old, which is considered advanced age for many medical conditions, but not necessarily a contraindication for survival with proper management. However, the presence of ischemic dilated cardiomyopathy and previous myocardial infarction suggest a higher risk of adverse outcomes.

2. NYHA Class II: The patient's NYHA class is II, indicating some limitation in physical activity due to heart failure symptoms. However, this classification does not necessarily preclude a favorable outcome with optimal treatment.

3. Medications: The patient is on beta blockers, statins, and ACE inhibitors, which are standard treatments for managing heart failure and preventing further cardiovascular events.

4. LVEF: The left ventricular ejection fraction (LVEF) is 55%, which is below the normal range. However, this is not uncommon in patients with ischemic dilated cardiomyopathy, and the patient is already on medications that aim to improve heart function.

5. Troponin levels: The patient's troponin level is 0.17 ng/mL, which is within the normal range. Elevated troponin levels are often associated with cardiac damage, but the patient's levels are not significantly elevated.

6. ECG Impression: The ECG shows ventricular extrasystoles, which may indicate a mild degree of ventricular dysfunction, but there is no evidence of ventricular tachycardia or other life-threatening arrhythmias.

Considering these factors, the patient's overall prognosis is ranked as a survivor, with a moderate risk of adverse outcomes. However, the patient's medical history, medication regimen, and current ECG findings suggest that with proper management, the patient can be expected to survive for the next few years.

The other two prognoses, sudden cardiac death and pump failure death, are less likely due to the following reasons:

- Sudden cardiac death: The patient's ECG does not show any life-threatening arrhythmias, and the troponin level is within the normal range, reducing the likelihood of sudden cardiac death.
- Pump failure death: The patient is already on medications that aim to improve heart function, and the LVEF is not severely impaired, reducing the risk of pump failure."
637,637,P1017,"Age: 53
Gender: Male 
Weight: 81 kg
Height: 170 cm
NYHA Class: II
Blood Pressure: 120/69 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Hypertension
Albumin (g/L): 45
ALT or GPT (IU/L): 24.0
AST or GOT (IU/L): 20.0
Total Cholesterol (mmol/L): 4,47
Creatinine (mmol/L): 80.0
Gamma-glutamil transpeptidase (IU/L): 12
Glucose (mmol/L): 5,8
Hemoglobin (g/L): 140.0
HDL (mmol/L): 0,93
Potassium (mEq/L): 4,7
LDL (mmol/L): 2,74
Sodium (mEq/L): 134.0
Protein (g/L): 72
T3 (pg/dL): 0,04
T4 (ng/L): 15
Troponin (ng/mL): 0,07
TSH (mIU/L): 1,26
Urea (mg/dL): 5,49
LVEF (%): 40.0
Medications: Beta Blockers, Statins, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"RANKING: 1. Survivor
REASONING: 

The patient has a history of ischemic dilated cardiomyopathy, which is a significant risk factor for cardiac events. However, the patient is currently on medications that are commonly used to manage heart failure and reduce the risk of cardiac events, such as beta blockers, statins, and ACE inhibitors. 

The patient's NYHA class II indicates that they have some limitations in physical activity but are still able to perform daily activities without severe symptoms. This suggests that the patient is relatively stable and has not experienced significant cardiac decompensation.

The patient's laboratory results show elevated creatinine levels, which may indicate some degree of renal impairment. However, the patient is also receiving medications that may be contributing to this finding, such as the ACE inhibitor.

The ECG results show non-sustained ventricular tachycardia and ventricular extrasystoles, which are concerning signs of arrhythmias. However, the patient is receiving beta blockers, which are effective in managing arrhythmias.

The patient's troponin level is slightly elevated, which may indicate some degree of cardiac injury. However, the patient is not experiencing symptoms, and the elevation is not severe.

Overall, considering the patient's medical history, medications, and laboratory results, the most likely outcome is that the patient will survive for the next few years. However, the patient will likely require close monitoring and adjustments to their medications to manage their cardiac risk factors and prevent future cardiac events.

RANKING: 2. Sudden cardiac death
REASONING: 

While the patient's ECG results show non-sustained ventricular tachycardia and ventricular extrasystoles, the patient is receiving beta blockers, which are effective in managing arrhythmias. However, the patient's history of ischemic dilated cardiomyopathy and elevated troponin levels increase the risk of sudden cardiac death.

The patient's elevated creatinine levels and NYHA class II may indicate some degree of cardiac decompensation, which could increase the risk of cardiac events.

RANKING: 3. Pump failure death
REASONING: 

The patient's LVEF of 40% indicates significant left ventricular dysfunction, which increases the risk of heart failure. However, the patient is receiving medications that are commonly used to manage heart failure, such as beta blockers, statins, and ACE inhibitors.

The patient's laboratory results show elevated creatinine levels, which may indicate some degree of renal impairment. This could increase the risk of heart failure, as the kidneys play a critical role in maintaining fluid balance and electrolyte homeostasis.

However, considering the patient's NYHA class II and the effectiveness of their medications, the risk of pump failure death is lower than sudden cardiac death."
638,638,P1019,"Age: 54
Gender: Male 
Weight: 87 kg
Height: 176 cm
NYHA Class: II
Blood Pressure: 110/65 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Diabetes
Albumin (g/L): 43
ALT or GPT (IU/L): 17.0
AST or GOT (IU/L): 15.0
Total Cholesterol (mmol/L): 5,15
Creatinine (mmol/L): 97.0
Gamma-glutamil transpeptidase (IU/L): 13
Glucose (mmol/L): 11,2
Hemoglobin (g/L): 164.0
HDL (mmol/L): 0,88
Potassium (mEq/L): 4,9
LDL (mmol/L): 3,8
Sodium (mEq/L): 139.0
Protein (g/L): 73
T3 (pg/dL): 0,06
T4 (ng/L): 16
Troponin (ng/mL): 0,04
TSH (mIU/L): 3,27
Urea (mg/dL): 8,65
LVEF (%): 35.0
Medications: Diabetes Medication, Angiotensin II Receptor Blocker, Beta Blockers, Statins, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"RANKING: 
1. Survivor 
REASONING: 
The patient has a history of ischemic dilated cardiomyopathy, which is a condition that weakens the heart muscle and can lead to poor cardiac function. However, the patient is currently on medications that are commonly used to manage heart failure, including beta blockers, angiotensin II receptor blockers, and statins. The patient's LVEF is 35%, which is significantly reduced but not extremely low, indicating some residual cardiac function.

The patient's laboratory results show elevated creatinine levels, which may indicate some degree of renal impairment, but this is not directly related to cardiac function. The patient's glucose and lipid profiles are also elevated, which may contribute to their overall cardiovascular risk.

The ECG findings are not particularly concerning, with no signs of ventricular tachycardia or bradycardia. The presence of ventricular extrasystoles may be a sign of underlying cardiac stress, but it is not uncommon in patients with heart failure.

Given the patient's age, comorbidities, and medication regimen, the patient is likely to survive for the next few years. The patient's NYHA class is II, indicating some limitation in physical activity, but this is not a contraindication for survival.

While the patient has a significant cardiac history, their current condition and treatment plan suggest that they are likely to survive for the next few years. However, regular monitoring and follow-up with a cardiologist will be crucial to adjust the treatment plan as needed and address any potential complications.

The probability of sudden cardiac death or pump failure death is relatively low in this patient, but cannot be ruled out entirely. However, given the patient's current condition and treatment plan, I would estimate the probability of these outcomes as follows:

- Sudden cardiac death: 5-10%
- Pump failure death: 20-30%

Please note that these estimates are based on the provided data and may vary depending on individual factors and the patient's response to treatment."
639,639,P1020,"Age: 73
Gender: Male 
Weight: 82 kg
Height: 165 cm
NYHA Class: II
Blood Pressure: 116/67 mmHg
Past Medical History: Ischemic dilated cardiomyopathy
Albumin (g/L): 39
ALT or GPT (IU/L): 6.0
AST or GOT (IU/L): 11.0
Total Cholesterol (mmol/L): 4,29
Creatinine (mmol/L): 97.0
Gamma-glutamil transpeptidase (IU/L): 31
Glucose (mmol/L): 5,8
Hemoglobin (g/L): 134.0
HDL (mmol/L): 0,57
Potassium (mEq/L): 4,8
LDL (mmol/L): 2,92
Sodium (mEq/L): 133.0
Protein (g/L): 68
T3 (pg/dL): 0,04
T4 (ng/L): 16
Troponin (ng/mL): 0,03
TSH (mIU/L): 0,95
Urea (mg/dL): 4,82
LVEF (%): 45.0
Medications: Calcium Channel Blocker, Beta Blockers, Statins, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"RANKING: 
1. Survivor
REASONING: 
Based on the patient's age, NYHA Class II, and LVEF of 45.0, which indicates significant left ventricular dysfunction, the patient is at a higher risk for cardiac-related complications. However, the patient's current ECG findings do not show any signs of ventricular tachycardia, non-sustained ventricular tachycardia, or other life-threatening arrhythmias. The patient's medication regimen, which includes beta blockers and ACE inhibitors, is also a positive prognostic factor. Additionally, the patient's hemoglobin and liver function tests are within normal limits, which reduces the risk of complications related to anemia or liver dysfunction. Overall, the patient's overall clinical presentation and medical history suggest that the patient is at a higher risk for cardiac events, but the absence of acute complications and the effectiveness of the current medication regimen contribute to a more favorable prognosis.

2. Sudden cardiac death
REASONING: 
Although the patient is at a higher risk for cardiac-related complications, the absence of any acute signs of ventricular tachycardia or other life-threatening arrhythmias on the ECG, as well as the effectiveness of the current medication regimen, reduce the likelihood of sudden cardiac death. However, the patient's significant left ventricular dysfunction (LVEF 45.0) and NYHA Class II symptoms suggest that the patient is at risk for cardiac events, and the patient's age (73 years) increases the risk of cardiac mortality. 

3. Pump failure death
REASONING: 
Given the patient's significant left ventricular dysfunction (LVEF 45.0) and NYHA Class II symptoms, pump failure is a significant concern. However, the patient's current medication regimen, which includes beta blockers and ACE inhibitors, is likely to reduce the risk of pump failure. Additionally, the patient's hemoglobin and liver function tests are within normal limits, which reduces the risk of complications related to anemia or liver dysfunction. However, the patient's age (73 years) and significant left ventricular dysfunction increase the risk of pump failure, making it the least likely outcome compared to sudden cardiac death."
640,640,P1021,"Age: 58
Gender: Female 
Weight: 82 kg
Height: 169 cm
NYHA Class: II
Blood Pressure: 160/94 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Diabetes, Hypertension
ALT or GPT (IU/L): 30.0
AST or GOT (IU/L): 15.0
Total Cholesterol (mmol/L): 6,21
Creatinine (mmol/L): 80.0
Gamma-glutamil transpeptidase (IU/L): 64
Glucose (mmol/L): 12,6
Hemoglobin (g/L): 156.0
HDL (mmol/L): 1,45
Potassium (mEq/L): 4,7
LDL (mmol/L): 2,48
Sodium (mEq/L): 138.0
T3 (pg/dL): 0,05
T4 (ng/L): 13
Troponin (ng/mL): 0,04
TSH (mIU/L): 0,42
Urea (mg/dL): 7,32
LVEF (%): 30.0
Medications: Diabetes Medication, Beta Blockers, Spironolactone, Statins, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"RANKING: 1. Survivor
REASONING: 
Given the patient's age, NYHA Class II, and the presence of ischemic dilated cardiomyopathy, Diabetes, and Hypertension, the patient's cardiovascular risk is elevated. However, the patient is currently taking a comprehensive regimen of medications, including beta blockers, ACE inhibitors, and statins, which are generally effective in managing hypertension and heart failure.

The patient's recent ECG results show ventricular extrasystoles, which can be a marker of underlying cardiac electrical instability. However, the absence of ventricular tachycardia, non-sustained ventricular tachycardia, and paroxysmal supraventricular tachyarrhythmia suggests that the patient's cardiac function is not severely compromised at this time.

The patient's biomarkers, including troponin and creatinine, are within relatively normal limits, indicating that there is no acute myocardial infarction or significant kidney dysfunction. The elevated TSH level suggests hypothyroidism, which can be a contributing factor to heart failure, but it is not immediately life-threatening.

Considering these factors, the patient's overall prognosis is favorable, and I predict that the patient will survive for the next few years. However, it is essential to closely monitor the patient's cardiovascular status, adjust medications as needed, and address any underlying conditions that may contribute to cardiac instability.

RANKING: 2. Sudden cardiac death
REASONING: 
The patient's history of ischemic dilated cardiomyopathy, Diabetes, and Hypertension increases the risk of sudden cardiac death. The patient's LVEF of 30.0 indicates significant left ventricular dysfunction, which can lead to arrhythmias and sudden cardiac death.

The patient's ECG results show ventricular extrasystoles, which can be a precursor to more severe arrhythmias. Although the patient is taking beta blockers, which can help reduce the risk of arrhythmias, the presence of ventricular extrasystoles suggests that the patient may still be at risk for sudden cardiac death.

The patient's elevated blood pressure and high cholesterol levels also contribute to the risk of cardiovascular events, including sudden cardiac death.

RANKING: 3. Pump failure death
REASONING: 
While the patient's NYHA Class II indicates that they have some symptoms of heart failure, the patient's LVEF of 30.0 suggests that the patient's left ventricular function is still relatively preserved. The patient is also taking medications that are effective in managing heart failure, including ACE inhibitors and beta blockers.

However, the patient's elevated creatinine level and elevated TSH level suggest that there may be some underlying kidney dysfunction and hypothyroidism, which can contribute to heart failure. Additionally, the patient's elevated blood pressure and high cholesterol levels increase the risk of cardiovascular events.

While pump failure is a possible outcome, I rank it as the least likely prognosis due to the patient's relatively preserved LVEF and the presence of medications that can help manage heart failure. However, close monitoring of the patient's cardiovascular status and adjustments to medications as needed are essential to prevent progression of heart failure."
641,641,P1027,"Age: 69
Gender: Male 
Weight: 66 kg
Height: 169 cm
NYHA Class: II
Blood Pressure: 127/80 mmHg
Past Medical History: Idiopathic dilated cardiomyopathy
Albumin (g/L): 48
ALT or GPT (IU/L): 23.0
AST or GOT (IU/L): 23.0
Total Cholesterol (mmol/L): 4,71
Creatinine (mmol/L): 106.0
Glucose (mmol/L): 4,9
Hemoglobin (g/L): 144.0
HDL (mmol/L): 1,09
Potassium (mEq/L): 4,6
LDL (mmol/L): 3,39
Sodium (mEq/L): 140.0
Protein (g/L): 78
T3 (pg/dL): 0,04
T4 (ng/L): 24
Troponin (ng/mL): 0,05
TSH (mIU/L): 3,74
Urea (mg/dL): 10,15
LVEF (%): 30.0
Medications: Amiodarone, Beta Blockers, Loop Diuretics, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: Sinus Node Dysfunction
            ",survivor,"RANKING: 

1. Survivor: 
The patient's age, NYHA Class II indicates a moderate level of heart failure, but the patient is still able to perform daily activities. The presence of idiopathic dilated cardiomyopathy suggests a chronic condition, but the patient's current LVEF of 30.0 indicates that the heart is still functioning, albeit at a reduced capacity. The patient's medication regimen includes Amiodarone, Beta Blockers, Loop Diuretics, and ACE Inhibitor, which are standard treatments for heart failure and arrhythmias. The patient's laboratory results, such as the normal blood pressure, low creatinine, and normal liver enzymes, also suggest that the patient is relatively stable.

2. Pump Failure Death: 
Given the patient's low LVEF of 30.0, this prognosis is a strong possibility. A LVEF of 30.0 indicates that the patient's heart is not pumping efficiently, which can lead to heart failure and potentially life-threatening complications. The patient's NYHA Class II indicates that they are experiencing some symptoms of heart failure, but it is not severe enough to be classified as NYHA Class III or IV.

3. Sudden Cardiac Death: 
While the patient's ECG shows ventricular extrasystole, the absence of ventricular tachycardia, non-sustained ventricular tachycardia, and paroxysmal supraventricular tachyarrhythmia reduces the likelihood of sudden cardiac death. The patient's medication regimen and laboratory results also suggest that they are being adequately managed for their heart failure and arrhythmias. Therefore, while there is some risk, the likelihood of sudden cardiac death is lower compared to pump failure death.

REASONING: The order of the prognoses is based on the patient's clinical presentation, laboratory results, and treatment regimen. The patient's low LVEF and NYHA Class II indicate a high risk of pump failure, which is the most likely outcome. While the patient's ECG shows ventricular extrasystole, the absence of other arrhythmias reduces the likelihood of sudden cardiac death. The patient's medication regimen and laboratory results suggest that they are being adequately managed, which further reduces the likelihood of sudden cardiac death."
642,642,P1029,"Age: 69
Gender: Male 
Weight: 68 kg
Height: 168 cm
NYHA Class: II
Blood Pressure: 88/58 mmHg
Past Medical History: Ischemic dilated cardiomyopathy
Albumin (g/L): 44
ALT or GPT (IU/L): 18.0
AST or GOT (IU/L): 15.0
Total Cholesterol (mmol/L): 5,38
Creatinine (mmol/L): 97.0
Gamma-glutamil transpeptidase (IU/L): 16
Glucose (mmol/L): 4,9
Hemoglobin (g/L): 158.0
HDL (mmol/L): 0,85
Potassium (mEq/L): 4,9
LDL (mmol/L): 3,08
Sodium (mEq/L): 140.0
Protein (g/L): 74
T3 (pg/dL): 0,05
T4 (ng/L): 19
Troponin (ng/mL): 0,04
TSH (mIU/L): 0,81
Urea (mg/dL): 7,65
LVEF (%): 35.0
Medications: Beta Blockers, Statins, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"RANKING: 
1. Survivor
REASONING: 

Based on the provided patient data, the patient is a 69-year-old male with a history of ischemic dilated cardiomyopathy (IDC), which is a significant risk factor for cardiac arrhythmias and sudden cardiac death. The patient's LVEF is severely impaired at 35%, indicating poor cardiac function.

The patient's ECG findings, including ventricular extrasystole and non-sustained ventricular tachycardia, suggest an increased risk of arrhythmias. However, the absence of sustained ventricular tachycardia (CH>10) and other arrhythmias such as paroxysmal supraventricular tachyarrhythmia, and bradycardia, suggests that the patient's cardiac arrhythmias are not severe.

The patient's medication regimen includes beta blockers, statins, and an ACE inhibitor, which are all appropriate for managing IDC and reducing the risk of arrhythmias. However, the patient's low HDL cholesterol level (0.85 mmol/L) and elevated triglyceride levels are not adequately controlled, which may contribute to the development of atherosclerotic cardiovascular disease.

Despite these factors, the patient's overall clinical presentation and ECG findings do not suggest an immediate life-threatening arrhythmia. The patient's hemoglobin level is within normal limits, and the troponin level is not elevated, indicating no acute myocardial infarction. The patient's creatinine level is elevated, but this is likely due to age-related renal decline rather than cardiac dysfunction.

Overall, based on the patient's age, medical history, and ECG findings, the most likely outcome for the next few years is a survivor, with some risk of arrhythmias and cardiac events, but with adequate management of their medications and lifestyle modifications, the patient can be expected to survive for several years.

The probability of sudden cardiac death is moderate (20-30%), given the patient's history of IDC, arrhythmias, and poor LVEF. However, this can be reduced with close monitoring and management of the patient's cardiac arrhythmias.

The probability of pump failure death is low (5-10%), as the patient's LVEF is not severely impaired, and the patient is receiving medications to manage their cardiac function. However, the patient's elevated creatinine level and low HDL cholesterol level may increase the risk of cardiovascular events.

In conclusion, the most likely outcome for the patient is a survivor, with a moderate risk of arrhythmias and cardiac events, but with adequate management and lifestyle modifications, the patient can be expected to survive for several years."
643,643,P1030,"Age: 69
Gender: Male 
Weight: 100 kg
Height: 177 cm
NYHA Class: II
Blood Pressure: 124/67 mmHg
Past Medical History: Idiopathic dilated cardiomyopathy
Albumin (g/L): 41
ALT or GPT (IU/L): 158.0
AST or GOT (IU/L): 105.0
Total Cholesterol (mmol/L): 5,4
Creatinine (mmol/L): 88.0
Gamma-glutamil transpeptidase (IU/L): 42
Glucose (mmol/L): 5,6
Hemoglobin (g/L): 136.0
HDL (mmol/L): 0,85
Potassium (mEq/L): 4,2
LDL (mmol/L): 4,16
Sodium (mEq/L): 140.0
Protein (g/L): 70
T3 (pg/dL): 0,05
T4 (ng/L): 23
Troponin (ng/mL): 0,04
TSH (mIU/L): 0,72
Urea (mg/dL): 8,49
LVEF (%): 53.0
Medications: Beta Blockers, Loop Diuretics, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",survivor,"RANKING: 1. Survivor
REASONING: 

The patient's prognosis is likely to be a survivor due to the following reasons:

1. Age: Although the patient is 69 years old, the age itself is not a significant factor in determining the prognosis, as many patients with heart disease can live for many years with proper management.

2. NYHA Class II: The patient's NYHA Class II indicates that the patient has some limitations in physical activity, but it is not severe. This suggests that the patient is still relatively active and has not experienced significant symptoms that would necessitate a more severe prognosis.

3. Medications: The patient is taking beta blockers, loop diuretics, and ACE inhibitors, which are standard treatments for heart failure and arrhythmias. These medications have been shown to improve outcomes in patients with heart disease.

4. LVEF: The patient's left ventricular ejection fraction (LVEF) is 53%, which is slightly below the normal range. However, this is not uncommon in patients with heart failure and is not a contraindication for survival.

5. Electrocardiogram (ECG) results: The patient has ventricular extrasystoles, which can be a sign of arrhythmia, but the ECG does not show any signs of ventricular tachycardia or bradycardia. The presence of ventricular extrasystoles is not uncommon in patients with heart disease and can be managed with medication.

6. Laboratory results: The patient's laboratory results are relatively normal, with no significant elevation in liver enzymes or creatinine levels. The patient's glucose and hemoglobin levels are also within normal ranges.

Overall, the patient's overall health status, medication regimen, and laboratory results suggest that the patient is likely to survive for several years with proper management and monitoring.

RANKING: 2. Sudden Cardiac Death
REASONING: 

The patient's prognosis is less likely to be sudden cardiac death due to the following reasons:

1. Age: Although the patient is 69 years old, the age itself is not a significant factor in determining the prognosis.

2. Medications: The patient is taking beta blockers, loop diuretics, and ACE inhibitors, which are standard treatments for heart failure and arrhythmias. These medications have been shown to improve outcomes in patients with heart disease.

3. LVEF: The patient's LVEF is 53%, which is slightly below the normal range. However, this is not uncommon in patients with heart failure and is not a contraindication for survival.

4. Electrocardiogram (ECG) results: The patient has ventricular extrasystoles, which can be a sign of arrhythmia, but the ECG does not show any signs of ventricular tachycardia or bradycardia. The presence of ventricular extrasystoles is not uncommon in patients with heart disease and can be managed with medication.

5. Laboratory results: The patient's laboratory results are relatively normal, with no significant elevation in liver enzymes or creatinine levels. The patient's glucose and hemoglobin levels are also within normal ranges.

However, the patient's past medical history of idiopathic dilated cardiomyopathy is a significant risk factor for sudden cardiac death. However, the patient is already taking medications that can help manage arrhythmias, and the patient's laboratory results are relatively normal.

RANKING: 3. Pump Failure Death
REASONING: 

The patient's prognosis is the least likely to be pump failure death due to the following reasons:

1. Medications: The patient is taking beta blockers, loop diuretics, and ACE inhibitors, which are standard treatments for heart failure and arrhythmias. These medications have been shown to improve outcomes in patients with heart disease.

2. LVEF: The patient's LVEF is 53%, which is slightly below the normal range. However, this is not uncommon in patients with heart failure and is not a contraindication for survival.

3. Electrocardiogram (ECG) results: The patient has ventricular extrasystoles, which can be a sign of arrhythmia, but the ECG does not show any signs of ventricular tachycardia or bradycardia. The presence of ventricular extrasystoles is not uncommon in patients with heart disease and can be managed with medication.

4. Laboratory results: The patient's laboratory results are relatively normal, with no significant elevation in liver enzymes or creatinine levels. The patient's glucose and hemoglobin levels are also within normal ranges.

However, the patient's past medical history of idiopathic dilated cardiomyopathy and elevated liver enzymes suggest that the patient may be at risk for pump failure. However, the patient is already taking medications that can help manage heart failure, and the patient's laboratory"
644,644,P1031,"Age: 78
Gender: Male 
Weight: 65 kg
Height: 165 cm
NYHA Class: II
Blood Pressure: 114/68 mmHg
Past Medical History: Ischemic dilated cardiomyopathy
Albumin (g/L): 41
ALT or GPT (IU/L): 15.0
AST or GOT (IU/L): 17.0
Total Cholesterol (mmol/L): 4,11
Creatinine (mmol/L): 124.0
Gamma-glutamil transpeptidase (IU/L): 56
Glucose (mmol/L): 5,9
Hemoglobin (g/L): 143.0
HDL (mmol/L): 0,96
Potassium (mEq/L): 4,7
LDL (mmol/L): 1,97
Sodium (mEq/L): 135.0
Protein (g/L): 68
T3 (pg/dL): 0,05
T4 (ng/L): 22
Troponin (ng/mL): 0,04
TSH (mIU/L): 1,86
Urea (mg/dL): 10,15
LVEF (%): 25.0
Medications: Calcium Channel Blocker, Beta Blockers, Spironolactone, Statins, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: TPSV
        - Bradycardia: First-degree Atrioventricular block (AVB)
            ",survivor,"RANKING: 1. Survivor
REASONING: 

Based on the provided patient data, the patient is a 78-year-old male with a history of ischemic dilated cardiomyopathy, which is a significant risk factor for cardiac complications. However, the patient's current NYHA Class II indicates that they are not experiencing severe symptoms, which is a positive prognostic sign.

The patient's laboratory results show a mildly elevated creatinine level (124.0 mol/L), which may indicate some degree of renal impairment. However, this is not uncommon in patients with heart failure. The patient's troponin level (0.04 ng/mL) is within the normal range, which suggests that there is no significant myocardial damage.

The patient's ECG findings, including the presence of ventricular extrasystoles, first-degree AV block, and the absence of ventricular tachycardia or non-sustained ventricular tachycardia, do not indicate any life-threatening arrhythmias. The presence of paroxysmal supraventricular tachycardia (PSVT) may be a concern, but it is not uncommon in patients with heart failure.

The patient's medication regimen includes a calcium channel blocker, beta blockers, spironolactone, statins, and an ACE inhibitor, which are all standard treatments for heart failure and ischemic cardiomyopathy.

Considering these factors, the patient's overall prognosis is relatively favorable, and they are likely to survive for the next few years. The presence of a first-degree AV block may require close monitoring, but it is not a contraindication for survival. Therefore, the most likely outcome is that the patient will survive.

RANKING: 2. Pump failure death
REASONING: 

While the patient's NYHA Class II indicates that they are not experiencing severe symptoms, their LVEF (25.0%) is significantly reduced, which is a negative prognostic sign. This indicates that the patient's heart is not functioning efficiently, and there is a higher risk of pump failure.

Additionally, the patient's creatinine level (124.0 mol/L) is elevated, which may indicate some degree of renal impairment. This can be a marker for underlying cardiac dysfunction, as the heart and kidneys are closely linked.

The patient's troponin level (0.04 ng/mL) is within the normal range, which suggests that there is no significant myocardial damage. However, the presence of ventricular extrasystoles on the ECG may indicate some degree of cardiac dysfunction.

Given these factors, while the patient is not at high risk of sudden cardiac death, there is still a significant risk of pump failure, especially given their reduced LVEF and elevated creatinine level.

RANKING: 3. Sudden cardiac death
REASONING: 

The patient's ECG findings, including ventricular extrasystoles, are concerning for a potential arrhythmic risk. However, the absence of ventricular tachycardia or non-sustained ventricular tachycardia on the ECG reduces the likelihood of sudden cardiac death.

The patient's NYHA Class II indicates that they are not experiencing severe symptoms, which is a positive prognostic sign. However, the presence of ventricular extrasystoles on the ECG suggests that there may be some degree of cardiac dysfunction, which increases the risk of arrhythmias.

The patient's medication regimen includes beta blockers, which are known to reduce the risk of arrhythmias. However, the presence of ventricular extrasystoles may indicate that the patient is not receiving adequate beta blocker therapy, or that the medication is not effective.

Given these factors, while the patient is not at high risk of pump failure or sudden cardiac death, the presence of ventricular extrasystoles on the ECG does increase the risk of arrhythmic complications. However, the overall prognosis is still relatively favorable, and the patient is likely to survive for the next few years."
645,645,P1054,"Age: 58
Gender: Male 
Weight: 91 kg
Height: 176 cm
NYHA Class: III
Blood Pressure: 110/70 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Dyslipemia, Hypertension, Myocardial Infarction
Albumin (g/L): 41,7
ALT or GPT (IU/L): 20.0
AST or GOT (IU/L): 32.0
Total Cholesterol (mmol/L): 4,63
Creatinine (mmol/L): 95.0
Gamma-glutamil transpeptidase (IU/L): 39
Glucose (mmol/L): 6,1
Hemoglobin (g/L): 145.0
HDL (mmol/L): 0,88
Potassium (mEq/L): 4,4
LDL (mmol/L): 3,08
Sodium (mEq/L): 139.0
Pro-BNP (ng/L): 4492.0
Protein (g/L): 78
T3 (pg/dL): 0,05
T4 (ng/L): 21
Troponin (ng/mL): 0,01
TSH (mIU/L): 2,45
Urea (mg/dL): 12,03
LVEF (%): 20.0
Medications: Amiodarone, Beta Blockers, Loop Diuretics, Spironolactone, Statins, ACE Inhibitor, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: TPSV
        - Bradycardia: No
            ",survivor,"RANKING: 1. Survivor 
REASONING: 
Given the patient's NYHA Class III status and the presence of ischemic dilated cardiomyopathy, the patient is already at a high risk for adverse cardiac events. However, the patient's current LVEF is 20%, which suggests significant left ventricular dysfunction. Despite this, the patient is on multiple medications, including beta blockers, ACE inhibitors, and amiodarone, which are standard treatments for heart failure and arrhythmias.

The patient's laboratory results show elevated troponin levels, indicating some degree of myocardial injury, but the troponin level is very low (0.01 ng/mL). The patient's creatinine level is also elevated (95.0 mmol/L), suggesting some degree of renal impairment, but the patient is on loop diuretics, which can help manage fluid overload and reduce creatinine levels.

The ECG results show ventricular extrasystoles and non-sustained ventricular tachycardia, which are concerning signs of arrhythmia. However, the patient is already on amiodarone, which is an antiarrhythmic medication that can help manage these conditions.

Considering these factors, I believe the patient is likely to survive for the next few years, given the current treatment regimen and the absence of any other life-threatening conditions. However, close monitoring and regular follow-up appointments will be necessary to adjust the treatment plan as needed to manage the patient's cardiac function and prevent further complications.

RANKING 2. Sudden Cardiac Death 
REASONING: 
While the patient is at high risk for adverse cardiac events, the patient's current LVEF is 20%, which suggests significant left ventricular dysfunction. This level of dysfunction increases the risk of sudden cardiac death. However, the patient's NYHA Class III status and the presence of multiple medications may help mitigate this risk.

RANKING 3. Pump Failure Death 
REASONING: 
Pump failure death is a concern given the patient's ischemic dilated cardiomyopathy and NYHA Class III status. However, the patient's elevated creatinine level and low LVEF suggest that the patient's cardiac function is already compromised. While the patient is on medications to manage heart failure, the presence of ventricular extrasystoles and non-sustained ventricular tachycardia on the ECG suggests that the patient's cardiac function may not be responding adequately to treatment."
646,646,P1056,"Age: 79
Gender: Male 
Weight: 78 kg
Height: 161 cm
NYHA Class: II
Blood Pressure: 111/76 mmHg
Past Medical History: Hypertensive cardiomyopathy, Hypertension
Albumin (g/L): 43
ALT or GPT (IU/L): 13.0
AST or GOT (IU/L): 15.0
Total Cholesterol (mmol/L): 4,86
Creatinine (mmol/L): 106.0
Gamma-glutamil transpeptidase (IU/L): 25
Glucose (mmol/L): 5,7
Hemoglobin (g/L): 147.0
HDL (mmol/L): 0,83
Potassium (mEq/L): 4,2
LDL (mmol/L): 3,65
Sodium (mEq/L): 137.0
Protein (g/L): 76
T3 (pg/dL): 0,04
T4 (ng/L): 15
Troponin (ng/mL): 0,005
TSH (mIU/L): 1,62
Urea (mg/dL): 9,82
LVEF (%): 39.0
Medications: Digoxin, Loop Diuretics, ACE Inhibitor, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Sinus Node Dysfunction
            ",survivor,"RANKING: 
1. Survivor
REASONING:
The patient's overall clinical presentation, laboratory results, and ECG findings suggest that they are at high risk for adverse cardiac events. However, the patient is currently being managed with a combination of medications, including digoxin, loop diuretics, ACE inhibitor, and nitrovasodilator, which are standard treatments for heart failure and hypertension.

The patient's NYHA Class II indicates mild symptoms, and their LVEF is 39%, which is within the range of 30-50% and is consistent with heart failure. However, their ECG shows non-sustained ventricular tachycardia (NSVT), which is a significant finding. NSVT is associated with an increased risk of sudden cardiac death.

The patient's creatinine level is elevated at 106.0 mmol/L, which may indicate renal impairment. Elevated creatinine levels can be associated with cardiac disease, and the patient's ECG shows signs of ventricular dysfunction. The patient's TSH level is slightly elevated at 1.62 mIU/L, which may indicate hypothyroidism, but this is not directly related to cardiac risk.

The patient's troponin level is within the normal range, which suggests that there is no significant myocardial injury. The patient's other laboratory results, including liver enzymes, electrolytes, and lipid profiles, are relatively normal.

Given the patient's complex medical history, the presence of NSVT, and the fact that they are already on medications for heart failure and hypertension, I believe that the patient is at high risk for cardiac events. However, the fact that they are currently being managed with standard therapies and do not have any other significant findings that would increase their risk, I rank the patient as having a higher likelihood of survival compared to the other options.

RANKING 2: Sudden Cardiac Death
REASONING:
The patient's ECG shows non-sustained ventricular tachycardia (NSVT), which is a significant finding. NSVT is associated with an increased risk of sudden cardiac death. Although the patient is currently being managed with medications, the presence of NSVT increases the risk of a more severe cardiac event.

RANKING 3: Pump Failure Death
REASONING:
The patient's LVEF is 39%, which is within the range of 30-50% and is consistent with heart failure. However, the patient is currently being managed with medications that are standard for heart failure, and their other laboratory results, including electrolytes and liver enzymes, are relatively normal. While the patient's creatinine level is elevated, this may not necessarily indicate pump failure. Additionally, the patient's troponin level is within the normal range, which suggests that there is no significant myocardial injury. Given the patient's relatively stable clinical presentation and the fact that they are already on medications for heart failure, I believe that pump failure is the least likely of the three options."
647,647,P1057,"Age: 72
Gender: Female 
Weight: 72 kg
Height: 150 cm
NYHA Class: II
Blood Pressure: 104/62 mmHg
Past Medical History: Idiopathic dilated cardiomyopathy, Diabetes, Dyslipemia
Albumin (g/L): 44
ALT or GPT (IU/L): 14.0
AST or GOT (IU/L): 16.0
Total Cholesterol (mmol/L): 5,3
Creatinine (mmol/L): 88.0
Gamma-glutamil transpeptidase (IU/L): 11
Glucose (mmol/L): 10,7
Hemoglobin (g/L): 124.0
HDL (mmol/L): 1,06
Potassium (mEq/L): 4,8
LDL (mmol/L): 2,59
Sodium (mEq/L): 139.0
Protein (g/L): 77
T3 (pg/dL): 0,05
T4 (ng/L): 15
Troponin (ng/mL): 0,33
TSH (mIU/L): 0,76
Urea (mg/dL): 12,31
LVEF (%): 35.0
Medications: Diabetes Medication, Beta Blockers, Loop Diuretics, Spironolactone, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"RANKING: 1. Survivor
REASONING:

Based on the provided patient data, the patient is likely to survive for the next few years due to the following reasons:

1. Age: Although the patient is 72 years old, her age alone is not a contraindication for survival. Many patients with advanced heart disease can survive for several years with proper management.

2. NYHA Class II: The patient's NYHA class indicates that she has moderate symptoms of heart failure, but it is not severe enough to be classified as NYHA Class III or IV. This suggests that she has some functional capacity and can still perform daily activities with some limitation.

3. Medications: The patient is on a combination of medications that are commonly used to manage heart failure, diabetes, and hypertension. The medications include beta blockers, loop diuretics, spironolactone, and an ACE inhibitor, which are all effective in managing symptoms and slowing disease progression.

4. Electrocardiogram (ECG) results: The ECG shows ventricular extrasystoles, non-sustained VT, and non-sustained ventricular tachycardia (CH>10), but these findings are not indicative of an immediate life-threatening arrhythmia. The absence of sustained VT and the presence of beta blockers suggest that the patient's heart is being adequately paced.

5. Biomarkers: The patient's troponin level is slightly elevated, but it is not significantly high, which suggests that there is no acute myocardial infarction. The patient's TSH level is within the normal range, and her kidney function is relatively preserved.

However, despite these positive factors, the patient's LVEF is severely impaired (35%), indicating significant left ventricular dysfunction. This, combined with her past medical history of idiopathic dilated cardiomyopathy, diabetes, and dyslipemia, suggests that the patient has a high risk of progression of her heart disease.

Therefore, while the patient is likely to survive for the next few years, her prognosis is guarded due to the presence of significant left ventricular dysfunction and her underlying heart disease. However, with proper management and close monitoring, she can still expect to survive for at least 5-7 years.

RANKING: 2. Sudden cardiac death
REASONING:

The patient's LVEF is severely impaired, and she has a history of ventricular tachycardia, which increases the risk of sudden cardiac death. Additionally, her past medical history of idiopathic dilated cardiomyopathy, diabetes, and dyslipemia further increases her risk of cardiac complications.

RANKING: 3. Pump failure death
REASONING:

Given the patient's severely impaired LVEF and her history of heart failure, pump failure death is a possible outcome. However, this ranking is less likely than sudden cardiac death due to the presence of beta blockers and other medications that are effective in managing heart failure symptoms.

It's worth noting that the patient's protein level is slightly elevated, which may indicate some degree of malnutrition or muscle wasting. This could potentially worsen her heart failure symptoms and increase her risk of pump failure. However, this factor is not a significant contributor to her overall prognosis."
648,648,P1058,"Age: 77
Gender: Male 
Weight: 63 kg
Height: 169 cm
NYHA Class: II
Blood Pressure: 131/60 mmHg
Past Medical History: Valvular cardiomyopathy, Dyslipemia
Albumin (g/L): 40
ALT or GPT (IU/L): 20.0
AST or GOT (IU/L): 22.0
Total Cholesterol (mmol/L): 5,28
Creatinine (mmol/L): 88.0
Gamma-glutamil transpeptidase (IU/L): 29
Glucose (mmol/L): 4,5
Hemoglobin (g/L): 136.0
HDL (mmol/L): 0,96
Potassium (mEq/L): 4,5
LDL (mmol/L): 3,9
Sodium (mEq/L): 140.0
Protein (g/L): 72
T3 (pg/dL): 0,05
T4 (ng/L): 17
Troponin (ng/mL): 0,03
TSH (mIU/L): 0,58
Urea (mg/dL): 9,98
LVEF (%): 19.0
Medications: Beta Blockers, Digoxin, Loop Diuretics, Statins, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",survivor,"RANKING: 
1. Survivor 
REASONING: 
The patient is 77 years old, with a history of valvular cardiomyopathy, dyslipidemia, and a reduced left ventricular ejection fraction (LVEF) of 19%. The presence of sustained ventricular tachycardia (VT) and non-sustained ventricular tachycardia (NSVT) on the ECG impression suggests an increased risk of arrhythmic events. However, the patient is on beta blockers, which are known to reduce the risk of arrhythmias. The patient is also taking digoxin, which can have a pro-arrhythmic effect, but the low dose used in this case may be less likely to cause significant harm. The patient's hemoglobin level is elevated, which may indicate anemia, but it is not directly related to the cardiac condition. The patient's creatinine level is slightly elevated, which may indicate some degree of renal impairment, but it is not severe. The patient's troponin level is normal, which suggests that there is no significant myocardial infarction. The patient's medications, including beta blockers, ACE inhibitor, and statins, are typical for managing heart failure and reducing cardiovascular risk. Overall, the patient's condition is stable, and the presence of sustained VT and NSVT on the ECG impression does not necessarily indicate a high risk of sudden cardiac death. 

2. Sudden Cardiac Death 
REASONING: 
The patient's history of valvular cardiomyopathy and reduced LVEF increases the risk of sudden cardiac death. The presence of sustained VT and NSVT on the ECG impression is a significant risk factor for sudden cardiac death. However, the patient is on beta blockers, which reduce the risk of arrhythmias. The patient's elevated creatinine level may indicate some degree of renal impairment, which can increase the risk of arrhythmias. The patient's low T3 level may indicate hypothyroidism, which can increase the risk of arrhythmias. The patient's elevated glucose level may also indicate diabetes, which is a risk factor for cardiac disease.

3. Pump Failure Death 
REASONING: 
The patient's reduced LVEF of 19% indicates significant left ventricular dysfunction, which increases the risk of pump failure. The patient's elevated creatinine level and low hemoglobin level may indicate some degree of renal impairment and anemia, respectively. The patient's history of valvular cardiomyopathy and dyslipidemia also increases the risk of pump failure. However, the patient is on medications that are typical for managing heart failure, including beta blockers, ACE inhibitor, and digoxin. The patient's elevated glucose level may indicate diabetes, which is a risk factor for pump failure. Overall, while the patient's condition is not ideal, the presence of beta blockers and other medications may mitigate the risk of pump failure."
649,649,P1064,"Age: 63
Gender: Female 
Weight: 67 kg
Height: 151 cm
NYHA Class: II
Blood Pressure: 163/94 mmHg
Past Medical History: Hypertensive cardiomyopathy, Diabetes, Hypertension
Albumin (g/L): 43
ALT or GPT (IU/L): 16.0
AST or GOT (IU/L): 12.0
Total Cholesterol (mmol/L): 5,38
Creatinine (mmol/L): 53.0
Gamma-glutamil transpeptidase (IU/L): 12
Glucose (mmol/L): 6,7
Hemoglobin (g/L): 128.0
HDL (mmol/L): 1,4
Potassium (mEq/L): 4,7
LDL (mmol/L): 3,28
Sodium (mEq/L): 141.0
Protein (g/L): 70
T3 (pg/dL): 0,05
T4 (ng/L): 17
Troponin (ng/mL): 0,005
TSH (mIU/L): 2,35
Urea (mg/dL): 6,32
LVEF (%): 30.0
Medications: Diabetes Medication, Angiotensin II Receptor Blocker, Beta Blockers, Loop Diuretics
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: Unknown bradycardia code
            ",survivor,"RANKING: 1. Survivor
REASONING: 

Based on the patient data provided, I predict that the patient will be a survivor. 

The patient's age (63) and NYHA Class II indicate a moderate level of cardiovascular disease. However, the patient's LVEF (30.0%) suggests a significant reduction in left ventricular function, which could be indicative of cardiomyopathy. 

The patient's blood pressure (163/94 mmHg) is elevated, and the presence of hypertension, hypertensive cardiomyopathy, and diabetes in the past medical history further supports this. 

However, the patient's troponin level (0.005 ng/mL) is within the normal range, which suggests that there is no acute myocardial infarction. The absence of ventricular tachycardia or non-sustained ventricular tachycardia on the ECG also reduces the risk of sudden cardiac death. 

The patient's hemoglobin level (128.0 g/L) and other laboratory values are within relatively normal limits, indicating that the patient does not appear to be in acute kidney injury or severe anemia. 

The patient's medications, including diabetes medication, angiotensin II receptor blocker, beta blockers, and loop diuretics, suggest that the patient is receiving standard treatment for hypertension, diabetes, and heart failure. 

Given these factors, I predict that the patient will survive, although it is essential to continue monitoring the patient's condition and adjusting the treatment plan as necessary to manage the patient's cardiovascular disease.

RANKING: 2. Sudden cardiac death
REASONING: 

Sudden cardiac death is a possible outcome for this patient due to the presence of ventricular extrasystoles and polymorphic ventricular extrasystoles on the ECG. However, the absence of ventricular tachycardia or non-sustained ventricular tachycardia on the ECG reduces this risk. 

Additionally, the patient's LVEF (30.0%) is significantly reduced, which could increase the risk of arrhythmias. However, the patient's troponin level is within the normal range, and the patient is not in acute kidney injury or severe anemia.

RANKING: 3. Pump failure death
REASONING: 

Pump failure death is a possible outcome for this patient due to the patient's significant reduction in LVEF (30.0%) and the presence of hypertension, hypertensive cardiomyopathy, and diabetes in the past medical history. However, the patient's NYHA Class II and the presence of beta blockers, which are standard treatments for heart failure, suggest that the patient is receiving appropriate management for heart failure.

Additionally, the patient's hemoglobin level and other laboratory values are within relatively normal limits, indicating that the patient does not appear to be in acute kidney injury or severe anemia. 

Given the patient's current treatment plan and the absence of acute myocardial infarction, I predict that pump failure death is the least likely outcome among the three options."
650,650,P1065,"Age: 80
Gender: Male 
Weight: 79 kg
Height: 164 cm
NYHA Class: II
Blood Pressure: 146/83 mmHg
Past Medical History: Idiopathic dilated cardiomyopathy
Albumin (g/L): 42
ALT or GPT (IU/L): 17.0
AST or GOT (IU/L): 26.0
Total Cholesterol (mmol/L): 4,91
Creatinine (mmol/L): 80.0
Gamma-glutamil transpeptidase (IU/L): 17
Glucose (mmol/L): 14,9
Hemoglobin (g/L): 179.0
HDL (mmol/L): 0,83
LDL (mmol/L): 3,21
Sodium (mEq/L): 135.0
Protein (g/L): 70
T3 (pg/dL): 0,05
T4 (ng/L): 13
Troponin (ng/mL): 0,03
TSH (mIU/L): 1,06
Urea (mg/dL): 13,98
LVEF (%): 56.0
Medications: Digoxin, Loop Diuretics, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: TPSV
        - Bradycardia: Unknown bradycardia code
            ",survivor,"RANKING: 

1. Survivor
REASONING:
The patient is a 80-year-old male with a history of idiopathic dilated cardiomyopathy, which is a condition where the heart's ability to pump blood is reduced. The patient's LVEF (left ventricular ejection fraction) is 56.0%, which is within the range of 40-60% and indicates moderate systolic dysfunction. The patient's NYHA Class is II, indicating mild symptoms, which suggests that the patient is still relatively functional.

The patient's laboratory results show mild elevations in liver enzymes (AST and ALT) and low albumin levels, which may indicate some degree of liver dysfunction or malnutrition. However, these findings are not directly related to the patient's cardiac condition.

The patient's ECG findings are concerning for ventricular extrasystoles and a TPSV (paroxysmal supraventricular tachyarrhythmia), but the absence of ventricular tachycardia and non-sustained ventricular tachycardia reduces the risk of sudden cardiac death.

The patient is on medications that are commonly used to treat heart failure and arrhythmias, which suggests that the patient's condition is being managed.

Considering these factors, the patient is likely to survive the next few years, although close monitoring and adjustments to their treatment plan may be necessary to manage their condition.

2. Sudden cardiac death
REASONING:
The patient's ECG findings, including ventricular extrasystoles, are concerning for an increased risk of sudden cardiac death. Additionally, the patient's LVEF is only 56%, which indicates significant systolic dysfunction and may increase the risk of sudden cardiac death.

However, the patient is not currently experiencing symptoms of ventricular tachycardia or non-sustained ventricular tachycardia, which reduces the risk of sudden cardiac death.

3. Pump failure death
REASONING:
The patient's LVEF is 56%, which is within the range of 40-60% and indicates moderate systolic dysfunction. However, the patient's NYHA Class is II, which suggests that the patient is still relatively functional.

The patient's laboratory results show mild elevations in liver enzymes and low albumin levels, which may indicate some degree of liver dysfunction or malnutrition. However, these findings are not directly related to the patient's cardiac condition.

Given the patient's current treatment plan and the absence of severe symptoms, it is less likely that the patient will experience pump failure death in the next few years. However, close monitoring and adjustments to their treatment plan may be necessary to manage their condition and prevent worsening of their cardiac function."
651,651,P1066,"Age: 72
Gender: Female 
Weight: 81 kg
Height: 156 cm
NYHA Class: II
Blood Pressure: 164/79 mmHg
Past Medical History: Hypertensive cardiomyopathy, Hypertension
Albumin (g/L): 40
ALT or GPT (IU/L): 12.0
AST or GOT (IU/L): 12.0
Total Cholesterol (mmol/L): 5,04
Creatinine (mmol/L): 71.0
Gamma-glutamil transpeptidase (IU/L): 10
Glucose (mmol/L): 5,7
Hemoglobin (g/L): 129.0
HDL (mmol/L): 0,85
Potassium (mEq/L): 4,6
LDL (mmol/L): 3,62
Sodium (mEq/L): 139.0
Protein (g/L): 69
T3 (pg/dL): 0,06
T4 (ng/L): 11
Troponin (ng/mL): 0,03
TSH (mIU/L): 1,38
Urea (mg/dL): 8,32
LVEF (%): 42.0
Medications: Loop Diuretics, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: TPSV
        - Bradycardia: Unknown bradycardia code
            ",survivor,"RANKING: 
1. Survivor 
REASONING: 
Based on the patient's data, I predict a high likelihood of survival for the next few years. The patient's age of 72 is not unusually high for a cardiomyopathy patient, and their NYHA class II indicates that they are still relatively functional. Their LVEF of 42.0 is significantly reduced, but it's not an indication of severe left ventricular dysfunction. The absence of ventricular tachycardia, non-sustained ventricular tachycardia, and paroxysmal supraventricular tachyarrhythmia on the ECG suggests that the patient does not have a high risk of sudden cardiac death. The patient is also on ACE inhibitor therapy, which is a standard treatment for hypertensive cardiomyopathy. The patient's electrolyte levels, liver enzymes, and kidney function are relatively normal, and their hemoglobin and potassium levels are within a relatively normal range. Overall, the patient's data suggests a relatively stable cardiovascular condition, which supports a high likelihood of survival.

RANKING: 
2. Pump failure death 
REASONING: 
A moderate likelihood of pump failure death cannot be ruled out. Although the patient's LVEF is significantly reduced, their NYHA class II indicates that they are still able to perform daily activities with some limitations. However, the patient's reduced LVEF and elevated creatinine levels suggest that their cardiac function is compromised. The patient's elevated blood pressure and hypertension are also contributing factors to their cardiac condition. Additionally, the patient's age is increasing, which can contribute to a higher risk of cardiac events.

RANKING: 
3. Sudden cardiac death 
REASONING: 
A low likelihood of sudden cardiac death cannot be ruled out, but it is the least likely of the three options. The absence of ventricular tachycardia, non-sustained ventricular tachycardia, and paroxysmal supraventricular tachyarrhythmia on the ECG reduces the risk of sudden cardiac death. However, the patient's reduced LVEF, elevated creatinine levels, and hypertension still pose a risk for cardiac events. The patient's age and NYHA class II also increase the risk of cardiac events, but overall, the patient's stable cardiovascular condition and treatment with ACE inhibitors reduce the risk of sudden cardiac death."
652,652,P1073,"Age: 70
Gender: Female 
Weight: 63 kg
Height: 144 cm
NYHA Class: II
Blood Pressure: 134/86 mmHg
Past Medical History: Idiopathic dilated cardiomyopathy, Diabetes
Albumin (g/L): 44
ALT or GPT (IU/L): 12.0
AST or GOT (IU/L): 13.0
Total Cholesterol (mmol/L): 6,21
Creatinine (mmol/L): 80.0
Gamma-glutamil transpeptidase (IU/L): 89
Glucose (mmol/L): 5,5
Hemoglobin (g/L): 145.0
HDL (mmol/L): 1,68
Potassium (mEq/L): 4,5
LDL (mmol/L): 3,23
Sodium (mEq/L): 141.0
Protein (g/L): 73
T3 (pg/dL): 0,05
T4 (ng/L): 12
Troponin (ng/mL): 0,03
TSH (mIU/L): 1,43
Urea (mg/dL): 8,82
LVEF (%): 40.0
Medications: Beta Blockers, Loop Diuretics, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",survivor,"RANKING: 
1. Survivor
2. Sudden cardiac death
3. Pump failure death

REASONING:

This patient's prognosis is generally favorable due to the following factors:

1. Age: The patient is 70 years old, which is considered old, but not extremely high-risk. Many patients in this age group can live for several more years with proper management.

2. NYHA Class II: The patient's heart failure symptoms are mild, indicating that the disease is not severely impacting their daily life. This suggests that the heart is still capable of maintaining adequate cardiac output.

3. Medications: The patient is taking beta blockers, loop diuretics, and ACE inhibitors, which are standard treatments for heart failure and cardiomyopathy. These medications have been shown to improve survival and reduce morbidity in patients with heart failure.

4. Laboratory results: The patient's laboratory results, such as low albumin, elevated creatinine, and low HDL cholesterol, indicate that the patient is experiencing some degree of malnutrition and kidney impairment, but these are not uncommon in patients with heart failure.

5. Troponin level: The patient's troponin level is normal, which suggests that there is no significant myocardial infarction or acute coronary syndrome.

6. ECG: The ECG shows ventricular extrasystoles, which are common in patients with heart failure and cardiomyopathy. However, the absence of ventricular tachycardia or non-sustained ventricular tachycardia suggests that the patient is not at high risk for sudden cardiac death.

However, despite these favorable factors, the patient's LVEF (left ventricular ejection fraction) is only 40%, which indicates significant left ventricular dysfunction. This suggests that the patient's heart is not functioning optimally, and there is a risk of pump failure.

Therefore, while the patient's prognosis is generally favorable, there is still a risk of pump failure death, especially if the patient's condition does not improve with ongoing treatment. Sudden cardiac death is less likely, given the absence of ventricular tachycardia or non-sustained ventricular tachycardia on the ECG."
653,653,P0008,"Age: 44
Gender: Male 
Weight: 114 kg
Height: 179 cm
NYHA Class: II
Blood Pressure: 140/80 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Diabetes, Dyslipemia, Hypertension
Albumin (g/L): 42,19
ALT or GPT (IU/L): 29.0
AST or GOT (IU/L): 24.0
Total Cholesterol (mmol/L): 5,07
Creatinine (mmol/L): 93.0
Gamma-glutamil transpeptidase (IU/L): 29
Glucose (mmol/L): 12,3
Hemoglobin (g/L): 143.0
HDL (mmol/L): 1,37
Potassium (mEq/L): 4,5
LDL (mmol/L): 2,77
Sodium (mEq/L): 136.0
Pro-BNP (ng/L): 623.0
Protein (g/L): 76
T3 (pg/dL): 0,02
T4 (ng/L): 16
Troponin (ng/mL): 0,01
TSH (mIU/L): 2,58
Urea (mg/dL): 9,8
LVEF (%): 30.0
Medications: Diabetes Medication, Beta Blockers, Loop Diuretics, Statins, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",sudden cardiac death,"RANKING: 1. Survivor
REASONING: 

Based on the provided patient data, the patient is at a high risk for cardiac complications due to their history of ischemic dilated cardiomyopathy, hypertension, diabetes, and dyslipidemia. The elevated Pro-BNP levels (623 ng/L) indicate significant cardiac stress and strain, suggesting left ventricular dysfunction. The LVEF (30.0%) is also low, indicating poor cardiac function.

The patient's ECG findings of ventricular extrasystoles are concerning for arrhythmias, which can be a predictor of sudden cardiac death. The presence of ventricular extrasystoles, particularly polymorphic, increases the risk of ventricular fibrillation or ventricular tachycardia, which can lead to sudden cardiac death.

The patient's medical history and ECG findings suggest that the patient is at high risk for cardiac complications, but the absence of other high-risk features such as ventricular tachycardia or non-sustained ventricular tachycardia (CH>10) and the presence of beta blockers, ACE inhibitors, and loop diuretics suggest that the patient is being adequately managed for their cardiovascular risk factors.

While the patient's prognosis is uncertain, the available data suggests that the patient is more likely to survive with proper management and monitoring, rather than experiencing sudden cardiac death or pump failure death. Therefore, I would rank the patient as a survivor."
654,654,P0012,"Age: 70
Gender: Male 
Weight: 88 kg
Height: 175 cm
NYHA Class: III
Blood Pressure: 130/80 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Dyslipemia, Hypertension, Myocardial Infarction
Albumin (g/L): 39,3
ALT or GPT (IU/L): 13.0
AST or GOT (IU/L): 15.0
Total Cholesterol (mmol/L): 4,32
Creatinine (mmol/L): 120.0
Gamma-glutamil transpeptidase (IU/L): 14
Glucose (mmol/L): 4,9
Hemoglobin (g/L): 137.0
HDL (mmol/L): 1,53
Potassium (mEq/L): 3,1
LDL (mmol/L): 2,43
Sodium (mEq/L): 145.0
Pro-BNP (ng/L): 958.0
Protein (g/L): 71
T3 (pg/dL): 0,03
T4 (ng/L): 17
Troponin (ng/mL): 0,01
TSH (mIU/L): 1,51
Urea (mg/dL): 8,02
LVEF (%): 35.0
Medications: Calcium Channel Blocker, Amiodarone, Angiotensin II Receptor Blocker, Loop Diuretics, Spironolactone, Statins, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: TPSV
        - Bradycardia: No
            ",sudden cardiac death,"RANKING: 1. Sudden cardiac death
REASONING: 

Based on the patient's data, the most likely prognosis is sudden cardiac death. The patient has a history of ischemic dilated cardiomyopathy, which is a significant risk factor for sudden cardiac death. The patient's left ventricular ejection fraction (LVEF) is 35%, which is significantly reduced, indicating poor cardiac function. The patient also has a history of myocardial infarction, which can lead to scarring and further cardiac dysfunction.

Additionally, the patient's ECG shows ventricular extrasystole, which is a marker of abnormal heart rhythm. The presence of ventricular extrasystole, particularly polymorphic, increases the risk of sudden cardiac death.

The patient's biomarkers also support this prognosis. The elevated troponin level (0.01 ng/mL) suggests some degree of cardiac damage, and the high Pro-BNP level (958 ng/L) indicates significant cardiac stress.

While the patient is on multiple medications, including beta-blockers, amiodarone, and spironolactone, which are often used to manage heart failure and arrhythmias, the patient's overall cardiac function is still compromised.

Therefore, based on the patient's history, ECG findings, and biomarkers, sudden cardiac death is the most likely prognosis."
655,655,P0016,"Age: 72
Gender: Male 
Weight: 78 kg
Height: 173 cm
NYHA Class: III
Blood Pressure: 95/70 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Dyslipemia, Myocardial Infarction
Albumin (g/L): 38,1
ALT or GPT (IU/L): 12.0
AST or GOT (IU/L): 19.0
Total Cholesterol (mmol/L): 6,72
Creatinine (mmol/L): 225.0
Gamma-glutamil transpeptidase (IU/L): 31
Glucose (mmol/L): 7
Hemoglobin (g/L): 151.0
HDL (mmol/L): 0,96
Potassium (mEq/L): 4,7
LDL (mmol/L): 4,78
Sodium (mEq/L): 136.0
Pro-BNP (ng/L): 15509.0
Protein (g/L): 70
T3 (pg/dL): 0,05
T4 (ng/L): 17
Troponin (ng/mL): 0,01
TSH (mIU/L): 2,56
Urea (mg/dL): 31,4
LVEF (%): 18.0
Medications: Beta Blockers, Digoxin, Loop Diuretics, Spironolactone, Statins, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",sudden cardiac death,"RANKING: 1. Sudden Cardiac Death
REASONING: 
The patient's ECG impression highlights several concerning features that suggest an increased risk of sudden cardiac death. The presence of ventricular extrasystole, non-sustained ventricular tachycardia (NSVT), and non-sustained ventricular tachycardia (CH>10) are all indicative of arrhythmogenic substrates that can lead to life-threatening ventricular arrhythmias. The patient's history of ischemic dilated cardiomyopathy, myocardial infarction, and current NYHA Class III symptoms also suggest a compromised cardiac function, which can contribute to the risk of sudden cardiac death.

Additionally, the elevated troponin levels (0.01 ng/mL) and low LVEF (18.0%) indicate myocardial damage and reduced cardiac function, respectively. The patient's elevated creatinine level (225.0 mmol/L) may also suggest some degree of renal impairment, which can be a risk factor for cardiac complications.

While the patient's medication regimen includes beta blockers, which are generally beneficial for patients with cardiac conditions, the presence of non-sustained ventricular tachycardia and ventricular extrasystole on the ECG suggests that the patient may not be adequately protected against arrhythmias.

In contrast, while the patient's other laboratory values, such as liver function tests, lipid profile, and glucose levels, do not appear to be significantly abnormal, they do not provide information that would alter the risk assessment. Therefore, based on the ECG findings and the patient's medical history, sudden cardiac death is the most likely outcome.

The other two prognoses, survivor and pump failure death, are less likely because the patient's cardiac function is already compromised, and the presence of non-sustained ventricular tachycardia and ventricular extrasystole on the ECG suggests an increased risk of arrhythmias that can lead to sudden cardiac death. While pump failure death is a possible outcome, it is less likely in the short term, given the patient's current medication regimen and the presence of non-sustained ventricular tachycardia."
656,656,P0018,"Age: 57
Gender: Male 
Weight: 88 kg
Height: 168 cm
NYHA Class: II
Blood Pressure: 120/80 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Dyslipemia, Hypertension, Myocardial Infarction
Albumin (g/L): 48
ALT or GPT (IU/L): 38.0
AST or GOT (IU/L): 33.0
Total Cholesterol (mmol/L): 3,78
Creatinine (mmol/L): 89.0
Gamma-glutamil transpeptidase (IU/L): 45
Glucose (mmol/L): 4,6
Hemoglobin (g/L): 147.0
HDL (mmol/L): 1,4
Potassium (mEq/L): 4,6
LDL (mmol/L): 1,78
Sodium (mEq/L): 140.0
Pro-BNP (ng/L): 110.0
Protein (g/L): 78
T3 (pg/dL): 0,04
T4 (ng/L): 13
Troponin (ng/mL): 0,01
TSH (mIU/L): 1,21
Urea (mg/dL): 9,35
LVEF (%): 58.0
Medications: Beta Blockers, Statins, ACE Inhibitor, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: Sinus Node Dysfunction
            ",sudden cardiac death,"RANKING: 
1. Sudden cardiac death
2. Pump failure death
3. Survivor

REASONING:

The patient's clinical presentation and test results suggest a high risk of adverse cardiac events. Here's a breakdown of the factors contributing to this ranking:

1. High risk of Sudden Cardiac Death (SCD): The patient has a history of ischemic dilated cardiomyopathy, which is a well-established risk factor for SCD. The patient's LVEF is significantly reduced at 58%, indicating poor cardiac function. The presence of ventricular extrasystoles on the ECG, although not sustained, suggests an increased risk of arrhythmias, which is a common cause of SCD. Additionally, the patient's low ejection fraction and elevated troponin levels indicate myocardial damage, further increasing the risk of arrhythmias.

2. Pump Failure Death: Given the patient's LVEF of 58%, pump failure is a significant concern. The patient's heart is unable to efficiently pump blood, which can lead to heart failure, especially in the context of his existing cardiomyopathy. However, the patient is currently receiving medications that are standard for heart failure management (beta blockers, statins, ACE inhibitor, and nitrovasodilator), which may help mitigate this risk.

3. Survivor: While the patient's past medical history and current test results do indicate a high risk of adverse cardiac events, the patient is currently on multiple medications that are aimed at managing his conditions. His blood pressure is well-controlled, and his lipid profile is not significantly abnormal. The patient's ejection fraction, while low, is not severely impaired, and the presence of ventricular extrasystoles, although concerning, is not an independent predictor of mortality in this case. Overall, while the patient's prognosis is guarded, it is not as severe as the risk of SCD or pump failure.

Please note that this ranking is based on the provided data and should be considered in the context of the patient's individual circumstances and the clinician's professional judgment."
657,657,P0028,"Age: 76
Gender: Male 
Weight: 72 kg
Height: 187 cm
NYHA Class: III
Blood Pressure: 110/60 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Diabetes, Dyslipemia, Peripheral vascular disease
Albumin (g/L): 41,5
ALT or GPT (IU/L): 12.0
AST or GOT (IU/L): 12.0
Total Cholesterol (mmol/L): 4,5
Creatinine (mmol/L): 130.0
Gamma-glutamil transpeptidase (IU/L): 20
Glucose (mmol/L): 10,2
Hemoglobin (g/L): 132.0
HDL (mmol/L): 0,88
Potassium (mEq/L): 5
LDL (mmol/L): 2,9
Sodium (mEq/L): 140.0
Pro-BNP (ng/L): 7822.0
Protein (g/L): 67
T3 (pg/dL): 0,05
T4 (ng/L): 19
Troponin (ng/mL): 0,01
TSH (mIU/L): 1,29
Urea (mg/dL): 10,91
LVEF (%): 35.0
Medications: Diabetes Medication, Beta Blockers, Loop Diuretics, ACE Inhibitor, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",sudden cardiac death,"RANKING: 1. Sudden cardiac death
REASONING:

Based on the provided patient data, the patient is at high risk for a poor outcome due to the presence of several factors that contribute to a high risk of sudden cardiac death (SCD). These factors include:

1. NYHA Class III heart failure, indicating severe symptoms and reduced functional capacity.
2. Ischemic dilated cardiomyopathy, which is a significant risk factor for SCD.
3. Elevated Pro-BNP levels (7822.0 ng/L), which indicate a high level of ventricular strain and stress.
4. Reduced LVEF (35.0%), which suggests severely impaired cardiac function.
5. Presence of ventricular extrasystoles, which may indicate electrical instability in the heart.
6. Elevated creatinine levels (130.0 mmol/L), which may indicate renal impairment and further compromise cardiac function.
7. Presence of peripheral vascular disease, which may contribute to reduced blood flow and oxygen delivery to the heart muscle.
8. High blood pressure (110/60 mmHg), which may be a sign of cardiovascular disease and increased risk of SCD.
9. Presence of diabetes, dyslipemia, and other comorbid conditions, which may contribute to a higher risk of cardiovascular events.

Considering these factors, the patient is at a high risk for sudden cardiac death, which is the most likely outcome. The other two options, pump failure death and survivor, are less likely due to the patient's severe cardiac impairment and multiple comorbid conditions."
658,658,P0043,"Age: 63
Gender: Male 
Weight: 87 kg
Height: 165 cm
NYHA Class: II
Blood Pressure: 115/80 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Diabetes, Dyslipemia, Peripheral vascular disease, Myocardial Infarction
Albumin (g/L): 41,9
ALT or GPT (IU/L): 19.0
AST or GOT (IU/L): 16.0
Total Cholesterol (mmol/L): 4,53
Creatinine (mmol/L): 102.0
Gamma-glutamil transpeptidase (IU/L): 29
Glucose (mmol/L): 6,8
Hemoglobin (g/L): 168.0
HDL (mmol/L): 1,01
Potassium (mEq/L): 3,9
LDL (mmol/L): 2,87
Sodium (mEq/L): 139.0
Pro-BNP (ng/L): 636.0
Protein (g/L): 81
T3 (pg/dL): 0,07
T4 (ng/L): 18
Troponin (ng/mL): 0,01
TSH (mIU/L): 1,57
Urea (mg/dL): 4,9
LVEF (%): 26.0
Medications: Diabetes Medication, Beta Blockers, Spironolactone, Statins, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",sudden cardiac death,"RANKING: 1. Sudden Cardiac Death
REASONING:

This patient's prognosis is at the highest risk of sudden cardiac death due to the presence of several high-risk factors and abnormal test results. The patient has a history of ischemic dilated cardiomyopathy, which is a significant risk factor for sudden cardiac death. The patient's left ventricular ejection fraction (LVEF) is severely impaired at 26%, indicating a significant reduction in cardiac function.

The patient's ECG results also show a high risk for arrhythmias, including ventricular extrasystole and non-sustained ventricular tachycardia (NSVT). The presence of NSVT is particularly concerning, as it indicates an increased risk of ventricular fibrillation or ventricular tachycardia, which can lead to sudden cardiac death.

Additionally, the patient's elevated troponin levels (0.01 ng/mL) may indicate some degree of myocardial injury, which can also contribute to an increased risk of sudden cardiac death.

The patient's other medical conditions, such as diabetes, dyslipidemia, and peripheral vascular disease, also increase the risk of cardiovascular events, including sudden cardiac death.

While the patient is on medications such as beta blockers, spironolactone, statins, and an ACE inhibitor, these medications may not be sufficient to mitigate the high risk of sudden cardiac death in this patient.

Overall, the combination of the patient's medical history, ECG results, and laboratory findings make sudden cardiac death the most likely outcome for this patient over the next few years.

RANKING: 2. Pump Failure Death
REASONING:

Given the patient's severely impaired LVEF and the presence of ischemic dilated cardiomyopathy, pump failure death is a likely outcome. The patient's reduced cardiac function may lead to decreased cardiac output, which can result in symptoms such as fatigue, shortness of breath, and edema.

The patient's elevated creatinine levels (102.0 mmol/L) may also indicate some degree of kidney dysfunction, which can contribute to fluid overload and further compromise cardiac function.

The patient's other medical conditions, such as diabetes and dyslipidemia, can also contribute to the development of heart failure.

While the patient is on medications that may help manage heart failure, the combination of the patient's underlying cardiac disease and other medical conditions may not be enough to prevent pump failure death.

RANKING: 3. Survivor
REASONING:

While the patient's prognosis is not the best, there is still a possibility of survival. The patient is on medications that may help manage their heart failure symptoms and prevent further cardiac events.

However, the patient's severely impaired LVEF and the presence of NSVT on ECG suggest that their cardiac function is severely compromised. The patient's other medical conditions, such as diabetes and dyslipidemia, also increase the risk of cardiovascular events.

Additionally, the patient's elevated troponin levels may indicate some degree of myocardial injury, which can be a predictor of poor outcomes.

While the patient's medications may help manage some of their symptoms, it is unlikely that they will be able to completely reverse the underlying cardiac disease and prevent further cardiac events."
659,659,P0049,"Age: 70
Gender: Male 
Weight: 88 kg
Height: 170 cm
NYHA Class: II
Blood Pressure: 120/70 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Diabetes, Dyslipemia, Myocardial Infarction
Albumin (g/L): 41,4
ALT or GPT (IU/L): 24.0
AST or GOT (IU/L): 18.0
Total Cholesterol (mmol/L): 3,78
Creatinine (mmol/L): 118.0
Gamma-glutamil transpeptidase (IU/L): 77
Glucose (mmol/L): 9
Hemoglobin (g/L): 139.0
HDL (mmol/L): 1,09
Potassium (mEq/L): 4
LDL (mmol/L): 2,04
Sodium (mEq/L): 142.0
Pro-BNP (ng/L): 2542.0
Protein (g/L): 74
T3 (pg/dL): 0,05
T4 (ng/L): 18
Troponin (ng/mL): 0,01
TSH (mIU/L): 2,21
Urea (mg/dL): 8,91
LVEF (%): 25.0
Medications: Beta Blockers, Digoxin, Loop Diuretics, Spironolactone, Statins, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",sudden cardiac death,"RANKING: 
1. Sudden cardiac death
2. Pump failure death
3. Survivor

REASONING:

Based on the provided patient data, I would rank the prognoses as follows:

1. Sudden cardiac death: The patient's ECG impression shows a high risk of ventricular arrhythmias, including non-sustained ventricular tachycardia (NSVT) and polymorphic ventricular extrasystoles. The presence of NSVT is a significant predictor of sudden cardiac death in patients with heart failure and cardiomyopathy. Additionally, the patient's LVEF of 25% indicates severe left ventricular dysfunction, which increases the risk of arrhythmias and sudden cardiac death. The patient's age, NYHA Class II, and history of ischemic dilated cardiomyopathy, myocardial infarction, and diabetes also contribute to the increased risk of sudden cardiac death.

2. Pump failure death: The patient's LVEF of 25% indicates severe left ventricular dysfunction, which is a significant predictor of heart failure and pump failure. The patient's NYHA Class II also indicates moderate symptoms of heart failure, which increases the risk of pump failure. The patient's history of ischemic dilated cardiomyopathy, diabetes, and dyslipemia also contribute to the risk of pump failure.

3. Survivor: While the patient's ECG impression shows some signs of arrhythmias, the presence of NSVT and polymorphic ventricular extrasystoles suggests a higher risk of sudden cardiac death. Additionally, the patient's severe left ventricular dysfunction and NYHA Class II symptoms indicate a higher risk of pump failure. However, the patient's relatively stable vital signs, normal blood pressure, and the absence of other significant findings (e.g., severe hypotension, severe hypoxia) suggest that the patient may have a better prognosis than pump failure death.

It is essential to note that this prognosis is based on the available data and should be confirmed by further evaluation and monitoring. Close monitoring of the patient's condition and adjustments to their treatment plan may be necessary to prevent sudden cardiac death and pump failure."
660,660,P0051,"Age: 52
Gender: Male 
Weight: 74 kg
Height: 176 cm
NYHA Class: III
Blood Pressure: 85/60 mmHg
Past Medical History: Idiopathic dilated cardiomyopathy, Dyslipemia
Albumin (g/L): 39
ALT or GPT (IU/L): 22.0
AST or GOT (IU/L): 17.0
Total Cholesterol (mmol/L): 2,74
Creatinine (mmol/L): 118.0
Gamma-glutamil transpeptidase (IU/L): 17
Glucose (mmol/L): 5,5
Hemoglobin (g/L): 133.0
HDL (mmol/L): 0,88
Potassium (mEq/L): 5
LDL (mmol/L): 1,4
Sodium (mEq/L): 141.0
Pro-BNP (ng/L): 693.0
Protein (g/L): 68
T3 (pg/dL): 0,04
T4 (ng/L): 19
Troponin (ng/mL): 0,01
TSH (mIU/L): 5,55
Urea (mg/dL): 8,91
LVEF (%): 26.0
Medications: Amiodarone, Beta Blockers, Loop Diuretics, Spironolactone, Statins, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",sudden cardiac death,"RANKING: 
1. Sudden cardiac death
2. Pump failure death
3. Survivor

REASONING:

The patient's prognosis is primarily determined by their underlying condition, NYHA Class III status, and laboratory results. The patient has idiopathic dilated cardiomyopathy, which is a significant risk factor for sudden cardiac death. The patient's LVEF of 26.0 is also a strong indicator of poor cardiac function, which increases the risk of heart failure and sudden cardiac death.

The patient's ECG findings, including ventricular extrasystole and polymorphic ventricular extrasystole, suggest an increased risk of arrhythmias, which can contribute to sudden cardiac death. The absence of ventricular tachycardia or non-sustained ventricular tachycardia on the ECG reduces the likelihood of ventricular arrhythmias as the primary cause of death.

The patient's medication regimen, which includes beta blockers, ACE inhibitors, and amiodarone, is generally well-tailored to their condition. However, the presence of polymorphic ventricular extrasystole on the ECG suggests that the patient may not be adequately protected against life-threatening arrhythmias.

The patient's laboratory results, including elevated troponin levels and low LVEF, indicate significant cardiac damage and dysfunction. The elevated BNP level of 693.0 ng/L is also consistent with heart failure.

While pump failure death is a possible outcome, it is less likely than sudden cardiac death due to the patient's ECG findings and the presence of polymorphic ventricular extrasystole. The patient's NYHA Class III status and elevated BNP level suggest that heart failure is a significant concern, but the presence of arrhythmias on the ECG increases the risk of sudden cardiac death.

Therefore, based on the available data, I would rank the patient's prognosis as sudden cardiac death, followed by pump failure death, and then survivor."
661,661,P0053,"Age: 68
Gender: Male 
Weight: 80 kg
Height: 172 cm
NYHA Class: II
Blood Pressure: 140/80 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Diabetes, Dyslipemia, Myocardial Infarction
Albumin (g/L): 47,19
ALT or GPT (IU/L): 24.0
AST or GOT (IU/L): 20.0
Total Cholesterol (mmol/L): 4,06
Creatinine (mmol/L): 112.0
Gamma-glutamil transpeptidase (IU/L): 34
Glucose (mmol/L): 4,9
Hemoglobin (g/L): 155.0
HDL (mmol/L): 1,01
Potassium (mEq/L): 3,8
LDL (mmol/L): 2,15
Sodium (mEq/L): 144.0
Pro-BNP (ng/L): 2234.0
Protein (g/L): 75
T3 (pg/dL): 0,05
T4 (ng/L): 18
Troponin (ng/mL): 0,01
TSH (mIU/L): 3,11
Urea (mg/dL): 9,57
LVEF (%): 39.0
Medications: Calcium Channel Blocker, Diabetes Medication, Statins, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",sudden cardiac death,"RANKING: 1. Sudden cardiac death 
REASONING: 

Based on the provided patient data, I would rank the prognosis as sudden cardiac death. The patient has a history of ischemic dilated cardiomyopathy, which is a significant risk factor for sudden cardiac death. The patient's left ventricular ejection fraction (LVEF) is severely reduced at 39%, indicating poor cardiac function. The presence of ventricular extrasystoles and polymorphic ventricular extrasystoles on the ECG also suggests an increased risk of arrhythmias, which can lead to sudden cardiac death. Additionally, the patient's elevated troponin levels (0.01 ng/mL) may indicate some myocardial damage, which can contribute to the risk of arrhythmias and sudden cardiac death.

The patient's other comorbidities, such as diabetes, dyslipidemia, and hypertension, also contribute to the overall risk of cardiac complications, including sudden cardiac death. However, the presence of ventricular extrasystoles and polymorphic ventricular extrasystoles on the ECG, combined with the patient's poor cardiac function and other comorbidities, make sudden cardiac death the most likely prognosis.

The other two prognoses, survivor and pump failure death, are less likely. While the patient's poor cardiac function and comorbidities do increase the risk of heart failure, the presence of ventricular extrasystoles and polymorphic ventricular extrasystoles on the ECG suggest a higher risk of sudden cardiac death. The patient's hemoglobin level of 15.5 g/dL is also within a relatively normal range, which reduces the risk of pump failure. Therefore, while pump failure is a possible outcome, it is less likely than sudden cardiac death in this patient."
662,662,P0057,"Age: 66
Gender: Male 
Weight: 77 kg
Height: 165 cm
NYHA Class: III
Blood Pressure: 110/60 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Diabetes, Dyslipemia, Hypertension, Myocardial Infarction
Albumin (g/L): 41,7
ALT or GPT (IU/L): 20.0
AST or GOT (IU/L): 24.0
Total Cholesterol (mmol/L): 4,14
Creatinine (mmol/L): 155.0
Gamma-glutamil transpeptidase (IU/L): 168
Glucose (mmol/L): 4,6
Hemoglobin (g/L): 152.0
HDL (mmol/L): 1,14
Potassium (mEq/L): 5
LDL (mmol/L): 2,48
Sodium (mEq/L): 141.0
Pro-BNP (ng/L): 3996.0
Protein (g/L): 81
T3 (pg/dL): 0,04
T4 (ng/L): 17
Troponin (ng/mL): 0,02
TSH (mIU/L): 8,79
Urea (mg/dL): 15,15
LVEF (%): 29.0
Medications: Beta Blockers, Loop Diuretics, Statins, ACE Inhibitor, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",sudden cardiac death,"RANKING: 1. Sudden cardiac death
REASONING: 

Based on the provided patient data, the patient's prognosis is at high risk for sudden cardiac death. Several factors contribute to this risk:

1. LVEF (Left Ventricular Ejection Fraction) of 29.0: A significantly reduced LVEF indicates severe left ventricular dysfunction, which is a hallmark of heart failure with reduced ejection fraction (HFrEF) and a major risk factor for sudden cardiac death.

2. NYHA Class III: This classification indicates severe heart failure symptoms, which often correlates with a worse prognosis and increased risk of sudden cardiac death.

3. History of Ischemic Dilated Cardiomyopathy: This condition is a significant risk factor for sudden cardiac death, as it can lead to electrical instability and arrhythmias.

4. Presence of Ventricular Extrasystole and Non-sustained Ventricular Tachycardia: The ECG findings of ventricular extrasystoles and non-sustained ventricular tachycardia indicate electrical instability, which can increase the risk of sudden cardiac death.

5. Medications: The patient is already on multiple medications, including beta blockers, loop diuretics, statins, ACE inhibitors, and a nitrovasodilator, which are commonly used to manage heart failure and reduce cardiovascular risk factors. However, the presence of ventricular extrasystoles and non-sustained ventricular tachycardia suggests that the patient may not be adequately controlled on these medications.

6. Pro-BNP levels of 3996.0 ng/L: Elevated BNP levels are a marker of heart failure and can indicate increased mortality risk.

Considering these factors, the patient's prognosis is at high risk for sudden cardiac death. However, it's essential to note that the patient is already on multiple medications and has a relatively stable vital sign profile, which may suggest that the patient is being managed adequately. Nevertheless, the presence of the mentioned arrhythmias and other risk factors necessitates close monitoring and further evaluation to adjust the treatment plan and prevent sudden cardiac death."
663,663,P0059,"Age: 78
Gender: Male 
Weight: 77 kg
Height: 163 cm
NYHA Class: II
Blood Pressure: 145/70 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Diabetes, Dyslipemia, Hypertension, Myocardial Infarction
Albumin (g/L): 36,9
ALT or GPT (IU/L): 16.0
AST or GOT (IU/L): 15.0
Total Cholesterol (mmol/L): 4,53
Creatinine (mmol/L): 171.0
Gamma-glutamil transpeptidase (IU/L): 27
Glucose (mmol/L): 8,5
Hemoglobin (g/L): 121.0
HDL (mmol/L): 1,29
Potassium (mEq/L): 5,1
LDL (mmol/L): 2,66
Sodium (mEq/L): 139.0
Pro-BNP (ng/L): 8283.0
Protein (g/L): 77
T3 (pg/dL): 0,04
T4 (ng/L): 17
Troponin (ng/mL): 0,03
TSH (mIU/L): 1,79
Urea (mg/dL): 13,14
LVEF (%): 30.0
Medications: Diabetes Medication, Beta Blockers, Digoxin, Loop Diuretics, Statins, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",sudden cardiac death,"RANKING: 
1. Survivor
REASONING:
The patient is 78 years old with a history of ischemic dilated cardiomyopathy, which is a significant comorbidity that can lead to heart failure and arrhythmias. The patient's left ventricular ejection fraction (LVEF) is 30%, which is a critical indicator of heart function, and it is significantly reduced. The patient also has a history of myocardial infarction, hypertension, diabetes, and dyslipemia, which are all risk factors for cardiac complications. The patient's creatinine level is elevated at 171.0 mmol/L, indicating impaired renal function, which can be a sign of heart failure.

The patient's ECG shows ventricular extrasystole, non-sustained ventricular tachycardia, and non-sustained ventricular tachycardia, which are all signs of arrhythmias that can be life-threatening. However, the patient is currently on beta blockers, digoxin, and ACE inhibitors, which are medications that can help manage these conditions.

Considering the patient's age, comorbidities, and ECG findings, I would rank the patient as a survivor. The patient is receiving treatment for their conditions, and with proper management, it is possible to improve their heart function and reduce the risk of cardiac complications.

RANKING: 
2. Pump failure death
REASONING:
The patient's LVEF is significantly reduced at 30%, which indicates poor heart function. The patient's elevated creatinine level and impaired renal function can also be a sign of heart failure. The patient's ECG shows signs of arrhythmias, which can further compromise cardiac function.

While the patient is receiving treatment for their conditions, the presence of significant comorbidities and impaired heart function may still lead to cardiac complications. However, with proper management, it is possible to improve the patient's heart function and reduce the risk of pump failure.

RANKING: 
3. Sudden cardiac death
REASONING:
The patient's ECG shows signs of ventricular extrasystole, non-sustained ventricular tachycardia, and non-sustained ventricular tachycardia, which are all life-threatening arrhythmias. The patient's LVEF is significantly reduced, and the patient has a history of myocardial infarction and other cardiac comorbidities.

While the patient is receiving treatment for their conditions, the presence of these arrhythmias and poor heart function may still lead to sudden cardiac death. The patient's age and comorbidities also increase the risk of cardiac complications.

However, considering the patient's treatment regimen and the presence of ventricular extrasystole, I would rank sudden cardiac death as the least likely outcome, as the patient is receiving treatment for their conditions, and it is possible to manage the arrhythmias and improve cardiac function with proper management."
664,664,P0073,"Age: 65
Gender: Male 
Weight: 101 kg
Height: 173 cm
NYHA Class: III
Blood Pressure: 110/85 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Dyslipemia, Peripheral vascular disease, Hypertension, Myocardial Infarction
Albumin (g/L): 39,8
ALT or GPT (IU/L): 15.0
AST or GOT (IU/L): 15.0
Total Cholesterol (mmol/L): 6,05
Creatinine (mmol/L): 103.0
Gamma-glutamil transpeptidase (IU/L): 26
Glucose (mmol/L): 6,7
Hemoglobin (g/L): 127.0
HDL (mmol/L): 1,16
Potassium (mEq/L): 4
LDL (mmol/L): 3,18
Sodium (mEq/L): 143.0
Pro-BNP (ng/L): 842.0
Protein (g/L): 73
T4 (ng/L): 17
TSH (mIU/L): 0,98
Urea (mg/dL): 5,66
LVEF (%): 32.0
Medications: Beta Blockers, Loop Diuretics, Spironolactone, Statins, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",sudden cardiac death,"RANKING: 1. Sudden cardiac death
REASONING:

Based on the provided patient data, I would rank the prognosis as sudden cardiac death as the most likely outcome. Here's the reasoning behind this ranking:

1. The patient has a history of ischemic dilated cardiomyopathy, which is a condition that significantly increases the risk of sudden cardiac death. The LVEF of 32.0% is a strong indicator of poor cardiac function, which can lead to arrhythmias and sudden cardiac death.

2. The patient has a history of ventricular tachycardia (VT) and non-sustained VT, which are both indicators of arrhythmogenic substrates that can lead to sudden cardiac death. The presence of monomorphic VT on the ECG further increases the risk.

3. The patient's NYHA Class III classification indicates severe symptoms of heart failure, which can lead to increased mortality and sudden cardiac death.

4. The patient's elevated Pro-BNP levels (842.0 ng/L) are a marker of cardiac stress and increased mortality risk.

5. The patient's history of hypertension, dyslipidemia, and peripheral vascular disease also contribute to the overall risk of cardiovascular events, including sudden cardiac death.

While the patient is on medications that may help manage some of these conditions, the presence of these risk factors and the patient's underlying cardiac condition make sudden cardiac death the most likely prognosis.

RANKING: 2. Pump failure death
REASONING: Pump failure death is a possible outcome, but it is less likely than sudden cardiac death due to the patient's relatively preserved renal function (creatinine 5.66 mg/dL) and the fact that the patient is on ACE inhibitors, which can help reduce mortality and morbidity in heart failure patients.

RANKING: 3. Survivor
REASONING: The patient's overall condition, including their cardiac function, age, and presence of multiple comorbidities, make survival a less likely outcome compared to sudden cardiac death. However, the patient is on medications that may help manage some of these conditions, and the patient's renal function is relatively preserved. With appropriate management and close monitoring, the patient may survive, but the risk of sudden cardiac death remains a significant concern."
665,665,P0079,"Age: 70
Gender: Male 
Weight: 75 kg
Height: 163 cm
NYHA Class: II
Blood Pressure: 110/80 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Diabetes, Dyslipemia, Peripheral vascular disease, Hypertension, Myocardial Infarction
Albumin (g/L): 43,4
ALT or GPT (IU/L): 11.0
AST or GOT (IU/L): 16.0
Total Cholesterol (mmol/L): 4,6
Creatinine (mmol/L): 91.0
Gamma-glutamil transpeptidase (IU/L): 11
Glucose (mmol/L): 6,6
Hemoglobin (g/L): 132.0
HDL (mmol/L): 1,16
Potassium (mEq/L): 4,7
LDL (mmol/L): 2,56
Sodium (mEq/L): 144.0
Pro-BNP (ng/L): 517.0
Protein (g/L): 75
T3 (pg/dL): 0,04
T4 (ng/L): 21
Troponin (ng/mL): 0,01
TSH (mIU/L): 3,45
Urea (mg/dL): 7,35
LVEF (%): 48.0
Medications: Calcium Channel Blocker, Diabetes Medication, Beta Blockers, Statins, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: TPSV
        - Bradycardia: Third-degree AVB
            ",sudden cardiac death,"RANKING: 1. Sudden Cardiac Death
REASONING: 
Based on the patient's clinical presentation and laboratory results, I predict that the patient is at high risk of sudden cardiac death in the next few years. The patient has a history of ischemic dilated cardiomyopathy, which is a well-established risk factor for sudden cardiac death. Additionally, the patient has a low left ventricular ejection fraction (LVEF) of 48%, indicating poor cardiac function. The presence of ventricular extrasystoles and polymorphic ventricular tachycardia on the ECG also suggests a high risk of arrhythmic events.

Furthermore, the patient's age (70) and gender (male) also contribute to the risk of sudden cardiac death. The patient's past medical history of myocardial infarction, hypertension, and diabetes further increases the risk.

While the patient is on several medications, including beta blockers and calcium channel blockers, which are generally used to reduce the risk of arrhythmias and cardiac events, the patient's underlying cardiac condition and other risk factors still pose a significant threat.

In contrast, while pump failure death is a possible outcome, it is less likely given the patient's relatively preserved renal function (creatinine 7.35 mg/dL) and absence of other indications of severe heart failure symptoms. Survivorship is also unlikely given the patient's poor cardiac function and high risk of arrhythmic events.

Overall, the combination of the patient's clinical presentation, laboratory results, and medical history make sudden cardiac death the most likely outcome in the next few years."
666,666,P0112,"Age: 51
Gender: Male 
Weight: 76 kg
Height: 165 cm
NYHA Class: II
Blood Pressure: 139/83 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Hypertension, Myocardial Infarction
Albumin (g/L): 35
ALT or GPT (IU/L): 11.0
AST or GOT (IU/L): 15.0
Total Cholesterol (mmol/L): 3,62
Creatinine (mmol/L): 71.0
Gamma-glutamil transpeptidase (IU/L): 15
Glucose (mmol/L): 4,9
Hemoglobin (g/L): 141.0
HDL (mmol/L): 1,14
Potassium (mEq/L): 4,1
LDL (mmol/L): 2,12
Sodium (mEq/L): 141.0
Pro-BNP (ng/L): 975.0
Protein (g/L): 60
T4 (ng/L): 14
Troponin (ng/mL): 0,01
TSH (mIU/L): 0,56
Urea (mg/dL): 4,49
LVEF (%): 20.0
Medications: Beta Blockers, Statins, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Unknown ventricular tachycardia code
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",sudden cardiac death,"RANKING: 
1. Survivor
REASONING:
The patient's age, weight, and NYHA Class II indicate a relatively moderate level of cardiac dysfunction, which is consistent with ischemic dilated cardiomyopathy. The patient's LVEF of 20% suggests significant left ventricular dysfunction, but not complete heart failure. The presence of hypertension, myocardial infarction, and ischemic dilated cardiomyopathy increases the risk of cardiac complications. However, the patient's current medication regimen, including beta blockers, statins, and ACE inhibitors, is standard for managing these conditions.

The patient's laboratory results, such as elevated troponin and BNP levels, also suggest ongoing cardiac stress and strain. However, the absence of significant electrolyte imbalances (e.g., hyperkalemia, hypokalemia) and the normal TSH level reduce the likelihood of acute cardiac arrhythmias.

The ECG findings, including ventricular extrasystole and polymorphic ventricular tachycardia, indicate an increased risk of arrhythmias. However, the absence of ventricular tachycardia and the presence of beta blockers, which can help regulate heart rate, reduce this risk.

Considering these factors, I rank the patient as having a relatively high chance of survival over the next few years. The patient's cardiac function is compromised, but the presence of beta blockers and other medications helps mitigate this risk.

RANKING: 2. Sudden Cardiac Death
REASONING:
The patient's ECG findings, including ventricular extrasystole and polymorphic ventricular tachycardia, significantly increase the risk of cardiac arrhythmias. The presence of these arrhythmias, combined with the patient's history of ischemic dilated cardiomyopathy and hypertension, increases the risk of sudden cardiac death.

The patient's LVEF of 20% and elevated troponin levels suggest significant cardiac dysfunction, which can contribute to arrhythmias. While the patient is on beta blockers, which can help regulate heart rate, the presence of ventricular extrasystole and polymorphic ventricular tachycardia suggests that the patient may still be at risk for sudden cardiac death.

RANKING: 3. Pump Failure Death
REASONING:
The patient's LVEF of 20% and elevated BNP levels suggest significant left ventricular dysfunction, which increases the risk of heart failure. The patient's NYHA Class II indicates moderate symptoms of heart failure, which can lead to pump failure.

The patient's elevated creatinine level (71.0) and urea level (4.49) also suggest impaired renal function, which can be a complication of heart failure. The presence of hypertension and myocardial infarction further increases the risk of pump failure.

However, the patient's current medication regimen, including beta blockers, statins, and ACE inhibitors, can help manage heart failure symptoms. While the patient's cardiac function is compromised, the presence of these medications and the absence of severe arrhythmias reduce the likelihood of pump failure death.

Note: The patient's ECG findings, including ventricular extrasystole and polymorphic ventricular tachycardia, increase the risk of sudden cardiac death, but the overall prognosis is still skewed towards pump failure due to the patient's significant cardiac dysfunction and elevated BNP levels."
667,667,P0127,"Age: 65
Gender: Male 
Weight: 70 kg
Height: 175 cm
NYHA Class: II
Blood Pressure: 120/70 mmHg
Past Medical History: Enolic dilated cardiomyopathy, Hypertension
Albumin (g/L): 42
ALT or GPT (IU/L): 27.0
AST or GOT (IU/L): 19.0
Total Cholesterol (mmol/L): 5,77
Creatinine (mmol/L): 80.0
Gamma-glutamil transpeptidase (IU/L): 23
Glucose (mmol/L): 5,3
Hemoglobin (g/L): 141.0
HDL (mmol/L): 1,58
Potassium (mEq/L): 4,4
LDL (mmol/L): 3,59
Sodium (mEq/L): 139.0
Pro-BNP (ng/L): 553.0
Protein (g/L): 72
T3 (pg/dL): 0,03
T4 (ng/L): 16
Troponin (ng/mL): 0,1
TSH (mIU/L): 1,1
Urea (mg/dL): 7,49
LVEF (%): 14.0
Medications: Digoxin, Loop Diuretics, Spironolactone, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",sudden cardiac death,"RANKING: 1. Survivor
REASONING: 

This patient's prognosis is ranked as a survivor due to the presence of several factors that suggest a relatively stable condition. The patient's age of 65 is not unusually high for a patient with heart failure, and the NYHA Class II classification indicates mild symptoms. The patient's blood pressure is well-controlled at 120/70 mmHg, and the absence of severe hypertension is a positive factor. The patient's laboratory values show no acute elevation in liver enzymes, creatinine, or troponin, suggesting that there is no acute cardiac or renal injury. The presence of mild anemia (Hemoglobin 141.0 g/L) may be a concern, but it is not uncommon in patients with heart failure.

The patient's medication regimen, which includes ACE inhibitors, digoxin, and loop diuretics, suggests that the patient is receiving standard therapy for heart failure. The presence of spironolactone may be beneficial for patients with heart failure and hypertension. The ECG findings of ventricular extrasystole, non-sustained VT, and non-sustained ventricular tachycardia are concerning, but the patient is not experiencing any symptoms. The absence of paroxysmal supraventricular tachyarrhythmia and bradycardia is also a positive factor.

Given these factors, the patient's prognosis is ranked as a survivor, with a moderate risk of progression to heart failure or arrhythmia-related complications.

RANKING: 2. Pump failure death
REASONING: 

This patient's prognosis is ranked as pump failure death due to the presence of several factors that suggest a high risk of cardiac dysfunction. The patient's left ventricular ejection fraction (LVEF) is significantly reduced at 14.0%, indicating severe systolic dysfunction. The patient's elevated BNP levels (Pro-BNP 553.0 ng/L) and elevated creatinine (80.0 mmol/L) suggest that the patient is experiencing some degree of cardiac congestion and renal impairment.

The patient's past medical history of dilated cardiomyopathy and hypertension also increases the risk of cardiac failure. The patient's lipid profile is not ideal, with high total cholesterol (5.77 mmol/L) and LDL cholesterol (3.59 mmol/L), which may contribute to further cardiac damage.

The patient's ECG findings of ventricular extrasystole and non-sustained VT are concerning, and the presence of non-sustained ventricular tachycardia (CH>10) increases the risk of arrhythmia-related complications. However, the patient is not experiencing any symptoms, which is a positive factor.

Given these factors, the patient's prognosis is ranked as pump failure death, with a moderate to high risk of progression to severe heart failure or cardiac arrest.

RANKING: 3. Sudden cardiac death
REASONING: 

This patient's prognosis is ranked as sudden cardiac death due to the presence of several factors that suggest a high risk of fatal arrhythmia. The patient's ECG findings of ventricular extrasystole, non-sustained VT, and non-sustained ventricular tachycardia (CH>10) are concerning, and the presence of these arrhythmias increases the risk of sudden cardiac death. The patient's reduced LVEF (14.0%) and elevated BNP levels (Pro-BNP 553.0 ng/L) also suggest that the patient is experiencing significant cardiac dysfunction.

The patient's past medical history of dilated cardiomyopathy and hypertension increases the risk of cardiac arrhythmia and sudden cardiac death. The patient's medication regimen, which includes ACE inhibitors and digoxin, is standard therapy for heart failure, but the presence of spironolactone may increase the risk of hyperkalemia, which can contribute to cardiac arrhythmia.

Given these factors, the patient's prognosis is ranked as sudden cardiac death, with a high risk of fatal arrhythmia."
668,668,P0138,"Age: 68
Gender: Male 
Weight: 67 kg
Height: 162 cm
NYHA Class: II
Blood Pressure: 120/60 mmHg
Past Medical History: Valvular cardiomyopathy
Albumin (g/L): 41
ALT or GPT (IU/L): 23.0
AST or GOT (IU/L): 27.0
Total Cholesterol (mmol/L): 5,2
Creatinine (mmol/L): 115.0
Gamma-glutamil transpeptidase (IU/L): 63
Glucose (mmol/L): 5,1
Hemoglobin (g/L): 126.0
HDL (mmol/L): 1,32
Potassium (mEq/L): 4,4
LDL (mmol/L): 3,49
Sodium (mEq/L): 142.0
Pro-BNP (ng/L): 2838.0
Protein (g/L): 69
T3 (pg/dL): 0,05
T4 (ng/L): 26
Troponin (ng/mL): 0,694
TSH (mIU/L): 0,894
Urea (mg/dL): 9,32
LVEF (%): 37.0
Medications: Beta Blockers, Loop Diuretics, Spironolactone, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Torsade de Points
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",sudden cardiac death,"RANKING: 1. Sudden cardiac death
REASONING: 

Based on the provided patient data, the patient is at high risk for sudden cardiac death. The patient's history of valvular cardiomyopathy, NYHA Class II, and elevated LVEF of 37.0 indicate significant left ventricular dysfunction, which is a well-known risk factor for arrhythmias and sudden cardiac death. The presence of ventricular extrasystoles, ventricular tachycardia (Torsade de Pointes), and non-sustained ventricular tachycardia further increases the risk of life-threatening arrhythmias.

The patient's elevated troponin levels (0.694 ng/mL) also suggest some degree of myocardial damage, which may be related to the underlying cardiomyopathy. The presence of paroxysmal supraventricular tachyarrhythmia code on the ECG impression suggests an underlying supraventricular arrhythmia, which can also contribute to sudden cardiac death.

The patient's medications, including beta blockers, loop diuretics, spironolactone, and ACE inhibitor, may help manage some of the underlying conditions, but they do not directly address the potential for sudden cardiac death. The patient's elevated creatinine level (9.32 mg/dL) may indicate some degree of renal impairment, which can also contribute to an increased risk of sudden cardiac death.

Given the combination of these factors, I would rank sudden cardiac death as the most likely outcome over the next few years."
669,669,P0148,"Age: 73
Gender: Female 
Weight: 68 kg
Height: 172 cm
NYHA Class: III
Blood Pressure: 130/85 mmHg
Past Medical History: Valvular cardiomyopathy, Peripheral vascular disease, Hypertension, Myocardial Infarction
Albumin (g/L): 36,7
ALT or GPT (IU/L): 54.0
AST or GOT (IU/L): 62.0
Total Cholesterol (mmol/L): 4,48
Creatinine (mmol/L): 77.0
Gamma-glutamil transpeptidase (IU/L): 78
Glucose (mmol/L): 4,9
Hemoglobin (g/L): 149.0
Potassium (mEq/L): 4,23
Sodium (mEq/L): 137.0
Pro-BNP (ng/L): 3527.0
Protein (g/L): 75,3
Troponin (ng/mL): 0,01
TSH (mIU/L): 1,08
Urea (mg/dL): 8,5
LVEF (%): 20.0
Medications: Angiotensin II Receptor Blocker, Beta Blockers, Digoxin, Loop Diuretics, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",sudden cardiac death,"RANKING: 
1. Sudden Cardiac Death
2. Pump Failure Death
3. Survivor

REASONING:

The patient's prognosis is influenced by several factors. The patient has a history of valvular cardiomyopathy, peripheral vascular disease, hypertension, and myocardial infarction, which indicate a high risk for cardiovascular events. The patient's NYHA Class III classification also suggests a significant impact on physical activity level and quality of life.

The patient's laboratory results, such as elevated creatinine (77.0 mmol/L) and low LVEF (20.0%), indicate impaired kidney function and significant left ventricular dysfunction, respectively. The elevated Pro-BNP level (3527.0 ng/L) suggests elevated ventricular wall stress, which is consistent with heart failure.

The patient's ECG findings of ventricular extrasystole, non-sustained VT, and non-sustained ventricular tachycardia indicate an increased risk for arrhythmic events. The presence of non-sustained ventricular tachycardia (CH>10) is particularly concerning, as it increases the risk for sudden cardiac death.

The patient's medication regimen, which includes beta blockers, ACE inhibitors, and digoxin, is standard for managing heart failure and arrhythmias. However, the patient's elevated troponin level (0.01 ng/mL) and low hemoglobin level (14.9 g/L) suggest some degree of myocardial ischemia or inflammation.

Considering these factors, the patient's prognosis is dominated by the risk of arrhythmic events, particularly sudden cardiac death. While pump failure death is a possible outcome, the patient's current medication regimen and the presence of non-sustained ventricular tachycardia make sudden cardiac death the most likely prognosis. The patient's overall condition, including impaired kidney function and low LVEF, also increases the risk for pump failure death, but it is less likely than sudden cardiac death. The patient's survival is the least likely outcome due to the combination of multiple risk factors and the presence of arrhythmic events."
670,670,P0157,"Age: 76
Gender: Male 
Weight: 70 kg
Height: 168 cm
NYHA Class: II
Blood Pressure: 120/70 mmHg
Past Medical History: Hypertropic cardiomyopathy, Hypertension, Myocardial Infarction
Albumin (g/L): 38,9
ALT or GPT (IU/L): 17.0
AST or GOT (IU/L): 20.0
Total Cholesterol (mmol/L): 5,13
Creatinine (mmol/L): 113.0
Gamma-glutamil transpeptidase (IU/L): 40
Glucose (mmol/L): 8,6
Hemoglobin (g/L): 139.0
HDL (mmol/L): 1,26
Potassium (mEq/L): 4,49
LDL (mmol/L): 3,06
Sodium (mEq/L): 134.0
Protein (g/L): 74,9
Troponin (ng/mL): 0,01
TSH (mIU/L): 3,36
Urea (mg/dL): 10,3
LVEF (%): 42.0
Medications: Spironolactone, ACE Inhibitor, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: TPSV
        - Bradycardia: No
            ",sudden cardiac death,"RANKING: 1. Sudden Cardiac Death
REASONING: 

Based on the patient's ECG impression, the presence of ventricular extrasystole, non-sustained ventricular tachycardia (CH>10), and non-sustained ventricular tachycardia are significant concerns for arrhythmia-related complications. The patient's history of myocardial infarction and hypertrophic cardiomyopathy also increases the risk of arrhythmias. Additionally, the patient's LVEF of 42% indicates reduced cardiac function, which can contribute to arrhythmias. The presence of these factors, particularly the non-sustained ventricular tachycardia, makes sudden cardiac death a more likely outcome.

RANKING: 2. Pump Failure Death
REASONING: 

The patient's reduced LVEF (42%) and elevated creatinine level (10.3 mg/dL) suggest impaired cardiac function, which can lead to heart failure. The patient's history of hypertension, myocardial infarction, and hypertrophic cardiomyopathy further exacerbates the risk of heart failure. While not directly indicated, the patient's medication regimen (ACE Inhibitor, Nitrovasodilator) suggests treatment for hypertension and possibly heart failure. However, the patient's current ECG findings do not directly indicate acute heart failure, but the presence of reduced LVEF and elevated creatinine level make pump failure a possible long-term complication.

RANKING: 3. Survivor
REASONING: 

While the patient's age (76) and reduced LVEF (42%) may increase the risk of mortality, the patient's current ECG findings do not indicate acute cardiac complications. The patient's medication regimen suggests treatment for hypertension and possibly heart failure, and the absence of other significant comorbidities or acute findings on the ECG. However, considering the patient's history of myocardial infarction, hypertrophic cardiomyopathy, and reduced LVEF, the likelihood of survival over a long period is lower compared to the other two options."
671,671,P0159,"Age: 81
Gender: Male 
Weight: 65 kg
Height: 158 cm
NYHA Class: III
Blood Pressure: 100/70 mmHg
Past Medical History: Idiopathic dilated cardiomyopathy, Peripheral vascular disease
Albumin (g/L): 38,4
ALT or GPT (IU/L): 12.0
AST or GOT (IU/L): 18.0
Total Cholesterol (mmol/L): 3,88
Creatinine (mmol/L): 165.0
Gamma-glutamil transpeptidase (IU/L): 46
Glucose (mmol/L): 7,3
Hemoglobin (g/L): 131.0
Potassium (mEq/L): 2,92
Sodium (mEq/L): 135.0
Protein (g/L): 70,9
T4 (ng/L): 10,1
Troponin (ng/mL): 0,02
TSH (mIU/L): 15,55
Urea (mg/dL): 15,9
LVEF (%): 22.0
Medications: Amiodarone, Loop Diuretics
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",sudden cardiac death,"RANKING: 
1. Sudden cardiac death
REASONING: 
Based on the provided patient data, the patient is at high risk for sudden cardiac death. The patient's age (81) and NYHA Class III status indicate significant heart disease, and the presence of idiopathic dilated cardiomyopathy further increases the risk. The patient's LVEF (22.0) is severely reduced, indicating significant left ventricular dysfunction. The presence of non-sustained ventricular tachycardia (NST) and polymorphic ventricular extrasystole on the ECG also suggests an increased risk of arrhythmias, which are a major contributor to sudden cardiac death. Additionally, the patient's elevated creatinine level (165.0) and elevated troponin level (0.02) suggest some degree of cardiac injury, which can increase the risk of arrhythmias. The presence of amiodarone, a medication that can increase the risk of QT interval prolongation and Torsades de Pointes, further supports this conclusion. Overall, the combination of advanced age, significant heart disease, reduced LVEF, and presence of arrhythmias make sudden cardiac death the most likely outcome.

2. Pump failure death
REASONING: 
While the patient's reduced LVEF (22.0) and elevated creatinine level (165.0) suggest significant cardiac dysfunction, the patient's NYHA Class III status indicates that the patient is already experiencing symptoms of heart failure. However, the presence of idiopathic dilated cardiomyopathy and peripheral vascular disease may limit the patient's ability to compensate for cardiac dysfunction. The patient's elevated troponin level (0.02) and elevated ALT/GPT (12.0) also suggest some degree of cardiac injury. However, the patient's relatively preserved ejection fraction and absence of overt signs of heart failure symptoms (such as edema or shortness of breath) make pump failure death less likely.

3. Survivor
REASONING: 
Given the patient's significant heart disease, reduced LVEF, and presence of arrhythmias, it is unlikely that the patient will survive for an extended period. However, the patient's relatively preserved ejection fraction and absence of overt signs of heart failure symptoms, combined with the presence of amiodarone, which may help control arrhythmias, make survival possible for a shorter period. Additionally, the patient's relatively normal creatinine level (165.0) and absence of other signs of end-organ dysfunction suggest that the patient's kidneys may be functioning relatively well. However, the patient's advanced age and presence of idiopathic dilated cardiomyopathy and peripheral vascular disease make survival for an extended period unlikely."
672,672,P0172,"Age: 69
Gender: Female 
Weight: 74 kg
Height: 154 cm
NYHA Class: II
Blood Pressure: 120/85 mmHg
Past Medical History: Idiopathic dilated cardiomyopathy, Hypertension
Albumin (g/L): 42
ALT or GPT (IU/L): 23.0
AST or GOT (IU/L): 21.0
Total Cholesterol (mmol/L): 5,45
Creatinine (mmol/L): 94.0
Gamma-glutamil transpeptidase (IU/L): 24
Glucose (mmol/L): 8,1
Hemoglobin (g/L): 131.0
Potassium (mEq/L): 4,61
Sodium (mEq/L): 138.0
Pro-BNP (ng/L): 1383.0
Protein (g/L): 70,2
Troponin (ng/mL): 0,01
TSH (mIU/L): 2,43
Urea (mg/dL): 6,1
LVEF (%): 22.0
Medications: Beta Blockers, Digoxin, Loop Diuretics, Spironolactone, Hydralazine
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",sudden cardiac death,"RANKING: 1. Survivor
REASONING: 
The patient's LVEF (Left Ventricular Ejection Fraction) is 22.0%, which indicates severe left ventricular dysfunction. However, the patient is also taking beta blockers, which are known to improve cardiac function and reduce mortality in patients with heart failure. The patient's NYHA Class is II, indicating mild to moderate symptoms, which suggests that the patient is not in a severely advanced stage of heart failure. Additionally, the patient's creatinine level is not significantly elevated, indicating preserved renal function. The presence of low Troponin levels (0.01 ng/mL) suggests that there is minimal myocardial damage. The patient's Pro-BNP level is elevated, indicating some degree of ventricular strain, but it is not excessively high. Considering these factors, the patient's overall prognosis is more favorable than initially apparent.

RANKING: 2. Pump failure death
REASONING: 
Given the patient's severe left ventricular dysfunction (LVEF 22.0%) and elevated Pro-BNP level, the patient is at risk for heart failure. The patient's NYHA Class II symptoms suggest that the patient is experiencing some level of cardiac stress, but the patient's beta blockers and other medications may help manage symptoms. However, the patient's severe left ventricular dysfunction increases the risk of heart failure, and the patient's elevated creatinine level suggests some degree of renal impairment. While the patient's renal function is not severely impaired, it is still a concern.

RANKING: 3. Sudden cardiac death
REASONING: 
The patient's ECG impression shows ventricular extrasystoles, which can be a sign of arrhythmia. The patient's beta blockers and other medications may help manage arrhythmia, but the presence of ventricular extrasystoles increases the risk of sudden cardiac death. The patient's Pro-BNP level is elevated, indicating some degree of ventricular strain, which can increase the risk of arrhythmia and sudden cardiac death. While the patient's other factors, such as NYHA Class II symptoms and preserved renal function, are less concerning, the presence of ventricular extrasystoles and elevated Pro-BNP level make sudden cardiac death a more likely outcome."
673,673,P0176,"Age: 78
Gender: Male 
Weight: 64 kg
Height: 158 cm
NYHA Class: III
Blood Pressure: 120/60 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Dyslipemia, Hypertension, Myocardial Infarction
Albumin (g/L): 43
ALT or GPT (IU/L): 39.0
AST or GOT (IU/L): 25.0
Total Cholesterol (mmol/L): 3,1
Creatinine (mmol/L): 186.0
Gamma-glutamil transpeptidase (IU/L): 46
Glucose (mmol/L): 5,9
Hemoglobin (g/L): 132.0
HDL (mmol/L): 1,16
Potassium (mEq/L): 3,8
LDL (mmol/L): 1,53
Sodium (mEq/L): 137.0
Pro-BNP (ng/L): 4853.0
Protein (g/L): 83
T3 (pg/dL): 0,05
T4 (ng/L): 21
Troponin (ng/mL): 0,01
TSH (mIU/L): 7,37
Urea (mg/dL): 24,13
LVEF (%): 36.0
Medications: Calcium Channel Blocker, Beta Blockers, Loop Diuretics, Statins, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: TPSV
        - Bradycardia: No
            ",sudden cardiac death,"RANKING: 
1. Survivor
REASONING: 
Given the patient's age, NYHA Class III heart failure, and multiple comorbidities such as ischemic dilated cardiomyopathy, hypertension, and myocardial infarction, the patient is at high risk for adverse outcomes. However, the patient's current hemoglobin level (132.0 g/L) and low troponin level (0.01 ng/mL) suggest that the patient is not in acute myocardial infarction. The patient's LVEF (36.0%) is also low, indicating poor cardiac function. The presence of ventricular extrasystole, non-sustained ventricular tachycardia, and paroxysmal supraventricular tachyarrhythmia on the ECG impression suggests underlying arrhythmia issues. 

Despite these concerning findings, the patient is not currently showing signs of acute coronary syndrome or acute heart failure exacerbation, which are common causes of sudden cardiac death. The patient is also taking multiple medications, including beta blockers, which can help reduce the risk of sudden cardiac death. Overall, while the patient has a high-risk profile, the absence of acute coronary syndrome or acute heart failure exacerbation suggests that the patient may be able to survive for the next few years with proper management and monitoring.

2. Pump failure death
REASONING: 
Given the patient's low LVEF (36.0%) and NYHA Class III heart failure, the patient is at high risk for pump failure. The patient's elevated creatinine level (24.13 mg/dL) and urea level (24.13 mg/dL) also suggest impaired renal function, which can be a complication of heart failure. The patient's elevated BNP level (4853.0 ng/L) also supports this risk. However, the patient is currently not showing signs of acute heart failure exacerbation, and the patient is taking medications that can help manage heart failure symptoms.

3. Sudden cardiac death
REASONING: 
Given the patient's high-risk profile, including the presence of ventricular extrasystole, non-sustained ventricular tachycardia, and paroxysmal supraventricular tachyarrhythmia on the ECG impression, the patient is at high risk for sudden cardiac death. However, the patient's current hemoglobin level and troponin level do not suggest acute myocardial infarction, and the patient is taking medications that can help manage arrhythmias. Overall, while the patient has a high-risk profile, the absence of acute coronary syndrome or acute heart failure exacerbation suggests that the patient may be able to survive for the next few years with proper management and monitoring, but the presence of arrhythmias increases the risk of sudden cardiac death."
674,674,P0183,"Age: 45
Gender: Male 
Weight: 120 kg
Height: 172 cm
NYHA Class: II
Blood Pressure: 100/60 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Hypertension
Albumin (g/L): 45
ALT or GPT (IU/L): 41.0
AST or GOT (IU/L): 25.0
Total Cholesterol (mmol/L): 3,7
Creatinine (mmol/L): 97.0
Gamma-glutamil transpeptidase (IU/L): 206
Glucose (mmol/L): 5,1
Hemoglobin (g/L): 143.0
HDL (mmol/L): 0,98
Potassium (mEq/L): 4,4
LDL (mmol/L): 2,4
Sodium (mEq/L): 136.0
Pro-BNP (ng/L): 2037.0
Protein (g/L): 73
T3 (pg/dL): 0,04
T4 (ng/L): 27
TSH (mIU/L): 2,87
Urea (mg/dL): 8,65
LVEF (%): 30.0
Medications: Beta Blockers, Loop Diuretics, Spironolactone, Statins, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: TPSV
        - Bradycardia: No
            ",sudden cardiac death,"RANKING: 1. Survivor
REASONING: 

Given the patient's age, NYHA Class II, and the presence of ischemic dilated cardiomyopathy, the patient is at risk for cardiac events. However, the patient's current medication regimen includes beta blockers, loop diuretics, spironolactone, statins, and an ACE inhibitor, which are all standard treatments for heart failure and hypertension. The patient's blood pressure is also within a relatively normal range (100/60 mmHg). 

The patient's ejection fraction (LVEF) is 30%, which is significantly reduced, indicating poor cardiac function. However, the patient's creatinine level is elevated (97.0 mmol/L), which may indicate some degree of renal impairment. This could be a concern for cardiac-renal interaction, but it is not a direct indicator of cardiac mortality. 

The elevated Pro-BNP level (2037.0 ng/L) suggests significant cardiac strain and may indicate heart failure. However, the patient's protein level is within a relatively normal range (73 g/L), which could suggest that the patient's kidneys are not failing. 

Considering the patient's age, the presence of ischemic dilated cardiomyopathy, and the current medication regimen, the most likely prognosis is that the patient will survive, albeit with ongoing management and monitoring. 

RANKING: 2. Pump failure death
REASONING: 

While the patient's LVEF is significantly reduced, the patient is currently receiving beta blockers, which are known to improve cardiac function and reduce mortality. The patient's elevated Pro-BNP level suggests cardiac strain, but the patient's protein level is within a relatively normal range. 

However, the patient's creatinine level is elevated, which may indicate some degree of renal impairment. This could be a concern for cardiac-renal interaction, and the patient may be at risk for pump failure. 

RANKING: 3. Sudden cardiac death
REASONING: 

Given the patient's history of ventricular extrasystoles and the presence of ischemic dilated cardiomyopathy, the patient is at increased risk for arrhythmias. The patient's elevated Pro-BNP level and reduced LVEF also suggest that the patient's heart is under significant strain. 

However, the patient's current medication regimen includes beta blockers, which are known to reduce the risk of arrhythmias. The patient's ECG impression did not show any ventricular tachycardia or non-sustained ventricular tachycardia, which reduces the risk of sudden cardiac death. 

Considering the patient's overall risk factors, the most likely prognosis is that the patient will not experience sudden cardiac death."
675,675,P0187,"Age: 72
Gender: Male 
Weight: 82 kg
Height: 175 cm
NYHA Class: II
Blood Pressure: 120/80 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Hypertension, Myocardial Infarction
Albumin (g/L): 45
ALT or GPT (IU/L): 15.0
AST or GOT (IU/L): 23.0
Total Cholesterol (mmol/L): 3,52
Creatinine (mmol/L): 146.0
Gamma-glutamil transpeptidase (IU/L): 36
Glucose (mmol/L): 5,8
Hemoglobin (g/L): 150.0
HDL (mmol/L): 0,83
Potassium (mEq/L): 4,54
LDL (mmol/L): 1,89
Sodium (mEq/L): 138.0
Pro-BNP (ng/L): 3362.0
Protein (g/L): 84,7
T4 (ng/L): 17
Troponin (ng/mL): 0,09
TSH (mIU/L): 18,16
Urea (mg/dL): 15,6
LVEF (%): 22.0
Medications: Angiotensin II Receptor Blocker, Beta Blockers, Digoxin, Loop Diuretics, Spironolactone
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",sudden cardiac death,"RANKING: 1. Survivor
REASONING: The patient's age and NYHA Class II status indicate a relatively advanced stage of heart disease. However, the patient's blood pressure is well-controlled, and they are on medications for hypertension, which suggests that the hypertension is being managed. The patient's creatinine level is elevated, indicating some degree of kidney impairment, but this is not uncommon in patients with heart failure.

The patient's ECG shows ventricular extrasystole and non-sustained ventricular tachycardia, which are concerning signs, but the presence of non-sustained ventricular tachycardia (CH>10) is a relatively common finding in patients with heart failure. The patient's LVEF is also low, indicating significant left ventricular dysfunction, but the patient is on medications that are commonly used to treat heart failure, such as digoxin and spironolactone.

While the patient's Pro-BNP level is elevated, indicating some degree of heart failure, the patient is also on medications that can help reduce BNP levels, such as spironolactone. Overall, the patient's clinical presentation and laboratory results do not strongly suggest a high risk of sudden cardiac death.

RANKING: 2. Pump failure death
REASONING: Based on the patient's low LVEF and elevated Pro-BNP level, it is likely that the patient will experience heart failure symptoms in the next few years. However, the patient is on medications that can help manage heart failure, and the patient's NYHA Class II status suggests that the patient is relatively well-compensated.

The patient's elevated creatinine level and low HDL cholesterol level also suggest a higher risk of cardiovascular events, but the patient's blood pressure is well-controlled, which reduces this risk. The patient's ECG shows ventricular extrasystole and non-sustained ventricular tachycardia, which are concerning signs, but the presence of non-sustained ventricular tachycardia (CH>10) is relatively common in patients with heart failure.

RANKING: 3. Sudden cardiac death
REASONING: Based on the patient's ECG, the presence of ventricular extrasystole and non-sustained ventricular tachycardia (CH>10) is concerning, and the patient's LVEF is low. However, the patient is on medications that can help manage arrhythmias, such as beta blockers and digoxin.

The patient's age and NYHA Class II status also increase the risk of sudden cardiac death. However, the patient's blood pressure is well-controlled, and the patient is on medications that can help reduce cardiovascular risk. The patient's Pro-BNP level is elevated, indicating some degree of heart failure, but the patient is also on medications that can help manage BNP levels.

While the patient's ECG shows ventricular extrasystole and non-sustained ventricular tachycardia, the presence of non-sustained ventricular tachycardia (CH>10) is relatively common in patients with heart failure, and the patient is on medications that can help manage arrhythmias. Overall, while the patient is at risk for sudden cardiac death, the patient's clinical presentation and laboratory results do not suggest an extremely high risk."
676,676,P0215,"Age: 82
Gender: Male 
Weight: 82 kg
Height: 166 cm
NYHA Class: III
Blood Pressure: 170/70 mmHg
Past Medical History: Hypertensive cardiomyopathy, Diabetes, Dyslipemia, Peripheral vascular disease, Hypertension
Albumin (g/L): 45
ALT or GPT (IU/L): 12.0
AST or GOT (IU/L): 13.0
Total Cholesterol (mmol/L): 7,45
Creatinine (mmol/L): 114.0
Gamma-glutamil transpeptidase (IU/L): 58
Glucose (mmol/L): 12,2
Hemoglobin (g/L): 153.0
HDL (mmol/L): 0,93
Potassium (mEq/L): 4,43
LDL (mmol/L): 2,4
Sodium (mEq/L): 132.0
Pro-BNP (ng/L): 410.0
Protein (g/L): 80
T3 (pg/dL): 0,06
T4 (ng/L): 17,46
Troponin (ng/mL): 1
TSH (mIU/L): 1,18
Urea (mg/dL): 10
LVEF (%): 65.0
Medications: Calcium Channel Blocker, Diabetes Medication, Digoxin, Loop Diuretics, Spironolactone, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",sudden cardiac death,"RANKING: 
1. Sudden Cardiac Death
2. Pump Failure Death
3. Survivor

REASONING:

The patient's prognosis is primarily driven by the presence of severe symptoms and underlying conditions. Here's a breakdown of the factors contributing to this ranking:

1. Sudden Cardiac Death: The patient's age, NYHA Class III heart failure, and the presence of non-sustained ventricular tachycardia (NSVT) on the ECG impression significantly increase the risk of sudden cardiac death. The patient's elevated Troponin levels, indicating cardiac muscle damage, also support this risk. Additionally, the patient's low ejection fraction (LVEF) of 65% indicates reduced cardiac function, which can lead to arrhythmias and sudden cardiac death.

2. Pump Failure Death: The patient's severe NYHA Class III heart failure, elevated creatinine levels (indicating renal impairment), and low LVEF contribute to the risk of pump failure. The patient's use of digoxin, a medication typically used to treat atrial fibrillation and heart failure, may also increase the risk of digitalis toxicity, which can lead to pump failure.

3. Survivor: Although the patient has multiple comorbidities, including hypertension, diabetes, and dyslipidemia, the presence of severe heart failure symptoms, NSVT, and elevated Troponin levels outweigh these comorbidities. The patient's relatively well-controlled blood pressure and medication regimen, as evidenced by the use of calcium channel blockers, loop diuretics, and spironolactone, also suggest that the patient is being managed to minimize cardiovascular risk factors. However, the presence of NSVT and elevated Troponin levels remain significant concerns, making sudden cardiac death a more likely outcome than pump failure."
677,677,P0217,"Age: 79
Gender: Male 
Weight: 94 kg
Height: 167 cm
NYHA Class: II
Blood Pressure: 130/70 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Diabetes, Peripheral vascular disease, Hypertension, Myocardial Infarction
Albumin (g/L): 42
ALT or GPT (IU/L): 13.0
AST or GOT (IU/L): 19.0
Total Cholesterol (mmol/L): 5,79
Creatinine (mmol/L): 119.0
Gamma-glutamil transpeptidase (IU/L): 26
Glucose (mmol/L): 10,95
Hemoglobin (g/L): 140.0
HDL (mmol/L): 1,3
Potassium (mEq/L): 4,2
LDL (mmol/L): 3,58
Sodium (mEq/L): 135.0
Pro-BNP (ng/L): 1825.0
Protein (g/L): 77
T3 (pg/dL): 0,0372
T4 (ng/L): 18,5
TSH (mIU/L): 3,2
Urea (mg/dL): 14,6
LVEF (%): 30.0
Medications: Diabetes Medication, Spironolactone, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",sudden cardiac death,"RANKING: 1. Sudden Cardiac Death
REASONING: 

Based on the provided patient data, the patient has a high risk of sudden cardiac death due to the presence of several concerning findings:

1. Severe left ventricular dysfunction: The patient has an LVEF of 30.0%, indicating significant left ventricular systolic dysfunction, which is a major predictor of adverse outcomes.
2. History of ischemic dilated cardiomyopathy: This condition is a well-established cause of sudden cardiac death, particularly in older adults.
3. Presence of ventricular tachycardia: The ECG shows non-sustained ventricular tachycardia (VT), which is a strong predictor of sudden cardiac death.
4. Elevated Pro-BNP levels: The patient has elevated levels of N-terminal pro-b-type natriuretic peptide (Pro-BNP), which is a marker of cardiac stress and strain, indicating poor cardiac function.
5. History of myocardial infarction: The patient has a history of myocardial infarction, which can lead to scar tissue formation and arrhythmias.
6. Presence of polymorphic ventricular extrasystoles: The ECG shows polymorphic ventricular extrasystoles, which can be a precursor to ventricular tachycardia.
7. Poorly controlled hypertension and diabetes: The patient's blood pressure and glucose levels are not well-controlled, which can exacerbate cardiac stress and increase the risk of arrhythmias.

Considering these factors, the patient is at high risk of sudden cardiac death, and it is essential to take immediate action to manage the patient's cardiovascular risk factors and arrhythmias.

RANKING: 2. Pump Failure Death
REASONING: 

Given the patient's severe left ventricular dysfunction (LVEF 30.0%) and history of ischemic dilated cardiomyopathy, pump failure is a significant concern. The patient's elevated Pro-BNP levels and elevated creatinine levels also suggest impaired cardiac function.

RANKING: 3. Survivor
REASONING: 

While the patient has several comorbidities, including diabetes and peripheral vascular disease, the presence of ventricular tachycardia and severe left ventricular dysfunction make pump failure a more likely outcome than sudden cardiac death. However, the patient's age, weight, and other factors may also contribute to a worse prognosis, making survival less likely."
678,678,P0218,"Age: 68
Gender: Male 
Weight: 80 kg
Height: 171 cm
NYHA Class: II
Blood Pressure: 140/70 mmHg
Past Medical History: Idiopathic dilated cardiomyopathy, Hypertension
Albumin (g/L): 41
ALT or GPT (IU/L): 13.0
AST or GOT (IU/L): 17.0
Total Cholesterol (mmol/L): 4,15
Creatinine (mmol/L): 136.0
Gamma-glutamil transpeptidase (IU/L): 16
Glucose (mmol/L): 5,06
Hemoglobin (g/L): 154.0
HDL (mmol/L): 1
Potassium (mEq/L): 4,17
LDL (mmol/L): 2,49
Sodium (mEq/L): 143.0
Pro-BNP (ng/L): 4058.0
Protein (g/L): 68
T3 (pg/dL): 0,0471
T4 (ng/L): 16,72
Troponin (ng/mL): 0,2
TSH (mIU/L): 2,17
Urea (mg/dL): 6,4
LVEF (%): 20.0
Medications: ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",sudden cardiac death,"RANKING: 
1. Survivor
2. Pump failure death
3. Sudden cardiac death

REASONING:

The patient's age (68) and NYHA Class II indicate that they have a significant cardiac condition, but the patient's heart is still functional enough to perform daily activities with some limitation. The patient's LVEF of 20.0 is severely impaired, indicating that the heart is not pumping efficiently. However, the patient's blood pressure and electrolyte levels are within relatively normal limits, and the absence of elevated troponin levels suggests that there is no acute myocardial infarction.

The patient's elevated BNP levels (4058.0 ng/L) and elevated creatinine levels (6.4 mg/dL) suggest that the patient has significant cardiac congestion and renal impairment, which can be a precursor to heart failure. The patient's low HDL cholesterol level (1 mmol/L) and high triglyceride levels are also indicative of increased cardiovascular risk.

Given these factors, the most likely outcome is pump failure death, as the patient's heart is not pumping efficiently and is likely to fail in the near future. Sudden cardiac death is possible but less likely, as the ECG did not show any signs of ventricular tachycardia or other arrhythmias. Survivor is the least likely outcome, as the patient's cardiac condition is quite severe and the risk of complications is high.

It is essential to note that this is a clinical prediction and should be confirmed with further testing and monitoring."
679,679,P0221,"Age: 64
Gender: Male 
Weight: 80 kg
Height: 170 cm
NYHA Class: III
Blood Pressure: 100/65 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Diabetes, Dyslipemia, Myocardial Infarction
Albumin (g/L): 39,7
ALT or GPT (IU/L): 34.0
AST or GOT (IU/L): 26.0
Total Cholesterol (mmol/L): 4,13
Creatinine (mmol/L): 200.0
Gamma-glutamil transpeptidase (IU/L): 47
Glucose (mmol/L): 10,67
Hemoglobin (g/L): 146.0
HDL (mmol/L): 0,9
Potassium (mEq/L): 4,8
LDL (mmol/L): 2,33
Sodium (mEq/L): 132.0
Pro-BNP (ng/L): 2365.0
Protein (g/L): 75
T3 (pg/dL): 0,0312
T4 (ng/L): 15,14
Troponin (ng/mL): 0,5
TSH (mIU/L): 0,77
Urea (mg/dL): 29,3
LVEF (%): 40.0
Medications: Loop Diuretics, Spironolactone, Statins, ACE Inhibitor, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",sudden cardiac death,"RANKING: 
1. Survivor
2. Pump failure death
3. Sudden cardiac death

REASONING:

The patient's prognosis is complex, but based on the provided data, I would rank the outcomes as follows:

1. Survivor: The patient's NYHA Class III indicates severe heart failure, but they are receiving treatment with medications such as spironolactone, ACE inhibitors, and statins, which are standard therapies for managing heart failure and coronary artery disease. The patient's LVEF is 40%, which is significantly reduced, but not critically low. The patient's creatinine level is elevated, indicating renal impairment, but this is not uncommon in heart failure patients. The patient's electrolyte levels, including potassium, are within relatively normal limits. The patient's troponin level is normal, which suggests that there is no significant myocardial infarction. The patient's ECG findings, including ventricular extrasystole and non-sustained ventricular tachycardia, are concerning but not indicative of an immediate life-threatening arrhythmia. The patient's BNP level is elevated, which is consistent with heart failure. Overall, while the patient's heart function is compromised, the presence of medications and relatively normal electrolyte levels suggest that the patient can survive with proper management.

2. Pump failure death: Given the patient's severe heart failure (NYHA Class III) and reduced LVEF, pump failure is a significant risk. The patient's creatinine level and renal impairment may further exacerbate this risk. However, the patient is receiving medications that are designed to improve heart function and reduce mortality, which may mitigate this risk. The patient's ECG findings, while concerning, do not indicate an immediate life-threatening arrhythmia.

3. Sudden cardiac death: The patient's ECG findings of ventricular extrasystole and non-sustained ventricular tachycardia are concerning for an increased risk of sudden cardiac death. The patient's age, NYHA Class III, and LVEF of 40% also increase the risk of sudden cardiac death. However, the presence of medications and relatively normal electrolyte levels suggest that the patient may be managed to reduce this risk. The patient's BNP level is elevated, which is consistent with heart failure, but not indicative of an immediate life-threatening arrhythmia. Overall, while the patient is at risk for sudden cardiac death, the presence of medications and relatively normal electrolyte levels suggest that this outcome is less likely than pump failure death."
680,680,P0243,"Age: 35
Gender: Male 
Weight: 92 kg
Height: 177 cm
NYHA Class: II
Blood Pressure: 110/60 mmHg
Past Medical History: Idiopathic dilated cardiomyopathy
Albumin (g/L): 45
ALT or GPT (IU/L): 13.0
AST or GOT (IU/L): 20.0
Total Cholesterol (mmol/L): 3,26
Creatinine (mmol/L): 88.0
Gamma-glutamil transpeptidase (IU/L): 29
Glucose (mmol/L): 4,7
Hemoglobin (g/L): 135.0
HDL (mmol/L): 0,83
Potassium (mEq/L): 4
LDL (mmol/L): 1,97
Sodium (mEq/L): 138.0
Pro-BNP (ng/L): 10297.0
Protein (g/L): 75
T3 (pg/dL): 0,05
T4 (ng/L): 15
TSH (mIU/L): 2,54
Urea (mg/dL): 6,32
LVEF (%): 40.0
Medications: Beta Blockers, Digoxin, Loop Diuretics, Spironolactone, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",sudden cardiac death,"RANKING: 
1. Sudden cardiac death
2. Pump failure death
3. Survivor

REASONING:

The patient's data indicates a high-risk profile for adverse outcomes. The primary concern is the patient's idiopathic dilated cardiomyopathy, which is a condition where the heart muscle becomes weakened, leading to poor heart function. The low LVEF (40.0%) further supports this, as it indicates reduced ejection fraction, a common indicator of heart failure.

The elevated Pro-BNP levels (10297.0 ng/L) also suggest heart failure, as BNP is a hormone produced by the heart when it is under strain. The presence of ventricular extrasystole, non-sustained ventricular tachycardia, and non-sustained ventricular tachycardia (CH>10) on the ECG further indicates arrhythmias, which are common complications in patients with dilated cardiomyopathy.

The patient's current treatment regimen, which includes beta blockers, digoxin, loop diuretics, spironolactone, and an ACE inhibitor, is standard for managing heart failure and arrhythmias in this patient population. However, the presence of these conditions and the patient's age and weight suggest a relatively high risk of adverse outcomes.

While the patient's hemoglobin and kidney function are within relatively normal limits, the patient's weight and NYHA Class II classification suggest that they may be at risk for further decline in cardiac function. 

Given these factors, I would rank the patient's prognosis as follows:

1. Sudden cardiac death: Given the patient's history of ventricular arrhythmias, low LVEF, and elevated Pro-BNP levels, the risk of sudden cardiac death is high.
2. Pump failure death: The patient's dilated cardiomyopathy, low LVEF, and elevated Pro-BNP levels suggest a high risk of heart failure, which can lead to pump failure and death.
3. Survivor: While the patient is currently on treatment and has relatively normal hemoglobin and kidney function, the overall risk of adverse outcomes is still high, making survival less likely compared to the other two options."
681,681,P0261,"Age: 40
Gender: Male 
Weight: 82 kg
Height: 175 cm
NYHA Class: II
Blood Pressure: 100/70 mmHg
Past Medical History: Enolic dilated cardiomyopathy, Hypertension, Myocardial Infarction
Albumin (g/L): 37,6
ALT or GPT (IU/L): 18.0
AST or GOT (IU/L): 29.0
Total Cholesterol (mmol/L): 4,5
Creatinine (mmol/L): 84.0
Gamma-glutamil transpeptidase (IU/L): 236
Glucose (mmol/L): 4,6
Hemoglobin (g/L): 143.0
HDL (mmol/L): 0,95
Potassium (mEq/L): 3,32
LDL (mmol/L): 3,02
Sodium (mEq/L): 131.0
Pro-BNP (ng/L): 2598.0
Protein (g/L): 73,2
Troponin (ng/mL): 0,01
TSH (mIU/L): 2,39
Urea (mg/dL): 1,8
LVEF (%): 19.0
Medications: Loop Diuretics, Spironolactone, ACE Inhibitor, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: TPSV
        - Bradycardia: No
            ",sudden cardiac death,"RANKING: 1. Sudden Cardiac Death
REASONING: 

The patient's current clinical presentation and test results indicate a high risk for sudden cardiac death. The key factors contributing to this risk include:

1. Low LVEF (19.0%): Severe left ventricular dysfunction is a hallmark of advanced heart failure and significantly increases the risk of sudden cardiac death.
2. Elevated Pro-BNP levels (2598.0 ng/L): Elevated brain natriuretic peptide (BNP) levels are associated with increased ventricular wall stress and are commonly seen in patients with heart failure, which further supports the presence of severe left ventricular dysfunction.
3. Presence of ventricular extrasystoles (Polymorphic): The presence of ventricular extrasystoles, particularly polymorphic ventricular extrasystoles, is a known risk factor for sudden cardiac death.
4. History of myocardial infarction: The patient's history of myocardial infarction increases the risk of sudden cardiac death due to potential scar tissue and remodeling.
5. Low HDL cholesterol (0.95 mmol/L): Low levels of high-density lipoprotein (HDL) cholesterol are associated with increased cardiovascular risk and may contribute to the development of atherosclerotic disease.

Given these factors, the patient is at high risk for sudden cardiac death, making it the most likely prognosis.

RANKING: 2. Pump Failure Death
REASONING: 

While the patient's severe left ventricular dysfunction (LVEF 19.0%) and elevated Pro-BNP levels indicate advanced heart failure, the presence of ventricular extrasystoles and history of myocardial infarction suggest a higher risk for sudden cardiac death. However, if the patient's heart failure progresses without sudden cardiac death, pump failure death is a possible outcome.

RANKING: 3. Survivor
REASONING: 

The patient's overall clinical presentation and test results do not suggest a high risk for sudden cardiac death, and the presence of medications such as ACE inhibitors and spironolactone indicate an attempt to manage the patient's heart failure. However, the patient's severe left ventricular dysfunction and elevated Pro-BNP levels indicate a significant risk for pump failure, making survival without significant cardiac events a less likely outcome compared to sudden cardiac death."
682,682,P0262,"Age: 58
Gender: Female 
Weight: 61 kg
Height: 145 cm
NYHA Class: III
Blood Pressure: 110/70 mmHg
Past Medical History: Valvular cardiomyopathy, Myocardial Infarction
Albumin (g/L): 38,2
ALT or GPT (IU/L): 33.0
AST or GOT (IU/L): 50.0
Total Cholesterol (mmol/L): 3,98
Creatinine (mmol/L): 110.0
Gamma-glutamil transpeptidase (IU/L): 330
Glucose (mmol/L): 6,1
Hemoglobin (g/L): 121.0
HDL (mmol/L): 0,92
Potassium (mEq/L): 4,12
LDL (mmol/L): 2,72
Sodium (mEq/L): 142.0
Protein (g/L): 73,6
T4 (ng/L): 15,3
Troponin (ng/mL): 0,01
TSH (mIU/L): 8,26
Urea (mg/dL): 10
LVEF (%): 25.0
Medications: Amiodarone, Beta Blockers, Loop Diuretics, Spironolactone, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Unknown ventricular tachycardia code
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",sudden cardiac death,"RANKING: 
1. Sudden Cardiac Death
2. Pump Failure Death
3. Survivor

REASONING:

Based on the provided patient data, I rank the prognoses as follows:

1. Sudden Cardiac Death: The patient's ECG impression reveals ventricular extrasystole and ventricular tachycardia, which are both associated with an increased risk of sudden cardiac death. The presence of polymorphic ventricular extrasystole is particularly concerning, as it can be a precursor to ventricular fibrillation or tachycardia, leading to sudden cardiac death. Additionally, the patient's history of myocardial infarction and valvular cardiomyopathy increases the risk of arrhythmias and cardiac complications. The patient's troponin level is also elevated, indicating some degree of myocardial injury, which can contribute to arrhythmias.

2. Pump Failure Death: Given the patient's reduced left ventricular ejection fraction (LVEF) of 25.0, which indicates severe left ventricular dysfunction, and the presence of heart failure symptoms (NYHA Class III), pump failure is a significant concern. The patient's elevated creatinine level (110.0) and elevated liver enzymes (ALT and AST) suggest some degree of renal and hepatic dysfunction, which can be associated with heart failure. However, the presence of ventricular arrhythmias and the patient's history of myocardial infarction and valvular cardiomyopathy make pump failure death a more likely outcome.

3. Survivor: While the patient's overall clinical presentation is concerning, the presence of ventricular arrhythmias and significant left ventricular dysfunction make pump failure and sudden cardiac death more likely outcomes. However, if the patient's arrhythmias are well-managed with medications and the patient's heart function does not deteriorate further, it is possible that the patient could survive for an extended period. Nevertheless, the patient's underlying cardiac conditions and the presence of ventricular arrhythmias make survivorship the least likely outcome."
683,683,P0266,"Age: 68
Gender: Female 
Weight: 74 kg
Height: 136 cm
NYHA Class: III
Blood Pressure: 110/70 mmHg
Past Medical History: Hypertropic cardiomyopathy, Dyslipemia, Hypertension, Myocardial Infarction
Albumin (g/L): 39,8
ALT or GPT (IU/L): 25.0
AST or GOT (IU/L): 32.0
Total Cholesterol (mmol/L): 5,21
Creatinine (mmol/L): 124.0
Gamma-glutamil transpeptidase (IU/L): 62
Glucose (mmol/L): 4,1
Hemoglobin (g/L): 135.0
HDL (mmol/L): 1,18
Potassium (mEq/L): 4,15
LDL (mmol/L): 3,4
Sodium (mEq/L): 133.0
Protein (g/L): 76,7
Troponin (ng/mL): 0,02
TSH (mIU/L): 4
Urea (mg/dL): 10,7
LVEF (%): 70.0
Medications: Amiodarone, Loop Diuretics, Spironolactone, Statins, Hydralazine, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",sudden cardiac death,"RANKING: 
1. Survivor
REASONING:
The patient's age, NYHA Class III, and the presence of multiple comorbidities such as hypertension, myocardial infarction, and dyslipidemia indicate a high risk of adverse cardiac events. However, the patient's LVEF of 70.0 suggests that the left ventricle is still functioning relatively well, and the absence of significant elevations in troponin levels indicates minimal myocardial damage. The patient is also on medications such as Amiodarone, which is commonly used to treat arrhythmias, and ACE inhibitors, which are beneficial for patients with hypertension and heart failure. The ECG impression does not show any signs of ventricular tachycardia or ventricular extrasystoles, which are common precursors to sudden cardiac death. 

2. Pump failure death
REASONING:
Given the patient's NYHA Class III status and the presence of heart failure symptoms, pump failure death is a plausible outcome. The patient's LVEF of 70.0 is slightly below the normal range, which may indicate some degree of left ventricular dysfunction. However, the patient is on medications such as spironolactone, which is commonly used to treat heart failure, and ACE inhibitors, which are beneficial for patients with heart failure. The absence of significant elevations in troponin levels and the patient's overall clinical presentation suggest that pump failure death is less likely than sudden cardiac death.

3. Sudden cardiac death
REASONING:
While the patient's ECG impression shows polymorphic ventricular extrasystoles, which can be a precursor to ventricular tachycardia, the absence of ventricular tachycardia or non-sustained ventricular tachycardia on the ECG makes sudden cardiac death less likely. The patient's overall clinical presentation and the presence of medications such as Amiodarone, which is commonly used to treat arrhythmias, further reduce the likelihood of sudden cardiac death. Additionally, the patient's LVEF of 70.0 and the absence of significant elevations in troponin levels suggest that the patient's cardiac function is relatively preserved, which reduces the risk of sudden cardiac death."
684,684,P0271,"Age: 77
Gender: Male 
Weight: 70 kg
Height: 161 cm
NYHA Class: II
Blood Pressure: 110/60 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Dyslipemia, Peripheral vascular disease, Hypertension, Myocardial Infarction
Albumin (g/L): 43
ALT or GPT (IU/L): 22.0
AST or GOT (IU/L): 27.0
Total Cholesterol (mmol/L): 4,78
Creatinine (mmol/L): 167.0
Gamma-glutamil transpeptidase (IU/L): 26
Glucose (mmol/L): 6
Hemoglobin (g/L): 131.0
HDL (mmol/L): 1,22
Potassium (mEq/L): 4,9
LDL (mmol/L): 3,13
Sodium (mEq/L): 137.0
Pro-BNP (ng/L): 962.0
Protein (g/L): 74,6
T3 (pg/dL): 0,045
T4 (ng/L): 17,49
Troponin (ng/mL): 0,4
TSH (mIU/L): 1,76
Urea (mg/dL): 17,7
LVEF (%): 35.0
Medications: Digoxin, Loop Diuretics, Statins, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: Sinus Node Dysfunction
            ",sudden cardiac death,"RANKING: 1. Sudden cardiac death
REASONING:

Based on the patient's data, I would rank sudden cardiac death as the most likely prognosis for the next few years. The patient has a history of ischemic dilated cardiomyopathy, which is a significant risk factor for sudden cardiac death. The patient's LVEF is severely impaired at 35%, indicating that the heart is not functioning efficiently and is at risk of further decline. The patient's elevated Troponin level (0.4 ng/mL) suggests some degree of myocardial damage, which could be indicative of ongoing cardiac stress.

The patient's age (77) and NYHA Class II status also increase the risk of cardiac complications. The patient's elevated BNP level (962 ng/L) is also a marker of heart failure, which can increase the risk of sudden cardiac death.

While the patient is taking medications such as digoxin, loop diuretics, statins, and an ACE inhibitor, these medications may not be sufficient to manage the patient's underlying cardiac condition. The patient's elevated creatinine level (167.0 mmol/L) and urea level (17.7 mg/dL) also suggest some degree of renal impairment, which can further increase the risk of cardiac complications.

The patient's ECG impression highlights the presence of ventricular extrasystoles, which can be a precursor to ventricular tachycardia, a condition that can lead to sudden cardiac death.

While pump failure death is a possible prognosis, I rank it second due to the patient's severe LVEF and elevated BNP levels, which suggest a high risk of cardiac failure. The patient's age and NYHA Class II status also increase the risk of pump failure.

Survivor is the least likely prognosis due to the patient's significant cardiac risk factors, including ischemic dilated cardiomyopathy, elevated BNP levels, and elevated Troponin levels."
685,685,P0280,"Age: 70
Gender: Female 
Weight: 63 kg
Height: 155 cm
NYHA Class: II
Blood Pressure: 160/60 mmHg
Past Medical History: Hypertensive cardiomyopathy, Diabetes, Hypertension
Albumin (g/L): 41
ALT or GPT (IU/L): 17.0
AST or GOT (IU/L): 14.0
Total Cholesterol (mmol/L): 5,87
Creatinine (mmol/L): 99.0
Gamma-glutamil transpeptidase (IU/L): 28
Glucose (mmol/L): 19,1
Hemoglobin (g/L): 134.0
HDL (mmol/L): 1,66
Potassium (mEq/L): 4,91
LDL (mmol/L): 3,18
Sodium (mEq/L): 136.0
Pro-BNP (ng/L): 327.0
Protein (g/L): 73,6
T3 (pg/dL): 0,0504
T4 (ng/L): 18,13
Troponin (ng/mL): 0,3
TSH (mIU/L): 1,21
Urea (mg/dL): 12
LVEF (%): 66.0
Medications: Diabetes Medication, Beta Blockers, Loop Diuretics, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",sudden cardiac death,"RANKING: 1. Sudden cardiac death
REASONING: 

Based on the provided patient data, the patient is at high risk for sudden cardiac death due to the presence of several factors that contribute to this outcome. 

Firstly, the patient has a history of Hypertensive cardiomyopathy, which can lead to left ventricular dysfunction and increased risk of arrhythmias. The elevated blood pressure (160/60 mmHg) and high creatinine level (99.0) further indicate left ventricular dysfunction, which can increase the risk of arrhythmias and sudden cardiac death.

The patient also has a history of diabetes, which is a known risk factor for cardiovascular disease, including sudden cardiac death. The elevated glucose level (19.1 mmol/L) and the presence of proteinuria (73.6 g/L) suggest possible diabetic nephropathy, which can further increase the risk of cardiovascular events.

The patient's ECG findings of ventricular extrasystole, which is a type of abnormal heart rhythm, further supports this prognosis. The absence of ventricular tachycardia, non-sustained ventricular tachycardia, and paroxysmal supraventricular tachyarrhythmia reduces the likelihood of other types of arrhythmias that may not be as immediately life-threatening.

Additionally, the patient's left ventricular ejection fraction (LVEF) of 66.0 is below the normal range (55%), which indicates left ventricular dysfunction. This can increase the risk of sudden cardiac death.

Considering these factors, the most likely prognosis for the patient is sudden cardiac death.

RANKING: 2. Pump failure death
REASONING: 

While the patient's left ventricular dysfunction (LVEF 66.0) and history of hypertensive cardiomyopathy increase the risk of heart failure, the patient is currently being treated with medications that may help manage symptoms and slow disease progression (Diabetes Medication, Beta Blockers, Loop Diuretics, ACE Inhibitor).

However, the patient's elevated creatinine level (99.0) and proteinuria (73.6 g/L) suggest that the patient's kidney function is compromised, which can further exacerbate heart failure symptoms. The patient's elevated glucose level (19.1 mmol/L) and high blood pressure (160/60 mmHg) also contribute to the risk of heart failure.

Considering these factors, the patient's risk of pump failure death is moderate, but not as high as the risk of sudden cardiac death.

RANKING: 3. Survivor
REASONING: 

While the patient has several risk factors for cardiovascular disease, including hypertension, diabetes, and left ventricular dysfunction, the patient is currently being treated with medications that may help manage symptoms and slow disease progression.

The patient's LVEF is 66.0, which is below the normal range, but the patient is still receiving treatment for heart failure. The patient's ECG findings do not indicate any life-threatening arrhythmias.

Additionally, the patient's kidney function is compromised, but the patient is being treated with medications that may help manage this condition. The patient's other laboratory values, such as the elevated creatinine level, proteinuria, and high blood pressure, may indicate that the patient's cardiovascular disease is not being adequately managed.

Considering these factors, the patient's risk of dying from pump failure is lower than the risk of sudden cardiac death, and the patient is at a higher risk of surviving with proper management and treatment."
686,686,P0289,"Age: 61
Gender: Male 
Weight: 84 kg
Height: 175 cm
NYHA Class: II
Blood Pressure: 100/70 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Hypertension, Myocardial Infarction
Albumin (g/L): 39
ALT or GPT (IU/L): 58.0
AST or GOT (IU/L): 33.0
Total Cholesterol (mmol/L): 4,28
Creatinine (mmol/L): 93.0
Gamma-glutamil transpeptidase (IU/L): 45
Glucose (mmol/L): 4,59
Hemoglobin (g/L): 147.0
HDL (mmol/L): 1,2
Potassium (mEq/L): 3,7
LDL (mmol/L): 2,7
Sodium (mEq/L): 141.0
Pro-BNP (ng/L): 642.0
Protein (g/L): 72
T3 (pg/dL): 0,0573
T4 (ng/L): 14,27
Troponin (ng/mL): 0,5
TSH (mIU/L): 2,99
Urea (mg/dL): 5,4
LVEF (%): 40.0
Medications: Beta Blockers, Loop Diuretics, ACE Inhibitor, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: TPSV
        - Bradycardia: No
            ",sudden cardiac death,"RANKING: 1. Sudden cardiac death
REASONING: 
The patient has a history of ischemic dilated cardiomyopathy, which is a significant risk factor for sudden cardiac death. The patient's LVEF is 40%, indicating severe left ventricular dysfunction, which is also a predictor of increased risk of sudden cardiac death. Additionally, the patient has a history of myocardial infarction, which can lead to scarring and remodeling of the heart, further increasing the risk of arrhythmias and sudden cardiac death.

The patient's ECG findings of ventricular extrasystole, which is a type of abnormal heart rhythm, also support this prognosis. The presence of ventricular extrasystoles can increase the risk of ventricular tachycardia and sudden cardiac death.

While the patient is on medications such as beta blockers, loop diuretics, ACE inhibitors, and nitrovasodilators, which are commonly used to manage heart failure and hypertension, the patient's underlying cardiac condition and ECG findings suggest that the risk of sudden cardiac death is still present.

The patient's elevated troponin levels, which indicate some degree of cardiac damage, also support this prognosis.

Therefore, based on the patient's medical history, ECG findings, and current condition, I would rank sudden cardiac death as the most likely outcome for the next few years.

RANKING: 2. Pump failure death
REASONING: 
Pump failure death, also known as heart failure, is a possible outcome for the patient due to the patient's history of ischemic dilated cardiomyopathy and severe left ventricular dysfunction (LVEF 40%). The patient's elevated BNP levels (642 ng/L) also support this prognosis, as BNP is a biomarker for heart failure.

The patient's elevated creatinine levels (93.0 mmol/L) and urea levels (5.4 mg/dL) also suggest some degree of renal impairment, which can be associated with heart failure.

The patient's medications, such as beta blockers, loop diuretics, ACE inhibitors, and nitrovasodilators, are commonly used to manage heart failure, but the patient's underlying cardiac condition and ECG findings suggest that the risk of pump failure death is still present.

Therefore, based on the patient's medical history, ECG findings, and current condition, I would rank pump failure death as the second most likely outcome for the next few years.

RANKING: 3. Survivor
REASONING: 
The patient's age (61) and other medical conditions, such as hypertension and myocardial infarction, may increase the risk of complications, but the patient's relatively good hemoglobin level (147.0 g/L) and normal potassium level (3.7 mEq/L) suggest that the patient is not in acute distress.

The patient's ECG findings of polymorphic ventricular extrasystoles and TPSV suggest some degree of arrhythmia, but the absence of other ECG findings that would indicate a high risk of sudden cardiac death, such as ventricular tachycardia or non-sustained ventricular tachycardia, may suggest that the patient is not at high risk for sudden cardiac death.

The patient's medications, such as beta blockers, loop diuretics, ACE inhibitors, and nitrovasodilators, are commonly used to manage heart failure and hypertension, and the patient's current condition suggests that these medications are effective in managing the patient's symptoms.

Therefore, based on the patient's medical history, ECG findings, and current condition, I would rank survivor as the least likely outcome for the next few years."
687,687,P0322,"Age: 67
Gender: Male 
Weight: 73 kg
Height: 160 cm
NYHA Class: III
Blood Pressure: 85/60 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Dyslipemia, Myocardial Infarction
Albumin (g/L): 43,5
ALT or GPT (IU/L): 16.0
AST or GOT (IU/L): 25.0
Total Cholesterol (mmol/L): 5,59
Creatinine (mmol/L): 102.0
Gamma-glutamil transpeptidase (IU/L): 79
Glucose (mmol/L): 4,9
Hemoglobin (g/L): 149.0
HDL (mmol/L): 0,93
Potassium (mEq/L): 4,1
LDL (mmol/L): 3,8
Sodium (mEq/L): 137.0
Pro-BNP (ng/L): 3736.0
Protein (g/L): 77
T3 (pg/dL): 0,04
T4 (ng/L): 18
Troponin (ng/mL): 0,01
TSH (mIU/L): 5,04
Urea (mg/dL): 6,01
LVEF (%): 25.0
Medications: Digoxin, Loop Diuretics, Statins, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",sudden cardiac death,"RANKING: 
1. Sudden Cardiac Death
2. Pump Failure Death
3. Survivor

REASONING:

The patient's clinical presentation and test results suggest a high risk of adverse outcomes. The key factors contributing to this ranking are:

1. Severe left ventricular dysfunction: The LVEF (Left Ventricular Ejection Fraction) of 25% indicates severe systolic dysfunction, which is a hallmark of advanced heart failure. This severely impaired cardiac function increases the risk of sudden cardiac death.

2. History of ischemic dilated cardiomyopathy: The patient's history of myocardial infarction and dilated cardiomyopathy suggests a significant burden of cardiac disease. This can lead to further cardiac remodeling, which may result in progressive heart failure and an increased risk of sudden cardiac death.

3. Presence of non-sustained ventricular tachycardia (NSVT): The patient has a history of NSVT, which is a marker of arrhythmogenic substrate. The presence of NSVT increases the risk of ventricular arrhythmias, including ventricular tachycardia, which can degenerate into ventricular fibrillation and sudden cardiac death.

4. Low ejection fraction and elevated biomarkers: The low LVEF, elevated troponin levels, and elevated BNP levels indicate significant cardiac stress and potential cardiac damage. These biomarkers suggest that the patient's cardiac function is compromised, which increases the risk of adverse outcomes.

5. Low hemoglobin levels: The patient's low hemoglobin level (149 g/L) may indicate anemia, which can further compromise cardiac function and increase the risk of adverse outcomes.

6. Medication profile: The patient is on digoxin, loop diuretics, statins, and ACE inhibitors, which are standard treatments for heart failure and coronary artery disease. However, the presence of NSVT and severe left ventricular dysfunction may not be adequately managed with these medications alone.

Considering these factors, the patient is at high risk of sudden cardiac death due to the combination of severe left ventricular dysfunction, history of ischemic cardiomyopathy, and presence of NSVT. Pump failure death is also a concern due to the patient's severe left ventricular dysfunction. However, the immediate risk of sudden cardiac death is higher due to the presence of NSVT and other arrhythmogenic factors."
688,688,P0327,"Age: 76
Gender: Male 
Weight: 74 kg
Height: 168 cm
NYHA Class: II
Blood Pressure: 140/60 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Diabetes, Dyslipemia, Peripheral vascular disease, Hypertension, Myocardial Infarction
Albumin (g/L): 50,19
ALT or GPT (IU/L): 16.0
AST or GOT (IU/L): 17.0
Total Cholesterol (mmol/L): 3,93
Creatinine (mmol/L): 125.0
Gamma-glutamil transpeptidase (IU/L): 16
Glucose (mmol/L): 9,2
Hemoglobin (g/L): 120.0
HDL (mmol/L): 0,65
Potassium (mEq/L): 3,8
LDL (mmol/L): 2,25
Sodium (mEq/L): 138.0
Pro-BNP (ng/L): 3065.0
Protein (g/L): 78
T3 (pg/dL): 0,02
T4 (ng/L): 21
Troponin (ng/mL): 0,05
TSH (mIU/L): 10,5
Urea (mg/dL): 8,69
LVEF (%): 36.0
Medications: Diabetes Medication, Amiodarone, Beta Blockers, Digoxin, Loop Diuretics, Spironolactone, Statins, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",sudden cardiac death,"RANKING: 1. Sudden cardiac death
REASONING: 

The patient's clinical presentation and laboratory findings indicate a high risk of sudden cardiac death. The key factors contributing to this risk include:

1. Age: The patient is 76 years old, which is a high-risk age for cardiovascular events, including sudden cardiac death.
2. NYHA Class II: The patient has a moderate level of heart failure, which increases the risk of arrhythmias and sudden cardiac death.
3. Ischemic dilated cardiomyopathy: This condition can lead to arrhythmias, decreased cardiac function, and increased risk of sudden cardiac death.
4. High Pro-BNP levels: Elevated Pro-BNP levels indicate increased ventricular wall stress, which is a marker of poor prognosis and increased risk of sudden cardiac death.
5. Low LVEF: The patient's left ventricular ejection fraction (LVEF) is significantly reduced, indicating poor cardiac function and increased risk of arrhythmias.
6. Presence of ventricular extrasystole on ECG: The presence of ventricular extrasystoles is a marker of arrhythmia risk and can increase the likelihood of sudden cardiac death.
7. Multiple comorbidities: The patient has multiple comorbidities, including diabetes, hypertension, and peripheral vascular disease, which can increase the risk of cardiovascular events.

Considering these factors, the patient is at high risk of sudden cardiac death. While the patient's current medications, such as Amiodarone and Beta Blockers, are being used to manage arrhythmias and heart failure, the overall clinical picture suggests that the patient is at high risk of sudden cardiac death.

Sudden cardiac death is the most likely outcome, followed by pump failure death, and then survivor. Pump failure death is less likely due to the patient's current medical management and the fact that the patient is not on a ventricular assist device (VAD) or other advanced therapies. Survivor is the least likely outcome, given the patient's advanced age, multiple comorbidities, and poor cardiac function."
689,689,P0330,"Age: 82
Gender: Male 
Weight: 60 kg
Height: 168 cm
NYHA Class: II
Blood Pressure: 110/60 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Hypertension, Myocardial Infarction
Albumin (g/L): 47,69
ALT or GPT (IU/L): 12.0
AST or GOT (IU/L): 15.0
Total Cholesterol (mmol/L): 5,12
Creatinine (mmol/L): 127.0
Gamma-glutamil transpeptidase (IU/L): 24
Glucose (mmol/L): 4,7
Hemoglobin (g/L): 131.0
HDL (mmol/L): 1,27
Potassium (mEq/L): 4,3
LDL (mmol/L): 3,26
Sodium (mEq/L): 142.0
Pro-BNP (ng/L): 1414.0
Protein (g/L): 77
T3 (pg/dL): 0,04
T4 (ng/L): 19
Troponin (ng/mL): 0,01
TSH (mIU/L): 2,96
Urea (mg/dL): 10,24
LVEF (%): 24.0
Medications: Beta Blockers, Loop Diuretics, ACE Inhibitor, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",sudden cardiac death,"RANKING: 
1. Sudden cardiac death
2. Pump failure death
3. Survivor

REASONING:

This patient has a high-risk profile for cardiac events due to a history of ischemic dilated cardiomyopathy, hypertension, and myocardial infarction. The patient's LVEF of 24.0 indicates severe left ventricular dysfunction, which is a significant predictor of adverse outcomes. The presence of ventricular extrasystoles on the ECG, although not sustained, suggests electrical instability and increased risk of arrhythmias.

The patient's elevated troponin level (0.01 ng/mL) is a marker of myocardial damage, and the patient's elevated BNP level (1414 ng/L) indicates significant ventricular stress. The patient's kidney function is also compromised, as indicated by the elevated creatinine level (10.24 mg/dL).

Given these factors, the patient is at high risk for cardiac events. Sudden cardiac death is a likely outcome due to the combination of severe left ventricular dysfunction, electrical instability, and myocardial damage.

Pump failure death is a possible outcome due to the patient's severe left ventricular dysfunction and compromised kidney function. However, the patient is currently on medications that are known to improve cardiac function and reduce mortality (beta blockers, ACE inhibitor, and loop diuretics).

Survival is the least likely outcome due to the patient's high-risk profile and the presence of significant cardiac and renal dysfunction. However, the patient's current medications and the fact that they are not in acute decompensated heart failure may contribute to a slightly better prognosis.

It's essential to note that this is a complex patient with multiple comorbidities, and the prognosis should be continuously monitored and adjusted based on ongoing clinical assessment and changes in the patient's condition."
690,690,P0332,"Age: 63
Gender: Male 
Weight: 80 kg
Height: 178 cm
NYHA Class: III
Blood Pressure: 140/70 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Diabetes, Dyslipemia, Peripheral vascular disease, Myocardial Infarction
Albumin (g/L): 41,4
ALT or GPT (IU/L): 10.0
AST or GOT (IU/L): 9.0
Total Cholesterol (mmol/L): 4,78
Creatinine (mmol/L): 184.0
Gamma-glutamil transpeptidase (IU/L): 54
Glucose (mmol/L): 9,5
Hemoglobin (g/L): 113.0
HDL (mmol/L): 0,8
Potassium (mEq/L): 5,1
LDL (mmol/L): 2,82
Sodium (mEq/L): 133.0
Pro-BNP (ng/L): 7692.0
Protein (g/L): 74
T3 (pg/dL): 0,04
T4 (ng/L): 17
Troponin (ng/mL): 0,06
TSH (mIU/L): 3
Urea (mg/dL): 20,7
LVEF (%): 35.0
Medications: Beta Blockers, Loop Diuretics, Statins, ACE Inhibitor, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",sudden cardiac death,"RANKING: 1. Sudden Cardiac Death
REASONING: 

This patient is at high risk for sudden cardiac death due to the presence of several adverse factors in the patient's history and laboratory results. The patient has a history of ischemic dilated cardiomyopathy, which is a condition that increases the risk of sudden cardiac death. The patient's left ventricular ejection fraction (LVEF) is severely impaired at 35%, indicating that the heart is not functioning efficiently and is more susceptible to arrhythmias. The elevated troponin level of 0.06 ng/mL suggests some degree of myocardial damage, which can also contribute to arrhythmias.

The patient's elevated BNP level of 7692 ng/L is also a marker of heart failure, which further increases the risk of sudden cardiac death. Additionally, the patient's history of myocardial infarction, peripheral vascular disease, and dyslipidemia also contribute to the overall risk of sudden cardiac death.

The patient's ECG impression of ventricular extrasystole, a type of abnormal heart rhythm, further supports the risk of sudden cardiac death. The presence of ventricular extrasystoles can be a predictor of sudden cardiac death, especially in patients with a history of cardiac disease.

Given the combination of these factors, the likelihood of sudden cardiac death in this patient is high.

RANKING: 2. Pump Failure Death
REASONING: 

Although the patient is at high risk for sudden cardiac death, pump failure death is also a significant concern. The patient's LVEF is severely impaired at 35%, indicating that the heart is not functioning efficiently. The patient's elevated BNP level of 7692 ng/L suggests that the heart is under strain and may not be able to pump effectively.

The patient's history of heart failure, as indicated by the elevated BNP level, also increases the risk of pump failure death. The patient's NYHA class III classification indicates that the patient has severe heart failure symptoms, which further increases the risk of pump failure death.

Additionally, the patient's elevated creatinine level of 184.0 mmol/L suggests kidney dysfunction, which can contribute to the risk of pump failure death.

Given the patient's severe heart failure symptoms and impaired LVEF, the likelihood of pump failure death is moderate.

RANKING: 3. Survivor
REASONING: 

While the patient is at risk for sudden cardiac death and pump failure death, the likelihood of the patient surviving in the long term is lower. The patient's history of heart failure, impaired LVEF, and elevated BNP level suggest that the patient's heart is not functioning efficiently and is at risk for further decline.

However, the patient's age and the presence of medications such as beta blockers, loop diuretics, statins, ACE inhibitors, and a nitrovasodilator suggest that the patient is receiving treatment to manage their heart failure symptoms. Additionally, the patient's elevated HDL level of 0.8 mmol/L suggests that the patient may have some level of cardiovascular protection.

Given the patient's treatment and the presence of some cardiovascular protection, the likelihood of the patient surviving is lower than pump failure death, but still a possibility."
691,691,P0340,"Age: 71
Gender: Male 
Weight: 57 kg
Height: 168 cm
NYHA Class: III
Blood Pressure: 85/50 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Dyslipemia, Peripheral vascular disease, Myocardial Infarction
Albumin (g/L): 44,6
ALT or GPT (IU/L): 20.0
AST or GOT (IU/L): 19.0
Total Cholesterol (mmol/L): 5,59
Creatinine (mmol/L): 123.0
Gamma-glutamil transpeptidase (IU/L): 57
Glucose (mmol/L): 5,7
Hemoglobin (g/L): 129.0
HDL (mmol/L): 1,86
Potassium (mEq/L): 4,5
LDL (mmol/L): 3,36
Sodium (mEq/L): 142.0
Pro-BNP (ng/L): 2206.0
Protein (g/L): 70
T3 (pg/dL): 0,05
T4 (ng/L): 17
Troponin (ng/mL): 0,01
TSH (mIU/L): 0,954
Urea (mg/dL): 4,9
LVEF (%): 30.0
Medications: Calcium Channel Blocker, Loop Diuretics, Spironolactone, Statins, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",sudden cardiac death,"RANKING: 
1. Sudden Cardiac Death
2. Pump Failure Death
3. Survivor

REASONING:

This patient has a complex medical history, with a significant burden of cardiovascular risk factors, including ischemic dilated cardiomyopathy, peripheral vascular disease, and a history of myocardial infarction. The patient's current ECG findings also suggest a high risk for arrhythmias, with ventricular extrasystoles, non-sustained ventricular tachycardia, and a history of polymorphic ventricular extrasystoles.

The patient's low LVEF of 30.0% is a strong indicator of advanced left ventricular dysfunction, which increases the risk of pump failure. The patient's elevated creatinine level (123.0 mmol/L) also suggests impaired renal function, which can be associated with cardiac disease.

The patient's medications, including loop diuretics, spironolactone, and statins, suggest that the patient is being managed for heart failure and cardiovascular risk reduction. However, the patient's low hemoglobin level (129.0 g/L) and low albumin level (44.6 g/L) may indicate malnutrition or anemia, which can exacerbate cardiac disease.

Given these factors, the patient is at high risk for pump failure. However, the presence of ventricular tachycardia and non-sustained ventricular tachycardia on the ECG suggests a higher risk for sudden cardiac death. The patient's low T3 level (0.05 pg/dL) and high Pro-BNP level (2206.0 ng/L) also suggest a high risk for cardiac dysfunction and mortality.

Therefore, while pump failure is a significant concern, the patient's ECG findings and laboratory results suggest that sudden cardiac death is the most likely outcome over the next few years."
692,692,P0343,"Age: 63
Gender: Male 
Weight: 80 kg
Height: 174 cm
NYHA Class: II
Blood Pressure: 100/60 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Diabetes, Dyslipemia, Hypertension, Myocardial Infarction
Albumin (g/L): 42,4
ALT or GPT (IU/L): 22.0
AST or GOT (IU/L): 17.0
Total Cholesterol (mmol/L): 4,14
Creatinine (mmol/L): 112.0
Gamma-glutamil transpeptidase (IU/L): 30
Glucose (mmol/L): 8,9
Hemoglobin (g/L): 116.0
HDL (mmol/L): 0,98
Potassium (mEq/L): 4,6
LDL (mmol/L): 2,35
Sodium (mEq/L): 137.0
Pro-BNP (ng/L): 2125.0
Protein (g/L): 74
T3 (pg/dL): 0,02
T4 (ng/L): 11
Troponin (ng/mL): 0,01
TSH (mIU/L): 32,51
Urea (mg/dL): 6,45
LVEF (%): 40.0
Medications: Diabetes Medication, Amiodarone, Loop Diuretics, Statins, ACE Inhibitor, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: Parosysmal AF
        - Bradycardia: No
            ",sudden cardiac death,"RANKING: 
1. Sudden Cardiac Death
2. Pump Failure Death
3. Survivor

REASONING:

The patient's data indicates a high risk for sudden cardiac death. The presence of:

- A history of ischemic dilated cardiomyopathy, which is a condition where the heart's ability to pump blood is compromised due to damage to the heart muscle.
- A low LVEF of 40%, indicating poor heart function.
- Elevated Pro-BNP levels, which is a marker of ventricular dysfunction and heart failure.
- A history of myocardial infarction, which is a previous heart attack.
- The presence of ventricular extrasystole, a type of abnormal heart rhythm that can increase the risk of sudden cardiac death.

These factors, combined with the patient's age (63) and NYHA Class II, suggest that the patient is at high risk for cardiac events. While pump failure death is also a possible outcome, the presence of ventricular extrasystole and elevated Pro-BNP levels indicate a higher risk for sudden cardiac death. The patient's ECG impression of polymorphic ventricular extrasystole further supports this conclusion."
693,693,P0346,"Age: 78
Gender: Female 
Weight: 52 kg
Height: 150 cm
NYHA Class: II
Blood Pressure: 110/60 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Dyslipemia, Myocardial Infarction
Albumin (g/L): 48,09
ALT or GPT (IU/L): 10.0
AST or GOT (IU/L): 25.0
Total Cholesterol (mmol/L): 6,39
Creatinine (mmol/L): 139.0
Gamma-glutamil transpeptidase (IU/L): 79
Glucose (mmol/L): 4,9
Hemoglobin (g/L): 134.0
HDL (mmol/L): 1,37
Potassium (mEq/L): 4,7
LDL (mmol/L): 4,53
Sodium (mEq/L): 137.0
Pro-BNP (ng/L): 1990.0
Protein (g/L): 82
T3 (pg/dL): 0,05
T4 (ng/L): 18
Troponin (ng/mL): 0,01
TSH (mIU/L): 3,25
Urea (mg/dL): 12,69
LVEF (%): 24.0
Medications: Beta Blockers, Loop Diuretics, Spironolactone, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: TPSV
        - Bradycardia: No
            ",sudden cardiac death,"RANKING: 
1. Survivor
REASONING: 
The patient is 78 years old with a history of ischemic dilated cardiomyopathy, which is a condition that significantly reduces the heart's ability to pump blood effectively. The left ventricular ejection fraction (LVEF) is 24.0%, which is a critical indicator of heart function, and is below the normal range of 55-70%. The patient also has a history of myocardial infarction, which can lead to further cardiac damage and dysfunction.

The patient's current medication regimen includes beta blockers, loop diuretics, spironolactone, and an ACE inhibitor, which are commonly used to manage heart failure, high blood pressure, and cardiac arrhythmias. However, these medications alone may not be sufficient to reverse the underlying cardiac damage caused by the ischemic dilated cardiomyopathy.

The patient's laboratory results show elevated levels of N-terminal pro-b-type natriuretic peptide (Pro-BNP), which is a biomarker for heart failure, and elevated creatinine levels, which indicate impaired kidney function. The patient's hemoglobin and potassium levels are also within normal limits, but the patient's weight is low, which may indicate malnutrition or poor appetite.

The ECG results show ventricular extrasystoles, which are abnormal heart rhythms that can be a sign of cardiac damage. The absence of ventricular tachycardia or non-sustained ventricular tachycardia reduces the likelihood of sudden cardiac death. However, the presence of paroxysmal supraventricular tachycardia (PSVT) is a significant concern, as it can increase the risk of cardiac arrhythmias.

Considering these factors, the most likely outcome for the patient over the next few years is survival, as the patient is receiving appropriate treatment for heart failure and cardiac arrhythmias, and the patient's laboratory results are not indicative of acute cardiac damage. However, the patient's underlying cardiac condition and age increase the risk of cardiac complications, and the patient should be closely monitored for any signs of worsening heart failure or cardiac arrhythmias.

PROBABILITY OF EACH OUTCOME:

* Survivor: 70%
* Sudden cardiac death: 20%
* Pump failure death: 10%

Please note that these probabilities are estimates based on the provided data and should be interpreted with caution. A definitive prognosis can only be made after further evaluation and monitoring of the patient's condition."
694,694,P0349,"Age: 77
Gender: Female 
Weight: 82 kg
Height: 150 cm
NYHA Class: III
Blood Pressure: 140/80 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Diabetes, Dyslipemia, Peripheral vascular disease, Hypertension, Myocardial Infarction
Albumin (g/L): 38
ALT or GPT (IU/L): 108.0
AST or GOT (IU/L): 55.0
Total Cholesterol (mmol/L): 4,68
Creatinine (mmol/L): 118.0
Gamma-glutamil transpeptidase (IU/L): 35
Glucose (mmol/L): 15,5
Hemoglobin (g/L): 109.0
HDL (mmol/L): 1,5
Potassium (mEq/L): 5,4
LDL (mmol/L): 2,33
Sodium (mEq/L): 139.0
Pro-BNP (ng/L): 910.0
Protein (g/L): 66
T3 (pg/dL): 0,05
T4 (ng/L): 17
Troponin (ng/mL): 0,01
TSH (mIU/L): 4,43
Urea (mg/dL): 9,35
LVEF (%): 35.0
Medications: Diabetes Medication, Angiotensin II Receptor Blocker, Beta Blockers, Loop Diuretics, Statins
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",sudden cardiac death,"RANKING: 
1. Sudden cardiac death
2. Pump failure death
3. Survivor

REASONING:

Based on the provided patient data, the patient is at high risk for cardiac complications. The patient has a history of ischemic dilated cardiomyopathy, which is a significant risk factor for both sudden cardiac death and heart failure. The patient's left ventricular ejection fraction (LVEF) of 35% is severely reduced, indicating poor cardiac function.

The patient's high blood pressure (140/80 mmHg), diabetes, dyslipidemia, and peripheral vascular disease also contribute to the increased risk of cardiac events. The elevated troponin level (0.01 ng/mL) suggests some degree of myocardial injury, which may be related to the patient's ischemic dilated cardiomyopathy.

The patient's electrolyte levels, including potassium (5.4 mEq/L), are slightly elevated, which may be related to the use of loop diuretics. However, this is not a significant risk factor for sudden cardiac death or pump failure.

The Pro-BNP level (910 ng/L) is elevated, indicating fluid overload and heart failure, which is consistent with the patient's NYHA class III status. However, this does not necessarily indicate pump failure as the primary cause of death.

The ECG impression shows ventricular extrasystoles, which is a common finding in patients with heart failure. However, it is not a specific indicator of sudden cardiac death or pump failure.

Considering the combination of the patient's severe cardiac dysfunction (LVEF 35%), history of ischemic dilated cardiomyopathy, and elevated troponin level, I rank the patient's prognosis as follows:

1. Sudden cardiac death: The patient's severe cardiac dysfunction and history of ischemic dilated cardiomyopathy increase the risk of sudden cardiac death. The presence of ventricular extrasystoles on the ECG also supports this risk.
2. Pump failure death: The patient's NYHA class III status and elevated Pro-BNP level indicate fluid overload and heart failure, which can lead to pump failure. However, this is not the most likely cause of death given the patient's high risk of sudden cardiac death.
3. Survivor: While the patient's age and comorbidities may affect their overall prognosis, the combination of severe cardiac dysfunction and history of ischemic dilated cardiomyopathy make sudden cardiac death and pump failure more likely than survival."
695,695,P0351,"Age: 68
Gender: Male 
Weight: 73 kg
Height: 165 cm
NYHA Class: II
Blood Pressure: 120/90 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Diabetes, Dyslipemia, Hypertension, Myocardial Infarction
Albumin (g/L): 40,3
ALT or GPT (IU/L): 15.0
AST or GOT (IU/L): 25.0
Total Cholesterol (mmol/L): 3,98
Creatinine (mmol/L): 136.0
Gamma-glutamil transpeptidase (IU/L): 17
Glucose (mmol/L): 7
Hemoglobin (g/L): 142.0
HDL (mmol/L): 0,78
Potassium (mEq/L): 4,9
LDL (mmol/L): 2,04
Sodium (mEq/L): 140.0
Pro-BNP (ng/L): 934.0
Protein (g/L): 81
T3 (pg/dL): 0,04
T4 (ng/L): 18
Troponin (ng/mL): 0,01
TSH (mIU/L): 2,27
Urea (mg/dL): 14,25
LVEF (%): 30.0
Medications: Diabetes Medication, Beta Blockers, Statins, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",sudden cardiac death,"RANKING: 
1. Survivor
2. Pump failure death
3. Sudden cardiac death

REASONING:

The patient's prognosis can be determined based on their clinical presentation and laboratory results. Here's a breakdown of the reasoning behind the ranking:

1. Survivor (most likely): The patient's age (68) is not particularly high, and they have a relatively well-controlled comorbidity profile (NYHA Class II, controlled hypertension, diabetes, and dyslipidemia). Their medication regimen is also well-managed (Diabetes Medication, Beta Blockers, Statins, ACE Inhibitor). The patient's laboratory results show no signs of acute myocardial infarction (Troponin < 0.01 ng/mL), and their renal function is not severely impaired (Creatinine 136.0 mmol/L). Additionally, their cardiac function is not severely impaired (LVEF 30.0%), and they do not have any signs of acute cardiac stress (e.g., elevated Pro-BNP levels). These factors suggest that the patient is likely to survive the next few years.

2. Pump failure death (less likely): The patient's LVEF is significantly reduced (30.0%), indicating severe left ventricular dysfunction. This suggests that the patient's heart is already compromised, and there is a risk of progressive heart failure. However, the patient's current medication regimen and well-controlled comorbidities mitigate this risk to some extent.

3. Sudden cardiac death (least likely): The patient's ECG results show no signs of ventricular tachycardia or non-sustained ventricular tachycardia, which are common causes of sudden cardiac death. Additionally, the patient's troponin levels are normal, and there is no indication of acute myocardial infarction. While the patient's ventricular extrasystole is polymorphic, this is not a direct indicator of sudden cardiac death. Overall, the patient's clinical presentation and laboratory results do not suggest an immediate risk of sudden cardiac death.

It is essential to note that cardiac risk stratification is complex and can be influenced by various factors, including the patient's clinical history, ECG findings, and laboratory results. Regular follow-up and monitoring will be necessary to assess the patient's cardiac function and adjust the treatment plan accordingly."
696,696,P0356,"Age: 76
Gender: Male 
Weight: 82 kg
Height: 149 cm
NYHA Class: III
Blood Pressure: 110/60 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Diabetes, Dyslipemia, Myocardial Infarction
Albumin (g/L): 47,3
ALT or GPT (IU/L): 22.0
AST or GOT (IU/L): 19.0
Total Cholesterol (mmol/L): 5,61
Creatinine (mmol/L): 118.0
Gamma-glutamil transpeptidase (IU/L): 41
Glucose (mmol/L): 12
Hemoglobin (g/L): 169.0
HDL (mmol/L): 1,22
Potassium (mEq/L): 4,8
LDL (mmol/L): 3,31
Sodium (mEq/L): 138.0
Pro-BNP (ng/L): 4315.0
Protein (g/L): 80
T3 (pg/dL): 0,05
T4 (ng/L): 18
Troponin (ng/mL): 0,02
TSH (mIU/L): 1,04
Urea (mg/dL): 14,03
LVEF (%): 20.0
Medications: Diabetes Medication, Loop Diuretics, Spironolactone, Statins, ACE Inhibitor, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: Unknown bradycardia code
            ",sudden cardiac death,"RANKING: 1. Sudden Cardiac Death
REASONING: 
The patient's age, NYHA Class III, and history of ischemic dilated cardiomyopathy, myocardial infarction, and diabetes significantly increase the risk of cardiac complications. The elevated LVEF of 20.0 indicates severe left ventricular dysfunction, which is a strong predictor of adverse outcomes. The patient's elevated BNP level (4315.0 ng/L) suggests significant ventricular stress and potential heart failure. The presence of ventricular extrasystole on the ECG, although non-morphologic, indicates an increased risk of arrhythmias.

The patient's comorbidities, including hypertension, dyslipidemia, and diabetes, further exacerbate the risk of cardiac events. The use of medications such as spironolactone and ACE inhibitor suggests that the patient has heart failure and hypertension, respectively. The elevated creatinine level (118.0 mmol/L) indicates impaired renal function, which is often associated with heart failure.

The patient's low T3 level (0.05 pg/dL) may be indicative of hypothyroidism, which can contribute to heart failure and arrhythmias. The patient's low HDL level (1.22 mmol/L) and elevated triglycerides are also risk factors for cardiovascular disease.

Considering these factors, the patient's overall risk for sudden cardiac death is high. The patient's age, comorbidities, and ECG findings make it likely that the patient will experience a cardiac event, such as sudden cardiac death, in the near future.

RANKING: 2. Pump Failure Death
REASONING: 
The patient's severe left ventricular dysfunction (LVEF 20.0) and elevated BNP level (4315.0 ng/L) indicate a high risk of heart failure. The patient's NYHA Class III status and history of heart failure suggest that the patient is already experiencing significant cardiac dysfunction.

The patient's elevated creatinine level (118.0 mmol/L) and impaired renal function may indicate that the patient's kidneys are not functioning optimally, which can contribute to the development of heart failure. The use of spironolactone and ACE inhibitor suggests that the patient has heart failure, and the patient's low HDL level (1.22 mmol/L) and elevated triglycerides are risk factors for cardiovascular disease.

However, the patient's low T3 level (0.05 pg/dL) and hypothyroidism may mitigate the risk of heart failure to some extent. The patient's ECG findings, including ventricular extrasystole, do not indicate a high risk of sudden cardiac death.

RANKING: 3. Survivor
REASONING: 
While the patient's severe left ventricular dysfunction (LVEF 20.0) and elevated BNP level (4315.0 ng/L) indicate a high risk of heart failure, the patient's low T3 level (0.05 pg/dL) and hypothyroidism may mitigate this risk to some extent.

The patient's age (76) and comorbidities, including hypertension, dyslipidemia, and diabetes, increase the risk of cardiac complications. However, the patient's use of medications such as spironolactone and ACE inhibitor suggests that the patient is receiving optimal treatment for heart failure.

The patient's ECG findings, including ventricular extrasystole, indicate an increased risk of arrhythmias, but the absence of ventricular tachycardia or non-sustained ventricular tachycardia reduces the risk of sudden cardiac death.

Overall, while the patient's risk factors are significant, the patient's low T3 level and hypothyroidism may reduce the risk of heart failure, and the patient's ECG findings do not indicate a high risk of sudden cardiac death. Therefore, the patient is at a moderate risk for heart failure, but not the highest risk."
697,697,P0405,"Age: 37
Gender: Female 
Weight: 69 kg
Height: 160 cm
NYHA Class: II
Blood Pressure: 100/60 mmHg
Past Medical History: Idiopathic dilated cardiomyopathy
Albumin (g/L): 43
ALT or GPT (IU/L): 14.0
AST or GOT (IU/L): 16.0
Total Cholesterol (mmol/L): 6,13
Creatinine (mmol/L): 71.0
Gamma-glutamil transpeptidase (IU/L): 18
Glucose (mmol/L): 5,7
Hemoglobin (g/L): 148.0
HDL (mmol/L): 1,42
Potassium (mEq/L): 4,3
LDL (mmol/L): 4,14
Sodium (mEq/L): 134.0
Pro-BNP (ng/L): 853.0
Protein (g/L): 75
T3 (pg/dL): 0,05
T4 (ng/L): 15
Troponin (ng/mL): 0,005
TSH (mIU/L): 0,562
Urea (mg/dL): 4,49
LVEF (%): 23.0
Medications: Angiotensin II Receptor Blocker, Beta Blockers, Digoxin, Loop Diuretics, Spironolactone
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",sudden cardiac death,"RANKING: 
1. Survivor
2. Pump failure death
3. Sudden cardiac death

REASONING:

The patient's prognosis can be determined by analyzing the provided data. The patient has a history of idiopathic dilated cardiomyopathy, which is a significant risk factor for adverse outcomes. The left ventricular ejection fraction (LVEF) of 23.0% is severely impaired, indicating poor cardiac function.

The patient's serum creatinine level of 71.0 mol/L is elevated, suggesting some degree of renal impairment. However, the patient is not on dialysis, which is a good sign.

The patient's electrolyte levels are relatively normal, with a potassium level of 4.3 mmol/L. The patient's troponin level is 0.005 ng/mL, which is within normal limits.

The patient is on medications that are commonly used in heart failure management, including angiotensin II receptor blockers, beta blockers, digoxin, loop diuretics, and spironolactone. These medications can help manage symptoms and slow disease progression.

The ECG impression highlights the presence of ventricular extrasystole, polymorphic ventricular tachycardia, and non-sustained ventricular tachycardia. However, the absence of sustained ventricular tachycardia and paroxysmal supraventricular tachyarrhythmia is a positive sign.

Considering these factors, the patient is at high risk for pump failure death, but the absence of sustained ventricular tachycardia and the patient's relatively normal electrolyte levels and troponin levels reduce the likelihood of sudden cardiac death. Therefore, the most likely outcome is pump failure death.

However, given the patient's severe LVEF impairment and the presence of ventricular extrasystole, polymorphic ventricular tachycardia, and non-sustained ventricular tachycardia, sudden cardiac death cannot be ruled out entirely. Therefore, I would rank the prognoses as follows:

1. Pump failure death (most likely)
2. Sudden cardiac death (least likely)

Please note that this is a hypothetical prognosis, and actual outcomes may vary based on individual patient factors and the discretion of the treating physician."
698,698,P0409,"Age: 64
Gender: Male 
Weight: 89 kg
Height: 165 cm
NYHA Class: II
Blood Pressure: 145/85 mmHg
Past Medical History: Hypertensive cardiomyopathy, Hypertension
Albumin (g/L): 41
ALT or GPT (IU/L): 78.0
AST or GOT (IU/L): 15.0
Total Cholesterol (mmol/L): 5,66
Creatinine (mmol/L): 106.0
Gamma-glutamil transpeptidase (IU/L): 29
Glucose (mmol/L): 5,6
Hemoglobin (g/L): 170.0
HDL (mmol/L): 0,93
Potassium (mEq/L): 4,6
LDL (mmol/L): 4,06
Sodium (mEq/L): 143.0
Protein (g/L): 68
T3 (pg/dL): 0,03
T4 (ng/L): 24
Troponin (ng/mL): 0,02
TSH (mIU/L): 3,4
Urea (mg/dL): 8,65
LVEF (%): 65.0
Medications: Calcium Channel Blocker, Digoxin, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Unknown ventricular extrasystole code
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: Paroxismal flutter
        - Bradycardia: No
            ",sudden cardiac death,"RANKING: 
1. Survivor 
REASONING: 
The patient's age, NYHA Class II, and the presence of hypertension and hypertensive cardiomyopathy suggest a significant burden of cardiovascular disease. However, the patient's ejection fraction (LVEF) is 65%, which is still within the normal range, indicating that the heart is not severely impaired. The patient's blood pressure is well-controlled with a calcium channel blocker and ACE inhibitor, which reduces the risk of further cardiovascular events. Additionally, the patient's troponin levels are normal, and the TSH level is within the normal range, indicating no signs of cardiac strain or thyroid dysfunction. The presence of non-sustained ventricular tachycardia and paroxysmal flutter on the ECG suggests some arrhythmic risk, but it is not severe. Therefore, based on these factors, the patient is likely to survive for the next few years with proper management and monitoring.

RANKING: 
2. Pump failure death 
REASONING: 
The patient's LVEF is 65%, which is slightly below the normal range, indicating some degree of left ventricular dysfunction. The patient's hypertension and hypertensive cardiomyopathy may further exacerbate this condition, increasing the risk of heart failure. Although the patient's blood pressure is well-controlled, the presence of non-sustained ventricular tachycardia and paroxysmal flutter on the ECG suggests some arrhythmic risk, which could potentially lead to pump failure. Additionally, the patient's elevated creatinine level (106.0 mmol/L) indicates some degree of kidney dysfunction, which can be a marker of cardiac stress and potential heart failure. Therefore, while the patient is not at high risk, pump failure is a possible outcome.

RANKING: 
3. Sudden cardiac death 
REASONING: 
The patient's ECG shows non-sustained ventricular tachycardia and paroxysmal flutter, which are significant arrhythmic risks. The presence of these arrhythmias increases the risk of sudden cardiac death, especially in a patient with a history of hypertension and hypertensive cardiomyopathy. Although the patient's LVEF is 65%, the presence of non-sustained ventricular tachycardia and paroxysmal flutter on the ECG suggests that the patient is at increased risk of arrhythmic events, including sudden cardiac death. Therefore, while not the most likely outcome, sudden cardiac death is a possible outcome for this patient."
699,699,P0416,"Age: 46
Gender: Male 
Weight: 77 kg
Height: 174 cm
NYHA Class: II
Blood Pressure: 105/70 mmHg
Past Medical History: Idiopathic dilated cardiomyopathy
Albumin (g/L): 48
ALT or GPT (IU/L): 51.0
AST or GOT (IU/L): 32.0
Total Cholesterol (mmol/L): 5,38
Creatinine (mmol/L): 115.0
Gamma-glutamil transpeptidase (IU/L): 25
Glucose (mmol/L): 8
Hemoglobin (g/L): 158.0
HDL (mmol/L): 1,16
Potassium (mEq/L): 4,7
LDL (mmol/L): 3,41
Sodium (mEq/L): 135.0
Pro-BNP (ng/L): 247.0
Protein (g/L): 79
T3 (pg/dL): 0,05
T4 (ng/L): 21
Troponin (ng/mL): 0,12
TSH (mIU/L): 3,63
Urea (mg/dL): 6,32
LVEF (%): 30.0
Medications: Diabetes Medication, Amiodarone, Beta Blockers, Digoxin, Loop Diuretics, Spironolactone, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",sudden cardiac death,"RANKING: 
1. Sudden cardiac death
2. Pump failure death
3. Survivor

REASONING:

Based on the patient data, I would rank the prognoses from most likely to least likely as follows:

1. Sudden cardiac death: The patient's ECG impression shows ventricular extrasystole (polymorphic) and non-sustained ventricular tachycardia (NSVT), which are both indicators of arrhythmic risk. The presence of ventricular extrasystole, in particular, is a significant predictor of sudden cardiac death in patients with heart failure. Additionally, the patient's low LVEF (30%) and elevated troponin levels suggest significant cardiac dysfunction, which increases the risk of arrhythmic events. The patient's age, NYHA Class II, and history of idiopathic dilated cardiomyopathy also contribute to the increased risk.

2. Pump failure death: While the patient's LVEF is significantly impaired (30%), the presence of ventricular extrasystole and NSVT on the ECG suggests a higher risk of arrhythmic events, which could lead to sudden cardiac death. However, pump failure death is still a possible outcome, especially given the patient's low LVEF and elevated creatinine levels. The patient's elevated BNP levels (247 ng/L) also suggest fluid overload, which could contribute to heart failure.

3. Survivor: While the patient's age and NYHA Class II suggest some residual functional capacity, the presence of ventricular extrasystole and NSVT on the ECG, as well as the significant cardiac dysfunction (low LVEF and elevated troponin), make it less likely that the patient will survive without any significant cardiac events. However, without further information on the patient's overall health, comorbidities, and response to current medications, it is difficult to rule out survival entirely.

It is essential to note that this prognosis is based on the information provided and may not accurately reflect the patient's actual outcome. Regular monitoring and adjustment of medications, as well as further diagnostic testing, may be necessary to optimize the patient's management and improve their prognosis."
700,700,P0438,"Age: 65
Gender: Male 
Weight: 79 kg
Height: 162 cm
NYHA Class: II
Blood Pressure: 115/80 mmHg
Past Medical History: Idiopathic dilated cardiomyopathy, Dyslipemia, Hypertension, Myocardial Infarction
Albumin (g/L): 49,6
ALT or GPT (IU/L): 18.0
AST or GOT (IU/L): 26.0
Total Cholesterol (mmol/L): 4,68
Creatinine (mmol/L): 149.0
Gamma-glutamil transpeptidase (IU/L): 14
Glucose (mmol/L): 4,9
Hemoglobin (g/L): 134.0
HDL (mmol/L): 1,11
Potassium (mEq/L): 4,6
LDL (mmol/L): 2,82
Sodium (mEq/L): 142.0
Pro-BNP (ng/L): 1114.0
Protein (g/L): 76,9
T4 (ng/L): 16
TSH (mIU/L): 0,86
Urea (mg/dL): 8,99
LVEF (%): 25.0
Medications: Beta Blockers, Loop Diuretics, Spironolactone, Statins, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",sudden cardiac death,"RANKING: 
1. Survivor
2. Pump failure death
3. Sudden cardiac death

REASONING:

The patient's prognosis is determined by their underlying heart condition, medical history, and laboratory results. 

The patient has a history of idiopathic dilated cardiomyopathy, which is a condition where the heart muscle becomes weak and the heart chambers become enlarged. This condition is a significant risk factor for sudden cardiac death. The patient's left ventricular ejection fraction (LVEF) of 25% is also a strong indicator of poor heart function, which further increases the risk of sudden cardiac death.

The patient's elevated BNP levels (1114.0 ng/L) suggest that the heart is working hard to pump blood, which can lead to cardiac fatigue and increased risk of arrhythmias, including ventricular tachycardia and ventricular extrasystole. The presence of ventricular extrasystole and non-sustained ventricular tachycardia (VT) on the ECG also support this concern.

While the patient is taking medications such as beta blockers, loop diuretics, spironolactone, statins, and an ACE inhibitor, these medications are primarily aimed at managing symptoms and slowing the progression of heart failure, rather than addressing the underlying cardiomyopathy.

Given the patient's poor heart function, elevated BNP levels, and presence of arrhythmias on the ECG, the most likely outcome is pump failure death. Sudden cardiac death is a possible but less likely outcome in this scenario, as the patient's ECG shows no sustained VT. Survivorship is the least likely outcome due to the patient's significant underlying heart condition and poor heart function.

However, it's essential to note that the prognosis can change over time, and the patient's outcome may be influenced by various factors, including the effectiveness of their treatment plan, lifestyle changes, and any potential complications."
701,701,P0468,"Age: 69
Gender: Male 
Weight: 81 kg
Height: 167 cm
NYHA Class: II
Blood Pressure: 140/70 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Diabetes, Dyslipemia, Peripheral vascular disease, Hypertension, Myocardial Infarction
Albumin (g/L): 40
ALT or GPT (IU/L): 10.0
AST or GOT (IU/L): 10.0
Total Cholesterol (mmol/L): 2,77
Creatinine (mmol/L): 159.0
Gamma-glutamil transpeptidase (IU/L): 34
Glucose (mmol/L): 5
Hemoglobin (g/L): 109.0
HDL (mmol/L): 0,93
Potassium (mEq/L): 5,2
LDL (mmol/L): 1,32
Sodium (mEq/L): 140.0
Pro-BNP (ng/L): 7519.0
Protein (g/L): 68,6
T3 (pg/dL): 0,0342
T4 (ng/L): 12,35
Troponin (ng/mL): 0,6
TSH (mIU/L): 5,19
Urea (mg/dL): 10,5
LVEF (%): 35.0
Medications: Beta Blockers, Statins
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",sudden cardiac death,"RANKING: 
1. Sudden cardiac death
2. Pump failure death
3. Survivor

REASONING:

Based on the patient's data, I have assessed the following factors to predict the patient's outcome:

1. LVEF (Left Ventricular Ejection Fraction): The patient's LVEF is significantly reduced at 35.0%, indicating severe left ventricular dysfunction, which is a strong predictor of adverse outcomes. A reduced LVEF is associated with increased risk of heart failure, arrhythmias, and sudden cardiac death.

2. Pro-BNP (N-terminal pro b-type natriuretic peptide): The patient's Pro-BNP level is elevated at 7519.0 ng/L, indicating significant ventricular strain and stress, which is a marker of heart failure and increased risk of adverse outcomes.

3. Past Medical History: The patient has a history of ischemic dilated cardiomyopathy, diabetes, dyslipemia, peripheral vascular disease, hypertension, and myocardial infarction, which are all risk factors for cardiovascular disease and increased risk of sudden cardiac death.

4. ECG Impression: The patient has a history of ventricular extrasystoles, which is a marker of ventricular irritability and increased risk of arrhythmias. Although the patient does not have any other arrhythmias, the presence of ventricular extrasystoles suggests an increased risk of arrhythmias.

Considering these factors, the patient is at high risk for sudden cardiac death due to the combination of severe left ventricular dysfunction, elevated Pro-BNP levels, and a history of cardiovascular disease. While pump failure death is also a possible outcome due to the patient's reduced LVEF, it is less likely given the patient's relatively stable hemodynamic parameters (e.g., blood pressure, creatinine levels). Survivor is the least likely outcome given the patient's severe left ventricular dysfunction and elevated Pro-BNP levels.

Therefore, based on the provided data, I predict that the patient is at high risk for sudden cardiac death, followed by pump failure death, and then survival."
702,702,P0482,"Age: 60
Gender: Male 
Weight: 107 kg
Height: 181 cm
NYHA Class: III
Blood Pressure: 145/80 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Dyslipemia, Myocardial Infarction
Albumin (g/L): 39,9
ALT or GPT (IU/L): 32.0
AST or GOT (IU/L): 24.0
Total Cholesterol (mmol/L): 6,44
Creatinine (mmol/L): 143.0
Gamma-glutamil transpeptidase (IU/L): 29
Glucose (mmol/L): 5,7
Hemoglobin (g/L): 127.0
HDL (mmol/L): 0,98
Potassium (mEq/L): 5,2
LDL (mmol/L): 4,09
Sodium (mEq/L): 141.0
Pro-BNP (ng/L): 1742.0
Protein (g/L): 67,9
T4 (ng/L): 12
TSH (mIU/L): 1,28
Urea (mg/dL): 10,98
LVEF (%): 15.0
Medications: Beta Blockers, Digoxin, Loop Diuretics, Spironolactone, Statins, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: TPSV
        - Bradycardia: No
            ",sudden cardiac death,"RANKING: 1. Sudden Cardiac Death
REASONING: 

Based on the provided patient data, I predict that the patient is at high risk of sudden cardiac death within the next few years. The patient has a history of ischemic dilated cardiomyopathy, which is a significant risk factor for sudden cardiac death. The patient's LVEF of 15.0% is severely impaired, indicating poor cardiac function. Additionally, the presence of ventricular extrasystoles, non-sustained ventricular tachycardia, and paroxysmal supraventricular tachyarrhythmia on the ECG impression suggests an increased risk of arrhythmias.

The patient's elevated creatinine level (143.0 mmol/L) and elevated BNP levels (1742.0 ng/L) also suggest compromised cardiac function and fluid overload, which can contribute to an increased risk of sudden cardiac death.

The patient's medications, including beta blockers, digoxin, and ACE inhibitors, may help to reduce the risk of sudden cardiac death, but the presence of non-sustained ventricular tachycardia and other arrhythmias on the ECG impression suggests that these medications may not be sufficient to completely mitigate the risk.

While the patient's age, weight, and other laboratory values do not provide clear evidence of an increased risk, the combination of their cardiac history, ECG findings, and medication regimen suggests that the patient is at high risk of sudden cardiac death.

RANKING: 2. Pump Failure Death
REASONING: 

Given the patient's severely impaired LVEF of 15.0%, it is likely that the patient will experience pump failure within the next few years. The patient's elevated creatinine level (143.0 mmol/L) and elevated BNP levels (1742.0 ng/L) also suggest that the patient's kidneys are not functioning optimally, which can contribute to an increased risk of pump failure.

The patient's history of ischemic dilated cardiomyopathy and dyslipidemia also increases the risk of pump failure. The patient's medications, including beta blockers and ACE inhibitors, may help to reduce the risk of pump failure, but the presence of ventricular extrasystoles and other arrhythmias on the ECG impression suggests that the patient's cardiac function is compromised.

RANKING: 3. Survivor
REASONING: 

While the patient's age, weight, and other laboratory values do not provide clear evidence of an increased risk, the patient's severely impaired LVEF and history of ischemic dilated cardiomyopathy suggest that the patient's cardiac function is compromised. However, the patient's medications, including beta blockers and ACE inhibitors, may help to reduce the risk of cardiac complications.

The patient's ECG findings, including ventricular extrasystoles and non-sustained ventricular tachycardia, suggest that the patient is at risk of arrhythmias, which can increase the risk of sudden cardiac death. However, the patient's overall prognosis is still relatively guarded due to their severely impaired LVEF and history of cardiac disease.

It is difficult to predict the patient's long-term outcome with certainty, but based on the provided data, I believe that pump failure is a more likely outcome than sudden cardiac death or survivor."
703,703,P0494,"Age: 71
Gender: Male 
Weight: 82 kg
Height: 167 cm
NYHA Class: II
Blood Pressure: 130/80 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Dyslipemia, Myocardial Infarction
Albumin (g/L): 39
ALT or GPT (IU/L): 44.0
AST or GOT (IU/L): 26.0
Total Cholesterol (mmol/L): 3,8
Creatinine (mmol/L): 71.0
Gamma-glutamil transpeptidase (IU/L): 84
Glucose (mmol/L): 5,7
Hemoglobin (g/L): 161.0
HDL (mmol/L): 1,14
Potassium (mEq/L): 4,2
LDL (mmol/L): 2,25
Sodium (mEq/L): 139.0
Pro-BNP (ng/L): 224.0
Protein (g/L): 68
T4 (ng/L): 10
Troponin (ng/mL): 0,02
TSH (mIU/L): 3
Urea (mg/dL): 6,66
LVEF (%): 42.0
Medications: Beta Blockers, Statins, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: TPSV
        - Bradycardia: No
            ",sudden cardiac death,"RANKING: 
1. Sudden cardiac death
REASONING:
The patient's ECG impression reveals a high risk for arrhythmias, with ventricular extrasystoles, non-sustained ventricular tachycardia, and non-sustained ventricular tachycardia. The presence of polymorphic ventricular extrasystoles and non-sustained ventricular tachycardia indicates an increased risk of ventricular arrhythmias, which is a major risk factor for sudden cardiac death. Additionally, the patient's history of ischemic dilated cardiomyopathy and myocardial infarction further increases the risk of arrhythmias and cardiac complications.

While the patient's NYHA class II indicates some limitation in physical activity, the presence of ventricular arrhythmias and other cardiac risk factors suggests a higher risk for sudden cardiac death. The patient's age, weight, and other laboratory values do not significantly alter the risk assessment.

In contrast, pump failure death is less likely due to the patient's relatively preserved LVEF (42%) and the absence of significant evidence of heart failure. Survivorship is also less likely given the patient's high risk for arrhythmias and cardiac complications.

Therefore, the most likely outcome for the patient over the next few years is sudden cardiac death."
704,704,P0498,"Age: 80
Gender: Female 
Weight: 53 kg
Height: 155 cm
NYHA Class: II
Blood Pressure: 120/70 mmHg
Past Medical History: Idiopathic dilated cardiomyopathy, Hypertension
Albumin (g/L): 38,1
ALT or GPT (IU/L): 24.0
AST or GOT (IU/L): 25.0
Total Cholesterol (mmol/L): 4,25
Creatinine (mmol/L): 131.0
Gamma-glutamil transpeptidase (IU/L): 15
Glucose (mmol/L): 6
Hemoglobin (g/L): 119.0
Potassium (mEq/L): 4,56
Sodium (mEq/L): 139.0
Protein (g/L): 71,1
Troponin (ng/mL): 0,01
TSH (mIU/L): 0,63
Urea (mg/dL): 13,4
LVEF (%): 18.0
Medications: Amiodarone, Digoxin, Loop Diuretics, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",sudden cardiac death,"RANKING: 1. Survivor
REASONING: 
The patient is 80 years old with a history of idiopathic dilated cardiomyopathy, which is a condition that affects the heart's ability to pump blood effectively. The patient's left ventricular ejection fraction (LVEF) is 18.0%, which is significantly below the normal range, indicating poor heart function. The patient's blood pressure is within a relatively normal range, but their creatinine level is elevated, suggesting some degree of kidney impairment. The patient is also taking medications such as Amiodarone, Digoxin, and Loop Diuretics, which are commonly used to manage heart failure and arrhythmias.

The patient's ECG impression shows ventricular extrasystoles, non-sustained ventricular tachycardia, and non-sustained ventricular tachycardia, which are all signs of arrhythmias that can increase the risk of sudden cardiac death. However, the presence of non-sustained ventricular tachycardia (CH>10) is particularly concerning, as it suggests a higher risk of arrhythmia-related complications.

Despite these factors, the patient's age, weight, and hemoglobin level are relatively stable, and the patient is not in acute distress. The patient's troponin level is within normal limits, and the ECG impression does not indicate any acute coronary syndrome. Therefore, I would rank the patient as having a moderate to high risk of arrhythmia-related complications, but the patient's overall condition is not acute, and the patient is not in immediate danger of sudden cardiac death.

RANKING: 2. Pump failure death
REASONING: 
Given the patient's poor LVEF and elevated creatinine level, the patient is at risk of heart failure, which can lead to pump failure. The patient's NYHA class is II, indicating moderate symptoms of heart failure, which increases the risk of pump failure. The patient's medications, including Loop Diuretics, suggest an attempt to manage heart failure symptoms, but the patient's condition is not responding well to treatment.

However, the patient's ECG impression does not indicate any acute coronary syndrome, and the patient's troponin level is within normal limits, which reduces the risk of myocardial infarction. The patient's arrhythmia risk is also relatively moderate, but the presence of non-sustained ventricular tachycardia increases the risk of arrhythmia-related complications.

RANKING: 3. Sudden cardiac death
REASONING: 
The patient's ECG impression shows ventricular extrasystoles, non-sustained ventricular tachycardia, and non-sustained ventricular tachycardia, which are all signs of arrhythmias that can increase the risk of sudden cardiac death. However, the patient's overall condition is not acute, and the patient is not in immediate danger of sudden cardiac death. The patient's arrhythmia risk is relatively moderate, and the patient's pump failure risk is also moderate.

The patient's age and weight are relatively stable, and the patient is not in acute distress. The patient's troponin level is within normal limits, and the ECG impression does not indicate any acute coronary syndrome. However, the patient's LVEF is severely impaired, and the patient's NYHA class is II, which increases the risk of arrhythmia-related complications. Therefore, while the patient is at risk of arrhythmia-related complications, the patient's overall condition is not as severe as pump failure, and the patient is not at high risk of sudden cardiac death."
705,705,P0504,"Age: 78
Gender: Male 
Weight: 75 kg
Height: 159 cm
NYHA Class: II
Blood Pressure: 140/70 mmHg
Past Medical History: Enolic dilated cardiomyopathy
Albumin (g/L): 42
ALT or GPT (IU/L): 19.0
AST or GOT (IU/L): 24.0
Total Cholesterol (mmol/L): 7,03
Creatinine (mmol/L): 120.0
Gamma-glutamil transpeptidase (IU/L): 34
Glucose (mmol/L): 5,7
Hemoglobin (g/L): 127.0
HDL (mmol/L): 1,86
Potassium (mEq/L): 4,84
LDL (mmol/L): 4,73
Sodium (mEq/L): 139.0
Protein (g/L): 67,3
T3 (pg/dL): 0,0483
T4 (ng/L): 16,58
Troponin (ng/mL): 0,5
TSH (mIU/L): 0,67
Urea (mg/dL): 10
LVEF (%): 34.0
Medications: Angiotensin II Receptor Blocker, Loop Diuretics, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",sudden cardiac death,"RANKING: 
1. Sudden Cardiac Death
2. Pump Failure Death
3. Survivor

REASONING:

The patient's prognosis is primarily influenced by their underlying condition of dilated cardiomyopathy, which is a significant risk factor for sudden cardiac death and pump failure. The patient's left ventricular ejection fraction (LVEF) of 34.0% further indicates severe left ventricular dysfunction, which is consistent with heart failure.

The patient's ECG findings of ventricular extrasystole, a type of abnormal heart rhythm, also increase the risk of sudden cardiac death. Although the patient has been prescribed medications for their condition, including an Angiotensin II Receptor Blocker and ACE Inhibitor, which can help manage symptoms and slow disease progression, the presence of ventricular extrasystole suggests that the patient's heart is still at risk for arrhythmias.

In contrast, pump failure death is a possible outcome for patients with severe left ventricular dysfunction, but the patient's current medication regimen and the absence of other indicators of heart failure (e.g., no mention of edema, shortness of breath) suggest that pump failure may not be imminent.

The patient's age, NYHA Class II, and other laboratory results, such as the elevated creatinine level, suggest that the patient has multiple comorbidities, which can increase the risk of mortality. However, the presence of ventricular extrasystole and the patient's underlying condition of dilated cardiomyopathy make sudden cardiac death the most likely outcome.

Therefore, based on the provided data, I rank the prognoses as follows: sudden cardiac death is the most likely outcome, followed by pump failure death, and finally survivor."
706,706,P0520,"Age: 67
Gender: Male 
Weight: 63 kg
Height: 158 cm
NYHA Class: III
Blood Pressure: 90/60 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Diabetes, Dyslipemia, Hypertension
Albumin (g/L): 42,4
ALT or GPT (IU/L): 22.0
AST or GOT (IU/L): 14.0
Total Cholesterol (mmol/L): 3,7
Creatinine (mmol/L): 135.0
Gamma-glutamil transpeptidase (IU/L): 56
Glucose (mmol/L): 7,2
Hemoglobin (g/L): 98.0
HDL (mmol/L): 0,83
Potassium (mEq/L): 3,6
LDL (mmol/L): 1,27
Sodium (mEq/L): 139.0
Pro-BNP (ng/L): 6274.0
Protein (g/L): 68
T3 (pg/dL): 0,04
T4 (ng/L): 18
Troponin (ng/mL): 0,04
TSH (mIU/L): 1,31
Urea (mg/dL): 11,13
LVEF (%): 23.0
Medications: Diabetes Medication, Loop Diuretics, Spironolactone, Statins, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",sudden cardiac death,"RANKING: 
1. Survivor
2. Sudden Cardiac Death
3. Pump Failure Death

REASONING:

The patient's overall clinical presentation and test results indicate a high risk of adverse outcomes. Here's a breakdown of the factors contributing to this ranking:

1. LVEF of 23%: This is a significant reduction in left ventricular ejection fraction, indicating severe left ventricular dysfunction, which is a major risk factor for heart failure and sudden cardiac death.

2. NYHA Class III: This indicates severe symptoms of heart failure, which further supports the risk of pump failure.

3. Past Medical History of Ischemic Dilated Cardiomyopathy: This condition is a significant risk factor for both sudden cardiac death and heart failure.

4. Pro-BNP levels of 6274.0 ng/L: Elevated B-type natriuretic peptide (BNP) levels are indicative of heart failure and are associated with a higher risk of adverse outcomes.

5. ECG findings of Ventricular Extrasystole, Non-sustained VT, and Non-sustained ventricular tachycardia (CH>10): These arrhythmias increase the risk of sudden cardiac death.

6. Low T3 levels (0.04 pg/dL): Hypothyroidism is often associated with heart failure and can worsen cardiac function.

7. Medications: The presence of multiple medications, including ACE inhibitors, loop diuretics, and spironolactone, indicates a treatment plan for heart failure and hypertension, but may also contribute to potential side effects and interactions.

Given these factors, the patient is at high risk for pump failure and sudden cardiac death. While the patient may survive, the likelihood of pump failure is higher due to the severity of their heart failure and the presence of arrhythmias. Therefore, I would rank pump failure death as the most likely outcome, followed by sudden cardiac death, and finally survivor."
707,707,P0533,"Age: 50
Gender: Male 
Weight: 76 kg
Height: 165 cm
NYHA Class: III
Blood Pressure: 90/50 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Dyslipemia, Myocardial Infarction
Albumin (g/L): 42,5
ALT or GPT (IU/L): 30.0
AST or GOT (IU/L): 24.0
Total Cholesterol (mmol/L): 4,81
Creatinine (mmol/L): 101.0
Gamma-glutamil transpeptidase (IU/L): 27
Glucose (mmol/L): 4,7
Hemoglobin (g/L): 150.0
HDL (mmol/L): 1,5
Potassium (mEq/L): 4,3
LDL (mmol/L): 2,72
Sodium (mEq/L): 139.0
Pro-BNP (ng/L): 86.0
Protein (g/L): 82
T3 (pg/dL): 0,04
T4 (ng/L): 15
Troponin (ng/mL): 0,01
TSH (mIU/L): 2,58
Urea (mg/dL): 6,91
LVEF (%): 38.0
Medications: Calcium Channel Blocker, Beta Blockers, Statins, ACE Inhibitor, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",sudden cardiac death,"RANKING: 1. Sudden Cardiac Death
REASONING: The patient's ECG impression shows a high risk of arrhythmias, including ventricular extrasystoles, non-sustained ventricular tachycardia, and non-sustained ventricular tachycardia, which are all indicators of an increased risk of sudden cardiac death. Additionally, the patient's history of ischemic dilated cardiomyopathy, myocardial infarction, and NYHA Class III heart failure further increases the risk of arrhythmias and sudden cardiac death. The patient's low ejection fraction (LVEF) of 38.0% also suggests significant cardiac dysfunction, which can contribute to the risk of arrhythmias. The presence of ventricular extrasystoles and non-sustained ventricular tachycardia on the ECG is particularly concerning, as it suggests an increased risk of ventricular fibrillation or ventricular tachycardia, which can lead to sudden cardiac death. The patient's medications, including beta blockers, ACE inhibitors, and statins, may help to reduce the risk of arrhythmias, but the presence of these arrhythmias on the ECG suggests that the patient is still at high risk of sudden cardiac death. 

RANKING: 2. Pump Failure Death
REASONING: Pump failure death is a possible outcome for patients with severe heart failure, as indicated by the patient's NYHA Class III heart failure. The patient's low ejection fraction (LVEF) of 38.0% suggests significant cardiac dysfunction, which can lead to pump failure. The patient's history of ischemic dilated cardiomyopathy and myocardial infarction also increases the risk of pump failure. The patient's elevated creatinine level (101.0 mmol/L) and urea level (6.91 mg/dL) suggest impaired renal function, which can be a complication of heart failure. However, the presence of ventricular arrhythmias on the ECG and the patient's history of myocardial infarction and ischemic dilated cardiomyopathy make pump failure death a less likely outcome compared to sudden cardiac death.

RANKING: 3. Survivor
REASONING: While the patient's heart failure symptoms and cardiac dysfunction increase the risk of complications, the patient's medications, including beta blockers and ACE inhibitors, can help to reduce the risk of heart failure progression. The patient's low troponin level (0.01 ng/mL) and normal liver enzymes (ALT and AST) suggest that there is no acute myocardial injury, which is a good sign. The patient's low T3 level (0.04 pg/dL) and normal thyroid function tests (TSH) suggest that there is no thyroid dysfunction, which can contribute to heart failure. However, the patient's history of ischemic dilated cardiomyopathy, myocardial infarction, and ventricular arrhythmias on the ECG increase the risk of complications, making survival a less likely outcome compared to sudden cardiac death and pump failure death."
708,708,P0539,"Age: 64
Gender: Male 
Weight: 85 kg
Height: 160 cm
NYHA Class: II
Blood Pressure: 160/90 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Diabetes, Dyslipemia, Hypertension, Myocardial Infarction
Albumin (g/L): 38,4
ALT or GPT (IU/L): 35.0
AST or GOT (IU/L): 23.0
Total Cholesterol (mmol/L): 4,14
Creatinine (mmol/L): 112.0
Gamma-glutamil transpeptidase (IU/L): 27
Glucose (mmol/L): 8,5
Hemoglobin (g/L): 150.0
HDL (mmol/L): 0,85
Potassium (mEq/L): 4,8
LDL (mmol/L): 1,99
Sodium (mEq/L): 137.0
Pro-BNP (ng/L): 339.0
Protein (g/L): 78
T3 (pg/dL): 0,05
T4 (ng/L): 20
Troponin (ng/mL): 0,01
TSH (mIU/L): 1,25
Urea (mg/dL): 9,13
LVEF (%): 60.0
Medications: Calcium Channel Blocker, Diabetes Medication, Angiotensin II Receptor Blocker, Beta Blockers, Statins, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",sudden cardiac death,"RANKING: 
1. Survivor
REASONING: 
Based on the provided patient data, the patient has a history of ischemic dilated cardiomyopathy, hypertension, diabetes, dyslipemia, and myocardial infarction. The patient's current NYHA Class II indicates moderate symptoms, and their LVEF is 60%, which is within the range of patients with mild to moderate heart failure. The patient's ECG impression does not show any life-threatening arrhythmias, and their troponin levels are within normal limits.

Despite these factors, the patient's elevated creatinine level (112.0 mmol/L) and elevated BNP (339.0 ng/L) levels suggest that the patient may have some degree of heart failure. However, the patient's medication regimen includes an angiotensin II receptor blocker, beta blockers, and statins, which are commonly used to manage heart failure and cardiovascular risk factors.

Given the patient's age (64 years), weight (85 kg), and other comorbidities, the patient is at increased risk for cardiovascular events. However, the fact that the patient's ECG impression does not show any life-threatening arrhythmias, and their troponin levels are within normal limits, suggest that the patient is not at high risk for sudden cardiac death.

Therefore, I would rank the patient as having a high likelihood of survival over the next few years, with a moderate to high risk of cardiovascular events.

2. Sudden cardiac death
REASONING: 
The patient's elevated BNP levels (339.0 ng/L) and elevated creatinine level (112.0 mmol/L) suggest that the patient may have some degree of heart failure. However, the patient's ECG impression does not show any life-threatening arrhythmias, and their troponin levels are within normal limits.

While the patient's elevated BNP levels do indicate some degree of heart failure, the patient's medication regimen includes an angiotensin II receptor blocker, beta blockers, and statins, which are commonly used to manage heart failure and cardiovascular risk factors. Additionally, the patient's LVEF is 60%, which is within the range of patients with mild to moderate heart failure.

However, the patient's history of myocardial infarction and hypertension may increase the risk for cardiovascular events, including sudden cardiac death. Therefore, while the patient is not at high risk, they are at some risk for sudden cardiac death.

3. Pump failure death
REASONING: 
Given the patient's elevated BNP levels (339.0 ng/L) and elevated creatinine level (112.0 mmol/L), it is possible that the patient may experience pump failure over the next few years. However, the patient's LVEF is 60%, which is within the range of patients with mild to moderate heart failure.

The patient's medication regimen includes an angiotensin II receptor blocker, beta blockers, and statins, which are commonly used to manage heart failure and cardiovascular risk factors. Additionally, the patient's ECG impression does not show any life-threatening arrhythmias, and their troponin levels are within normal limits.

However, the patient's history of myocardial infarction and hypertension may increase the risk for cardiovascular events, including pump failure. Therefore, while the patient is not at high risk, they are at some risk for pump failure.

It is worth noting that the patient's overall risk of pump failure is difficult to estimate without further testing, such as echocardiography or cardiac MRI, to assess the extent of heart failure and the patient's cardiac function."
709,709,P0559,"Age: 51
Gender: Male 
Weight: 62 kg
Height: 163 cm
NYHA Class: II
Blood Pressure: 130/90 mmHg
Past Medical History: Idiopathic dilated cardiomyopathy, Hypertension
Albumin (g/L): 45
ALT or GPT (IU/L): 32.0
AST or GOT (IU/L): 24.0
Total Cholesterol (mmol/L): 5,4
Creatinine (mmol/L): 94.0
Gamma-glutamil transpeptidase (IU/L): 49
Glucose (mmol/L): 5,2
Hemoglobin (g/L): 147.0
HDL (mmol/L): 1,68
Potassium (mEq/L): 3,08
LDL (mmol/L): 3,23
Sodium (mEq/L): 142.0
Pro-BNP (ng/L): 2928.0
Protein (g/L): 71
T3 (pg/dL): 0,0573
T4 (ng/L): 16,58
Troponin (ng/mL): 0,1
TSH (mIU/L): 3,94
Urea (mg/dL): 5,8
LVEF (%): 20.0
Medications: Calcium Channel Blocker, Amiodarone, Beta Blockers, Digoxin, Loop Diuretics, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",sudden cardiac death,"RANKING: 
1. Sudden Cardiac Death
2. Pump Failure Death
3. Survivor

REASONING:

The patient's prognosis can be determined based on the provided data. 

The patient's LVEF of 20.0% indicates severe left ventricular dysfunction, which is a significant predictor of adverse outcomes in patients with cardiomyopathy. The presence of ventricular tachycardia and non-sustained ventricular tachycardia (CH>10) on the ECG further increases the risk of arrhythmic events. 

The patient's elevated BNP levels (2928.0 ng/L) and elevated creatinine (5.8 mg/dL) levels also suggest significant cardiac stress and potential kidney impairment. The combination of these factors increases the likelihood of a poor outcome.

The patient's age, gender, and NYHA Class II status are also important factors. A 51-year-old male with severe left ventricular dysfunction and multiple cardiac arrhythmias is at high risk for cardiac events.

In comparison, while the patient's current medications, including beta blockers, amiodarone, and ACE inhibitors, suggest an attempt to manage the condition, the severity of the cardiac dysfunction and arrhythmias suggests that the patient is at high risk for a poor outcome.

Therefore, based on the provided data, sudden cardiac death is the most likely prognosis due to the combination of severe left ventricular dysfunction, arrhythmias, and elevated biomarkers. Pump failure death is the second most likely outcome due to the patient's significant cardiac stress and kidney impairment. The patient's survival is the least likely outcome due to the severity of the cardiac condition and the presence of arrhythmias."
710,710,P0616,"Age: 71
Gender: Male 
Weight: 63 kg
Height: 164 cm
NYHA Class: II
Blood Pressure: 115/70 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Dyslipemia, Peripheral vascular disease, Hypertension, Myocardial Infarction
Albumin (g/L): 42,4
ALT or GPT (IU/L): 33.0
AST or GOT (IU/L): 36.0
Total Cholesterol (mmol/L): 4,86
Creatinine (mmol/L): 125.0
Gamma-glutamil transpeptidase (IU/L): 114
Glucose (mmol/L): 6
Hemoglobin (g/L): 129.0
HDL (mmol/L): 0,9
Potassium (mEq/L): 3,94
LDL (mmol/L): 2,92
Sodium (mEq/L): 140.0
Pro-BNP (ng/L): 1139.0
Protein (g/L): 67,2
Troponin (ng/mL): 0,01
TSH (mIU/L): 1,56
Urea (mg/dL): 11,6
LVEF (%): 18.0
Medications: Angiotensin II Receptor Blocker, Digoxin, Loop Diuretics, Statins, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",sudden cardiac death,"RANKING: 1. Sudden Cardiac Death
REASONING:

Based on the patient's data, I predict a high risk of sudden cardiac death over the next few years. The patient has a history of ischemic dilated cardiomyopathy, which is a condition that significantly increases the risk of sudden cardiac death. The patient's left ventricular ejection fraction (LVEF) is 18.0%, which is a marker of poor cardiac function and a predictor of increased mortality. Additionally, the patient's troponin level is within the normal range, which may suggest some residual cardiac function, but the overall clinical picture is concerning.

The patient's ECG impression of ventricular extrasystoles is also a risk factor for sudden cardiac death, as these abnormal heart rhythms can lead to life-threatening arrhythmias. Furthermore, the patient's age (71 years) and NYHA Class II heart failure classification indicate a high risk of cardiac events.

While the patient is on medications, including an angiotensin II receptor blocker, digoxin, and statins, which are standard treatments for heart failure and cardiovascular risk factors, the patient's overall clinical profile suggests that these medications may not be sufficient to mitigate the risk of sudden cardiac death.

In contrast, the other two prognoses (survivor and pump failure death) seem less likely, as the patient's cardiac function is already compromised, and the presence of ventricular extrasystoles on ECG increases the risk of cardiac events. While pump failure death is a possible outcome, it is less likely in the short term, as the patient is already showing some residual cardiac function (normal troponin levels)."
711,711,P0618,"Age: 65
Gender: Male 
Weight: 93 kg
Height: 176 cm
NYHA Class: II
Blood Pressure: 130/70 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Diabetes, Hypertension, Myocardial Infarction
Albumin (g/L): 40,7
ALT or GPT (IU/L): 57.0
AST or GOT (IU/L): 24.0
Total Cholesterol (mmol/L): 2,96
Creatinine (mmol/L): 106.0
Gamma-glutamil transpeptidase (IU/L): 95
Glucose (mmol/L): 8
Hemoglobin (g/L): 121.0
HDL (mmol/L): 1,11
Potassium (mEq/L): 4,56
LDL (mmol/L): 1,45
Sodium (mEq/L): 144.0
Pro-BNP (ng/L): 12518.0
Protein (g/L): 66,2
Troponin (ng/mL): 0,01
TSH (mIU/L): 1,43
Urea (mg/dL): 6,8
LVEF (%): 20.0
Medications: Diabetes Medication, Beta Blockers, Loop Diuretics, Spironolactone, Statins, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: TPSV
        - Bradycardia: No
            ",sudden cardiac death,"RANKING: 1. Sudden Cardiac Death
REASONING:

Based on the provided patient data, I would rank sudden cardiac death as the most likely prognosis for the next few years. The patient has a history of ischemic dilated cardiomyopathy, which is a condition that significantly increases the risk of sudden cardiac death. The patient's left ventricular ejection fraction (LVEF) is 20%, which is a critical indicator of cardiac function. A low LVEF is associated with an increased risk of sudden cardiac death.

Additionally, the patient has a history of myocardial infarction, which further increases the risk of cardiac arrhythmias and sudden cardiac death. The presence of ventricular extrasystoles, non-sustained ventricular tachycardia, and paroxysmal supraventricular tachyarrhythmia on the ECG impression also suggest an increased risk of arrhythmias, which can lead to sudden cardiac death.

The patient's laboratory results, such as the elevated troponin level and the high Pro-BNP level, also suggest cardiac strain and increased stress on the heart, which can contribute to the risk of sudden cardiac death.

While the patient is taking medications that are typically used to manage heart failure and arrhythmias, the underlying cardiac condition and the presence of arrhythmias suggest that the risk of sudden cardiac death remains high.

RANKING: 2. Pump Failure Death
REASONING:

Pump failure death is a possible outcome for this patient, given the patient's history of ischemic dilated cardiomyopathy and the current low LVEF. However, the patient is currently taking medications that are typically used to manage heart failure, such as loop diuretics and ACE inhibitors, which can help to improve cardiac function.

While the patient's kidney function is impaired, as indicated by the elevated creatinine level, the patient's eGFR is not explicitly provided, making it difficult to assess the severity of kidney dysfunction. However, the patient's elevated urea level suggests some degree of renal impairment.

The patient's weight is also high, which can increase the risk of heart failure and pump failure.

RANKING: 3. Survivor
REASONING:

Given the patient's history of cardiac conditions, arrhythmias, and laboratory results, I would rank survivor as the least likely prognosis for the next few years. While the patient is taking medications that can help manage heart failure and arrhythmias, the underlying cardiac condition and the presence of arrhythmias suggest that the risk of sudden cardiac death and pump failure remains high.

However, the patient's age, gender, and the absence of other comorbidities, such as chronic obstructive pulmonary disease (COPD) or severe hypertension, may contribute to a slightly better prognosis compared to the other two options.

It is essential to note that this prognosis is based on the provided data and should be interpreted with caution. A more accurate prognosis would require a comprehensive assessment of the patient's overall health, including a thorough evaluation of their cardiac function, kidney function, and other comorbidities."
712,712,P0626,"Age: 74
Gender: Female 
Weight: 55 kg
Height: 144 cm
NYHA Class: III
Blood Pressure: 150/80 mmHg
Past Medical History: Hypertropic cardiomyopathy, Hypertension
Albumin (g/L): 39
ALT or GPT (IU/L): 26.0
AST or GOT (IU/L): 21.0
Total Cholesterol (mmol/L): 2,84
Creatinine (mmol/L): 76.0
Gamma-glutamil transpeptidase (IU/L): 81
Glucose (mmol/L): 4,9
Hemoglobin (g/L): 117.0
HDL (mmol/L): 0,91
Potassium (mEq/L): 3,2
LDL (mmol/L): 1,51
Sodium (mEq/L): 147.0
Pro-BNP (ng/L): 7158.0
Protein (g/L): 65,8
Troponin (ng/mL): 0,01
TSH (mIU/L): 1,31
Urea (mg/dL): 7
LVEF (%): 62.0
Medications: Calcium Channel Blocker, Beta Blockers, Loop Diuretics, Spironolactone, Statins, ACE Inhibitor, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",sudden cardiac death,"RANKING: 
1. Pump failure death 
REASONING: 
Based on the patient's NYHA Class III status and elevated LVEF of 62%, which indicates significant left ventricular dysfunction, along with a history of Hypertrophic cardiomyopathy and hypertension, the patient is at high risk for pump failure. The elevated Creatinine level (76.0 mmol/L) and elevated Pro-BNP level (7158.0 ng/L) also support this prognosis. The presence of multiple medications, including ACE Inhibitor, which is typically used to treat heart failure, further increases the risk of pump failure.

2. Survivor 
REASONING: 
Although the patient's NYHA Class III status and elevated LVEF suggest a significant impairment of cardiac function, the presence of multiple medications, including ACE Inhibitor and Beta Blockers, which are typically used to manage heart failure and hypertension, suggests that the patient is receiving optimal medical therapy. Additionally, the absence of other high-risk features such as ventricular tachycardia or significant electrolyte imbalances may reduce the risk of sudden cardiac death. However, the patient's age (74 years) and elevated Pro-BNP level may still increase the risk of pump failure.

3. Sudden cardiac death 
REASONING: 
The patient's ECG impression of monomorphic ventricular extrasystoles suggests an increased risk of arrhythmias, which can increase the risk of sudden cardiac death. However, the absence of other high-risk features such as ventricular tachycardia or significant electrolyte imbalances reduces this risk. Additionally, the patient's age (74 years) and elevated Pro-BNP level increase the risk of pump failure, which is a more likely cause of death than sudden cardiac death in this patient."
713,713,P0649,"Age: 70
Gender: Male 
Weight: 110 kg
Height: 180 cm
NYHA Class: II
Blood Pressure: 120/70 mmHg
Past Medical History: Enolic dilated cardiomyopathy, Diabetes, Dyslipemia, Hypertension
Albumin (g/L): 44
ALT or GPT (IU/L): 10.0
AST or GOT (IU/L): 18.0
Total Cholesterol (mmol/L): 3,49
Creatinine (mmol/L): 85.0
Gamma-glutamil transpeptidase (IU/L): 29
Glucose (mmol/L): 10,8
Hemoglobin (g/L): 129.0
HDL (mmol/L): 0,98
Potassium (mEq/L): 5,4
LDL (mmol/L): 2,22
Sodium (mEq/L): 143.0
Pro-BNP (ng/L): 437.0
Protein (g/L): 72
T3 (pg/dL): 0,04
T4 (ng/L): 16
Troponin (ng/mL): 0,01
TSH (mIU/L): 3,99
Urea (mg/dL): 6,24
LVEF (%): 40.0
Medications: Diabetes Medication, Loop Diuretics, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",sudden cardiac death,"RANKING: 1. Sudden Cardiac Death
REASONING: 
Based on the patient's ECG impression, the presence of ventricular extrasystole (Monomorphic) is a significant concern. Monomorphic ventricular extrasystoles are a type of abnormal heart rhythm that can be a precursor to ventricular tachycardia or fibrillation, which can lead to sudden cardiac death. The patient's LVEF of 40.0 indicates severe left ventricular dysfunction, which is a risk factor for sudden cardiac death. Additionally, the patient's NYHA Class II indicates moderate heart failure, which can also increase the risk of sudden cardiac death. The patient's past medical history of dilated cardiomyopathy, diabetes, dyslipemia, and hypertension further increases the risk of cardiac complications. 

The patient's biomarkers, such as the elevated Pro-BNP level (437.0 ng/L) and Troponin level (0.01 ng/mL), also suggest cardiac stress and damage, which can contribute to the risk of sudden cardiac death. The patient's medication regimen, including ACE inhibitors, may not be sufficient to manage the patient's cardiac condition effectively, which could further increase the risk of cardiac complications. 

Given the combination of these factors, the patient is at high risk for sudden cardiac death. 

RANKING: 2. Pump Failure Death
REASONING: 
The patient's severe left ventricular dysfunction (LVEF of 40.0) and NYHA Class II heart failure indicate that the patient is at risk for pump failure. The patient's elevated Pro-BNP level (437.0 ng/L) and Troponin level (0.01 ng/mL) suggest cardiac stress and damage, which can contribute to the progression of heart failure. The patient's past medical history of dilated cardiomyopathy, diabetes, dyslipemia, and hypertension further increases the risk of heart failure.

The patient's elevated creatinine level (6.24 mg/dL) and low eGFR may indicate renal impairment, which can be a complication of heart failure. The patient's medications, including ACE inhibitors, may not be sufficient to manage the patient's cardiac condition effectively, which could further increase the risk of pump failure.

Given the patient's severe left ventricular dysfunction and elevated biomarkers, pump failure is a significant concern. 

RANKING: 3. Survivor
REASONING: 
Although the patient has a history of dilated cardiomyopathy, diabetes, dyslipemia, and hypertension, which increase the risk of cardiac complications, the patient's current LVEF of 40.0 and NYHA Class II heart failure suggest that the patient's cardiac condition is not as severe as it could be. The patient's Pro-BNP level (437.0 ng/L) and Troponin level (0.01 ng/mL) are not excessively elevated, which may indicate some level of cardiac reserve.

The patient's medication regimen, including ACE inhibitors, may be effective in managing the patient's cardiac condition, although the patient's blood pressure is within a relatively normal range. The patient's weight and BMI are also within a relatively normal range, which may reduce the risk of cardiac complications.

Given the patient's overall condition, pump failure is less likely, but the patient is still at risk for cardiac complications. Therefore, the patient's survival is possible, but not guaranteed."
714,714,P0650,"Age: 73
Gender: Male 
Weight: 75 kg
Height: 162 cm
NYHA Class: III
Blood Pressure: 130/80 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Diabetes, Peripheral vascular disease, Hypertension
Albumin (g/L): 40,9
ALT or GPT (IU/L): 17.0
AST or GOT (IU/L): 13.0
Total Cholesterol (mmol/L): 2,87
Creatinine (mmol/L): 96.0
Gamma-glutamil transpeptidase (IU/L): 34
Glucose (mmol/L): 15,3
Hemoglobin (g/L): 145.0
HDL (mmol/L): 1,22
Potassium (mEq/L): 4,7
LDL (mmol/L): 3,03
Sodium (mEq/L): 142.0
Pro-BNP (ng/L): 1670.0
Protein (g/L): 71
T3 (pg/dL): 0,04
T4 (ng/L): 20
Troponin (ng/mL): 0,02
TSH (mIU/L): 2,25
Urea (mg/dL): 5,79
LVEF (%): 25.0
Medications: Diabetes Medication, Beta Blockers, Loop Diuretics, Spironolactone, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",sudden cardiac death,"RANKING: 
1. Survivor
REASONING: 
The patient's age (73) and NYHA Class III status indicate a significant cardiac impairment, which increases the risk of adverse outcomes. However, the patient's current medications (Diabetes Medication, Beta Blockers, Loop Diuretics, Spironolactone, ACE Inhibitor) are commonly used to manage heart failure and reduce cardiovascular risk factors. The elevated Pro-BNP levels (1670.0 ng/L) suggest a high level of cardiac stress, but the patient's LVEF (25.0%) is relatively preserved, indicating some residual cardiac function.

The presence of non-sustained ventricular tachycardia (CH>10) on the ECG is a significant concern, as it indicates an increased risk of ventricular arrhythmias. However, the absence of sustained ventricular tachycardia and other arrhythmias on the ECG reduces the likelihood of sudden cardiac death. The patient's creatinine level (96.0 mmol/L) is elevated, which may indicate some degree of renal impairment, but this is not directly related to cardiac function.

Given these factors, the patient's overall prognosis is most likely to be survival, as the patient is receiving appropriate treatment for heart failure and has a relatively preserved LVEF. However, the presence of non-sustained ventricular tachycardia and elevated Pro-BNP levels do increase the risk of adverse outcomes.

RANKING: 
2. Pump Failure Death
REASONING: 
The patient's NYHA Class III status and elevated Pro-BNP levels suggest a high risk of heart failure exacerbation. The patient's LVEF (25.0%) is significantly reduced, indicating severe cardiac impairment. The presence of non-sustained ventricular tachycardia on the ECG is a significant concern, as it can increase the risk of ventricular arrhythmias and heart failure exacerbation.

The patient's elevated creatinine level (96.0 mmol/L) may indicate some degree of renal impairment, which can contribute to fluid overload and worsen heart failure. The patient's medications, including Beta Blockers and ACE Inhibitor, are commonly used to manage heart failure, but may not be sufficient to completely prevent pump failure.

Given these factors, the patient's overall prognosis is less likely to be survival, as the patient is at high risk of heart failure exacerbation and pump failure.

RANKING: 
3. Sudden Cardiac Death
REASONING: 
The patient's ECG findings of non-sustained ventricular tachycardia (CH>10) are a significant concern, as they increase the risk of ventricular arrhythmias. The patient's elevated Pro-BNP levels (1670.0 ng/L) and reduced LVEF (25.0%) suggest a high level of cardiac stress and impairment.

While the patient is receiving appropriate treatment for heart failure, the presence of non-sustained ventricular tachycardia on the ECG increases the risk of sudden cardiac death. The patient's age (73) and NYHA Class III status also increase the risk of adverse outcomes.

Given these factors, the patient's overall prognosis is the least likely to be survival, as the patient is at high risk of ventricular arrhythmias and sudden cardiac death."
715,715,P0656,"Age: 57
Gender: Male 
Weight: 70 kg
Height: 164 cm
NYHA Class: III
Blood Pressure: 140/70 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Diabetes, Dyslipemia, Hypertension, Myocardial Infarction
Albumin (g/L): 33,5
ALT or GPT (IU/L): 41.0
AST or GOT (IU/L): 30.0
Total Cholesterol (mmol/L): 3,15
Creatinine (mmol/L): 226.0
Gamma-glutamil transpeptidase (IU/L): 73
Glucose (mmol/L): 3,1
Hemoglobin (g/L): 97.0
HDL (mmol/L): 1,06
Potassium (mEq/L): 5,9
LDL (mmol/L): 1,58
Sodium (mEq/L): 133.0
Pro-BNP (ng/L): 19425.0
Protein (g/L): 68
T3 (pg/dL): 0,03
T4 (ng/L): 20
Troponin (ng/mL): 0,19
TSH (mIU/L): 4,39
Urea (mg/dL): 18,94
LVEF (%): 20.0
Medications: Diabetes Medication, Beta Blockers, Loop Diuretics, Spironolactone, Statins, ACE Inhibitor, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",sudden cardiac death,"RANKING: 1. Sudden Cardiac Death
REASONING:

The patient's clinical presentation and laboratory results indicate a high risk of adverse outcomes. The patient has a history of ischemic dilated cardiomyopathy, which is a significant risk factor for sudden cardiac death. The patient's left ventricular ejection fraction (LVEF) is severely impaired at 20%, indicating advanced cardiac dysfunction.

The patient's elevated troponin levels (0.19 ng/mL) suggest some degree of cardiac damage, which may be related to their underlying cardiomyopathy. The patient's ECG shows ventricular extrasystoles, which can be a sign of abnormal electrical activity in the heart, increasing the risk of arrhythmias.

The patient's high creatinine level (18.94 mg/dL) and elevated serum urea level (not provided) suggest some degree of renal impairment, which can be a complication of heart failure. The patient's NYHA class III status indicates severe symptoms of heart failure, which further increases the risk of adverse outcomes.

Additionally, the patient's medication list includes a nitrovasodilator, which can be used to treat heart failure, but in this case, it may be contributing to the patient's instability.

Given the combination of advanced cardiac dysfunction, elevated troponin, and the presence of ventricular extrasystoles, I believe that the patient is at high risk of sudden cardiac death. The likelihood of pump failure death is also high due to the patient's advanced heart failure status. Survivor is the least likely outcome given the patient's severe cardiac dysfunction and multiple comorbidities.

It's worth noting that the patient's Pro-BNP level (19425.0 ng/L) is extremely elevated, which is a strong indicator of heart failure. However, in this case, the combination of elevated troponin and ventricular extrasystoles suggests that the patient's cardiac dysfunction is more related to arrhythmias rather than pure heart failure.

In summary, the patient's clinical presentation and laboratory results indicate a high risk of sudden cardiac death, making it the most likely outcome."
716,716,P0661,"Age: 67
Gender: Female 
Weight: 65 kg
Height: 154 cm
NYHA Class: II
Blood Pressure: 140/80 mmHg
Past Medical History: Idiopathic dilated cardiomyopathy, Diabetes, Hypertension
Albumin (g/L): 43,2
ALT or GPT (IU/L): 6.0
AST or GOT (IU/L): 11.0
Total Cholesterol (mmol/L): 4,58
Creatinine (mmol/L): 61.0
Gamma-glutamil transpeptidase (IU/L): 42
Glucose (mmol/L): 8,3
Hemoglobin (g/L): 128.0
HDL (mmol/L): 1,22
Potassium (mEq/L): 4,7
LDL (mmol/L): 2,69
Sodium (mEq/L): 134.0
Pro-BNP (ng/L): 928.0
Protein (g/L): 68,5
T4 (ng/L): 15
TSH (mIU/L): 1,1
Urea (mg/dL): 6,82
LVEF (%): 20.0
Medications: Diabetes Medication, Beta Blockers, Digoxin, Spironolactone, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",sudden cardiac death,"RANKING: 1. Sudden Cardiac Death
REASONING:

Based on the patient's data, I rank sudden cardiac death as the most likely outcome for the next few years. The patient has a significant history of idiopathic dilated cardiomyopathy, which is a condition where the heart becomes enlarged and cannot pump blood effectively. This condition is a major risk factor for sudden cardiac death.

The patient's left ventricular ejection fraction (LVEF) is 20.0%, which is significantly below the normal range of 50-70%. This indicates that the patient's heart is not pumping efficiently, and the risk of cardiac arrhythmias and sudden cardiac death is increased.

The patient's ECG impression also supports this prediction, with the presence of ventricular extrasystoles and non-sustained ventricular tachycardia. These findings suggest that the patient's heart is experiencing abnormal electrical activity, which can increase the risk of sudden cardiac death.

Additionally, the patient's medications, including beta blockers and digoxin, are standard treatments for heart failure and arrhythmias, but they may not be sufficient to reverse the underlying disease process. The patient's high levels of B-type natriuretic peptide (Pro-BNP) also suggest that the heart is under significant stress, which can contribute to the risk of sudden cardiac death.

While the patient's other medical conditions, such as diabetes and hypertension, are also relevant, they do not directly contribute to the risk of sudden cardiac death. The patient's weight and height are also within normal limits, and the patient's blood pressure is not excessively high.

Therefore, based on the available data, I predict that the patient is at high risk for sudden cardiac death in the next few years."
717,717,P0667,"Age: 75
Gender: Male 
Weight: 76 kg
Height: 161 cm
NYHA Class: II
Blood Pressure: 150/75 mmHg
Past Medical History: Hypertensive cardiomyopathy, Diabetes, Dyslipemia, Peripheral vascular disease, Hypertension
Albumin (g/L): 37,4
ALT or GPT (IU/L): 11.0
AST or GOT (IU/L): 18.0
Total Cholesterol (mmol/L): 5,95
Creatinine (mmol/L): 160.0
Gamma-glutamil transpeptidase (IU/L): 16
Glucose (mmol/L): 7,1
Hemoglobin (g/L): 133.0
HDL (mmol/L): 1,47
Potassium (mEq/L): 4,4
LDL (mmol/L): 3,72
Sodium (mEq/L): 141.0
Pro-BNP (ng/L): 6950.0
Protein (g/L): 77
T3 (pg/dL): 0,05
T4 (ng/L): 15
Troponin (ng/mL): 0,03
TSH (mIU/L): 1,67
Urea (mg/dL): 13,14
LVEF (%): 50.0
Medications: Calcium Channel Blocker, Loop Diuretics, Statins
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",sudden cardiac death,"RANKING: 
1. Sudden cardiac death
2. Pump failure death
3. Survivor

REASONING:

Based on the provided patient data, the patient is at high risk for sudden cardiac death due to the presence of several factors:

1. Hypertensive cardiomyopathy: The patient's history of hypertension and cardiomyopathy increases the risk of cardiac arrhythmias and sudden cardiac death.
2. Electrolyte Imbalance: The patient has a low potassium level (4.4 mEq/L), which can contribute to cardiac arrhythmias, including ventricular extrasystoles and ventricular tachycardia.
3. Electrocardiogram (ECG) findings: The presence of ventricular extrasystoles and non-sustained ventricular tachycardia (VT) on the ECG indicates an increased risk of cardiac arrhythmias.
4. Low LVEF (50%): A left ventricular ejection fraction of 50% indicates reduced cardiac function, which can contribute to an increased risk of arrhythmias and sudden cardiac death.
5. Medication non-adherence: The patient is not taking beta-blockers, which are often recommended for patients with heart failure and arrhythmias to reduce mortality.

While pump failure death is also a possible outcome, the presence of the above factors, particularly the ECG findings and electrolyte imbalance, make sudden cardiac death the most likely prognosis. The patient's reduced LVEF and hypertension also increase the risk of pump failure death. However, the patient's overall condition and the presence of multiple comorbidities make sudden cardiac death the most likely outcome.

In contrast, a survivor prognosis is less likely due to the presence of several risk factors that increase the risk of cardiac complications."
718,718,P0671,"Age: 69
Gender: Male 
Weight: 72 kg
Height: 154 cm
NYHA Class: II
Blood Pressure: 150/90 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Diabetes, Dyslipemia, Hypertension, Myocardial Infarction
Albumin (g/L): 44,1
ALT or GPT (IU/L): 23.0
AST or GOT (IU/L): 28.0
Total Cholesterol (mmol/L): 5,74
Creatinine (mmol/L): 145.0
Gamma-glutamil transpeptidase (IU/L): 70
Glucose (mmol/L): 11,2
Hemoglobin (g/L): 163.0
HDL (mmol/L): 0,88
Potassium (mEq/L): 4,5
LDL (mmol/L): 3,93
Sodium (mEq/L): 142.0
Pro-BNP (ng/L): 1824.0
Protein (g/L): 76,6
T4 (ng/L): 19
TSH (mIU/L): 0,36
Urea (mg/dL): 10,65
LVEF (%): 35.0
Medications: Calcium Channel Blocker, Diabetes Medication
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",sudden cardiac death,"RANKING: 1. Survivor
REASONING: 

Based on the provided patient data, the patient is at high risk for a poor outcome due to the presence of ischemic dilated cardiomyopathy, which is a condition where the heart's ability to pump blood is significantly impaired. This condition is a common cause of heart failure and sudden cardiac death. The patient's left ventricular ejection fraction (LVEF) of 35% is a strong indicator of poor cardiac function. Additionally, the patient's history of myocardial infarction and hypertension further increases the risk of cardiac complications.

The patient's elevated creatinine level (145.0 mmol/L) and elevated BNP levels (1824.0 ng/L) suggest significant cardiac strain and potential kidney impairment. The presence of non-sustained ventricular tachycardia (NSVT) and polymorphic ventricular extrasystoles on the ECG also indicate an increased risk of arrhythmias, which can lead to sudden cardiac death.

While the patient's NYHA Class II indicates some limitations in physical activity, the presence of significant comorbidities and cardiac dysfunction suggest that the patient's quality of life may be severely impacted. Therefore, despite the NYHA Class II classification, the patient's overall prognosis is likely to be poor, with a high risk of sudden cardiac death.

RANKING: 2. Pump failure death
REASONING: 

Although pump failure death is a possible outcome for this patient, it is less likely than sudden cardiac death due to the presence of non-sustained ventricular tachycardia and polymorphic ventricular extrasystoles on the ECG. These arrhythmias can increase the risk of sudden cardiac death. However, the patient's cardiac function is severely impaired, and pump failure is a possible complication of the underlying ischemic dilated cardiomyopathy.

RANKING: 3. Survivor
REASONING: 

A survivor outcome is the least likely due to the patient's significant cardiac dysfunction, comorbidities, and elevated risk of arrhythmias. While the patient is currently receiving medications for hypertension and diabetes, the presence of non-sustained ventricular tachycardia and polymorphic ventricular extrasystoles on the ECG suggests a high risk of cardiac complications. The patient's overall health status and the presence of significant comorbidities make a full recovery unlikely, and the patient's prognosis is likely to be poor."
719,719,P0734,"Age: 67
Gender: Male 
Weight: 64 kg
Height: 159 cm
NYHA Class: II
Blood Pressure: 125/80 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Dyslipemia, Hypertension
Albumin (g/L): 43
ALT or GPT (IU/L): 28.0
AST or GOT (IU/L): 19.0
Total Cholesterol (mmol/L): 2,87
Creatinine (mmol/L): 106.0
Gamma-glutamil transpeptidase (IU/L): 14
Glucose (mmol/L): 5
Hemoglobin (g/L): 149.0
HDL (mmol/L): 0,7
Potassium (mEq/L): 5,3
LDL (mmol/L): 1,68
Sodium (mEq/L): 137.0
Pro-BNP (ng/L): 2362.0
Protein (g/L): 69
T3 (pg/dL): 0,05
T4 (ng/L): 19
Troponin (ng/mL): 0,03
TSH (mIU/L): 1,53
Urea (mg/dL): 10,65
LVEF (%): 20.0
Medications: Beta Blockers, Loop Diuretics, Spironolactone, Statins, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",sudden cardiac death,"RANKING: 1. Survivor
REASONING: The patient's age is 67, which is relatively advanced for a healthy heart. However, the patient has a history of ischemic dilated cardiomyopathy, which is a significant risk factor for heart failure and sudden cardiac death. Despite this, the patient's NYHA Class is II, indicating mild symptoms of heart failure. The patient's ejection fraction (LVEF) is 20.0%, which is lower than the normal range, indicating some degree of heart failure. However, the patient is receiving medications for heart failure and hypertension, which suggests that the condition is being managed.

The patient's electrolyte levels, including potassium (5.3 mEq/L) and troponin (0.03 ng/mL), are within normal limits, and the liver function tests (ALT and AST) are also within normal limits. The patient's lipid profile, including total cholesterol (2.87 mmol/L) and HDL (0.7 mmol/L), is not ideal, but these values are not excessively high. The patient's creatinine level (106.0 mmol/L) is elevated, but this is likely due to dehydration or other non-cardiac factors.

The patient's ECG findings, including ventricular extrasystoles, non-sustained ventricular tachycardia, and non-sustained ventricular tachycardia, are concerning for cardiac arrhythmias. However, the absence of sustained ventricular tachycardia and paroxysmal supraventricular tachyarrhythmia reduces the risk of sudden cardiac death.

Considering these factors, the patient's overall prognosis is guarded but not extremely poor. With optimal management of medications and lifestyle modifications, the patient may be able to survive for several years. However, the presence of ischemic dilated cardiomyopathy and cardiac arrhythmias makes it difficult to predict the exact outcome.

RANKING: 2. Sudden cardiac death
REASONING: The patient's history of ischemic dilated cardiomyopathy, ventricular extrasystoles, non-sustained ventricular tachycardia, and non-sustained ventricular tachycardia increase the risk of sudden cardiac death. The patient's ejection fraction is low, and the presence of cardiac arrhythmias suggests that the heart is not functioning optimally.

RANKING: 3. Pump failure death
REASONING: While the patient's NYHA Class is II, indicating mild symptoms of heart failure, the patient's LVEF is only 20.0%, which is significantly lower than the normal range. The patient's creatinine level (106.0 mmol/L) is also elevated, indicating impaired renal function, which may be related to heart failure. The patient's cardiac medications and lifestyle modifications may not be sufficient to prevent pump failure, and the patient's underlying condition of ischemic dilated cardiomyopathy makes it difficult to predict a favorable outcome.

Note: The patient's outcome is not explicitly stated, but based on the provided information, a sudden cardiac death is the most likely outcome. However, the patient's overall prognosis is guarded, and it is essential to closely monitor the patient's condition and adjust the treatment plan as needed."
720,720,P0743,"Age: 57
Gender: Male 
Weight: 73 kg
Height: 162 cm
NYHA Class: II
Blood Pressure: 110/70 mmHg
Past Medical History: Enolic dilated cardiomyopathy, Diabetes, Dyslipemia, Hypertension, Myocardial Infarction
Albumin (g/L): 41,4
ALT or GPT (IU/L): 15.0
AST or GOT (IU/L): 13.0
Total Cholesterol (mmol/L): 5,79
Creatinine (mmol/L): 86.0
Gamma-glutamil transpeptidase (IU/L): 22
Glucose (mmol/L): 8,9
Hemoglobin (g/L): 153.0
HDL (mmol/L): 0,91
Potassium (mEq/L): 3,9
LDL (mmol/L): 4,01
Sodium (mEq/L): 141.0
Pro-BNP (ng/L): 313.0
Protein (g/L): 71,6
T4 (ng/L): 19
TSH (mIU/L): 0,36
Urea (mg/dL): 6,66
LVEF (%): 55.0
Medications: Beta Blockers, Loop Diuretics, Statins, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: TPSV
        - Bradycardia: No
            ",sudden cardiac death,"RANKING: 
1. Sudden cardiac death
2. Pump failure death
3. Survivor

REASONING:

Based on the patient data, I have assessed the risk of each possible outcome. Here's the reasoning behind the ranking:

1. Sudden Cardiac Death (SCD): The patient has a history of myocardial infarction, which is a significant risk factor for SCD. The ECG impression reveals ventricular extrasystoles, non-sustained ventricular tachycardia (NSVT), and non-sustained ventricular tachycardia (CH>10), all of which are indicative of arrhythmias. The presence of these arrhythmias, combined with the patient's history of myocardial infarction, makes SCD a highly likely outcome. The elevated Pro-BNP levels (313.0 ng/L) also suggest heart failure, which can contribute to SCD.

2. Pump Failure Death: The patient has a history of dilated cardiomyopathy, which is a significant risk factor for heart failure. The LVEF (55.0) is low, indicating poor cardiac function. The elevated creatinine level (86.0 mmol/L) and urea (6.66 mg/dL) suggest impaired renal function, which can be a consequence of heart failure. The patient's medications, including beta blockers, loop diuretics, and ACE inhibitors, are standard treatments for heart failure. However, the presence of arrhythmias and the patient's history of myocardial infarction make SCD a more likely outcome than pump failure.

3. Survivor: While the patient's medications and medical history suggest that they may be able to manage their condition, the presence of arrhythmias and poor cardiac function make it more likely that they will experience a cardiac-related event. The patient's age (57) and other comorbidities, such as diabetes and hypertension, also contribute to their overall risk. However, the patient's relatively stable blood pressure (110/70 mmHg) and low to moderate levels of cardiac biomarkers (e.g., Troponin not mentioned, but ALT/GPT and AST/GOT are within normal limits) suggest that they may be able to manage their condition with treatment, making survival a possible outcome.

Please note that this is a prognosis based on the provided data, and actual outcomes may vary depending on various factors, including the patient's response to treatment and the presence of unforeseen complications."
721,721,P0765,"Age: 72
Gender: Female 
Weight: 48 kg
Height: 143 cm
NYHA Class: II
Blood Pressure: 100/70 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Diabetes, Dyslipemia, Peripheral vascular disease, Hypertension, Myocardial Infarction
Albumin (g/L): 39,3
ALT or GPT (IU/L): 37.0
AST or GOT (IU/L): 38.0
Total Cholesterol (mmol/L): 5,63
Creatinine (mmol/L): 81.0
Gamma-glutamil transpeptidase (IU/L): 60
Glucose (mmol/L): 10,5
Hemoglobin (g/L): 135.0
HDL (mmol/L): 0,97
Potassium (mEq/L): 4,28
LDL (mmol/L): 3,21
Sodium (mEq/L): 139.0
Pro-BNP (ng/L): 2910.0
Protein (g/L): 75,9
Troponin (ng/mL): 0,2
TSH (mIU/L): 1,31
Urea (mg/dL): 9,5
LVEF (%): 20.0
Medications: Diabetes Medication, Digoxin, Loop Diuretics, Spironolactone, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: TPSV
        - Bradycardia: Sinus Node Dysfunction
            ",sudden cardiac death,"RANKING: 1. Sudden Cardiac Death
REASONING:

Based on the provided patient data, the patient is at high risk for sudden cardiac death due to the following reasons:

1. Low LVEF (20.0%): This indicates severe left ventricular dysfunction, which is a significant predictor of adverse outcomes, including sudden cardiac death.
2. History of Ischemic Dilated Cardiomyopathy: This condition is a well-known risk factor for sudden cardiac death, as it can lead to arrhythmias and decreased cardiac function.
3. Presence of Ventricular Extrasystole (Polymorphic): This ECG finding suggests a high risk of ventricular arrhythmias, which can be life-threatening.
4. Presence of Pro-BNP (2910.0 ng/L): Elevated levels of BNP are associated with increased mortality and morbidity in patients with heart failure.
5. History of Myocardial Infarction: This history increases the risk of future cardiac events, including sudden cardiac death.
6. Presence of Diabetes, Dyslipemia, and Hypertension: These conditions are risk factors for cardiovascular disease and can contribute to the development of cardiac arrhythmias and decreased cardiac function.
7. Low Hemoglobin (135.0 g/L): This may indicate anemia, which can increase the risk of cardiac events.

Given these factors, the patient is at high risk for sudden cardiac death in the next few years. Regular monitoring and management of the patient's cardiac function, arrhythmias, and other risk factors are crucial to mitigate this risk.

RANKING: 2. Pump Failure Death
REASONING:

While pump failure is a concern due to the patient's severe left ventricular dysfunction (LVEF 20.0%), the patient is already receiving treatment with ACE inhibitors, Digoxin, Loop Diuretics, and Spironolactone, which are standard therapies for heart failure management. However, the presence of severe ventricular dysfunction and other risk factors may still increase the risk of pump failure.

RANKING: 3. Survivor
REASONING:

While the patient has a history of cardiovascular disease, the patient is currently not showing any signs of acute cardiac decompensation or severe arrhythmias. The patient is also receiving optimal medical therapy for their conditions, which may help manage symptoms and prevent further cardiac events. However, the patient's severe left ventricular dysfunction and history of myocardial infarction increase the risk of future cardiac events, making it less likely that the patient will survive for an extended period without any significant cardiac complications."
722,722,P0776,"Age: 61
Gender: Male 
Weight: 75 kg
Height: 170 cm
NYHA Class: II
Blood Pressure: 105/80 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Diabetes, Hypertension, Myocardial Infarction
Albumin (g/L): 40,4
ALT or GPT (IU/L): 14.0
AST or GOT (IU/L): 15.0
Total Cholesterol (mmol/L): 4,95
Creatinine (mmol/L): 259.0
Gamma-glutamil transpeptidase (IU/L): 19
Glucose (mmol/L): 8,8
Hemoglobin (g/L): 143.0
HDL (mmol/L): 0,86
Potassium (mEq/L): 4,1
LDL (mmol/L): 3,45
Sodium (mEq/L): 141.0
Pro-BNP (ng/L): 3274.0
Protein (g/L): 69
Troponin (ng/mL): 0,01
TSH (mIU/L): 1,7
Urea (mg/dL): 15,8
LVEF (%): 33.0
Medications: Calcium Channel Blocker, Amiodarone, Beta Blockers, Loop Diuretics, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: Second-degree AVB - type II
            ",sudden cardiac death,"RANKING: 1. Sudden Cardiac Death
REASONING: 

This patient has a high-risk profile for sudden cardiac death due to several factors. Firstly, the patient has a history of ischemic dilated cardiomyopathy, which is a well-established risk factor for sudden cardiac death. Additionally, the patient's left ventricular ejection fraction (LVEF) is severely reduced at 33%, indicating significant cardiac dysfunction.

The patient's ECG impression also highlights several concerning features, including ventricular extrasystole, non-sustained ventricular tachycardia, and non-sustained ventricular tachycardia, all of which are associated with an increased risk of sudden cardiac death. The presence of ventricular extrasystole and non-sustained ventricular tachycardia, in particular, suggests a high risk of arrhythmic events.

Furthermore, the patient's medication regimen, including amiodarone, a medication known to increase the risk of arrhythmias, does not appear to be adequately controlling the patient's heart rhythm. The patient's troponin levels are also elevated, which may indicate some degree of cardiac damage.

Given these factors, I would rank sudden cardiac death as the most likely outcome for this patient over the next few years. The patient's overall health status, including his age, weight, and comorbidities, also contribute to this prognosis.

RANKING: 2. Pump Failure Death
REASONING: 

While pump failure death is a concern for patients with advanced heart failure, this patient's current ejection fraction is not severely impaired, and his NYHA class is II, indicating that he is still able to perform moderate physical activity without excessive symptoms. However, his ejection fraction is still significantly reduced, and his cardiac dysfunction may be progressing.

Additionally, the patient's elevated creatinine levels and urea levels suggest some degree of renal impairment, which can be a complication of advanced heart failure. The patient's electrolyte imbalances, including low potassium levels, also suggest some degree of cardiac dysfunction.

Given the patient's cardiac dysfunction and renal impairment, pump failure death is a possible outcome, but it is less likely than sudden cardiac death given the patient's ECG findings and medication regimen.

RANKING: 3. Survivor
REASONING: 

While the patient's age and comorbidities do increase his risk for mortality, his relatively preserved NYHA class and ejection fraction suggest that he may still have some residual cardiac function. However, his ECG findings and medication regimen raise concerns about his risk for arrhythmic events.

Given the patient's complex medical history and the presence of several risk factors, it is difficult to predict with certainty whether he will survive the next few years. However, compared to the other two options, I would rank survivor as the least likely outcome due to the patient's high risk of arrhythmic events and cardiac dysfunction."
723,723,P0779,"Age: 73
Gender: Female 
Weight: 68 kg
Height: 155 cm
NYHA Class: III
Blood Pressure: 100/75 mmHg
Past Medical History: Idiopathic dilated cardiomyopathy, Dyslipemia
Albumin (g/L): 44,8
ALT or GPT (IU/L): 19.0
AST or GOT (IU/L): 17.0
Total Cholesterol (mmol/L): 3,91
Creatinine (mmol/L): 107.0
Gamma-glutamil transpeptidase (IU/L): 30
Glucose (mmol/L): 5,2
Hemoglobin (g/L): 135.0
HDL (mmol/L): 1,13
Potassium (mEq/L): 4,14
LDL (mmol/L): 2,02
Sodium (mEq/L): 140.0
Pro-BNP (ng/L): 2428.0
Protein (g/L): 75,2
Troponin (ng/mL): 0,02
TSH (mIU/L): 1,7
Urea (mg/dL): 9,9
LVEF (%): 31.0
Medications: Digoxin, Loop Diuretics, Spironolactone, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",sudden cardiac death,"RANKING: 
1. Survivor
REASONING: 
The patient's overall clinical presentation and test results indicate a high risk of adverse outcomes, but the presence of ventricular extrasystole, non-sustained ventricular tachycardia, and a high level of Pro-BNP (2428.0 ng/L) suggest a high risk of sudden cardiac death. However, the patient is currently being treated with medications for heart failure (Digoxin, Loop Diuretics, Spironolactone, and ACE Inhibitor), which indicates a level of management for heart failure. Additionally, the patient's hemoglobin level is within a relatively normal range, and the troponin level is within the normal range. These factors suggest that the patient is currently stable, and with proper management, the patient may survive the next few years. 

2. Pump failure death
REASONING: 
Given the patient's NYHA Class III status, indicating severe heart failure, and the elevated creatinine level (107.0 mmol/L), indicating impaired renal function, there is a high risk of pump failure. However, the patient is currently being treated with medications for heart failure, which suggests that some level of management is in place. The elevated Pro-BNP level and the presence of non-sustained ventricular tachycardia also suggest a high risk of adverse outcomes. However, the patient's overall clinical presentation and test results do not indicate an immediate risk of pump failure.

3. Sudden cardiac death
REASONING: 
The patient's ECG impression highlights a high risk of sudden cardiac death, with the presence of ventricular extrasystole, non-sustained ventricular tachycardia, and a high level of Pro-BNP. However, the patient is currently being treated with medications for heart failure, which may mitigate some of these risks. The patient's overall clinical presentation and test results do not indicate an immediate risk of pump failure, but the high risk of sudden cardiac death cannot be entirely ruled out."
724,724,P0784,"Age: 59
Gender: Male 
Weight: 79 kg
Height: 162 cm
NYHA Class: II
Blood Pressure: 120/80 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Diabetes, Peripheral vascular disease, Hypertension, Myocardial Infarction
Albumin (g/L): 48,1
ALT or GPT (IU/L): 80.0
AST or GOT (IU/L): 51.0
Total Cholesterol (mmol/L): 5,7
Creatinine (mmol/L): 117.0
Gamma-glutamil transpeptidase (IU/L): 109
Glucose (mmol/L): 8,3
Hemoglobin (g/L): 158.0
HDL (mmol/L): 0,99
Potassium (mEq/L): 4,39
LDL (mmol/L): 3,5
Sodium (mEq/L): 141.0
Pro-BNP (ng/L): 543.0
Protein (g/L): 84,9
Troponin (ng/mL): 0,01
TSH (mIU/L): 1,62
Urea (mg/dL): 7,1
LVEF (%): 29.0
Medications: Amiodarone, Beta Blockers, Digoxin, Loop Diuretics, ACE Inhibitor, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",sudden cardiac death,"RANKING: 
1. Sudden Cardiac Death
2. Pump Failure Death
3. Survivor

REASONING:

Based on the provided patient data, I predict that the patient is at high risk for sudden cardiac death. The patient has a history of ischemic dilated cardiomyopathy, which is a condition that significantly increases the risk of arrhythmias and sudden cardiac death. The presence of ventricular extrasystole, polymorphic ventricular tachycardia, and non-sustained ventricular tachycardia on the ECG impression further supports this prediction. The patient's low left ventricular ejection fraction (LVEF) of 29.0% is also a significant indicator of poor cardiac function, which increases the risk of arrhythmias and sudden cardiac death.

While pump failure death is also a possible outcome, it is less likely in this patient. The patient is already on medications to manage heart failure, including ACE inhibitors, beta blockers, and digoxin, which suggest that the patient has some level of heart failure management. Additionally, the patient's current renal function (creatinine level of 117.0 mmol/L) is not severely impaired, which would suggest that the patient is not in acute kidney injury or severe heart failure.

The patient's survival is the least likely outcome due to the presence of multiple risk factors, including ischemic dilated cardiomyopathy, arrhythmias, and poor cardiac function. The patient's age (59 years) and gender (male) are also risk factors for sudden cardiac death. The patient's biomarkers, such as troponin and BNP, are not indicative of acute myocardial infarction or significant cardiac stress, which would suggest a more favorable prognosis.

Overall, the combination of the patient's cardiac history, ECG findings, and laboratory results make sudden cardiac death the most likely outcome."
725,725,P0804,"Age: 73
Gender: Male 
Weight: 81 kg
Height: 162 cm
NYHA Class: II
Blood Pressure: 80/40 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Myocardial Infarction
Albumin (g/L): 42,2
ALT or GPT (IU/L): 24.0
AST or GOT (IU/L): 33.0
Total Cholesterol (mmol/L): 5,55
Creatinine (mmol/L): 110.0
Gamma-glutamil transpeptidase (IU/L): 95
Glucose (mmol/L): 5,2
Hemoglobin (g/L): 125.0
HDL (mmol/L): 1,34
Potassium (mEq/L): 4,3
LDL (mmol/L): 3,89
Sodium (mEq/L): 136.0
Pro-BNP (ng/L): 949.0
Protein (g/L): 80,2
Troponin (ng/mL): 0,04
TSH (mIU/L): 2,06
Urea (mg/dL): 8,1
LVEF (%): 25.0
Medications: Beta Blockers, Digoxin, Loop Diuretics, Spironolactone, ACE Inhibitor, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",sudden cardiac death,"RANKING: 1. Sudden Cardiac Death
REASONING:

Based on the provided patient data, I predict that the patient is at high risk of sudden cardiac death over the next few years. The following factors contribute to this prediction:

1. Age and NYHA Class II: The patient is 73 years old and has a moderate to severe heart failure (NYHA Class II), which increases the risk of cardiac events.
2. History of Ischemic Dilated Cardiomyopathy and Myocardial Infarction: These conditions indicate a significant burden of coronary artery disease, which can lead to arrhythmias and sudden cardiac death.
3. Low Ejection Fraction (LVEF) of 25%: A severely reduced LVEF is a hallmark of advanced heart failure and a significant predictor of mortality.
4. Presence of Ventricular Extrasystoles and Non-sustained Ventricular Tachycardia: These arrhythmias are indicative of electrical instability in the heart, which can degenerate into more severe arrhythmias, including ventricular fibrillation or ventricular tachycardia.
5. Low Blood Pressure (80/40 mmHg): Hypotension can further compromise cardiac function and increase the risk of cardiac events.
6. Presence of Elevated Pro-BNP: Elevated B-type natriuretic peptide levels indicate increased ventricular stretch and stress, which is associated with a higher risk of cardiac events.
7. Medication list: The patient is already taking multiple medications for heart failure and arrhythmias, which may not be sufficient to control the underlying cardiac disease.

Given these factors, I predict that the patient is at high risk of sudden cardiac death over the next few years. The presence of ventricular arrhythmias, low ejection fraction, and other comorbidities make it challenging to manage the patient's condition effectively, and sudden cardiac death is a likely outcome."
726,726,P0806,"Age: 71
Gender: Male 
Weight: 78 kg
Height: 170 cm
NYHA Class: II
Blood Pressure: 115/70 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Dyslipemia, Hypertension
Albumin (g/L): 42
ALT or GPT (IU/L): 16.0
AST or GOT (IU/L): 16.0
Total Cholesterol (mmol/L): 4,09
Creatinine (mmol/L): 133.0
Gamma-glutamil transpeptidase (IU/L): 22
Glucose (mmol/L): 5,1
Hemoglobin (g/L): 158.0
HDL (mmol/L): 1,09
Potassium (mEq/L): 4,3
LDL (mmol/L): 2,4
Sodium (mEq/L): 140.0
Pro-BNP (ng/L): 170.0
Protein (g/L): 68
T4 (ng/L): 17
Troponin (ng/mL): 0,01
TSH (mIU/L): 1,77
Urea (mg/dL): 8,32
LVEF (%): 35.0
Medications: Beta Blockers, Spironolactone, Statins, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",sudden cardiac death,"RANKING: 
1. Sudden cardiac death
2. Pump failure death
3. Survivor

REASONING:

The patient's prognosis is predominantly influenced by their underlying conditions, specifically their ischemic dilated cardiomyopathy and the low left ventricular ejection fraction (LVEF) of 35%. This suggests that the heart is not functioning efficiently, and the patient is at risk of experiencing cardiac complications.

The patient's elevated BNP levels (170 ng/L) and the presence of ventricular extrasystoles on the ECG further indicate increased cardiac stress and potential cardiac strain. The patient's age, weight, and NYHA Class II also contribute to the risk of cardiac events.

While the patient's blood pressure is within a relatively normal range, their elevated creatinine level (8.32 mg/dL) suggests some degree of renal impairment, which can be a risk factor for cardiac complications.

The patient's lipid profile shows dyslipidemia, which can contribute to cardiovascular disease progression. However, the presence of statins and an ACE inhibitor suggests that the patient is receiving standard cardiovascular risk management.

Considering these factors, the most likely outcome is sudden cardiac death, as the patient's underlying cardiac condition, combined with the elevated BNP levels and ventricular extrasystoles, increases the risk of cardiac arrhythmias and sudden cardiac death.

Pump failure death is a possible outcome due to the patient's low LVEF and the presence of heart failure symptoms (NYHA Class II). However, the patient's current medication regimen and the absence of other heart failure symptoms suggest that pump failure is not an imminent risk.

Survival is the least likely outcome, as the patient's cardiac condition and risk factors suggest a higher likelihood of cardiac complications, such as sudden cardiac death or pump failure."
727,727,P0838,"Age: 75
Gender: Male 
Weight: 67 kg
Height: 165 cm
NYHA Class: II
Blood Pressure: 130/80 mmHg
Past Medical History: Hypertropic cardiomyopathy
Albumin (g/L): 42,1
ALT or GPT (IU/L): 16.0
AST or GOT (IU/L): 18.0
Total Cholesterol (mmol/L): 7,1
Creatinine (mmol/L): 119.0
Gamma-glutamil transpeptidase (IU/L): 31
Glucose (mmol/L): 5,8
Hemoglobin (g/L): 130.0
HDL (mmol/L): 1,3
Potassium (mEq/L): 3,92
LDL (mmol/L): 5,23
Sodium (mEq/L): 134.0
Pro-BNP (ng/L): 8831.0
Protein (g/L): 80
Troponin (ng/mL): 0,03
TSH (mIU/L): 3,01
Urea (mg/dL): 10,8
LVEF (%): 15.0
Medications: Beta Blockers, Loop Diuretics, Spironolactone
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: First-degree Atrioventricular block (AVB)
            ",sudden cardiac death,"RANKING: 
1. Survivor
2. Pump failure death
3. Sudden cardiac death

REASONING:

Based on the provided patient data, I would rank the prognoses as follows:

1. Survivor: 
The patient's age (75) is a significant risk factor for cardiac events. However, the patient's NYHA Class II indicates that they have some limitation in physical activity but can still perform daily activities without excessive fatigue. The patient's LVEF is 15%, which is significantly reduced, indicating left ventricular dysfunction. Despite this, the patient is on beta blockers, loop diuretics, and spironolactone, which are standard treatments for heart failure and hypertension. The patient's biomarkers, such as troponin and BNP, are not excessively elevated, suggesting that the patient may not be in acute heart failure. Additionally, the patient's ECG shows no signs of ventricular tachycardia or other life-threatening arrhythmias. Overall, while the patient has significant cardiac dysfunction, their current treatment regimen and lack of acute biomarkers suggest that they may be able to survive for an extended period.

2. Pump failure death:
Given the patient's reduced LVEF and NYHA Class II, pump failure is a significant concern. The patient's elevated BNP (8831.0 ng/L) suggests significant left ventricular dysfunction, which can lead to heart failure. The patient's elevated creatinine (10.8 mg/dL) also indicates impaired renal function, which can be a complication of heart failure. While the patient is on diuretics and spironolactone, which are standard treatments for heart failure, the patient's elevated BNP and creatinine levels suggest that they may still be at risk for pump failure.

3. Sudden cardiac death:
The patient's ECG shows a first-degree AV block, which is a risk factor for sudden cardiac death. Additionally, the patient's LVEF is significantly reduced, which increases the risk of arrhythmias and sudden cardiac death. While the patient is on beta blockers, which can help reduce the risk of sudden cardiac death, the patient's other risk factors, such as the ECG findings and reduced LVEF, suggest that they are still at risk for sudden cardiac death. However, considering the patient's relatively stable biomarkers and lack of acute arrhythmias, sudden cardiac death is the least likely of the three prognoses."
728,728,P0846,"Age: 58
Gender: Male 
Weight: 86 kg
Height: 165 cm
NYHA Class: II
Blood Pressure: 90/60 mmHg
Past Medical History: Idiopathic dilated cardiomyopathy
Albumin (g/L): 45
ALT or GPT (IU/L): 16.0
AST or GOT (IU/L): 19.0
Total Cholesterol (mmol/L): 5,35
Creatinine (mmol/L): 164.0
Gamma-glutamil transpeptidase (IU/L): 7
Glucose (mmol/L): 4,7
Hemoglobin (g/L): 139.0
HDL (mmol/L): 0,96
Potassium (mEq/L): 5,3
LDL (mmol/L): 3,65
Sodium (mEq/L): 141.0
Pro-BNP (ng/L): 3551.0
Protein (g/L): 76
T3 (pg/dL): 0,04
T4 (ng/L): 16
Troponin (ng/mL): 0,01
TSH (mIU/L): 1,04
Urea (mg/dL): 11,65
LVEF (%): 36.0
Medications: Beta Blockers, Loop Diuretics, Spironolactone, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",sudden cardiac death,"RANKING: 1. Sudden cardiac death
REASONING:

Based on the provided patient data, I would rank sudden cardiac death as the most likely outcome over the next few years. Here's why:

1. Severe left ventricular dysfunction: The patient has an LVEF of 36.0%, which indicates significant left ventricular dysfunction. This is a strong predictor of adverse outcomes, including sudden cardiac death.

2. Low ejection fraction: The LVEF is a key indicator of cardiac function. A low ejection fraction, such as 36.0%, suggests that the heart is not pumping efficiently, which increases the risk of arrhythmias and sudden cardiac death.

3. NYHA Class II: The patient has a moderate level of symptoms, indicating that the heart is not functioning well enough to maintain normal physical activity. This suggests that the heart is not able to meet the body's demands, increasing the risk of cardiac complications.

4. History of idiopathic dilated cardiomyopathy: The patient has a history of dilated cardiomyopathy, which is a condition characterized by the enlargement of the heart's chambers, leading to decreased cardiac function. This condition increases the risk of arrhythmias and sudden cardiac death.

5. High troponin levels: The patient has a mildly elevated troponin level (0.01 ng/mL), which indicates some degree of cardiac muscle damage. Elevated troponin levels are associated with an increased risk of cardiac events, including sudden cardiac death.

6. Low eGFR: The patient has a low creatinine level (11.65 mg/dL), which may indicate some degree of kidney dysfunction. Kidney dysfunction can lead to fluid overload, which can increase the risk of cardiac complications, including heart failure and arrhythmias.

While the patient is on medications, including beta blockers, loop diuretics, spironolactone, and an ACE inhibitor, which are commonly used to manage heart failure and hypertension, the patient's underlying cardiac condition and other risk factors suggest that sudden cardiac death is the most likely outcome.

Given the combination of severe left ventricular dysfunction, low ejection fraction, history of idiopathic dilated cardiomyopathy, mildly elevated troponin levels, and low eGFR, I rank sudden cardiac death as the most likely outcome over the next few years."
729,729,P0848,"Age: 63
Gender: Female 
Weight: 72 kg
Height: 175 cm
NYHA Class: III
Blood Pressure: 120/90 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Diabetes, Dyslipemia, Myocardial Infarction
Albumin (g/L): 43
ALT or GPT (IU/L): 13.0
AST or GOT (IU/L): 17.0
Total Cholesterol (mmol/L): 4,53
Creatinine (mmol/L): 84.0
Gamma-glutamil transpeptidase (IU/L): 30
Glucose (mmol/L): 5,7
Hemoglobin (g/L): 124.0
HDL (mmol/L): 1,11
Potassium (mEq/L): 4,9
LDL (mmol/L): 2,74
Sodium (mEq/L): 137.0
Pro-BNP (ng/L): 11195.0
Protein (g/L): 70
T3 (pg/dL): 0,02
T4 (ng/L): 18
Troponin (ng/mL): 0,1
TSH (mIU/L): 3,97
Urea (mg/dL): 7,32
LVEF (%): 25.0
Medications: Diabetes Medication, Beta Blockers, Loop Diuretics, Spironolactone, Statins, ACE Inhibitor, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",sudden cardiac death,"RANKING: 1. Survivor
REASONING: The patient's age is 63, which is considered advanced for a female patient. However, the patient's NYHA Class III indicates a severe heart failure, which is a significant risk factor for cardiac events. The patient has a history of ischemic dilated cardiomyopathy, which is a well-established risk factor for sudden cardiac death. The patient's LVEF of 25.0 is significantly reduced, indicating severe left ventricular dysfunction. Additionally, the patient has a history of myocardial infarction, which further increases the risk of cardiac events.

Although the patient has a number of comorbidities, including diabetes, dyslipemia, and hypertension, the presence of severe left ventricular dysfunction and a history of myocardial infarction outweigh these factors. The patient's ECG shows non-sustained ventricular tachycardia, which is a significant risk factor for sudden cardiac death. However, it's worth noting that the patient is on medications that are commonly used to manage heart failure and arrhythmias, which may help to reduce the risk of cardiac events.

Given the patient's advanced age, severe left ventricular dysfunction, and history of myocardial infarction, the likelihood of sudden cardiac death is still relatively high. However, the patient's current ECG findings and medication regimen suggest that they are being adequately managed, which may mitigate some of this risk.

RANKING: 2. Pump Failure Death
REASONING: Pump failure death is a possible outcome for this patient, given their severe left ventricular dysfunction (LVEF of 25.0) and NYHA Class III heart failure. The patient's history of myocardial infarction and ischemic dilated cardiomyopathy also increase the risk of pump failure. However, the patient is currently on medications that are commonly used to manage heart failure, including loop diuretics, spironolactone, and ACE inhibitors, which may help to reduce the risk of pump failure.

The patient's ECG findings, including non-sustained ventricular tachycardia, also suggest that they are at risk of cardiac events. However, the patient's current medication regimen and ECG findings do not suggest that pump failure is imminent.

RANKING: 3. Sudden Cardiac Death
REASONING: While the patient's ECG shows non-sustained ventricular tachycardia, which is a significant risk factor for sudden cardiac death, the patient is currently on medications that are commonly used to manage arrhythmias, including beta blockers and nitrovasodilators. Additionally, the patient's LVEF is not severely impaired, and they are not currently experiencing symptoms of heart failure.

However, the patient's advanced age and history of myocardial infarction and ischemic dilated cardiomyopathy do increase the risk of cardiac events, including sudden cardiac death. While the patient's current ECG findings and medication regimen suggest that they are being adequately managed, the presence of non-sustained ventricular tachycardia and severe left ventricular dysfunction increase the risk of cardiac events, making sudden cardiac death a possible outcome."
730,730,P0860,"Age: 67
Gender: Male 
Weight: 90 kg
Height: 166 cm
NYHA Class: II
Blood Pressure: 190/110 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Diabetes, Dyslipemia, Peripheral vascular disease, Hypertension, Myocardial Infarction
Albumin (g/L): 49,4
ALT or GPT (IU/L): 14.0
AST or GOT (IU/L): 14.0
Total Cholesterol (mmol/L): 3,31
Creatinine (mmol/L): 79.0
Gamma-glutamil transpeptidase (IU/L): 17
Glucose (mmol/L): 7,5
Hemoglobin (g/L): 140.0
HDL (mmol/L): 1,19
Potassium (mEq/L): 4,1
LDL (mmol/L): 1,55
Sodium (mEq/L): 141.0
Pro-BNP (ng/L): 597.0
Protein (g/L): 84,2
T3 (pg/dL): 0,06
T4 (ng/L): 19
TSH (mIU/L): 0,07
Urea (mg/dL): 6,32
LVEF (%): 35.0
Medications: Calcium Channel Blocker, Beta Blockers, Statins, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: TPSV
        - Bradycardia: No
            ",sudden cardiac death,"RANKING: 
1. Sudden cardiac death
2. Pump failure death
3. Survivor

REASONING:

Based on the patient data provided, I would rank the prognoses as follows:

1. Sudden cardiac death: The patient's history of ischemic dilated cardiomyopathy, hypertension, and myocardial infarction, combined with the current ECG findings of ventricular extrasystole, suggest a high risk of arrhythmias. The patient's elevated Pro-BNP levels (597.0 ng/L) and low LVEF (35.0%) indicate severe cardiac dysfunction. The presence of ventricular extrasystole on the ECG further supports this risk. The patient's medications, including beta blockers and nitrovasodilators, may not be adequately addressing the underlying cardiac issues, and the patient's high blood pressure (190/110 mmHg) may be contributing to the risk of sudden cardiac death.

2. Pump failure death: The patient's low LVEF (35.0%) and elevated Pro-BNP levels (597.0 ng/L) indicate severe cardiac dysfunction, which increases the risk of pump failure. The patient's history of heart failure (NYHA Class II) and the presence of ventricular extrasystole on the ECG also support this risk.

3. Survivor: While the patient's history and current data suggest a high risk of cardiac-related complications, the patient's age (67) and overall physical condition (weight: 90 kg, height: 166 cm) are not particularly severe. However, the patient's elevated blood pressure, high cholesterol, and diabetes may still pose a risk for cardiovascular events. Additionally, the patient's ECG findings do not indicate any acute arrhythmias, which reduces the risk of sudden cardiac death. Nevertheless, the patient's overall prognosis is still guarded due to the presence of multiple comorbidities and cardiac dysfunction.

Please note that this prognosis is based on the information provided and should be used as a general guideline. A comprehensive evaluation by a cardiologist and further testing (e.g., echocardiogram, stress test) may be necessary to confirm the diagnosis and develop an individualized treatment plan."
731,731,P0880,"Age: 84
Gender: Male 
Weight: 80 kg
Height: 162 cm
NYHA Class: II
Blood Pressure: 110/70 mmHg
Past Medical History: Hypertensive cardiomyopathy, Diabetes, Hypertension
Albumin (g/L): 42
ALT or GPT (IU/L): 24.0
AST or GOT (IU/L): 20.0
Total Cholesterol (mmol/L): 3,49
Creatinine (mmol/L): 106.0
Gamma-glutamil transpeptidase (IU/L): 16
Glucose (mmol/L): 8,8
Hemoglobin (g/L): 132.0
HDL (mmol/L): 1,01
Potassium (mEq/L): 4,2
LDL (mmol/L): 2,09
Sodium (mEq/L): 144.0
Pro-BNP (ng/L): 444.0
Protein (g/L): 71
T4 (ng/L): 17
Troponin (ng/mL): 0,01
TSH (mIU/L): 1,46
Urea (mg/dL): 10,48
LVEF (%): 30.0
Medications: Diabetes Medication, Beta Blockers, Statins, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",sudden cardiac death,"RANKING: 1. Sudden cardiac death
REASONING:

Based on the provided patient data, I would rank the patient's prognosis as sudden cardiac death. The patient's age (84 years) and NYHA Class II heart failure status indicate a high risk for cardiac complications. The patient's LVEF of 30.0% is significantly reduced, suggesting severe left ventricular dysfunction, which is a common cause of sudden cardiac death. 

Additionally, the presence of non-sustained ventricular tachycardia (NSVT) on the ECG impression further increases the risk of sudden cardiac death. NSVT is a marker of arrhythmogenic substrate and can lead to ventricular fibrillation, which is a common cause of sudden cardiac death.

The patient's past medical history of hypertensive cardiomyopathy, diabetes, and hypertension also contributes to the risk of cardiac complications. The elevated creatinine level (106.0 mmol/L) and the low albumin level (42 g/L) suggest chronic kidney disease, which can further exacerbate cardiac dysfunction and increase the risk of sudden cardiac death.

The patient's medication regimen, which includes beta blockers, statins, and an ACE inhibitor, is generally well-tailored to manage the patient's hypertension and heart failure. However, the presence of NSVT on the ECG impression suggests that the patient may require more aggressive management of arrhythmias, which may not be adequately addressed by the current medication regimen.

While the patient's troponin level is within normal limits, the patient's overall clinical presentation and ECG findings make sudden cardiac death the most likely prognosis."
732,732,P0898,"Age: 67
Gender: Male 
Weight: 85 kg
Height: 177 cm
NYHA Class: II
Blood Pressure: 130/80 mmHg
Past Medical History: Hypertropic cardiomyopathy
Albumin (g/L): 37,1
ALT or GPT (IU/L): 86.0
AST or GOT (IU/L): 49.0
Total Cholesterol (mmol/L): 4,58
Creatinine (mmol/L): 96.0
Gamma-glutamil transpeptidase (IU/L): 177
Glucose (mmol/L): 4,2
Hemoglobin (g/L): 140.0
HDL (mmol/L): 1,29
Potassium (mEq/L): 4,4
LDL (mmol/L): 2,95
Sodium (mEq/L): 140.0
Pro-BNP (ng/L): 5629.0
Protein (g/L): 59,4
T4 (ng/L): 13
TSH (mIU/L): 1,06
Urea (mg/dL): 5,16
LVEF (%): 40.0
Medications: Diabetes Medication, Loop Diuretics, Spironolactone, ACE Inhibitor, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: TPSV
        - Bradycardia: No
            ",sudden cardiac death,"RANKING: 1. Survivor
REASONING: 

The patient's NYHA Class II indicates a moderate level of heart failure, but the patient is still able to perform daily activities with some limitation. The presence of hypertension, diabetes, and a history of hypertrophic cardiomyopathy increases the risk of cardiovascular events. However, the patient's current medications (diabetes medication, loop diuretics, spironolactone, ACE inhibitor, and nitrovasodilator) suggest a well-managed cardiovascular disease. The ECG findings of ventricular extrasystole (polymorphic) and paroxysmal supraventricular tachyarrhythmia (TPSV) are concerning, but the absence of ventricular tachycardia and non-sustained ventricular tachycardia makes it less likely that the patient will experience sudden cardiac death in the near future. The patient's elevated Pro-BNP levels (5629.0 ng/L) indicate significant heart failure, but the patient's hemoglobin level (140.0 g/L) and lack of anemia suggest that the patient's heart failure is not severely decompensated.

RANKING: 2. Pump failure death
REASONING: 

Given the patient's NYHA Class II and elevated Pro-BNP levels (5629.0 ng/L), it is likely that the patient will experience heart failure exacerbation or decompensation in the near future. The patient's elevated creatinine level (5.16 mg/dL) suggests kidney impairment, which can exacerbate heart failure. The patient's medications may not be sufficient to manage the patient's heart failure, and the patient's LVEF (40.0%) is significantly reduced, indicating poor cardiac function.

RANKING: 3. Sudden cardiac death
REASONING: 

While the patient's ECG findings of ventricular extrasystole (polymorphic) and paroxysmal supraventricular tachyarrhythmia (TPSV) are concerning, the absence of ventricular tachycardia and non-sustained ventricular tachycardia makes it less likely that the patient will experience sudden cardiac death in the near future. The patient's overall clinical presentation and laboratory findings do not suggest a high risk of sudden cardiac death. The patient's medications and medical history suggest a more chronic and manageable condition, rather than an acute life-threatening event."
733,733,P0938,"Age: 71
Gender: Male 
Weight: 94 kg
Height: 171 cm
NYHA Class: III
Blood Pressure: 96/67 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Myocardial Infarction
Albumin (g/L): 37,1
ALT or GPT (IU/L): 13.0
AST or GOT (IU/L): 15.0
Total Cholesterol (mmol/L): 4,24
Creatinine (mmol/L): 88.0
Gamma-glutamil transpeptidase (IU/L): 37
Glucose (mmol/L): 6,9
Hemoglobin (g/L): 103.0
HDL (mmol/L): 1,03
Potassium (mEq/L): 4,6
LDL (mmol/L): 2,82
Sodium (mEq/L): 143.0
Protein (g/L): 71,9
T4 (ng/L): 16
TSH (mIU/L): 3,71
Urea (mg/dL): 7,15
LVEF (%): 25.0
Medications: Calcium Channel Blocker, Loop Diuretics, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",sudden cardiac death,"RANKING: 
1. Sudden cardiac death
2. Pump failure death
3. Survivor

REASONING:

Based on the provided patient data, I rank the three prognoses as follows:

1. Sudden cardiac death: The patient's history of ischemic dilated cardiomyopathy, myocardial infarction, and current NYHA Class III symptoms suggest a high risk of cardiac arrhythmias. The ECG impression of ventricular extrasystole, a type of abnormal heart rhythm, further increases the risk of sudden cardiac death. Additionally, the patient's low left ventricular ejection fraction (LVEF) of 25.0 indicates significant left ventricular dysfunction, which can lead to arrhythmias and sudden cardiac death.

2. Pump failure death: Given the patient's history of myocardial infarction and current NYHA Class III symptoms, pump failure is a plausible outcome. The patient's low LVEF and elevated creatinine levels (7.15 mg/dL) suggest compromised cardiac function, which can lead to heart failure. However, the presence of ventricular extrasystole on the ECG and the patient's overall clinical picture make sudden cardiac death a more likely outcome.

3. Survivor: While the patient's age (71) and other comorbidities (e.g., hypertension, diabetes) contribute to the risk of mortality, the patient's current clinical status and ECG findings make sudden cardiac death a more likely outcome than pump failure. The patient's low HDL cholesterol (1.03 mmol/L) and elevated triglycerides (not provided) also suggest an increased risk of cardiovascular events, but the presence of ventricular extrasystole and low LVEF make sudden cardiac death a more probable outcome.

In summary, the combination of the patient's cardiac history, ECG findings, and current clinical status make sudden cardiac death the most likely outcome, followed by pump failure, and then survivor."
734,734,P0951,"Age: 63
Gender: Male 
Weight: 55 kg
Height: 165 cm
NYHA Class: II
Blood Pressure: 156/85 mmHg
Past Medical History: Enolic dilated cardiomyopathy, Hypertension
Albumin (g/L): 44
ALT or GPT (IU/L): 14.0
AST or GOT (IU/L): 14.0
Total Cholesterol (mmol/L): 4,86
Creatinine (mmol/L): 88.0
Gamma-glutamil transpeptidase (IU/L): 18
Glucose (mmol/L): 5,2
HDL (mmol/L): 1,55
Potassium (mEq/L): 5,8
LDL (mmol/L): 2,92
Sodium (mEq/L): 134.0
Pro-BNP (ng/L): 167.0
Protein (g/L): 73
T3 (pg/dL): 0,06
T4 (ng/L): 16
TSH (mIU/L): 1,13
Urea (mg/dL): 5,66
LVEF (%): 21.0
Medications: Beta Blockers, Digoxin, Loop Diuretics, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",sudden cardiac death,"RANKING: 
1. Pump failure death
2. Sudden cardiac death
3. Survivor

REASONING:

Based on the provided patient data, I would rank the prognoses as follows:

1. Pump failure death: The patient has a history of dilated cardiomyopathy, which is a condition where the heart's ability to pump blood is compromised. The LVEF (Left Ventricular Ejection Fraction) of 21.0 indicates severely impaired cardiac function. The patient's NYHA Class II classification suggests moderate symptoms, and the elevated creatinine level (88.0) may indicate some degree of renal impairment, which can be associated with heart failure. The presence of digoxin, a medication typically used to treat heart failure, further supports this prognosis. The patient's elevated BNP levels (167.0 ng/L) also suggest elevated ventricular wall stress, which is a hallmark of heart failure.

2. Sudden cardiac death: The patient's ECG findings of ventricular extrasystoles (polymorphic) and elevated T-wave inversions may indicate an increased risk of arrhythmias. While the patient does not have a history of ventricular tachycardia or bradycardia, the presence of ventricular extrasystoles and elevated T-wave inversions can increase the risk of sudden cardiac death.

3. Survivor: While the patient's overall condition is concerning, the presence of beta blockers, digoxin, and an ACE inhibitor, which are commonly used to manage heart failure and hypertension, suggests that the patient is receiving standard treatment. The patient's age (63) and weight (55 kg) are not particularly concerning, and the patient's HDL and glucose levels are within normal ranges. However, the patient's overall clinical presentation and the presence of ventricular extrasystoles and elevated T-wave inversions on the ECG make this prognosis less likely compared to pump failure death and sudden cardiac death.

Please note that this prognosis is based on the provided data and should be interpreted with caution. A thorough clinical evaluation and further testing may be necessary to confirm the patient's prognosis."
735,735,P0967,"Age: 69
Gender: Male 
Weight: 58 kg
Height: 156 cm
NYHA Class: II
Blood Pressure: 156/79 mmHg
Past Medical History: Hypertensive cardiomyopathy
Albumin (g/L): 39
ALT or GPT (IU/L): 16.0
AST or GOT (IU/L): 11.0
Total Cholesterol (mmol/L): 6,41
Creatinine (mmol/L): 124.0
Gamma-glutamil transpeptidase (IU/L): 15
Glucose (mmol/L): 4,6
Hemoglobin (g/L): 119.0
Pro-BNP (ng/L): 4999.0
Protein (g/L): 70
T3 (pg/dL): 0,05
T4 (ng/L): 23
Troponin (ng/mL): 0,01
TSH (mIU/L): 2,17
Urea (mg/dL): 9,32
LVEF (%): 35.0
Medications: Calcium Channel Blocker, Beta Blockers, Loop Diuretics, Statins, Hydralazine
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: TPSV
        - Bradycardia: No
            ",sudden cardiac death,"RANKING: 1. Sudden cardiac death
REASONING: 

This patient's prognosis is ranked as sudden cardiac death due to the combination of several high-risk factors. The patient has a history of hypertensive cardiomyopathy, which is a condition that can lead to left ventricular dysfunction and arrhythmias. The patient's LVEF (left ventricular ejection fraction) is significantly reduced at 35.0%, indicating poor left ventricular function, which is a strong predictor of adverse outcomes.

The patient's ECG shows ventricular extrasystoles, which are abnormal heartbeats that originate in the ventricles and can increase the risk of sudden cardiac death. Additionally, the patient's troponin level is slightly elevated, which may indicate some degree of myocardial injury.

The patient's age, weight, and blood pressure are also factors that contribute to the risk of sudden cardiac death. The patient is 69 years old, which is an advanced age for a heart attack, and the patient's blood pressure is slightly elevated, which can increase the risk of cardiac events.

While the patient is taking medications to manage their condition, including beta blockers, calcium channel blockers, and diuretics, the patient's overall risk factors and ECG findings suggest that they are at high risk for sudden cardiac death. 

The other two options, survivor and pump failure death, are less likely given the patient's high-risk factors and ECG findings. Pump failure death is a possibility, but it is typically seen in patients with more advanced heart failure, which is not clearly present in this case. Survivor is also less likely given the patient's high-risk factors and ECG findings."
736,736,P0968,"Age: 71
Gender: Male 
Weight: 87 kg
Height: 160 cm
NYHA Class: II
Blood Pressure: 130/85 mmHg
Past Medical History: Idiopathic dilated cardiomyopathy, Dyslipemia, Hypertension, Myocardial Infarction
Albumin (g/L): 45
ALT or GPT (IU/L): 13.0
AST or GOT (IU/L): 10.0
Total Cholesterol (mmol/L): 4,4
Creatinine (mmol/L): 150.0
Gamma-glutamil transpeptidase (IU/L): 30
Glucose (mmol/L): 5,7
Hemoglobin (g/L): 144.0
HDL (mmol/L): 1,01
Potassium (mEq/L): 5,6
LDL (mmol/L): 2,12
Sodium (mEq/L): 135.0
Protein (g/L): 75
T3 (pg/dL): 0,05
T4 (ng/L): 17
Troponin (ng/mL): 0,01
TSH (mIU/L): 2,26
Urea (mg/dL): 13,31
LVEF (%): 35.0
Medications: Beta Blockers, Spironolactone, Statins, Hydralazine
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",sudden cardiac death,"RANKING: 
1. Sudden cardiac death
2. Pump failure death
3. Survivor

REASONING:

This patient has a high-risk profile for cardiac events. The key factors contributing to this risk include:

- Age: 71 years, which increases the likelihood of cardiac events.
- NYHA Class II, indicating mild symptoms of heart failure.
- Idiopathic dilated cardiomyopathy, which is a significant risk factor for sudden cardiac death and heart failure.
- Hypertension and dyslipidemia, which can contribute to cardiac damage and increase the risk of cardiac events.
- Elevated creatinine levels (150.0 mmol/L), indicating impaired kidney function, which can be a marker of cardiac dysfunction.
- Low LVEF (35.0%), which indicates significant left ventricular dysfunction.
- Presence of ventricular extrasystole (polymorphic) on the ECG, which can be a precursor to ventricular tachycardia.
- Elevated troponin levels (0.01 ng/mL), indicating some degree of cardiac damage.
- Low HDL (1.01 mmol/L), which can contribute to increased cardiovascular risk.

Given these factors, the patient is at high risk for cardiac events. Sudden cardiac death is a possible outcome due to the combination of advanced age, underlying heart disease, and abnormal ECG findings. Pump failure death is also a possibility due to the patient's severe left ventricular dysfunction and impaired kidney function. However, the presence of ventricular extrasystole and elevated troponin levels suggest that sudden cardiac death is a more immediate and likely risk compared to pump failure death."
737,737,P0972,"Age: 69
Gender: Female 
Weight: 80 kg
Height: 154 cm
NYHA Class: III
Blood Pressure: 130/80 mmHg
Past Medical History: Hypertensive cardiomyopathy, Diabetes, Dyslipemia, Hypertension, Myocardial Infarction
Albumin (g/L): 34
ALT or GPT (IU/L): 29.0
AST or GOT (IU/L): 14.0
Total Cholesterol (mmol/L): 5,25
Creatinine (mmol/L): 53.0
Gamma-glutamil transpeptidase (IU/L): 43
Glucose (mmol/L): 8,8
Hemoglobin (g/L): 139.0
HDL (mmol/L): 1,55
Potassium (mEq/L): 3,8
LDL (mmol/L): 2,64
Sodium (mEq/L): 138.0
Pro-BNP (ng/L): 436.0
Protein (g/L): 69
T4 (ng/L): 12
Troponin (ng/mL): 0,01
TSH (mIU/L): 3,4
Urea (mg/dL): 4,49
LVEF (%): 60.0
Medications: Calcium Channel Blocker, Diabetes Medication, Loop Diuretics, Statins, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: TPSV
        - Bradycardia: No
            ",sudden cardiac death,"RANKING: 1. Survivor
REASONING: 

This patient is at high risk for a poor outcome due to several factors. The patient's NYHA Class III indicates severe heart failure, which is a significant predictor of mortality. The patient's left ventricular ejection fraction (LVEF) is also low at 60%, indicating reduced cardiac function. The presence of hypertension, diabetes, and dyslipidemia further increases the risk of cardiovascular events. Additionally, the patient's elevated creatinine level (53.0 mmol/L) suggests impaired renal function, which is a common comorbidity in patients with heart failure. The patient's elevated troponin level (0.01 ng/mL) is not significantly elevated, but it is still a marker of cardiac stress. The patient's ECG impression shows ventricular extrasystole, which is a marker of arrhythmia risk. However, the patient is not experiencing any ventricular tachycardia or other life-threatening arrhythmias. Despite these factors, the patient is not currently experiencing any symptoms of acute cardiac failure or acute coronary syndrome, which suggests that they may still be able to survive with optimal management.

RANKING: 2. Pump failure death
REASONING: 

Given the patient's severe heart failure (NYHA Class III) and low LVEF, pump failure death is a possible outcome. The patient's elevated creatinine level and impaired renal function may also contribute to a higher risk of pump failure. The patient's ECG impression shows ventricular extrasystole, which can increase the risk of cardiac arrhythmias and potentially lead to pump failure. However, the patient is not experiencing any ventricular tachycardia or other life-threatening arrhythmias.

RANKING: 3. Sudden cardiac death
REASONING: 

Based on the patient's ECG impression, ventricular extrasystole is present, which is a risk factor for sudden cardiac death. However, the patient is not experiencing any ventricular tachycardia or other life-threatening arrhythmias. The patient's other comorbidities, such as hypertension, diabetes, and dyslipidemia, increase the risk of cardiovascular events, but the patient is not currently experiencing any acute cardiac symptoms. The patient's elevated troponin level and low LVEF also suggest cardiac stress, but the absence of other markers of acute cardiac failure or acute coronary syndrome reduces the risk of sudden cardiac death."
738,738,P0974,"Age: 80
Gender: Female 
Weight: 52 kg
Height: 154 cm
NYHA Class: III
Blood Pressure: 130/70 mmHg
Past Medical History: Idiopathic dilated cardiomyopathy
Albumin (g/L): 42
ALT or GPT (IU/L): 25.0
AST or GOT (IU/L): 17.0
Total Cholesterol (mmol/L): 6,03
Creatinine (mmol/L): 97.0
Gamma-glutamil transpeptidase (IU/L): 30
Glucose (mmol/L): 5,8
Hemoglobin (g/L): 135.0
HDL (mmol/L): 1,11
Potassium (mEq/L): 4,1
LDL (mmol/L): 4,37
Sodium (mEq/L): 137.0
Pro-BNP (ng/L): 4255.0
Protein (g/L): 75
T4 (ng/L): 15
Troponin (ng/mL): 0,01
TSH (mIU/L): 0,609
Urea (mg/dL): 9,32
LVEF (%): 27.0
Medications: Digoxin, Loop Diuretics, Spironolactone, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",sudden cardiac death,"RANKING: 
1. Sudden cardiac death
2. Pump failure death
3. Survivor

REASONING:

The patient's data suggests a high risk of adverse cardiac events. Here's a breakdown of the key factors contributing to this prognosis:

1. Low LVEF (27.0%): This indicates severely impaired cardiac function, which is a hallmark of advanced heart failure. A low ejection fraction is a strong predictor of poor outcomes, including sudden cardiac death.

2. NYHA Class III: This classification indicates severe symptoms of heart failure, suggesting that the patient experiences significant limitations in physical activity due to symptoms such as shortness of breath, fatigue, and swelling in the legs.

3. ECG Impression: The presence of ventricular extrasystoles, non-sustained ventricular tachycardia, and non-sustained ventricular tachycardia (CH>10) indicates arrhythmias, which are a significant risk factor for sudden cardiac death. The patient's heart is already compromised, and these arrhythmias can further destabilize the cardiac function.

4. Pro-BNP (4255.0 ng/L): Elevated B-type natriuretic peptide levels are a marker of increased cardiac stress and strain, which is consistent with heart failure.

5. Medications: The patient is on digoxin, loop diuretics, spironolactone, and an ACE inhibitor, which are standard treatments for heart failure. However, the presence of these medications does not necessarily improve the patient's prognosis.

Considering these factors, the patient is at high risk for cardiac complications. The combination of severely impaired cardiac function, arrhythmias, and elevated biomarkers of cardiac stress points towards a high risk of sudden cardiac death. Pump failure death is also a possible outcome due to the patient's advanced heart failure. However, given the presence of arrhythmias, I rank sudden cardiac death as the most likely outcome.

While the patient may survive, the risk of cardiac complications is still significant, and close monitoring and adjustments to the treatment plan are necessary to minimize the risk of adverse events."
739,739,P1001,"Age: 46
Gender: Male 
Weight: 90 kg
Height: 176 cm
NYHA Class: II
Blood Pressure: 130/70 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Dyslipemia, Hypertension, Myocardial Infarction
Albumin (g/L): 39
ALT or GPT (IU/L): 48.0
AST or GOT (IU/L): 39.0
Total Cholesterol (mmol/L): 2,79
Creatinine (mmol/L): 71.0
Gamma-glutamil transpeptidase (IU/L): 74
Glucose (mmol/L): 5,1
Hemoglobin (g/L): 137.0
HDL (mmol/L): 0,72
Potassium (mEq/L): 4,3
LDL (mmol/L): 1,71
Sodium (mEq/L): 139.0
Pro-BNP (ng/L): 766.0
Protein (g/L): 64
T4 (ng/L): 10
Troponin (ng/mL): 0,01
TSH (mIU/L): 2,89
Urea (mg/dL): 9,65
LVEF (%): 30.0
Medications: Beta Blockers, Loop Diuretics, Spironolactone, Statins, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: TPSV
        - Bradycardia: No
            ",sudden cardiac death,"RANKING: 1. Sudden Cardiac Death
REASONING: 
Based on the patient's medical history, physical examination, and test results, the most likely prognosis is sudden cardiac death. The patient has a history of ischemic dilated cardiomyopathy, which is a condition that significantly increases the risk of sudden cardiac death. The patient's left ventricular ejection fraction (LVEF) is severely impaired at 30%, indicating poor cardiac function. Additionally, the presence of ventricular extrasystole, non-sustained ventricular tachycardia, and non-sustained ventricular tachycardia (CH>10) on the ECG impression suggests a high risk of arrhythmic events. The patient's low ejection fraction and the presence of these arrhythmic disturbances make it likely that the patient's cardiac function will deteriorate rapidly, leading to sudden cardiac death. 

The patient's medications, such as beta blockers and ACE inhibitors, are aimed at managing symptoms and reducing the risk of further cardiac events, but in this case, the underlying cardiac pathology is too severe to be effectively managed by these medications alone. The presence of a high level of N-terminal pro-b-type natriuretic peptide (Pro-BNP) at 766.0 ng/L also supports the diagnosis of heart failure, but the patient's prognosis is still dominated by the risk of sudden cardiac death. 

The patient's weight, age, and other laboratory results, such as the elevated creatinine level and low HDL cholesterol, do not significantly alter the prognosis. Overall, the combination of the patient's severe cardiac dysfunction, arrhythmic disturbances, and other comorbid conditions makes sudden cardiac death the most likely outcome."
740,740,P1018,"Age: 60
Gender: Male 
Weight: 63 kg
Height: 159 cm
NYHA Class: II
Blood Pressure: 100/60 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Diabetes, Hypertension
Albumin (g/L): 42
ALT or GPT (IU/L): 34.0
AST or GOT (IU/L): 24.0
Total Cholesterol (mmol/L): 3,85
Creatinine (mmol/L): 265.0
Gamma-glutamil transpeptidase (IU/L): 87
Glucose (mmol/L): 12
HDL (mmol/L): 1,03
Potassium (mEq/L): 6,1
LDL (mmol/L): 1,91
Sodium (mEq/L): 131.0
Protein (g/L): 87
T3 (pg/dL): 0,04
T4 (ng/L): 15
TSH (mIU/L): 3,73
Urea (mg/dL): 25,29
LVEF (%): 25.0
Medications: Diabetes Medication, Beta Blockers, Loop Diuretics, Spironolactone, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",sudden cardiac death,"RANKING: 1. Sudden Cardiac Death
REASONING:

Based on the patient's data, the most likely prognosis is sudden cardiac death. The patient has a history of ischemic dilated cardiomyopathy, which is a condition that increases the risk of arrhythmias and sudden cardiac death. The patient's left ventricular ejection fraction (LVEF) is significantly reduced at 25%, indicating poor cardiac function. The presence of ventricular extrasystoles on the ECG impression also raises concerns about arrhythmic risk.

Additionally, the patient's medications, such as beta blockers, loop diuretics, and spironolactone, may be contributing to the development of hypotension (blood pressure 100/60 mmHg), which can further increase the risk of arrhythmias and sudden cardiac death.

The patient's electrolyte levels, such as low potassium (6.1 mEq/L), can also contribute to the risk of arrhythmias. The patient's creatinine level is elevated at 25.29 mg/dL, which may indicate kidney dysfunction, which can also contribute to electrolyte imbalances and arrhythmias.

While the patient's diabetes, hypertension, and other comorbidities are present, they do not seem to be directly contributing to the patient's current cardiac condition. Therefore, sudden cardiac death is the most likely prognosis.

Sudden cardiac death is more likely than pump failure death because the patient's cardiac function is already compromised, and the patient's medications and electrolyte imbalances may exacerbate the condition. Pump failure death is less likely because the patient's cardiac function is severely impaired, and the patient's medications may not be effective in improving cardiac function.

Survivor is the least likely prognosis because the patient's cardiac condition is severe, and the patient's medications and electrolyte imbalances may not be sufficient to prevent sudden cardiac death."
741,741,P0011,"Age: 59
Gender: Male 
Weight: 85 kg
Height: 163 cm
NYHA Class: III
Blood Pressure: 130/80 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Diabetes, Dyslipemia, Hypertension, Myocardial Infarction
Albumin (g/L): 41,8
ALT or GPT (IU/L): 25.0
AST or GOT (IU/L): 24.0
Total Cholesterol (mmol/L): 6,49
Creatinine (mmol/L): 125.0
Gamma-glutamil transpeptidase (IU/L): 45
Glucose (mmol/L): 9
Hemoglobin (g/L): 170.0
HDL (mmol/L): 1,68
Potassium (mEq/L): 4,6
LDL (mmol/L): 4,03
Sodium (mEq/L): 141.0
Pro-BNP (ng/L): 2382.0
Protein (g/L): 75
T3 (pg/dL): 0,05
T4 (ng/L): 16
Troponin (ng/mL): 0,02
TSH (mIU/L): 1,66
Urea (mg/dL): 9,8
LVEF (%): 22.0
Medications: Diabetes Medication, Beta Blockers, Loop Diuretics, Statins, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: TPSV
        - Bradycardia: No
            ",pump failure death,"RANKING: 
1. Sudden cardiac death
2. Pump failure death
3. Survivor

REASONING:

The patient's data indicates a high-risk profile for cardiac-related complications. The key factors contributing to this ranking are:

1. Low LVEF (22.0%): This severely impaired left ventricular function is a strong predictor of adverse outcomes, including sudden cardiac death and pump failure. The patient's history of ischemic dilated cardiomyopathy further exacerbates this risk.

2. Pro-BNP levels (2382.0 ng/L): Elevated B-type natriuretic peptide (BNP) levels are associated with increased risk of heart failure and sudden cardiac death. The high level in this patient suggests significant cardiac stress and strain.

3. NYHA Class III: This indicates severe symptoms, indicating a high level of functional impairment. Patients with NYHA Class III heart failure are at increased risk of adverse outcomes, including pump failure and sudden cardiac death.

4. History of myocardial infarction: This increases the risk of further cardiac events, including sudden cardiac death and pump failure.

5. Medication regimen: The patient is already on beta blockers, which can be beneficial for heart failure management, but the presence of diabetes, hypertension, and dyslipidemia may not be adequately controlled, contributing to ongoing cardiac stress.

6. ECG findings: While the ECG shows ventricular extrasystole, the absence of ventricular tachycardia and non-sustained ventricular tachycardia reduces the risk of sudden cardiac death, but the presence of ventricular extrasystoles is a marker of cardiac instability.

Considering these factors, the patient is at high risk for both sudden cardiac death and pump failure. However, the combination of severely impaired LVEF, elevated Pro-BNP levels, and NYHA Class III symptoms makes pump failure death the more likely outcome in the short term. Sudden cardiac death remains a concern, but it is less likely given the absence of ventricular tachycardia and non-sustained ventricular tachycardia on the ECG."
742,742,P0027,"Age: 79
Gender: Male 
Weight: 74 kg
Height: 150 cm
NYHA Class: II
Blood Pressure: 115/75 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Diabetes, Dyslipemia, Peripheral vascular disease, Myocardial Infarction
Albumin (g/L): 42,1
ALT or GPT (IU/L): 20.0
AST or GOT (IU/L): 19.0
Total Cholesterol (mmol/L): 3,44
Creatinine (mmol/L): 96.0
Gamma-glutamil transpeptidase (IU/L): 22
Glucose (mmol/L): 9,4
Hemoglobin (g/L): 137.0
HDL (mmol/L): 1,09
Potassium (mEq/L): 4,2
LDL (mmol/L): 1,6
Sodium (mEq/L): 141.0
Pro-BNP (ng/L): 990.0
Protein (g/L): 71
T3 (pg/dL): 0,05
T4 (ng/L): 19
Troponin (ng/mL): 0,01
TSH (mIU/L): 1,5
Urea (mg/dL): 6,24
LVEF (%): 27.0
Medications: Diabetes Medication, Beta Blockers, Loop Diuretics, Statins, ACE Inhibitor, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",pump failure death,"RANKING: 
1. Pump failure death
2. Sudden cardiac death
3. Survivor

REASONING:

The patient's clinical presentation and test results suggest a high risk of adverse outcomes. 

Firstly, the patient has a history of ischemic dilated cardiomyopathy, which is a significant risk factor for heart failure and arrhythmias. The left ventricular ejection fraction (LVEF) is severely impaired at 27%, indicating poor cardiac function. This, combined with the presence of ventricular tachycardia (VT) and non-sustained VT on the ECG, increases the risk of arrhythmic events.

The patient's elevated BNP levels (990 ng/L) and the presence of ventricular extrasystoles also suggest a high risk of heart failure and arrhythmias. The low LVEF and the presence of ventricular tachycardia on the ECG further support this.

The patient's age, weight, and comorbid conditions (diabetes, dyslipidemia, and peripheral vascular disease) also contribute to the overall risk of adverse outcomes. The patient's elevated creatinine level (96.0 mmol/L) suggests impaired renal function, which can be a complication of heart failure.

While the patient is on medications that are commonly used to manage heart failure and arrhythmias (diabetes medication, beta blockers, loop diuretics, statins, ACE inhibitor, and nitrovasodilator), the presence of pump failure death as the patient's outcome is still more likely than sudden cardiac death. This is because the patient's underlying heart condition (ischemic dilated cardiomyopathy) is the primary driver of the adverse outcome, and the medications are primarily aimed at managing symptoms and slowing disease progression rather than reversing the underlying pathology.

In contrast, sudden cardiac death is less likely in this case because the patient's ECG shows non-sustained VT, which is a transient and self-limiting condition. While the patient's ventricular extrasystoles are concerning, they are not a direct cause of sudden cardiac death.

Therefore, based on the patient's clinical presentation and test results, pump failure death is the most likely outcome, followed by sudden cardiac death, and then survivor."
743,743,P0030,"Age: 77
Gender: Female 
Weight: 60 kg
Height: 146 cm
NYHA Class: II
Blood Pressure: 95/70 mmHg
Past Medical History: Idiopathic dilated cardiomyopathy, Diabetes
Albumin (g/L): 42,9
ALT or GPT (IU/L): 8.0
AST or GOT (IU/L): 16.0
Total Cholesterol (mmol/L): 6,31
Creatinine (mmol/L): 100.0
Gamma-glutamil transpeptidase (IU/L): 26
Glucose (mmol/L): 9,9
Hemoglobin (g/L): 138.0
HDL (mmol/L): 1,53
Potassium (mEq/L): 4,7
LDL (mmol/L): 4,03
Sodium (mEq/L): 137.0
Pro-BNP (ng/L): 2118.0
Protein (g/L): 75
T3 (pg/dL): 0,05
T4 (ng/L): 17
Troponin (ng/mL): 0,01
TSH (mIU/L): 1,71
Urea (mg/dL): 10,02
LVEF (%): 20.0
Medications: Diabetes Medication, Beta Blockers, Loop Diuretics, ACE Inhibitor, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",pump failure death,"RANKING: 
1. Pump failure death 
REASONING: 
The patient's LVEF (Left Ventricular Ejection Fraction) is significantly reduced at 20.0%, indicating severe left ventricular dysfunction, which is a hallmark of advanced heart failure. The presence of idiopathic dilated cardiomyopathy, a condition characterized by the heart's inability to pump blood effectively, further supports this prognosis. Additionally, the elevated Pro-BNP levels (2118.0 ng/L) suggest significant ventricular strain, indicating that the heart is working hard to pump blood, which is consistent with heart failure. The patient's age, NYHA Class II symptoms, and the presence of diabetes also contribute to the likelihood of pump failure death.

The patient's blood pressure, lipid profile, and electrolyte levels are not indicative of acute cardiovascular instability, which could have suggested a more acute cardiac event. The absence of other significant ECG abnormalities, such as ventricular tachycardia or non-sustained ventricular tachycardia, further reduces the likelihood of an acute cardiac event. 

While the patient is on multiple medications for heart failure and diabetes, the severity of the patient's condition, as indicated by the low LVEF and elevated Pro-BNP levels, suggests that the patient's current medical management may not be sufficient to prevent pump failure death."
744,744,P0031,"Age: 76
Gender: Male 
Weight: 81 kg
Height: 166 cm
NYHA Class: II
Blood Pressure: 130/60 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Diabetes, Dyslipemia, Myocardial Infarction
Albumin (g/L): 43,2
ALT or GPT (IU/L): 10.0
AST or GOT (IU/L): 16.0
Total Cholesterol (mmol/L): 7,14
Creatinine (mmol/L): 195.0
Gamma-glutamil transpeptidase (IU/L): 26
Glucose (mmol/L): 5,4
Hemoglobin (g/L): 138.0
HDL (mmol/L): 0,85
Potassium (mEq/L): 4,4
LDL (mmol/L): 4,91
Sodium (mEq/L): 140.0
Pro-BNP (ng/L): 310.0
Protein (g/L): 77
T3 (pg/dL): 0,05
T4 (ng/L): 18
Troponin (ng/mL): 0,01
TSH (mIU/L): 2,1
Urea (mg/dL): 23,82
LVEF (%): 33.0
Medications: Diabetes Medication, Beta Blockers, Digoxin, Loop Diuretics, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",pump failure death,"RANKING: 1. Sudden cardiac death
REASONING: The patient has a history of ischemic dilated cardiomyopathy, which is a significant risk factor for sudden cardiac death. The patient's LVEF is severely impaired at 33%, indicating poor cardiac function. The presence of ventricular extrasystoles, non-sustained VT, and non-sustained ventricular tachycardia (CH>10) on the ECG impression further increases the risk of sudden cardiac death. Additionally, the patient's elevated BNP levels (310 ng/L) suggest significant ventricular strain and possible heart failure. The combination of these factors suggests a high risk of sudden cardiac death in the short term.

RANKING: 2. Pump failure death
REASONING: Pump failure death is a likely outcome due to the patient's severe heart failure symptoms, as indicated by the NYHA Class II classification and elevated BNP levels. The patient's impaired LVEF and history of myocardial infarction further support this prognosis. The presence of ventricular extrasystoles and non-sustained VT on the ECG impression may also contribute to the risk of pump failure.

RANKING: 3. Survivor
REASONING: While the patient's elevated BNP levels and ventricular extrasystoles suggest a significant risk of heart failure, the patient's overall clinical presentation and the presence of medications (e.g., beta blockers, ACE inhibitor) suggest that they may be receiving adequate management for their condition. However, the patient's severe heart failure symptoms and impaired LVEF make it less likely that they will survive without any significant cardiac events. Additionally, the patient's age (76) and multiple comorbidities (e.g., diabetes, dyslipemia) may also contribute to the overall poor prognosis."
745,745,P0034,"Age: 71
Gender: Male 
Weight: 61 kg
Height: 151 cm
NYHA Class: III
Blood Pressure: 110/60 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Dyslipemia, Myocardial Infarction
Albumin (g/L): 39,7
ALT or GPT (IU/L): 9.0
AST or GOT (IU/L): 17.0
Total Cholesterol (mmol/L): 4,84
Creatinine (mmol/L): 102.0
Gamma-glutamil transpeptidase (IU/L): 9
Glucose (mmol/L): 4,2
Hemoglobin (g/L): 124.0
HDL (mmol/L): 1,32
Potassium (mEq/L): 4,4
LDL (mmol/L): 2,97
Sodium (mEq/L): 141.0
Pro-BNP (ng/L): 32552.0
Protein (g/L): 79
T3 (pg/dL): 0,04
T4 (ng/L): 16
Troponin (ng/mL): 0,05
TSH (mIU/L): 4,9
Urea (mg/dL): 10,24
LVEF (%): 26.0
Medications: Digoxin, Loop Diuretics, Statins, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: TPSV
        - Bradycardia: No
            ",pump failure death,"RANKING: 
1. Pump failure death
2. Sudden cardiac death
3. Survivor

REASONING:

Pump failure death is the most likely outcome in this patient due to the presence of severe left ventricular dysfunction (LVEF 26.0) and the patient's history of ischemic dilated cardiomyopathy. The elevated BNP levels (32552.0 ng/L) further support this prognosis, indicating significant ventricular strain. The patient's NYHA Class III classification also suggests advanced heart failure. The presence of digoxin, loop diuretics, and ACE inhibitor medications suggests that the patient is already receiving optimal treatment for heart failure.

Sudden cardiac death is a possible outcome, but it is less likely in this patient due to the absence of any ECG findings suggestive of ventricular arrhythmias (ventricular tachycardia, non-sustained ventricular tachycardia, or ventricular extrasystoles). While the patient does have a history of myocardial infarction and dyslipemia, which can contribute to arrhythmias, the ECG does not indicate any immediate risk for ventricular arrhythmias.

The patient's survival is the least likely outcome due to the presence of advanced heart failure and the patient's age (71 years). The patient's LVEF is severely impaired, and the patient's NYHA Class III classification suggests that the patient is already experiencing significant symptoms of heart failure. While the patient is receiving optimal medical therapy, the underlying cardiac dysfunction is severe, making survival without any major cardiac event (pump failure or sudden cardiac death) less likely."
746,746,P0035,"Age: 73
Gender: Male 
Weight: 83 kg
Height: 169 cm
NYHA Class: II
Blood Pressure: 120/80 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Diabetes, Dyslipemia, Peripheral vascular disease, Hypertension, Myocardial Infarction
Albumin (g/L): 33,19
ALT or GPT (IU/L): 15.0
AST or GOT (IU/L): 16.0
Total Cholesterol (mmol/L): 3,03
Creatinine (mmol/L): 93.0
Gamma-glutamil transpeptidase (IU/L): 36
Glucose (mmol/L): 9,7
Hemoglobin (g/L): 122.0
HDL (mmol/L): 1,16
Potassium (mEq/L): 3,9
LDL (mmol/L): 1,4
Sodium (mEq/L): 138.0
Pro-BNP (ng/L): 752.0
Protein (g/L): 65
T3 (pg/dL): 0,05
T4 (ng/L): 16
Troponin (ng/mL): 0,01
TSH (mIU/L): 1,29
Urea (mg/dL): 7,8
LVEF (%): 39.0
Medications: Calcium Channel Blocker, Diabetes Medication, Beta Blockers, Statins, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: TPSV
        - Bradycardia: No
            ",pump failure death,"RANKING: 
1. Pump failure death
2. Sudden cardiac death
3. Survivor

REASONING:

Based on the patient's data, the most likely outcome is pump failure death. The patient has a history of ischemic dilated cardiomyopathy, which is a significant risk factor for heart failure. The LVEF is severely reduced at 39%, indicating poor cardiac function. The patient also has a history of myocardial infarction, which can further compromise cardiac function.

The patient's current ECG findings, including non-sustained ventricular tachycardia (VT) and polymorphic ventricular extrasystole, suggest an increased risk of arrhythmias, which can lead to sudden cardiac death. However, the presence of these arrhythmias is not as concerning as the patient's severely reduced LVEF and history of ischemic dilated cardiomyopathy.

The patient's medication regimen, including beta blockers and statins, is standard for managing heart failure and coronary artery disease. However, the fact that the patient is not receiving an ACE inhibitor or an ARB suggests that the management of heart failure may be inadequate.

While the patient's electrolytes and liver function tests are within normal limits, the patient's kidney function is mildly impaired, which can be a contributing factor to the development of heart failure.

In contrast, the patient's age, weight, and other demographic factors are not as significant of a risk factor for pump failure death as their cardiac history and current LVEF. Therefore, the likelihood of sudden cardiac death is lower than pump failure death.

Overall, the combination of the patient's severe cardiac dysfunction, history of myocardial infarction, and arrhythmias makes pump failure death the most likely outcome."
747,747,P0040,"Age: 83
Gender: Male 
Weight: 88 kg
Height: 159 cm
NYHA Class: II
Blood Pressure: 110/80 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Dyslipemia, Myocardial Infarction
Albumin (g/L): 42,9
ALT or GPT (IU/L): 15.0
AST or GOT (IU/L): 18.0
Total Cholesterol (mmol/L): 4,63
Creatinine (mmol/L): 128.0
Gamma-glutamil transpeptidase (IU/L): 30
Glucose (mmol/L): 7
Hemoglobin (g/L): 156.0
HDL (mmol/L): 1,11
Potassium (mEq/L): 4,8
LDL (mmol/L): 2,84
Sodium (mEq/L): 140.0
Pro-BNP (ng/L): 1184.0
Protein (g/L): 75
T3 (pg/dL): 0,06
T4 (ng/L): 15
Troponin (ng/mL): 0,01
TSH (mIU/L): 5,8
Urea (mg/dL): 10,91
LVEF (%): 40.0
Medications: Statins, ACE Inhibitor, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: First-degree Atrioventricular block (AVB)
            ",pump failure death,"RANKING: 1. Sudden cardiac death
REASONING: 

The patient has several risk factors that increase the likelihood of sudden cardiac death. These include:

1. Age: The patient is 83 years old, which is an advanced age for many cardiac events.
2. NYHA Class II: The patient has a moderate level of heart failure, which can increase the risk of arrhythmias and cardiac events.
3. Ischemic dilated cardiomyopathy: This condition can lead to electrical instability and increased risk of arrhythmias.
4. Previous myocardial infarction: This increases the risk of further cardiac events, including arrhythmias and cardiac death.
5. ECG Impression: The presence of ventricular extrasystole, non-sustained ventricular tachycardia, and first-degree atrioventricular block indicate electrical instability of the heart.
6. Pro-BNP levels: Elevated levels of B-type natriuretic peptide (BNP) are associated with increased risk of cardiac events, including sudden cardiac death.

Given these factors, the patient is at high risk for sudden cardiac death. The presence of non-sustained ventricular tachycardia and ventricular extrasystole on the ECG, combined with the patient's age, NYHA class, and history of ischemic cardiomyopathy, make sudden cardiac death the most likely outcome.

RANKING: 2. Pump failure death
REASONING: 

While the patient has a history of heart failure, the current LVEF is 40%, which is relatively low, indicating poor cardiac function. However, the patient is receiving medications for heart failure (ACE inhibitor and nitrovasodilator), which may help manage symptoms. The patient's BNP levels are elevated, indicating some degree of heart failure.

Given the patient's age, history of ischemic cardiomyopathy, and current LVEF, pump failure death is a possible outcome. However, the presence of medications for heart failure and the relatively low LVEF suggest that pump failure death is less likely than sudden cardiac death.

RANKING: 3. Survivor
REASONING: 

While the patient has a history of heart failure, the presence of medications for heart failure and the relatively low LVEF suggest that the patient may be able to manage symptoms and avoid severe cardiac events. The patient's age and NYHA class are also relatively mild, which may indicate a better prognosis.

However, the patient's ECG findings, including ventricular extrasystole and non-sustained ventricular tachycardia, indicate electrical instability of the heart. Additionally, the patient's history of ischemic cardiomyopathy and previous myocardial infarction increase the risk of cardiac events.

Overall, while the patient may survive, the presence of risk factors and ECG findings make pump failure death or sudden cardiac death more likely outcomes."
748,748,P0046,"Age: 71
Gender: Male 
Weight: 93 kg
Height: 170 cm
NYHA Class: II
Blood Pressure: 140/80 mmHg
Past Medical History: Idiopathic dilated cardiomyopathy, Hypertension
Albumin (g/L): 45,4
ALT or GPT (IU/L): 12.0
AST or GOT (IU/L): 19.0
Total Cholesterol (mmol/L): 4,5
Creatinine (mmol/L): 125.0
Gamma-glutamil transpeptidase (IU/L): 24
Glucose (mmol/L): 5
Hemoglobin (g/L): 143.0
HDL (mmol/L): 1,32
Potassium (mEq/L): 4,5
LDL (mmol/L): 2,69
Sodium (mEq/L): 143.0
Pro-BNP (ng/L): 475.0
Protein (g/L): 75
T3 (pg/dL): 0,03
T4 (ng/L): 5
Troponin (ng/mL): 0,01
TSH (mIU/L): 78,34
Urea (mg/dL): 10,02
LVEF (%): 30.0
Medications: Amiodarone, Spironolactone, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",pump failure death,"RANKING: 
1. Pump failure death
2. Sudden cardiac death
3. Survivor

REASONING:

Based on the provided patient data, the patient is at high risk for pump failure death due to the following reasons:

- The patient has a history of idiopathic dilated cardiomyopathy, which is a condition that weakens the heart muscle and impairs its ability to pump blood effectively. This condition is a significant risk factor for pump failure.
- The patient's left ventricular ejection fraction (LVEF) is 30.0%, which is significantly reduced, indicating that the heart is not pumping efficiently. A LVEF below 35% is generally considered a marker for pump failure.
- The patient has a history of hypertension, which can contribute to the progression of cardiomyopathy and worsen heart function.
- The patient's current medication regimen includes an ACE inhibitor, which is a common treatment for heart failure, but may not be sufficient to manage the patient's condition given the severity of the LVEF.
- The presence of non-sustained ventricular tachycardia (NSVT) on the ECG is also a concern, as it can be a marker for increased risk of sudden cardiac death.

While the patient's ECG also shows ventricular extrasystole and polymorphic ventricular tachycardia, these findings, while concerning, do not outweigh the significant impact of the patient's reduced LVEF and history of cardiomyopathy.

Sudden cardiac death is a possible outcome, but given the patient's reduced LVEF and history of cardiomyopathy, pump failure death is a more likely outcome in the next few years. Survivor is the least likely outcome due to the patient's advanced heart disease and the presence of NSVT on the ECG."
749,749,P0054,"Age: 55
Gender: Male 
Weight: 72 kg
Height: 170 cm
NYHA Class: III
Blood Pressure: 90/60 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Diabetes, Hypertension, Myocardial Infarction
Albumin (g/L): 47
ALT or GPT (IU/L): 30.0
AST or GOT (IU/L): 28.0
Total Cholesterol (mmol/L): 3
Creatinine (mmol/L): 147.0
Gamma-glutamil transpeptidase (IU/L): 246
Glucose (mmol/L): 9,3
Hemoglobin (g/L): 139.0
HDL (mmol/L): 1,09
Potassium (mEq/L): 5,1
LDL (mmol/L): 1,66
Sodium (mEq/L): 137.0
Pro-BNP (ng/L): 3765.0
Protein (g/L): 77
T3 (pg/dL): 0,05
T4 (ng/L): 24
Troponin (ng/mL): 0,01
TSH (mIU/L): 2,46
Urea (mg/dL): 16,26
LVEF (%): 25.0
Medications: Diabetes Medication, Beta Blockers, Digoxin, Loop Diuretics, Spironolactone, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",pump failure death,"RANKING: 
1. Pump failure death
2. Sudden cardiac death
3. Survivor

REASONING:

The patient's prognosis can be determined by analyzing the provided data, which indicates a high-risk profile for cardiac events. Here's the reasoning behind the ranking:

1. Pump failure death: The patient's left ventricular ejection fraction (LVEF) is severely impaired at 25%, indicating significant left ventricular dysfunction. This is a critical factor for predicting pump failure. Additionally, the patient's history of ischemic dilated cardiomyopathy, hypertension, and myocardial infarction further exacerbate the risk of pump failure. The patient's elevated creatinine level (147.0 mmol/L) and low eGFR (not provided) suggest compromised renal function, which is often associated with pump failure. The patient's current medication regimen, including digoxin, loop diuretics, and ACE inhibitors, aims to manage symptoms and slow disease progression but may not be sufficient to prevent pump failure.

2. Sudden cardiac death: The patient's ECG findings of ventricular extrasystole (monomorphic) suggest an increased risk of ventricular arrhythmias. While not indicative of ventricular tachycardia or tachycardia, ventricular extrasystoles can be a precursor to more severe arrhythmias. The patient's history of myocardial infarction and hypertension also increases the risk of arrhythmias. However, the absence of other high-risk ECG findings (e.g., ventricular tachycardia or non-sustained ventricular tachycardia) reduces the likelihood of sudden cardiac death.

3. Survivor: While the patient's age (55) and NYHA Class III status indicate a significant impairment of cardiac function, the patient's overall clinical presentation and ECG findings do not suggest an immediate and catastrophic cardiac event. The patient's serum creatinine level is elevated, but not critically high, and the patient's current medications are being used to manage symptoms and slow disease progression. Additionally, the patient's hemoglobin level (139.0 g/L) is within a relatively normal range, which suggests adequate oxygen delivery to tissues. Overall, while the patient is at risk for cardiac events, the available data suggest that pump failure death is the most likely outcome, followed by sudden cardiac death, and finally, survivor."
750,750,P0056,"Age: 54
Gender: Male 
Weight: 80 kg
Height: 160 cm
NYHA Class: III
Blood Pressure: 110/70 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Diabetes, Dyslipemia, Peripheral vascular disease, Myocardial Infarction
Albumin (g/L): 47,19
ALT or GPT (IU/L): 22.0
AST or GOT (IU/L): 15.0
Total Cholesterol (mmol/L): 3,72
Creatinine (mmol/L): 124.0
Gamma-glutamil transpeptidase (IU/L): 249
Glucose (mmol/L): 6,3
Hemoglobin (g/L): 151.0
HDL (mmol/L): 1,01
Potassium (mEq/L): 4
LDL (mmol/L): 1,99
Sodium (mEq/L): 141.0
Pro-BNP (ng/L): 3258.0
Protein (g/L): 75
T3 (pg/dL): 0,05
T4 (ng/L): 19
Troponin (ng/mL): 0,01
TSH (mIU/L): 3,58
Urea (mg/dL): 12,03
LVEF (%): 25.0
Medications: Calcium Channel Blocker, Beta Blockers, Loop Diuretics, Spironolactone, Statins, ACE Inhibitor, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: No
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",pump failure death,"RANKING: 1. Sudden cardiac death
REASONING: 

This patient has a high-risk profile for sudden cardiac death due to the presence of a significant history of ischemic dilated cardiomyopathy, which is a major risk factor for sudden cardiac death. The patient's LVEF is severely reduced at 25%, indicating a severely impaired cardiac function. Additionally, the patient's ECG shows no evidence of ventricular tachycardia or non-sustained ventricular tachycardia, but the presence of ventricular extrasystoles cannot be ruled out. The patient's troponin level is elevated at 0.01 ng/mL, which suggests some degree of myocardial damage.

The patient's medications, including beta blockers and ACE inhibitors, may not be sufficient to manage the patient's cardiac function and reduce the risk of sudden cardiac death. The patient's low ejection fraction and elevated BNP levels also suggest that the patient's heart is under significant strain, increasing the risk of sudden cardiac death.

While pump failure death is a possible outcome for this patient, it is likely that the patient's cardiac function will deteriorate further, leading to a sudden cardiac arrest. The patient's severe impairment of cardiac function, combined with the presence of risk factors for sudden cardiac death, make sudden cardiac death the most likely prognosis.

RANKING: 2. Pump failure death
REASONING: 

Given the patient's severely reduced LVEF and elevated BNP levels, pump failure death is a significant risk. The patient's cardiac function is severely impaired, and the patient's heart is under significant strain. The patient's medications, including beta blockers and ACE inhibitors, may help to reduce the risk of pump failure, but the patient's underlying cardiac disease is likely to continue to progress.

The patient's elevated creatinine level and urea level also suggest impaired renal function, which can contribute to the development of pump failure. The patient's low HDL cholesterol level and high triglyceride level also increase the risk of cardiovascular events.

While pump failure death is a possible outcome for this patient, it is less likely than sudden cardiac death due to the patient's severely impaired cardiac function.

RANKING: 3. Survivor
REASONING: 

Given the patient's severely reduced LVEF and elevated BNP levels, pump failure death is a significant risk. However, the patient's medications, including beta blockers and ACE inhibitors, may help to reduce the risk of pump failure. The patient's low ejection fraction and elevated creatinine level suggest that the patient's cardiac function is severely impaired, but the patient's survival is possible if the patient's cardiac function can be adequately managed.

The patient's age, gender, and comorbidities, including diabetes and peripheral vascular disease, also increase the risk of cardiovascular events. However, the patient's medications, including statins and spironolactone, may help to reduce the risk of cardiovascular events.

Overall, while pump failure death is a significant risk for this patient, the patient's survival is possible if the patient's cardiac function can be adequately managed."
751,751,P0065,"Age: 66
Gender: Male 
Weight: 106 kg
Height: 174 cm
NYHA Class: II
Blood Pressure: 110/60 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Myocardial Infarction
Albumin (g/L): 43,3
ALT or GPT (IU/L): 31.0
AST or GOT (IU/L): 23.0
Total Cholesterol (mmol/L): 5,22
Creatinine (mmol/L): 143.0
Gamma-glutamil transpeptidase (IU/L): 30
Glucose (mmol/L): 5,5
Hemoglobin (g/L): 152.0
HDL (mmol/L): 1,47
Potassium (mEq/L): 4,9
LDL (mmol/L): 3
Sodium (mEq/L): 135.0
Pro-BNP (ng/L): 114.0
Protein (g/L): 76
T3 (pg/dL): 0,05
T4 (ng/L): 18
Troponin (ng/mL): 0,17
TSH (mIU/L): 0,85
Urea (mg/dL): 16,7
LVEF (%): 40.0
Medications: Spironolactone, ACE Inhibitor, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",pump failure death,"RANKING: 1. Sudden cardiac death
REASONING: 

The patient has a history of ischemic dilated cardiomyopathy, myocardial infarction, and a low left ventricular ejection fraction (LVEF) of 40%. These factors indicate significant cardiac dysfunction. The patient's elevated creatinine level (143.0 mmol/L) and low albumin level (43.3 g/L) suggest renal impairment, which can be a complication of cardiac disease. The patient's elevated troponin level (0.17 ng/mL) also suggests myocardial damage.

Given these factors, the patient is at high risk for cardiac arrhythmias, particularly ventricular arrhythmias, which can lead to sudden cardiac death. The presence of ventricular extrasystole (Monomorphic) on the ECG impression further supports this risk.

While pump failure death is a possible outcome, the patient's current medications, including spironolactone, ACE inhibitor, and nitrovasodilator, suggest that the patient is receiving optimal medical therapy for heart failure. However, the patient's LVEF is still low, indicating that cardiac function is compromised.

Therefore, based on the patient's medical history, laboratory results, and ECG findings, sudden cardiac death is the most likely outcome over the next few years."
752,752,P0066,"Age: 47
Gender: Male 
Weight: 95 kg
Height: 175 cm
NYHA Class: III
Blood Pressure: 110/85 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Diabetes, Dyslipemia, Peripheral vascular disease
Albumin (g/L): 33,4
ALT or GPT (IU/L): 15.0
AST or GOT (IU/L): 28.0
Total Cholesterol (mmol/L): 4,58
Creatinine (mmol/L): 167.0
Gamma-glutamil transpeptidase (IU/L): 121
Glucose (mmol/L): 10,6
Hemoglobin (g/L): 125.0
HDL (mmol/L): 0,78
Potassium (mEq/L): 5,3
LDL (mmol/L): 3
Sodium (mEq/L): 138.0
Pro-BNP (ng/L): 4797.0
Protein (g/L): 85
T3 (pg/dL): 0,04
T4 (ng/L): 12
Troponin (ng/mL): 0,06
TSH (mIU/L): 4,36
Urea (mg/dL): 15,15
LVEF (%): 35.0
Medications: Diabetes Medication, Angiotensin II Receptor Blocker, Loop Diuretics, Spironolactone, Statins
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: TPSV
        - Bradycardia: No
            ",pump failure death,"RANKING: 1. Sudden cardiac death
REASONING: The patient has a high-risk profile with a history of ischemic dilated cardiomyopathy, diabetes, dyslipemia, and peripheral vascular disease, which increases the risk of sudden cardiac death. The patient's left ventricular ejection fraction (LVEF) is severely impaired at 35%, indicating poor cardiac function. Additionally, the patient has a high level of N-terminal pro-b-type natriuretic peptide (Pro-BNP) at 4797.0 ng/L, which is a marker of cardiac stress and strain. The patient's ECG shows ventricular extrasystole, which is a precursor to ventricular fibrillation, a common cause of sudden cardiac death.

The patient's current medications, including a beta-blocker, diuretics, and statins, may not be sufficient to manage the underlying cardiac conditions, and the patient's electrolyte levels (e.g., low potassium) may be contributing to arrhythmias. The patient's overall risk factors and ECG findings make sudden cardiac death the most likely prognosis.

RANKING: 2. Pump failure death
REASONING: Pump failure death is a likely outcome given the patient's severe left ventricular dysfunction (LVEF 35%) and the presence of heart failure symptoms (NYHA Class III). The patient's elevated Pro-BNP level and elevated creatinine level suggest that the heart is under strain, and the patient may be at risk of progressive heart failure.

The patient's medications, including loop diuretics and spironolactone, are intended to manage symptoms of heart failure, but the patient's underlying cardiac conditions and risk factors may still lead to progressive heart failure and pump failure.

RANKING: 3. Survivor
REASONING: While the patient has a high-risk profile, the patient's current medications and the presence of a beta-blocker suggest that the patient may be receiving some level of cardiac protection. Additionally, the patient's age and overall health status are not extremely poor, which may contribute to a slightly better prognosis.

However, the patient's severe left ventricular dysfunction, high Pro-BNP level, and presence of ventricular extrasystole on ECG make pump failure death a more likely outcome than survivor. Furthermore, the patient's elevated creatinine level and electrolyte imbalances may indicate underlying kidney dysfunction, which can exacerbate heart failure and worsen outcomes."
753,753,P0078,"Age: 75
Gender: Male 
Weight: 59 kg
Height: 163 cm
NYHA Class: III
Blood Pressure: 110/60 mmHg
Past Medical History: Idiopathic dilated cardiomyopathy, Diabetes, Hypertension
Albumin (g/L): 42,8
ALT or GPT (IU/L): 17.0
AST or GOT (IU/L): 26.0
Total Cholesterol (mmol/L): 3,9
Creatinine (mmol/L): 215.0
Gamma-glutamil transpeptidase (IU/L): 29
Glucose (mmol/L): 5,1
Hemoglobin (g/L): 127.0
HDL (mmol/L): 1,06
Potassium (mEq/L): 5,5
LDL (mmol/L): 1,99
Sodium (mEq/L): 146.0
Pro-BNP (ng/L): 7468.0
Protein (g/L): 75
T3 (pg/dL): 0,04
T4 (ng/L): 17
Troponin (ng/mL): 0,16
TSH (mIU/L): 4,97
Urea (mg/dL): 15,82
LVEF (%): 25.0
Medications: Amiodarone, Digoxin, Loop Diuretics
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",pump failure death,"RANKING: 1. Sudden cardiac death
REASONING: The patient's clinical presentation, laboratory results, and ECG findings suggest a high risk of sudden cardiac death. The patient has a history of idiopathic dilated cardiomyopathy, which is a significant risk factor for sudden cardiac death. The patient's LVEF of 25.0 is severely reduced, indicating significant left ventricular dysfunction. The presence of non-sustained ventricular tachycardia (NSVT) on the ECG, which is a marker of electrical instability, further increases the risk of sudden cardiac death. Additionally, the patient's elevated Troponin level (0.16 ng/mL) suggests some degree of cardiac injury, which may be related to the underlying cardiomyopathy. The patient's NYHA class III also indicates severe symptoms, which can be a sign of advanced heart failure.

RANKING: 2. Pump failure death
REASONING: Given the patient's severe left ventricular dysfunction (LVEF 25.0) and NYHA class III symptoms, it is likely that the patient will eventually experience pump failure. The patient's elevated creatinine level (215.0 mol/L) and urea level (15.82 mg/dL) also suggest impaired renal function, which can be a complication of heart failure. The patient's medications, including loop diuretics, may help manage symptoms, but the underlying cardiac condition will likely lead to pump failure in the long term.

RANKING: 3. Survivor
REASONING: While the patient's condition is severe, the patient's age (75) and the presence of certain medications (e.g., Amiodarone) may suggest that the patient could potentially survive for some time with optimal management. However, the patient's significant left ventricular dysfunction and NYHA class III symptoms make it less likely that they will survive for an extended period without experiencing either sudden cardiac death or pump failure. Additionally, the patient's elevated creatinine level and urea level suggest that their renal function is compromised, which can further increase the risk of complications."
754,754,P0083,"Age: 81
Gender: Male 
Weight: 70 kg
Height: 165 cm
NYHA Class: III
Blood Pressure: 100/70 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Diabetes, Peripheral vascular disease, Myocardial Infarction
Albumin (g/L): 40,9
ALT or GPT (IU/L): 16.0
AST or GOT (IU/L): 12.0
Total Cholesterol (mmol/L): 3,9
Creatinine (mmol/L): 207.0
Gamma-glutamil transpeptidase (IU/L): 19
Glucose (mmol/L): 6,9
Hemoglobin (g/L): 119.0
HDL (mmol/L): 1,03
Potassium (mEq/L): 4,5
LDL (mmol/L): 2,53
Sodium (mEq/L): 144.0
Pro-BNP (ng/L): 428.0
Protein (g/L): 71
T3 (pg/dL): 0,03
T4 (ng/L): 17
Troponin (ng/mL): 0,02
TSH (mIU/L): 2,14
Urea (mg/dL): 28,28
LVEF (%): 35.0
Medications: Diabetes Medication, Digoxin, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",pump failure death,"RANKING: 1. Sudden cardiac death
REASONING: The patient's ECG findings, particularly the presence of ventricular tachycardia (non-sustained VT) and ventricular extrasystole (polymorphic), indicate an increased risk of arrhythmias. The patient's NYHA Class III classification and history of ischemic dilated cardiomyopathy, myocardial infarction, and peripheral vascular disease suggest a compromised cardiac function. The elevated Pro-BNP levels (428 ng/L) also indicate heart failure. The presence of non-sustained ventricular tachycardia (CH>10) is a significant predictor of sudden cardiac death. The patient's low LVEF (35.0%) further increases the risk of arrhythmias and cardiac events.

RANKING: 2. Pump failure death
REASONING: The patient's NYHA Class III classification, history of heart failure, and elevated Pro-BNP levels (428 ng/L) indicate a high risk of pump failure. The patient's LVEF (35.0%) is also low, suggesting severe cardiac dysfunction. The presence of non-sustained ventricular tachycardia (CH>10) further increases the risk of pump failure. The patient's elevated creatinine level (207.0 mmol/L) may indicate some degree of renal impairment, which can contribute to pump failure.

RANKING: 3. Survivor
REASONING: While the patient's age (81 years) and some of their comorbidities (e.g., diabetes, peripheral vascular disease) may increase the risk of mortality, the presence of medications (e.g., ACE inhibitor, digoxin) and the relatively stable blood pressure (100/70 mmHg) suggest some level of cardiac protection. However, the patient's ECG findings and cardiac dysfunction (NYHA Class III, LVEF 35.0%) and elevated Pro-BNP levels indicate a high risk of cardiac events, making a favorable outcome (survivor) less likely."
755,755,P0099,"Age: 68
Gender: Male 
Weight: 81 kg
Height: 160 cm
NYHA Class: II
Blood Pressure: 120/60 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Diabetes, Dyslipemia, Peripheral vascular disease, Hypertension, Myocardial Infarction
Albumin (g/L): 44,3
ALT or GPT (IU/L): 19.0
AST or GOT (IU/L): 15.0
Total Cholesterol (mmol/L): 4,63
Creatinine (mmol/L): 95.0
Gamma-glutamil transpeptidase (IU/L): 33
Glucose (mmol/L): 16,5
Hemoglobin (g/L): 146.0
HDL (mmol/L): 0,93
Potassium (mEq/L): 4,7
LDL (mmol/L): 2,87
Sodium (mEq/L): 136.0
Pro-BNP (ng/L): 103.0
Protein (g/L): 69
T3 (pg/dL): 0,04
T4 (ng/L): 21
Troponin (ng/mL): 0,01
TSH (mIU/L): 0,89
Urea (mg/dL): 6,45
LVEF (%): 25.0
Medications: Diabetes Medication, Angiotensin II Receptor Blocker, Beta Blockers, Statins
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",pump failure death,"RANKING: 1. Survivor
REASONING: The patient's age (68) and NYHA Class II heart failure classification indicate a moderate level of cardiac dysfunction. However, the patient's left ventricular ejection fraction (LVEF) is 25%, which suggests a significant impairment of cardiac function. Despite this, the patient's blood pressure is well-controlled (120/60 mmHg), and they are receiving medications for diabetes, hypertension, and dyslipidemia, which are all relevant to cardiovascular health.

The patient's biomarker results, such as troponin (0.01 ng/mL), TSH (0.89 mIU/L), and creatinine (6.45 mg/dL), do not indicate acute cardiac stress or significant renal impairment. The presence of anemia (Hemoglobin 146.0 g/L) may contribute to a slightly higher risk of cardiovascular events, but it is not a contraindication for survival.

In contrast, the patient's Pro-BNP level (103 ng/L) is elevated, indicating some degree of ventricular strain. However, it is not excessively high, and the patient's other biomarkers do not suggest acute cardiac stress. The patient's lipid profile, with total cholesterol 4.63 mmol/L, is not particularly high, and their LDL level (2.87 mmol/L) is within a relatively safe range.

Given these factors, I would rank the patient as having a moderate risk of adverse outcomes. However, the presence of ischemic dilated cardiomyopathy, diabetes, and hypertension suggests that the patient is at increased risk for cardiovascular events. Therefore, I would rank the patient's prognosis as survivor, but with a moderate risk of cardiovascular events.

RANKING: 2. Sudden cardiac death
REASONING: While the patient's Pro-BNP level is elevated, which may indicate some degree of ventricular strain, it is not excessively high. The patient's ECG impression does not show any signs of ventricular tachycardia or other arrhythmias that would increase the risk of sudden cardiac death.

However, the patient's history of myocardial infarction, ischemic dilated cardiomyopathy, and hypertension increase the risk of sudden cardiac death. The patient's LVEF is also significantly impaired, which may contribute to a higher risk of arrhythmias and sudden cardiac death.

Additionally, the patient's creatinine level (6.45 mg/dL) is elevated, which may indicate some degree of renal impairment. This can contribute to a higher risk of cardiovascular events, including sudden cardiac death.

While the patient's blood pressure is well-controlled, the presence of diabetes, hypertension, and dyslipidemia may increase the risk of cardiovascular events, including sudden cardiac death.

RANKING: 3. Pump failure death
REASONING: The patient's LVEF is significantly impaired (25%), and they have a history of ischemic dilated cardiomyopathy, which increases the risk of heart failure. The patient's NYHA Class II classification indicates moderate heart failure, and their creatinine level is elevated, which may indicate some degree of renal impairment.

The patient's Pro-BNP level is elevated, which suggests some degree of ventricular strain. While the patient's blood pressure is well-controlled, the presence of diabetes, hypertension, and dyslipidemia may contribute to a higher risk of cardiovascular events, including heart failure.

The patient's medication regimen includes beta blockers, which are typically used to reduce the risk of heart failure, but the patient's LVEF is still significantly impaired. The patient's lipid profile is not particularly high, but the presence of ischemic dilated cardiomyopathy and hypertension increases the risk of cardiovascular events, including pump failure."
756,756,P0107,"Age: 53
Gender: Male 
Weight: 74 kg
Height: 167 cm
NYHA Class: III
Blood Pressure: 127/76 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Dyslipemia, Peripheral vascular disease, Hypertension, Myocardial Infarction
Albumin (g/L): 43,5
ALT or GPT (IU/L): 29.0
AST or GOT (IU/L): 27.0
Total Cholesterol (mmol/L): 4,99
Creatinine (mmol/L): 105.0
Gamma-glutamil transpeptidase (IU/L): 41
Glucose (mmol/L): 7,3
Hemoglobin (g/L): 138.0
HDL (mmol/L): 1,01
Potassium (mEq/L): 4,5
LDL (mmol/L): 2,87
Sodium (mEq/L): 136.0
Pro-BNP (ng/L): 670.0
Protein (g/L): 74,1
T3 (pg/dL): 0,01
T4 (ng/L): 11
TSH (mIU/L): 2,3
Urea (mg/dL): 8,32
LVEF (%): 27.0
Medications: Loop Diuretics, Spironolactone, Statins, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",pump failure death,"RANKING: 1. Survivor
REASONING: The patient's current medical history and test results suggest that they are at high risk for cardiovascular events, but they are not currently experiencing any life-threatening symptoms. The patient has a history of ischemic dilated cardiomyopathy, which is a significant risk factor for pump failure, but they are currently on medications that are aimed at managing this condition (Loop Diuretics, Spironolactone, Statins, ACE Inhibitor). The patient's LVEF is 27.0, which is significantly reduced, indicating a compromised cardiac function. However, the patient's blood pressure is well-controlled, and their renal function is not severely impaired. Additionally, the patient's electrolyte levels and liver function tests are relatively normal. The presence of non-sustained ventricular tachycardia (CH>10) is a concerning finding, but it is not a guarantee of pump failure death. Given the patient's overall condition and the absence of acute symptoms, I would estimate a higher likelihood of survival with appropriate management and monitoring.

RANKING: 2. Sudden cardiac death
REASONING: The patient's history of ischemic dilated cardiomyopathy, non-sustained ventricular tachycardia (CH>10), and reduced LVEF (27.0) increase the risk of sudden cardiac death. The patient's ECG impression also shows ventricular extrasystole and polymorphic ventricular tachycardia, which are associated with an increased risk of ventricular arrhythmias. However, the patient is currently on medications that are aimed at managing their cardiovascular risk factors, and their blood pressure is well-controlled. While the patient's risk of sudden cardiac death is increased, the presence of a low level of beta-endorphins (T3: 0.01 pg/dL) and low HDL cholesterol (1.01 mmol/L) may indicate a lower risk of cardiac death.

RANKING: 3. Pump failure death
REASONING: The patient's reduced LVEF (27.0), history of ischemic dilated cardiomyopathy, and current medication regimen suggest a high risk of pump failure death. The patient's renal function is impaired (Creatinine: 105.0 mg/dL), which can contribute to worsening cardiac function and increased risk of pump failure. The patient's low HDL cholesterol (1.01 mmol/L) and elevated triglycerides (not provided) also increase the risk of cardiovascular events. The patient's protein level (74.1 g/L) is elevated, which may indicate fluid overload, a common complication in heart failure. While the patient is currently on diuretics and ACE inhibitors, the combination of these factors suggests a high risk of pump failure death."
757,757,P0129,"Age: 86
Gender: Male 
Weight: 80 kg
Height: 170 cm
NYHA Class: II
Blood Pressure: 140/70 mmHg
Past Medical History: Hypertensive cardiomyopathy, Hypertension
Albumin (g/L): 39
ALT or GPT (IU/L): 31.0
AST or GOT (IU/L): 20.0
Total Cholesterol (mmol/L): 4,4
Creatinine (mmol/L): 212.0
Gamma-glutamil transpeptidase (IU/L): 71
Glucose (mmol/L): 5,1
Hemoglobin (g/L): 129.0
HDL (mmol/L): 0,72
Potassium (mEq/L): 4,5
LDL (mmol/L): 2,82
Sodium (mEq/L): 143.0
Pro-BNP (ng/L): 2036.0
Protein (g/L): 70
T3 (pg/dL): 0,02
T4 (ng/L): 18
Troponin (ng/mL): 0,01
TSH (mIU/L): 5
Urea (mg/dL): 19,8
LVEF (%): 50.0
Medications: Loop Diuretics, Spironolactone, Hydralazine, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: TPSV
        - Bradycardia: No
            ",pump failure death,"RANKING: 1. Survivor
REASONING: The patient is 86 years old with a history of hypertensive cardiomyopathy, hypertension, and NYHA Class II heart failure. Despite this, the patient's current eGFR is 212.0 mmol/L, which is within the normal range (90-120 mmol/L). The patient's LVEF is 50.0%, which is lower than the normal range (50-70%), but not significantly low. The patient's troponin level is 0.01 ng/mL, which is within the normal range (0-10 ng/mL). The patient's creatinine level is elevated, but the patient is on medications for heart failure (loop diuretics, spironolactone, hydralazine, and nitrovasodilator), which suggests that the patient is being adequately managed for heart failure.

The patient's ECG shows non-sustained ventricular tachycardia, which is a significant finding, but it is not the only abnormality. The patient also has ventricular extrasystoles and paroxysmal supraventricular tachyarrhythmia, which may indicate underlying cardiac electrical instability. However, the patient is not experiencing symptoms, and the presence of these arrhythmias is not necessarily indicative of a poor prognosis.

Given the patient's age, comorbidities, and current medications, I would rank the patient as a survivor with a high likelihood of survival for the next few years. The patient's pump failure death is unlikely, and the patient's cardiac function is not severely impaired.

RANKING: 2. Sudden cardiac death
REASONING: While the patient has a history of ventricular tachycardia and non-sustained ventricular tachycardia, the patient is not experiencing symptoms, and the patient's ECG does not show any life-threatening arrhythmias. The patient's LVEF is 50.0%, which is lower than the normal range, but the patient is on medications for heart failure, which suggests that the patient is being adequately managed.

However, the patient's elevated creatinine level (212.0 mmol/L) and the presence of ventricular extrasystoles on the ECG are concerning signs that may indicate underlying cardiac dysfunction. The patient's age and comorbidities also increase the risk of sudden cardiac death. While the patient is not currently experiencing symptoms, the presence of these factors may increase the risk of sudden cardiac death in the future.

RANKING: 3. Pump failure death
REASONING: The patient's pump failure death is the most likely outcome, given the patient's age, comorbidities, and current cardiac function. The patient's LVEF is 50.0%, which is lower than the normal range, and the patient's elevated creatinine level (212.0 mmol/L) suggests that the patient's kidneys are not functioning optimally. The patient's NYHA Class II heart failure suggests that the patient's cardiac function is not being adequately managed, and the patient is at risk of developing pump failure.

The patient's medications for heart failure (loop diuretics, spironolactone, hydralazine, and nitrovasodilator) may not be sufficient to manage the patient's cardiac function, and the patient's elevated creatinine level suggests that the patient's kidneys are not functioning optimally. The patient's age and comorbidities also increase the risk of pump failure."
758,758,P0134,"Age: 62
Gender: Male 
Weight: 84 kg
Height: 166 cm
NYHA Class: II
Blood Pressure: 120/60 mmHg
Past Medical History: Idiopathic dilated cardiomyopathy, Diabetes, Hypertension
Albumin (g/L): 38
ALT or GPT (IU/L): 19.0
AST or GOT (IU/L): 19.0
Total Cholesterol (mmol/L): 5,87
Creatinine (mmol/L): 141.0
Gamma-glutamil transpeptidase (IU/L): 17
Glucose (mmol/L): 3,9
Hemoglobin (g/L): 164.0
HDL (mmol/L): 1,14
Potassium (mEq/L): 4,2
LDL (mmol/L): 2,1
Sodium (mEq/L): 146.0
Pro-BNP (ng/L): 1528.0
Protein (g/L): 73
T3 (pg/dL): 0,04
T4 (ng/L): 16
TSH (mIU/L): 2,34
Urea (mg/dL): 7,65
LVEF (%): 41.0
Medications: Angiotensin II Receptor Blocker, Beta Blockers, Digoxin, Loop Diuretics, Statins, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",pump failure death,"RANKING: 1. Sudden cardiac death
REASONING: 

The patient's ECG impression reveals the presence of non-sustained ventricular tachycardia (NSVT), which is a significant indicator of increased risk of sudden cardiac death. The patient's LVEF is also severely impaired at 41%, which suggests significant left ventricular dysfunction. The presence of ventricular extrasystoles and polymorphic ventricular tachycardia on the ECG further increases the risk of arrhythmic events. Additionally, the patient's NYHA Class II indicates moderate symptoms of heart failure, which can contribute to an increased risk of sudden cardiac death. While the patient's medication regimen includes beta blockers, which are often used to reduce the risk of sudden cardiac death, the presence of NSVT and other arrhythmic events on the ECG suggests that these medications may not be sufficient to mitigate the risk. Therefore, based on the available data, sudden cardiac death is the most likely outcome.

RANKING: 2. Pump failure death
REASONING: 

The patient's severely impaired LVEF of 41% and NYHA Class II symptoms suggest significant left ventricular dysfunction and heart failure. The patient's elevated creatinine level (141.0 mmol/L) also indicates impaired renal function, which is often associated with heart failure. The patient's elevated BNP level (1528.0 ng/L) further supports the presence of heart failure. However, the patient is currently being treated with medications that are commonly used to manage heart failure, including loop diuretics, ACE inhibitors, and beta blockers. While the patient's medication regimen may help manage symptoms and slow disease progression, the presence of significant left ventricular dysfunction and impaired renal function suggests that pump failure death is still a possible outcome.

RANKING: 3. Survivor
REASONING: 

While the patient's severe left ventricular dysfunction and heart failure symptoms are concerning, the patient is currently being treated with a comprehensive medication regimen that includes beta blockers, ACE inhibitors, and loop diuretics, which are commonly used to manage heart failure. The patient's elevated BNP level and impaired renal function suggest that the patient is not currently experiencing acute decompensated heart failure, and the patient's LVEF is not severely impaired. Additionally, the patient's age and overall health status are not extremely poor, which may suggest that the patient has a relatively better prognosis. However, given the patient's significant left ventricular dysfunction and impaired renal function, the likelihood of pump failure death is still a concern, making survivor the least likely outcome."
759,759,P0139,"Age: 83
Gender: Female 
Weight: 53 kg
Height: 155 cm
NYHA Class: III
Blood Pressure: 110/80 mmHg
Past Medical History: Valvular cardiomyopathy, Hypertension
Albumin (g/L): 40
ALT or GPT (IU/L): 26.0
AST or GOT (IU/L): 22.0
Total Cholesterol (mmol/L): 4,51
Creatinine (mmol/L): 137.0
Gamma-glutamil transpeptidase (IU/L): 61
Glucose (mmol/L): 5,2
Hemoglobin (g/L): 115.0
Potassium (mEq/L): 3,79
Sodium (mEq/L): 138.0
Protein (g/L): 73,6
Troponin (ng/mL): 0,01
TSH (mIU/L): 3,55
Urea (mg/dL): 8,9
LVEF (%): 68.0
Medications: Angiotensin II Receptor Blocker, Digoxin, Loop Diuretics, Spironolactone, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",pump failure death,"RANKING: 1. Sudden cardiac death
REASONING: 

Based on the provided patient data, the patient's prognosis is uncertain due to the presence of valvular cardiomyopathy, hypertension, and elevated creatinine levels, which suggest significant cardiac dysfunction. However, the patient's ejection fraction (LVEF) is 68%, which is within a relatively normal range, indicating that the patient's heart is still pumping effectively.

The presence of ventricular extrasystoles and a polymorphic pattern on the ECG suggests a high risk of arrhythmias, which is a significant concern for sudden cardiac death. Additionally, the patient's age and NYHA class III status indicate a high risk of cardiac events.

However, the patient is not currently experiencing any symptoms of heart failure, and the medications they are taking, such as the Angiotensin II Receptor Blocker and Digoxin, are intended to manage these conditions.

Given these factors, I would rank sudden cardiac death as the most likely outcome over the next few years, followed by pump failure death, and finally, survivor.

RANKING: 2. Pump failure death
REASONING: 

Pump failure death is a possible outcome due to the patient's valvular cardiomyopathy and hypertension, which can lead to progressive heart failure. The patient's elevated creatinine levels also suggest some degree of renal impairment, which can be a complication of heart failure.

However, the patient's ejection fraction is relatively preserved, and they are not currently experiencing any symptoms of heart failure. The presence of ventricular extrasystoles and polymorphic patterns on the ECG suggests a high risk of arrhythmias, which can contribute to sudden cardiac death.

While pump failure death is a possible outcome, it is less likely than sudden cardiac death due to the patient's relatively preserved cardiac function.

RANKING: 3. Survivor
REASONING: 

Given the patient's relatively preserved ejection fraction and the presence of medications that are intended to manage their conditions, the patient has a higher chance of survival over the next few years. However, the patient's age, NYHA class III status, and presence of ventricular extrasystoles and polymorphic patterns on the ECG suggest a high risk of cardiac events.

While the patient's cardiac function is relatively preserved, the presence of valvular cardiomyopathy and hypertension means that they are at risk of cardiac complications. However, the patient's relatively good renal function and lack of symptoms of heart failure suggest that they may be able to manage their condition effectively with their current medications.

Overall, while the patient's prognosis is uncertain, their relatively preserved cardiac function and absence of symptoms of heart failure make survivor the least likely outcome over the next few years."
760,760,P0141,"Age: 76
Gender: Female 
Weight: 70 kg
Height: 161 cm
NYHA Class: II
Blood Pressure: 100/70 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Hypertension, Myocardial Infarction
Albumin (g/L): 39,9
ALT or GPT (IU/L): 28.0
AST or GOT (IU/L): 23.0
Total Cholesterol (mmol/L): 3,05
Creatinine (mmol/L): 167.0
Gamma-glutamil transpeptidase (IU/L): 39
Glucose (mmol/L): 8,5
Hemoglobin (g/L): 123.0
Potassium (mEq/L): 3,15
Sodium (mEq/L): 132.0
Pro-BNP (ng/L): 5387.0
Protein (g/L): 71,4
Troponin (ng/mL): 0,01
TSH (mIU/L): 17,69
Urea (mg/dL): 25
LVEF (%): 25.0
Medications: Loop Diuretics, Spironolactone, Statins, Hydralazine, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: Parosysmal AF
        - Bradycardia: No
            ",pump failure death,"RANKING: 
1. Pump failure death
REASONING: 
Based on the patient's data, pump failure death is the most likely outcome. The patient has a history of ischemic dilated cardiomyopathy, which is a condition where the heart's ability to pump blood is compromised due to damage to the heart muscle. The patient's left ventricular ejection fraction (LVEF) is 25.0%, which is significantly below the normal range (50-70%), indicating poor heart function. The patient's elevated creatinine level (167.0 mmol/L) and urea level (25 mg/dL) suggest impaired renal function, which can be a consequence of cardiac failure. Additionally, the patient's high troponin level (0.01 ng/mL) may indicate some degree of myocardial damage.

The patient's symptoms and ECG findings, such as ventricular extrasystole, non-sustained ventricular tachycardia, and non-sustained ventricular tachycardia, also suggest a high risk of cardiac arrhythmias, which can lead to pump failure.

While the patient's NYHA Class II indicates some limitation of physical activity, the patient's overall clinical presentation and laboratory findings suggest that pump failure is a more likely outcome than sudden cardiac death or survival. The patient's blood pressure is well-controlled (100/70 mmHg), and the patient is on medications that are commonly used to manage heart failure, such as loop diuretics, spironolactone, statins, hydralazine, and a nitrovasodilator. However, the patient's poor LVEF and elevated creatinine level suggest that these medications may not be sufficient to prevent pump failure."
761,761,P0143,"Age: 56
Gender: Female 
Weight: 83 kg
Height: 163 cm
NYHA Class: III
Blood Pressure: 110/65 mmHg
Past Medical History: Valvular cardiomyopathy, Dyslipemia, Peripheral vascular disease, Myocardial Infarction
Albumin (g/L): 38,2
ALT or GPT (IU/L): 19.0
AST or GOT (IU/L): 19.0
Total Cholesterol (mmol/L): 4,66
Creatinine (mmol/L): 110.0
Gamma-glutamil transpeptidase (IU/L): 70
Glucose (mmol/L): 5,6
Hemoglobin (g/L): 86.0
HDL (mmol/L): 0,98
Potassium (mEq/L): 3,39
LDL (mmol/L): 3,86
Sodium (mEq/L): 135.0
Pro-BNP (ng/L): 1036.0
Protein (g/L): 68,1
Troponin (ng/mL): 0,01
TSH (mIU/L): 1,87
Urea (mg/dL): 8,4
LVEF (%): 40.0
Medications: Digoxin, Loop Diuretics, Spironolactone, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: Unknown ventricular tachycardia code
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",pump failure death,"RANKING: 1. Sudden cardiac death
REASONING: 

The patient's clinical presentation and ECG findings suggest a high risk of sudden cardiac death. The patient has a history of valvular cardiomyopathy, myocardial infarction, and peripheral vascular disease, which are all risk factors for arrhythmias and cardiac sudden death. The ECG findings of ventricular extrasystole and unknown ventricular tachycardia code further increase the risk of arrhythmic events. Additionally, the patient's low LVEF (40.0) indicates significant left ventricular dysfunction, which can contribute to a higher risk of arrhythmias and sudden cardiac death. The presence of pro-BNP (1036.0) is also elevated, which is a marker of cardiac stress and can be associated with a higher risk of arrhythmic events.

The patient's age, weight, and NYHA Class III status also contribute to the risk of sudden cardiac death. The patient's medications, including digoxin and spironolactone, can also increase the risk of arrhythmias.

While pump failure death is a possible outcome, the patient's ECG findings and clinical presentation suggest a higher risk of sudden cardiac death. 

RANKING: 2. Pump failure death
REASONING: 

The patient's clinical presentation and ECG findings suggest a high risk of pump failure death. The patient has a history of valvular cardiomyopathy, myocardial infarction, and peripheral vascular disease, which can all contribute to left ventricular dysfunction and decreased cardiac output. The patient's LVEF (40.0) is significantly reduced, indicating poor cardiac function.

The patient's elevated creatinine (110.0) and urea (8.4) levels suggest renal impairment, which can be associated with heart failure and decreased cardiac output. The patient's medications, including loop diuretics, can also contribute to fluid overload and decreased cardiac output.

The patient's pro-BNP (1036.0) level is elevated, which is a marker of cardiac stress and can be associated with heart failure. However, the patient's ECG findings and clinical presentation suggest a higher risk of sudden cardiac death.

RANKING: 3. Survivor
REASONING: 

While the patient's clinical presentation and ECG findings suggest a high risk of cardiac complications, the patient's age and NYHA Class III status may not necessarily predict a poor outcome. The patient's medications, including spironolactone, can help manage symptoms and improve cardiac function.

However, the patient's significant left ventricular dysfunction (LVEF 40.0), elevated pro-BNP level (1036.0), and history of valvular cardiomyopathy and myocardial infarction increase the risk of pump failure death. Additionally, the patient's elevated creatinine and urea levels suggest renal impairment, which can be associated with heart failure and decreased cardiac output.

Overall, while the patient's prognosis is uncertain, the combination of their clinical presentation, ECG findings, and medical history suggest a higher risk of pump failure death, making this the least likely outcome."
762,762,P0151,"Age: 74
Gender: Male 
Weight: 78 kg
Height: 173 cm
NYHA Class: III
Blood Pressure: 90/60 mmHg
Past Medical History: Valvular cardiomyopathy
Albumin (g/L): 43,2
ALT or GPT (IU/L): 17.0
AST or GOT (IU/L): 37.0
Total Cholesterol (mmol/L): 4,27
Creatinine (mmol/L): 105.0
Gamma-glutamil transpeptidase (IU/L): 162
Glucose (mmol/L): 4,7
Hemoglobin (g/L): 123.0
Potassium (mEq/L): 3,85
Sodium (mEq/L): 133.0
Protein (g/L): 84,8
Troponin (ng/mL): 0,01
TSH (mIU/L): 4,31
Urea (mg/dL): 8
LVEF (%): 70.0
Medications: Digoxin, Loop Diuretics, Spironolactone, ACE Inhibitor, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",pump failure death,"RANKING: 1. Survivor
REASONING: 

The patient's age of 74 and NYHA Class III indicates that the patient has significant heart failure symptoms, which may suggest that the patient's heart is already compromised. However, the patient's LVEF of 70.0 is not severely impaired, indicating that the heart is still capable of maintaining some level of function. The patient's blood pressure is relatively low (90/60 mmHg), but this can be managed with the current medications. The patient's electrolytes and liver enzymes are within normal limits, and the troponin level is normal, which suggests that there is no acute myocardial infarction or significant cardiac injury. The patient's medications, including ACE inhibitors and spironolactone, are standard treatments for heart failure, and the nitrovasodilator may help to reduce blood pressure. The ECG impression does not show any life-threatening arrhythmias, and the patient does not have a history of sudden cardiac death. Overall, given the patient's relatively preserved LVEF and absence of acute cardiac events, the patient is likely to survive for the next few years with proper management of their heart failure.

RANKING: 2. Sudden cardiac death
REASONING: 

The patient's history of valvular cardiomyopathy and NYHA Class III indicates that the patient has significant heart failure, which increases the risk of sudden cardiac death. The patient's low blood pressure (90/60 mmHg) and low LVEF (70.0) suggest that the patient's heart is not functioning optimally. The patient's ECG impression shows ventricular extrasystoles, which can be a precursor to ventricular tachycardia or fibrillation. While the patient does not have a history of ventricular tachycardia or fibrillation, the presence of ventricular extrasystoles increases the risk of sudden cardiac death. However, the patient's medications and ECG impression do not suggest an immediate risk of life-threatening arrhythmias.

RANKING: 3. Pump failure death
REASONING: 

The patient's history of NYHA Class III indicates that the patient has significant heart failure symptoms, and the patient's LVEF of 70.0 suggests that the patient's heart is not functioning optimally. The patient's low blood pressure (90/60 mmHg) and elevated creatinine level (105.0) suggest that the patient may have some degree of renal impairment, which can be exacerbated by heart failure. The patient's medications, including loop diuretics and ACE inhibitors, are standard treatments for heart failure, but the patient's current symptoms and ECG impression suggest that the patient's heart failure is not well-controlled. The patient's ECG impression shows ventricular extrasystoles, which can increase the risk of pump failure. While the patient's troponin level is normal, the patient's heart failure symptoms and ECG impression suggest that the patient is at risk of pump failure. Overall, the combination of significant heart failure symptoms, low LVEF, and ECG abnormalities makes pump failure death a possible outcome for the patient."
763,763,P0155,"Age: 59
Gender: Male 
Weight: 81 kg
Height: 165 cm
NYHA Class: II
Blood Pressure: 90/60 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Diabetes, Dyslipemia, Peripheral vascular disease, Myocardial Infarction
Albumin (g/L): 35,5
ALT or GPT (IU/L): 29.0
AST or GOT (IU/L): 20.0
Total Cholesterol (mmol/L): 4,52
Creatinine (mmol/L): 141.0
Gamma-glutamil transpeptidase (IU/L): 89
Glucose (mmol/L): 11,6
Hemoglobin (g/L): 133.0
Potassium (mEq/L): 4,75
Sodium (mEq/L): 137.0
Pro-BNP (ng/L): 10534.0
Protein (g/L): 66,2
Troponin (ng/mL): 0,01
TSH (mIU/L): 1,82
Urea (mg/dL): 20,8
LVEF (%): 25.0
Medications: Diabetes Medication, Angiotensin II Receptor Blocker, Beta Blockers, Loop Diuretics, Spironolactone, Statins, ACE Inhibitor, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: TPSV
        - Bradycardia: No
            ",pump failure death,"RANKING: 1. Sudden Cardiac Death
REASONING: The patient has a high risk of sudden cardiac death due to the presence of ventricular extrasystoles, which is a type of abnormal heart rhythm that can increase the risk of sudden cardiac death. The patient's LVEF (Left Ventricular Ejection Fraction) of 25% is also a significant indicator of poor cardiac function, which can contribute to a higher risk of sudden cardiac death. Additionally, the patient's age, NYHA class II, and history of myocardial infarction and ischemic dilated cardiomyopathy further increase the risk of sudden cardiac death.

RANKING: 2. Pump Failure Death
REASONING: The patient's LVEF of 25% indicates severely impaired cardiac function, which increases the risk of pump failure. The patient's history of heart failure, diabetes, and hypertension also contribute to this risk. The patient's elevated creatinine level (141.0 mmol/L) and urea level (20.8 mg/dL) suggest impaired renal function, which can further increase the risk of pump failure. The patient's medication regimen, including ACE inhibitors and beta blockers, may also contribute to a higher risk of pump failure due to their effects on blood pressure and cardiac output.

RANKING: 3. Survivor
REASONING: While the patient has a high risk of sudden cardiac death and pump failure, the presence of certain factors may suggest a better prognosis. The patient's hemoglobin level (133.0 g/L) is within the normal range, which suggests adequate oxygen delivery to tissues. The patient's troponin level (0.01 ng/mL) is also normal, which suggests that there is no significant myocardial damage. Additionally, the patient's medication regimen includes spironolactone, which may help to reduce mortality risk. However, the patient's age, NYHA class II, and history of heart failure and myocardial infarction still pose a significant risk, and the patient's LVEF of 25% indicates severely impaired cardiac function."
764,764,P0160,"Age: 71
Gender: Male 
Weight: 62 kg
Height: 165 cm
NYHA Class: III
Blood Pressure: 120/70 mmHg
Past Medical History: Valvular cardiomyopathy
Albumin (g/L): 41
ALT or GPT (IU/L): 8.0
AST or GOT (IU/L): 20.0
Total Cholesterol (mmol/L): 4,11
Creatinine (mmol/L): 156.0
Gamma-glutamil transpeptidase (IU/L): 107
Glucose (mmol/L): 4,7
Hemoglobin (g/L): 123.0
Potassium (mEq/L): 4,59
Sodium (mEq/L): 137.0
Pro-BNP (ng/L): 27357.0
Protein (g/L): 74,9
Troponin (ng/mL): 0,01
TSH (mIU/L): 3,15
Urea (mg/dL): 19,2
LVEF (%): 13.0
Medications: Beta Blockers, Digoxin, Loop Diuretics, Spironolactone, Hydralazine, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",pump failure death,"RANKING: 
1. Pump failure death 
REASONING: 
The patient has a history of valvular cardiomyopathy, which is a condition that affects the heart's ability to pump blood effectively. The patient's left ventricular ejection fraction (LVEF) is significantly reduced at 13%, indicating severe left ventricular dysfunction. The patient is also taking medications such as Digoxin, Loop Diuretics, and Spironolactone, which are commonly used to manage heart failure. Additionally, the patient has a high level of N-terminal pro b-type natriuretic peptide (Pro-BNP) at 27,357 ng/L, which is a biomarker for heart failure. The presence of ventricular extrasystole, non-sustained VT, and the patient's NYHA class III symptoms also suggest a high risk of pump failure. 

Given these factors, pump failure death is the most likely outcome for this patient over the next few years. 

2. Sudden cardiac death 
REASONING: 
While the patient has a high risk of pump failure, the presence of ventricular extrasystole and non-sustained VT on the ECG impression suggests an increased risk of arrhythmic events. However, the patient is not classified as having a high risk of non-sustained ventricular tachycardia (CH>10) and the exact nature of the bradycardia and paroxysmal supraventricular tachyarrhythmia is unknown. Additionally, the patient's blood pressure and electrolyte levels are relatively stable, which reduces the likelihood of sudden cardiac death.

3. Survivor 
REASONING: 
While the patient has a significant medical condition and multiple comorbidities, the presence of a high-risk ECG impression and biomarkers for heart failure suggest a poor prognosis. However, the patient's age, weight, and blood pressure are relatively stable, which could potentially contribute to a better outcome. Additionally, the patient is on multiple medications that are commonly used to manage heart failure, which may help to slow disease progression. However, considering the overall risk factors and the presence of severe left ventricular dysfunction, the likelihood of the patient surviving without any major cardiac events is lower compared to pump failure death and sudden cardiac death."
765,765,P0186,"Age: 57
Gender: Male 
Weight: 65 kg
Height: 175 cm
NYHA Class: III
Blood Pressure: 90/50 mmHg
Past Medical History: Idiopathic dilated cardiomyopathy
Albumin (g/L): 46
ALT or GPT (IU/L): 17.0
AST or GOT (IU/L): 27.0
Total Cholesterol (mmol/L): 2,84
Creatinine (mmol/L): 141.0
Gamma-glutamil transpeptidase (IU/L): 59
Glucose (mmol/L): 5,5
Hemoglobin (g/L): 120.0
HDL (mmol/L): 0,78
Potassium (mEq/L): 4,4
LDL (mmol/L): 1,68
Sodium (mEq/L): 142.0
Pro-BNP (ng/L): 5098.0
Protein (g/L): 79
T3 (pg/dL): 0,05
T4 (ng/L): 15
Troponin (ng/mL): 0,07
TSH (mIU/L): 5,32
Urea (mg/dL): 8,49
LVEF (%): 27.0
Medications: Beta Blockers, Digoxin, Loop Diuretics, Spironolactone, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",pump failure death,"RANKING: 
1. Sudden cardiac death
2. Pump failure death
3. Survivor

REASONING:

Based on the provided patient data, the patient's prognosis is likely to be sudden cardiac death. The following factors contribute to this ranking:

- The patient's New York Heart Association (NYHA) class III indicates severe heart failure, which increases the risk of sudden cardiac death.
- The LVEF of 27% is significantly reduced, indicating severe left ventricular dysfunction, which is a strong predictor of sudden cardiac death.
- The presence of ventricular extrasystoles, non-sustained ventricular tachycardia, and non-sustained ventricular tachycardia (CH>10) on the ECG suggests an increased risk of arrhythmic events, which is a major cause of sudden cardiac death.
- The patient's low serum potassium level (4.4 mEq/L) may indicate hypokalemia, which can contribute to arrhythmias and increase the risk of sudden cardiac death.
- The presence of idiopathic dilated cardiomyopathy, a condition that can lead to arrhythmias and sudden cardiac death, further supports this ranking.

While pump failure death is a possible outcome, it is less likely in the short term, as the patient is already experiencing severe heart failure symptoms (NYHA class III). Sudden cardiac death is a more immediate and likely consequence of the patient's current cardiac status."
766,766,P0188,"Age: 59
Gender: Female 
Weight: 49 kg
Height: 155 cm
NYHA Class: II
Blood Pressure: 140/80 mmHg
Past Medical History: Valvular cardiomyopathy, Hypertension
Albumin (g/L): 33,9
ALT or GPT (IU/L): 27.0
AST or GOT (IU/L): 66.0
Total Cholesterol (mmol/L): 5,77
Creatinine (mmol/L): 143.0
Gamma-glutamil transpeptidase (IU/L): 334
Glucose (mmol/L): 4,6
Hemoglobin (g/L): 113.0
HDL (mmol/L): 1,53
Potassium (mEq/L): 3,93
LDL (mmol/L): 3,44
Sodium (mEq/L): 135.0
Pro-BNP (ng/L): 7574.0
Protein (g/L): 65
T3 (pg/dL): 0,0306
T4 (ng/L): 9,59
Troponin (ng/mL): 0,1
TSH (mIU/L): 26,88
Urea (mg/dL): 14,4
LVEF (%): 70.0
Medications: Amiodarone, Loop Diuretics, Spironolactone
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",pump failure death,"RANKING: 1. Survivor
REASONING: 
Based on the provided data, the patient is a 59-year-old female with a history of valvular cardiomyopathy and hypertension. Her NYHA class is II, indicating mild symptoms of heart failure. Her LVEF is 70%, which is within the normal range. Her blood pressure is controlled at 140/80 mmHg. 

Her laboratory results show elevated creatinine levels (143.0 mmol/L) and a slightly elevated liver enzymes (AST/GOT 66.0 IU/L). Her electrolyte levels are mostly within normal ranges, except for a slightly elevated potassium level (3.93 mEq/L). Her troponin level is within normal limits, indicating no acute myocardial infarction. 

The patient is on medications for heart failure (loop diuretics and spironolactone) and has a history of amiodarone, which is used for arrhythmia management. However, there is no indication of current arrhythmia on the ECG impression.

Given the patient's age, mild symptoms, controlled blood pressure, and normal LVEF, the likelihood of pump failure death in the next few years is lower. The patient's valvular cardiomyopathy and hypertension are manageable conditions, and with proper treatment and monitoring, the patient can be expected to survive for several years.

RANKING: 2. Sudden cardiac death
REASONING: 
The patient's ECG impression shows ventricular extrasystole, which is a type of abnormal heart rhythm. While not a life-threatening condition, it can be a marker for underlying cardiac dysfunction. The presence of ventricular extrasystoles can increase the risk of ventricular arrhythmias, including ventricular tachycardia.

Although the patient is on amiodarone, which is used to manage arrhythmias, the ECG impression does not indicate any current arrhythmia. However, the presence of ventricular extrasystoles and the patient's history of valvular cardiomyopathy and hypertension increase the risk of arrhythmias and sudden cardiac death.

RANKING: 3. Pump failure death
REASONING: 
The patient's elevated creatinine levels (143.0 mmol/L) and slightly elevated liver enzymes (AST/GOT 66.0 IU/L) suggest some degree of cardiac dysfunction and potential kidney impairment. The patient's NYHA class is II, indicating mild symptoms of heart failure, which can progress to more severe heart failure over time.

While the patient's LVEF is within normal limits, the patient's age and history of valvular cardiomyopathy and hypertension increase the risk of pump failure. The patient's elevated troponin level (0.1 ng/mL) is within normal limits, but the patient's slightly elevated creatinine levels and liver enzymes suggest some degree of cardiac dysfunction.

Given the patient's age, history, and laboratory results, the likelihood of pump failure death in the next few years is higher than sudden cardiac death, but lower than the likelihood of the patient surviving."
767,767,P0192,"Age: 83
Gender: Female 
Weight: 69 kg
Height: 148 cm
NYHA Class: III
Blood Pressure: 150/85 mmHg
Past Medical History: Hypertensive cardiomyopathy, Diabetes, Hypertension, Myocardial Infarction
Albumin (g/L): 39
ALT or GPT (IU/L): 7.0
AST or GOT (IU/L): 17.0
Total Cholesterol (mmol/L): 6,47
Creatinine (mmol/L): 122.0
Gamma-glutamil transpeptidase (IU/L): 15
Glucose (mmol/L): 7,5
Hemoglobin (g/L): 117.0
HDL (mmol/L): 1,32
Potassium (mEq/L): 5,25
LDL (mmol/L): 4,24
Sodium (mEq/L): 142.0
Pro-BNP (ng/L): 5541.0
Protein (g/L): 72
T3 (pg/dL): 0,0237
T4 (ng/L): 18,93
TSH (mIU/L): 0,92
Urea (mg/dL): 19,3
LVEF (%): 65.0
Medications: Diabetes Medication, Loop Diuretics, ACE Inhibitor, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: TPSV
        - Bradycardia: No
            ",pump failure death,"RANKING: 
1. Sudden cardiac death
2. Pump failure death
3. Survivor

REASONING:

The patient's age (83) and NYHA Class III status indicate advanced heart failure, which significantly increases the risk of adverse outcomes. The patient's elevated creatinine level (122.0 mmol/L) suggests impaired renal function, which is often associated with heart failure. The presence of ventricular extrasystole (Polymorphic) on the ECG suggests ventricular arrhythmias, which can lead to sudden cardiac death.

The patient's LVEF (65.0%) is below the normal range, indicating reduced left ventricular function, which is a strong predictor of mortality. The elevated Pro-BNP level (5541.0 ng/L) further supports the presence of heart failure.

While pump failure death is a significant concern, the presence of ventricular arrhythmias and reduced LVEF make sudden cardiac death a more immediate and likely risk. Therefore, I would rank sudden cardiac death as the most likely outcome.

Pump failure death is still a significant concern due to the patient's advanced heart failure and reduced LVEF. However, the patient is already taking medications for heart failure (Loop Diuretics, ACE Inhibitor, and Nitrovasodilator), which may help manage symptoms but may not address the underlying cardiac dysfunction.

Survivor is the least likely outcome, as the patient's advanced age, NYHA Class III status, and evidence of ventricular arrhythmias and reduced LVEF make it challenging to predict a favorable outcome.

It's essential to note that this is a prediction, and individual outcomes can vary. Close monitoring and further evaluation are necessary to adjust the prognosis and develop a personalized treatment plan."
768,768,P0194,"Age: 89
Gender: Male 
Weight: 70 kg
Height: 171 cm
NYHA Class: III
Blood Pressure: 160/90 mmHg
Past Medical History: Hypertensive cardiomyopathy, Hypertension
Albumin (g/L): 49
ALT or GPT (IU/L): 26.0
AST or GOT (IU/L): 34.0
Total Cholesterol (mmol/L): 6,1
Creatinine (mmol/L): 103.0
Gamma-glutamil transpeptidase (IU/L): 20
Glucose (mmol/L): 5,6
Hemoglobin (g/L): 143.0
HDL (mmol/L): 1,81
Potassium (mEq/L): 4,4
LDL (mmol/L): 3,78
Sodium (mEq/L): 141.0
Pro-BNP (ng/L): 3179.0
Protein (g/L): 78,1
T3 (pg/dL): 0,0252
T4 (ng/L): 18,79
Troponin (ng/mL): 1,2
TSH (mIU/L): 0,99
Urea (mg/dL): 8,2
LVEF (%): 70.0
Medications: Digoxin, Loop Diuretics, Spironolactone, ACE Inhibitor, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: Sinus Node Dysfunction
            ",pump failure death,"RANKING: 1. Sudden Cardiac Death 
REASONING: 

The patient's ECG impression shows ventricular extrasystole and non-sustained ventricular tachycardia, which are both indicators of an increased risk of sudden cardiac death. The presence of ventricular extrasystole and non-sustained ventricular tachycardia (CH>10) in the ECG impression is particularly concerning, as these conditions can lead to a sudden and unexpected cardiac arrest. Additionally, the patient's age, NYHA class III, and history of hypertensive cardiomyopathy increase the risk of sudden cardiac death. The patient's elevated troponin levels (1.2 ng/mL) also suggest myocardial damage, which can contribute to an increased risk of sudden cardiac death. Given these factors, I would rank sudden cardiac death as the most likely prognosis for this patient.

RANKING: 2. Pump Failure Death 
REASONING: 

While the patient's NYHA class III indicates significant heart failure, the presence of medications such as spironolactone and ACE inhibitors suggest that the patient is receiving standard treatment for heart failure. However, the patient's elevated creatinine level (103.0 mmol/L) and LVEF of 70.0% suggest that the patient's heart failure is not optimally managed. The patient's elevated troponin levels and elevated BNP (3179.0 ng/L) also suggest that the patient's heart is under significant stress, which could lead to pump failure. Additionally, the patient's age and history of hypertensive cardiomyopathy increase the risk of pump failure death. Given these factors, I would rank pump failure death as the second most likely prognosis for this patient.

RANKING: 3. Survivor 
REASONING: 

While the patient's age and history of hypertensive cardiomyopathy increase the risk of mortality, the patient's current treatment regimen and the presence of medications such as spironolactone and ACE inhibitors suggest that the patient is receiving standard treatment for heart failure. The patient's LVEF of 70.0% and lack of evidence of significant myocardial damage (troponin < 10 ng/mL) suggest that the patient's heart function is not severely compromised. Additionally, the patient's elevated HDL (1.81 mmol/L) and normal TSH (0.99 mIU/L) suggest that the patient's cardiovascular risk factors are being adequately managed. Given these factors, I would rank survivor as the least likely prognosis for this patient."
769,769,P0200,"Age: 80
Gender: Male 
Weight: 69 kg
Height: 155 cm
NYHA Class: III
Blood Pressure: 110/60 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Dyslipemia, Peripheral vascular disease, Myocardial Infarction
Albumin (g/L): 39
ALT or GPT (IU/L): 9.0
AST or GOT (IU/L): 15.0
Total Cholesterol (mmol/L): 4,11
Creatinine (mmol/L): 146.0
Gamma-glutamil transpeptidase (IU/L): 21
Glucose (mmol/L): 5,1
Hemoglobin (g/L): 119.0
HDL (mmol/L): 0,75
Potassium (mEq/L): 4,2
LDL (mmol/L): 2,72
Sodium (mEq/L): 138.0
Pro-BNP (ng/L): 2129.0
Protein (g/L): 67
T3 (pg/dL): 0,0429
T4 (ng/L): 15,56
Troponin (ng/mL): 0,2
TSH (mIU/L): 0,58
Urea (mg/dL): 13,9
LVEF (%): 39.0
Medications: Beta Blockers, Loop Diuretics, ACE Inhibitor, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: Second-degree AVB - type I
            ",pump failure death,"RANKING: 1. Sudden cardiac death
REASONING: 

The patient's data suggests a high risk of sudden cardiac death due to the presence of several factors. The patient has a history of ischemic dilated cardiomyopathy, which is a condition that can lead to arrhythmias and sudden cardiac death. The patient's LVEF (Left Ventricular Ejection Fraction) is significantly reduced at 39%, indicating poor cardiac function. The patient is also taking medications that can increase the risk of arrhythmias, such as beta blockers and nitrovasodilators.

The patient's ECG impression shows polymorphic ventricular extrasystole, which is a type of abnormal heart rhythm that can be life-threatening. The patient's troponin level is also elevated, indicating some degree of myocardial damage.

The patient's weight and height are not ideal, but they do not seem to be the primary factors contributing to the patient's risk of sudden cardiac death.

While the patient's past medical history of myocardial infarction and peripheral vascular disease may increase the risk of cardiovascular events, the combination of ischemic dilated cardiomyopathy, poor LVEF, and the presence of polymorphic ventricular extrasystole make sudden cardiac death the most likely outcome.

RANKING: 2. Pump failure death
REASONING: 

The patient's LVEF is significantly reduced, indicating poor cardiac function. The patient is also taking medications that can increase the risk of pump failure, such as beta blockers and loop diuretics.

The patient's creatinine level is elevated, indicating some degree of kidney impairment. This can be a contributing factor to pump failure, as the kidneys play a crucial role in regulating fluid balance and electrolytes.

However, the patient's elevated troponin level and polymorphic ventricular extrasystole suggest that the patient's cardiac function is already compromised, making pump failure death a possible outcome.

RANKING: 3. Survivor
REASONING: 

While the patient's past medical history and medications do increase the risk of cardiovascular events, the patient's overall health status and the presence of certain risk factors (such as elevated creatinine and troponin) suggest that the patient may not be at an extremely high risk of sudden cardiac death.

The patient's ECG impression does not show any life-threatening arrhythmias, and the patient's medications may be effective in managing the patient's cardiac function. Additionally, the patient's weight and height are not ideal, but they do not seem to be the primary factors contributing to the patient's risk of cardiovascular events.

Overall, while the patient's cardiac function is compromised, the patient's overall health status and the presence of certain risk factors suggest that the patient may be more likely to survive than to experience sudden cardiac death or pump failure."
770,770,P0212,"Age: 65
Gender: Male 
Weight: 79 kg
Height: 162 cm
NYHA Class: II
Blood Pressure: 150/85 mmHg
Past Medical History: Hypertensive cardiomyopathy, Diabetes, Dyslipemia, Hypertension
Albumin (g/L): 42
ALT or GPT (IU/L): 32.0
AST or GOT (IU/L): 44.0
Total Cholesterol (mmol/L): 3,98
Creatinine (mmol/L): 150.0
Gamma-glutamil transpeptidase (IU/L): 688
Glucose (mmol/L): 5,4
Hemoglobin (g/L): 122.0
HDL (mmol/L): 1,27
Potassium (mEq/L): 4,08
LDL (mmol/L): 2,22
Sodium (mEq/L): 136.0
Pro-BNP (ng/L): 709.0
Protein (g/L): 79
T3 (pg/dL): 0,0492
T4 (ng/L): 16,35
Troponin (ng/mL): 3,1
TSH (mIU/L): 0,79
Urea (mg/dL): 10
LVEF (%): 70.0
Medications: Diabetes Medication, Loop Diuretics, Statins, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",pump failure death,"RANKING: 1. Sudden Cardiac Death
REASONING: The patient's ECG impression shows a monomorphic ventricular extrasystole, which is a significant finding indicating an increased risk of sudden cardiac death. The presence of ventricular extrasystoles is often associated with a higher risk of arrhythmic events, particularly in patients with underlying heart disease. The patient's age, NYHA class II, and history of hypertension, cardiomyopathy, and diabetes also contribute to this risk. The patient's elevated Troponin levels (3.1 ng/mL) may indicate some myocardial injury, which can increase the risk of arrhythmic events.

RANKING: 2. Pump Failure Death
REASONING: While the patient's LVEF is 70.0, which is below the normal range, the patient's NYHA class II suggests that the patient's symptoms are not severe enough to indicate pump failure. However, the patient's elevated creatinine level (150.0 mmol/L) and elevated Pro-BNP levels (709.0 ng/L) suggest some degree of heart failure. The patient's history of hypertension, cardiomyopathy, and diabetes also increases the risk of pump failure. Therefore, while pump failure is a possible outcome, it is less likely than sudden cardiac death.

RANKING: 3. Survivor
REASONING: The patient's age, NYHA class II, and history of hypertension, cardiomyopathy, and diabetes suggest a higher risk of adverse outcomes. However, the patient's elevated LVEF (70.0) and the absence of symptoms indicative of severe heart failure (e.g., orthopnea, paroxysmal nocturnal dyspnea) suggest that the patient's heart function is relatively preserved. Additionally, the patient's medication regimen, including ACE inhibitors and statins, suggests that the patient is receiving standard management for their conditions. Therefore, while the patient is at risk for adverse outcomes, the likelihood of survival for at least the next few years is the highest among the three options."
771,771,P0213,"Age: 72
Gender: Male 
Weight: 94 kg
Height: 171 cm
NYHA Class: III
Blood Pressure: 115/70 mmHg
Past Medical History: Idiopathic dilated cardiomyopathy, Diabetes, Hypertension
Albumin (g/L): 37
ALT or GPT (IU/L): 12.0
AST or GOT (IU/L): 16.0
Total Cholesterol (mmol/L): 4,24
Creatinine (mmol/L): 120.0
Gamma-glutamil transpeptidase (IU/L): 23
Glucose (mmol/L): 12,4
Hemoglobin (g/L): 124.0
HDL (mmol/L): 0,91
Potassium (mEq/L): 3,44
LDL (mmol/L): 2,59
Sodium (mEq/L): 138.0
Pro-BNP (ng/L): 1100.0
Protein (g/L): 66,399
T4 (ng/L): 17,63
Troponin (ng/mL): 0,7
TSH (mIU/L): 0,77
Urea (mg/dL): 12,1
LVEF (%): 30.0
Medications: Diabetes Medication, Digoxin, Loop Diuretics, Spironolactone, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",pump failure death,"RANKING: 1. Sudden Cardiac Death
REASONING: 
Based on the patient's data, I rank sudden cardiac death as the most likely prognosis. The patient has a history of idiopathic dilated cardiomyopathy, which is a significant risk factor for sudden cardiac death. The patient's left ventricular ejection fraction (LVEF) is severely impaired at 30%, indicating advanced cardiac dysfunction. The presence of ventricular extrasystoles, a type of abnormal heart rhythm, is also a significant concern. Additionally, the patient's elevated troponin levels suggest some degree of cardiac muscle damage. While the patient is on medications that are commonly used to manage heart failure and arrhythmias, the combination of these factors suggests a high risk of sudden cardiac death.

RANKING: 2. Pump Failure Death
REASONING: 
Given the patient's severe left ventricular dysfunction (LVEF 30%) and the presence of heart failure symptoms (NYHA Class III), pump failure death is a plausible prognosis. The patient's elevated creatinine levels and urea levels also indicate compromised renal function, which is often seen in advanced heart failure. The patient's elevated BNP levels further support the presence of heart failure. However, the patient's age, weight, and blood pressure are not as concerning as the cardiac dysfunction, which is the primary factor in this case.

RANKING: 3. Survivor
REASONING: 
While the patient's overall health status is compromised, I rank survivor as the least likely prognosis. The patient's age and weight are not as concerning as the cardiac dysfunction, and the patient is on medications that are commonly used to manage heart failure and arrhythmias. However, the patient's severe left ventricular dysfunction and elevated BNP levels suggest a high risk of adverse outcomes. Additionally, the presence of ventricular extrasystoles and elevated troponin levels increase the risk of sudden cardiac death. Overall, while the patient may survive, the risk of adverse outcomes is still significant."
772,772,P0223,"Age: 64
Gender: Male 
Weight: 64 kg
Height: 168 cm
NYHA Class: III
Blood Pressure: 110/70 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Diabetes, Dyslipemia, Hypertension, Myocardial Infarction
Albumin (g/L): 41
ALT or GPT (IU/L): 25.0
AST or GOT (IU/L): 24.0
Total Cholesterol (mmol/L): 4,2
Creatinine (mmol/L): 254.0
Gamma-glutamil transpeptidase (IU/L): 175
Glucose (mmol/L): 15,78
Hemoglobin (g/L): 125.0
HDL (mmol/L): 1,5
Potassium (mEq/L): 4,71
LDL (mmol/L): 2,29
Sodium (mEq/L): 127.0
Pro-BNP (ng/L): 12746.0
Protein (g/L): 81
T3 (pg/dL): 0,0114
T4 (ng/L): 17,74
Troponin (ng/mL): 1,5
TSH (mIU/L): 2,65
Urea (mg/dL): 20,37
LVEF (%): 30.0
Medications: Diabetes Medication, Beta Blockers, Loop Diuretics, Spironolactone, Statins, Hydralazine, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",pump failure death,"RANKING: 1. Survivor
REASONING: The patient's age is 64, which is still relatively young for a heart failure diagnosis. The patient has a history of ischemic dilated cardiomyopathy, which is a significant risk factor for heart failure. However, the patient's NYHA Class III indicates that they are still able to perform moderate physical activity without symptoms. The patient's medication regimen includes beta blockers, loop diuretics, and spironolactone, which are standard treatments for heart failure. Additionally, the patient's creatinine level is not severely elevated, suggesting that kidney function is not significantly impaired. The patient's troponin level is also not excessively elevated, indicating that there is no significant myocardial damage. The ECG impression does not show any signs of ventricular tachycardia or ventricular extrasystoles, which are common causes of sudden cardiac death. Therefore, based on these factors, I would rank the patient's prognosis as a survivor.

RANKING: 2. Sudden cardiac death
REASONING: Although the patient's ECG shows polymorphic ventricular extrasystoles, which is a risk factor for sudden cardiac death, the patient's overall clinical presentation and medication regimen do not suggest an immediate high risk for sudden cardiac death. The patient's LVEF is 30%, which is significantly reduced, indicating advanced heart failure. However, the patient's medication regimen includes beta blockers, which are known to improve survival in heart failure patients. Additionally, the patient's creatinine level and troponin level are not excessively elevated, suggesting that the patient's kidney and myocardial function are not severely impaired. Therefore, while the patient's ECG shows a risk factor for sudden cardiac death, the overall clinical presentation and medication regimen suggest a lower risk for sudden cardiac death.

RANKING: 3. Pump failure death
REASONING: The patient's LVEF is 30%, which is significantly reduced, indicating advanced heart failure. The patient's NYHA Class III indicates that they are experiencing significant symptoms with moderate physical activity. The patient's creatinine level is elevated, indicating impaired kidney function, which is a common complication of heart failure. The patient's troponin level is also elevated, indicating some degree of myocardial damage. The patient's ECG shows polymorphic ventricular extrasystoles, which is a risk factor for sudden cardiac death. Additionally, the patient's medication regimen does not include any medications that are specifically indicated for heart failure exacerbation. Therefore, based on these factors, I would rank the patient's prognosis as pump failure death, as the patient's advanced heart failure and impaired kidney function increase the risk of death due to cardiac failure."
773,773,P0239,"Age: 67
Gender: Male 
Weight: 90 kg
Height: 164 cm
NYHA Class: III
Blood Pressure: 110/60 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Diabetes, Dyslipemia, Peripheral vascular disease, Hypertension, Myocardial Infarction
Albumin (g/L): 40
ALT or GPT (IU/L): 18.0
AST or GOT (IU/L): 22.0
Total Cholesterol (mmol/L): 5,2
Creatinine (mmol/L): 212.0
Gamma-glutamil transpeptidase (IU/L): 17
Glucose (mmol/L): 6,9
Hemoglobin (g/L): 114.0
HDL (mmol/L): 1,35
Potassium (mEq/L): 5,2
LDL (mmol/L): 3,7
Sodium (mEq/L): 132.0
Pro-BNP (ng/L): 9992.0
Protein (g/L): 70
T3 (pg/dL): 0,04
T4 (ng/L): 15
Troponin (ng/mL): 0,42
TSH (mIU/L): 7,83
Urea (mg/dL): 24,79
LVEF (%): 10.0
Medications: Diabetes Medication, Beta Blockers, Digoxin, Loop Diuretics, Spironolactone, Statins, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",pump failure death,"RANKING: 
1. Pump failure death
REASONING: 
The patient's data suggests a high risk of pump failure death. The patient has a history of ischemic dilated cardiomyopathy, which is a condition that weakens the heart muscle and can lead to heart failure. The patient's left ventricular ejection fraction (LVEF) is significantly reduced at 10.0%, indicating poor heart function. Additionally, the patient has multiple comorbidities, including hypertension, diabetes, and peripheral vascular disease, which can further exacerbate heart failure. The presence of ventricular tachycardia and non-sustained ventricular tachycardia on the ECG also suggests a high risk of arrhythmia-related complications.

The patient's medication regimen includes digoxin, a medication typically used to treat heart failure, but also has a narrow therapeutic index and can be pro-arrhythmic. The patient's elevated troponin level (0.42 ng/mL) may indicate some degree of myocardial injury, which can contribute to the risk of pump failure.

While the patient's blood pressure is relatively well-controlled, the patient's creatinine level (212.0 mol/L) is elevated, indicating some degree of kidney dysfunction, which can also contribute to the risk of pump failure.

The other two prognoses, survivor and sudden cardiac death, are less likely due to the patient's advanced age (67 years) and the presence of multiple comorbidities. While the patient's eGFR is not provided, the elevated creatinine level suggests some degree of kidney dysfunction, which can increase the risk of cardiovascular events.

Overall, the combination of the patient's heart disease, comorbidities, and laboratory results make pump failure death the most likely outcome."
774,774,P0242,"Age: 69
Gender: Female 
Weight: 57 kg
Height: 150 cm
NYHA Class: III
Blood Pressure: 110/70 mmHg
Past Medical History: Idiopathic dilated cardiomyopathy, Diabetes, Dyslipemia, Hypertension
Albumin (g/L): 34
ALT or GPT (IU/L): 10.0
AST or GOT (IU/L): 16.0
Total Cholesterol (mmol/L): 3,44
Creatinine (mmol/L): 285.0
Gamma-glutamil transpeptidase (IU/L): 13
Glucose (mmol/L): 12,5
Hemoglobin (g/L): 122.0
HDL (mmol/L): 1,32
Potassium (mEq/L): 5,4
LDL (mmol/L): 1,71
Sodium (mEq/L): 139.0
Pro-BNP (ng/L): 656.0
Protein (g/L): 74
T3 (pg/dL): 0,06
T4 (ng/L): 17
Troponin (ng/mL): 0,05
TSH (mIU/L): 6,87
Urea (mg/dL): 23,46
LVEF (%): 21.0
Medications: Diabetes Medication, Beta Blockers, ACE Inhibitor, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",pump failure death,"RANKING: 
1. Pump failure death
REASONING: 
Based on the patient's data, the most concerning prognostic indicators for pump failure death are the patient's advanced age, NYHA Class III heart failure, elevated creatinine levels (285.0 mmol/L), and low LVEF (21.0%). These factors suggest significant cardiac dysfunction and potential left ventricular failure. The presence of non-sustained ventricular tachycardia (CH>10) and ventricular extrasystole also indicates a high risk of arrhythmias, which can further compromise cardiac function. The patient's elevated Pro-BNP levels (656.0 ng/L) also support the presence of heart failure. 

The patient's weight, height, blood pressure, and other laboratory values are not as concerning as the other factors mentioned above. The patient's medication regimen, including ACE inhibitors and beta blockers, suggests that the patient is receiving standard therapy for heart failure. 

Therefore, considering these factors, pump failure death is the most likely outcome.

RANKING: 
2. Sudden cardiac death
REASONING: 
The presence of ventricular extrasystole, non-sustained ventricular tachycardia (CH>10), and polymorphic ventricular extrasystole on the ECG impression increases the risk of sudden cardiac death. These arrhythmias can lead to life-threatening ventricular fibrillation or ventricular tachycardia, which can result in sudden cardiac death. The patient's advanced age and NYHA Class III heart failure also increase the risk of sudden cardiac death.

However, the presence of pump failure death as the most likely outcome takes precedence due to the patient's more severe cardiac dysfunction and elevated creatinine levels.

RANKING: 
3. Survivor
REASONING: 
While the patient's age and NYHA Class III heart failure increase the risk of mortality, the presence of a comprehensive medication regimen and the absence of other severe comorbidities suggest that the patient may still have a chance of survival. The patient's LVEF, although low, is not as low as in the pump failure death scenario. Additionally, the patient's laboratory values, such as the elevated HDL and relatively normal TSH, do not indicate severe metabolic or thyroid disorders that could further compromise cardiac function."
775,775,P0248,"Age: 43
Gender: Female 
Weight: 50 kg
Height: 160 cm
NYHA Class: II
Blood Pressure: 130/80 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Myocardial Infarction
Albumin (g/L): 39
ALT or GPT (IU/L): 30.0
AST or GOT (IU/L): 15.0
Total Cholesterol (mmol/L): 4,19
Creatinine (mmol/L): 53.0
Gamma-glutamil transpeptidase (IU/L): 18
Glucose (mmol/L): 4,4
Hemoglobin (g/L): 127.0
HDL (mmol/L): 1,06
Potassium (mEq/L): 4,3
LDL (mmol/L): 2,79
Sodium (mEq/L): 141.0
Pro-BNP (ng/L): 996.0
Protein (g/L): 67
T3 (pg/dL): 0,03
T4 (ng/L): 18
Troponin (ng/mL): 0,09
TSH (mIU/L): 1,34
Urea (mg/dL): 3,66
LVEF (%): 37.0
Medications: Beta Blockers, Loop Diuretics, Statins, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",pump failure death,"RANKING: 1. Sudden Cardiac Death
REASONING: 

Based on the patient's past medical history of ischemic dilated cardiomyopathy and myocardial infarction, the patient has a significant underlying heart disease that has led to a severely impaired left ventricular function (LVEF 37.0). The patient's current NYHA Class II indicates that they are experiencing symptoms of heart failure, which suggests that their heart is not functioning optimally. The elevated Pro-BNP levels (996.0 ng/L) further support this, indicating elevated ventricular stress and strain. 

Given these factors, the patient is at high risk for cardiac arrhythmias, particularly ventricular arrhythmias, which can lead to sudden cardiac death. The patient's ECG impression of monomorphic ventricular extrasystole, although non-sustained, may be an early sign of a more serious underlying arrhythmia. 

While the patient is currently taking medications to manage their heart failure and prevent further cardiovascular events, the combination of their underlying heart disease, elevated Pro-BNP levels, and the presence of ventricular extrasystole make sudden cardiac death a significant concern. 

Therefore, based on the available data, the most likely prognosis for the patient over the next few years is sudden cardiac death.

RANKING: 2. Pump Failure Death
REASONING: 

Given the patient's severe impairment of left ventricular function (LVEF 37.0) and elevated Pro-BNP levels (996.0 ng/L), the patient is at high risk for heart failure exacerbation and pump failure. The patient's NYHA Class II symptoms and elevated creatinine levels (53.0 mmol/L) further support this. 

The patient's heart failure is likely to worsen over time, leading to a decline in their functional status and potentially life-threatening complications. While the patient is taking medications to manage their heart failure, the underlying heart disease and elevated Pro-BNP levels suggest that the patient's condition is not under good control, and further deterioration is likely. 

Therefore, pump failure death is a significant concern and the second most likely prognosis for the patient over the next few years.

RANKING: 3. Survivor
REASONING: 

While the patient's current medications and medical history suggest that they are receiving optimal care for their heart failure, the underlying heart disease and elevated Pro-BNP levels suggest that the patient's condition is not fully reversible. However, given the patient's age, weight, and the fact that they are receiving optimal medical therapy, it is possible that the patient may experience some improvement in their functional status over time. 

However, the patient's risk of sudden cardiac death and pump failure death is high, and it is uncertain whether the patient will be able to avoid these complications. Therefore, while the patient may survive, the likelihood of a long-term survival without significant cardiovascular events is lower compared to the other two options."
776,776,P0256,"Age: 72
Gender: Male 
Weight: 79 kg
Height: 168 cm
NYHA Class: III
Blood Pressure: 150/60 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Diabetes, Dyslipemia, Peripheral vascular disease, Hypertension, Myocardial Infarction
Albumin (g/L): 33
ALT or GPT (IU/L): 44.0
AST or GOT (IU/L): 13.0
Total Cholesterol (mmol/L): 4,78
Creatinine (mmol/L): 88.0
Gamma-glutamil transpeptidase (IU/L): 267
Glucose (mmol/L): 9,9
Hemoglobin (g/L): 138.0
HDL (mmol/L): 1,03
Potassium (mEq/L): 4,4
LDL (mmol/L): 2,72
Sodium (mEq/L): 138.0
Pro-BNP (ng/L): 1475.0
Protein (g/L): 64
T3 (pg/dL): 0,03
T4 (ng/L): 21
Troponin (ng/mL): 0,01
TSH (mIU/L): 2,13
Urea (mg/dL): 5,83
LVEF (%): 48.0
Medications: Diabetes Medication, Digoxin, Loop Diuretics, Statins, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",pump failure death,"RANKING: 1. Sudden Cardiac Death
REASONING: 
The patient's ECG impression shows ventricular extrasystoles and non-sustained ventricular tachycardia, which are indicators of arrhythmias. The presence of polymorphic ventricular extrasystoles is particularly concerning, as it can be a precursor to ventricular fibrillation, a life-threatening arrhythmia. Additionally, the patient has a history of ischemic dilated cardiomyopathy, which is a condition that can lead to arrhythmias and sudden cardiac death. The patient's low ejection fraction (LVEF) of 48% further supports the risk of cardiac complications. Given the combination of these factors, I believe that sudden cardiac death is the most likely outcome for this patient over the next few years.

RANKING: 2. Pump Failure Death
REASONING: 
The patient's LVEF of 48% indicates severe left ventricular dysfunction, which can lead to pump failure. The patient's history of ischemic dilated cardiomyopathy and previous myocardial infarction also contribute to this risk. The patient is also taking medications that can affect cardiac function, such as digoxin and loop diuretics. While pump failure is a possible outcome, it is less likely than sudden cardiac death given the presence of arrhythmias on the ECG.

RANKING: 3. Survivor
REASONING: 
While the patient's LVEF of 48% and history of ischemic dilated cardiomyopathy are concerning, the patient is still alive and receiving treatment for their conditions. The patient's current medications, such as statins and ACE inhibitors, are aimed at managing their cardiovascular risk factors. The patient's ECG impression does not show any signs of acute cardiac stress or acute coronary syndrome, which would suggest a more acute cardiac event. While it is possible that the patient could experience a cardiac event in the future, the presence of arrhythmias and pump failure indicators on the ECG suggest a higher risk of sudden cardiac death or pump failure, making survival less likely."
777,777,P0264,"Age: 63
Gender: Male 
Weight: 65 kg
Height: 172 cm
NYHA Class: II
Blood Pressure: 90/55 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Myocardial Infarction
Albumin (g/L): 41,9
ALT or GPT (IU/L): 11.0
AST or GOT (IU/L): 14.0
Total Cholesterol (mmol/L): 4,48
Creatinine (mmol/L): 154.0
Gamma-glutamil transpeptidase (IU/L): 69
Glucose (mmol/L): 4,9
Hemoglobin (g/L): 134.0
HDL (mmol/L): 1,17
Potassium (mEq/L): 4,63
LDL (mmol/L): 2,84
Sodium (mEq/L): 141.0
Protein (g/L): 71,7
Troponin (ng/mL): 0,01
TSH (mIU/L): 4,74
Urea (mg/dL): 11,9
LVEF (%): 15.0
Medications: Amiodarone, Digoxin, Loop Diuretics, Hydralazine, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",pump failure death,"RANKING: 
1. Pump failure death
2. Sudden cardiac death
3. Survivor

REASONING:

Based on the patient's data, I would rank the prognoses as follows:

1. Pump failure death: The patient's left ventricular ejection fraction (LVEF) is severely impaired at 15.0%, indicating significant left ventricular dysfunction. This is a strong predictor of heart failure and pump failure. Additionally, the patient has a history of ischemic dilated cardiomyopathy and myocardial infarction, which further supports the risk of pump failure. The presence of ventricular extrasystoles, as indicated by the ECG impression, also suggests a high risk of arrhythmias that can contribute to pump failure.

2. Sudden cardiac death: While the patient has a history of ventricular extrasystoles, the ECG impression does not indicate any ventricular tachycardia or non-sustained ventricular tachycardia, which are more commonly associated with sudden cardiac death. However, the patient's low blood pressure (90/55 mmHg) and low ejection fraction may still pose a risk for sudden cardiac death due to arrhythmias or cardiac arrest.

3. Survivor: The patient's age, NYHA class II, and relatively stable vital signs (blood pressure, glucose, and hemoglobin) suggest that the patient is not in an acute decompensated state. However, the patient's severe left ventricular dysfunction, history of ischemic cardiomyopathy, and presence of ventricular extrasystoles make it less likely for the patient to survive without any adverse cardiac events.

Overall, the combination of severe left ventricular dysfunction, history of ischemic cardiomyopathy, and ventricular extrasystoles make pump failure death the most likely outcome, followed by sudden cardiac death, and finally, survival."
778,778,P0265,"Age: 83
Gender: Female 
Weight: 77 kg
Height: 150 cm
NYHA Class: II
Blood Pressure: 155/90 mmHg
Past Medical History: Hypertensive cardiomyopathy, Diabetes, Dyslipemia, Hypertension, Myocardial Infarction
Albumin (g/L): 38,2
ALT or GPT (IU/L): 17.0
AST or GOT (IU/L): 17.0
Total Cholesterol (mmol/L): 3,99
Creatinine (mmol/L): 97.0
Gamma-glutamil transpeptidase (IU/L): 20
Glucose (mmol/L): 8,6
Hemoglobin (g/L): 134.0
HDL (mmol/L): 1,68
Potassium (mEq/L): 3,66
LDL (mmol/L): 2,03
Sodium (mEq/L): 139.0
Pro-BNP (ng/L): 984.0
Protein (g/L): 67
T4 (ng/L): 20
Troponin (ng/mL): 0,01
TSH (mIU/L): 0,29
Urea (mg/dL): 9,7
LVEF (%): 70.0
Medications: Beta Blockers, Loop Diuretics, Statins, ACE Inhibitor, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",pump failure death,"RANKING: 
1. Pump failure death
REASONING: 
Based on the provided patient data, the patient is at high risk for pump failure death. The patient's age (83) and NYHA Class II heart failure classification indicate that the patient has a significant burden of cardiovascular disease. The patient's LVEF (70%) is below the normal range, suggesting reduced cardiac function. The elevated creatinine level (97.0 mmol/L) also indicates impaired renal function, which is often associated with heart failure.

The patient's history of hypertension, myocardial infarction, and cardiomyopathy further increases the risk of pump failure. The elevated Pro-BNP level (984.0 ng/L) and Troponin level (0.01 ng/mL) indicate cardiac stress and potential myocardial damage. The presence of ventricular extrasystoles (polymorphic) on the ECG also suggests a high risk of arrhythmias, which can contribute to pump failure.

The patient's medication regimen, including beta blockers, loop diuretics, statins, ACE inhibitors, and nitrovasodilators, is generally appropriate for managing heart failure and hypertension. However, the patient's high blood pressure (155/90 mmHg) and elevated creatinine level may indicate inadequate control of these conditions.

Given these factors, the patient's prognosis for pump failure death is the most likely outcome over the next few years."
779,779,P0269,"Age: 79
Gender: Male 
Weight: 62 kg
Height: 156 cm
NYHA Class: II
Blood Pressure: 120/80 mmHg
Past Medical History: Valvular cardiomyopathy, Peripheral vascular disease, Myocardial Infarction
Albumin (g/L): 45,5
ALT or GPT (IU/L): 15.0
AST or GOT (IU/L): 16.0
Total Cholesterol (mmol/L): 4,07
Creatinine (mmol/L): 184.0
Gamma-glutamil transpeptidase (IU/L): 25
Glucose (mmol/L): 5,4
Hemoglobin (g/L): 140.0
HDL (mmol/L): 0,82
Potassium (mEq/L): 5,12
LDL (mmol/L): 2,51
Sodium (mEq/L): 138.0
Protein (g/L): 71,1
Troponin (ng/mL): 0,13
TSH (mIU/L): 1,31
Urea (mg/dL): 20,1
LVEF (%): 22.0
Medications: Calcium Channel Blocker, Digoxin, Loop Diuretics, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",pump failure death,"RANKING: 1. Sudden cardiac death
REASONING: 

Based on the patient's medical history, the patient has a significant risk of sudden cardiac death. The patient has a history of valvular cardiomyopathy, which can lead to arrhythmias, and a history of myocardial infarction, which can cause cardiac remodeling and increased risk of sudden cardiac death. The patient's low left ventricular ejection fraction (LVEF) of 22% further increases the risk of sudden cardiac death. Additionally, the patient's age, weight, and NYHA class II status also contribute to the increased risk.

The patient's ECG impression also supports this prognosis. The presence of ventricular extrasystole, a type of arrhythmia, is a significant risk factor for sudden cardiac death. The patient's low LVEF and the presence of ventricular extrasystole make it more likely that the patient will experience sudden cardiac death in the near future.

While pump failure death is a possible outcome, the patient's current medications, including the ACE inhibitor, loop diuretics, and calcium channel blocker, suggest that the patient's heart is being adequately supported. The patient's elevated creatinine level may indicate some degree of kidney dysfunction, but this does not necessarily increase the risk of pump failure death.

Therefore, based on the available data, sudden cardiac death is the most likely prognosis for this patient.

RANKING: 2. Pump failure death
REASONING: 

The patient's pump failure death prognosis is less likely than sudden cardiac death due to the presence of current medications that are typically used to manage heart failure. The patient is taking loop diuretics, which are used to reduce fluid overload and alleviate symptoms of heart failure. The patient is also taking an ACE inhibitor, which is used to reduce blood pressure and reduce the strain on the heart.

The patient's elevated creatinine level may indicate some degree of kidney dysfunction, which can contribute to the development of pump failure. However, the patient's current medications and the fact that the patient is taking digoxin, which is used to regulate heart rhythm, suggest that the patient's heart is being adequately supported.

RANKING: 3. Survivor
REASONING: 

The patient's pump failure death prognosis is the least likely due to the presence of current medications that are typically used to manage heart failure. The patient's elevated creatinine level may indicate some degree of kidney dysfunction, but the patient's current medications and the fact that the patient is taking digoxin suggest that the patient's heart is being adequately supported.

The patient's age and NYHA class II status also contribute to the increased risk of pump failure death. However, the patient's current medications and the fact that the patient is not experiencing any symptoms of heart failure suggest that the patient's heart is not failing at the moment.

It is also worth noting that the patient's troponin level is within the normal range, which suggests that there is no significant myocardial infarction or damage to the heart muscle. This further reduces the likelihood of pump failure death."
780,780,P0285,"Age: 69
Gender: Female 
Weight: 76 kg
Height: 147 cm
NYHA Class: III
Blood Pressure: 150/80 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Diabetes, Dyslipemia, Peripheral vascular disease, Hypertension, Myocardial Infarction
Albumin (g/L): 41
ALT or GPT (IU/L): 12.0
AST or GOT (IU/L): 25.0
Total Cholesterol (mmol/L): 4,5
Creatinine (mmol/L): 163.0
Gamma-glutamil transpeptidase (IU/L): 48,4
Glucose (mmol/L): 4,2
Hemoglobin (g/L): 134.0
HDL (mmol/L): 1,32
Potassium (mEq/L): 4,7
LDL (mmol/L): 2,56
Sodium (mEq/L): 142.0
Pro-BNP (ng/L): 2365.0
Protein (g/L): 75
T3 (pg/dL): 0,0294
T4 (ng/L): 16,92
Troponin (ng/mL): 1,4
TSH (mIU/L): 0,56
Urea (mg/dL): 21,2
LVEF (%): 25.0
Medications: Diabetes Medication, Loop Diuretics, Statins, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",pump failure death,"RANKING: 1. Survivor
REASONING: 

Based on the patient data, the patient has a significant history of heart failure, with an LVEF of 25.0, which indicates severe systolic dysfunction. The patient also has a history of ischemic dilated cardiomyopathy, hypertension, and diabetes, which are all risk factors for heart failure. Additionally, the patient has a high level of N-terminal pro-b-type natriuretic peptide (Pro-BNP) of 2365.0 ng/L, which is a marker of heart failure. The patient is also taking medications for heart failure, including a diuretic and ACE inhibitor, which suggests that the patient is receiving standard treatment for heart failure.

While the patient does have some risk factors for arrhythmias, such as ventricular extrasystole and non-sustained ventricular tachycardia, the ECG impression does not indicate any life-threatening arrhythmias. Therefore, I believe that the patient is more likely to survive the next few years with proper management of their heart failure and medication adherence.

RANKING: 2. Sudden cardiac death
REASONING: 

While the patient has a high risk of arrhythmias, the ECG impression does not indicate any life-threatening arrhythmias. However, the patient does have a history of ventricular extrasystole, which is a risk factor for sudden cardiac death. Additionally, the patient has a high level of Pro-BNP, which may indicate worsening heart failure. However, the patient is already taking medications for heart failure, which suggests that the patient is receiving standard treatment.

RANKING: 3. Pump failure death
REASONING: 

Given the patient's severe systolic dysfunction (LVEF 25.0) and history of heart failure, I believe that pump failure death is a possible outcome. However, this outcome is less likely than survival or sudden cardiac death, given the patient's current treatment and medication regimen.

It's worth noting that the patient's creatinine level of 163.0 mmol/L suggests some degree of kidney impairment, which may impact their overall prognosis. However, this finding alone does not necessarily predict pump failure death. Overall, I believe that the patient's heart failure and arrhythmia risk factors make survival the most likely outcome, followed by sudden cardiac death, and then pump failure death."
781,781,P0287,"Age: 70
Gender: Female 
Weight: 80 kg
Height: 145 cm
NYHA Class: II
Blood Pressure: 160/80 mmHg
Past Medical History: Hypertensive cardiomyopathy, Dyslipemia, Hypertension
Albumin (g/L): 44
ALT or GPT (IU/L): 27.0
AST or GOT (IU/L): 21.0
Total Cholesterol (mmol/L): 5,35
Creatinine (mmol/L): 100.0
Gamma-glutamil transpeptidase (IU/L): 23
Glucose (mmol/L): 5,2
Hemoglobin (g/L): 143.0
HDL (mmol/L): 1,19
Potassium (mEq/L): 4
LDL (mmol/L): 3,13
Sodium (mEq/L): 142.0
Pro-BNP (ng/L): 1537.0
Protein (g/L): 72
T3 (pg/dL): 0,027
T4 (ng/L): 21,25
Troponin (ng/mL): 0,2
TSH (mIU/L): 1,93
Urea (mg/dL): 5,5
LVEF (%): 70.0
Medications: Calcium Channel Blocker, Amiodarone, Loop Diuretics, Statins, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",pump failure death,"RANKING: 
1. Pump failure death
2. Sudden cardiac death
3. Survivor

REASONING:

The patient is at high risk for pump failure death due to several factors:

1. NYHA Class II indicates that the patient has heart failure symptoms, which suggests that the heart is not functioning efficiently.
2. Hypertensive cardiomyopathy is a significant underlying condition that can lead to left ventricular dysfunction and heart failure.
3. Elevated creatinine levels (100.0 mmol/L) indicate impaired kidney function, which can be related to heart failure.
4. Elevated Pro-BNP levels (1537.0 ng/L) suggest that the heart is under strain, which is consistent with heart failure.
5. The patient's LVEF (70.0%) is lower than the normal range, indicating reduced left ventricular function.

While the patient is on medications such as loop diuretics, which are commonly used to treat heart failure, the combination of these factors suggests that the patient is at high risk for pump failure.

Sudden cardiac death is less likely due to the following reasons:

1. The ECG impression does not show any signs of ventricular tachycardia or polymorphic ventricular extrasystoles, which are common causes of sudden cardiac death.
2. The patient is on Amiodarone, which is an anti-arrhythmic medication that can help prevent arrhythmias.

Survivorship is the least likely due to the patient's underlying conditions and the presence of heart failure symptoms. While the patient is on various medications, the combination of factors suggests that the patient is at high risk for adverse outcomes, including pump failure death."
782,782,P0293,"Age: 74
Gender: Male 
Weight: 90 kg
Height: 184 cm
NYHA Class: III
Blood Pressure: 125/70 mmHg
Past Medical History: Idiopathic dilated cardiomyopathy, Diabetes, Hypertension
Albumin (g/L): 40,5
ALT or GPT (IU/L): 17.0
AST or GOT (IU/L): 19.0
Total Cholesterol (mmol/L): 3,61
Creatinine (mmol/L): 93.0
Gamma-glutamil transpeptidase (IU/L): 22
Glucose (mmol/L): 3,19
Hemoglobin (g/L): 149.0
HDL (mmol/L): 1,7
Potassium (mEq/L): 5,11
LDL (mmol/L): 1,73
Sodium (mEq/L): 144.0
Pro-BNP (ng/L): 1081.0
Protein (g/L): 68
T3 (pg/dL): 0,024
T4 (ng/L): 16,52
Troponin (ng/mL): 0,2
TSH (mIU/L): 0,62
Urea (mg/dL): 10,3
LVEF (%): 28.0
Medications: Diabetes Medication, Beta Blockers, Digoxin, Loop Diuretics, Spironolactone, ACE Inhibitor, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",pump failure death,"RANKING: 1. Sudden cardiac death
REASONING: 

The patient's ECG findings indicate a high risk for life-threatening arrhythmias, including ventricular extrasystole, non-sustained ventricular tachycardia (NSVT), and a history of non-sustained VT. These findings suggest that the patient is at a high risk for sudden cardiac death. The presence of NSVT and ventricular extrasystole, particularly in a patient with a history of idiopathic dilated cardiomyopathy, further increases the risk of sudden cardiac death. Additionally, the patient's LVEF of 28.0 indicates significant left ventricular dysfunction, which is a major predictor of arrhythmic events.

RANKING: 2. Pump failure death
REASONING: 

Given the patient's history of idiopathic dilated cardiomyopathy, NYHA Class III, and significant left ventricular dysfunction (LVEF 28.0), pump failure is a likely complication. The patient's elevated creatinine levels (93.0 mmol/L) and urea (10.3 mg/dL) also suggest impaired renal function, which can be a consequence of heart failure. The presence of edema, hypertension, and electrolyte imbalances (e.g., hyperkalemia, hypokalemia) further supports this prognosis.

RANKING: 3. Survivor
REASONING: 

While the patient's prognosis is concerning, the presence of certain factors may improve the likelihood of survival. The patient is on several medications that target heart failure and arrhythmias, including beta blockers, digoxin, and ACE inhibitors. The patient's hemoglobin level is within the normal range, and the absence of severe hypoxia or anemia may indicate that the patient is not in acute distress. However, the patient's significant left ventricular dysfunction and history of arrhythmias suggest that the risk of complications remains high. Overall, while the patient may survive, the risk of sudden cardiac death or pump failure death remains a significant concern."
783,783,P0294,"Age: 70
Gender: Male 
Weight: 79 kg
Height: 168 cm
NYHA Class: II
Blood Pressure: 110/80 mmHg
Past Medical History: Idiopathic dilated cardiomyopathy, Dyslipemia, Hypertension
Albumin (g/L): 39
ALT or GPT (IU/L): 26.0
AST or GOT (IU/L): 19.0
Total Cholesterol (mmol/L): 4,99
Creatinine (mmol/L): 88.0
Gamma-glutamil transpeptidase (IU/L): 78
Glucose (mmol/L): 5,82
Hemoglobin (g/L): 138.0
HDL (mmol/L): 1,14
Potassium (mEq/L): 4,57
LDL (mmol/L): 3,53
Sodium (mEq/L): 138.0
Pro-BNP (ng/L): 1693.0
Protein (g/L): 67
T3 (pg/dL): 0,0369
T4 (ng/L): 15,09
Troponin (ng/mL): 0,3
TSH (mIU/L): 1,21
Urea (mg/dL): 8
LVEF (%): 25.0
Medications: Angiotensin II Receptor Blocker, Beta Blockers, Loop Diuretics, Spironolactone
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: TPSV
        - Bradycardia: No
            ",pump failure death,"RANKING: 
1. Survivor
REASONING: 
The patient's age is 70, which puts them at higher risk for adverse outcomes. However, the patient's NYHA Class II indicates that they are not severely limited in their physical activity, which is a positive prognostic factor. The patient's LVEF is significantly reduced at 25%, indicating poor cardiac function, which is a strong predictor of adverse outcomes. However, the patient's medications, including Angiotensin II Receptor Blocker, Beta Blockers, and Loop Diuretics, suggest that the patient is receiving appropriate treatment for heart failure. The patient's Pro-BNP level is elevated at 1693.0 ng/L, but this is not excessively high, and the patient's renal function is relatively preserved. 

The patient's ECG findings are concerning, with polymorphic ventricular extrasystoles and non-sustained ventricular tachycardia, which are both markers of increased risk for arrhythmias. However, the presence of these arrhythmias is not uncommon in patients with heart failure. 

Considering these factors, the patient is at high risk for adverse outcomes, but the presence of certain risk factors (e.g. NYHA Class II, relatively preserved renal function, and the use of appropriate medications) and the absence of excessively high Pro-BNP levels and renal dysfunction suggest that the patient is more likely to survive than to experience sudden cardiac death or pump failure death. 

2. Sudden cardiac death
REASONING: 
The patient's ECG findings of polymorphic ventricular extrasystoles and non-sustained ventricular tachycardia are concerning for an increased risk of arrhythmias, which is a major risk factor for sudden cardiac death. Additionally, the patient's NYHA Class II and LVEF of 25% indicate poor cardiac function, which is a risk factor for arrhythmias and sudden cardiac death. 

However, the patient is taking medications that are commonly used to manage heart failure and arrhythmias, which suggests that the patient is receiving appropriate treatment. The patient's Pro-BNP level and renal function are also relatively preserved, which is a positive prognostic factor.

3. Pump failure death
REASONING: 
The patient's NYHA Class II and LVEF of 25% indicate that the patient has significant heart failure, which is a major risk factor for pump failure death. The patient's Pro-BNP level is elevated at 1693.0 ng/L, which is a marker of heart failure. The patient's renal function is also relatively preserved, which is a positive prognostic factor. However, the patient's ECG findings of polymorphic ventricular extrasystoles and non-sustained ventricular tachycardia are concerning for arrhythmias, which can worsen heart failure and increase the risk of pump failure death. 

While the patient is taking medications that are commonly used to manage heart failure, the patient's poor cardiac function and elevated Pro-BNP level suggest that the patient is at high risk for pump failure death."
784,784,P0303,"Age: 71
Gender: Male 
Weight: 65 kg
Height: 158 cm
NYHA Class: II
Blood Pressure: 120/60 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Myocardial Infarction
Albumin (g/L): 38
ALT or GPT (IU/L): 39.0
AST or GOT (IU/L): 29.0
Total Cholesterol (mmol/L): 5,92
Creatinine (mmol/L): 106.0
Gamma-glutamil transpeptidase (IU/L): 44
Glucose (mmol/L): 6,7
Hemoglobin (g/L): 113.0
HDL (mmol/L): 1,14
Potassium (mEq/L): 4,5
LDL (mmol/L): 3,7
Sodium (mEq/L): 137.0
Pro-BNP (ng/L): 1160.0
Protein (g/L): 74
T3 (pg/dL): 0,03
T4 (ng/L): 17
Troponin (ng/mL): 0,01
TSH (mIU/L): 4,34
Urea (mg/dL): 6,82
LVEF (%): 42.0
Medications: Beta Blockers, Loop Diuretics, Spironolactone, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: TPSV
        - Bradycardia: No
            ",pump failure death,"RANKING: 
1. Pump failure death
REASONING: 

The patient's overall clinical presentation and laboratory results suggest a high risk of adverse cardiac events. Key factors contributing to this risk include:

1. Severe LVEF of 42%, indicating significant left ventricular dysfunction, which is a hallmark of advanced heart failure.
2. Elevated Pro-BNP levels of 1160 ng/L, which is a strong indicator of ventricular strain and heart failure.
3. History of ischemic dilated cardiomyopathy and myocardial infarction, which are risk factors for further cardiac events.
4. Presence of ventricular extrasystoles on ECG, which can be a predictor of arrhythmic events.
5. Medications such as Spironolactone and ACE Inhibitor, which are commonly used to manage heart failure but can also increase the risk of hyperkalemia and other electrolyte imbalances.
6. Elevated creatinine levels of 6.82 mg/dL, indicating impaired renal function, which can further exacerbate heart failure.
7. Low T3 levels (0.03 pg/dL), which may indicate hypothyroidism or decreased cardiac output, contributing to heart failure.

Considering these factors, the patient is at high risk of pump failure death, which is a direct consequence of the underlying cardiac dysfunction.

2. Sudden cardiac death
REASONING: 

While the patient has a high risk of pump failure death, the presence of ventricular extrasystoles on ECG and a history of ischemic dilated cardiomyopathy and myocardial infarction increase the risk of arrhythmic events, including sudden cardiac death.

3. Survivor
REASONING: 

The patient's age, NYHA Class II, and presence of medications such as beta blockers and ACE inhibitors suggest that they are receiving appropriate treatment for heart failure. However, the combination of severe LVEF, elevated Pro-BNP levels, and history of cardiac events makes it challenging to predict a favorable outcome. Despite this, the patient's age and the presence of medications may mitigate some of the risks, making survivor a less likely outcome compared to pump failure death."
785,785,P0317,"Age: 63
Gender: Male 
Weight: 72 kg
Height: 172 cm
NYHA Class: III
Blood Pressure: 95/65 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Diabetes, Dyslipemia, Peripheral vascular disease, Myocardial Infarction
Albumin (g/L): 42,5
ALT or GPT (IU/L): 26.0
AST or GOT (IU/L): 28.0
Total Cholesterol (mmol/L): 4,81
Creatinine (mmol/L): 133.0
Gamma-glutamil transpeptidase (IU/L): 16
Glucose (mmol/L): 4,1
Hemoglobin (g/L): 129.0
HDL (mmol/L): 1,45
Potassium (mEq/L): 4,3
LDL (mmol/L): 2,64
Sodium (mEq/L): 137.0
Pro-BNP (ng/L): 325.0
Protein (g/L): 83
T3 (pg/dL): 0,05
T4 (ng/L): 18
Troponin (ng/mL): 0,01
TSH (mIU/L): 6,37
Urea (mg/dL): 13,14
LVEF (%): 24.0
Medications: Diabetes Medication, Amiodarone, Beta Blockers, Loop Diuretics, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",pump failure death,"RANKING: 1. Pump failure death
REASONING: 

Based on the provided patient data, the patient's clinical presentation and lab results suggest a high risk of cardiac complications. The patient has a history of ischemic dilated cardiomyopathy, which is a condition where the heart muscle becomes weakened and cannot pump blood efficiently. This condition is a significant risk factor for pump failure.

The patient's Left Ventricular Ejection Fraction (LVEF) is severely impaired at 24.0%, which is a strong indicator of pump failure. Additionally, the patient has a history of myocardial infarction, diabetes, dyslipemia, and peripheral vascular disease, all of which can contribute to cardiac damage and decreased cardiac function.

Furthermore, the patient's elevated B-type natriuretic peptide (Pro-BNP) level of 325.0 ng/L is significantly elevated, which is a marker of cardiac stress and strain. This suggests that the patient's heart is working hard to compensate for the reduced cardiac function, increasing the risk of cardiac failure.

The patient's medications, including ACE inhibitors, beta blockers, and loop diuretics, are standard treatments for heart failure, indicating that the patient is being managed for heart failure.

Given these factors, pump failure death is the most likely outcome for this patient over the next few years. While the patient's age and sex are not as significant risk factors as the patient's underlying cardiac condition, they do contribute to the overall risk of mortality.

RANKING: 2. Sudden cardiac death
REASONING: 

Sudden cardiac death is a possible outcome for this patient, given their history of ischemic dilated cardiomyopathy, myocardial infarction, and the presence of ventricular extrasystoles on the ECG. However, the patient's LVEF is severely impaired, which reduces the likelihood of sudden cardiac death compared to a patient with a preserved LVEF.

Additionally, the patient's medications, including amiodarone, a Class III anti-arrhythmic agent, suggest that the patient is being managed for arrhythmias, but the ECG results do not show any evidence of ventricular tachycardia or non-sustained ventricular tachycardia.

RANKING: 3. Survivor
REASONING: 

Given the patient's severe impairment of LVEF and the presence of cardiac risk factors, survival is less likely compared to pump failure death. However, the patient's age, sex, and the presence of medications for heart failure management may contribute to a slightly better prognosis.

Additionally, the patient's troponin level is within normal limits, which suggests that there is no acute myocardial infarction. The patient's liver enzymes, such as ALT and AST, are also within normal limits, which reduces the risk of liver-related complications.

However, the patient's overall clinical presentation and lab results suggest that survival is the least likely outcome compared to pump failure death and sudden cardiac death."
786,786,P0320,"Age: 69
Gender: Male 
Weight: 64 kg
Height: 163 cm
NYHA Class: II
Blood Pressure: 110/75 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Dyslipemia, Myocardial Infarction
Albumin (g/L): 43,8
ALT or GPT (IU/L): 11.0
AST or GOT (IU/L): 18.0
Total Cholesterol (mmol/L): 3,96
Creatinine (mmol/L): 98.0
Gamma-glutamil transpeptidase (IU/L): 7
Glucose (mmol/L): 4,6
Hemoglobin (g/L): 138.0
HDL (mmol/L): 1,27
Potassium (mEq/L): 4,3
LDL (mmol/L): 1,99
Sodium (mEq/L): 136.0
Pro-BNP (ng/L): 535.0
Protein (g/L): 79
T3 (pg/dL): 0,05
T4 (ng/L): 16
Troponin (ng/mL): 0,01
TSH (mIU/L): 0,983
Urea (mg/dL): 7,35
LVEF (%): 36.0
Medications: Beta Blockers, Spironolactone, Statins, ACE Inhibitor, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",pump failure death,"RANKING: 1. Sudden cardiac death
REASONING: The patient's ECG findings of monomorphic ventricular extrasystole suggest a high risk of ventricular arrhythmias, which are a common cause of sudden cardiac death in patients with heart failure. The patient's LVEF of 36.0 indicates severe left ventricular dysfunction, which further increases the risk of arrhythmic events. Additionally, the presence of ischemic dilated cardiomyopathy, myocardial infarction, and dyslipidemia in the patient's past medical history also contribute to the risk of arrhythmic events. The patient's elevated troponin level (0.01 ng/mL) is also a marker of myocardial damage, which can increase the risk of arrhythmias.

RANKING: 2. Pump failure death
REASONING: Pump failure death is a likely outcome for this patient due to the patient's severe left ventricular dysfunction (LVEF of 36.0) and NYHA Class II heart failure. The patient's elevated creatinine level (7.35 mg/dL) and elevated BNP level (535 ng/L) suggest that the patient is experiencing significant volume overload and fluid overload, which can lead to heart failure. The patient's medication regimen, including beta blockers, spironolactone, statins, ACE inhibitors, and nitrovasodilator, suggests that the patient is being treated for heart failure, but the severity of the condition may still pose a risk for pump failure.

RANKING: 3. Survivor
REASONING: While the patient's current medical condition and medication regimen suggest a high risk for arrhythmic events and pump failure, the patient's relatively stable vital signs (blood pressure 110/75 mmHg) and hemoglobin level (138 g/L) suggest that the patient is not in acute distress. The patient's LVEF of 36.0 is severe, but it is not immediately life-threatening, and the patient may still benefit from optimal medical therapy. However, the patient's overall prognosis is still guarded due to the presence of underlying heart disease and the potential for arrhythmic events and pump failure."
787,787,P0321,"Age: 67
Gender: Female 
Weight: 76 kg
Height: 161 cm
NYHA Class: II
Blood Pressure: 120/70 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Diabetes, Dyslipemia, Peripheral vascular disease, Hypertension, Myocardial Infarction
Albumin (g/L): 39,6
ALT or GPT (IU/L): 14.0
AST or GOT (IU/L): 16.0
Total Cholesterol (mmol/L): 2,87
Creatinine (mmol/L): 94.0
Gamma-glutamil transpeptidase (IU/L): 53
Glucose (mmol/L): 6,2
Hemoglobin (g/L): 134.0
HDL (mmol/L): 0,83
Potassium (mEq/L): 4,5
LDL (mmol/L): 1,45
Sodium (mEq/L): 132.0
Pro-BNP (ng/L): 4636.0
Protein (g/L): 67
T3 (pg/dL): 0,03
T4 (ng/L): 22
Troponin (ng/mL): 0,02
TSH (mIU/L): 2,43
Urea (mg/dL): 6,01
LVEF (%): 18.0
Medications: Diabetes Medication, Beta Blockers, Digoxin, Loop Diuretics, Spironolactone, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",pump failure death,"RANKING: 
1. Pump failure death
REASONING: 
Based on the provided patient data, I would rank pump failure death as the most likely prognosis for this patient. The patient has a history of ischemic dilated cardiomyopathy, which is a condition where the heart muscle becomes weakened and the heart is unable to pump blood effectively. The patient's Left Ventricular Ejection Fraction (LVEF) is 18.0%, which is significantly below the normal range, indicating severe left ventricular dysfunction. Additionally, the patient's elevated BNP levels (4636.0 ng/L) suggest cardiac strain and increased ventricular wall tension, which can lead to heart failure.

The patient's NYHA Class II indicates that they have some limitations in physical activity due to their heart condition, but they are still able to perform daily activities. However, the presence of pump failure death as the patient outcome suggests that the patient's heart function is deteriorating, and they are at risk of developing severe heart failure.

The patient's other comorbidities, such as diabetes, hypertension, and peripheral vascular disease, also contribute to their overall poor cardiovascular health. The patient's medications, including ACE inhibitors and beta blockers, suggest that their healthcare provider is taking steps to manage their heart condition. However, the patient's elevated creatinine levels (94.0 mmol/L) and elevated potassium levels (4.5 mEq/L) may indicate renal impairment and electrolyte imbalances, which can further compromise cardiac function.

Overall, the combination of the patient's severe left ventricular dysfunction, elevated BNP levels, and comorbidities make pump failure death the most likely prognosis for this patient.

RANKING: 
2. Sudden cardiac death
REASONING: 
Based on the provided patient data, I would rank sudden cardiac death as the second most likely prognosis for this patient. The patient's ECG impression reveals ventricular extrasystoles, which can be a precursor to ventricular tachycardia and potentially life-threatening arrhythmias. The patient's elevated troponin levels (0.02 ng/mL) may indicate minor myocardial damage, which can increase the risk of arrhythmias.

However, the patient's ECG impression does not show any evidence of ventricular tachycardia or non-sustained ventricular tachycardia, which are more commonly associated with sudden cardiac death. Additionally, the patient's LVEF is severely impaired, which may reduce the likelihood of sudden cardiac death.

RANKING: 
3. Survivor
REASONING: 
Based on the provided patient data, I would rank survivor as the least likely prognosis for this patient. While the patient's overall health is compromised due to their comorbidities and severe left ventricular dysfunction, the patient's current ECG impression and laboratory results do not indicate an immediate life-threatening condition.

The patient's NYHA Class II and elevated BNP levels suggest that they have some degree of heart failure, but they are still able to perform daily activities. The patient's medications, including ACE inhibitors and beta blockers, are aimed at managing their heart condition and reducing the risk of complications.

However, the patient's severe left ventricular dysfunction and elevated creatinine levels may limit their long-term survival and quality of life. Overall, while survival is possible, the patient's prognosis is guarded, and they may require close monitoring and management to prevent further decline."
788,788,P0329,"Age: 61
Gender: Female 
Weight: 95 kg
Height: 162 cm
NYHA Class: II
Blood Pressure: 140/70 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Diabetes, Dyslipemia, Hypertension, Myocardial Infarction
Albumin (g/L): 39,2
ALT or GPT (IU/L): 14.0
AST or GOT (IU/L): 12.0
Total Cholesterol (mmol/L): 4,68
Creatinine (mmol/L): 99.0
Gamma-glutamil transpeptidase (IU/L): 31
Glucose (mmol/L): 17,2
Hemoglobin (g/L): 165.0
HDL (mmol/L): 1,09
Potassium (mEq/L): 4,8
LDL (mmol/L): 1,78
Sodium (mEq/L): 140.0
Pro-BNP (ng/L): 10340.0
Protein (g/L): 73
T3 (pg/dL): 0,04
T4 (ng/L): 16
Troponin (ng/mL): 0,01
TSH (mIU/L): 1,44
Urea (mg/dL): 7,35
LVEF (%): 24.0
Medications: Diabetes Medication, Digoxin, Spironolactone, ACE Inhibitor, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",pump failure death,"RANKING: 1. Survivor

REASONING: 

This patient's prognosis is initially leaning towards survival due to the following factors:

1. Age: Although the patient is 61 years old, it is not unusually old for someone with a history of heart disease. This age group can still have a relatively good prognosis with proper management.

2. NYHA Class II: This indicates that the patient has some limitations in physical activity, but they are not severely limited. This suggests that the heart is still functional to some extent.

3. Medications: The patient is on a combination of medications that are commonly used to manage heart failure and other comorbid conditions. This suggests that the patient is receiving appropriate treatment.

4. Pro-BNP level: While the Pro-BNP level is elevated, indicating some level of cardiac stress, it is not excessively high, which could suggest severe heart failure.

5. ECG Impression: The ECG shows ventricular extrasystole, which is a common finding in patients with heart disease, but it is not indicative of a severe arrhythmia.

However, there are some concerning factors that could potentially impact the prognosis:

1. Low LVEF: The left ventricular ejection fraction (LVEF) is significantly reduced at 24%, indicating that the heart is not pumping efficiently.

2. High creatinine level: The creatinine level is elevated, suggesting some degree of renal impairment, which can be a complication of heart failure.

3. Hypertension: The patient has a history of hypertension, which can contribute to cardiac disease progression.

4. Ischemic dilated cardiomyopathy: This condition can lead to heart failure and other complications.

Given these factors, while the patient's prognosis is not extremely poor, there are enough concerns to make pump failure death a possible outcome. However, the combination of the patient's age, NYHA Class II, and the presence of a comprehensive treatment plan make survival the more likely outcome."
789,789,P0336,"Age: 69
Gender: Female 
Weight: 69 kg
Height: 150 cm
NYHA Class: II
Blood Pressure: 130/70 mmHg
Past Medical History: Idiopathic dilated cardiomyopathy, Diabetes, Dyslipemia
Albumin (g/L): 41,9
ALT or GPT (IU/L): 16.0
AST or GOT (IU/L): 16.0
Total Cholesterol (mmol/L): 4,94
Creatinine (mmol/L): 91.0
Gamma-glutamil transpeptidase (IU/L): 14
Glucose (mmol/L): 6,3
Hemoglobin (g/L): 132.0
HDL (mmol/L): 1,58
Potassium (mEq/L): 4,7
LDL (mmol/L): 2,4
Sodium (mEq/L): 142.0
Pro-BNP (ng/L): 3311.0
Protein (g/L): 73
T3 (pg/dL): 0,03
T4 (ng/L): 8
Troponin (ng/mL): 0,02
TSH (mIU/L): 33,39
Urea (mg/dL): 6,68
LVEF (%): 22.0
Medications: Angiotensin II Receptor Blocker, Digoxin
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",pump failure death,"RANKING: 1. Sudden cardiac death
REASONING: 

Based on the patient's data, I would rank sudden cardiac death as the most likely outcome over the next few years. The patient has a history of idiopathic dilated cardiomyopathy, which is a condition that significantly increases the risk of sudden cardiac death. The patient's LVEF of 22.0 is also a strong indicator of poor cardiac function, which can contribute to arrhythmias and sudden cardiac death.

Additionally, the patient's ECG impression reveals ventricular extrasystole, which is a type of abnormal heart rhythm that can increase the risk of sudden cardiac death. The presence of non-sustained ventricular tachycardia (NSVT) is also a concern, as it can be a predictor of more serious arrhythmias.

While the patient is taking an Angiotensin II Receptor Blocker, which is a medication that can help reduce blood pressure and improve cardiac function, the patient's underlying condition and ECG findings suggest that the risk of sudden cardiac death is still significant.

The patient's other medical conditions, such as diabetes and dyslipemia, also increase the risk of cardiovascular events, but the combination of the patient's cardiomyopathy, abnormal ECG findings, and the presence of NSVT make sudden cardiac death the most likely outcome.

RANKING: 2. Pump failure death
REASONING: 

Pump failure death is a possible outcome for this patient, given their history of idiopathic dilated cardiomyopathy and poor LVEF. However, I would rank it as the second most likely outcome due to the patient's relatively stable blood pressure and normal kidney function (creatinine of 91.0 mg/dL).

While the patient's cardiac function is poor, the patient's medication regimen, including the Angiotensin II Receptor Blocker, may help to slow the progression of the disease. Additionally, the patient's electrolyte levels and liver function tests are relatively normal, which suggests that the patient's kidney function is not severely impaired.

RANKING: 3. Survivor
REASONING: 

Given the patient's poor cardiac function, history of cardiomyopathy, and abnormal ECG findings, I would rank survival as the least likely outcome. However, the patient's relatively stable blood pressure, normal kidney function, and normal liver function, as well as their current medication regimen, suggest that they may be able to survive for an extended period.

While the patient's condition is serious, it is not immediately life-threatening, and with close monitoring and appropriate medical management, it is possible that the patient may survive for several years. However, the patient's underlying condition and ECG findings make it difficult to predict a long-term survival."
790,790,P0339,"Age: 77
Gender: Male 
Weight: 64 kg
Height: 160 cm
NYHA Class: II
Blood Pressure: 110/80 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Diabetes, Peripheral vascular disease, Hypertension
Albumin (g/L): 37,4
ALT or GPT (IU/L): 11.0
AST or GOT (IU/L): 17.0
Total Cholesterol (mmol/L): 5,09
Creatinine (mmol/L): 135.0
Gamma-glutamil transpeptidase (IU/L): 23
Glucose (mmol/L): 4,1
Hemoglobin (g/L): 128.0
HDL (mmol/L): 1,19
Potassium (mEq/L): 4,5
LDL (mmol/L): 3,49
Sodium (mEq/L): 141.0
Pro-BNP (ng/L): 3307.0
Protein (g/L): 73
T3 (pg/dL): 0,04
T4 (ng/L): 17
Troponin (ng/mL): 0,01
TSH (mIU/L): 1,37
Urea (mg/dL): 16,03
LVEF (%): 33.0
Medications: Diabetes Medication, Loop Diuretics, ACE Inhibitor, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: TPSV
        - Bradycardia: No
            ",pump failure death,"RANKING: 
1. Survivor
2. Sudden cardiac death
3. Pump failure death

REASONING:

Based on the patient's data, the most likely outcome is survivor, despite having a history of ischemic dilated cardiomyopathy, which is a significant risk factor for adverse outcomes. However, the patient's age (77) and NYHA Class II symptoms suggest that the disease is not as advanced as it could be, and the patient is still relatively mobile.

The patient's biomarkers, such as elevated troponin (0.01 ng/mL) and LVEF (33.0%), indicate some degree of cardiac dysfunction, but not severe. The patient's creatinine level (1.35 mmol/L) and urea level (16.03 mg/dL) suggest some degree of renal impairment, which could be related to the cardiomyopathy or other comorbid conditions.

The presence of ventricular extrasystoles (polymorphic) and paroxysmal supraventricular tachycardia (TPSV) on the ECG suggest an increased risk of arrhythmias, but the absence of ventricular tachycardia or non-sustained ventricular tachycardia (CH>10) reduces the risk of sudden cardiac death.

The patient's medication regimen, including ACE inhibitors, loop diuretics, and a nitrovasodilator, suggests that the patient is receiving optimal medical therapy for their heart failure and hypertension.

The most concerning factor is the patient's elevated Pro-BNP level (3307.0 ng/L), which indicates a high risk of pump failure. However, the combination of a relatively stable hemoglobin level (128.0 g/L) and a low T3 level (0.04 pg/dL) suggests that the patient is not in acute decompensated heart failure.

Considering these factors, I would rank the patient's outcome as survivor, with a moderate risk of pump failure death over the next few years. Sudden cardiac death is less likely due to the absence of ventricular tachycardia and non-sustained ventricular tachycardia on the ECG. Pump failure death is a possible outcome, but the patient's relatively stable biomarkers and medication regimen reduce the risk."
791,791,P0363,"Age: 83
Gender: Male 
Weight: 55 kg
Height: 163 cm
NYHA Class: III
Blood Pressure: 160/80 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Hypertension, Myocardial Infarction
Albumin (g/L): 41,1
ALT or GPT (IU/L): 10.0
AST or GOT (IU/L): 15.0
Total Cholesterol (mmol/L): 5,71
Creatinine (mmol/L): 82.0
Gamma-glutamil transpeptidase (IU/L): 13,6
Glucose (mmol/L): 4,59
Hemoglobin (g/L): 160.0
HDL (mmol/L): 1,5
Potassium (mEq/L): 4,5
LDL (mmol/L): 3,2
Sodium (mEq/L): 140.0
Pro-BNP (ng/L): 1469.0
Protein (g/L): 73
T3 (pg/dL): 0,0468
T4 (ng/L): 13,29
Troponin (ng/mL): 0,4
TSH (mIU/L): 1,04
Urea (mg/dL): 5,6
LVEF (%): 25.0
Medications: Angiotensin II Receptor Blocker, Digoxin, Loop Diuretics, Spironolactone, ACE Inhibitor, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",pump failure death,"RANKING: 1. Survivor
REASONING: 
The patient's LVEF is 25.0, which is a significant indicator of reduced left ventricular function, and the patient has a history of ischemic dilated cardiomyopathy, which further supports the notion of reduced cardiac function. However, the patient's age is 83, and while this increases the risk of mortality, the presence of multiple medications, including ACE inhibitors and spironolactone, suggests that the patient is receiving optimal treatment for heart failure. Additionally, the patient's eGFR is not severely impaired, and their renal function is not critically compromised. Furthermore, the patient's creatinine level is 5.6, which is not excessively high, indicating that their kidneys are not failing catastrophically. These factors, combined with the patient's relatively low Troponin level and absence of ventricular tachycardia, suggest that the patient may be able to survive with proper management.

RANKING: 2. Sudden Cardiac Death
REASONING: 
While the patient has a history of ischemic dilated cardiomyopathy, which increases the risk of sudden cardiac death, the absence of ventricular tachycardia or non-sustained ventricular tachycardia on the ECG, and the patient's relatively low Troponin level, suggest that the risk of sudden cardiac death may be lower than expected. However, the patient's NYHA Class III classification indicates significant symptoms, and the patient's LVEF is severely impaired, which increases the risk of arrhythmias. Additionally, the patient's age and history of myocardial infarction also contribute to the risk of sudden cardiac death.

RANKING: 3. Pump Failure Death
REASONING: 
Given the patient's severely impaired LVEF (25.0), history of ischemic dilated cardiomyopathy, and NYHA Class III classification, the patient is at high risk of pump failure. The patient's current medication regimen, including ACE inhibitors and spironolactone, suggests that they are receiving optimal treatment for heart failure. However, the patient's relatively low eGFR and elevated creatinine level suggest that their renal function is compromised, which may limit their ability to tolerate certain medications or increase their risk of fluid overload. The patient's age and history of hypertension also increase the risk of pump failure. While the patient's Pro-BNP level is elevated, which may indicate fluid overload, the patient's current medication regimen and clinical presentation do not strongly suggest that pump failure is imminent."
792,792,P0391,"Age: 82
Gender: Female 
Weight: 77 kg
Height: 159 cm
NYHA Class: II
Blood Pressure: 125/65 mmHg
Past Medical History: Hypertensive cardiomyopathy, Dyslipemia, Hypertension
Albumin (g/L): 40
ALT or GPT (IU/L): 15.0
AST or GOT (IU/L): 12.0
Total Cholesterol (mmol/L): 4,63
Creatinine (mmol/L): 159.0
Gamma-glutamil transpeptidase (IU/L): 9
Glucose (mmol/L): 4,9
Hemoglobin (g/L): 112.0
HDL (mmol/L): 1,06
Potassium (mEq/L): 3,9
LDL (mmol/L): 2,97
Sodium (mEq/L): 139.0
Pro-BNP (ng/L): 950.0
Protein (g/L): 67
T3 (pg/dL): 0,03
T4 (ng/L): 21
TSH (mIU/L): 0,79
Urea (mg/dL): 14,64
LVEF (%): 37.0
Medications: Amiodarone, Loop Diuretics, Hydralazine, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: No
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",pump failure death,"RANKING: 1. Pump failure death
REASONING: 

Based on the provided patient data, the patient has several factors that suggest a high risk of pump failure death. The patient is 82 years old, which increases the risk of cardiac complications. The NYHA Class II classification indicates moderate symptoms, suggesting that the patient has some limitations in physical activity. The patient's LVEF of 37.0% is significantly reduced, indicating left ventricular dysfunction.

The patient's past medical history of hypertensive cardiomyopathy, dyslipemia, and hypertension further increases the risk of cardiac complications. The elevated creatinine level (159.0 mmol/L) may indicate some degree of renal impairment, which can be a contributing factor to cardiac disease.

The elevated Pro-BNP level (950.0 ng/L) is a strong indicator of heart failure, as it suggests that the heart is working harder to pump blood and is likely to be a marker for increased risk of pump failure.

The patient's medication regimen includes Amiodarone, Loop Diuretics, Hydralazine, and Nitrovasodilator, which are commonly used to manage heart failure and hypertension. However, the patient's current medication regimen does not appear to be adequately addressing the patient's underlying cardiac issues.

Given these factors, the most likely prognosis for the patient is pump failure death within the next few years. The patient's reduced LVEF and elevated Pro-BNP levels, combined with their age and medical history, make them a high-risk patient for cardiac complications.

The other two prognoses, sudden cardiac death and survivor, are less likely due to the following reasons:

- Sudden cardiac death is less likely due to the absence of any indications of arrhythmias or other conditions that could lead to sudden cardiac death.
- Survivor is less likely due to the patient's advanced age, reduced LVEF, and the presence of heart failure indicators such as elevated Pro-BNP and creatinine levels."
793,793,P0448,"Age: 71
Gender: Male 
Weight: 60 kg
Height: 165 cm
NYHA Class: II
Blood Pressure: 130/70 mmHg
Past Medical History: Hypertensive cardiomyopathy, Diabetes, Dyslipemia, Hypertension
Albumin (g/L): 38
ALT or GPT (IU/L): 45.0
AST or GOT (IU/L): 31.0
Total Cholesterol (mmol/L): 4,42
Creatinine (mmol/L): 194.0
Gamma-glutamil transpeptidase (IU/L): 52
Glucose (mmol/L): 4,8
Hemoglobin (g/L): 149.0
HDL (mmol/L): 1,4
Potassium (mEq/L): 4,9
LDL (mmol/L): 2,69
Sodium (mEq/L): 140.0
Pro-BNP (ng/L): 2285.0
Protein (g/L): 69
T3 (pg/dL): 0,03
T4 (ng/L): 10
Troponin (ng/mL): 0,01
TSH (mIU/L): 3,69
Urea (mg/dL): 15,14
LVEF (%): 55.0
Medications: Diabetes Medication, Angiotensin II Receptor Blocker, Statins, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: No
            ",pump failure death,"RANKING: 1. Sudden cardiac death 
REASONING: The patient's ECG shows polymorphic ventricular extrasystoles, which is a marker of an increased risk of sudden cardiac death. Additionally, the patient has a history of hypertensive cardiomyopathy, which can lead to arrhythmias and sudden cardiac death. The patient's LVEF of 55% is also a concern, as a lower LVEF is associated with a higher risk of sudden cardiac death. Furthermore, the patient's elevated troponin level (0.01 ng/mL) suggests some degree of cardiac damage, which may increase the risk of sudden cardiac death. The patient's medications, including an ACE inhibitor and statins, are being used to manage their underlying conditions, but the presence of polymorphic ventricular extrasystoles suggests that the patient is still at risk of sudden cardiac death.

RANKING: 2. Pump failure death 
REASONING: Pump failure death is a concern for the patient due to their history of hypertensive cardiomyopathy and the presence of elevated creatinine levels (194.0 mmol/L). The patient's LVEF of 55% is also a concern, as a lower LVEF is associated with a higher risk of pump failure. The patient's elevated troponin level (0.01 ng/mL) suggests some degree of cardiac damage, which may contribute to pump failure. However, the patient's current ECG and lab results do not suggest an acute myocardial infarction or significant cardiac dysfunction.

RANKING: 3. Survivor 
REASONING: While the patient's current lab results and ECG do not suggest an immediate risk of sudden cardiac death or pump failure, the patient's history of hypertensive cardiomyopathy, diabetes, and dyslipemia may still pose a risk of long-term cardiac complications. The patient's elevated creatinine level (194.0 mmol/L) and LVEF of 55% suggest that the patient's heart function may be compromised, but the patient is currently being treated with medications that are intended to manage these conditions. The patient's age (71) and NYHA class (II) also suggest that the patient may be at risk of long-term cardiac complications, but the patient's current condition does not appear to be life-threatening."
794,794,P0460,"Age: 66
Gender: Female 
Weight: 56 kg
Height: 154 cm
NYHA Class: III
Blood Pressure: 110/60 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Diabetes, Dyslipemia, Myocardial Infarction
Albumin (g/L): 44
ALT or GPT (IU/L): 30.0
AST or GOT (IU/L): 15.0
Total Cholesterol (mmol/L): 5,46
Creatinine (mmol/L): 186.0
Gamma-glutamil transpeptidase (IU/L): 25
Glucose (mmol/L): 7,3
Hemoglobin (g/L): 102.0
HDL (mmol/L): 0,88
Potassium (mEq/L): 5,2
LDL (mmol/L): 4,5
Sodium (mEq/L): 130.0
Pro-BNP (ng/L): 4471.0
Protein (g/L): 82
T4 (ng/L): 12
Troponin (ng/mL): 0,02
TSH (mIU/L): 2,11
Urea (mg/dL): 16,31
LVEF (%): 32.0
Medications: Diabetes Medication, Angiotensin II Receptor Blocker, Loop Diuretics, Spironolactone, Statins, ACE Inhibitor, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",pump failure death,"RANKING: 1. Sudden cardiac death
REASONING: The patient's ECG impression reveals ventricular extrasystole, which is a sign of abnormal heart rhythm and can be a predictor of sudden cardiac death. Additionally, the patient's LVEF of 32.0 indicates severe left ventricular dysfunction, which is a significant risk factor for sudden cardiac death. The patient's NYHA Class III classification also suggests that the patient has severe symptoms, which can be indicative of advanced heart failure and an increased risk of sudden cardiac death. Furthermore, the presence of diabetes, dyslipemia, and ischemic dilated cardiomyopathy also contribute to the patient's overall cardiovascular risk. While the patient's current treatment regimen includes medications for heart failure and cardiovascular risk reduction, the presence of ventricular extrasystole on the ECG suggests an increased risk of sudden cardiac death.

RANKING: 2. Pump failure death
REASONING: The patient's LVEF of 32.0 and NYHA Class III classification indicate severe left ventricular dysfunction and significant symptoms, which suggest that the patient is at risk of pump failure. The patient's elevated creatinine level (186.0) also indicates impaired renal function, which is often seen in advanced heart failure. The patient's treatment regimen includes loop diuretics and spironolactone, which are commonly used to manage symptoms of heart failure. However, the presence of ventricular extrasystole on the ECG and the patient's overall cardiovascular risk factors suggest that pump failure death is a possible outcome.

RANKING: 3. Survivor
REASONING: While the patient's current treatment regimen includes medications for heart failure and cardiovascular risk reduction, the presence of ventricular extrasystole on the ECG and the patient's overall cardiovascular risk factors suggest that the patient is at increased risk of adverse outcomes. However, the patient's age (66) and relatively low weight (56 kg) may suggest a slightly better prognosis compared to patients with a higher BMI. Additionally, the patient's hemoglobin level (102.0) is within the normal range, which may indicate adequate oxygenation and perfusion. However, the patient's overall risk factors and ECG abnormalities suggest that survivor is the least likely outcome."
795,795,P0461,"Age: 65
Gender: Male 
Weight: 113 kg
Height: 176 cm
NYHA Class: II
Blood Pressure: 140/80 mmHg
Past Medical History: Hypertensive cardiomyopathy, Peripheral vascular disease, Hypertension
Albumin (g/L): 38
ALT or GPT (IU/L): 40.0
AST or GOT (IU/L): 28.0
Total Cholesterol (mmol/L): 5,09
Creatinine (mmol/L): 88.0
Gamma-glutamil transpeptidase (IU/L): 115
Glucose (mmol/L): 8,3
Hemoglobin (g/L): 168.0
HDL (mmol/L): 1,03
Potassium (mEq/L): 4,2
LDL (mmol/L): 3,44
Sodium (mEq/L): 139.0
Pro-BNP (ng/L): 339.0
Protein (g/L): 76
T4 (ng/L): 8
Troponin (ng/mL): 0,01
TSH (mIU/L): 5,21
Urea (mg/dL): 3,83
LVEF (%): 60.0
Medications: Amiodarone, Digoxin, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",pump failure death,"RANKING: 
1. Survivor
REASONING: 
Given the patient's age, NYHA Class II, and the presence of hypertensive cardiomyopathy, peripheral vascular disease, and hypertension, the patient has a significant cardiovascular risk profile. However, the patient's current LVEF is 60.0%, which is within the normal range, and the patient is not in heart failure (NYHA Class II). The patient is also on ACE inhibitor therapy, which is beneficial for patients with hypertensive cardiomyopathy.

The patient's ECG shows non-sustained ventricular tachycardia, which is a significant finding, but the patient is not in cardiac arrest. The patient's troponin level is normal, and the patient's biomarkers for cardiac stress and strain (ALT, AST, creatinine, and urea) are not elevated. The patient's renal function is also within a relatively normal range.

Considering these factors, I would predict that the patient has a high likelihood of survival over the next few years, provided that the patient adheres to their medication regimen and makes lifestyle modifications to manage their cardiovascular risk factors.

2. Sudden cardiac death
REASONING: 
While the patient's ECG shows non-sustained ventricular tachycardia, the patient is not in cardiac arrest. However, the presence of ventricular extrasystoles and polymorphic ventricular tachycardia on the ECG is a significant concern. The patient's age, NYHA Class II, and presence of hypertensive cardiomyopathy also increase the risk of sudden cardiac death.

However, the patient's LVEF is within the normal range, and the patient is on ACE inhibitor therapy, which reduces the risk of sudden cardiac death. Additionally, the patient's biomarkers for cardiac stress and strain are not elevated, which suggests that the patient's cardiac function is relatively preserved.

Given these factors, I would predict that the patient has a moderate likelihood of sudden cardiac death over the next few years, but this is still a relatively low risk compared to other patients with more severe cardiac dysfunction.

3. Pump failure death
REASONING: 
Given the patient's NYHA Class II and the presence of hypertensive cardiomyopathy, there is a significant risk of cardiac dysfunction and heart failure. However, the patient's LVEF is within the normal range, and the patient is on ACE inhibitor therapy, which is beneficial for patients with hypertensive cardiomyopathy.

The patient's biomarkers for cardiac stress and strain (ALT, AST, creatinine, and urea) are not elevated, which suggests that the patient's cardiac function is relatively preserved. However, the patient's elevated troponin level (0.01 ng/mL) is a concern, as it suggests some degree of cardiac stress.

Given these factors, I would predict that the patient has a low likelihood of pump failure death over the next few years, but this is still a potential risk given the patient's underlying cardiovascular disease."
796,796,P0480,"Age: 78
Gender: Female 
Weight: 46 kg
Height: 143 cm
NYHA Class: II
Blood Pressure: 140/80 mmHg
Past Medical History: Hypertensive cardiomyopathy, Dyslipemia
Albumin (g/L): 42,5
ALT or GPT (IU/L): 19.0
AST or GOT (IU/L): 23.0
Total Cholesterol (mmol/L): 4,03
Creatinine (mmol/L): 84.0
Gamma-glutamil transpeptidase (IU/L): 26
Glucose (mmol/L): 5,8
Hemoglobin (g/L): 113.0
HDL (mmol/L): 1,22
Potassium (mEq/L): 4,7
LDL (mmol/L): 1,81
Sodium (mEq/L): 138.0
Pro-BNP (ng/L): 1816.0
Protein (g/L): 71,6
T4 (ng/L): 16
TSH (mIU/L): 1,88
Urea (mg/dL): 6,82
LVEF (%): 27.0
Medications: Beta Blockers, Digoxin, Loop Diuretics, Spironolactone, Statins
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: TPSV
        - Bradycardia: No
            ",pump failure death,"RANKING: 
1. Pump failure death
2. Sudden cardiac death
3. Survivor

REASONING:

Based on the provided patient data, the patient is at high risk for pump failure death due to several factors:

1. Low LVEF (Left Ventricular Ejection Fraction) of 27.0%, indicating severe left ventricular dysfunction, which is a hallmark of cardiomyopathy.
2. Elevated Pro-BNP levels of 1816.0 ng/L, which is significantly above the normal range, suggesting elevated ventricular wall stress and increased risk of heart failure.
3. Presence of ventricular extrasystole and non-sustained ventricular tachycardia on the ECG, indicating arrhythmic instability.
4. History of hypertension and dyslipidemia, which are risk factors for cardiovascular disease and heart failure.

Considering these factors, pump failure death is the most likely outcome. Sudden cardiac death is a possible but less likely outcome due to the absence of any signs of acute coronary syndrome or severe arrhythmia. The patient's survival is possible, but it would require close monitoring and aggressive management of the underlying conditions.

However, given the patient's age (78 years) and the severity of the cardiac dysfunction, the likelihood of long-term survival is low. The patient's NYHA class II indicates moderate symptoms, which may not be sufficient to support long-term survival without significant intervention.

Therefore, the most likely prognosis is pump failure death."
797,797,P0481,"Age: 66
Gender: Male 
Weight: 73 kg
Height: 168 cm
NYHA Class: II
Blood Pressure: 120/70 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Dyslipemia, Myocardial Infarction
Albumin (g/L): 47,9
ALT or GPT (IU/L): 14.0
AST or GOT (IU/L): 24.0
Total Cholesterol (mmol/L): 6,23
Creatinine (mmol/L): 122.0
Gamma-glutamil transpeptidase (IU/L): 33
Glucose (mmol/L): 5,9
Hemoglobin (g/L): 131.0
HDL (mmol/L): 1,19
Potassium (mEq/L): 5
LDL (mmol/L): 3,57
Sodium (mEq/L): 138.0
Pro-BNP (ng/L): 2035.0
Protein (g/L): 73,6
T4 (ng/L): 15
TSH (mIU/L): 2,12
Urea (mg/dL): 13,64
LVEF (%): 20.0
Medications: Beta Blockers, Loop Diuretics, Spironolactone, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: First-degree Atrioventricular block (AVB)
            ",pump failure death,"RANKING: 1. Survivor
REASONING:

Although the patient has a history of ischemic dilated cardiomyopathy, the current data does not indicate an immediate life-threatening condition. The patient's LVEF is 20%, which is significantly below the normal range, but this is not uncommon in patients with a history of myocardial infarction and cardiomyopathy. The patient is also on medications that are commonly used to manage heart failure and arrhythmias, such as beta blockers, loop diuretics, and spironolactone. 

The patient's laboratory results, including the elevated creatinine level, indicate some degree of renal impairment, but this is not uncommon in patients with heart failure. The patient's electrolyte levels are within normal limits, and the potassium level is actually slightly low, which may be a result of the spironolactone medication. The patient's glucose and hemoglobin levels are also within normal limits.

The ECG findings, including the presence of non-sustained ventricular tachycardia, are concerning, but the patient is already on beta blockers, which can help manage arrhythmias. The patient's Pro-BNP level is elevated, indicating some degree of ventricular strain, but this is not uncommon in patients with heart failure.

Given the patient's overall clinical presentation and laboratory results, I believe that the patient is likely to survive for the next few years. However, it is essential to closely monitor the patient's condition, adjust medications as needed, and perform regular follow-up evaluations to prevent potential complications.

RANKING: 2. Sudden cardiac death
REASONING:

While the patient's ECG findings, including the presence of non-sustained ventricular tachycardia and polymorphic ventricular extrasystole, are concerning, the patient's overall clinical presentation and laboratory results do not indicate an immediate life-threatening condition. The patient is already on beta blockers, which can help manage arrhythmias.

However, the patient's LVEF is significantly below the normal range, and the patient has a history of myocardial infarction and cardiomyopathy. These factors increase the risk of sudden cardiac death. Additionally, the patient's renal impairment, indicated by the elevated creatinine level, may increase the risk of arrhythmias and sudden cardiac death.

Despite this, I do not believe that the patient is at high risk of sudden cardiac death in the short term. The patient's medications, including beta blockers, can help manage arrhythmias, and the patient's overall clinical presentation does not indicate an immediate life-threatening condition.

RANKING: 3. Pump failure death
REASONING:

The patient's LVEF is significantly below the normal range, indicating a high risk of heart failure. The patient's history of ischemic dilated cardiomyopathy, myocardial infarction, and dyslipemia also increase the risk of heart failure. The patient's elevated creatinine level and elevated Pro-BNP level indicate some degree of ventricular strain, which can lead to heart failure.

The patient's ECG findings, including the presence of non-sustained ventricular tachycardia, also increase the risk of pump failure. The patient's medications, including beta blockers and loop diuretics, can help manage heart failure, but the patient's overall clinical presentation and laboratory results indicate a high risk of pump failure.

Given the patient's high-risk factors and clinical presentation, I believe that the patient is at high risk of pump failure death in the next few years. Close monitoring and regular follow-up evaluations are essential to prevent potential complications."
798,798,P0487,"Age: 79
Gender: Male 
Weight: 83 kg
Height: 168 cm
NYHA Class: III
Blood Pressure: 110/60 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Diabetes, Dyslipemia, Myocardial Infarction
Albumin (g/L): 45,8
ALT or GPT (IU/L): 9.0
AST or GOT (IU/L): 26.0
Total Cholesterol (mmol/L): 3,36
Creatinine (mmol/L): 95.0
Gamma-glutamil transpeptidase (IU/L): 100
Glucose (mmol/L): 8,3
Hemoglobin (g/L): 137.0
HDL (mmol/L): 1,22
Potassium (mEq/L): 4,9
LDL (mmol/L): 1,84
Sodium (mEq/L): 133.0
Pro-BNP (ng/L): 3407.0
Protein (g/L): 76,8
T4 (ng/L): 16
TSH (mIU/L): 1,24
Urea (mg/dL): 4,82
LVEF (%): 15.0
Medications: Diabetes Medication, Beta Blockers, Loop Diuretics, Spironolactone, Statins, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",pump failure death,"RANKING: 
1. Sudden cardiac death
2. Pump failure death
3. Survivor

REASONING:

The patient's prognosis can be determined based on the provided data. Here's a breakdown of the key factors that influence the ranking:

1. Age and NYHA Class III: The patient's age of 79 and NYHA Class III classification indicate advanced heart failure, which increases the risk of adverse outcomes. The NYHA classification system is a widely used indicator of heart failure severity, with Class III indicating severe symptoms and limitations in daily activities.

2. LVEF of 15.0%: A left ventricular ejection fraction (LVEF) of 15% is a strong indicator of severe left ventricular dysfunction, which is a hallmark of cardiomyopathy. A low LVEF is associated with a higher risk of heart failure and sudden cardiac death.

3. Pro-BNP of 3407.0 ng/L: Elevated B-type natriuretic peptide (BNP) levels are a marker of cardiac stress and strain. High BNP levels are associated with increased risk of heart failure and mortality.

4. Past Medical History: The patient's history of ischemic dilated cardiomyopathy, myocardial infarction, diabetes, and dyslipemia increases the risk of adverse outcomes. These conditions can lead to further cardiac damage and deterioration.

5. ECG Impression: The presence of ventricular extrasystole, non-sustained ventricular tachycardia, and non-sustained ventricular tachycardia (CH>10) indicates an increased risk of arrhythmias, which can lead to sudden cardiac death.

Considering these factors, the patient is at high risk for adverse outcomes. While pump failure death is a possible outcome, the presence of arrhythmias and advanced heart failure severity suggest that sudden cardiac death is a more likely prognosis. Therefore, I rank the patient's prognosis as sudden cardiac death, followed by pump failure death, and finally, survivor."
799,799,P0489,"Age: 52
Gender: Male 
Weight: 76 kg
Height: 161 cm
NYHA Class: II
Blood Pressure: 150/80 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Peripheral vascular disease, Myocardial Infarction
Albumin (g/L): 40,4
ALT or GPT (IU/L): 20.0
AST or GOT (IU/L): 19.0
Total Cholesterol (mmol/L): 4,29
Creatinine (mmol/L): 95.0
Gamma-glutamil transpeptidase (IU/L): 25
Glucose (mmol/L): 5,5
Hemoglobin (g/L): 122.0
HDL (mmol/L): 0,98
Potassium (mEq/L): 4,1
LDL (mmol/L): 2,28
Sodium (mEq/L): 138.0
Pro-BNP (ng/L): 1198.0
Protein (g/L): 74,2
T4 (ng/L): 17
TSH (mIU/L): 1,79
Urea (mg/dL): 6,16
LVEF (%): 15.0
Medications: Beta Blockers, Digoxin, Loop Diuretics, Spironolactone, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: TPSV
        - Bradycardia: No
            ",pump failure death,"RANKING: 1. Survivor
REASONING: 
Based on the provided patient data, the patient's overall condition appears to be quite severe. The patient has a history of ischemic dilated cardiomyopathy, which is a condition where the heart muscle becomes weakened and cannot pump blood effectively. This condition is often associated with a high risk of heart failure and sudden cardiac death. The patient's left ventricular ejection fraction (LVEF) is 15%, which is significantly below the normal range, indicating poor heart function.

The patient's elevated BNP levels (1198 ng/L) and elevated creatinine levels (6.16 mg/dL) also suggest significant cardiac dysfunction and potential kidney impairment. Additionally, the patient's history of myocardial infarction, peripheral vascular disease, and elevated blood pressure further increases the risk of cardiac complications.

The patient is also taking medications that are commonly used to manage heart failure, including beta blockers, digoxin, and ACE inhibitors, which suggests that the patient is receiving standard treatment for heart failure.

While the patient has some cardiac arrhythmias, including ventricular tachycardia and ventricular extrasystole, the presence of non-sustained ventricular tachycardia and polymorphic ventricular extrasystoles may indicate a higher risk of arrhythmic events. However, the patient is not currently experiencing any symptoms that would suggest an immediate life-threatening arrhythmia.

Considering these factors, the most likely prognosis for the next few years is that the patient will survive, but it is likely that the patient will require ongoing medical management and possibly additional interventions to manage their heart failure and prevent further cardiac complications.

RANKING: 2. Sudden cardiac death
REASONING: 
While the patient's heart failure and cardiac arrhythmias increase the risk of sudden cardiac death, the patient's current clinical status does not suggest an immediate high risk of sudden cardiac death. The patient is not currently experiencing any symptoms that would suggest an acute cardiac event, and the patient is receiving standard treatment for heart failure.

However, the patient's history of myocardial infarction and peripheral vascular disease increases the risk of cardiac complications, and the patient's elevated BNP levels and creatinine levels suggest significant cardiac dysfunction. The presence of non-sustained ventricular tachycardia and polymorphic ventricular extrasystoles may also increase the risk of arrhythmic events.

Given these factors, it is possible that the patient may experience a cardiac event in the next few years, but the likelihood of sudden cardiac death is not the highest among the three options.

RANKING: 3. Pump failure death
REASONING: 
Pump failure death is a possible outcome for the patient, given the patient's history of heart failure and cardiac dysfunction. However, the patient is currently receiving standard treatment for heart failure, and the patient's LVEF is not extremely low, which suggests that the patient may still have some residual cardiac function.

Additionally, the patient's BNP levels and creatinine levels are not extremely elevated, which suggests that the patient's heart failure is not currently in a state of severe decompensation. While the patient's heart failure is likely to worsen over time, the likelihood of pump failure death is not the highest among the three options.

Therefore, while pump failure death is a possible outcome, it is not the most likely prognosis for the patient in the next few years."
800,800,P0501,"Age: 71
Gender: Male 
Weight: 69 kg
Height: 170 cm
NYHA Class: III
Blood Pressure: 100/70 mmHg
Past Medical History: Valvular cardiomyopathy
Albumin (g/L): 42,8
ALT or GPT (IU/L): 32.0
AST or GOT (IU/L): 27.0
Total Cholesterol (mmol/L): 4,34
Creatinine (mmol/L): 140.0
Gamma-glutamil transpeptidase (IU/L): 166
Glucose (mmol/L): 5,3
Hemoglobin (g/L): 139.0
HDL (mmol/L): 1,74
Potassium (mEq/L): 4,26
LDL (mmol/L): 2,23
Sodium (mEq/L): 134.0
Pro-BNP (ng/L): 2309.0
Protein (g/L): 82,3
Troponin (ng/mL): 0,02
TSH (mIU/L): 1,8
Urea (mg/dL): 24,5
LVEF (%): 40.0
Medications: Digoxin, Loop Diuretics, Spironolactone, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",pump failure death,"RANKING: 1. Sudden cardiac death
REASONING: 

The patient's data suggests a high risk of sudden cardiac death. The patient's NYHA Class III indicates severe heart failure, which is a significant predictor of mortality. The presence of ventricular extrasystole, non-sustained ventricular tachycardia, and non-sustained ventricular tachycardia (CH>10) on the ECG impression further increases the risk of sudden cardiac death. Additionally, the patient's low LVEF of 40.0 indicates severe left ventricular dysfunction, which can lead to arrhythmias and sudden cardiac death. The patient's elevated troponin level (0.02 ng/mL) also suggests some degree of myocardial damage, which can contribute to arrhythmias and sudden cardiac death. The patient's medication regimen, including digoxin, loop diuretics, spironolactone, and nitrovasodilator, may be contributing to the development of arrhythmias.

RANKING: 2. Pump failure death
REASONING: 

The patient's severe heart failure (NYHA Class III) and low LVEF (40.0) indicate a high risk of pump failure death. The patient's elevated creatinine level (24.5 mg/dL) and urea level (24.5 mg/dL) also suggest renal impairment, which can exacerbate heart failure. The patient's elevated BNP level (2309 ng/L) and elevated troponin level (0.02 ng/mL) suggest significant cardiac stress and myocardial damage. The patient's medication regimen, including digoxin and loop diuretics, may be contributing to the development of pump failure.

RANKING: 3. Survivor
REASONING: 

While the patient's severe heart failure and low LVEF indicate a high risk of mortality, the patient's current ECG impression does not suggest a high risk of sudden cardiac death. The patient's elevated BNP level and troponin level suggest some degree of cardiac stress, but the patient's medication regimen and other laboratory results do not suggest a high risk of pump failure death. The patient's age, weight, and other laboratory results do not suggest any significant comorbidities that would increase the risk of mortality. Therefore, while the patient's prognosis is uncertain, the patient is less likely to die from sudden cardiac death or pump failure compared to the other two options."
801,801,P0509,"Age: 76
Gender: Female 
Weight: 60 kg
Height: 160 cm
NYHA Class: II
Blood Pressure: 140/80 mmHg
Past Medical History: Idiopathic dilated cardiomyopathy
Albumin (g/L): 36,7
ALT or GPT (IU/L): 22.0
AST or GOT (IU/L): 24.0
Total Cholesterol (mmol/L): 4,4
Creatinine (mmol/L): 108.0
Gamma-glutamil transpeptidase (IU/L): 67
Glucose (mmol/L): 4,7
Hemoglobin (g/L): 114.0
HDL (mmol/L): 1,63
Potassium (mEq/L): 4,3
LDL (mmol/L): 2,28
Sodium (mEq/L): 140.0
Pro-BNP (ng/L): 2094.0
Protein (g/L): 67
T3 (pg/dL): 0,04
T4 (ng/L): 17
Troponin (ng/mL): 0,01
TSH (mIU/L): 3,58
Urea (mg/dL): 13,14
LVEF (%): 24.0
Medications: Digoxin, Loop Diuretics, Spironolactone, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",pump failure death,"RANKING: 1. Pump failure death
REASONING: The patient has a history of idiopathic dilated cardiomyopathy, which is a significant risk factor for heart failure and pump failure. The patient's LVEF is 24.0%, indicating a severely reduced ejection fraction, which further supports this prognosis. The patient is also taking medications such as ACE inhibitors and spironolactone, which are commonly used to manage heart failure. Additionally, the patient's elevated BNP levels (2094.0 ng/L) and elevated urea levels (13.14 mg/dL) suggest a significant burden of cardiac congestion. The patient's age, weight, and NYHA Class II symptoms also contribute to the risk of pump failure.

RANKING: 2. Sudden cardiac death
REASONING: The patient's ECG impression shows ventricular extrasystoles, which are a type of abnormal heart rhythm that can increase the risk of sudden cardiac death. The patient's age and NYHA Class II symptoms also increase the risk of sudden cardiac death. However, the patient's LVEF is not severely reduced, and the patient is taking medications that are commonly used to manage heart failure, which reduces the risk of sudden cardiac death.

RANKING: 3. Survivor
REASONING: While the patient's ECG impression shows ventricular extrasystoles, the patient's overall clinical presentation and medical history do not suggest a high risk of sudden cardiac death. The patient is taking medications that are commonly used to manage heart failure, and the patient's LVEF is not severely reduced. The patient's age and NYHA Class II symptoms do increase the risk of mortality, but the patient's overall clinical presentation suggests that pump failure death is a more likely outcome than sudden cardiac death."
802,802,P0513,"Age: 76
Gender: Male 
Weight: 83 kg
Height: 169 cm
NYHA Class: II
Blood Pressure: 130/80 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Diabetes, Dyslipemia, Peripheral vascular disease, Myocardial Infarction
Albumin (g/L): 46,7
ALT or GPT (IU/L): 18.0
AST or GOT (IU/L): 19.0
Total Cholesterol (mmol/L): 5,38
Creatinine (mmol/L): 101.0
Gamma-glutamil transpeptidase (IU/L): 33
Glucose (mmol/L): 8
Hemoglobin (g/L): 138.0
HDL (mmol/L): 1,27
Potassium (mEq/L): 4,2
LDL (mmol/L): 3,13
Sodium (mEq/L): 136.0
Pro-BNP (ng/L): 200.0
Protein (g/L): 81
T3 (pg/dL): 0,05
T4 (ng/L): 17
Troponin (ng/mL): 0,01
TSH (mIU/L): 1,46
Urea (mg/dL): 7,8
LVEF (%): 38.0
Medications: Calcium Channel Blocker, Diabetes Medication, Angiotensin II Receptor Blocker, Beta Blockers, Loop Diuretics, Statins, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",pump failure death,"RANKING: 
1. Sudden cardiac death
2. Pump failure death
3. Survivor

REASONING:

Based on the provided patient data, I would rank the prognoses as follows:

1. Sudden cardiac death: The patient has a history of ischemic dilated cardiomyopathy, which is a significant risk factor for sudden cardiac death. Additionally, the patient's LVEF of 38.0 is significantly reduced, indicating poor cardiac function. The presence of ventricular extrasystoles on the ECG impression also raises concerns for arrhythmias, which can lead to sudden cardiac death. Furthermore, the patient's elevated troponin level (0.01 ng/mL) suggests some degree of cardiac damage, which can contribute to arrhythmias and sudden cardiac death.

2. Pump failure death: Given the patient's history of ischemic dilated cardiomyopathy, diabetes, and peripheral vascular disease, it is likely that the patient's cardiac function is severely compromised. The patient's LVEF of 38.0 and elevated creatinine level (101.0 mmol/L) indicate poor cardiac output and renal impairment, which can lead to pump failure. The patient's use of Loop Diuretics and Beta Blockers suggests that the healthcare provider is attempting to manage heart failure, but the patient's underlying cardiac condition is likely severe.

3. Survivor: While the patient's age and comorbidities are significant, the patient's LVEF of 38.0 and elevated creatinine level suggest that the patient's cardiac function is severely impaired. However, the patient's NYHA Class II classification and the absence of ventricular tachycardia or non-sustained ventricular tachycardia on the ECG impression suggest that the patient may be able to tolerate some level of physical activity. Additionally, the patient's use of medications such as Beta Blockers and Angiotensin II Receptor Blockers suggests that the healthcare provider is attempting to manage the patient's cardiovascular risk factors. However, the patient's overall prognosis is still uncertain, and it is possible that the patient may experience cardiac complications in the near future."
803,803,P0529,"Age: 65
Gender: Male 
Weight: 80 kg
Height: 160 cm
NYHA Class: II
Blood Pressure: 150/90 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Diabetes, Hypertension
Albumin (g/L): 43,4
ALT or GPT (IU/L): 95.0
AST or GOT (IU/L): 105.0
Total Cholesterol (mmol/L): 5,28
Creatinine (mmol/L): 103.0
Gamma-glutamil transpeptidase (IU/L): 150
Glucose (mmol/L): 8,7
Hemoglobin (g/L): 162.0
HDL (mmol/L): 0,7
Potassium (mEq/L): 4,8
LDL (mmol/L): 2,74
Sodium (mEq/L): 140.0
Pro-BNP (ng/L): 221.0
Protein (g/L): 85
T3 (pg/dL): 0,05
T4 (ng/L): 19
Troponin (ng/mL): 0,01
TSH (mIU/L): 2,35
Urea (mg/dL): 8,69
LVEF (%): 27.0
Medications: Beta Blockers, Digoxin, Spironolactone, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",pump failure death,"RANKING: 
1. Pump failure death 
2. Sudden cardiac death 
3. Survivor 

REASONING: 

The patient's prognosis is primarily determined by the combination of their underlying conditions, laboratory results, and ECG findings. 

1. Pump failure death is the most likely outcome due to the patient's history of ischemic dilated cardiomyopathy, which is a condition where the heart muscle becomes weakened and cannot pump blood effectively. This condition, coupled with a left ventricular ejection fraction (LVEF) of 27%, indicates significant impairment of the heart's pumping function. The patient's elevated creatinine levels (103.0 mmol/L) and low hemoglobin level (162.0 g/L) also suggest compromised kidney function and anemia, which can further contribute to the risk of pump failure. Additionally, the patient's elevated troponin level (0.01 ng/mL) indicates some degree of myocardial damage.

2. Sudden cardiac death is a possible outcome due to the patient's history of ventricular tachycardia (VT) and polymorphic ventricular extrasystoles, which are abnormal heart rhythms that can increase the risk of sudden cardiac death. The patient's ECG findings also suggest the presence of non-sustained VT, which can be a marker for a higher risk of sudden cardiac death.

3. Survivor is the least likely outcome, given the patient's significant cardiac impairment, anemia, and other comorbid conditions. However, the patient's age (65) and relatively normal potassium level (4.8 mEq/L) may suggest that they may be able to survive for a longer period with proper management and treatment. Nevertheless, the overall clinical picture suggests that pump failure death is the most likely outcome."
804,804,P0540,"Age: 37
Gender: Male 
Weight: 70 kg
Height: 164 cm
NYHA Class: II
Blood Pressure: 100/60 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Dyslipemia, Myocardial Infarction
Albumin (g/L): 48,2
ALT or GPT (IU/L): 24.0
AST or GOT (IU/L): 21.0
Total Cholesterol (mmol/L): 2,79
Creatinine (mmol/L): 92.0
Gamma-glutamil transpeptidase (IU/L): 19
Glucose (mmol/L): 5
Hemoglobin (g/L): 163.0
HDL (mmol/L): 0,62
Potassium (mEq/L): 3,9
LDL (mmol/L): 1,42
Sodium (mEq/L): 138.0
Pro-BNP (ng/L): 1481.0
Protein (g/L): 76
T3 (pg/dL): 0,06
T4 (ng/L): 19
Troponin (ng/mL): 0,01
TSH (mIU/L): 2,08
Urea (mg/dL): 7,12
LVEF (%): 35.0
Medications: Beta Blockers, Statins, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",pump failure death,"RANKING: 1. Sudden cardiac death 
REASONING: 

This patient has a history of ischemic dilated cardiomyopathy, which is a significant risk factor for sudden cardiac death. The patient's left ventricular ejection fraction (LVEF) is severely impaired at 35%, indicating poor cardiac function. Additionally, the presence of ventricular extrasystole and non-sustained ventricular tachycardia (VT) on the ECG suggests a high risk of arrhythmias, which can lead to sudden cardiac death. The patient's low HDL cholesterol level (0.62 mmol/L) and high triglycerides are also risk factors for cardiovascular disease.

While the patient's NYHA class is II, indicating mild symptoms, the presence of ventricular arrhythmias and poor cardiac function suggest a high risk of cardiac events. The patient's serum creatinine level is elevated at 7.12 mg/dL, indicating kidney impairment, which can also contribute to a higher risk of cardiac events.

In contrast, pump failure death is a less likely outcome in this patient, as the patient is already experiencing ventricular arrhythmias and has a severely impaired LVEF. While the patient's protein level is elevated at 76 g/L, this is not a direct indicator of pump failure.

Overall, the combination of ventricular arrhythmias, poor cardiac function, and kidney impairment make sudden cardiac death the most likely outcome for this patient."
805,805,P0545,"Age: 71
Gender: Male 
Weight: 71 kg
Height: 175 cm
NYHA Class: II
Blood Pressure: 140/80 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Diabetes, Dyslipemia, Peripheral vascular disease, Hypertension, Myocardial Infarction
Albumin (g/L): 39,5
ALT or GPT (IU/L): 16.0
AST or GOT (IU/L): 24.0
Total Cholesterol (mmol/L): 3,75
Creatinine (mmol/L): 82.0
Gamma-glutamil transpeptidase (IU/L): 13
Glucose (mmol/L): 4,9
Hemoglobin (g/L): 149.0
HDL (mmol/L): 1,58
Potassium (mEq/L): 4,3
LDL (mmol/L): 1,86
Sodium (mEq/L): 142.0
Pro-BNP (ng/L): 353.0
Protein (g/L): 81
T3 (pg/dL): 0,05
T4 (ng/L): 21
Troponin (ng/mL): 0,01
TSH (mIU/L): 0,818
Urea (mg/dL): 7,12
LVEF (%): 27.0
Medications: Diabetes Medication, Angiotensin II Receptor Blocker, Beta Blockers, Statins, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",pump failure death,"RANKING: 
1. Sudden cardiac death
REASONING: 
This patient has a high-risk profile for sudden cardiac death due to a combination of factors. The patient has a history of ischemic dilated cardiomyopathy, which is a significant risk factor for arrhythmias and sudden cardiac death. The presence of ventricular extrasystole and non-sustained ventricular tachycardia on the ECG impression further supports this risk. Additionally, the patient's low LVEF (27.0) and elevated Pro-BNP levels (353.0) indicate significant cardiac dysfunction, which can contribute to an increased risk of arrhythmias. The patient's medications, including beta blockers, which can be pro-arrhythmic in certain contexts, also contribute to this risk.

2. Pump failure death
REASONING: 
Pump failure death is a possible outcome for this patient due to the patient's history of ischemic dilated cardiomyopathy and significant left ventricular dysfunction (LVEF 27.0). The patient's elevated Pro-BNP levels (353.0) and low LVEF suggest that the patient's heart is not pumping efficiently, which can lead to heart failure. The patient's medications, including beta blockers, may also contribute to this risk.

3. Survivor
REASONING: 
While the patient's history and current data suggest a high-risk profile, the patient's age (71) and relatively stable hemodynamic parameters (BP 140/80 mmHg, Hb 149.0 g/L) suggest that the patient may still have some residual cardiac function. The patient's medications, including beta blockers and statins, may also help to reduce the risk of arrhythmias and improve cardiac function. However, the patient's significant cardiac dysfunction and elevated Pro-BNP levels suggest that the patient's survival is still uncertain, and the patient should be closely monitored."
806,806,P0555,"Age: 80
Gender: Male 
Weight: 76 kg
Height: 159 cm
NYHA Class: II
Blood Pressure: 120/70 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Dyslipemia, Hypertension, Myocardial Infarction
Albumin (g/L): 45
ALT or GPT (IU/L): 18.0
AST or GOT (IU/L): 13.0
Total Cholesterol (mmol/L): 4,6
Creatinine (mmol/L): 133.0
Gamma-glutamil transpeptidase (IU/L): 20
Glucose (mmol/L): 4,9
Hemoglobin (g/L): 155.0
HDL (mmol/L): 1,29
Potassium (mEq/L): 4,9
LDL (mmol/L): 2,66
Sodium (mEq/L): 141.0
Protein (g/L): 71
T3 (pg/dL): 0,06
T4 (ng/L): 18
Troponin (ng/mL): 0,08
TSH (mIU/L): 1,72
Urea (mg/dL): 13,31
LVEF (%): 25.0
Medications: Calcium Channel Blocker, Beta Blockers, Loop Diuretics, Statins, ACE Inhibitor, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: TPSV
        - Bradycardia: No
            ",pump failure death,"RANKING: 
1. Survivor
REASONING: 
Based on the provided patient data, the patient's overall clinical presentation and lab results suggest a high risk of adverse outcomes. However, the patient's age, NYHA class II, and the presence of medications such as ACE inhibitors and beta blockers indicate that the patient is receiving optimal management for heart failure. The elevated LVEF of 25% suggests significant left ventricular dysfunction, but the patient's hemoglobin level of 15.5 g/dL is at the lower limit of normal, which could be indicative of anemia, which is a common comorbidity in patients with heart failure. 

The patient's creatinine level of 133.0 mmol/L is elevated, indicating some degree of renal impairment. The presence of ventricular extrasystole, non-sustained ventricular tachycardia, and paroxysmal supraventricular tachyarrhythmia on ECG suggests an increased risk of arrhythmic events. However, the patient is already on medications that target these conditions, such as beta blockers and ACE inhibitors. 

Considering these factors, the patient is likely to survive for the next few years, but it is crucial to closely monitor the patient's condition and adjust the treatment plan as necessary to minimize the risk of adverse outcomes.

2. Sudden cardiac death
REASONING: 
The patient's ECG findings of ventricular extrasystole, non-sustained ventricular tachycardia, and paroxysmal supraventricular tachyarrhythmia suggest an increased risk of arrhythmic events. The presence of these arrhythmias, combined with the patient's significant left ventricular dysfunction (LVEF 25%), may increase the risk of sudden cardiac death. However, the patient's medications and NYHA class II classification indicate that the patient is receiving optimal management for heart failure, which may mitigate some of this risk.

3. Pump failure death
REASONING: 
Given the patient's significant left ventricular dysfunction (LVEF 25%), anemia (hemoglobin 15.5 g/dL), and elevated creatinine level (133.0 mmol/L), the patient is at high risk of pump failure. The patient's NYHA class II classification and the presence of medications such as ACE inhibitors and beta blockers suggest that the patient is receiving optimal management for heart failure. However, the patient's elevated LVEF and the presence of anemia may indicate that the patient's heart is not responding optimally to treatment, increasing the risk of pump failure. 

While the patient's ECG findings and laboratory results suggest an increased risk of arrhythmic events, the patient's overall clinical presentation and management plan suggest that pump failure is a more immediate concern."
807,807,P0567,"Age: 60
Gender: Female 
Weight: 70 kg
Height: 163 cm
NYHA Class: II
Blood Pressure: 97/58 mmHg
Past Medical History: Idiopathic dilated cardiomyopathy, Dyslipemia
Albumin (g/L): 43
ALT or GPT (IU/L): 25.0
AST or GOT (IU/L): 29.0
Total Cholesterol (mmol/L): 3,8
Creatinine (mmol/L): 106.0
Gamma-glutamil transpeptidase (IU/L): 35
Glucose (mmol/L): 6,1
Hemoglobin (g/L): 135.0
HDL (mmol/L): 1,24
Potassium (mEq/L): 4,3
LDL (mmol/L): 1,99
Sodium (mEq/L): 139.0
Pro-BNP (ng/L): 10365.0
Protein (g/L): 70
T4 (ng/L): 15
Troponin (ng/mL): 0,04
TSH (mIU/L): 12,33
Urea (mg/dL): 9,48
LVEF (%): 20.0
Medications: Amiodarone, Digoxin, Loop Diuretics, Statins, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",pump failure death,"RANKING: 1. Sudden cardiac death
REASONING: The patient's ECG impression shows polymorphic ventricular extrasystoles and non-sustained ventricular tachycardia, which are both indicators of an increased risk of sudden cardiac death. Additionally, the patient has a history of idiopathic dilated cardiomyopathy, which is a condition that can lead to arrhythmias and sudden cardiac death. The patient's low ejection fraction (LVEF) of 20.0 also suggests significant left ventricular dysfunction, which can increase the risk of sudden cardiac death. The patient's current medications, including Amiodarone, also support this prognosis.

RANKING: 2. Pump failure death
REASONING: The patient's low ejection fraction (LVEF) of 20.0 and the presence of idiopathic dilated cardiomyopathy increase the risk of pump failure. The patient's current medications, including Digoxin and Loop Diuretics, suggest an attempt to manage heart failure symptoms. However, the patient's elevated creatinine level (106.0) and urea level (9.48) suggest impaired renal function, which can be a complication of heart failure.

RANKING: 3. Survivor
REASONING: While the patient's past medical history and current ECG impression suggest a high risk of cardiac complications, the patient's current medications and laboratory results do not indicate an immediate life-threatening situation. The patient's hemoglobin level is within normal limits, and the troponin level is normal, which suggests that there is no significant myocardial infarction. Additionally, the patient's blood pressure is well-controlled, and the electrolyte levels are within normal limits. However, the patient's low ejection fraction and elevated creatinine level suggest a risk of cardiac complications, making survival less likely compared to sudden cardiac death."
808,808,P0583,"Age: 61
Gender: Male 
Weight: 81 kg
Height: 178 cm
NYHA Class: II
Blood Pressure: 150/75 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Diabetes, Dyslipemia, Hypertension
Albumin (g/L): 38
ALT or GPT (IU/L): 21.0
AST or GOT (IU/L): 20.0
Total Cholesterol (mmol/L): 4,09
Creatinine (mmol/L): 186.0
Gamma-glutamil transpeptidase (IU/L): 25
Glucose (mmol/L): 6,6
Hemoglobin (g/L): 123.0
HDL (mmol/L): 1,19
Potassium (mEq/L): 4,7
LDL (mmol/L): 2,59
Sodium (mEq/L): 140.0
Pro-BNP (ng/L): 3292.0
Protein (g/L): 73
T4 (ng/L): 17
Troponin (ng/mL): 0,06
TSH (mIU/L): 1,63
Urea (mg/dL): 19,47
LVEF (%): 30.0
Medications: Diabetes Medication, Beta Blockers, Loop Diuretics, Statins, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",pump failure death,"RANKING: 1. Sudden cardiac death
REASONING: 

Based on the provided patient data, the patient is at high risk for sudden cardiac death. The key factors contributing to this risk include:

1. Low LVEF (30.0%): A left ventricular ejection fraction of 30% indicates severe left ventricular dysfunction, which is a hallmark of advanced heart failure. This condition significantly increases the risk of sudden cardiac death.
2. NYHA Class II: This classification indicates moderate symptoms of heart failure, which suggests that the patient is already experiencing significant impairment of cardiac function.
3. Pro-BNP (3292.0 ng/L): Elevated B-type natriuretic peptide levels are a sensitive marker for heart failure and are associated with increased mortality risk.
4. History of Ischemic dilated cardiomyopathy: This condition is a significant risk factor for sudden cardiac death, as it can lead to arrhythmias and cardiac arrest.
5. Medications: The patient is on beta blockers, loop diuretics, and statins, which are commonly used to manage heart failure and hypertension. However, the presence of a nitrovasodilator, which can lower blood pressure, may be contributing to the patient's hypotension (BP 150/75 mmHg), which can further compromise cardiac function.

While pump failure death is a significant concern, the presence of these factors suggests that sudden cardiac death is the more immediate and likely outcome in the next few years. Pump failure death may occur in the longer term, but the patient's current clinical presentation and risk factors make sudden cardiac death a more pressing concern.

Please note that this is a prediction and the actual outcome may vary based on various factors, including the patient's response to treatment and any unforeseen events."
809,809,P0589,"Age: 71
Gender: Male 
Weight: 75 kg
Height: 159 cm
NYHA Class: II
Blood Pressure: 90/60 mmHg
Past Medical History: Enolic dilated cardiomyopathy, Diabetes, Peripheral vascular disease
Albumin (g/L): 40
ALT or GPT (IU/L): 16.0
AST or GOT (IU/L): 7.0
Total Cholesterol (mmol/L): 4,78
Creatinine (mmol/L): 88.0
Gamma-glutamil transpeptidase (IU/L): 63
Glucose (mmol/L): 11,7
Hemoglobin (g/L): 139.0
HDL (mmol/L): 0,85
Potassium (mEq/L): 4,7
LDL (mmol/L): 3,15
Sodium (mEq/L): 137.0
Protein (g/L): 67
T3 (pg/dL): 0,05
T4 (ng/L): 16
Troponin (ng/mL): 0,005
TSH (mIU/L): 0,93
Urea (mg/dL): 9,98
LVEF (%): 12.0
Medications: Diabetes Medication, Digoxin, Loop Diuretics, Spironolactone, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",pump failure death,"RANKING: 
1. Pump failure death
REASONING: 
Based on the provided patient data, the patient's clinical presentation and laboratory results suggest a high risk of heart failure. The patient has a history of dilated cardiomyopathy, which is a significant risk factor for heart failure. The low left ventricular ejection fraction (LVEF) of 12.0% further supports this conclusion. The patient's symptoms and ECG findings are also consistent with heart failure, including the presence of ventricular extrasystoles, which can be a sign of ventricular dysfunction.

The patient's current NYHA Class II indicates moderate symptoms of heart failure, which suggests that the patient is already experiencing significant impairment of cardiac function. The patient's elevated creatinine level (88.0 mmol/L) and urea level (9.98 mg/dL) may indicate impaired renal function, which can be a complication of heart failure.

The patient's medication regimen includes loop diuretics, which are commonly used to treat heart failure. However, the presence of elevated troponin levels (0.005 ng/mL) suggests some degree of myocardial injury, which may indicate ongoing cardiac stress.

Given these factors, the most likely prognosis for this patient is pump failure death. The patient's underlying heart disease, combined with the presence of heart failure symptoms and laboratory abnormalities, make this outcome the most likely.

RANKING: 
2. Sudden cardiac death
REASONING: 
While the patient's ECG findings do not show ventricular tachycardia or non-sustained ventricular tachycardia, the presence of ventricular extrasystoles and elevated troponin levels do suggest some degree of cardiac stress. However, the patient's LVEF is quite low, which reduces the likelihood of sudden cardiac death. Additionally, the patient's medication regimen includes an ACE inhibitor, which is commonly used to reduce the risk of sudden cardiac death.

RANKING: 
3. Survivor
REASONING: 
Given the patient's significant heart failure symptoms and laboratory abnormalities, as well as the presence of ventricular extrasystoles, it is unlikely that the patient will survive without any significant cardiac events. However, the patient's age, gender, and medication regimen do suggest that there is some chance of survival. With aggressive management of heart failure and cardiac stress, it is possible that the patient may survive, but this outcome is less likely compared to pump failure death."
810,810,P0594,"Age: 78
Gender: Male 
Weight: 61 kg
Height: 151 cm
NYHA Class: II
Blood Pressure: 128/83 mmHg
Past Medical History: Hypertropic cardiomyopathy, Hypertension
Albumin (g/L): 39
ALT or GPT (IU/L): 24.0
AST or GOT (IU/L): 17.0
Total Cholesterol (mmol/L): 6,28
Creatinine (mmol/L): 115.0
Gamma-glutamil transpeptidase (IU/L): 32
Glucose (mmol/L): 4,5
Hemoglobin (g/L): 140.0
HDL (mmol/L): 1,19
Potassium (mEq/L): 4,9
LDL (mmol/L): 4,47
Sodium (mEq/L): 139.0
Pro-BNP (ng/L): 1627.0
Protein (g/L): 67
T3 (pg/dL): 0,04
T4 (ng/L): 19
TSH (mIU/L): 2,39
Urea (mg/dL): 11,82
LVEF (%): 40.0
Medications: Amiodarone, Loop Diuretics, ACE Inhibitor, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: TPSV
        - Bradycardia: No
            ",pump failure death,"RANKING: 
1. Pump failure death
2. Sudden cardiac death
3. Survivor

REASONING:

Based on the provided patient data, I would rank the prognoses from most likely to least likely as follows:

Pump failure death is the most likely outcome in this patient. The patient has a history of Hypertrophic cardiomyopathy, which is a condition that can lead to left ventricular dysfunction and heart failure. The patient's LVEF of 40.0 indicates significant left ventricular dysfunction, which is a strong predictor of heart failure. Additionally, the patient's elevated creatinine level (115.0 mmol/L) suggests impaired renal function, which is often associated with heart failure. The presence of ventricular extrasystoles on the ECG, which is a marker of ventricular instability, further supports this prediction.

Sudden cardiac death is the second most likely outcome. The patient's ECG shows polymorphic ventricular extrasystoles, which can be a marker of ventricular instability and an increased risk of sudden cardiac death. The patient's NYHA Class II status also indicates some limitation in physical activity, which can increase the risk of sudden cardiac death.

Survivor is the least likely outcome. While the patient has a history of hypertension and Hypertrophic cardiomyopathy, the patient's current LVEF of 40.0 is relatively low, and the presence of ventricular extrasystoles on the ECG suggests a higher risk of adverse outcomes. Additionally, the patient's elevated creatinine level and impaired renal function may indicate underlying kidney disease, which can further complicate the patient's prognosis.

Overall, the combination of left ventricular dysfunction, ventricular instability, and impaired renal function make pump failure death the most likely outcome in this patient."
811,811,P0619,"Age: 62
Gender: Female 
Weight: 50 kg
Height: 167 cm
NYHA Class: II
Blood Pressure: 90/60 mmHg
Past Medical History: Hypertropic cardiomyopathy
Albumin (g/L): 45,9
ALT or GPT (IU/L): 47.0
AST or GOT (IU/L): 29.0
Total Cholesterol (mmol/L): 7,15
Creatinine (mmol/L): 113.0
Gamma-glutamil transpeptidase (IU/L): 53
Glucose (mmol/L): 5,5
Hemoglobin (g/L): 146.0
HDL (mmol/L): 2,05
Potassium (mEq/L): 4,51
LDL (mmol/L): 4,65
Sodium (mEq/L): 135.0
Protein (g/L): 72,9
Troponin (ng/mL): 0,15
TSH (mIU/L): 3,77
Urea (mg/dL): 9,5
LVEF (%): 62.0
Medications: Beta Blockers, Loop Diuretics, Spironolactone, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",pump failure death,"RANKING: 1. Survivor
REASONING: 

This patient has a history of Hypertrophic Cardiomyopathy, which is a condition that can lead to sudden cardiac death. However, the patient's current LVEF (ejection fraction) is 62%, which is within the normal range. The patient is also on medications that are commonly used to manage heart failure and arrhythmias, such as beta blockers, loop diuretics, spironolactone, and an ACE inhibitor. 

Additionally, the patient's troponin levels are normal, which suggests that there is no significant myocardial infarction or acute cardiac injury. The ECG findings of ventricular extrasystoles and non-sustained VT are concerning, but they are not indicative of a high risk of sudden cardiac death. 

The patient's low hemoglobin level (146.0 g/L) is also a concern, as anemia can contribute to a higher risk of cardiac complications. However, the patient's other laboratory values, including creatinine, urea, and electrolytes, are within normal limits. 

Considering these factors, I would rank the patient as having a high likelihood of survival for the next few years. However, close monitoring and regular follow-up with the patient are essential to assess for any potential complications.

RANKING: 2. Sudden Cardiac Death
REASONING: 

While the patient has a history of Hypertrophic Cardiomyopathy, the patient's current LVEF is within the normal range, and the patient is on medications that are commonly used to manage heart failure and arrhythmias. However, the patient's ECG findings of ventricular extrasystoles and non-sustained VT are concerning and may indicate an increased risk of sudden cardiac death. 

The patient's low hemoglobin level (146.0 g/L) is also a concern, as anemia can contribute to a higher risk of cardiac complications. Additionally, the patient's creatinine level (113.0 mmol/L) is elevated, which may indicate some degree of renal impairment. 

Considering these factors, I would rank the patient as having a moderate likelihood of sudden cardiac death over the next few years.

RANKING: 3. Pump Failure Death
REASONING: 

While the patient has a history of Hypertrophic Cardiomyopathy and is on medications that are commonly used to manage heart failure, the patient's current LVEF is within the normal range, and the patient's laboratory values are generally within normal limits. 

However, the patient's ECG findings of ventricular extrasystoles and non-sustained VT are concerning and may indicate an increased risk of cardiac complications. Additionally, the patient's low hemoglobin level (146.0 g/L) and elevated creatinine level (113.0 mmol/L) may indicate some degree of cardiac and renal impairment. 

Considering these factors, I would rank the patient as having a low likelihood of pump failure death over the next few years. However, close monitoring and regular follow-up with the patient are essential to assess for any potential complications."
812,812,P0624,"Age: 85
Gender: Male 
Weight: 85 kg
Height: 166 cm
NYHA Class: III
Blood Pressure: 125/80 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Dyslipemia, Hypertension, Myocardial Infarction
Albumin (g/L): 38,9
ALT or GPT (IU/L): 25.0
AST or GOT (IU/L): 39.0
Total Cholesterol (mmol/L): 3,78
Creatinine (mmol/L): 156.0
Gamma-glutamil transpeptidase (IU/L): 26
Glucose (mmol/L): 4,7
Hemoglobin (g/L): 132.0
HDL (mmol/L): 1,49
Potassium (mEq/L): 3,92
LDL (mmol/L): 1,82
Sodium (mEq/L): 144.0
Pro-BNP (ng/L): 4440.0
Protein (g/L): 68,8
Troponin (ng/mL): 0,01
TSH (mIU/L): 0,39
Urea (mg/dL): 10,6
LVEF (%): 20.0
Medications: Beta Blockers, Loop Diuretics, Statins, Hydralazine, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",pump failure death,"RANKING: 1. Pump failure death
REASONING:

Based on the patient's data, pump failure death is the most likely outcome. The patient has a history of ischemic dilated cardiomyopathy, which is a condition where the heart's ability to pump blood is weakened, leading to potential heart failure. The patient's left ventricular ejection fraction (LVEF) is significantly reduced at 20.0%, indicating poor cardiac function. Additionally, the patient's elevated creatinine level (156.0 mmol/L) and elevated urea level (10.6 mg/dL) suggest impaired renal function, which is often associated with heart failure.

The patient's elevated B-type natriuretic peptide (Pro-BNP) level (4440.0 ng/L) is also indicative of heart failure, as it is a biomarker for ventricular strain and cardiac dysfunction. Furthermore, the patient's history of myocardial infarction and hypertension further exacerbates the risk of heart failure.

While the patient's NYHA Class III indicates severe heart failure, the presence of ventricular extrasystole, polymorphic, and non-sustained ventricular tachycardia, and the patient's age (85 years) also contribute to the risk of pump failure death.

The other two prognoses, sudden cardiac death and survivor, are less likely due to the following reasons:

* Sudden cardiac death is more likely in patients with a normal or near-normal LVEF and no history of ventricular arrhythmias.
* Survivor is the least likely outcome, given the patient's advanced age, significant comorbidities, and poor cardiac function.

Overall, the combination of the patient's cardiac history, laboratory results, and ECG findings suggest that pump failure death is the most likely outcome."
813,813,P0635,"Age: 70
Gender: Female 
Weight: 57 kg
Height: 157 cm
NYHA Class: III
Blood Pressure: 120/70 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Diabetes, Myocardial Infarction
Albumin (g/L): 44
ALT or GPT (IU/L): 43.0
AST or GOT (IU/L): 37.0
Total Cholesterol (mmol/L): 5,09
Creatinine (mmol/L): 100.0
Gamma-glutamil transpeptidase (IU/L): 70
Glucose (mmol/L): 10,5
Hemoglobin (g/L): 121.0
HDL (mmol/L): 1,76
Potassium (mEq/L): 4,99
LDL (mmol/L): 2,93
Sodium (mEq/L): 136.0
Pro-BNP (ng/L): 3190.0
Protein (g/L): 76
T3 (pg/dL): 0,0477
T4 (ng/L): 13,4
Troponin (ng/mL): 0,5
TSH (mIU/L): 1,72
Urea (mg/dL): 9,6
LVEF (%): 25.0
Medications: Calcium Channel Blocker, Diabetes Medication, Loop Diuretics, ACE Inhibitor, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",pump failure death,"RANKING: 
1. Pump failure death 
REASONING: 
The patient's current clinical presentation, laboratory results, and ECG findings suggest a high risk of adverse cardiac events. The patient has a history of ischemic dilated cardiomyopathy, which is a significant risk factor for pump failure. The patient's LVEF of 25% indicates severe left ventricular dysfunction, which is a strong predictor of pump failure. Additionally, the patient's elevated BNP levels (3190 ng/L) and elevated NT-proBNP levels are indicative of significant left ventricular stress and strain, further supporting the risk of pump failure.

The patient's NYHA Class III classification indicates severe heart failure symptoms, and the presence of ventricular extrasystoles on the ECG suggests an increased risk of arrhythmias, which can contribute to pump failure. The patient's use of medications, including ACE inhibitors and loop diuretics, indicates a standard treatment approach for heart failure, but the patient's severe left ventricular dysfunction and elevated BNP levels suggest that these medications may not be sufficient to manage the patient's condition.

While the patient's blood pressure and electrolyte levels are within relatively normal limits, the patient's elevated creatinine level (100.0 mmol/L) suggests some degree of renal impairment, which can be a complication of heart failure. However, the patient's overall clinical presentation and laboratory results suggest that pump failure is the most likely outcome over the next few years.

While the patient's ECG findings do not indicate any acute life-threatening arrhythmias, the presence of ventricular extrasystoles suggests an increased risk of arrhythmias, which can contribute to pump failure. The patient's age and gender also increase the risk of pump failure, as older adults with heart failure are at higher risk of adverse outcomes.

Overall, the combination of the patient's severe left ventricular dysfunction, elevated BNP levels, and ventricular extrasystoles on the ECG make pump failure the most likely outcome over the next few years."
814,814,P0643,"Age: 70
Gender: Male 
Weight: 85 kg
Height: 160 cm
NYHA Class: II
Blood Pressure: 135/85 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Diabetes, Dyslipemia, Peripheral vascular disease, Hypertension
Albumin (g/L): 42
ALT or GPT (IU/L): 18.0
AST or GOT (IU/L): 20.0
Total Cholesterol (mmol/L): 5,64
Creatinine (mmol/L): 156.0
Gamma-glutamil transpeptidase (IU/L): 19
Glucose (mmol/L): 10,1
Hemoglobin (g/L): 149.0
HDL (mmol/L): 1,03
Potassium (mEq/L): 5,4
LDL (mmol/L): 2,74
Sodium (mEq/L): 137.0
Pro-BNP (ng/L): 177.0
Protein (g/L): 78
T3 (pg/dL): 0,05
T4 (ng/L): 14
Troponin (ng/mL): 0,01
TSH (mIU/L): 1,83
Urea (mg/dL): 14,25
LVEF (%): 30.0
Medications: Calcium Channel Blocker, Diabetes Medication, Angiotensin II Receptor Blocker, Spironolactone, Statins, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",pump failure death,"RANKING: 1. Sudden cardiac death
REASONING: 

Based on the provided patient data, the patient's prognosis is most likely to be sudden cardiac death. The patient has a history of ischemic dilated cardiomyopathy, which is a condition that significantly increases the risk of sudden cardiac death. Additionally, the patient's left ventricular ejection fraction (LVEF) is severely impaired at 30%, indicating poor cardiac function. The presence of elevated troponin levels (0.01 ng/mL) also suggests myocardial damage, which can be a precursor to sudden cardiac death. Furthermore, the patient's elevated creatinine levels (14.25 mg/dL) and low eGFR (not provided) suggest chronic kidney disease, which can increase the risk of sudden cardiac death.

The patient's medication list, including an angiotensin II receptor blocker and a nitrovasodilator, suggests that the patient is being managed for heart failure, but the severity of the condition is likely to be high enough to increase the risk of sudden cardiac death.

While pump failure death is a possible outcome, it is less likely than sudden cardiac death given the patient's severe cardiac dysfunction and the presence of other risk factors."
815,815,P0651,"Age: 76
Gender: Male 
Weight: 84 kg
Height: 161 cm
NYHA Class: II
Blood Pressure: 140/80 mmHg
Past Medical History: Hypertensive cardiomyopathy, Diabetes, Dyslipemia, Hypertension
Albumin (g/L): 39,5
ALT or GPT (IU/L): 22.0
AST or GOT (IU/L): 30.0
Total Cholesterol (mmol/L): 4,94
Creatinine (mmol/L): 120.0
Gamma-glutamil transpeptidase (IU/L): 267
Glucose (mmol/L): 7,9
Hemoglobin (g/L): 161.0
HDL (mmol/L): 1,14
Potassium (mEq/L): 5
LDL (mmol/L): 2,48
Sodium (mEq/L): 133.0
Pro-BNP (ng/L): 1627.0
Protein (g/L): 73
T3 (pg/dL): 0,04
T4 (ng/L): 18
Troponin (ng/mL): 0,01
TSH (mIU/L): 1,31
Urea (mg/dL): 15,59
LVEF (%): 38.0
Medications: Amiodarone, Loop Diuretics, Spironolactone, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",pump failure death,"RANKING: 
1. Sudden cardiac death
REASONING: 
The patient's ECG findings, particularly the presence of ventricular extrasystoles, non-sustained ventricular tachycardia (NSVT), and polymorphic ventricular extrasystoles, indicate a high risk of arrhythmias. The patient's NYHA class II indicates some limitation of physical activity due to heart failure, and the elevated Pro-BNP level (1627.0 ng/L) suggests significant cardiac stress. The patient's LVEF of 38.0% is also indicative of poor cardiac function. The presence of NSVT and polymorphic ventricular extrasystoles increases the risk of sudden cardiac death, which is a common outcome in patients with advanced heart failure and arrhythmias.

2. Pump failure death
REASONING: 
The patient's NYHA class II indicates some limitation of physical activity due to heart failure, and the elevated Pro-BNP level suggests significant cardiac stress. The patient's LVEF of 38.0% is also indicative of poor cardiac function. The presence of NSVT and polymorphic ventricular extrasystoles increases the risk of arrhythmias, which can contribute to pump failure. The patient's elevated creatinine level (15.59 mg/dL) and urea level (15.59 mg/dL) also suggest impaired renal function, which can be a complication of heart failure.

3. Survivor
REASONING: 
While the patient's past medical history of hypertension, diabetes, and dyslipemia increases the risk of cardiovascular disease, the patient's current clinical presentation and ECG findings do not indicate a high risk of sudden cardiac death or pump failure. The patient's LVEF of 38.0% is not as severe as expected for pump failure, and the patient is receiving medications for heart failure (loop diuretics, spironolactone, and an ACE inhibitor). The patient's renal function is also not severely impaired, and the patient's hemoglobin and potassium levels are within normal limits. However, the patient's arrhythmias and elevated Pro-BNP level do increase the risk of adverse outcomes, making survival less likely compared to the other two options."
816,816,P0679,"Age: 67
Gender: Male 
Weight: 76 kg
Height: 170 cm
NYHA Class: II
Blood Pressure: 140/55 mmHg
Past Medical History: Idiopathic dilated cardiomyopathy
Albumin (g/L): 47
ALT or GPT (IU/L): 16.0
AST or GOT (IU/L): 11.0
Total Cholesterol (mmol/L): 5,61
Creatinine (mmol/L): 135.0
Gamma-glutamil transpeptidase (IU/L): 47
Glucose (mmol/L): 5,27
Hemoglobin (g/L): 109.0
HDL (mmol/L): 0,93
Potassium (mEq/L): 4,75
LDL (mmol/L): 1,81
Sodium (mEq/L): 140.0
Pro-BNP (ng/L): 62.0
Protein (g/L): 75,3
T3 (pg/dL): 0,0429
T4 (ng/L): 14,14
Troponin (ng/mL): 0,7
TSH (mIU/L): 4,1
Urea (mg/dL): 19,6
LVEF (%): 30.0
Medications: Amiodarone, Beta Blockers, Digoxin, Loop Diuretics, Spironolactone, ACE Inhibitor, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",pump failure death,"RANKING: 1. Sudden cardiac death 
REASONING: 

This patient is at high risk for sudden cardiac death due to the presence of a history of idiopathic dilated cardiomyopathy, which is a condition that significantly increases the risk of sudden cardiac death. The patient's left ventricular ejection fraction (LVEF) is also severely impaired at 30%, which is a strong indicator of poor cardiac function. Additionally, the patient's ECG impression shows ventricular extrasystoles, which can be a precursor to ventricular tachycardia, a life-threatening arrhythmia. The patient's medication list includes Amiodarone, which is often used to treat and prevent ventricular arrhythmias. The patient's blood pressure is also elevated, which can increase the risk of sudden cardiac death. 

While pump failure death is a possible outcome, the presence of ventricular extrasystoles and the patient's overall clinical presentation make sudden cardiac death the more likely prognosis.

RANKING: 2. Pump failure death 
REASONING: 

The patient's impaired LVEF and elevated creatinine levels indicate poor cardiac function, which increases the risk of pump failure. The patient's NYHA class is also II, indicating mild heart failure symptoms. The patient's medication list includes Loop Diuretics, Spironolactone, and ACE Inhibitor, which are commonly used to manage heart failure. However, the patient's elevated BNP levels (62.0 ng/L) suggest that the patient's heart is working harder than normal, which can lead to pump failure.

While pump failure death is a possible outcome, the patient's overall clinical presentation and medication list suggest that sudden cardiac death is a more likely prognosis.

RANKING: 3. Survivor 
REASONING: 

The patient's overall clinical presentation and laboratory results do not suggest a high risk for sudden cardiac death or pump failure. The patient's LVEF is not severely impaired, and the patient's medication list includes treatments for heart failure and arrhythmias. The patient's elevated BNP levels do suggest that the patient's heart is working harder than normal, but the patient's overall clinical presentation and medication list suggest that the patient can be managed with current treatments.

However, the patient's age (67) and NYHA class (II) do increase the risk for long-term complications, and the patient's impaired LVEF and elevated creatinine levels suggest that the patient may not be as healthy as other patients of the same age. Therefore, while the patient is likely to survive, the patient's prognosis is not as favorable as it could be, making survival the least likely prognosis."
817,817,P0680,"Age: 73
Gender: Female 
Weight: 71 kg
Height: 157 cm
NYHA Class: III
Blood Pressure: 140/80 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Diabetes, Dyslipemia, Peripheral vascular disease, Hypertension, Myocardial Infarction
Albumin (g/L): 38
ALT or GPT (IU/L): 25.0
AST or GOT (IU/L): 17.0
Total Cholesterol (mmol/L): 4,42
Creatinine (mmol/L): 106.0
Gamma-glutamil transpeptidase (IU/L): 7
Glucose (mmol/L): 10,9
Hemoglobin (g/L): 122.0
HDL (mmol/L): 1,09
Potassium (mEq/L): 5,2
LDL (mmol/L): 2,48
Sodium (mEq/L): 141.0
Pro-BNP (ng/L): 1690.0
Protein (g/L): 74
T4 (ng/L): 9
Troponin (ng/mL): 0,01
TSH (mIU/L): 1,69
Urea (mg/dL): 7,49
LVEF (%): 25.0
Medications: Diabetes Medication, Amiodarone, Beta Blockers, Loop Diuretics, Statins, ACE Inhibitor, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",pump failure death,"RANKING: 1. Sudden cardiac death
REASONING: The patient's clinical presentation and test results suggest a high risk of sudden cardiac death. The patient's age, NYHA Class III status, and history of ischemic dilated cardiomyopathy, myocardial infarction, and hypertension are all risk factors for sudden cardiac death. Additionally, the patient's elevated LVEF of 25.0 indicates significant left ventricular dysfunction, which is a common cause of sudden cardiac death. The presence of ventricular extrasystole on the ECG further supports this risk. Furthermore, the patient's low ejection fraction and elevated BNP levels suggest that the patient's heart is under significant stress, increasing the risk of arrhythmic events.

RANKING: 2. Pump failure death
REASONING: Given the patient's severe left ventricular dysfunction (LVEF 25.0), the patient is already at risk for pump failure. The patient's elevated creatinine levels (106.0) and urea levels (7.49) suggest impaired renal function, which is often seen in advanced heart failure. The patient's NYHA Class III status and history of heart failure medications (Loop Diuretics) further support this risk. However, the patient's elevated troponin levels (0.01 ng/mL) and normal TSH levels suggest that the patient's heart failure is not due to cardiac dysfunction, but rather, it may be due to other factors such as fluid overload or renal failure.

RANKING: 3. Survivor
REASONING: While the patient's pump failure death is a significant risk, the patient's overall clinical presentation and test results do not suggest a high risk of sudden cardiac death. The patient's elevated BNP levels and ventricular extrasystole on ECG do suggest some level of cardiac stress, but the patient's age, NYHA Class III status, and history of heart failure medications suggest that the patient's heart failure is a significant burden, but not necessarily a fatal outcome. The patient's elevated creatinine levels and urea levels suggest some level of renal impairment, but the patient's overall clinical presentation does not suggest a high risk of sudden cardiac death."
818,818,P0688,"Age: 66
Gender: Male 
Weight: 74 kg
Height: 156 cm
NYHA Class: II
Blood Pressure: 120/70 mmHg
Past Medical History: Valvular cardiomyopathy, Hypertension, Myocardial Infarction
Albumin (g/L): 38,1
ALT or GPT (IU/L): 21.0
AST or GOT (IU/L): 36.0
Total Cholesterol (mmol/L): 4,12
Creatinine (mmol/L): 181.0
Gamma-glutamil transpeptidase (IU/L): 105
Glucose (mmol/L): 6,44
Hemoglobin (g/L): 115.0
HDL (mmol/L): 1,67
Potassium (mEq/L): 4,42
LDL (mmol/L): 2,16
Sodium (mEq/L): 143.0
Pro-BNP (ng/L): 11467.0
Protein (g/L): 71,8
T3 (pg/dL): 0,0366
T4 (ng/L): 15,51
Troponin (ng/mL): 0,7
TSH (mIU/L): 3,31
Urea (mg/dL): 19,5
LVEF (%): 30.0
Medications: Loop Diuretics, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",pump failure death,"RANKING: 1. Survivor
REASONING: 

Based on the provided patient data, the patient's current condition is severe, with a left ventricular ejection fraction (LVEF) of 30.0%, indicating significant left ventricular dysfunction. The patient's history of valvular cardiomyopathy, hypertension, and myocardial infarction also suggest a high risk of further cardiac complications. However, the patient's age and the absence of any recent cardiac events or acute symptoms suggest that the patient may still be in a window of opportunity for intervention and potential recovery.

The patient's biomarkers, such as elevated troponin levels and elevated creatinine, indicate ongoing cardiac and renal stress. However, the patient's hemoglobin level and potassium levels are within relatively normal limits, which may suggest some level of cardiovascular reserve.

The patient's ECG findings, including ventricular extrasystole, non-sustained ventricular tachycardia, and paroxysmal supraventricular tachyarrhythmia, indicate a high risk of arrhythmic events. However, the presence of non-sustained ventricular tachycardia (CH>10) is a relatively common finding in patients with left ventricular dysfunction and may not necessarily be a contraindication for further intervention.

Given these factors, I would rank the patient's prognosis as ""survivor"" with a high likelihood of survival for the next few years, provided that the patient receives aggressive management of their cardiac and renal issues, including optimization of their medications, control of hypertension, and monitoring for arrhythmic events.

RANKING: 2. Sudden cardiac death
REASONING: 

While the patient's current condition is severe, the patient's ECG findings, including ventricular extrasystole and non-sustained ventricular tachycardia, suggest a high risk of arrhythmic events. The presence of paroxysmal supraventricular tachyarrhythmia is also concerning. However, the patient's relatively stable hemodynamic status and lack of recent cardiac events suggest that the patient may not be at immediate risk of sudden cardiac death.

The patient's LVEF of 30.0% indicates significant left ventricular dysfunction, which increases the risk of cardiac arrhythmias and sudden cardiac death. However, the patient's biomarkers, such as troponin levels, are not elevated, which may suggest that the patient's cardiac injury is not acute.

Given these factors, I would rank the patient's prognosis as ""sudden cardiac death"" with a moderate likelihood of occurrence over the next few years, provided that the patient receives aggressive management of their cardiac and renal issues and monitoring for arrhythmic events.

RANKING: 3. Pump failure death
REASONING: 

While the patient's LVEF of 30.0% indicates significant left ventricular dysfunction, the patient's biomarkers, such as troponin levels, are not elevated, which may suggest that the patient's cardiac injury is not acute. However, the patient's elevated creatinine level indicates ongoing renal stress, which may compromise the patient's cardiovascular reserve.

The patient's history of valvular cardiomyopathy, hypertension, and myocardial infarction also increases the risk of further cardiac complications, including pump failure. The patient's ECG findings, including ventricular extrasystole and non-sustained ventricular tachycardia, also suggest a high risk of arrhythmic events.

Given these factors, I would rank the patient's prognosis as ""pump failure death"" with a low likelihood of occurrence over the next few years, provided that the patient receives aggressive management of their cardiac and renal issues and monitoring for arrhythmic events. However, the patient's relatively stable hemodynamic status and lack of recent cardiac events suggest that pump failure may not be imminent."
819,819,P0716,"Age: 80
Gender: Male 
Weight: 66 kg
Height: 160 cm
NYHA Class: III
Blood Pressure: 210/100 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Diabetes, Hypertension
Albumin (g/L): 37
ALT or GPT (IU/L): 25.0
AST or GOT (IU/L): 9.0
Total Cholesterol (mmol/L): 3,62
Creatinine (mmol/L): 159.0
Gamma-glutamil transpeptidase (IU/L): 124
Glucose (mmol/L): 4,9
HDL (mmol/L): 0,91
Potassium (mEq/L): 3,9
LDL (mmol/L): 2,15
Sodium (mEq/L): 141.0
Protein (g/L): 64
T3 (pg/dL): 0,05
T4 (ng/L): 14
TSH (mIU/L): 1,33
Urea (mg/dL): 13,81
LVEF (%): 35.0
Medications: Diabetes Medication, Beta Blockers, Digoxin, Loop Diuretics, ACE Inhibitor, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",pump failure death,"RANKING: 1. Sudden cardiac death
REASONING: 

Based on the provided patient data, the patient is at high risk for sudden cardiac death due to the presence of several concerning factors. The patient's NYHA Class III indicates severe heart failure, which is a significant predictor of mortality. The elevated blood pressure (210/100 mmHg) and high creatinine level (159.0 mmol/L) suggest severe left ventricular dysfunction, which can lead to arrhythmias and sudden cardiac death. The presence of non-sustained ventricular tachycardia (CH>10) on the ECG impression further increases the risk of sudden cardiac death.

The patient's history of ischemic dilated cardiomyopathy, diabetes, and hypertension also contribute to the risk of sudden cardiac death. The elevated troponin levels (ALT or GPT: 25.0) and low LVEF (35.0%) suggest significant cardiac damage and dysfunction, which can increase the risk of arrhythmias and sudden cardiac death.

While pump failure death is a possible outcome, the presence of non-sustained ventricular tachycardia and severe left ventricular dysfunction make sudden cardiac death a more likely and immediate concern.

RANKING: 2. Pump failure death
REASONING: 

Pump failure death is a possible outcome for this patient due to their severe heart failure (NYHA Class III) and significant left ventricular dysfunction (LVEF: 35.0%). The patient's elevated creatinine level (159.0 mmol/L) and high blood pressure (210/100 mmHg) suggest severe cardiac damage and dysfunction, which can lead to pump failure.

The patient's history of ischemic dilated cardiomyopathy, diabetes, and hypertension also contribute to the risk of pump failure. The presence of non-sustained ventricular tachycardia (CH>10) on the ECG impression may also increase the risk of pump failure.

However, the patient's current LVEF is relatively low, and the presence of non-sustained ventricular tachycardia makes pump failure death a more likely outcome compared to sudden cardiac death.

RANKING: 3. Survivor
REASONING: 

While the patient's severe heart failure (NYHA Class III) and significant left ventricular dysfunction (LVEF: 35.0%) make pump failure a possible outcome, the presence of non-sustained ventricular tachycardia (CH>10) and severe cardiac damage (elevated creatinine and troponin levels) suggest a higher risk of sudden cardiac death.

Additionally, the patient's age (80 years) and history of hypertension and diabetes increase the risk of mortality. However, the patient is currently receiving medications for their conditions, including beta blockers, ACE inhibitors, and digoxin, which may help manage their symptoms and reduce the risk of pump failure.

Given the patient's complex medical history and current ECG findings, the likelihood of pump failure death is lower compared to sudden cardiac death."
820,820,P0725,"Age: 72
Gender: Male 
Weight: 66 kg
Height: 158 cm
NYHA Class: III
Blood Pressure: 120/80 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Diabetes, Dyslipemia, Hypertension
Albumin (g/L): 42
ALT or GPT (IU/L): 13.0
AST or GOT (IU/L): 13.0
Total Cholesterol (mmol/L): 3,47
Creatinine (mmol/L): 71.0
Gamma-glutamil transpeptidase (IU/L): 33
Glucose (mmol/L): 10,4
Hemoglobin (g/L): 122.0
HDL (mmol/L): 0,62
Potassium (mEq/L): 4,2
LDL (mmol/L): 2,25
Sodium (mEq/L): 135.0
Protein (g/L): 74
T3 (pg/dL): 0,05
T4 (ng/L): 23
TSH (mIU/L): 1,2
Urea (mg/dL): 6,99
LVEF (%): 55.0
Medications: Diabetes Medication, Beta Blockers, Digoxin, Loop Diuretics, Spironolactone, Statins, ACE Inhibitor, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",pump failure death,"RANKING: 
1. Sudden Cardiac Death
REASONING: 
The patient's ECG impression reveals a high risk of ventricular arrhythmias, including non-sustained ventricular tachycardia and ventricular extrasystole, which are both associated with an increased risk of sudden cardiac death. Additionally, the patient's LVEF of 55% indicates a severely reduced left ventricular function, which can contribute to an increased risk of sudden cardiac death. The patient's age, NYHA Class III, and history of ischemic dilated cardiomyopathy also increase the risk of sudden cardiac death.

2. Pump Failure Death
REASONING: 
The patient's LVEF of 55% indicates severely reduced left ventricular function, which can lead to heart failure and potentially pump failure. The patient's NYHA Class III indicates severe symptoms, and the patient's history of ischemic dilated cardiomyopathy and other comorbidities (diabetes, dyslipemia, hypertension) further increase the risk of pump failure. The patient's elevated creatinine level (71.0 mmol/L) also suggests impaired renal function, which can be associated with heart failure.

3. Survivor
REASONING: 
While the patient's comorbidities and reduced LVEF increase the risk of adverse outcomes, the patient's relatively stable blood pressure (120/80 mmHg), normal liver enzymes, and relatively low creatinine level suggest that the patient may still have some residual cardiac function. However, the presence of ventricular arrhythmias and a history of ischemic dilated cardiomyopathy make it difficult to rule out a poor prognosis. Overall, the patient's overall clinical picture suggests a higher risk of adverse outcomes, but the likelihood of survival is still possible, albeit uncertain."
821,821,P0735,"Age: 59
Gender: Male 
Weight: 91 kg
Height: 170 cm
NYHA Class: II
Blood Pressure: 139/76 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Dyslipemia, Peripheral vascular disease, Hypertension, Myocardial Infarction
Albumin (g/L): 42
ALT or GPT (IU/L): 22.0
AST or GOT (IU/L): 14.0
Total Cholesterol (mmol/L): 7,34
Creatinine (mmol/L): 106.0
Gamma-glutamil transpeptidase (IU/L): 75
Glucose (mmol/L): 11,7
Hemoglobin (g/L): 140.0
HDL (mmol/L): 0,96
Potassium (mEq/L): 3,4
LDL (mmol/L): 5,66
Sodium (mEq/L): 136.0
Pro-BNP (ng/L): 108.0
Protein (g/L): 68
T3 (pg/dL): 0,05
T4 (ng/L): 23
Troponin (ng/mL): 0,1
TSH (mIU/L): 1,63
Urea (mg/dL): 8,65
LVEF (%): 50.0
Medications: Calcium Channel Blocker, Statins, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",pump failure death,"RANKING: 
1. Pump failure death
REASONING: 
Based on the provided patient data, the patient has a significant history of ischemic dilated cardiomyopathy, hypertension, and peripheral vascular disease, which suggests a compromised cardiac function. The patient's left ventricular ejection fraction (LVEF) is 50.0%, indicating severe left ventricular dysfunction. The presence of elevated troponin levels (0.1 ng/mL) also suggests myocardial damage. The patient's past medical history and current clinical presentation are consistent with a high risk of cardiac events.

The patient's elevated creatinine level (106.0 mmol/L) and low eGFR are indicative of chronic kidney disease, which can be a complication of advanced heart failure. The patient's low albumin level (42 g/L) and elevated BNP level (108 ng/L) further support the presence of heart failure.

Given these factors, the patient is at high risk of developing heart failure, and pump failure death is the most likely outcome over the next few years. The patient's current medication regimen, including ACE inhibitors and statins, is standard treatment for heart failure, but the underlying cardiac dysfunction and other comorbidities may limit its effectiveness.

While the patient's ECG results show no evidence of ventricular tachycardia or ventricular extrasystole, the presence of ventricular arrhythmias is a known complication of heart failure. However, in this case, the patient's ECG results do not suggest an immediate risk of life-threatening arrhythmias.

In contrast, sudden cardiac death is less likely in this patient, given the absence of evidence of ventricular tachycardia, ventricular extrasystole, or other conditions that increase the risk of sudden cardiac death.

Therefore, pump failure death is the most likely outcome for this patient over the next few years."
822,822,P0752,"Age: 55
Gender: Male 
Weight: 77 kg
Height: 171 cm
NYHA Class: III
Blood Pressure: 120/80 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Diabetes, Peripheral vascular disease, Myocardial Infarction
Albumin (g/L): 29,6
ALT or GPT (IU/L): 12.0
AST or GOT (IU/L): 16.0
Total Cholesterol (mmol/L): 4,46
Creatinine (mmol/L): 135.0
Gamma-glutamil transpeptidase (IU/L): 151
Glucose (mmol/L): 16,6
Hemoglobin (g/L): 117.0
HDL (mmol/L): 0,66
Potassium (mEq/L): 3,88
LDL (mmol/L): 2,46
Sodium (mEq/L): 134.0
Pro-BNP (ng/L): 5416.0
Protein (g/L): 58,9
Troponin (ng/mL): 0,02
TSH (mIU/L): 2,08
Urea (mg/dL): 14,4
LVEF (%): 21.0
Medications: Digoxin, Loop Diuretics, Spironolactone, Hydralazine, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Unknown ventricular extrasystole code
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",pump failure death,"RANKING: 1. Sudden cardiac death
REASONING: 

Based on the provided patient data, the patient is at high risk for sudden cardiac death due to the presence of several factors that contribute to this outcome. The patient has a history of ischemic dilated cardiomyopathy, which is a condition that increases the risk of arrhythmias and sudden cardiac death. Additionally, the patient has a low left ventricular ejection fraction (LVEF) of 21%, which is a strong indicator of poor cardiac function. The presence of non-sustained ventricular tachycardia (NSVT) on the ECG also increases the risk of sudden cardiac death.

The patient's elevated creatinine level (135.0 mmol/L) and urea level (14.4 mg/dL) suggest impaired renal function, which can be a complication of heart failure. The patient's low HDL cholesterol level (0.66 mmol/L) and elevated triglyceride level (not mentioned but implied by the total cholesterol level of 4.46 mmol/L) also increase the risk of cardiovascular events.

The patient's current medications, including digoxin, loop diuretics, spironolactone, hydralazine, and nitrovasodilator, are commonly used to manage heart failure and control symptoms, but they do not address the underlying cardiac dysfunction.

Considering these factors, the patient is at high risk for sudden cardiac death, and it is more likely than pump failure death. However, pump failure death cannot be ruled out, and close monitoring and management of the patient's condition are essential.

RANKING: 2. Pump failure death
REASONING: 

The patient's LVEF of 21% and the presence of NSVT on the ECG suggest that the patient is at risk for pump failure. The patient's elevated creatinine and urea levels also indicate impaired renal function, which can be a complication of heart failure.

The patient's NYHA Class III classification indicates severe heart failure, and the presence of edema, fatigue, and shortness of breath are common symptoms of pump failure. The patient's elevated troponin level (0.02 ng/mL) suggests some degree of cardiac damage, which can contribute to pump failure.

However, the patient's current medications and the presence of NSVT on the ECG suggest that the patient is at risk for sudden cardiac death, which may be a more immediate concern than pump failure.

RANKING: 3. Survivor
REASONING: 

While the patient is at risk for pump failure and sudden cardiac death, the presence of NSVT on the ECG and the patient's elevated troponin level suggest that the patient is at high risk for cardiac complications. However, the patient's age, weight, and hemoglobin level (117 g/L) are relatively favorable, which may contribute to a better prognosis.

The patient's elevated creatinine and urea levels indicate impaired renal function, which can be a complication of heart failure. However, the patient's current medications and the presence of NSVT on the ECG suggest that the patient is at risk for cardiac complications, which may outweigh the risks associated with pump failure.

Overall, while the patient is at risk for pump failure and sudden cardiac death, the presence of NSVT on the ECG and the patient's elevated troponin level suggest that the patient is at higher risk for cardiac complications, making survival less likely."
823,823,P0754,"Age: 73
Gender: Male 
Weight: 58 kg
Height: 162 cm
NYHA Class: III
Blood Pressure: 115/80 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Diabetes, Dyslipemia, Peripheral vascular disease, Myocardial Infarction
Albumin (g/L): 42,3
ALT or GPT (IU/L): 22.0
AST or GOT (IU/L): 30.0
Total Cholesterol (mmol/L): 5,36
Creatinine (mmol/L): 92.0
Gamma-glutamil transpeptidase (IU/L): 291
Glucose (mmol/L): 10,3
Hemoglobin (g/L): 157.0
HDL (mmol/L): 1,48
Potassium (mEq/L): 3,42
LDL (mmol/L): 3,05
Sodium (mEq/L): 135.0
Pro-BNP (ng/L): 2057.0
Protein (g/L): 70,2
Troponin (ng/mL): 0,13
TSH (mIU/L): 2,47
Urea (mg/dL): 9,5
LVEF (%): 20.0
Medications: Calcium Channel Blocker, Diabetes Medication, Beta Blockers, Digoxin, Loop Diuretics, Spironolactone, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",pump failure death,"RANKING: 
1. Pump failure death
REASONING:
The patient's current clinical presentation, laboratory results, and ECG findings suggest a high risk of cardiac dysfunction. Key factors contributing to this risk include:

- Low LVEF (20.0%) indicating severely reduced cardiac function.
- Elevated Pro-BNP levels (2057.0 ng/L) suggesting cardiac stress and potential heart failure.
- Presence of non-sustained ventricular tachycardia (NSVT) and ventricular extrasystoles, which are markers of arrhythmia and possible cardiac instability.
- Elevated troponin levels (0.13 ng/mL) indicating some degree of cardiac muscle damage, which could be related to ischemia or infarction.
- History of ischemic dilated cardiomyopathy, myocardial infarction, and peripheral vascular disease, which increase the risk of cardiac complications.
- Presence of multiple medications (Calcium Channel Blocker, Beta Blockers, Digoxin, Loop Diuretics, Spironolactone, Nitrovasodilator) that may be contributing to the patient's current clinical condition.

Considering these factors, the most likely outcome for the patient in the next few years is pump failure death, as the patient's cardiac function is severely compromised, and the presence of arrhythmias and cardiac stress markers suggests an increased risk of cardiac events.

While sudden cardiac death is a possible risk due to the presence of arrhythmias, it is less likely than pump failure death given the patient's severely reduced LVEF and the presence of cardiac stress markers. Survivor is the least likely outcome, as the patient's overall clinical presentation and laboratory results indicate a high risk of cardiac complications."
824,824,P0762,"Age: 68
Gender: Male 
Weight: 99 kg
Height: 174 cm
NYHA Class: II
Blood Pressure: 120/70 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Peripheral vascular disease, Myocardial Infarction
Albumin (g/L): 38,8
ALT or GPT (IU/L): 187.0
AST or GOT (IU/L): 146.0
Total Cholesterol (mmol/L): 2,62
Creatinine (mmol/L): 188.0
Gamma-glutamil transpeptidase (IU/L): 154
Glucose (mmol/L): 9,7
Hemoglobin (g/L): 119.0
HDL (mmol/L): 0,64
Potassium (mEq/L): 3,73
LDL (mmol/L): 1,59
Sodium (mEq/L): 130.0
Pro-BNP (ng/L): 19001.0
Protein (g/L): 69,9
Troponin (ng/mL): 0,01
TSH (mIU/L): 1,85
Urea (mg/dL): 21,3
LVEF (%): 20.0
Medications: Beta Blockers, Digoxin, Loop Diuretics, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",pump failure death,"RANKING: 1. Sudden Cardiac Death
REASONING: The patient's ECG impression highlights several concerning features, including ventricular extrasystoles, non-sustained ventricular tachycardia, and non-sustained ventricular tachycardia with a heart rate >10. These findings suggest a high risk of arrhythmic events, which are a major predictor of sudden cardiac death in patients with heart failure. The patient's history of ischemic dilated cardiomyopathy, myocardial infarction, and NYHA class II heart failure also increase the risk of sudden cardiac death. Additionally, the elevated troponin levels and reduced LVEF further indicate significant cardiac dysfunction.

RANKING: 2. Pump Failure Death
REASONING: The patient's LVEF of 20% indicates severe left ventricular dysfunction, which is a major predictor of pump failure death. The patient's history of ischemic dilated cardiomyopathy and myocardial infarction also contribute to this risk. The patient's elevated creatinine levels and urea levels suggest renal impairment, which can be a complication of heart failure. The patient's current medications, including beta blockers, digoxin, and loop diuretics, are standard treatments for heart failure, but the presence of ventricular extrasystoles and non-sustained ventricular tachycardia on the ECG suggests that the patient is at high risk of arrhythmic events, which can contribute to pump failure death.

RANKING: 3. Survivor
REASONING: While the patient's elevated troponin levels and reduced LVEF indicate significant cardiac dysfunction, the presence of severe arrhythmic events on the ECG and the patient's history of ischemic dilated cardiomyopathy and myocardial infarction make pump failure death a more likely outcome than sudden cardiac death. However, the patient's current medications and the presence of NYHA class II heart failure suggest that the patient is receiving adequate treatment for heart failure, and with close monitoring and optimization of therapy, it is possible that the patient could survive with proper management."
825,825,P0766,"Age: 64
Gender: Male 
Weight: 48 kg
Height: 165 cm
NYHA Class: III
Blood Pressure: 140/85 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Peripheral vascular disease, Hypertension, Myocardial Infarction
Albumin (g/L): 37,6
ALT or GPT (IU/L): 17.0
AST or GOT (IU/L): 22.0
Total Cholesterol (mmol/L): 4,32
Creatinine (mmol/L): 132.0
Gamma-glutamil transpeptidase (IU/L): 338
Glucose (mmol/L): 3,5
Hemoglobin (g/L): 127.0
HDL (mmol/L): 0,83
Potassium (mEq/L): 3,18
LDL (mmol/L): 2,89
Sodium (mEq/L): 136.0
Pro-BNP (ng/L): 9695.0
Protein (g/L): 81,4
Troponin (ng/mL): 0,04
TSH (mIU/L): 3,73
Urea (mg/dL): 10,4
LVEF (%): 30.0
Medications: Digoxin, Loop Diuretics, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",pump failure death,"RANKING: 1. Sudden cardiac death
REASONING: 

This patient has several high-risk factors that suggest a high likelihood of sudden cardiac death. The patient's age, NYHA Class III, and history of ischemic dilated cardiomyopathy, myocardial infarction, and peripheral vascular disease all contribute to this risk. The patient's low LVEF of 30.0 indicates severe left ventricular dysfunction, which is a common cause of sudden cardiac death. The presence of ventricular extrasystoles, non-sustained ventricular tachycardia, and non-sustained ventricular tachycardia (CH>10) on the ECG further increase the risk of sudden cardiac death. The patient's elevated troponin level (0.04 ng/mL) also suggests myocardial injury, which can be a precursor to arrhythmias leading to sudden cardiac death. The patient's elevated BNP level (9695.0 ng/L) and elevated creatinine level (10.4 mg/dL) indicate severe cardiac and renal impairment, which can contribute to the risk of sudden cardiac death.

RANKING: 2. Pump failure death
REASONING:

The patient's severe left ventricular dysfunction (LVEF 30.0), elevated BNP level (9695.0 ng/L), and elevated creatinine level (10.4 mg/dL) make pump failure a significant concern. The patient's NYHA Class III classification indicates severe heart failure, and the patient's medications (Digoxin, Loop Diuretics, Nitrovasodilator) suggest treatment for heart failure. However, the patient's severe left ventricular dysfunction and elevated BNP level indicate that the patient is at risk of pump failure, which can be fatal if not properly managed.

RANKING: 3. Survivor
REASONING:

While the patient has several risk factors for cardiac complications, the patient's overall clinical presentation and laboratory results do not suggest a high risk of sudden cardiac death. The patient's elevated troponin level (0.04 ng/mL) is mild, and the patient's ECG findings are primarily indicative of arrhythmias rather than structural heart disease. The patient's medications and laboratory results suggest that the patient is being managed for heart failure, which may mitigate some of the risks associated with severe left ventricular dysfunction. However, the patient's severe left ventricular dysfunction and elevated BNP level still make pump failure a concern, and the patient's overall prognosis is uncertain."
826,826,P0772,"Age: 74
Gender: Male 
Weight: 60 kg
Height: 168 cm
NYHA Class: III
Blood Pressure: 80/60 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Myocardial Infarction
Albumin (g/L): 42
ALT or GPT (IU/L): 16.0
AST or GOT (IU/L): 15.0
Total Cholesterol (mmol/L): 3,54
Creatinine (mmol/L): 150.0
Gamma-glutamil transpeptidase (IU/L): 114
Glucose (mmol/L): 5,8
Hemoglobin (g/L): 117.0
HDL (mmol/L): 0,72
Potassium (mEq/L): 4,3
LDL (mmol/L): 2,46
Sodium (mEq/L): 138.0
Pro-BNP (ng/L): 8916.0
Protein (g/L): 79
T4 (ng/L): 17
Troponin (ng/mL): 0,01
TSH (mIU/L): 1,87
Urea (mg/dL): 27,12
LVEF (%): 13.0
Medications: Beta Blockers, Loop Diuretics, Spironolactone, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",pump failure death,"RANKING: 1. Pump failure death
REASONING:

Based on the provided patient data, the patient is at high risk for pump failure death. The patient has a history of ischemic dilated cardiomyopathy and myocardial infarction, which are both conditions that can lead to left ventricular dysfunction and heart failure. The patient's left ventricular ejection fraction (LVEF) is significantly reduced at 13%, indicating poor cardiac function.

Additionally, the patient has a history of heart failure, as indicated by a NYHA Class III classification, which suggests that the patient experiences symptoms of heart failure, such as shortness of breath, fatigue, and swelling. The patient's low blood pressure (80/60 mmHg) and low hemoglobin level (117.0 g/L) may also indicate poor perfusion and oxygen delivery to tissues.

The patient's elevated creatinine level (27.12 mg/dL) and urea level (27.12 mg/dL) suggest impaired renal function, which is a common complication of heart failure. The patient's elevated Pro-BNP level (8916.0 ng/L) further supports the diagnosis of heart failure.

The patient's medication regimen, which includes beta blockers, loop diuretics, spironolactone, and ACE inhibitors, is standard treatment for heart failure. However, the fact that the patient is already experiencing symptoms of heart failure and has a poor LVEF suggests that the current treatment may not be sufficient to manage the condition effectively.

Given the patient's poor cardiac function, history of heart failure, and elevated biomarkers, the most likely outcome is pump failure death. This is the most likely prognosis due to the high risk of cardiac complications and the severity of the patient's condition.

Sudden cardiac death is less likely, as the ECG impression does not show any signs of ventricular tachycardia or other arrhythmias that could lead to sudden cardiac death. Survivor is the least likely outcome, given the patient's poor cardiac function and history of heart failure.

It is essential to note that this prognosis is based on the provided data and should be confirmed with further evaluation and monitoring. Close follow-up and adjustments to the treatment plan may be necessary to improve the patient's outcome."
827,827,P0781,"Age: 70
Gender: Female 
Weight: 62 kg
Height: 154 cm
NYHA Class: II
Blood Pressure: 100/75 mmHg
Past Medical History: Valvular cardiomyopathy, Hypertension
Albumin (g/L): 38,5
ALT or GPT (IU/L): 13.0
AST or GOT (IU/L): 17.0
Total Cholesterol (mmol/L): 5,04
Creatinine (mmol/L): 108.0
Gamma-glutamil transpeptidase (IU/L): 97
Glucose (mmol/L): 5,5
Hemoglobin (g/L): 122.0
HDL (mmol/L): 1,33
Potassium (mEq/L): 4,42
LDL (mmol/L): 3,08
Sodium (mEq/L): 140.0
Pro-BNP (ng/L): 5911.0
Protein (g/L): 82,3
T3 (pg/dL): 0,01
T4 (ng/L): 12
Troponin (ng/mL): 0,02
TSH (mIU/L): 1,9
Urea (mg/dL): 10,5
LVEF (%): 35.0
Medications: Amiodarone, Beta Blockers, Digoxin, Loop Diuretics, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",pump failure death,"RANKING: 1. Sudden cardiac death
REASONING: 

The patient's ECG impression shows a polymorphic ventricular extrasystole and non-sustained ventricular tachycardia, which are both indicators of a high risk for sudden cardiac death. Additionally, the presence of non-sustained ventricular tachycardia (CH>10) further increases the risk. The patient's NYHA Class II indicates some limitations in physical activity, which may be related to the underlying valvular cardiomyopathy and hypertension. The patient's low LVEF (35.0) also suggests significant left ventricular dysfunction, which can increase the risk for arrhythmic events. The presence of amiodarone, a medication commonly used to treat arrhythmias, may also contribute to the increased risk of sudden cardiac death. Overall, the combination of these factors makes sudden cardiac death the most likely prognosis.

RANKING: 2. Pump failure death
REASONING: 

The patient's low LVEF (35.0) and significant left ventricular dysfunction are strong indicators of pump failure. The patient's elevated creatinine level (108.0) also suggests impaired renal function, which can be a consequence of heart failure. The patient's elevated BNP levels (5911.0) further support this, as BNP is a biomarker for heart failure. The patient's history of valvular cardiomyopathy and hypertension also increases the risk of heart failure. However, the presence of medications such as loop diuretics and nitrovasodilators suggests that the patient is being treated for heart failure, which reduces the likelihood of pump failure death compared to sudden cardiac death.

RANKING: 3. Survivor
REASONING: 

While the patient's low LVEF and elevated BNP levels suggest heart failure, the presence of medications such as beta blockers and digoxin, which are commonly used to treat heart failure, suggests that the patient is receiving treatment to manage their condition. Additionally, the patient's relatively normal electrolyte levels and lack of evidence of severe renal dysfunction reduce the likelihood of pump failure death. However, the presence of ventricular extrasystoles and non-sustained ventricular tachycardia on the ECG still increases the risk of arrhythmic events, which could potentially lead to sudden cardiac death. Overall, while the patient has a significant heart condition, the presence of treatment and relatively stable laboratory values make survival a possible outcome."
828,828,P0790,"Age: 79
Gender: Male 
Weight: 88 kg
Height: 178 cm
NYHA Class: II
Blood Pressure: 120/70 mmHg
Past Medical History: Idiopathic dilated cardiomyopathy, Hypertension
Albumin (g/L): 37
ALT or GPT (IU/L): 26.0
AST or GOT (IU/L): 25.0
Total Cholesterol (mmol/L): 3,88
Creatinine (mmol/L): 133.0
Gamma-glutamil transpeptidase (IU/L): 24
Glucose (mmol/L): 6,9
Hemoglobin (g/L): 145.0
HDL (mmol/L): 0,96
Potassium (mEq/L): 4
LDL (mmol/L): 2,46
Sodium (mEq/L): 135.0
Pro-BNP (ng/L): 4762.0
Protein (g/L): 65
T4 (ng/L): 9
Troponin (ng/mL): 0,04
TSH (mIU/L): 1,8
Urea (mg/dL): 6,66
LVEF (%): 28.0
Medications: Beta Blockers, Digoxin, Loop Diuretics, Spironolactone, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",pump failure death,"RANKING: 
1. Survivor
REASONING: 
The patient's age (79) and NYHA Class II heart failure status indicate a moderate level of heart failure, but the patient is not in New York Heart Association (NYHA) Class III or IV, which suggests that the patient is still relatively functional and may have some residual cardiac reserve. The patient's LVEF is 28%, which is significantly reduced, indicating severe left ventricular dysfunction. However, the patient's creatinine level (133.0) is not severely elevated, and the patient is not on dialysis. The patient's troponin level (0.04 ng/mL) is within normal limits, which suggests that there is no significant myocardial infarction or acute coronary syndrome. The patient's ECG findings, including ventricular extrasystole and non-sustained ventricular tachycardia, are concerning for arrhythmias, but the patient is not in a high-risk category for sudden cardiac death. The patient's medication regimen, which includes beta blockers, digoxin, loop diuretics, spironolactone, and an ACE inhibitor, is standard for managing heart failure and arrhythmias. Overall, the patient's prognosis is guarded but not immediately dire.

2. Sudden cardiac death
REASONING: 
While the patient's ECG findings, including ventricular extrasystole and non-sustained ventricular tachycardia, are concerning for arrhythmias, the patient's overall clinical presentation and laboratory results do not suggest an acute or life-threatening condition. The patient's LVEF is severely reduced, and the patient has a history of idiopathic dilated cardiomyopathy, which increases the risk of sudden cardiac death. However, the patient is not on any medications that are commonly associated with an increased risk of sudden cardiac death, such as amiodarone or beta blockers with a high risk of torsades de pointes. The patient's creatinine level is not severely elevated, and the patient is not in NYHA Class III or IV.

3. Pump failure death
REASONING: 
While the patient's LVEF is severely reduced, the patient's creatinine level is not severely elevated, and the patient is not in NYHA Class III or IV. The patient's medication regimen, which includes beta blockers, digoxin, loop diuretics, spironolactone, and an ACE inhibitor, is standard for managing heart failure. The patient's ECG findings, while concerning for arrhythmias, do not suggest an acute or life-threatening condition. However, the patient's severe LVEF reduction and history of idiopathic dilated cardiomyopathy do increase the risk of pump failure. Additionally, the patient's elevated troponin level (0.04 ng/mL) may indicate some degree of myocardial injury, which could contribute to the risk of pump failure. Overall, while pump failure is a concern, it is not the most likely outcome based on the patient's clinical presentation and laboratory results."
829,829,P0792,"Age: 85
Gender: Male 
Weight: 86 kg
Height: 170 cm
NYHA Class: III
Blood Pressure: 140/80 mmHg
Past Medical History: Idiopathic dilated cardiomyopathy, Diabetes
Albumin (g/L): 37
ALT or GPT (IU/L): 42.0
AST or GOT (IU/L): 19.0
Total Cholesterol (mmol/L): 4,34
Creatinine (mmol/L): 141.0
Gamma-glutamil transpeptidase (IU/L): 50
Glucose (mmol/L): 7
Hemoglobin (g/L): 127.0
HDL (mmol/L): 1,14
Potassium (mEq/L): 4,4
LDL (mmol/L): 2,84
Sodium (mEq/L): 139.0
Protein (g/L): 68
T4 (ng/L): 10
Troponin (ng/mL): 0,01
TSH (mIU/L): 2,62
Urea (mg/dL): 9,32
LVEF (%): 25.0
Medications: Diabetes Medication, Beta Blockers, Digoxin, Loop Diuretics, Spironolactone, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Unknown ventricular extrasystole code
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",pump failure death,"RANKING: 
1. Survivor
REASONING: 

Given the patient's advanced age (85), NYHA Class III heart failure, and significant left ventricular dysfunction (LVEF 25%), the patient is at high risk for cardiogenic shock and pump failure. The presence of non-sustained ventricular tachycardia (NSTVT) on the ECG further increases this risk. The patient's creatinine level (141.0 mmol/L) also suggests impaired renal function, which can be a complication of heart failure. The patient's medications, including digoxin and spironolactone, may be contributing to the development of hypokalemia (potassium 4.4 mEq/L), which can also increase the risk of arrhythmias and cardiac arrest. However, the patient's troponin level (0.01 ng/mL) is within normal limits, suggesting that the patient has not experienced significant myocardial injury recently. 

While the patient's past medical history of idiopathic dilated cardiomyopathy and diabetes may suggest a high risk for cardiovascular events, the patient's current ECG findings and laboratory results do not indicate an acute cardiac event. Therefore, I would predict that the patient is likely to survive with appropriate medical management and monitoring.

2. Sudden cardiac death
REASONING: 

The patient's ECG findings of non-sustained ventricular tachycardia (NSTVT) and unknown ventricular extrasystole code suggest an increased risk for arrhythmias. However, the patient's troponin level is normal, and the patient's ECG did not show any signs of acute myocardial infarction. The patient's NYHA Class III heart failure and significant LVEF reduction also increase the risk for cardiac events. However, the patient's age and comorbidities may also contribute to the development of fatal arrhythmias. Given the patient's high risk for arrhythmias and the potential for cardiac events, I would rank sudden cardiac death as a possible outcome.

3. Pump failure death
REASONING: 

Given the patient's advanced age, NYHA Class III heart failure, and significant LVEF reduction, the patient is at high risk for pump failure. However, the patient's current ECG findings and laboratory results do not indicate an acute cardiac event. The patient's creatinine level is elevated, which may suggest impaired renal function, but this is not directly related to pump failure. The patient's medications, including digoxin and spironolactone, may be contributing to the development of hypokalemia, which can increase the risk of arrhythmias and cardiac arrest. However, the patient's troponin level is normal, suggesting that the patient has not experienced significant myocardial injury recently. Given the patient's current medical status, I would rank pump failure death as a possible outcome, but it is less likely than sudden cardiac death."
830,830,P0835,"Age: 78
Gender: Female 
Weight: 77 kg
Height: 159 cm
NYHA Class: III
Blood Pressure: 110/60 mmHg
Past Medical History: Valvular cardiomyopathy, Hypertension
Albumin (g/L): 41,5
ALT or GPT (IU/L): 11.0
AST or GOT (IU/L): 12.0
Total Cholesterol (mmol/L): 4,79
Creatinine (mmol/L): 89.0
Gamma-glutamil transpeptidase (IU/L): 43
Glucose (mmol/L): 14,6
Hemoglobin (g/L): 158.0
HDL (mmol/L): 0,9
Potassium (mEq/L): 4,39
LDL (mmol/L): 3,17
Sodium (mEq/L): 134.0
Pro-BNP (ng/L): 155.0
Protein (g/L): 80,4
Troponin (ng/mL): 0,01
TSH (mIU/L): 2,1
Urea (mg/dL): 9,9
LVEF (%): 60.0
Medications: Angiotensin II Receptor Blocker, Digoxin, Loop Diuretics, Spironolactone
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",pump failure death,"RANKING: 
1. Pump failure death
REASONING: 
Based on the patient's age (78), NYHA Class III status, and the presence of valvular cardiomyopathy, hypertension, and elevated creatinine levels (89.0 mmol/L), the patient is at high risk for pump failure. The patient's left ventricular ejection fraction (LVEF) is 60.0%, which is below the normal range (50-70%), indicating left ventricular dysfunction. The presence of elevated troponin levels (0.01 ng/mL) also suggests myocardial injury, which can contribute to pump failure. The patient's current medications, including Loop Diuretics and Spironolactone, are aimed at managing heart failure symptoms, but the underlying cardiac dysfunction may still pose a risk for pump failure. 

2. Sudden cardiac death
REASONING: 
While the patient has a history of ventricular extrasystole (polymorphic), the ECG impression does not indicate any sustained ventricular tachycardia or non-sustained ventricular tachycardia, and the presence of paroxysmal supraventricular tachyarrhythmia is unknown. However, the patient's elevated Pro-BNP levels (155.0 ng/L) and elevated creatinine levels suggest that the patient may be at risk for cardiac events, including sudden cardiac death. The patient's age and NYHA Class III status also increase the risk for cardiac events.

3. Survivor
REASONING: 
While the patient has a history of valvular cardiomyopathy and hypertension, the patient's current LVEF is 60.0%, and the patient is on medications that aim to manage heart failure symptoms. The patient's Pro-BNP levels are not excessively elevated, and the patient's other laboratory values are relatively stable. However, considering the patient's advanced age, NYHA Class III status, and underlying cardiac dysfunction, the likelihood of long-term survival is lower compared to the other two options."
831,831,P0839,"Age: 68
Gender: Male 
Weight: 70 kg
Height: 174 cm
NYHA Class: III
Blood Pressure: 120/50 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Diabetes, Myocardial Infarction
Albumin (g/L): 37,9
ALT or GPT (IU/L): 17.0
AST or GOT (IU/L): 11.0
Total Cholesterol (mmol/L): 4,09
Creatinine (mmol/L): 133.0
Gamma-glutamil transpeptidase (IU/L): 18
Glucose (mmol/L): 7,2
Hemoglobin (g/L): 97.0
HDL (mmol/L): 1,34
Potassium (mEq/L): 4
LDL (mmol/L): 2,35
Sodium (mEq/L): 141.0
Pro-BNP (ng/L): 1635.0
Protein (g/L): 66,1
Troponin (ng/mL): 0,01
TSH (mIU/L): 2,39
Urea (mg/dL): 12,1
LVEF (%): 44.0
Medications: Amiodarone, Loop Diuretics, Spironolactone, Statins, ACE Inhibitor, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",pump failure death,"RANKING: 1. Survivor
REASONING: 

This patient has a high risk of cardiac events due to their severe heart failure (NYHA Class III), ischemic dilated cardiomyopathy, and multiple comorbidities such as diabetes and myocardial infarction. Their left ventricular ejection fraction (LVEF) is significantly reduced at 44%, indicating poor cardiac function. Additionally, their elevated BNP levels (1635.0 ng/L) suggest a high burden of ventricular remodeling and stress. 

Despite these factors, the patient is on multiple medications for heart failure management, including ACE inhibitors, spironolactone, and loop diuretics, which are standard treatments for heart failure. The absence of ventricular tachycardia or non-sustained ventricular tachycardia on the ECG is also a positive prognostic sign. 

While pump failure death is a possible outcome, the patient's current management plan and the absence of more severe cardiac arrhythmias or signs of acute decompensation make a survivor outcome more likely.

RANKING: 2. Sudden cardiac death
REASONING: 

The patient's history of ischemic dilated cardiomyopathy and myocardial infarction increases the risk of sudden cardiac death. Their LVEF is also a significant predictor of sudden cardiac death, with a low value of 44%. However, the patient is on medications that are commonly used to reduce the risk of sudden cardiac death, such as amiodarone and beta-blockers (not explicitly listed but implied by the nitrovasodilator). 

The absence of ventricular tachycardia or non-sustained ventricular tachycardia on the ECG is a positive prognostic sign, but the presence of ventricular extrasystoles (polymorphic) is a concern. The patient's overall risk of sudden cardiac death is still elevated due to their underlying cardiac condition and the presence of ventricular extrasystoles.

RANKING: 3. Pump failure death
REASONING: 

Pump failure death is a possible outcome for this patient, given their severe heart failure (NYHA Class III) and reduced LVEF. However, the patient is on medications that are commonly used to manage heart failure, and their current ECG findings do not suggest acute decompensation. The absence of ventricular tachycardia or non-sustained ventricular tachycardia on the ECG also reduces the risk of sudden cardiac death. 

While pump failure death is a concern, the patient's current management plan and the absence of more severe cardiac arrhythmias or signs of acute decompensation make this outcome less likely compared to sudden cardiac death."
832,832,P0853,"Age: 74
Gender: Male 
Weight: 70 kg
Height: 158 cm
NYHA Class: II
Blood Pressure: 110/75 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Peripheral vascular disease, Hypertension, Myocardial Infarction
Albumin (g/L): 41
ALT or GPT (IU/L): 24.0
AST or GOT (IU/L): 27.0
Total Cholesterol (mmol/L): 5,2
Creatinine (mmol/L): 115.0
Gamma-glutamil transpeptidase (IU/L): 28
Glucose (mmol/L): 6,1
Hemoglobin (g/L): 135.0
HDL (mmol/L): 1,06
Potassium (mEq/L): 5
LDL (mmol/L): 3,78
Sodium (mEq/L): 138.0
Pro-BNP (ng/L): 4185.0
Protein (g/L): 77
T4 (ng/L): 19
Troponin (ng/mL): 0,02
TSH (mIU/L): 1,5
Urea (mg/dL): 12,15
LVEF (%): 30.0
Medications: Beta Blockers, Loop Diuretics, ACE Inhibitor, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",pump failure death,"RANKING: 1. Pump failure death
REASONING:

Based on the provided patient data, the most likely prognosis is pump failure death. The patient has a history of ischemic dilated cardiomyopathy, which is a condition where the heart's ability to pump blood is compromised due to damage to the heart muscle. The patient's left ventricular ejection fraction (LVEF) of 30.0% further indicates severe systolic dysfunction, which is a hallmark of pump failure.

The patient's elevated creatinine level (115.0 mmol/L) also suggests impaired renal function, which can be a consequence of cardiac failure. Additionally, the patient's elevated Pro-BNP level (4185.0 ng/L) is a strong indicator of heart failure, as it is a marker of ventricular stress and strain.

The patient's past medical history of myocardial infarction and peripheral vascular disease also increases the risk of pump failure. The patient's medications, including beta blockers, loop diuretics, ACE inhibitors, and nitrovasodilator, are commonly used to manage heart failure and reduce the risk of pump failure.

While the patient's ECG findings, including ventricular extrasystole and non-sustained ventricular tachycardia, suggest an increased risk of arrhythmias, the presence of pump failure is a more direct indicator of the patient's prognosis.

Therefore, based on the provided data, pump failure death is the most likely outcome for this patient."
833,833,P0872,"Age: 57
Gender: Male 
Weight: 62 kg
Height: 165 cm
NYHA Class: II
Blood Pressure: 100/70 mmHg
Past Medical History: Hypertensive cardiomyopathy
Albumin (g/L): 47
ALT or GPT (IU/L): 18.0
AST or GOT (IU/L): 22.0
Total Cholesterol (mmol/L): 5,56
Creatinine (mmol/L): 86.0
Gamma-glutamil transpeptidase (IU/L): 38
Glucose (mmol/L): 6,3
Hemoglobin (g/L): 153.0
HDL (mmol/L): 1,22
Potassium (mEq/L): 4,6
LDL (mmol/L): 3,57
Sodium (mEq/L): 137.0
Pro-BNP (ng/L): 2299.0
Protein (g/L): 74
T3 (pg/dL): 0,07
T4 (ng/L): 19
Troponin (ng/mL): 0,17
TSH (mIU/L): 2,47
Urea (mg/dL): 7,15
LVEF (%): 22.0
Medications: Angiotensin II Receptor Blocker, Beta Blockers, Digoxin, Loop Diuretics, Spironolactone, Statins
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: Unknown bradycardia code
            ",pump failure death,"RANKING: 1. Sudden cardiac death
REASONING: 

This patient's data suggests a high risk of sudden cardiac death due to the presence of ventricular tachycardia (VT), specifically non-sustained VT, and polymorphic ventricular extrasystoles on the ECG. The patient's left ventricular ejection fraction (LVEF) is also significantly reduced at 22%, which is consistent with advanced heart failure. The patient's history of hypertensive cardiomyopathy further increases the risk of arrhythmias and cardiac events.

While the patient is on multiple medications for heart failure and hypertension, the presence of VT and polymorphic extrasystoles on the ECG indicates a high risk of arrhythmic events. The patient's Troponin levels are not elevated, which suggests that the cardiac damage is not significant enough to indicate acute myocardial infarction. However, the presence of non-sustained VT and polymorphic ventricular extrasystoles increases the risk of sudden cardiac death.

The patient's LVEF is also a significant concern, as a reduced ejection fraction is a strong predictor of adverse outcomes in heart failure patients. The patient's weight and height are also on the lower side, which may contribute to a higher risk of arrhythmias.

While pump failure death is a possible outcome, the patient's current ECG findings and LVEF suggest that sudden cardiac death is a more immediate concern. Therefore, I would rank sudden cardiac death as the most likely outcome.

RANKING: 2. Pump failure death
REASONING: 

Pump failure death is a possible outcome for this patient, given the patient's history of hypertensive cardiomyopathy and reduced LVEF. The patient's weight and height are also on the lower side, which may contribute to a higher risk of heart failure.

The patient is on multiple medications for heart failure and hypertension, which should help manage the condition. However, the presence of non-sustained VT and polymorphic ventricular extrasystoles on the ECG increases the risk of arrhythmias and cardiac events. The patient's LVEF is also a significant concern, as a reduced ejection fraction is a strong predictor of adverse outcomes in heart failure patients.

While the patient's current ECG findings and LVEF suggest that pump failure is a possible outcome, the presence of non-sustained VT and polymorphic ventricular extrasystoles on the ECG increases the risk of sudden cardiac death. Therefore, I would rank pump failure death as the second most likely outcome.

RANKING: 3. Survivor
REASONING: 

Given the patient's history of hypertensive cardiomyopathy, reduced LVEF, and the presence of non-sustained VT and polymorphic ventricular extrasystoles on the ECG, it is likely that the patient will experience some level of cardiac event or death. However, the patient is currently on multiple medications for heart failure and hypertension, which should help manage the condition.

The patient's weight and height are also on the lower side, which may contribute to a higher risk of heart failure. However, the patient's current ECG findings and LVEF suggest that pump failure is a more immediate concern than sudden cardiac death.

While it is possible that the patient may survive, the presence of non-sustained VT and polymorphic ventricular extrasystoles on the ECG increases the risk of cardiac events. Therefore, I would rank survivor as the least likely outcome."
834,834,P0873,"Age: 81
Gender: Female 
Weight: 49 kg
Height: 145 cm
NYHA Class: III
Blood Pressure: 180/90 mmHg
Past Medical History: Hypertensive cardiomyopathy, Hypertension
Albumin (g/L): 42
ALT or GPT (IU/L): 19.0
AST or GOT (IU/L): 33.0
Total Cholesterol (mmol/L): 4,69
Creatinine (mmol/L): 209.0
Gamma-glutamil transpeptidase (IU/L): 41
Glucose (mmol/L): 3,94
Hemoglobin (g/L): 131.0
HDL (mmol/L): 1,1
Potassium (mEq/L): 4,54
LDL (mmol/L): 3,01
Sodium (mEq/L): 139.0
Protein (g/L): 81
T3 (pg/dL): 0,0441
T4 (ng/L): 22,5
Troponin (ng/mL): 1,2
TSH (mIU/L): 1,27
Urea (mg/dL): 26,1
LVEF (%): 65.0
Medications: Digoxin, Loop Diuretics, Spironolactone, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",pump failure death,"RANKING: 
1. Pump failure death 
2. Sudden cardiac death 
3. Survivor 

REASONING:

The patient's prognosis is primarily driven by the presence of severe left ventricular dysfunction (NYHA Class III), hypertension, and elevated creatinine levels, indicating possible renal impairment. The patient's LVEF is 65%, which is significantly reduced, suggesting advanced left ventricular dysfunction.

The patient's ECG findings of ventricular extrasystoles and the presence of hypertension and renal impairment increase the risk of arrhythmias and cardiac complications. The patient's elevated troponin levels also suggest myocardial injury.

The patient's elevated troponin levels and the presence of ventricular extrasystoles suggest a high risk of cardiac complications, including sudden cardiac death. However, the patient's medication regimen, including ACE inhibitors and beta-blockers (not explicitly mentioned but implied by the presence of digoxin), may provide some protective effects against arrhythmias and cardiac remodeling.

Given the patient's advanced age, severe left ventricular dysfunction, and renal impairment, the most likely outcome is pump failure death. The patient's elevated troponin levels and ventricular extrasystoles increase the risk of cardiac complications, but the patient's medication regimen and age may mitigate some of these risks.

While sudden cardiac death is a possible outcome, it is less likely due to the presence of medications that may help prevent arrhythmias and cardiac remodeling. The patient's survival is the least likely outcome, given the patient's advanced age, severe left ventricular dysfunction, and renal impairment.

It is essential to note that this prognosis is based on the provided data and may not accurately reflect the patient's actual outcome. A comprehensive re-evaluation and further diagnostic testing may be necessary to refine the prognosis."
835,835,P0882,"Age: 79
Gender: Female 
Weight: 70 kg
Height: 155 cm
NYHA Class: II
Blood Pressure: 160/80 mmHg
Past Medical History: Hypertensive cardiomyopathy, Diabetes, Dyslipemia, Hypertension, Myocardial Infarction
Albumin (g/L): 40,2
ALT or GPT (IU/L): 18.0
AST or GOT (IU/L): 16.0
Total Cholesterol (mmol/L): 6,73
Creatinine (mmol/L): 93.0
Gamma-glutamil transpeptidase (IU/L): 17
Glucose (mmol/L): 7,13
Hemoglobin (g/L): 125.0
HDL (mmol/L): 1,74
Potassium (mEq/L): 4,14
LDL (mmol/L): 4,76
Sodium (mEq/L): 140.0
Protein (g/L): 66,7
T3 (pg/dL): 0,0549
T4 (ng/L): 16,02
TSH (mIU/L): 4,15
Urea (mg/dL): 7,4
LVEF (%): 50.0
Medications: Calcium Channel Blocker, Diabetes Medication, Beta Blockers, Loop Diuretics, Statins, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: TPSV
        - Bradycardia: No
            ",pump failure death,"RANKING: 1. Survivor

REASONING: 

Based on the patient's age, NYHA Class II, and the presence of multiple comorbidities such as hypertension, diabetes, and dyslipemia, the patient is already at an increased risk for cardiovascular events. The patient's LVEF of 50.0 indicates a significant impairment of cardiac function, which further increases the risk of adverse outcomes.

The patient's laboratory results show elevated creatinine levels, which may indicate some degree of renal impairment, and a low albumin level, which could be related to malnutrition or kidney dysfunction. The patient's lipid profile is also suboptimal, with high LDL and low HDL levels.

Despite the presence of multiple medications, including beta blockers and statins, the patient's cardiovascular risk factors and laboratory results suggest that the patient is still at a high risk for cardiovascular events. However, the absence of evidence for acute coronary syndrome or significant left ventricular dysfunction on the ECG impression suggests that the patient may not be at immediate risk for sudden cardiac death.

While the patient's TSH level is slightly elevated, which may indicate some degree of thyroid dysfunction, it is not sufficient to explain the patient's cardiac impairment. The patient's T3 and T4 levels are within the normal range, and the TSH level is not significantly elevated.

Given these factors, the most likely outcome for this patient over the next few years is a gradual decline in cardiac function, leading to pump failure. The patient's renal impairment, malnutrition, and suboptimal lipid profile will likely contribute to this decline. Therefore, the patient is most likely to survive, but with a high risk of developing cardiovascular events, including pump failure."
836,836,P0884,"Age: 70
Gender: Female 
Weight: 70 kg
Height: 165 cm
NYHA Class: II
Blood Pressure: 140/80 mmHg
Past Medical History: Hypertensive cardiomyopathy, Hypertension
Albumin (g/L): 34
ALT or GPT (IU/L): 43.0
AST or GOT (IU/L): 34.0
Total Cholesterol (mmol/L): 4,01
Creatinine (mmol/L): 53.0
Gamma-glutamil transpeptidase (IU/L): 39
Glucose (mmol/L): 6,6
Hemoglobin (g/L): 146.0
HDL (mmol/L): 1,32
Potassium (mEq/L): 4,3
LDL (mmol/L): 2,22
Sodium (mEq/L): 144.0
Pro-BNP (ng/L): 2773.0
Protein (g/L): 75
T4 (ng/L): 15
Troponin (ng/mL): 0,01
TSH (mIU/L): 2,23
Urea (mg/dL): 4,99
LVEF (%): 60.0
Medications: Loop Diuretics, Spironolactone, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: TPSV
        - Bradycardia: No
            ",pump failure death,"RANKING: 1. Sudden cardiac death
REASONING: 

Based on the provided patient data, the patient is at high risk for sudden cardiac death due to the presence of several concerning ECG findings, including:

- Ventricular Extrasystole: Polymorphic, which is a marker of ventricular instability and potential for life-threatening arrhythmias.
- Non-sustained ventricular tachycardia (CH>10): This indicates a high risk of ventricular arrhythmias, which can degenerate into sustained ventricular tachycardia and potentially lead to sudden cardiac death.
- Elevated Pro-BNP levels: 2773.0 ng/L, which suggests cardiac strain and potential heart failure, increasing the risk of sudden cardiac death.

Additionally, the patient's age, NYHA Class II, and hypertension history also contribute to the increased risk of sudden cardiac death.

RANKING: 2. Pump failure death
REASONING: 

Pump failure death is a possible outcome due to the patient's:

- Elevated Pro-BNP levels, indicating cardiac strain and potential heart failure.
- NYHA Class II, suggesting some limitation in physical activity due to heart failure symptoms.
- Elevated creatinine levels (53.0 mmol/L), indicating impaired renal function, which can be associated with heart failure.
- Presence of hypertension, which is a risk factor for heart failure.

However, the patient is on medications for heart failure (Loop Diuretics and Spironolactone) and ACE Inhibitor, which may help manage symptoms and slow disease progression.

RANKING: 3. Survivor
REASONING: 

Although the patient has several concerning features, the patient's age, medication regimen, and relatively preserved LVEF (60.0%) suggest that the patient may be able to manage their condition with optimal treatment and lifestyle modifications. The patient's weight and BMI are not significantly elevated, which may reduce the risk of sudden cardiac death. However, the patient's overall risk profile, including the presence of polymorphic ventricular extrasystole and non-sustained ventricular tachycardia, makes it challenging to predict a favorable outcome."
837,837,P0888,"Age: 77
Gender: Male 
Weight: 60 kg
Height: 170 cm
NYHA Class: II
Blood Pressure: 130/80 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Diabetes, Peripheral vascular disease, Myocardial Infarction
Albumin (g/L): 43
ALT or GPT (IU/L): 24.0
AST or GOT (IU/L): 33.0
Total Cholesterol (mmol/L): 5,74
Creatinine (mmol/L): 101.0
Gamma-glutamil transpeptidase (IU/L): 30
Glucose (mmol/L): 9,8
Hemoglobin (g/L): 146.0
HDL (mmol/L): 1,09
Potassium (mEq/L): 4,54
LDL (mmol/L): 4,01
Sodium (mEq/L): 137.0
Protein (g/L): 75,8
T3 (pg/dL): 0,0642
T4 (ng/L): 15,87
Troponin (ng/mL): 0,3
TSH (mIU/L): 2,14
Urea (mg/dL): 12,9
LVEF (%): 30.0
Medications: Diabetes Medication, Loop Diuretics, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: TPSV
        - Bradycardia: Unknown bradycardia code
            ",pump failure death,"RANKING: 
1. Pump failure death
REASONING: 
The patient's clinical presentation, laboratory results, and ECG findings suggest a high risk of adverse cardiac events. The patient has a history of ischemic dilated cardiomyopathy, which is a condition where the heart's ability to pump blood is severely impaired. The LVEF of 30.0% indicates a significant reduction in the heart's pumping function. The patient's age, weight, and NYHA Class II classification also contribute to the risk of pump failure. The presence of ventricular tachycardia and non-sustained ventricular tachycardia on the ECG further increases the risk of sudden cardiac death. The patient's elevated creatinine level (101.0 mmol/L) suggests renal impairment, which can be a complication of heart failure. The patient's medications, such as the ACE inhibitor, are also indicative of heart failure management. Considering these factors, pump failure death is the most likely outcome.

2. Sudden cardiac death
REASONING: 
While the patient has a high risk of pump failure, the presence of ventricular tachycardia and non-sustained ventricular tachycardia on the ECG increases the risk of sudden cardiac death. The patient's LVEF of 30.0% and NYHA Class II classification also suggest a high risk of cardiac events. However, the patient's age and overall clinical presentation are not as severe as those in the pump failure category.

3. Survivor
REASONING: 
The patient's age, LVEF of 30.0%, and NYHA Class II classification do suggest a poor prognosis. However, the patient's current medications and the presence of ventricular tachycardia on the ECG may indicate some level of cardiac management. The patient's laboratory results, such as the elevated creatinine level, may also suggest some level of renal impairment, which can be managed with current treatment. Considering these factors, the patient's overall prognosis is less favorable than the pump failure and sudden cardiac death categories."
838,838,P0891,"Age: 72
Gender: Male 
Weight: 57 kg
Height: 158 cm
NYHA Class: III
Blood Pressure: 130/90 mmHg
Past Medical History: Other HF etiology, Diabetes, Hypertension
Albumin (g/L): 43
ALT or GPT (IU/L): 18.0
AST or GOT (IU/L): 18.0
Total Cholesterol (mmol/L): 5,28
Creatinine (mmol/L): 115.0
Gamma-glutamil transpeptidase (IU/L): 13
Glucose (mmol/L): 6,2
Hemoglobin (g/L): 143.0
HDL (mmol/L): 1,27
Potassium (mEq/L): 4,5
LDL (mmol/L): 3,49
Sodium (mEq/L): 144.0
Pro-BNP (ng/L): 4127.0
Protein (g/L): 72
T4 (ng/L): 19
Troponin (ng/mL): 0,01
TSH (mIU/L): 2,56
Urea (mg/dL): 12,81
LVEF (%): 20.0
Medications: Diabetes Medication, Angiotensin II Receptor Blocker, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",pump failure death,"RANKING: 
1. Sudden cardiac death
2. Pump failure death
3. Survivor

REASONING:

The patient's age, NYHA Class III, and elevated BNP levels (4127.0 ng/L) indicate advanced heart failure, which increases the risk of cardiac complications. The patient's left ventricular ejection fraction (LVEF) of 20.0% further supports this, as it is significantly below the normal range (typically >55%). 

The presence of ventricular extrasystoles and non-sustained ventricular tachycardia on the ECG suggest an increased risk of arrhythmias, which can lead to sudden cardiac death. However, the absence of sustained ventricular tachycardia and other arrhythmias on the ECG suggests that the patient's arrhythmias are non-life-threatening.

The patient's elevated creatinine level (12.81 mg/dL) and high blood pressure (130/90 mmHg) also indicate kidney dysfunction, which is a common complication in advanced heart failure. The patient's proteinuria (elevated albumin levels) and elevated creatinine level suggest that the patient may be at risk of progressive kidney damage and further exacerbation of heart failure.

Given these factors, the most likely outcome for the patient over the next few years is pump failure death. The combination of advanced heart failure, kidney dysfunction, and arrhythmias makes it more likely that the patient's heart will deteriorate further, leading to pump failure and death.

While sudden cardiac death is a possibility, it is less likely given the absence of sustained ventricular tachycardia on the ECG. The patient's medications, such as the ACE inhibitor, may help mitigate some of the cardiac risks, but the overall clinical picture suggests that pump failure is the more likely outcome."
839,839,P0907,"Age: 50
Gender: Male 
Weight: 69 kg
Height: 169 cm
NYHA Class: II
Blood Pressure: 100/70 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Dyslipemia, Hypertension, Myocardial Infarction
Albumin (g/L): 39,4
ALT or GPT (IU/L): 25.0
AST or GOT (IU/L): 32.0
Total Cholesterol (mmol/L): 2,79
Creatinine (mmol/L): 156.0
Gamma-glutamil transpeptidase (IU/L): 66
Glucose (mmol/L): 5,7
Hemoglobin (g/L): 138.0
HDL (mmol/L): 0,87
Potassium (mEq/L): 3,78
LDL (mmol/L): 1,37
Sodium (mEq/L): 141.0
Pro-BNP (ng/L): 9416.0
Protein (g/L): 64,6
Troponin (ng/mL): 0,01
TSH (mIU/L): 1,85
Urea (mg/dL): 9,2
LVEF (%): 20.0
Medications: Amiodarone, Beta Blockers, Loop Diuretics, Statins, Hydralazine, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",pump failure death,"RANKING: 
1. Pump failure death 
REASONING: 
The patient's data indicates a severe cardiac condition, with a left ventricular ejection fraction (LVEF) of 20%, which is significantly below the normal range. This suggests that the patient's heart is not pumping efficiently, which increases the risk of heart failure. Additionally, the patient has a history of ischemic dilated cardiomyopathy, which is a condition that can lead to heart failure. The presence of elevated BNP levels (9416.0 ng/L) also supports this, as BNP is a marker of ventricular strain and is often elevated in patients with heart failure.

The patient's medications, including Amiodarone, Beta Blockers, Loop Diuretics, and Hydralazine, are commonly used to manage heart failure, and the patient is already on these medications, indicating that the healthcare provider is taking steps to manage the condition.

While the patient's ECG shows some signs of arrhythmia, including ventricular extrasystole and non-sustained VT, these are not the primary concerns given the patient's overall clinical picture. The patient's blood pressure and electrolyte levels are within normal limits, and there is no indication of acute kidney injury or other life-threatening conditions.

Overall, based on the patient's clinical presentation, history, and laboratory results, pump failure death is the most likely outcome over the next few years."
840,840,P0913,"Age: 69
Gender: Female 
Weight: 70 kg
Height: 151 cm
NYHA Class: III
Blood Pressure: 130/80 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Diabetes, Peripheral vascular disease, Hypertension, Myocardial Infarction
Albumin (g/L): 40,7
ALT or GPT (IU/L): 12.0
AST or GOT (IU/L): 33.0
Total Cholesterol (mmol/L): 4,94
Creatinine (mmol/L): 63.0
Gamma-glutamil transpeptidase (IU/L): 13
Glucose (mmol/L): 5,7
Hemoglobin (g/L): 119.0
HDL (mmol/L): 1,4
Potassium (mEq/L): 4
LDL (mmol/L): 3,08
Sodium (mEq/L): 141.0
Pro-BNP (ng/L): 475.0
Protein (g/L): 70,7
T3 (pg/dL): 0,04
T4 (ng/L): 14
TSH (mIU/L): 1,94
Urea (mg/dL): 6,16
LVEF (%): 35.0
Medications: Calcium Channel Blocker, Diabetes Medication, Beta Blockers, Loop Diuretics, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",pump failure death,"RANKING: 1. Sudden cardiac death
REASONING:

Based on the provided patient data, I would rank the prognoses as follows:

1. Sudden cardiac death: This is the most likely outcome due to the patient's severe left ventricular dysfunction (LVEF 35.0), which is a hallmark of advanced heart failure. The patient's NYHA Class III indicates a severe level of symptoms, and the presence of ischemic dilated cardiomyopathy further exacerbates the risk of sudden cardiac death. The elevated Pro-BNP levels (475 ng/L) also support this prediction, as they are a marker of ventricular stretch and stress, indicating increased strain on the heart.

2. Pump failure death: This is the second most likely outcome due to the patient's advanced heart failure symptoms and the presence of NYHA Class III. The patient's elevated creatinine levels (6.16 mg/dL) and urea levels (6.16 mg/dL) indicate renal impairment, which is a common complication of advanced heart failure. The patient's elevated LVEF of 35.0 also supports this prediction, as it indicates significant ventricular dysfunction.

3. Survivor: Although the patient's age (69) and other comorbidities (diabetes, hypertension, peripheral vascular disease) increase the risk of mortality, the patient's severe heart failure symptoms and advanced LVEF make pump failure death a more likely outcome than sudden cardiac death. However, the patient's overall health status and the presence of multiple comorbidities make survival less likely compared to the first two outcomes.

It is essential to note that this prognosis is based on the provided data and should be interpreted in the context of a comprehensive clinical evaluation, including a thorough medical history, physical examination, and other diagnostic tests."
841,841,P0940,"Age: 79
Gender: Male 
Weight: 58 kg
Height: 160 cm
NYHA Class: II
Blood Pressure: 130/70 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Dyslipemia, Peripheral vascular disease, Hypertension
Albumin (g/L): 39
ALT or GPT (IU/L): 12.0
AST or GOT (IU/L): 9.0
Total Cholesterol (mmol/L): 3,62
Creatinine (mmol/L): 141.0
Gamma-glutamil transpeptidase (IU/L): 13
Glucose (mmol/L): 6,2
Hemoglobin (g/L): 105.0
HDL (mmol/L): 0,44
Potassium (mEq/L): 5,3
LDL (mmol/L): 1,89
Sodium (mEq/L): 138.0
Pro-BNP (ng/L): 5482.0
Protein (g/L): 68
T3 (pg/dL): 0,05
T4 (ng/L): 16
Troponin (ng/mL): 0,13
TSH (mIU/L): 2,56
Urea (mg/dL): 18,14
LVEF (%): 30.0
Medications: Calcium Channel Blocker, Beta Blockers, Loop Diuretics, Statins, ACE Inhibitor, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",pump failure death,"RANKING: 
1. Pump failure death
2. Sudden cardiac death
3. Survivor

REASONING:

Based on the provided patient data, I predict the following prognosis:

Pump failure death is the most likely outcome (Rank 1) due to the following reasons:

1. Severe left ventricular dysfunction: The patient has an LVEF of 30.0%, indicating significant left ventricular dysfunction, which is a strong predictor of heart failure and pump failure.
2. Advanced age: The patient is 79 years old, which increases the risk of complications and mortality.
3. Multiple comorbidities: The patient has a history of ischemic dilated cardiomyopathy, dyslipemia, peripheral vascular disease, and hypertension, all of which can contribute to cardiac dysfunction and pump failure.
4. Elevated BNP levels: The patient's Pro-BNP level is significantly elevated at 5482.0 ng/L, indicating increased ventricular wall stress and a high risk of heart failure.

Sudden cardiac death (Rank 2) is a possible outcome due to the presence of:

1. Ventricular extrasystole: The ECG impression mentions ventricular extrasystoles, which can be a precursor to ventricular arrhythmias and sudden cardiac death.
2. History of ischemic dilated cardiomyopathy: This condition can increase the risk of ventricular arrhythmias and sudden cardiac death.

Survivor (Rank 3) is the least likely outcome due to the patient's advanced age, severe left ventricular dysfunction, and multiple comorbidities, which increase the risk of complications and mortality. However, the presence of a strong treatment regimen, including ACE inhibitors and beta blockers, may help mitigate some of these risks."
842,842,P0961,"Age: 76
Gender: Female 
Weight: 93 kg
Height: 166 cm
NYHA Class: II
Blood Pressure: 134/64 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Myocardial Infarction
Albumin (g/L): 45
ALT or GPT (IU/L): 14.0
AST or GOT (IU/L): 14.0
Total Cholesterol (mmol/L): 4,55
Creatinine (mmol/L): 115.0
Gamma-glutamil transpeptidase (IU/L): 10
Glucose (mmol/L): 7,3
Hemoglobin (g/L): 149.0
HDL (mmol/L): 0,72
Potassium (mEq/L): 4,2
LDL (mmol/L): 2,77
Sodium (mEq/L): 142.0
Pro-BNP (ng/L): 2876.0
Protein (g/L): 71
T3 (pg/dL): 0,04
T4 (ng/L): 19
TSH (mIU/L): 2,86
Urea (mg/dL): 9,82
LVEF (%): 30.0
Medications: Digoxin, Loop Diuretics, Spironolactone, Statins
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",pump failure death,"RANKING: 1. Survivor
REASONING: 

The patient's LVEF (Left Ventricular Ejection Fraction) is significantly reduced at 30.0%, indicating severe left ventricular dysfunction. This is a strong indicator of the patient's compromised cardiac function. The presence of ischemic dilated cardiomyopathy and myocardial infarction in the patient's past medical history also suggests that the cardiac damage is extensive and long-standing. 

The patient's elevated BNP levels (2876.0 ng/L) also support the presence of heart failure, as BNP is a biomarker for cardiac strain. The patient's NYHA Class II classification indicates that the patient experiences symptoms of heart failure, such as shortness of breath, fatigue, and swelling, on ordinary physical activity. 

Given these factors, the patient is at high risk of experiencing a heart-related event, such as pump failure. However, the patient is on medications that are commonly used to manage heart failure, including digoxin, loop diuretics, and spironolactone. The patient's blood pressure is also within a relatively normal range, which may reduce the risk of sudden cardiac death. 

Therefore, based on the available data, the most likely outcome for the patient is survival, albeit with ongoing management and monitoring to mitigate the progression of heart failure.

RANKING: 2. Sudden cardiac death
REASONING: 

While the patient is at high risk of experiencing a heart-related event, the likelihood of sudden cardiac death is lower compared to pump failure. The patient's ECG impression does not indicate ventricular tachycardia or non-sustained ventricular tachycardia, which are common precursors to sudden cardiac death. 

However, the presence of ventricular extrasystole (polymorphic) on the ECG suggests that the patient is at risk of arrhythmias, which can contribute to sudden cardiac death. Nevertheless, the absence of ventricular tachycardia or non-sustained ventricular tachycardia on the ECG reduces the likelihood of sudden cardiac death.

RANKING: 3. Pump failure death
REASONING: 

Pump failure death is the most likely outcome for this patient, given the patient's severely reduced LVEF (30.0%) and elevated BNP levels (2876.0 ng/L). The patient's NYHA Class II classification indicates that the patient experiences symptoms of heart failure, and the patient's medications are primarily focused on managing heart failure symptoms rather than preventing sudden cardiac death. 

The patient's elevated creatinine level (115.0 mmol/L) also suggests that the patient may have chronic kidney disease, which can further compromise cardiac function and increase the risk of pump failure. 

While the patient is on medications to manage heart failure, the patient's underlying cardiac damage and reduced LVEF make pump failure the most likely outcome."
843,843,P0978,"Age: 69
Gender: Male 
Weight: 106 kg
Height: 170 cm
NYHA Class: II
Blood Pressure: 130/70 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Diabetes, Dyslipemia, Peripheral vascular disease, Hypertension, Myocardial Infarction
Albumin (g/L): 34
ALT or GPT (IU/L): 30.0
AST or GOT (IU/L): 16.0
Total Cholesterol (mmol/L): 4,55
Creatinine (mmol/L): 186.0
Gamma-glutamil transpeptidase (IU/L): 40
Glucose (mmol/L): 8,1
Hemoglobin (g/L): 118.0
HDL (mmol/L): 0,83
Potassium (mEq/L): 4
LDL (mmol/L): 2,82
Sodium (mEq/L): 143.0
Pro-BNP (ng/L): 6603.0
Protein (g/L): 67
T4 (ng/L): 14
Troponin (ng/mL): 0,01
TSH (mIU/L): 2,22
Urea (mg/dL): 14,48
LVEF (%): 35.0
Medications: Diabetes Medication, Beta Blockers, Loop Diuretics, Statins, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: Unknown bradycardia code
            ",pump failure death,"RANKING: 1. Survivor
REASONING: 

The patient is 69 years old with a history of ischemic dilated cardiomyopathy, which is a significant underlying condition that can lead to heart failure. However, the patient is currently on ACE inhibitor, which is a standard treatment for heart failure. The patient's LVEF is 35%, which is relatively preserved, indicating that the heart is still functioning to some extent. The patient's creatinine level is elevated at 186.0 mmol/L, but this is likely due to renal impairment rather than cardiac failure. The patient's electrolytes, liver enzymes, and blood glucose levels are also within normal or near-normal limits.

The patient's ECG shows ventricular extrasystoles, which are common in patients with heart failure, but there is no indication of ventricular tachycardia or other life-threatening arrhythmias. The patient is also on beta blockers, which are often used to slow the heart rate and reduce the workload on the heart.

Considering these factors, the patient's overall prognosis is good, and it is likely that they will survive for the next few years. The patient's condition is manageable with current treatment, and with proper management, they can expect to live a relatively normal life.

RANKING: 2. Sudden cardiac death
REASONING: 

While the patient's LVEF is low, the patient's ECG does not show any signs of ventricular tachycardia or other life-threatening arrhythmias. The patient is also on beta blockers, which are known to reduce the risk of sudden cardiac death. The patient's electrolytes, liver enzymes, and blood glucose levels are also within normal or near-normal limits.

However, the patient's past medical history of myocardial infarction and peripheral vascular disease increases the risk of sudden cardiac death. Additionally, the patient's low LVEF may indicate some level of cardiac dysfunction, which could increase the risk of sudden cardiac death.

Considering these factors, while the patient's prognosis is still relatively good, there is a moderate risk of sudden cardiac death. However, this risk is not as high as in the case of pump failure death.

RANKING: 3. Pump failure death
REASONING: 

The patient's LVEF is only 35%, which is a significant indicator of cardiac dysfunction. The patient's creatinine level is elevated at 186.0 mmol/L, which suggests that the kidneys are not functioning properly, and this may be related to cardiac dysfunction. The patient's NYHA Class II indicates that they have some level of heart failure symptoms, but they are still able to perform moderate physical activity.

The patient's ECG shows ventricular extrasystoles, which are a common finding in patients with heart failure. The patient's electrolytes, liver enzymes, and blood glucose levels are also within normal or near-normal limits.

Considering these factors, the patient's prognosis is poor, and pump failure death is a significant risk. The patient's cardiac dysfunction and renal impairment increase the risk of pump failure, and the patient's symptoms of heart failure suggest that they are already experiencing significant cardiac stress."
844,844,P0981,"Age: 73
Gender: Male 
Weight: 63 kg
Height: 160 cm
NYHA Class: II
Blood Pressure: 110/70 mmHg
Past Medical History: Other HF etiology, Diabetes, Dyslipemia, Hypertension, Myocardial Infarction
Albumin (g/L): 40,5
ALT or GPT (IU/L): 8.0
AST or GOT (IU/L): 14.0
Total Cholesterol (mmol/L): 4,06
Creatinine (mmol/L): 111.0
Gamma-glutamil transpeptidase (IU/L): 29
Glucose (mmol/L): 4,4
Hemoglobin (g/L): 106.0
HDL (mmol/L): 1,73
Potassium (mEq/L): 5,1
LDL (mmol/L): 2,02
Sodium (mEq/L): 144.0
Protein (g/L): 74
T4 (ng/L): 19
TSH (mIU/L): 0,19
Urea (mg/dL): 9,48
LVEF (%): 69.0
Medications: Diabetes Medication, Angiotensin II Receptor Blocker, Beta Blockers, Loop Diuretics, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: TPSV
        - Bradycardia: No
            ",pump failure death,"RANKING: 
1. Survivor
REASONING: 
This patient is likely to survive for the next few years due to several factors. Firstly, the patient's age (73) is not extremely high, and with proper management of their conditions, many people of this age can live for several years. The patient's NYHA Class II indicates that they have some symptoms of heart failure, but it's not severe enough to classify them as NYHA Class III or IV. This suggests that they are still relatively functional and can tolerate some level of physical activity.

The patient's medication regimen is also well-managed, with a combination of medications for diabetes, hypertension, and heart failure, which should help control their conditions. The patient's laboratory results, such as low albumin and elevated creatinine, suggest some degree of kidney impairment, but this is not uncommon in patients with heart failure.

The ECG results show no signs of ventricular tachycardia or ventricular extrasystoles, which are significant predictors of sudden cardiac death. The presence of paroxysmal supraventricular tachycardia (PSVT) is not uncommon in patients with heart failure, but it is not typically a cause of sudden death.

Overall, while the patient has several comorbidities, their current condition and management plan suggest that they are likely to survive for the next few years.

RANKING: 2. Sudden cardiac death
REASONING: 
Sudden cardiac death is a possible outcome for this patient, but it is less likely than survival. The patient's age and NYHA Class II indicate a moderate level of heart failure, which can increase the risk of sudden cardiac death. The patient's ECG results show no signs of ventricular tachycardia or ventricular extrasystoles, but the presence of paroxysmal supraventricular tachycardia (PSVT) is a risk factor for sudden cardiac death.

The patient's laboratory results, such as low albumin and elevated creatinine, suggest some degree of kidney impairment, which can increase the risk of sudden cardiac death. However, this is not a significant risk factor in this case, as the patient is on medications to manage their kidney function.

RANKING: 3. Pump failure death
REASONING: 
Pump failure death is the least likely outcome for this patient. The patient's NYHA Class II indicates that they have some symptoms of heart failure, but it's not severe enough to classify them as NYHA Class III or IV. The patient's medication regimen is well-managed, and they are on medications to control their heart failure, which should help prevent pump failure.

The patient's laboratory results, such as low albumin and elevated creatinine, suggest some degree of kidney impairment, which can increase the risk of pump failure. However, this is not a significant risk factor in this case, as the patient is on medications to manage their kidney function.

The ECG results show no signs of ventricular tachycardia or ventricular extrasystoles, which are significant predictors of sudden cardiac death. The presence of paroxysmal supraventricular tachycardia (PSVT) is not typically a cause of pump failure. Overall, while the patient has several comorbidities, their current condition and management plan suggest that pump failure is not a significant risk."
845,845,P0983,"Age: 68
Gender: Male 
Weight: 90 kg
Height: 164 cm
NYHA Class: III
Blood Pressure: 120/80 mmHg
Past Medical History: Idiopathic dilated cardiomyopathy, Dyslipemia, Hypertension
Albumin (g/L): 39
ALT or GPT (IU/L): 26.0
AST or GOT (IU/L): 36.0
Total Cholesterol (mmol/L): 5,07
Creatinine (mmol/L): 187.0
Gamma-glutamil transpeptidase (IU/L): 61
Glucose (mmol/L): 4,9
Hemoglobin (g/L): 154.0
HDL (mmol/L): 1,03
Potassium (mEq/L): 5,4
LDL (mmol/L): 3,15
Sodium (mEq/L): 144.0
Protein (g/L): 70
T4 (ng/L): 15
TSH (mIU/L): 3,68
Urea (mg/dL): 12,64
LVEF (%): 21.0
Medications: Angiotensin II Receptor Blocker, Digoxin, Loop Diuretics, Spironolactone
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",pump failure death,"RANKING: 
1. Sudden cardiac death
2. Pump failure death
3. Survivor

REASONING:

The patient's data suggests that the patient is at high risk for cardiac-related complications. Here's a breakdown of the factors contributing to each prognosis:

1. Sudden cardiac death (SCD) is the most likely outcome. The patient's age (68) and NYHA Class III status indicate advanced heart failure, which increases the risk of arrhythmias and cardiac arrest. The ECG findings of ventricular extrasystoles, non-sustained ventricular tachycardia, and polymorphic ventricular extrasystoles further support this risk. Additionally, the patient's low LVEF (21.0) indicates severe left ventricular dysfunction, which is a common precursor to SCD.

2. Pump failure death is a close second. The patient's advanced NYHA Class III status and severely reduced LVEF (21.0) indicate significant heart failure. The presence of non-sustained ventricular tachycardia and ventricular extrasystoles on the ECG also suggests ongoing cardiac instability. The patient's elevated creatinine level (12.64 mg/dL) and anemia (Hemoglobin: 154.0) may also contribute to the risk of pump failure.

3. Survivor is the least likely outcome. While the patient's age and medical history are concerning, the presence of certain medications (e.g., Angiotensin II Receptor Blocker, Digoxin) may help manage symptoms and slow disease progression. However, the patient's advanced NYHA Class III status, severely reduced LVEF, and high risk of arrhythmias and cardiac instability make a full recovery less likely.

Overall, the combination of advanced heart failure, significant arrhythmias, and reduced cardiac function make SCD and pump failure death more likely outcomes than survival."
846,846,P0997,"Age: 72
Gender: Male 
Weight: 95 kg
Height: 159 cm
NYHA Class: III
Blood Pressure: 120/80 mmHg
Past Medical History: Ischemic dilated cardiomyopathy
Albumin (g/L): 40,9
ALT or GPT (IU/L): 41.0
AST or GOT (IU/L): 45.0
Total Cholesterol (mmol/L): 4,76
Creatinine (mmol/L): 110.0
Gamma-glutamil transpeptidase (IU/L): 39
Glucose (mmol/L): 6,3
Hemoglobin (g/L): 155.0
HDL (mmol/L): 1,11
Potassium (mEq/L): 5,2
LDL (mmol/L): 3
Sodium (mEq/L): 137.0
Protein (g/L): 73,8
T4 (ng/L): 14
TSH (mIU/L): 1,53
Urea (mg/dL): 10,82
LVEF (%): 20.0
Medications: Loop Diuretics, Spironolactone, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",pump failure death,"RANKING: 
1. Sudden Cardiac Death
REASONING: 
The patient's ECG findings of ventricular extrasystole, polymorphic ventricular tachycardia, and non-sustained ventricular tachycardia (CH>10) indicate a high risk of life-threatening arrhythmias. The presence of these findings, combined with a history of ischemic dilated cardiomyopathy, suggests a high likelihood of ventricular arrhythmias leading to sudden cardiac death. The patient's low LVEF (20.0) also indicates significant left ventricular dysfunction, which can increase the risk of arrhythmias and sudden cardiac death.

2. Pump Failure Death
REASONING: 
The patient's history of ischemic dilated cardiomyopathy and current LVEF of 20.0 indicates severe left ventricular dysfunction, which can lead to heart failure. The patient's NYHA Class III classification also suggests significant symptoms of heart failure. The use of loop diuretics, spironolactone, and ACE inhibitor suggests that the patient is receiving standard treatment for heart failure. However, the patient's elevated creatinine (110.0) and urea (10.82) levels indicate some degree of renal impairment, which may affect the patient's ability to tolerate these medications and increase the risk of pump failure.

3. Survivor
REASONING: 
While the patient's history and ECG findings suggest a high risk of arrhythmias and heart failure, the patient's age (72) and relatively normal blood pressure (120/80 mmHg) suggest that the patient may be more likely to survive with proper management. The patient's hemoglobin level (155.0) is also within a normal range, which may indicate that the patient does not have significant anemia. However, the patient's low HDL (1.11) and high LDL (3) levels suggest a high risk of cardiovascular disease, which may affect the patient's long-term survival. Overall, while the patient has a high risk of arrhythmias and heart failure, the patient's age and relatively normal blood pressure and hemoglobin levels suggest that the patient may be more likely to survive with proper management."
847,847,P1023,"Age: 77
Gender: Male 
Weight: 84 kg
Height: 159 cm
NYHA Class: II
Blood Pressure: 116/79 mmHg
Past Medical History: Valvular cardiomyopathy
Albumin (g/L): 42
ALT or GPT (IU/L): 11.0
AST or GOT (IU/L): 13.0
Total Cholesterol (mmol/L): 3,88
Creatinine (mmol/L): 177.0
Gamma-glutamil transpeptidase (IU/L): 9
Glucose (mmol/L): 5,8
Hemoglobin (g/L): 117.0
HDL (mmol/L): 1,24
Potassium (mEq/L): 5,9
LDL (mmol/L): 3,1
Sodium (mEq/L): 140.0
Protein (g/L): 78
T3 (pg/dL): 0,04
T4 (ng/L): 18
Troponin (ng/mL): 0,03
TSH (mIU/L): 0,36
Urea (mg/dL): 19,64
LVEF (%): 70.0
Medications: Digoxin, Loop Diuretics, Spironolactone
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",pump failure death,"RANKING: 1. Sudden Cardiac Death
REASONING: 
Given the patient's age, NYHA Class II heart failure, and history of valvular cardiomyopathy, the patient is at a high risk for cardiac arrhythmias. The ECG impression reveals ventricular extrasystole, non-sustained ventricular tachycardia, and non-sustained ventricular tachycardia, which are all indicators of arrhythmic instability. The presence of ventricular tachycardia, particularly non-sustained ventricular tachycardia, significantly increases the risk of sudden cardiac death. The patient's elevated troponin levels (0.03 ng/mL) also suggest some myocardial damage, which can contribute to arrhythmias and sudden cardiac death. 

The patient's LVEF of 70.0 is below the normal range, indicating some degree of left ventricular dysfunction, which can also contribute to arrhythmias and sudden cardiac death. The patient's medication regimen, including digoxin, loop diuretics, and spironolactone, may be contributing to the arrhythmias.

While pump failure death is a possible outcome, the patient's current ECG findings and laboratory results suggest that sudden cardiac death is the more likely outcome over the next few years.

RANKING: 2. Pump Failure Death
REASONING: 
The patient's NYHA Class II heart failure and elevated creatinine levels (19.64 mg/dL) indicate that the patient has some degree of cardiac dysfunction. The patient's LVEF of 70.0 is below the normal range, and the patient's elevated troponin levels (0.03 ng/mL) suggest some degree of myocardial damage. The patient's medication regimen, including digoxin and spironolactone, may be contributing to the cardiac dysfunction.

While the patient's ECG findings do not indicate any overt arrhythmias, the patient's history of valvular cardiomyopathy and NYHA Class II heart failure increase the risk of pump failure. However, the patient's current ECG findings and laboratory results do not suggest an immediate risk of sudden cardiac death, making pump failure death a more likely outcome over the next few years.

RANKING: 3. Survivor
REASONING: 
The patient's age (77) and NYHA Class II heart failure increase the risk of cardiac-related complications. However, the patient's LVEF of 70.0 is not severely impaired, and the patient's medication regimen, including digoxin and spironolactone, is well-tolerated. The patient's ECG findings do not indicate any overt arrhythmias, and the patient's laboratory results are relatively normal.

While the patient's history of valvular cardiomyopathy and elevated creatinine levels increase the risk of cardiac-related complications, the patient's current ECG findings and laboratory results do not suggest an immediate risk of sudden cardiac death or pump failure. Therefore, the patient is at a higher risk of survival over the next few years compared to the other two options."
848,848,P1026,"Age: 68
Gender: Male 
Weight: 60 kg
Height: 162 cm
NYHA Class: II
Blood Pressure: 92/64 mmHg
Past Medical History: Idiopathic dilated cardiomyopathy, Hypertension
Albumin (g/L): 27
ALT or GPT (IU/L): 15.0
AST or GOT (IU/L): 28.0
Total Cholesterol (mmol/L): 3,49
Creatinine (mmol/L): 186.0
Gamma-glutamil transpeptidase (IU/L): 349
Glucose (mmol/L): 4,8
Hemoglobin (g/L): 117.0
HDL (mmol/L): 0,78
Potassium (mEq/L): 5,2
LDL (mmol/L): 2,09
Sodium (mEq/L): 134.0
Protein (g/L): 51
T3 (pg/dL): 0,04
T4 (ng/L): 15
TSH (mIU/L): 9,94
Urea (mg/dL): 25,79
LVEF (%): 30.0
Medications: Beta Blockers, Loop Diuretics, Spironolactone
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",pump failure death,"RANKING: 1. Sudden cardiac death
REASONING: 

The patient has a significant number of risk factors that increase the likelihood of sudden cardiac death. The patient's age, NYHA Class II heart failure, and idiopathic dilated cardiomyopathy are all predictors of poor outcomes. The patient's low LVEF (30.0%) further indicates severe left ventricular dysfunction, which can lead to sudden cardiac death.

The patient's ECG findings of ventricular extrasystole, non-sustained VT, and non-sustained ventricular tachycardia also suggest a high risk of arrhythmic events. The presence of ventricular extrasystole and non-sustained VT on the ECG is particularly concerning, as these can be precursors to more serious arrhythmic events.

The patient's medication regimen, which includes beta blockers and loop diuretics, is also a positive factor, as these medications can help reduce the risk of arrhythmias and improve cardiac function. However, the presence of non-sustained VT and ventricular extrasystole on the ECG suggests that the patient's risk of sudden cardiac death is still relatively high.

While pump failure death is a possible outcome, it is less likely than sudden cardiac death given the patient's acute ECG findings and the presence of ventricular extrasystole. Pump failure death is more commonly associated with chronic heart failure and a longer duration of symptoms, whereas the patient's recent ECG findings suggest a more acute risk of arrhythmias.

In contrast, the patient's low T3 and T4 levels, which indicate hypothyroidism, may actually be a protective factor, as hypothyroidism is often associated with a lower risk of arrhythmias and sudden cardiac death. However, this effect is likely to be small and may not outweigh the other risk factors present in this patient.

Overall, the combination of severe left ventricular dysfunction, arrhythmic ECG findings, and the patient's other risk factors make sudden cardiac death the most likely outcome in this case."
